{"qid": "Q1_abbr+unitswap", "query": "AOM in 5-yo, wt 18 kg — amox dose (mg/kg/day) + volume using 400 mg/5 mL suspension?", "base_qid": "Q1", "variant_type": "abbr+unitswap", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 64.94818074663878, "bm25_max": 66.91539207199092, "bge_top3": 0.6709433992703756, "bge_max": 0.6722792983055115, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "mesalamine-mesalazine-drug-information", "bm25_top3": 46.55765334970522, "bm25_max": 46.55765334970522, "bge_top3": null, "bge_max": null, "title": "Mesalamine (mesalazine): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Mesalamine (mesalazine): Pediatric drug information\")  Ulcerative colitis (treatment): Children ≥5 years and Adolescents: Oral: Delzicol:  17 to 32 kg: 800 mg in the mo…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 45.27187309063558, "bm25_max": 45.55707927845931, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ibuprofen: Pediatric drug information\")  Analgesia:  IV (Caldolor): Note: Patients should be well hydrated prior to administration.  Infants ≥6 months and Children <12…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 42.04424692259329, "bm25_max": 42.04424692259329, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": 40.937331316596314, "bm25_max": 40.937331316596314, "bge_top3": 0.656345009803772, "bge_max": 0.656345009803772, "title": "Cefixime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefixime: Pediatric drug information\")  Note: Suprax 400 mg tablets have been discontinued in the US for more than 1 year.  Susceptible infections: Oral: Note: Otitis m…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 33.295666875847125, "bm25_max": 40.55858368613342, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": 39.81803788824373, "bm25_max": 39.81803788824373, "bge_top3": null, "bge_max": null, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftaroline: Pediatric drug information\")  Pneumonia, community acquired: IV:  Infants ≥2 months and Children <2 years: 8 mg/kg/dose every 8 hours for 5 to 14 days  Chi…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 39.643306634670516, "bm25_max": 39.643306634670516, "bge_top3": null, "bge_max": null, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "1-day regimen: 30 mg/kg as a single dose (maximum dose: 1,500 mg)  3-day regimen: 10 mg/kg once daily for 3 days (maximum: 500 mg daily)  5-day regimen: 10 mg/kg on day 1 (maximum: 500 mg daily) followed by 5 mg/kg/day o…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 39.61350599073124, "bm25_max": 39.61350599073124, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "14 to <18.5 kg: 250 mg every 6 hours  18.5 to <23 kg: 300 mg every 6 hours  23 to <32 kg: 350 mg every 6 hours  32 to <41 kg: 400 mg every 6 hours  41 to ≤50 kg: 450 mg every 6 hours  >50 kg: 500 mg every 6 hours  Altern…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 38.519048562028594, "bm25_max": 39.40920364452552, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Hematopoietic cell transplantation (HCT) with hypogammaglobulinemia (IgG <400 mg/dL), prevention of bacterial infection (off-label use): Note: Increase dose or frequency to maintain IgG concentration >400 mg/dL.  ≤100 da…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": 38.05546459356127, "bm25_max": 38.05546459356127, "bge_top3": 0.6627580523490906, "bge_max": 0.6627580523490906, "title": "Phenytoin: Drug information", "rep_snippet": "Immediate release: Children and Adolescents: Tablet and suspension: Initial: 5 mg/kg/day in 2 to 3 equally divided doses, individualize dosage with dosage adjustments at no less than 7- to 10-day intervals; maintenance d…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 37.50874176245216, "bm25_max": 37.50874176245216, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Raltegravir: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Note: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioe…"}, {"doc_id": "pegfilgrastim-drug-information", "bm25_top3": 36.565103338965166, "bm25_max": 37.4255348846188, "bge_top3": null, "bge_max": null, "title": "Pegfilgrastim: Drug information", "rep_snippet": "Hematopoietic radiation injury syndrome (acute): Obtain a baseline CBC prior to administration, but do not delay pegfilgrastim use if a CBC is not readily obtainable. Administer the first dose as soon as possible after s…"}, {"doc_id": "ceftibuten-drug-information", "bm25_top3": 37.323914486001115, "bm25_max": 37.323914486001115, "bge_top3": null, "bge_max": null, "title": "Ceftibuten: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥50 mL//minute: No dosage adjustment necessary.  CrCl 30 to 49 mL//minute: 4.5 mg/kg or 200 mg every 24 hours.  CrCl 5 to 29 mL/minute: 2.25 mg/kg or 100 mg every 24 hours.  End-stage renal…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": 36.81796728576654, "bm25_max": 37.2294424168504, "bge_top3": null, "bge_max": null, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Immune thrombocytopenia, refractory (off-label use): Oral: 5 mg/kg/day in 2 divided doses (every 12 hours) for 6 days, followed by 2.5 to 3 mg/kg/day (titrate to serum levels of 100 to 200 ng/mL); time to response in cli…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 37.073308266202616, "bm25_max": 37.073308266202616, "bge_top3": 0.6466558575630188, "bge_max": 0.6505581140518188, "title": "Voriconazole: Drug information", "rep_snippet": "Infants and Children <2 years (off-label): IV, Oral (oral suspension): Initial: 9 mg/kg/dose every 12 hours followed by monitoring of serum trough concentrations typically initiated after 3 to 5 days; adjust dose to achi…"}, {"doc_id": "carbamazepine-drug-information", "bm25_top3": 37.025099064829135, "bm25_max": 37.025099064829135, "bge_top3": null, "bge_max": null, "title": "Carbamazepine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Carbamazepine: Pediatric drug information\")  Dosage must be adjusted according to patient's response and serum concentrations. Children <12 years who receive ≥400 mg/da…"}, {"doc_id": "methylnaltrexone-drug-information", "bm25_top3": 36.89875855644847, "bm25_max": 36.89875855644847, "bge_top3": null, "bge_max": null, "title": "Methylnaltrexone: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥60 mL/minute: No dosage adjustment necessary.  CrCl <60 mL/minute:  Opioid-induced constipation with advanced illness: SubQ:  <38 kg: 0.075 mg/kg every other day (round dose up to nearest…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": 36.065621719463614, "bm25_max": 36.79395636436138, "bge_top3": null, "bge_max": null, "title": "Topiramate: Drug information", "rep_snippet": "Immediate release: Initial: 25 mg (1 to 3 mg/kg/day) once daily (in evening) for 1 week; may increase every 1 to 2 weeks in increments of 1 to 3 mg/kg/day up to the recommended dose of 5 to 9 mg/kg/day in 2 divided doses…"}, {"doc_id": "deferiprone-drug-information", "bm25_top3": 36.66027591889559, "bm25_max": 36.66027591889559, "bge_top3": null, "bge_max": null, "title": "Deferiprone: Drug information", "rep_snippet": "Dosing: Adult  Note: Round dose to the nearest 250 mg (or 1/2 tablet) or 2.5 mL (oral solution). If serum ferritin falls consistently below 500 mcg/L, consider temporary treatment interruption.  Transfusional iron overlo…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": 36.608966009516976, "bm25_max": 36.608966009516976, "bge_top3": null, "bge_max": null, "title": "Amikacin: Drug information", "rep_snippet": "GFR 30 to 50 mL/minute/1.73 m2: Administer every 12 to 18 hours  GFR 10 to 29 mL/minute/1.73 m2: Administer every 18 to 24 hours  GFR <10 mL/minute/1.73 m2: Administer every 48 to 72 hours  Intermittent hemodialysis: 5 m…"}, {"doc_id": "hydrochlorothiazide-drug-information", "bm25_top3": 35.97395279590067, "bm25_max": 35.97395279590067, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydrochlorothiazide: Pediatric drug information\")  Edema, hypertension: Note: In pediatric patients, chlorothiazide may be preferred over hydrochlorothiazide as there a…"}, {"doc_id": "colistin-colistimethate-drug-information", "bm25_top3": 35.84611919474385, "bm25_max": 35.84611919474385, "bge_top3": null, "bge_max": null, "title": "Colistin (colistimethate): Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Dosage expressed in terms of colistin base activity (CBA); although reported conversions have varied slightly in the literature, CBA 1 mg is defined to be equivalent to colistimethate sodi…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 35.576828304351686, "bm25_max": 35.576828304351686, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 34.91870861939161, "bm25_max": 35.351899102441315, "bge_top3": 0.6349521279335022, "bge_max": 0.6349521279335022, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Non-HIV-exposed/-positive:  Children <12 years: Oral: 40 to 80 mg/kg/day divided in 3 to 4 doses per day for 5 to 10 days; maximum daily dose: 1,200 mg/day (Bradley 2015; Red Book [AAP 2015])  Children and Adolescents ≥1…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 35.204119697287084, "bm25_max": 35.204119697287084, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 35.120014360576675, "bm25_max": 35.120014360576675, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "prochlorperazine-drug-information", "bm25_top3": 34.978695544766055, "bm25_max": 34.978695544766055, "bge_top3": null, "bge_max": null, "title": "Prochlorperazine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prochlorperazine: Pediatric drug information\")  Note: Injection solution mesylate formulation is a Canadian product (not available in US).  Use is contraindicated in ch…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": 34.73313495194448, "bm25_max": 34.73313495194448, "bge_top3": null, "bge_max": null, "title": "Hyoscyamine: Drug information", "rep_snippet": "Tablets (regular release [Levsin], sublingual [Levsin/SL], dispersible [ED-SPAZ, NuLev]): 0.0625 to 0.125 mg every 4 hours or as needed; maximum: 0.75 mg/day  Drops (Hyosyne [0.125 mg/mL]): 0.03125 mg (0.25 mL) to 0.125…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 34.638033009658535, "bm25_max": 34.638033009658535, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "Maintenance therapy for frequently relapsing SSNS: Taper previous dose down to lowest effective dose which maintains remission using an alternate day schedule; usual effective range: 0.1 to 0.5 mg/kg/day on alternating d…"}, {"doc_id": "atovaquone-and-proguanil-drug-information", "bm25_top3": 34.53831059882959, "bm25_max": 34.53831059882959, "bge_top3": null, "bge_max": null, "title": "Atovaquone and proguanil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atovaquone and proguanil: Pediatric drug information\")  Prevention of malaria: Oral: Start 1-2 days prior to entering a malaria-endemic area, continue throughout the st…"}, {"doc_id": "methimazole-drug-information", "bm25_top3": 34.328177099976415, "bm25_max": 34.328177099976415, "bge_top3": null, "bge_max": null, "title": "Methimazole: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Methimazole: Pediatric drug information\")  Hyperthyroidism: Children and Adolescents: Oral: Initial: 0.4 mg/kg/day; maintenance: 0.2 mg/kg/day Note: The manufacturer su…"}, {"doc_id": "hydroxychloroquine-drug-information", "bm25_top3": 34.3225703556635, "bm25_max": 34.3225703556635, "bge_top3": null, "bge_max": null, "title": "Hydroxychloroquine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydroxychloroquine: Pediatric drug information\")  Note: Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phospha…"}, {"doc_id": "atenolol-drug-information", "bm25_top3": 33.89996383537655, "bm25_max": 33.89996383537655, "bge_top3": 0.640514075756073, "bge_max": 0.640514075756073, "title": "Atenolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atenolol: Pediatric drug information\")  Hypertension: Oral: Children and Adolescents: Initial: 0.5 to 1 mg/kg/dose either once daily or divided in doses twice daily; ti…"}, {"doc_id": "epinephrine-adrenaline-systemic-drug-information", "bm25_top3": 33.86276331785057, "bm25_max": 33.86276331785057, "bge_top3": null, "bge_max": null, "title": "Epinephrine (adrenaline) (systemic): Drug information", "rep_snippet": "IM (preferred), SubQ: 0.01 mg/kg (0.01 mL/kg of 1 mg/mL solution) not to exceed 0.3 to 0.5 mg every 5 to 15 minutes (Hegenbarth 2008; Simons 2011; Simons 2015).  Self-administration following severe allergic reactions (e…"}, {"doc_id": "aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information", "bm25_top3": 28.380029676794507, "bm25_max": 28.380029676794507, "bge_top3": null, "bge_max": null, "title": "Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information", "rep_snippet": "Pricing: US  Chewable (Almacone Oral)  200-200-25 mg (100): $3.82  Chewable (Gelusil Oral)  200-200-25 mg (100): $6.67  Chewable (Mintox Plus Oral)  200-200-25 mg (100): $2.99  Suspension (Almacone Double Strength Oral)…"}, {"doc_id": "edrophonium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6620350480079651, "bge_max": 0.6620350480079651, "title": "Edrophonium: Drug information", "rep_snippet": "Alternate dosing: Weight-directed dosing: Limited data available: Children and Adolescents: IV, IM, SubQ: Initial: 0.01 to 0.02 mg/kg every 30 to 45 seconds up to the maximum dose (Kliegman 2015; Swaiman 2012). Note: Typ…"}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6618261337280273, "bge_max": 0.6618261337280273, "title": "Hydroxyzine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydroxyzine: Pediatric drug information\")  Antiemetic: IM: 1.1 mg/kg/dose  Anxiety: Oral:  Children <6 years: 50 mg/day in divided doses  Children ≥6 years and Adolesce…"}, {"doc_id": "sodium-phenylacetate-and-sodium-benzoate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6519218981266022, "bge_max": 0.6561639308929443, "title": "Sodium phenylacetate and sodium benzoate: Drug information", "rep_snippet": "Dosing: Adult  Note: Administer as a loading dose over 90 to 120 minutes, followed by an equivalent maintenance infusion given over 24 hours. Initiate therapy as soon as the diagnosis of hyperammonemia is made; hyperammo…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6540523171424866, "bge_max": 0.6540523171424866, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Weight-based dosing: Infants, Children, and Adolescents: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (APS, 2008; Sullivan, 2011); do not exceed 5 doses in 24 hours; maximum daily dose: 75 mg/kg/day not to exceed 4 g…"}, {"doc_id": "pralidoxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6511314511299133, "bge_max": 0.6511314511299133, "title": "Pralidoxime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pralidoxime: Pediatric drug information\")  Organophosphate poisoning: Note: Use in conjunction with atropine; a response to atropine should be established before pralid…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6472865343093872, "bge_max": 0.6505700349807739, "title": "Amoxicillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amoxicillin: Pediatric drug information\")  Note: Unless otherwise specified, all pediatric dosing recommendations based on immediate release product formulations (oral…"}, {"doc_id": "desmopressin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6502104997634888, "bge_max": 0.6502104997634888, "title": "Desmopressin: Drug information", "rep_snippet": "Children: Initial: 60 mcg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis. Usual maintenance: 120 to 720 mcg equally divided 2 to 3 times daily; divide daily dos…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6485902070999146, "bge_max": 0.6485902070999146, "title": "Everolimus: Drug information", "rep_snippet": "Initial: 4.5 mg/m2 once daily; round to nearest tablet (tablet or tablet for oral suspension) size; continue until disease progression or unacceptable toxicity.  If trough <5 ng/mL: Increase dose by 2.5 mg daily (tablets…"}, {"doc_id": "aliskiren-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6465736031532288, "bge_max": 0.6465736031532288, "title": "Aliskiren: Drug information", "rep_snippet": "Dosing: Pediatric  Hypertension: Children ≥6 years of age and Adolescents: Oral: Initial:  <20 kg: Not recommended.  20 kg to 50 kg: 75 mg once daily (maximum: 150 mg/day). Note: Prior to initiation, correct hypovolemia…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6449225544929504, "bge_max": 0.6449225544929504, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Dosing: Pediatric  Partial-onset seizures (epilepsy) (monotherapy or adjunctive therapy): Children ≥4 years of age and Adolescents: Oral:  11 to 21 kg: Initial: 200 mg once daily; increase in weekly increments of no more…"}, {"doc_id": "simethicone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6427733302116394, "bge_max": 0.6427733302116394, "title": "Simethicone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Simethicone: Pediatric drug information\")  Gas retention: Oral:  Infants and Children <2 years or <11 kg: 20 mg 4 times daily after meals and at bedtime, as needed (max…"}, {"doc_id": "megestrol-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6423051357269287, "bge_max": 0.6423051357269287, "title": "Megestrol acetate: Drug information", "rep_snippet": "Administration  Oral: Shake suspension well before use.  The 625 mg/5 mL suspension may be administered without regard to meals."}, {"doc_id": "carglumic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6416409015655518, "bge_max": 0.6417548656463623, "title": "Carglumic acid: Drug information", "rep_snippet": "Dosing: Adult  Acute hyperammonemia: Oral: 100 to 250 mg/kg/day given in 2 or 4 divided doses (rounded to the nearest 100 mg); titrate to age-appropriate plasma ammonia levels. Concomitant adjunctive ammonia-lowering the…"}, {"doc_id": "imatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6413540244102478, "bge_max": 0.6413540244102478, "title": "Imatinib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Hematologic toxicity:  Chronic phase CML (initial dose 400 mg daily in adults or 340 mg/m2/day in children); ASM, MDS/MPD, and HES/CEL (initial dose 400 mg daily); or GIST (initial dose 4…"}, {"doc_id": "lidocaine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6409508585929871, "bge_max": 0.6409508585929871, "title": "Lidocaine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Antiarrhythmic (ACLS 2010; ACLS 2015):  VF or pulseless VT (after defibrillation attempts, CPR, and vasopressor administration), alternative to amiodarone: IV, intraosseous (IO): Initial: 1 to 1.5 mg/kg. I…"}, {"doc_id": "cefuroxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.640946090221405, "bge_max": 0.640946090221405, "title": "Cefuroxime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefuroxime: Pediatric drug information\")  Note: Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg bas…"}, {"doc_id": "amiloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6404557228088379, "bge_max": 0.6404557228088379, "title": "Amiloride: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amiloride: Pediatric drug information\")  Hypertension (off-label use): Children and Adolescents 1 to 17 years: Oral: 0.4 to 0.625 mg/kg/day (maximum: 20 mg daily) (NHBP…"}, {"doc_id": "cycloserine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6392775177955627, "bge_max": 0.6392775177955627, "title": "Cycloserine: Drug information", "rep_snippet": "Children and Adolescents <15 years of age weighing >40 kg or Adolescents ≥15 years of age: Oral: 10 to 15 mg/kg/day divided every 12 to 24 hours; usual dose 250 to 500 mg; maximum daily dose: 1,000 mg/day. Note: Patients…"}, {"doc_id": "atomoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6383863091468811, "bge_max": 0.6383863091468811, "title": "Atomoxetine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atomoxetine: Pediatric drug information\")  ADHD treatment: Oral: Note: Atomoxetine may be discontinued without the need for tapering dose.  Children ≥6 years and ≤70 kg…"}, {"doc_id": "morphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6381808519363403, "bge_max": 0.6381808519363403, "title": "Morphine: Drug information", "rep_snippet": "Demand dose: Usual initial: 0.02 mg/kg/dose; usual range: 0.01 to 0.03 mg/kg/dose  Lockout: Usual initial: 5 doses/hour  Lockout interval: Range: 6 to 8 minutes  Usual basal rate: 0 to 0.03 mg/kg/hour  Children ≥5 years…"}, {"doc_id": "magnesium-hydroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6378533840179443, "bge_max": 0.6378533840179443, "title": "Magnesium hydroxide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Magnesium hydroxide: Pediatric drug information\")  Antacid: OTC labeling: Oral:  Liquid: Magnesium hydroxide 400 mg/5 mL: Children ≥12 years: Refer to adult dosing.  Ta…"}, {"doc_id": "valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6368440389633179, "bge_max": 0.6368440389633179, "title": "Valsartan: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Valsartan: Pediatric drug information\")  Note: Due to increased bioavailability of extemporaneously prepared oral suspension (not commercially available), patients may…"}, {"doc_id": "ketotifen-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6367654204368591, "bge_max": 0.6367654204368591, "title": "Ketotifen (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  Atopic asthma (prophylactic treatment): Oral:  Infants and Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg/dose twice daily (maxim…"}, {"doc_id": "minoxidil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6363381743431091, "bge_max": 0.6363381743431091, "title": "Minoxidil (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Minoxidil (systemic): Pediatric drug information\")  Hypertension:  Children <12 years: Oral: Initial: 0.2 mg/kg once daily; maximum daily initial dose: 5 mg daily; titr…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.636243999004364, "bge_max": 0.636243999004364, "title": "Aprepitant: Drug information", "rep_snippet": "Capsules: Children ≥12 years, and Adolescents: Oral: 125 mg 1 hour prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3 (in combination with a 5-HT3 antagonist antiemetic and dexamethasone on day…"}, {"doc_id": "levetiracetam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6353078484535217, "bge_max": 0.6353078484535217, "title": "Levetiracetam: Drug information", "rep_snippet": "20 to 40 kg: Initial: 250 mg twice daily, increase every 2 weeks by 250 mg twice daily to the maximum recommended dose of 750 mg twice daily  >40 kg: Initial: 500 mg twice daily, increase every 2 weeks by 500 mg twice da…"}, {"doc_id": "procainamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.635200560092926, "bge_max": 0.635200560092926, "title": "Procainamide: Drug information", "rep_snippet": "Dosing: Adult  Dose must be individualized and titrated to patient response.  Ventricular arrhythmias:  IM: 50 mg/kg/day divided every 3 to 6 hours or 0.5 to 1 g every 4 to 8 hours (Koch-Weser, 1971)  IV:  Manufacturer’s…"}, {"doc_id": "ammonium-chloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6351370811462402, "bge_max": 0.6351370811462402, "title": "Ammonium chloride: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Injection, solution: Ammonium 5 mEq/mL and chloride 5 mEq/mL (20 mL) [equivalent to a…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6350110173225403, "bge_max": 0.6350110173225403, "title": "Doxycycline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Doxycycline: Pediatric drug information\")  Usual dosage range:  Immediate and delayed-release:  Children >8 years and Adolescents (<45 kg): Oral, IV: 2 to 4 mg/kg/day i…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6348395347595215, "bge_max": 0.6348395347595215, "title": "Amiodarone: Drug information", "rep_snippet": "Dosing: Adult  Note: Lower loading and maintenance doses are preferable in women and all patients with low body weight.  Ventricular arrhythmias:  Prevention of recurrent life-threatening ventricular arrhythmias (eg, VF…"}, {"doc_id": "alprazolam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.634732723236084, "bge_max": 0.634732723236084, "title": "Alprazolam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Alprazolam: Pediatric drug information\")  Anxiety (off-label use): Oral: Immediate release: Initial: 0.005 mg/kg/dose or 0.125 mg/dose 3 times/day; increase in incremen…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6346225738525391, "bge_max": 0.6346225738525391, "title": "Aluminum hydroxide and magnesium carbonate: Drug information", "rep_snippet": "Dosing: Pediatric  Antacid: Oral: Children ≥12 years and Adolescents: Liquid: Acid Gone (aluminum hydroxide 31.7 mg/magnesium carbonate 119.3 mg per 5 mL): 15 to 30 mL 4 times daily (maximum: 120 mL per 24 hours)"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6344389915466309, "bge_max": 0.6344389915466309, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Theophylline: Pediatric drug information\")  Note: Individualize dose based on steady-state serum concentrations; use ideal body weight (theophylline distributes poorly…"}, {"doc_id": "cytarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6341840028762817, "bge_max": 0.6341840028762817, "title": "Cytarabine: Drug information", "rep_snippet": "Administration  IV: Infuse standard dose therapy for AML (100 to 200 mg/m2/day) as a continuous infusion. Infuse high-dose therapy (off-label) over 1 to 3 hours (usually). Other rates have been used, refer to specific re…"}]}
{"qid": "Q1_noise+distractor-drug", "query": "Ear pain dx AOM; kid 5y (18kg). Need **amoxicillin** dosing & mL with 400/5 syrup — NOT amox-clav.", "base_qid": "Q1", "variant_type": "noise+distractor-drug", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 37.46133843360511, "bm25_max": 37.858753947899, "bge_top3": 0.682838241259257, "bge_max": 0.7061625719070435, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "ciprofloxacin-otic-drug-information", "bm25_top3": 32.35918973670458, "bm25_max": 32.35918973670458, "bge_top3": 0.6569474637508392, "bge_max": 0.6613996028900146, "title": "Ciprofloxacin (otic): Drug information", "rep_snippet": "Dosing: Adult  Acute otitis externa: Otic:  Solution 0.2%: Instill 0.25 mL (0.5 mg) solution (contents of 1 single-dose container) into affected ear twice daily for 7 days  Suspension 6%: Instill 0.2 mL (12 mg) suspensio…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 24.125964522236504, "bm25_max": 28.66205314191982, "bge_top3": 0.6704792181650797, "bge_max": 0.6919745206832886, "title": "Amoxicillin: Drug information", "rep_snippet": "Ear, nose, throat, genitourinary tract, or skin/skin structure infections: Note: IDSA guidelines recommend amoxicillin-clavulanate as preferred first-line treatment of acute bacterial rhinosinusitis (ABRS) (IDSA [Chow 20…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 28.273808454540962, "bm25_max": 28.273808454540962, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling.  CrCl <30 mL/minute: Use is not recommended per the manufacturer’s labeling although a decreased dose…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": 27.981854905155487, "bm25_max": 27.981854905155487, "bge_top3": null, "bge_max": null, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Geriatric  Reversible airflow obstruction, acute symptoms:  Loading dose: Oral (immediate release oral solution), IV: Refer to adult dosing.  Maintenance dose: IV: 0.3 mg/kg/hour; maximum: 400 mg/day unless serum…"}, {"doc_id": "pentoxifylline-drug-information", "bm25_top3": 27.54719703960953, "bm25_max": 27.54719703960953, "bge_top3": null, "bge_max": null, "title": "Pentoxifylline: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: CrCl <30 mL/minute: 400 mg once daily  The following guidelines have been used by some clinicians:  Aronoff, 2007: Adults:  CrCl >50 mL/minute: 400 mg every 8 to 12 hour…"}, {"doc_id": "guaifenesin-and-dextromethorphan-drug-information", "bm25_top3": 21.6739753779603, "bm25_max": 24.62284125459172, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and dextromethorphan: Drug information", "rep_snippet": "5-100 mg/5 mL (118 mL): $5.38  20-400 mg/20 mL (118 mL): $6.60  Liquid (Robitussin To Go Cgh/Chest DM Oral)  100-10 mg/5 mL (10 mL): $0.82  Liquid (Safe Tussin DM Oral)  100-10 mg/5 mL (120 mL): $5.26  Liquid (Trispec DM…"}, {"doc_id": "carbamide-peroxide-drug-information", "bm25_top3": 23.55547300121622, "bm25_max": 23.55547300121622, "bge_top3": 0.6646645665168762, "bge_max": 0.6646645665168762, "title": "Carbamide peroxide: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Solution, Mouth/Throat:  Gly-Oxide: 10% (15 mL, 60 mL) […"}, {"doc_id": "guaifenesin-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 14.038034363572088, "bm25_max": 20.830866003322363, "bge_top3": 0.6454843282699585, "bge_max": 0.6454843282699585, "title": "Guaifenesin, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Also refer to specific product labeling.  Cough/decongestant: Oral:  Liquid (Robitussin Peak Cold Multi-Symptom Cold): Guaifenesin 200 mg, dextromethorphan 20 mg, and phenylephrine 10 mg (10 mL) every 4 ho…"}, {"doc_id": "hydrocodone-and-guaifenesin-drug-information", "bm25_top3": 18.963225216469706, "bm25_max": 18.963225216469706, "bge_top3": null, "bge_max": null, "title": "Hydrocodone and guaifenesin: Drug information", "rep_snippet": "Dosing: Adult  Cough: Oral: Hydrocodone 5 mg/guaifenesin 400 mg (10 mL) every 4 to 6 hours (maximum: hydrocodone 30 mg/guaifenesin 2,400 mg [60 mL] per 24 hours)"}, {"doc_id": "guaifenesin-drug-information", "bm25_top3": 18.733578558815196, "bm25_max": 18.93343195368522, "bge_top3": null, "bge_max": null, "title": "Guaifenesin: Drug information", "rep_snippet": "Packet, Oral:  Mucinex For Kids: 50 mg (12 ea [DSC]) [contains aspartame]  Mucinex For Kids: 100 mg (12 ea) [contains aspartame; bubble-gum flavor]  Solution, Oral:  Q-Tussin: 100 mg/5 mL (118 mL [DSC], 240 mL [DSC], 473…"}, {"doc_id": "magnesium-hydroxide-drug-information", "bm25_top3": 17.97844855221878, "bm25_max": 18.03124438231305, "bge_top3": null, "bge_max": null, "title": "Magnesium hydroxide: Drug information", "rep_snippet": "Dosing: Adult  Antacid: OTC labeling: Oral:  Liquid: Magnesium hydroxide 400 mg/5 mL: 5 to 15 mL as needed up to 4 times/day; do not exceed 60 mL in 24 hours  Tablet, chewable: Magnesium hydroxide 311 mg/tablet: 2 to 4 t…"}, {"doc_id": "acetic-acid-and-hydrocortisone-otic-drug-information", "bm25_top3": 17.9454523409112, "bm25_max": 17.9454523409112, "bge_top3": null, "bge_max": null, "title": "Acetic acid and hydrocortisone otic: Drug information", "rep_snippet": "Dosing: Adult  Otitis externa (superficial): Otic: Instill 3 to 5 drops in affected ear(s) every 4 to 6 hours while cotton wick inserted; after cotton wick removed, instill 5 drops in affected ear(s) 3 or 4 times daily.…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 17.833562258796746, "bm25_max": 17.833562258796746, "bge_top3": null, "bge_max": null, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Pricing: US  Liquid (Mucinex Fast-Max Cold & Sinus Oral)  10-650-400 mg/20 mL (177 mL): $10.13  Liquid (Mucinex Fast-Max Oral)  10-650-400 mg/20 mL (180 mL): $11.27  Liquid (Mucinex Sinus-Max Congestion Oral)  10-650-400…"}, {"doc_id": "triprolidine-and-pseudoephedrine-drug-information", "bm25_top3": 17.810346986437104, "bm25_max": 17.810346986437104, "bge_top3": null, "bge_max": null, "title": "Triprolidine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Adult  Cold, allergy symptoms: Oral:  Liquid (triprolidine 0.938 mg and pseudoephedrine 10 mg per 1 mL): 2.67 mL every 6 hours (maximum: 4 doses [10.68 mL]/24 hours)  Syrup (triprolidine 1.25 mg and pseudoephedri…"}, {"doc_id": "oxycodone-and-ibuprofen-drug-information", "bm25_top3": 17.652291998439733, "bm25_max": 17.652291998439733, "bge_top3": null, "bge_max": null, "title": "Oxycodone and ibuprofen: Drug information", "rep_snippet": "Dosing: Adult  Pain: Oral: Oxycodone 5 mg/ibuprofen 400 mg (1 tablet) every 6 hours as needed (maximum: oxycodone 20 mg/ibuprofen 1,600 mg [4 tablets] per 24 hours); do not take for longer than 7 days"}, {"doc_id": "brompheniramine-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": 10.447015775389751, "bm25_max": 10.447015775389751, "bge_top3": null, "bge_max": null, "title": "Brompheniramine, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Liquid, Oral:  Brotapp-DM: Brompheniramine maleate 1 mg,…"}, {"doc_id": "aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information", "bm25_top3": 7.2377915518577245, "bm25_max": 8.233037695329674, "bge_top3": null, "bge_max": null, "title": "Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Liquid, Oral:  Aldroxicon I: Aluminum hydroxide 200 mg,…"}, {"doc_id": "promethazine-and-codeine-drug-information", "bm25_top3": 7.620970689450143, "bm25_max": 7.620970689450143, "bge_top3": null, "bge_max": null, "title": "Promethazine and codeine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Syrup, oral: Promethazine hydrochloride 6.25 mg and codeine phosphate 10 mg per 5 mL…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": 7.422221165238049, "bm25_max": 7.422221165238049, "bge_top3": null, "bge_max": null, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Suspension, Oral:  Entre-Cough Tannate: Guaifenesin 175 mg, pseudoephedrine hydrochloride 30 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (473 mL [DSC]) [contains aspartame, fd&c red #40, methylparaben, sodium be…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": 7.073795634040099, "bm25_max": 7.073795634040099, "bge_top3": null, "bge_max": null, "title": "Zidovudine: Drug information", "rep_snippet": "Hepatic: Increased serum transaminases (1% to 3%)  Neuromuscular & skeletal: Weakness (9%), arthralgia (≥5%), musculoskeletal pain (≥5%), myalgia (≥5%)  Otic: Auricular edema (≤7%), ear redness (≤7%), ear residue, debris…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 6.932627058663936, "bm25_max": 6.932627058663936, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Flebogamma DIF: 0.5 g/10 mL (10 mL); 5 g/50 mL (50 mL); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 20 g/400 mL (400 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL) [contains polyethylene glycol]  Gam…"}, {"doc_id": "promethazine-and-dextromethorphan-drug-information", "bm25_top3": 6.767420064973756, "bm25_max": 6.767420064973756, "bge_top3": null, "bge_max": null, "title": "Promethazine and dextromethorphan: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Syrup: Promethazine hydrochloride 6.25 mg and dextromethorphan hydrobromide 15 mg per…"}, {"doc_id": "ketotifen-systemic-drug-information", "bm25_top3": 5.591974413579049, "bm25_max": 5.591974413579049, "bge_top3": null, "bge_max": null, "title": "Ketotifen (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Dietary Considerations  Syrup contains carbohydrate 4 g/5 mL."}, {"doc_id": "diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 4.028943318819373, "bm25_max": 4.028943318819373, "bge_top3": null, "bge_max": null, "title": "Diphenhydramine and phenylephrine: Drug information", "rep_snippet": "Pricing: US  Liquid (Dimetapp Night Cold/Congestion Oral)  6.25-2.5 mg/5 mL (118 mL): $5.38  Misc (Sudafed PE Day & Night Oral)  25-10 & 10 mg (20): $6.08  Solution (Benadryl-D Allergy/Sinus Child Oral)  12.5-5 mg/5 mL (…"}, {"doc_id": "mecasermin-recombinant-human-insulin-like-growth-factor-i-drug-information", "bm25_top3": 3.817827386348302, "bm25_max": 3.817827386348302, "bge_top3": null, "bge_max": null, "title": "Mecasermin (recombinant human insulin-like growth factor I): Drug information", "rep_snippet": "Adverse Reactions  ≥5%:  Cardiovascular: Heart murmur  Central nervous system: Dizziness, headache, seizure  Endocrine & metabolic: Hypoglycemia (42%), lipohypertrophy (injection site), thymus hypertrophy  Gastrointestin…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 3.787117836401208, "bm25_max": 3.787117836401208, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Pricing: US  Solution (Sulfamethoxazole-Trimethoprim Intravenous)  400-80 mg/5 mL (5 mL): $7.53  Suspension (Sulfamethoxazole-Trimethoprim Oral)  200-40 mg/5 mL (473 mL): $215.40  Suspension (Sulfatrim Pediatric Oral)  2…"}, {"doc_id": "ciprofloxacin-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6774215698242188, "bge_max": 0.6774215698242188, "title": "Ciprofloxacin and dexamethasone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin and dexamethasone: Pediatric drug information\")  Acute otitis externa: Infants ≥6 months of age, Children, and Adolescents: Otic: Refer to adult dosing.…"}, {"doc_id": "acetic-acid-otic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6690993905067444, "bge_max": 0.6690993905067444, "title": "Acetic acid (otic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Acetic acid (otic): Pediatric drug information\")  Otitis externa: Children ≥3 years and Adolescents: Otic: Insert saturated wick; keep moist 24 hours by adding 3 to 5 d…"}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6684343814849854, "bge_max": 0.6684343814849854, "title": "Hydroxyzine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydroxyzine: Pediatric drug information\")  Antiemetic: IM: 1.1 mg/kg/dose  Anxiety: Oral:  Children <6 years: 50 mg/day in divided doses  Children ≥6 years and Adolesce…"}, {"doc_id": "oxaprozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6657214164733887, "bge_max": 0.6657214164733887, "title": "Oxaprozin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oxaprozin: Pediatric drug information\")  Juvenile idiopathic arthritis (JIA): Oral:  Note: Individualize dosage to lowest effective dose for the shortest duration to mi…"}, {"doc_id": "neomycin-colistin-hydrocortisone-and-thonzonium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6549394130706787, "bge_max": 0.6643105149269104, "title": "Neomycin, colistin, hydrocortisone, and thonzonium: Drug information", "rep_snippet": "Dosing: Pediatric  Otic infections: Children ≥1 year and Adolescents: Otic: Instill 4 drops in affected ear(s) 3 or 4 times daily  Note: Duration of use should be limited to 10 days. Use calibrated dropper provided in pa…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6594468355178833, "bge_max": 0.6594468355178833, "title": "Oxacillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oxacillin: Pediatric drug information\")  Note: May contain a significant amount of sodium; consult product specific labeling for amount.  General dosing, susceptible in…"}, {"doc_id": "dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.658584713935852, "bge_max": 0.658584713935852, "title": "Dextromethorphan and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  General dosing guidelines. Also refer to specific product labeling.  Cough/decongestant: Oral: Liquid (dextromethorphan 5 mg and phenylephrine 2.5 mg per 5 mL):  Children 4 to 5 years: 5 mL every 4 hou…"}, {"doc_id": "cefuroxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6577138304710388, "bge_max": 0.6577138304710388, "title": "Cefuroxime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefuroxime: Pediatric drug information\")  Note: Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg bas…"}, {"doc_id": "ciprofloxacin-and-fluocinolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656879186630249, "bge_max": 0.656879186630249, "title": "Ciprofloxacin and fluocinolone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin and fluocinolone: Pediatric drug information\")  Acute otitis media in patients with tympanostomy tubes: Infants ≥6 months, Children, and Adolescents: Inst…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6566168665885925, "bge_max": 0.6566168665885925, "title": "Ampicillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ampicillin: Pediatric drug information\")  Usual dosage range: Infants, Children, and Adolescents:  Oral: 50 to 100 mg/kg/day divided every 6 hours (maximum: 2 to 4 g/da…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6556065082550049, "bge_max": 0.6556065082550049, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Erythromycin and sulfisoxazole (United States: Not available): Pediatric drug information\")  Note: All erythromycin and sulfisoxazole products (brand and generic) have…"}, {"doc_id": "m-cresyl-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6553744077682495, "bge_max": 0.6553744077682495, "title": "m-Cresyl acetate: Drug information", "rep_snippet": "Dosing: Adult  Otitis externa: Otic: Instill 3 to 5 drops into the affected ear(s) 3 times daily (maximum duration: 14 days). Note: Manufacturer's labeling recommends a dose reduction in children, but does not provide sp…"}, {"doc_id": "vitamin-c-ascorbic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6545969247817993, "bge_max": 0.6545969247817993, "title": "Vitamin C (ascorbic acid): Drug information", "rep_snippet": "Administration  Oral administration is preferred unless malabsorption is suspected. IM administration is preferred when the parenteral route is required. Oral products may be administered with food.  Injection: For IM (p…"}, {"doc_id": "polysaccharide-iron-complex-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6538973450660706, "bge_max": 0.6538973450660706, "title": "Polysaccharide-iron complex: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Polysaccharide-iron complex: Pediatric drug information\")  Iron deficiency anemia: Oral:  Infants and Children <4 years: 15 mg daily  Children ≥12 years: 50 mg daily"}, {"doc_id": "oxycodone-and-aspirin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6535335779190063, "bge_max": 0.6535335779190063, "title": "Oxycodone and aspirin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oxycodone and aspirin: Pediatric drug information\")  Analgesic: Oral (dose based on total oxycodone content): Oxycodone 0.1 to 0.2 mg/kg/dose (maximum oxycodone: 5 mg/d…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6531895399093628, "bge_max": 0.6531895399093628, "title": "Hyoscyamine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hyoscyamine: Pediatric drug information\")  Note: Oral dosage forms (drops and elixirs) are different (ie, 0.125 mg/mL [drops] and 0.125 mg/5 mL [elixir]); precaution sh…"}, {"doc_id": "chlordiazepoxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.649316132068634, "bge_max": 0.6530470848083496, "title": "Chlordiazepoxide: Drug information", "rep_snippet": "Dosing: Pediatric  Anxiety: Oral:  Children ≥6 years and Adolescents: Usual dose: 5 mg 2 to 4 times daily. Dose may be increased to 10 mg 2 to 3 times daily in some patients, if necessary."}, {"doc_id": "nitrazepam-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6523211002349854, "bge_max": 0.6523211002349854, "title": "Nitrazepam (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Myoclonic seizures: Infants and Children ≤30 kg: Oral: Usual dosage: 0.3 to 1 mg/kg/day in 3 equally divided doses; if doses are not divided equally, administer larger dose at bedtime. Note: Therapy sh…"}, {"doc_id": "phenylephrine-pyrilamine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6500346660614014, "bge_max": 0.6500346660614014, "title": "Phenylephrine, pyrilamine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Relief of cough, congestion: Oral: Note: All dosing is presented in terms of phenylephrine hydrochloride, pyrilamine maleate, and dextromethorphan hydrobromide.  Children 6-11 years: Liquid:  Phenyleph…"}, {"doc_id": "dextromethorphan-and-menthol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6496289968490601, "bge_max": 0.6496289968490601, "title": "Dextromethorphan and menthol: Drug information", "rep_snippet": "Dosing: Pediatric  Cough suppressant/sore throat: Oral:  Children <6 years: Not for OTC use.  Children 6 to <12 years: One lozenge (dextromethorphan 5 mg/menthol 5 mg per lozenge) dissolved in mouth. May repeat every 4 h…"}, {"doc_id": "diflunisal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.649341344833374, "bge_max": 0.649341344833374, "title": "Diflunisal: Drug information", "rep_snippet": "Dosing: Pediatric  Osteoarthritis/Rheumatoid arthritis: Adolescents ≥12 years: Oral: Refer to adult dosing  Pain, mild to moderate: Adolescents ≥12 years: Oral: Refer to adult dosing"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6493247747421265, "bge_max": 0.6493247747421265, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Acyclovir (systemic): Pediatric drug information\")  Note: Obese patients should be dosed using ideal body weight. Parenteral IV doses >15 mg/kg/dose or 500 mg/m2 may be…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6490238308906555, "bge_max": 0.6490238308906555, "title": "Linezolid: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Linezolid: Pediatric drug information\")  Usual dosage: Oral, IV:  Children ≤11 years: 10 mg/kg (maximum: 600 mg/dose) every 8 hours  Children ≥12 years and Adolescents:…"}, {"doc_id": "palivizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6486161947250366, "bge_max": 0.6486161947250366, "title": "Palivizumab: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Palivizumab: Pediatric drug information\")  Respiratory syncytial virus prophylaxis: IM: Infants and children <2 years: 15 mg/kg, monthly throughout RSV season (first do…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6476078033447266, "bge_max": 0.6476078033447266, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to 11 years: Vicks DayQuil Cold & Flu Multi-Symptom Liquid: Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maxim…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6467325091362, "bge_max": 0.6467325091362, "title": "Amlodipine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amlodipine: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents: Oral: 2.5 to 5 mg once daily"}, {"doc_id": "meloxicam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6465442180633545, "bge_max": 0.6465442180633545, "title": "Meloxicam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Meloxicam: Pediatric drug information\")  Juvenile rheumatoid arthritis: Oral:  Note: Capsules are not interchangeable with other formulations of oral meloxicam even if…"}, {"doc_id": "levomepromazine-methotrimeprazine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.646510660648346, "bge_max": 0.646510660648346, "title": "Levomepromazine (methotrimeprazine) (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Note: Patients receiving parenteral therapy should be switched to oral therapy as soon as possible. If pronounced sedation occurs, administer smaller doses during the day and higher doses at night.  Or…"}, {"doc_id": "atropine-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6461387872695923, "bge_max": 0.6461387872695923, "title": "Atropine (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atropine (ophthalmic): Pediatric drug information\")  Amblyopia, healthy eye penalization: Ophthalmic: Solution:  Infants ≥3 months and Children <3 years: Instill 1 drop…"}, {"doc_id": "disopyramide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.645839512348175, "bge_max": 0.645839512348175, "title": "Disopyramide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Disopyramide: Pediatric drug information\")  Arrhythmias: Oral: Immediate release:  <1 year: 10 to 30 mg/kg/24 hours in 4 divided doses  1 to 4 years: 10 to 20 mg/kg/24…"}, {"doc_id": "clotrimazole-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6452295780181885, "bge_max": 0.6452295780181885, "title": "Clotrimazole (oral): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Clotrimazole (oral): Pediatric drug information \")  Oropharyngeal candidiasis (treatment): Children ≥3 years and Adolescents: Refer to adult dosing."}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6451885104179382, "bge_max": 0.6451885104179382, "title": "Oseltamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oseltamivir: Pediatric drug information\")  Community-acquired pneumonia (influenza suspected or confirmed) (off-label use) (IDSA [Bradley 2011]): Oral:  Prophylaxis:  I…"}, {"doc_id": "aspirin-citric-acid-and-sodium-bicarbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6447576284408569, "bge_max": 0.6447576284408569, "title": "Aspirin, citric acid, and sodium Bicarbonate: Drug information", "rep_snippet": "Dosing: Pediatric  Antacid/pain: Children ≥12 years and Adolescents: Oral: Refer to adult dosing"}, {"doc_id": "dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6445060968399048, "bge_max": 0.6445060968399048, "title": "Dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dextromethorphan: Pediatric drug information\")  Cough suppressant: Oral:  <4 years: Not for OTC use  4 to 6 years (syrup): 2.5 to 7.5 mg every 4 to 8 hours; extended re…"}]}
{"qid": "Q1_spelling+unicode-confusable", "query": "5yo (18 kg) akut otitis media — calc am0xicillin mg/kg/day & mL for 400 mg∕5 mL.", "base_qid": "Q1", "variant_type": "spelling+unicode-confusable", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 49.63225869060093, "bm25_max": 51.068676524082, "bge_top3": 0.7446501652399699, "bge_max": 0.7931092977523804, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "ceftibuten-drug-information", "bm25_top3": 27.9977869726624, "bm25_max": 31.29293208756276, "bge_top3": 0.7071612477302551, "bge_max": 0.7170287370681763, "title": "Ceftibuten: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftibuten: Pediatric drug information\")  Acute bacterial otitis media:  Infants and Children 6 months to <12 years: Oral: 9 mg/kg/dose once daily (maximum dose: 400 mg…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 26.896961312471625, "bm25_max": 29.615181456702437, "bge_top3": 0.7266989350318909, "bge_max": 0.7525409460067749, "title": "Amoxicillin: Drug information", "rep_snippet": "eradication: Children and Adolescents: Oral: 50 mg/kg/day in 2 divided doses for 10 to 14 days; maximum daily dose: 2,000 mg/day. Administer in combination with a proton pump inhibitor or bismuth subsalicylate and at lea…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 26.796215242685122, "bm25_max": 28.763710613278974, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": 28.341785602339755, "bm25_max": 28.341785602339755, "bge_top3": null, "bge_max": null, "title": "Cefixime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefixime: Pediatric drug information\")  Note: Suprax 400 mg tablets have been discontinued in the US for more than 1 year.  Susceptible infections: Oral: Note: Otitis m…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 28.1050408353021, "bm25_max": 28.1050408353021, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefdinir: Pediatric drug information\")  Infants ≥6 months and Children:  Acute bacterial otitis media, pharyngitis/tonsillitis: Oral: 7 mg/kg/dose twice daily for 5 to…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 27.122230710882892, "bm25_max": 27.7207464107817, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Repeat dose of 0.2 mL/kg every 2 months for anticipated risk of exposure ≥2 months  Postexposure prophylaxis: 0.1 mL/kg given within 14 days of exposure and/or prior to manifestation of disease; not needed if at least 1…"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": 27.58502361291241, "bm25_max": 27.58502361291241, "bge_top3": null, "bge_max": null, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftaroline: Pediatric drug information\")  Pneumonia, community acquired: IV:  Infants ≥2 months and Children <2 years: 8 mg/kg/dose every 8 hours for 5 to 14 days  Chi…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 26.91431498185313, "bm25_max": 26.91431498185313, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "didanosine-drug-information", "bm25_top3": 26.897645104224836, "bm25_max": 26.897645104224836, "bge_top3": null, "bge_max": null, "title": "Didanosine: Drug information", "rep_snippet": "Dosing: Adult  Treatment of HIV-1 infection: Oral:  Dosing based on patient weight:  Pediatric powder for oral solution:  <60 kg: 125 mg twice daily (preferred) or 250 mg once daily  ≥60 kg: 200 mg twice daily (preferred…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": 25.515883036494234, "bm25_max": 26.469455823462148, "bge_top3": null, "bge_max": null, "title": "Hyoscyamine: Drug information", "rep_snippet": "Tablets (regular release [Levsin], sublingual [Levsin/SL], dispersible [ED-SPAZ, NuLev]): 0.0625 to 0.125 mg every 4 hours or as needed; maximum: 0.75 mg/day  Drops (Hyosyne [0.125 mg/mL]): 0.03125 mg (0.25 mL) to 0.125…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": 26.308618433427604, "bm25_max": 26.308618433427604, "bge_top3": null, "bge_max": null, "title": "Amikacin: Drug information", "rep_snippet": "GFR 30 to 50 mL/minute/1.73 m2: Administer every 12 to 18 hours  GFR 10 to 29 mL/minute/1.73 m2: Administer every 18 to 24 hours  GFR <10 mL/minute/1.73 m2: Administer every 48 to 72 hours  Intermittent hemodialysis: 5 m…"}, {"doc_id": "propranolol-drug-information", "bm25_top3": 26.1012531919706, "bm25_max": 26.1012531919706, "bge_top3": null, "bge_max": null, "title": "Propranolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Propranolol: Pediatric drug information\")  Proliferating infantile hemangioma (Hemangeol): Infants ≥2 kg: Oral: Note: Initiate treatment at age 5 weeks to 5 months; dos…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 25.77520203159476, "bm25_max": 25.77520203159476, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "14 to <18.5 kg: 250 mg every 6 hours  18.5 to <23 kg: 300 mg every 6 hours  23 to <32 kg: 350 mg every 6 hours  32 to <41 kg: 400 mg every 6 hours  41 to ≤50 kg: 450 mg every 6 hours  >50 kg: 500 mg every 6 hours  Altern…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 25.486210038873402, "bm25_max": 25.486210038873402, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 25.1074872532329, "bm25_max": 25.482079824471555, "bge_top3": null, "bge_max": null, "title": "Amiodarone: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Solution, Intravenous, as hydrochloride:  Nexterone: 150…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 25.459126421463232, "bm25_max": 25.459126421463232, "bge_top3": 0.7133857607841492, "bge_max": 0.7133857607841492, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Erythromycin and sulfisoxazole (United States: Not available): Pediatric drug information\")  Note: All erythromycin and sulfisoxazole products (brand and generic) have…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 25.144971098830567, "bm25_max": 25.144971098830567, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 24.886101719225877, "bm25_max": 24.886101719225877, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 24.81907665901315, "bm25_max": 24.81907665901315, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "omalizumab-drug-information", "bm25_top3": 24.655881489375663, "bm25_max": 24.722121050186892, "bge_top3": null, "bge_max": null, "title": "Omalizumab: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Omalizumab: Pediatric drug information\")  Asthma:  Children 6 to <12 years: SubQ:  Pretreatment serum IgE ≥30 to 100 units/mL:  20 to 40 kg: 75 mg every 4 weeks  >40 to…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": 24.504852050779007, "bm25_max": 24.504852050779007, "bge_top3": null, "bge_max": null, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Immune thrombocytopenia, refractory (off-label use): Oral: 5 mg/kg/day in 2 divided doses (every 12 hours) for 6 days, followed by 2.5 to 3 mg/kg/day (titrate to serum levels of 100 to 200 ng/mL); time to response in cli…"}, {"doc_id": "deferiprone-drug-information", "bm25_top3": 24.39594695736958, "bm25_max": 24.39594695736958, "bge_top3": null, "bge_max": null, "title": "Deferiprone: Drug information", "rep_snippet": "Dosing: Adult  Note: Round dose to the nearest 250 mg (or 1/2 tablet) or 2.5 mL (oral solution). If serum ferritin falls consistently below 500 mcg/L, consider temporary treatment interruption.  Transfusional iron overlo…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 24.370308846319567, "bm25_max": 24.370308846319567, "bge_top3": 0.7240316867828369, "bge_max": 0.7240316867828369, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Acute otitis media (off-label use): Oral: 30 to 40 mg/kg/day in 3 divided doses for 5 to 10 days. Use with or without concomitant third-generation cephalosporin for failure of initial antibiotic therapy; use with a third…"}, {"doc_id": "calcium-carbonate-and-magnesium-hydroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.708595871925354, "bge_max": 0.708595871925354, "title": "Calcium carbonate and magnesium hydroxide: Drug information", "rep_snippet": "Dosing: Adult  Antacid: Oral:  Chewable tablet: Calcium carbonate 700 mg/magnesium hydroxide 300 mg: Chew 2 to 4 tablets 4 times daily (maximum: 8 tablets per 24 hours)  Liquid: Calcium carbonate 400 mg/magnesium hydroxi…"}, {"doc_id": "magnesium-oxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7079486846923828, "bge_max": 0.7079486846923828, "title": "Magnesium oxide: Drug information", "rep_snippet": "Dosing: Adult  OTC labeling:  Antacid (dosage in terms of magnesium oxide salt): Oral: One tablet (400 mg) twice daily; maximum: 2 tablets (800 mg)/24 hours  Dietary supplement (dosage in terms of magnesium oxide salt):…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.70729660987854, "bge_max": 0.70729660987854, "title": "Aluminum hydroxide and magnesium carbonate: Drug information", "rep_snippet": "Dosing: Pediatric  Antacid: Oral: Children ≥12 years and Adolescents: Liquid: Acid Gone (aluminum hydroxide 31.7 mg/magnesium carbonate 119.3 mg per 5 mL): 15 to 30 mL 4 times daily (maximum: 120 mL per 24 hours)"}, {"doc_id": "calcium-carbonate-and-simethicone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7023488879203796, "bge_max": 0.7071129083633423, "title": "Calcium carbonate and simethicone: Drug information", "rep_snippet": "Dosing: Pediatric  Antacid: Oral:  Children ≥12 years and Adolescents:  Calcium carbonate 750 mg/simethicone 80 mg: Refer to adult dosing.  Calcium carbonate 750 mg/simethicone 250 mg: Refer to adult dosing.  Calcium car…"}, {"doc_id": "calcium-glubionate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7067717909812927, "bge_max": 0.7067717909812927, "title": "Calcium glubionate: Drug information", "rep_snippet": "Dosing: Adult  Dietary supplement: Oral: Note: Each 5 mL contains elemental calcium 115 mg: 15 mL 3 times daily or 15 mL 4 times daily (pregnancy/lactating)"}, {"doc_id": "calcium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7042496800422668, "bge_max": 0.7042496800422668, "title": "Calcium carbonate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Calcium carbonate: Pediatric drug information\")  Note: One gram of calcium carbonate is equal to 400 mg of elemental calcium.  Dosage is in terms of calcium carbonate,…"}, {"doc_id": "magnesium-hydroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6954048573970795, "bge_max": 0.7025889158248901, "title": "Magnesium hydroxide: Drug information", "rep_snippet": "Dosing: Adult  Antacid: OTC labeling: Oral:  Liquid: Magnesium hydroxide 400 mg/5 mL: 5 to 15 mL as needed up to 4 times/day; do not exceed 60 mL in 24 hours  Tablet, chewable: Magnesium hydroxide 311 mg/tablet: 2 to 4 t…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-hydroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7016946077346802, "bge_max": 0.7016946077346802, "title": "Aluminum hydroxide and magnesium hydroxide: Drug information", "rep_snippet": "Dosing: Adult  Antacid: Oral: Liquid: Aluminum hydroxide 200 mg/magnesium hydroxide 200 mg per 5 mL: 10 to 20 mL 4 times daily (maximum: 80 mL per 24 hours)"}, {"doc_id": "ciprofloxacin-otic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6992057859897614, "bge_max": 0.7015228867530823, "title": "Ciprofloxacin (otic): Drug information", "rep_snippet": "Dosing: Adult  Acute otitis externa: Otic:  Solution 0.2%: Instill 0.25 mL (0.5 mg) solution (contents of 1 single-dose container) into affected ear twice daily for 7 days  Suspension 6%: Instill 0.2 mL (12 mg) suspensio…"}, {"doc_id": "calcium-citrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7005008459091187, "bge_max": 0.7005008459091187, "title": "Calcium citrate: Drug information", "rep_snippet": "Dosing: Adult  OTC labeling: Dietary supplementation: Oral: 200 mg to 4 g (as elemental calcium) daily in 1 to 3 divided doses"}, {"doc_id": "acetic-acid-otic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6998783349990845, "bge_max": 0.6998783349990845, "title": "Acetic acid (otic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Acetic acid (otic): Pediatric drug information\")  Otitis externa: Children ≥3 years and Adolescents: Otic: Insert saturated wick; keep moist 24 hours by adding 3 to 5 d…"}, {"doc_id": "rupatadine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6992707252502441, "bge_max": 0.6992707252502441, "title": "Rupatadine (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Allergic rhinitis, chronic spontaneous urticaria: Oral:  Children ≥2 to <12 years:  10 kg to 25 kg: 2.5 mg once daily (maximum: 2.5 mg/day).  >25 kg: 5 mg once daily (maximum: 5 mg/day).  Children ≥12…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6990714073181152, "bge_max": 0.6990714073181152, "title": "Clarithromycin: Drug information", "rep_snippet": "Primary prophylaxis: 7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily  Secondary prophylaxis: 7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily, plus ethambutol, with or without rifabutin  Treatment: 7.5-15 mg/kg/dose (…"}, {"doc_id": "ciprofloxacin-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.698577880859375, "bge_max": 0.698577880859375, "title": "Ciprofloxacin and dexamethasone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin and dexamethasone: Pediatric drug information\")  Acute otitis externa: Infants ≥6 months of age, Children, and Adolescents: Otic: Refer to adult dosing.…"}, {"doc_id": "calcium-lactate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6982591152191162, "bge_max": 0.6982591152191162, "title": "Calcium lactate: Drug information", "rep_snippet": "Dosing: Adult  OTC labeling: Dietary supplement: Oral: 252 mg (as elemental calcium) daily"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6974278688430786, "bge_max": 0.6974278688430786, "title": "Oxacillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oxacillin: Pediatric drug information\")  Note: May contain a significant amount of sodium; consult product specific labeling for amount.  General dosing, susceptible in…"}, {"doc_id": "ciprofloxacin-and-fluocinolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6961016654968262, "bge_max": 0.6961016654968262, "title": "Ciprofloxacin and fluocinolone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin and fluocinolone: Pediatric drug information\")  Acute otitis media in patients with tympanostomy tubes: Infants ≥6 months, Children, and Adolescents: Inst…"}, {"doc_id": "leflunomide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.695438027381897, "bge_max": 0.695438027381897, "title": "Leflunomide: Drug information", "rep_snippet": "Dosing: Pediatric  Juvenile idiopathic arthritis (off-label use) (Silverman 2005): Children ≥3 years and Adolescents: Oral:  <20 kg: 100 mg as a single dose followed by 10 mg every other day  20 kg to 40 kg: 100 mg once…"}, {"doc_id": "choline-magnesium-trisalicylate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6953665018081665, "bge_max": 0.6953665018081665, "title": "Choline magnesium trisalicylate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Choline magnesium trisalicylate: Pediatric drug information\")  Note: Dosing is based on salicylate content. Individualize dose based on response; may require 2 to 3 wee…"}, {"doc_id": "levocetirizine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6932878494262695, "bge_max": 0.6932878494262695, "title": "Levocetirizine: Drug information", "rep_snippet": "Dosing: Adult  Chronic idiopathic urticaria: Oral: 5 mg once daily (in the evening); some patients may experience relief of symptoms with 2.5 mg once daily. In one clinical trial, the titrated use of higher doses (up to…"}, {"doc_id": "aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6932207345962524, "bge_max": 0.6932207345962524, "title": "Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information", "rep_snippet": "Dosing: Adult  Antacid/antigas: Oral:  Products containing aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg per tablet: 1 to 4 tablets 4 times daily; may also take as needed, up to 12 to 16 ta…"}, {"doc_id": "oxandrolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6915671825408936, "bge_max": 0.6915671825408936, "title": "Oxandrolone: Drug information", "rep_snippet": "Dosing: Geriatric  Weight gain (adjunct): Oral: 5 mg twice daily"}, {"doc_id": "magnesium-l-aspartate-hydrochloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6915572881698608, "bge_max": 0.6915572881698608, "title": "Magnesium L-aspartate hydrochloride: Drug information", "rep_snippet": "Dosing: Adult  Dietary supplement (dosage in terms of magnesium-L-aspartate hydrochloride salt): OTC labeling: Oral: Two tablets daily or 1 packet up to 3 times daily"}, {"doc_id": "entecavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6897757053375244, "bge_max": 0.6897757053375244, "title": "Entecavir: Drug information", "rep_snippet": ">30 kg: 1 mg once daily (oral solution or tablet)"}, {"doc_id": "demeclocycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6894891858100891, "bge_max": 0.6894891858100891, "title": "Demeclocycline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Demeclocycline: Pediatric drug information\")  Susceptible infections: Oral: Children >8 years and Adolescents: 7 to 13 mg/kg/day (maximum: 600 mg/day) divided every 6-1…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6884472966194153, "bge_max": 0.6884472966194153, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Dosing: Pediatric  Juvenile idiopathic arthritis: Children and Adolescents ≥12 years and weight ≥38 kg: Oral:  38 to <50 kg: One tablet (naproxen 375 mg/esomeprazole 20 mg) twice daily  >50 kg: One tablet (naproxen 375 m…"}, {"doc_id": "magnesium-gluconate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6880699992179871, "bge_max": 0.6880699992179871, "title": "Magnesium gluconate: Drug information", "rep_snippet": "Dosing: Adult  OTC labeling: Dietary supplement: Oral: 550 mg (30 mg as elemental magnesium) once or twice daily"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6877870559692383, "bge_max": 0.6877870559692383, "title": "Ceftriaxone: Drug information", "rep_snippet": "Neurologic: 50 to 75 mg/kg once daily (maximum: 2,000 mg) for 14 days (Halperin 2007)  Meningitis: 50 to 75 mg/kg once daily (maximum: 2,000 mg) for 14 to 21 days (Red Book [AAP 2015])  Recurrent arthritis: 50 to 75 mg/k…"}, {"doc_id": "polycarbophil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6877643465995789, "bge_max": 0.6877643465995789, "title": "Polycarbophil: Drug information", "rep_snippet": "Dosing: Adult  Constipation or diarrhea: General dosing guidelines (OTC labeling): Oral: 1250 mg calcium polycarbophil 1-4 times/day"}, {"doc_id": "neomycin-polymyxin-b-and-hydrocortisone-otic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.687616229057312, "bge_max": 0.687616229057312, "title": "Neomycin, polymyxin B, and hydrocortisone (otic): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution, Otic:  Generic: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortiso…"}]}
{"qid": "Q2_abbr+unitswap", "query": "12 kg child fever—acetaminophen (paracetamol) dose mg/kg per dose + mL for 160 mg/5 mL?", "base_qid": "Q2", "variant_type": "abbr+unitswap", "candidates": [{"doc_id": "acetaminophen-paracetamol-and-codeine-drug-information", "bm25_top3": 54.85067154933804, "bm25_max": 61.03784868991456, "bge_top3": 0.6606162190437317, "bge_max": 0.6606162190437317, "title": "Acetaminophen (paracetamol) and codeine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Acetaminophen (paracetamol) and codeine: Pediatric drug information\")  Note: The FDA has recommended that codeine not be used in pediatric patients <12 years of age and…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information", "bm25_top3": 49.58103005200155, "bm25_max": 56.58340005702523, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), dextromethorphan, and doxylamine: Drug information", "rep_snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Cold and flu…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 54.15864118477127, "bm25_max": 54.15864118477127, "bge_top3": null, "bge_max": null, "title": "Streptomycin: Drug information", "rep_snippet": "Tuberculosis:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: 12 to 15 mg/kg/dose (maximum dose: 1 g) 2 to 3 times weekly  End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): 12 t…"}, {"doc_id": "acetaminophen-paracetamol-caffeine-and-dihydrocodeine-drug-information", "bm25_top3": 53.68294536204322, "bm25_max": 53.68294536204322, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), caffeine, and dihydrocodeine: Drug information", "rep_snippet": "Dosing: Adult  Pain management: Oral:  Capsule (acetaminophen 320.5 mg/caffeine 30 mg/dihydrocodeine bitartrate 16 mg): Two capsules every 4 hours as needed; adjust dose based on severity of pain (maximum dose: 10 capsul…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 52.23988484245608, "bm25_max": 52.23988484245608, "bge_top3": 0.6663118898868561, "bge_max": 0.6701679229736328, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Cold and flu…"}, {"doc_id": "oxycodone-and-acetaminophen-paracetamol-drug-information", "bm25_top3": 50.67020342197359, "bm25_max": 50.67020342197359, "bge_top3": null, "bge_max": null, "title": "Oxycodone and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oxycodone and acetaminophen (paracetamol): Pediatric drug information\")  Note: Initial dose is based on the oxycodone content; however, the maximum daily dose is based…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 45.05170910385078, "bm25_max": 49.61606851101145, "bge_top3": 0.6659739017486572, "bge_max": 0.683568000793457, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Dimetapp Children's Multi-Symptom Cold & Flu: Acetaminophen 160 mg, diphenhydramine hydrochloride 6.25 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [alcohol free; contains edetate disodium, menthol, polye…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 49.01049158743254, "bm25_max": 49.01049158743254, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Infants and Children <2 years (off-label): IV, Oral (oral suspension): Initial: 9 mg/kg/dose every 12 hours followed by monitoring of serum trough concentrations typically initiated after 3 to 5 days; adjust dose to achi…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 45.567636203111505, "bm25_max": 46.86558226238921, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 43.32338941112283, "bm25_max": 46.58802066858949, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": 43.447758129971085, "bm25_max": 46.4059205558479, "bge_top3": 0.6694328387578329, "bge_max": 0.6821939945220947, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Pricing: US  Capsules (Tylenol Oral)  325 mg (20): $3.60  Chewable (Acetaminophen Oral)  80 mg (30): $1.37  Chewable (Mapap Childrens Oral)  160 mg (24): $2.10  Gel (ElixSure Fever/Pain Oral)  160 mg/5 mL (120 mL): $4.86…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 45.473811732396165, "bm25_max": 45.473811732396165, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 45.04083829013988, "bm25_max": 45.04083829013988, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 40.5756505240971, "bm25_max": 44.57271238239588, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 44.152856500589735, "bm25_max": 44.152856500589735, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "GFR 10 to 29 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 24 hours  Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours  Peritoneal dialysis: 25 to 37.5 m…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 43.44411864674572, "bm25_max": 43.44411864674572, "bge_top3": null, "bge_max": null, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)  IV:  If the usual recommended dose is 10 mg/kg/dose every 8 hours:  CrCl >50 mL/minute/1.73 m2: No dosage adjustment necessary…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 40.07051480384639, "bm25_max": 42.95770700662017, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 42.23590386990371, "bm25_max": 42.23590386990371, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Infants, Children, Adolescents, and Adults: Oral:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: Reduce dose by 50%.  End-stage renal disease…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 41.48245080946925, "bm25_max": 41.48245080946925, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "plerixafor-drug-information", "bm25_top3": 40.723072462719195, "bm25_max": 40.723072462719195, "bge_top3": null, "bge_max": null, "title": "Plerixafor: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Creatinine clearance estimate based on Cockcroft-Gault formula:  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl ≤50 mL/minute:  Patients ≤83 kg: 13 mg fixed dose or 0.16 mg/kg o…"}, {"doc_id": "stavudine-drug-information", "bm25_top3": 40.63484860835855, "bm25_max": 40.63484860835855, "bge_top3": null, "bge_max": null, "title": "Stavudine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl >50 mL/minute:  <60 kg: 30 mg every 12 hours  ≥60 kg: 40 mg every 12 hours  CrCl 26-50 mL/minute:  <60 kg: 15 mg every 12 hours  ≥60 kg: 20 mg every 12 hours  CrCl 10-25 mL/minute…"}, {"doc_id": "hydrocodone-and-acetaminophen-paracetamol-drug-information", "bm25_top3": 40.57005941225879, "bm25_max": 40.57005941225879, "bge_top3": null, "bge_max": null, "title": "Hydrocodone and acetaminophen (paracetamol): Drug information", "rep_snippet": "Generic: Hydrocodone bitartrate 7.5 mg and acetaminophen 325 mg per 15 mL (5 mL, 10 mL, 15 mL, 118 mL, 473 mL); hydrocodone bitartrate 7.5 mg and acetaminophen 500 mg per 15 mL (5 mL [DSC], 10 mL [DSC], 15 mL [DSC], 118…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": 40.561550742603885, "bm25_max": 40.561550742603885, "bge_top3": null, "bge_max": null, "title": "Amikacin: Drug information", "rep_snippet": "GFR 30 to 50 mL/minute/1.73 m2: Administer every 12 to 18 hours  GFR 10 to 29 mL/minute/1.73 m2: Administer every 18 to 24 hours  GFR <10 mL/minute/1.73 m2: Administer every 48 to 72 hours  Intermittent hemodialysis: 5 m…"}, {"doc_id": "dinutuximab-drug-information", "bm25_top3": 39.895458078564474, "bm25_max": 39.895458078564474, "bge_top3": null, "bge_max": null, "title": "Dinutuximab: Drug information", "rep_snippet": "Antiemetics: Dinutuximab is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.  Antihistamine: Administer an antihistamine (eg, diphenhydramine 0.5 to 1 mg/kg/dose; m…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 39.73415644812886, "bm25_max": 39.73415644812886, "bge_top3": null, "bge_max": null, "title": "Iodixanol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Iodixanol: Pediatric drug information\")  Children <12 years:  Angiocardiography, cerebral arteriography, visceral arteriography: Intra-arterial: Iodixanol 320 mg iodine…"}, {"doc_id": "famotidine-drug-information", "bm25_top3": 39.62180494909385, "bm25_max": 39.62180494909385, "bge_top3": null, "bge_max": null, "title": "Famotidine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl <50 mL/minute: Administer 50% of dose or increase the dosing interval to every 36 to 48 hours.  Pediatric: There are no specifi…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": 39.08005526901441, "bm25_max": 39.08005526901441, "bge_top3": null, "bge_max": null, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "The following adjustments have been recommended (Aronoff 2007): Note: Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours:  GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 38.886262311902314, "bm25_max": 38.886262311902314, "bge_top3": 0.649544894695282, "bge_max": 0.649544894695282, "title": "Amoxicillin: Drug information", "rep_snippet": "Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 8 to 20 mg/kg/dose every 24 hours; give after dialysis.  Peritoneal dialysis: 8 to 20 mg/kg/dose every 24 hours.  Severe infection (h…"}, {"doc_id": "pegfilgrastim-drug-information", "bm25_top3": 38.76000090490146, "bm25_max": 38.76000090490146, "bge_top3": null, "bge_max": null, "title": "Pegfilgrastim: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pegfilgrastim: Pediatric drug information\")  Prevention of chemotherapy-induced neutropenia: Note: Do not administer in the period between 14 days before and 24 hours a…"}, {"doc_id": "rilonacept-drug-information", "bm25_top3": 38.6717349985478, "bm25_max": 38.6717349985478, "bge_top3": null, "bge_max": null, "title": "Rilonacept: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Rilonacept: Pediatric drug information\")  Cryopyrin-associated periodic syndromes: SubQ:  Children ≥12 years and Adolescents <18 years:  Initial: 4.4 mg/kg (maximum loa…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": 38.58185523890083, "bm25_max": 38.58185523890083, "bge_top3": null, "bge_max": null, "title": "Diazepam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Diazepam: Pediatric drug information\")  Conscious sedation for procedures:  Oral:  Children: 0.2 to 0.3 mg/kg (maximum dose: 10 mg) 45 to 60 minutes prior to procedure…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": 38.1754951240799, "bm25_max": 38.1754951240799, "bge_top3": null, "bge_max": null, "title": "Zidovudine: Drug information", "rep_snippet": "Infants (born at or near term with PMA ≥35 weeks) weighing ≥4 kg, Children, and Adolescents: Note: The 3-times-daily dosing is FDA approved but rarely used in practice; twice-daily dosing is recommended in the current pe…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": 38.01781378646668, "bm25_max": 38.01781378646668, "bge_top3": null, "bge_max": null, "title": "Hyoscyamine: Drug information", "rep_snippet": "Tablets (regular release [Levsin], sublingual [Levsin/SL], dispersible [ED-SPAZ, NuLev]): 0.0625 to 0.125 mg every 4 hours or as needed; maximum: 0.75 mg/day  Drops (Hyosyne [0.125 mg/mL]): 0.03125 mg (0.25 mL) to 0.125…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 36.99243098095825, "bm25_max": 36.99243098095825, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Raltegravir: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Note: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioe…"}, {"doc_id": "thonzylamine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6735103130340576, "bge_max": 0.6735103130340576, "title": "Thonzylamine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Contains phenylephrine 10 mg and thonzylamine 50 mg per 15 mL.  Symptoms of common cold or upper respiratory allergies:  Children 6 to <12 years: Oral: 7.5 mL every 4-6 hours; maximum 6 doses (45…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6732704043388367, "bge_max": 0.6732704043388367, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "10 to 15 kg: 0.63 to 1.25 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maximum: 10 mg/day)  >15 kg: 0.63 to 2.5 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maxim…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6574041247367859, "bge_max": 0.6701529026031494, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prednisolone (systemic): Pediatric drug information\")  Dose depends upon condition being treated and response of patient; dosage for infants and children should be base…"}, {"doc_id": "omalizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.666856586933136, "bge_max": 0.666856586933136, "title": "Omalizumab: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Omalizumab: Pediatric drug information\")  Asthma:  Children 6 to <12 years: SubQ:  Pretreatment serum IgE ≥30 to 100 units/mL:  20 to 40 kg: 75 mg every 4 weeks  >40 to…"}, {"doc_id": "peramivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6658375263214111, "bge_max": 0.6658375263214111, "title": "Peramivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Peramivir: Pediatric drug information\")  Influenza: IV: Note: Administer within 2 days of onset of symptoms of influenza.  Children: 2 to 12 years: 12 mg/kg as a single…"}, {"doc_id": "chloramphenicol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6641318202018738, "bge_max": 0.6641318202018738, "title": "Chloramphenicol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Chloramphenicol: Pediatric drug information\")  Serious infections: Infants, Children, and Adolescents: IV:  Manufacturer’s labeling: 50 mg/kg/day in divided doses every…"}, {"doc_id": "diphenhydramine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6639230847358704, "bge_max": 0.6639230847358704, "title": "Diphenhydramine (systemic): Drug information", "rep_snippet": "Children ≥12 years and Adolescents: Refer to adult dosing.  Motion sickness:  Prophylaxis: Oral:  Manufacturer's labeling: Infants, Children, and Adolescents: Note: Administer 30 minutes before motion  Weight-directed do…"}, {"doc_id": "diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.662855327129364, "bge_max": 0.662855327129364, "title": "Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "CDC recommendations: Children ≥18 months and Adolescents: 6 mg/kg/day as a single dose or 6 mg/kg/day in 3 divided doses for 12 days (14 to 21 days in patients with tropical pulmonary eosinophilia) (CDC 2013; Red Book [A…"}, {"doc_id": "chlorpheniramine-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6585022211074829, "bge_max": 0.6585022211074829, "title": "Chlorpheniramine and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to <12 years: One tablet (chlorpheniramine 2 mg/acetaminophen 325 mg) every 4 to 6 hours (maximum: 5 tablets in 24 hours [chlorpheniramine 10 mg/acetaminophen 1…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6522751450538635, "bge_max": 0.6577006578445435, "title": "Oseltamivir: Drug information", "rep_snippet": ">40 kg: 75 mg twice daily  Adolescents ≥13 years: Refer to adult dosing.  Alternate recommendations:  American Academy of Pediatrics: Infants <12 months (off-label dosing; AAP 2013): Note: Age defined as postmenstrual ag…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6562279462814331, "bge_max": 0.6562279462814331, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Penicillin V potassium (oral): Pediatric drug information\")  General dosing, susceptible infections:  Infants and Children <12 years: Mild to moderate infection: Oral:…"}, {"doc_id": "bosentan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6548651456832886, "bge_max": 0.6548651456832886, "title": "Bosentan: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Bosentan: Pediatric drug information\")  Pulmonary artery hypertension: Oral:  Manufacturer’s labeling: Children 3 to ≤ 12 years:  ≥4 to 8 kg: Initial and maintenance: 1…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6534914970397949, "bge_max": 0.6534914970397949, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "1-day regimen: 30 mg/kg as a single dose (maximum dose: 1,500 mg)  3-day regimen: 10 mg/kg once daily for 3 days (maximum: 500 mg daily)  5-day regimen: 10 mg/kg on day 1 (maximum: 500 mg daily) followed by 5 mg/kg/day o…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6527000665664673, "bge_max": 0.6527000665664673, "title": "Esomeprazole: Drug information", "rep_snippet": ">7.5 to 12 kg: 10 mg once daily for up to 6 weeks  Children 1 to 11 years: Note: Safety and efficacy of doses >1 mg/kg/day and/or therapy beyond 8 weeks have not been established.  <20 kg: 10 mg once daily for 8 weeks  ≥…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6517210006713867, "bge_max": 0.6517210006713867, "title": "Sulfadiazine: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Oral: 2 to 4 g/day in 3 to 6 divided doses  Rheumatic fever prophylaxis (off-label dose) (Gerber [AHA 2009]): Oral:  ≤27 kg: 500 mg once daily  >27 kg: 1,000 mg once daily  Toxop…"}, {"doc_id": "acetaminophen-paracetamol-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6515471339225769, "bge_max": 0.6515471339225769, "title": "Acetaminophen (paracetamol) and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Allergies/common cold/hay fever: Oral: Note: OTC dosing recommendations may vary by product and/or manufacturer. When calculating the maximum daily dose, consider all sources of acetaminophen (prescription…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6501703262329102, "bge_max": 0.6501703262329102, "title": "Aminophylline: Drug information", "rep_snippet": "Infants 6 to 52 weeks: Dose (mg/kg/hour) = [(0.008 x age in weeks) + 0.21] divided by 0.79  Children 1 to <9 years: 1.01 mg/kg/hour  Children 9 to <12 years: 0.89 mg/kg/hour  Adolescents 12 to <16 years (cigarette or mar…"}, {"doc_id": "levetiracetam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6497425436973572, "bge_max": 0.6497425436973572, "title": "Levetiracetam: Drug information", "rep_snippet": "Children ≥6 years and weighing 20 kg to 40 kg: Initial: 250 mg twice daily; increase every 2 weeks by 250 mg/dose to the maximum recommended dose of 750 mg twice daily.  Children ≥6 years (weighing >40 kg) and Adolescent…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6482916176319122, "bge_max": 0.6491676568984985, "title": "Theophylline: Drug information", "rep_snippet": "Children 6 years to Adolescents 15 years and weight ≤45 kg: Initial: 12 to 14 mg/kg/day divided every 12 hours (maximum: 300 mg/day); if tolerated, after 3 days increase to 16 mg/kg/day divided every 12 hours (maximum: 4…"}, {"doc_id": "dimenhydrinate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6490161418914795, "bge_max": 0.6490161418914795, "title": "Dimenhydrinate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dimenhydrinate: Pediatric drug information\")  US labeling: Motion sickness, nausea/vomiting, or vertigo:  Oral:  Children 2 to 5 years: 12.5 to 25 mg every 6 to 8 hours…"}, {"doc_id": "cefepime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6480764746665955, "bge_max": 0.6480764746665955, "title": "Cefepime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefepime: Pediatric drug information\")  General dosing, susceptible infection (Red Book [AAP 2015]): Infants, Children, and Adolescents: IM, IV:  Mild to moderate infec…"}, {"doc_id": "polymyxin-b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6480134725570679, "bge_max": 0.6480134725570679, "title": "Polymyxin B: Drug information", "rep_snippet": "Alternate dosing: Children ≥2 years and Adolescents: Very limited data available: Dosing based on previous recommendations (Hoeprich 1970) and extrapolations from adult pharmacokinetic modeling (Sandri 2013a) which assum…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6479405760765076, "bge_max": 0.6479405760765076, "title": "Cefotaxime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefotaxime: Pediatric drug information\")  Usual dosage range for susceptible infections:  Infants, Children, and Adolescents:  Manufacturer's labeling:  <50 kg: IM, IV:…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6475222110748291, "bge_max": 0.6475222110748291, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dexamethasone (systemic): Pediatric drug information\")  Anti-inflammatory/immunosuppressive/endocrine disorders: Infants, Children, and Adolescents: Oral, IM, IV: Initi…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6464281678199768, "bge_max": 0.6464281678199768, "title": "Sodium phosphate: Drug information", "rep_snippet": "Children 5-9 years: 7.5 mL as a single dose; maximum single daily dose: 7.5 mL  Children 10-11 years: 15 mL as a single dose; maximum single daily dose: 15 mL  Children ≥12 years: Refer to adult dosing."}, {"doc_id": "doxycycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6462284922599792, "bge_max": 0.6462284922599792, "title": "Doxycycline: Drug information", "rep_snippet": "Children ≥45 kg: 100 mg every 12 hours for 14 to 21 days"}, {"doc_id": "dextroamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6460669040679932, "bge_max": 0.6460669040679932, "title": "Dextroamphetamine: Drug information", "rep_snippet": "Children 6 to 12 years: Oral: Initial: 5 mg once daily; may increase in increments of 5 mg at weekly intervals until optimal response is obtained; usual dosage: 5 to 60 mg daily in divided doses.  Children >12 years and…"}, {"doc_id": "zafirlukast-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6459519863128662, "bge_max": 0.6459519863128662, "title": "Zafirlukast: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Zafirlukast: Pediatric drug information\")  Asthma: Oral:  Children 5 to 11 years: 10 mg twice daily  Children ≥12 years and Adolescents: Refer to adult dosing."}, {"doc_id": "aspirin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6452680230140686, "bge_max": 0.6452680230140686, "title": "Aspirin: Drug information", "rep_snippet": "Moderate dose: 30 to 50 mg/kg/day divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AHA [McCrindle 2017]).  Subsequent therapy (low-dose; antiplatelet effects): 3 to 5 mg/kg/day on…"}, {"doc_id": "pentobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6451396942138672, "bge_max": 0.6451396942138672, "title": "Pentobarbital: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pentobarbital: Pediatric drug information\")  Note: Adjust dose based on patient's age, weight, and condition.  Sedative/hypnotic/preanesthesia: Infants, Children, and A…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.644736647605896, "bge_max": 0.644736647605896, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Allergies/co…"}, {"doc_id": "flunisolide-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6446922421455383, "bge_max": 0.6446922421455383, "title": "Flunisolide (oral inhalation): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Flunisolide (oral inhalation): Pediatric drug information\")  Asthma: Metered-dose inhaler: Inhalation:  Note: The recommended starting dose is based upon previous asthm…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.644119143486023, "bge_max": 0.644119143486023, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "\"Low\" dose: 80 to 160 mcg daily  \"Medium\" dose: >160 to 320 mcg daily  \"High\" dose: >320 mcg daily  Children ≥12 years of age and Adolescents: Refer to adult dosing.  Global Initiative for Asthma guidelines (GINA 2017):…"}, {"doc_id": "trimeprazine-alimemazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6434507966041565, "bge_max": 0.6434507966041565, "title": "Trimeprazine (alimemazine): Drug information", "rep_snippet": "Dosing: Pediatric  Cough, pruritus: Note: Initiate at low dosage and titrate as needed.  Children 2 to 12 years: Oral: Initial: 2.5 mg to 5 mg once daily at bedtime; if necessary, administer additional dosage of 2.5 mg t…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6424615383148193, "bge_max": 0.6424615383148193, "title": "Ondansetron: Drug information", "rep_snippet": "Infants ≥1 month and Children ≤12 years: IV:  ≤40 kg: 0.1 mg/kg as a single dose over 2 to 5 minutes  >40 kg: 4 mg as a single dose over 2 to 5 minutes  Adolescents >12 years: IV, IM: Refer to adult dosing."}, {"doc_id": "cefazolin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6420656442642212, "bge_max": 0.6420656442642212, "title": "Cefazolin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefazolin: Pediatric drug information\")  Usual dosage range: IM, IV: Infants >1 month, Children, and Adolescents: 25 to 100 mg/kg/day divided every 6 to 8 hours; maximu…"}]}
{"qid": "Q2_noise+brand", "query": "12-kg toddler febrile—what Tylenol dose (mg/kg) and how many mL with 160/5 liquid?", "base_qid": "Q2", "variant_type": "noise+brand", "candidates": [{"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 37.39243182491015, "bm25_max": 44.360933262064655, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Panzyga [Canadian product]: IV: 1,000 mg/kg/day for 2 consecutive days; may repeat treatment in patients who relapse  American College of Obstetricians and Gynecologists Guidelines: IV: Initial: 1,000 mg/kg as a one-time…"}, {"doc_id": "diphenoxylate-and-atropine-drug-information", "bm25_top3": 44.13108999303831, "bm25_max": 44.13108999303831, "bge_top3": null, "bge_max": null, "title": "Diphenoxylate and atropine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Diphenoxylate and atropine: Pediatric drug information\")  Diarrhea, adjunct therapy: Note: Clinical improvement of acute diarrhea is usually observed within 48 hours. I…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": 39.90660963697855, "bm25_max": 41.38120717806389, "bge_top3": 0.6853169798851013, "bge_max": 0.7223622798919678, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Pricing: US  Capsules (Tylenol Oral)  325 mg (20): $3.60  Chewable (Acetaminophen Oral)  80 mg (30): $1.37  Chewable (Mapap Childrens Oral)  160 mg (24): $2.10  Gel (ElixSure Fever/Pain Oral)  160 mg/5 mL (120 mL): $4.86…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 39.52728203844682, "bm25_max": 39.81703411174999, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 32.09483687553549, "bm25_max": 34.72351299609959, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 32.666969432141144, "bm25_max": 34.233194784355454, "bge_top3": 0.6524934768676758, "bge_max": 0.6524934768676758, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Pricing: US  Liquid (Delsym Cgh/Cld Nighttime Child Oral)  12.5-5-325 mg/10 mL (180 mL): $10.13  Liquid (Delsym Cough/Cold Night Time Oral)  12.5-5-325 mg/10 mL (180 mL): $10.13  Liquid (Dimetapp MultiSymptom Cold/Flu Or…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 31.23816016213697, "bm25_max": 33.55469643985859, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 33.483067495518426, "bm25_max": 33.483067495518426, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 32.985814712657216, "bm25_max": 32.985814712657216, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Infants, Children, Adolescents, and Adults: Oral:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: Reduce dose by 50%.  End-stage renal disease…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 32.41828535039134, "bm25_max": 32.41828535039134, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "GFR 10 to 29 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 24 hours  Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours  Peritoneal dialysis: 25 to 37.5 m…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 32.302817155353715, "bm25_max": 32.302817155353715, "bge_top3": null, "bge_max": null, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Pricing: US  Liquid (Mucinex Fast-Max Cold & Sinus Oral)  10-650-400 mg/20 mL (177 mL): $10.13  Liquid (Mucinex Fast-Max Oral)  10-650-400 mg/20 mL (180 mL): $11.27  Liquid (Mucinex Sinus-Max Congestion Oral)  10-650-400…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 32.11200407636798, "bm25_max": 32.11200407636798, "bge_top3": 0.6184003353118896, "bge_max": 0.6184003353118896, "title": "Streptomycin: Drug information", "rep_snippet": "Tuberculosis:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: 12 to 15 mg/kg/dose (maximum dose: 1 g) 2 to 3 times weekly  End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): 12 t…"}, {"doc_id": "acetaminophen-paracetamol-and-diphenhydramine-drug-information", "bm25_top3": 32.09465326990281, "bm25_max": 32.09465326990281, "bge_top3": 0.6233878135681152, "bge_max": 0.6233878135681152, "title": "Acetaminophen (paracetamol) and diphenhydramine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Liquid, Oral:  Tylenol PM: Acetaminophen 500 mg and diph…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 31.753382812875287, "bm25_max": 31.753382812875287, "bge_top3": null, "bge_max": null, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)  IV:  If the usual recommended dose is 10 mg/kg/dose every 8 hours:  CrCl >50 mL/minute/1.73 m2: No dosage adjustment necessary…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": 29.655646496591867, "bm25_max": 31.67638212419912, "bge_top3": null, "bge_max": null, "title": "Zidovudine: Drug information", "rep_snippet": "Infants (born at or near term with PMA ≥35 weeks) weighing ≥4 kg, Children, and Adolescents: Note: The 3-times-daily dosing is FDA approved but rarely used in practice; twice-daily dosing is recommended in the current pe…"}, {"doc_id": "acetaminophen-paracetamol-and-codeine-drug-information", "bm25_top3": 28.914036628430615, "bm25_max": 31.568802211603423, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol) and codeine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Solution, Oral:  Generic: Acetaminophen 120 mg and codei…"}, {"doc_id": "plerixafor-drug-information", "bm25_top3": 31.325736046279413, "bm25_max": 31.325736046279413, "bge_top3": null, "bge_max": null, "title": "Plerixafor: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Creatinine clearance estimate based on Cockcroft-Gault formula:  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl ≤50 mL/minute:  Patients ≤83 kg: 13 mg fixed dose or 0.16 mg/kg o…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 30.902222507341428, "bm25_max": 30.902222507341428, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "stavudine-drug-information", "bm25_top3": 30.26890728687101, "bm25_max": 30.26890728687101, "bge_top3": null, "bge_max": null, "title": "Stavudine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl >50 mL/minute:  <60 kg: 30 mg every 12 hours  ≥60 kg: 40 mg every 12 hours  CrCl 26-50 mL/minute:  <60 kg: 15 mg every 12 hours  ≥60 kg: 20 mg every 12 hours  CrCl 10-25 mL/minute…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": 30.208119661076836, "bm25_max": 30.208119661076836, "bge_top3": null, "bge_max": null, "title": "Amikacin: Drug information", "rep_snippet": "GFR 30 to 50 mL/minute/1.73 m2: Administer every 12 to 18 hours  GFR 10 to 29 mL/minute/1.73 m2: Administer every 18 to 24 hours  GFR <10 mL/minute/1.73 m2: Administer every 48 to 72 hours  Intermittent hemodialysis: 5 m…"}, {"doc_id": "foscarnet-drug-information", "bm25_top3": 30.038525328374572, "bm25_max": 30.038525328374572, "bge_top3": null, "bge_max": null, "title": "Foscarnet: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  See tables.  Induction Dosing of Foscarnet in Patients With Abnormal Renal Function  CrCl (mL/min/kg)  HSV  HSV  CMV  CMV  Equivalent to 40 mg/kg every 12 hours  Equivalent to 40 mg/kg e…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 28.784730135976066, "bm25_max": 29.970683596896748, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": 29.579554180323086, "bm25_max": 29.579554180323086, "bge_top3": 0.6189673542976379, "bge_max": 0.6189673542976379, "title": "Diazepam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Diazepam: Pediatric drug information\")  Conscious sedation for procedures:  Oral:  Children: 0.2 to 0.3 mg/kg (maximum dose: 10 mg) 45 to 60 minutes prior to procedure…"}, {"doc_id": "rilonacept-drug-information", "bm25_top3": 29.492307949625793, "bm25_max": 29.492307949625793, "bge_top3": null, "bge_max": null, "title": "Rilonacept: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Rilonacept: Pediatric drug information\")  Cryopyrin-associated periodic syndromes: SubQ:  Children ≥12 years and Adolescents <18 years:  Initial: 4.4 mg/kg (maximum loa…"}, {"doc_id": "digoxin-immune-fab-drug-information", "bm25_top3": 29.41793590760833, "bm25_max": 29.41793590760833, "bge_top3": null, "bge_max": null, "title": "Digoxin immune Fab: Drug information", "rep_snippet": "Infants and Small Children Dose Estimates of Digoxin Immune Fab (in mg) From Steady-State Serum Digoxin Concentration  Patient Weight  (kg)  Serum Digoxin Concentration (ng/mL)  1  2  4  8  12  16  20  1Dilution of recon…"}, {"doc_id": "famotidine-drug-information", "bm25_top3": 29.290212625294153, "bm25_max": 29.290212625294153, "bge_top3": null, "bge_max": null, "title": "Famotidine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl <50 mL/minute: Administer 50% of dose or increase the dosing interval to every 36 to 48 hours.  Pediatric: There are no specifi…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 28.966251479459746, "bm25_max": 28.966251479459746, "bge_top3": null, "bge_max": null, "title": "Iodixanol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Iodixanol: Pediatric drug information\")  Children <12 years:  Angiocardiography, cerebral arteriography, visceral arteriography: Intra-arterial: Iodixanol 320 mg iodine…"}, {"doc_id": "cloxacillin-united-states-not-available-drug-information", "bm25_top3": 28.948864396903442, "bm25_max": 28.948864396903442, "bge_top3": null, "bge_max": null, "title": "Cloxacillin (United States: Not available): Drug information", "rep_snippet": "Skin and soft tissue infections (off-label dosing) (WHO 2001): Empiric therapy:  Contaminated soft tissue injuries: Children and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for 5 to 10 days…"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": 28.624830167491364, "bm25_max": 28.624830167491364, "bge_top3": null, "bge_max": null, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftaroline: Pediatric drug information\")  Pneumonia, community acquired: IV:  Infants ≥2 months and Children <2 years: 8 mg/kg/dose every 8 hours for 5 to 14 days  Chi…"}, {"doc_id": "cefepime-drug-information", "bm25_top3": 28.50885232652481, "bm25_max": 28.50885232652481, "bge_top3": null, "bge_max": null, "title": "Cefepime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefepime: Pediatric drug information\")  General dosing, susceptible infection (Red Book [AAP 2015]): Infants, Children, and Adolescents: IM, IV:  Mild to moderate infec…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 28.389334556703872, "bm25_max": 28.389334556703872, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Infants and Children <2 years (off-label): IV, Oral (oral suspension): Initial: 9 mg/kg/dose every 12 hours followed by monitoring of serum trough concentrations typically initiated after 3 to 5 days; adjust dose to achi…"}, {"doc_id": "asfotase-alfa-drug-information", "bm25_top3": 28.275992603764205, "bm25_max": 28.275992603764205, "bge_top3": null, "bge_max": null, "title": "Asfotase alfa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Asfotase alfa: Pediatric drug information\")  Hypophosphatasia (HPP): SubQ: Note: Round patient weight to the nearest kg when determining dose. Do not administer the 80…"}, {"doc_id": "leuprolide-drug-information", "bm25_top3": 28.209407129728245, "bm25_max": 28.209407129728245, "bge_top3": null, "bge_max": null, "title": "Leuprolide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Leuprolide: Pediatric drug information\")  Precocious puberty (consider discontinuing by age 11 for females and by age 12 for males):  IM:  Lupron Depot-Ped (monthly):…"}, {"doc_id": "paregoric-drug-information", "bm25_top3": 25.72352766611162, "bm25_max": 25.72352766611162, "bge_top3": null, "bge_max": null, "title": "Paregoric: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Paregoric: Pediatric drug information\")  Note: Paregoric oral liquid contains morphine 2 mg/5 mL (0.4 mg/mL)  Diarrhea: Children and Adolescents: Oral: 0.25 to 0.5 mL/k…"}, {"doc_id": "thonzylamine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6676007807254791, "bge_max": 0.6849254965782166, "title": "Thonzylamine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Contains phenylephrine 10 mg and thonzylamine 50 mg per 15 mL.  Symptoms of common cold or upper respiratory allergies:  Children 6 to <12 years: Oral: 7.5 mL every 4-6 hours; maximum 6 doses (45…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6603595018386841, "bge_max": 0.6603595018386841, "title": "Cefotaxime: Drug information", "rep_snippet": "Typhoid fever: Infants and Children ≤12 years: IM, IV: 150 to 200 mg/kg/day in 3 to 4 divided doses (maximum: 12 g daily); fluoroquinolone resistant: 80 mg/kg/day in 3 to 4 divided doses (maximum: 12 g daily)"}, {"doc_id": "triprolidine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6435587108135223, "bge_max": 0.6579676270484924, "title": "Triprolidine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Triprolidine and pseudoephedrine: Pediatric drug information\")  Cold, allergy symptoms: Oral:  Liquid (triprolidine 0.938 mg and pseudoephedrine 10 mg per 1 mL):  Child…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6526879668235779, "bge_max": 0.6526879668235779, "title": "Aminophylline: Drug information", "rep_snippet": "Infants 6 to 52 weeks: Dose (mg/kg/hour) = [(0.008 x age in weeks) + 0.21] divided by 0.79  Children 1 to <9 years: 1.01 mg/kg/hour  Children 9 to <12 years: 0.89 mg/kg/hour  Adolescents 12 to <16 years (cigarette or mar…"}, {"doc_id": "terbutaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6464377641677856, "bge_max": 0.6464377641677856, "title": "Terbutaline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Terbutaline: Pediatric drug information\")  Asthma/bronchospasm:  Oral:  Children ≥12 years to Adolescents ≤15 years: 2.5 mg 3 times daily (approximately every 6 hours);…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6411470174789429, "bge_max": 0.6462997198104858, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to 11 years: Vicks DayQuil Cold & Flu Multi-Symptom Liquid: Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maxim…"}, {"doc_id": "atenolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.641869068145752, "bge_max": 0.641869068145752, "title": "Atenolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atenolol: Pediatric drug information\")  Hypertension: Oral: Children and Adolescents: Initial: 0.5 to 1 mg/kg/dose either once daily or divided in doses twice daily; ti…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.631758451461792, "bge_max": 0.631758451461792, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Theophylline: Pediatric drug information\")  Note: Individualize dose based on steady-state serum concentrations; use ideal body weight (theophylline distributes poorly…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6316288709640503, "bge_max": 0.6316288709640503, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prednisolone (systemic): Pediatric drug information\")  Dose depends upon condition being treated and response of patient; dosage for infants and children should be base…"}, {"doc_id": "zinc-gluconate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6298336982727051, "bge_max": 0.6298336982727051, "title": "Zinc gluconate: Drug information", "rep_snippet": "Dosing: Pediatric  Common cold: Note: For best results, begin therapy 24 to 48 hours prior to symptom onset: Children ≥12 years and Adolescents ≤17 years of age: Dissolve one 13.3 mg lozenge in mouth every 2 to 4 hours a…"}, {"doc_id": "flunisolide-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6292400360107422, "bge_max": 0.6292400360107422, "title": "Flunisolide (oral inhalation): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Flunisolide (oral inhalation): Pediatric drug information\")  Asthma: Metered-dose inhaler: Inhalation:  Note: The recommended starting dose is based upon previous asthm…"}, {"doc_id": "minoxidil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6282050609588623, "bge_max": 0.6282050609588623, "title": "Minoxidil (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Minoxidil (systemic): Pediatric drug information\")  Hypertension:  Children <12 years: Oral: Initial: 0.2 mg/kg once daily; maximum daily initial dose: 5 mg daily; titr…"}, {"doc_id": "para-aminosalicylic-acid-aminosalicylate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6271851658821106, "bge_max": 0.6271851658821106, "title": "Para-aminosalicylic acid (aminosalicylate) : Drug information", "rep_snippet": "Dosing: Pediatric  Tuberculosis (second-line agent):  Children ≤40 kg and Adolescents <15 years: Oral: 200 to 300 mg/kg/day (usually 100 mg/kg/dose 2 to 3 times daily). Note: Use in combination with other antituberculous…"}, {"doc_id": "tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6234973669052124, "bge_max": 0.6234973669052124, "title": "Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information\")  Plasma volume expansion: IV infusion: Note: With severe dehydration, administer crysta…"}, {"doc_id": "triamcinolone-nasal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6232636570930481, "bge_max": 0.6232636570930481, "title": "Triamcinolone (nasal): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Triamcinolone (nasal): Pediatric drug information\")  Allergic rhinitis/upper respiratory symptoms: Intranasal: Note: Discontinue therapy if adequate symptomatic relief…"}, {"doc_id": "dimenhydrinate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6218585968017578, "bge_max": 0.6218585968017578, "title": "Dimenhydrinate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dimenhydrinate: Pediatric drug information\")  US labeling: Motion sickness, nausea/vomiting, or vertigo:  Oral:  Children 2 to 5 years: 12.5 to 25 mg every 6 to 8 hours…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.618807852268219, "bge_max": 0.6212937831878662, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Pricing: US  Liquid (Actinel Oral)  30-15-200 mg/5 mL (474 mL): $8.50  Liquid (Actinel Pediatric Oral)  15-5-50 mg/5 mL (474 mL): $8.50  Liquid (Trispec PSE Pediatric Oral)  30-10-187 mg/5 mL (59 mL): $12.77  Liquid (Tus…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6211131811141968, "bge_max": 0.6211131811141968, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "10 to 15 kg: 0.63 to 1.25 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maximum: 10 mg/day)  >15 kg: 0.63 to 2.5 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maxim…"}, {"doc_id": "levalbuterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6199543476104736, "bge_max": 0.6199543476104736, "title": "Levalbuterol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Levalbuterol: Pediatric drug information\")  Bronchospasm:  Metered-dose inhaler: Children ≥4 years and Adolescents: 2 inhalations (90 mcg) every 4 to 6 hours as needed;…"}, {"doc_id": "abaloparatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6193124055862427, "bge_max": 0.6193124055862427, "title": "Abaloparatide: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution Pen-injector, Subcutaneous:  Tymlos: 3120 mcg/1.56 mL (1.56 mL) [contains ph…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6187909841537476, "bge_max": 0.6187909841537476, "title": "Sodium phosphate: Drug information", "rep_snippet": "Children 5-9 years: 7.5 mL as a single dose; maximum single daily dose: 7.5 mL  Children 10-11 years: 15 mL as a single dose; maximum single daily dose: 15 mL  Children ≥12 years: Refer to adult dosing."}, {"doc_id": "diphenhydramine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6185178756713867, "bge_max": 0.6185178756713867, "title": "Diphenhydramine (systemic): Drug information", "rep_snippet": "Children ≥12 years and Adolescents: Refer to adult dosing.  Motion sickness:  Prophylaxis: Oral:  Manufacturer's labeling: Infants, Children, and Adolescents: Note: Administer 30 minutes before motion  Weight-directed do…"}, {"doc_id": "chloramphenicol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6181781888008118, "bge_max": 0.6181781888008118, "title": "Chloramphenicol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Chloramphenicol: Pediatric drug information\")  Serious infections: Infants, Children, and Adolescents: IV:  Manufacturer’s labeling: 50 mg/kg/day in divided doses every…"}, {"doc_id": "propranolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6172310709953308, "bge_max": 0.6172310709953308, "title": "Propranolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Propranolol: Pediatric drug information\")  Proliferating infantile hemangioma (Hemangeol): Infants ≥2 kg: Oral: Note: Initiate treatment at age 5 weeks to 5 months; dos…"}, {"doc_id": "metaproterenol-orciprenaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6170128583908081, "bge_max": 0.6170128583908081, "title": "Metaproterenol (orciprenaline): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Metaproterenol (orciprenaline): Pediatric drug information\")  Asthma/Bronchospasm: Oral: Note: Oral bronchodilators are not recommended for routine use in the managemen…"}, {"doc_id": "dyclonine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169548630714417, "bge_max": 0.6169548630714417, "title": "Dyclonine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dyclonine: Pediatric drug information\")  Mouth/throat symptoms: Oral topical: Lozenge:  2 mg: Children ≥6 years and Adolescents: Refer to adult dosing.  2 mg (with ment…"}, {"doc_id": "guaifenesin-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169437766075134, "bge_max": 0.6169437766075134, "title": "Guaifenesin, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Also refer to specific product labeling.  Cough/decongestant: Oral:  Tablet:  Children 6 to 11 years (Deconex DMX): Guaifenesin 192.5 mg, dextromethorphan 8.75 mg, and phenylephrine 5 mg (1/2 tablet) e…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169111728668213, "bge_max": 0.6169111728668213, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Penicillin V potassium (oral): Pediatric drug information\")  General dosing, susceptible infections:  Infants and Children <12 years: Mild to moderate infection: Oral:…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6168952584266663, "bge_max": 0.6168952584266663, "title": "Linezolid: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Linezolid: Pediatric drug information\")  Usual dosage: Oral, IV:  Children ≤11 years: 10 mg/kg (maximum: 600 mg/dose) every 8 hours  Children ≥12 years and Adolescents:…"}, {"doc_id": "chlophedianol-and-dexbrompheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6164817214012146, "bge_max": 0.6164817214012146, "title": "Chlophedianol and dexbrompheniramine: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and cold symptoms:  Children 6 to <12 years: Oral: Chlophedianol 12.5 mg/dexbrompheniramine 1 mg (5 mL) every 6 hours (Maximum: Chlophedianol 50 mg/dexbrompheniramine 4 mg (20 mL) per 24 hours.…"}, {"doc_id": "terbinafine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6161433458328247, "bge_max": 0.6161433458328247, "title": "Terbinafine (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Terbinafine (systemic): Pediatric drug information\")  Note: Lamisil granules have been discontinued in the United States for more than 1 year.  Tinea capitis: Oral: Gra…"}, {"doc_id": "dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6154918670654297, "bge_max": 0.6154918670654297, "title": "Dextromethorphan and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  General dosing guidelines. Also refer to specific product labeling.  Cough/decongestant: Oral: Liquid (dextromethorphan 5 mg and phenylephrine 2.5 mg per 5 mL):  Children 4 to 5 years: 5 mL every 4 hou…"}, {"doc_id": "cefaclor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6153664588928223, "bge_max": 0.6153664588928223, "title": "Cefaclor: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefaclor: Pediatric drug information\")  Treatment of susceptible infections: Usual dosage range:  Infants ≥1 month, Children, and Adolescents: Oral: Immediate-release:…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6150914430618286, "bge_max": 0.6150914430618286, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Tenofovir disoproxil fumarate: Pediatric drug information\")  Hepatitis B infection: Oral: Children ≥12 years (and ≥35 kg) and Adolescents: Refer to adult dosing.  HIV-1…"}]}
{"qid": "Q2_spelling", "query": "Child 12 kg, feaver — calc acetaminophen mg/kg and volume using 160 mg per 5 mL.", "base_qid": "Q2", "variant_type": "spelling", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 45.59461755975726, "bm25_max": 46.43011592159013, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Severe infections: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or 200 mg or 400 mg chewable tablets) (maximum single dose: Amoxicillin 875 mg) or amoxici…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 41.9944810403748, "bm25_max": 46.012511211268695, "bge_top3": 0.6789840857187907, "bge_max": 0.7086234092712402, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Dimetapp Children's Multi-Symptom Cold & Flu: Acetaminophen 160 mg, diphenhydramine hydrochloride 6.25 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [alcohol free; contains edetate disodium, menthol, polye…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": 43.282742012248164, "bm25_max": 43.282742012248164, "bge_top3": 0.678121417760849, "bge_max": 0.6830790042877197, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Pricing: US  Capsules (Tylenol Oral)  325 mg (20): $3.60  Chewable (Acetaminophen Oral)  80 mg (30): $1.37  Chewable (Mapap Childrens Oral)  160 mg (24): $2.10  Gel (ElixSure Fever/Pain Oral)  160 mg/5 mL (120 mL): $4.86…"}, {"doc_id": "acetaminophen-paracetamol-and-codeine-drug-information", "bm25_top3": 41.24504716698577, "bm25_max": 42.87224775740693, "bge_top3": 0.6555799245834351, "bge_max": 0.6555799245834351, "title": "Acetaminophen (paracetamol) and codeine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Acetaminophen (paracetamol) and codeine: Pediatric drug information\")  Note: The FDA has recommended that codeine not be used in pediatric patients <12 years of age and…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information", "bm25_top3": 39.14415913153555, "bm25_max": 39.39660842466015, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), dextromethorphan, and doxylamine: Drug information", "rep_snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Cold and flu…"}, {"doc_id": "hydrocodone-and-acetaminophen-paracetamol-drug-information", "bm25_top3": 36.94162235422138, "bm25_max": 37.66003108908604, "bge_top3": null, "bge_max": null, "title": "Hydrocodone and acetaminophen (paracetamol): Drug information", "rep_snippet": "Generic: Hydrocodone bitartrate 7.5 mg and acetaminophen 325 mg per 15 mL (5 mL, 10 mL, 15 mL, 118 mL, 473 mL); hydrocodone bitartrate 7.5 mg and acetaminophen 500 mg per 15 mL (5 mL [DSC], 10 mL [DSC], 15 mL [DSC], 118…"}, {"doc_id": "acetaminophen-paracetamol-caffeine-and-dihydrocodeine-drug-information", "bm25_top3": 37.65939853972469, "bm25_max": 37.65939853972469, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), caffeine, and dihydrocodeine: Drug information", "rep_snippet": "Dosing: Adult  Pain management: Oral:  Capsule (acetaminophen 320.5 mg/caffeine 30 mg/dihydrocodeine bitartrate 16 mg): Two capsules every 4 hours as needed; adjust dose based on severity of pain (maximum dose: 10 capsul…"}, {"doc_id": "acetaminophen-paracetamol-and-diphenhydramine-drug-information", "bm25_top3": 37.37316365788584, "bm25_max": 37.37316365788584, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol) and diphenhydramine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Liquid, Oral:  Tylenol PM: Acetaminophen 500 mg and diph…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 36.06201264926806, "bm25_max": 37.0163394961171, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Cuvitru:  Injection sites: ≤4 simultaneous injection sites (spaced 4 inches apart or more).  Maximum infusion rate: 10 to 20 mL/hour per injection site (first 2 infusions); may be increased to 60 mL/hour per injection si…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 36.212236065683356, "bm25_max": 36.861090365997974, "bge_top3": 0.6758534908294678, "bge_max": 0.6878243684768677, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to 11 years: Vicks DayQuil Cold & Flu Multi-Symptom Liquid: Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maxim…"}, {"doc_id": "valsartan-and-hydrochlorothiazide-drug-information", "bm25_top3": 36.167590642768054, "bm25_max": 36.167590642768054, "bge_top3": null, "bge_max": null, "title": "Valsartan and hydrochlorothiazide: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Tablet, oral: 80 mg/12.5 mg: Valsartan 80 mg and hydrochlorothiazide 12.5 mg; 160 mg/…"}, {"doc_id": "oxycodone-and-acetaminophen-paracetamol-drug-information", "bm25_top3": 36.126559879810706, "bm25_max": 36.126559879810706, "bge_top3": null, "bge_max": null, "title": "Oxycodone and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Capsule, Oral: 5/500: Oxycodone hydrochloride 5 mg and a…"}, {"doc_id": "ethanol-topical-and-injection-drug-information", "bm25_top3": 35.82129159060971, "bm25_max": 35.82129159060971, "bge_top3": null, "bge_max": null, "title": "Ethanol (topical and injection): Drug information", "rep_snippet": "Chronic drinker: 154 mg/kg/hour [equivalent to 1.96 mL/kg/hour using a 10% solution]  Dosage adjustment for hemodialysis: Maintenance dose:  Nondrinker: 169 mg/kg/hour [equivalent to 2.13 mL/kg/hour using a 10% solution]…"}, {"doc_id": "sodium-picosulfate-magnesium-oxide-and-citric-acid-drug-information", "bm25_top3": 35.68718602512499, "bm25_max": 35.68718602512499, "bge_top3": null, "bge_max": null, "title": "Sodium picosulfate, magnesium oxide, and citric acid: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Powder for solution, Oral [kit]:  Prepopik: Sodium picosulfate 10 mg, magnesium oxide…"}, {"doc_id": "pegfilgrastim-drug-information", "bm25_top3": 29.21206108059946, "bm25_max": 30.890105883595623, "bge_top3": null, "bge_max": null, "title": "Pegfilgrastim: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pegfilgrastim: Pediatric drug information\")  Prevention of chemotherapy-induced neutropenia: Note: Do not administer in the period between 14 days before and 24 hours a…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 26.12805356642118, "bm25_max": 28.496677987456607, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "methylnaltrexone-drug-information", "bm25_top3": 26.977702461726565, "bm25_max": 28.14233612836812, "bge_top3": null, "bge_max": null, "title": "Methylnaltrexone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Opioid-induced constipation with advanced illness: There are no dosage adjustments provided in the manufacturer's labeling. For the injection, consider following the subcutaneous dosing recomm…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 27.972855193363266, "bm25_max": 27.972855193363266, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 26.82441520021517, "bm25_max": 26.82441520021517, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 25.91817245893962, "bm25_max": 26.674189024406388, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Dosing: Adult  Note: Weight-based dosing recommendations are based on the trimethoprim (TMP) component. Each double-strength tablet contains TMP 160 mg and sulfamethoxazole (SMX) 800 mg. Each single-strength tablet conta…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 26.34949017941657, "bm25_max": 26.34949017941657, "bge_top3": null, "bge_max": null, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Tenofovir disoproxil fumarate: Pediatric drug information\")  Hepatitis B infection: Oral: Children ≥12 years (and ≥35 kg) and Adolescents: Refer to adult dosing.  HIV-1…"}, {"doc_id": "benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 26.126646770946564, "bm25_max": 26.126646770946564, "bge_top3": null, "bge_max": null, "title": "Benznidazole (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Administration  Administer with or without food, approximately 12 hours apart.  To make slurry using 12.5 or 100 mg tablets:  Place prescribed dose in a cup and add the specified volume of water (also refer to manufactur…"}, {"doc_id": "foscarnet-drug-information", "bm25_top3": 25.862413674052274, "bm25_max": 26.062393902684555, "bge_top3": null, "bge_max": null, "title": "Foscarnet: Drug information", "rep_snippet": "Administration  IV: Foscarnet is administered by intravenous infusion, using an infusion pump, at a rate not exceeding 1 mg/kg/minute. Undiluted (24 mg/mL) solution can be administered without further dilution when using…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 25.404804347819933, "bm25_max": 25.404804347819933, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "digoxin-immune-fab-drug-information", "bm25_top3": 25.292305718491285, "bm25_max": 25.292305718491285, "bge_top3": null, "bge_max": null, "title": "Digoxin immune Fab: Drug information", "rep_snippet": "Infants and Small Children Dose Estimates of Digoxin Immune Fab (in mg) From Steady-State Serum Digoxin Concentration  Patient Weight  (kg)  Serum Digoxin Concentration (ng/mL)  1  2  4  8  12  16  20  1Dilution of recon…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 24.39812275321731, "bm25_max": 24.39812275321731, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 24.392033056976196, "bm25_max": 24.392033056976196, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "GFR 10 to 29 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 24 hours  Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours  Peritoneal dialysis: 25 to 37.5 m…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": 24.252999333466256, "bm25_max": 24.252999333466256, "bge_top3": null, "bge_max": null, "title": "Zidovudine: Drug information", "rep_snippet": "Infants (born at or near term with PMA ≥35 weeks) weighing ≥4 kg, Children, and Adolescents: Note: The 3-times-daily dosing is FDA approved but rarely used in practice; twice-daily dosing is recommended in the current pe…"}, {"doc_id": "etidronate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.684708833694458, "bge_max": 0.684708833694458, "title": "Etidronate: Drug information", "rep_snippet": "Reference Range  Calcium (total): Adults: 9.0 to 11.0 mg/dL"}, {"doc_id": "chlorpheniramine-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6842729449272156, "bge_max": 0.6842729449272156, "title": "Chlorpheniramine and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to <12 years: One tablet (chlorpheniramine 2 mg/acetaminophen 325 mg) every 4 to 6 hours (maximum: 5 tablets in 24 hours [chlorpheniramine 10 mg/acetaminophen 1…"}, {"doc_id": "magnesium-sulfate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.680760383605957, "bge_max": 0.680760383605957, "title": "Magnesium sulfate: Drug information", "rep_snippet": "≤50 kg: 0.3 to 0.5 mEq elemental magnesium/kg/day  >50 kg: 10 to 30 mEq elemental magnesium daily  Asthma (acute severe exacerbations) (off-label use): IV: Children and Adolescents: 25 to 75 mg/kg (maximum: 2000 mg) as a…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6798965930938721, "bge_max": 0.6798965930938721, "title": "Sodium phosphate: Drug information", "rep_snippet": "Reference Range  Note: Reference ranges may vary depending on the laboratory  Serum calcium: 8.4-10.2 mg/dL  Serum phosphorus: Both low and high ends of the normal range are higher in children than in adults.  Infants: 4…"}, {"doc_id": "sodium-glycerophosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6761775016784668, "bge_max": 0.6761775016784668, "title": "Sodium glycerophosphate: Drug information", "rep_snippet": "Reference Range  Note: Reference ranges may vary depending on the laboratory.  Serum calcium: 8.4-10.2 mg/dL  Serum phosphorus: Both low and high ends of the normal range are higher in children than in adults.  Infants:…"}, {"doc_id": "chlophedianol-and-dexbrompheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6761617660522461, "bge_max": 0.6761617660522461, "title": "Chlophedianol and dexbrompheniramine: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and cold symptoms:  Children 6 to <12 years: Oral: Chlophedianol 12.5 mg/dexbrompheniramine 1 mg (5 mL) every 6 hours (Maximum: Chlophedianol 50 mg/dexbrompheniramine 4 mg (20 mL) per 24 hours.…"}, {"doc_id": "polycarbophil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6761608123779297, "bge_max": 0.6761608123779297, "title": "Polycarbophil: Drug information", "rep_snippet": "Dosing: Pediatric  Constipation or diarrhea: General dosing guidelines (OTC labeling): Oral:  Children 6-12 years: 625 mg calcium polycarbophil 1-4 times/day  Children ≥12 years: Refer to adult dosing."}, {"doc_id": "calcium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6758636832237244, "bge_max": 0.6758636832237244, "title": "Calcium carbonate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Calcium carbonate: Pediatric drug information\")  Note: One gram of calcium carbonate is equal to 400 mg of elemental calcium.  Dosage is in terms of calcium carbonate,…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6722884178161621, "bge_max": 0.6722884178161621, "title": "Esomeprazole: Drug information", "rep_snippet": ">7.5 to 12 kg: 10 mg once daily for up to 6 weeks  Children 1 to 11 years: Note: Safety and efficacy of doses >1 mg/kg/day and/or therapy beyond 8 weeks have not been established.  <20 kg: 10 mg once daily for 8 weeks  ≥…"}, {"doc_id": "thonzylamine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6713512539863586, "bge_max": 0.6713512539863586, "title": "Thonzylamine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Contains phenylephrine 10 mg and thonzylamine 50 mg per 15 mL.  Symptoms of common cold or upper respiratory allergies:  Children 6 to <12 years: Oral: 7.5 mL every 4-6 hours; maximum 6 doses (45…"}, {"doc_id": "chlorpheniramine-phenylephrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6711784601211548, "bge_max": 0.6711784601211548, "title": "Chlorpheniramine, phenylephrine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Note: All dosing is presented in terms of chlorpheniramine maleate, phenylephrine hydrochloride, and dextromethorphan hydrobromide.  Cough and upper respiratory symptoms: Oral: Dosing may vary by produ…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6661427617073059, "bge_max": 0.6710134744644165, "title": "Doxycycline: Drug information", "rep_snippet": "Children ≥45 kg: 100 mg every 12 hours for 14 to 21 days"}, {"doc_id": "peramivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6696679592132568, "bge_max": 0.6696679592132568, "title": "Peramivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Peramivir: Pediatric drug information\")  Influenza: IV: Note: Administer within 2 days of onset of symptoms of influenza.  Children: 2 to 12 years: 12 mg/kg as a single…"}, {"doc_id": "calcium-carbonate-and-simethicone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6690915822982788, "bge_max": 0.6690915822982788, "title": "Calcium carbonate and simethicone: Drug information", "rep_snippet": "Dosing: Pediatric  Antacid: Oral:  Children ≥12 years and Adolescents:  Calcium carbonate 750 mg/simethicone 80 mg: Refer to adult dosing.  Calcium carbonate 750 mg/simethicone 250 mg: Refer to adult dosing.  Calcium car…"}, {"doc_id": "dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6679663062095642, "bge_max": 0.6679663062095642, "title": "Dextromethorphan and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  General dosing guidelines. Also refer to specific product labeling.  Cough/decongestant: Oral: Liquid (dextromethorphan 5 mg and phenylephrine 2.5 mg per 5 mL):  Children 4 to 5 years: 5 mL every 4 hou…"}, {"doc_id": "dexchlorpheniramine-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6673082113265991, "bge_max": 0.6673082113265991, "title": "Dexchlorpheniramine, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and upper respiratory symptoms: Oral:  Children 2 to <6 years of age: Dexchlorpheniramine 1 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 5 mL: 2.5 mL every 4 hours (maximum: 15 mL/24 hours)…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6669650673866272, "bge_max": 0.6669650673866272, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "\"Low\" dose: 80 to 160 mcg daily  \"Medium\" dose: >160 to 320 mcg daily  \"High\" dose: >320 mcg daily  Children ≥12 years of age and Adolescents: Refer to adult dosing.  Global Initiative for Asthma guidelines (GINA 2017):…"}, {"doc_id": "dexbrompheniramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6668382883071899, "bge_max": 0.6668382883071899, "title": "Dexbrompheniramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Common cold/upper respiratory allergies: Oral:  Children 6 to <12 years:  Dexbrompheniramine 1 mg/phenylephrine 5 mg: One tablet or 5 mL every 4 hours (maximum: 6 tablets or 30 mL [dexbrompheniramine 6…"}, {"doc_id": "dextromethorphan-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6662986278533936, "bge_max": 0.6662986278533936, "title": "Dextromethorphan and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Pediatric  General dosing guidelines; consult specific product labeling.  Cough, cold symptoms: Oral:  Children 6 to 11 years: Dextromethorphan 15 mg and chlorpheniramine 2 mg every 6 hours as needed (maximum: 60…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6661863327026367, "bge_max": 0.6661863327026367, "title": "Aluminum hydroxide and magnesium carbonate: Drug information", "rep_snippet": "Dosing: Pediatric  Antacid: Oral: Children ≥12 years and Adolescents: Liquid: Acid Gone (aluminum hydroxide 31.7 mg/magnesium carbonate 119.3 mg per 5 mL): 15 to 30 mL 4 times daily (maximum: 120 mL per 24 hours)"}, {"doc_id": "chlorpheniramine-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6654994487762451, "bge_max": 0.6654994487762451, "title": "Chlorpheniramine, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Note: All dosing is presented in terms of chlorpheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide.  Cough and upper respiratory symptoms: Oral: Dosing may vary by pro…"}, {"doc_id": "clofedanol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.665457010269165, "bge_max": 0.665457010269165, "title": "Clofedanol (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Cough: Oral:  Children 2 to <6 years: 12.5 mg 3 to 4 times daily as needed  Children 6 to <12 years: 12.5 to 25 mg 3 to 4 times daily as needed  Children ≥12 years and Adolescents: Refer to adult dosin…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.665184736251831, "bge_max": 0.665184736251831, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Allergies/co…"}, {"doc_id": "trimeprazine-alimemazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6651220917701721, "bge_max": 0.6651220917701721, "title": "Trimeprazine (alimemazine): Drug information", "rep_snippet": "Dosing: Pediatric  Cough, pruritus: Note: Initiate at low dosage and titrate as needed.  Children 2 to 12 years: Oral: Initial: 2.5 mg to 5 mg once daily at bedtime; if necessary, administer additional dosage of 2.5 mg t…"}, {"doc_id": "ethacrynic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6646947860717773, "bge_max": 0.6646947860717773, "title": "Ethacrynic acid: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ethacrynic acid: Pediatric drug information\")  Edema: Oral: Children: 1 mg/kg/dose once daily; increase at intervals of 2 to 3 days as needed, to a maximum of 3 mg/kg/d…"}, {"doc_id": "calcium-glubionate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6644654273986816, "bge_max": 0.6644654273986816, "title": "Calcium glubionate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Calcium glubionate: Pediatric drug information\")  Dietary supplement: Oral: Note: Each 5 mL contains elemental calcium 115 mg  Infants <12 months: 5 mL 5 times daily; m…"}, {"doc_id": "potassium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6631069183349609, "bge_max": 0.6631069183349609, "title": "Potassium phosphate: Drug information", "rep_snippet": "Reference Range  Note: Reference ranges may vary depending on the laboratory  Serum calcium: 8.4 to 10.2 mg/dL  Serum phosphorus: Both low and high ends of the normal range are higher in children than in adults.  Infants…"}, {"doc_id": "acetaminophen-paracetamol-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6631012558937073, "bge_max": 0.6631012558937073, "title": "Acetaminophen (paracetamol) and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Allergies/common cold/hay fever: Oral: Note: OTC dosing recommendations may vary by product and/or manufacturer. When calculating the maximum daily dose, consider all sources of acetaminophen (prescription…"}, {"doc_id": "chloramphenicol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6618083715438843, "bge_max": 0.6618083715438843, "title": "Chloramphenicol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Chloramphenicol: Pediatric drug information\")  Serious infections: Infants, Children, and Adolescents: IV:  Manufacturer’s labeling: 50 mg/kg/day in divided doses every…"}, {"doc_id": "potassium-phosphate-and-sodium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6617966890335083, "bge_max": 0.6617966890335083, "title": "Potassium phosphate and sodium phosphate: Drug information", "rep_snippet": "Reference Range  Note: Reference ranges may vary depending on the laboratory  Serum potassium: 3.5 to 5.2 mEq/L  Serum phosphorus: Both low and high ends of the normal range are higher in children than in adults.  Infant…"}, {"doc_id": "cefepime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6614792943000793, "bge_max": 0.6614792943000793, "title": "Cefepime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefepime: Pediatric drug information\")  General dosing, susceptible infection (Red Book [AAP 2015]): Infants, Children, and Adolescents: IM, IV:  Mild to moderate infec…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6600258350372314, "bge_max": 0.6600258350372314, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "10 to 15 kg: 0.63 to 1.25 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maximum: 10 mg/day)  >15 kg: 0.63 to 2.5 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maxim…"}, {"doc_id": "carglumic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6593029499053955, "bge_max": 0.6593029499053955, "title": "Carglumic acid: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Carglumic acid: Pediatric drug information\")  Acute hyperammonemia: Infants, Children, and Adolescents: Oral: 100 to 250 mg/kg/day given in 2 or 4 divided doses; titrat…"}, {"doc_id": "chlorpheniramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6591843962669373, "bge_max": 0.6591843962669373, "title": "Chlorpheniramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Upper respiratory tract conditions: Oral: Note: Chlorpheniramine dosing in terms of chlorpheniramine maleate; phenylephrine dosing in terms of phenylephrine hydrochloride:  Children 2 to 5 years:  Liqu…"}, {"doc_id": "magnesium-citrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6591601371765137, "bge_max": 0.6591601371765137, "title": "Magnesium citrate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Magnesium citrate: Pediatric drug information\")  Laxative: Oral: Solution:  Children 2-6 years: 60-90 mL given once or in divided doses (maximum: 90 mL/24 hours)  Child…"}, {"doc_id": "vitamin-c-ascorbic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6583072543144226, "bge_max": 0.6583072543144226, "title": "Vitamin C (ascorbic acid): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Vitamin C (ascorbic acid): Pediatric drug information\")  Parenteral nutrition, maintenance requirement: IV:  Infants: 15 to 25 mg/kg/day; maximum daily dose: 80 mg/day…"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6571990251541138, "bge_max": 0.6571990251541138, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftaroline: Pediatric drug information\")  Pneumonia, community acquired: IV:  Infants ≥2 months and Children <2 years: 8 mg/kg/dose every 8 hours for 5 to 14 days  Chi…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6569727063179016, "bge_max": 0.6569727063179016, "title": "Cefazolin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefazolin: Pediatric drug information\")  Usual dosage range: IM, IV: Infants >1 month, Children, and Adolescents: 25 to 100 mg/kg/day divided every 6 to 8 hours; maximu…"}, {"doc_id": "clemastine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6561875343322754, "bge_max": 0.6561875343322754, "title": "Clemastine: Drug information", "rep_snippet": "Children ≥12 years and Adolescents: Syrup, tablets: Clemastine fumarate 2.68 mg (2 mg base) twice daily or a single 2.68 mg dose, repeat as needed up to a maximum of 2.68 mg 3 times a day. Maximum daily dose: Clemastine…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6556010246276855, "bge_max": 0.6556010246276855, "title": "Aminophylline: Drug information", "rep_snippet": "Infants 6 to 52 weeks: Dose (mg/kg/hour) = [(0.008 x age in weeks) + 0.21] divided by 0.79  Children 1 to <9 years: 1.01 mg/kg/hour  Children 9 to <12 years: 0.89 mg/kg/hour  Adolescents 12 to <16 years (cigarette or mar…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.655236542224884, "bge_max": 0.655236542224884, "title": "Oseltamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oseltamivir: Pediatric drug information\")  Community-acquired pneumonia (influenza suspected or confirmed) (off-label use) (IDSA [Bradley 2011]): Oral:  Prophylaxis:  I…"}]}
{"qid": "Q3_abbr", "query": "12 kg peds fever — ibuprofen dose (mg/kg) + mL with 100 mg/5 mL susp?", "base_qid": "Q3", "variant_type": "abbr", "candidates": [{"doc_id": "articaine-and-epinephrine-drug-information", "bm25_top3": 49.12733700504584, "bm25_max": 49.12733700504584, "bge_top3": null, "bge_max": null, "title": "Articaine and epinephrine: Drug information", "rep_snippet": "Dosing: Adult  Dental anesthesia: Submucosal infiltration and/or nerve block: Articaine 4%/epinephrine: Note: These dosages are guides only; other dosages may be used; however, do not exceed maximum recommended dose. The…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 47.096539055249266, "bm25_max": 47.096539055249266, "bge_top3": null, "bge_max": null, "title": "Doxycycline: Drug information", "rep_snippet": "Children ≥8 years and Adolescents: 2.2 mg/kg/dose (maximum: 100 mg per dose) twice daily for 14 days (CDC 2013).  Chronic: ID consult recommended for treatment of chronic Q fever (CDC 2013)  Rocky Mountain spotted fever:…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 40.81354726576877, "bm25_max": 44.43596253736867, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 40.502036393862674, "bm25_max": 43.331783203791744, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 42.45720162635559, "bm25_max": 42.45720162635559, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 42.07603080432261, "bm25_max": 42.07603080432261, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 41.72362885873353, "bm25_max": 41.72362885873353, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 38.51349484295153, "bm25_max": 41.22893884016931, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 38.465348093135255, "bm25_max": 40.798695188369294, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "GFR 10 to 29 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 24 hours  Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours  Peritoneal dialysis: 25 to 37.5 m…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 40.22915169965451, "bm25_max": 40.22915169965451, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Infants, Children, Adolescents, and Adults: Oral:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: Reduce dose by 50%.  End-stage renal disease…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 39.90923368339047, "bm25_max": 39.90923368339047, "bge_top3": null, "bge_max": null, "title": "Streptomycin: Drug information", "rep_snippet": "Tuberculosis:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: 12 to 15 mg/kg/dose (maximum dose: 1 g) 2 to 3 times weekly  End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): 12 t…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 39.775914382947946, "bm25_max": 39.775914382947946, "bge_top3": null, "bge_max": null, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)  IV:  If the usual recommended dose is 10 mg/kg/dose every 8 hours:  CrCl >50 mL/minute/1.73 m2: No dosage adjustment necessary…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 39.41601246536683, "bm25_max": 39.41601246536683, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Raltegravir: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Note: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioe…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 38.81443616669456, "bm25_max": 39.31168953782209, "bge_top3": 0.6292906999588013, "bge_max": 0.6420342922210693, "title": "Ibuprofen: Drug information", "rep_snippet": "Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&c red #40, fd&c yellow #10 (quinoline yellow), sodium benzoate; berry flavor]  Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&c red #40…"}, {"doc_id": "stavudine-drug-information", "bm25_top3": 38.45400646915895, "bm25_max": 38.45400646915895, "bge_top3": null, "bge_max": null, "title": "Stavudine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl >50 mL/minute:  <60 kg: 30 mg every 12 hours  ≥60 kg: 40 mg every 12 hours  CrCl 26-50 mL/minute:  <60 kg: 15 mg every 12 hours  ≥60 kg: 20 mg every 12 hours  CrCl 10-25 mL/minute…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 37.22738355429873, "bm25_max": 38.16023668396134, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "dinutuximab-drug-information", "bm25_top3": 38.06684154441585, "bm25_max": 38.06684154441585, "bge_top3": null, "bge_max": null, "title": "Dinutuximab: Drug information", "rep_snippet": "Antiemetics: Dinutuximab is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.  Antihistamine: Administer an antihistamine (eg, diphenhydramine 0.5 to 1 mg/kg/dose; m…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": 37.83644180508925, "bm25_max": 37.83644180508925, "bge_top3": null, "bge_max": null, "title": "Amikacin: Drug information", "rep_snippet": "GFR 30 to 50 mL/minute/1.73 m2: Administer every 12 to 18 hours  GFR 10 to 29 mL/minute/1.73 m2: Administer every 18 to 24 hours  GFR <10 mL/minute/1.73 m2: Administer every 48 to 72 hours  Intermittent hemodialysis: 5 m…"}, {"doc_id": "ceftibuten-drug-information", "bm25_top3": 37.7091200200509, "bm25_max": 37.7091200200509, "bge_top3": null, "bge_max": null, "title": "Ceftibuten: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥50 mL//minute: No dosage adjustment necessary.  CrCl 30 to 49 mL//minute: 4.5 mg/kg or 200 mg every 24 hours.  CrCl 5 to 29 mL/minute: 2.25 mg/kg or 100 mg every 24 hours.  End-stage renal…"}, {"doc_id": "lamivudine-drug-information", "bm25_top3": 37.66809627619165, "bm25_max": 37.68812279219484, "bge_top3": null, "bge_max": null, "title": "Lamivudine: Drug information", "rep_snippet": "Dosing: Renal Impairment  HIV-1 infection:  Adults:  ESRD requiring hemodialysis: Administer 50 mg first dose, then 25 mg once daily (IDSA [Lucas 2014]). Negligible amounts are removed by 4-hour hemodialysis or peritonea…"}, {"doc_id": "ethanol-topical-and-injection-drug-information", "bm25_top3": 37.217851537785776, "bm25_max": 37.217851537785776, "bge_top3": null, "bge_max": null, "title": "Ethanol (topical and injection): Drug information", "rep_snippet": "Chronic drinker: 154 mg/kg/hour [equivalent to 1.96 mL/kg/hour using a 10% solution]  Dosage adjustment for hemodialysis: Maintenance dose:  Nondrinker: 169 mg/kg/hour [equivalent to 2.13 mL/kg/hour using a 10% solution]…"}, {"doc_id": "famotidine-drug-information", "bm25_top3": 37.09434693030722, "bm25_max": 37.09434693030722, "bge_top3": null, "bge_max": null, "title": "Famotidine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl <50 mL/minute: Administer 50% of dose or increase the dosing interval to every 36 to 48 hours.  Pediatric: There are no specifi…"}, {"doc_id": "peramivir-drug-information", "bm25_top3": 37.09099719668037, "bm25_max": 37.09099719668037, "bge_top3": null, "bge_max": null, "title": "Peramivir: Drug information", "rep_snippet": "CrCl 10 to 29 mL/minute: 2 mg/kg as a single dose (maximum single dose: 100 mg)  ESRD requiring hemodialysis: 2 mg/kg as a single dose, administered after dialysis (maximum single dose: 100 mg)"}, {"doc_id": "foscarnet-drug-information", "bm25_top3": 36.60124689119333, "bm25_max": 36.60124689119333, "bge_top3": null, "bge_max": null, "title": "Foscarnet: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  See tables.  Induction Dosing of Foscarnet in Patients With Abnormal Renal Function  CrCl (mL/min/kg)  HSV  HSV  CMV  CMV  Equivalent to 40 mg/kg every 12 hours  Equivalent to 40 mg/kg e…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 36.36283764147572, "bm25_max": 36.36283764147572, "bge_top3": null, "bge_max": null, "title": "Iodixanol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Iodixanol: Pediatric drug information\")  Children <12 years:  Angiocardiography, cerebral arteriography, visceral arteriography: Intra-arterial: Iodixanol 320 mg iodine…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": 36.184533890029954, "bm25_max": 36.184533890029954, "bge_top3": null, "bge_max": null, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "The following adjustments have been recommended (Aronoff 2007): Note: Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours:  GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.…"}, {"doc_id": "methohexital-drug-information", "bm25_top3": 36.06606481236185, "bm25_max": 36.06606481236185, "bge_top3": null, "bge_max": null, "title": "Methohexital: Drug information", "rep_snippet": "Preoperative, anesthesia induction, or preprocedural: Children and Adolescents: ﻿Rectal: Usual: 25 mg/kg/dose; range: 20 to 35 mg/kg/dose; maximum dose: 500 mg/dose; give as 10% (100 mg/mL) aqueous solution 5 to15 minute…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 35.93234174781359, "bm25_max": 35.93234174781359, "bge_top3": null, "bge_max": null, "title": "Amoxicillin: Drug information", "rep_snippet": "Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 8 to 20 mg/kg/dose every 24 hours; give after dialysis.  Peritoneal dialysis: 8 to 20 mg/kg/dose every 24 hours.  Severe infection (h…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": 35.425743870016845, "bm25_max": 35.52471737413013, "bge_top3": null, "bge_max": null, "title": "Hyoscyamine: Drug information", "rep_snippet": "Tablets (regular release [Levsin], sublingual [Levsin/SL], dispersible [ED-SPAZ, NuLev]): 0.0625 to 0.125 mg every 4 hours or as needed; maximum: 0.75 mg/day  Drops (Hyosyne [0.125 mg/mL]): 0.03125 mg (0.25 mL) to 0.125…"}, {"doc_id": "iohexol-drug-information", "bm25_top3": 34.8349520229114, "bm25_max": 34.8349520229114, "bge_top3": null, "bge_max": null, "title": "Iohexol: Drug information", "rep_snippet": "Iohexol 350: 1.25 mL/kg (range: 1 to 1.5 mL/kg); if multiple injections are given, do not exceed 5 mL/kg or up to a total of 250 mL  Pulmonary angiography: Iohexol 350: 1 mL/kg  Combined angiocardiographic procedures: Ma…"}, {"doc_id": "omalizumab-drug-information", "bm25_top3": 34.474703558320705, "bm25_max": 34.474703558320705, "bge_top3": 0.610070526599884, "bge_max": 0.6157549619674683, "title": "Omalizumab: Drug information", "rep_snippet": ">90 kg: Do not administer  Pretreatment serum IgE >500 to 600 units/mL:  20 to 30 kg: 300 mg every 4 weeks  >30 to 40 kg: 225 mg every 2 weeks  >40 to 60 kg: 300 mg every 2 weeks  >60 to 70 kg: 375 mg every 2 weeks  >70…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 24.999770926997286, "bm25_max": 25.346539120219305, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Bivigam 10%: Primary humoral immunodeficiency: Initial (first 10 minutes): 0.5 mg/kg/minute (0.3 mL/kg/hour); Maintenance: Increase every 20 minutes (if tolerated) by 0.8 mg/kg/minute (0.48 mL/kg/hour) up to 6 mg/kg/minu…"}, {"doc_id": "promethazine-drug-information", "bm25_top3": 23.455789509942434, "bm25_max": 23.455789509942434, "bge_top3": null, "bge_max": null, "title": "Promethazine: Drug information", "rep_snippet": "Pricing: US  Solution (Phenergan Injection)  25 mg/mL (1 mL): $3.85  50 mg/mL (1 mL): $5.35  Solution (Promethazine HCl Injection)  25 mg/mL (1 mL): $2.40  50 mg/mL (1 mL): $4.32  Suppository (Phenadoz Rectal)  12.5 mg (…"}, {"doc_id": "guaifenesin-drug-information", "bm25_top3": 23.313174452211392, "bm25_max": 23.313174452211392, "bge_top3": null, "bge_max": null, "title": "Guaifenesin: Drug information", "rep_snippet": "Pricing: US  Liquid (Buckleys Chest Congestion Oral)  100 mg/5 mL (118 mL): $4.79  Liquid (Diabetic Tussin Oral)  100 mg/5 mL (118 mL): $4.20  Liquid (GuaiFENesin Oral)  100 mg/5 mL (10 mL): $0.64  Liquid (Mucinex Chest…"}, {"doc_id": "guaifenesin-and-dextromethorphan-drug-information", "bm25_top3": 21.6071833867342, "bm25_max": 21.6071833867342, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and dextromethorphan: Drug information", "rep_snippet": "5-100 mg/5 mL (118 mL): $5.38  20-400 mg/20 mL (118 mL): $6.60  Liquid (Robitussin To Go Cgh/Chest DM Oral)  100-10 mg/5 mL (10 mL): $0.82  Liquid (Safe Tussin DM Oral)  100-10 mg/5 mL (120 mL): $5.26  Liquid (Trispec DM…"}, {"doc_id": "pseudoephedrine-and-ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6528797745704651, "bge_max": 0.6644353866577148, "title": "Pseudoephedrine and ibuprofen: Drug information", "rep_snippet": "Dosing: Adult  Cold, sinus, and flu symptoms: Oral: One capsule/tablet (pseudoephedrine 30 mg/ibuprofen 200 mg) every 4 to 6 hours while symptoms persist; may increase to 2 tablets/capsules (pseudoephedrine 60 mg/ibuprof…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6305081844329834, "bge_max": 0.6412808299064636, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Common cold/flu: Oral: Ibuprofen 200 mg/phenylephrine 10 mg every 4 hours (maximum: ibuprofen 1,200 mg/phenylephrine 60 mg per 24 hours)"}, {"doc_id": "naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6286190152168274, "bge_max": 0.6286190152168274, "title": "Naproxen: Drug information", "rep_snippet": "OTC labeling: Pain, fever: 200 mg every 8 to 12 hours; if needed, may take 400 mg for the initial dose; maximum: 400 mg in any 8- to 12-hour period or 600 mg/24 hours"}, {"doc_id": "ibuprofen-phenylephrine-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6170253157615662, "bge_max": 0.6252265572547913, "title": "Ibuprofen, phenylephrine, and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  Common cold/upper respiratory allergies: Oral: One tablet (ibuprofen 200 mg/phenylephrine 10 mg/chlorpheniramine 4 mg) every 4 hours. Maximum: 6 tablets (ibuprofen 1,200 mg/phenylephrine 60 mg/chlorphenira…"}, {"doc_id": "hydrocodone-and-ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.622471034526825, "bge_max": 0.622471034526825, "title": "Hydrocodone and ibuprofen: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = discontinued product  Tablet, oral:  Ibudone:  5/200: Hydrocodone bitartrate 5…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6220874786376953, "bge_max": 0.6220874786376953, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Tylenol Extra Strength: 500 mg/15 mL (240 mL [DSC]) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]  Solution, oral: 160 mg/5 mL (5 mL, 10 mL, 20 mL)  Pain & Fever Children's: 160 mg/5 mL (118 m…"}, {"doc_id": "ibuprofen-pseudoephedrine-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6215471625328064, "bge_max": 0.6215471625328064, "title": "Ibuprofen, pseudoephedrine, and chlorpheniramine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Caplet:  Advil Allergy Sinus, Advil® Multi-Symptom Cold: Ibuprofen 200 mg, pseudoephe…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6214261651039124, "bge_max": 0.6214261651039124, "title": "Prednisone: Drug information", "rep_snippet": "Class III-IV lupus nephritis: 0.5 to 1 mg/kg/day (after glucocorticoid pulse) tapered after a few weeks to lowest effective dose, in combination with an immunosuppressive agent (Hahn 2012).  Class V lupus nephritis: 0.5…"}, {"doc_id": "aspirin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6203806400299072, "bge_max": 0.6203806400299072, "title": "Aspirin: Drug information", "rep_snippet": "Moderate dose: 30 to 50 mg/kg/day divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AHA [McCrindle 2017]).  Subsequent therapy (low-dose; antiplatelet effects): 3 to 5 mg/kg/day on…"}, {"doc_id": "canakinumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.620243489742279, "bge_max": 0.620243489742279, "title": "Canakinumab: Drug information", "rep_snippet": "Dosing: Adult  Cryopyrin-associated periodic syndromes (CAPS): SubQ: 150 mg (>40 kg) or 2 mg/kg (15 to 40 kg) every 8 weeks; in clinical trials, dosage adjustments up to 600 mg (>40 kg) or 8 mg/kg (≤40 kg) and/or increas…"}, {"doc_id": "epinephrine-adrenaline-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6190450191497803, "bge_max": 0.6190450191497803, "title": "Epinephrine (adrenaline) (systemic): Drug information", "rep_snippet": "Dosing: Adult  Note: As of May 1, 2016, ratio expressions of epinephrine concentrations are prohibited on drug labels. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory…"}, {"doc_id": "buprenorphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6131222546100616, "bge_max": 0.6176500916481018, "title": "Buprenorphine: Drug information", "rep_snippet": "Dosing: Adult  Note: Buprenorphine 8 mg sublingual tablet = buprenorphine/naloxone 8 mg/2 mg sublingual film = buprenorphine/naloxone 4.2 mg/0.7 mg buccal film = buprenorphine/naloxone 5.7 mg/1.4 mg sublingual tablet.  A…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6161798238754272, "bge_max": 0.6161798238754272, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Adult  Cough and upper respiratory tract symptoms: Oral: Note: Dosing may vary by product. Consult specific product labeling.  Liquid (dextromethorphan 15 mg/guaifenesin 175 mg/pseudoephedrine 30 mg per 5 mL): 10…"}, {"doc_id": "naproxen-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6147233843803406, "bge_max": 0.6147233843803406, "title": "Naproxen and pseudoephedrine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Caplet, extended release:  Aleve-D Sinus & Cold [DSC], A…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6123186349868774, "bge_max": 0.6123186349868774, "title": "Phenobarbital: Drug information", "rep_snippet": "Dosing: Adult  Sedation:  Oral, IV, IM: 30 to 120 mg/day in 2 to 3 divided doses; maximum: 400 mg/day  Preoperative sedation: IM: 100 to 200 mg 60 to 90 minutes before surgery  Status epilepticus: IV:  American Epilepsy…"}, {"doc_id": "pentobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6117568016052246, "bge_max": 0.6117568016052246, "title": "Pentobarbital: Drug information", "rep_snippet": "Dosing: Adult  Note: Adjust dose based on patient's age, weight, and condition.  Sedative/hypnotic/preanesthesia:  IM: 150 to 200 mg, as a single dose.  IV: Initial: 100 mg; if needed, may administer additional increment…"}, {"doc_id": "inosine-pranobex-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6110610365867615, "bge_max": 0.6110610365867615, "title": "Inosine pranobex (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Subacute sclerosing panencephalitis (SSPE): Oral: 50 mg/kg/day in 3-4 equally divided doses (maximum: 3 g daily)"}, {"doc_id": "cefepime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6107499599456787, "bge_max": 0.6107499599456787, "title": "Cefepime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefepime: Pediatric drug information\")  General dosing, susceptible infection (Red Book [AAP 2015]): Infants, Children, and Adolescents: IM, IV:  Mild to moderate infec…"}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6099222898483276, "bge_max": 0.6099222898483276, "title": "Fosphenytoin: Drug information", "rep_snippet": "Dosing: Adult  Note: The dose, concentration, and infusion rates for fosphenytoin are expressed as phenytoin equivalents (PE); fosphenytoin should always be prescribed and dispensed in phenytoin equivalents (PE); fosphen…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6087291240692139, "bge_max": 0.6087291240692139, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Caplet, oral:  Comtrex Maximum Strength, Non-Drowsy Cold…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6084485650062561, "bge_max": 0.6084485650062561, "title": "Sulfadiazine: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Oral: 2 to 4 g/day in 3 to 6 divided doses  Rheumatic fever prophylaxis (off-label dose) (Gerber [AHA 2009]): Oral:  ≤27 kg: 500 mg once daily  >27 kg: 1,000 mg once daily  Toxop…"}, {"doc_id": "buprenorphine-and-naloxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6062552630901337, "bge_max": 0.6082780361175537, "title": "Buprenorphine and naloxone: Drug information", "rep_snippet": "Sublingual film (Suboxone: Buprenorphine 2 mg/naloxone 0.5 mg; buprenorphine 4 mg/naloxone 1 mg; buprenorphine 8 mg/naloxone 2 mg; buprenorphine 12 mg/naloxone 3 mg): Sublingual or buccal: Target dose: Buprenorphine 16 m…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6078915596008301, "bge_max": 0.6078915596008301, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Theraflu Warming Cold & Chest: Acetaminophen 325 mg, guaifenesin 200 mg, and phenylephrine hydrochloride 5 mg per 15 mL (245.5 mL [DSC]) [contains benzyl alcohol, edetate disodium, fd&c yellow #6 (sunset yellow), propyle…"}, {"doc_id": "isoflurane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6074532270431519, "bge_max": 0.6074532270431519, "title": "Isoflurane: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution, Inhalation:  Forane: USP: >= 99.9 mL/100 mL (100 mL, 250 mL)  Terrell: USP:…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6074095368385315, "bge_max": 0.6074095368385315, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Dosing: Pediatric  Partial-onset seizures (epilepsy) (monotherapy or adjunctive therapy): Children ≥4 years of age and Adolescents: Oral:  11 to 21 kg: Initial: 200 mg once daily; increase in weekly increments of no more…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6072022318840027, "bge_max": 0.6072022318840027, "title": "Phenytoin: Drug information", "rep_snippet": "Dosing: Adult  Note: Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitor…"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6064192056655884, "bge_max": 0.6064192056655884, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Dosing: Adult  Adjunctive therapy, partial seizures (epilepsy): Oral:  Immediate release: Initial: 600 mg daily in 2 divided doses; dose may be increased by as much as 600 mg/day increments at weekly intervals; maximum r…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6058946251869202, "bge_max": 0.6058946251869202, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Upper respiratory symptoms: Oral: 5 mL (promethazine 6.25 mg/phenylephrine 5 mg) every 4 to 6 hours; maximum: 30 mL (promethazine 37.5 mg/phenylephrine 30 mg)/24 hours"}, {"doc_id": "acetaminophen-paracetamol-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.605834424495697, "bge_max": 0.605834424495697, "title": "Acetaminophen (paracetamol) and phenylephrine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product.  Caplet, oral:  Contac Cold + Flu Maximum Strength Non D…"}, {"doc_id": "piperacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6055597066879272, "bge_max": 0.6055597066879272, "title": "Piperacillin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Community-acquired pneumonia: IM, IV: Usual dosage: 6 to 8 g daily (100 to 125 mg/kg daily) in divided doses every 6 to 12 hours  Severe infections (eg, gynecologic, intra-abdominal, nosocomial pneumonia,…"}, {"doc_id": "valproate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6048442125320435, "bge_max": 0.6048442125320435, "title": "Valproate: Drug information", "rep_snippet": "Status epilepticus (off-label use): Infants, Children, and Adolescents: IV: 20 to 40 mg/kg administered at rate of 1.5 to 3 mg/kg/minute; if necessary, may give an additional dose of 20 mg/kg 10 minutes after the loading…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6045731902122498, "bge_max": 0.6045731902122498, "title": "Methylprednisolone: Drug information", "rep_snippet": "Status asthmaticus (previous NAEPP guidelines; still used by some clinicians): Children: IV: Loading dose: 2 mg/kg/dose, then 0.5 to 1 mg/kg/dose every 6 hours; Note: See NAEPP 2007 guidelines for asthma exacerbations (e…"}, {"doc_id": "guaifenesin-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6044366359710693, "bge_max": 0.6044366359710693, "title": "Guaifenesin, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Also refer to specific product labeling.  Cough/decongestant: Oral:  Liquid (Robitussin Peak Cold Multi-Symptom Cold): Guaifenesin 200 mg, dextromethorphan 20 mg, and phenylephrine 10 mg (10 mL) every 4 ho…"}, {"doc_id": "ketamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.604266881942749, "bge_max": 0.604266881942749, "title": "Ketamine: Drug information", "rep_snippet": "Analgesia (subanesthetic dosing) (off-label use):  Acute pain: Intranasal (off-label route): 0.5 to 1 mg/kg; may repeat in 10 to 15 minutes with 0.25 to 0.5 mg/kg if necessary (Andolfatto 2013; Corrigan 2015; Yeaman 2014…"}, {"doc_id": "midazolam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6042178273200989, "bge_max": 0.6042178273200989, "title": "Midazolam: Drug information", "rep_snippet": "Intranasal: Limited data available: 0.2 mg/kg (NCS [Brophy 2012]). Note: Use 5 mg/mL injectable concentrated solution to deliver dose. Due to the low pH of the solution, burning upon administration is likely to occur (Ba…"}, {"doc_id": "triprolidine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6039307713508606, "bge_max": 0.6039307713508606, "title": "Triprolidine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Triprolidine and pseudoephedrine: Pediatric drug information\")  Cold, allergy symptoms: Oral:  Liquid (triprolidine 0.938 mg and pseudoephedrine 10 mg per 1 mL):  Child…"}, {"doc_id": "acetaminophen-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6037131547927856, "bge_max": 0.6037131547927856, "title": "Acetaminophen and pseudoephedrine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Tablet, Oral:  Nexafed Sinus Pressure + Pain: Acetaminophen 325 mg and pseudoephedrin…"}]}
{"qid": "Q3_distractor-conc", "query": "12-kg child; use the 100/5 ibuprofen (not 200/5). What mg/kg and mL per dose?", "base_qid": "Q3", "variant_type": "distractor-conc", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 55.603610560642025, "bm25_max": 56.05863886125093, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "lidocaine-topical-drug-information", "bm25_top3": 51.05601779759285, "bm25_max": 51.05601779759285, "bge_top3": null, "bge_max": null, "title": "Lidocaine (topical): Drug information", "rep_snippet": "Anesthesia of the pharynx: 15 mL gargled no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg per dose]; 8 doses per 24-hour period); may be swallowed  Oral topical solution (4%):  Note: For use in mucous…"}, {"doc_id": "articaine-and-epinephrine-drug-information", "bm25_top3": 49.10829323535389, "bm25_max": 49.10829323535389, "bge_top3": null, "bge_max": null, "title": "Articaine and epinephrine: Drug information", "rep_snippet": "Dosing: Adult  Dental anesthesia: Submucosal infiltration and/or nerve block: Articaine 4%/epinephrine: Note: These dosages are guides only; other dosages may be used; however, do not exceed maximum recommended dose. The…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 48.37782970306734, "bm25_max": 48.37782970306734, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Antibody-mediated rejection in cardiac transplantation, treatment (off-label use): Dose/frequency/duration of treatment varies greatly: 100 to 2,000 mg/kg (dose may be divided into 2 or 4 doses) 1 to 3 times per week, of…"}, {"doc_id": "ioxaglate-meglumine-and-ioxaglate-sodium-drug-information", "bm25_top3": 47.54228307733174, "bm25_max": 47.54228307733174, "bge_top3": null, "bge_max": null, "title": "Ioxaglate meglumine and ioxaglate sodium: Drug information", "rep_snippet": "Dosing: Pediatric  Pediatric angiocardiography: Catheter injection into heart or associated large vessels: Usual total dose per procedure (including diagnostic and test dose) is ~4 mL/kg (range 1.5 to 5 mL/kg)  Infants a…"}, {"doc_id": "lidocaine-and-epinephrine-drug-information", "bm25_top3": 47.13595659338347, "bm25_max": 47.13595659338347, "bge_top3": null, "bge_max": null, "title": "Lidocaine and epinephrine: Drug information", "rep_snippet": "Dosing: Adult  Anesthesia:  Dental: Oral infiltration/mandibular block: Initial: 1 to 5 mL (lidocaine 20 mg to 100 mg). Note: For most routine dental procedures, lidocaine 2% with epinephrine 1:100,000 is preferred. When…"}, {"doc_id": "atovaquone-and-proguanil-drug-information", "bm25_top3": 46.45467640880802, "bm25_max": 46.45467640880802, "bge_top3": null, "bge_max": null, "title": "Atovaquone and proguanil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atovaquone and proguanil: Pediatric drug information\")  Prevention of malaria: Oral: Start 1-2 days prior to entering a malaria-endemic area, continue throughout the st…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 40.18453265980223, "bm25_max": 40.18453265980223, "bge_top3": null, "bge_max": null, "title": "Itraconazole: Drug information", "rep_snippet": "HSCT, allogeneic: 2.5 mg/kg every 12 hours after completion of the conditioning regimen; continue until at least day +100.  HSCT, autologous: 2.5 mg/kg every 12 hours after last dose of chemotherapy; continue until neutr…"}, {"doc_id": "hydrocodone-and-ibuprofen-drug-information", "bm25_top3": 39.4937797782186, "bm25_max": 39.4937797782186, "bge_top3": 0.6578279733657837, "bge_max": 0.6578279733657837, "title": "Hydrocodone and ibuprofen: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = discontinued product  Tablet, oral:  Ibudone:  5/200: Hydrocodone bitartrate 5…"}, {"doc_id": "minocycline-drug-information", "bm25_top3": 37.851785810757626, "bm25_max": 39.41434701470197, "bge_top3": null, "bge_max": null, "title": "Minocycline: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range:  IV: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours (maximum: 400 mg daily)  Oral: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours; more frequent dosing i…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 38.70497107848073, "bm25_max": 39.206894664805915, "bge_top3": 0.7010017037391663, "bge_max": 0.7268227338790894, "title": "Ibuprofen: Drug information", "rep_snippet": "Pricing: US  Capsules (Advil Migraine Oral)  200 mg (40): $6.97  Capsules (Advil Oral)  200 mg (2): $0.27  Capsules (Ibuprofen Oral)  200 mg (80): $6.32  Chewable (Advil Junior Strength Oral)  100 mg (24): $4.32  Kit (Ib…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 37.867589189089706, "bm25_max": 38.82764065369725, "bge_top3": 0.6594054500261942, "bge_max": 0.6620336174964905, "title": "Voriconazole: Drug information", "rep_snippet": "IV: Maintenance dose may be reduced from 4 mg/kg every 12 hours to 3 mg/kg every 12 hours, depending upon condition.  Oral: Maintenance dose may be reduced in 50 mg decrements to a minimum dosage of 200 mg every 12 hours…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 38.4761577154192, "bm25_max": 38.4761577154192, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 37.661752739453156, "bm25_max": 38.472399641705266, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Alternate dosing:  Hematopoietic cell transplant recipients (allogeneic): 5 mg/kg/dose every 12 hours for 5 to 7 days, then 5 mg/kg/dose every 24 hours until day 100 post-transplant (Tomblyn 2009).  Solid organ transplan…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 38.46104476205756, "bm25_max": 38.46104476205756, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "guaifenesin-and-dextromethorphan-drug-information", "bm25_top3": 37.981400720046835, "bm25_max": 38.2506067685441, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and dextromethorphan: Drug information", "rep_snippet": "Robitussin Peak Cold Cough + Chest Congestion DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL ( 120 mL, 240 mL) [contains menthol, propylene glycol, sodium 3.5 mg/5 mL, sodium benzoate]  Robitussi…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 37.72228781269041, "bm25_max": 37.72228781269041, "bge_top3": null, "bge_max": null, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Powder for oral suspension: Erythromycin ethylsuccinate…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 37.69681492263842, "bm25_max": 37.69681492263842, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "iothalamate-meglumine-drug-information", "bm25_top3": 37.663705891498054, "bm25_max": 37.663705891498054, "bge_top3": null, "bge_max": null, "title": "Iothalamate meglumine: Drug information", "rep_snippet": "Conray 43: Usual dose: 200 to 250 mL by bolus injection, rapid infusion or both; when using the combination bolus and infusion technique, 50 to 100 mL bolus injection followed by a rapid infusion of 100 to 150 mL may be…"}, {"doc_id": "prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information", "bm25_top3": 35.960029290337125, "bm25_max": 37.25639668208529, "bge_top3": null, "bge_max": null, "title": "Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information", "rep_snippet": "Other severe hemorrhage (eg, intracranial hemorrhage): 100 units/kg every 6 to 12 hours; continue until resolution of bleed (maximum: 100 units/kg/dose; 200 units/kg/day).  Perioperative management:  Preoperative: 50 to…"}, {"doc_id": "guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 37.085700296204756, "bm25_max": 37.085700296204756, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and phenylephrine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Liquid, oral:  Ed Bron GP: Guaifenesin 100 mg and phenyl…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 36.86303876272471, "bm25_max": 36.86303876272471, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Raltegravir: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Note: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioe…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 36.14508170259499, "bm25_max": 36.71819981521626, "bge_top3": null, "bge_max": null, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)  IV:  If the usual recommended dose is 10 mg/kg/dose every 8 hours:  CrCl >50 mL/minute/1.73 m2: No dosage adjustment necessary…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 36.52302393769401, "bm25_max": 36.52302393769401, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "GFR 10 to 29 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 24 hours  Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours  Peritoneal dialysis: 25 to 37.5 m…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 34.91444533639013, "bm25_max": 36.40842396389262, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "ceftibuten-drug-information", "bm25_top3": 36.09427477961934, "bm25_max": 36.09427477961934, "bge_top3": null, "bge_max": null, "title": "Ceftibuten: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥50 mL//minute: No dosage adjustment necessary.  CrCl 30 to 49 mL//minute: 4.5 mg/kg or 200 mg every 24 hours.  CrCl 5 to 29 mL/minute: 2.25 mg/kg or 100 mg every 24 hours.  End-stage renal…"}, {"doc_id": "atazanavir-drug-information", "bm25_top3": 35.929685207035924, "bm25_max": 35.929685207035924, "bge_top3": null, "bge_max": null, "title": "Atazanavir: Drug information", "rep_snippet": "5 to <15 kg: Atazanavir 200 mg (4 packets) plus ritonavir 80 mg once daily. In antiretroviral-naïve patients weighing 5 to <10 kg unable to tolerate this dose, may use atazanavir 150 mg (3 packets) plus ritonavir 80 mg o…"}, {"doc_id": "didanosine-drug-information", "bm25_top3": 35.80290174973189, "bm25_max": 35.80290174973189, "bge_top3": null, "bge_max": null, "title": "Didanosine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Dosing based on patient weight, creatinine clearance, and dosage form: See table.  Recommended Dose (mg) of Didanosine by Body Weight − Adults  Creatinine Clearance (mL/min)  ≥60 kg  <60…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": 34.82815454731774, "bm25_max": 34.82815454731774, "bge_top3": null, "bge_max": null, "title": "Zidovudine: Drug information", "rep_snippet": "Infants (born at or near term with PMA ≥35 weeks) weighing ≥4 kg, Children, and Adolescents: Note: The 3-times-daily dosing is FDA approved but rarely used in practice; twice-daily dosing is recommended in the current pe…"}, {"doc_id": "guaifenesin-drug-information", "bm25_top3": 34.69114322561125, "bm25_max": 34.69114322561125, "bge_top3": null, "bge_max": null, "title": "Guaifenesin: Drug information", "rep_snippet": "Pricing: US  Liquid (Buckleys Chest Congestion Oral)  100 mg/5 mL (118 mL): $4.79  Liquid (Diabetic Tussin Oral)  100 mg/5 mL (118 mL): $4.20  Liquid (GuaiFENesin Oral)  100 mg/5 mL (10 mL): $0.64  Liquid (Mucinex Chest…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6769087910652161, "bge_max": 0.6769087910652161, "title": "Doxycycline: Drug information", "rep_snippet": "Children ≥45 kg: 100 mg every 12 hours for 14 to 21 days"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6734039783477783, "bge_max": 0.6734039783477783, "title": "Aminophylline: Drug information", "rep_snippet": "Infants 6 to 52 weeks: Dose (mg/kg/hour) = [(0.008 x age in weeks) + 0.21] divided by 0.79  Children 1 to <9 years: 1.01 mg/kg/hour  Children 9 to <12 years: 0.89 mg/kg/hour  Adolescents 12 to <16 years (cigarette or mar…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6726356148719788, "bge_max": 0.6726356148719788, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "10 to 15 kg: 0.63 to 1.25 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maximum: 10 mg/day)  >15 kg: 0.63 to 2.5 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maxim…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.672448992729187, "bge_max": 0.672448992729187, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Children 2 to 12 years: 12.5 mg/kg every 4 hours or 15 mg/kg every 6 hours; maximum single dose: 15 mg/kg/dose (≤750 mg/dose); maximum daily dose: 75 mg/kg/day (≤3.75 g/day)  Adolescents: Refer to adult dosing."}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6719727516174316, "bge_max": 0.6719727516174316, "title": "Esomeprazole: Drug information", "rep_snippet": ">7.5 to 12 kg: 10 mg once daily for up to 6 weeks  Children 1 to 11 years: Note: Safety and efficacy of doses >1 mg/kg/day and/or therapy beyond 8 weeks have not been established.  <20 kg: 10 mg once daily for 8 weeks  ≥…"}, {"doc_id": "amphetamine-sulfate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.670127272605896, "bge_max": 0.670127272605896, "title": "Amphetamine sulfate: Drug information", "rep_snippet": "Children ≥6 years of age and Adolescents: Oral: Initial: 5 mg once or twice daily; increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to…"}, {"doc_id": "buprenorphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6592698097229004, "bge_max": 0.6668497920036316, "title": "Buprenorphine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Buprenorphine: Pediatric drug information\")  Acute pain (moderate to severe):  Immediate-release injection:  Children 2 to 12 years: IM, slow IV: 2 to 6 mcg/kg every 4…"}, {"doc_id": "haloperidol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6633822023868561, "bge_max": 0.6643379926681519, "title": "Haloperidol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Haloperidol: Pediatric drug information\")  Behavior disorders, nonpsychotic:  Children 3 to 12 years weighing 15 to 40 kg: Oral: Initial: 0.5 mg/day in 2 to 3 divided d…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6640264987945557, "bge_max": 0.6640264987945557, "title": "Sodium phosphate: Drug information", "rep_snippet": "Children 5-9 years: 7.5 mL as a single dose; maximum single daily dose: 7.5 mL  Children 10-11 years: 15 mL as a single dose; maximum single daily dose: 15 mL  Children ≥12 years: Refer to adult dosing."}, {"doc_id": "para-aminosalicylic-acid-aminosalicylate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6629687547683716, "bge_max": 0.6629687547683716, "title": "Para-aminosalicylic acid (aminosalicylate) : Drug information", "rep_snippet": "Dosing: Pediatric  Tuberculosis (second-line agent):  Children ≤40 kg and Adolescents <15 years: Oral: 200 to 300 mg/kg/day (usually 100 mg/kg/dose 2 to 3 times daily). Note: Use in combination with other antituberculous…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6624161601066589, "bge_max": 0.6624161601066589, "title": "Ondansetron: Drug information", "rep_snippet": "Infants ≥1 month and Children ≤12 years: IV:  ≤40 kg: 0.1 mg/kg as a single dose over 2 to 5 minutes  >40 kg: 4 mg as a single dose over 2 to 5 minutes  Adolescents >12 years: IV, IM: Refer to adult dosing."}, {"doc_id": "diphenhydramine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.662036657333374, "bge_max": 0.662036657333374, "title": "Diphenhydramine (systemic): Drug information", "rep_snippet": "Children ≥12 years and Adolescents: Refer to adult dosing.  Motion sickness:  Prophylaxis: Oral:  Manufacturer's labeling: Infants, Children, and Adolescents: Note: Administer 30 minutes before motion  Weight-directed do…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6616357564926147, "bge_max": 0.6616357564926147, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Infants and Children: 2 mg/kg/dose or 15 mg/m2/dose once daily (maximum daily dose: 25 mg/day), in combination with pyrimethamine and leucovorin (HHS [OI pediatric] 2015)  Adolescents (mild to moderate disease): Refer to…"}, {"doc_id": "nalbuphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6615912914276123, "bge_max": 0.6615912914276123, "title": "Nalbuphine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nalbuphine: Pediatric drug information\")  Pain, moderate to severe (off-label use): Children ≥1 year and Adolescents: IM, IV, SubQ: 0.1 to 0.2 mg/kg every 3 to 4 hours…"}, {"doc_id": "dextroamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6606253981590271, "bge_max": 0.6606253981590271, "title": "Dextroamphetamine: Drug information", "rep_snippet": "Children 6 to 12 years: Oral: Initial: 5 mg once daily; may increase in increments of 5 mg at weekly intervals until optimal response is obtained; usual dosage: 5 to 60 mg daily in divided doses.  Children >12 years and…"}, {"doc_id": "ethosuximide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6603955030441284, "bge_max": 0.6603955030441284, "title": "Ethosuximide: Drug information", "rep_snippet": "Alternate dosing: Children ≥2 years and Adolescents: Oral: Initial: 10 mg/kg/day, titrated to response in 5 to 10 mg/kg/day increments every 7 days as required; usual range: 20 to 30 mg/kg/day in 2 to 3 divided doses (Gl…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6603536605834961, "bge_max": 0.6603536605834961, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and upper respiratory tract symptoms: Oral:  Note: Dosing may vary by product. Consult specific product labeling.  Drops (dextromethorphan 2.5 mg/guaifenesin 25 mg/pseudoephedrine 7.5 mg per mL):…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6603235006332397, "bge_max": 0.6603235006332397, "title": "Diazepam: Drug information", "rep_snippet": "Children >12 years and Adolescents: 0.2 mg/kg  Spasticity in cerebral palsy (off-label use): Oral: Dose should be individualized:  Children ≤5 years: <8.5 kg: 0.5 to 1 mg at bedtime; 8.5 to 15 kg: 1 to 2 mg at bedtime (M…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6598454117774963, "bge_max": 0.6598454117774963, "title": "Oseltamivir: Drug information", "rep_snippet": ">40 kg: 75 mg twice daily  Adolescents ≥13 years: Refer to adult dosing.  Alternate recommendations:  American Academy of Pediatrics: Infants <12 months (off-label dosing; AAP 2013): Note: Age defined as postmenstrual ag…"}, {"doc_id": "omalizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6594524383544922, "bge_max": 0.6594524383544922, "title": "Omalizumab: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Omalizumab: Pediatric drug information\")  Asthma:  Children 6 to <12 years: SubQ:  Pretreatment serum IgE ≥30 to 100 units/mL:  20 to 40 kg: 75 mg every 4 weeks  >40 to…"}, {"doc_id": "edrophonium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6590965986251831, "bge_max": 0.6590965986251831, "title": "Edrophonium: Drug information", "rep_snippet": "Alternate dosing: Weight-directed dosing: Limited data available: Children and Adolescents: IV, IM, SubQ: Initial: 0.01 to 0.02 mg/kg every 30 to 45 seconds up to the maximum dose (Kliegman 2015; Swaiman 2012). Note: Typ…"}, {"doc_id": "rupatadine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6590206623077393, "bge_max": 0.6590206623077393, "title": "Rupatadine (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Allergic rhinitis, chronic spontaneous urticaria: Oral:  Children ≥2 to <12 years:  10 kg to 25 kg: 2.5 mg once daily (maximum: 2.5 mg/day).  >25 kg: 5 mg once daily (maximum: 5 mg/day).  Children ≥12…"}, {"doc_id": "cycloserine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6574962735176086, "bge_max": 0.6574962735176086, "title": "Cycloserine: Drug information", "rep_snippet": "Children and Adolescents <15 years of age weighing >40 kg or Adolescents ≥15 years of age: Oral: 10 to 15 mg/kg/day divided every 12 to 24 hours; usual dose 250 to 500 mg; maximum daily dose: 1,000 mg/day. Note: Patients…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6557814478874207, "bge_max": 0.6571094989776611, "title": "Phenobarbital: Drug information", "rep_snippet": "Usual dosing range: Oral, IV: Note: Dosage should be individualized based upon clinical response and serum concentration; once daily doses usually administered at bedtime in children and adolescents. Some centers have us…"}, {"doc_id": "pentobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6562072038650513, "bge_max": 0.6562072038650513, "title": "Pentobarbital: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pentobarbital: Pediatric drug information\")  Note: Adjust dose based on patient's age, weight, and condition.  Sedative/hypnotic/preanesthesia: Infants, Children, and A…"}, {"doc_id": "trimeprazine-alimemazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6558542847633362, "bge_max": 0.6558542847633362, "title": "Trimeprazine (alimemazine): Drug information", "rep_snippet": "Dosing: Pediatric  Cough, pruritus: Note: Initiate at low dosage and titrate as needed.  Children 2 to 12 years: Oral: Initial: 2.5 mg to 5 mg once daily at bedtime; if necessary, administer additional dosage of 2.5 mg t…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6537386476993561, "bge_max": 0.6558295488357544, "title": "Theophylline: Drug information", "rep_snippet": "Children 1 year to Adolescents 15 years and weight ≤45 kg: Initial: 12 to 14 mg/kg/day in divided doses every 4 to 6 hours (maximum: 300 mg/day); if tolerated, after 3 days increase to 16 mg/kg/day in divided doses every…"}, {"doc_id": "chloramphenicol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.655542254447937, "bge_max": 0.655542254447937, "title": "Chloramphenicol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Chloramphenicol: Pediatric drug information\")  Serious infections: Infants, Children, and Adolescents: IV:  Manufacturer’s labeling: 50 mg/kg/day in divided doses every…"}, {"doc_id": "lactulose-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6555021405220032, "bge_max": 0.6555021405220032, "title": "Lactulose: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Lactulose: Pediatric drug information\")  Note: Doses in pediatric patients may be expressed in volume (mL) or weight (g); use extra precaution.  Portal systemic encepha…"}, {"doc_id": "propiverine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6545648574829102, "bge_max": 0.6545648574829102, "title": "Propiverine (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Overactive bladder: Children and Adolescents: Oral: Immediate release: 0.8 mg/kg/day in 2 divided doses or alternatively the following body weight adjusted dosing may be used:  12 to 16 kg: 5 mg two ti…"}, {"doc_id": "factor-ix-recombinant-human-glycopegylated-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6536108255386353, "bge_max": 0.6536108255386353, "title": "Factor IX, recombinant human glycopegylated: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Distribution:  Single dose: Vd: Children ≤6 years of age: 72.3 mL/kg; Children 7 to 12 years: 68.3 mL/kg; Adolescents 13 to 17 years: 58.6 mL/kg; Adults: 47 mL/kg.  After multiple once-weekly p…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6535802483558655, "bge_max": 0.6535802483558655, "title": "Pegylated interferon (peginterferon) alfa-2b: Drug information", "rep_snippet": "105 to 125 kg: 108 mcg once weekly; may further reduce to 64 mcg once weekly if needed  >125 kg: 135 mcg once weekly; may further reduce to 72 mcg once weekly if needed  Peginterferon alfa-2b monotherapy: Reduce to avera…"}, {"doc_id": "gadodiamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6533344388008118, "bge_max": 0.6533344388008118, "title": "Gadodiamide: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Dosing for patients >130 kg (286 pounds) has not been studied.  Body imaging: Children ≥2 years and Adolescents: IV: Refer to adult dosing  CNS imaging: Children ≥2 years and Adolescents ≤16 year…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6532389521598816, "bge_max": 0.6532389521598816, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Dosing: Pediatric  Partial-onset seizures (epilepsy) (monotherapy or adjunctive therapy): Children ≥4 years of age and Adolescents: Oral:  11 to 21 kg: Initial: 200 mg once daily; increase in weekly increments of no more…"}, {"doc_id": "pneumococcal-conjugate-vaccine-10-valent-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6521376371383667, "bge_max": 0.6521376371383667, "title": "Pneumococcal conjugate vaccine (10-valent) (United States: Not available): Drug information", "rep_snippet": "Children 12 to 23 months: 0.5 mL/dose for a total of 2 doses, administered at least 2 months apart. Note: Two-dose regimen in children 12 to 23 months of age at high risk for pneumococcal disease (eg, asplenia, sickle-ce…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6520260572433472, "bge_max": 0.6520260572433472, "title": "Ritonavir: Drug information", "rep_snippet": "Infants >1 month and Children: Oral: Initiate dose at 250 mg/m2/dose twice daily; titrate dose upward every 2 to 3 days by 50 mg/m2 twice daily to recommended dosage of 350 to 400 mg/m2/dose twice daily (maximum dose: 60…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6519272327423096, "bge_max": 0.6519272327423096, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prednisolone (systemic): Pediatric drug information\")  Dose depends upon condition being treated and response of patient; dosage for infants and children should be base…"}, {"doc_id": "morphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6517232060432434, "bge_max": 0.6517232060432434, "title": "Morphine: Drug information", "rep_snippet": "Analgesia: Children and Adolescents able to swallow tablets whole: Oral:  20 to <35 kg: Suggested initial dose: 15 mg every 8 to 12 hours (Berde 2002)  35 to <50 kg: Suggested initial dose: 15 to 30 mg every 8 to 12 hour…"}]}
{"qid": "Q3_noise+brand", "query": "Kid 12 kg febrile — Advil/Motrin pediatric: compute mg/kg and volume w/ 100 mg per 5 mL.", "base_qid": "Q3", "variant_type": "noise+brand", "candidates": [{"doc_id": "ibuprofen-drug-information", "bm25_top3": 49.85714348864786, "bm25_max": 51.265815027613314, "bge_top3": 0.6986871957778931, "bge_max": 0.7084625363349915, "title": "Ibuprofen: Drug information", "rep_snippet": "Pricing: US  Capsules (Advil Migraine Oral)  200 mg (40): $6.97  Capsules (Advil Oral)  200 mg (2): $0.27  Capsules (Ibuprofen Oral)  200 mg (80): $6.32  Chewable (Advil Junior Strength Oral)  100 mg (24): $4.32  Kit (Ib…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 41.52772947004594, "bm25_max": 42.84268200588804, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amoxicillin and clavulanate: Pediatric drug information\")  Note: Dose is based on the amoxicillin component. Dose and frequency are product specific; not all products a…"}, {"doc_id": "guaifenesin-and-dextromethorphan-drug-information", "bm25_top3": 37.95179338974047, "bm25_max": 40.93200577920312, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and dextromethorphan: Drug information", "rep_snippet": "Diabetic Tussin DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [dye free, ethanol free, sugar free; contains phenylalanine 8.4 mg/5 mL]  Diabetic Tussin DM Maximum Strength: Guaifenesin…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": 38.459392304122716, "bm25_max": 38.459392304122716, "bge_top3": null, "bge_max": null, "title": "Diazepam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Diazepam: Pediatric drug information\")  Conscious sedation for procedures:  Oral:  Children: 0.2 to 0.3 mg/kg (maximum dose: 10 mg) 45 to 60 minutes prior to procedure…"}, {"doc_id": "atovaquone-and-proguanil-drug-information", "bm25_top3": 38.38892402484002, "bm25_max": 38.38892402484002, "bge_top3": null, "bge_max": null, "title": "Atovaquone and proguanil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atovaquone and proguanil: Pediatric drug information\")  Prevention of malaria: Oral: Start 1-2 days prior to entering a malaria-endemic area, continue throughout the st…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 37.0163394961171, "bm25_max": 37.0163394961171, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Cuvitru:  Injection sites: ≤4 simultaneous injection sites (spaced 4 inches apart or more).  Maximum infusion rate: 10 to 20 mL/hour per injection site (first 2 infusions); may be increased to 60 mL/hour per injection si…"}, {"doc_id": "guaifenesin-and-codeine-drug-information", "bm25_top3": 36.80147990624893, "bm25_max": 36.80147990624893, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and codeine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Guaifenesin and codeine: Pediatric drug information\")  Note: Due to risk of adverse effects (slowed or difficult breathing, misuse, abuse, addiction, overdose, and deat…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 36.55799616934179, "bm25_max": 36.55799616934179, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 32.06401832858573, "bm25_max": 35.50013080205697, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "pegfilgrastim-drug-information", "bm25_top3": 30.762666777464943, "bm25_max": 33.99131727732659, "bge_top3": null, "bge_max": null, "title": "Pegfilgrastim: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pegfilgrastim: Pediatric drug information\")  Prevention of chemotherapy-induced neutropenia: Note: Do not administer in the period between 14 days before and 24 hours a…"}, {"doc_id": "iron-dextran-drug-information", "bm25_top3": 33.895109440838944, "bm25_max": 33.895109440838944, "bge_top3": null, "bge_max": null, "title": "Iron dextran: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Iron dextran: Pediatric drug information\")  Note: Dexferrum has been discontinued in the US for more than 1 year.  Note: A 0.5 mL test dose (0.25 mL in infants) should…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 29.548820716926684, "bm25_max": 29.548820716926684, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 28.94877218361671, "bm25_max": 28.94877218361671, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "ustekinumab-drug-information", "bm25_top3": 28.543865778453508, "bm25_max": 28.543865778453508, "bge_top3": null, "bge_max": null, "title": "Ustekinumab: Drug information", "rep_snippet": "Dosing: Pediatric  Plaque psoriasis: Children ≥12 years of age and Adolescents: SubQ:  <60 kg: 0.75 mg/kg at 0 and 4 weeks, and then every 12 weeks thereafter  ≥60 kg to ≤100 kg: 45 mg at 0 and 4 weeks, and then every 12…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 28.43909576029995, "bm25_max": 28.43909576029995, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Raltegravir: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Note: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioe…"}, {"doc_id": "dolasetron-drug-information", "bm25_top3": 27.279239724819682, "bm25_max": 27.279239724819682, "bge_top3": null, "bge_max": null, "title": "Dolasetron: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dolasetron: Pediatric drug information\")  Note: Anzemet injection has been discontinued in the US for more than 1 year.  Prevention of chemotherapy-associated nausea an…"}, {"doc_id": "minocycline-drug-information", "bm25_top3": 26.96777484583974, "bm25_max": 26.96777484583974, "bge_top3": null, "bge_max": null, "title": "Minocycline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Minocycline: Pediatric drug information\")  Usual dosage range: Children >8 years and Adolescents: Oral, IV: Initial: 4 mg/kg/dose for 1 dose; Maintenance: 2 mg/kg/dose…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 26.82441520021517, "bm25_max": 26.82441520021517, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "efavirenz-drug-information", "bm25_top3": 26.732555251338887, "bm25_max": 26.732555251338887, "bge_top3": null, "bge_max": null, "title": "Efavirenz: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Efavirenz: Pediatric drug information\")  HIV-1 infection, treatment:  Manufacturer's labeling: Infants ≥3 months and ≥3.5 kg: Oral:  Note: Although FDA approved in pedi…"}, {"doc_id": "docusate-drug-information", "bm25_top3": 26.722461330252067, "bm25_max": 26.722461330252067, "bge_top3": null, "bge_max": null, "title": "Docusate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Docusate: Pediatric drug information\")  Note: The following are general dosing guidelines; refer to specific product labeling for dosing instructions.  Stool softener:…"}, {"doc_id": "rupatadine-united-states-not-available-drug-information", "bm25_top3": 26.59429124332405, "bm25_max": 26.59429124332405, "bge_top3": 0.6523342132568359, "bge_max": 0.6523342132568359, "title": "Rupatadine (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Allergic rhinitis, chronic spontaneous urticaria: Oral:  Children ≥2 to <12 years:  10 kg to 25 kg: 2.5 mg once daily (maximum: 2.5 mg/day).  >25 kg: 5 mg once daily (maximum: 5 mg/day).  Children ≥12…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 26.576026985842127, "bm25_max": 26.576026985842127, "bge_top3": null, "bge_max": null, "title": "Iodixanol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Iodixanol: Pediatric drug information\")  Children <12 years:  Angiocardiography, cerebral arteriography, visceral arteriography: Intra-arterial: Iodixanol 320 mg iodine…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 26.435622756816464, "bm25_max": 26.435622756816464, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "GFR 10 to 29 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 24 hours  Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours  Peritoneal dialysis: 25 to 37.5 m…"}, {"doc_id": "leuprolide-drug-information", "bm25_top3": 26.366608958327262, "bm25_max": 26.366608958327262, "bge_top3": null, "bge_max": null, "title": "Leuprolide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Leuprolide: Pediatric drug information\")  Precocious puberty (consider discontinuing by age 11 for females and by age 12 for males):  IM:  Lupron Depot-Ped (monthly):…"}, {"doc_id": "methenamine-drug-information", "bm25_top3": 26.33789596087417, "bm25_max": 26.33789596087417, "bge_top3": null, "bge_max": null, "title": "Methenamine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Methenamine: Pediatric drug information\")  Urinary tract infection, prophylaxis/suppression: Oral:  US labeling:  Children <6 years: Mandelate: 250 mg per 14 kg body we…"}, {"doc_id": "stavudine-drug-information", "bm25_top3": 26.205004335150406, "bm25_max": 26.205004335150406, "bge_top3": null, "bge_max": null, "title": "Stavudine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Stavudine: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Neonates postnatal age (PNA) 0 to 13 days: 0.5 mg/kg every 12 hours  Neonates PNA ≥14 days:…"}, {"doc_id": "methylnaltrexone-drug-information", "bm25_top3": 25.81306879508501, "bm25_max": 25.81306879508501, "bge_top3": null, "bge_max": null, "title": "Methylnaltrexone: Drug information", "rep_snippet": "Dosing: Adult  Opioid-induced constipation with advanced illness: SubQ: Dosing is according to body weight: Administer 1 dose every other day as needed; maximum: 1 dose/24 hours  <38 kg: 0.15 mg/kg (round dose up to near…"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": 25.78367898429846, "bm25_max": 25.78367898429846, "bge_top3": null, "bge_max": null, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftaroline: Pediatric drug information\")  Pneumonia, community acquired: IV:  Infants ≥2 months and Children <2 years: 8 mg/kg/dose every 8 hours for 5 to 14 days  Chi…"}, {"doc_id": "omalizumab-drug-information", "bm25_top3": 25.681315775783368, "bm25_max": 25.681315775783368, "bge_top3": null, "bge_max": null, "title": "Omalizumab: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Omalizumab: Pediatric drug information\")  Asthma:  Children 6 to <12 years: SubQ:  Pretreatment serum IgE ≥30 to 100 units/mL:  20 to 40 kg: 75 mg every 4 weeks  >40 to…"}, {"doc_id": "foscarnet-drug-information", "bm25_top3": 25.662433445419992, "bm25_max": 25.662433445419992, "bge_top3": null, "bge_max": null, "title": "Foscarnet: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  See tables.  Induction Dosing of Foscarnet in Patients With Abnormal Renal Function  CrCl (mL/min/kg)  HSV  HSV  CMV  CMV  Equivalent to 40 mg/kg every 12 hours  Equivalent to 40 mg/kg e…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 25.614790884177097, "bm25_max": 25.614790884177097, "bge_top3": null, "bge_max": null, "title": "Amiodarone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amiodarone: Pediatric drug information\")  Pulseless VT or VF (PALS dosing): Infants, Children, and Adolescents: IV, Intraosseous: 5 mg/kg (maximum: 300 mg per dose) rap…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 25.404804347819933, "bm25_max": 25.404804347819933, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": 25.401254600022746, "bm25_max": 25.401254600022746, "bge_top3": null, "bge_max": null, "title": "Cefixime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefixime: Pediatric drug information\")  Note: Suprax 400 mg tablets have been discontinued in the US for more than 1 year.  Susceptible infections: Oral: Note: Otitis m…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6806589961051941, "bge_max": 0.6806589961051941, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to 11 years: Vicks DayQuil Cold & Flu Multi-Symptom Liquid: Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maxim…"}, {"doc_id": "minoxidil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6765682697296143, "bge_max": 0.6765682697296143, "title": "Minoxidil (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Minoxidil (systemic): Pediatric drug information\")  Hypertension:  Children <12 years: Oral: Initial: 0.2 mg/kg once daily; maximum daily initial dose: 5 mg daily; titr…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6720400452613831, "bge_max": 0.6720400452613831, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Flu/cold symptoms: Oral: General dosing guidelines; refer to specific product labeling:  Children 6 to 11 years: Liquid: Acetaminophen 325 mg/diphenhydramine 12.5 mg/phenylephrine 5 mg every 4 hours as…"}, {"doc_id": "botulism-immune-globulin-intravenous-human-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6666508913040161, "bge_max": 0.6666508913040161, "title": "Botulism immune globulin (intravenous human): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Botulism immune globulin (intravenous human): Pediatric drug information\")  Infant botulism: Infants <1 year: IV: 50 mg/kg as a single dose as soon as diagnosis of infa…"}, {"doc_id": "thonzylamine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6660881042480469, "bge_max": 0.6660881042480469, "title": "Thonzylamine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Contains phenylephrine 10 mg and thonzylamine 50 mg per 15 mL.  Symptoms of common cold or upper respiratory allergies:  Children 6 to <12 years: Oral: 7.5 mL every 4-6 hours; maximum 6 doses (45…"}, {"doc_id": "almotriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636852025985718, "bge_max": 0.6636852025985718, "title": "Almotriptan: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Almotriptan: Pediatric drug information\")  Migraine: Oral: Children ≥12 years: Refer to adult dosing."}, {"doc_id": "dyclonine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6635321974754333, "bge_max": 0.6635321974754333, "title": "Dyclonine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dyclonine: Pediatric drug information\")  Mouth/throat symptoms: Oral topical: Lozenge:  2 mg: Children ≥6 years and Adolescents: Refer to adult dosing.  2 mg (with ment…"}, {"doc_id": "atenolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6617660522460938, "bge_max": 0.6617660522460938, "title": "Atenolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atenolol: Pediatric drug information\")  Hypertension: Oral: Children and Adolescents: Initial: 0.5 to 1 mg/kg/dose either once daily or divided in doses twice daily; ti…"}, {"doc_id": "peramivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6607919931411743, "bge_max": 0.6607919931411743, "title": "Peramivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Peramivir: Pediatric drug information\")  Influenza: IV: Note: Administer within 2 days of onset of symptoms of influenza.  Children: 2 to 12 years: 12 mg/kg as a single…"}, {"doc_id": "alfentanil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6591120958328247, "bge_max": 0.6591120958328247, "title": "Alfentanil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Alfentanil: Pediatric drug information\")  Children ≥12 years and Adolescents: Refer to adult dosing."}, {"doc_id": "ampicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6583606004714966, "bge_max": 0.6583606004714966, "title": "Ampicillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ampicillin: Pediatric drug information\")  Usual dosage range: Infants, Children, and Adolescents:  Oral: 50 to 100 mg/kg/day divided every 6 hours (maximum: 2 to 4 g/da…"}, {"doc_id": "benazepril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6583142280578613, "bge_max": 0.6583142280578613, "title": "Benazepril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Benazepril: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents: Oral: Initial: 0.2 mg/kg once daily (maximum initial dose: 10 mg/day) as mono…"}, {"doc_id": "triprolidine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6583040356636047, "bge_max": 0.6583040356636047, "title": "Triprolidine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Triprolidine and pseudoephedrine: Pediatric drug information\")  Cold, allergy symptoms: Oral:  Liquid (triprolidine 0.938 mg and pseudoephedrine 10 mg per 1 mL):  Child…"}, {"doc_id": "droperidol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6546828746795654, "bge_max": 0.6546828746795654, "title": "Droperidol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Droperidol: Pediatric drug information\")  Note: Titrate carefully to desired effect  Postoperative nausea/vomiting (PONV): IM, IV: Children 2 to 12 years:  Manufacturer…"}, {"doc_id": "fosinopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6541014909744263, "bge_max": 0.6541014909744263, "title": "Fosinopril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fosinopril: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents >50 kg: Oral: Initial: 5 to 10 mg once daily (maximum: 40 mg once daily)"}, {"doc_id": "chlorpheniramine-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6540020704269409, "bge_max": 0.6540020704269409, "title": "Chlorpheniramine and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to <12 years: One tablet (chlorpheniramine 2 mg/acetaminophen 325 mg) every 4 to 6 hours (maximum: 5 tablets in 24 hours [chlorpheniramine 10 mg/acetaminophen 1…"}, {"doc_id": "formoterol-and-mometasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6529524326324463, "bge_max": 0.6529524326324463, "title": "Formoterol and mometasone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Formoterol and mometasone: Pediatric drug information\")  Asthma: Children ≥12 years and Adolescents: Metered-dose inhaler: Inhalation: Refer to adult dosing."}, {"doc_id": "bacitracin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6523160934448242, "bge_max": 0.6523160934448242, "title": "Bacitracin (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Bacitracin (systemic): Pediatric drug information\")  Do not administer IV  Treatment of pneumonia and empyema: Infants: IM:  ≤2.5 kg: 900 units/kg/day in 2 to 3 divided…"}, {"doc_id": "aliskiren-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6521093249320984, "bge_max": 0.6521093249320984, "title": "Aliskiren: Drug information", "rep_snippet": "Dosing: Pediatric  Hypertension: Children ≥6 years of age and Adolescents: Oral: Initial:  <20 kg: Not recommended.  20 kg to 50 kg: 75 mg once daily (maximum: 150 mg/day). Note: Prior to initiation, correct hypovolemia…"}, {"doc_id": "meclizine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6520901322364807, "bge_max": 0.6520901322364807, "title": "Meclizine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Meclizine: Pediatric drug information\")  Children ≥12 years and Adolescents: Refer to adult dosing."}, {"doc_id": "ketotifen-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6517460942268372, "bge_max": 0.6517460942268372, "title": "Ketotifen (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  Atopic asthma (prophylactic treatment): Oral:  Infants and Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg/dose twice daily (maxim…"}, {"doc_id": "pizotifen-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6509311199188232, "bge_max": 0.6509311199188232, "title": "Pizotifen (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Migraine prophylaxis: Children ≥12 years and Adolescents: Oral: Initial: 0.5 mg at bedtime; may increase dose gradually up to maximum of 1 mg at bedtime or a maximum of 1.5 mg/day.  Note: Therapeutic r…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6502976417541504, "bge_max": 0.6502976417541504, "title": "Amlodipine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amlodipine: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents: Oral: 2.5 to 5 mg once daily"}, {"doc_id": "multiple-vitamins-injectable-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6496919989585876, "bge_max": 0.6496919989585876, "title": "Multiple vitamins (injectable): Drug information", "rep_snippet": "Dosing: Pediatric  Dietary supplement: IV (not for direct infusion):  Children: ≥3 kg to 11 years: Pediatric formulation: 5 mL/day added to TPN or ≥100 mL of appropriate solution  Children >11 years and Adults: Refer to…"}, {"doc_id": "potassium-p-aminobenzoate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.649276852607727, "bge_max": 0.649276852607727, "title": "Potassium p-aminobenzoate: Drug information", "rep_snippet": "Dosing: Pediatric  Oral: 1 g/10 pounds of weight/day; administer in divided doses"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6492335200309753, "bge_max": 0.6492335200309753, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Theophylline: Pediatric drug information\")  Note: Individualize dose based on steady-state serum concentrations; use ideal body weight (theophylline distributes poorly…"}, {"doc_id": "dimenhydrinate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6488841772079468, "bge_max": 0.6488841772079468, "title": "Dimenhydrinate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dimenhydrinate: Pediatric drug information\")  US labeling: Motion sickness, nausea/vomiting, or vertigo:  Oral:  Children 2 to 5 years: 12.5 to 25 mg every 6 to 8 hours…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6477317810058594, "bge_max": 0.6477317810058594, "title": "Oseltamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oseltamivir: Pediatric drug information\")  Community-acquired pneumonia (influenza suspected or confirmed) (off-label use) (IDSA [Bradley 2011]): Oral:  Prophylaxis:  I…"}, {"doc_id": "amiloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6476907730102539, "bge_max": 0.6476907730102539, "title": "Amiloride: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amiloride: Pediatric drug information\")  Hypertension (off-label use): Children and Adolescents 1 to 17 years: Oral: 0.4 to 0.625 mg/kg/day (maximum: 20 mg daily) (NHBP…"}, {"doc_id": "trimeprazine-alimemazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6472723484039307, "bge_max": 0.6472723484039307, "title": "Trimeprazine (alimemazine): Drug information", "rep_snippet": "Dosing: Pediatric  Cough, pruritus: Note: Initiate at low dosage and titrate as needed.  Children 2 to 12 years: Oral: Initial: 2.5 mg to 5 mg once daily at bedtime; if necessary, administer additional dosage of 2.5 mg t…"}, {"doc_id": "metoprolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6463806629180908, "bge_max": 0.6463806629180908, "title": "Metoprolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Metoprolol: Pediatric drug information\")  Hypertension: Oral:  Immediate-release tablet (metoprolol tartrate): Children ≥1 year and Adolescents ≤17 years (off-label pop…"}, {"doc_id": "naloxegol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6462877988815308, "bge_max": 0.6462877988815308, "title": "Naloxegol: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Tablet, Oral:  Movantik: 12.5 mg, 25 mg"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6459763646125793, "bge_max": 0.6459763646125793, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Promethazine and phenylephrine: Pediatric drug information\")  Upper respiratory symptoms: Oral:  Children 2 to <6 years: 1.25 to 2.5 mL (promethazine 1.56 to 3.12 mg/ph…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6457229852676392, "bge_max": 0.6457229852676392, "title": "Amoxicillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amoxicillin: Pediatric drug information\")  Note: Unless otherwise specified, all pediatric dosing recommendations based on immediate release product formulations (oral…"}, {"doc_id": "amobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6451120376586914, "bge_max": 0.6451120376586914, "title": "Amobarbital: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amobarbital: Pediatric drug information\")  Sedative, hypnotic: Children ≥6 years and Adolescents: IM (preferred), IV: 2 to 3 mg/kg/dose; maximum dose: 500 mg/dose (AHFS…"}, {"doc_id": "chlorpheniramine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6437851786613464, "bge_max": 0.6437851786613464, "title": "Chlorpheniramine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Pediatric  Upper respiratory tract conditions: Oral: Note: All dosing is presented in terms of chlorpheniramine maleate and pseudoephedrine hydrochloride. Dosing may vary by product. Consult specific product labe…"}, {"doc_id": "cefditoren-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6431217193603516, "bge_max": 0.6431217193603516, "title": "Cefditoren: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefditoren: Pediatric drug information\")  Children ≥12 years and Adolescents: Refer to adult dosing."}, {"doc_id": "cefadroxil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6428338885307312, "bge_max": 0.6428338885307312, "title": "Cefadroxil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefadroxil: Pediatric drug information\")  Pharyngitis: Children and Adolescents: Oral:  Manufacturer’s labeling: 30 mg/kg/day in a single dose or divided every 12 hours…"}, {"doc_id": "dexbrompheniramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6426470279693604, "bge_max": 0.6426470279693604, "title": "Dexbrompheniramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Common cold/upper respiratory allergies: Oral:  Children 6 to <12 years:  Dexbrompheniramine 1 mg/phenylephrine 5 mg: One tablet or 5 mL every 4 hours (maximum: 6 tablets or 30 mL [dexbrompheniramine 6…"}, {"doc_id": "captopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6411805152893066, "bge_max": 0.6411805152893066, "title": "Captopril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Captopril: Pediatric drug information\")  Note: Titrate dose according to patient's response; use lowest effective dose.  Hypertension (off label use): Children ≤1 year…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6409534215927124, "bge_max": 0.6409534215927124, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Infants and Children: 2 mg/kg/dose or 15 mg/m2/dose once daily (maximum daily dose: 25 mg/day), in combination with pyrimethamine and leucovorin (HHS [OI pediatric] 2015)  Adolescents (mild to moderate disease): Refer to…"}, {"doc_id": "nedocromil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6404209733009338, "bge_max": 0.6404209733009338, "title": "Nedocromil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nedocromil: Pediatric drug information\")  Allergic conjunctivitis: Ophthalmic: Children ≥3 years: Refer to adult dosing."}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6400529146194458, "bge_max": 0.6400529146194458, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Penicillin G procaine (intermediate-acting intramuscular): Pediatric drug information\")  Anthrax, inhalational (postexposure prophylaxis): Infants, Children, and Adoles…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.639782190322876, "bge_max": 0.639782190322876, "title": "Ondansetron: Drug information", "rep_snippet": "Infants ≥1 month and Children ≤12 years: IV:  ≤40 kg: 0.1 mg/kg as a single dose over 2 to 5 minutes  >40 kg: 4 mg as a single dose over 2 to 5 minutes  Adolescents >12 years: IV, IM: Refer to adult dosing."}, {"doc_id": "metyrapone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6394021511077881, "bge_max": 0.6394021511077881, "title": "Metyrapone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Metyrapone: Pediatric drug information\")  ACTH function testing: Oral:  Single-dose/overnight test: 30 mg/kg (maximum: 3 g) at midnight  Multiple-dose test: 15 mg/kg (m…"}]}
{"qid": "Q4_abbr+criteria-cue", "query": "NVAF: 82 y, 58 kg, SCr 1.6 mg/dL — apixaban dose? (consider dose-reduction rule)", "base_qid": "Q4", "variant_type": "abbr+criteria-cue", "candidates": [{"doc_id": "apixaban-drug-information", "bm25_top3": 36.67707224591361, "bm25_max": 42.506316788096484, "bge_top3": 0.6328794558842977, "bge_max": 0.651165246963501, "title": "Apixaban: Drug information", "rep_snippet": "Conversion from apixaban to other non-warfarin anticoagulants (oral or parenteral): Discontinue apixaban and begin taking the new non-warfarin anticoagulant at the usual time of the next scheduled dose of apixaban.  Conv…"}, {"doc_id": "tranexamic-acid-drug-information", "bm25_top3": 36.912816667020074, "bm25_max": 36.912816667020074, "bge_top3": null, "bge_max": null, "title": "Tranexamic acid: Drug information", "rep_snippet": "Dosing: Renal Impairment  IV formulation:  Tooth extraction in patients with hemophilia:  Serum creatinine 1.36 to 2.83 mg/dL: Maintenance dose of 10 mg/kg/dose twice daily  Serum creatinine 2.83 to 5.66 mg/dL: Maintenan…"}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 36.24716911769035, "bm25_max": 36.24716911769035, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment  Deterioration of renal function during IV therapy: Stop treatment.  Clasteon [DSC]:  Serum creatinine (Scr) >5 mg/dL: Use is contraindicated.  Scr ≥2.5 to 5 mg/dL: There are no specific dosage a…"}, {"doc_id": "edetate-calcium-disodium-calcium-edta-drug-information", "bm25_top3": 36.21017959819092, "bm25_max": 36.21017959819092, "bge_top3": null, "bge_max": null, "title": "Edetate calcium disodium (calcium EDTA): Drug information", "rep_snippet": "Lead nephropathy: An alternative dosing regimen reflecting the reduction in renal clearance is based upon the serum creatinine; Note: Repeat regimen monthly until lead levels are reduced to an acceptable level: IM, IV:…"}, {"doc_id": "ribavirin-systemic-drug-information", "bm25_top3": 29.46622256412239, "bm25_max": 32.32191539759834, "bge_top3": null, "bge_max": null, "title": "Ribavirin (systemic): Drug information", "rep_snippet": "Children and Adolescents: Oral capsules, solution: Decrease ribavirin by 200 mg daily (regardless of the patient’s initial dose); decrease peginterferon alfa-2b dose by 50%; monitor and evaluate weekly. If hemoglobin <8.…"}, {"doc_id": "sodium-glycerophosphate-drug-information", "bm25_top3": 28.890166253606772, "bm25_max": 30.714486200890793, "bge_top3": null, "bge_max": null, "title": "Sodium glycerophosphate: Drug information", "rep_snippet": "Low dose, serum phosphorus level 2.3-3 mg/dL (0.74-0.96 mmol/L): 0.16-0.32 mmol/kg over 4-6 hours  Intermediate dose, serum phosphorus level 1.6-2.2 mg/dL (0.51-0.71 mmol/L): 0.32-0.64 mmol/kg over 4-6 hours  High dose,…"}, {"doc_id": "fibrinogen-concentrate-from-human-plasma-drug-information", "bm25_top3": 30.47535608364265, "bm25_max": 30.47535608364265, "bge_top3": null, "bge_max": null, "title": "Fibrinogen, concentrate from human plasma: Drug information", "rep_snippet": "Dosing: Adult  Congenital fibrinogen deficiency: IV: Note: Maintain a target fibrinogen level of 100 mg/dL for minor bleeding and 150 mg/dL for major bleeding.  When baseline fibrinogen level is known:  Fibryga: Dose (mg…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-drug-information", "bm25_top3": 29.20940768866098, "bm25_max": 29.988370622890226, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2b and ribavirin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: Recommendations (per manufacturer labeling - also refer to dosing in renal and hepatic impairment):  Hemoglobin:  HCV genotype 1 (treatment-naive):  Hemoglobin <10 g/dL: Continue cu…"}, {"doc_id": "fluoride-drug-information", "bm25_top3": 29.667651761927022, "bm25_max": 29.667651761927022, "bge_top3": null, "bge_max": null, "title": "Fluoride: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fluoride: Pediatric drug information\")  Oral: Children 6 months to 16 years: Fluor-A-Day, Fluorabon, Fluoritab drops, Flura-drops, Lozi-flur:  The recommended daily dos…"}, {"doc_id": "succinylcholine-suxamethonium-drug-information", "bm25_top3": 27.45647674205258, "bm25_max": 29.644935803036784, "bge_top3": null, "bge_max": null, "title": "Succinylcholine (suxamethonium): Drug information", "rep_snippet": "Dosing: Adult  Neuromuscular blockade: Dose to effect; doses will vary due to interpatient variability. Use carefully and/or consider dose reduction in patients with reduced plasma cholinesterase activity due to genetic…"}, {"doc_id": "ramucirumab-drug-information", "bm25_top3": 29.24765492822903, "bm25_max": 29.24765492822903, "bge_top3": null, "bge_max": null, "title": "Ramucirumab: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Infusion-related reaction:  Grade 1 or 2: Reduce infusion rate by 50%  Grade 3 or 4: Permanently discontinue  Hypertension:  Severe hypertension: Interrupt infusion until controlled with…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": 26.861679544971718, "bm25_max": 29.151346807568547, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Weight-based dosing: Infants, Children, and Adolescents: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (APS, 2008; Sullivan, 2011); do not exceed 5 doses in 24 hours; maximum daily dose: 75 mg/kg/day not to exceed 4 g…"}, {"doc_id": "daunorubicin-drug-information", "bm25_top3": 25.97005152846632, "bm25_max": 28.048807578568645, "bge_top3": null, "bge_max": null, "title": "Daunorubicin: Drug information", "rep_snippet": "Dosing: Renal Impairment  The manufacturer's labeling recommends the following adjustment: Scr >3 mg/dL: Administer 50% of normal dose  The following adjustments have also been recommended (Aronoff, 2007):  Adults: No do…"}, {"doc_id": "epoetin-alfa-drug-information", "bm25_top3": 28.04776300847235, "bm25_max": 28.04776300847235, "bge_top3": null, "bge_max": null, "title": "Epoetin alfa: Drug information", "rep_snippet": "Anemia due to zidovudine in HIV-infected patients: Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions. Hemoglobin levels should not exceed 12 g/dL.…"}, {"doc_id": "arsenic-trioxide-drug-information", "bm25_top3": 28.01581501135545, "bm25_max": 28.01581501135545, "bge_top3": null, "bge_max": null, "title": "Arsenic trioxide: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Dosage reduction levels (for hematologic and nonhematologic toxicities; tretinoin may also require dose reduction):  Initial dosage: 0.15 mg/kg once daily  First dose reduction level: 0.1…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 26.38862891568083, "bm25_max": 28.009973989712186, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Critically-ill adult patients receiving concurrent enteral/parenteral nutrition (Brown, 2006; Clark, 1995): Note: Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing pa…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-drug-information", "bm25_top3": 26.866699823133622, "bm25_max": 27.86473493883565, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2b: Drug information", "rep_snippet": "Peginterferon alfa-2b combination therapy: Refer to adult weight-based dosage reduction with combination therapy for depression below  Peginterferon alfa-2b monotherapy: Refer to adult weight-based dosage reduction with…"}, {"doc_id": "hydroxyurea-hydroxycarbamide-drug-information", "bm25_top3": 26.799113225857916, "bm25_max": 27.813852369191718, "bge_top3": null, "bge_max": null, "title": "Hydroxyurea (hydroxycarbamide): Drug information", "rep_snippet": "Droxia: Initial: 15 mg/kg/day as a single daily dose. Monitor blood counts every 2 weeks; if blood counts are in an acceptable range, may increase by 5 mg/kg/day every 12 weeks until the maximum tolerated dose of 35 mg/k…"}, {"doc_id": "guanfacine-drug-information", "bm25_top3": 27.69253517305379, "bm25_max": 27.69253517305379, "bge_top3": null, "bge_max": null, "title": "Guanfacine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Guanfacine: Pediatric drug information\")  ADHD: Extended release: Children ≥6 years and Adolescents ≤17 years: Oral: Initial: 1 mg once daily; may adjust by increments…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 27.400211037292397, "bm25_max": 27.400211037292397, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Infants and Children 6 months to 11 years: See table; use of weight to select dose is preferred; doses may be repeated every 6 to 8 hours (maximum: 4 doses/day)  Children ≥12 years and Adolescents: Refer to adult dosing.…"}, {"doc_id": "bezafibrate-united-states-not-available-drug-information", "bm25_top3": 26.811114176482434, "bm25_max": 26.811114176482434, "bge_top3": null, "bge_max": null, "title": "Bezafibrate (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  CrCl ≥60 mL/minute: No dosage adjustment required  CrCl <60 mL/minute or Scr >1.5 mg/dL [>135 micromol/L]: Use is contraindicated  Dialysis: Use is contraindicated."}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 26.68075228506476, "bm25_max": 26.68075228506476, "bge_top3": null, "bge_max": null, "title": "Pantoprazole: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pantoprazole: Pediatric drug information\")  Erosive esophagitis associated with GERD:  Oral:  Children 1 to 5 years: Limited data available: 0.3, 0.6, or 1.2 mg/kg/day…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": 26.601483830704943, "bm25_max": 26.601483830704943, "bge_top3": null, "bge_max": null, "title": "Furosemide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Furosemide: Pediatric drug information\")  Note: Oral dose equivalency (approximate) for patients with normal renal function (Brater 1983; Cody 1994; Vargo 1995): Furose…"}, {"doc_id": "ado-trastuzumab-emtansine-drug-information", "bm25_top3": 26.519183977522488, "bm25_max": 26.519183977522488, "bge_top3": null, "bge_max": null, "title": "Ado-trastuzumab emtansine: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: After a dose reduction is implemented, do not re-escalate dose.  Infusion-related reaction: Slow infusion rate or interrupt infusion. Permanently discontinue if life-threatening inf…"}, {"doc_id": "potassium-phosphate-drug-information", "bm25_top3": 26.039445931868002, "bm25_max": 26.208384387262495, "bge_top3": null, "bge_max": null, "title": "Potassium phosphate: Drug information", "rep_snippet": "Note: The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic. Do not exceed the maximum dose of 0.24 mmol/kg/…"}, {"doc_id": "amsacrine-united-states-not-available-drug-information", "bm25_top3": 25.664879216678568, "bm25_max": 25.664879216678568, "bge_top3": null, "bge_max": null, "title": "Amsacrine (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment  BUN >20 mg/dL and/or serum creatinine >1.2 mg/dL: Dosage reduction is recommended; however there are no specific adjustments provided in the manufacturer’s labeling. The following adjustments ha…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 25.56452052399111, "bm25_max": 25.56452052399111, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "14 to <18.5 kg: 250 mg every 6 hours  18.5 to <23 kg: 300 mg every 6 hours  23 to <32 kg: 350 mg every 6 hours  32 to <41 kg: 400 mg every 6 hours  41 to ≤50 kg: 450 mg every 6 hours  >50 kg: 500 mg every 6 hours  Altern…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 24.2848622587019, "bm25_max": 25.34416029418707, "bge_top3": null, "bge_max": null, "title": "Fluconazole: Drug information", "rep_snippet": "CNS disease (alternative therapy in patients intolerant of amphotericin B):  Children:  Induction: 12 mg/kg/dose for 1 dose, then 6 to 12 mg/kg/day (maximum: 800 mg/day) for ≥2 weeks (in combination with flucytosine) (CD…"}, {"doc_id": "metoprolol-drug-information", "bm25_top3": 24.818179675587764, "bm25_max": 24.818179675587764, "bge_top3": null, "bge_max": null, "title": "Metoprolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Metoprolol: Pediatric drug information\")  Hypertension: Oral:  Immediate-release tablet (metoprolol tartrate): Children ≥1 year and Adolescents ≤17 years (off-label pop…"}, {"doc_id": "acetohydroxamic-acid-drug-information", "bm25_top3": 24.742837327857337, "bm25_max": 24.742837327857337, "bge_top3": null, "bge_max": null, "title": "Acetohydroxamic acid: Drug information", "rep_snippet": "Dosing: Renal Impairment  Serum creatinine >1.8 mg/dL: 10 to 15 mg/kg/day divided every 12 hours; maximum dose: 1000 mg daily  Serum creatinine >2.5 mg/dL (or CrCl <20 mL/minute): Use contraindicated"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 24.358427766779165, "bm25_max": 24.358427766779165, "bge_top3": null, "bge_max": null, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)  IV:  If the usual recommended dose is 10 mg/kg/dose every 8 hours:  CrCl >50 mL/minute/1.73 m2: No dosage adjustment necessary…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": 23.779423777013697, "bm25_max": 23.779423777013697, "bge_top3": null, "bge_max": null, "title": "Methotrexate: Drug information", "rep_snippet": "Serum creatinine <1.5 mg/dL: No dosage adjustment necessary  Serum creatinine 1.5 to 2 mg/dL: Administer 75% of dose  Serum creatinine >2 mg/dL: Administer 50% of dose"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": 23.354844985856907, "bm25_max": 23.354844985856907, "bge_top3": 0.5715778470039368, "bge_max": 0.5715778470039368, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Initial: 8 to 10 mg/kg once daily (not to exceed 600 mg/day in the first week)  Maintenance: The target maintenance dose should be achieved over 2 to 3 weeks with dose increases of 8 to 10 mg/kg/day increments at weekly…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": 23.25164632345439, "bm25_max": 23.25164632345439, "bge_top3": null, "bge_max": null, "title": "Topiramate: Drug information", "rep_snippet": "Newly diagnosed infantile spasm: Weight-directed dosing: Infants and Children 3 to 24 months: Immediate release: Initial: 1 to 3 mg/kg/day administered as 1 or 2 daily doses; titrate every 3 to 7 days in 1 to 3 mg/kg/day…"}, {"doc_id": "thyroid-extract-desiccated-thyroid-drug-information", "bm25_top3": 22.08091394831148, "bm25_max": 22.08091394831148, "bge_top3": null, "bge_max": null, "title": "Thyroid extract (desiccated thyroid): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Thyroid extract (desiccated thyroid): Pediatric drug information\")  Note: The American Thyroid Association/American Association of Clinical Endocrinologists do not reco…"}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": 11.232780356489378, "bm25_max": 11.232780356489378, "bge_top3": null, "bge_max": null, "title": "Cabozantinib: Drug information", "rep_snippet": "Pricing: US  Kit (Cometriq (100 mg Daily Dose) Oral)  1 X 80 & 1 X 20 mg (56): $17,746.61  Kit (Cometriq (140 mg Daily Dose) Oral)  1 X 80 & 3 X 20 mg (112): $17,746.61  Kit (Cometriq (60 mg Daily Dose) Oral)  20 mg (84)…"}, {"doc_id": "afatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6071484684944153, "bge_max": 0.6071484684944153, "title": "Afatinib: Drug information", "rep_snippet": "Dosing: Adult  Non-small cell lung cancer (NSCLC), metastatic, with nonresistant EGFR mutations: Oral: 40 mg once daily until disease progression or unacceptable toxicity  NSCLC, metastatic squamous (previously treated):…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.596777617931366, "bge_max": 0.596777617931366, "title": "Itraconazole: Drug information", "rep_snippet": "Apixaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Apixaban. Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 1…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5960633754730225, "bge_max": 0.5960633754730225, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Apixaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Apixaban. Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 1…"}, {"doc_id": "vigabatrin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5890840291976929, "bge_max": 0.5890840291976929, "title": "Vigabatrin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Renal function may be estimated using the Schwartz equation (children 10 to <12 years) and the Cockcroft-Gault formula (children ≥12 years, adolescents, and adults):  Children (≥10 years),…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5859330594539642, "bge_max": 0.5875163078308105, "title": "Edoxaban: Drug information", "rep_snippet": "• Nonvalvular atrial fibrillation: [US Boxed Warning]: Do not administer to nonvalvular atrial fibrillation (NVAF) patients with CrCl >95 mL/minute (calculated using the Cockcroft-Gault formula). In clinical trials, thes…"}, {"doc_id": "nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.581302672624588, "bge_max": 0.5849096775054932, "title": "Nanoparticle albumin bound paclitaxel (nabpaclitaxel): Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Dosage adjustment for hepatic impairment at treatment initiation:  Breast cancer (every 3 week regimen):  Mild impairment (AST ≤10 times ULN and bilirubin >1 to ≤1.5 times ULN): No dosage adju…"}, {"doc_id": "primidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5833382606506348, "bge_max": 0.5833382606506348, "title": "Primidone: Drug information", "rep_snippet": "Afatinib: Primidone may decrease the serum concentration of Afatinib. Management: Per US labeling: if requiring chronic use of primidone, increase afatinib dose by 10 mg as tolerated; reduce to original afatinib dose 2-3…"}, {"doc_id": "interferon-beta-1a-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.582743763923645, "bge_max": 0.582743763923645, "title": "Interferon beta-1a: Drug information", "rep_snippet": "Dosing: Adult  Multiple sclerosis (MS): Note: Analgesics and/or antipyretics may help decrease flu-like symptoms on treatment days:  IM (Avonex):  US labeling: 30 mcg once weekly; to decrease flu-like symptoms, may initi…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5812201499938965, "bge_max": 0.5812201499938965, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Canagliflozin: RifAMPin may decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR >60 mL/min/1.73 m2 who tolerate canagliflozin…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5812201499938965, "bge_max": 0.5812201499938965, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "Canagliflozin: RifAMPin may decrease the serum concentration of Canagliflozin. Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR >60 mL/min/1.73 m2 who tolerate canagliflozin…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772861242294312, "bge_max": 0.5806686878204346, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Adult  VTE (prophylaxis): Oral: 160 mg as a single dose on day 1, followed by 80 mg once daily for 35 to 42 days  Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5798910856246948, "bge_max": 0.5798910856246948, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Edoxaban: RifAMPin may decrease the serum concentration of Edoxaban. Risk X: Avoid combination  Efavirenz: RifAMPin may decrease the serum concentration of Efavirenz. Management: Increase efavirenz adult dose to 800 mg d…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5793447494506836, "bge_max": 0.5793447494506836, "title": "Verapamil: Drug information", "rep_snippet": "Calan SR, Isoptin SR (Canadian product): Initial: 180 mg once daily in the morning; in patients with increased response to verapamil (eg, small stature): 120 mg once daily; if inadequate response to 180 mg once daily, ma…"}, {"doc_id": "gefitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5791924595832825, "bge_max": 0.5791924595832825, "title": "Gefitinib: Drug information", "rep_snippet": "Dosing: Adult  Non-small cell lung cancer (NSCLC), metastatic, with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations: Oral: 250 mg once daily until disease progression or unacceptable toxicity.  Missed do…"}, {"doc_id": "rucaparib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5780467391014099, "bge_max": 0.5780467391014099, "title": "Rucaparib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Consider therapy interruption or dose reduction if adverse events occur.  Recommended rucaparib dose reductions:  Starting dose: 600 mg twice daily  1st dose reduction: 500 mg twice daily…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5777915716171265, "bge_max": 0.5777915716171265, "title": "Enoxaparin: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal failure; dosage adjustment needed if CrCl <30 mL/minute.  Special populations:  • Elderly: Use with caution in the elderly; delayed elimination may occur. Dosag…"}, {"doc_id": "lumacaftor-and-ivacaftor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5767197012901306, "bge_max": 0.5767197012901306, "title": "Lumacaftor and ivacaftor: Drug information", "rep_snippet": "Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib. Management: Per US labeling: reduce afatinib by 10mg if not tolerated. Per Canadian labeling: avoid combination if possible; if…"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5764895081520081, "bge_max": 0.5764895081520081, "title": "Vemurafenib: Drug information", "rep_snippet": "Non-small cell lung cancer, refractory (with BRAF V600 mutation) (off-label use): Oral: 960 mg twice daily (Hyman 2015). Additional data may be necessary to further define the role of vemurafenib in this condition.  Dosa…"}, {"doc_id": "bevacizumab-including-biosimilars-of-bevacizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5763867497444153, "bge_max": 0.5763867497444153, "title": "Bevacizumab (including biosimilars of bevacizumab): Drug information", "rep_snippet": "Dosing: Adult  Note: Do not administer bevacizumab products until at least 28 days after surgery and the wound is fully healed.  Cervical cancer, persistent/recurrent/metastatic (Avastin [bevacizumab], Mvasi [bevacizumab…"}, {"doc_id": "nicardipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5761727690696716, "bge_max": 0.5761727690696716, "title": "Nicardipine: Drug information", "rep_snippet": "Dosing: Geriatric  Initiate at the low end of the dosage range. Specific guidelines for adjustment of nicardipine are not available, but careful monitoring is warranted and adjustment may be necessary."}, {"doc_id": "flibanserin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5758844017982483, "bge_max": 0.5758844017982483, "title": "Flibanserin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib. Management: Per US labeling: reduce afatinib…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5755103230476379, "bge_max": 0.5755103230476379, "title": "Ritonavir: Drug information", "rep_snippet": "AmLODIPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of AmLODIPine. Risk C: Monitor therapy  Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5753964781761169, "bge_max": 0.5753964781761169, "title": "Phenobarbital: Drug information", "rep_snippet": "Afatinib: PHENobarbital may decrease the serum concentration of Afatinib. Management: Per US labeling: if requiring chronic use of phenobarbital, increase afatinib dose by 10 mg as tolerated; reduce to original afatinib…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5753772258758545, "bge_max": 0.5753772258758545, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff, 2007): Dosing based on a usual dose of 200 t…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5744733512401581, "bge_max": 0.5753000974655151, "title": "Dabigatran: Drug information", "rep_snippet": "CrCl >50 mL/minute: No dosage adjustment necessary. Use with caution in mild renal impairment (CrCl 50 to 80 mL/minute) due to risk for increased dabigatran exposure (area under the curve may be increased 1.5 times highe…"}, {"doc_id": "candesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747487545013428, "bge_max": 0.5747487545013428, "title": "Candesartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: No initial dosage adjustment necessary; however, in patients with severe renal impairment (CrCl <30 mL/minute/1.73 m2) AUC and Cmax were approximately doubled after repeated dosing.  Chi…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747348666191101, "bge_max": 0.5747348666191101, "title": "Nilotinib: Drug information", "rep_snippet": "Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy  Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Api…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.574335515499115, "bge_max": 0.574335515499115, "title": "Rosuvastatin: Drug information", "rep_snippet": "Patient has clinical ASCVD (eg, coronary heart disease, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) or is post-CABG (AHA [Kulik 2015]) and:  Age ≤75 years: High-intensity therapy:…"}, {"doc_id": "efavirenz-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5739399790763855, "bge_max": 0.5739399790763855, "title": "Efavirenz, emtricitabine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz. Risk X: Avoid com…"}, {"doc_id": "efavirenz-lamivudine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5739399790763855, "bge_max": 0.5739399790763855, "title": "Efavirenz, lamivudine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz. Risk X: Avoid com…"}, {"doc_id": "tezacaftor-and-ivacaftor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5735437870025635, "bge_max": 0.5735437870025635, "title": "Tezacaftor and ivacaftor: Drug information", "rep_snippet": "Dosing: Hepatic Impairment (Adult)  Mild impairment (Child-Pugh class A): No dosage adjustment necessary.  Moderate impairment (Child-Pugh class B): Tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning. The eveni…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5735170841217041, "bge_max": 0.5735170841217041, "title": "Rivaroxaban: Drug information", "rep_snippet": "Dosing: Obesity  Body weight >120 kg did not significantly influence rivaroxaban exposure (Kubitza 2007). Clinical outcomes in postoperative thromboprophylaxis trials were also not affected by weight (up to 190 kg) (Turp…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5727174282073975, "bge_max": 0.5727174282073975, "title": "Fluvastatin: Drug information", "rep_snippet": "Immediate release: 40 mg twice daily.  Extended release: 80 mg once daily.  Type 1 or 2 diabetes, age 40 to 75 years, and an estimated 10-year ASCVD risk ≥7.5%: High-intensity therapy necessary; use alternate statin ther…"}, {"doc_id": "ethambutol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5723528861999512, "bge_max": 0.5723528861999512, "title": "Ethambutol: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis, pulmonary (drug-susceptible): Oral: Note: Always administer in combination with other antitubercular drugs.  ATS/CDC/IDSA drug-susceptible tuberculosis guideline recommendations (Nahid 2016):…"}, {"doc_id": "arginine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5722722411155701, "bge_max": 0.5722722411155701, "title": "Arginine: Drug information", "rep_snippet": "Weight-directed dosing:  Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency: Oral: 400 to 700 mg/kg/day in 3 to 4 divided doses (Batshaw 2001; Berry 2001; Brusilow 1996;…"}, {"doc_id": "ixabepilone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5722593069076538, "bge_max": 0.5722593069076538, "title": "Ixabepilone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Ixabepilone monotherapy (initial cycle; adjust doses for subsequent cycles based on toxicity):  AST and ALT ≤2.5 times ULN and bilirubin ≤1 times ULN: No dosage adjustment necessary  AST and A…"}]}
{"qid": "Q4_negation-trap", "query": "Nonvalvular AF, 82y/58kg/SCr1.6 — choose apixaban dose; no dialysis, no CYP3A4 issues.", "base_qid": "Q4", "variant_type": "negation-trap", "candidates": [{"doc_id": "apixaban-drug-information", "bm25_top3": 30.39331242981718, "bm25_max": 33.30817239858848, "bge_top3": 0.6799070636431376, "bge_max": 0.7025532126426697, "title": "Apixaban: Drug information", "rep_snippet": "Conversion from apixaban to other non-warfarin anticoagulants (oral or parenteral): Discontinue apixaban and begin taking the new non-warfarin anticoagulant at the usual time of the next scheduled dose of apixaban.  Conv…"}, {"doc_id": "daptomycin-drug-information", "bm25_top3": 21.406120386181023, "bm25_max": 21.48259525753922, "bge_top3": null, "bge_max": null, "title": "Daptomycin: Drug information", "rep_snippet": "Slow extended daily dialysis (or extended dialysis): 6 mg/kg every 24 hours (Kielstein 2010); Note: Dialysis should be initiated within 8 hours of administering daptomycin dose to avoid dose accumulation.  Children and A…"}, {"doc_id": "thalidomide-drug-information", "bm25_top3": 21.20345523691717, "bm25_max": 21.20345523691717, "bge_top3": null, "bge_max": null, "title": "Thalidomide: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary for patients with renal impairment and on dialysis (per manufacturer). In a study of 6 patients with end-stage renal disease on dialysis, although clearance was in…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 21.084213221702523, "bm25_max": 21.084213221702523, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Infants, Children, Adolescents, and Adults: Oral:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: Reduce dose by 50%.  End-stage renal disease…"}, {"doc_id": "cefaclor-drug-information", "bm25_top3": 20.135986334415165, "bm25_max": 20.135986334415165, "bge_top3": null, "bge_max": null, "title": "Cefaclor: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer’s labeling:  Oral, immediate-release: There are no dosage adjustments provided in the manufacturer's labeling; however, half-life is increased in anuric patients; use with caution.…"}, {"doc_id": "valsartan-drug-information", "bm25_top3": 20.03496648181119, "bm25_max": 20.03496648181119, "bge_top3": null, "bge_max": null, "title": "Valsartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  Children and Adolescents 6 to 16 years of age:  Glomerular filtration rate (GFR) ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR <30 mL/minute/1.73m2: There are no dosage adjustments…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": 19.849543118851493, "bm25_max": 19.849543118851493, "bge_top3": null, "bge_max": null, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff, 2007): Dosing based on a usual dose of 200 t…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": 19.64773682329917, "bm25_max": 19.64773682329917, "bge_top3": null, "bge_max": null, "title": "Zidovudine: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥15 mL/minute: No dosage adjustment necessary.  CrCl <15 mL/minute:  Oral:  Manufacturer’s labeling: 100 mg every 6 to 8 hours  Alternate dosing: 100 mg 3 times daily or 300 mg once daily (…"}, {"doc_id": "lisinopril-drug-information", "bm25_top3": 19.5061918466075, "bm25_max": 19.5061918466075, "bge_top3": null, "bge_max": null, "title": "Lisinopril: Drug information", "rep_snippet": "GFR <10 mL/minute: Administer 25% to 50% of usual dose.  Intermittent hemodialysis: Dose after dialysis.  Continuous renal replacement therapy (CRRT): Administer 50% to 75% of usual dose.  Children ≥ 6 years and Adolesce…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": 19.242965176453602, "bm25_max": 19.242965176453602, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral (Aronoff 2007):  Adults:  GFR ≥50 mL/minute: No dosage adjustment necessary.  GFR 10 to 50 mL/minute: Administer every 6 hours.  GFR <10 mL/minute: Administer every 8 hours.  CRRT: Administ…"}, {"doc_id": "recombinant-hepatitis-b-vaccine-non-adjuvanted-drug-information", "bm25_top3": 18.173211554689082, "bm25_max": 18.173211554689082, "bge_top3": null, "bge_max": null, "title": "Recombinant hepatitis B vaccine (non-adjuvanted): Drug information", "rep_snippet": "Dialysis and predialysis patients (CrCl <60 mL/minute/1.73 m2): Infants, Children, and Adolescents: IM: There are no specific ACIP recommendations regarding dosing in dialysis patients; however, some experts suggest that…"}, {"doc_id": "quinine-drug-information", "bm25_top3": 17.93117275046918, "bm25_max": 17.93117275046918, "bge_top3": null, "bge_max": null, "title": "Quinine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use caution.  Severe chronic impairment:  US labeling: Patients not o…"}, {"doc_id": "caspofungin-drug-information", "bm25_top3": 17.74728642542568, "bm25_max": 17.74728642542568, "bge_top3": null, "bge_max": null, "title": "Caspofungin: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary.  End-stage renal disease (ESRD) requiring dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary in patients on intermittent hemodialysis…"}, {"doc_id": "isosorbide-mononitrate-drug-information", "bm25_top3": 17.59017238130795, "bm25_max": 17.59017238130795, "bge_top3": null, "bge_max": null, "title": "Isosorbide mononitrate: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary.  Hemodialysis: Supplemental dose is not necessary. Dose after dialysis (Aronoff 2007)  Continuous ambulatory peritoneal dialysis: Supplemental dose is not necessa…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": 17.57450264159373, "bm25_max": 17.57450264159373, "bge_top3": null, "bge_max": null, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling:  Oral, immediate release:  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl 30 to 50 mL/minute: 250 to 500 mg every 12 hours  CrCl 5 to 29 mL/minute: 2…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 17.56233528662401, "bm25_max": 17.56233528662401, "bge_top3": null, "bge_max": null, "title": "Doxycycline: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary.  Dialysis: Poorly dialyzed (0% to 5%); no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis,…"}, {"doc_id": "lincomycin-drug-information", "bm25_top3": 17.34166950486884, "bm25_max": 17.34166950486884, "bge_top3": null, "bge_max": null, "title": "Lincomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling.  Severe impairment: Use with caution; decrease dose by 70% to 75%.  End stage renal disease…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 17.298827270116988, "bm25_max": 17.298827270116988, "bge_top3": null, "bge_max": null, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to severe impairment: No dosage adjustment necessary  End-stage renal disease (ESRD) on hemodialysis or peritoneal dialysis: Not removed from serum (eg, poorly dialyzed); no supplemental do…"}, {"doc_id": "tigecycline-drug-information", "bm25_top3": 17.281851434324743, "bm25_max": 17.281851434324743, "bge_top3": null, "bge_max": null, "title": "Tigecycline: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary.  End-stage renal disease (ESRD) on dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis…"}, {"doc_id": "gemfibrozil-drug-information", "bm25_top3": 17.22334750055921, "bm25_max": 17.22334750055921, "bge_top3": null, "bge_max": null, "title": "Gemfibrozil: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Manufacturer's labeling:  Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; deterioration of renal function has been…"}, {"doc_id": "quinidine-drug-information", "bm25_top3": 17.170296260549236, "bm25_max": 17.170296260549236, "bge_top3": null, "bge_max": null, "title": "Quinidine: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in manufacturer’s labeling. Use with caution. The following guidelines have been used by some clinicians (Aronoff, 2007): Oral:  CrCl ≥10 mL/minute: No dosage adjus…"}, {"doc_id": "chloroquine-drug-information", "bm25_top3": 17.151500817309525, "bm25_max": 17.151500817309525, "bge_top3": null, "bge_max": null, "title": "Chloroquine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; the following guidelines have been used by some clinicians (Aronoff 2007):  GFR ≥10 mL/minute: No dosage adjustment neces…"}, {"doc_id": "lidocaine-and-epinephrine-drug-information", "bm25_top3": 17.123651751163564, "bm25_max": 17.123651751163564, "bge_top3": null, "bge_max": null, "title": "Lidocaine and epinephrine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. However, accumulation of metabolites may be increased in renal impairment.  Dialysis: Not dialyzable (0% to 5%) by hemo-…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 16.641746142503234, "bm25_max": 16.641746142503234, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild, moderate, and severe impairment: No dosage adjustment necessary.  End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Dose after dialysis on dialysis days."}, {"doc_id": "diltiazem-drug-information", "bm25_top3": 16.31385607241819, "bm25_max": 16.31385607241819, "bge_top3": null, "bge_max": null, "title": "Diltiazem: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.  Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary."}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": 16.1746734983519, "bm25_max": 16.1746734983519, "bge_top3": null, "bge_max": null, "title": "Ceftriaxone: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; however, in patients with concurrent renal and hepatic impairment, maximum daily dose should not exceed 2 g.  ESRD requir…"}, {"doc_id": "vinorelbine-drug-information", "bm25_top3": 16.102466459736068, "bm25_max": 16.102466459736068, "bge_top3": null, "bge_max": null, "title": "Vinorelbine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Renal insufficiency: No dosage adjustment necessary.  Hemodialysis: Initial: IV: Reduce dose to 20 mg/m2/week; administer either after dialysis (on dialysis days) or on nondialysis days (Janus,…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": 16.006588402163693, "bm25_max": 16.006588402163693, "bge_top3": null, "bge_max": null, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary.  Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal r…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": 16.006588402163693, "bm25_max": 16.006588402163693, "bge_top3": null, "bge_max": null, "title": "Aprepitant: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary.  ESRD undergoing dialysis: No dosage adjustment necessary. Aprepitant is not removed by hemodialysis (<0.2% of a dose is recovered in the dialysate)."}, {"doc_id": "amlodipine-drug-information", "bm25_top3": 15.998844404216634, "bm25_max": 15.998844404216634, "bge_top3": null, "bge_max": null, "title": "Amlodipine: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary (Doyle 1989; Kungys 2003).  End-stage renal disease (ESRD) on dialysis: Hemodialysis and peritoneal dialysis do not enhance elimination; supplemental dose is not n…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 15.948165465859592, "bm25_max": 15.948165465859592, "bge_top3": null, "bge_max": null, "title": "Linezolid: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to severe impairment: No dosage adjustment necessary. The two primary metabolites may accumulate in patients with renal impairment but the clinical significance is unknown; use with caution…"}, {"doc_id": "esmolol-drug-information", "bm25_top3": 15.770992240928773, "bm25_max": 15.770992240928773, "bge_top3": null, "bge_max": null, "title": "Esmolol: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary. Not removed by hemo- or peritoneal dialysis. Supplemental dose is not necessary."}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": 15.500371361921026, "bm25_max": 15.500371361921026, "bge_top3": null, "bge_max": null, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling.  Dialysis: Slightly dialyzable (5% to 20%). Supplemental dose is not necessary in hemo- or peritoneal dialysis or in cont…"}, {"doc_id": "isosorbide-dinitrate-drug-information", "bm25_top3": 15.256049154851214, "bm25_max": 15.256049154851214, "bge_top3": null, "bge_max": null, "title": "Isosorbide dinitrate: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  There are no dosage adjustments provided in the manufacturer’s labeling.  Hemodialysis: Supplemental dose is not necessary.  Peritoneal dialysis: Supplemental dose is not necessary."}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": 13.325910046885632, "bm25_max": 13.325910046885632, "bge_top3": null, "bge_max": null, "title": "Rivaroxaban: Drug information", "rep_snippet": "Use  Deep vein thrombosis prophylaxis: Postoperative thromboprophylaxis of deep vein thrombosis (DVT) which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery.  Deep vein thrombosis or…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 8.30491129048331, "bm25_max": 10.296831987150469, "bge_top3": null, "bge_max": null, "title": "Dabigatran: Drug information", "rep_snippet": "• Renal impairment: Evaluate renal function prior to and during therapy, particularly if used in patients with any degree of preexisting renal impairment or in any condition that may result in a decline in renal function…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": 10.162741618364368, "bm25_max": 10.162741618364368, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban. Risk X: Avoid combination  Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. Risk X: Avoid combi…"}, {"doc_id": "carbamazepine-drug-information", "bm25_top3": 10.162741618364368, "bm25_max": 10.162741618364368, "bge_top3": null, "bge_max": null, "title": "Carbamazepine: Drug information", "rep_snippet": "Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban. Risk X: Avoid combination  Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. Risk X: Avoid combi…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": 10.162741618364368, "bm25_max": 10.162741618364368, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban. Risk X: Avoid combination  Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. Risk X: Avoid combi…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": 10.162741618364368, "bm25_max": 10.162741618364368, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban. Risk X: Avoid combination  Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. Risk X: Avoid combi…"}, {"doc_id": "enzalutamide-drug-information", "bm25_top3": 10.162741618364368, "bm25_max": 10.162741618364368, "bge_top3": null, "bge_max": null, "title": "Enzalutamide: Drug information", "rep_snippet": "Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban. Risk X: Avoid combination  Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. Risk X: Avoid combi…"}, {"doc_id": "mitotane-drug-information", "bm25_top3": 10.162741618364368, "bm25_max": 10.162741618364368, "bge_top3": null, "bge_max": null, "title": "Mitotane: Drug information", "rep_snippet": "Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban. Risk X: Avoid combination  Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. Risk X: Avoid combi…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": 8.799576776177268, "bm25_max": 8.799576776177268, "bge_top3": 0.6326775550842285, "bge_max": 0.6326775550842285, "title": "Edoxaban: Drug information", "rep_snippet": "Note: The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines for the management of AF recommend oral anticoagulation for patients with nonvalvular AF or atrial flutter with pri…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 8.692404176163613, "bm25_max": 8.692404176163613, "bge_top3": null, "bge_max": null, "title": "Warfarin: Drug information", "rep_snippet": "Use  Thromboembolic complications: Prophylaxis and treatment of thromboembolic disorders (eg, venous, pulmonary) and embolic complications arising from atrial fibrillation or cardiac valve replacement:  Nonvalvular AF or…"}, {"doc_id": "arginine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6482005715370178, "bge_max": 0.6482005715370178, "title": "Arginine: Drug information", "rep_snippet": "Unconfirmed/pending diagnosis: IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (NORD 2012); if ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 mg/kg/day  BSA-dir…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6448282599449158, "bge_max": 0.6448282599449158, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Adult  Note: Individualize dose based on steady-state serum concentrations; use ideal body weight (theophylline distributes poorly into body fat) to calculate dose.  Reversible airflow obstruction, acute symptoms…"}, {"doc_id": "gadopentetate-dimeglumine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6402483582496643, "bge_max": 0.6402483582496643, "title": "Gadopentetate dimeglumine: Drug information", "rep_snippet": "Dosing: Adult  Body, CNS, head, and neck imaging: IV: 0.1 mmol/kg (0.2 mL/kg)  Note: Dosing for patients >130 kg (286 pounds) has not been studied."}, {"doc_id": "agalsidase-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6402458548545837, "bge_max": 0.6402458548545837, "title": "Agalsidase alfa: Drug information", "rep_snippet": "Dosing: Adult  Note: Premedication with oral antihistamines and corticosteroids may alleviate infusion-related reactions associated with agalsidase alfa.  Fabry disease: IV: 0.2 mg/kg every 2 weeks"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6388680338859558, "bge_max": 0.6388680338859558, "title": "Vemurafenib: Drug information", "rep_snippet": "Non-small cell lung cancer, refractory (with BRAF V600 mutation) (off-label use): Oral: 960 mg twice daily (Hyman 2015). Additional data may be necessary to further define the role of vemurafenib in this condition.  Dosa…"}, {"doc_id": "ivacaftor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6303815543651581, "bge_max": 0.6368250250816345, "title": "Ivacaftor: Drug information", "rep_snippet": "Dosing: Adult  Cystic fibrosis: Oral: Tablet: 150 mg every 12 hours  Dosage adjustment for ivacaftor with concomitant medications:  CYP3A strong inhibitors (eg, ketoconazole, itraconazole, posaconazole, voriconazole, cla…"}, {"doc_id": "ixabepilone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6289921402931213, "bge_max": 0.6358004212379456, "title": "Ixabepilone: Drug information", "rep_snippet": "Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).…"}, {"doc_id": "gadodiamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6351921558380127, "bge_max": 0.6351921558380127, "title": "Gadodiamide: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing for patients >130 kg (286 pounds) has not been studied.  Body imaging: IV:  Kidney: 0.05 mmol/kg (0.1 mL/kg)  Intrathoracic (noncardiac), intra-abdominal, pelvic cavities: 0.1 mmol/kg (0.2 mL/…"}, {"doc_id": "pravastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6292832493782043, "bge_max": 0.6292832493782043, "title": "Pravastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "cilazapril-and-hydrochlorothiazide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6289734244346619, "bge_max": 0.6289734244346619, "title": "Cilazapril and hydrochlorothiazide (United States: Not available): Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Cirrhotic patients (without ascites): Cilazapril dose reduction is necessary; see individual agents."}, {"doc_id": "cobimetinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6287579536437988, "bge_max": 0.6287579536437988, "title": "Cobimetinib: Drug information", "rep_snippet": "Dosing: Adult  Melanoma, unresectable or metastatic (with BRAF V600E or V600K mutations): Oral: 60 mg once daily days 1 to 21 of each 28-day treatment cycle (in combination with vemurafenib); continue until disease progr…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6283104419708252, "bge_max": 0.6283104419708252, "title": "Itraconazole: Drug information", "rep_snippet": "Apixaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Apixaban. Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 1…"}, {"doc_id": "darifenacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6281561851501465, "bge_max": 0.6281561851501465, "title": "Darifenacin: Drug information", "rep_snippet": "Dosing: Adult  Overactive bladder: Oral: Initial: 7.5 mg once daily. If response is not adequate after a minimum of 2 weeks, dosage may be increased to 15 mg once daily.  Dosage adjustment with concomitant potent CYP3A4…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6281411051750183, "bge_max": 0.6281411051750183, "title": "Atorvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6280978322029114, "bge_max": 0.6280978322029114, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Apixaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Apixaban. Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 1…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279599666595459, "bge_max": 0.6279599666595459, "title": "Alirocumab: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279599666595459, "bge_max": 0.6279599666595459, "title": "Rosuvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "evolocumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279599666595459, "bge_max": 0.6279599666595459, "title": "Evolocumab: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279599666595459, "bge_max": 0.6279599666595459, "title": "Pitavastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "ezetimibe-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279599666595459, "bge_max": 0.6279599666595459, "title": "Ezetimibe: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279599666595459, "bge_max": 0.6279599666595459, "title": "Simvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279599666595459, "bge_max": 0.6279599666595459, "title": "Fluvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "lovastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279599666595459, "bge_max": 0.6279599666595459, "title": "Lovastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "fesoterodine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6271868944168091, "bge_max": 0.6271868944168091, "title": "Fesoterodine: Drug information", "rep_snippet": "Dosing: Adult  Overactive bladder: Oral: 4 mg once daily; may be increased to 8 mg once daily based on individual response and tolerability  Dosing adjustment for concomitant strong CYP3A4 inhibitors (eg, ketoconazole, i…"}, {"doc_id": "dexrazoxane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6267024278640747, "bge_max": 0.6267024278640747, "title": "Dexrazoxane: Drug information", "rep_snippet": "Dosing: Adult  Prevention of doxorubicin cardiomyopathy: IV: A 10:1 ratio of dexrazoxane:doxorubicin (dexrazoxane 500 mg/m2:doxorubicin 50 mg/m2). Note: Cardiac monitoring should continue during dexrazoxane therapy; doxo…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.626541793346405, "bge_max": 0.626541793346405, "title": "Nilotinib: Drug information", "rep_snippet": "Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy  Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Api…"}, {"doc_id": "pasireotide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6264439225196838, "bge_max": 0.6264439225196838, "title": "Pasireotide: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Acromegaly (Signifor LAR):  Mild impairment (Child-Pugh class A): No dosage adjustment necessary.  Moderate hepatic impairment (Child-Pugh class B): Initial: 20 mg every 28 days (maximum: 40 m…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6257310509681702, "bge_max": 0.6257310509681702, "title": "Ritonavir: Drug information", "rep_snippet": "AmLODIPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of AmLODIPine. Risk C: Monitor therapy  Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic…"}, {"doc_id": "cyclophosphamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6254894733428955, "bge_max": 0.6254894733428955, "title": "Cyclophosphamide: Drug information", "rep_snippet": "Dosing: Obesity  American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer (Note: Excludes HSCT dosing): Utilize patient’s actual body weight (full weight) fo…"}, {"doc_id": "bromocriptine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6254249215126038, "bge_max": 0.6254249215126038, "title": "Bromocriptine: Drug information", "rep_snippet": "Dosing: Adult  Acromegaly: Oral: Initial: 1.25 to 2.5 mg daily increasing by 1.25 to 2.5 mg daily as necessary every 3 to 7 days; usual dose: 20 to 30 mg daily (maximum: 100 mg/day)  Diabetes mellitus, type 2 (Cycloset o…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.625270664691925, "bge_max": 0.625270664691925, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Adult  Note: If present, correct volume depletion prior to initiation. Should only be initiated in patients who already tolerate dapagliflozin 10 mg/day.  Diabetes mellitus, type 2: Oral: Dapagliflozin 10mg/saxag…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6252487897872925, "bge_max": 0.6252487897872925, "title": "Methotrexate: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing; adjust for renal impairment.  Breast cancer: Patients >60 years: IV: CMF regimen: 30 mg/m2 days 1 and 8 every 4 weeks (in combination with cyclophosphamide and fluorouracil) for…"}, {"doc_id": "ivabradine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6251479387283325, "bge_max": 0.6251479387283325, "title": "Ivabradine: Drug information", "rep_snippet": "Contraindications  Acute decompensated heart failure; blood pressure <90/50 mm Hg; sick sinus syndrome, sinoatrial block, or third-degree AV block (unless a functioning demand pacemaker is present); resting heart rate <6…"}, {"doc_id": "tezacaftor-and-ivacaftor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6250659227371216, "bge_max": 0.6250659227371216, "title": "Tezacaftor and ivacaftor: Drug information", "rep_snippet": "Dosing: Hepatic Impairment (Adult)  Mild impairment (Child-Pugh class A): No dosage adjustment necessary.  Moderate impairment (Child-Pugh class B): Tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning. The eveni…"}, {"doc_id": "heparin-unfractionated-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6246012449264526, "bge_max": 0.6246012449264526, "title": "Heparin (unfractionated): Drug information", "rep_snippet": "Dosing: Adult  Note: Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen…"}, {"doc_id": "deflazacort-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6238147020339966, "bge_max": 0.6238147020339966, "title": "Deflazacort: Drug information", "rep_snippet": "Dosing: Adult  Duchenne muscular dystrophy: Oral: Usual dose: 0.9 mg/kg once daily. Note: Round up to nearest possible dose when using tablets; round up to nearest tenth of a mL when using suspension.  Concomitant modera…"}, {"doc_id": "bevacizumab-including-biosimilars-of-bevacizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6230784058570862, "bge_max": 0.6230784058570862, "title": "Bevacizumab (including biosimilars of bevacizumab): Drug information", "rep_snippet": "Dosing: Adult  Note: Do not administer bevacizumab products until at least 28 days after surgery and the wound is fully healed.  Cervical cancer, persistent/recurrent/metastatic (Avastin [bevacizumab], Mvasi [bevacizumab…"}, {"doc_id": "raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6228041648864746, "bge_max": 0.6228041648864746, "title": "Raxibacumab (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department) : Drug information", "rep_snippet": "Dosing: Adult  Anthrax, prophylaxis or treatment: IV: 40 mg/kg as a single dose  Note: Administer diphenhydramine 25-50 mg (may administer oral or IV depending on the proximity to start of raxibacumab infusion) ≤1 hour p…"}]}
{"qid": "Q4_spelling", "query": "NV-AF 82 yrs, wt 58 kg, Scr 1.6 — which apixiban dose applies?", "base_qid": "Q4", "variant_type": "spelling", "candidates": [{"doc_id": "carmustine-drug-information", "bm25_top3": 24.048122813300782, "bm25_max": 24.048122813300782, "bge_top3": null, "bge_max": null, "title": "Carmustine: Drug information", "rep_snippet": "ABW25: Adjusted wt (kg) = Ideal body weight (kg) + 0.25 [actual wt (kg) - ideal body weight (kg)]"}, {"doc_id": "cyclophosphamide-drug-information", "bm25_top3": 24.048122813300782, "bm25_max": 24.048122813300782, "bge_top3": null, "bge_max": null, "title": "Cyclophosphamide: Drug information", "rep_snippet": "ABW25: Adjusted wt (kg) = Ideal body weight (kg) + 0.25 [actual wt (kg) - ideal body weight (kg)]"}, {"doc_id": "guanfacine-drug-information", "bm25_top3": 14.694408482667194, "bm25_max": 21.708480766266717, "bge_top3": null, "bge_max": null, "title": "Guanfacine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Guanfacine: Pediatric drug information\")  ADHD: Extended release: Children ≥6 years and Adolescents ≤17 years: Oral: Initial: 1 mg once daily; may adjust by increments…"}, {"doc_id": "busulfan-drug-information", "bm25_top3": 19.13517858849117, "bm25_max": 20.589935687409852, "bge_top3": null, "bge_max": null, "title": "Busulfan: Drug information", "rep_snippet": "Dosing: Obesity  American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity (Bubalo 2014):  Busulfan (oral): Note: For total doses over…"}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 20.50315260804762, "bm25_max": 20.50315260804762, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment  Deterioration of renal function during IV therapy: Stop treatment.  Clasteon [DSC]:  Serum creatinine (Scr) >5 mg/dL: Use is contraindicated.  Scr ≥2.5 to 5 mg/dL: There are no specific dosage a…"}, {"doc_id": "diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 20.335126595914083, "bm25_max": 20.335126595914083, "bge_top3": null, "bge_max": null, "title": "Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Prophylaxis: 300 mg once weekly; continue as long as exposure occurs (CDC 2015; Parasitic Infections 2013; WHO 2008)  Lymphatic filariasis: Oral:  CDC recommendations: 6 mg/kg/day as a single dose or 6 mg/kg/day in 3 div…"}, {"doc_id": "edetate-calcium-disodium-calcium-edta-drug-information", "bm25_top3": 20.18342372109512, "bm25_max": 20.18342372109512, "bge_top3": null, "bge_max": null, "title": "Edetate calcium disodium (calcium EDTA): Drug information", "rep_snippet": "Lead nephropathy: An alternative dosing regimen reflecting the reduction in renal clearance is based upon the serum creatinine; Note: Repeat regimen monthly until lead levels are reduced to an acceptable level: IM, IV:…"}, {"doc_id": "magnesium-sulfate-drug-information", "bm25_top3": 20.110819497028697, "bm25_max": 20.110819497028697, "bge_top3": null, "bge_max": null, "title": "Magnesium sulfate: Drug information", "rep_snippet": "Obesity: Weight >130% of ideal body weight (IBW) or body mass index (BMI) ≥30 kg/m2: When determining maximum per kg dose for replacement, some clinicians suggest using adjusted body weight (AdjBW) (Kraft, 2005).  AdjBW…"}, {"doc_id": "laronidase-drug-information", "bm25_top3": 18.769622653239598, "bm25_max": 19.26578721476144, "bge_top3": null, "bge_max": null, "title": "Laronidase: Drug information", "rep_snippet": "Dosing: Adult  Note: Premedicate with antipyretic and/or antihistamines 1 hour prior to start of infusion.  MPS I (Hurler syndrome, Hurler-Scheie, and Scheie forms): IV: 0.58 mg/kg once weekly; dose should be rounded up…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": 19.100789847997806, "bm25_max": 19.100789847997806, "bge_top3": null, "bge_max": null, "title": "Furosemide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Furosemide: Pediatric drug information\")  Note: Oral dose equivalency (approximate) for patients with normal renal function (Brater 1983; Cody 1994; Vargo 1995): Furose…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 18.111449595879186, "bm25_max": 18.635829382452243, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "14 to <18.5 kg: 250 mg every 6 hours  18.5 to <23 kg: 300 mg every 6 hours  23 to <32 kg: 350 mg every 6 hours  32 to <41 kg: 400 mg every 6 hours  41 to ≤50 kg: 450 mg every 6 hours  >50 kg: 500 mg every 6 hours  Altern…"}, {"doc_id": "praziquantel-drug-information", "bm25_top3": 18.100793253022722, "bm25_max": 18.100793253022722, "bge_top3": null, "bge_max": null, "title": "Praziquantel: Drug information", "rep_snippet": "Dosing: Adult  Schistosomiasis: Oral: 20 mg/kg/dose 3 times daily at 4- to 6-hour intervals for 1 day  Clonorchiasis/opisthorchiasis: Oral:  Manufacturer’s labeling: 25 mg/kg/dose 3 times daily at 4- to 6-hour intervals…"}, {"doc_id": "thiotepa-drug-information", "bm25_top3": 17.951504585971897, "bm25_max": 17.951504585971897, "bge_top3": null, "bge_max": null, "title": "Thiotepa: Drug information", "rep_snippet": "Dosing: Obesity  American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity: Utilize actual body weight (full weight) for calculation o…"}, {"doc_id": "etoposide-drug-information", "bm25_top3": 17.83938192595728, "bm25_max": 17.83938192595728, "bge_top3": null, "bge_max": null, "title": "Etoposide: Drug information", "rep_snippet": "Dosing: Obesity  American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer (Note: Excludes HSCT dosing): Utilize patient’s actual body weight (full weight) fo…"}, {"doc_id": "iobenguane-drug-information", "bm25_top3": 17.748979149806722, "bm25_max": 17.748979149806722, "bge_top3": null, "bge_max": null, "title": "Iobenguane: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Thyroid protective agents (SSKI, Lugol's solution or potassium iodide), should be given at least 1 hour prior to administration (in patients at risk for accumulation in thyroid).  Radioimaging: P…"}, {"doc_id": "methohexital-drug-information", "bm25_top3": 17.645914969828773, "bm25_max": 17.645914969828773, "bge_top3": null, "bge_max": null, "title": "Methohexital: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Methohexital: Pediatric drug information\")  Anesthesia: Doses must be titrated to effect.  Manufacturer recommendations:  Induction:  Infants ≥1 month, Children, and Ad…"}, {"doc_id": "tranexamic-acid-drug-information", "bm25_top3": 17.099212332670845, "bm25_max": 17.099212332670845, "bge_top3": null, "bge_max": null, "title": "Tranexamic acid: Drug information", "rep_snippet": "Dosing: Renal Impairment  IV formulation:  Tooth extraction in patients with hemophilia:  Serum creatinine 1.36 to 2.83 mg/dL: Maintenance dose of 10 mg/kg/dose twice daily  Serum creatinine 2.83 to 5.66 mg/dL: Maintenan…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 16.778003003207996, "bm25_max": 16.778003003207996, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "Maintenance therapy for frequently relapsing SSNS: Taper previous dose down to lowest effective dose which maintains remission using an alternate day schedule; usual effective range: 0.1 to 0.5 mg/kg/day on alternating d…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 16.586701876000845, "bm25_max": 16.586701876000845, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 15.040747496657215, "bm25_max": 16.34787329238369, "bge_top3": 0.5439162850379944, "bge_max": 0.5439162850379944, "title": "Fluconazole: Drug information", "rep_snippet": "CNS disease (alternative therapy in patients intolerant of amphotericin B):  Children:  Induction: 12 mg/kg/dose for 1 dose, then 6 to 12 mg/kg/day (maximum: 800 mg/day) for ≥2 weeks (in combination with flucytosine) (CD…"}, {"doc_id": "filgrastim-including-biosimilars-of-filgrastim-drug-information", "bm25_top3": 16.313785322416578, "bm25_max": 16.313785322416578, "bge_top3": null, "bge_max": null, "title": "Filgrastim (including biosimilars of filgrastim): Drug information", "rep_snippet": "Congenital: Initial: 6 mcg/kg/day in 2 divided doses; adjust the dose based on ANC and clinical response; mean dose: 6 mcg/kg/day.  Idiopathic: Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical resp…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": 16.280256372698787, "bm25_max": 16.280256372698787, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Regular strength: 650 mg every 4 to 6 hours; maximum daily dose: 3250 mg daily unless directed by health care provider; under health care provider supervision, daily doses ≤4 g may be used  Extra strength: 1000 mg every…"}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": 16.172932581443426, "bm25_max": 16.172932581443426, "bge_top3": null, "bge_max": null, "title": "Hydroxyzine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydroxyzine: Pediatric drug information\")  Antiemetic: IM: 1.1 mg/kg/dose  Anxiety: Oral:  Children <6 years: 50 mg/day in divided doses  Children ≥6 years and Adolesce…"}, {"doc_id": "ioxaglate-meglumine-and-ioxaglate-sodium-drug-information", "bm25_top3": 16.1598667905402, "bm25_max": 16.1598667905402, "bge_top3": null, "bge_max": null, "title": "Ioxaglate meglumine and ioxaglate sodium: Drug information", "rep_snippet": "Dosing: Pediatric  Pediatric angiocardiography: Catheter injection into heart or associated large vessels: Usual total dose per procedure (including diagnostic and test dose) is ~4 mL/kg (range 1.5 to 5 mL/kg)  Infants a…"}, {"doc_id": "loperamide-drug-information", "bm25_top3": 16.029074380784486, "bm25_max": 16.029074380784486, "bge_top3": null, "bge_max": null, "title": "Loperamide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Loperamide: Pediatric drug information\")  Acute diarrhea: Oral: Children ≥2 years and Adolescents:  Initial (first 24 hours):  2 to 5 years (13 to 20 kg): 1 mg 3 times…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": 15.97746281085993, "bm25_max": 15.97746281085993, "bge_top3": null, "bge_max": null, "title": "Cefixime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefixime: Pediatric drug information\")  Note: Suprax 400 mg tablets have been discontinued in the US for more than 1 year.  Susceptible infections: Oral: Note: Otitis m…"}, {"doc_id": "benazepril-drug-information", "bm25_top3": 15.920995051873152, "bm25_max": 15.920995051873152, "bge_top3": null, "bge_max": null, "title": "Benazepril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Benazepril: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents: Oral: Initial: 0.2 mg/kg once daily (maximum initial dose: 10 mg/day) as mono…"}, {"doc_id": "sodium-glycerophosphate-drug-information", "bm25_top3": 15.78923136677075, "bm25_max": 15.78923136677075, "bge_top3": null, "bge_max": null, "title": "Sodium glycerophosphate: Drug information", "rep_snippet": "Low dose, serum phosphorus level 2.3-3 mg/dL (0.74-0.96 mmol/L): 0.16-0.32 mmol/kg over 4-6 hours  Intermediate dose, serum phosphorus level 1.6-2.2 mg/dL (0.51-0.71 mmol/L): 0.32-0.64 mmol/kg over 4-6 hours  High dose,…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": 15.719078336225252, "bm25_max": 15.719078336225252, "bge_top3": null, "bge_max": null, "title": "Aprepitant: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Aprepitant: Pediatric drug information\")  Manufacturer's labeling:  Prevention of acute and delayed nausea and vomiting associated with highly-emetogenic chemotherapy:…"}, {"doc_id": "lacosamide-drug-information", "bm25_top3": 15.625661519223051, "bm25_max": 15.625661519223051, "bge_top3": null, "bge_max": null, "title": "Lacosamide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Lacosamide: Pediatric drug information\")  Partial onset seizure:  Children ≥4 to 17 years and <50 kg: Oral:  Monotherapy and adjunctive therapy:  11 to <30 kg:  Initial…"}, {"doc_id": "mesalamine-mesalazine-drug-information", "bm25_top3": 15.550625358261247, "bm25_max": 15.550625358261247, "bge_top3": null, "bge_max": null, "title": "Mesalamine (mesalazine): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Mesalamine (mesalazine): Pediatric drug information\")  Ulcerative colitis (treatment): Children ≥5 years and Adolescents: Oral: Delzicol:  17 to 32 kg: 800 mg in the mo…"}, {"doc_id": "thyroid-extract-desiccated-thyroid-drug-information", "bm25_top3": 14.838529869313243, "bm25_max": 14.838529869313243, "bge_top3": null, "bge_max": null, "title": "Thyroid extract (desiccated thyroid): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Thyroid extract (desiccated thyroid): Pediatric drug information\")  Note: The American Thyroid Association/American Association of Clinical Endocrinologists do not reco…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 13.711157614816877, "bm25_max": 13.711157614816877, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Raltegravir: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Note: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioe…"}, {"doc_id": "tolnaftate-drug-information", "bm25_top3": 10.468739291789056, "bm25_max": 10.468739291789056, "bge_top3": null, "bge_max": null, "title": "Tolnaftate: Drug information", "rep_snippet": "Pricing: US  Aerosol (Tinactin External)  1% (150 g): $5.52  Aerosol powder (LamISIL AF Defense External)  1% (133 g): $6.12  Cream (Fungoid-D External)  1% (113 g): $28.36  Cream (Medi-First Anti-Fungal External)  1% (1…"}, {"doc_id": "factor-ix-recombinant-human-glycopegylated-drug-information", "bm25_top3": 8.77064767778069, "bm25_max": 8.77064767778069, "bge_top3": null, "bge_max": null, "title": "Factor IX, recombinant human glycopegylated: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Distribution:  Single dose: Vd: Children ≤6 years of age: 72.3 mL/kg; Children 7 to 12 years: 68.3 mL/kg; Adolescents 13 to 17 years: 58.6 mL/kg; Adults: 47 mL/kg.  After multiple once-weekly p…"}, {"doc_id": "factor-viia-activated-recombinant-human-drug-information", "bm25_top3": 6.406117365768509, "bm25_max": 6.406117365768509, "bge_top3": null, "bge_max": null, "title": "Factor VIIa (activated), recombinant human: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Hemophilia A or B:  Distribution: Vss: Children 2 to 12 years: 164 mL/kg; Adults: 107 to 128 mL/kg  Half-life, terminal: Children 2 to 12 years: 2.6 hours; Adults: 2.9 to 3.1 hours  Excretion:…"}, {"doc_id": "ketorolac-systemic-drug-information", "bm25_top3": 6.274794470200916, "bm25_max": 6.274794470200916, "bge_top3": null, "bge_max": null, "title": "Ketorolac (systemic): Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: Analgesic: Oral: 30-60 minutes; IM, IV: ~30 minutes  Peak effect: Analgesic: Oral: 2 to 3 hours; IM, IV: ≤2-3 hours  Duration: Analgesic: 4-6 hours  Absorption: Oral: Well abso…"}, {"doc_id": "bumetanide-drug-information", "bm25_top3": 5.748657174344785, "bm25_max": 5.748657174344785, "bge_top3": null, "bge_max": null, "title": "Bumetanide: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: Oral, IM: 0.5 to 1 hour; IV: 2 to 3 minutes  Peak effect: Oral: 1 to 2 hours; IV: 15 to 30 minutes  Duration: Oral: 4 to 6 hours; IV: 2 to 3 hours  Distribution: Vd: Neonates a…"}, {"doc_id": "ibutilide-drug-information", "bm25_top3": 5.65588775804094, "bm25_max": 5.65588775804094, "bge_top3": null, "bge_max": null, "title": "Ibutilide: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: Conversion to sinus rhythm: ≤90 minutes after start of infusion  Distribution: Vdss: ~11 L/kg  Protein binding: ~40%  Metabolism: Extensively hepatic; 8 metabolites via oxidati…"}, {"doc_id": "levocetirizine-drug-information", "bm25_top3": 5.375754995135981, "bm25_max": 5.375754995135981, "bge_top3": null, "bge_max": null, "title": "Levocetirizine: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: 1 hour (Devillier 2008)  Duration: 24 hours (Devillier 2008)  Absorption: Rapid and extensive  Distribution: Vd: Children 1 to 2 years: Oral solution: 0.37 ± 0.06 L/kg (Cranswi…"}, {"doc_id": "micafungin-drug-information", "bm25_top3": 5.302828057264655, "bm25_max": 5.302828057264655, "bge_top3": null, "bge_max": null, "title": "Micafungin: Drug information", "rep_snippet": "Excretion: Primarily feces (71%); urine (<1%, unchanged [Herbert 2005])  Clearance:  Preterm infants:  PNA 0 to 1 day: 1.48 mL/minute/kg (Kawada 2009)  PNA 4 days: 0.58 mL/minute (Smith 2009)  PNA >3 weeks: 0.64 mL/minut…"}, {"doc_id": "gadoteridol-drug-information", "bm25_top3": 4.8632841460434815, "bm25_max": 4.8632841460434815, "bge_top3": null, "bge_max": null, "title": "Gadoteridol: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Distribution: Vd: 204 ± 58 mL/kg; distribution half-life: 0.2 ± 0.04 hours  Half-life elimination: 1.57 ± 0.08 hours  Excretion: Urine (~94%)"}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": 4.154751441656863, "bm25_max": 4.154751441656863, "bge_top3": null, "bge_max": null, "title": "Cabozantinib: Drug information", "rep_snippet": "Pricing: US  Kit (Cometriq (100 mg Daily Dose) Oral)  1 X 80 & 1 X 20 mg (56): $17,746.61  Kit (Cometriq (140 mg Daily Dose) Oral)  1 X 80 & 3 X 20 mg (112): $17,746.61  Kit (Cometriq (60 mg Daily Dose) Oral)  20 mg (84)…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 2.9537538647059556, "bm25_max": 2.9537538647059556, "bge_top3": null, "bge_max": null, "title": "Pantoprazole: Drug information", "rep_snippet": "Pricing: US  Pack (Protonix Oral)  40 mg (1): $17.22  Solution (reconstituted) (Pantoprazole Sodium Intravenous)  40 mg (1): $8.50  Solution (reconstituted) (Protonix Intravenous)  40 mg (1): $6.00  Tablet, EC (Pantopraz…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5783482988675436, "bge_max": 0.605715274810791, "title": "Apixaban: Drug information", "rep_snippet": "• Elderly: Systemic exposure is increased ~32% in patients >65 years of age; however, dose reductions are not required. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation who are ≥80 years…"}, {"doc_id": "afatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5791983604431152, "bge_max": 0.5791983604431152, "title": "Afatinib: Drug information", "rep_snippet": "Dosing: Adult  Non-small cell lung cancer (NSCLC), metastatic, with nonresistant EGFR mutations: Oral: 40 mg once daily until disease progression or unacceptable toxicity  NSCLC, metastatic squamous (previously treated):…"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5577278137207031, "bge_max": 0.5748435854911804, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Initial: 8 to 10 mg/kg once daily (not to exceed 600 mg/day in the first week)  Maintenance: The target maintenance dose should be achieved over 2 to 3 weeks with dose increases of 8 to 10 mg/kg/day increments at weekly…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5682799220085144, "bge_max": 0.5682799220085144, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Adult  VTE (prophylaxis): Oral: 160 mg as a single dose on day 1, followed by 80 mg once daily for 35 to 42 days  Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5668315887451172, "bge_max": 0.5668315887451172, "title": "Phenobarbital: Drug information", "rep_snippet": "Dosing: Adult  Sedation:  Oral, IV, IM: 30 to 120 mg/day in 2 to 3 divided doses; maximum: 400 mg/day  Preoperative sedation: IM: 100 to 200 mg 60 to 90 minutes before surgery  Status epilepticus: IV:  American Epilepsy…"}, {"doc_id": "gefitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5664239525794983, "bge_max": 0.5664239525794983, "title": "Gefitinib: Drug information", "rep_snippet": "Dosing: Adult  Non-small cell lung cancer (NSCLC), metastatic, with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations: Oral: 250 mg once daily until disease progression or unacceptable toxicity.  Missed do…"}, {"doc_id": "neostigmine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5549410382906595, "bge_max": 0.5630322098731995, "title": "Neostigmine: Drug information", "rep_snippet": "Bloxiverz: IV: Note: An anticholinergic agent (atropine or glycopyrrolate) should be given intravenously prior to or in conjunction with neostigmine; in the presence of bradycardia, administer the anticholinergic prior t…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5619835257530212, "bge_max": 0.5619835257530212, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "M. avium complex (nodular/bronchiectatic disease) (ATS/IDSA [Griffith 2007]): 600 mg 3 times weekly in combination with a 3-times-weekly regimen of a macrolide (azithromycin or clarithromycin) and ethambutol; continue tr…"}, {"doc_id": "raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5611495971679688, "bge_max": 0.5611495971679688, "title": "Raxibacumab (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department) : Drug information", "rep_snippet": "Dosing: Adult  Anthrax, prophylaxis or treatment: IV: 40 mg/kg as a single dose  Note: Administer diphenhydramine 25-50 mg (may administer oral or IV depending on the proximity to start of raxibacumab infusion) ≤1 hour p…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5572142004966736, "bge_max": 0.5572142004966736, "title": "Amiodarone: Drug information", "rep_snippet": "Dosing: Adult  Note: Lower loading and maintenance doses are preferable in women and all patients with low body weight.  Ventricular arrhythmias:  Prevention of recurrent life-threatening ventricular arrhythmias (eg, VF…"}, {"doc_id": "ethambutol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5554553270339966, "bge_max": 0.5554553270339966, "title": "Ethambutol: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis, pulmonary (drug-susceptible): Oral: Note: Always administer in combination with other antitubercular drugs.  ATS/CDC/IDSA drug-susceptible tuberculosis guideline recommendations (Nahid 2016):…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.554436981678009, "bge_max": 0.554436981678009, "title": "Hyoscyamine: Drug information", "rep_snippet": "Dosing: Adult  Gastrointestinal disorders:  Oral:  Tablet, dispersible:  Anaspaz, ED-SPAZ, NuLev, Symax FasTab: 0.125 to 0.25 mg every 4 hours or as needed; maximum: 1.5 mg/day  Oscimin: 0.125 to 0.25 mg 3 to 4 times dai…"}, {"doc_id": "bevacizumab-including-biosimilars-of-bevacizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537392497062683, "bge_max": 0.5537392497062683, "title": "Bevacizumab (including biosimilars of bevacizumab): Drug information", "rep_snippet": "Dosing: Adult  Note: Do not administer bevacizumab products until at least 28 days after surgery and the wound is fully healed.  Cervical cancer, persistent/recurrent/metastatic (Avastin [bevacizumab], Mvasi [bevacizumab…"}, {"doc_id": "alpha-1-proteinase-inhibitor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5521461367607117, "bge_max": 0.5521461367607117, "title": "Alpha-1 proteinase inhibitor: Drug information", "rep_snippet": "Dosing: Adult  Note: The vial strength (mg) of some products (ie, Prolastin-C, Zemaira) varies by manufacturer lot; consult individual vial labels for exact amount prior to preparation for administration.  Alpha1-antitry…"}, {"doc_id": "belatacept-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5520785450935364, "bge_max": 0.5520785450935364, "title": "Belatacept: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing is based on actual body weight at the time of transplantation; do not modify weight-based dosing during course of therapy unless the change in body weight is >10%. The prescribed dose must be…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.55165696144104, "bge_max": 0.55165696144104, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Extended release suspension (Zmax): Infants ≥6 months and Children: Oral:  <75 lbs (34 kg): 60 mg/kg as a single dose  ≥75 lbs (34 kg): Refer to adult dosing  Disseminated M. avium complex disease in patients with advanc…"}, {"doc_id": "nivolumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.551559567451477, "bge_max": 0.551559567451477, "title": "Nivolumab: Drug information", "rep_snippet": "Single agent: IV: 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity (Antonia 2016)  Combination therapy: IV: 1 mg/kg once every 3 weeks (in combination with ipilimumab) for 4 doses, followed b…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5504938960075378, "bge_max": 0.5504938960075378, "title": "Edoxaban: Drug information", "rep_snippet": "Dosing: Adult  Note: Prior to initiation of edoxaban, assess creatinine clearance (CrCl) using the Cockcroft-Gault equation. For patients with nonvalvular atrial fibrillation, do not use edoxaban if CrCl is >95 mL/minute…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5504559278488159, "bge_max": 0.5504559278488159, "title": "Amoxicillin: Drug information", "rep_snippet": "Low dose: Oral: 45 mg/kg/day in divided doses every 12 hours  High dose (use reserved for select patients; see Note): Oral: 80 to 90 mg/kg/day in divided doses every 12 hours (maximum dose: 1,000 mg/dose). Note: Should o…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5471478700637817, "bge_max": 0.5503262281417847, "title": "Rivaroxaban: Drug information", "rep_snippet": "Dosing: Adult  Note: Extremes of body weight (<50 kg or >120 kg) do not significantly influence rivaroxaban exposure (Kubitza 2007). However, The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline…"}, {"doc_id": "pregabalin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.550263524055481, "bge_max": 0.550263524055481, "title": "Pregabalin: Drug information", "rep_snippet": "Neuropathic pain, spinal cord injury associated: Immediate release: Oral: Initial: 150 mg daily in divided doses (75 mg twice daily); may be increased to 300 mg daily (150 mg twice daily) within 1 week based on tolerabil…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5502521991729736, "bge_max": 0.5502521991729736, "title": "Fluvastatin: Drug information", "rep_snippet": "Immediate release: 40 mg twice daily.  Extended release: 80 mg once daily.  Type 1 or 2 diabetes, age 40 to 75 years, and an estimated 10-year ASCVD risk ≥7.5%: High-intensity therapy necessary; use alternate statin ther…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5482737421989441, "bge_max": 0.5482737421989441, "title": "Clozapine: Drug information", "rep_snippet": "Dosing: Adult  Note: Prior to initiating treatment, obtain a baseline CBC, including the ANC; the ANC must be ≥1,500/mm3 for the general population and ≥1,000/mm3 for patients with documented Benign Ethnic Neutropenia (B…"}, {"doc_id": "total-parenteral-nutrition-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5473836660385132, "bge_max": 0.5478700399398804, "title": "Total parenteral nutrition: Drug information", "rep_snippet": "Dosing: Adult  Nutritional supplementation: IV:  Fixed-combination solutions:  Note: Dosage should be individualized based on patient status. These products contain a fixed combination of amino acids, dextrose, lipids, a…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5470964908599854, "bge_max": 0.5470964908599854, "title": "Topiramate: Drug information", "rep_snippet": "23 to 31 kg: 350 mg daily in 2 divided doses  32 to 38 kg: 350 mg daily in 2 divided doses  ≥39 kg: 400 mg daily in 2 divided doses  Extended release (Qudexy XR only):  Initial: 25 mg once daily (in the evening); if tole…"}, {"doc_id": "antithrombin-concentrate-from-human-plasma-and-recombinant-human-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5467866659164429, "bge_max": 0.5467866659164429, "title": "Antithrombin, concentrate from human plasma and recombinant human: Drug information", "rep_snippet": "Dosing: Adult  Antithrombin deficiency: IV:  ATryn: Prophylaxis of thrombosis during perioperative and peripartum procedures:  Dosing is individualized based on pretherapy antithrombin (AT) activity levels. Therapy shoul…"}, {"doc_id": "norepinephrine-noradrenaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5465404391288757, "bge_max": 0.5465404391288757, "title": "Norepinephrine (noradrenaline): Drug information", "rep_snippet": "Dosing: Adult  Note: Dose is stated in terms of norepinephrine base.  Hypotension/shock: Continuous IV infusion:  Initial: 8 to 12 mcg/minute; titrate to desired response. Usual maintenance range: 2 to 4 mcg/minute; dosa…"}, {"doc_id": "arginine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5462459921836853, "bge_max": 0.5462459921836853, "title": "Arginine: Drug information", "rep_snippet": "Weight-directed dosing:  Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency: Oral: 400 to 700 mg/kg/day in 3 to 4 divided doses (Batshaw 2001; Berry 2001; Brusilow 1996;…"}, {"doc_id": "liposomal-amphotericin-b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5459228157997131, "bge_max": 0.5459228157997131, "title": "Liposomal amphotericin B: Drug information", "rep_snippet": "Dosing: Adult  Note: Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin…"}, {"doc_id": "trabectedin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5458959937095642, "bge_max": 0.5458959937095642, "title": "Trabectedin: Drug information", "rep_snippet": "Dosing: Adult  Note: Prior to each treatment cycle, ANC should be ≥1,500/mm3, platelets ≥100,000/mm3 total bilirubin ≤ ULN, and alkaline phosphatase, ALT, AST, and CPK ≤2.5 times ULN.  Premedications: Administer dexameth…"}, {"doc_id": "pyrazinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.544893205165863, "bge_max": 0.544893205165863, "title": "Pyrazinamide: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis, treatment (drug-susceptible): Oral: Note: Always administer in combination with other antitubercular drugs (Nahid 2016).  ATS/CDC/IDSA drug-sensitive tuberculosis guideline recommendations (N…"}, {"doc_id": "pravastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5446382164955139, "bge_max": 0.5446382164955139, "title": "Pravastatin: Drug information", "rep_snippet": "Age 40 to 75 years and an estimated 10-year ASCVD risk ≥7.5%: Moderate to high intensity therapy: 40 to 80 mg once daily or consider using high intensity statin therapy (eg, atorvastatin or rosuvastatin)  Secondary preve…"}, {"doc_id": "piperacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5445601940155029, "bge_max": 0.5445601940155029, "title": "Piperacillin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Community-acquired pneumonia: IM, IV: Usual dosage: 6 to 8 g daily (100 to 125 mg/kg daily) in divided doses every 6 to 12 hours  Severe infections (eg, gynecologic, intra-abdominal, nosocomial pneumonia,…"}, {"doc_id": "clopidogrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5443700551986694, "bge_max": 0.5443700551986694, "title": "Clopidogrel: Drug information", "rep_snippet": "Dosing: Adult  Acute coronary syndrome (ACS): Oral:  Unstable angina, non-ST-segment elevation myocardial infarction (UA/NSTEMI) (also referred to as NSTE-ACS): Initial: 300 mg or 600 mg loading dose, followed by 75 mg o…"}, {"doc_id": "necitumumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5427801609039307, "bge_max": 0.5427801609039307, "title": "Necitumumab: Drug information", "rep_snippet": "Dosing: Adult  Note: For patients with a prior grade 1 or 2 infusion reaction, premedicate (prior to all subsequent necitumumab infusions) with diphenhydramine (or equivalent). For patients with a recurrent grade 1 or 2…"}, {"doc_id": "nebivolol-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5427652597427368, "bge_max": 0.5427652597427368, "title": "Nebivolol and valsartan: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial therapy and patients not controlled on valsartan 80 mg or nebivolol ≤10 mg: Nebivolol 5 mg/valsartan 80 mg once daily. Note: May be substituted for individual components in pati…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.542681097984314, "bge_max": 0.542681097984314, "title": "Sulfadiazine: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Oral: 2 to 4 g/day in 3 to 6 divided doses  Rheumatic fever prophylaxis (off-label dose) (Gerber [AHA 2009]): Oral:  ≤27 kg: 500 mg once daily  >27 kg: 1,000 mg once daily  Toxop…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5420776605606079, "bge_max": 0.5420776605606079, "title": "Pegylated interferon (peginterferon) alfa-2b: Drug information", "rep_snippet": "105 to 125 kg: 108 mcg once weekly; may further reduce to 64 mcg once weekly if needed  >125 kg: 135 mcg once weekly; may further reduce to 72 mcg once weekly if needed  Peginterferon alfa-2b monotherapy: Reduce to avera…"}, {"doc_id": "propafenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5417602062225342, "bge_max": 0.5417602062225342, "title": "Propafenone: Drug information", "rep_snippet": "Dosing: Adult  Note: Patients who exhibit significant widening of QRS complex or second- or third-degree AV block may need dose reduction.  Atrial fibrillation (to prevent recurrence): Oral:  Extended release capsule: In…"}, {"doc_id": "edrophonium-and-atropine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5417451858520508, "bge_max": 0.5417451858520508, "title": "Edrophonium and atropine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Enlon-Plus is no longer available in the U.S.  Reversal of neuromuscular blockade: IV: 0.05 to 0.1 mL/kg given over 45 to 60 seconds. The dose delivered is 0.5 to 1 mg/kg of edrophonium and 0.007 to…"}]}
{"qid": "Q5_abbr", "query": "Acute DVT, normal renal — enoxaparin therapeutic regimen?", "base_qid": "Q5", "variant_type": "abbr", "candidates": [{"doc_id": "enoxaparin-drug-information", "bm25_top3": 21.51852454894778, "bm25_max": 22.398803576739635, "bge_top3": 0.6120042602221171, "bge_max": 0.6213882565498352, "title": "Enoxaparin: Drug information", "rep_snippet": "Pregnant women (off-label use): 1 mg/kg/dose every 12 hours. Discontinue ≥24 hours prior to the induction of labor or cesarean section. Enoxaparin therapy may be substituted with heparin near term. Continue anticoagulati…"}, {"doc_id": "protamine-sulfate-drug-information", "bm25_top3": 9.403595456230505, "bm25_max": 12.111850366580743, "bge_top3": 0.5539632439613342, "bge_max": 0.5539632439613342, "title": "Protamine sulfate: Drug information", "rep_snippet": "Heparin-mediated (full dose infusions): 1 mg protamine for every 100 units of heparin administered in the previous 2 to 3 hours; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If the aPTT r…"}, {"doc_id": "nadroparin-united-states-not-available-drug-information", "bm25_top3": 9.065569244294922, "bm25_max": 9.065569244294922, "bge_top3": 0.5880364775657654, "bge_max": 0.6066031455993652, "title": "Nadroparin (United States: Not available): Drug information", "rep_snippet": "Use  Fraxiparine:  Acute coronary syndromes: Treatment of unstable angina and non-ST-elevation myocardial infarction (NSTEMI) myocardial infarction (ie, non-Q wave MI)  Anticoagulation during hemodialysis: Prevention of…"}, {"doc_id": "pregabalin-drug-information", "bm25_top3": 7.725780970899146, "bm25_max": 9.046595380417854, "bge_top3": null, "bge_max": null, "title": "Pregabalin: Drug information", "rep_snippet": "Extended release: Renal function may be estimated using the Cockcroft-Gault formula. Then determine recommended dosage regimen based on the indication-specific total daily dose for normal renal function (CrCl ≥60 mL/minu…"}, {"doc_id": "fludarabine-drug-information", "bm25_top3": 8.838208075314991, "bm25_max": 8.838208075314991, "bge_top3": null, "bge_max": null, "title": "Fludarabine: Drug information", "rep_snippet": "Use: Off-Label  Acute myeloid leukemia (adults) (newly diagnosed); Acute myeloid leukemia (adults) (refractory or high/poor risk); Acute lymphocytic leukemia (pediatric) (relapsed); Acute myeloid leukemia (pediatrics) (n…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 8.389221544031301, "bm25_max": 8.389221544031301, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary ed…"}, {"doc_id": "iothalamate-meglumine-drug-information", "bm25_top3": 8.144143309843596, "bm25_max": 8.144143309843596, "bge_top3": null, "bge_max": null, "title": "Iothalamate meglumine: Drug information", "rep_snippet": "• Renal failure: Acute renal failure has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent, in diabetic patients wit…"}, {"doc_id": "ioxaglate-meglumine-and-ioxaglate-sodium-drug-information", "bm25_top3": 7.272933694613689, "bm25_max": 8.097867196214942, "bge_top3": null, "bge_max": null, "title": "Ioxaglate meglumine and ioxaglate sodium: Drug information", "rep_snippet": "• Renal failure: Acute renal failure has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent, and in diabetic patients…"}, {"doc_id": "pegaspargase-drug-information", "bm25_top3": 8.073600259686444, "bm25_max": 8.073600259686444, "bge_top3": null, "bge_max": null, "title": "Pegaspargase: Drug information", "rep_snippet": "Use  Acute lymphoblastic leukemia and hypersensitivity to asparaginase: Treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to native forms of L-asparaginase (as a component of a multiagent…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 7.920187915324286, "bm25_max": 8.024306993253873, "bge_top3": null, "bge_max": null, "title": "Iodixanol: Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with cardiovascular disease and heart failure patients receiving concurrent diuretic therapy; they may have intravascular volume depletion, which may affect the rena…"}, {"doc_id": "entecavir-drug-information", "bm25_top3": 8.012310603614814, "bm25_max": 8.012310603614814, "bge_top3": null, "bge_max": null, "title": "Entecavir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Daily-dosage regimen preferred:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl 30-49 mL/minute: Administer 50% of usual dose daily or administer the normal dose every 48 hour…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 7.974168650534441, "bm25_max": 7.974168650534441, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Use  Acute lymphoblastic leukemia: Treatment of acute lymphoblastic leukemia (ALL), as part of a combination chemotherapy regimen"}, {"doc_id": "botulism-immune-globulin-intravenous-human-drug-information", "bm25_top3": 7.887486079050191, "bm25_max": 7.887486079050191, "bge_top3": null, "bge_max": null, "title": "Botulism immune globulin (intravenous human): Drug information", "rep_snippet": "• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with IGIV use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxe…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 7.863933552027968, "bm25_max": 7.863933552027968, "bge_top3": 0.573749303817749, "bge_max": 0.573749303817749, "title": "Warfarin: Drug information", "rep_snippet": "• Heparin-induced thrombocytopenia: Use with caution in patients with heparin-induced thrombocytopenia and DVT; limb ischemia, necrosis, and gangrene have occurred when warfarin was started or continued after heparin was…"}, {"doc_id": "basiliximab-drug-information", "bm25_top3": 7.8354776426584625, "bm25_max": 7.8354776426584625, "bge_top3": 0.5779134035110474, "bge_max": 0.5779134035110474, "title": "Basiliximab: Drug information", "rep_snippet": "Use  Renal transplant (prophylaxis of acute rejection): Prophylaxis of acute organ rejection in renal transplantation in combination with cyclosporine (modified) and corticosteroids  Guideline recommendations: While basi…"}, {"doc_id": "iopromide-drug-information", "bm25_top3": 7.622796248214115, "bm25_max": 7.622796248214115, "bge_top3": null, "bge_max": null, "title": "Iopromide: Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with cardiovascular disease or heart failure. Iodinated contrast media may result in an increased circulatory osmotic load and subsequent acute or delayed hemodynami…"}, {"doc_id": "melphalan-drug-information", "bm25_top3": 7.560463263518603, "bm25_max": 7.560463263518603, "bge_top3": null, "bge_max": null, "title": "Melphalan: Drug information", "rep_snippet": "Dosing: Renal Impairment  The manufacturer's labeling contains the following adjustment recommendations (for approved dosing levels) based on route of administration:  Oral: Moderate to severe renal impairment: Consider…"}, {"doc_id": "cytomegalovirus-immune-globulin-drug-information", "bm25_top3": 7.299552507905423, "bm25_max": 7.299552507905423, "bge_top3": null, "bge_max": null, "title": "Cytomegalovirus immune globulin: Drug information", "rep_snippet": "• Pulmonary edema: Monitor for adverse pulmonary events including transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characteriz…"}, {"doc_id": "mitoxantrone-drug-information", "bm25_top3": 7.185310011233778, "bm25_max": 7.185310011233778, "bge_top3": 0.5483385920524597, "bge_max": 0.5483385920524597, "title": "Mitoxantrone: Drug information", "rep_snippet": "Use: Off-Label  Acute lymphocytic leukemia (ALL); Autologous hematopoietic stem cell transplantation (HSCT) (conditioning regimen); Breast cancer (metastatic); Hodgkin lymphoma (refractory); Non-Hodgkin lymphomas (NHL);…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": 7.054273222376377, "bm25_max": 7.054273222376377, "bge_top3": 0.5719491243362427, "bge_max": 0.5848158001899719, "title": "Dalteparin: Drug information", "rep_snippet": "Use  Deep vein thrombosis prophylaxis: Prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE), in patients requiring abdominal surgery who are at risk for thromboembolism complications (eg, >4…"}, {"doc_id": "alteplase-drug-information", "bm25_top3": 7.028787059584378, "bm25_max": 7.028787059584378, "bge_top3": null, "bge_max": null, "title": "Alteplase: Drug information", "rep_snippet": "High-dose regimen: Load with 10 mg, followed by 90 mg over 90 to 180 minutes (without heparin during infusion)  Low-dose regimen (preferred for very small adults): Load with 20 mg, followed by 10 mg/hour for 3 hours (wit…"}, {"doc_id": "ioversol-drug-information", "bm25_top3": 6.975151284143896, "bm25_max": 6.975151284143896, "bge_top3": null, "bge_max": null, "title": "Ioversol: Drug information", "rep_snippet": "Disease-related concerns:  • Cardiovascular disease: Use with caution in severe cardiovascular disease and HF; transitory increase in circulatory osmotic load could occur. Observe patients with HF for several hours follo…"}, {"doc_id": "diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information", "bm25_top3": 6.922840515857731, "bm25_max": 6.922840515857731, "bge_top3": null, "bge_max": null, "title": "Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Drug information", "rep_snippet": "• Renal failure: Renal failure has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent. Avoid fluid restriction and ma…"}, {"doc_id": "lithium-drug-information", "bm25_top3": 6.920928535141144, "bm25_max": 6.920928535141144, "bge_top3": null, "bge_max": null, "title": "Lithium: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl 10 to 50 mL/minute: Administer 50% to 75% of normal dose (Aronoff 2007).  CrCl <10 mL/minute: Administer 25% to 50% of normal dose (Aronoff 2007).  End-stage renal disease (ESRD) with hemod…"}, {"doc_id": "danaparoid-united-states-not-available-drug-information", "bm25_top3": 6.863304580863451, "bm25_max": 6.863304580863451, "bge_top3": null, "bge_max": null, "title": "Danaparoid (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing recommendations per manufacturer labeling unless otherwise noted. Dose expressed as anti-Xa units.  Prevention of DVT following orthopedic, major abdominal, or thoracic surgery: SubQ: 750 unit…"}, {"doc_id": "ibritumomab-tiuxetan-drug-information", "bm25_top3": 6.830607547631807, "bm25_max": 6.830607547631807, "bge_top3": null, "bge_max": null, "title": "Ibritumomab tiuxetan: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Serious infusion reactions:  Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ibritumomab tiuxetan therapeutic regimen. These fatalities were associated w…"}, {"doc_id": "dalbavancin-drug-information", "bm25_top3": 6.537756320996152, "bm25_max": 6.537756320996152, "bge_top3": null, "bge_max": null, "title": "Dalbavancin: Drug information", "rep_snippet": "Dosing: Adult  Acute bacterial skin and skin structure infections: IV:  Single-dose regimen: 1,500 mg as a single dose  Two-dose regimen: 1,000 mg as a single dose initially, followed by 500 mg as a single dose 1 week la…"}, {"doc_id": "lenalidomide-drug-information", "bm25_top3": 6.491940856430027, "bm25_max": 6.491940856430027, "bge_top3": null, "bge_max": null, "title": "Lenalidomide: Drug information", "rep_snippet": "• Elderly: Certain adverse reactions (DVT, pulmonary embolism, atrial fibrillation, renal failure) are more likely in elderly patients. Monitor renal function closely, and select dose accordingly.  • Pediatric: If used i…"}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": 6.484037742494916, "bm25_max": 6.484037742494916, "bge_top3": null, "bge_max": null, "title": "Hydroxyzine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007):  Adults:  GFR >50 mL/minute: No adju…"}, {"doc_id": "dyphylline-drug-information", "bm25_top3": 6.285450390934571, "bm25_max": 6.285450390934571, "bge_top3": null, "bge_max": null, "title": "Dyphylline: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in manufacturer’s labeling; primarily undergoes renal elimination and an increase in systemic exposure is likely. The following adjustments have been recommended (A…"}, {"doc_id": "fondaparinux-drug-information", "bm25_top3": 6.284409144165279, "bm25_max": 6.284409144165279, "bge_top3": 0.6052668690681458, "bge_max": 0.6052668690681458, "title": "Fondaparinux: Drug information", "rep_snippet": "Use  Acute deep vein thrombosis: Treatment of acute DVT in conjunction with warfarin.  Acute pulmonary embolism: Treatment of acute PE in conjunction with warfarin.  Venous thromboembolism: Prophylaxis of venous thromboe…"}, {"doc_id": "iohexol-drug-information", "bm25_top3": 6.248801303828582, "bm25_max": 6.248801303828582, "bge_top3": null, "bge_max": null, "title": "Iohexol: Drug information", "rep_snippet": "• Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia…"}, {"doc_id": "cobicistat-drug-information", "bm25_top3": 4.377306445959075, "bm25_max": 4.377306445959075, "bge_top3": null, "bge_max": null, "title": "Cobicistat: Drug information", "rep_snippet": "Renal: Nephrolithiasis (<2%), renal disease (<2%), decreased creatinine clearance (no effect on renal glomerular function in patients with normal renal function), increased serum creatinine, renal insufficiency"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": 2.607844090349557, "bm25_max": 2.607844090349557, "bge_top3": 0.5747316479682922, "bge_max": 0.5859119892120361, "title": "Rivaroxaban: Drug information", "rep_snippet": "Reduction in the risk (secondary prevention) of recurrent deep vein thrombosis and/or pulmonary embolism: Reduction in the risk of recurrence of DVT and pulmonary embolism in patients at continued risk of DVT and PE foll…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5777627229690552, "bge_max": 0.5937548279762268, "title": "Edoxaban: Drug information", "rep_snippet": "Use  Deep vein thrombosis and pulmonary embolism, treatment: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant  Note: The Americ…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5846742391586304, "bge_max": 0.5920692682266235, "title": "Apixaban: Drug information", "rep_snippet": "Use  Deep vein thrombosis: Treatment of deep vein thrombosis; to reduce the risk of recurrent deep vein thrombosis following initial therapy  Note: The American College of Chest Physicians (ACCP) guidelines for VTE sugge…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5721285343170166, "bge_max": 0.5721285343170166, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "• Renal toxicity: Tenofovir disoproxil fumarate may cause renal toxicity, including acute renal failure and Fanconi syndrome; avoid use with concurrent or recent nephrotoxic therapy (including high dose or multiple NSAID…"}, {"doc_id": "bevacizumab-including-biosimilars-of-bevacizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5670608282089233, "bge_max": 0.5670608282089233, "title": "Bevacizumab (including biosimilars of bevacizumab): Drug information", "rep_snippet": "Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-resistant recurrent) (Avastin): Treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (in…"}, {"doc_id": "tinzaparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.566592276096344, "bge_max": 0.566592276096344, "title": "Tinzaparin: Drug information", "rep_snippet": "Dosing: Adult  Note: 1 mg of tinzaparin equals 70 to 120 units of anti-Xa activity  DVT and/or PE treatment: SubQ: 175 anti-Xa units/kg once daily; maximum dose: 18,000 anti-Xa units/day. Note: In patients with VTE and w…"}, {"doc_id": "prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5642018914222717, "bge_max": 0.5642018914222717, "title": "Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information", "rep_snippet": "Direct thrombin inhibitor-mediated (argatroban, dabigatran [if idarucizumab unavailable], bivalirudin, desirudin): 50 units/kg if direct thrombin inhibitor was administered within a period of 3 to 5 half-lives prior and…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5617420077323914, "bge_max": 0.5631511211395264, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Intensification: High-risk patients: 30 mg/m2 on day 1 of every 3-week cycle (with dexrazoxane; cumulative doxorubicin dose: 300 mg/m2) (Vrooman 2013)  Ewing sarcoma: Children and Adolescents: IV:  VAC/IE regimen: 75 mg/…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.562015175819397, "bge_max": 0.562015175819397, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "recombinant-human-growth-hormone-somatropin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5610912442207336, "bge_max": 0.5610912442207336, "title": "Recombinant human growth hormone (somatropin): Drug information", "rep_snippet": "Note: Therapy should be discontinued when patient has reached satisfactory height, when epiphyses have fused, or when the patient ceases to respond. Some guidelines recommend discontinuing therapy when growth velocity is…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5592072010040283, "bge_max": 0.5592072010040283, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "• Renal impairment: Assess renal function prior to initiation and periodically during treatment. Do not initiate therapy in patients with eGFR <60 mL/minute/1.73 m2 and discontinue use if eGFR falls persistently below 60…"}, {"doc_id": "trandolapril-and-verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5575584471225739, "bge_max": 0.5583903789520264, "title": "Trandolapril and verapamil: Drug information", "rep_snippet": "Dabigatran Etexilate: Verapamil may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. Management: Consider giving dabigatran 2 hrs before oral verapamil; other dose reductions may be need…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5583903789520264, "bge_max": 0.5583903789520264, "title": "Verapamil: Drug information", "rep_snippet": "Dabigatran Etexilate: Verapamil may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. Management: Consider giving dabigatran 2 hrs before oral verapamil; other dose reductions may be need…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5569177269935608, "bge_max": 0.5569177269935608, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Peritoneal dialysis (PD): 2.5 to 5 mg/kg/dose every 24 hours; no supplemental dose needed (Aronoff 2007). Note: Use higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.  Continuous re…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5559954047203064, "bge_max": 0.5559954047203064, "title": "Vancomycin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "amlodipine-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5548043847084045, "bge_max": 0.5548043847084045, "title": "Amlodipine and valsartan: Drug information", "rep_snippet": "• Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this con…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5519525408744812, "bge_max": 0.5540328025817871, "title": "Dabigatran: Drug information", "rep_snippet": "Contraindications  Serious hypersensitivity (eg, anaphylaxis or anaphylactic shock) to dabigatran or any component of the formulation; active pathological bleeding; patients with mechanical prosthetic heart valve(s)  Can…"}, {"doc_id": "enalapril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5531976819038391, "bge_max": 0.5531976819038391, "title": "Enalapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Renal artery stenosis: Use enalapril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the el…"}, {"doc_id": "ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5520634651184082, "bge_max": 0.5520634651184082, "title": "Ticarcillin and clavulanate potassium (United States: Not available): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT): 50 to 75 mg ticarcillin/kg every 8 hours"}, {"doc_id": "brentuximab-vedotin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5517658591270447, "bge_max": 0.5517658591270447, "title": "Brentuximab vedotin: Drug information", "rep_snippet": "• Renal impairment: Avoid use in patients with severe renal impairment (CrCl <30 mL/minute). The frequency of grade 3/4 toxicities (and deaths) was increased in patients with severe impairment (compared to patients with…"}, {"doc_id": "oxaprozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5504372119903564, "bge_max": 0.5504372119903564, "title": "Oxaprozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  In general, NSAIDs are not recommended for use in patients with advanced renal disease but the manufacturer of oxaprozin does provide some guidelines for adjustment in renal dysfunction.  Severe…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5498490333557129, "bge_max": 0.5498490333557129, "title": "Fluconazole: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "azathioprine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5494095087051392, "bge_max": 0.5494095087051392, "title": "Azathioprine: Drug information", "rep_snippet": "Use  Renal transplantation: Adjunctive therapy in prevention of rejection of kidney transplants  Guideline recommendations: While azathioprine is FDA approved for adjunctive therapy in prevention of rejection after renal…"}]}
{"qid": "Q5_noise", "query": "New DVT (no PE mentioned), kidneys ok — what is the tx dosing schedule for enoxaparin?", "base_qid": "Q5", "variant_type": "noise", "candidates": [{"doc_id": "enoxaparin-drug-information", "bm25_top3": 31.147342259929125, "bm25_max": 31.741698709801764, "bge_top3": 0.6341200868288676, "bge_max": 0.6563282012939453, "title": "Enoxaparin: Drug information", "rep_snippet": "Pregnant women (off-label use): 1 mg/kg/dose every 12 hours. Discontinue ≥24 hours prior to the induction of labor or cesarean section. Enoxaparin therapy may be substituted with heparin near term. Continue anticoagulati…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": 23.936410720381442, "bm25_max": 23.936410720381442, "bge_top3": null, "bge_max": null, "title": "Alirocumab: Drug information", "rep_snippet": "Dosing: Adult  Hyperlipidemia, primary: SubQ: Initial: 75 mg every 2 weeks or 300 mg every 4 weeks; for both regimens, if an adequate LDL-C response is not achieved, may increase or modify dosing regimen to a maximum of…"}, {"doc_id": "evolocumab-drug-information", "bm25_top3": 22.767115817014748, "bm25_max": 22.767115817014748, "bge_top3": null, "bge_max": null, "title": "Evolocumab: Drug information", "rep_snippet": "Switching regimens: Administer the first dose of the new regimen on the next scheduled day of the prior regimen.  Missed dose: Administer within 7 days from the missed dose and resume original schedule. If an every-2-wee…"}, {"doc_id": "irinotecan-conventional-drug-information", "bm25_top3": 21.974890614880472, "bm25_max": 21.974890614880472, "bge_top3": null, "bge_max": null, "title": "Irinotecan (conventional): Drug information", "rep_snippet": "Dosing: Geriatric  Weekly dosing schedule: No dosing adjustment is recommended  Every 3-week dosing colorectal cancer schedule: Recommended initial dose is 300 mg/m2/dose for patients ≥70 years"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": 15.544746539614323, "bm25_max": 21.898705604901778, "bge_top3": 0.5846650203069051, "bge_max": 0.6090596318244934, "title": "Rivaroxaban: Drug information", "rep_snippet": "Extended therapy (after first 3 months and no scheduled stop date): May be considered in patients with unprovoked first DVT of the leg or PE who do not have a high bleeding risk. Extended therapy is recommended in patien…"}, {"doc_id": "belimumab-drug-information", "bm25_top3": 20.701831770938018, "bm25_max": 20.701831770938018, "bge_top3": null, "bge_max": null, "title": "Belimumab: Drug information", "rep_snippet": "Dosing: Adult  Systemic lupus erythematosus (SLE):  IV: Initial: 10 mg/kg every 2 weeks for 3 doses; Maintenance: 10 mg/kg every 4 weeks  SubQ: 200 mg once weekly  Switching from IV therapy: Administer the first SubQ dos…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 19.41862317213758, "bm25_max": 19.41862317213758, "bge_top3": 0.5999912023544312, "bge_max": 0.5999912023544312, "title": "Warfarin: Drug information", "rep_snippet": "LV = left ventricular; DVT = deep vein thrombosis, AF = atrial flutter, VTE = venous thromboembolism, PE = pulmonary embolism, LMWH = low molecular weight heparin, MI = myocardial infarction  AF (including AF and mitral…"}, {"doc_id": "protamine-sulfate-drug-information", "bm25_top3": 18.372333212724644, "bm25_max": 19.318369323011254, "bge_top3": 0.6001203656196594, "bge_max": 0.6126601099967957, "title": "Protamine sulfate: Drug information", "rep_snippet": "Dalteparin, nadroparin, and tinzaparin: 1 mg protamine for every 100 anti-Xa units of LMWH administered in the past 3 to 5 half-lives; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If life…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": 19.222404722778315, "bm25_max": 19.222404722778315, "bge_top3": 0.5672524571418762, "bge_max": 0.5672524571418762, "title": "Apixaban: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Deep vein thrombosis (DVT), pulmonary embolism (PE), reduction in the risk of recurrent DVT and PE  : No dosage adjustment is recommended by the manufacturer for any degree of renal imp…"}, {"doc_id": "ethinyl-estradiol-and-norethindrone-drug-information", "bm25_top3": 19.030833833992514, "bm25_max": 19.030833833992514, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and norethindrone: Drug information", "rep_snippet": "Dosing: Adult  Acne: Adolescents ≥15 years and Adults: Females: Oral (Estrostep Fe, Tilia Fe, Tri-Legest Fe): Refer to dosing for contraception  Contraception: Females: One tablet once daily  Schedule 1 (Sunday starter):…"}, {"doc_id": "ethinyl-estradiol-and-desogestrel-drug-information", "bm25_top3": 18.776140982707425, "bm25_max": 18.776140982707425, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and desogestrel: Drug information", "rep_snippet": "Dosing: Adult  Females: Contraception: Oral: One tablet once daily  Schedule 1 (Sunday starter): Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that v…"}, {"doc_id": "exenatide-drug-information", "bm25_top3": 18.44730483467938, "bm25_max": 18.44730483467938, "bge_top3": null, "bge_max": null, "title": "Exenatide: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: SubQ:  Immediate release: Initial: 5 mcg twice daily within 60 minutes prior to morning and evening meals (or before the two main meals of the day, ≥6 hours apart); after 1 month…"}, {"doc_id": "etidronate-drug-information", "bm25_top3": 18.154225644380332, "bm25_max": 18.154225644380332, "bge_top3": null, "bge_max": null, "title": "Etidronate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer’s labeling recommends decreasing the dose when GFR is reduced; however, no specific dosage adjustments are provided. Use with caution and monitor closely; etidronate is eliminated i…"}, {"doc_id": "tromethamine-tham-united-states-not-available-drug-information", "bm25_top3": 18.069553304569354, "bm25_max": 18.069553304569354, "bge_top3": null, "bge_max": null, "title": "Tromethamine (THAM) (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in manufacturer’s labeling. Tromethamine is substantially excreted by the kidneys; use with caution; monitor ECG and potassium levels."}, {"doc_id": "edoxaban-drug-information", "bm25_top3": 9.959732925872427, "bm25_max": 18.02649648442667, "bge_top3": 0.6061751544475555, "bge_max": 0.6085283160209656, "title": "Edoxaban: Drug information", "rep_snippet": "Long-term (first 3 months): 3 months is the minimum duration for most patients without cancer following their first episode of VTE (provoked or unprovoked) (Kearon 2012; Kearon 2016)  Extended therapy (after first 3 mont…"}, {"doc_id": "ethinyl-estradiol-and-drospirenone-drug-information", "bm25_top3": 17.88440588189402, "bm25_max": 17.88440588189402, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and drospirenone: Drug information", "rep_snippet": "Dosing: Adult  Acne (Gianvi, Loryna, Nikki, Vestura, Yaz): Females: Oral: Refer to dosing for contraception.  PMDD (Gianvi, Yaz): Females: Oral: Refer to dosing for contraception.  Contraception: Female: Oral: One tablet…"}, {"doc_id": "ethinyl-estradiol-and-norgestimate-drug-information", "bm25_top3": 17.752846359921776, "bm25_max": 17.752846359921776, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and norgestimate: Drug information", "rep_snippet": "Dosing: Adult  Females:  Acne (Ortho Tri-Cyclen, Tri-Estaryllla, TriNessa, Tri-Previfem, Tri-Sprintec): Oral: Refer to dosing for contraception  Contraception: Oral: 1 tablet once daily  Schedule 1 (Sunday starter): Dose…"}, {"doc_id": "hydroxyprogesterone-caproate-drug-information", "bm25_top3": 17.531685721163193, "bm25_max": 17.531685721163193, "bge_top3": null, "bge_max": null, "title": "Hydroxyprogesterone caproate: Drug information", "rep_snippet": "Dosing: Adult  Pregnancy indications: Preterm birth (Makena): Pregnant females ≥16 years of age: Note: Treatment may begin between 16 weeks 0 days and 20 weeks 6 days of gestation. Continue weekly administration until 37…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 9.562342767029493, "bm25_max": 17.19310031994336, "bge_top3": 0.5810290575027466, "bge_max": 0.5810290575027466, "title": "Dabigatran: Drug information", "rep_snippet": "Extended therapy (after first 3 months and no scheduled stop date): May be considered in patients with unprovoked first DVT of the leg or PE who do not have a high bleeding risk. Extended therapy is recommended in patien…"}, {"doc_id": "danaparoid-united-states-not-available-drug-information", "bm25_top3": 16.93295467306546, "bm25_max": 16.93295467306546, "bge_top3": 0.6054316759109497, "bge_max": 0.6054316759109497, "title": "Danaparoid (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing recommendations per manufacturer labeling unless otherwise noted. Dose expressed as anti-Xa units.  Prevention of DVT following orthopedic, major abdominal, or thoracic surgery: SubQ: 750 unit…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 16.755528158459594, "bm25_max": 16.755528158459594, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in manufacturer's labeling. However, since ionized inorganic phosphate is excreted by the kidneys, use all forms of sodium phosphate (including enemas) with caution…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": 16.643496074400407, "bm25_max": 16.643496074400407, "bge_top3": null, "bge_max": null, "title": "Procarbazine: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in manufacturer’s labeling; use with caution; may result in increased toxicity. However, because predominantly inactive metabolites are excreted via the kidneys, do…"}, {"doc_id": "sodium-phenylacetate-and-sodium-benzoate-drug-information", "bm25_top3": 16.146471439462484, "bm25_max": 16.146471439462484, "bge_top3": null, "bge_max": null, "title": "Sodium phenylacetate and sodium benzoate: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; however, the drug metabolites and ammonia are excreted by the kidneys. Use with caution; monitor closely."}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": 12.980003336195255, "bm25_max": 12.980003336195255, "bge_top3": null, "bge_max": null, "title": "Fosphenytoin: Drug information", "rep_snippet": "Manufacturer's labeling: Loading dose: 15 to 20 mg PE/kg administered at 2 mg PE/kg/minute or 150 mg PE/minute, whichever is slower. Follow loading dose with maintenance doses of either fosphenytoin or phenytoin.  Noneme…"}, {"doc_id": "trametinib-drug-information", "bm25_top3": 12.071674202582088, "bm25_max": 12.071674202582088, "bge_top3": null, "bge_max": null, "title": "Trametinib: Drug information", "rep_snippet": "• Pulmonary toxicity: Interstitial lung disease (ILD) and pneumonitis were observed in clinical trials. The median time to initial presentation in melanoma patients was ~5 months (range: 2 to ~6 months). Monitor for new…"}, {"doc_id": "dabrafenib-drug-information", "bm25_top3": 9.40230464450632, "bm25_max": 9.40230464450632, "bge_top3": null, "bge_max": null, "title": "Dabrafenib: Drug information", "rep_snippet": "• QT prolongation: QTcF prolongation >60 msec above baseline or to >500 msec was reported (rare), both as a single agent or when used in combination with trametinib. Use with caution in patients who may be at increased r…"}, {"doc_id": "raloxifene-drug-information", "bm25_top3": 5.314940280816559, "bm25_max": 8.624873795469231, "bge_top3": null, "bge_max": null, "title": "Raloxifene: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Thromboembolic events: [US Boxed Warning]: Raloxifene may increase the risk for DVT and PE; use is contraindicated in patients with history of or current veno…"}, {"doc_id": "medroxyprogesterone-acetate-drug-information", "bm25_top3": 6.5153820813610395, "bm25_max": 6.5153820813610395, "bge_top3": null, "bge_max": null, "title": "Medroxyprogesterone acetate: Drug information", "rep_snippet": "• Cardiovascular disease: [US Boxed Warning]: Estrogens with progestin should not be used to prevent cardiovascular disease. Using data from the Women’s Health Initiative (WHI) studies, an increased risk of deep vein thr…"}, {"doc_id": "estrone-united-states-not-available-drug-information", "bm25_top3": 5.591548960429925, "bm25_max": 5.591548960429925, "bge_top3": null, "bge_max": null, "title": "Estrone (United States: Not available): Drug information", "rep_snippet": "• Carbohydrate intolerance: May impair glucose tolerance; use caution in women with diabetes.  • Cardiovascular disease: [Canadian Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiov…"}, {"doc_id": "estradiol-systemic-drug-information", "bm25_top3": 5.591548960429925, "bm25_max": 5.591548960429925, "bge_top3": null, "bge_max": null, "title": "Estradiol (systemic): Drug information", "rep_snippet": "• Cardiovascular disease:[US Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease. Using data from the Women’s Health Initiative (WHI) studies, an increased risk of dee…"}, {"doc_id": "nadroparin-united-states-not-available-drug-information", "bm25_top3": 3.5002096821755853, "bm25_max": 5.023524886759532, "bge_top3": 0.5928426384925842, "bge_max": 0.6221938729286194, "title": "Nadroparin (United States: Not available): Drug information", "rep_snippet": "Brand Names: International  Fraksyparyn (UA);  Fraxiparin (AT, DE, KW);  Fraxiparina (BR, ES, IT, PT, VE);  Fraxiparine (AE, AR, AU, BE, BG, BH, CH, CL, CN, CR, CU, CY, CZ, DO, EC, EE, EG, FI, FR, GR, GT, HK, HN, HR, HU,…"}, {"doc_id": "venetoclax-drug-information", "bm25_top3": 5.001730064045761, "bm25_max": 5.001730064045761, "bge_top3": null, "bge_max": null, "title": "Venetoclax: Drug information", "rep_snippet": "Administration  Oral: Administer with a meal and water at approximately the same time each day. Swallow whole; do not crush, chew, or break.  Missed or vomited doses: If a dose is missed and it is within 8 hours of the m…"}, {"doc_id": "sodium-tetradecyl-sulfate-drug-information", "bm25_top3": 4.275767016197754, "bm25_max": 4.275767016197754, "bge_top3": null, "bge_max": null, "title": "Sodium tetradecyl sulfate: Drug information", "rep_snippet": "Monitoring Parameters  Monitor for DVT or PE (up to 4 weeks after injection); allergic reactions; pain, urticarial, matting, and pigmentation changes"}, {"doc_id": "polidocanol-drug-information", "bm25_top3": 4.056361404200974, "bm25_max": 4.056361404200974, "bge_top3": null, "bge_max": null, "title": "Polidocanol: Drug information", "rep_snippet": "Monitoring Parameters  Monitor patient for anaphylactic or allergic reaction for at least 10 to 20 minutes after injection, and for signs/symptoms of DVT or PE."}, {"doc_id": "dalteparin-drug-information", "bm25_top3": 2.063863796017973, "bm25_max": 2.063863796017973, "bge_top3": 0.5958429972330729, "bge_max": 0.6462947726249695, "title": "Dalteparin: Drug information", "rep_snippet": "Use  Deep vein thrombosis prophylaxis: Prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE), in patients requiring abdominal surgery who are at risk for thromboembolism complications (eg, >4…"}, {"doc_id": "tinzaparin-drug-information", "bm25_top3": -1.8325121957370563, "bm25_max": -1.8325121957370563, "bge_top3": 0.6281722784042358, "bge_max": 0.6538567543029785, "title": "Tinzaparin: Drug information", "rep_snippet": "Use  Note: Not available in the US  Anticoagulation in extracorporeal circuit during hemodialysis: Prevention of clotting in indwelling intravenous lines and extracorporeal circuit during hemodialysis (in patients withou…"}, {"doc_id": "valproate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5775588750839233, "bge_max": 0.5819562077522278, "title": "Valproate: Drug information", "rep_snippet": "Dosing: Adult  Note: Stavzor has been discontinued in the US for more than 1 year.  Seizures: Note: Administer doses >250 mg/day in divided doses. Extended-release formulation is not available in Canada.  Oral:  Simple a…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5808631181716919, "bge_max": 0.5808631181716919, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Adult  VTE (prophylaxis): Oral: 160 mg as a single dose on day 1, followed by 80 mg once daily for 35 to 42 days  Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.577858030796051, "bge_max": 0.577858030796051, "title": "Ampicillin: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range:  Oral: 250 to 500 mg every 6 hours  IM, IV: 1 to 2 g every 4 to 6 hours or 50 to 250 mg/kg/day in divided doses (maximum: 12 g/day)  Endocarditis, treatment (off-label dose; AHA [Baddou…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5701156258583069, "bge_max": 0.5729639530181885, "title": "Topiramate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Topiramate: Pediatric drug information\")  Note: Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects. Bioequivalence has not been demo…"}, {"doc_id": "recombinant-human-growth-hormone-somatropin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.571503758430481, "bge_max": 0.571503758430481, "title": "Recombinant human growth hormone (somatropin): Drug information", "rep_snippet": "Note: Therapy should be discontinued when patient has reached satisfactory height, when epiphyses have fused, or when the patient ceases to respond. Some guidelines recommend discontinuing therapy when growth velocity is…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.571473240852356, "bge_max": 0.571473240852356, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Kit, Oral:  Entex PAC: Entex S liquid - Dextromethorphan…"}, {"doc_id": "ethinyl-estradiol-and-levonorgestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5713565349578857, "bge_max": 0.5713565349578857, "title": "Ethinyl estradiol and levonorgestrel: Drug information", "rep_snippet": "Dosage Forms: Canada  Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.  Excipient information present…"}, {"doc_id": "cytarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5675743818283081, "bge_max": 0.5675743818283081, "title": "Cytarabine: Drug information", "rep_snippet": "Adults ≤70 years: 2000 mg/m2 over 3 hours every 12 hours day 2 (total of 2 doses/cycle) every 3 to 4 weeks for 6 to 10 cycles (in combination with dexamethasone and cisplatin) (Velasquez, 1988)  Adults >70 years: 1000 mg…"}, {"doc_id": "mexiletine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5669598579406738, "bge_max": 0.5669598579406738, "title": "Mexiletine: Drug information", "rep_snippet": "Dosing: Adult  Ventricular arrhythmias (life-threatening): Oral: Initial: 200 mg every 8 hours (may load with 400 mg if necessary); adjust dose in 50 or 100 mg increments no more frequently than every 2 to 3 days; usual…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5660959482192993, "bge_max": 0.5660959482192993, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Dosing: Adult  Doxorubicin is associated with a moderate to high emetic potential (depending on dose or regimen); antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).  Manufacturer's lab…"}, {"doc_id": "fondaparinux-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5639926195144653, "bge_max": 0.5639926195144653, "title": "Fondaparinux: Drug information", "rep_snippet": "Dosing: Adult  Note: PT and aPTT are insensitive measures of fondaparinux activity. If unexpected changes in coagulation parameters or major bleeding occur, discontinue fondaparinux.  Acute DVT/PE treatment: SubQ:  <50 k…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5636832118034363, "bge_max": 0.5636832118034363, "title": "Sulfadiazine: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Oral: 2 to 4 g/day in 3 to 6 divided doses  Rheumatic fever prophylaxis (off-label dose) (Gerber [AHA 2009]): Oral:  ≤27 kg: 500 mg once daily  >27 kg: 1,000 mg once daily  Toxop…"}, {"doc_id": "daunorubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5630316734313965, "bge_max": 0.5630316734313965, "title": "Daunorubicin: Drug information", "rep_snippet": "Dexrazoxane: Adults: 1000 mg/m2 (maximum dose: 2000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m2 (maximum dose: 1000 mg) IV over 1 to 2 hours day 3;…"}, {"doc_id": "ifosfamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5625345706939697, "bge_max": 0.5625345706939697, "title": "Ifosfamide: Drug information", "rep_snippet": "VIDE regimen: 3,000 mg/m2/day over 1 to 3 hours for 3 days every 3 weeks for 6 courses (in combination with vincristine, doxorubicin, etoposide, and mesna) (Juergens 2006)  IE regimen: 1,800 mg/m2/day over 1 hour for 5 d…"}, {"doc_id": "ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5624141693115234, "bge_max": 0.5624141693115234, "title": "Ombitasvir, paritaprevir, ritonavir, plus dasabuvir: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Combination package:  Viekira Pak [28 day supply]:  Tablet, oral: Ombitasvir 12.5 mg,…"}, {"doc_id": "tiagabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.562166154384613, "bge_max": 0.562166154384613, "title": "Tiagabine: Drug information", "rep_snippet": "Dosing: Adult  Partial seizures (adjunct): Oral: Note: Do not use a loading dose, rapid titration, and/or increases with large dose increments.  Patients receiving enzyme-inducing AED regimens: Initial: 4 mg once daily f…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5621127486228943, "bge_max": 0.5621127486228943, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Peritoneal dialysis (PD): 2.5 to 5 mg/kg/dose every 24 hours; no supplemental dose needed (Aronoff 2007). Note: Use higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.  Continuous re…"}, {"doc_id": "dexrazoxane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5620136857032776, "bge_max": 0.5620136857032776, "title": "Dexrazoxane: Drug information", "rep_snippet": "Dosing: Adult  Prevention of doxorubicin cardiomyopathy: IV: A 10:1 ratio of dexrazoxane:doxorubicin (dexrazoxane 500 mg/m2:doxorubicin 50 mg/m2). Note: Cardiac monitoring should continue during dexrazoxane therapy; doxo…"}]}
{"qid": "Q5_distractor-route", "query": "Acute DVT; avoid prophylactic dose — give treatment enoxaparin regimen (normal renal).", "base_qid": "Q5", "variant_type": "distractor-route", "candidates": [{"doc_id": "enoxaparin-drug-information", "bm25_top3": 35.05800851953926, "bm25_max": 37.47355976998563, "bge_top3": 0.7106749018033346, "bge_max": 0.7235487103462219, "title": "Enoxaparin: Drug information", "rep_snippet": "Note: The following recommendations are based on use of therapeutic doses of enoxaparin (eg, 1 mg/kg every 12 hours). If converting from a prophylactic enoxaparin dose (eg, 30 mg twice daily) to a therapeutic IV UFH dose…"}, {"doc_id": "protamine-sulfate-drug-information", "bm25_top3": 20.502297913918675, "bm25_max": 23.917562969285502, "bge_top3": null, "bge_max": null, "title": "Protamine sulfate: Drug information", "rep_snippet": "Heparin-mediated (full dose infusions): 1 mg protamine for every 100 units of heparin administered in the previous 2 to 3 hours; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If the aPTT r…"}, {"doc_id": "danaparoid-united-states-not-available-drug-information", "bm25_top3": 21.603033744609643, "bm25_max": 21.603033744609643, "bge_top3": null, "bge_max": null, "title": "Danaparoid (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing recommendations per manufacturer labeling unless otherwise noted. Dose expressed as anti-Xa units.  Prevention of DVT following orthopedic, major abdominal, or thoracic surgery: SubQ: 750 unit…"}, {"doc_id": "melphalan-drug-information", "bm25_top3": 18.74571859534593, "bm25_max": 18.74571859534593, "bge_top3": null, "bge_max": null, "title": "Melphalan: Drug information", "rep_snippet": "Dosing: Renal Impairment  The manufacturer's labeling contains the following adjustment recommendations (for approved dosing levels) based on route of administration:  Oral: Moderate to severe renal impairment: Consider…"}, {"doc_id": "vincristine-conventional-drug-information", "bm25_top3": 18.55282997062269, "bm25_max": 18.55282997062269, "bge_top3": null, "bge_max": null, "title": "Vincristine (conventional): Drug information", "rep_snippet": "CHOP regimen: 1.4 mg/m2/dose (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle for 8 cycles (in combination with cyclophosphamide, doxorubicin, and prednisone [± rituximab]) (Coiffier 2002)  EPOCH regimen: 0.4 mg…"}, {"doc_id": "pregabalin-drug-information", "bm25_top3": 17.129463820762595, "bm25_max": 18.258414812715767, "bge_top3": null, "bge_max": null, "title": "Pregabalin: Drug information", "rep_snippet": "Extended release: Renal function may be estimated using the Cockcroft-Gault formula. Then determine recommended dosage regimen based on the indication-specific total daily dose for normal renal function (CrCl ≥60 mL/minu…"}, {"doc_id": "dalbavancin-drug-information", "bm25_top3": 18.00691192760235, "bm25_max": 18.00691192760235, "bge_top3": null, "bge_max": null, "title": "Dalbavancin: Drug information", "rep_snippet": "Dosing: Adult  Acute bacterial skin and skin structure infections: IV:  Single-dose regimen: 1,500 mg as a single dose  Two-dose regimen: 1,000 mg as a single dose initially, followed by 500 mg as a single dose 1 week la…"}, {"doc_id": "entecavir-drug-information", "bm25_top3": 17.8214309133989, "bm25_max": 17.8214309133989, "bge_top3": null, "bge_max": null, "title": "Entecavir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Daily-dosage regimen preferred:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl 30-49 mL/minute: Administer 50% of usual dose daily or administer the normal dose every 48 hour…"}, {"doc_id": "digoxin-drug-information", "bm25_top3": 17.158904641663288, "bm25_max": 17.158904641663288, "bge_top3": null, "bge_max": null, "title": "Digoxin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Digoxin: Pediatric drug information\")  Atrial dysrhythmias (rate control), HF: When changing from oral (tablets or liquid) or IM to IV therapy, dosage should be reduced…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": 16.899454103990617, "bm25_max": 16.899454103990617, "bge_top3": null, "bge_max": null, "title": "Methotrexate: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. The following adjustments have been recommended:  Aronoff 2007:  Adults:  CrCl 10 to 50 mL/minute: Administer 50% of dose…"}, {"doc_id": "lithium-drug-information", "bm25_top3": 16.61919370229429, "bm25_max": 16.61919370229429, "bge_top3": null, "bge_max": null, "title": "Lithium: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl 10 to 50 mL/minute: Administer 50% to 75% of normal dose (Aronoff 2007).  CrCl <10 mL/minute: Administer 25% to 50% of normal dose (Aronoff 2007).  End-stage renal disease (ESRD) with hemod…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 16.601137309836954, "bm25_max": 16.601137309836954, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; avoid use in advanced renal disease.  KDIGO 2012 guidelines provide the following recommendations for N…"}, {"doc_id": "gold-sodium-thiomalate-drug-information", "bm25_top3": 16.543526609296578, "bm25_max": 16.543526609296578, "bge_top3": null, "bge_max": null, "title": "Gold sodium thiomalate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Aronoff, 2007:  CrCl 50-80 mL/minute: Administer 50% of normal dose.  CrCl <50 mL/minute: Avoid use."}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": 16.081287603582993, "bm25_max": 16.081287603582993, "bge_top3": null, "bge_max": null, "title": "Hydroxyzine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007):  Adults:  GFR >50 mL/minute: No adju…"}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 16.046991635842986, "bm25_max": 16.046991635842986, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment  Deterioration of renal function during IV therapy: Stop treatment.  Clasteon [DSC]:  Serum creatinine (Scr) >5 mg/dL: Use is contraindicated.  Scr ≥2.5 to 5 mg/dL: There are no specific dosage a…"}, {"doc_id": "nevirapine-drug-information", "bm25_top3": 16.04282743662331, "bm25_max": 16.04282743662331, "bge_top3": null, "bge_max": null, "title": "Nevirapine: Drug information", "rep_snippet": "Prevention of perinatal HIV transmission (HHS [perinatal], 2017): Note: Nevirapine is used as part of a prophylactic 2-drug regimen with zidovudine or an empiric 3-drug regimen with zidovudine and lamivudine in infants a…"}, {"doc_id": "lomustine-drug-information", "bm25_top3": 15.936902281154273, "bm25_max": 15.936902281154273, "bge_top3": null, "bge_max": null, "title": "Lomustine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. The following adjustments have been recommended:  Aronoff 2007: Adults:  CrCl 10 to 50 mL/minute: Reduce dose to 75% of n…"}, {"doc_id": "indomethacin-drug-information", "bm25_top3": 15.872453164527343, "bm25_max": 15.872453164527343, "bge_top3": null, "bge_max": null, "title": "Indomethacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral/rectal: There are no dosage adjustments provided in the manufacturer's labeling; not recommended in patients with advanced renal disease.  Injection: If anuria or marked oliguria (urinary o…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 10.376419665450296, "bm25_max": 10.376419665450296, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary ed…"}, {"doc_id": "nelarabine-drug-information", "bm25_top3": 10.224584711340636, "bm25_max": 10.224584711340636, "bge_top3": null, "bge_max": null, "title": "Nelarabine: Drug information", "rep_snippet": "• Tumor lysis syndrome: Tumor lysis syndrome (TLS) may occur as a consequence of leukemia treatment. May lead to life-threatening acute renal failure; adequate hydration and prophylactic allopurinol should be instituted…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 9.628443686203708, "bm25_max": 10.00942026559699, "bge_top3": 0.7044463753700256, "bge_max": 0.7044463753700256, "title": "Iodixanol: Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with cardiovascular disease and heart failure patients receiving concurrent diuretic therapy; they may have intravascular volume depletion, which may affect the rena…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": 9.666478138209866, "bm25_max": 9.666478138209866, "bge_top3": null, "bge_max": null, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "• Renal toxicity: Tenofovir disoproxil fumarate may cause renal toxicity, including acute renal failure and Fanconi syndrome; avoid use with concurrent or recent nephrotoxic therapy (including high dose or multiple NSAID…"}, {"doc_id": "bendamustine-drug-information", "bm25_top3": 9.08952369961151, "bm25_max": 9.08952369961151, "bge_top3": null, "bge_max": null, "title": "Bendamustine: Drug information", "rep_snippet": "• Secondary malignancy: Malignancies (including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial cancer) and premalignant diseases have been reported in patients who have recei…"}, {"doc_id": "iopromide-drug-information", "bm25_top3": 9.04514683577615, "bm25_max": 9.04514683577615, "bge_top3": null, "bge_max": null, "title": "Iopromide: Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with cardiovascular disease or heart failure. Iodinated contrast media may result in an increased circulatory osmotic load and subsequent acute or delayed hemodynami…"}, {"doc_id": "lamivudine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 8.893752207002567, "bm25_max": 8.893752207002567, "bge_top3": null, "bge_max": null, "title": "Lamivudine and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "• Renal toxicity: Tenofovir disoproxil fumarate may cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy (including high dose or multiple NSAID use).…"}, {"doc_id": "rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 8.838769334098572, "bm25_max": 8.838769334098572, "bge_top3": null, "bge_max": null, "title": "Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "• Renal toxicity: May cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy (including high dose or multiple NSAID use). Acute renal failure has occur…"}, {"doc_id": "clofarabine-drug-information", "bm25_top3": 8.813328977812349, "bm25_max": 8.813328977812349, "bge_top3": null, "bge_max": null, "title": "Clofarabine: Drug information", "rep_snippet": "• Renal toxicity: Elevated creatinine, acute renal failure, and hematuria were observed in clinical studies. Infection, sepsis, or tumor lysis syndrome may cause an increased risk of renal toxicity in patients receiving…"}, {"doc_id": "iothalamate-meglumine-drug-information", "bm25_top3": 8.798336099214396, "bm25_max": 8.798336099214396, "bge_top3": null, "bge_max": null, "title": "Iothalamate meglumine: Drug information", "rep_snippet": "• Renal failure: Acute renal failure has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent, in diabetic patients wit…"}, {"doc_id": "ioxaglate-meglumine-and-ioxaglate-sodium-drug-information", "bm25_top3": 8.743340960351222, "bm25_max": 8.743340960351222, "bge_top3": null, "bge_max": null, "title": "Ioxaglate meglumine and ioxaglate sodium: Drug information", "rep_snippet": "• Renal failure: Acute renal failure has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent, and in diabetic patients…"}, {"doc_id": "epirubicin-drug-information", "bm25_top3": 8.46236984956817, "bm25_max": 8.46236984956817, "bge_top3": 0.6966080665588379, "bge_max": 0.6966080665588379, "title": "Epirubicin: Drug information", "rep_snippet": "• Radiation recipients: Epirubicin may have radiosensitizing activity; radiation recall (inflammatory) has also been reported.  Other warnings/precautions:  • Appropriate use: Patients should recover from acute toxicitie…"}, {"doc_id": "ioversol-drug-information", "bm25_top3": 8.44714578164011, "bm25_max": 8.44714578164011, "bge_top3": null, "bge_max": null, "title": "Ioversol: Drug information", "rep_snippet": "Disease-related concerns:  • Cardiovascular disease: Use with caution in severe cardiovascular disease and HF; transitory increase in circulatory osmotic load could occur. Observe patients with HF for several hours follo…"}, {"doc_id": "pegaspargase-drug-information", "bm25_top3": 5.266624320867905, "bm25_max": 5.266624320867905, "bge_top3": null, "bge_max": null, "title": "Pegaspargase: Drug information", "rep_snippet": "Use  Acute lymphoblastic leukemia and hypersensitivity to asparaginase: Treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to native forms of L-asparaginase (as a component of a multiagent…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 5.018962752566281, "bm25_max": 5.018962752566281, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Use  Acute lymphoblastic leukemia: Treatment of acute lymphoblastic leukemia (ALL), as part of a combination chemotherapy regimen"}, {"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 4.533261017350094, "bm25_max": 4.533261017350094, "bge_top3": null, "bge_max": null, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "Use  Asthma:  ArmonAir Respiclick and Arnuity Ellipta: Maintenance treatment of asthma as prophylactic therapy in patients 12 years and older.  Flovent Diskus and Flovent HFA: Maintenance treatment of asthma as prophylac…"}, {"doc_id": "fondaparinux-drug-information", "bm25_top3": 3.3512782014019606, "bm25_max": 3.3512782014019606, "bge_top3": 0.7227886915206909, "bge_max": 0.7227886915206909, "title": "Fondaparinux: Drug information", "rep_snippet": "Use  Acute deep vein thrombosis: Treatment of acute DVT in conjunction with warfarin.  Acute pulmonary embolism: Treatment of acute PE in conjunction with warfarin.  Venous thromboembolism: Prophylaxis of venous thromboe…"}, {"doc_id": "nadroparin-united-states-not-available-drug-information", "bm25_top3": 3.0902895026815003, "bm25_max": 3.0902895026815003, "bge_top3": null, "bge_max": null, "title": "Nadroparin (United States: Not available): Drug information", "rep_snippet": "Use  Fraxiparine:  Acute coronary syndromes: Treatment of unstable angina and non-ST-elevation myocardial infarction (NSTEMI) myocardial infarction (ie, non-Q wave MI)  Anticoagulation during hemodialysis: Prevention of…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": 2.9536663774925245, "bm25_max": 2.9536663774925245, "bge_top3": null, "bge_max": null, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Use  Cluster headaches (injection): Acute treatment of cluster headaches.  Migraines (intranasal; injection): Acute treatment of migraine headaches with or without aura; not intended for the prophylactic therapy of migra…"}, {"doc_id": "tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7341262698173523, "bge_max": 0.7418742179870605, "title": "Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Avoid use in patients with preexisting renal dysfunction. Use is contraindicated in oliguric/anuric renal failure unrelated to hypovolemia or patients receiving dialysis. Discontinue use…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7347649931907654, "bge_max": 0.7347649931907654, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Adult  VTE (prophylaxis): Oral: 160 mg as a single dose on day 1, followed by 80 mg once daily for 35 to 42 days  Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7109911739826202, "bge_max": 0.723734438419342, "title": "Furosemide: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Acute renal failure: Doses up to 1 to 3 g daily may be necessary to initiate desired response; avoid use in oliguric states.  Dialysis: Not removed by hemo- or peritoneal dialysis; suppl…"}, {"doc_id": "hetastarch-hydroxyethyl-starch-450-0-7-hespan-hextend-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7116124033927917, "bge_max": 0.7209813594818115, "title": "Hetastarch (Hydroxyethyl starch 450/0.7; Hespan, Hextend): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Avoid use in patients with preexisting renal impairment. Use is contraindicated in renal disease with oliguria or anuria (not related to hypovolemia)."}, {"doc_id": "mannitol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7202273607254028, "bge_max": 0.7202273607254028, "title": "Mannitol (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Contraindicated in severe renal impairment. Use caution in patients with underlying renal disease. May be used to reduce the incidence of acute tubular necrosis when administered prior to revasc…"}, {"doc_id": "anthrax-immunoglobulin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7158271074295044, "bge_max": 0.7158271074295044, "title": "Anthrax immunoglobulin (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information", "rep_snippet": "Dosing: Renal Impairment  Use with caution and infuse at the minimum rate possible; patients with preexisting renal impairment are at a higher risk of developing acute renal dysfunction."}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7083528637886047, "bge_max": 0.7156323790550232, "title": "Rivaroxaban: Drug information", "rep_snippet": "Postoperative DVT thromboprophylaxis: Oral: Note: Initiate therapy after hemostasis has been established, 6 to 10 hours postoperatively.  Knee replacement: 10 mg once daily; recommended total duration of therapy: 12 days…"}, {"doc_id": "enalapril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7155197262763977, "bge_max": 0.7155197262763977, "title": "Enalapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Renal artery stenosis: Use enalapril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the el…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": 0.7148809149543354, "bm25_max": 0.7148809149543354, "bge_top3": null, "bge_max": null, "title": "Dalteparin: Drug information", "rep_snippet": "Use  Deep vein thrombosis prophylaxis: Prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE), in patients requiring abdominal surgery who are at risk for thromboembolism complications (eg, >4…"}, {"doc_id": "pralatrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7124810814857483, "bge_max": 0.7124810814857483, "title": "Pralatrexate: Drug information", "rep_snippet": "• Renal impairment: Patients with moderate to severe renal impairment are at higher risk for increased exposure and toxicity. Monitor renal function and for systemic toxicity due to increased exposure. Dosage adjustment…"}, {"doc_id": "delafloxacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.711735188961029, "bge_max": 0.711735188961029, "title": "Delafloxacin: Drug information", "rep_snippet": "• Injection: Avoid use of IV formulation in patients with end-stage renal disease (eGFR <15 mL/minute/1.73 m2); injection contains excipient cyclodextrin (sulfobutylether-beta-cyclodextrin [SBECD]), which may accumulate.…"}, {"doc_id": "amiloride-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7100054621696472, "bge_max": 0.7100054621696472, "title": "Amiloride and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Renal Impairment  Use with caution; contraindicated in patients with anuria, acute or chronic renal insufficiency, or evidence of diabetic nephropathy. For additional considerations, also see individual agents."}, {"doc_id": "trandolapril-and-verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7066736817359924, "bge_max": 0.7066736817359924, "title": "Trandolapril and verapamil: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with hepatic impairment; lower doses are recommended.  • Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM with out…"}, {"doc_id": "netupitant-and-palonosetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7028695940971375, "bge_max": 0.7028695940971375, "title": "Netupitant and palonosetron: Drug information", "rep_snippet": "• Renal impairment: Avoid use in severe renal impairment or end stage renal disease. Dosage adjustment not necessary in mild or moderate impairment.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7019561529159546, "bge_max": 0.7019561529159546, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "• Renal impairment: Avoid use in patients with severe renal impairment (creatinine clearance not defined) unless patient has already tolerated simvastatin at a dose ≥5 mg; use doses of simvastatin >20 mg/day with caution…"}, {"doc_id": "felbamate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7019469141960144, "bge_max": 0.7019469141960144, "title": "Felbamate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Use caution; reduce initial and maintenance doses by 50%. Adjunctive therapy with medications that affect felbamate plasma concentrations, especially AEDs, may warrant further reductions in felb…"}, {"doc_id": "total-parenteral-nutrition-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.701931357383728, "bge_max": 0.701931357383728, "title": "Total parenteral nutrition: Drug information", "rep_snippet": "Dosing: Renal Impairment  Kabiven, Perikabiven: No dosage adjustments necessary for renal impairment. Correct severe fluid or electrolyte imbalances prior to administration. Closely monitor electrolytes and adjust admini…"}, {"doc_id": "oxycodone-and-naloxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7012971639633179, "bge_max": 0.7012971639633179, "title": "Oxycodone and naloxone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild or moderate impairment: Reduce dose to 33% to 50% of the usual starting dose; titrate cautiously; consider use of alternative treatments without naloxone in patients with severe renal impai…"}, {"doc_id": "nesiritide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7009011507034302, "bge_max": 0.7009011507034302, "title": "Nesiritide: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary. Use cautiously in patients with renal impairment or those patients who rely on the renin-angiotensin-aldosterone system for renal perfusion. Monitor renal functio…"}, {"doc_id": "mitoxantrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7003709077835083, "bge_max": 0.7003709077835083, "title": "Mitoxantrone: Drug information", "rep_snippet": "Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate e…"}, {"doc_id": "nivolumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7000483870506287, "bge_max": 0.7000483870506287, "title": "Nivolumab: Drug information", "rep_snippet": "Dosing: Renal Impairment  Renal impairment prior to treatment initiation: No dosage adjustment necessary.  Renal toxicity  during  treatment (nephritis or renal dysfunction):  Creatinine >1.5 to 6 × ULN: Withhold treatme…"}, {"doc_id": "dimercaprol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6998540163040161, "bge_max": 0.6998540163040161, "title": "Dimercaprol: Drug information", "rep_snippet": "Dosing: Renal Impairment  No adjustment provided in manufacturer’s labeling. Use with extreme caution or discontinue if acute renal insufficiency develops during therapy."}, {"doc_id": "capreomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6993446350097656, "bge_max": 0.6993446350097656, "title": "Capreomycin: Drug information", "rep_snippet": "End-stage renal disease (ESRD) on hemodialysis: Administer dose after hemodialysis only  Continuous renal replacement therapy (CRRT): 5 mg/kg every 24 hours"}, {"doc_id": "apixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6988016963005066, "bge_max": 0.6988016963005066, "title": "Apixaban: Drug information", "rep_snippet": "Use  Deep vein thrombosis: Treatment of deep vein thrombosis; to reduce the risk of recurrent deep vein thrombosis following initial therapy  Note: The American College of Chest Physicians (ACCP) guidelines for VTE sugge…"}, {"doc_id": "ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.69869065284729, "bge_max": 0.69869065284729, "title": "Ticarcillin and clavulanate potassium (United States: Not available): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT): 50 to 75 mg ticarcillin/kg every 8 hours"}, {"doc_id": "dulaglutide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6983805894851685, "bge_max": 0.6983805894851685, "title": "Dulaglutide: Drug information", "rep_snippet": "Disease-related concerns:  • Gastrointestinal disease: Use is not recommended in patients with preexisting severe gastrointestinal disease, including severe gastroparesis.  • Hepatic impairment: Use with caution in patie…"}, {"doc_id": "oxaprozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6983298063278198, "bge_max": 0.6983298063278198, "title": "Oxaprozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  In general, NSAIDs are not recommended for use in patients with advanced renal disease but the manufacturer of oxaprozin does provide some guidelines for adjustment in renal dysfunction.  Severe…"}, {"doc_id": "prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6982155442237854, "bge_max": 0.6982155442237854, "title": "Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information", "rep_snippet": "Direct thrombin inhibitor-mediated (argatroban, dabigatran [if idarucizumab unavailable], bivalirudin, desirudin): 50 units/kg if direct thrombin inhibitor was administered within a period of 3 to 5 half-lives prior and…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6979398727416992, "bge_max": 0.6979398727416992, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Administration  Oral: Administer with or without food.  IV: Avoid rapid infusion; infuse over 1 hour to prevent renal damage; maintain adequate hydration of patient; check for phlebitis and rotate infusion sites. Do not…"}, {"doc_id": "ethacrynic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6976109743118286, "bge_max": 0.6976109743118286, "title": "Ethacrynic acid: Drug information", "rep_snippet": "• Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.  Concurrent drug therapy issues:  • Antihypertensives: Coadministration of antihypertensives may increase t…"}, {"doc_id": "captopril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6975370645523071, "bge_max": 0.6975370645523071, "title": "Captopril and hydrochlorothiazide: Drug information", "rep_snippet": "• Renal artery stenosis: Use captopril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the el…"}, {"doc_id": "amlodipine-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6970870494842529, "bge_max": 0.6970870494842529, "title": "Amlodipine and valsartan: Drug information", "rep_snippet": "• Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this con…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6969760656356812, "bge_max": 0.6969760656356812, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate e…"}, {"doc_id": "idarubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6968754529953003, "bge_max": 0.6968754529953003, "title": "Idarubicin: Drug information", "rep_snippet": "Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate e…"}, {"doc_id": "antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6966065168380737, "bge_max": 0.6966065168380737, "title": "Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information", "rep_snippet": "Dosing: Adult  Note: Premedicate with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to infusion to reduce the incidence and severity of infusion-related reactions. Administer antifungal and antibac…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.696164071559906, "bge_max": 0.696164071559906, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "• Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated ris…"}, {"doc_id": "ipilimumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6960678696632385, "bge_max": 0.6960678696632385, "title": "Ipilimumab: Drug information", "rep_snippet": "Severe enterocolitis: Permanently discontinue. Initiate systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent). Upon improvement to ≤ grade 1, taper corticosteroids slowly over ≥1 month (rapid tapering may…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6951926946640015, "bge_max": 0.6951926946640015, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "• Renal impairment: Assess renal function prior to initiation and periodically during treatment. Do not initiate therapy in patients with eGFR <60 mL/minute/1.73 m2 and discontinue use if eGFR falls persistently below 60…"}, {"doc_id": "choline-magnesium-trisalicylate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6950127482414246, "bge_max": 0.6950127482414246, "title": "Choline magnesium trisalicylate: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution in acute or chronic renal impairment. Avoid use in severe renal impairment; monitor salicylate levels an…"}, {"doc_id": "bupropion-and-naltrexone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6946072578430176, "bge_max": 0.6946072578430176, "title": "Bupropion and naltrexone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild impairment: There are no dosage adjustment provided in the manufacturer’s labeling (has not been studied); use with caution.  Moderate or severe impairment: Maximum dose: One tablet (naltre…"}, {"doc_id": "bevacizumab-including-biosimilars-of-bevacizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6944959759712219, "bge_max": 0.6944959759712219, "title": "Bevacizumab (including biosimilars of bevacizumab): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Renal impairment prior to treatment: There are no dosage adjustments provided in the manufacturer's labeling.  Renal toxicity during treatment:  Nephrotic syndrome: Discontinue bevacizum…"}]}
{"qid": "Q6_abbr+threshold", "query": "T2DM with eGFR 28 — metformin: contraindicated vs adjust? recommendation?", "base_qid": "Q6", "variant_type": "abbr+threshold", "candidates": [{"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 26.494044489524, "bm25_max": 30.979666687684574, "bge_top3": 0.6238874594370524, "bge_max": 0.6356492042541504, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 22.251579642228414, "bm25_max": 29.05654941252167, "bge_top3": 0.6327219009399414, "bge_max": 0.6374526023864746, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": 23.209799778316743, "bm25_max": 28.560966995605195, "bge_top3": 0.6351449688275655, "bge_max": 0.638477087020874, "title": "Glipizide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformi…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 22.133524265899478, "bm25_max": 27.312576422204856, "bge_top3": 0.6173649430274963, "bge_max": 0.6311986446380615, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <60 mL/minute/1.73 m2: Use is contraindicated.  Hemodialysis: Use is contraindicated."}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 23.12521249698575, "bm25_max": 27.087657753277938, "bge_top3": 0.6335979501406351, "bge_max": 0.6450044512748718, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when e…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 20.821294443841822, "bm25_max": 26.35117162734625, "bge_top3": 0.6197883486747742, "bge_max": 0.6302748918533325, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR <45 mL/minute/1.73 m2: Use is contraindicated by the manufacturer; refer also to indiv…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 21.230712243262577, "bm25_max": 26.008247403738103, "bge_top3": 0.6226050853729248, "bge_max": 0.624306321144104, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >60 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR 30 to 60 mL/minute/1.73 m2: Use is not recommended.  eGFR <30 mL/minute/1.73 m2: Use i…"}, {"doc_id": "glyburide-and-metformin-drug-information", "bm25_top3": 21.018219445712433, "bm25_max": 24.725576702915713, "bge_top3": 0.6070261597633362, "bge_max": 0.6238757967948914, "title": "Glyburide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Glyburide is generally not recommended in chronic kidney disease; if sulfonylurea therapy is needed other agents are preferred (ADA [Tuttle 2014]; Alsahli 2015; KDOQI [Nelson 2012]). Use of glyb…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 18.89282716751103, "bm25_max": 20.83672682141606, "bge_top3": 0.6223544875780741, "bge_max": 0.628261387348175, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin and sitagliptin are substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR).…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 18.9245609449164, "bm25_max": 20.765581643745236, "bge_top3": 0.6265845696131388, "bge_max": 0.6483485698699951, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 18.91172843244325, "bm25_max": 20.58520659968412, "bge_top3": 0.6124556064605713, "bge_max": 0.624306321144104, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "• Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes with liver…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 18.888510382609688, "bm25_max": 20.570098471864462, "bge_top3": 0.6125349402427673, "bge_max": 0.6300710439682007, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "• Hepatic impairment: The manufacturer recommends to generally avoid metformin use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes w…"}, {"doc_id": "metformin-drug-information", "bm25_top3": 19.10151585871615, "bm25_max": 20.506216965963905, "bge_top3": 0.6337558229764303, "bge_max": 0.6417858600616455, "title": "Metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 18.766382027899056, "bm25_max": 20.294513790595726, "bge_top3": 0.6204341948032379, "bge_max": 0.624306321144104, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "• Ischemic heart disease: Do not initiate rosiglitazone in patients with stable ischemic heart disease due to an increased risk of cardiovascular complications (Fihn 2012).  • Renal impairment: Metformin is substantially…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": 16.457480992727376, "bm25_max": 17.57626452666959, "bge_top3": null, "bge_max": null, "title": "Fenofibrate: Drug information", "rep_snippet": "Dialysis: Use is contraindicated.  TriCor:  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 59 mL/minute/1.73 m2: Initiate at 48 mg once daily  eGFR <30 mL/minute/1.73 m2: Use is contraindicated.…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 17.196179153124874, "bm25_max": 17.196179153124874, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 45 to <60 mL/minute/1.73 m2: Do not initiate therapy if eGFR <60 mL/minute/1.73 m2; discontinue therapy if eGFR falls persistentl…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 16.72256845382227, "bm25_max": 16.72256845382227, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Use is not recommended for initiation of therapy or when eGFR is persistently between 30 and <60 mL…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 16.13999770693695, "bm25_max": 16.13999770693695, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": 16.13999770693695, "bm25_max": 16.13999770693695, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 15.842146191815463, "bm25_max": 15.842146191815463, "bge_top3": null, "bge_max": null, "title": "Canagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Maximum dose: 100 mg once daily. If patient receiving concurrent UDP-glucuronosyl transferase (UGT)…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 15.438074584044955, "bm25_max": 15.438074584044955, "bge_top3": null, "bge_max": null, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, t…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 12.221533829420252, "bm25_max": 12.221533829420252, "bge_top3": null, "bge_max": null, "title": "Empagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, d…"}]}
{"qid": "Q6_negation-trap", "query": "Type 2 DM, eGFR 28 mL/min — metformin use? (not on dialysis).", "base_qid": "Q6", "variant_type": "negation-trap", "candidates": [{"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 27.762868120884647, "bm25_max": 29.342657978824242, "bge_top3": 0.6804821491241455, "bge_max": 0.6888844966888428, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 26.23608358887464, "bm25_max": 28.531918497921158, "bge_top3": 0.6729953289031982, "bge_max": 0.6780937910079956, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity to empagliflozin, metformin, or any component of the formulation; moderate to severe renal impairment (eGFR <45 mL/minute/1.73 m2); end-stage renal disease (ESRD) or…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 26.4935954934981, "bm25_max": 27.978101853033927, "bge_top3": 0.675800641377767, "bge_max": 0.6868058443069458, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity (eg, anaphylaxis, angioedema) to canagliflozin, metformin, or any component of the formulation; moderate to severe renal impairment (eGFR <45 mL/minute/1.73 m2); end…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 27.978101853033927, "bm25_max": 27.978101853033927, "bge_top3": 0.6599122285842896, "bge_max": 0.6599122285842896, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity to dapagliflozin, metformin, or any component of the formulation; moderate to severe renal impairment (eGFR <60 mL/minute/1.73 m2), end-stage renal disease or patien…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 27.18502845258498, "bm25_max": 27.66084917127669, "bge_top3": 0.6780824263890585, "bge_max": 0.6830915808677673, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": 26.1195100918034, "bm25_max": 27.100082380257312, "bge_top3": 0.6759095191955566, "bge_max": 0.6894273161888123, "title": "Glipizide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformi…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 24.087666174725882, "bm25_max": 24.087666174725882, "bge_top3": 0.6727038224538168, "bge_max": 0.6892679929733276, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "• Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes with liver…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 23.90476599850684, "bm25_max": 23.998885030996743, "bge_top3": 0.6672640442848206, "bge_max": 0.6727058291435242, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "• Ischemic heart disease: Do not initiate rosiglitazone in patients with stable ischemic heart disease due to an increased risk of cardiovascular complications (Fihn 2012).  • Renal impairment: Metformin is substantially…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 23.62200111156448, "bm25_max": 23.755272076413185, "bge_top3": 0.6663359006245931, "bge_max": 0.6688481569290161, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: Oral: Initial doses should be based on current daily dose of linagliptin and metformin; range: Linagliptin 2.5 mg and metformin 500 to 1,000 mg twice daily (immediate release) or…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 23.595801111390962, "bm25_max": 23.732111297993942, "bge_top3": 0.6715369820594788, "bge_max": 0.6735568046569824, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: Oral:  Extended release (ER) formulation: Note: Initial doses should be based on current daily dose of saxagliptin and metformin. Daily dose should generally be administered once…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 23.722946449149344, "bm25_max": 23.722946449149344, "bge_top3": 0.6704039573669434, "bge_max": 0.6755095720291138, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin and sitagliptin are substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR).…"}, {"doc_id": "metformin-drug-information", "bm25_top3": 23.38491647580538, "bm25_max": 23.38491647580538, "bge_top3": 0.6689063111941019, "bge_max": 0.6725744009017944, "title": "Metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 16.078480043844962, "bm25_max": 18.468687173536328, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Contraindications  Serious hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions) to dapagliflozin, saxagliptin, or any component of the formulation; moderate to severe renal impairment (eGFR <45 mL/…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": 15.531932903994552, "bm25_max": 18.136087700541083, "bge_top3": null, "bge_max": null, "title": "Fenofibrate: Drug information", "rep_snippet": "Dialysis: Use is contraindicated.  TriCor:  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 59 mL/minute/1.73 m2: Initiate at 48 mg once daily  eGFR <30 mL/minute/1.73 m2: Use is contraindicated.…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 15.722471648092531, "bm25_max": 16.510082976718753, "bge_top3": null, "bge_max": null, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions, urticaria, bronchial hyperreactivity) to empagliflozin, linagliptin, or any component of the formulation;…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 16.08586193022208, "bm25_max": 16.08586193022208, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": 14.382847697207886, "bm25_max": 16.08586193022208, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 15.85198358063952, "bm25_max": 15.85198358063952, "bge_top3": 0.6632041931152344, "bge_max": 0.6632041931152344, "title": "Canagliflozin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity to canagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2); end-stage renal disease or patients on dialysis.  Canadia…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 15.303655853040034, "bm25_max": 15.303655853040034, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity to dapagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or patients on dialysis…"}, {"doc_id": "saxagliptin-drug-information", "bm25_top3": 15.283357753365621, "bm25_max": 15.283357753365621, "bge_top3": null, "bge_max": null, "title": "Saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <45 mL/minute/1.73 m2: 2.5 mg once daily.  ESRD requiring hemodialysis: 2.5 mg once daily; administer postdialysis  Peritoneal d…"}, {"doc_id": "meropenem-and-vaborbactam-drug-information", "bm25_top3": 14.846182514381567, "bm25_max": 14.982708916059103, "bge_top3": null, "bge_max": null, "title": "Meropenem and vaborbactam: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Estimation of renal function for the purpose of drug dosing should be done using the Modification of Diet in Renal Disease (MDRD) formula. Dosage recommendations are expressed as g…"}, {"doc_id": "guaifenesin-and-dextromethorphan-drug-information", "bm25_top3": 14.285683107209021, "bm25_max": 14.285683107209021, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and dextromethorphan: Drug information", "rep_snippet": "5-100 mg/5 mL (118 mL): $5.38  20-400 mg/20 mL (118 mL): $6.60  Liquid (Robitussin To Go Cgh/Chest DM Oral)  100-10 mg/5 mL (10 mL): $0.82  Liquid (Safe Tussin DM Oral)  100-10 mg/5 mL (120 mL): $5.26  Liquid (Trispec DM…"}, {"doc_id": "brompheniramine-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 13.577375249064104, "bm25_max": 13.577375249064104, "bge_top3": null, "bge_max": null, "title": "Brompheniramine, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Pricing: US  Elixir (Dimaphen DM Cold/Cough Oral)  2.5-1-5 mg/5 mL (118 mL): $4.26  Liquid (BroveX PEB DM Oral)  10-4-20 mg/5 mL (473 mL): $194.74  Liquid (Dimetapp DM Cold/Cough Oral)  2.5-1-5 mg/5 mL (118 mL): $5.38  L…"}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": 13.210508131891846, "bm25_max": 13.210508131891846, "bge_top3": null, "bge_max": null, "title": "Cabozantinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The estimated glomerular filtration rate (eGFR) is estimated using MDRD (modification of diet in renal disease) equation.  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR…"}, {"doc_id": "phentermine-drug-information", "bm25_top3": 13.141755658305797, "bm25_max": 13.141755658305797, "bge_top3": null, "bge_max": null, "title": "Phentermine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Capsule, tablet (excluding Lomaira):  eGFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased; use with caution.…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 12.63045880243529, "bm25_max": 13.064415454232634, "bge_top3": 0.6673345565795898, "bge_max": 0.6673345565795898, "title": "Empagliflozin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity to empagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or dialysis  Canadian lab…"}, {"doc_id": "delafloxacin-drug-information", "bm25_top3": 12.73985692019722, "bm25_max": 12.73985692019722, "bge_top3": null, "bge_max": null, "title": "Delafloxacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral, IV:  Estimated glomerular filtration rate (eGFR) 30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 15 to 29 mL/minute/1.73 m2:  Oral: No dosage adjustment necessary.  IV: 2…"}, {"doc_id": "flurbiprofen-systemic-drug-information", "bm25_top3": 12.388080742043435, "bm25_max": 12.388080742043435, "bge_top3": null, "bge_max": null, "title": "Flurbiprofen (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  US labeling:  Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.  Moderate to severe impairment: There are no dosage adjustments provided…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": 12.185576273472943, "bm25_max": 12.185576273472943, "bge_top3": null, "bge_max": null, "title": "Sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR ≥30 to <45 mL/minute/1.73 m2: 50 mg once daily  eGFR <30 mL/minute/1.73 m2: 25 mg once daily  ESRD requiring hemodialysis or per…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6684991518656412, "bge_max": 0.6796867847442627, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "nateglinide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6686887741088867, "bge_max": 0.6686887741088867, "title": "Nateglinide: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control  Guideline recommendations: Meglitinides (eg, nateglinide) are generally no…"}, {"doc_id": "glyburide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6606366634368896, "bge_max": 0.6607705354690552, "title": "Glyburide and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}]}
{"qid": "Q6_spelling", "query": "T2D, eGFR=28 — metformin okay or stop; what’s advised?", "base_qid": "Q6", "variant_type": "spelling", "candidates": [{"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": 20.082952834821942, "bm25_max": 20.64269059149754, "bge_top3": 0.6713359951972961, "bge_max": 0.6728806495666504, "title": "Glipizide and metformin: Drug information", "rep_snippet": "• Renal impairment: The metabolism and excretion of glipizide may be slowed in patients with renal impairment. Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and p…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 19.877206456861845, "bm25_max": 20.33169091528856, "bge_top3": 0.6605374217033386, "bge_max": 0.662255048751831, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 19.419083189279032, "bm25_max": 20.229928552424624, "bge_top3": 0.6430248816808065, "bge_max": 0.661354660987854, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "metformin-drug-information", "bm25_top3": 19.506757780413068, "bm25_max": 20.027005872932072, "bge_top3": 0.6440743207931519, "bge_max": 0.662255048751831, "title": "Metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 19.46254008007214, "bm25_max": 19.91789694453737, "bge_top3": 0.6552391648292542, "bge_max": 0.6670516729354858, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin and sitagliptin are substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR).…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 19.285323624500943, "bm25_max": 19.823021767535927, "bge_top3": 0.6451934576034546, "bge_max": 0.6673926115036011, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "glyburide-and-metformin-drug-information", "bm25_top3": 17.062794572881774, "bm25_max": 19.813649141556397, "bge_top3": 0.6364317536354065, "bge_max": 0.6678217053413391, "title": "Glyburide and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 19.09833384008398, "bm25_max": 19.725373063526042, "bge_top3": 0.6365731159845988, "bge_max": 0.661501407623291, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 45 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 19.01754182376933, "bm25_max": 19.71023647786078, "bge_top3": 0.6471283137798309, "bge_max": 0.6711389422416687, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 19.55688597314417, "bm25_max": 19.68555536291476, "bge_top3": 0.6544712781906128, "bge_max": 0.662255048751831, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 19.02512981585487, "bm25_max": 19.68555536291476, "bge_top3": 0.6334164142608643, "bge_max": 0.662255048751831, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 18.75266172563652, "bm25_max": 19.68555536291476, "bge_top3": 0.6337296962738037, "bge_max": 0.6597073674201965, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 45 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 19.53969977443097, "bm25_max": 19.68555536291476, "bge_top3": 0.6379209558169047, "bge_max": 0.662255048751831, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 18.40896913465521, "bm25_max": 19.081853263197942, "bge_top3": 0.6384468972682953, "bge_max": 0.6422330141067505, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with a history of hepatic disease, alcoholism, or heart failure; or in patients who will…"}, {"doc_id": "azilsartan-and-chlorthalidone-drug-information", "bm25_top3": 4.600744727711502, "bm25_max": 4.600744727711502, "bge_top3": null, "bge_max": null, "title": "Azilsartan and chlorthalidone: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute per 1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute per 1.73 m2: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); u…"}, {"doc_id": "insulin-degludec-drug-information", "bm25_top3": 4.415946297185165, "bm25_max": 4.415946297185165, "bge_top3": null, "bge_max": null, "title": "Insulin degludec: Drug information", "rep_snippet": "initiation: Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3 months wit…"}, {"doc_id": "insulin-detemir-drug-information", "bm25_top3": 4.415946297185165, "bm25_max": 4.415946297185165, "bge_top3": null, "bge_max": null, "title": "Insulin detemir: Drug information", "rep_snippet": "initiation: Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3 months wit…"}, {"doc_id": "insulin-lispro-protamine-and-insulin-lispro-drug-information", "bm25_top3": 4.415946297185165, "bm25_max": 4.415946297185165, "bge_top3": null, "bge_max": null, "title": "Insulin lispro protamine and insulin lispro: Drug information", "rep_snippet": "initiation: Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3 months wit…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": 4.408526016313335, "bm25_max": 4.408526016313335, "bge_top3": null, "bge_max": null, "title": "Apalutamide: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Renal function estimated by the modification of diet in renal disease (MDRD) equation.  eGFR 30 to 89 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer’s labe…"}, {"doc_id": "insulin-aspart-drug-information", "bm25_top3": 4.353157092881846, "bm25_max": 4.353157092881846, "bge_top3": null, "bge_max": null, "title": "Insulin aspart: Drug information", "rep_snippet": "Timing of initiation: Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3…"}, {"doc_id": "insulin-aspart-protamine-and-insulin-aspart-drug-information", "bm25_top3": 4.353157092881846, "bm25_max": 4.353157092881846, "bge_top3": null, "bge_max": null, "title": "Insulin aspart protamine and insulin aspart: Drug information", "rep_snippet": "Timing of initiation: Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3…"}]}
{"qid": "Q7_abbr+renal", "query": "Uncomplicated cystitis; eGFR 25 — is nitrofurantoin appropriate?", "base_qid": "Q7", "variant_type": "abbr+renal", "candidates": [{"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 28.122712324236833, "bm25_max": 33.5773193514878, "bge_top3": 0.638672928015391, "bge_max": 0.7176852822303772, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Use  Cystitis, acute uncomplicated:  Nitrofurantoin monohydrate/macrocrystals (Macrobid): Treatment of acute uncomplicated cystitis caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus in pat…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 8.561080145395225, "bm25_max": 11.773933321304476, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Use: Off-Label  Cystitis, acute uncomplicated"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 11.31976385779329, "bm25_max": 11.31976385779329, "bge_top3": null, "bge_max": null, "title": "Cefpodoxime: Drug information", "rep_snippet": "Use  Chronic bronchitis, acute bacterial exacerbation: Treatment of acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (non-beta-lactamase-producing strains only…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": 8.480491983431595, "bm25_max": 10.623643761176915, "bge_top3": 0.5684953331947327, "bge_max": 0.5778018236160278, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Cystitis, acute uncomplicated: Note: Use for uncomplicated urinary tract infections is discouraged due to significant E. coli resistance and safety issues; reserve for clinical situations where other appropriate treatmen…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": 7.817892906569796, "bm25_max": 7.817892906569796, "bge_top3": 0.5627481341362, "bge_max": 0.5627481341362, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "Use  Treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia, skin and skin structure infections (uncomplicated), urethral and cervical gonorrhea (acute, uncomplicated), urethritis and cervic…"}, {"doc_id": "fosfomycin-drug-information", "bm25_top3": 7.659282697595874, "bm25_max": 7.659282697595874, "bge_top3": 0.5928698182106018, "bge_max": 0.5928698182106018, "title": "Fosfomycin: Drug information", "rep_snippet": "Use  Uncomplicated urinary tract infections: Treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis.  Limitations of use: No…"}, {"doc_id": "cefaclor-drug-information", "bm25_top3": 7.482758481626355, "bm25_max": 7.482758481626355, "bge_top3": null, "bge_max": null, "title": "Cefaclor: Drug information", "rep_snippet": "Skin and skin structure infections, uncomplicated: Treatment of uncomplicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible) or S. pyogenes (capsules and oral suspension only).…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": 7.141079809896908, "bm25_max": 7.141079809896908, "bge_top3": null, "bge_max": null, "title": "Trimethoprim: Drug information", "rep_snippet": "Use  Cystitis, acute uncomplicated, treatment (tablets, oral solution): Treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of Escherichia coli, Proteus mirabilis, Klebsiell…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": 6.921909498741327, "bm25_max": 6.921909498741327, "bge_top3": null, "bge_max": null, "title": "Sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR ≥30 to <45 mL/minute/1.73 m2: 50 mg once daily  eGFR <30 mL/minute/1.73 m2: 25 mg once daily  ESRD requiring hemodialysis or per…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 6.411896240042369, "bm25_max": 6.411896240042369, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Urinary tract infection (off-label dose):  Cystitis, acute uncomplicated (empiric use [avoid if resistance prevalence is known to exceed 20% or if used for UTI in previous 3 months] or targeted therapy [if the isolate is…"}, {"doc_id": "sulfanilamide-drug-information", "bm25_top3": 6.0333962539240815, "bm25_max": 6.0333962539240815, "bge_top3": null, "bge_max": null, "title": "Sulfanilamide: Drug information", "rep_snippet": "• Appropriate use: Topical antifungal agents or oral fluconazole are generally considered to be the preferred treatment for uncomplicated vulvovaginal candidiasis (Pappas, 2009; Reef, 1993; Sobel, 2007). Sulfanilamide is…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 5.913156272002103, "bm25_max": 5.913156272002103, "bge_top3": 0.5728467702865601, "bge_max": 0.5728467702865601, "title": "Spironolactone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling:  Tablet: Contraindicated in patients with anuria, acute renal impairment, or significant impairment of renal excretory function.  Suspension:  Edema, hypertension: There…"}, {"doc_id": "norfloxacin-united-states-not-available-drug-information", "bm25_top3": 5.809247619666815, "bm25_max": 5.809247619666815, "bge_top3": 0.5653612017631531, "bge_max": 0.5653612017631531, "title": "Norfloxacin (United States: not available): Drug information", "rep_snippet": "• G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.  • Pediatric: Safety and efficacy have not been established in children; other quinolones ha…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": 4.359337635677836, "bm25_max": 4.957687118470339, "bge_top3": null, "bge_max": null, "title": "Fenofibrate: Drug information", "rep_snippet": "Dialysis: Use is contraindicated.  TriCor:  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 59 mL/minute/1.73 m2: Initiate at 48 mg once daily  eGFR <30 mL/minute/1.73 m2: Use is contraindicated.…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 4.830986087747629, "bm25_max": 4.830986087747629, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 45 to <60 mL/minute/1.73 m2: Do not initiate therapy if eGFR <60 mL/minute/1.73 m2; discontinue therapy if eGFR falls persistentl…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 4.621207846861255, "bm25_max": 4.621207846861255, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Use is not recommended for initiation of therapy or when eGFR is persistently between 30 and <60 mL…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": 4.5973162875825295, "bm25_max": 4.5973162875825295, "bge_top3": null, "bge_max": null, "title": "Mirabegron: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl 30 to 89 mL/minute or eGFR 30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary.  CrCl 15 to 29 mL/minute or eGFR 15 to 29 mL/minute/1.73 m2: Do not exceed 25 mg once daily.  CrCl <15…"}, {"doc_id": "osimertinib-drug-information", "bm25_top3": 4.475830642416302, "bm25_max": 4.475830642416302, "bge_top3": null, "bge_max": null, "title": "Osimertinib: Drug information", "rep_snippet": "Mechanism of Action  Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which binds to select mutant forms of EGFR, including T790M, L858R, and exon 19 deletion at lower conc…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 4.446074441152092, "bm25_max": 4.446074441152092, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "• Elderly: Avoid use of spironolactone doses >25 mg/day in elderly patients with heart failure or with reduced renal function (eg, CrCl <30 mL/minute or eGFR ≤30 mL/minute/1.73 m2 [Yancy 2013 ]).  Other warnings/precauti…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 4.445773470665159, "bm25_max": 4.445773470665159, "bge_top3": 0.5524165034294128, "bge_max": 0.5524165034294128, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": 4.445773470665159, "bm25_max": 4.445773470665159, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 4.408249990998868, "bm25_max": 4.408249990998868, "bge_top3": 0.5580198168754578, "bge_max": 0.5632408857345581, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when e…"}, {"doc_id": "gefitinib-drug-information", "bm25_top3": 4.267093911250696, "bm25_max": 4.275429031570182, "bge_top3": null, "bge_max": null, "title": "Gefitinib: Drug information", "rep_snippet": "• Appropriate use: Establish EGFR mutation status prior to treatment. Do not use in patients with EGFR mutation-negative tumors. Studies have demonstrated a subset of patients who are more likely to respond to gefitinib…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 4.250774793273749, "bm25_max": 4.250774793273749, "bge_top3": null, "bge_max": null, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 4.211742382733087, "bm25_max": 4.211742382733087, "bge_top3": null, "bge_max": null, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during ther…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 4.211742382733087, "bm25_max": 4.211742382733087, "bge_top3": 0.5530983209609985, "bge_max": 0.5530983209609985, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 4.154429277386644, "bm25_max": 4.154429277386644, "bge_top3": 0.554463267326355, "bge_max": 0.554463267326355, "title": "Canagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Maximum dose: 100 mg once daily. If patient receiving concurrent UDP-glucuronosyl transferase (UGT)…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 4.138490616810765, "bm25_max": 4.138490616810765, "bge_top3": null, "bge_max": null, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >60 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR 30 to 60 mL/minute/1.73 m2: Use is not recommended.  eGFR <30 mL/minute/1.73 m2: Use i…"}, {"doc_id": "cyclophosphamide-drug-information", "bm25_top3": 4.036343198648238, "bm25_max": 4.036343198648238, "bge_top3": null, "bge_max": null, "title": "Cyclophosphamide: Drug information", "rep_snippet": "• Urinary/renal toxicity: Cyclophosphamide is associated with the development of hemorrhagic cystitis, pyelitis, ureteritis, and hematuria. Hemorrhagic cystitis may rarely be severe or fatal. Bladder fibrosis may also oc…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 3.9389551721610783, "bm25_max": 3.9389551721610783, "bge_top3": 0.5615480840206146, "bge_max": 0.5661197900772095, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, t…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 3.8305412629935347, "bm25_max": 3.8305412629935347, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <60 mL/minute/1.73 m2: Use is contraindicated.  Hemodialysis: Use is contraindicated."}, {"doc_id": "dimethyl-sulfoxide-drug-information", "bm25_top3": 3.6968898167939592, "bm25_max": 3.6968898167939592, "bge_top3": null, "bge_max": null, "title": "Dimethyl sulfoxide: Drug information", "rep_snippet": "Use  Interstitial cystitis: Symptomatic relief of interstitial cystitis.  Limitation of use: There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial urinary tract infections."}, {"doc_id": "eplerenone-drug-information", "bm25_top3": 3.6566581335054575, "bm25_max": 3.6566581335054575, "bge_top3": null, "bge_max": null, "title": "Eplerenone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hypertension:  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <50 mL/minute or serum creatinine >2 mg/dL (males) or >1.8 mg/dL (females): Use…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 3.6181694878225805, "bm25_max": 3.6181694878225805, "bge_top3": 0.567341685295105, "bge_max": 0.567341685295105, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 3.5669309981964528, "bm25_max": 3.5669309981964528, "bge_top3": 0.5618417263031006, "bge_max": 0.5618417263031006, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5706364214420319, "bge_max": 0.5767338275909424, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5680414438247681, "bge_max": 0.5748756527900696, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Nephropathic cystinosis: Oral: Note: Begin therapy as soon as the diagnosis of nephropathic cystinosis has been confirmed.  Immediate release (Cystagon):  Initial: Initiate therapy with 1/6 to 1/4 of maint…"}, {"doc_id": "pralatrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5689710974693298, "bge_max": 0.5689710974693298, "title": "Pralatrexate: Drug information", "rep_snippet": "500 to 1,000/mm3 with fever or ANC <500/mm3 (recurrent or for 2-week duration): Omit dose and give filgrastim or sargramostim support; decrease to 20 mg/m2 (10 mg/m2 in patients with eGFR 15 to <30 mL/minute/1.73 m2) wit…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5673710703849792, "bge_max": 0.5673710703849792, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Pulmonary disease (severe nodular/bronchiectatic or cavitary disease) in non-HIV-infected patients (off-label use): 250 to 300 mg once daily in combination with a rifamycin plus ethambutol; continue treatment until patie…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5672680735588074, "bge_max": 0.5672680735588074, "title": "Cefixime: Drug information", "rep_snippet": "Use  Treatment of uncomplicated urinary tract infections (due to Escherichia coli and Proteus mirabilis), otitis media (due to Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes), pharyngitis and t…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5590097010135651, "bge_max": 0.5641269683837891, "title": "Erlotinib: Drug information", "rep_snippet": "Use  Non-small cell lung cancer, metastatic: Treatment of metastatic non-small cell lung cancer (NSCLC) in tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations a…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5599003732204437, "bge_max": 0.5638566017150879, "title": "Apixaban: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Deep vein thrombosis (DVT), pulmonary embolism (PE), reduction in the risk of recurrent DVT and PE  : No dosage adjustment is recommended by the manufacturer for any degree of renal imp…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5634059906005859, "bge_max": 0.5634059906005859, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Use  Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis: Reduction of the risk of NSAID-associated gastric ulcers in patients at risk of developing gastric ulcers who require an NSAID for the relief of signs an…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5619465708732605, "bge_max": 0.5619465708732605, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using eGFR; the risk of metformin accumulation and lactic acidosis i…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5576538443565369, "bge_max": 0.5612425804138184, "title": "Glipizide and metformin: Drug information", "rep_snippet": "• Renal impairment: The metabolism and excretion of glipizide may be slowed in patients with renal impairment. Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and p…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5608083605766296, "bge_max": 0.5608083605766296, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute/1.73 m2: Initial: Sacubitril 24 mg/valsartan 26 mg twice daily"}, {"doc_id": "diclofenac-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5603291988372803, "bge_max": 0.5603291988372803, "title": "Diclofenac (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral:  Mild or moderate impairment: No dosage adjustment necessary.  Significant impairment or advanced renal disease: Use is not recommended.  Injection:  Mild impairment: There are no dosage a…"}, {"doc_id": "tofacitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5598766803741455, "bge_max": 0.5598766803741455, "title": "Tofacitinib: Drug information", "rep_snippet": "Use  Psoriatic arthritis: Treatment of active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).  Rheumatoid arthriti…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.556362509727478, "bge_max": 0.556362509727478, "title": "Ibuprofen: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; avoid use in advanced renal disease.  KDIGO 2012 guidelines provide the following recommendations for N…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5556391477584839, "bge_max": 0.5556391477584839, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥15 mL/minute/1.73 m2 to <90 mL/minute/1.73 m2: There are no specific dosage adjustments provided in the manufacturer’s labeling for the combination product; insulin requirements may be red…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5551971197128296, "bge_max": 0.5551971197128296, "title": "Empagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, d…"}, {"doc_id": "levofloxacin-united-states-not-available-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5551222562789917, "bge_max": 0.5551222562789917, "title": "Levofloxacin (United States: Not available) (oral inhalation): Drug information", "rep_snippet": "Use  Note: Not approved in the US.  Cystic fibrosis: Management of cystic fibrosis in patients 18 years and older with chronic pulmonary Pseudomonas aeruginosa infections.  Limitations of use: Safety and efficacy not dem…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5550602674484253, "bge_max": 0.5550602674484253, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5544522404670715, "bge_max": 0.5544522404670715, "title": "Ceftriaxone: Drug information", "rep_snippet": "Cervicitis, proctitis, urethritis (off-label  ), pharyngitis (off-label)  :  Dual-therapy regimen (preferred): IM: 250 mg in a single dose plus oral azithromycin (CDC [Workowski 2015])  Treatment  failure:  Note: Reinfec…"}, {"doc_id": "metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5535639524459839, "bge_max": 0.5535639524459839, "title": "Metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually. More frequent monitoring (every 3 to 6 months) and a maximum dose of 2,000 mg/day has been r…"}, {"doc_id": "sofosbuvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5533507466316223, "bge_max": 0.5533507466316223, "title": "Sofosbuvir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Estimated glomerular filtration rate (eGFR) ≥30 mL/minute: No dosage adjustment necessary.  eGFR <30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not b…"}, {"doc_id": "epirubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5531126856803894, "bge_max": 0.5531126856803894, "title": "Epirubicin: Drug information", "rep_snippet": "ECF regimen: 50 mg/m2 on day 1 every 21 days for 3 preoperative and 3 postoperative cycles in combination with cisplatin and fluorouracil (Cunningham 2006)  Gastric cancer (off-label use): IV:  ECF, ECX, EOF, and EOX reg…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5528697967529297, "bge_max": 0.5528697967529297, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Renal Impairment  US labeling: There are no dosage adjustments provided in the manufacturer’s labeling; however the following adjustments have been recommended (Aronoff 2007): Cetirizine:  Adults:  GFR >50 mL/min…"}]}
{"qid": "Q7_distractor-indication", "query": "Simple UTI (not pyelo), eGFR 25 mL/min — use nitrofurantoin or avoid?", "base_qid": "Q7", "variant_type": "distractor-indication", "candidates": [{"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 28.064160299508394, "bm25_max": 29.283695898175928, "bge_top3": 0.6096946994463602, "bge_max": 0.6174338459968567, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nitrofurantoin: Pediatric drug information\")  UTI, treatment:  Infants, Children, and Adolescents: Nitrofurantoin macrocrystals (Furadantin, Macrodantin): Oral: 5 to 7…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": 16.390943324234836, "bm25_max": 16.390943324234836, "bge_top3": null, "bge_max": null, "title": "Mirabegron: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl 30 to 89 mL/minute or eGFR 30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary.  CrCl 15 to 29 mL/minute or eGFR 15 to 29 mL/minute/1.73 m2: Do not exceed 25 mg once daily.  CrCl <15…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 14.023163754355085, "bm25_max": 16.04560187770193, "bge_top3": 0.5768616596857706, "bge_max": 0.5826369524002075, "title": "Empagliflozin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity to empagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or dialysis  Canadian lab…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 14.200497337958755, "bm25_max": 15.959942764675336, "bge_top3": 0.5607810616493225, "bge_max": 0.5607810616493225, "title": "Canagliflozin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity to canagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2); end-stage renal disease or patients on dialysis.  Canadia…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": 14.044277493689245, "bm25_max": 15.05928914562637, "bge_top3": null, "bge_max": null, "title": "Fenofibrate: Drug information", "rep_snippet": "Dialysis: Use is contraindicated.  TriCor:  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 59 mL/minute/1.73 m2: Initiate at 48 mg once daily  eGFR <30 mL/minute/1.73 m2: Use is contraindicated.…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 14.900997622650127, "bm25_max": 14.900997622650127, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "• Elderly: Avoid use of spironolactone doses >25 mg/day in elderly patients with heart failure or with reduced renal function (eg, CrCl <30 mL/minute or eGFR ≤30 mL/minute/1.73 m2 [Yancy 2013 ]).  Other warnings/precauti…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": 14.865422363001727, "bm25_max": 14.865422363001727, "bge_top3": null, "bge_max": null, "title": "Sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR ≥30 to <45 mL/minute/1.73 m2: 50 mg once daily  eGFR <30 mL/minute/1.73 m2: 25 mg once daily  ESRD requiring hemodialysis or per…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 14.4423932009821, "bm25_max": 14.4423932009821, "bge_top3": 0.5707295536994934, "bge_max": 0.5707295536994934, "title": "Spironolactone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling:  Tablet: Contraindicated in patients with anuria, acute renal impairment, or significant impairment of renal excretory function.  Suspension:  Edema, hypertension: There…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 14.043672528239522, "bm25_max": 14.043672528239522, "bge_top3": 0.5700172185897827, "bge_max": 0.5700172185897827, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": 14.043672528239522, "bm25_max": 14.043672528239522, "bge_top3": 0.5603305697441101, "bge_max": 0.5603305697441101, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 13.974723338190135, "bm25_max": 13.974723338190135, "bge_top3": 0.5847549438476562, "bge_max": 0.5847549438476562, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when e…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 13.96151221365157, "bm25_max": 13.96151221365157, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Use is not recommended for initiation of therapy or when eGFR is persistently between 30 and <60 mL…"}, {"doc_id": "delafloxacin-drug-information", "bm25_top3": 12.970118206790067, "bm25_max": 13.850547184325762, "bge_top3": 0.5696060657501221, "bge_max": 0.5696060657501221, "title": "Delafloxacin: Drug information", "rep_snippet": "• Injection: Avoid use of IV formulation in patients with end-stage renal disease (eGFR <15 mL/minute/1.73 m2); injection contains excipient cyclodextrin (sulfobutylether-beta-cyclodextrin [SBECD]), which may accumulate.…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 13.462749113290311, "bm25_max": 13.462749113290311, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 45 to <60 mL/minute/1.73 m2: Do not initiate therapy if eGFR <60 mL/minute/1.73 m2; discontinue therapy if eGFR falls persistentl…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": 13.400927219205258, "bm25_max": 13.400927219205258, "bge_top3": null, "bge_max": null, "title": "Eplerenone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hypertension:  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <50 mL/minute or serum creatinine >2 mg/dL (males) or >1.8 mg/dL (females): Use…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 12.503137763372784, "bm25_max": 13.257596340555704, "bge_top3": 0.5791102250417074, "bge_max": 0.5913041830062866, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, t…"}, {"doc_id": "phentermine-drug-information", "bm25_top3": 13.015960963195319, "bm25_max": 13.015960963195319, "bge_top3": null, "bge_max": null, "title": "Phentermine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Capsule, tablet (excluding Lomaira):  eGFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased; use with caution.…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 12.745404746269116, "bm25_max": 12.745404746269116, "bge_top3": null, "bge_max": null, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during ther…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 12.745404746269116, "bm25_max": 12.745404746269116, "bge_top3": 0.5746898651123047, "bge_max": 0.5746898651123047, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 12.739378098207183, "bm25_max": 12.739378098207183, "bge_top3": 0.5720648169517517, "bge_max": 0.5720648169517517, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >60 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR 30 to 60 mL/minute/1.73 m2: Use is not recommended.  eGFR <30 mL/minute/1.73 m2: Use i…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 12.44175642639691, "bm25_max": 12.44175642639691, "bge_top3": null, "bge_max": null, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 12.088293696173693, "bm25_max": 12.088293696173693, "bge_top3": 0.5777913630008698, "bge_max": 0.581886351108551, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": 12.035220452586834, "bm25_max": 12.035220452586834, "bge_top3": null, "bge_max": null, "title": "Naproxen: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥30 mL/minute: There are no specific dosage adjustments provided in the manufacturer's labeling; use with caution and consider using a reduced dose.  CrCl <30 mL/minute: Use is not recommen…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 11.804747163866754, "bm25_max": 11.804747163866754, "bge_top3": null, "bge_max": null, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 11.473838053361685, "bm25_max": 11.473838053361685, "bge_top3": 0.5888456702232361, "bge_max": 0.5888456702232361, "title": "Ibuprofen: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; avoid use in advanced renal disease.  KDIGO 2012 guidelines provide the following recommendations for N…"}, {"doc_id": "crizotinib-drug-information", "bm25_top3": 11.282303489945086, "bm25_max": 11.282303489945086, "bge_top3": null, "bge_max": null, "title": "Crizotinib: Drug information", "rep_snippet": "Adverse Reactions  >10%:  Cardiovascular: Edema (31% to 49%), bradycardia (5% to 14%)  Central nervous system: Fatigue (27% to 29%), neuropathy (19% to 25%; includes dysesthesia, gait disturbance, hypoesthesia, muscular…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": 11.16692721574211, "bm25_max": 11.16692721574211, "bge_top3": null, "bge_max": null, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥15 mL/minute/1.73 m2 to <90 mL/minute/1.73 m2: There are no specific dosage adjustments provided in the manufacturer’s labeling for the combination product; insulin requirements may be red…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": 11.14621157931786, "bm25_max": 11.14621157931786, "bge_top3": null, "bge_max": null, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.  KDIGO 2012 guidelines provide the following recommendations for NSAIDs:  eGFR 30 to <60 mL/minute/1.73…"}, {"doc_id": "sulindac-drug-information", "bm25_top3": 11.113082636859989, "bm25_max": 11.113082636859989, "bge_top3": 0.5720022320747375, "bge_max": 0.5720022320747375, "title": "Sulindac: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Avoid use in patients with advanced renal disease; monitor renal function closely if therapy must be in…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 11.11080962885821, "bm25_max": 11.11080962885821, "bge_top3": 0.5742354989051819, "bge_max": 0.5818768739700317, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "meloxicam-drug-information", "bm25_top3": 11.000754099202666, "bm25_max": 11.000754099202666, "bge_top3": null, "bge_max": null, "title": "Meloxicam: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥20 mL/minute: No dosage adjustment necessary.  CrCl <20 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use is not recommended.…"}, {"doc_id": "mefenamic-acid-drug-information", "bm25_top3": 10.821826186595125, "bm25_max": 10.821826186595125, "bge_top3": 0.5817393064498901, "bge_max": 0.5817393064498901, "title": "Mefenamic acid: Drug information", "rep_snippet": "Dosing: Renal Impairment  Avoid use in patients with preexisting renal disease and in patients with advanced renal disease.  KDIGO 2012 guidelines provide the following recommendations for NSAIDs:  eGFR 30 to <60 mL/minu…"}, {"doc_id": "diclofenac-systemic-drug-information", "bm25_top3": 10.792808611642908, "bm25_max": 10.792808611642908, "bge_top3": 0.5725067853927612, "bge_max": 0.5725067853927612, "title": "Diclofenac (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral:  Mild or moderate impairment: No dosage adjustment necessary.  Significant impairment or advanced renal disease: Use is not recommended.  Injection:  Mild impairment: There are no dosage a…"}, {"doc_id": "azilsartan-and-chlorthalidone-drug-information", "bm25_top3": 10.69431856000297, "bm25_max": 10.69431856000297, "bge_top3": null, "bge_max": null, "title": "Azilsartan and chlorthalidone: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute per 1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute per 1.73 m2: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); u…"}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": 10.615430059223868, "bm25_max": 10.615430059223868, "bge_top3": null, "bge_max": null, "title": "Cabozantinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The estimated glomerular filtration rate (eGFR) is estimated using MDRD (modification of diet in renal disease) equation.  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR…"}, {"doc_id": "etodolac-drug-information", "bm25_top3": 10.591376864165419, "bm25_max": 10.591376864165419, "bge_top3": null, "bge_max": null, "title": "Etodolac: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl >88 mL/minute: No dosage adjustment necessary.  CrCl 37 to 88 mL/minute: No dosage adjustment necessary; however, use with caution.  CrCl <37 mL/minute: There are no specific dosage adjustm…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 10.515404474485418, "bm25_max": 10.515404474485418, "bge_top3": 0.5745677351951599, "bge_max": 0.5748080611228943, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "meclofenamate-drug-information", "bm25_top3": 10.514278806967749, "bm25_max": 10.514278806967749, "bge_top3": 0.5695673227310181, "bge_max": 0.5695673227310181, "title": "Meclofenamate: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. Avoid use in patients with advanced renal disease.  KDIGO 2012 guidelines provide the following recommendations for NSAID…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 10.456522156813744, "bm25_max": 10.456522156813744, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <60 mL/minute/1.73 m2: Use is contraindicated.  Hemodialysis: Use is contraindicated."}, {"doc_id": "flurbiprofen-systemic-drug-information", "bm25_top3": 10.427521457340518, "bm25_max": 10.427521457340518, "bge_top3": null, "bge_max": null, "title": "Flurbiprofen (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  US labeling:  Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.  Moderate to severe impairment: There are no dosage adjustments provided…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5970656275749207, "bge_max": 0.5970656275749207, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using eGFR; the risk of metformin accumulation and lactic acidosis i…"}, {"doc_id": "metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5723600089550018, "bge_max": 0.5829774737358093, "title": "Metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5785925686359406, "bge_max": 0.5801706314086914, "title": "Glipizide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformi…"}, {"doc_id": "glipizide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5712628960609436, "bge_max": 0.5712628960609436, "title": "Glipizide: Drug information", "rep_snippet": "• GI tract stricture/narrowing: The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable prod…"}, {"doc_id": "gadobutrol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5691685080528259, "bge_max": 0.5691685080528259, "title": "Gadobutrol: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis (NSF): [US Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure increases the risk for NSF in patients with renal impairment; avoid use unless GBCA-enhanced imaging is essential…"}, {"doc_id": "pralatrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5666903257369995, "bge_max": 0.5689538717269897, "title": "Pralatrexate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Peripheral T-cell lymphoma (PTCL), relapsed or refractory:  Estimated glomerular filtration rate (eGFR) ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 15 to <30 mL/minute/1.73 m2:…"}, {"doc_id": "isosorbide-mononitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5686693787574768, "bge_max": 0.5686693787574768, "title": "Isosorbide mononitrate: Drug information", "rep_snippet": "• PDE-5 inhibitors: Avoid concurrent use with PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil). When nitrate administration becomes medically necessary, may administer nitrates only if 24 hours have elapsed after…"}, {"doc_id": "amphotericin-b-deoxycholate-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5674822330474854, "bge_max": 0.5674822330474854, "title": "Amphotericin B deoxycholate (conventional): Drug information", "rep_snippet": "ALERT: US Boxed Warning  Appropriate use:  This drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; it should not be used to treat noninvasive form…"}, {"doc_id": "indomethacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5659612417221069, "bge_max": 0.5659612417221069, "title": "Indomethacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral/rectal: There are no dosage adjustments provided in the manufacturer's labeling; not recommended in patients with advanced renal disease.  Injection: If anuria or marked oliguria (urinary o…"}, {"doc_id": "desirudin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5659486055374146, "bge_max": 0.5659486055374146, "title": "Desirudin: Drug information", "rep_snippet": "• Renal impairment: Use with caution, especially in patients with moderate-to-severe renal impairment (CrCl <60 mL/minute/1.73 m2); dosage reduction is necessary; monitor aPTT and renal function daily.  Special populatio…"}, {"doc_id": "glyburide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5648998618125916, "bge_max": 0.5648998618125916, "title": "Glyburide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Glyburide is generally not recommended in chronic kidney disease; if sulfonylurea therapy is needed other agents are preferred (ADA [Tuttle 2014]; Alsahli 2015; KDOQI [Nelson 2012]). Use of glyb…"}, {"doc_id": "probenecid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5640642642974854, "bge_max": 0.5640642642974854, "title": "Probenecid: Drug information", "rep_snippet": "Dosing: Renal Impairment  GFR <30 mL/minute: Avoid use (reduced efficacy with renal impairment)  Note: Probenecid is not recommended as first-line urate-lowering therapy (ULT) monotherapy in patients with renal impairmen…"}, {"doc_id": "gadofosveset-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5626596808433533, "bge_max": 0.5626596808433533, "title": "Gadofosveset: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis: [US Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5614526867866516, "bge_max": 0.5614526867866516, "title": "Dabigatran: Drug information", "rep_snippet": "• Antithrombotic agents: Due to an increased risk of bleeding, avoid use, if possible, with other direct thrombin inhibitors (eg, bivalirudin), unfractionated heparin or heparin derivatives, low molecular weight heparins…"}, {"doc_id": "gadoxetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5592109560966492, "bge_max": 0.5592109560966492, "title": "Gadoxetate: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis: [US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBC…"}]}
{"qid": "Q7_noise", "query": "UCystitis, renal fxn low (eGFR 25) — greenlight nitrofurantoin?", "base_qid": "Q7", "variant_type": "noise", "candidates": [{"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 20.623333069644662, "bm25_max": 21.246047805348443, "bge_top3": 0.6121494372685751, "bge_max": 0.6256051063537598, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Pricing: US  Capsules (Macrobid Oral)  100 mg (100): $693.00  Capsules (Macrodantin Oral)  25 mg (100): $1,406.40  50 mg (100): $315.00  100 mg (100): $661.50  Capsules (Nitrofurantoin Macrocrystal Oral)  25 mg (100): $7…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": 9.814046344359504, "bm25_max": 9.814046344359504, "bge_top3": null, "bge_max": null, "title": "Sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR ≥30 to <45 mL/minute/1.73 m2: 50 mg once daily  eGFR <30 mL/minute/1.73 m2: 25 mg once daily  ESRD requiring hemodialysis or per…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 8.291342382632202, "bm25_max": 8.291342382632202, "bge_top3": 0.577966570854187, "bge_max": 0.577966570854187, "title": "Spironolactone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling:  Tablet: Contraindicated in patients with anuria, acute renal impairment, or significant impairment of renal excretory function.  Suspension:  Edema, hypertension: There…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": 7.215190557645126, "bm25_max": 7.215190557645126, "bge_top3": null, "bge_max": null, "title": "Mirabegron: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl 30 to 89 mL/minute or eGFR 30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary.  CrCl 15 to 29 mL/minute or eGFR 15 to 29 mL/minute/1.73 m2: Do not exceed 25 mg once daily.  CrCl <15…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 6.269659767227278, "bm25_max": 6.269659767227278, "bge_top3": null, "bge_max": null, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >60 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR 30 to 60 mL/minute/1.73 m2: Use is not recommended.  eGFR <30 mL/minute/1.73 m2: Use i…"}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": 5.594326931427517, "bm25_max": 5.594326931427517, "bge_top3": null, "bge_max": null, "title": "Cabozantinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The estimated glomerular filtration rate (eGFR) is estimated using MDRD (modification of diet in renal disease) equation.  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 5.292330716978292, "bm25_max": 5.512704402048023, "bge_top3": 0.574651300907135, "bge_max": 0.574651300907135, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, t…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 5.469603635304946, "bm25_max": 5.469603635304946, "bge_top3": 0.5647433996200562, "bge_max": 0.5647433996200562, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 5.419746575456909, "bm25_max": 5.419746575456909, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 45 to <60 mL/minute/1.73 m2: Do not initiate therapy if eGFR <60 mL/minute/1.73 m2; discontinue therapy if eGFR falls persistentl…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 5.057115240946528, "bm25_max": 5.257506451083756, "bge_top3": null, "bge_max": null, "title": "Canagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Maximum dose: 100 mg once daily. If patient receiving concurrent UDP-glucuronosyl transferase (UGT)…"}, {"doc_id": "afatinib-drug-information", "bm25_top3": 5.243033069099226, "bm25_max": 5.243033069099226, "bge_top3": null, "bge_max": null, "title": "Afatinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The manufacturer recommends using the Modification of Diet in Renal Disease (MDRD) formula to estimate the glomerular filtration rate (eGFR).  Preexisting impairment:  eGFR >30 mL/minute/1…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 5.182282366187385, "bm25_max": 5.182282366187385, "bge_top3": null, "bge_max": null, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 5.148485620310131, "bm25_max": 5.148485620310131, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <60 mL/minute/1.73 m2: Use is contraindicated.  Hemodialysis: Use is contraindicated."}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 5.039785722868778, "bm25_max": 5.137238189196342, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin: Drug information", "rep_snippet": "Contraindications  History of serious hypersensitivity to dapagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or patients on dialysis…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 4.591522869596496, "bm25_max": 5.137238189196342, "bge_top3": 0.5791581869125366, "bge_max": 0.5791581869125366, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR <45 mL/minute/1.73 m2: Use is contraindicated by the manufacturer; refer also to indiv…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 4.816994710190711, "bm25_max": 5.135789547599785, "bge_top3": 0.5654421448707581, "bge_max": 0.5658761262893677, "title": "Empagliflozin: Drug information", "rep_snippet": "• Renal impairment: Glycemic efficacy may be decreased in renal impairment. Assess renal function prior to initiation and periodically during treatment. Use is contraindicated in severe renal impairment (eGFR <30 mL/minu…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 5.133514039355099, "bm25_max": 5.133514039355099, "bge_top3": null, "bge_max": null, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during ther…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 5.133514039355099, "bm25_max": 5.133514039355099, "bge_top3": null, "bge_max": null, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "meropenem-and-vaborbactam-drug-information", "bm25_top3": 4.945321179333386, "bm25_max": 5.1080070021040545, "bge_top3": null, "bge_max": null, "title": "Meropenem and vaborbactam: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Estimation of renal function for the purpose of drug dosing should be done using the Modification of Diet in Renal Disease (MDRD) formula. Dosage recommendations are expressed as g…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 5.085140575404386, "bm25_max": 5.085140575404386, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": 5.085140575404386, "bm25_max": 5.085140575404386, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 5.052892615572295, "bm25_max": 5.052892615572295, "bge_top3": null, "bge_max": null, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 5.037156302793424, "bm25_max": 5.037156302793424, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when e…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": 4.986473566317601, "bm25_max": 4.986473566317601, "bge_top3": null, "bge_max": null, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute/1.73 m2: Initial: Sacubitril 24 mg/valsartan 26 mg twice daily"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 4.972542157116008, "bm25_max": 4.972542157116008, "bge_top3": 0.5657667517662048, "bge_max": 0.5657667517662048, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": 4.918188228077753, "bm25_max": 4.918188228077753, "bge_top3": null, "bge_max": null, "title": "Eplerenone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hypertension:  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <50 mL/minute or serum creatinine >2 mg/dL (males) or >1.8 mg/dL (females): Use…"}, {"doc_id": "acalabrutinib-drug-information", "bm25_top3": 4.8567240308093, "bm25_max": 4.8567240308093, "bge_top3": null, "bge_max": null, "title": "Acalabrutinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling; however, renal excretion is minimal.  eGFR <30/mL/minute/1.73 m2: There are no dosage adjustm…"}, {"doc_id": "mefenamic-acid-drug-information", "bm25_top3": 4.621632525310387, "bm25_max": 4.621632525310387, "bge_top3": null, "bge_max": null, "title": "Mefenamic acid: Drug information", "rep_snippet": "Dosing: Renal Impairment  Avoid use in patients with preexisting renal disease and in patients with advanced renal disease.  KDIGO 2012 guidelines provide the following recommendations for NSAIDs:  eGFR 30 to <60 mL/minu…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": 4.566688544354577, "bm25_max": 4.566688544354577, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling; predominate sofosbuvir metabolit…"}, {"doc_id": "delafloxacin-drug-information", "bm25_top3": 4.40887301892952, "bm25_max": 4.5478388267613195, "bge_top3": 0.576545238494873, "bge_max": 0.576545238494873, "title": "Delafloxacin: Drug information", "rep_snippet": "• Injection: Avoid use of IV formulation in patients with end-stage renal disease (eGFR <15 mL/minute/1.73 m2); injection contains excipient cyclodextrin (sulfobutylether-beta-cyclodextrin [SBECD]), which may accumulate.…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 4.472743127950345, "bm25_max": 4.472743127950345, "bge_top3": null, "bge_max": null, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "sofosbuvir-drug-information", "bm25_top3": 4.451729356882954, "bm25_max": 4.451729356882954, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Estimated glomerular filtration rate (eGFR) ≥30 mL/minute: No dosage adjustment necessary.  eGFR <30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not b…"}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": 4.402663599450797, "bm25_max": 4.402663599450797, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling. However, sofosbuvir and metaboli…"}, {"doc_id": "albiglutide-drug-information", "bm25_top3": 4.231128269288899, "bm25_max": 4.231128269288899, "bge_top3": null, "bge_max": null, "title": "Albiglutide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥15 to 89 mL/minute/1.73 m2: No dosage adjustment necessary; use caution when initiating or escalating doses.  eGFR <15 mL/minute/1.73 m2: There are no dosage adjustments provided in the ma…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": 4.183237947142334, "bm25_max": 4.183237947142334, "bge_top3": null, "bge_max": null, "title": "Glipizide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformi…"}, {"doc_id": "azilsartan-and-chlorthalidone-drug-information", "bm25_top3": 4.1602287390817985, "bm25_max": 4.1602287390817985, "bge_top3": null, "bge_max": null, "title": "Azilsartan and chlorthalidone: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute per 1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute per 1.73 m2: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); u…"}, {"doc_id": "lixisenatide-drug-information", "bm25_top3": 4.097582194366396, "bm25_max": 4.097582194366396, "bge_top3": 0.5807799100875854, "bge_max": 0.5807799100875854, "title": "Lixisenatide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary; monitor closely for increased adverse GI effects (eg, diarrhea, nausea, vomiting) which may lead to dehydration and worsening of…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5920137166976929, "bge_max": 0.5920137166976929, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5854899883270264, "bge_max": 0.5854899883270264, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "• Renal toxicity: Tenofovir disoproxil fumarate may cause renal toxicity, including acute renal failure and Fanconi syndrome; avoid use with concurrent or recent nephrotoxic therapy (including high dose or multiple NSAID…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5843169689178467, "bge_max": 0.5843169689178467, "title": "Cefotaxime: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5833550691604614, "bge_max": 0.5833550691604614, "title": "Fluconazole: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5823025107383728, "bge_max": 0.5823025107383728, "title": "Amikacin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5805425047874451, "bge_max": 0.5805425047874451, "title": "Voriconazole: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5795502066612244, "bge_max": 0.5795502066612244, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "• Nephrotoxicity: [US Boxed Warning]: Renal impairment, including structural kidney damage has occurred (when used at high doses); risk is increased with increasing doses/duration; monitor renal function closely. Use cau…"}, {"doc_id": "norfloxacin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5789571404457092, "bge_max": 0.5789571404457092, "title": "Norfloxacin (United States: not available): Drug information", "rep_snippet": "Use  Uncomplicated and complicated urinary tract infections caused by susceptible gram-negative and gram-positive bacteria; sexually transmitted disease (eg, uncomplicated urethral and cervical gonorrhea) caused by N. go…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5784027576446533, "bge_max": 0.5784027576446533, "title": "Vancomycin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5782958269119263, "bge_max": 0.5782958269119263, "title": "Ampicillin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz, 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5770613551139832, "bge_max": 0.5770613551139832, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, sign…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5764435529708862, "bge_max": 0.5764435529708862, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "colistin-colistimethate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5753540396690369, "bge_max": 0.5753540396690369, "title": "Colistin (colistimethate): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747364163398743, "bge_max": 0.5747364163398743, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment. Dosage adjustments may be necessary. Patients with mild to moderate renal impairment (eGFR ≥30 to 89 mL/minute/1.73 m2) may be at increased risk of…"}, {"doc_id": "gadobutrol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5741817951202393, "bge_max": 0.5741817951202393, "title": "Gadobutrol: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis (NSF): [US Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure increases the risk for NSF in patients with renal impairment; avoid use unless GBCA-enhanced imaging is essential…"}, {"doc_id": "docetaxel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5736278891563416, "bge_max": 0.5736278891563416, "title": "Docetaxel: Drug information", "rep_snippet": "Gastric cancer, head and neck cancer: Note: Cisplatin may require dose reductions/therapy delays for peripheral neuropathy, ototoxicity, and/or nephrotoxicity. Patients experiencing febrile neutropenia, documented infect…"}, {"doc_id": "aztreonam-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5718626976013184, "bge_max": 0.5718626976013184, "title": "Aztreonam (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring o…"}, {"doc_id": "cefepime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5711281895637512, "bge_max": 0.5711281895637512, "title": "Cefepime: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5693767666816711, "bge_max": 0.5693767666816711, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Peritoneal dialysis (PD): 2.5 to 5 mg/kg/dose every 24 hours; no supplemental dose needed (Aronoff 2007). Note: Use higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.  Continuous re…"}, {"doc_id": "meropenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5693557858467102, "bge_max": 0.5693557858467102, "title": "Meropenem: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Kuti 2005; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close mon…"}, {"doc_id": "colchicine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5691714882850647, "bge_max": 0.5691714882850647, "title": "Colchicine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Concurrent use of colchicine and P-gp or strong CYP3A4 inhibitors is contraindicated in renal impairment. Fatal toxicity has been reported. Use of colchicine to treat gout flares is not recommen…"}, {"doc_id": "ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5678722858428955, "bge_max": 0.5690646171569824, "title": "Ticarcillin and clavulanate potassium (United States: Not available): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT): 50 to 75 mg ticarcillin/kg every 8 hours"}, {"doc_id": "gadofosveset-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5689124464988708, "bge_max": 0.5689124464988708, "title": "Gadofosveset: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis: [US Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA…"}, {"doc_id": "potassium-phosphate-and-sodium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5682721138000488, "bge_max": 0.5682721138000488, "title": "Potassium phosphate and sodium phosphate: Drug information", "rep_snippet": "Contraindications  Hyperphosphatemia; infected urinary phosphate stones; severe renal impairment (<30% of normal)"}, {"doc_id": "zoledronic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5674741864204407, "bge_max": 0.5674741864204407, "title": "Zoledronic acid: Drug information", "rep_snippet": "Oncology indications: Dosage adjustment required with renal impairment. Use is not recommended in patients with severe renal impairment (serum creatinine >3 mg/dL or CrCl <30 mL/minute) and bone metastases (limited data)…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5662035942077637, "bge_max": 0.5662035942077637, "title": "Cefixime: Drug information", "rep_snippet": "Use  Treatment of uncomplicated urinary tract infections (due to Escherichia coli and Proteus mirabilis), otitis media (due to Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes), pharyngitis and t…"}, {"doc_id": "gadobenate-dimeglumine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5661686062812805, "bge_max": 0.5661686062812805, "title": "Gadobenate dimeglumine: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis: [US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure increases the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA e…"}, {"doc_id": "gadoxetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5660592317581177, "bge_max": 0.5660592317581177, "title": "Gadoxetate: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis: [US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBC…"}, {"doc_id": "gadopentetate-dimeglumine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5655421614646912, "bge_max": 0.5655421614646912, "title": "Gadopentetate dimeglumine: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis: [US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBC…"}, {"doc_id": "gadodiamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5655421614646912, "bge_max": 0.5655421614646912, "title": "Gadodiamide: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis: [US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBC…"}, {"doc_id": "gadoversetamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5655421614646912, "bge_max": 0.5655421614646912, "title": "Gadoversetamide: Drug information", "rep_snippet": "• Nephrogenic systemic fibrosis: [US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBC…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5650304555892944, "bge_max": 0.5650304555892944, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5647690296173096, "bge_max": 0.5647690296173096, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}]}
{"qid": "Q8_abbr+severity", "query": "Warfarin + TMP-SMX — interaction severity & what action to take?", "base_qid": "Q8", "variant_type": "abbr+severity", "candidates": [{"doc_id": "warfarin-drug-information", "bm25_top3": 17.77273566033228, "bm25_max": 22.810972873448396, "bge_top3": 0.5743417143821716, "bge_max": 0.5743417143821716, "title": "Warfarin: Drug information", "rep_snippet": "Food Interactions  Ethanol: Acute ethanol ingestion (binge drinking) decreases the metabolism of oral anticoagulants and increases PT/INR. Chronic daily ethanol use increases the metabolism of oral anticoagulants and dec…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 21.945128765165155, "bm25_max": 22.622154623382087, "bge_top3": 0.5656306743621826, "bge_max": 0.5656306743621826, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Absorption: Oral: Rapid; almost completely (90% to 100%)  Distribution: Both SMX and TMP distribute to middle ear fluid, sputum, vaginal fluid; TMP also distributes into bronchial secretions  V…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": 12.159826670810729, "bm25_max": 18.892456532032277, "bge_top3": null, "bge_max": null, "title": "Ceftazidime: Drug information", "rep_snippet": "Severe, acute phase: Infants ≥3 months, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours for ≥10 days with or without TMP/SMX (maximum dose: 2,000 mg/dose) (Lipsitz 2012). Note: Depending on infection severity,…"}, {"doc_id": "eszopiclone-drug-information", "bm25_top3": 7.223618672662466, "bm25_max": 10.248120276046862, "bge_top3": null, "bge_max": null, "title": "Eszopiclone: Drug information", "rep_snippet": "Food Interactions  Onset of action may be reduced if taken with or immediately after a heavy meal. Management: Take immediately prior to bedtime, not with or immediately after a heavy or high-fat meal."}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 9.810474015135668, "bm25_max": 9.810474015135668, "bge_top3": null, "bge_max": null, "title": "Dabigatran: Drug information", "rep_snippet": "Antacids: May decrease the serum concentration of Dabigatran Etexilate. Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other si…"}, {"doc_id": "tinzaparin-drug-information", "bm25_top3": 9.15151907426359, "bm25_max": 9.15151907426359, "bge_top3": 0.5588559508323669, "bge_max": 0.5588559508323669, "title": "Tinzaparin: Drug information", "rep_snippet": "Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocou…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": 9.15151907426359, "bm25_max": 9.15151907426359, "bge_top3": null, "bge_max": null, "title": "Dalteparin: Drug information", "rep_snippet": "Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocou…"}, {"doc_id": "nadroparin-united-states-not-available-drug-information", "bm25_top3": 9.15151907426359, "bm25_max": 9.15151907426359, "bge_top3": null, "bge_max": null, "title": "Nadroparin (United States: Not available): Drug information", "rep_snippet": "Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocou…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": 9.15151907426359, "bm25_max": 9.15151907426359, "bge_top3": null, "bge_max": null, "title": "Enoxaparin: Drug information", "rep_snippet": "Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocou…"}, {"doc_id": "protein-c-concentrate-from-human-plasma-drug-information", "bm25_top3": 9.056312326569493, "bm25_max": 9.056312326569493, "bge_top3": null, "bge_max": null, "title": "Protein C, concentrate from human plasma: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants…"}, {"doc_id": "antithrombin-concentrate-from-human-plasma-and-recombinant-human-drug-information", "bm25_top3": 9.056312326569493, "bm25_max": 9.056312326569493, "bge_top3": null, "bge_max": null, "title": "Antithrombin, concentrate from human plasma and recombinant human: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants…"}, {"doc_id": "danaparoid-united-states-not-available-drug-information", "bm25_top3": 9.056312326569493, "bm25_max": 9.056312326569493, "bge_top3": null, "bge_max": null, "title": "Danaparoid (United States: Not available): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants…"}, {"doc_id": "argatroban-drug-information", "bm25_top3": 6.317569889041397, "bm25_max": 9.056312326569493, "bge_top3": 0.5574523210525513, "bge_max": 0.5574523210525513, "title": "Argatroban: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants…"}, {"doc_id": "fondaparinux-drug-information", "bm25_top3": 9.056312326569493, "bm25_max": 9.056312326569493, "bge_top3": null, "bge_max": null, "title": "Fondaparinux: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants…"}, {"doc_id": "bivalirudin-drug-information", "bm25_top3": 9.056312326569493, "bm25_max": 9.056312326569493, "bge_top3": null, "bge_max": null, "title": "Bivalirudin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": 9.056312326569493, "bm25_max": 9.056312326569493, "bge_top3": null, "bge_max": null, "title": "Betrixaban: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants…"}, {"doc_id": "dronabinol-drug-information", "bm25_top3": 8.984436337713827, "bm25_max": 8.984436337713827, "bge_top3": null, "bge_max": null, "title": "Dronabinol: Drug information", "rep_snippet": "Warfarin: Dronabinol may increase the serum concentration of Warfarin. Specifically, dronabinol may displace warfarin from its protein-binding sites, leading to an increased concentration of active, unbound drug. Risk C:…"}, {"doc_id": "atovaquone-drug-information", "bm25_top3": 5.757517070090025, "bm25_max": 7.143743173139521, "bge_top3": null, "bge_max": null, "title": "Atovaquone: Drug information", "rep_snippet": "Use  Pneumocystis jirovecii pneumonia (PCP), prophylaxis: Prevention of PCP in adults and adolescents 13 years and older who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMZ)  Pneumocystis jirovecii pneumonia (PC…"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 6.552456587969187, "bm25_max": 6.552456587969187, "bge_top3": null, "bge_max": null, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Mechanism of Action  Combination of fluticasone (corticosteroid) and salmeterol (long-acting beta2-agonist) designed to improve pulmonary function and control over what is produced by either agent when used alone. Becaus…"}, {"doc_id": "triazolam-drug-information", "bm25_top3": 5.637053974620095, "bm25_max": 5.637053974620095, "bge_top3": null, "bge_max": null, "title": "Triazolam: Drug information", "rep_snippet": "Administration  Administer on an empty stomach; do not take with a meal or immediately after a meal. Tablet may be crushed or swallowed whole. Onset of action is rapid; patient should take immediately before bedtime."}, {"doc_id": "hydroxyamphetamine-and-tropicamide-drug-information", "bm25_top3": 5.38267169834802, "bm25_max": 5.38267169834802, "bge_top3": null, "bge_max": null, "title": "Hydroxyamphetamine and tropicamide: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: 15 minutes  Duration: 3 hours; complete recovery usually occurs in 6-8 hours, but may take up to 24 hours  Time to peak: 60 minutes"}, {"doc_id": "apixaban-drug-information", "bm25_top3": 4.882803574794256, "bm25_max": 4.882803574794256, "bge_top3": null, "bge_max": null, "title": "Apixaban: Drug information", "rep_snippet": "Serum creatinine ≥1.5 mg/dL and either ≥80 years of age or body weight ≤60 kg: 2.5 mg twice daily. Note: Patients with a serum creatinine >2.5 mg/dL or CrCl <25 mL/minute (as determined by Cockcroft-Gault equation) were…"}, {"doc_id": "capecitabine-drug-information", "bm25_top3": 4.700915395910114, "bm25_max": 4.700915395910114, "bge_top3": 0.601885199546814, "bge_max": 0.601885199546814, "title": "Capecitabine: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Warfarin interaction:  Frequently monitor the anticoagulant response (international normalized ratio [INR] or prothrombin time [PT]) of patients receiving concomitant capecitabine and oral coumar…"}, {"doc_id": "castor-oil-drug-information", "bm25_top3": 4.619279769008116, "bm25_max": 4.619279769008116, "bge_top3": null, "bge_max": null, "title": "Castor oil: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: 1 to 3 hours (Brunton 2006) but may take up to 12 hours"}, {"doc_id": "fingolimod-drug-information", "bm25_top3": 4.486976548642076, "bm25_max": 4.486976548642076, "bge_top3": null, "bge_max": null, "title": "Fingolimod: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "lifitegrast-drug-information", "bm25_top3": 3.871016096529919, "bm25_max": 3.871016096529919, "bge_top3": null, "bge_max": null, "title": "Lifitegrast: Drug information", "rep_snippet": "Mechanism of Action  Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1) and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1)."}, {"doc_id": "chlorpromazine-drug-information", "bm25_top3": 3.7558439486680193, "bm25_max": 3.7558439486680193, "bge_top3": null, "bge_max": null, "title": "Chlorpromazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Chlorpromazine and its metabolites have been detected in breast milk; concentrations in the milk do not correlate with those in the mother and may be higher than what is in the maternal pla…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 3.5624682485153283, "bm25_max": 3.5624682485153283, "bge_top3": null, "bge_max": null, "title": "Lansoprazole: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication, patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools. Prior to use, patients should c…"}, {"doc_id": "flunarizine-united-states-not-available-drug-information", "bm25_top3": 3.51284232835879, "bm25_max": 3.51284232835879, "bge_top3": null, "bge_max": null, "title": "Flunarizine (United States: Not available): Drug information", "rep_snippet": "Mechanism of Action  Flunarizine is a selective calcium channel blocker that prevents cellular calcium overload by reducing excessive transmembrane calcium influx; also has antihistamine properties. Has greater effect on…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 3.474506678366639, "bm25_max": 3.474506678366639, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "budesonide-and-formoterol-drug-information", "bm25_top3": 3.447387519285712, "bm25_max": 3.447387519285712, "bge_top3": null, "bge_max": null, "title": "Budesonide and formoterol: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  See individual agents.  Onset of action: Asthma: 15 minutes; maximum benefit: may take ≥2 weeks"}, {"doc_id": "topical-tretinoin-topical-all-trans-retinoic-acid-drug-information", "bm25_top3": 2.0754644532360302, "bm25_max": 2.0754644532360302, "bge_top3": null, "bge_max": null, "title": "Topical tretinoin (topical all-trans retinoic acid): Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: Acne: ≥2 weeks, may take ≥7 weeks; Facial wrinkles: Up to 6 months  Absorption: Minimal  Bioavailability: Avita cream and gel: <0.3%; Retin A Micro 0.1% gel: ~1%  Metabolism: H…"}, {"doc_id": "tigecycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6177979707717896, "bge_max": 0.6177979707717896, "title": "Tigecycline: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Warfarin: Tigecycline may increase the serum concentration of Warfarin. Risk C: Monitor therapy"}, {"doc_id": "fluorouracil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5948591828346252, "bge_max": 0.5948591828346252, "title": "Fluorouracil (systemic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "palifermin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5773583650588989, "bge_max": 0.5900301933288574, "title": "Palifermin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Antineoplastic Agents: Palifermin may enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity…"}, {"doc_id": "sucroferric-oxyhydroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5875927209854126, "bge_max": 0.5875927209854126, "title": "Sucroferric oxyhydroxide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Levothyroxine: Sucroferric Oxyhydroxide may decrease the serum concentration of Levothyroxine. Management: Avoid the use of oral/enteral…"}, {"doc_id": "telaprevir-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5848205089569092, "bge_max": 0.5862091779708862, "title": "Telaprevir (United States: Not available): Drug information", "rep_snippet": "• Skin reactions: [US Boxed Warning]: Serious skin reactions (some fatal) including Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), hav…"}, {"doc_id": "sorafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5673976937929789, "bge_max": 0.5799539089202881, "title": "Sorafenib: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5779728889465332, "bge_max": 0.5779728889465332, "title": "Vemurafenib: Drug information", "rep_snippet": "Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Warfarin: Vemurafenib may increase the serum concentration of Warfarin. Risk C: Monitor therapy  Xipam…"}, {"doc_id": "tuberculin-skin-test-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772451162338257, "bge_max": 0.5772451162338257, "title": "Tuberculin skin test: Drug information", "rep_snippet": "Warnings/Precautions  Disease-related concerns:  • Viral infections: Skin testing may be deferred with major viral infections.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interacti…"}, {"doc_id": "methyl-salicylate-and-menthol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5752905607223511, "bge_max": 0.5752905607223511, "title": "Methyl salicylate and menthol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Warfarin: Salicylates (Topical) may enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy"}, {"doc_id": "trolamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5752905607223511, "bge_max": 0.5752905607223511, "title": "Trolamine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Warfarin: Salicylates (Topical) may enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5714626908302307, "bge_max": 0.5714626908302307, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Antimalarial Age…"}, {"doc_id": "clofarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5714437365531921, "bge_max": 0.5714437365531921, "title": "Clofarabine: Drug information", "rep_snippet": "• Dermatologic reactions: Serious and fatal cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. Discontinue clofarabine for exfoliative or bullous rash, or if SJS or TEN are s…"}, {"doc_id": "infliximab-including-biosimilars-of-infliximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.571015477180481, "bge_max": 0.571015477180481, "title": "Infliximab (including biosimilars of infliximab): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant u…"}, {"doc_id": "interferon-beta-1a-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5708568692207336, "bge_max": 0.5708568692207336, "title": "Interferon beta-1a: Drug information", "rep_snippet": "• Thrombotic microangiopathy: Cases of thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS) (some fatal) have been reported (Hunt 2014; Mahe 2013; Rebif C…"}, {"doc_id": "certolizumab-pegol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5704029202461243, "bge_max": 0.5704029202461243, "title": "Certolizumab pegol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant u…"}, {"doc_id": "lenalidomide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5694750547409058, "bge_max": 0.5694750547409058, "title": "Lenalidomide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant u…"}, {"doc_id": "etanercept-including-biosimilars-of-etanercept-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5689128637313843, "bge_max": 0.5689128637313843, "title": "Etanercept (including biosimilars of etanercept): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant u…"}, {"doc_id": "adalimumab-including-biosimilars-of-adalimumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5676789879798889, "bge_max": 0.5676789879798889, "title": "Adalimumab (including biosimilars of adalimumab): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant u…"}, {"doc_id": "golimumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5631137490272522, "bge_max": 0.5676789879798889, "title": "Golimumab: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant u…"}, {"doc_id": "carfilzomib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5676028728485107, "bge_max": 0.5676028728485107, "title": "Carfilzomib: Drug information", "rep_snippet": "• Combination therapy toxicity: An increased incidence of serious and fatal adverse events was observed in a clinical trial comparing the combination of carfilzomib, melphalan, and prednisone (KMP) to bortezomib, melphal…"}, {"doc_id": "erythromycin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.56598961353302, "bge_max": 0.56598961353302, "title": "Erythromycin (ophthalmic): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Vitamin K Antagonists (eg, warfarin): Erythromycin (Ophthalmic) may increase the serum concentration of Vitamin K Antagonists. Risk C: Mo…"}, {"doc_id": "mitoxantrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5659653544425964, "bge_max": 0.5659653544425964, "title": "Mitoxantrone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "carboplatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5656704306602478, "bge_max": 0.5656704306602478, "title": "Carboplatin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "simeprevir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5655674934387207, "bge_max": 0.5655674934387207, "title": "Simeprevir: Drug information", "rep_snippet": "• Skin reactions: Rash has been typically observed within first 4 weeks of therapy initiation, but can occur at any time during treatment. Severe rashes and rash requiring discontinuation have occurred in combination wit…"}, {"doc_id": "clopidogrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5652338266372681, "bge_max": 0.5652338266372681, "title": "Clopidogrel: Drug information", "rep_snippet": "• Thienopyridine hypersensitivity: Because of structural similarities, cross-reactivity has been reported among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with hy…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.564726710319519, "bge_max": 0.564726710319519, "title": "Aminophylline: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "dapsone-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5644949674606323, "bge_max": 0.5644949674606323, "title": "Dapsone (topical): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be incr…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5640202164649963, "bge_max": 0.5640202164649963, "title": "Aprepitant: Drug information", "rep_snippet": "Monitoring Parameters  In patients receiving concurrent warfarin, monitor INR/PT for 2 weeks (particularly at 7 to 10 days) following aprepitant administration; monitor for signs/symptoms of hypersensitivity reaction."}, {"doc_id": "tirofiban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5624077916145325, "bge_max": 0.5624077916145325, "title": "Tirofiban: Drug information", "rep_snippet": "Adverse Reactions  Bleeding is the major drug-related adverse effect. Patients received background treatment with aspirin and heparin. Adverse reactions reported are derived from both the high-dose bolus regimen and the…"}, {"doc_id": "sodium-chloride-preparations-saline-and-oral-salt-tablets-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5614346861839294, "bge_max": 0.5614346861839294, "title": "Sodium chloride preparations (saline and oral salt tablets): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Lithium: Sodium Chloride may increase the excretion of Lithium. Risk C: Monitor therapy  Tolvaptan: Sodium Chloride may enhance the adver…"}, {"doc_id": "melphalan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5612057447433472, "bge_max": 0.5612057447433472, "title": "Melphalan: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "interferon-alfa-n3-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5611490607261658, "bge_max": 0.5611490607261658, "title": "Interferon alfa-n3: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicit…"}, {"doc_id": "interferon-alfacon-1-consensus-interferon-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5611490607261658, "bge_max": 0.5611490607261658, "title": "Interferon alfacon-1 (consensus interferon) (United States: Not available): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicit…"}, {"doc_id": "tesamorelin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.560853123664856, "bge_max": 0.560853123664856, "title": "Tesamorelin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Cortisone: Tesamorelin may decrease serum concentrations of the active metabolite(s) of Cortisone. Risk D: Consider therapy modification…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5601804852485657, "bge_max": 0.5601804852485657, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "• Hypersensitivity: Severe hypersensitivity reactions, including severe skin reactions (eg, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN])…"}, {"doc_id": "teriflunomide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5592443943023682, "bge_max": 0.5592443943023682, "title": "Teriflunomide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amodiaquine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. Risk X: Avoid combination  Asunaprevir: OA…"}, {"doc_id": "tetanus-toxoid-adsorbed-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5590952634811401, "bge_max": 0.5590952634811401, "title": "Tetanus Toxoid (Adsorbed) (United States: Not available): Drug information", "rep_snippet": "• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from IM administration.  • Guilla…"}, {"doc_id": "sulfanilamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5587844252586365, "bge_max": 0.5587844252586365, "title": "Sulfanilamide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Risk C:…"}, {"doc_id": "rilonacept-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5587143898010254, "bge_max": 0.5587143898010254, "title": "Rilonacept: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Anti-TNF Agents: May enhance the adverse/toxic effect of Rilonacept. Risk X: Avoid combination  BCG (Intravesical): Immunosuppressants ma…"}, {"doc_id": "loperamide-and-simethicone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5573295950889587, "bge_max": 0.5573295950889587, "title": "Loperamide and simethicone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Desmopressin: Loperamide-Loperamide Oxide may increase the serum concentration of Desmopressin. Risk C: Monitor therapy  Eluxadoline: Lop…"}]}
{"qid": "Q8_brand+noise", "query": "Warfarin with Bactrim — how serious is it and how to manage?", "base_qid": "Q8", "variant_type": "brand+noise", "candidates": [{"doc_id": "mifepristone-and-misoprostol-united-states-not-available-drug-information", "bm25_top3": 23.533908897492992, "bm25_max": 23.533908897492992, "bge_top3": null, "bge_max": null, "title": "Mifepristone and misoprostol (United States: Not available): Drug information", "rep_snippet": "Prescribing and Access Restrictions  Prior to initiating therapy, patients are required to sign a consent form and both the patient and physician must sign a patient information card. Physicians are also required to comp…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 20.94953659210116, "bm25_max": 22.776244700636898, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Brand Names: International  Abacin (IT);  Acuco (ZA);  Alcorim-F (IN);  Anitrim (MX);  Avlotrin (BD);  Bacdan (TW);  Bacin (MY, SG, TH);  Bactelan (MX);  Bacteric (MX);  Bacterol (CL);  Bacterol Forte (CL);  Bacticel (AR…"}, {"doc_id": "ammonium-lactate-topical-drug-information", "bm25_top3": 22.670218727449964, "bm25_max": 22.670218727449964, "bge_top3": null, "bge_max": null, "title": "Ammonium lactate (topical): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known how this medication affects normal levels of lactic acid in human milk. Because studies have not been done in nursing women, use with caution when needed."}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 21.777491488208703, "bm25_max": 21.777491488208703, "bge_top3": null, "bge_max": null, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Administration  Following administration, rinse mouth with water after use (do not swallow) to reduce risk of oral candidiasis.  Advair Diskus: Dry powder inhaler: After removing from box and foil pouch, write the “Pouch…"}, {"doc_id": "clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 21.279718641655393, "bm25_max": 21.279718641655393, "bge_top3": null, "bge_max": null, "title": "Clofazimine (United States: Available via National Hansen’s Disease Program and FDA investigational drug [IND] protocol only): Drug information", "rep_snippet": "International: No longer available commercially. In nations where a national leprosy elimination program exists, the Ministries of Health make an official request to the World Health Organization (WHO) for clofazimine. I…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 21.065611733455402, "bm25_max": 21.065611733455402, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 21.065611733455402, "bm25_max": 21.065611733455402, "bge_top3": null, "bge_max": null, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 19.611789291895207, "bm25_max": 19.97942685606877, "bge_top3": 0.5616838733355204, "bge_max": 0.5792049765586853, "title": "Warfarin: Drug information", "rep_snippet": "According to the American College of Cardiology/American Heart Association (ACCF/AHA) guidelines for the management of patients with ST-elevation myocardial infarction (STEMI), warfarin should be administered to patients…"}, {"doc_id": "sodium-chloride-preparations-saline-and-oral-salt-tablets-drug-information", "bm25_top3": 19.660483005852623, "bm25_max": 19.660483005852623, "bge_top3": null, "bge_max": null, "title": "Sodium chloride preparations (saline and oral salt tablets): Drug information", "rep_snippet": "• Sodium toxicity: Rate of correction is dependent upon whether or not hyponatremia is acute or chronic. Sodium toxicity (eg, osmotic demyelination syndrome [ODS]) is almost exclusively related to how fast a sodium defic…"}, {"doc_id": "felbamate-drug-information", "bm25_top3": 18.91835603157799, "bm25_max": 18.91835603157799, "bge_top3": null, "bge_max": null, "title": "Felbamate: Drug information", "rep_snippet": "Treatment with felbamate should be initiated only in individuals without active liver disease and with normal baseline serum transaminases. It has not been proved that periodic serum transaminase testing will prevent ser…"}, {"doc_id": "sacrosidase-drug-information", "bm25_top3": 18.7764227347172, "bm25_max": 18.7764227347172, "bge_top3": null, "bge_max": null, "title": "Sacrosidase: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Sucraid® is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to http://www.sucraid.net/how-to-order-sucraid or call 1-866-740-2743."}, {"doc_id": "uridine-triacetate-drug-information", "bm25_top3": 18.316665301454275, "bm25_max": 18.316665301454275, "bge_top3": null, "bge_max": null, "title": "Uridine triacetate: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Fluorouracil accidental overdose/overexposure: Uridine triacetate (formerly called vistonuridine) is available through select specialty pharmacies. Procurement information is availabl…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 18.014698389461678, "bm25_max": 18.014698389461678, "bge_top3": 0.5365375876426697, "bge_max": 0.5365375876426697, "title": "Mifepristone: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Korlym is only available through a restricted access program. For prescriber registration and patient enrollment forms, please refer to http://www.korlym.com/hcp/how-to-prescribe-korl…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 17.91092689299562, "bm25_max": 17.91092689299562, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Mercaptopurine is the active metabolite of azathioprine. Following administration of azathioprine, mercaptopurine can be detected in breast milk (Gardiner 2006). It is not known if/how much…"}, {"doc_id": "lutropin-alfa-united-states-not-available-drug-information", "bm25_top3": 15.090638893876104, "bm25_max": 15.090638893876104, "bge_top3": null, "bge_max": null, "title": "Lutropin alfa (United States: Not available): Drug information", "rep_snippet": "Administration  SubQ: Administer in the stomach or thigh; rotate injection sites. Do not shake solution; allow any bubbles to settle prior to administration. Contents of lutropin alfa vial may be mixed in the same syring…"}, {"doc_id": "lindane-drug-information", "bm25_top3": 11.673497883398486, "bm25_max": 14.242606098276038, "bge_top3": null, "bge_max": null, "title": "Lindane: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Appropriate use:  Only use lindane in patients who cannot tolerate or have failed first-line treatment with safer medications for the treatment of scabies. Instruct patients on the proper use of…"}, {"doc_id": "glucagon-drug-information", "bm25_top3": 11.87576133989419, "bm25_max": 11.87576133989419, "bge_top3": null, "bge_max": null, "title": "Glucagon: Drug information", "rep_snippet": "Use  Diagnostic aid: As a diagnostic aid during radiologic examinations to temporarily inhibit movement of the GI tract in adults.  Hypoglycemia: Treatment of severe hypoglycemia in pediatric and adult patients. Note: Th…"}, {"doc_id": "esmolol-drug-information", "bm25_top3": 11.633511657875147, "bm25_max": 11.633511657875147, "bge_top3": null, "bge_max": null, "title": "Esmolol: Drug information", "rep_snippet": "Administration  IV: Loading doses may be administered over 30 seconds to 1 minute depending on how urgent the need for effect. Infusion into small veins or through a butterfly catheter should be avoided (can cause thromb…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 10.065611733455402, "bm25_max": 10.065611733455402, "bge_top3": null, "bge_max": null, "title": "Clarithromycin: Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": 9.685195519824354, "bm25_max": 9.685195519824354, "bge_top3": null, "bge_max": null, "title": "Phenytoin: Drug information", "rep_snippet": "Vitamin B: Phenytoin use has been associated with low serum concentrations of vitamin B2 (riboflavin), B6 (pyridoxine) and B12 (cyanocobalamin), which may contribute to hyperhomocysteinemia. Hyperhomocysteinemia may cont…"}, {"doc_id": "idelalisib-drug-information", "bm25_top3": 9.4899529267689, "bm25_max": 9.4899529267689, "bge_top3": null, "bge_max": null, "title": "Idelalisib: Drug information", "rep_snippet": "• Hypersensitivity reactions: Serious allergic/hypersensitivity reactions, including anaphylaxis, have been reported. Discontinue permanently for serious reactions and manage appropriately."}, {"doc_id": "argatroban-drug-information", "bm25_top3": 9.44501012584057, "bm25_max": 9.44501012584057, "bge_top3": 0.5478026270866394, "bge_max": 0.5478026270866394, "title": "Argatroban: Drug information", "rep_snippet": "Conversion to oral anticoagulant: Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expec…"}, {"doc_id": "clofarabine-drug-information", "bm25_top3": 9.399768059894434, "bm25_max": 9.399768059894434, "bge_top3": 0.551072895526886, "bge_max": 0.551072895526886, "title": "Clofarabine: Drug information", "rep_snippet": "• Dermatologic reactions: Serious and fatal cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. Discontinue clofarabine for exfoliative or bullous rash, or if SJS or TEN are s…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": 9.309884449146963, "bm25_max": 9.309884449146963, "bge_top3": null, "bge_max": null, "title": "Nilotinib: Drug information", "rep_snippet": "Special Alerts  Nilotinib Treatment Discontinuation  December 2017  The FDA has updated the product label for Novartis' Tasigna (nilotinib) oral capsules to include information on how to discontinue the drug in certain p…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": 8.822783718412571, "bm25_max": 8.822783718412571, "bge_top3": null, "bge_max": null, "title": "Everolimus: Drug information", "rep_snippet": "Grade 3 (severe pain; interfering with oral intake): Interrupt treatment until symptoms improve to ≤grade 1; then reinitiate at a lower dose. Also manage with topical (oral) analgesics (eg, benzocaine, butyl aminobenzoat…"}, {"doc_id": "bacitracin-ophthalmic-drug-information", "bm25_top3": 8.732183571240881, "bm25_max": 8.732183571240881, "bge_top3": 0.5442245602607727, "bge_max": 0.5442245602607727, "title": "Bacitracin (ophthalmic): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Bacitracin may be confused with Bactrim, Bactroban"}, {"doc_id": "bacitracin-topical-drug-information", "bm25_top3": 8.732183571240881, "bm25_max": 8.732183571240881, "bge_top3": null, "bge_max": null, "title": "Bacitracin (topical): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Bacitracin may be confused with Bactrim, Bactroban"}, {"doc_id": "bacitracin-systemic-drug-information", "bm25_top3": 8.732183571240881, "bm25_max": 8.732183571240881, "bge_top3": 0.5365097522735596, "bge_max": 0.5397595167160034, "title": "Bacitracin (systemic): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Bacitracin may be confused with Bactrim, Bactroban"}, {"doc_id": "mupirocin-drug-information", "bm25_top3": 8.59384487088504, "bm25_max": 8.59384487088504, "bge_top3": null, "bge_max": null, "title": "Mupirocin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Bactroban may be confused with bacitracin, baclofen, Bactrim"}, {"doc_id": "fibrin-sealant-kit-drug-information", "bm25_top3": 8.461368311782604, "bm25_max": 8.461368311782604, "bge_top3": null, "bge_max": null, "title": "Fibrin sealant kit: Drug information", "rep_snippet": "Evarrest: For topical use only; apply to surface of bleeding site only. Prior to applying, remove excess blood or fluid from the site of application to improve visibility. The anatomic location and surface area of the bl…"}, {"doc_id": "rimantadine-drug-information", "bm25_top3": 8.447739718712551, "bm25_max": 8.447739718712551, "bge_top3": null, "bge_max": null, "title": "Rimantadine: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if rimantadine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended by the manufacturer.…"}, {"doc_id": "axicabtagene-ciloleucel-drug-information", "bm25_top3": 7.667612345963741, "bm25_max": 8.365513911553133, "bge_top3": null, "bge_max": null, "title": "Axicabtagene ciloleucel: Drug information", "rep_snippet": "• Hypersensitivity: Allergic reactions may occur with axicabtagene ciloleucel infusion. Serious hypersensitivity reactions, including anaphylaxis, may occur due to the dimethyl sulfoxide (DMSO) or residual gentamicin in…"}, {"doc_id": "ramucirumab-drug-information", "bm25_top3": 8.359801671681614, "bm25_max": 8.359801671681614, "bge_top3": null, "bge_max": null, "title": "Ramucirumab: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if ramucirumab is excreted in breast milk. Immunoglobulins are excreted in breast milk, and it is assumed that ramucirumab may appear in breast milk. Due to the potential fo…"}, {"doc_id": "alemtuzumab-drug-information", "bm25_top3": 8.218238630451744, "bm25_max": 8.218238630451744, "bge_top3": null, "bge_max": null, "title": "Alemtuzumab: Drug information", "rep_snippet": "Alemtuzumab causes serious, sometimes fatal, autoimmune conditions, such as immune thrombocytopenia and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels,…"}, {"doc_id": "pegfilgrastim-drug-information", "bm25_top3": 8.063474381609023, "bm25_max": 8.063474381609023, "bge_top3": null, "bge_max": null, "title": "Pegfilgrastim: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Capillary leak syndrome: Capillary leak syndrome (CLS), characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration, may occur in patients rec…"}, {"doc_id": "bevacizumab-including-biosimilars-of-bevacizumab-drug-information", "bm25_top3": 8.048548772569797, "bm25_max": 8.048548772569797, "bge_top3": null, "bge_max": null, "title": "Bevacizumab (including biosimilars of bevacizumab): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if bevacizumab is present in breast milk. Immunoglobulins are excreted in breast milk, and it is assumed that bevacizumab may appear in breast milk. Due to the potential for…"}, {"doc_id": "degarelix-drug-information", "bm25_top3": 7.986973639766161, "bm25_max": 7.986973639766161, "bge_top3": null, "bge_max": null, "title": "Degarelix: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anemia: Testosterone suppression is associated with the development of anemia.  • Decreased bone mineral density: Androgen deprivation therapy is associated w…"}, {"doc_id": "tisagenlecleucel-drug-information", "bm25_top3": 7.3614140874293135, "bm25_max": 7.3614140874293135, "bge_top3": null, "bge_max": null, "title": "Tisagenlecleucel: Drug information", "rep_snippet": "• Infection: Serious infections (including life-threatening or fatal infections) occurred in patients after tisagenlecleucel infusion, including grades 3 and 4 infections. Viral, bacterial, and fungal infections were rep…"}, {"doc_id": "alitretinoin-systemic-united-states-not-available-systemic-drug-information", "bm25_top3": 7.041696464162648, "bm25_max": 7.041696464162648, "bge_top3": null, "bge_max": null, "title": "Alitretinoin (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if alitretinoin is excreted in breast milk; however, it is highly lipophilic and is likely excreted in human breast milk. Due to the potential for serious adverse reactions…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": 6.711909537844408, "bm25_max": 6.711909537844408, "bge_top3": null, "bge_max": null, "title": "Apixaban: Drug information", "rep_snippet": "Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for PE  Conversion from one anticoagulant to another:  Conversion from warfarin to apixaban: Discontinue warfarin and initiate…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": 6.4867161482244935, "bm25_max": 6.4867161482244935, "bge_top3": null, "bge_max": null, "title": "Procarbazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if procarbazine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, nursing is not recommended during treatment with procar…"}, {"doc_id": "tamoxifen-drug-information", "bm25_top3": 6.374115996045063, "bm25_max": 6.374115996045063, "bge_top3": null, "bge_max": null, "title": "Tamoxifen: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if tamoxifen is present in breast milk; however, it has been shown to inhibit lactation. Due to the potential for serious adverse reactions in the breastfed infant, breastfe…"}, {"doc_id": "flumazenil-drug-information", "bm25_top3": 5.973403326806055, "bm25_max": 5.973403326806055, "bge_top3": null, "bge_max": null, "title": "Flumazenil: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Seizures:  The use of flumazenil has been associated with the occurrence of seizures. These are most frequent in patients who have been on benzodiazepines for long-term sedation or in overdose ca…"}, {"doc_id": "ruxolitinib-drug-information", "bm25_top3": 5.945083314177298, "bm25_max": 5.945083314177298, "bge_top3": null, "bge_max": null, "title": "Ruxolitinib: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if ruxolitinib is present in breast milk. Due to the potential for serious adverse reactions, discontinue breastfeeding during ruxolitinib treatment and for 2 weeks after th…"}, {"doc_id": "fondaparinux-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5655390620231628, "bge_max": 0.5655390620231628, "title": "Fondaparinux: Drug information", "rep_snippet": "Use  Acute deep vein thrombosis: Treatment of acute DVT in conjunction with warfarin.  Acute pulmonary embolism: Treatment of acute PE in conjunction with warfarin.  Venous thromboembolism: Prophylaxis of venous thromboe…"}, {"doc_id": "capecitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5647287964820862, "bge_max": 0.5647287964820862, "title": "Capecitabine: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Warfarin interaction:  Frequently monitor the anticoagulant response (international normalized ratio [INR] or prothrombin time [PT]) of patients receiving concomitant capecitabine and oral coumar…"}, {"doc_id": "regorafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5623400211334229, "bge_max": 0.5623400211334229, "title": "Regorafenib: Drug information", "rep_snippet": "Warfarin: May enhance the adverse/toxic effect of Regorafenib. Specifically, the risk for bleeding may be increased. Risk C: Monitor therapy"}, {"doc_id": "prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5477387607097626, "bge_max": 0.5579615831375122, "title": "Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Drug information", "rep_snippet": "Intracranial hemorrhage associated with warfarin (off-label use): IV: Note: Factor IX complex (human) products contain low or nontherapeutic levels of factor VII component (ie, considered a 3-factor PCC). Four-factor PCC…"}, {"doc_id": "lincomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5509814620018005, "bge_max": 0.5509814620018005, "title": "Lincomycin: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Colitis:  Clostridium difficile–associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin, and may range in severity from mild diarrhea to fat…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5502248406410217, "bge_max": 0.5502248406410217, "title": "Dabigatran: Drug information", "rep_snippet": "Conversion to warfarin: Since dabigatran contributes to INR elevation, warfarin's effect on the INR will be better reflected only after dabigatran has been stopped for ≥2 days. Start time must be adjusted based on CrCl:…"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5488672852516174, "bge_max": 0.5488672852516174, "title": "Vemurafenib: Drug information", "rep_snippet": "Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Warfarin: Vemurafenib may increase the serum concentration of Warfarin. Risk C: Monitor therapy  Xipam…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5475054383277893, "bge_max": 0.5475054383277893, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "• Pancreatitis: Cases of acute pancreatitis, including fatalities, have been reported with linagliptin. Monitor for signs/symptoms of pancreatitis; discontinue use immediately if pancreatitis is suspected and initiate ap…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5469458699226379, "bge_max": 0.5469458699226379, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "• Pancreatitis: Cases of acute pancreatitis have been reported with saxagliptin use. Monitor for signs/symptoms of pancreatitis; discontinue use immediately if pancreatitis is suspected and initiate appropriate managemen…"}, {"doc_id": "tigecycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5465208292007446, "bge_max": 0.5465208292007446, "title": "Tigecycline: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Warfarin: Tigecycline may increase the serum concentration of Warfarin. Risk C: Monitor therapy"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5440319180488586, "bge_max": 0.5440319180488586, "title": "Dalteparin: Drug information", "rep_snippet": "Unstable angina or non-Q-wave myocardial infarction: SubQ: 120 units/kg (maximum dose: 10,000 units) every 12 hours with concurrent aspirin therapy. Discontinue dalteparin once patient is clinically stable; usual duratio…"}, {"doc_id": "penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5439156293869019, "bge_max": 0.5439156293869019, "title": "Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Drug information", "rep_snippet": "• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including Clostridium difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic t…"}, {"doc_id": "fluorouracil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5433063507080078, "bge_max": 0.5433063507080078, "title": "Fluorouracil (systemic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5424314737319946, "bge_max": 0.5424314737319946, "title": "Erlotinib: Drug information", "rep_snippet": "Teriflunomide: May decrease the serum concentration of Erlotinib. Management: Avoid the concomitant use of erlotinib and teriflunomide if possible. If concomitant use is unavoidable, increase the erlotinib dose by 50 mg…"}, {"doc_id": "sorafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.54060298204422, "bge_max": 0.54060298204422, "title": "Sorafenib: Drug information", "rep_snippet": "Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5397417545318604, "bge_max": 0.5397417545318604, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Warfarin: Boceprevir may decrease the serum concentration of Warfarin. Boceprevir may increase the serum concentration of Warfarin. Risk C: Monitor therapy  Zolpidem: CYP3A4 Inhibitors (Strong) may increase the serum con…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5387477278709412, "bge_max": 0.5387477278709412, "title": "Aprepitant: Drug information", "rep_snippet": "Monitoring Parameters  In patients receiving concurrent warfarin, monitor INR/PT for 2 weeks (particularly at 7 to 10 days) following aprepitant administration; monitor for signs/symptoms of hypersensitivity reaction."}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5385486483573914, "bge_max": 0.5385486483573914, "title": "Sulfadiazine: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenyto…"}, {"doc_id": "venetoclax-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5380380153656006, "bge_max": 0.5380380153656006, "title": "Venetoclax: Drug information", "rep_snippet": "Vaccines (Live): Venetoclax may enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live, attenuated vaccines before, during, o…"}, {"doc_id": "lamotrigine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5378130674362183, "bge_max": 0.5378130674362183, "title": "Lamotrigine: Drug information", "rep_snippet": "• Skin reactions: [US Boxed Warning]: Serious skin rashes requiring hospitalization and discontinuation of treatment have been reported; incidence of serious rash is higher in pediatric patients than adults; risk may be…"}, {"doc_id": "ribavirin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5367770195007324, "bge_max": 0.5367770195007324, "title": "Ribavirin (systemic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hemolytic anemia: [US Boxed Warning]: Hemolytic anemia is the primary clinical toxicity of oral therapy; anemia associated with ribavirin may worsen underlyin…"}, {"doc_id": "vitamin-k-phytonadione-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5362801551818848, "bge_max": 0.5362801551818848, "title": "Vitamin K (phytonadione): Drug information", "rep_snippet": "If major bleeding at any INR elevation: The 2012 ACCP guidelines recommend administration of four-factor prothrombin complex concentrate (PCC) and IV vitamin K 5 to 10 mg in this setting (Guyatt 2012). The only available…"}, {"doc_id": "tofacitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5357686877250671, "bge_max": 0.5357686877250671, "title": "Tofacitinib: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Serious infections:  Patients treated with tofacitinib are at increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infectio…"}, {"doc_id": "telavancin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5357539057731628, "bge_max": 0.5357539057731628, "title": "Telavancin: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Moderate to severe renal impairment:  Patients with preexisting moderate to severe renal impairment (creatinine clearance [CrCl] 50 mL/minute or less) who were treated with telavancin for hospita…"}, {"doc_id": "quinine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5338281393051147, "bge_max": 0.5338281393051147, "title": "Quinine: Drug information", "rep_snippet": "Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. Risk C: Monitor therapy  Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine. Management: Ar…"}, {"doc_id": "chloroquine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5335603356361389, "bge_max": 0.5335603356361389, "title": "Chloroquine: Drug information", "rep_snippet": "Lanthanum: May decrease the serum concentration of Chloroquine. Management: Administer chloroquine at least two hours before or after lanthanum. Risk D: Consider therapy modification  Lumefantrine: Antimalarial Agents ma…"}, {"doc_id": "dicloxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5335211753845215, "bge_max": 0.5335211753845215, "title": "Dicloxacillin: Drug information", "rep_snippet": "Monitoring Parameters  Baseline and periodic CBC with differential; periodic BUN, serum creatinine, AST and ALT (especially with prolonged therapy); prothrombin time if patient concurrently on warfarin; signs of anaphyla…"}, {"doc_id": "infliximab-including-biosimilars-of-infliximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5334246158599854, "bge_max": 0.5334246158599854, "title": "Infliximab (including biosimilars of infliximab): Drug information", "rep_snippet": "ALERT: US Boxed Warning  Serious infections:  Patients treated with infliximab are at an increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infect…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.533210039138794, "bge_max": 0.533210039138794, "title": "Amiodarone: Drug information", "rep_snippet": "• Drugs with QT prolongation potential: Particular caution must be used when a drug with QTc-prolonging potential relies on metabolism via enzymes amiodarone inhibits, since the effect of elevated concentrations may be a…"}, {"doc_id": "intravesical-bacillus-calmette-guerin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5329079627990723, "bge_max": 0.5329079627990723, "title": "Intravesical Bacillus Calmette-Guerin: Drug information", "rep_snippet": "• Disseminated infections: [US Boxed Warning]: May cause disseminated (including fatal) infections following intravesical administration. Instillation to actively bleeding mucosa may promote systemic BCG infection or sep…"}, {"doc_id": "obeticholic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5328617095947266, "bge_max": 0.5328617095947266, "title": "Obeticholic acid: Drug information", "rep_snippet": "TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine. Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and…"}, {"doc_id": "zafirlukast-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5327903628349304, "bge_max": 0.5327903628349304, "title": "Zafirlukast: Drug information", "rep_snippet": "• Infections: An increased proportion of patients >55 years of age reported infections as compared to placebo-treated patients. These infections were mostly mild or moderate in intensity and predominantly affected the re…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5321918725967407, "bge_max": 0.5321918725967407, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Valproic Acid and Derivatives: Cholestyramine Resin may decrease the serum concentration of Valproic Acid and Derivatives. Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whene…"}]}
{"qid": "Q8_spelling", "query": "Warfain co-admin TMP/SMX — mgmt plan?", "base_qid": "Q8", "variant_type": "spelling", "candidates": [{"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 30.666132088494557, "bm25_max": 31.68022529046757, "bge_top3": 0.43286122878392536, "bge_max": 0.45044833421707153, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information\")  Note: Weight-based dosing recommendations are based on the trimethoprim (TMP) component. E…"}, {"doc_id": "levonorgestrel-systemic-drug-information", "bm25_top3": 15.20457632070112, "bm25_max": 17.306850444400112, "bge_top3": null, "bge_max": null, "title": "Levonorgestrel (systemic): Drug information", "rep_snippet": "Brand Names: US  Aftera [OTC];  EContra EZ [OTC];  EContra One-Step [OTC];  Fallback Solo [OTC] [DSC];  My Choice [OTC];  My Way [OTC];  Next Choice One Dose [DSC];  Next Choice One Dose [OTC];  Opcicon One-Step [OTC];…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": 6.7630442498068355, "bm25_max": 11.167724270093416, "bge_top3": null, "bge_max": null, "title": "Ceftazidime: Drug information", "rep_snippet": "Severe, acute phase: Infants ≥3 months, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours for ≥10 days with or without TMP/SMX (maximum dose: 2,000 mg/dose) (Lipsitz 2012). Note: Depending on infection severity,…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": 10.905035296677898, "bm25_max": 10.905035296677898, "bge_top3": null, "bge_max": null, "title": "Atorvastatin: Drug information", "rep_snippet": "Lipiterol (KR);  Lipitin (HR);  Lipitor (AE, AR, AU, BB, BD, BE, BF, BH, BJ, BO, BR, CI, CL, CN, CO, CR, CY, DO, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, GT, HK, HN, ID, IE, IL, IQ, IR, JO, JP, KE, KR, KW, LB, LR, LU, LY,…"}, {"doc_id": "temozolomide-drug-information", "bm25_top3": 10.625413504970847, "bm25_max": 10.625413504970847, "bge_top3": null, "bge_max": null, "title": "Temozolomide: Drug information", "rep_snippet": "• Temozolomide resistance: Increased MGMT (O-6-methylguanine-DNA methyltransferase) activity/levels within tumor tissue is associated with temozolomide resistance. Glioblastoma patients with decreased levels (due to meth…"}, {"doc_id": "ribociclib-and-letrozole-co-packaged-drug-information", "bm25_top3": 9.579815501074284, "bm25_max": 9.579815501074284, "bge_top3": null, "bge_max": null, "title": "Ribociclib and letrozole (co-packaged): Drug information", "rep_snippet": "Brand Names: US  Kisqali Femara Co-Pack"}, {"doc_id": "atovaquone-drug-information", "bm25_top3": 2.7037177572380244, "bm25_max": 3.915465153175461, "bge_top3": null, "bge_max": null, "title": "Atovaquone: Drug information", "rep_snippet": "Use  Pneumocystis jirovecii pneumonia (PCP), prophylaxis: Prevention of PCP in adults and adolescents 13 years and older who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMZ)  Pneumocystis jirovecii pneumonia (PC…"}, {"doc_id": "buprenorphine-and-naloxone-drug-information", "bm25_top3": 3.021719528507651, "bm25_max": 3.021719528507651, "bge_top3": null, "bge_max": null, "title": "Buprenorphine and naloxone: Drug information", "rep_snippet": "Use  Opioid dependence: Treatment of opioid dependence.  General information: Buprenorphine/naloxone should be used as part of a complete treatment plan to include counseling and psychosocial support."}, {"doc_id": "warfarin-drug-information", "bm25_top3": 1.1786973510462513, "bm25_max": 1.1786973510462513, "bge_top3": 0.42354606588681537, "bge_max": 0.43627235293388367, "title": "Warfarin: Drug information", "rep_snippet": "Brand Names: International  Aldocumar (ES);  Azwar (LK);  Befarin (TH);  Circuvit (AR);  Cofarin (TW);  Coumadan (AR);  Coumadin (AE, AU, BB, BF, BH, BJ, CI, CL, CY, DE, EC, EG, ET, GH, GM, GN, IL, IQ, IR, IT, JO, KE, KR…"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4325641989707947, "bge_max": 0.4325641989707947, "title": "Vemurafenib: Drug information", "rep_snippet": "Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Warfarin: Vemurafenib may increase the serum concentration of Warfarin. Risk C: Monitor therapy  Xipam…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.41720928251743317, "bge_max": 0.42383068799972534, "title": "Simvastatin: Drug information", "rep_snippet": "Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered,…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.42383068799972534, "bge_max": 0.42383068799972534, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered,…"}, {"doc_id": "lovastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.42343854904174805, "bge_max": 0.42343854904174805, "title": "Lovastatin: Drug information", "rep_snippet": "Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered,…"}, {"doc_id": "palifermin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4231168031692505, "bge_max": 0.4231168031692505, "title": "Palifermin: Drug information", "rep_snippet": "Use  Oral mucositis: To decrease the incidence and duration of severe oral mucositis associated with hematologic malignancies in patients receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4193951189517975, "bge_max": 0.4193951189517975, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Lomitapide: Ciprofloxacin (Systemic) may increase the serum concentration of Lomitapide. Risk X: Avoid combination  Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Risk X: Avo…"}, {"doc_id": "mepenzolate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.41828233003616333, "bge_max": 0.41828233003616333, "title": "Mepenzolate: Drug information", "rep_snippet": "Administration  Administration with meals and at bedtime is preferred."}, {"doc_id": "nusinersen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.417976438999176, "bge_max": 0.417976438999176, "title": "Nusinersen: Drug information", "rep_snippet": "Mechanism of Action  Treats spinal muscular atrophy caused by mutations in chromosome 5q that lead to survival motor neuron (SMN) protein deficiency by binding to a specific sequence in the intron downstream of exon 7 of…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.41594207286834717, "bge_max": 0.41594207286834717, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine. Risk X: Avoid combination  Terfenadine: CYP3A4 Inhibitor…"}, {"doc_id": "butalbital-compound-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.415129154920578, "bge_max": 0.415129154920578, "title": "Butalbital compound and codeine: Drug information", "rep_snippet": "Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs. Risk C: Monitor therapy  Stiripentol: May in…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.41497451066970825, "bge_max": 0.41497451066970825, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "Etravirine: May decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine.…"}, {"doc_id": "safinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.413875550031662, "bge_max": 0.413875550031662, "title": "Safinamide: Drug information", "rep_snippet": "Methylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Methylphenidate. Risk X: Avoid combination  Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4127333164215088, "bge_max": 0.4127333164215088, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine. Risk X: Avoid combination  Terfenadine: CYP3A4 Inhibitor…"}, {"doc_id": "capecitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4122251272201538, "bge_max": 0.4122251272201538, "title": "Capecitabine: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Warfarin interaction:  Frequently monitor the anticoagulant response (international normalized ratio [INR] or prothrombin time [PT]) of patients receiving concomitant capecitabine and oral coumar…"}, {"doc_id": "rasagiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4121059477329254, "bge_max": 0.4121059477329254, "title": "Rasagiline: Drug information", "rep_snippet": "Methylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Methylphenidate. Risk X: Avoid combination  Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide…"}, {"doc_id": "interferon-beta-1a-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4120118021965027, "bge_max": 0.4120118021965027, "title": "Interferon beta-1a: Drug information", "rep_snippet": "• Thrombotic microangiopathy: Cases of thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS) (some fatal) have been reported (Hunt 2014; Mahe 2013; Rebif C…"}, {"doc_id": "dimethyl-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.41156819462776184, "bge_max": 0.41156819462776184, "title": "Dimethyl fumarate: Drug information", "rep_snippet": "Mechanism of Action  DMF and its active metabolite, monomethyl fumarate (MMF), have been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which is involved in cellular response to oxidati…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4115035831928253, "bge_max": 0.4115035831928253, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine. Risk X: Avoid combination  Tetrahydrocannabinol: CYP3A4…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.41149190068244934, "bge_max": 0.41149190068244934, "title": "Clarithromycin: Drug information", "rep_snippet": "Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine. Risk X: Avoid combination  Terfenadine: CYP3A4 Inhibitor…"}, {"doc_id": "lisdexamfetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.41140857338905334, "bge_max": 0.41140857338905334, "title": "Lisdexamfetamine: Drug information", "rep_snippet": "Food Interactions  High-fat meal prolongs Tmax by ~1 hour. Management: Administer without regard to meals."}, {"doc_id": "procarbazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4090055028597514, "bge_max": 0.410562127828598, "title": "Procarbazine: Drug information", "rep_snippet": "OxyMORphone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination  Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and seve…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4099508225917816, "bge_max": 0.4099508225917816, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Isavuconazonium Sulfate: May increase the serum concentration of MetFORMIN. Risk C: Monitor therapy  LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph…"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4096300005912781, "bge_max": 0.4096300005912781, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Reference Range  The metabolite of oxcarbazepine, 10-monohydroxy metabolite (MHD), is considered the active entity primarily responsible for the therapeutic effects. A number of studies have suggested optimal MHD concent…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4095242917537689, "bge_max": 0.4095242917537689, "title": "Raltegravir: Drug information", "rep_snippet": "HMG-CoA Reductase Inhibitors (Statins): Raltegravir may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Magnesium Salts: May decrease the serum concentrat…"}, {"doc_id": "chlorpheniramine-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40923917293548584, "bge_max": 0.40923917293548584, "title": "Chlorpheniramine, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Thioridazine: Chlorpheniramine may enhance the arrhythmogenic effect of Thioridazine. Thioridazine may increase the serum concentration of Chlorpheniramine. Management: Avoid this combination when possible. If used, moni…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40904417634010315, "bge_max": 0.40904417634010315, "title": "Pitavastatin: Drug information", "rep_snippet": "Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased. Risk C: Monitor therapy  Simeprevir: M…"}, {"doc_id": "hyoscyamine-methenamine-methylene-blue-and-sodium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40891677141189575, "bge_max": 0.40891677141189575, "title": "Hyoscyamine, methenamine, methylene blue, and sodium phosphate: Drug information", "rep_snippet": "Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. Risk X: Avoid combination  Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor th…"}, {"doc_id": "methylene-blue-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40891677141189575, "bge_max": 0.40891677141189575, "title": "Methylene blue: Drug information", "rep_snippet": "Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. Risk X: Avoid combination  Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor th…"}, {"doc_id": "methenamine-phenyl-salicylate-methylene-blue-benzoic-acid-and-hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40891677141189575, "bge_max": 0.40891677141189575, "title": "Methenamine, phenyl salicylate, methylene blue, benzoic acid, and hyoscyamine: Drug information", "rep_snippet": "Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. Risk X: Avoid combination  Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor th…"}, {"doc_id": "methenamine-sodium-biphosphate-phenyl-salicylate-methylene-blue-and-hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40891677141189575, "bge_max": 0.40891677141189575, "title": "Methenamine, sodium biphosphate, phenyl salicylate, methylene blue, and hyoscyamine: Drug information", "rep_snippet": "Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. Risk X: Avoid combination  Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor th…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4088847041130066, "bge_max": 0.4088847041130066, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, duri…"}, {"doc_id": "mirtazapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40887483954429626, "bge_max": 0.40887483954429626, "title": "Mirtazapine: Drug information", "rep_snippet": "Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a rel…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40861111879348755, "bge_max": 0.40861111879348755, "title": "Linezolid: Drug information", "rep_snippet": "Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. Risk X: Avoid combination  Mirtazapine: Linezolid may enhance the serotonergic effect of Mirtazapine. This could result in serotonin…"}, {"doc_id": "carfilzomib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4083826243877411, "bge_max": 0.4083826243877411, "title": "Carfilzomib: Drug information", "rep_snippet": "• Combination therapy toxicity: An increased incidence of serious and fatal adverse events was observed in a clinical trial comparing the combination of carfilzomib, melphalan, and prednisone (KMP) to bortezomib, melphal…"}, {"doc_id": "azathioprine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4080582857131958, "bge_max": 0.4080582857131958, "title": "Azathioprine: Drug information", "rep_snippet": "• TPMT or xanthine oxidase inhibitors: Patients on concurrent therapy with drugs which may inhibit TPMT (eg, olsalazine) or xanthine oxidase (eg, allopurinol) may be sensitive to myelosuppressive effects. Dose adjustment…"}, {"doc_id": "tinzaparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40801024436950684, "bge_max": 0.40801024436950684, "title": "Tinzaparin: Drug information", "rep_snippet": "Months 1 to 6: Initial: 175 anti-Xa units/kg once daily; continue for up to 6 months for maintenance therapy. Warfarin may be used for maintenance therapy; however, meta-analyses and randomized control trials have valida…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40787869691848755, "bge_max": 0.40787869691848755, "title": "Fluvoxamine: Drug information", "rep_snippet": "Melatonin: FluvoxaMINE may increase the serum concentration of Melatonin. Management: Consider the use of alternative agents in order to avoid this combination. If combined, monitor for increased melatonin effects (eg, s…"}, {"doc_id": "pravastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40776824951171875, "bge_max": 0.40776824951171875, "title": "Pravastatin: Drug information", "rep_snippet": "Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered,…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40770575404167175, "bge_max": 0.40770575404167175, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Risk X: Avoid combination  Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral qui…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.40764909982681274, "bge_max": 0.40764909982681274, "title": "Dalteparin: Drug information", "rep_snippet": "Unstable angina or non-Q-wave myocardial infarction: SubQ: 120 units/kg (maximum dose: 10,000 units) every 12 hours with concurrent aspirin therapy. Discontinue dalteparin once patient is clinically stable; usual duratio…"}, {"doc_id": "glutamine-supplements-drug-information", "bm25_top3": -0.09548017000186704, "bm25_max": -0.09548017000186704, "bge_top3": null, "bge_max": null, "title": "Glutamine supplements: Drug information", "rep_snippet": "Brand Names: International  Adamin-G (CZ);  An Kai Shu (CN);  Convales (IN);  Diamin (BR);  Glutamin (AR);  Glutapak-10 (MX);  Glutapure (EC);  Glutaven (IT);  Glutrop (ID);  Pure Warrior Powered By Swisse (AU);  Shi Lin…"}, {"doc_id": "acetaminophen-paracetamol-and-codeine-drug-information", "bm25_top3": -0.4219727507438762, "bm25_max": -0.4219727507438762, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol) and codeine: Drug information", "rep_snippet": "Brand Names: International  Algimide (CO);  Algimide F (CO);  Algocod (LB);  An Du Fen (CN);  Aprix (CO);  Aprix F (CO);  Citodon (SE);  Claradol Codeine (FR);  Co-Cadamol (LV);  Co-Codamol (HK);  Co-Tipol (IE);  Cod-Aca…"}, {"doc_id": "valsartan-and-hydrochlorothiazide-drug-information", "bm25_top3": -0.5045986828581395, "bm25_max": -0.5045986828581395, "bge_top3": null, "bge_max": null, "title": "Valsartan and hydrochlorothiazide: Drug information", "rep_snippet": "Brand Names: International  Aralter Plus (ES);  Arbiten Plus (QA);  Cardival Plus (BD);  Co-Aginet (JO);  Co-Dio (JP);  Co-Diopass (KR);  Co-Diovan (AE, AT, AU, BG, BH, CH, CY, CZ, EE, ES, GR, HK, HR, ID, IL, JO, KW, LB,…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": -0.7736718070172177, "bm25_max": -0.7736718070172177, "bge_top3": null, "bge_max": null, "title": "Trimethoprim: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Trimethoprim crosses the placenta and can be detected in the fetal serum and amniotic fluid (Reid 1975). Adverse events may be ass…"}, {"doc_id": "irbesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": -1.0896155912937902, "bm25_max": -1.0896155912937902, "bge_top3": null, "bge_max": null, "title": "Irbesartan and hydrochlorothiazide: Drug information", "rep_snippet": "Brand Names: International  Aprozide (BR);  Arbitan PLUS (BD);  Avalide (BZ, SR);  Avapro HCT (AR, AU);  Co-Aprovel (HK, TH);  Co-Besartin (SG);  Co-Irvebal (ID);  Co-Ivyzar (PH);  CoApprovel (DE);  Coaprovel (AE, AR, AT…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": -1.1715700736921253, "bm25_max": -1.1715700736921253, "bge_top3": null, "bge_max": null, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Brand Names: International  Benpen (AU, NZ);  Bentapen (PH);  Broncobiot (PE);  Lascacilin (PY);  Pencarv (PH);  Pengesod (MX);  Penicilina Northia (AR);  Penicillin G (BG);  Penicillin G- Natrium (AT);  Pisacilina (CO);…"}, {"doc_id": "hydrocodone-and-ibuprofen-drug-information", "bm25_top3": -1.2726056052481765, "bm25_max": -1.2726056052481765, "bge_top3": null, "bge_max": null, "title": "Hydrocodone and ibuprofen: Drug information", "rep_snippet": "Brand Names: International  Dovir (CO)"}, {"doc_id": "levalbuterol-drug-information", "bm25_top3": -1.2726056052481765, "bm25_max": -1.2726056052481765, "bge_top3": null, "bge_max": null, "title": "Levalbuterol: Drug information", "rep_snippet": "Brand Names: International  Seramar (CO)"}, {"doc_id": "exemestane-drug-information", "bm25_top3": -1.347106466185509, "bm25_max": -1.347106466185509, "bge_top3": null, "bge_max": null, "title": "Exemestane: Drug information", "rep_snippet": "Brand Names: Canada  Aromasin;  CO Exemestane"}, {"doc_id": "lithium-drug-information", "bm25_top3": -1.347106466185509, "bm25_max": -1.347106466185509, "bge_top3": null, "bge_max": null, "title": "Lithium: Drug information", "rep_snippet": "Sicolitio (UY);  Teralithe (FR);  Theralite (CO)"}, {"doc_id": "deflazacort-drug-information", "bm25_top3": -1.4403097431691299, "bm25_max": -1.4403097431691299, "bge_top3": null, "bge_max": null, "title": "Deflazacort: Drug information", "rep_snippet": "Brand Names: International  Aflazacort (PE);  Alcoza (IN);  Alnacort (IN);  Arocort (IN);  Arrumal (CL);  Asfor (PT);  Asodef (IN);  Avantium (CO);  Azacortid (AR, AU, CL, PY, UY);  Calcorrt (EC);  Calcort (BR, BS, CH, C…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": -1.4531237049952157, "bm25_max": -1.4531237049952157, "bge_top3": null, "bge_max": null, "title": "Sertraline: Drug information", "rep_snippet": "Brand Names: International  Aleval (MX);  Altisben (ES);  Altruline (CR, DO, GT, HN, MX, NI, PA, SV);  Aluprex (MX);  Andep (BD);  Aremis (ES);  Asentra (LV);  Aserin (ES);  Besiran (ES);  Chear (BD);  Conexine (EC);  De…"}, {"doc_id": "pyrantel-pamoate-drug-information", "bm25_top3": -1.4609069557997154, "bm25_max": -1.4609069557997154, "bge_top3": null, "bge_max": null, "title": "Pyrantel pamoate: Drug information", "rep_snippet": "Brand Names: International  Anthel (AU, TW);  Anthelmin (PK);  Aut (AR);  Bearantel (SG);  Bifantrel (CO);  Combantril (CH);  Combantrin (AT, BG, BH, CL, CO, EC, EG, FR, GB, GR, IT, KR, NZ, PE, PH, PT, QA, SA, VE, VN, ZA…"}, {"doc_id": "nimodipine-drug-information", "bm25_top3": -1.5397784120170854, "bm25_max": -1.5397784120170854, "bge_top3": null, "bge_max": null, "title": "Nimodipine: Drug information", "rep_snippet": "Brand Names: International  Amocure (TW);  Brainal (ES);  Eftipine (VN);  Eugerial (AR, CO, PE);  Grifonimod (PE);  Irrigor (PE);  Kenesil (ES);  Kenzolol (MX);  Modip (CR, DO, GT, HN, NI, PA, SV);  Nemotan (UA);  Nidip…"}, {"doc_id": "gemtuzumab-ozogamicin-drug-information", "bm25_top3": -1.5622320646707317, "bm25_max": -1.5622320646707317, "bge_top3": null, "bge_max": null, "title": "Gemtuzumab ozogamicin: Drug information", "rep_snippet": "Brand Names: International  Mylotarg (CO, GR, JP, KR, VE)"}, {"doc_id": "calcium-carbonate-and-magnesium-hydroxide-drug-information", "bm25_top3": -1.6312778772005192, "bm25_max": -1.6312778772005192, "bge_top3": null, "bge_max": null, "title": "Calcium carbonate and magnesium hydroxide: Drug information", "rep_snippet": "Brand Names: International  Mylanta 2go Rolltabs (NZ);  Mylanta Rolltab (CO)"}, {"doc_id": "artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": -1.6776633283671964, "bm25_max": -1.6776633283671964, "bge_top3": null, "bge_max": null, "title": "Artesunate (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "- IV artesunate must be the preferred treatment: IV artesunate is at least as readily available as IV quinidine or the patient has experienced quinidine failure (eg, parasitemia >10% baseline after 48 hours of quinidine…"}, {"doc_id": "norfloxacin-united-states-not-available-drug-information", "bm25_top3": -1.6990535571845893, "bm25_max": -1.6990535571845893, "bge_top3": null, "bge_max": null, "title": "Norfloxacin (United States: not available): Drug information", "rep_snippet": "Brand Names: Canada  Apo-Norflox;  CO Norfloxacin;  PMS-Norfloxacin;  Teva-Norfloxacin"}, {"doc_id": "secnidazole-drug-information", "bm25_top3": -1.7498254107125835, "bm25_max": -1.7498254107125835, "bge_top3": null, "bge_max": null, "title": "Secnidazole: Drug information", "rep_snippet": "Brand Names: International  Ambese (VE);  Ambiform (IN);  Amitab (IN);  Bianos (CO, EC, PE);  Daksol (CO, VE);  Dazoserc (VN);  Deprozol (BR);  Dysen Forte (LK);  Ecuzol (EC);  Entosec (IN);  Etisec (IN);  Flagentyl (KR,…"}, {"doc_id": "clomipramine-drug-information", "bm25_top3": -1.76559383229956, "bm25_max": -1.76559383229956, "bge_top3": null, "bge_max": null, "title": "Clomipramine: Drug information", "rep_snippet": "Brand Names: Canada  Anafranil;  Apo-Clomipramine;  CO Clomipramine;  Dom-Clomipramine;  Novo-Clomipramine"}]}
{"qid": "Q9_abbr+mechanism", "query": "Atorvastatin + clarithromycin — risk (CYP3A4) and action: hold/switch/monitor?", "base_qid": "Q9", "variant_type": "abbr+mechanism", "candidates": [{"doc_id": "atorvastatin-drug-information", "bm25_top3": 23.025449387319206, "bm25_max": 25.515090903190462, "bge_top3": 0.6882678270339966, "bge_max": 0.6882678270339966, "title": "Atorvastatin: Drug information", "rep_snippet": "Clarithromycin: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patient…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 22.071680993161305, "bm25_max": 25.144873392463424, "bge_top3": 0.6955660879611969, "bge_max": 0.703734815120697, "title": "Clarithromycin: Drug information", "rep_snippet": "Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. Risk X: Avoid combination  Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. Risk X: A…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 21.95327996334562, "bm25_max": 24.843006201794708, "bge_top3": 0.7137796878814697, "bge_max": 0.7137796878814697, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, mo…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 22.055905238612578, "bm25_max": 24.843006201794708, "bge_top3": 0.7137796878814697, "bge_max": 0.7137796878814697, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, mo…"}, {"doc_id": "amlodipine-and-atorvastatin-drug-information", "bm25_top3": 22.939456931613265, "bm25_max": 24.41037287223895, "bge_top3": 0.6855242252349854, "bge_max": 0.6855242252349854, "title": "Amlodipine and atorvastatin: Drug information", "rep_snippet": "Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). Risk C: Monitor therapy  Telaprevir: May increase the serum concentration of AtorvaSTATin.…"}, {"doc_id": "lumacaftor-and-ivacaftor-drug-information", "bm25_top3": 21.019387751254552, "bm25_max": 21.019387751254552, "bge_top3": null, "bge_max": null, "title": "Lumacaftor and ivacaftor: Drug information", "rep_snippet": "Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. Risk X: Avoid combination  Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. Risk C…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": 20.431260270073164, "bm25_max": 20.431260270073164, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": 20.431260270073164, "bm25_max": 20.431260270073164, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information", "bm25_top3": 19.515662687421866, "bm25_max": 19.515662687421866, "bge_top3": null, "bge_max": null, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya): Drug information", "rep_snippet": "Clarithromycin: May increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin. Management: Consider alternative antibiotics. Reduce clarithromycin dose by 50% in pa…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": 19.41352979285977, "bm25_max": 19.515662687421866, "bge_top3": null, "bge_max": null, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "Clarithromycin: May increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin. Management: Consider alternative antibiotics. Reduce clarithromycin dose by 50% in pa…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": 19.311396898297676, "bm25_max": 19.311396898297676, "bge_top3": null, "bge_max": null, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "AtorvaSTATin: Cobicistat may increase the serum concentration of AtorvaSTATin. Management: Initiate atorvastatin at the lowest recommended dose and titrate slowly as needed while monitoring closely for evidence of atorva…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 10.850051544900673, "bm25_max": 10.850051544900673, "bge_top3": 0.6994361877441406, "bge_max": 0.6994361877441406, "title": "Telithromycin: Drug information", "rep_snippet": "Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. Risk X: Avoid combination  Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. Risk X: A…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": 10.146979024738954, "bm25_max": 10.146979024738954, "bge_top3": null, "bge_max": null, "title": "Apalutamide: Drug information", "rep_snippet": "Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. Risk X: Avoid combination  Celiprolol: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. Risk C:…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": 9.851499412933968, "bm25_max": 9.851499412933968, "bge_top3": null, "bge_max": null, "title": "Phenytoin: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "enzalutamide-drug-information", "bm25_top3": 9.84048294655448, "bm25_max": 9.84048294655448, "bge_top3": null, "bge_max": null, "title": "Enzalutamide: Drug information", "rep_snippet": "Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. Risk X: Avoid combination  Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. Risk X: Avoid c…"}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": 9.709235971077952, "bm25_max": 9.709235971077952, "bge_top3": null, "bge_max": null, "title": "Fosphenytoin: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "primidone-drug-information", "bm25_top3": 9.689079039112883, "bm25_max": 9.689079039112883, "bge_top3": null, "bge_max": null, "title": "Primidone: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "mitotane-drug-information", "bm25_top3": 9.66912721020704, "bm25_max": 9.66912721020704, "bge_top3": null, "bge_max": null, "title": "Mitotane: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": 9.646805099799877, "bm25_max": 9.646805099799877, "bge_top3": null, "bge_max": null, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin. Management: C…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": 9.431260270073164, "bm25_max": 9.431260270073164, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "fosamprenavir-drug-information", "bm25_top3": 9.351045345909206, "bm25_max": 9.351045345909206, "bge_top3": 0.6841983199119568, "bge_max": 0.6841983199119568, "title": "Fosamprenavir: Drug information", "rep_snippet": "Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. Risk C: Monitor therapy  Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. Risk X: Avoid…"}, {"doc_id": "nafcillin-drug-information", "bm25_top3": 9.328561099187738, "bm25_max": 9.328561099187738, "bge_top3": null, "bge_max": null, "title": "Nafcillin: Drug information", "rep_snippet": "Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. Risk X: Avoid combination  Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Risk X: Avoid combi…"}, {"doc_id": "bexarotene-systemic-drug-information", "bm25_top3": 9.136604398158724, "bm25_max": 9.136604398158724, "bge_top3": null, "bge_max": null, "title": "Bexarotene (systemic): Drug information", "rep_snippet": "Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. Risk C: Monitor therapy  Bosutinib: CYP3A4 Induce…"}, {"doc_id": "rifapentine-drug-information", "bm25_top3": 8.86544364482171, "bm25_max": 8.86544364482171, "bge_top3": null, "bge_max": null, "title": "Rifapentine: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin. Management: C…"}, {"doc_id": "letermovir-drug-information", "bm25_top3": 8.781551199640102, "bm25_max": 8.781551199640102, "bge_top3": null, "bge_max": null, "title": "Letermovir: Drug information", "rep_snippet": "ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be requi…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": 8.747461423844598, "bm25_max": 8.747461423844598, "bge_top3": null, "bge_max": null, "title": "Phenobarbital: Drug information", "rep_snippet": "Cholestyramine Resin: May decrease the serum concentration of PHENobarbital. Management: Administer phenobarbital at least 1 hour before or 4-6 hours after administration of cholestyramine in order to minimize the risk f…"}, {"doc_id": "modafinil-drug-information", "bm25_top3": 8.661902997702814, "bm25_max": 8.661902997702814, "bge_top3": null, "bge_max": null, "title": "Modafinil: Drug information", "rep_snippet": "Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy  Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. Risk X: Avo…"}, {"doc_id": "etravirine-drug-information", "bm25_top3": 8.479949823109823, "bm25_max": 8.479949823109823, "bge_top3": null, "bge_max": null, "title": "Etravirine: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin. Management: C…"}, {"doc_id": "nelfinavir-drug-information", "bm25_top3": 8.377203476408724, "bm25_max": 8.377203476408724, "bge_top3": 0.688843846321106, "bge_max": 0.688843846321106, "title": "Nelfinavir: Drug information", "rep_snippet": "Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may ne…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 8.34309310498572, "bm25_max": 8.34309310498572, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may ne…"}, {"doc_id": "elbasvir-and-grazoprevir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7047472596168518, "bge_max": 0.7080490589141846, "title": "Elbasvir and grazoprevir: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  ARIPiprazole:…"}, {"doc_id": "tolvaptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6967835426330566, "bge_max": 0.6967835426330566, "title": "Tolvaptan: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Angiotensin II Receptor Blockers: Tolvaptan may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Risk C: Monitor ther…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6954851150512695, "bge_max": 0.6954851150512695, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination  CycloSPORINE (Systemic): Erythromycin (Systemic) may increase the serum concentration of Cyclo…"}, {"doc_id": "palbociclib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6950241327285767, "bge_max": 0.6950241327285767, "title": "Palbociclib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  ARIPiprazole:…"}, {"doc_id": "aliskiren-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6895364224910736, "bge_max": 0.6926461458206177, "title": "Aliskiren and amlodipine: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "trandolapril-and-verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6915421187877655, "bge_max": 0.6926106810569763, "title": "Trandolapril and verapamil: Drug information", "rep_snippet": "Aprotinin: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole. M…"}, {"doc_id": "ergotamine-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6915305852890015, "bge_max": 0.6915305852890015, "title": "Ergotamine and caffeine: Drug information", "rep_snippet": "Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination  Crizotinib: May increase the serum concentration of Ergotamine. Risk X: Avoid combination  CYP…"}, {"doc_id": "amlodipine-and-olmesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6906358003616333, "bge_max": 0.6906358003616333, "title": "Amlodipine and olmesartan: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "felodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6899851560592651, "bge_max": 0.6899851560592651, "title": "Felodipine: Drug information", "rep_snippet": "Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination  CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum con…"}, {"doc_id": "amlodipine-and-benazepril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6898173093795776, "bge_max": 0.6898173093795776, "title": "Amlodipine and benazepril: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6898173093795776, "bge_max": 0.6898173093795776, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6896966099739075, "bge_max": 0.6896966099739075, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole. Man…"}, {"doc_id": "valbenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6881132125854492, "bge_max": 0.6881132125854492, "title": "Valbenazine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Bosentan: May…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6869805157184601, "bge_max": 0.6879056096076965, "title": "Erlotinib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Antacids: May decrease the serum concentration of Erlotinib. Management: Separate the administration of erlotinib and any antacid by seve…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6877768039703369, "bge_max": 0.6877768039703369, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "alprazolam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6877254843711853, "bge_max": 0.6877254843711853, "title": "Alprazolam: Drug information", "rep_snippet": "Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination  CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High ri…"}, {"doc_id": "axitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6873522996902466, "bge_max": 0.6873522996902466, "title": "Axitinib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Bisphosphonat…"}, {"doc_id": "idelalisib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6870851516723633, "bge_max": 0.6870851516723633, "title": "Idelalisib: Drug information", "rep_snippet": "Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib. Management: If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest…"}, {"doc_id": "macitentan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6867396831512451, "bge_max": 0.6867396831512451, "title": "Macitentan: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Bosentan: May…"}, {"doc_id": "ixabepilone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6867362856864929, "bge_max": 0.6867362856864929, "title": "Ixabepilone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  BCG (Intraves…"}, {"doc_id": "lovastatin-and-niacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6865155100822449, "bge_max": 0.6865155100822449, "title": "Lovastatin and niacin: Drug information", "rep_snippet": "CycloSPORINE (Systemic): May increase the serum concentration of Lovastatin. Risk X: Avoid combination  CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Ris…"}, {"doc_id": "armodafinil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6863158941268921, "bge_max": 0.6863158941268921, "title": "Armodafinil: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Risk X: Avoid combination  Alcohol (Ethyl): May diminish the therap…"}, {"doc_id": "irinotecan-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6859493255615234, "bge_max": 0.6859493255615234, "title": "Irinotecan (conventional): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  BCG (Intraves…"}, {"doc_id": "abemaciclib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6859493255615234, "bge_max": 0.6859493255615234, "title": "Abemaciclib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  BCG (Intraves…"}, {"doc_id": "vinblastine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6859493255615234, "bge_max": 0.6859493255615234, "title": "Vinblastine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  BCG (Intraves…"}, {"doc_id": "liposomal-vincristine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6859493255615234, "bge_max": 0.6859493255615234, "title": "Liposomal vincristine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  BCG (Intraves…"}, {"doc_id": "liposomal-irinotecan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6859493255615234, "bge_max": 0.6859493255615234, "title": "Liposomal irinotecan: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  BCG (Intraves…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6859026551246643, "bge_max": 0.6859026551246643, "title": "Verapamil: Drug information", "rep_snippet": "ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be requi…"}, {"doc_id": "niacin-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6856701374053955, "bge_max": 0.6856701374053955, "title": "Niacin and simvastatin: Drug information", "rep_snippet": "CycloSPORINE (Systemic): May increase the serum concentration of Simvastatin. Risk X: Avoid combination  CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Ri…"}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6850771903991699, "bge_max": 0.6850771903991699, "title": "Cabozantinib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Bisphosphonat…"}, {"doc_id": "atazanavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6849228143692017, "bge_max": 0.6849228143692017, "title": "Atazanavir: Drug information", "rep_snippet": "ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil. Management: Please refer to the full interaction monograph for details concerning…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6848883032798767, "bge_max": 0.6848883032798767, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. Risk X: Avoid combination  ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole. Man…"}, {"doc_id": "telaprevir-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6848849654197693, "bge_max": 0.6848849654197693, "title": "Telaprevir (United States: Not available): Drug information", "rep_snippet": "Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib. Management: If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest…"}, {"doc_id": "maraviroc-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6847423315048218, "bge_max": 0.6847423315048218, "title": "Maraviroc: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Bosentan: May…"}, {"doc_id": "amlodipine-valsartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6841868162155151, "bge_max": 0.6841868162155151, "title": "Amlodipine, valsartan, and hydrochlorothiazide: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.683983325958252, "bge_max": 0.683983325958252, "title": "Amlodipine: Drug information", "rep_snippet": "Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible. If used together, avoid doses of simvastatin greater than 20…"}, {"doc_id": "methylergonovine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6838751435279846, "bge_max": 0.6838751435279846, "title": "Methylergonovine: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}]}
{"qid": "Q9_brand", "query": "Lipitor + Biaxin co-rx — what’s the risk and what should we do?", "base_qid": "Q9", "variant_type": "brand", "candidates": [{"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 27.532319523099556, "bm25_max": 27.532319523099556, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-indacaterol-drug-information", "bm25_top3": 23.634890591428352, "bm25_max": 23.634890591428352, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and indacaterol: Drug information", "rep_snippet": "• Lactose: Some products may contain lactose; allergic reactions possible in patients with severe milk protein allergy. Use with caution in patients with severe hypersensitivity to milk proteins.  Other warnings:  • Appr…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 23.62917728653999, "bm25_max": 23.62917728653999, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 20.35495899340508, "bm25_max": 21.881565268158056, "bge_top3": null, "bge_max": null, "title": "Clarithromycin: Drug information", "rep_snippet": "Brand Names: US  Biaxin XL Pac [DSC];  Biaxin XL [DSC];  Biaxin [DSC]"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 21.363436119174022, "bm25_max": 21.363436119174022, "bge_top3": null, "bge_max": null, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Mechanism of Action  Combination of fluticasone (corticosteroid) and salmeterol (long-acting beta2-agonist) designed to improve pulmonary function and control over what is produced by either agent when used alone. Becaus…"}, {"doc_id": "chlorpromazine-drug-information", "bm25_top3": 18.820665182368757, "bm25_max": 18.820665182368757, "bge_top3": null, "bge_max": null, "title": "Chlorpromazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Chlorpromazine and its metabolites have been detected in breast milk; concentrations in the milk do not correlate with those in the mother and may be higher than what is in the maternal pla…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": 17.14089647536685, "bm25_max": 17.14089647536685, "bge_top3": null, "bge_max": null, "title": "Atorvastatin: Drug information", "rep_snippet": "Brand Names: US  Lipitor"}, {"doc_id": "triprolidine-pseudoephedrine-and-codeine-drug-information", "bm25_top3": 15.97837324315936, "bm25_max": 15.97837324315936, "bge_top3": null, "bge_max": null, "title": "Triprolidine, pseudoephedrine, and codeine: Drug information", "rep_snippet": "Hypersensitivity to triprolidine or other antihistamines of similar chemical structure, pseudoephedrine or other sympathomimetic amines, codeine or other opioids, or any component of the formulation (some formulations co…"}, {"doc_id": "ceftazidime-and-avibactam-drug-information", "bm25_top3": 15.558594542369278, "bm25_max": 15.558594542369278, "bge_top3": null, "bge_max": null, "title": "Ceftazidime and avibactam: Drug information", "rep_snippet": "Disease-related concerns:  • Renal impairment: In a complicated intra-abdominal infection clinical trial, patients with a creatinine clearance (CrCl) of 30 to 50 mL/minute had lower clinical cure rates than those with Cr…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 14.947289886861707, "bm25_max": 14.947289886861707, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Panzyga [Canadian product]: IV: 1,000 mg/kg/day for 2 consecutive days; may repeat treatment in patients who relapse  American College of Obstetricians and Gynecologists Guidelines: IV: Initial: 1,000 mg/kg as a one-time…"}, {"doc_id": "naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-drug-information", "bm25_top3": 14.754524382679378, "bm25_max": 14.754524382679378, "bge_top3": null, "bge_max": null, "title": "Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Drug information", "rep_snippet": "Dosing: Adult  Decrease in eye redness (vasoconstrictor): Ophthalmic:  Rx: 0.1% solution: 1 to 2 drops into conjunctival sac every 3 to 4 hours as needed  OTC: 0.012% or 0.03% solution: 1 to 2 drops into affected eye(s)…"}, {"doc_id": "dorzolamide-and-timolol-drug-information", "bm25_top3": 14.252812556927017, "bm25_max": 14.252812556927017, "bge_top3": null, "bge_max": null, "title": "Dorzolamide and timolol: Drug information", "rep_snippet": "Brand Names: International  Anhigot (MX);  Azopt (BD);  Besser (MX);  Citol Dorzotim (PY);  Co-Dorzal (LK);  Cosopt (AE, AR, AT, AU, BB, BE, BH, BM, BR, BS, BZ, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, ES, FI, FR, GR, GT,…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": 14.250544023758977, "bm25_max": 14.250544023758977, "bge_top3": null, "bge_max": null, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  ZyrTEC may be confused with Lipitor, Serax, Xanax, Zantac, Zocor, Zyprexa, Zyrtec-D  ZyrTEC-D may be confused with ZyrTEC"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": 14.133449609425206, "bm25_max": 14.133449609425206, "bge_top3": null, "bge_max": null, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Brand Names: International  Actimibe Plus (PY);  Adacai (CR, DO, GT, HN, NI, PA, SV);  Beartorin (KR);  Colmibe (EC);  Duolip (CO);  Inegy (AE, AT, BE, BH, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, IE, IL, IT, JO,…"}, {"doc_id": "sulfacetamide-and-prednisolone-drug-information", "bm25_top3": 13.970384697168136, "bm25_max": 13.970384697168136, "bge_top3": null, "bge_max": null, "title": "Sulfacetamide and prednisolone: Drug information", "rep_snippet": "Brand Names: International  Blefamide (CO, CR, DO, GT, HN, NI, PA, SV);  Blefamide SF (EC, MX);  Blefamide SOP (CO, MX);  Blephamide (AT, AU, BG, BH, CH, DE, EG, KW, LB, QA, SA, TW);  Deltamid Ofteno (GT, HN, NI, PA);  M…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 11.771965177711643, "bm25_max": 11.771965177711643, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 10.167020027807608, "bm25_max": 10.287057017772113, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "• Patient education: [US Boxed Warning]: When used for the termination of pregnancy, patient must be instructed of the treatment procedure and expected effects. A signed agreement form must be kept in the patient's file.…"}, {"doc_id": "betaxolol-systemic-drug-information", "bm25_top3": 9.692029678388632, "bm25_max": 9.692029678388632, "bge_top3": null, "bge_max": null, "title": "Betaxolol (systemic): Drug information", "rep_snippet": "The maternal half-life and serum concentration of betaxolol immediately postpartum are not significantly different than what is observed in nonpregnant women (Boutroy 1990; Morselli 1990). Untreated chronic maternal hype…"}, {"doc_id": "levalbuterol-drug-information", "bm25_top3": 9.042413524892797, "bm25_max": 9.042413524892797, "bge_top3": null, "bge_max": null, "title": "Levalbuterol: Drug information", "rep_snippet": "Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": 8.45023286122678, "bm25_max": 8.45023286122678, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": 7.958661750858159, "bm25_max": 7.958661750858159, "bge_top3": null, "bge_max": null, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "Pregnancy Implications  Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthm…"}, {"doc_id": "montelukast-drug-information", "bm25_top3": 7.880147324246774, "bm25_max": 7.880147324246774, "bge_top3": null, "bge_max": null, "title": "Montelukast: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Birth defects have been reported (rarely) following maternal use; however, a causal relationship with montelukast has not been…"}, {"doc_id": "penbutolol-drug-information", "bm25_top3": 7.789009948223878, "bm25_max": 7.789009948223878, "bge_top3": null, "bge_max": null, "title": "Penbutolol: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Levatol may be confused with Lipitor  International issues:  Levatol [U.S.] may be confused with Lovacol brand name for lovastatin [Chile and Finland]"}, {"doc_id": "olodaterol-drug-information", "bm25_top3": 7.680617850318107, "bm25_max": 7.680617850318107, "bge_top3": null, "bge_max": null, "title": "Olodaterol: Drug information", "rep_snippet": "• Bronchospasm: Rarely, paradoxical, life-threatening bronchospasm may occur with use of inhaled beta2-agonists; distinguish from inadequate response, discontinue medication immediately, institute alternative therapy.  •…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 7.31636992279611, "bm25_max": 7.31636992279611, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased…"}, {"doc_id": "asfotase-alfa-drug-information", "bm25_top3": 7.2026198855549985, "bm25_max": 7.2026198855549985, "bge_top3": null, "bge_max": null, "title": "Asfotase alfa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Asfotase alfa: Pediatric drug information\")  Hypophosphatasia (HPP): SubQ: Note: Round patient weight to the nearest kg when determining dose. Do not administer the 80…"}, {"doc_id": "hydrocortisone-systemic-drug-information", "bm25_top3": 7.135719347588523, "bm25_max": 7.135719347588523, "bge_top3": null, "bge_max": null, "title": "Hydrocortisone (systemic): Drug information", "rep_snippet": "Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": 6.903451356039827, "bm25_max": 6.903451356039827, "bge_top3": null, "bge_max": null, "title": "Paroxetine: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.  • Seizure disorder: Use with caution in patients with…"}, {"doc_id": "testosterone-drug-information", "bm25_top3": 6.899799504388291, "bm25_max": 6.899799504388291, "bge_top3": null, "bge_max": null, "title": "Testosterone: Drug information", "rep_snippet": "Dosage Forms Considerations  EC-RX Testosterone, First-Testosterone MC cream, and First-Testosterone ointment are compounding kits. Refer to manufacturer’s labeling for compounding instructions."}, {"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 6.6295750892596494, "bm25_max": 6.6295750892596494, "bge_top3": null, "bge_max": null, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "Pregnancy Implications  Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy (Battista 2016). Uncontrolled asthma is associated with adverse events on pregnancy (increased…"}, {"doc_id": "fingolimod-drug-information", "bm25_top3": 6.293184012537235, "bm25_max": 6.293184012537235, "bge_top3": null, "bge_max": null, "title": "Fingolimod: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 5.45493735765874, "bm25_max": 5.891040985144363, "bge_top3": null, "bge_max": null, "title": "Esomeprazole: Drug information", "rep_snippet": "Gastroesophageal reflux disease (Rx only): Short-term (≤10 days) treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis in pediatric patients 1 month to 17 years of age and adults when oral therapy…"}, {"doc_id": "etonogestrel-implant-drug-information", "bm25_top3": 5.449298587853134, "bm25_max": 5.449298587853134, "bge_top3": null, "bge_max": null, "title": "Etonogestrel implant: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Breast cancer: Breast cancer is a hormonal sensitive tumor and the prognosis for women with current or a recent history of breast cancer may be worse with pro…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": 4.927107910199709, "bm25_max": 4.927107910199709, "bge_top3": null, "bge_max": null, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported fo…"}, {"doc_id": "cetirizine-systemic-drug-information", "bm25_top3": 4.9141495006529095, "bm25_max": 4.9141495006529095, "bge_top3": null, "bge_max": null, "title": "Cetirizine (systemic): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Cetirizine may be confused with sertraline, stavudine  ZyrTEC may be confused with Lipitor, Serax, Xanax, Zantac, Zerit, Zocor, ZyPREXA, ZyrTEC-D  ZyrTEC (cetiriz…"}, {"doc_id": "gemfibrozil-drug-information", "bm25_top3": 4.543224850593623, "bm25_max": 4.543224850593623, "bge_top3": null, "bge_max": null, "title": "Gemfibrozil: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Lopid may be confused with Levbid, Lipitor, Lodine"}, {"doc_id": "bicalutamide-drug-information", "bm25_top3": 4.27026663736687, "bm25_max": 4.27026663736687, "bge_top3": null, "bge_max": null, "title": "Bicalutamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Gynecomastia: May cause gynecomastia or breast pain at higher (off-label) doses.  • Hematologic: Anemia may occur with testosterone suppression; monitor CBC p…"}, {"doc_id": "practice-changing-updates", "bm25_top3": 4.250852826372977, "bm25_max": 4.250852826372977, "bge_top3": null, "bge_max": null, "title": "practice-changing-updates", "rep_snippet": "INTRODUCTION — This section highlights selected specific new recommendations and/or updates that we anticipate may change usual clinical practice. Practice Changing UpDates focus on changes that may have significant and…"}, {"doc_id": "colchicine-drug-information", "bm25_top3": 3.908878441754542, "bm25_max": 3.908878441754542, "bge_top3": null, "bge_max": null, "title": "Colchicine: Drug information", "rep_snippet": "Dosing: Adult  Familial Mediterranean fever (FMF): Oral: Tablet (eg, Colcrys): 1.2 to 2.4 mg daily in 1 to 2 divided doses. Titration: Increase or decrease dose in 0.3 mg daily increments based on efficacy or adverse eff…"}, {"doc_id": "fluticasone-nasal-drug-information", "bm25_top3": 3.5718741765633144, "bm25_max": 3.7092875841207142, "bge_top3": null, "bge_max": null, "title": "Fluticasone (nasal): Drug information", "rep_snippet": "Dosing: Adult  Allergic rhinitis (fluticasone furoate): Intranasal:  Veramyst (Rx): Initial: Two sprays (27.5 mcg/spray) per nostril once daily (110 mcg/day); once symptoms are controlled, may reduce dosage to 1 spray pe…"}, {"doc_id": "lovastatin-drug-information", "bm25_top3": 3.6719423046656026, "bm25_max": 3.6719423046656026, "bge_top3": null, "bge_max": null, "title": "Lovastatin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Lovastatin may be confused with atorvaSTATin, Leustatin, Livostin, Lotensin, nystatin, pitavastatin  Mevacor may be confused with Benicar, Lipitor  International…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": 3.600925781936631, "bm25_max": 3.600925781936631, "bge_top3": null, "bge_max": null, "title": "Naproxen: Drug information", "rep_snippet": "Use  Acute gout, Ankylosing spondylitis, Bursitis, Polyarticular juvenile idiopathic arthritis, Osteoarthritis, Rheumatoid arthritis, Tendonitis (Rx products only): Relief of the signs and symptoms of acute gout, ankylos…"}, {"doc_id": "phenylephrine-systemic-drug-information", "bm25_top3": 3.3693535938455366, "bm25_max": 3.3693535938455366, "bge_top3": null, "bge_max": null, "title": "Phenylephrine (systemic): Drug information", "rep_snippet": "Brand Names: International  AK-Dilate (PE);  Albalon Relief (AU, NZ);  Davinefrina (PT);  Denason (BR);  Drosyn (IN);  Efrin-10 (IL);  Ethifrin (PK);  Fadalefrina (AR, UY);  Fenilefrina (BR);  Fenylefrinhydroklorid (NO);…"}, {"doc_id": "deflazacort-drug-information", "bm25_top3": 3.2098167885538054, "bm25_max": 3.2098167885538054, "bge_top3": null, "bge_max": null, "title": "Deflazacort: Drug information", "rep_snippet": "Brand Names: International  Aflazacort (PE);  Alcoza (IN);  Alnacort (IN);  Arocort (IN);  Arrumal (CL);  Asfor (PT);  Asodef (IN);  Avantium (CO);  Azacortid (AR, AU, CL, PY, UY);  Calcorrt (EC);  Calcort (BR, BS, CH, C…"}, {"doc_id": "protein-c-concentrate-from-human-plasma-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6492694616317749, "bge_max": 0.6492694616317749, "title": "Protein C, concentrate from human plasma: Drug information", "rep_snippet": "Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding. Risk X: Avoid combination"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6328786611557007, "bge_max": 0.6328786611557007, "title": "Nilotinib: Drug information", "rep_snippet": "Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Risk X: Avoid combination  Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. Risk X: Avoid combination  Pit…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6220912337303162, "bge_max": 0.6302372217178345, "title": "Fluoxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Lithium: May enhance the serotonergic effect of Selective Ser…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6288171410560608, "bge_max": 0.6288171410560608, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Lithium: May enhance the serotonergic effect of Selective Ser…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6173610687255859, "bge_max": 0.6241052150726318, "title": "Procarbazine: Drug information", "rep_snippet": "Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be a…"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6221847534179688, "bge_max": 0.6221847534179688, "title": "Vemurafenib: Drug information", "rep_snippet": "Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.620229184627533, "bge_max": 0.620229184627533, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor thera…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6200395226478577, "bge_max": 0.6200395226478577, "title": "Citalopram: Drug information", "rep_snippet": "Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide. Risk X: Avoid combination  Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducer…"}, {"doc_id": "rituximab-intravenous-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6182875633239746, "bge_max": 0.6182875633239746, "title": "Rituximab (intravenous): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: RiTUXimab may enhance the adverse/toxic effect of Abatacept. Risk X: Avoid combination  BCG (Intravesical): Immunosuppressants…"}, {"doc_id": "belimumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6177687644958496, "bge_max": 0.6177687644958496, "title": "Belimumab: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: May enhance the adverse/toxic effect of Belimumab. Risk X: Avoid combination  BCG (Intravesical): Immunosuppressants may dimin…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6175954341888428, "bge_max": 0.6175954341888428, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. Risk X: Avoid combination  RifAMPin: Pyrazinamide may enhance the hepatotoxic effect of RifAMPin. Severe (even fatal) liver injury…"}, {"doc_id": "ergoloid-mesylates-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6173176765441895, "bge_max": 0.6173176765441895, "title": "Ergoloid mesylates: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor thera…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6167430877685547, "bge_max": 0.6167430877685547, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "Insulins: Pioglitazone may enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combi…"}, {"doc_id": "ergotamine-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6165064573287964, "bge_max": 0.6165064573287964, "title": "Ergotamine and caffeine: Drug information", "rep_snippet": "Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination  Crizotinib: May increase the serum concentration of Ergotamine. Risk X: Avoid combination  CYP…"}, {"doc_id": "cyclophosphamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6164534091949463, "bge_max": 0.6164534091949463, "title": "Cyclophosphamide: Drug information", "rep_snippet": "Lipegfilgrastim: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be increased. Cyclophosphamide may diminish the therapeutic effect of Lipegfilgrastim. Managemen…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6148664951324463, "bge_max": 0.6148664951324463, "title": "Ergotamine: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor thera…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6142721176147461, "bge_max": 0.6142721176147461, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Pindolol: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Pindolol. Management: Canadian labeling for pindolol states that concurrent use with a monoamine oxidase inhibitor is not recommended. Risk D:…"}, {"doc_id": "pimozide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6093926429748535, "bge_max": 0.6093926429748535, "title": "Pimozide: Drug information", "rep_snippet": "Protease Inhibitors: May increase the serum concentration of Pimozide. Risk X: Avoid combination  QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).…"}, {"doc_id": "tedizolid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6092501878738403, "bge_max": 0.6092501878738403, "title": "Tedizolid: Drug information", "rep_snippet": "Pholcodine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Pindolol: Monoamine Oxidase Inhibitors may enhance the hypotensive effe…"}, {"doc_id": "ruxolitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6088290214538574, "bge_max": 0.6088290214538574, "title": "Ruxolitinib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  BCG (Intraves…"}, {"doc_id": "osimertinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6077141761779785, "bge_max": 0.6077141761779785, "title": "Osimertinib: Drug information", "rep_snippet": "Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Risk D: Consider therapy modification  Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Risk C: Monitor therapy…"}, {"doc_id": "hyoscyamine-methenamine-methylene-blue-and-sodium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6075419187545776, "bge_max": 0.6075419187545776, "title": "Hyoscyamine, methenamine, methylene blue, and sodium phosphate: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Deutetrabenazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. Risk X: Avoid…"}, {"doc_id": "methenamine-phenyl-salicylate-methylene-blue-benzoic-acid-and-hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6075419187545776, "bge_max": 0.6075419187545776, "title": "Methenamine, phenyl salicylate, methylene blue, benzoic acid, and hyoscyamine: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Deutetrabenazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. Risk X: Avoid…"}, {"doc_id": "methenamine-sodium-biphosphate-phenyl-salicylate-methylene-blue-and-hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6075419187545776, "bge_max": 0.6075419187545776, "title": "Methenamine, sodium biphosphate, phenyl salicylate, methylene blue, and hyoscyamine: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Deutetrabenazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. Risk X: Avoid…"}, {"doc_id": "rasagiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6058675944805145, "bge_max": 0.6073916554450989, "title": "Rasagiline: Drug information", "rep_snippet": "CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Rasagiline. Risk D: Consider therapy modification  Cyproheptadine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Cyproheptadi…"}, {"doc_id": "isotretinoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6070468425750732, "bge_max": 0.6070468425750732, "title": "Isotretinoin: Drug information", "rep_snippet": "Vitamin A: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. Risk X: Avoid combination"}, {"doc_id": "belatacept-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6064396500587463, "bge_max": 0.6064396500587463, "title": "Belatacept: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Antithymocyte Globulin (Equine): May enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the…"}, {"doc_id": "ribociclib-and-letrozole-co-packaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.605844259262085, "bge_max": 0.605844259262085, "title": "Ribociclib and letrozole (co-packaged): Drug information", "rep_snippet": "Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk…"}, {"doc_id": "tofacitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6057249307632446, "bge_max": 0.6057249307632446, "title": "Tofacitinib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abatacept: May enhance the adverse/toxic effect of Tofacitinib. Risk X: Avoid combination  Anakinra: May enhance the adverse/toxic effect…"}, {"doc_id": "inotuzumab-ozogamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6055740118026733, "bge_max": 0.6055740118026733, "title": "Inotuzumab ozogamicin: Drug information", "rep_snippet": "Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Risk X: Avoid combination  Nivolumab: Immunosuppressants may diminish…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.60556960105896, "bge_max": 0.60556960105896, "title": "Rivaroxaban: Drug information", "rep_snippet": "Cobicistat: May increase the serum concentration of Rivaroxaban. Risk X: Avoid combination  Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6042889356613159, "bge_max": 0.6042889356613159, "title": "Ritonavir: Drug information", "rep_snippet": "Disulfiram: Ritonavir may enhance the adverse/toxic effect of Disulfiram. Specifically, the combination of ritonavir oral solution, which contains 43% alcohol, may result in a disulfiram-alcohol reaction if combined. Ris…"}, {"doc_id": "domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6039046049118042, "bge_max": 0.6042073369026184, "title": "Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Bilastine: May e…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6038407683372498, "bge_max": 0.6038407683372498, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Levomilnacipran: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran. Management: Do not exceed a maximum adult levomilnacipran dose of 80 mg/day in patients also receiving strong CYP3A4 in…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6037565469741821, "bge_max": 0.6037565469741821, "title": "Furosemide: Drug information", "rep_snippet": "Bilastine: Loop Diuretics may enhance the QTc-prolonging effect of Bilastine. Risk C: Monitor therapy  Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics. Risk D: Consider therapy modification  Brigati…"}, {"doc_id": "rifaximin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6036058664321899, "bge_max": 0.6036058664321899, "title": "Rifaximin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG Vaccine (Immuni…"}, {"doc_id": "raltitrexed-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6035897731781006, "bge_max": 0.6035897731781006, "title": "Raltitrexed (United States: Not available): Drug information", "rep_snippet": "Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Raltitrexed. Risk X: Avoid combination  Levomefolate: May diminish the therapeutic effect of Raltitrexed. Risk X: Avoid combination  Lipegfilgrast…"}, {"doc_id": "tranylcypromine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6027593016624451, "bge_max": 0.602820873260498, "title": "Tranylcypromine: Drug information", "rep_snippet": "Pindolol: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Pindolol. Management: Canadian labeling for pindolol states that concurrent use with a monoamine oxidase inhibitor is not recommended. Risk D:…"}, {"doc_id": "isocarboxazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6027593016624451, "bge_max": 0.602820873260498, "title": "Isocarboxazid: Drug information", "rep_snippet": "Pindolol: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Pindolol. Management: Canadian labeling for pindolol states that concurrent use with a monoamine oxidase inhibitor is not recommended. Risk D:…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6027593016624451, "bge_max": 0.602820873260498, "title": "Phenelzine: Drug information", "rep_snippet": "Pindolol: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Pindolol. Management: Canadian labeling for pindolol states that concurrent use with a monoamine oxidase inhibitor is not recommended. Risk D:…"}, {"doc_id": "dronedarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6027728319168091, "bge_max": 0.6027728319168091, "title": "Dronedarone: Drug information", "rep_snippet": "Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. Risk C: Monitor therapy  Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. Risk X: Avoid comb…"}, {"doc_id": "vandetanib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6026742458343506, "bge_max": 0.6026742458343506, "title": "Vandetanib: Drug information", "rep_snippet": "Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk C: Mo…"}, {"doc_id": "pimavanserin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6023996472358704, "bge_max": 0.6023996472358704, "title": "Pimavanserin: Drug information", "rep_snippet": "Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination  Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agent…"}]}
{"qid": "Q9_noise", "query": "Patient on atorva now needs clarithro — proceed? adjust? monitor CK/LFTs?", "base_qid": "Q9", "variant_type": "noise", "candidates": [{"doc_id": "esomeprazole-drug-information", "bm25_top3": 21.07632475471356, "bm25_max": 21.07632475471356, "bge_top3": null, "bge_max": null, "title": "Esomeprazole: Drug information", "rep_snippet": "Pathological hypersecretory conditions (Zollinger-Ellison syndrome): Oral: Esomeprazole magnesium, esomeprazole strontium: 40 mg twice daily; adjust regimen to individual patient needs; doses up to 240 mg daily have been…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": 20.249221641458377, "bm25_max": 20.249221641458377, "bge_top3": null, "bge_max": null, "title": "Atorvastatin: Drug information", "rep_snippet": "High-intensity therapy (≥50% reduction of LDL-C generally): 40 to 80 mg once daily  Cardiac risk reduction for non-cardiac surgery (off-label use): Oral: 20 mg once daily for 45 days; surgical intervention (vascular surg…"}, {"doc_id": "metolazone-drug-information", "bm25_top3": 18.44318864431906, "bm25_max": 18.44318864431906, "bge_top3": null, "bge_max": null, "title": "Metolazone: Drug information", "rep_snippet": "Dosing: Adult  Edema (renal disease): Oral: Initial: 5-20 mg once daily.  Edema (heart failure) (off-label dose): Oral: Initial: 2.5 mg once daily; maximum daily dose: 20 mg (ACCF/AHA [Yancy, 2013]); Note: Dosing frequen…"}, {"doc_id": "sonidegib-drug-information", "bm25_top3": 7.845399289794037, "bm25_max": 16.32201176694242, "bge_top3": null, "bge_max": null, "title": "Sonidegib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Withhold treatment for any of the following (may resume at 200 mg daily upon resolution of toxicity):  Creatine kinase (CK) serum elevation between 2.5 and 10 times ULN (first occurrence)…"}, {"doc_id": "sodium-chloride-preparations-saline-and-oral-salt-tablets-drug-information", "bm25_top3": 16.3033922179693, "bm25_max": 16.3033922179693, "bge_top3": null, "bge_max": null, "title": "Sodium chloride preparations (saline and oral salt tablets): Drug information", "rep_snippet": "Hyponatremic encephalopathy (off-label dose): IV: Hypertonic saline: Initial: 100 mL bolus of NaCl 3% over 10 minutes; if signs/symptoms persist, may repeat until clinical response achieved (serum sodium should not be co…"}, {"doc_id": "trimethobenzamide-drug-information", "bm25_top3": 14.49460968884818, "bm25_max": 14.665371382226802, "bge_top3": null, "bge_max": null, "title": "Trimethobenzamide: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing; increase the dosing interval and adjust as needed based on patient response."}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 14.629123961546846, "bm25_max": 14.629123961546846, "bge_top3": null, "bge_max": null, "title": "Pantoprazole: Drug information", "rep_snippet": "Dosing: Adult  Erosive esophagitis associated with GERD:  Oral:  Treatment: 40 mg once daily for up to 8 weeks; an additional 8 weeks may be used in patients who have not healed after an 8-week course. Lower doses (20 mg…"}, {"doc_id": "conjugated-equine-estrogens-topical-drug-information", "bm25_top3": 14.56627397076284, "bm25_max": 14.56627397076284, "bge_top3": null, "bge_max": null, "title": "Conjugated equine estrogens (topical): Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: When treating postmenopausal women, use estrogens for the shortest duration possible at the lowest effective dose consistent with treatment goals. Reevaluate patients as clinical…"}, {"doc_id": "conjugated-equine-estrogens-systemic-drug-information", "bm25_top3": 13.396763873557315, "bm25_max": 14.181417568640025, "bge_top3": null, "bge_max": null, "title": "Conjugated equine estrogens (systemic): Drug information", "rep_snippet": "Hypoestrogenism (female) due to hypogonadism: Oral: 0.3 or 0.625 mg/day given cyclically*; dose may be titrated in 6- to 12-month intervals; progestin treatment should be added to maintain bone mineral density once skele…"}, {"doc_id": "insulin-degludec-drug-information", "bm25_top3": 13.438300610087772, "bm25_max": 13.438300610087772, "bge_top3": null, "bge_max": null, "title": "Insulin degludec: Drug information", "rep_snippet": "Dosage adjustment: Individualize and titrate dose every 3 to 4 days based on patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal.  Missed dose: Decision to administer or withhold dose u…"}, {"doc_id": "ruxolitinib-drug-information", "bm25_top3": 13.365151455622325, "bm25_max": 13.365151455622325, "bge_top3": null, "bge_max": null, "title": "Ruxolitinib: Drug information", "rep_snippet": "Note: Avoid concomitant use with fluconazole doses >200 mg daily.  Myelofibrosis: Initial dose:  Platelets ≥100,000/mm3: 10 mg twice daily.  Platelets 50,000/mm3 to < 100,000/mm3: 5 mg once daily.  Monitor closely and fu…"}, {"doc_id": "potassium-citrate-and-citric-acid-powder-or-solution-drug-information", "bm25_top3": 13.225776006964045, "bm25_max": 13.225776006964045, "bge_top3": null, "bge_max": null, "title": "Potassium citrate and citric acid (powder or solution): Drug information", "rep_snippet": "Dosing: Adult  Systemic alkalinizer, Acidosis, Gout (adjuvant): Oral:  Powder: One packet dissolved in water 4 times daily; adjust dose to urinary pH  Solution: 10 to 30 mL 4 times daily; adjust dose based on urinary pH"}, {"doc_id": "fenoprofen-drug-information", "bm25_top3": 13.176092097257381, "bm25_max": 13.176092097257381, "bge_top3": null, "bge_max": null, "title": "Fenoprofen: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest possible duration.  Osteoarthritis, rheumatoid arthritis: Oral: 400 to 600 mg 3 to 4 times daily; adjust dose based on patient response; maximum dose: 3…"}, {"doc_id": "tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information", "bm25_top3": 13.154996141689299, "bm25_max": 13.154996141689299, "bge_top3": null, "bge_max": null, "title": "Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information", "rep_snippet": "Dosing: Adult  Plasma volume expansion: IV infusion: May administer up to 50 mL/kg/day (or up to 3500 mL per day in a 70 kg patient); may administer repetitively over several days. Note: With severe dehydration, administ…"}, {"doc_id": "insulin-glargine-drug-information", "bm25_top3": 10.02240858277327, "bm25_max": 13.135965959342059, "bge_top3": null, "bge_max": null, "title": "Insulin glargine: Drug information", "rep_snippet": "Dosage adjustment: Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage…"}, {"doc_id": "obinutuzumab-drug-information", "bm25_top3": 13.12153325228808, "bm25_max": 13.12153325228808, "bge_top3": null, "bge_max": null, "title": "Obinutuzumab: Drug information", "rep_snippet": "Dosing: Adult  Note: Premedication with acetaminophen, an antihistamine, and a glucocorticoid (dexamethasone or methylprednisolone) 30 to 60 minutes prior to treatment may be necessary (see Administration). Antihyperuric…"}, {"doc_id": "nabumetone-drug-information", "bm25_top3": 13.097297527964566, "bm25_max": 13.097297527964566, "bge_top3": null, "bge_max": null, "title": "Nabumetone: Drug information", "rep_snippet": "Dosing: Adult  Arthritis: Oral: Initial: 1,000 mg as a single dose; adjust dose based on patient response up to 2,000 mg/day in 1 to 2 divided doses; doses >2,000 mg/day have not been studied.  Note: Patients <50 kg are…"}, {"doc_id": "lomitapide-drug-information", "bm25_top3": 12.614747371081704, "bm25_max": 12.614747371081704, "bge_top3": null, "bge_max": null, "title": "Lomitapide: Drug information", "rep_snippet": "AST or ALT ≥ 5 times ULN: Withhold doses, obtain additional LFTs (eg, alkaline phosphatase, total bilirubin, and INR); investigate for probable cause. If resuming after transaminase resolution to <3 times ULN, reduce dos…"}, {"doc_id": "inhaled-insulin-drug-information", "bm25_top3": 12.585554640890832, "bm25_max": 12.585554640890832, "bge_top3": null, "bge_max": null, "title": "Inhaled insulin: Drug information", "rep_snippet": "≤4 units injected dose per meal: 4 units inhalation dose per meal  5 to 8 units injected dose per meal: 8 units inhalation dose per meal  9 to 12 units injected dose per meal: 12 units inhalation dose per meal  13 to 16…"}, {"doc_id": "protein-c-concentrate-from-human-plasma-drug-information", "bm25_top3": 12.278323254167907, "bm25_max": 12.278323254167907, "bge_top3": null, "bge_max": null, "title": "Protein C, concentrate from human plasma: Drug information", "rep_snippet": "Dosing: Adult  Patient variables (including age, clinical condition, severity of protein C deficiency, and plasma levels of protein C) will influence dosing and duration of therapy. Individualize frequency, duration, and…"}, {"doc_id": "bivalirudin-drug-information", "bm25_top3": 11.994235725467668, "bm25_max": 11.994235725467668, "bge_top3": null, "bge_max": null, "title": "Bivalirudin: Drug information", "rep_snippet": "Dosing: Adult  Cardiac surgery in patients with acute or subacute heparin-induced thrombocytopenia, urgent surgery required (off-label use) (Linkins 2012): IV: Intraoperative:  Off-pump: Initial bolus: 0.75 mg/kg, follow…"}, {"doc_id": "ziconotide-drug-information", "bm25_top3": 11.788802796287479, "bm25_max": 11.788802796287479, "bge_top3": null, "bge_max": null, "title": "Ziconotide: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Cognitive impairment: Reduce dose or discontinue. Effects are generally reversible within 3-15 days of discontinuation.  Reduced level of consciousness: Discontinue until event resolves.…"}, {"doc_id": "metoprolol-drug-information", "bm25_top3": 11.694564774492848, "bm25_max": 11.694564774492848, "bge_top3": null, "bge_max": null, "title": "Metoprolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Metoprolol: Pediatric drug information\")  Hypertension: Oral:  Immediate-release tablet (metoprolol tartrate): Children ≥1 year and Adolescents ≤17 years (off-label pop…"}, {"doc_id": "bromazepam-united-states-not-available-drug-information", "bm25_top3": 10.410604773180664, "bm25_max": 10.410604773180664, "bge_top3": null, "bge_max": null, "title": "Bromazepam (United States: Not available): Drug information", "rep_snippet": "Dosing: Geriatric  Anxiety: Oral: Initial dose: 3 mg/day in divided doses; may adjust dose cautiously based on response and tolerance"}, {"doc_id": "filgrastim-including-biosimilars-of-filgrastim-drug-information", "bm25_top3": 10.078532802426459, "bm25_max": 10.078532802426459, "bge_top3": null, "bge_max": null, "title": "Filgrastim (including biosimilars of filgrastim): Drug information", "rep_snippet": "Congenital: Initial: 6 mcg/kg/day in 2 divided doses; adjust the dose based on ANC and clinical response; mean dose: 6 mcg/kg/day.  Idiopathic: Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical resp…"}, {"doc_id": "fat-emulsion-drug-information", "bm25_top3": 9.712119507597505, "bm25_max": 9.712119507597505, "bge_top3": null, "bge_max": null, "title": "Fat emulsion: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fat emulsion: Pediatric drug information\")  Note: At the onset of therapy, the patient should be observed for any immediate allergic reactions (eg, dyspnea, cyanosis, a…"}, {"doc_id": "clotrimazole-oral-drug-information", "bm25_top3": 3.5050337434589434, "bm25_max": 3.5050337434589434, "bge_top3": null, "bge_max": null, "title": "Clotrimazole (oral): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hepatic effects: Abnormal LFTs have been reported, including abnormal aspartate aminotransferase (AST). Elevations are usually minimal. Monitor LFTs periodica…"}, {"doc_id": "ezetimibe-drug-information", "bm25_top3": 1.55771951071236, "bm25_max": 1.55771951071236, "bge_top3": 0.6103217005729675, "bge_max": 0.6103217005729675, "title": "Ezetimibe: Drug information", "rep_snippet": "Monitoring Parameters  Total cholesterol profile prior to therapy, and when clinically indicated and/or periodically thereafter. When used in combination with fenofibrate, monitor LFTs and signs and symptoms of cholelith…"}, {"doc_id": "sotalol-drug-information", "bm25_top3": 0.949081600431704, "bm25_max": 0.949081600431704, "bge_top3": null, "bge_max": null, "title": "Sotalol: Drug information", "rep_snippet": "• Proarrhythmic effects: [US Boxed Warning]: Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation (ie, torsades de pointes). Do not initiate if baseline QTc interval is >450…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5959824919700623, "bge_max": 0.6066296696662903, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "bismuth-subcitrate-metronidazole-and-tetracycline-drug-information", "bm25_top3": 0.6057645539611087, "bm25_max": 0.6057645539611087, "bge_top3": null, "bge_max": null, "title": "Bismuth subcitrate, metronidazole, and tetracycline: Drug information", "rep_snippet": "Disease-related concerns:  • Blood dyscrasias: Use metronidazole with caution in patients with or history of blood dyscrasias; mild leukopenia has occurred. Monitor CBC with differential at baseline and after treatment.…"}, {"doc_id": "sirolimus-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5927123427391052, "bge_max": 0.5927123427391052, "title": "Sirolimus: Drug information", "rep_snippet": "Monitor LFTs and CBC during treatment. Monitor sirolimus levels in all patients (especially in pediatric patients, patients ≥13 years of age weighing <40 kg, patients with hepatic impairment, or on concurrent potent inhi…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5923537611961365, "bge_max": 0.5923537611961365, "title": "Fluconazole: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5922555327415466, "bge_max": 0.5922555327415466, "title": "Amikacin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5909372568130493, "bge_max": 0.5909372568130493, "title": "Ticarcillin and clavulanate potassium (United States: Not available): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring o…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5888375043869019, "bge_max": 0.5888375043869019, "title": "Ampicillin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz, 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic…"}, {"doc_id": "crizotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.588661789894104, "bge_max": 0.588661789894104, "title": "Crizotinib: Drug information", "rep_snippet": "Grade 4 bradycardia (life-threatening with urgent intervention indicated): Withhold until recovery to asymptomatic bradycardia or to a heart rate of ≥60 beats/minute and evaluate concomitant medications. If contributing…"}, {"doc_id": "colistin-colistimethate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5872580409049988, "bge_max": 0.5872580409049988, "title": "Colistin (colistimethate): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5864952206611633, "bge_max": 0.5864952206611633, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, sign…"}, {"doc_id": "tolcapone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5864887237548828, "bge_max": 0.5864887237548828, "title": "Tolcapone: Drug information", "rep_snippet": "Monitoring Parameters  Blood pressure; symptoms of Parkinson's disease; mental status; liver enzymes at baseline and then every 2-4 weeks for the first 6 months of therapy; thereafter, periodic monitoring should be condu…"}, {"doc_id": "cetuximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5852762460708618, "bge_max": 0.5852762460708618, "title": "Cetuximab: Drug information", "rep_snippet": "Monitoring Parameters  Vital signs during infusion and observe for at least 1 hour postinfusion. Patients developing dermatologic toxicities should be monitored for the development of complications. Periodic monitoring o…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5852649807929993, "bge_max": 0.5852649807929993, "title": "Voriconazole: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic…"}, {"doc_id": "aztreonam-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5847908854484558, "bge_max": 0.5847908854484558, "title": "Aztreonam (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring o…"}, {"doc_id": "hepatitis-a-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5837723016738892, "bge_max": 0.5837723016738892, "title": "Hepatitis A vaccine: Drug information", "rep_snippet": "Monitoring Parameters  Liver function tests; monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5837054252624512, "bge_max": 0.5837054252624512, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Monitoring Parameters  General: Monitor blood counts and LFTs (including alkaline phosphatase) during therapy; monitor for signs and symptoms of gastrointestinal ulceration and bleeding, skin and bone lesions, skin rashe…"}, {"doc_id": "eltrombopag-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5833157300949097, "bge_max": 0.5833157300949097, "title": "Eltrombopag: Drug information", "rep_snippet": "Monitoring Parameters  Monitor liver function tests, including ALT, AST, and bilirubin (baseline, every 2 weeks during dosage titration, then monthly after a stable dose is achieved; evaluate abnormal liver function test…"}, {"doc_id": "meropenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5831448435783386, "bge_max": 0.5831448435783386, "title": "Meropenem: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Kuti 2005; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close mon…"}, {"doc_id": "dantrolene-drug-information", "bm25_top3": 0.5823034806628691, "bm25_max": 0.5823034806628691, "bge_top3": null, "bge_max": null, "title": "Dantrolene: Drug information", "rep_snippet": "Monitoring Parameters  Motor performance should be monitored for therapeutic outcomes; nausea, vomiting, and liver function tests (baseline and at appropriate intervals thereafter) should be monitored for potential hepat…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5767837564150492, "bge_max": 0.5809437036514282, "title": "Clarithromycin: Drug information", "rep_snippet": "Clarithromycin triple therapy: 500 mg twice daily, in combination with a standard-dose or double-dose proton pump inhibitor, and either amoxicillin 1 g twice daily or metronidazole 500 mg three times daily; continue regi…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": -0.8043233555217757, "bm25_max": 0.15423643068736226, "bge_top3": 0.5808057188987732, "bge_max": 0.5808057188987732, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.…"}, {"doc_id": "tolvaptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5801296830177307, "bge_max": 0.5801296830177307, "title": "Tolvaptan: Drug information", "rep_snippet": "Maintenance: Maintain patient on highest tolerated dose to decrease urine osmolality 200 to 300 mOsm/kg (preferable in most cases) from baseline. Urine osmolality or specific gravity should be measured before morning dos…"}, {"doc_id": "dofetilide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5793092846870422, "bge_max": 0.5793092846870422, "title": "Dofetilide: Drug information", "rep_snippet": "• Arrhythmias: Appropriate use: Reserve for patients who are highly symptomatic with atrial fibrillation/atrial flutter. [US Boxed Warning]: Must be initiated (or reinitiated) in a setting that can provide continuous mon…"}, {"doc_id": "gemtuzumab-ozogamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5790313482284546, "bge_max": 0.5790313482284546, "title": "Gemtuzumab ozogamicin: Drug information", "rep_snippet": "Monitoring Parameters  Monitor liver function tests (ALT, AST, total bilirubin, and alkaline phosphatase) prior to each dose, and more frequently if clinically indicated, particularly if veno-occlusive disease (VOD) is s…"}, {"doc_id": "albendazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5787964463233948, "bge_max": 0.5787964463233948, "title": "Albendazole: Drug information", "rep_snippet": "Monitoring Parameters  LFTs and CBC with differential at start of each 28-day cycle and every 2 weeks during therapy (more frequent monitoring for patients with liver disease); ophthalmic exam for retinal lesions (patien…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5787510871887207, "bge_max": 0.5787510871887207, "title": "Vancomycin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5786442160606384, "bge_max": 0.5786442160606384, "title": "Cefazolin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747037827968597, "bge_max": 0.5785287022590637, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747037827968597, "bge_max": 0.5785287022590637, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "brigatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5779262185096741, "bge_max": 0.5779262185096741, "title": "Brigatinib: Drug information", "rep_snippet": "Monitoring Parameters  ALK positivity; monitor creatine phosphokinase (CPK) and amylase/lipase levels periodically throughout therapy; fasting serum glucose at baseline and periodically thereafter; monitor heart rate and…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5777876377105713, "bge_max": 0.5777876377105713, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5757693648338318, "bge_max": 0.5757693648338318, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "clevidipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.575673520565033, "bge_max": 0.575673520565033, "title": "Clevidipine: Drug information", "rep_snippet": "Monitoring Parameters  Blood pressure and heart rate continually during infusion and until vital signs are stable after discontinuation (Keating 2014); patients who receive prolonged infusions of clevidipine and are not…"}, {"doc_id": "calcitriol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5754667520523071, "bge_max": 0.5754667520523071, "title": "Calcitriol (systemic): Drug information", "rep_snippet": "Monitoring Parameters  Manufacturer’s labeling:  Oral therapy:  Dialysis patients: Serum calcium, phosphorus, magnesium, and alkaline phosphate monitored periodically  Hypoparathyroid patients: Serum calcium, phosphorus,…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5754650831222534, "bge_max": 0.5754650831222534, "title": "Cefotaxime: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "cefepime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5752303600311279, "bge_max": 0.5752303600311279, "title": "Cefepime: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "etelcalcetide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.574866771697998, "bge_max": 0.574866771697998, "title": "Etelcalcetide: Drug information", "rep_snippet": "Monitoring Parameters  Signs/symptoms of hypocalcemia, worsening of heart failure, GI bleeding/ulcerations; QT interval in patients at risk for QT interval prolongation and ventricular arrhythmia.  Corrected serum calciu…"}, {"doc_id": "felodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5744975805282593, "bge_max": 0.5744975805282593, "title": "Felodipine: Drug information", "rep_snippet": "Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. Risk C: Monitor therapy  Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therap…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.573221743106842, "bge_max": 0.573221743106842, "title": "Phenytoin: Drug information", "rep_snippet": "Monitoring Parameters  CBC, liver function; vitamin D status (chronic use); suicidality (eg, suicidal thoughts, depression, behavioral changes); plasma phenytoin concentrations (if available, free phenytoin concentration…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": -0.4358627893515763, "bm25_max": -0.4358627893515763, "bge_top3": 0.5726532340049744, "bge_max": 0.5726532340049744, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Monitoring Parameters  Creatinine, BUN, CBC with differential, PT, PTT, serum electrolytes, LFTs, urinalysis; signs of bleeding; monitor for signs of anaphylaxis during first dose"}, {"doc_id": "baclofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5722014307975769, "bge_max": 0.5722014307975769, "title": "Baclofen: Drug information", "rep_snippet": "Note: Dosage adjustments may be required often during the first few months of therapy to adjust for life style changes due to alleviation of spasticity. Maintain lowest dose that produces adequate response. Most patients…"}, {"doc_id": "fluocinolone-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5714941024780273, "bge_max": 0.5714941024780273, "title": "Fluocinolone (ophthalmic): Drug information", "rep_snippet": "Monitoring Parameters  Iluvien: Following injection, monitor for increased intraocular pressure and endophthalmitis; check for perfusion of optic nerve head immediately after injection, tonometry within 30 minutes, and b…"}, {"doc_id": "sunitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5714821815490723, "bge_max": 0.5714821815490723, "title": "Sunitinib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Dosage modifications should be done in increments or decrements of 12.5 mg; individualize based on safety and tolerability.  Cardiac toxicity:  Ejection fraction <50% but >20% below basel…"}, {"doc_id": "sulfasalazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5702435374259949, "bge_max": 0.5702435374259949, "title": "Sulfasalazine: Drug information", "rep_snippet": "Monitoring Parameters  Manufacturer's labeling: CBC with differential and liver function tests (prior to therapy, then every other week for first 3 months of therapy, followed by every month for the second 3 months, then…"}, {"doc_id": "vedolizumab-drug-information", "bm25_top3": -1.3896986407757979, "bm25_max": -1.3896986407757979, "bge_top3": 0.5699797868728638, "bge_max": 0.5699797868728638, "title": "Vedolizumab: Drug information", "rep_snippet": "Monitoring Parameters  Observe patients during infusion (until complete) and monitor for hypersensitivity reactions; LFTs; tuberculosis screening according to local practice; signs/symptoms of infection; any new onset or…"}, {"doc_id": "technetium-tc-99m-disofenin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5698037147521973, "bge_max": 0.5698037147521973, "title": "Technetium Tc-99m disofenin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: There is a potential for allergic reactions to occur.  Disease-related concerns:  • Acute cholecystitis in other conditions: False…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 0.5076918558648043, "bm25_max": 0.5076918558648043, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or…"}, {"doc_id": "treprostinil-drug-information", "bm25_top3": -0.12283577135589852, "bm25_max": -0.12283577135589852, "bge_top3": null, "bge_max": null, "title": "Treprostinil: Drug information", "rep_snippet": "SubQ infusion (preferred): Administer undiluted via continuous SubQ infusion using an appropriately designed infusion pump. The ambulatory infusion pump should be small and lightweight; be able to adjust infusion rates i…"}, {"doc_id": "lincomycin-drug-information", "bm25_top3": -0.4760582887159064, "bm25_max": -0.4760582887159064, "bge_top3": null, "bge_max": null, "title": "Lincomycin: Drug information", "rep_snippet": "Monitoring Parameters  Change in bowel frequency or consistency (eg, diarrhea); baseline serum creatinine and liver function tests (LFTs); periodically during prolonged therapy: renal function and LFTs, complete blood ce…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": -0.6430743721954322, "bm25_max": -0.6430743721954322, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Monitoring Parameters  Acetaminophen overdose: Monitor patient for the development of anaphylaxis or anaphylactoid reactions; monitor serum acetaminophen concentrations, AST, ALT, bilirubin, PT, INR, serum creatinine, BU…"}, {"doc_id": "ceritinib-drug-information", "bm25_top3": -0.7218575437369879, "bm25_max": -0.7218575437369879, "bge_top3": null, "bge_max": null, "title": "Ceritinib: Drug information", "rep_snippet": "Administration  Ceritinib is associated with a moderate emetic potential (Hesketh 2017; Roila 2016); antiemetics may be needed to prevent nausea and vomiting.  Oral: Administer with food. Note: Ceritinib was previously r…"}, {"doc_id": "zafirlukast-drug-information", "bm25_top3": -0.8715233373119595, "bm25_max": -0.8715233373119595, "bge_top3": null, "bge_max": null, "title": "Zafirlukast: Drug information", "rep_snippet": "Monitoring Parameters  Monitor for improvements in air flow; monitor closely for sign/symptoms of hepatic injury; periodic monitoring of LFTs may be considered (not proved to prevent serious injury, but early detection m…"}, {"doc_id": "gemfibrozil-drug-information", "bm25_top3": -1.2696307068887425, "bm25_max": -1.2696307068887425, "bge_top3": null, "bge_max": null, "title": "Gemfibrozil: Drug information", "rep_snippet": "Monitoring Parameters  Serum cholesterol, LFTs periodically, CBC periodically (first year)"}, {"doc_id": "hepatitis-b-immune-globulin-drug-information", "bm25_top3": -1.3775237366509803, "bm25_max": -1.3775237366509803, "bge_top3": null, "bge_max": null, "title": "Hepatitis B immune globulin: Drug information", "rep_snippet": "Monitoring Parameters  Liver transplant: Serum HBsAg; LFTs; infusion-related adverse events"}, {"doc_id": "tamoxifen-drug-information", "bm25_top3": -1.7905819447231472, "bm25_max": -1.7905819447231472, "bge_top3": null, "bge_max": null, "title": "Tamoxifen: Drug information", "rep_snippet": "Monitoring Parameters  CBC with platelets, serum calcium, LFTs; triglycerides and cholesterol (in patients with pre-existing hyperlipidemias); INR and PT (in patients on vitamin K antagonists); pregnancy test (prior to t…"}, {"doc_id": "fluorouracil-systemic-drug-information", "bm25_top3": -2.060711329169564, "bm25_max": -2.060711329169564, "bge_top3": null, "bge_max": null, "title": "Fluorouracil (systemic): Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelet count (prior to each treatment cycle, weekly if administered on a weekly or similar schedule, and as clinically indicated), renal function tests, LFTs, INR, and p…"}]}
{"qid": "Q10_abbr+MAOI-cue", "query": "Linezolid with sertraline — safe? need washout or just monitor for serotonin tox?", "base_qid": "Q10", "variant_type": "abbr+MAOI-cue", "candidates": [{"doc_id": "sertraline-drug-information", "bm25_top3": 24.496317375595705, "bm25_max": 24.97684539076372, "bge_top3": 0.66745525598526, "bge_max": 0.679784893989563, "title": "Sertraline: Drug information", "rep_snippet": "Disulfiram: May enhance the adverse/toxic effect of Sertraline. This is specifically related to sertraline oral concentrate due to its alcohol content (12%). Management: Sertraline Oral Concentrate contains 12% alcohol,…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 23.496461917264938, "bm25_max": 23.496461917264938, "bge_top3": 0.6662268042564392, "bge_max": 0.6871015429496765, "title": "Linezolid: Drug information", "rep_snippet": "Serotonin Modulators: Linezolid may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue seroto…"}, {"doc_id": "clomipramine-drug-information", "bm25_top3": 21.650062537409546, "bm25_max": 21.650062537409546, "bge_top3": null, "bge_max": null, "title": "Clomipramine: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": 13.915969569945652, "bm25_max": 13.915969569945652, "bge_top3": null, "bge_max": null, "title": "Amitriptyline: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "doxepin-systemic-drug-information", "bm25_top3": 13.915969569945652, "bm25_max": 13.915969569945652, "bge_top3": null, "bge_max": null, "title": "Doxepin (systemic): Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "imipramine-drug-information", "bm25_top3": 13.915969569945652, "bm25_max": 13.915969569945652, "bge_top3": null, "bge_max": null, "title": "Imipramine: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 13.915969569945652, "bm25_max": 13.915969569945652, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "amitriptyline-and-perphenazine-drug-information", "bm25_top3": 13.893117206259053, "bm25_max": 13.893117206259053, "bge_top3": null, "bge_max": null, "title": "Amitriptyline and perphenazine: Drug information", "rep_snippet": "Serotonin Reuptake Inhibitor/Antagonists: Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Serotonin Reuptake Inhibitor/Antagonists. Specifically, this may be manifest as symptoms consistent…"}, {"doc_id": "promethazine-phenylephrine-and-codeine-drug-information", "bm25_top3": 13.007486511243172, "bm25_max": 13.007486511243172, "bge_top3": 0.664863109588623, "bge_max": 0.664863109588623, "title": "Promethazine, phenylephrine, and codeine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": 11.621466008757983, "bm25_max": 12.969407059037, "bge_top3": null, "bge_max": null, "title": "Trimipramine: Drug information", "rep_snippet": "Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior t…"}, {"doc_id": "amitriptyline-and-chlordiazepoxide-drug-information", "bm25_top3": 12.969407059037, "bm25_max": 12.969407059037, "bge_top3": null, "bge_max": null, "title": "Amitriptyline and chlordiazepoxide: Drug information", "rep_snippet": "Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior t…"}, {"doc_id": "isocarboxazid-drug-information", "bm25_top3": 12.62223962173119, "bm25_max": 12.62223962173119, "bge_top3": null, "bge_max": null, "title": "Isocarboxazid: Drug information", "rep_snippet": "If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving isocarboxazid and potential benefits outweigh potential risks, discontinue isocarboxazid promptly and administer linezoli…"}, {"doc_id": "ergotamine-and-caffeine-drug-information", "bm25_top3": 12.568664900455602, "bm25_max": 12.568664900455602, "bge_top3": 0.6710572838783264, "bge_max": 0.6710572838783264, "title": "Ergotamine and caffeine: Drug information", "rep_snippet": "Letermovir: May increase the serum concentration of Ergot Derivatives. Risk X: Avoid combination  Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic ag…"}, {"doc_id": "lorcaserin-drug-information", "bm25_top3": 12.130280566014726, "bm25_max": 12.130280566014726, "bge_top3": 0.6946232318878174, "bge_max": 0.6946232318878174, "title": "Lorcaserin: Drug information", "rep_snippet": "Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin s…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": 12.120402074783765, "bm25_max": 12.120402074783765, "bge_top3": 0.6274914145469666, "bge_max": 0.6282687187194824, "title": "Phenelzine: Drug information", "rep_snippet": "If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving phenelzine and potential benefits outweigh potential risks, discontinue phenelzine promptly and administer linezolid or I…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": 11.935349406439197, "bm25_max": 11.935349406439197, "bge_top3": 0.6738234162330627, "bge_max": 0.6738234162330627, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "promethazine-drug-information", "bm25_top3": 11.935349406439197, "bm25_max": 11.935349406439197, "bge_top3": 0.6738234162330627, "bge_max": 0.6738234162330627, "title": "Promethazine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 11.568864368559176, "bm25_max": 11.568864368559176, "bge_top3": 0.6756442785263062, "bge_max": 0.6756442785263062, "title": "Fluoxetine: Drug information", "rep_snippet": "Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with other MAO inhibitors (linezolid or IV methylene blue):  Do not initiate fluox…"}, {"doc_id": "milnacipran-drug-information", "bm25_top3": 10.911619158758798, "bm25_max": 11.509859154938006, "bge_top3": 0.6382158398628235, "bge_max": 0.6382158398628235, "title": "Milnacipran: Drug information", "rep_snippet": "Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased. Risk C: Monitor therapy  Metoclopramide: May enhance the…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": 11.47359991458654, "bm25_max": 11.47359991458654, "bge_top3": null, "bge_max": null, "title": "Maprotiline: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing maprotiline and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with other MAO inhibitors (such as linezolid or IV methylene blue):  Do not initi…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": 11.061831225998043, "bm25_max": 11.47359991458654, "bge_top3": null, "bge_max": null, "title": "Amoxapine: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing amoxapine and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with reversible MAO inhibitors (such as linezolid or IV methylene blue):  Do not in…"}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": 11.228675637917668, "bm25_max": 11.228675637917668, "bge_top3": null, "bge_max": null, "title": "Fosphenytoin: Drug information", "rep_snippet": "Rufinamide: Fosphenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Fosphenytoin. Risk C: Monitor therapy  Ruxolitinib: CYP3A4 Inducers (Strong) may decrease th…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 11.218776047127815, "bm25_max": 11.218776047127815, "bge_top3": null, "bge_max": null, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Canadian labeling does not provide further recommendations regarding use of linezolid and methylene blue in patients receiving moclobemide. The US Food and Drug Administration (FDA) recommends that when urgent treatment…"}, {"doc_id": "eletriptan-drug-information", "bm25_top3": 11.083652354546423, "bm25_max": 11.083652354546423, "bge_top3": 0.6408051252365112, "bge_max": 0.6408051252365112, "title": "Eletriptan: Drug information", "rep_snippet": "Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives. Exceptions: Nicergoline.…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 10.879414030458314, "bm25_max": 10.879414030458314, "bge_top3": 0.6448949575424194, "bge_max": 0.6448949575424194, "title": "Naratriptan: Drug information", "rep_snippet": "Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Risk C: Monitor therapy  Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. S…"}, {"doc_id": "frovatriptan-drug-information", "bm25_top3": 10.879414030458314, "bm25_max": 10.879414030458314, "bge_top3": 0.6448949575424194, "bge_max": 0.6448949575424194, "title": "Frovatriptan: Drug information", "rep_snippet": "Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Risk C: Monitor therapy  Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. S…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": 10.815428113225764, "bm25_max": 10.815428113225764, "bge_top3": 0.6715890169143677, "bge_max": 0.6715890169143677, "title": "Vortioxetine: Drug information", "rep_snippet": "Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotan…"}, {"doc_id": "promethazine-and-codeine-drug-information", "bm25_top3": 10.764919662832497, "bm25_max": 10.764919662832497, "bge_top3": 0.6369444727897644, "bge_max": 0.6369444727897644, "title": "Promethazine and codeine: Drug information", "rep_snippet": "Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Risk C: Monitor therapy  Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy  Levosulpiride: Antic…"}, {"doc_id": "levomilnacipran-drug-information", "bm25_top3": 10.709349368765277, "bm25_max": 10.709349368765277, "bge_top3": null, "bge_max": null, "title": "Levomilnacipran: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of levomilnacipran.  Allow 7 days to elapse between discontinuing levomilnacipran and initiation of an…"}, {"doc_id": "protriptyline-drug-information", "bm25_top3": 10.637234392426931, "bm25_max": 10.650062537409546, "bge_top3": null, "bge_max": null, "title": "Protriptyline: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "nortriptyline-drug-information", "bm25_top3": 10.650062537409546, "bm25_max": 10.650062537409546, "bge_top3": null, "bge_max": null, "title": "Nortriptyline: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "escitalopram-drug-information", "bm25_top3": 10.490652489490103, "bm25_max": 10.490652489490103, "bge_top3": 0.6442147493362427, "bge_max": 0.6442147493362427, "title": "Escitalopram: Drug information", "rep_snippet": "MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Risk X: Avoid combination  Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Mana…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": 10.366023251372471, "bm25_max": 10.366023251372471, "bge_top3": 0.6566804051399231, "bge_max": 0.6781903505325317, "title": "Ergotamine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": 10.366023251372471, "bm25_max": 10.366023251372471, "bge_top3": 0.6568952202796936, "bge_max": 0.6781903505325317, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "ergoloid-mesylates-drug-information", "bm25_top3": 10.366023251372471, "bm25_max": 10.366023251372471, "bge_top3": 0.6581082940101624, "bge_max": 0.6781903505325317, "title": "Ergoloid mesylates: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "acetaminophen-paracetamol-and-tramadol-drug-information", "bm25_top3": 10.336295256172932, "bm25_max": 10.336295256172932, "bge_top3": 0.6388087272644043, "bge_max": 0.6388087272644043, "title": "Acetaminophen (paracetamol) and tramadol: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "bromocriptine-drug-information", "bm25_top3": 10.32359219857699, "bm25_max": 10.32359219857699, "bge_top3": 0.6889535784721375, "bge_max": 0.6889535784721375, "title": "Bromocriptine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": 10.273524958478966, "bm25_max": 10.273524958478966, "bge_top3": null, "bge_max": null, "title": "Citalopram: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of citalopram.  Allow…"}, {"doc_id": "methylergonovine-drug-information", "bm25_top3": 10.252750060524455, "bm25_max": 10.252750060524455, "bge_top3": 0.639343649148941, "bge_max": 0.6527305245399475, "title": "Methylergonovine: Drug information", "rep_snippet": "Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk…"}, {"doc_id": "ergonovine-united-states-not-available-drug-information", "bm25_top3": 10.252750060524455, "bm25_max": 10.252750060524455, "bge_top3": 0.6393650472164154, "bge_max": 0.6438666582107544, "title": "Ergonovine (United States: Not available): Drug information", "rep_snippet": "Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk…"}, {"doc_id": "tramadol-drug-information", "bm25_top3": 10.249998900106263, "bm25_max": 10.249998900106263, "bge_top3": 0.6296941041946411, "bge_max": 0.6296941041946411, "title": "Tramadol: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6634707152843475, "bge_max": 0.6813856363296509, "title": "Lithium: Drug information", "rep_snippet": "Desmopressin: Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. Risk C: Monitor therapy  Eplerenone: May increase the serum concentration of Lithiu…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6800328493118286, "bge_max": 0.6800328493118286, "title": "Duloxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Metaxalone: May enhance the serotonergic effect of Serot…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6785012483596802, "bge_max": 0.6785012483596802, "title": "Paroxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Lithium: May enhance the serotonergic effect of Selective Ser…"}, {"doc_id": "cabergoline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6708171963691711, "bge_max": 0.6708171963691711, "title": "Cabergoline: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Manage…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6566756367683411, "bge_max": 0.6566756367683411, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Lithium: May enhance the serotonergic effect of Selective Ser…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6356364190578461, "bge_max": 0.6404097676277161, "title": "Fluvoxamine: Drug information", "rep_snippet": "Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result…"}, {"doc_id": "trazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6332365274429321, "bge_max": 0.6332365274429321, "title": "Trazodone: Drug information", "rep_snippet": "Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Risk C: Monitor therapy  Methylene Blue: TraZODone may enhance the serotonergic effect of Methylene Blue.…"}, {"doc_id": "rizatriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6326459050178528, "bge_max": 0.6326459050178528, "title": "Rizatriptan: Drug information", "rep_snippet": "Propranolol: May increase the serum concentration of Rizatriptan. Management: Rizatriptan adult dose should be reduced to 5 mg in patients who are also being treated with propranolol. Risk D: Consider therapy modificatio…"}, {"doc_id": "methamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6306777000427246, "bge_max": 0.6306777000427246, "title": "Methamphetamine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "methadone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6304762363433838, "bge_max": 0.6304762363433838, "title": "Methadone: Drug information", "rep_snippet": "Interferons (Alfa): May increase the serum concentration of Methadone. Risk C: Monitor therapy  Isavuconazonium Sulfate: May decrease the serum concentration of Methadone. Risk C: Monitor therapy  Itraconazole: May incre…"}, {"doc_id": "sumatriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6286450028419495, "bge_max": 0.6286450028419495, "title": "Sumatriptan: Drug information", "rep_snippet": "Serotonin 5-HT1D Receptor Agonists: May enhance the adverse/toxic effect of SUMAtriptan. Risk X: Avoid combination  Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The developmen…"}, {"doc_id": "safinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6285480260848999, "bge_max": 0.6285480260848999, "title": "Safinamide: Drug information", "rep_snippet": "• Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with concomitant use of serotonergic agents (eg, SSRIs, SNRIs, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John's wor…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6283432841300964, "bge_max": 0.6283432841300964, "title": "Procarbazine: Drug information", "rep_snippet": "Serotonin Reuptake Inhibitor/Antagonists: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Serotonin Reuptake Inhibitor/Antagonists. While methylene blue and linezolid are expected to interact, specif…"}, {"doc_id": "zolmitriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6277264952659607, "bge_max": 0.6277264952659607, "title": "Zolmitriptan: Drug information", "rep_snippet": "Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur. Exceptions: Nicergoline; Tedizolid. Risk C: Monitor therapy  SUMAtriptan: Seroton…"}]}
{"qid": "Q10_negation-trap", "query": "Starting linezolid; pt on sertraline (no other serotonergics). Is combo acceptable; what monitoring?", "base_qid": "Q10", "variant_type": "negation-trap", "candidates": [{"doc_id": "sertraline-drug-information", "bm25_top3": 20.03640134973552, "bm25_max": 21.25875348319113, "bge_top3": 0.640768806139628, "bge_max": 0.6568320989608765, "title": "Sertraline: Drug information", "rep_snippet": "Contraindications  Use of MAOIs including linezolid or methylene blue (concurrently or within 14 days of stopping an MAOI or sertraline); concurrent use with pimozide; hypersensitivity (eg, anaphylaxis, angioedema) to se…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 17.481182668870364, "bm25_max": 17.481182668870364, "bge_top3": 0.6624573866526285, "bge_max": 0.6687172651290894, "title": "Linezolid: Drug information", "rep_snippet": "Serotonin Modulators: Linezolid may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue seroto…"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": 8.278485718614125, "bm25_max": 8.278485718614125, "bge_top3": null, "bge_max": null, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong…"}, {"doc_id": "disulfiram-drug-information", "bm25_top3": 8.120818198737892, "bm25_max": 8.120818198737892, "bge_top3": null, "bge_max": null, "title": "Disulfiram: Drug information", "rep_snippet": "Phenytoin: Disulfiram may increase the serum concentration of Phenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible. Phenytoin dose adjustment will likely be necessary when starting and/o…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 7.230434908003353, "bm25_max": 7.230434908003353, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 6.78769274042093, "bm25_max": 6.78769274042093, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  The manufacturer's labeling recommends considering a reduced dose (starting at the low end of the dosing range) with close monitoring for toxicity dose in patients with baseline hepatic impair…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 6.658647414511236, "bm25_max": 6.658647414511236, "bge_top3": null, "bge_max": null, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Canadian labeling does not provide further recommendations regarding use of linezolid and methylene blue in patients receiving moclobemide. The US Food and Drug Administration (FDA) recommends that when urgent treatment…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 6.515343665475815, "bm25_max": 6.515343665475815, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": 6.486192387946561, "bm25_max": 6.486192387946561, "bge_top3": 0.6362696886062622, "bge_max": 0.6362696886062622, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "promethazine-drug-information", "bm25_top3": 6.486192387946561, "bm25_max": 6.486192387946561, "bge_top3": 0.6362696886062622, "bge_max": 0.6362696886062622, "title": "Promethazine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 6.467170119051831, "bm25_max": 6.467170119051831, "bge_top3": 0.641923189163208, "bge_max": 0.641923189163208, "title": "Fluoxetine: Drug information", "rep_snippet": "Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with other MAO inhibitors (linezolid or IV methylene blue):  Do not initiate fluox…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": 6.406162114994208, "bm25_max": 6.406162114994208, "bge_top3": null, "bge_max": null, "title": "Maprotiline: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing maprotiline and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with other MAO inhibitors (such as linezolid or IV methylene blue):  Do not initi…"}, {"doc_id": "axitinib-drug-information", "bm25_top3": 6.319836984042045, "bm25_max": 6.319836984042045, "bge_top3": null, "bge_max": null, "title": "Axitinib: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Mild impairment (Child-Pugh class A): No starting dosage adjustment necessary.  Moderate impairment (Child-Pugh class B): Reduce starting dose by ~50%; increase or decrease based on individual…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": 6.305901767353998, "bm25_max": 6.305901767353998, "bge_top3": null, "bge_max": null, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported fo…"}, {"doc_id": "vilazodone-drug-information", "bm25_top3": 5.997406219595975, "bm25_max": 6.228441762746918, "bge_top3": 0.6286345720291138, "bge_max": 0.6286345720291138, "title": "Vilazodone: Drug information", "rep_snippet": "Do not initiate vilazodone in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.  If urgent treatment with linezolid or IV methylene blue is required in a patient a…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": 6.190897682984891, "bm25_max": 6.190897682984891, "bge_top3": null, "bge_max": null, "title": "Erlotinib: Drug information", "rep_snippet": "CYP3A4 inducers: Avoid concurrent use if possible; if concomitant administration with CYP3A4 inducers cannot be avoided, increase erlotinib dose in 50 mg increments at 2-week intervals to a maximum of 450 mg; reduce erlo…"}, {"doc_id": "cariprazine-drug-information", "bm25_top3": 6.17160256182858, "bm25_max": 6.17160256182858, "bge_top3": null, "bge_max": null, "title": "Cariprazine: Drug information", "rep_snippet": "Initiating cariprazine therapy while already on a strong CYP3A4 inhibitor: Administer cariprazine 1.5 mg on day 1 and day 3 (no dose administered on day 2). Administer 1.5 mg daily starting on day 4 and increase to a max…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": 6.119800436314051, "bm25_max": 6.119800436314051, "bge_top3": null, "bge_max": null, "title": "Enoxaparin: Drug information", "rep_snippet": "Monitoring Parameters  Platelets, occult blood, anti-Xa levels, serum creatinine; monitoring of PT and/or aPTT is not necessary. Routine monitoring of anti-Xa levels is not required, but has been utilized in patients wit…"}, {"doc_id": "oxymorphone-drug-information", "bm25_top3": 6.0055335010033755, "bm25_max": 6.058855758434664, "bge_top3": null, "bge_max": null, "title": "Oxymorphone: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling.  CrCl <50 mL/minute: Use with caution; bioavailability increased.  Oral:  Extended release:  Opioid n…"}, {"doc_id": "guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 6.054575145737088, "bm25_max": 6.054575145737088, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and phenylephrine: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.…"}, {"doc_id": "phenylephrine-systemic-drug-information", "bm25_top3": 6.054575145737088, "bm25_max": 6.054575145737088, "bge_top3": null, "bge_max": null, "title": "Phenylephrine (systemic): Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.…"}, {"doc_id": "lorcaserin-drug-information", "bm25_top3": 5.982463615147207, "bm25_max": 5.982463615147207, "bge_top3": 0.6355698108673096, "bge_max": 0.6355698108673096, "title": "Lorcaserin: Drug information", "rep_snippet": "Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin s…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": 5.968241069596715, "bm25_max": 5.968241069596715, "bge_top3": 0.6320083737373352, "bge_max": 0.6320083737373352, "title": "Procarbazine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alpha-/Beta-Agonists (Indirect-Acting): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirec…"}, {"doc_id": "cabergoline-drug-information", "bm25_top3": 5.940867029490377, "bm25_max": 5.940867029490377, "bge_top3": 0.6370587348937988, "bge_max": 0.6370587348937988, "title": "Cabergoline: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Manage…"}, {"doc_id": "levomilnacipran-drug-information", "bm25_top3": 5.912336957440646, "bm25_max": 5.912336957440646, "bge_top3": null, "bge_max": null, "title": "Levomilnacipran: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of levomilnacipran.  Allow 7 days to elapse between discontinuing levomilnacipran and initiation of an…"}, {"doc_id": "bromocriptine-drug-information", "bm25_top3": 5.908541898871544, "bm25_max": 5.908541898871544, "bge_top3": 0.6640618443489075, "bge_max": 0.6640618443489075, "title": "Bromocriptine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "ergotamine-and-caffeine-drug-information", "bm25_top3": 5.887944870803993, "bm25_max": 5.887944870803993, "bge_top3": 0.6507871448993683, "bge_max": 0.6688895225524902, "title": "Ergotamine and caffeine: Drug information", "rep_snippet": "Letermovir: May increase the serum concentration of Ergot Derivatives. Risk X: Avoid combination  Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic ag…"}, {"doc_id": "protriptyline-drug-information", "bm25_top3": 5.856974408105872, "bm25_max": 5.856974408105872, "bge_top3": null, "bge_max": null, "title": "Protriptyline: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of protriptyline.  Allow 14 days to elapse between discontinuing protriptyline and initiation of an MA…"}, {"doc_id": "cyclobenzaprine-drug-information", "bm25_top3": 5.8338111745284, "bm25_max": 5.8338111745284, "bge_top3": null, "bge_max": null, "title": "Cyclobenzaprine: Drug information", "rep_snippet": "Monitoring Parameters  Signs/symptoms of serotonin syndrome (patients receiving other serotonergic drugs)"}, {"doc_id": "benazepril-drug-information", "bm25_top3": 5.808701916257746, "bm25_max": 5.808701916257746, "bge_top3": null, "bge_max": null, "title": "Benazepril: Drug information", "rep_snippet": "Breast-Feeding Considerations  Small amounts of benazepril and benazeprilat are present in breast milk. Some guidelines consider benazepril to be acceptable for use in breastfeeding women. Monitoring of the breastfeeding…"}, {"doc_id": "nesiritide-drug-information", "bm25_top3": 5.78338103268924, "bm25_max": 5.78338103268924, "bge_top3": null, "bge_max": null, "title": "Nesiritide: Drug information", "rep_snippet": "Administration  IV: Do not administer through a heparin-coated catheter (concurrent administration of heparin via a separate catheter is acceptable, per manufacturer).  Prime IV tubing with 5 mL of infusion prior to conn…"}, {"doc_id": "tetracaine-and-oxymetazoline-drug-information", "bm25_top3": 5.750678076990447, "bm25_max": 5.750678076990447, "bge_top3": null, "bge_max": null, "title": "Tetracaine and oxymetazoline: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 5.699740699763806, "bm25_max": 5.699740699763806, "bge_top3": 0.6389562487602234, "bge_max": 0.6389562487602234, "title": "Naratriptan: Drug information", "rep_snippet": "Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Risk C: Monitor therapy  Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. S…"}, {"doc_id": "frovatriptan-drug-information", "bm25_top3": 5.699740699763806, "bm25_max": 5.699740699763806, "bge_top3": 0.6389562487602234, "bge_max": 0.6389562487602234, "title": "Frovatriptan: Drug information", "rep_snippet": "Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Risk C: Monitor therapy  Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. S…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 5.635754563279754, "bm25_max": 5.635754563279754, "bge_top3": null, "bge_max": null, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy  SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. Risk…"}, {"doc_id": "milnacipran-drug-information", "bm25_top3": 5.614412183816489, "bm25_max": 5.614412183816489, "bge_top3": 0.6326427459716797, "bge_max": 0.6326427459716797, "title": "Milnacipran: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow ≥14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of milnacipran.  Allo…"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": 5.588102529612451, "bm25_max": 5.588102529612451, "bge_top3": null, "bge_max": null, "title": "Trimipramine: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of trimipramine.  Allo…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": 5.588102529612451, "bm25_max": 5.588102529612451, "bge_top3": null, "bge_max": null, "title": "Citalopram: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of citalopram.  Allow…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": 5.57750817188508, "bm25_max": 5.57750817188508, "bge_top3": null, "bge_max": null, "title": "Amoxapine: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing amoxapine and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with reversible MAO inhibitors (such as linezolid or IV methylene blue):  Do not in…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": 5.551368384799602, "bm25_max": 5.551368384799602, "bge_top3": null, "bge_max": null, "title": "Amitriptyline: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 5.551368384799602, "bm25_max": 5.551368384799602, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6718865036964417, "bge_max": 0.6718865036964417, "title": "Ergotamine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6718865036964417, "bge_max": 0.6718865036964417, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "ergoloid-mesylates-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6718865036964417, "bge_max": 0.6718865036964417, "title": "Ergoloid mesylates: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6646276712417603, "bge_max": 0.6646276712417603, "title": "Vortioxetine: Drug information", "rep_snippet": "Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6507524847984314, "bge_max": 0.6507524847984314, "title": "Paroxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Lithium: May enhance the serotonergic effect of Selective Ser…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.645755797624588, "bge_max": 0.649145245552063, "title": "Duloxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Metaxalone: May enhance the serotonergic effect of Serot…"}, {"doc_id": "acetaminophen-paracetamol-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6458911895751953, "bge_max": 0.6458911895751953, "title": "Acetaminophen (paracetamol), aspirin, and caffeine: Drug information", "rep_snippet": "Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin. Ris…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6457355618476868, "bge_max": 0.6457355618476868, "title": "Fluvoxamine: Drug information", "rep_snippet": "Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result…"}, {"doc_id": "escitalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6378773748874664, "bge_max": 0.6445618867874146, "title": "Escitalopram: Drug information", "rep_snippet": "Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. Risk C: Monitor therapy  Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properti…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.644196093082428, "bge_max": 0.644196093082428, "title": "Lithium: Drug information", "rep_snippet": "Desmopressin: Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. Risk C: Monitor therapy  Eplerenone: May increase the serum concentration of Lithiu…"}, {"doc_id": "promethazine-phenylephrine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6436098217964172, "bge_max": 0.6436098217964172, "title": "Promethazine, phenylephrine, and codeine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6413089036941528, "bge_max": 0.6413089036941528, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Lithium: May enhance the serotonergic effect of Selective Ser…"}, {"doc_id": "butalbital-compound-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6376643180847168, "bge_max": 0.6376643180847168, "title": "Butalbital compound: Drug information", "rep_snippet": "LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine. Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate,…"}, {"doc_id": "butalbital-compound-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6376643180847168, "bge_max": 0.6376643180847168, "title": "Butalbital compound and codeine: Drug information", "rep_snippet": "LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine. Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate,…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6320177316665649, "bge_max": 0.6320177316665649, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "acetaminophen-paracetamol-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6320177316665649, "bge_max": 0.6320177316665649, "title": "Acetaminophen (paracetamol) and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "topical-cocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6319199204444885, "bge_max": 0.6319199204444885, "title": "Topical cocaine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "methamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6316843032836914, "bge_max": 0.6316843032836914, "title": "Methamphetamine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "ergonovine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6312158107757568, "bge_max": 0.6312158107757568, "title": "Ergonovine (United States: Not available): Drug information", "rep_snippet": "Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk…"}, {"doc_id": "ibuprofen-phenylephrine-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6311740875244141, "bge_max": 0.6311740875244141, "title": "Ibuprofen, phenylephrine, and chlorpheniramine: Drug information", "rep_snippet": "Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination  Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride.…"}, {"doc_id": "methylergonovine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6302734017372131, "bge_max": 0.6302734017372131, "title": "Methylergonovine: Drug information", "rep_snippet": "Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk…"}, {"doc_id": "acetaminophen-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6299037933349609, "bge_max": 0.6299037933349609, "title": "Acetaminophen and pseudoephedrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "doxapram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6273954510688782, "bge_max": 0.6273954510688782, "title": "Doxapram: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "dextromethorphan-and-quinidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.626382052898407, "bge_max": 0.626382052898407, "title": "Dextromethorphan and quinidine: Drug information", "rep_snippet": "Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur. Exceptions: Nicergoline; Tedizolid. Risk C: Monitor therapy  Silodosin: P-glycopr…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6263584494590759, "bge_max": 0.6263584494590759, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination  Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Ag…"}, {"doc_id": "ephedrine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6263249516487122, "bge_max": 0.6263249516487122, "title": "Ephedrine (systemic): Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoam…"}, {"doc_id": "ephedrine-and-guaifenesin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6263249516487122, "bge_max": 0.6263249516487122, "title": "Ephedrine and guaifenesin: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoam…"}, {"doc_id": "telaprevir-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.625186026096344, "bge_max": 0.625186026096344, "title": "Telaprevir (United States: Not available): Drug information", "rep_snippet": "Ergoloid Mesylates: Telaprevir may increase the serum concentration of Ergoloid Mesylates. Risk X: Avoid combination  Ergonovine: Telaprevir may increase the serum concentration of Ergonovine. Risk X: Avoid combination…"}]}
{"qid": "Q10_spelling", "query": "Linezolid + sertralin — concomitant use ok?", "base_qid": "Q10", "variant_type": "spelling", "candidates": [{"doc_id": "linezolid-drug-information", "bm25_top3": 14.265487472991694, "bm25_max": 15.410945669248445, "bge_top3": 0.6440229217211405, "bge_max": 0.6501504778862, "title": "Linezolid: Drug information", "rep_snippet": "Complicated: Treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by S. aureus (methicillin-susceptible and -resistant isolates), Stre…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": 4.86993796220947, "bm25_max": 7.355952407886981, "bge_top3": 0.6399315297603607, "bge_max": 0.6413313746452332, "title": "Sertraline: Drug information", "rep_snippet": "Contraindications  Use of MAOIs including linezolid or methylene blue (concurrently or within 14 days of stopping an MAOI or sertraline); concurrent use with pimozide; hypersensitivity (eg, anaphylaxis, angioedema) to se…"}, {"doc_id": "buspirone-drug-information", "bm25_top3": 5.565309053839467, "bm25_max": 5.565309053839467, "bge_top3": null, "bge_max": null, "title": "Buspirone: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to buspirone or any component of the formulation; concomitant use of MAOIs intended to treat depression or within 14 days of discontinuing MAOIs intended to treat depression; concomita…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": 5.014248183101724, "bm25_max": 5.014248183101724, "bge_top3": 0.6404751539230347, "bge_max": 0.6404751539230347, "title": "Paroxetine: Drug information", "rep_snippet": "Contraindications  Concurrent use with or within 14 days of MAOIs intended to treat psychiatric disorders; initiation in patients being treated with linezolid or methylene blue IV; concomitant use with pimozide or thiori…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 3.9034566015786076, "bm25_max": 3.9034566015786076, "bge_top3": 0.6361709833145142, "bge_max": 0.6361709833145142, "title": "Fluoxetine: Drug information", "rep_snippet": "Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with other MAO inhibitors (linezolid or IV methylene blue):  Do not initiate fluox…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": 3.860347463928239, "bm25_max": 3.860347463928239, "bge_top3": null, "bge_max": null, "title": "Maprotiline: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing maprotiline and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with other MAO inhibitors (such as linezolid or IV methylene blue):  Do not initi…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": 3.860347463928239, "bm25_max": 3.860347463928239, "bge_top3": null, "bge_max": null, "title": "Amoxapine: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing amoxapine and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with reversible MAO inhibitors (such as linezolid or IV methylene blue):  Do not in…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 3.805010166209687, "bm25_max": 3.805010166209687, "bge_top3": 0.6147547960281372, "bge_max": 0.6147547960281372, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Canadian labeling does not provide further recommendations regarding use of linezolid and methylene blue in patients receiving moclobemide. The US Food and Drug Administration (FDA) recommends that when urgent treatment…"}, {"doc_id": "promethazine-phenylephrine-and-codeine-drug-information", "bm25_top3": 3.660648640105615, "bm25_max": 3.660648640105615, "bge_top3": 0.6003288626670837, "bge_max": 0.6003288626670837, "title": "Promethazine, phenylephrine, and codeine: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.…"}, {"doc_id": "pseudoephedrine-and-codeine-drug-information", "bm25_top3": 3.5673525908853776, "bm25_max": 3.5673525908853776, "bge_top3": null, "bge_max": null, "title": "Pseudoephedrine and codeine: Drug information", "rep_snippet": "MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy  Minocycline: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Monoamine Oxidase Inhibi…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-codeine-drug-information", "bm25_top3": 3.5673525908853776, "bm25_max": 3.5673525908853776, "bge_top3": null, "bge_max": null, "title": "Guaifenesin, pseudoephedrine, and codeine: Drug information", "rep_snippet": "MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy  Minocycline: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Monoamine Oxidase Inhibi…"}, {"doc_id": "vilazodone-drug-information", "bm25_top3": 3.548750317248798, "bm25_max": 3.548750317248798, "bge_top3": null, "bge_max": null, "title": "Vilazodone: Drug information", "rep_snippet": "Do not initiate vilazodone in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.  If urgent treatment with linezolid or IV methylene blue is required in a patient a…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": 3.4061653398401477, "bm25_max": 3.536085633013247, "bge_top3": null, "bge_max": null, "title": "Citalopram: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to citalopram or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either citalopram or t…"}, {"doc_id": "levomilnacipran-drug-information", "bm25_top3": 3.5091075027710197, "bm25_max": 3.5091075027710197, "bge_top3": null, "bge_max": null, "title": "Levomilnacipran: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of levomilnacipran.  Allow 7 days to elapse between discontinuing levomilnacipran and initiation of an…"}, {"doc_id": "disulfiram-drug-information", "bm25_top3": 3.5011913984013656, "bm25_max": 3.5011913984013656, "bge_top3": null, "bge_max": null, "title": "Disulfiram: Drug information", "rep_snippet": "Phenytoin: Disulfiram may increase the serum concentration of Phenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible. Phenytoin dose adjustment will likely be necessary when starting and/o…"}, {"doc_id": "protriptyline-drug-information", "bm25_top3": 3.469473366790238, "bm25_max": 3.469473366790238, "bge_top3": null, "bge_max": null, "title": "Protriptyline: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of protriptyline.  Allow 14 days to elapse between discontinuing protriptyline and initiation of an MA…"}, {"doc_id": "desloratadine-and-pseudoephedrine-drug-information", "bm25_top3": 3.312294707800433, "bm25_max": 3.312294707800433, "bge_top3": null, "bge_max": null, "title": "Desloratadine and pseudoephedrine: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoam…"}, {"doc_id": "milnacipran-drug-information", "bm25_top3": 3.2952073205928567, "bm25_max": 3.2952073205928567, "bge_top3": null, "bge_max": null, "title": "Milnacipran: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow ≥14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of milnacipran.  Allo…"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": 2.755853072357774, "bm25_max": 3.2762450466670483, "bge_top3": null, "bge_max": null, "title": "Trimipramine: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of trimipramine.  Allo…"}, {"doc_id": "triprolidine-phenylephrine-and-codeine-drug-information", "bm25_top3": 3.2105146100856743, "bm25_max": 3.2105146100856743, "bge_top3": null, "bge_max": null, "title": "Triprolidine, phenylephrine, and codeine: Drug information", "rep_snippet": "MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy  Minocycline: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Mirabegron: Anticholiner…"}, {"doc_id": "chlorpheniramine-pseudoephedrine-and-codeine-drug-information", "bm25_top3": 3.1251702655831775, "bm25_max": 3.1251702655831775, "bge_top3": null, "bge_max": null, "title": "Chlorpheniramine, pseudoephedrine, and codeine: Drug information", "rep_snippet": "MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy  Minocycline: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Mirabegron: Anticholiner…"}, {"doc_id": "triprolidine-pseudoephedrine-and-codeine-drug-information", "bm25_top3": 3.1251702655831775, "bm25_max": 3.1251702655831775, "bge_top3": null, "bge_max": null, "title": "Triprolidine, pseudoephedrine, and codeine: Drug information", "rep_snippet": "MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy  Minocycline: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Mirabegron: Anticholiner…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 3.109026029084866, "bm25_max": 3.109026029084866, "bge_top3": 0.6300965547561646, "bge_max": 0.6300965547561646, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "MAO inhibitor recommendations:  Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and i…"}, {"doc_id": "bupropion-and-naltrexone-drug-information", "bm25_top3": 3.099461173081778, "bm25_max": 3.099461173081778, "bge_top3": null, "bge_max": null, "title": "Bupropion and naltrexone: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to bupropion, naltrexone, or any other component of the formulation; concomitant use of other bupropion-containing products (eg, including [but not limited to] Wellbutrin, Wellbutrin S…"}, {"doc_id": "amitriptyline-and-chlordiazepoxide-drug-information", "bm25_top3": 2.654072383529802, "bm25_max": 3.072683669011104, "bge_top3": null, "bge_max": null, "title": "Amitriptyline and chlordiazepoxide: Drug information", "rep_snippet": "MAO inhibitor recommendations:  Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and i…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": 2.9796056692383193, "bm25_max": 2.9796056692383193, "bge_top3": null, "bge_max": null, "title": "Clozapine: Drug information", "rep_snippet": "Dosage adjustment with concomitant therapy:  Strong CYP1A2 inhibitors (eg, fluvoxamine, ciprofloxacin):  Initiating clozapine with concomitant medication or adding a concomitant medication while taking clozapine: Use one…"}, {"doc_id": "isocarboxazid-drug-information", "bm25_top3": 2.9578727107123317, "bm25_max": 2.9578727107123317, "bge_top3": 0.6147547960281372, "bge_max": 0.6147547960281372, "title": "Isocarboxazid: Drug information", "rep_snippet": "If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving isocarboxazid and potential benefits outweigh potential risks, discontinue isocarboxazid promptly and administer linezoli…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": 2.779111558600432, "bm25_max": 2.779111558600432, "bge_top3": 0.6160421967506409, "bge_max": 0.6160421967506409, "title": "Phenelzine: Drug information", "rep_snippet": "If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving phenelzine and potential benefits outweigh potential risks, discontinue phenelzine promptly and administer linezolid or I…"}, {"doc_id": "safinamide-drug-information", "bm25_top3": 2.64846204942339, "bm25_max": 2.64846204942339, "bge_top3": 0.6055235862731934, "bge_max": 0.6055235862731934, "title": "Safinamide: Drug information", "rep_snippet": "Contraindications  Hypersensitivity (eg, swelling of the tongue and oral mucosa, dyspnea) to safinamide or any component of the formulation; severe hepatic impairment (Child-Pugh class C); concomitant use of other monoam…"}, {"doc_id": "dopamine-drug-information", "bm25_top3": 2.6159660869443346, "bm25_max": 2.6159660869443346, "bge_top3": null, "bge_max": null, "title": "Dopamine: Drug information", "rep_snippet": "Hyaluronidase: May enhance the adverse/toxic effect of DOPamine. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine. Use of hyaluronidase for other purposes in patients receiving d…"}, {"doc_id": "tramadol-drug-information", "bm25_top3": 2.5254524660184554, "bm25_max": 2.5254524660184554, "bge_top3": null, "bge_max": null, "title": "Tramadol: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "ergotamine-and-caffeine-drug-information", "bm25_top3": 2.4198947000568367, "bm25_max": 2.4198947000568367, "bge_top3": 0.6225174963474274, "bge_max": 0.639563262462616, "title": "Ergotamine and caffeine: Drug information", "rep_snippet": "Letermovir: May increase the serum concentration of Ergot Derivatives. Risk X: Avoid combination  Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic ag…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 2.3277244256647975, "bm25_max": 2.3277244256647975, "bge_top3": null, "bge_max": null, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "acetaminophen-paracetamol-and-phenylephrine-drug-information", "bm25_top3": 2.3277244256647975, "bm25_max": 2.3277244256647975, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol) and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "pseudoephedrine-and-ibuprofen-drug-information", "bm25_top3": 2.3100212180702684, "bm25_max": 2.3100212180702684, "bge_top3": 0.6103177070617676, "bge_max": 0.6103177070617676, "title": "Pseudoephedrine and ibuprofen: Drug information", "rep_snippet": "Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of symp…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": 2.305638720790723, "bm25_max": 2.305638720790723, "bge_top3": 0.6197181940078735, "bge_max": 0.6197181940078735, "title": "Procarbazine: Drug information", "rep_snippet": "Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemothera…"}, {"doc_id": "naproxen-and-pseudoephedrine-drug-information", "bm25_top3": 2.2805148394766945, "bm25_max": 2.2805148394766945, "bge_top3": null, "bge_max": null, "title": "Naproxen and pseudoephedrine: Drug information", "rep_snippet": "Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination  Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk…"}, {"doc_id": "acetaminophen-and-pseudoephedrine-drug-information", "bm25_top3": 2.2732829866924504, "bm25_max": 2.2732829866924504, "bge_top3": null, "bge_max": null, "title": "Acetaminophen and pseudoephedrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6687987446784973, "bge_max": 0.6687987446784973, "title": "Ergotamine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6687987446784973, "bge_max": 0.6687987446784973, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "ergoloid-mesylates-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6687987446784973, "bge_max": 0.6687987446784973, "title": "Ergoloid mesylates: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "bromocriptine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6527541279792786, "bge_max": 0.6527541279792786, "title": "Bromocriptine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "cabergoline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6351200938224792, "bge_max": 0.6351200938224792, "title": "Cabergoline: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Manage…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6310681700706482, "bge_max": 0.6310681700706482, "title": "Vortioxetine: Drug information", "rep_snippet": "Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6131091713905334, "bge_max": 0.6247323155403137, "title": "Duloxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Metaxalone: May enhance the serotonergic effect of Serot…"}, {"doc_id": "eletriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6222963333129883, "bge_max": 0.6222963333129883, "title": "Eletriptan: Drug information", "rep_snippet": "Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives. Exceptions: Nicergoline.…"}, {"doc_id": "acetaminophen-paracetamol-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6212648749351501, "bge_max": 0.6212648749351501, "title": "Acetaminophen (paracetamol), aspirin, and caffeine: Drug information", "rep_snippet": "Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin. Ris…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6151107549667358, "bge_max": 0.6151107549667358, "title": "Naratriptan: Drug information", "rep_snippet": "Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Risk C: Monitor therapy  Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. S…"}, {"doc_id": "frovatriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6151107549667358, "bge_max": 0.6151107549667358, "title": "Frovatriptan: Drug information", "rep_snippet": "Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Risk C: Monitor therapy  Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. S…"}, {"doc_id": "tranylcypromine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6147547960281372, "bge_max": 0.6147547960281372, "title": "Tranylcypromine: Drug information", "rep_snippet": "Serotonin Reuptake Inhibitor/Antagonists: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Serotonin Reuptake Inhibitor/Antagonists. While methylene blue and linezolid are expected to interact, specif…"}, {"doc_id": "ergonovine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6080016791820526, "bge_max": 0.6105316281318665, "title": "Ergonovine (United States: Not available): Drug information", "rep_snippet": "Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6066073179244995, "bge_max": 0.6066073179244995, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.  • Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; ma…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6055850982666016, "bge_max": 0.6055850982666016, "title": "Lithium: Drug information", "rep_snippet": "Desmopressin: Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. Risk C: Monitor therapy  Eplerenone: May increase the serum concentration of Lithiu…"}, {"doc_id": "selegiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6055235862731934, "bge_max": 0.6055235862731934, "title": "Selegiline: Drug information", "rep_snippet": "Serotonin Modulators: Anti-Parkinson Agents (Monoamine Oxidase Inhibitor) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms o…"}, {"doc_id": "rasagiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.604217141866684, "bge_max": 0.6055235862731934, "title": "Rasagiline: Drug information", "rep_snippet": "Serotonin Modulators: Anti-Parkinson Agents (Monoamine Oxidase Inhibitor) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms o…"}, {"doc_id": "methylergonovine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6049983501434326, "bge_max": 0.6054717302322388, "title": "Methylergonovine: Drug information", "rep_snippet": "Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect…"}, {"doc_id": "lorcaserin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6040786504745483, "bge_max": 0.6040786504745483, "title": "Lorcaserin: Drug information", "rep_snippet": "Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin s…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6038797497749329, "bge_max": 0.6038797497749329, "title": "Fluvoxamine: Drug information", "rep_snippet": "Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result…"}, {"doc_id": "tetracaine-and-oxymetazoline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6032755970954895, "bge_max": 0.6032755970954895, "title": "Tetracaine and oxymetazoline: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6031078100204468, "bge_max": 0.6031078100204468, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination  Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Ag…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6027121543884277, "bge_max": 0.6027121543884277, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "promethazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6027121543884277, "bge_max": 0.6027121543884277, "title": "Promethazine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "methamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6026328206062317, "bge_max": 0.6026328206062317, "title": "Methamphetamine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.60204017162323, "bge_max": 0.60204017162323, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy  Lithium: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lithium. MetroNI…"}]}
{"qid": "Q11_abbr+mechanism", "query": "Starting amiodarone in pt on digoxin — interaction mech & digoxin dose/monitor adj?", "base_qid": "Q11", "variant_type": "abbr+mechanism", "candidates": [{"doc_id": "digoxin-immune-fab-drug-information", "bm25_top3": 40.148436717528156, "bm25_max": 44.05572590938954, "bge_top3": null, "bge_max": null, "title": "Digoxin immune Fab: Drug information", "rep_snippet": "Approximate Dose of Digoxin Immune Fab (in vials) for Reversal of a Single Large Digoxin Overdose  Number of Digoxin Tablets or Capsules Ingested1  Dose of Digoxin Immune Fab  (# of Vials)  1250 mcg tablets with 80% bioa…"}, {"doc_id": "digoxin-drug-information", "bm25_top3": 38.33053861084201, "bm25_max": 40.27670198112887, "bge_top3": 0.6348487734794617, "bge_max": 0.6479799747467041, "title": "Digoxin: Drug information", "rep_snippet": "Eliglustat: May increase the serum concentration of Digoxin. Management: In patients receiving digoxin, measure digoxin serum concentrations prior to initiating eliglustat. Preemptively reduce digoxin doses by 30% and co…"}, {"doc_id": "etravirine-drug-information", "bm25_top3": 25.577808002012752, "bm25_max": 25.577808002012752, "bge_top3": null, "bge_max": null, "title": "Etravirine: Drug information", "rep_snippet": "Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. Risk X: Avoid combination  Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": 22.566706923114456, "bm25_max": 22.566706923114456, "bge_top3": null, "bge_max": null, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Digoxin: Boceprevir may increase the serum concentration of Digoxin. Management: In patients initiating digoxin during boceprevir treatment, initiate at the lowest possible digoxin dose, monitor serum digoxin concentrati…"}, {"doc_id": "ombitasvir-paritaprevir-and-ritonavir-drug-information", "bm25_top3": 22.29513059565874, "bm25_max": 22.29513059565874, "bge_top3": null, "bge_max": null, "title": "Ombitasvir, paritaprevir, and ritonavir: Drug information", "rep_snippet": "Digoxin: Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of Digoxin. Management: When initiating the ombitasvir/paritaprevir/ritonavir combination product in patients taking digoxin, decrease…"}, {"doc_id": "dronedarone-drug-information", "bm25_top3": 21.771020723983636, "bm25_max": 21.771020723983636, "bge_top3": 0.6358453035354614, "bge_max": 0.6358453035354614, "title": "Dronedarone: Drug information", "rep_snippet": "Digoxin: May enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin. Management: Avoid con…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": 20.911527845395387, "bm25_max": 20.911527845395387, "bge_top3": null, "bge_max": null, "title": "Mirabegron: Drug information", "rep_snippet": "Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Risk C: Monitor therapy  CY…"}, {"doc_id": "mifepristone-and-misoprostol-united-states-not-available-drug-information", "bm25_top3": 20.612231156935188, "bm25_max": 20.612231156935188, "bge_top3": 0.601760745048523, "bge_max": 0.601760745048523, "title": "Mifepristone and misoprostol (United States: Not available): Drug information", "rep_snippet": "Digoxin: MiFEPRIStone may increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereaft…"}, {"doc_id": "polyethylene-glycol-3350-drug-information", "bm25_top3": 20.591992360259116, "bm25_max": 20.591992360259116, "bge_top3": null, "bge_max": null, "title": "Polyethylene glycol 3350: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Digoxin: Polyethylene Glycol 3350 may decrease the serum concentration of Digoxin. Risk C: Monitor therapy"}, {"doc_id": "glecaprevir-and-pibrentasvir-drug-information", "bm25_top3": 20.554325233632603, "bm25_max": 20.554325233632603, "bge_top3": null, "bge_max": null, "title": "Glecaprevir and pibrentasvir: Drug information", "rep_snippet": "Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. Management: Dabigatran dose reductions may be needed. Specific recommendations…"}, {"doc_id": "telaprevir-united-states-not-available-drug-information", "bm25_top3": 20.456761299292992, "bm25_max": 20.456761299292992, "bge_top3": null, "bge_max": null, "title": "Telaprevir (United States: Not available): Drug information", "rep_snippet": "Deflazacort: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deflazacort. Management: Administer one third of the recommended deflazacort dose when used together with a strong…"}, {"doc_id": "eliglustat-drug-information", "bm25_top3": 19.59767329638297, "bm25_max": 19.59767329638297, "bge_top3": null, "bge_max": null, "title": "Eliglustat: Drug information", "rep_snippet": "Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clin…"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": 19.343946439301078, "bm25_max": 19.343946439301078, "bge_top3": null, "bge_max": null, "title": "Vemurafenib: Drug information", "rep_snippet": "Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clin…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 18.748115406545704, "bm25_max": 18.748115406545704, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "Digoxin: Spironolactone may increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasi…"}, {"doc_id": "milnacipran-drug-information", "bm25_top3": 18.562009267113616, "bm25_max": 18.562009267113616, "bge_top3": null, "bge_max": null, "title": "Milnacipran: Drug information", "rep_snippet": "Digoxin: Milnacipran may enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased, particularly with IV digoxin. Management: Avoid concurrent use of intravenous (IV)…"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": 18.32221419062418, "bm25_max": 18.32221419062418, "bge_top3": null, "bge_max": null, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "Didanosine: Darunavir may decrease the serum concentration of Didanosine. More specifically, this interaction is likely due to the effects of food (with which darunavir/ritonavir and darunavir/cobicistat are taken) on di…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 18.255492797625593, "bm25_max": 18.255492797625593, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "Dasatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib. Management: This combination should be avoided; consider reducing dasatinib dose if a strong CYP3A4 inhibitor must be used. If usin…"}, {"doc_id": "ivabradine-drug-information", "bm25_top3": 17.82791589803674, "bm25_max": 17.82791589803674, "bge_top3": 0.6152855157852173, "bge_max": 0.6152855157852173, "title": "Ivabradine: Drug information", "rep_snippet": "Monitoring Parameters  Heart rate (prior to initiation, prior to increasing dose, or after decreasing dose); monitor heart rate more closely if receiving other negative chronotropes (eg, amiodarone, beta-blockers, digoxi…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 17.60445839797812, "bm25_max": 17.60445839797812, "bge_top3": null, "bge_max": null, "title": "Spironolactone: Drug information", "rep_snippet": "Cholestyramine Resin: May enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination. Risk C: Monitor therapy  Cipr…"}, {"doc_id": "niacin-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6300759315490723, "bge_max": 0.6300759315490723, "title": "Niacin and simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alcohol (…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.627572774887085, "bge_max": 0.627572774887085, "title": "Simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Amiodaron…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.627572774887085, "bge_max": 0.627572774887085, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Amiodaron…"}, {"doc_id": "lovastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6230497360229492, "bge_max": 0.6230497360229492, "title": "Lovastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Amiodaron…"}, {"doc_id": "lovastatin-and-niacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6203962564468384, "bge_max": 0.6203962564468384, "title": "Lovastatin and niacin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alcohol (…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6168326139450073, "bge_max": 0.6168326139450073, "title": "Atorvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Aliskiren…"}, {"doc_id": "propranolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6118881702423096, "bge_max": 0.6118881702423096, "title": "Propranolol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "mipomersen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6105411052703857, "bge_max": 0.6105411052703857, "title": "Mipomersen: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acetaminophen: May enhance the hepatotoxic effect of Mipomersen. Risk C: Monitor therapy  Alcohol (Ethyl): May enhance the hepatotoxic ef…"}, {"doc_id": "amlodipine-and-atorvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6099715232849121, "bge_max": 0.6099715232849121, "title": "Amlodipine and atorvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alfuzosin…"}, {"doc_id": "codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6095549464225769, "bge_max": 0.6095549464225769, "title": "Codeine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "guaifenesin-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6095549464225769, "bge_max": 0.6095549464225769, "title": "Guaifenesin and codeine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "acetaminophen-paracetamol-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6095549464225769, "bge_max": 0.6095549464225769, "title": "Acetaminophen (paracetamol) and codeine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6080063978830973, "bge_max": 0.6086620688438416, "title": "Amiodarone: Drug information", "rep_snippet": "• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia, hypomagnesemia, or hypocalcemia, prior to use and throughout therapy.  • Myocardial infarction: In the setting of acute myocardial infarc…"}, {"doc_id": "methadone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6085360050201416, "bge_max": 0.6085360050201416, "title": "Methadone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abacavir: Methadone may diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Methadone. Risk C:…"}, {"doc_id": "alendronate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6052343845367432, "bge_max": 0.6052343845367432, "title": "Alendronate: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives. Risk C: Monitor therapy  Angiogenesis Inhibitors (Sys…"}, {"doc_id": "procainamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6050865054130554, "bge_max": 0.6050865054130554, "title": "Procainamide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "metoprolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6040135025978088, "bge_max": 0.6040135025978088, "title": "Metoprolol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "timolol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6040135025978088, "bge_max": 0.6040135025978088, "title": "Timolol (systemic): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "flecainide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6039290428161621, "bge_max": 0.6039290428161621, "title": "Flecainide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "brimonidine-and-timolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6024131774902344, "bge_max": 0.6024131774902344, "title": "Brimonidine and timolol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "carvedilol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6023345589637756, "bge_max": 0.6023345589637756, "title": "Carvedilol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "rasagiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6013934016227722, "bge_max": 0.6013934016227722, "title": "Rasagiline: Drug information", "rep_snippet": "Diethylpropion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Diethylpropion. Risk X: Avoid combination  Dihydrocodeine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This cou…"}, {"doc_id": "nebivolol-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6007488965988159, "bge_max": 0.6007488965988159, "title": "Nebivolol and valsartan: Drug information", "rep_snippet": "Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers. Risk C: Monitor therapy  Amphetamines: May dimin…"}, {"doc_id": "hydrocodone-and-guaifenesin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6005744934082031, "bge_max": 0.6005744934082031, "title": "Hydrocodone and guaifenesin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alcohol (Ethyl): May enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodon…"}, {"doc_id": "hydrocodone-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6005744934082031, "bge_max": 0.6005744934082031, "title": "Hydrocodone and acetaminophen (paracetamol): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alcohol (Ethyl): May enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodon…"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6005744934082031, "bge_max": 0.6005744934082031, "title": "Hydrocodone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alcohol (Ethyl): May enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodon…"}, {"doc_id": "brexpiprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6004319787025452, "bge_max": 0.6004319787025452, "title": "Brexpiprazole: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "metoprolol-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6004093289375305, "bge_max": 0.6004093289375305, "title": "Metoprolol and hydrochlorothiazide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "iloperidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5995992422103882, "bge_max": 0.5995992422103882, "title": "Iloperidone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "regadenoson-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5993439555168152, "bge_max": 0.5993439555168152, "title": "Regadenoson: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aminophylline: May diminish the vasodilatory effect of Regadenoson. Risk D: Consider therapy modification  Caffeine and Caffeine Containi…"}, {"doc_id": "fingolimod-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5988361835479736, "bge_max": 0.5988361835479736, "title": "Fingolimod: Drug information", "rep_snippet": "• Cardiovascular: Due to the risk of bradycardia and AV conduction delays, an ECG is required prior to initiation of therapy and after the initial observation period (6 hours) in all patients. Patients receiving concomit…"}, {"doc_id": "quinidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5986235737800598, "bge_max": 0.5986235737800598, "title": "Quinidine: Drug information", "rep_snippet": "Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Avoid whenever possible. While consi…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5985116362571716, "bge_max": 0.5985116362571716, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5979354977607727, "bge_max": 0.5979354977607727, "title": "Aminophylline: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Aceb…"}, {"doc_id": "levothyroxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5978877544403076, "bge_max": 0.5978877544403076, "title": "Levothyroxine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aluminum Hydroxide: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and…"}, {"doc_id": "dolasetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5975871086120605, "bge_max": 0.5975871086120605, "title": "Dolasetron: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. Risk X: Avoid combination  Hydroxychloroqu…"}, {"doc_id": "tedizolid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5973012447357178, "bge_max": 0.5973012447357178, "title": "Tedizolid: Drug information", "rep_snippet": "Diphenoxylate: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination  Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranul…"}, {"doc_id": "acetaminophen-paracetamol-caffeine-and-dihydrocodeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5968232154846191, "bge_max": 0.5968232154846191, "title": "Acetaminophen (paracetamol), caffeine, and dihydrocodeine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Aceb…"}]}
{"qid": "Q11_noise", "query": "Digoxin → add amio — what happens pharmacokinetically and how do we adjust?", "base_qid": "Q11", "variant_type": "noise", "candidates": [{"doc_id": "insulin-lispro-protamine-and-insulin-lispro-drug-information", "bm25_top3": 23.867649036529194, "bm25_max": 23.867649036529194, "bge_top3": null, "bge_max": null, "title": "Insulin lispro protamine and insulin lispro: Drug information", "rep_snippet": "Initial: Insulin lispro protamine and insulin lispro premix dose is obtained by dividing the current total daily basal insulin dose into 2 doses administered either as two-thirds of the dose before the morning meal and o…"}, {"doc_id": "insulin-aspart-protamine-and-insulin-aspart-drug-information", "bm25_top3": 23.867649036529194, "bm25_max": 23.867649036529194, "bge_top3": null, "bge_max": null, "title": "Insulin aspart protamine and insulin aspart: Drug information", "rep_snippet": "Initial: Insulin aspart protamine and insulin aspart premix dose is obtained by dividing the current total daily basal insulin dose into 2 doses administered either as two-thirds of the dose before the morning meal and o…"}, {"doc_id": "digoxin-immune-fab-drug-information", "bm25_top3": 17.187834093598802, "bm25_max": 23.162886847736765, "bge_top3": null, "bge_max": null, "title": "Digoxin immune Fab: Drug information", "rep_snippet": "Approximate Dose of Digoxin Immune Fab (in vials) for Reversal of a Single Large Digoxin Overdose  Number of Digoxin Tablets or Capsules Ingested1  Dose of Digoxin Immune Fab  (# of Vials)  1250 mcg tablets with 80% bioa…"}, {"doc_id": "digoxin-drug-information", "bm25_top3": 13.86210568959771, "bm25_max": 16.50986966528352, "bge_top3": 0.5688788692156473, "bge_max": 0.57722407579422, "title": "Digoxin: Drug information", "rep_snippet": "Eliglustat: May increase the serum concentration of Digoxin. Management: In patients receiving digoxin, measure digoxin serum concentrations prior to initiating eliglustat. Preemptively reduce digoxin doses by 30% and co…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 15.113909560545576, "bm25_max": 15.113909560545576, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "tinzaparin-drug-information", "bm25_top3": 6.025694145026418, "bm25_max": 13.668220119731993, "bge_top3": null, "bge_max": null, "title": "Tinzaparin: Drug information", "rep_snippet": "Anticoagulant in extracorporeal circuit during hemodialysis (recommendations apply to stable patients with chronic renal failure): IV:  Dialysis session ≤4 hours (no hemorrhage risk): Initial bolus (via arterial side of…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 13.196184981798325, "bm25_max": 13.196184981798325, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "camphor-and-menthol-drug-information", "bm25_top3": 13.13572445155259, "bm25_max": 13.13572445155259, "bge_top3": null, "bge_max": null, "title": "Camphor and menthol: Drug information", "rep_snippet": "• Self-medication (OTC use): Do not heat, microwave, or add to hot water or any container where heating water; do not get into eyes or mucous membranes; do not bandage tightly. Discontinue use and contact a healthcare pr…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-indacaterol-drug-information", "bm25_top3": 12.268348382594716, "bm25_max": 12.268348382594716, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and indacaterol: Drug information", "rep_snippet": "• Lactose: Some products may contain lactose; allergic reactions possible in patients with severe milk protein allergy. Use with caution in patients with severe hypersensitivity to milk proteins.  Other warnings:  • Appr…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 11.201544923676636, "bm25_max": 11.201544923676636, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Administration  Capsules: Administer with water.  Powder for solution: Dissolve one packet in 240 mL hot water; consume within 10 to 15 minutes. If using microwave, add one packet to 240 mL of cool water and stir briskly…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 9.861831371562058, "bm25_max": 9.861831371562058, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Administration  Administer without regard to meals.  Liquid: Only use enclosed dosing cup; do not use other devices.  Powder for solution: Dissolve contents of 1 packet into 8 ounces of hot water; sip while hot and consu…"}, {"doc_id": "quinidine-drug-information", "bm25_top3": 5.210675306640907, "bm25_max": 5.210675306640907, "bge_top3": null, "bge_max": null, "title": "Quinidine: Drug information", "rep_snippet": "• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.  • G6PD deficiency: Hemolysis may occur in patients with G6PD (glucose-6-phosphate…"}, {"doc_id": "chlorpromazine-drug-information", "bm25_top3": 4.856031232216278, "bm25_max": 4.856031232216278, "bge_top3": null, "bge_max": null, "title": "Chlorpromazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Chlorpromazine and its metabolites have been detected in breast milk; concentrations in the milk do not correlate with those in the mother and may be higher than what is in the maternal pla…"}, {"doc_id": "etravirine-drug-information", "bm25_top3": 2.4705600387695057, "bm25_max": 3.7901356145095733, "bge_top3": null, "bge_max": null, "title": "Etravirine: Drug information", "rep_snippet": "Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. Risk X: Avoid combination  Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C…"}, {"doc_id": "patiromer-drug-information", "bm25_top3": 1.8382376063065884, "bm25_max": 1.8382376063065884, "bge_top3": null, "bge_max": null, "title": "Patiromer: Drug information", "rep_snippet": "Administration  Administer with food. Do not administer patiromer in its dry form. Following reconstitution, drink mixture immediately. If powder remains in the glass after drinking, add more water, stir, and drink immed…"}, {"doc_id": "adenosine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5858789682388306, "bge_max": 0.5858789682388306, "title": "Adenosine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Caffeine and Caffeine Containing Products: May diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of…"}, {"doc_id": "milnacipran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5729144215583801, "bge_max": 0.5729144215583801, "title": "Milnacipran: Drug information", "rep_snippet": "Digoxin: Milnacipran may enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased, particularly with IV digoxin. Management: Avoid concurrent use of intravenous (IV)…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5711473226547241, "bge_max": 0.5711473226547241, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "Digoxin: Spironolactone may increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasi…"}, {"doc_id": "acarbose-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5687852501869202, "bge_max": 0.5687852501869202, "title": "Acarbose: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy  Androgens: May enhance the hypogl…"}, {"doc_id": "penicillamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5680484771728516, "bge_max": 0.5680484771728516, "title": "Penicillamine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Antacids: May decrease the serum concentration of PenicillAMINE. Risk D: Consider therapy modification  Digoxin: PenicillAMINE may decrea…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5656147599220276, "bge_max": 0.5656147599220276, "title": "Duloxetine: Drug information", "rep_snippet": "Allow ≥5 to 14 days to elapse between discontinuing duloxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders."}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5655723810195923, "bge_max": 0.5655723810195923, "title": "Sitagliptin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy  Androgens: May enhance the hypogl…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5655723810195923, "bge_max": 0.5655723810195923, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy  Androgens: May enhance the hypogl…"}, {"doc_id": "niacin-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5655155777931213, "bge_max": 0.5655155777931213, "title": "Niacin and simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alcohol (…"}, {"doc_id": "imipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5644515752792358, "bge_max": 0.5644515752792358, "title": "Imipramine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to imipramine (cross-reactivity with other dibenzodiazepines may occur) or any component of the formulation; acute recovery period after a myocardial infarction (MI); use of MAO inhibi…"}, {"doc_id": "pseudoephedrine-and-ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5634310245513916, "bge_max": 0.5634310245513916, "title": "Pseudoephedrine and ibuprofen: Drug information", "rep_snippet": "Diclofenac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAI…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5634310245513916, "bge_max": 0.5634310245513916, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Diclofenac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAI…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5626002550125122, "bge_max": 0.5626002550125122, "title": "Procarbazine: Drug information", "rep_snippet": "Pizotifen: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Pizotifen. Risk X: Avoid combination  Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor thera…"}, {"doc_id": "tedizolid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.55949267745018, "bge_max": 0.5619064569473267, "title": "Tedizolid: Drug information", "rep_snippet": "Diphenoxylate: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination  Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranul…"}, {"doc_id": "doxepin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5609484910964966, "bge_max": 0.5609484910964966, "title": "Doxepin (systemic): Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing doxepin and initiation of an MAO inhibitor intended to treat psychiatric disorders."}, {"doc_id": "dronedarone-drug-information", "bm25_top3": -0.21769387775184867, "bm25_max": -0.21769387775184867, "bge_top3": 0.5603589415550232, "bge_max": 0.5603589415550232, "title": "Dronedarone: Drug information", "rep_snippet": "Digoxin: May enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin. Management: Avoid con…"}, {"doc_id": "rasagiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5602290034294128, "bge_max": 0.5602290034294128, "title": "Rasagiline: Drug information", "rep_snippet": "Diethylpropion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Diethylpropion. Risk X: Avoid combination  Dihydrocodeine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This cou…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5584255456924438, "bge_max": 0.5584255456924438, "title": "Linezolid: Drug information", "rep_snippet": "Dihydrocodeine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Risk C: Monitor therapy  Diphenoxylate: May enhance the hypertensive effect of Monoamine Oxida…"}, {"doc_id": "gemfibrozil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5579225420951843, "bge_max": 0.5579225420951843, "title": "Gemfibrozil: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives. Risk C: Monitor therapy  Alitretinoin (Systemic):…"}, {"doc_id": "sumatriptan-and-naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.557877242565155, "bge_max": 0.557877242565155, "title": "Sumatriptan and naproxen: Drug information", "rep_snippet": "Diclofenac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAI…"}, {"doc_id": "dacarbazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5573986172676086, "bge_max": 0.5573986172676086, "title": "Dacarbazine: Drug information", "rep_snippet": "Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Risk X: Avoid combination  Echinacea: May diminish the therapeutic e…"}, {"doc_id": "clofarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5572080016136169, "bge_max": 0.5572080016136169, "title": "Clofarabine: Drug information", "rep_snippet": "Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Risk C: Monitor therapy  Diazoxide: May enhance the hypotensive effect of Blood Press…"}, {"doc_id": "midodrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5568602681159973, "bge_max": 0.5568602681159973, "title": "Midodrine: Drug information", "rep_snippet": "Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart…"}, {"doc_id": "regadenoson-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5567183494567871, "bge_max": 0.5567183494567871, "title": "Regadenoson: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aminophylline: May diminish the vasodilatory effect of Regadenoson. Risk D: Consider therapy modification  Caffeine and Caffeine Containi…"}, {"doc_id": "doxapram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5550975203514099, "bge_max": 0.5550975203514099, "title": "Doxapram: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.…"}, {"doc_id": "methylene-blue-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5550036430358887, "bge_max": 0.5550036430358887, "title": "Methylene blue: Drug information", "rep_snippet": "Guanethidine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination  Heroin: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Heroin. Risk X: Avoid combinatio…"}, {"doc_id": "paricalcitol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5549359321594238, "bge_max": 0.5549359321594238, "title": "Paricalcitol: Drug information", "rep_snippet": "Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs. Risk C: Monitor therapy  Digoxin: Paricalcitol may enhance the adverse/toxic effect of Digoxin. Risk C: Monitor therapy  Mineral Oil: May decrease the s…"}, {"doc_id": "ombitasvir-paritaprevir-and-ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5543347001075745, "bge_max": 0.5543347001075745, "title": "Ombitasvir, paritaprevir, and ritonavir: Drug information", "rep_snippet": "Digoxin: Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of Digoxin. Management: When initiating the ombitasvir/paritaprevir/ritonavir combination product in patients taking digoxin, decrease…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5540307760238647, "bge_max": 0.5540307760238647, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Diclofenac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAI…"}, {"doc_id": "hydrocodone-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5539348125457764, "bge_max": 0.5539348125457764, "title": "Hydrocodone and pseudoephedrine: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of HYDROcodone. Management: Consider alternatives to this combination when possible. Risk D: Consider therapy modification  Nabilone: May enhance the CNS…"}, {"doc_id": "hydrocodone-pseudoephedrine-and-guaifenesin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5539348125457764, "bge_max": 0.5539348125457764, "title": "Hydrocodone, pseudoephedrine, and guaifenesin: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of HYDROcodone. Management: Consider alternatives to this combination when possible. Risk D: Consider therapy modification  Nabilone: May enhance the CNS…"}, {"doc_id": "carisoprodol-aspirin-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537752509117126, "bge_max": 0.5537752509117126, "title": "Carisoprodol, aspirin, and codeine: Drug information", "rep_snippet": "Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations. Risk D: Consider therapy modif…"}, {"doc_id": "butalbital-compound-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537752509117126, "bge_max": 0.5537752509117126, "title": "Butalbital compound and codeine: Drug information", "rep_snippet": "Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations. Risk D: Consider therapy modif…"}, {"doc_id": "enalapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Enalapril: Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "perindopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Perindopril: Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "lisinopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Lisinopril: Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "enalaprilat-intravenous-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Enalaprilat (intravenous): Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "moexipril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Moexipril: Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "ramipril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Ramipril: Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "benazepril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Benazepril: Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "cilazapril-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Cilazapril (United States: Not available): Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "trandolapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537676811218262, "bge_max": 0.5537676811218262, "title": "Trandolapril: Drug information", "rep_snippet": "Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  Cipro…"}, {"doc_id": "lovastatin-and-niacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.552921712398529, "bge_max": 0.552921712398529, "title": "Lovastatin and niacin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alcohol (…"}, {"doc_id": "sufentanil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5517533421516418, "bge_max": 0.5517533421516418, "title": "Sufentanil: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy  Alvimopan: Opioid Analgesics ma…"}, {"doc_id": "remifentanil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5517533421516418, "bge_max": 0.5517533421516418, "title": "Remifentanil: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy  Alvimopan: Opioid Analgesics ma…"}, {"doc_id": "lutropin-alfa-united-states-not-available-drug-information", "bm25_top3": 0.4231276925777081, "bm25_max": 0.4231276925777081, "bge_top3": null, "bge_max": null, "title": "Lutropin alfa (United States: Not available): Drug information", "rep_snippet": "Administration  SubQ: Administer in the stomach or thigh; rotate injection sites. Do not shake solution; allow any bubbles to settle prior to administration. Contents of lutropin alfa vial may be mixed in the same syring…"}, {"doc_id": "ammonium-lactate-topical-drug-information", "bm25_top3": 0.3372268198668493, "bm25_max": 0.3372268198668493, "bge_top3": null, "bge_max": null, "title": "Ammonium lactate (topical): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known how this medication affects normal levels of lactic acid in human milk. Because studies have not been done in nursing women, use with caution when needed."}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": 0.27465424605416544, "bm25_max": 0.27465424605416544, "bge_top3": null, "bge_max": null, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Digoxin: Boceprevir may increase the serum concentration of Digoxin. Management: In patients initiating digoxin during boceprevir treatment, initiate at the lowest possible digoxin dose, monitor serum digoxin concentrati…"}, {"doc_id": "hydroxyurea-hydroxycarbamide-drug-information", "bm25_top3": 0.1473973177511887, "bm25_max": 0.1473973177511887, "bge_top3": null, "bge_max": null, "title": "Hydroxyurea (hydroxycarbamide): Drug information", "rep_snippet": "Administration  Oral: Administer at the same time each day. Swallow whole, do not open capsules.  Siklos: Administer with water. If unable to swallow tablets whole, may disperse immediately before use in a small amount o…"}, {"doc_id": "camphor-drug-information", "bm25_top3": -0.2036768651928007, "bm25_max": -0.2036768651928007, "bge_top3": null, "bge_max": null, "title": "Camphor: Drug information", "rep_snippet": "Administration  Inhalation: Add solution to a hot steam vaporizer only. Breathe in medicated vapors.  Topical:  Cream: Cleanse, rinse and dry skin. Apply generously to painful muscles and joints. Gently massage until the…"}, {"doc_id": "efavirenz-drug-information", "bm25_top3": -0.7018209049291926, "bm25_max": -0.628789857718294, "bge_top3": null, "bge_max": null, "title": "Efavirenz: Drug information", "rep_snippet": "Capsule contents may also be mixed with infant formula only for young infants who cannot reliably consume solid foods. Combine entire contents of capsule(s) with 10 mL of reconstituted, room temperature infant formula in…"}, {"doc_id": "practice-changing-updates", "bm25_top3": -0.640234305541858, "bm25_max": -0.640234305541858, "bge_top3": null, "bge_max": null, "title": "practice-changing-updates", "rep_snippet": "INTRODUCTION — This section highlights selected specific new recommendations and/or updates that we anticipate may change usual clinical practice. Practice Changing UpDates focus on changes that may have significant and…"}, {"doc_id": "methadone-drug-information", "bm25_top3": -0.8854956682162829, "bm25_max": -0.8854956682162829, "bge_top3": null, "bge_max": null, "title": "Methadone: Drug information", "rep_snippet": "Administration  Tablets for oral suspension (for detoxification and maintenance): For oral administration only; do not inject (contains insoluble excipients). Disperse tablet in ~120 mL of water, orange juice, or other a…"}, {"doc_id": "sacrosidase-drug-information", "bm25_top3": -1.1223930122124237, "bm25_max": -1.1223930122124237, "bge_top3": null, "bge_max": null, "title": "Sacrosidase: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Sucraid® is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to http://www.sucraid.net/how-to-order-sucraid or call 1-866-740-2743."}, {"doc_id": "mifepristone-drug-information", "bm25_top3": -1.2720373384360641, "bm25_max": -1.2720373384360641, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Korlym is only available through a restricted access program. For prescriber registration and patient enrollment forms, please refer to http://www.korlym.com/hcp/how-to-prescribe-korl…"}, {"doc_id": "uridine-triacetate-drug-information", "bm25_top3": -1.3811226637016158, "bm25_max": -1.3811226637016158, "bge_top3": null, "bge_max": null, "title": "Uridine triacetate: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Fluorouracil accidental overdose/overexposure: Uridine triacetate (formerly called vistonuridine) is available through select specialty pharmacies. Procurement information is availabl…"}, {"doc_id": "pembrolizumab-drug-information", "bm25_top3": -1.7082493595615702, "bm25_max": -1.7082493595615702, "bge_top3": null, "bge_max": null, "title": "Pembrolizumab: Drug information", "rep_snippet": "Administration  IV: Infuse over 30 minutes through a 0.2 to 5 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter. Do not infuse other medications through the same infusion line.  Non-small cell lun…"}]}
{"qid": "Q11_spelling", "query": "Digox + amiodrone — dose change needed?", "base_qid": "Q11", "variant_type": "spelling", "candidates": [{"doc_id": "digoxin-drug-information", "bm25_top3": 11.618497352867617, "bm25_max": 16.146543936693647, "bge_top3": 0.5848738849163055, "bge_max": 0.5917643904685974, "title": "Digoxin: Drug information", "rep_snippet": "Brand Names: US  Digitek;  Digox;  Lanoxin;  Lanoxin Pediatric"}, {"doc_id": "silver-containing-dressings-drug-information", "bm25_top3": 12.846704350737154, "bm25_max": 12.846704350737154, "bge_top3": null, "bge_max": null, "title": "Silver-containing dressings: Drug information", "rep_snippet": "Acticoat Flex: Apply directly to wound, keep dressing moist and secure with appropriate secondary dressing. If wound is dry or there is minimal exudate, moisten dressing with drinking water prior to application. Acticoat…"}, {"doc_id": "argatroban-drug-information", "bm25_top3": 12.389969500692644, "bm25_max": 12.389969500692644, "bge_top3": null, "bge_max": null, "title": "Argatroban: Drug information", "rep_snippet": "If dissection, impending abrupt closure, thrombus formation during PCI, or inability to achieve ACT >300 seconds: An additional bolus of 150 mcg/kg, followed by an increase in infusion rate to 40 mcg/kg/minute may be adm…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 3.9649434699833273, "bm25_max": 11.619646339796185, "bge_top3": 0.610873281955719, "bge_max": 0.6168730854988098, "title": "Amiodarone: Drug information", "rep_snippet": "Maintenance dose: 100 to 200 mg daily (maximum maintenance dose: 200 mg daily) (ACC/AHA/HRS [Page 2015])  IV: 150 mg over 10 minutes, then 1 mg/minute for 6 hours, then 0.5 mg/minute for 18 hours or may change to oral do…"}, {"doc_id": "insulin-aspart-drug-information", "bm25_top3": 10.671008812193293, "bm25_max": 10.671008812193293, "bge_top3": null, "bge_max": null, "title": "Insulin aspart: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be needed. Renal impairment may change insulin requirements; monitor blood glucose closel…"}, {"doc_id": "nadroparin-united-states-not-available-drug-information", "bm25_top3": 10.525866504844998, "bm25_max": 10.525866504844998, "bge_top3": null, "bge_max": null, "title": "Nadroparin (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl ≥30 to <50 mL/minute: Decrease dose by 25% to 33%. Some have suggested that no dose adjustment is needed when used for prophylax…"}, {"doc_id": "ruxolitinib-drug-information", "bm25_top3": 10.273811918980288, "bm25_max": 10.273811918980288, "bge_top3": null, "bge_max": null, "title": "Ruxolitinib: Drug information", "rep_snippet": "15 mg twice/day  10 mg twice/day  5 mg twice/day  Platelet Count  New Dose  New Dose  New Dose  New Dose  New Dose  100,000 to <125,000/mm3  20 mg twice/day  15 mg twice/day  No change  No change  No change  75,000 to <1…"}, {"doc_id": "oxycodone-and-acetaminophen-paracetamol-drug-information", "bm25_top3": 8.505090326189844, "bm25_max": 9.886532795052654, "bge_top3": null, "bge_max": null, "title": "Oxycodone and acetaminophen (paracetamol): Drug information", "rep_snippet": "Manufacturer's labeling: Initial dose, based on oxycodone content: 2.5 to 10 mg every 6 hours as needed. Titrate according to pain severity and individual response. Do not exceed acetaminophen 4 g/day.  Discontinuation o…"}, {"doc_id": "treprostinil-drug-information", "bm25_top3": 9.74532992609671, "bm25_max": 9.74532992609671, "bge_top3": 0.5787093639373779, "bge_max": 0.5787093639373779, "title": "Treprostinil: Drug information", "rep_snippet": "Maintain current dose plus additional 5% to 10% as needed"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": 9.688011811495269, "bm25_max": 9.688011811495269, "bge_top3": null, "bge_max": null, "title": "Hydrocodone: Drug information", "rep_snippet": "Vantrela ER: Initial: 15 mg every 12 hours. Dose increases may occur every 3 to 7 days as needed to achieve adequate analgesia (maximum: 180 mg/day).  Zohydro ER: Initial: 10 mg every 12 hours. Dose increases may occur i…"}, {"doc_id": "factor-xiii-concentrate-from-human-plasma-drug-information", "bm25_top3": 9.669521283609562, "bm25_max": 9.669521283609562, "bge_top3": null, "bge_max": null, "title": "Factor XIII, concentrate from human plasma: Drug information", "rep_snippet": "Dosing: Adult  Congenital factor XIII deficiency: IV:  Prophylaxis:  Initial: 40 units/kg  Maintenance: Dose adjustment should be based on factor XIII activity trough levels (target level of 5% to 20% using Berichrom act…"}, {"doc_id": "liraglutide-drug-information", "bm25_top3": 9.416996782426457, "bm25_max": 9.416996782426457, "bge_top3": null, "bge_max": null, "title": "Liraglutide: Drug information", "rep_snippet": "Dosing: Adult  Chronic weight management (Saxenda): SubQ: Initial: 0.6 mg once daily for one week; increase by 0.6 mg daily at weekly intervals to a target dose of 3 mg once daily. If the patient cannot tolerate an incre…"}, {"doc_id": "benzonatate-drug-information", "bm25_top3": 9.31533260452165, "bm25_max": 9.31533260452165, "bge_top3": null, "bge_max": null, "title": "Benzonatate: Drug information", "rep_snippet": "Dosing: Adult  Cough: Oral: 100 to 200 mg 3 times/day as needed for cough (maximum single dose: 200 mg; maximum dose: 600 mg/day)"}, {"doc_id": "acetaminophen-paracetamol-caffeine-and-dihydrocodeine-drug-information", "bm25_top3": 9.224497849693686, "bm25_max": 9.224497849693686, "bge_top3": 0.5731430649757385, "bge_max": 0.5731430649757385, "title": "Acetaminophen (paracetamol), caffeine, and dihydrocodeine: Drug information", "rep_snippet": "Dosing: Adult  Pain management: Oral:  Capsule (acetaminophen 320.5 mg/caffeine 30 mg/dihydrocodeine bitartrate 16 mg): Two capsules every 4 hours as needed; adjust dose based on severity of pain (maximum dose: 10 capsul…"}, {"doc_id": "pegylated-liposomal-doxorubicin-drug-information", "bm25_top3": 8.207825537615626, "bm25_max": 8.207825537615626, "bge_top3": null, "bge_max": null, "title": "Pegylated liposomal doxorubicin: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  US labeling: There are no dosage adjustments provided in the manufacturer’s labeling. However, doxorubicin is predominantly hepatically eliminated and reduced doxorubicin liposomal doses are r…"}, {"doc_id": "gabapentin-enacarbil-drug-information", "bm25_top3": 7.961950637502364, "bm25_max": 7.961950637502364, "bge_top3": null, "bge_max": null, "title": "Gabapentin enacarbil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.  PHN:  CrCl 30-59 mL/minute: Initial: 300 mg every morning for 3 days, then in…"}, {"doc_id": "misoprostol-drug-information", "bm25_top3": 7.740699204287921, "bm25_max": 7.740699204287921, "bge_top3": 0.5739216208457947, "bge_max": 0.5739216208457947, "title": "Misoprostol: Drug information", "rep_snippet": "Dosing: Renal Impairment  Dose adjustment is not routinely needed; however, the dose may be reduced if the recommended dose is not tolerated. It is not known if misoprostol is removed by dialysis."}, {"doc_id": "everolimus-drug-information", "bm25_top3": 7.700744792178197, "bm25_max": 7.700744792178197, "bge_top3": null, "bge_max": null, "title": "Everolimus: Drug information", "rep_snippet": "SEGA: Adjustment to initial dose may not be necessary; subsequent dosing is based on therapeutic drug monitoring (monitor ~2 weeks after initiation, dosage modifications, or after any change in hepatic status; target tro…"}, {"doc_id": "floctafenine-united-states-not-available-drug-information", "bm25_top3": 7.283925097956692, "bm25_max": 7.283925097956692, "bge_top3": null, "bge_max": null, "title": "Floctafenine (United States: Not available): Drug information", "rep_snippet": "Dosing: Geriatric  Elderly/debilitated: Initiate therapy with reduced dosage; adjust dose as needed and monitor closely"}, {"doc_id": "morphine-drug-information", "bm25_top3": 7.231980341864972, "bm25_max": 7.231980341864972, "bge_top3": null, "bge_max": null, "title": "Morphine: Drug information", "rep_snippet": "Patient weight <50 kg: 0.2 to 0.5 mg/kg/dose every 3 to 4 hours as needed; some experts have recommended an initial dose of 0.3 mg/kg for severe pain; usual initial maximum dose: 15 to 20 mg (American Pain Society 2008;…"}, {"doc_id": "promethazine-drug-information", "bm25_top3": 6.918684858715633, "bm25_max": 6.918684858715633, "bge_top3": null, "bge_max": null, "title": "Promethazine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Promethazine: Pediatric drug information\")  Allergic conditions, treatment: Children ≥2 years and Adolescents: Oral: 0.125 mg/kg/dose (maximum dose: 12.5 mg) every 6 ho…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": 6.873316258233192, "bm25_max": 6.873316258233192, "bge_top3": null, "bge_max": null, "title": "Hyoscyamine: Drug information", "rep_snippet": "Tablets (regular release [Levsin], sublingual [Levsin/SL], dispersible [ED-SPAZ, NuLev]): 0.0625 to 0.125 mg every 4 hours or as needed; maximum: 0.75 mg/day  Drops (Hyosyne [0.125 mg/mL]): 0.03125 mg (0.25 mL) to 0.125…"}, {"doc_id": "prochlorperazine-drug-information", "bm25_top3": 3.9777037372833757, "bm25_max": 3.9777037372833757, "bge_top3": null, "bge_max": null, "title": "Prochlorperazine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prochlorperazine: Pediatric drug information\")  Note: Injection solution mesylate formulation is a Canadian product (not available in US).  Use is contraindicated in ch…"}, {"doc_id": "pentobarbital-drug-information", "bm25_top3": 1.201185487545846, "bm25_max": 1.201185487545846, "bge_top3": null, "bge_max": null, "title": "Pentobarbital: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists. Management: Monitor INR more closely. An anticoagulant dose increase may be needed after a barbiturate is initiated…"}, {"doc_id": "methohexital-drug-information", "bm25_top3": 1.201185487545846, "bm25_max": 1.201185487545846, "bge_top3": null, "bge_max": null, "title": "Methohexital: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists. Management: Monitor INR more closely. An anticoagulant dose increase may be needed after a barbiturate is initiated…"}, {"doc_id": "butalbital-and-acetaminophen-paracetamol-drug-information", "bm25_top3": 0.6954398488172302, "bm25_max": 0.6954398488172302, "bge_top3": null, "bge_max": null, "title": "Butalbital and acetaminophen (paracetamol): Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists. Management: Monitor INR more closely. An anticoagulant dose increase may be needed after a barbiturate is initiated…"}, {"doc_id": "butabarbital-drug-information", "bm25_top3": 0.6954398488172302, "bm25_max": 0.6954398488172302, "bge_top3": null, "bge_max": null, "title": "Butabarbital: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists. Management: Monitor INR more closely. An anticoagulant dose increase may be needed after a barbiturate is initiated…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6088738441467285, "bge_max": 0.6088738441467285, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Initial episode: 2 mg/kg/day or 60 mg/m2/day once daily, maximum daily dose: 60 mg/day for 4 to 6 weeks; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/m2/dose on alternate days as a single dose, max…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5926214158535004, "bge_max": 0.6084824204444885, "title": "Prednisone: Drug information", "rep_snippet": "Initial episode: 2 mg/kg/day or 60 mg/m2/day once daily, maximum daily dose: 60 mg/day for 4 to 6 weeks; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/m2/dose on alternate days as a single dose, max…"}, {"doc_id": "dronedarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5917407274246216, "bge_max": 0.6077624559402466, "title": "Dronedarone: Drug information", "rep_snippet": "Digoxin: May enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin. Management: Avoid con…"}, {"doc_id": "abiraterone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5999284386634827, "bge_max": 0.5999284386634827, "title": "Abiraterone: Drug information", "rep_snippet": "Dosing: Adult  Note: Patients receiving abiraterone should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently (or have had a bilateral orchiectomy).  Prostate cancer, metastatic, castration-resistan…"}, {"doc_id": "nesiritide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5992575883865356, "bge_max": 0.5992575883865356, "title": "Nesiritide: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary. Use cautiously in patients with renal impairment or those patients who rely on the renin-angiotensin-aldosterone system for renal perfusion. Monitor renal functio…"}, {"doc_id": "dextroamphetamine-and-amphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.585956335067749, "bge_max": 0.5963975787162781, "title": "Dextroamphetamine and amphetamine: Drug information", "rep_snippet": "Immediate release: Initial: 5 mg once or twice daily; may increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained; usual dosage range: 5 to 40 mg/day in 1 to 3 divided doses.  Extend…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5944924354553223, "bge_max": 0.5944924354553223, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.  Hemodialysis: Supplemental dose is not necessary (Aronoff 2007).  Peritoneal dialysis: Supplemental do…"}, {"doc_id": "propafenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.594383180141449, "bge_max": 0.594383180141449, "title": "Propafenone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "testosterone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5942094922065735, "bge_max": 0.5942094922065735, "title": "Testosterone: Drug information", "rep_snippet": "Dose adjustment based on testosterone levels: Less than normal range: Increase dose from 50 mg to 100 mg once daily  Solution (Axiron): 60 mg once daily (dosage range: 30 to 120 mg daily). Apply to the axilla at the same…"}, {"doc_id": "procainamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5921434164047241, "bge_max": 0.5921434164047241, "title": "Procainamide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent…"}, {"doc_id": "oxycodone-and-naltrexone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5917742848396301, "bge_max": 0.5917742848396301, "title": "Oxycodone and naltrexone: Drug information", "rep_snippet": "Dose adjustment: Dose is individualized; titrate dose cautiously in increments of oxycodone 20 mg/naltrexone 2.4 mg every 2 to 3 days based on patient response.  Discontinuation of therapy: Dose should be gradually taper…"}, {"doc_id": "atomoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5911715626716614, "bge_max": 0.5911715626716614, "title": "Atomoxetine: Drug information", "rep_snippet": "Dosing: Adult  Attention-deficit/hyperactivity disorder (ADHD) treatment: Oral: Note: Atomoxetine may be discontinued without the need for tapering dose.  Initial: 40 mg/day, increased after minimum of 3 days to ~80 mg/d…"}, {"doc_id": "niacin-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5890675783157349, "bge_max": 0.5890675783157349, "title": "Niacin and simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alcohol (…"}, {"doc_id": "medroxyprogesterone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5844708681106567, "bge_max": 0.5844708681106567, "title": "Medroxyprogesterone acetate: Drug information", "rep_snippet": "Dosing: Adult  Abnormal uterine bleeding: Oral: 5 or 10 mg daily for 5 to 10 days starting on day 16 or 21 of menstrual cycle. A suggested dose of 10 mg daily for 10 days starting on day 16 of the cycle induces optimum s…"}, {"doc_id": "cetirizine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5829538702964783, "bge_max": 0.5829538702964783, "title": "Cetirizine (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; however, the following adjustments have been recommended (Aronoff, 2007):  Adults:  GFR >50 mL/minute: No dosage adjustme…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5827741622924805, "bge_max": 0.5827741622924805, "title": "Simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Amiodaron…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5794996619224548, "bge_max": 0.5827741622924805, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Amiodaron…"}, {"doc_id": "lovastatin-and-niacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5827521085739136, "bge_max": 0.5827521085739136, "title": "Lovastatin and niacin: Drug information", "rep_snippet": "Dosage adjustment with concomitant medications:  Amiodarone: Maximum lovastatin dose: 40 mg/day  Danazol, diltiazem, dronedarone, or verapamil: Initial lovastatin dose: 10 mg once daily (dosage unavailable with combinati…"}, {"doc_id": "minocycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5797293782234192, "bge_max": 0.5797293782234192, "title": "Minocycline: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range:  IV: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours (maximum: 400 mg daily)  Oral: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours; more frequent dosing i…"}, {"doc_id": "quinidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5787531137466431, "bge_max": 0.5787531137466431, "title": "Quinidine: Drug information", "rep_snippet": "Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Avoid whenever possible. While consi…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5785523653030396, "bge_max": 0.5785523653030396, "title": "Tinidazole: Drug information", "rep_snippet": "Dosing: Adult  Amebiasis, intestinal: Oral: 2 g once daily for 3 days  Amebiasis, liver abscess: Oral: 2 g once daily for 3 to 5 days  Bacterial vaginosis: Oral: 2 g once daily for 2 days or 1 g once daily for 5 days  Ba…"}, {"doc_id": "fexofenadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5782287120819092, "bge_max": 0.5782287120819092, "title": "Fexofenadine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustment provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007):  Adults:  GFR >50 mL/minute: No dosage adjustment…"}, {"doc_id": "baclofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5774511098861694, "bge_max": 0.5774511098861694, "title": "Baclofen: Drug information", "rep_snippet": "Note: Dosage adjustments may be required often during the first few months of therapy to adjust for life style changes due to alleviation of spasticity. Maintain lowest dose that produces adequate response. Most patients…"}, {"doc_id": "cobicistat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5768113732337952, "bge_max": 0.5768113732337952, "title": "Cobicistat: Drug information", "rep_snippet": "Amiodarone: Cobicistat may increase the serum concentration of Amiodarone. Risk C: Monitor therapy  AmLODIPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of AmLODIPine. Risk C: Monitor therapy  Apix…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5755993127822876, "bge_max": 0.5755993127822876, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "The following adjustments have been recommended (Aronoff 2007): Note: Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours:  GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.…"}, {"doc_id": "oxycodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5752485990524292, "bge_max": 0.5752485990524292, "title": "Oxycodone: Drug information", "rep_snippet": "Maintenance dose: Dosage adjustment (titration): After initiation of oxycodone ER, adjust dose in increments (25% to 50%) no more frequently than every 1 to 2 days until desired pain control. Recommended maximum dose of…"}, {"doc_id": "acenocoumarol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5744385123252869, "bge_max": 0.5744385123252869, "title": "Acenocoumarol (United States: Not available): Drug information", "rep_snippet": "Amiodarone: May enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists. Management: Monitor patients extra closely for evidence of increased an…"}, {"doc_id": "aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5743539333343506, "bge_max": 0.5743539333343506, "title": "Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information", "rep_snippet": ">6 weeks since last dose: Administer oral aripiprazole for 14 days with next injection  Dosage adjustment for adverse effects: Consider reducing dose to 300 mg once monthly  Depression (adjunctive with antidepressants):…"}, {"doc_id": "hydralazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.573883056640625, "bge_max": 0.573883056640625, "title": "Hydralazine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007):  Children and Adolescents: Note: Renally adjuste…"}, {"doc_id": "pemetrexed-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5722212791442871, "bge_max": 0.5722212791442871, "title": "Pemetrexed: Drug information", "rep_snippet": "Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Risk X: Avoid combination  Echinacea: May diminish the therapeutic e…"}, {"doc_id": "lidocaine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5720288753509521, "bge_max": 0.5720288753509521, "title": "Lidocaine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Antiarrhythmic (ACLS 2010; ACLS 2015):  VF or pulseless VT (after defibrillation attempts, CPR, and vasopressor administration), alternative to amiodarone: IV, intraosseous (IO): Initial: 1 to 1.5 mg/kg. I…"}, {"doc_id": "regadenoson-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5719984173774719, "bge_max": 0.5719984173774719, "title": "Regadenoson: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aminophylline: May diminish the vasodilatory effect of Regadenoson. Risk D: Consider therapy modification  Caffeine and Caffeine Containi…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": -0.10614020442278971, "bm25_max": -0.10614020442278971, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Amiodarone: RifAMPin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically, desethylamiodarone concentrations may decrease. RifAMPin may decrease the serum concentration of Amiodarone.…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": -0.10614020442278971, "bm25_max": -0.10614020442278971, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "Amiodarone: RifAMPin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically, desethylamiodarone concentrations may decrease. RifAMPin may decrease the serum concentration of Amiodarone.…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": -0.10614020442278971, "bm25_max": -0.10614020442278971, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Amiodarone: RifAMPin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically, desethylamiodarone concentrations may decrease. RifAMPin may decrease the serum concentration of Amiodarone.…"}, {"doc_id": "butalbital-compound-and-codeine-drug-information", "bm25_top3": -0.5131554089498174, "bm25_max": -0.5131554089498174, "bge_top3": null, "bge_max": null, "title": "Butalbital compound and codeine: Drug information", "rep_snippet": "Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin…"}, {"doc_id": "fosamprenavir-drug-information", "bm25_top3": -1.2026375062762256, "bm25_max": -1.2026375062762256, "bge_top3": null, "bge_max": null, "title": "Fosamprenavir: Drug information", "rep_snippet": "Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may ne…"}, {"doc_id": "tipranavir-drug-information", "bm25_top3": -1.2668034350264712, "bm25_max": -1.2668034350264712, "bge_top3": null, "bge_max": null, "title": "Tipranavir: Drug information", "rep_snippet": "Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may ne…"}, {"doc_id": "sirolimus-drug-information", "bm25_top3": -1.6321230883024036, "bm25_max": -1.6321230883024036, "bge_top3": null, "bge_max": null, "title": "Sirolimus: Drug information", "rep_snippet": "Isavuconazonium Sulfate: May increase the serum concentration of Sirolimus. Risk C: Monitor therapy  Itraconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be…"}, {"doc_id": "etravirine-drug-information", "bm25_top3": -1.765734863882889, "bm25_max": -1.765734863882889, "bge_top3": null, "bge_max": null, "title": "Etravirine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amiodarone: Etravirine may decrease the serum concentration of Amiodarone. Risk C: Monitor therapy  Antifungal Agents (Azole Derivatives,…"}, {"doc_id": "acitretin-drug-information", "bm25_top3": -2.160988870777315, "bm25_max": -2.160988870777315, "bge_top3": null, "bge_max": null, "title": "Acitretin: Drug information", "rep_snippet": "The potential of acitretin therapy to induce hepatotoxicity was prospectively evaluated using liver biopsies in an open-label study of 128 patients. Pretreatment and posttreatment biopsies were available for 87 patients.…"}, {"doc_id": "docusate-drug-information", "bm25_top3": -2.234253941939828, "bm25_max": -2.234253941939828, "bge_top3": null, "bge_max": null, "title": "Docusate: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication (OTC), patients should be instructed to contact healthcare provider prior to use if nausea, stomach pain, or vomiting are present, or if a sudden change in bowel…"}, {"doc_id": "ethinyl-estradiol-and-norelgestromin-drug-information", "bm25_top3": -2.4629194526312475, "bm25_max": -2.4629194526312475, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and norelgestromin: Drug information", "rep_snippet": "Forgetting to change patch in the middle of the cycle (week 2/day 8 or week 3/day 15): If <48 hours from normal “patch change day,” apply new patch immediately. No back-up contraception is needed. If >48 hours from norma…"}, {"doc_id": "ethinyl-estradiol-and-desogestrel-drug-information", "bm25_top3": -4.02496068045129, "bm25_max": -4.02496068045129, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and desogestrel: Drug information", "rep_snippet": "Gastrointestinal: Abdominal cramps, abdominal pain, bloating, carbohydrate intolerance, change in appetite, nausea, vomiting  Genitourinary: Breakthrough bleeding, change in cervical ectropion, change in cervical erosion…"}]}
{"qid": "Q12_abbr+renal", "query": "Influenza tx, eGFR 45 — oseltamivir dose (renal-adjusted)?", "base_qid": "Q12", "variant_type": "abbr+renal", "candidates": [{"doc_id": "oseltamivir-drug-information", "bm25_top3": 29.200653721578526, "bm25_max": 30.590224842572496, "bge_top3": 0.6423323154449463, "bge_max": 0.669092059135437, "title": "Oseltamivir: Drug information", "rep_snippet": "Note: Data suggest that increased doses (>150 mg daily) in critically ill patients is not necessary since blood concentrations of oseltamivir were comparable or higher compared to ambulatory patients given similar dosing…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 17.034914044571327, "bm25_max": 25.59579217466686, "bge_top3": 0.6334035396575928, "bge_max": 0.6334035396575928, "title": "Canagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Maximum dose: 100 mg once daily. If patient receiving concurrent UDP-glucuronosyl transferase (UGT)…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 15.714797521887318, "bm25_max": 25.418349220900136, "bge_top3": 0.6413653492927551, "bge_max": 0.6413653492927551, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 13.783727685952378, "bm25_max": 24.165057904670263, "bge_top3": 0.6149327158927917, "bge_max": 0.6149327158927917, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 13.92814184855009, "bm25_max": 24.029423934909957, "bge_top3": 0.6167192459106445, "bge_max": 0.6167192459106445, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, t…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 14.044827861733763, "bm25_max": 23.982556288023627, "bge_top3": 0.6258106827735901, "bge_max": 0.6258106827735901, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 12.995218307396648, "bm25_max": 23.31711608657951, "bge_top3": null, "bge_max": null, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR <45 mL/minute/1.73 m2: Use is contraindicated by the manufacturer; refer also to indiv…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 10.712659025823958, "bm25_max": 22.399123785694194, "bge_top3": 0.6241176128387451, "bge_max": 0.6241176128387451, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "metformin-drug-information", "bm25_top3": 13.2745139228868, "bm25_max": 22.336224344547013, "bge_top3": 0.6084930896759033, "bge_max": 0.6084930896759033, "title": "Metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually. More frequent monitoring (every 3 to 6 months) and a maximum dose of 2,000 mg/day has been r…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 22.037536625408876, "bm25_max": 22.037536625408876, "bge_top3": 0.6085004806518555, "bge_max": 0.6085004806518555, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during ther…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 14.913518583005246, "bm25_max": 22.037536625408876, "bge_top3": 0.6060609221458435, "bge_max": 0.6060609221458435, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": 10.911983670345299, "bm25_max": 21.945729535200552, "bge_top3": 0.6165319085121155, "bge_max": 0.6165319085121155, "title": "Glipizide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformi…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 11.206156258918314, "bm25_max": 21.12613635737065, "bge_top3": 0.6165603995323181, "bge_max": 0.6165603995323181, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 45 to <60 mL/minute/1.73 m2: Do not initiate therapy if eGFR <60 mL/minute/1.73 m2; discontinue therapy if eGFR falls persistentl…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 21.101838982240366, "bm25_max": 21.101838982240366, "bge_top3": 0.6078544855117798, "bge_max": 0.6078544855117798, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": 20.55411823382071, "bm25_max": 20.55411823382071, "bge_top3": 0.6239628195762634, "bge_max": 0.6239628195762634, "title": "Sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR ≥30 to <45 mL/minute/1.73 m2: 50 mg once daily  eGFR <30 mL/minute/1.73 m2: 25 mg once daily  ESRD requiring hemodialysis or per…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 13.503302379244111, "bm25_max": 20.32345437349845, "bge_top3": null, "bge_max": null, "title": "Empagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, d…"}, {"doc_id": "peramivir-drug-information", "bm25_top3": 20.025739011460434, "bm25_max": 20.025739011460434, "bge_top3": null, "bge_max": null, "title": "Peramivir: Drug information", "rep_snippet": "Dosing: Adult  Influenza (acute, uncomplicated): IV: 600 mg as a single dose; initiate within 2 days of onset of symptoms of influenza  Influenza (hospitalized, high-risk) (off-label use): IV: 600 mg once daily for up to…"}, {"doc_id": "saxagliptin-drug-information", "bm25_top3": 19.542310799919676, "bm25_max": 19.542310799919676, "bge_top3": 0.6195302605628967, "bge_max": 0.6195302605628967, "title": "Saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <45 mL/minute/1.73 m2: 2.5 mg once daily.  ESRD requiring hemodialysis: 2.5 mg once daily; administer postdialysis  Peritoneal d…"}, {"doc_id": "afatinib-drug-information", "bm25_top3": 16.676429998685244, "bm25_max": 16.676429998685244, "bge_top3": 0.6242322325706482, "bge_max": 0.6242322325706482, "title": "Afatinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The manufacturer recommends using the Modification of Diet in Renal Disease (MDRD) formula to estimate the glomerular filtration rate (eGFR).  Preexisting impairment:  eGFR >30 mL/minute/1…"}, {"doc_id": "meropenem-and-vaborbactam-drug-information", "bm25_top3": 16.510904275874694, "bm25_max": 16.510904275874694, "bge_top3": null, "bge_max": null, "title": "Meropenem and vaborbactam: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Estimation of renal function for the purpose of drug dosing should be done using the Modification of Diet in Renal Disease (MDRD) formula. Dosage recommendations are expressed as g…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 15.770898070087195, "bm25_max": 15.770898070087195, "bge_top3": null, "bge_max": null, "title": "Spironolactone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling:  Tablet: Contraindicated in patients with anuria, acute renal impairment, or significant impairment of renal excretory function.  Suspension:  Edema, hypertension: There…"}, {"doc_id": "glyburide-and-metformin-drug-information", "bm25_top3": 3.3064874320496997, "bm25_max": 3.3064874320496997, "bge_top3": null, "bge_max": null, "title": "Glyburide and metformin: Drug information", "rep_snippet": "Monitoring Parameters  Signs and symptoms of hypoglycemia, blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treat…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 2.933918306955821, "bm25_max": 2.933918306955821, "bge_top3": 0.6055618524551392, "bge_max": 0.6055618524551392, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Monitoring Parameters  HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a]); pla…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6401070356369019, "bge_max": 0.6401070356369019, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Dosing: Renal Impairment  GFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR <60 mL/minute/1.73 m2: Ezetimibe 10 mg and simvastatin 20 mg once daily in the evening (higher doses should be used with caution)."}, {"doc_id": "amantadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6341922283172607, "bge_max": 0.6341922283172607, "title": "Amantadine: Drug information", "rep_snippet": "Dosing: Adult  Note: Osmolex ER tablets: FDA approved February 2018; anticipated availability is currently unknown. Dosing for Osmolex ER differs from Gocovri extended release capsules; monograph edits for Osmolex ER are…"}, {"doc_id": "pralatrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6301509141921997, "bge_max": 0.6301509141921997, "title": "Pralatrexate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Peripheral T-cell lymphoma (PTCL), relapsed or refractory:  Estimated glomerular filtration rate (eGFR) ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 15 to <30 mL/minute/1.73 m2:…"}, {"doc_id": "delafloxacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6245037317276001, "bge_max": 0.6245037317276001, "title": "Delafloxacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral, IV:  Estimated glomerular filtration rate (eGFR) 30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 15 to 29 mL/minute/1.73 m2:  Oral: No dosage adjustment necessary.  IV: 2…"}, {"doc_id": "tetracycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6229090690612793, "bge_max": 0.6229090690612793, "title": "Tetracycline: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer’s labeling: There are no specific dosage adjustments provided in the manufacturer’s labeling; decrease dose and/or extend dosing interval.  Alternative dosing (Aronoff 2007…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6225612163543701, "bge_max": 0.6225612163543701, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥15 mL/minute/1.73 m2 to <90 mL/minute/1.73 m2: There are no specific dosage adjustments provided in the manufacturer’s labeling for the combination product; insulin requirements may be red…"}, {"doc_id": "pentazocine-and-naloxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6216812133789062, "bge_max": 0.6216812133789062, "title": "Pentazocine and naloxone: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution. The following recommendations have been used by some clinicians based on pentazocine component (Aronoff…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6215530633926392, "bge_max": 0.6215530633926392, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Renal Impairment  US labeling: There are no dosage adjustments provided in the manufacturer’s labeling; however the following adjustments have been recommended (Aronoff 2007): Cetirizine:  Adults:  GFR >50 mL/min…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6167870759963989, "bge_max": 0.6167870759963989, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute/1.73 m2: Initial: Sacubitril 24 mg/valsartan 26 mg twice daily"}, {"doc_id": "cetirizine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6167544722557068, "bge_max": 0.6167544722557068, "title": "Cetirizine (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; however, the following adjustments have been recommended (Aronoff, 2007):  Adults:  GFR >50 mL/minute: No dosage adjustme…"}, {"doc_id": "pentazocine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6153339147567749, "bge_max": 0.6153339147567749, "title": "Pentazocine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution. The following recommendations have been used by some clinicians (Aronoff, 2007):  GFR ≥50 mL/minute: No…"}, {"doc_id": "telaprevir-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6145958304405212, "bge_max": 0.6145958304405212, "title": "Telaprevir (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Telaprevir: No dosage adjustment necessary. Not studied in patients with CrCl ≤50 mL/minute or in hemodialysis.  Peginterferon Alfa and Ribavirin: Refer to individual monographs."}, {"doc_id": "lisdexamfetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6134992241859436, "bge_max": 0.6134992241859436, "title": "Lisdexamfetamine: Drug information", "rep_snippet": "Dosing: Renal Impairment  GFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  GFR 15 to <30 mL/minute/1.73 m2: Maximum dose: 50 mg/day.  GFR <15 mL/minute/1.73 m2: Maximum…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.613349437713623, "bge_max": 0.613349437713623, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Note: Renally adjusted dose recommendations are based on the amoxicillin 250 mg/clavulanate 125 mg and amoxicillin 500 mg/clavulanate 125 mg tablets.  CrCl ≥30 mL/minute: No dosage adjus…"}, {"doc_id": "perindopril-and-indapamide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6111427545547485, "bge_max": 0.6111427545547485, "title": "Perindopril and indapamide (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  GFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 59 mL/minute/1.73 m2: There are no specific dosage recommendations provided in the manufacturer's labeling; use lowe…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6101266145706177, "bge_max": 0.6101266145706177, "title": "Posaconazole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Delayed-release tablets and oral suspension:  eGFR 20 to 80 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <20 mL/minute/1.73 m2: No dosage adjustment necessary; however, monitor for b…"}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6078440546989441, "bge_max": 0.6078440546989441, "title": "Cabozantinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The estimated glomerular filtration rate (eGFR) is estimated using MDRD (modification of diet in renal disease) equation.  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR…"}, {"doc_id": "albiglutide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6073273420333862, "bge_max": 0.6073273420333862, "title": "Albiglutide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥15 to 89 mL/minute/1.73 m2: No dosage adjustment necessary; use caution when initiating or escalating doses.  eGFR <15 mL/minute/1.73 m2: There are no dosage adjustments provided in the ma…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.605691134929657, "bge_max": 0.605691134929657, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "The following adjustments have been recommended (Aronoff 2007): Note: Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours:  GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.…"}, {"doc_id": "nateglinide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6046123504638672, "bge_max": 0.6046123504638672, "title": "Nateglinide: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to moderate impairment: No dosage adjustment necessary.  Severe impairment: Initiate conservatively at 60 mg 3 times daily with meals if eGFR <30 mL/minute/1.73 m2 (ADA 2018d). Use with cau…"}, {"doc_id": "hydralazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6042128801345825, "bge_max": 0.6042128801345825, "title": "Hydralazine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007):  Children and Adolescents: Note: Renally adjuste…"}, {"doc_id": "zanamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6041784882545471, "bge_max": 0.6041784882545471, "title": "Zanamivir: Drug information", "rep_snippet": "Dosing: Adult  Influenza: Oral inhalation:  Manufacturer's labeling:  Prophylaxis, household setting: Two inhalations (10 mg) once daily for 10 days. Begin within 36 hours following onset of signs or symptoms of index ca…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.603880763053894, "bge_max": 0.603880763053894, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "Atazanavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Tenofovir Disoproxil Fumarate. Management: Must use ritonavir-boosting in a…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6038482785224915, "bge_max": 0.6038482785224915, "title": "Sulfadiazine: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Oral: 2 to 4 g/day in 3 to 6 divided doses  Rheumatic fever prophylaxis (off-label dose) (Gerber [AHA 2009]): Oral:  ≤27 kg: 500 mg once daily  >27 kg: 1,000 mg once daily  Toxop…"}, {"doc_id": "auranofin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6030969619750977, "bge_max": 0.6030969619750977, "title": "Auranofin: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. The following guidelines have been used by some clinicians (Aronoff 2007):  GFR 51 to 80 mL/minute: Administer 50% of dos…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6022566556930542, "bge_max": 0.6022566556930542, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6022415161132812, "bge_max": 0.6022415161132812, "title": "Dapagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Use is not recommended for initiation of therapy or when eGFR is persistently between 30 and <60 mL…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6018579602241516, "bge_max": 0.6018579602241516, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "indapamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6006571054458618, "bge_max": 0.6006571054458618, "title": "Indapamide: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended:  GFR 10 to 50 mL/minute: 1.25 to 2.5 mg once daily (Golightly 2…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6003801822662354, "bge_max": 0.6003801822662354, "title": "Amikacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Some patients may require larger or more frequent doses if serum levels document the need (ie, cystic fibrosis or febrile granulocytopenic patients).  Adults: The following adjustments have been…"}]}
{"qid": "Q12_brand", "query": "Flu treatment; CrCl≈45 — Tamiflu dosing?", "base_qid": "Q12", "variant_type": "brand", "candidates": [{"doc_id": "oseltamivir-drug-information", "bm25_top3": 22.182760269697834, "bm25_max": 24.344396640479694, "bge_top3": 0.6245974898338318, "bge_max": 0.6308202743530273, "title": "Oseltamivir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Treatment: Adults:  CrCl >60 mL/minute: No dosage adjustment necessary  CrCl >30 to 60 mL/minute: 30 mg twice daily  CrCl >10 to 30 mL/minute: 30 mg once daily  ESRD not undergoing dialysis: Use…"}, {"doc_id": "lesinurad-drug-information", "bm25_top3": 12.734621163919275, "bm25_max": 22.291523850733903, "bge_top3": null, "bge_max": null, "title": "Lesinurad: Drug information", "rep_snippet": "Dosing: Renal Impairment  Preexisting renal impairment:  Estimated CrCl ≥60 mL/minute: No dosage adjustment necessary.  Estimated CrCl 45 to <60 mL/minute: No dosage adjustment is necessary; monitor more frequently.  Est…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": 21.548978411616318, "bm25_max": 21.548978411616318, "bge_top3": null, "bge_max": null, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Common cold/flu: Children ≥12 years and Adolescents: Oral: Refer to adult dosing."}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information", "bm25_top3": 21.45169456601787, "bm25_max": 21.45169456601787, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), dextromethorphan, and doxylamine: Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral: Children ≥12 years and Adolescents: Refer to adult dosing."}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 20.61133766414641, "bm25_max": 20.61133766414641, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to 11 years: Vicks DayQuil Cold & Flu Multi-Symptom Liquid: Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maxim…"}, {"doc_id": "lesinurad-and-allopurinol-drug-information", "bm25_top3": 12.83332894175876, "bm25_max": 20.233041785466632, "bge_top3": null, "bge_max": null, "title": "Lesinurad and allopurinol: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note  : Use of this combination product is not recommended in patients with an estimated CrCl <60 mL/minute who are receiving allopurinol <200 mg/day.  Prior to initiation: Preexisting r…"}, {"doc_id": "carmustine-drug-information", "bm25_top3": 18.667631749911948, "bm25_max": 18.667631749911948, "bge_top3": null, "bge_max": null, "title": "Carmustine: Drug information", "rep_snippet": "Dosing: Renal Impairment  IV: Manufacturer’s labeling: CrCl <10 mL/minute: Discontinue treatment.  The following dosage adjustments have also been reported (Kintzel 1995):  CrCl 46 to 60 mL/minute: Reduce dose to 80% of…"}, {"doc_id": "pemetrexed-drug-information", "bm25_top3": 17.33591684631827, "bm25_max": 17.33591684631827, "bge_top3": null, "bge_max": null, "title": "Pemetrexed: Drug information", "rep_snippet": "Dosing: Renal Impairment  Renal function may be estimated using the Cockcroft-Gault formula.  CrCl ≥45 mL/minute: No dosage adjustment necessary.  CrCl <45 mL/minute: Use is not recommended by the manufacturer (an insuff…"}, {"doc_id": "etoposide-drug-information", "bm25_top3": 17.020108980154756, "bm25_max": 17.020108980154756, "bge_top3": 0.6266335844993591, "bge_max": 0.6375212669372559, "title": "Etoposide: Drug information", "rep_snippet": "CrCl 31 to 45 mL/minute: Administer 80% of dose  CrCl ≤30 mL/minute: Administer 75% of dose"}, {"doc_id": "dacarbazine-drug-information", "bm25_top3": 17.000723026884145, "bm25_max": 17.000723026884145, "bge_top3": null, "bge_max": null, "title": "Dacarbazine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling. The following adjustments have been recommended (Kintzel 1995):  CrCl 46 to 60 mL/minute: Reduce dose to 80% of usual dos…"}, {"doc_id": "bleomycin-drug-information", "bm25_top3": 16.86094052292077, "bm25_max": 16.86094052292077, "bge_top3": null, "bge_max": null, "title": "Bleomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling (creatinine clearance should be estimated using the Cockcroft-Gault formula):  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl 40 to 50 mL/minute: Reduce dose t…"}, {"doc_id": "pentostatin-drug-information", "bm25_top3": 16.669628210013222, "bm25_max": 16.669628210013222, "bge_top3": null, "bge_max": null, "title": "Pentostatin: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; although not adequately studied, two patients with CrCl 50 to 60 mL/minute achieved responses when treated with 2 mg/m2/d…"}, {"doc_id": "topotecan-drug-information", "bm25_top3": 15.932602132979174, "bm25_max": 15.932602132979174, "bge_top3": 0.6401380896568298, "bge_max": 0.6401380896568298, "title": "Topotecan: Drug information", "rep_snippet": "CrCl <10 mL/minute: Administer 25% of dose  Continuous renal replacement therapy (CRRT): Administer 50% of dose  Kintzel 1995: IV:  CrCl 46 to 60 mL/minute: Administer 80% of dose  CrCl 31 to 45 mL/minute: Administer 75%…"}, {"doc_id": "alogliptin-and-pioglitazone-drug-information", "bm25_top3": 15.381210175788677, "bm25_max": 15.381210175788677, "bge_top3": null, "bge_max": null, "title": "Alogliptin and pioglitazone: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥60 mL/minute: No dosage adjustment necessary.  CrCl ≥30 to <60 mL/minute:  Patients inadequately controlled on diet and exercise, metformin alone, or alogliptin alone: Initial dose: Alogli…"}, {"doc_id": "nebivolol-and-valsartan-drug-information", "bm25_top3": 15.247214112719854, "bm25_max": 15.247214112719854, "bge_top3": null, "bge_max": null, "title": "Nebivolol and valsartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl 30 to 80 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: Not recommended as initial treatment."}, {"doc_id": "lomustine-drug-information", "bm25_top3": 14.949864749457547, "bm25_max": 14.949864749457547, "bge_top3": null, "bge_max": null, "title": "Lomustine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. The following adjustments have been recommended:  Aronoff 2007: Adults:  CrCl 10 to 50 mL/minute: Reduce dose to 75% of n…"}, {"doc_id": "pegylated-interferon-peginterferon-beta-1a-drug-information", "bm25_top3": 14.812608447806634, "bm25_max": 14.812608447806634, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) beta-1a: Drug information", "rep_snippet": "Dosing: Adult  Multiple sclerosis: SubQ: Initial: 63 mcg on day 1; 94 mcg on day 15. Maintenance: 125 mcg every 14 days beginning on day 29. Note: Analgesics and/or antipyretics may help decrease flu-like symptoms during…"}, {"doc_id": "pomalidomide-drug-information", "bm25_top3": 14.646569047345114, "bm25_max": 14.646569047345114, "bge_top3": null, "bge_max": null, "title": "Pomalidomide: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥15 to <60 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling. Compared to patients with normal renal function, pomalidomide pharmacokinetics were not signif…"}, {"doc_id": "ifosfamide-drug-information", "bm25_top3": 14.626977755748252, "bm25_max": 14.626977755748252, "bge_top3": null, "bge_max": null, "title": "Ifosfamide: Drug information", "rep_snippet": "Dosing: Renal Impairment  Consider dosage reduction in patients with renal impairment; however, there are no dosage adjustments provided in the manufacturer’s labeling; ifosfamide (and metabolites) are excreted renally a…"}, {"doc_id": "azathioprine-drug-information", "bm25_top3": 14.422052784742824, "bm25_max": 14.422052784742824, "bge_top3": 0.6188990473747253, "bge_max": 0.6188990473747253, "title": "Azathioprine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no specific dosage adjustments provided in the manufacturer’s labeling; however, oliguric patients, particularly those with tubular necrosis in the immediate post-transplant period (de…"}, {"doc_id": "ethambutol-drug-information", "bm25_top3": 14.179118122017615, "bm25_max": 14.179118122017615, "bge_top3": 0.6486303210258484, "bge_max": 0.6486303210258484, "title": "Ethambutol: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Reduce dosing as determined by serum levels (specific dosing adjustments not provided); primarily renally excreted.  Alternate recommendations:  Treatment of drug-suscep…"}, {"doc_id": "trifluridine-and-tipiracil-drug-information", "bm25_top3": 14.172584951726188, "bm25_max": 14.172584951726188, "bge_top3": null, "bge_max": null, "title": "Trifluridine and tipiracil: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥30 mL/minute: No initial dosage adjustment is necessary. Monitor closely; patients with moderate impairment (CrCl 30 to 59 mL/minute) may experience greater toxicity and may require dose r…"}, {"doc_id": "naproxen-and-pseudoephedrine-drug-information", "bm25_top3": 12.362843578297745, "bm25_max": 14.077828862727195, "bge_top3": null, "bge_max": null, "title": "Naproxen and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Adult  Cold, sinus, and flu symptoms: Oral: One caplet every 12 hours (maximum dose: 2 caplets/24 hours); treatment for >7 days is not recommended unless directed by healthcare provider."}, {"doc_id": "cisplatin-drug-information", "bm25_top3": 14.032471820062774, "bm25_max": 14.032471820062774, "bge_top3": null, "bge_max": null, "title": "Cisplatin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The manufacturer(s) recommend that repeat courses of cisplatin should not be given until serum creatinine is <1.5 mg/dL and/or BUN is <25 mg/dL and use is contraindicated in preexisting re…"}, {"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 14.027179181689874, "bm25_max": 14.027179181689874, "bge_top3": null, "bge_max": null, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥60 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <60 mL/minute:  Manufacturer's labeling: Use is contraindicated.  Alternate dosing: Limited dat…"}, {"doc_id": "atovaquone-and-proguanil-drug-information", "bm25_top3": 13.982553870679066, "bm25_max": 13.982553870679066, "bge_top3": null, "bge_max": null, "title": "Atovaquone and proguanil: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute:  Prophylaxis: Use is contraindicated.  Treatment: No dosage adjustment necessary; however, use with extreme caution and o…"}, {"doc_id": "tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information", "bm25_top3": 13.94409141250047, "bm25_max": 13.94409141250047, "bge_top3": 0.632345974445343, "bge_max": 0.632345974445343, "title": "Tenofovir disoproxil fumarate and emtricitabine: Drug information", "rep_snippet": "Dosing: Renal Impairment  HIV-1 infection, treatment: Adults:  Manufacturer's labeling:  CrCl ≥50 mL/minute: No dosage adjustment necessary  CrCl 30 to 49 mL/minute: Increase interval to every 48 hours.  CrCl <30 mL/minu…"}, {"doc_id": "capecitabine-drug-information", "bm25_top3": 13.928763891317148, "bm25_max": 13.928763891317148, "bge_top3": null, "bge_max": null, "title": "Capecitabine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.  Renal impairment at treatment initiation:  CrCl ≥51 mL/minute: Initial: No dosage adjustm…"}, {"doc_id": "lamivudine-drug-information", "bm25_top3": 13.886735174060309, "bm25_max": 13.886735174060309, "bge_top3": 0.6226552128791809, "bge_max": 0.6226552128791809, "title": "Lamivudine: Drug information", "rep_snippet": "CrCl <5 mL/minute: Administer 1.3 mg/kg first dose, then 0.7 mg/kg once daily  Treatment of hepatitis B patients: Adults:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl 30 to 49 mL/minute: Administer 100 mg f…"}, {"doc_id": "nizatidine-drug-information", "bm25_top3": 13.783492539996466, "bm25_max": 13.783492539996466, "bge_top3": 0.6141582727432251, "bge_max": 0.6141582727432251, "title": "Nizatidine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling:  Adults and Pediatrics:  Active treatment:  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl 20 to 50 mL/minute: 150 mg once daily  CrCl <20 mL/minute: 150 mg e…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": 13.617643916380402, "bm25_max": 13.617643916380402, "bge_top3": null, "bge_max": null, "title": "Methotrexate: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. The following adjustments have been recommended:  Aronoff 2007:  Adults:  CrCl 10 to 50 mL/minute: Administer 50% of dose…"}, {"doc_id": "lenalidomide-drug-information", "bm25_top3": 13.551114664457435, "bm25_max": 13.551114664457435, "bge_top3": null, "bge_max": null, "title": "Lenalidomide: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Maintain appropriate number of treatment days per cycle based on indication and/or protocol. Further individualize (increase or decrease dose) based on tolerance.  Recommended initial dose…"}, {"doc_id": "gabapentin-drug-information", "bm25_top3": 13.374002833029275, "bm25_max": 13.374002833029275, "bge_top3": 0.6291162371635437, "bge_max": 0.6291162371635437, "title": "Gabapentin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Estimation of renal function for dosing adjustments should be done using the Cockcroft-Gault formula.  Immediate release:  CrCl ≥60 mL/minute: 300 to 1,200 mg 3 times daily  CrCl >…"}, {"doc_id": "interferon-alfa-2b-drug-information", "bm25_top3": 13.337804922159036, "bm25_max": 13.337804922159036, "bge_top3": null, "bge_max": null, "title": "Interferon alfa-2b: Drug information", "rep_snippet": "Dosing: Renal Impairment  Renal impairment at treatment initiation: Combination therapy with ribavirin (hepatitis C) is contraindicated in patients with CrCl <50 mL/minute; use combination therapy with ribavirin (hepatit…"}, {"doc_id": "phentermine-and-topiramate-drug-information", "bm25_top3": 13.236305686296376, "bm25_max": 13.236305686296376, "bge_top3": 0.6394376754760742, "bge_max": 0.6394376754760742, "title": "Phentermine and topiramate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl <50 mL/minute: Maximum dose: Phentermine 7.5 mg/topiramate 46 mg once daily  Dialysis: Avoid use (has not been…"}, {"doc_id": "imipenem-and-cilastatin-drug-information", "bm25_top3": 13.068351309867841, "bm25_max": 13.068351309867841, "bge_top3": 0.6136007308959961, "bge_max": 0.6136007308959961, "title": "Imipenem and cilastatin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  US labeling (estimation of renal function for the purpose of dosing adjustment should be done using the Cockcroft-Gault formula):  Usual dosing regimen of 500 mg every 6 hours:  CrCl ≥9…"}, {"doc_id": "silodosin-drug-information", "bm25_top3": 12.816456961528754, "bm25_max": 12.816456961528754, "bge_top3": null, "bge_max": null, "title": "Silodosin: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl 30-50 mL/minute: 4 mg once daily.  CrCl <30 mL/minute: Use is contraindicated."}, {"doc_id": "telmisartan-and-hydrochlorothiazide-drug-information", "bm25_top3": 12.683911919980176, "bm25_max": 12.683911919980176, "bge_top3": null, "bge_max": null, "title": "Telmisartan and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl >30 mL/minute: No dosage adjustment necessary.  CrCl ≤30 mL/minute: Not recommended."}, {"doc_id": "efavirenz-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 12.683911919980176, "bm25_max": 12.683911919980176, "bge_top3": null, "bge_max": null, "title": "Efavirenz, emtricitabine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥ 50 mL/minute: No dosage adjustment necessary.  CrCl <50 mL/minute: Not recommended."}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 4.376749352074247, "bm25_max": 4.376749352074247, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics: Additional Considerations  Renal function impairment: Formoterol systemic exposure (AUC0-12) in subjects with moderate renal impairment (CrCl 45 mL/minute) is expected to be approximately 45% h…"}, {"doc_id": "flecainide-drug-information", "bm25_top3": 0.7127611441899955, "bm25_max": 0.7127611441899955, "bge_top3": null, "bge_max": null, "title": "Flecainide: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Flecainide may be confused with fluconazole  Tambocor [DSC] may be confused with Pamelor, Temodar, tamoxifen, Tamiflu"}, {"doc_id": "peramivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6531174182891846, "bge_max": 0.6531174182891846, "title": "Peramivir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Renal function may be estimated using the Cockcroft-Gault formula.  Adolescents ≥13 years of age and Adults:  Uncomplicated influenza:  CrCl ≥50 mL/minute: No dosage adjustment necessary.…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6409834623336792, "bge_max": 0.6409834623336792, "title": "Ranitidine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl <50 mL/minute:  Oral: 150 mg every 24 hours; adjust dose cautiously if needed (frequency of dosing may be increased to every 12…"}, {"doc_id": "pyrazinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6373494863510132, "bge_max": 0.6373494863510132, "title": "Pyrazinamide: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl <30 mL/minute or receiving intermittent hemodialysis: Treatment of drug-susceptible TB: Adults: 25 to 35 mg/kg/dose 3 times per week administered after dialysis (do not administer daily) (N…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6338013410568237, "bge_max": 0.6338013410568237, "title": "Streptomycin: Drug information", "rep_snippet": "Tuberculosis:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: 12 to 15 mg/kg/dose (maximum dose: 1 g) 2 to 3 times weekly  End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): 12 t…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6336265802383423, "bge_max": 0.6336265802383423, "title": "Topiramate: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥70 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <70 mL/minute/1.73 m2: Reduce dose to 50% of normal dose and titrate more slowly.  Hemo…"}, {"doc_id": "gemifloxacin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6311568021774292, "bge_max": 0.6311568021774292, "title": "Gemifloxacin (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  CrCl >40 mL/minute: No dosage adjustment necessary.  CrCl ≤40 mL/minute (or patients on hemodialysis/CAPD): 160 mg once daily (administer dose following hemodialysis)."}, {"doc_id": "famciclovir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6307509541511536, "bge_max": 0.6307509541511536, "title": "Famciclovir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Herpes zoster:  CrCl ≥60 mL/minute: No dosage adjustment necessary.  CrCl 40 to 59 mL/minute: Administer 500 mg every 12 hours  CrCl 20 to 39 mL/minute: Administer 500 mg every 24 hours  CrCl <2…"}, {"doc_id": "valganciclovir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6234925985336304, "bge_max": 0.6301799416542053, "title": "Valganciclovir: Drug information", "rep_snippet": "CrCl 40 to 59 mL/minute: 450 mg once daily  CrCl 25 to 39 mL/minute: 450 mg every 2 days  CrCl 10 to 24 mL/minute: 450 mg twice weekly  CrCl <10 mL/minute:  Manufacturer labeling: Use not recommended; ganciclovir (with a…"}, {"doc_id": "pramipexole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6299749612808228, "bge_max": 0.6299749612808228, "title": "Pramipexole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Parkinson disease:  Immediate release:  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl 30 to 50 mL/minute: Initial: 0.125 mg twice daily (maximum: 0.75 mg 3 times daily)  CrCl 15 to 2…"}, {"doc_id": "melphalan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6295888423919678, "bge_max": 0.6295888423919678, "title": "Melphalan: Drug information", "rep_snippet": "IV (high-dose melphalan for autologous stem cell transplant conditioning regimen):  CrCl >60 mL/minute: Usual dose: 200 mg/m2 per treatment course  CrCl <15 to 59 mL/minute: Reduce dose to 140 mg/m2 per treatment course;…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6293022036552429, "bge_max": 0.6293022036552429, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "gabapentin-enacarbil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6287738680839539, "bge_max": 0.6287738680839539, "title": "Gabapentin enacarbil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.  PHN:  CrCl 30-59 mL/minute: Initial: 300 mg every morning for 3 days, then in…"}, {"doc_id": "valacyclovir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6282144784927368, "bge_max": 0.6282144784927368, "title": "Valacyclovir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Herpes zoster: Adults:  CrCl 30 to 49 mL/minute: 1 g every 12 hours  CrCl 10 to 29 mL/minute: 1 g every 24 hours  CrCl <10 mL/minute: 500 mg every 24 hours  Genital herpes: Adults:  US labeling:…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6259712278842926, "bge_max": 0.6271701455116272, "title": "Edoxaban: Drug information", "rep_snippet": "CrCl 15 to 50 mL/minute: 30 mg once daily. Note: Patients with CrCl <30 mL/minute (as determined by Cockcroft-Gault equation) at baseline were excluded from the ENGAGE AF-TIMI 48 trial (Giugliano 2013). However, a post-h…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6268768310546875, "bge_max": 0.6268768310546875, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "tadalafil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6265747547149658, "bge_max": 0.6265747547149658, "title": "Tadalafil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Benign prostatic hyperplasia (with or without concomitant erectile dysfunction) (Cialis):  CrCl ≥51 mL/minute: No dosage adjustment necessary.  CrCl 30 to 50 mL/minute: Initial: 2.5 mg once dail…"}, {"doc_id": "metoclopramide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6241229772567749, "bge_max": 0.6241229772567749, "title": "Metoclopramide: Drug information", "rep_snippet": "Dosing: Renal Impairment  IV:  CrCl ≥40 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <40 mL/minute: Initial: Administer ~50% of normal dose.  Oral:  Diabetic gastroparesis:  C…"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6229159832000732, "bge_max": 0.6229159832000732, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adult: Note: Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl >30 to ≤50 mL/minute: 40…"}, {"doc_id": "hydroxyurea-hydroxycarbamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6223484873771667, "bge_max": 0.6223484873771667, "title": "Hydroxyurea (hydroxycarbamide): Drug information", "rep_snippet": "Dosing: Renal Impairment  CML, head and neck cancer (manufacturer's labeling):  CrCl ≥60 mL/minute: No dosage adjustment (of initial dose) necessary.  CrCl <60 mL/minute: Reduce initial dose by 50%; titrate to response/a…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6208094954490662, "bge_max": 0.6208094954490662, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  IV, Oral:  Normal renal function dosing of 250 mg daily:  CrCl 20 to 49 mL/minute: No dosage adjustment required.  CrCl 10 to 19 mL/minute: Administer 250 mg every 48 hours (except in uncomplica…"}, {"doc_id": "telavancin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6206089854240417, "bge_max": 0.6206089854240417, "title": "Telavancin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.  US labeling:  CrCl >50 mL/minute: No dosage adjustment necessary  CrCl 30 to 50 mL/minute…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6204723119735718, "bge_max": 0.6204723119735718, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling: Oral, IV:  CrCl >30 mL/minute: No dosage adjustment necessary.  CrCl 15 to 30 mL/minute: Administer 50% of recommended dose.  CrCl <15 mL/minute: Use is not rec…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6197417974472046, "bge_max": 0.6197417974472046, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Dosing: Renal Impairment  Treatment of drug-susceptible TB: Adults:  CrCl <30 mL/minute: 600 mg once daily or 600 mg administered 3 times weekly (Nahid 2016)  Intermittent hemodialysis: 600 mg once daily or 600 mg admini…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6190136671066284, "bge_max": 0.6190136671066284, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Traditional infusion method (ie, IV infusion over 30 minutes): Manufacturer’s labeling:  CrCl >40 mL/minute: No dosage adjustment necessary.  CrCl 20 to 40 mL/minute: Administer 2.25 g…"}, {"doc_id": "bosutinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6187936067581177, "bge_max": 0.6187936067581177, "title": "Bosutinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Preexisting impairment:  Ph+ CML, newly diagnosed chronic phase:  CrCl >50 to 80 mL/minute: There are no dosage adjustments provided in manufacturer's labeling, however, based on the pharmacokin…"}, {"doc_id": "memantine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6184579730033875, "bge_max": 0.6184579730033875, "title": "Memantine: Drug information", "rep_snippet": "Canadian labeling: CrCl 15 to 29 mL/minute: Initial: 5 mg once daily; after at least 1 week of therapy and if tolerated, may titrate up to a target dose of 5 mg twice daily"}, {"doc_id": "dofetilide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6181508302688599, "bge_max": 0.6181508302688599, "title": "Dofetilide: Drug information", "rep_snippet": "Dosing: Adult  Note: CrCl and QTc (or QT interval if heart rate is <60 beats/minute) must be determined prior to first dose. If QTc >440 msec (>500 msec in patients with ventricular conduction abnormalities), dofetilide…"}, {"doc_id": "entecavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6177287101745605, "bge_max": 0.6177287101745605, "title": "Entecavir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Daily-dosage regimen preferred:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl 30-49 mL/minute: Administer 50% of usual dose daily or administer the normal dose every 48 hour…"}, {"doc_id": "lisinopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6175308227539062, "bge_max": 0.6175308227539062, "title": "Lisinopril: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Acute myocardial infarction (within 24 hours in hemodynamically stable patients):  CrCl >30 mL/minute: No dosage adjustment necessary.  CrCl 10 to 30 mL/minute: Initial: 2.5 mg once dai…"}, {"doc_id": "isoniazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6171348094940186, "bge_max": 0.6171348094940186, "title": "Isoniazid: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer’s labeling: There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe impairment.  Alternate recommendations: Adults:  CrCl <30 mL/minute:…"}, {"doc_id": "desvenlafaxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.61700838804245, "bge_max": 0.61700838804245, "title": "Desvenlafaxine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Renal function may be estimated using the Cockcroft-Gault formula.  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl 30 to 50 mL/minute: 50 mg once daily (maximum)  CrCl <30 mL/mi…"}, {"doc_id": "atenolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6148849129676819, "bge_max": 0.6148849129676819, "title": "Atenolol: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl >35 mL/minute/1.73 m2: No dosage adjustment necessary.  CrCl 15 to 35 mL/minute/1.73 m2: Maximum dose: 50 mg daily  CrCl <15 mL/minute/1.73 m2: Maximum dose: 25 mg daily  Hemodialysis: Mode…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6139264106750488, "bge_max": 0.6139264106750488, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl 30 to 49 mL/minute: 300 mg every 48 hours  CrCl 10 to 29 mL/minute: 300 mg every 72-96 hours  CrCl <1…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6136715412139893, "bge_max": 0.6136715412139893, "title": "Fluconazole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Note: Renal function estimated using the Cockcroft-Gault formula  No adjustment for vaginal candidiasis single-dose therapy  For multiple dosing in adults, administer lo…"}, {"doc_id": "daptomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6128331422805786, "bge_max": 0.6128331422805786, "title": "Daptomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute:  Skin and soft tissue infections: 4 mg/kg every 48 hours  Staphylococcal bacteremia: 6 mg/kg every 48 hours  End…"}]}
{"qid": "Q12_noise", "query": "Adult, eGFR ~45 mL/min — what oseltamivir regimen should we use?", "base_qid": "Q12", "variant_type": "noise", "candidates": [{"doc_id": "oseltamivir-drug-information", "bm25_top3": 24.689667650603045, "bm25_max": 28.44712279336585, "bge_top3": 0.6237919926643372, "bge_max": 0.6237919926643372, "title": "Oseltamivir: Drug information", "rep_snippet": "Pricing: US  Capsules (Oseltamivir Phosphate Oral)  30 mg (10): $141.80  45 mg (10): $141.80  75 mg (10): $154.57  Capsules (Tamiflu Oral)  30 mg (10): $167.21  45 mg (10): $167.21  75 mg (10): $182.26  Suspension (recon…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 19.277866544333452, "bm25_max": 19.277866544333452, "bge_top3": 0.6074938774108887, "bge_max": 0.6074938774108887, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during ther…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 19.277866544333452, "bm25_max": 19.277866544333452, "bge_top3": 0.607495903968811, "bge_max": 0.607495903968811, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 18.85552572467144, "bm25_max": 18.85552572467144, "bge_top3": 0.6089100241661072, "bge_max": 0.6089100241661072, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 45 to <60 mL/minute/1.73 m2: Do not initiate therapy if eGFR <60 mL/minute/1.73 m2; discontinue therapy if eGFR falls persistentl…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 14.615891769193267, "bm25_max": 18.776299177284724, "bge_top3": 0.6395997405052185, "bge_max": 0.6395997405052185, "title": "Canagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Maximum dose: 100 mg once daily. If patient receiving concurrent UDP-glucuronosyl transferase (UGT)…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 15.225660109150121, "bm25_max": 18.14308109541426, "bge_top3": 0.6298464834690094, "bge_max": 0.6511794924736023, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, t…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 14.470026786680341, "bm25_max": 18.070978194789234, "bge_top3": 0.621299147605896, "bge_max": 0.621299147605896, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": 13.460133838478649, "bm25_max": 18.045893982814125, "bge_top3": 0.6523600816726685, "bge_max": 0.6523600816726685, "title": "Glipizide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformi…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 17.97966017622166, "bm25_max": 17.97966017622166, "bge_top3": 0.6079165935516357, "bge_max": 0.6079165935516357, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 13.203384538716398, "bm25_max": 17.6381363499718, "bge_top3": 0.6536465883255005, "bge_max": 0.6536465883255005, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 14.450109320100363, "bm25_max": 17.237542371161304, "bge_top3": 0.6506587266921997, "bge_max": 0.6506587266921997, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 15.319922703196264, "bm25_max": 17.01178596330876, "bge_top3": 0.6382156610488892, "bge_max": 0.6611580848693848, "title": "Empagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, d…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 13.941356620434611, "bm25_max": 16.39610574285927, "bge_top3": 0.6525168418884277, "bge_max": 0.6525168418884277, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 14.416998390348107, "bm25_max": 16.318196554438195, "bge_top3": 0.622711181640625, "bge_max": 0.622711181640625, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR <45 mL/minute/1.73 m2: Use is contraindicated by the manufacturer; refer also to indiv…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": 13.55405368581297, "bm25_max": 15.802872341230113, "bge_top3": null, "bge_max": null, "title": "Fenofibrate: Drug information", "rep_snippet": "Dialysis: Use is contraindicated.  TriCor:  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 59 mL/minute/1.73 m2: Initiate at 48 mg once daily  eGFR <30 mL/minute/1.73 m2: Use is contraindicated.…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": 15.695080597244601, "bm25_max": 15.695080597244601, "bge_top3": 0.6099675893783569, "bge_max": 0.6099675893783569, "title": "Sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR ≥30 to <45 mL/minute/1.73 m2: 50 mg once daily  eGFR <30 mL/minute/1.73 m2: 25 mg once daily  ESRD requiring hemodialysis or per…"}, {"doc_id": "saxagliptin-drug-information", "bm25_top3": 14.095215569996569, "bm25_max": 14.095215569996569, "bge_top3": 0.6040515303611755, "bge_max": 0.6040515303611755, "title": "Saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <45 mL/minute/1.73 m2: 2.5 mg once daily.  ESRD requiring hemodialysis: 2.5 mg once daily; administer postdialysis  Peritoneal d…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 13.718957644295639, "bm25_max": 13.718957644295639, "bge_top3": 0.6121727228164673, "bge_max": 0.6121727228164673, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when e…"}, {"doc_id": "metformin-drug-information", "bm25_top3": 12.005277706406927, "bm25_max": 13.569223427738166, "bge_top3": 0.6299569606781006, "bge_max": 0.6299569606781006, "title": "Metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually. More frequent monitoring (every 3 to 6 months) and a maximum dose of 2,000 mg/day has been r…"}, {"doc_id": "glyburide-and-metformin-drug-information", "bm25_top3": 11.432108242429589, "bm25_max": 11.432108242429589, "bge_top3": null, "bge_max": null, "title": "Glyburide and metformin: Drug information", "rep_snippet": "Monitoring Parameters  Signs and symptoms of hypoglycemia, blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treat…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 11.373921439146454, "bm25_max": 11.373921439146454, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Use is not recommended for initiation of therapy or when eGFR is persistently between 30 and <60 mL…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 10.999645050437632, "bm25_max": 10.999645050437632, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": 10.999645050437632, "bm25_max": 10.999645050437632, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 10.989132143710556, "bm25_max": 10.989132143710556, "bge_top3": null, "bge_max": null, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >60 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR 30 to 60 mL/minute/1.73 m2: Use is not recommended.  eGFR <30 mL/minute/1.73 m2: Use i…"}, {"doc_id": "meropenem-and-vaborbactam-drug-information", "bm25_top3": 10.949747530329162, "bm25_max": 10.949747530329162, "bge_top3": null, "bge_max": null, "title": "Meropenem and vaborbactam: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Estimation of renal function for the purpose of drug dosing should be done using the Modification of Diet in Renal Disease (MDRD) formula. Dosage recommendations are expressed as g…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 10.456522156813744, "bm25_max": 10.456522156813744, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <60 mL/minute/1.73 m2: Use is contraindicated.  Hemodialysis: Use is contraindicated."}, {"doc_id": "glimepiride-drug-information", "bm25_top3": 10.268585665425832, "bm25_max": 10.268585665425832, "bge_top3": null, "bge_max": null, "title": "Glimepiride: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Initial: 1 mg once daily; dose titration and maintenance dosing should be conservative to avoid hypoglycemia. Consider alternative therapy if eGFR <15 mL/minute/1.73 m2 (Alsahli 2015)."}, {"doc_id": "pralatrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6269198060035706, "bge_max": 0.6530956625938416, "title": "Pralatrexate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Peripheral T-cell lymphoma (PTCL), relapsed or refractory:  Estimated glomerular filtration rate (eGFR) ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 15 to <30 mL/minute/1.73 m2:…"}, {"doc_id": "delafloxacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6293590068817139, "bge_max": 0.6293590068817139, "title": "Delafloxacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral, IV:  Estimated glomerular filtration rate (eGFR) 30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 15 to 29 mL/minute/1.73 m2:  Oral: No dosage adjustment necessary.  IV: 2…"}, {"doc_id": "osimertinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6262510418891907, "bge_max": 0.6262510418891907, "title": "Osimertinib: Drug information", "rep_snippet": "Dosing: Adult  Note: Confirm tumor T790M EGFR mutation status prior to treatment initiation (in the absence of tumor biopsy, a plasma specimen may be utilized).  Non-small cell lung cancer, metastatic (T790M EGFR mutatio…"}, {"doc_id": "afatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6215862035751343, "bge_max": 0.6215862035751343, "title": "Afatinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The manufacturer recommends using the Modification of Diet in Renal Disease (MDRD) formula to estimate the glomerular filtration rate (eGFR).  Preexisting impairment:  eGFR >30 mL/minute/1…"}, {"doc_id": "phentermine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6211332678794861, "bge_max": 0.6211332678794861, "title": "Phentermine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Capsule, tablet (excluding Lomaira):  eGFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased; use with caution.…"}, {"doc_id": "fluorouracil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6143621206283569, "bge_max": 0.61995530128479, "title": "Fluorouracil (systemic): Drug information", "rep_snippet": "ECF or EOF regimen (advanced disease): 200 mg/m2/day continuous infusion days 1 to 21 every 3 weeks (in combination with epirubicin and either cisplatin or oxaliplatin) for a planned duration of 24 weeks (Sumpter 2005)…"}, {"doc_id": "fludarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6198114156723022, "bge_max": 0.6198114156723022, "title": "Fludarabine: Drug information", "rep_snippet": "Dosing: Adult  Chronic lymphocytic leukemia (CLL), refractory or progressive:  IV: 25 mg/m2 once daily for 5 consecutive days every 28 days; continue for at least 3 additional cycles after maximal response is achieved  O…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6172386407852173, "bge_max": 0.6172386407852173, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Dosing: Renal Impairment  GFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR <60 mL/minute/1.73 m2: Ezetimibe 10 mg and simvastatin 20 mg once daily in the evening (higher doses should be used with caution)."}, {"doc_id": "epirubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6167963743209839, "bge_max": 0.6167963743209839, "title": "Epirubicin: Drug information", "rep_snippet": "ECF regimen: 50 mg/m2 on day 1 every 21 days for 3 preoperative and 3 postoperative cycles in combination with cisplatin and fluorouracil (Cunningham 2006)  Gastric cancer (off-label use): IV:  ECF, ECX, EOF, and EOX reg…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6143364906311035, "bge_max": 0.6143364906311035, "title": "Hyoscyamine: Drug information", "rep_snippet": "Dosing: Adult  Gastrointestinal disorders:  Oral:  Tablet, dispersible:  Anaspaz, ED-SPAZ, NuLev, Symax FasTab: 0.125 to 0.25 mg every 4 hours or as needed; maximum: 1.5 mg/day  Oscimin: 0.125 to 0.25 mg 3 to 4 times dai…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6118783950805664, "bge_max": 0.6118783950805664, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "Efavirenz: May decrease the serum concentration of Atazanavir. Management: When used with efavirenz, the adult atazanavir dose should be 400 mg daily, boosted with ritonavir 100 mg daily or cobicistat 150 mg daily, for t…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6116587519645691, "bge_max": 0.6116587519645691, "title": "Edoxaban: Drug information", "rep_snippet": "ESRD requiring hemodialysis: A small, single-dose pharmacokinetic study showed edoxaban was not dialyzable to a clinically significant degree (Parasrampuria 2015). Due to the paucity of data, use with caution in patients…"}, {"doc_id": "ifosfamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6077078183492025, "bge_max": 0.6082600355148315, "title": "Ifosfamide: Drug information", "rep_snippet": "Diffuse large B-cell lymphoma (RICE regimen): 5,000 mg/m2 (over 24 hours) beginning on day 4 every 2 weeks for 3 cycles (in combination with mesna, carboplatin, etoposide, and rituximab) (Kewalramani 2004)  Osteosarcoma…"}, {"doc_id": "lisinopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6076230406761169, "bge_max": 0.6076230406761169, "title": "Lisinopril: Drug information", "rep_snippet": "GFR <10 mL/minute: Administer 25% to 50% of usual dose.  Intermittent hemodialysis: Dose after dialysis.  Continuous renal replacement therapy (CRRT): Administer 50% to 75% of usual dose.  Children ≥ 6 years and Adolesce…"}, {"doc_id": "carboplatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6044430732727051, "bge_max": 0.6067094802856445, "title": "Carboplatin: Drug information", "rep_snippet": "Infants ≥6 months and Children ≤3 years: Consolidation regimen: 17 mg/kg over 2 hours on days 0 and 1 of a 21-day cycle for 3 cycles (in combination with thiotepa), followed by stem cell infusion at least 48 hours after…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6064311265945435, "bge_max": 0.6064311265945435, "title": "Sulfadiazine: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Oral: 2 to 4 g/day in 3 to 6 divided doses  Rheumatic fever prophylaxis (off-label dose) (Gerber [AHA 2009]): Oral:  ≤27 kg: 500 mg once daily  >27 kg: 1,000 mg once daily  Toxop…"}, {"doc_id": "enalapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6035884618759155, "bge_max": 0.6035884618759155, "title": "Enalapril: Drug information", "rep_snippet": "Manufacturer's labeling: Use in infants, children, and adolescents ≤16 years with GFR <30 mL/minute/1.73 m2 is not recommended (no dosing data available).  Alternate recommendations (Aronoff 2007):  GFR >50 mL/minute/1.7…"}, {"doc_id": "sofosbuvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6033039093017578, "bge_max": 0.6033039093017578, "title": "Sofosbuvir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Estimated glomerular filtration rate (eGFR) ≥30 mL/minute: No dosage adjustment necessary.  eGFR <30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not b…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6026147603988647, "bge_max": 0.6026147603988647, "title": "Fluvastatin: Drug information", "rep_snippet": "Dosing: Adult  Heterozygous familial and nonfamilial hypercholesterolemia: Oral:  Immediate release: 40 mg once daily in the evening or 40 mg twice daily  Extended release: 80 mg once daily (anytime)  Mixed dyslipidemia:…"}, {"doc_id": "cytarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6015093624591827, "bge_max": 0.6025354862213135, "title": "Cytarabine: Drug information", "rep_snippet": "FLAG regimen: 2000 mg/m2/day over 4 hours for 5 days (in combination with fludarabine and G-CSF); may repeat once if needed (Montillo, 1998)  GCLAC regimen: Adults 18 to 70 years (Becker, 2011):  Induction: 2,000 mg/m2 o…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6022418737411499, "bge_max": 0.6022418737411499, "title": "Amoxicillin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Oral:  Immediate-release: Note: Avoid immediate-release 875 mg tablet in patients with GFR <30 mL/minute.  GFR ≥30 mL/minute: No dosage adjustment necessary.  GFR 10 to 30 mL/minute: 250…"}, {"doc_id": "valproate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5999780297279358, "bge_max": 0.5999780297279358, "title": "Valproate: Drug information", "rep_snippet": "Dosing: Geriatric  Oral, IV: Lower initial doses are recommended due to decreased elimination and increased incidences of somnolence in the elderly; no specific dosage recommendations are provided by the manufacturer. Up…"}, {"doc_id": "rivastigmine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.599818766117096, "bge_max": 0.599818766117096, "title": "Rivastigmine: Drug information", "rep_snippet": "Dosing: Adult  Note: Exelon oral solution and capsules are bioequivalent.  Note: Exelon oral solution has been discontinued in the US for more than 1 year.  Alzheimer dementia, mild to moderate:  Oral: Initial: 1.5 mg tw…"}, {"doc_id": "imatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.599766194820404, "bge_max": 0.599766194820404, "title": "Imatinib: Drug information", "rep_snippet": "Ph+ acute lymphoblastic leukemia (ALL) (relapsed or refractory): Oral: 600 mg once daily  Gastrointestinal stromal tumors (GIST) (adjuvant treatment following complete resection): Oral: 400 mg once daily; recommended tre…"}]}
{"qid": "Q13_abbr", "query": "HTN adult — lisinopril start dose & max dose; any renal adjustments/CI?", "base_qid": "Q13", "variant_type": "abbr", "candidates": [{"doc_id": "lisinopril-and-hydrochlorothiazide-drug-information", "bm25_top3": 22.113752325286953, "bm25_max": 32.99621564183757, "bge_top3": 0.6463771164417267, "bge_max": 0.6639559864997864, "title": "Lisinopril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Not for initial therapy. Dose is individualized; may be substituted for individual components in patients currently maintained on both agents separately or in patients not controlled with monotherapy…"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": 17.775714882444905, "bm25_max": 21.36429721528889, "bge_top3": 0.6493232250213623, "bge_max": 0.6493232250213623, "title": "Hydrocodone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hysingla ER, Vantrela ER:  Mild impairment: No dosage adjustment necessary.  Moderate to severe impairment: Initial: Start with 50% of the initial dose; titrate carefully; monitor closely.  End-…"}, {"doc_id": "fomepizole-drug-information", "bm25_top3": 18.95896375210431, "bm25_max": 18.95896375210431, "bge_top3": null, "bge_max": null, "title": "Fomepizole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant or worsening metabolic acidosis, or ethylene glycol or methanol concentrations ≥50…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 17.979760469820707, "bm25_max": 17.979760469820707, "bge_top3": null, "bge_max": null, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; however, single-dose pharmacokinetic data suggests that dosage adjustments are not necessary (m…"}, {"doc_id": "isosorbide-dinitrate-drug-information", "bm25_top3": 17.642061743983643, "bm25_max": 17.642061743983643, "bge_top3": null, "bge_max": null, "title": "Isosorbide dinitrate: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  There are no dosage adjustments provided in the manufacturer’s labeling.  Hemodialysis: Supplemental dose is not necessary.  Peritoneal dialysis: Supplemental dose is not necessary."}, {"doc_id": "fosinopril-drug-information", "bm25_top3": 17.297013045725805, "bm25_max": 17.297013045725805, "bge_top3": null, "bge_max": null, "title": "Fosinopril: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Moderate-severe impairment: Initial dose reduction to 5 mg once daily recommended for heart failure patients. No other dose adjustments are required; hepatobiliary elimination partially…"}, {"doc_id": "dextroamphetamine-drug-information", "bm25_top3": 17.258926255071778, "bm25_max": 17.258926255071778, "bge_top3": null, "bge_max": null, "title": "Dextroamphetamine: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing; start at lowest dose. Use with caution."}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 16.39772913486387, "bm25_max": 16.39772913486387, "bge_top3": 0.6621472239494324, "bge_max": 0.6621472239494324, "title": "Flucytosine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: The manufacturer recommends dose reduction for elevated BUN or serum creatinine (or other signs of renal impairment); however, no specific dosage adjustments are provided. The following…"}, {"doc_id": "ethinyl-estradiol-and-drospirenone-drug-information", "bm25_top3": 16.03703249696436, "bm25_max": 16.03703249696436, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and drospirenone: Drug information", "rep_snippet": "Dosing: Adult  Acne (Gianvi, Loryna, Nikki, Vestura, Yaz): Females: Oral: Refer to dosing for contraception.  PMDD (Gianvi, Yaz): Females: Oral: Refer to dosing for contraception.  Contraception: Female: Oral: One tablet…"}, {"doc_id": "gadobutrol-drug-information", "bm25_top3": 15.968500797697278, "bm25_max": 15.968500797697278, "bge_top3": null, "bge_max": null, "title": "Gadobutrol: Drug information", "rep_snippet": "Dosing: Hepatic Impairment (Adult)  There are no dosage adjustments provided in the manufacturer’s labeling; however, based on exclusive renal excretion of gadobutrol, dose adjustment in hepatic impairment is likely unne…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": 15.819589162828933, "bm25_max": 15.819589162828933, "bge_top3": null, "bge_max": null, "title": "Enoxaparin: Drug information", "rep_snippet": "Note: The following recommendations are based on use of therapeutic doses of enoxaparin (eg, 1 mg/kg every 12 hours). If converting from a prophylactic enoxaparin dose (eg, 30 mg twice daily) to a therapeutic IV UFH dose…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": 15.805146740354672, "bm25_max": 15.805146740354672, "bge_top3": null, "bge_max": null, "title": "Duloxetine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder: Oral: Initial: 40 to 60 mg daily; dose may be divided (ie, 20 or 30 mg twice daily) or given as a single daily dose of 60 mg. For some patients it may be desirable to start at 30…"}, {"doc_id": "isavuconazole-isavuconazonium-sulfate-drug-information", "bm25_top3": 15.71892142995166, "bm25_max": 15.71892142995166, "bge_top3": null, "bge_max": null, "title": "Isavuconazole (isavuconazonium sulfate): Drug information", "rep_snippet": "Dosing: Adult  Note: Dosage expressed as milligrams of isavuconazonium sulfate; switching between the intravenous (IV) and oral formulations of isavuconazonium sulfate is acceptable; for maintenance dosing, it is not nec…"}, {"doc_id": "liposomal-daunorubicin-and-cytarabine-drug-information", "bm25_top3": 15.658125060970573, "bm25_max": 15.658125060970573, "bge_top3": null, "bge_max": null, "title": "Liposomal daunorubicin and cytarabine: Drug information", "rep_snippet": "Consolidation: Daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 (liposomal) on days 1 and 3; administer the first consolidation cycle 5 to 8 weeks after the start of the last induction; administer the second consolidation c…"}, {"doc_id": "lamotrigine-drug-information", "bm25_top3": 15.505052354094017, "bm25_max": 15.505052354094017, "bge_top3": null, "bge_max": null, "title": "Lamotrigine: Drug information", "rep_snippet": "Patients not taking concomitant carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir, or atazanavir/ritonavir: Lamotrigine maintenance dose may need increased by twofold over target dose. If…"}, {"doc_id": "gemfibrozil-drug-information", "bm25_top3": 15.503427406402938, "bm25_max": 15.503427406402938, "bge_top3": null, "bge_max": null, "title": "Gemfibrozil: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Manufacturer's labeling:  Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; deterioration of renal function has been…"}, {"doc_id": "laronidase-drug-information", "bm25_top3": 15.46920063855245, "bm25_max": 15.46920063855245, "bge_top3": null, "bge_max": null, "title": "Laronidase: Drug information", "rep_snippet": "Dosing: Adult  Note: Premedicate with antipyretic and/or antihistamines 1 hour prior to start of infusion.  MPS I (Hurler syndrome, Hurler-Scheie, and Scheie forms): IV: 0.58 mg/kg once weekly; dose should be rounded up…"}, {"doc_id": "chlorzoxazone-drug-information", "bm25_top3": 15.366379626748266, "bm25_max": 15.366379626748266, "bge_top3": null, "bge_max": null, "title": "Chlorzoxazone: Drug information", "rep_snippet": "Dosing: Adult  Musculoskeletal conditions: Oral: 250 to 500 mg 3 or 4 times daily, may increase to 750 mg 3 or 4 times daily; for painful musculoskeletal conditions, start with 500 mg 3 or 4 times daily. Consider dose re…"}, {"doc_id": "belimumab-drug-information", "bm25_top3": 15.188546059370918, "bm25_max": 15.188546059370918, "bge_top3": null, "bge_max": null, "title": "Belimumab: Drug information", "rep_snippet": "Dosing: Adult  Systemic lupus erythematosus (SLE):  IV: Initial: 10 mg/kg every 2 weeks for 3 doses; Maintenance: 10 mg/kg every 4 weeks  SubQ: 200 mg once weekly  Switching from IV therapy: Administer the first SubQ dos…"}, {"doc_id": "ethinyl-estradiol-and-norgestimate-drug-information", "bm25_top3": 15.17785772473486, "bm25_max": 15.17785772473486, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and norgestimate: Drug information", "rep_snippet": "Dosing: Adult  Females:  Acne (Ortho Tri-Cyclen, Tri-Estaryllla, TriNessa, Tri-Previfem, Tri-Sprintec): Oral: Refer to dosing for contraception  Contraception: Oral: 1 tablet once daily  Schedule 1 (Sunday starter): Dose…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": 15.161019317560717, "bm25_max": 15.161019317560717, "bge_top3": null, "bge_max": null, "title": "Alirocumab: Drug information", "rep_snippet": "Dosing: Adult  Hyperlipidemia, primary: SubQ: Initial: 75 mg every 2 weeks or 300 mg every 4 weeks; for both regimens, if an adequate LDL-C response is not achieved, may increase or modify dosing regimen to a maximum of…"}, {"doc_id": "ruxolitinib-drug-information", "bm25_top3": 15.100440210907546, "bm25_max": 15.100440210907546, "bge_top3": null, "bge_max": null, "title": "Ruxolitinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Myelofibrosis:  CrCl 15 to 59 mL/minute and platelets >150,000/mm3: No dosage adjustment is necessary.  CrCl 15 to 59 mL/minute and platelets 100,000 to 150,000/mm3: Initial dose: 10 mg twice da…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": 14.96433532556881, "bm25_max": 14.96433532556881, "bge_top3": null, "bge_max": null, "title": "Dalteparin: Drug information", "rep_snippet": "Conversion from IV unfractionated heparin (UFH) infusion to SubQ dalteparin (Nutescu 2007): Calculate specific dose for dalteparin based on indication, discontinue UFH and begin dalteparin within 1 hour  Conversion from…"}, {"doc_id": "dacarbazine-drug-information", "bm25_top3": 14.866301737565141, "bm25_max": 14.866301737565141, "bge_top3": null, "bge_max": null, "title": "Dacarbazine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling. The following adjustments have been recommended (Kintzel 1995):  CrCl 46 to 60 mL/minute: Reduce dose to 80% of usual dos…"}, {"doc_id": "technetium-tc-99m-aggregated-albumin-drug-information", "bm25_top3": 14.62484394016456, "bm25_max": 14.62484394016456, "bge_top3": null, "bge_max": null, "title": "Technetium Tc-99m aggregated albumin: Drug information", "rep_snippet": "Dosing: Pediatric  Lung imaging: IV:  Newborns: 200 to 500 μCi (7.4 to 18.5 MBq); minimum dose: 200 μCi (7.4 MBq)  Children: 25 to 50 μCi/kg (0.925 to 1.85 MBq/kg); usual dose: 30 μCi/kg (1.11 MBq/kg)"}, {"doc_id": "trace-metals-drug-information", "bm25_top3": 14.610302657047532, "bm25_max": 14.610302657047532, "bge_top3": null, "bge_max": null, "title": "Trace metals: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; use chromium with caution and decrease dose in pediatric patients. Decrease dose or omit selenium in pediatric patients w…"}, {"doc_id": "ezogabine-retigabine-united-states-not-available-drug-information", "bm25_top3": 14.531832673433838, "bm25_max": 14.531832673433838, "bge_top3": null, "bge_max": null, "title": "Ezogabine (retigabine) (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl <50 mL/minute: Initial: 50 mg 3 times daily; may increase at weekly intervals in increments of ≤150 mg per day to a maximum dose…"}, {"doc_id": "lutetium-lu-177-dotatate-drug-information", "bm25_top3": 14.525474636819354, "bm25_max": 14.525474636819354, "bge_top3": null, "bge_max": null, "title": "Lutetium Lu-177 dotatate: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Calculate CrCl using the Cockcroft-Gault equation with actual body weight.  Renal impairment prior to treatment initiation:  CrCl ≥30 mL/minute: No dosage adjustment necessary. Mon…"}, {"doc_id": "technetium-tc-99m-mertiatide-drug-information", "bm25_top3": 14.408114148252718, "bm25_max": 14.408114148252718, "bge_top3": null, "bge_max": null, "title": "Technetium Tc-99m mertiatide: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Measure dose with appropriate radioactivity calibration system immediately prior to administration.  Renal function and imaging: I.V.: 70 to 140 μCi/kg (2.6 to 5.2 MBq/kg); minimum dose: 1 mCi (3…"}, {"doc_id": "promethazine-phenylephrine-and-codeine-drug-information", "bm25_top3": 14.309489308461925, "bm25_max": 14.309489308461925, "bge_top3": null, "bge_max": null, "title": "Promethazine, phenylephrine, and codeine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; reduce initial dose in significant renal impairment."}, {"doc_id": "neostigmine-drug-information", "bm25_top3": 14.309264717596252, "bm25_max": 14.309264717596252, "bge_top3": null, "bge_max": null, "title": "Neostigmine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in manufacturer's labeling. The manufacturer recommends close monitoring in patients with impaired renal function.  The following adjustments have been r…"}, {"doc_id": "promethazine-and-codeine-drug-information", "bm25_top3": 14.208344532930962, "bm25_max": 14.208344532930962, "bge_top3": null, "bge_max": null, "title": "Promethazine and codeine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no specific dosage adjustments provided in the manufacturer's labeling. Use with caution; reduce initial dose in significant renal impairment."}, {"doc_id": "fluorouracil-systemic-drug-information", "bm25_top3": 14.20617135794717, "bm25_max": 14.20617135794717, "bge_top3": null, "bge_max": null, "title": "Fluorouracil (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; use with caution. The following adjustments have been suggested:  CrCl <50 mL/minute and continuous renal replacement the…"}, {"doc_id": "chlorambucil-drug-information", "bm25_top3": 13.984290528671336, "bm25_max": 13.984290528671336, "bge_top3": null, "bge_max": null, "title": "Chlorambucil: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination of unchanged chlorambucil and active metabolite (phenylacetic acid mustard) is minimal and ren…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 13.46428505517181, "bm25_max": 13.46428505517181, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Dosing: Geriatric  Depression: Oral: Initial dose: Start at a lower dosage level and increase based on tolerance and response to a usual maximum of 100 mg daily; usual maintenance dose: 25 to 100 mg once daily or in divi…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 13.29603670529481, "bm25_max": 13.29603670529481, "bge_top3": null, "bge_max": null, "title": "Naratriptan: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. Dosing should generally start at the lower end of the dosing range due to possible increased incidence of hepatic, renal, and cardiac impairment."}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": 12.650652157707743, "bm25_max": 12.650652157707743, "bge_top3": null, "bge_max": null, "title": "Fosphenytoin: Drug information", "rep_snippet": "Manufacturer's labeling: Loading dose: 15 to 20 mg PE/kg administered at 2 mg PE/kg/minute or 150 mg PE/minute, whichever is slower. Follow loading dose with maintenance doses of either fosphenytoin or phenytoin.  Noneme…"}, {"doc_id": "lisinopril-drug-information", "bm25_top3": 12.301609381862088, "bm25_max": 12.301609381862088, "bge_top3": 0.6628111004829407, "bge_max": 0.6628111004829407, "title": "Lisinopril: Drug information", "rep_snippet": "(For additional information see \"Lisinopril: Patient drug information\" and see \"Lisinopril: Pediatric drug information\")  For abbreviations and symbols that may be used in Lexicomp (show table)"}, {"doc_id": "tizanidine-drug-information", "bm25_top3": 6.959103023920335, "bm25_max": 6.959103023920335, "bge_top3": null, "bge_max": null, "title": "Tizanidine: Drug information", "rep_snippet": "Lisinopril: TiZANidine may enhance the hypotensive effect of Lisinopril. Risk C: Monitor therapy  Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Lormetazepam: May enhance t…"}, {"doc_id": "losartan-drug-information", "bm25_top3": 4.964566569134902, "bm25_max": 4.964566569134902, "bge_top3": null, "bge_max": null, "title": "Losartan: Drug information", "rep_snippet": "• Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.  • Hepatic impairment: Use with caution in patients with hepatic impairment or a history of hepatic impairment; dose adjustm…"}, {"doc_id": "sirolimus-drug-information", "bm25_top3": 4.836525243173936, "bm25_max": 4.836525243173936, "bge_top3": 0.6319955587387085, "bge_max": 0.6319955587387085, "title": "Sirolimus: Drug information", "rep_snippet": "Isavuconazonium Sulfate: May increase the serum concentration of Sirolimus. Risk C: Monitor therapy  Itraconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be…"}, {"doc_id": "iloperidone-drug-information", "bm25_top3": 4.694687014630976, "bm25_max": 4.694687014630976, "bge_top3": null, "bge_max": null, "title": "Iloperidone: Drug information", "rep_snippet": "Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide. Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease th…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 4.520420264598808, "bm25_max": 4.520420264598808, "bge_top3": 0.6659364104270935, "bge_max": 0.6659364104270935, "title": "Spironolactone: Drug information", "rep_snippet": "• Renal impairment: Risk of hyperkalemia is increased with declining renal function and with the concurrent use of larger doses of ACE inhibitors (eg, ≥ lisinopril 10 mg daily in adults) (ACCF/AHA [Yancy 2013]). Use with…"}, {"doc_id": "testosterone-drug-information", "bm25_top3": 3.566868397732417, "bm25_max": 3.566868397732417, "bge_top3": null, "bge_max": null, "title": "Testosterone: Drug information", "rep_snippet": "Hypogonadal men with osteoporosis or low trauma fracture: Monitor after 1 to 2 years of therapy (Endocrine Society [Bhasin 2010]).  PSA: In men >40 years of age with baseline PSA >0.6 ng/mL, PSA and prostate exam at 3 to…"}, {"doc_id": "alprazolam-drug-information", "bm25_top3": 3.0254434196736426, "bm25_max": 3.0254434196736426, "bge_top3": null, "bge_max": null, "title": "Alprazolam: Drug information", "rep_snippet": "Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide. Management: Patients on lomitapide 5…"}, {"doc_id": "quinupristin-and-dalfopristin-drug-information", "bm25_top3": 2.9926738754562905, "bm25_max": 2.9926738754562905, "bge_top3": null, "bge_max": null, "title": "Quinupristin and dalfopristin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazo…"}, {"doc_id": "rubidium-rb-82-drug-information", "bm25_top3": 1.8988748322024218, "bm25_max": 1.8988748322024218, "bge_top3": null, "bge_max": null, "title": "Rubidium rb-82: Drug information", "rep_snippet": "Stress imaging: Begin study 10 minutes after completion of rest dose infusion; administer pharmacologic stress agent; after 3 minutes infuse single dose of rubidium-82 chloride; start imaging 60 to 90 seconds after compl…"}, {"doc_id": "argatroban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6467205584049225, "bge_max": 0.6557945609092712, "title": "Argatroban: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Adults:  Heparin-induced thrombocytopenia (HIT): Moderate to severe hepatic impairment (Child-Pugh class B and C): Continuous IV infusion: Initial: 0.5 mcg/kg/minute; monitor aPTT closely and…"}, {"doc_id": "enalapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6491698622703552, "bge_max": 0.6494022607803345, "title": "Enalapril: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling:  CrCl >30 mL/minute: No dosage adjustment necessary.  CrCl ≤30 mL/minute: Initial: 2.5 mg once daily; titrate upward as needed (maximum: 40 mg/day).  HF patient…"}, {"doc_id": "inotuzumab-ozogamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6454468369483948, "bge_max": 0.6454468369483948, "title": "Inotuzumab ozogamicin: Drug information", "rep_snippet": "Dosing: Hepatic Impairment (Adult)  Hepatic impairment prior to treatment initiation:  Total bilirubin ≤1.5 times ULN and AST/ALT ≤2.5 times ULN: No initial dosage adjustment necessary.  Total bilirubin >1.5 times ULN an…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6452146172523499, "bge_max": 0.6452146172523499, "title": "Erlotinib: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic impairment at treatment initiation:  Total bilirubin > ULN or Child-Pugh classes A, B, and C: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution…"}, {"doc_id": "lenvatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6443889737129211, "bge_max": 0.6443889737129211, "title": "Lenvatinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Preexisting renal impairment:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute:  Renal cell cancer, advanced: 10 mg once daily  Thyroid cancer, differentiated: 14 mg once…"}, {"doc_id": "valganciclovir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6415920853614807, "bge_max": 0.6415920853614807, "title": "Valganciclovir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Infants, Children, and Adolescents 1 month to 16 years: No dosage adjustment necessary; calculation for pediatric dosing adjusts for renal function.  Adolescents >16 years and Adults:  Induction…"}, {"doc_id": "cytarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6410084366798401, "bge_max": 0.6410084366798401, "title": "Cytarabine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended:  Aronoff, 2007 (cytarabine 100 to 200 mg/m2): Children and Adul…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6408714652061462, "bge_max": 0.6408714652061462, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Note: Renally adjusted dose recommendations are based on the amoxicillin 250 mg/clavulanate 125 mg and amoxicillin 500 mg/clavulanate 125 mg tablets.  CrCl ≥30 mL/minute: No dosage adjus…"}, {"doc_id": "maraviroc-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6402335166931152, "bge_max": 0.6402335166931152, "title": "Maraviroc: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥30 mL/minute: No dosage adjustment necessary  CrCl <30 mL/minute:  Concomitant potent CYP3A inhibitors (with or without a potent CYP3A inducer) or concomitant potent CYP3A inducer…"}, {"doc_id": "ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6393814086914062, "bge_max": 0.6393814086914062, "title": "Ticarcillin and clavulanate potassium (United States: Not available): Drug information", "rep_snippet": "Dosing: Hepatic Impairment (Adult)  With concomitant renal dysfunction (Clcr <10 mL/minute): 2 g of ticarcillin component every 24 hours."}, {"doc_id": "risperidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6363790333271027, "bge_max": 0.6387410759925842, "title": "Risperidone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Adults:  Oral: Note: Limiting initial doses to 1 mg daily (in 2 divided doses) may reduce the risk of orthostatic hypotension/syncope. The mean free fraction of risperidone in plasma may be in…"}, {"doc_id": "ramipril-and-hydrochlorothiazide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6386696100234985, "bge_max": 0.6386696100234985, "title": "Ramipril and hydrochlorothiazide (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  CrCl >60 mL/minute/1.73 m2: No dosage adjustment necessary.  CrCl 30 to 60 mL/minute/1.73 m2: Initial dose: Ramipril 2.5 mg/hydrochlorothiazide 12.5 mg once daily; Maximum dose: Ramipril…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6382623314857483, "bge_max": 0.6382623314857483, "title": "Streptomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; however, the following adjustments have been recommended:  Adults:  Aronoff 2007: Note: Recommendations are based on dose…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6380938291549683, "bge_max": 0.6380938291549683, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Oral: Infants, Children, Adolescents, and Adults: There are no specific dosage adjustments provided in manufacturer's labeling. Dose reduction and frequent monitoring of serum theophylline con…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6378592252731323, "bge_max": 0.6378592252731323, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling: Oral, IV:  CrCl >30 mL/minute: No dosage adjustment necessary.  CrCl 15 to 30 mL/minute: Administer 50% of recommended dose.  CrCl <15 mL/minute: Use is not rec…"}, {"doc_id": "nivolumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6378132104873657, "bge_max": 0.6378132104873657, "title": "Nivolumab: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic impairment prior to treatment initiation:  Mild (total bilirubin ≤ ULN and AST > ULN or total bilirubin >1 to 1.5 × ULN and any AST) or moderate (total bilirubin >1.5 to 3 × ULN and an…"}, {"doc_id": "axitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6368615031242371, "bge_max": 0.6368615031242371, "title": "Axitinib: Drug information", "rep_snippet": "Dosing: Adult  Renal cell cancer, advanced: Oral: Initial: 5 mg twice daily (approximately every 12 hours)  Dose increases: If dose is tolerated (no adverse events above grade 2, blood pressure is normal and no antihyper…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6353136301040649, "bge_max": 0.6353136301040649, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Nephropathic cystinosis: Oral: Note: Begin therapy as soon as the diagnosis of nephropathic cystinosis has been confirmed.  Immediate release (Cystagon):  Initial: Initiate therapy with 1/6 to 1/4 of maint…"}, {"doc_id": "captopril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6351436376571655, "bge_max": 0.6351436376571655, "title": "Captopril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Dose is individualized; may be substituted for previously titrated dosages of the individual components; alternatively, may initiate as follows: Oral:  Hypertension: Initial: Captopril 25 mg/hydrochl…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6351220607757568, "bge_max": 0.6351220607757568, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff, 2007): Dosing based on a usual dose of 200 t…"}, {"doc_id": "nitisinone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6334802806377411, "bge_max": 0.634932279586792, "title": "Nitisinone: Drug information", "rep_snippet": "Dosing: Adult  Note: Must be used in conjunction with a diet restricted in tyrosine and phenylalanine. Titrate dose as needed based on biochemical and/or clinical response. If the biochemical response is satisfactory, th…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6344876289367676, "bge_max": 0.6344876289367676, "title": "Pegylated interferon (peginterferon) alfa-2b: Drug information", "rep_snippet": "Dosing: Adult  Note  : PegIntron Redipen and PegIntron 80 mcg, 120 mcg, and 150 mcg vials have been discontinued in the US for more than 1 year.  Melanoma: SubQ: Initial: 6 mcg/kg/week for 8 doses; Maintenance: 3 mcg/kg/…"}, {"doc_id": "abiraterone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.633442759513855, "bge_max": 0.633442759513855, "title": "Abiraterone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic impairment prior to treatment initiation:  Mild (Child-Pugh class A): No dosage adjustment necessary.  Moderate (Child-Pugh class B): 250 mg once daily. Permanently discontinue if ALT…"}, {"doc_id": "gemcitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6325536668300629, "bge_max": 0.6333964467048645, "title": "Gemcitabine: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution in patients with pre-existing renal dysfunction. Discontinue if severe renal toxicity or hemolyt…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2a-and-ribavirin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6323287487030029, "bge_max": 0.6323287487030029, "title": "Pegylated interferon (peginterferon) alfa-2a and ribavirin (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Peginterferon alfa-2a: SubQ:  CrCl >20 mL/minute: No dosage adjustment necessary. Monitor closely as dose reduction may be warranted with onset of adverse events.  End-stage renal diseas…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6319964528083801, "bge_max": 0.6319964528083801, "title": "Amikacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Some patients may require larger or more frequent doses if serum levels document the need (ie, cystic fibrosis or febrile granulocytopenic patients).  Adults: The following adjustments have been…"}, {"doc_id": "neratinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6318159699440002, "bge_max": 0.6318159699440002, "title": "Neratinib: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Preexisting hepatic impairment:  Mild to moderate (Child-Pugh class A or B) impairment: No dosage adjustment is necessary.  Severe (Child-Pugh class C) impairment: Reduce initial dose to 80 mg…"}, {"doc_id": "imatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.631050169467926, "bge_max": 0.631050169467926, "title": "Imatinib: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Mild-to-moderate impairment: No dosage adjustment necessary.  Severe impairment: Reduce dose by 25%.  Dosage adjustment for hepatotoxicity (during therapy): If elevations of bilirubin >3 times…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.630767285823822, "bge_max": 0.630767285823822, "title": "Aminophylline: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Infants, Children, Adolescents, and Adults: Initial: 0.25 mg/kg/hour; maximum dose: 507 mg/day unless serum concentrations indicate need for larger dose. Use with caution and monitor serum the…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6307576894760132, "bge_max": 0.6307576894760132, "title": "Fenofibrate: Drug information", "rep_snippet": "Dosing: Geriatric  Oral: Initial: Adjust dosage based on renal function; additional product-specific recommendations for initial dose:  Lipidil EZ [Canadian product]: 48 mg once daily  Lofibra (micronized): 67 mg once da…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6304980516433716, "bge_max": 0.6304980516433716, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Renal Impairment  US labeling: There are no dosage adjustments provided in the manufacturer’s labeling; however the following adjustments have been recommended (Aronoff 2007): Cetirizine:  Adults:  GFR >50 mL/min…"}, {"doc_id": "bortezomib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6300526857376099, "bge_max": 0.6300526857376099, "title": "Bortezomib: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Mild impairment (bilirubin ≤1 times ULN and AST >ULN or bilirubin >1 to 1.5 times ULN): No initial dose adjustment is necessary (LoRusso, 2012).  Moderate (bilirubin >1.5 to 3 times ULN) and s…"}, {"doc_id": "ribociclib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6292210817337036, "bge_max": 0.6292210817337036, "title": "Ribociclib: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic impairment at baseline:  Mild impairment (Child-Pugh class A): No dosage adjustment necessary.  Moderate or severe impairment (Child-Pugh class B or C): Reduce initial dose to 400 mg/d…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6292049884796143, "bge_max": 0.6292049884796143, "title": "Paroxetine: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Adults: In hepatic dysfunction, plasma concentration is 2 times that seen in normal function.  Brisdelle: No dosage adjustment necessary.  Paxil, Paxil CR, Pexeva:  Mild-to-moderate impairment…"}, {"doc_id": "quinapril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6290934681892395, "bge_max": 0.6290934681892395, "title": "Quinapril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Not for initial therapy. Correct volume and/or salt depletion before initiating therapy.  Replacement therapy: Combination product may be substituted for individually titrated age…"}, {"doc_id": "candesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.62784743309021, "bge_max": 0.62784743309021, "title": "Candesartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: No initial dosage adjustment necessary; however, in patients with severe renal impairment (CrCl <30 mL/minute/1.73 m2) AUC and Cmax were approximately doubled after repeated dosing.  Chi…"}, {"doc_id": "paricalcitol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6275928020477295, "bge_max": 0.6275928020477295, "title": "Paricalcitol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Paricalcitol: Pediatric drug information\")  Secondary hyperparathyroidism associated with chronic renal failure (stage 5 CKD):  IV: Children ≥5 years and Adolescents: R…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6272069215774536, "bge_max": 0.6272069215774536, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Children ≥12 years (and ≥35 kg) and Adolescents: Refer to adult dosing. Note: Tenofovir is a component of recommended initial regimens in adolescent treatment-naive patients (when coadministered with emtricitabine plus d…"}]}
{"qid": "Q13_noise", "query": "New HTN; considering lisinopril — initial and max dosing, renal cautions?", "base_qid": "Q13", "variant_type": "noise", "candidates": [{"doc_id": "lisinopril-and-hydrochlorothiazide-drug-information", "bm25_top3": 23.41175089115574, "bm25_max": 33.562870126201304, "bge_top3": 0.6363096038500468, "bge_max": 0.6670364141464233, "title": "Lisinopril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Not for initial therapy. Dose is individualized; may be substituted for individual components in patients currently maintained on both agents separately or in patients not controlled with monotherapy…"}, {"doc_id": "lisinopril-drug-information", "bm25_top3": 19.2173354018001, "bm25_max": 24.91997706696464, "bge_top3": 0.6376027464866638, "bge_max": 0.6376027464866638, "title": "Lisinopril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Lisinopril: Pediatric drug information\")  Hypertension: Note: Compounded and commercially available oral solutions available in multiple concentrations; precautions sho…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. Metformin initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 24.899335471762416, "bm25_max": 24.899335471762416, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "promethazine-phenylephrine-and-codeine-drug-information", "bm25_top3": 24.756980251093566, "bm25_max": 24.756980251093566, "bge_top3": null, "bge_max": null, "title": "Promethazine, phenylephrine, and codeine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; reduce initial dose in significant renal impairment."}, {"doc_id": "promethazine-and-codeine-drug-information", "bm25_top3": 24.670233086073683, "bm25_max": 24.670233086073683, "bge_top3": null, "bge_max": null, "title": "Promethazine and codeine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no specific dosage adjustments provided in the manufacturer's labeling. Use with caution; reduce initial dose in significant renal impairment."}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 24.19870689974671, "bm25_max": 24.19870689974671, "bge_top3": null, "bge_max": null, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Dosing: Geriatric  Immediate-release or extended-release tablet: Refer to adult dosing. The initial and maintenance dosing of metformin should be conservative, due to the potential for decreased renal function (monitor)."}, {"doc_id": "oxacillin-drug-information", "bm25_top3": 17.65477194446133, "bm25_max": 17.65477194446133, "bge_top3": null, "bge_max": null, "title": "Oxacillin: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, manufacturer suggests considering a reduction in total dosage if renal impairment is known or suspected."}, {"doc_id": "dexmethylphenidate-drug-information", "bm25_top3": 16.972268759146196, "bm25_max": 16.972268759146196, "bge_top3": null, "bge_max": null, "title": "Dexmethylphenidate: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, considering extensive metabolism to inactive compounds, renal insufficiency expected to h…"}, {"doc_id": "gadobutrol-drug-information", "bm25_top3": 16.092904157783742, "bm25_max": 16.092904157783742, "bge_top3": null, "bge_max": null, "title": "Gadobutrol: Drug information", "rep_snippet": "Dosing: Pediatric  Diagnostic imaging: IV:  US labeling: CNS imaging, supra-aortic or renal artery angiography: Neonates, Children, and Adolescents: Refer to adult dosing  Canadian labeling: CNS imaging/CE-MRA or renal i…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 15.721810183385418, "bm25_max": 15.721810183385418, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Dosing: Adult  Bulimia nervosa (off-label use): Oral: Initial: 25 mg/day for 3 days, then increase in 25 to 50 mg increments every 3 to 5 days based on response and tolerability up to 300 mg/day. Average doses in clinica…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": 15.20942966749365, "bm25_max": 15.20942966749365, "bge_top3": null, "bge_max": null, "title": "Alirocumab: Drug information", "rep_snippet": "Dosing: Adult  Hyperlipidemia, primary: SubQ: Initial: 75 mg every 2 weeks or 300 mg every 4 weeks; for both regimens, if an adequate LDL-C response is not achieved, may increase or modify dosing regimen to a maximum of…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 14.104869521543204, "bm25_max": 14.804100899076818, "bge_top3": null, "bge_max": null, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Initial: No dosage adjustment necessary. Use with caution and titrate dose per seizure control and tolerability; metabolites primarily undergo renal elimination."}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 14.624222546020867, "bm25_max": 14.624222546020867, "bge_top3": null, "bge_max": null, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "• Hepatic impairment: Avoid use in patients with hepatic impairment; bioavailability is significantly increased in chronic liver disease.  • Myasthenia gravis: Use clarithromycin with caution in patients with myasthenia…"}, {"doc_id": "calcium-chloride-drug-information", "bm25_top3": 14.45548576572688, "bm25_max": 14.45548576572688, "bge_top3": null, "bge_max": null, "title": "Calcium chloride: Drug information", "rep_snippet": "Dosing: Renal Impairment  No initial dosage adjustment necessary; however, accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations."}, {"doc_id": "potassium-acetate-drug-information", "bm25_top3": 14.325775322618417, "bm25_max": 14.325775322618417, "bge_top3": null, "bge_max": null, "title": "Potassium acetate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Reduce initial dose by at least 50% in patients with renal impairment (Kraft 2005). Potassium acetate administration may also increase serum aluminum and bicarbonate. Contraindicated in patients…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 14.123691305829462, "bm25_max": 14.123691305829462, "bge_top3": null, "bge_max": null, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Brand Names: US  CCP Caffeine Free [OTC] [DSC];  GoodSense Cold & Head Congest [OTC];  GoodSense Pressure/Pain/Mucus [OTC];  GoodSense Sinus Relief Max St [OTC];  GoodSense Sinus Severe Daytime [OTC];  Mucinex Fast-Max C…"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": 14.03979924602107, "bm25_max": 14.03979924602107, "bge_top3": 0.6380940079689026, "bge_max": 0.6380940079689026, "title": "Hydrocodone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hysingla ER, Vantrela ER:  Mild impairment: No dosage adjustment necessary.  Moderate to severe impairment: Initial: Start with 50% of the initial dose; titrate carefully; monitor closely.  End-…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 13.717228330953763, "bm25_max": 13.717228330953763, "bge_top3": null, "bge_max": null, "title": "Naratriptan: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to moderate renal impairment:  Initial: 1 mg; maximum dose: 2.5 mg in 24 hours.  Severe renal impairment (CrCl <15 mL/minute): Use is contraindicated."}, {"doc_id": "almotriptan-drug-information", "bm25_top3": 13.670233086073683, "bm25_max": 13.670233086073683, "bge_top3": null, "bge_max": null, "title": "Almotriptan: Drug information", "rep_snippet": "Dosing: Renal Impairment  Severe renal impairment (CrCl ≤30 mL/minute): Initial: 6.25 mg in a single dose; maximum daily dose: 12.5 mg"}, {"doc_id": "glimepiride-drug-information", "bm25_top3": 13.651184455589844, "bm25_max": 13.651184455589844, "bge_top3": null, "bge_max": null, "title": "Glimepiride: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Initial: 1 mg once daily; dose titration and maintenance dosing should be conservative to avoid hypoglycemia. Consider alternative therapy if eGFR <15 mL/minute/1.73 m2 (Alsahli 2015)."}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 13.617386801694522, "bm25_max": 13.617386801694522, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  The manufacturer's labeling recommends considering a reduced dose (starting at the low end of the dosing range) with close monitoring for toxicity dose in patients with baseline hepatic impair…"}, {"doc_id": "felbamate-drug-information", "bm25_top3": 13.604342886272718, "bm25_max": 13.604342886272718, "bge_top3": null, "bge_max": null, "title": "Felbamate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Use caution; reduce initial and maintenance doses by 50%. Adjunctive therapy with medications that affect felbamate plasma concentrations, especially AEDs, may warrant further reductions in felb…"}, {"doc_id": "tolbutamide-drug-information", "bm25_top3": 13.5882264542307, "bm25_max": 13.5882264542307, "bge_top3": null, "bge_max": null, "title": "Tolbutamide: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in manufacturer’s labeling. However, conservative initial and maintenance doses are recommended.  Hemodialysis: Not dialyzable (0% to 5%)"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": 13.561956487994381, "bm25_max": 13.561956487994381, "bge_top3": null, "bge_max": null, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Brand Names: International  Ibalgin Grip (CZ);  Lemsip Max All Day Cold & Flu (GB);  Lemsip Max All Day Flu Relief (GB);  Lemsip Max All Night Cold & Flu (GB);  Lemsip Max All Night Flu Relief (GB);  Nurofen Sinus Pain R…"}, {"doc_id": "kanamycin-united-states-not-available-drug-information", "bm25_top3": 13.42384654833717, "bm25_max": 13.42384654833717, "bge_top3": null, "bge_max": null, "title": "Kanamycin (United States: Not available): Drug information", "rep_snippet": "Dosing: Geriatric  IM, IV: Initial dose should be 5-7.5 mg/kg based on ideal body weight (except in obese patients); maintenance dose and interval should be adjusted for estimated renal function; dosing interval in most…"}, {"doc_id": "butorphanol-drug-information", "bm25_top3": 13.358427133248833, "bm25_max": 13.358427133248833, "bge_top3": null, "bge_max": null, "title": "Butorphanol: Drug information", "rep_snippet": "Dosing: Renal Impairment  IM: Initial: 1 mg; repeated dosing must be based on initial response rather than fixed intervals, but generally should be at least 6 hours apart  IV: Initial: 0.5 mg; repeated dosing must be bas…"}, {"doc_id": "potassium-chloride-drug-information", "bm25_top3": 13.350575982123658, "bm25_max": 13.350575982123658, "bge_top3": null, "bge_max": null, "title": "Potassium chloride: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no specific dosage adjustments provided in the manufacturer's labeling. Reduce initial dose by at least 50% in patients with renal impairment (Kraft 2005). Contraindicated in patients…"}, {"doc_id": "pyridostigmine-drug-information", "bm25_top3": 13.335671696057503, "bm25_max": 13.335671696057503, "bge_top3": null, "bge_max": null, "title": "Pyridostigmine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling. However, lower initial doses dosages may be required due to prolonged elimination in renal impairment."}, {"doc_id": "mivacurium-drug-information", "bm25_top3": 13.251034122239513, "bm25_max": 13.251034122239513, "bge_top3": null, "bge_max": null, "title": "Mivacurium: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to severe impairment: IV: Initial bolus: 0.15 mg/kg; subsequent dosing is based on clinical response."}, {"doc_id": "clevidipine-drug-information", "bm25_top3": 11.674672575635682, "bm25_max": 11.674672575635682, "bge_top3": null, "bge_max": null, "title": "Clevidipine: Drug information", "rep_snippet": "Dosing: Renal Impairment  No adjustment required with initial infusion rate."}, {"doc_id": "nicardipine-drug-information", "bm25_top3": 4.8058153036913005, "bm25_max": 4.8058153036913005, "bge_top3": null, "bge_max": null, "title": "Nicardipine: Drug information", "rep_snippet": "Lacosamide: NiCARdipine may increase the serum concentration of Lacosamide. Management: Lacosamide prescribing information cautions that a lacosamide dose reduction may be warranted in patients with renal dysfunction or…"}, {"doc_id": "delavirdine-drug-information", "bm25_top3": 4.498429616654443, "bm25_max": 4.498429616654443, "bge_top3": null, "bge_max": null, "title": "Delavirdine: Drug information", "rep_snippet": "Lacosamide: Delavirdine may increase the serum concentration of Lacosamide. Management: Lacosamide prescribing information cautions that a lacosamide dose reduction may be warranted in patients with renal dysfunction or…"}, {"doc_id": "leflunomide-drug-information", "bm25_top3": 4.409084553836703, "bm25_max": 4.409084553836703, "bge_top3": null, "bge_max": null, "title": "Leflunomide: Drug information", "rep_snippet": "• Infections: May increase susceptibility to infection, including opportunistic pathogens (especially Pneumocystis jirovecii pneumonia, tuberculosis [including extrapulmonary tuberculosis], and aspergillosis). Severe inf…"}, {"doc_id": "teriflunomide-drug-information", "bm25_top3": 3.852570907503825, "bm25_max": 3.852570907503825, "bge_top3": null, "bge_max": null, "title": "Teriflunomide: Drug information", "rep_snippet": "• Infections: May increase susceptibility to infection, including opportunistic pathogens. Severe infections, sepsis, and fatalities have been reported with leflunomide. One case of fatal sepsis has been reported with te…"}, {"doc_id": "pegylated-interferon-peginterferon-beta-1a-drug-information", "bm25_top3": 2.330200226785001, "bm25_max": 2.330200226785001, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) beta-1a: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelets, transaminase levels; signs and symptoms of hepatic injury, hypersensitivity, infections, bleeding, new onset autoimmune disorders, psychiatric disorders (includ…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6428139408429464, "bge_max": 0.6756401062011719, "title": "Spironolactone: Drug information", "rep_snippet": "• Renal impairment: Risk of hyperkalemia is increased with declining renal function and with the concurrent use of larger doses of ACE inhibitors (eg, ≥ lisinopril 10 mg daily in adults) (ACCF/AHA [Yancy 2013]). Use with…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6449882388114929, "bge_max": 0.6449882388114929, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment. Dosage adjustments may be necessary. Patients with mild to moderate renal impairment (eGFR ≥30 to 89 mL/minute/1.73 m2) may be at increased risk of…"}, {"doc_id": "losartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6384075284004211, "bge_max": 0.6384075284004211, "title": "Losartan: Drug information", "rep_snippet": "• Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.  • Hepatic impairment: Use with caution in patients with hepatic impairment or a history of hepatic impairment; dose adjustm…"}, {"doc_id": "perindopril-and-indapamide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6365917921066284, "bge_max": 0.6365917921066284, "title": "Perindopril and indapamide (United States: Not available): Drug information", "rep_snippet": "• Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (ACC…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6347218155860901, "bge_max": 0.6347218155860901, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic impairment prior to initiation: There are no specific dosage adjustments provided in the manufacturer’s labeling; use with caution.  Hepatic impairment during therapy: If liver injury…"}, {"doc_id": "tinzaparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6341832280158997, "bge_max": 0.6341832280158997, "title": "Tinzaparin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6333855390548706, "bge_max": 0.6333855390548706, "title": "Lixisenatide: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with mild renal impairment (eGFR ≥60 to 89 mL/minute/1.73 m2) or moderate renal impairment (≥30 to <60 mL/minute/1.73 m2); may be at increased risk of adverse effects (eg,…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6321051716804504, "bge_max": 0.6321051716804504, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Disease-related concerns:  • Chronic hepatitis B: [US Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation. Monitor liver function several months after discontinuing treatment; reiniti…"}, {"doc_id": "fosinopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6310943365097046, "bge_max": 0.6310943365097046, "title": "Fosinopril: Drug information", "rep_snippet": "• Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.  • Hypertrophic cardiomyopathy (HC…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6291581392288208, "bge_max": 0.6291581392288208, "title": "Canagliflozin: Drug information", "rep_snippet": "• Renal impairment: Glycemic efficacy may be decreased in renal impairment. Assess renal function prior to initiation and periodically during treatment. Dosage adjustment recommended if eGFR <60 mL/minute/1.73m2; use is…"}, {"doc_id": "gemcitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6265800297260284, "bge_max": 0.6281955242156982, "title": "Gemcitabine: Drug information", "rep_snippet": "Dosing: Renal Impairment (Pediatric)  There are no dosage adjustments provided in the manufacturer’s labeling; based on experience in adult patients, use with caution in patients with preexisting renal dysfunction; disco…"}, {"doc_id": "interferon-alfa-2b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6240544319152832, "bge_max": 0.6240544319152832, "title": "Interferon alfa-2b: Drug information", "rep_snippet": "Dosing: Renal Impairment  Renal impairment at treatment initiation: Combination therapy with ribavirin (hepatitis C) is contraindicated in patients with CrCl <50 mL/minute; use combination therapy with ribavirin (hepatit…"}, {"doc_id": "captopril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6224791407585144, "bge_max": 0.6224791407585144, "title": "Captopril and hydrochlorothiazide: Drug information", "rep_snippet": "• Renal artery stenosis: Use captopril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the el…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6222410202026367, "bge_max": 0.6222410202026367, "title": "Erlotinib: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic impairment at treatment initiation:  Total bilirubin > ULN or Child-Pugh classes A, B, and C: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6220139265060425, "bge_max": 0.6220139265060425, "title": "Hyoscyamine: Drug information", "rep_snippet": "• Hiatal hernia: Use with caution in patients with hiatal hernia with reflux esophagitis.  • Hyperthyroidism: Use with caution in patients with hyperthyroidism.  • Neuropathy: Use with caution in patients with autonomic…"}, {"doc_id": "enalapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6187357604503632, "bge_max": 0.621866762638092, "title": "Enalapril: Drug information", "rep_snippet": "Dosing: Adult  Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe HF, decreased renal function, or in those receiving diuretics.  Asymptomatic left ventricular dysfunction: Oral: Initial: 2.…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6213120818138123, "bge_max": 0.6213120818138123, "title": "Topiramate: Drug information", "rep_snippet": "• Hepatic impairment: Use caution with hepatic impairment; clearance may be reduced. Dosage adjustment may be required.  • Renal impairment: Use caution with renal impairment; clearance may be reduced. Dosage adjustment…"}, {"doc_id": "pioglitazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6212321519851685, "bge_max": 0.6212321519851685, "title": "Pioglitazone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic impairment prior to initiation: No dosage adjustment necessary; use with caution if baseline liver tests are abnormal  Hepatic impairment during therapy: If liver injury is suspected (…"}, {"doc_id": "crizotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6182680726051331, "bge_max": 0.6199003458023071, "title": "Crizotinib: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with hepatic impairment; has not been studied; patients with ALT or AST >2.5 times ULN (>5 times ULN if due to liver metastases) and total bilirubin >1.5 times ULN were…"}, {"doc_id": "paregoric-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6198492646217346, "bge_max": 0.6198492646217346, "title": "Paregoric: Drug information", "rep_snippet": "• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.  • Renal impairment: Use with caution in patients with severe renal dysfunction.  • Respiratory…"}, {"doc_id": "protein-c-concentrate-from-human-plasma-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.619763195514679, "bge_max": 0.619763195514679, "title": "Protein C, concentrate from human plasma: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Heparin-induced thrombocytopenia (HIT): Trace amounts of heparin contained within the formulation may lead to HIT; evaluate platelet counts if HIT is suspecte…"}, {"doc_id": "dextran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6195595264434814, "bge_max": 0.6195595264434814, "title": "Dextran: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; fluid status including urine output should be monitored closely. Excessive dosing may precipitate renal failure in patients with advanced renal dise…"}, {"doc_id": "sunitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6171542108058929, "bge_max": 0.6192324161529541, "title": "Sunitinib: Drug information", "rep_snippet": "• Renal insufficiency: An increased incidence of fatigue, thyroid dysfunction and treatment-induced hypertension was reported in patients with renal insufficiency (CrCl ≤60 mL/minute) who received sunitinib for the treat…"}, {"doc_id": "zoledronic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6188405752182007, "bge_max": 0.6188405752182007, "title": "Zoledronic acid: Drug information", "rep_snippet": "Oncology indications: Dosage adjustment required with renal impairment. Use is not recommended in patients with severe renal impairment (serum creatinine >3 mg/dL or CrCl <30 mL/minute) and bone metastases (limited data)…"}, {"doc_id": "ezetimibe-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6176024079322815, "bge_max": 0.6176024079322815, "title": "Ezetimibe: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with severe renal impairment (CrCl ≤30 mL/minute/1.73 m2); systemic exposure is increased ~1.5-fold. If using concurrent simvastatin in patients with moderate to severe re…"}, {"doc_id": "lenvatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6174073219299316, "bge_max": 0.6174073219299316, "title": "Lenvatinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Preexisting renal impairment:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute:  Renal cell cancer, advanced: 10 mg once daily  Thyroid cancer, differentiated: 14 mg once…"}, {"doc_id": "famciclovir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169712543487549, "bge_max": 0.6169712543487549, "title": "Famciclovir: Drug information", "rep_snippet": "Warnings/Precautions  Disease-related concerns:  • Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. Acute renal failure has been reported with use of inappropriate high do…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.616148829460144, "bge_max": 0.616148829460144, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "Disease-related concerns:  • Chronic hepatitis B: [US Boxed Warning]: Safety and efficacy during coinfection of HIV-1 and HBV have not been established; acute, severe exacerbations of hepatitis B have been reported in th…"}, {"doc_id": "phentermine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6160944700241089, "bge_max": 0.6160944700241089, "title": "Phentermine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Capsule, tablet (excluding Lomaira):  eGFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased; use with caution.…"}, {"doc_id": "bictegravir-emtricitabine-and-tenofovir-alafenamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6159244775772095, "bge_max": 0.6159244775772095, "title": "Bictegravir, emtricitabine, and tenofovir alafenamide: Drug information", "rep_snippet": "• Chronic hepatitis B: [US Boxed Warning]: Severe acute exacerbations of HBV have been reported in patients coinfected with HIV-1 and HBV following discontinuation of antiretroviral therapy. Closely monitor hepatic funct…"}, {"doc_id": "sevoflurane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6157270669937134, "bge_max": 0.6157270669937134, "title": "Sevoflurane: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with hepatic impairment; safety with severe impairment has not been established.  • Renal impairment: Use with caution in patients with renal impairment (ie, creatinine…"}, {"doc_id": "meropenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6155663132667542, "bge_max": 0.6155663132667542, "title": "Meropenem: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with creatinine clearance ≤50 mL/minute. Increased seizure risk and thrombocytopenia have been reported in pa…"}, {"doc_id": "inotuzumab-ozogamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6155210733413696, "bge_max": 0.6155210733413696, "title": "Inotuzumab ozogamicin: Drug information", "rep_snippet": "Dosing: Hepatic Impairment (Adult)  Hepatic impairment prior to treatment initiation:  Total bilirubin ≤1.5 times ULN and AST/ALT ≤2.5 times ULN: No initial dosage adjustment necessary.  Total bilirubin >1.5 times ULN an…"}, {"doc_id": "dolutegravir-and-rilpivirine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6154477596282959, "bge_max": 0.6154477596282959, "title": "Dolutegravir and rilpivirine: Drug information", "rep_snippet": "• Renal impairment: Use with caution and increased monitoring for adverse reactions in patients with CrCl <30 mL/minute or end-stage renal disease (ESRD). In addition, in INSTI-experienced patients with severe renal impa…"}, {"doc_id": "treprostinil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6152958273887634, "bge_max": 0.6152958273887634, "title": "Treprostinil: Drug information", "rep_snippet": "- Oral: Dose reduction is recommended for patients with mild hepatic impairment. Avoid use in patients with moderate impairment; use is contraindicated in patients with severe impairment.  • Renal impairment: Inhalation,…"}, {"doc_id": "gabapentin-enacarbil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6144795417785645, "bge_max": 0.6144795417785645, "title": "Gabapentin enacarbil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.  PHN:  CrCl 30-59 mL/minute: Initial: 300 mg every morning for 3 days, then in…"}, {"doc_id": "vitamin-b3-niacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6141034364700317, "bge_max": 0.6141034364700317, "title": "Vitamin B3 (niacin): Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment,…"}, {"doc_id": "procyclidine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6138619184494019, "bge_max": 0.6138619184494019, "title": "Procyclidine (United States: Not available): Drug information", "rep_snippet": "• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture or retention.  • Renal impairment: Use with caution in patients with renal impairment.  Concurre…"}, {"doc_id": "butalbital-compound-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.613822877407074, "bge_max": 0.613822877407074, "title": "Butalbital compound: Drug information", "rep_snippet": "• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.  • Hepatic impairment: Use with caution in pati…"}]}
{"qid": "Q13_spelling", "query": "Lisinopril for hypertenion — starting vs ceiling dose; renal issues?", "base_qid": "Q13", "variant_type": "spelling", "candidates": [{"doc_id": "lisinopril-and-hydrochlorothiazide-drug-information", "bm25_top3": 23.061800955902093, "bm25_max": 33.00359015633741, "bge_top3": 0.6512483557065328, "bge_max": 0.6592027544975281, "title": "Lisinopril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Not for initial therapy. Dose is individualized; may be substituted for individual components in patients currently maintained on both agents separately or in patients not controlled with monotherapy…"}, {"doc_id": "sildenafil-drug-information", "bm25_top3": 20.251164077967395, "bm25_max": 24.641826087670932, "bge_top3": null, "bge_max": null, "title": "Sildenafil: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute:  Revatio: No dosage adjustment necessary.  Viagra: Starting dose of 25 mg should be considered."}, {"doc_id": "lisinopril-drug-information", "bm25_top3": 18.41934122325789, "bm25_max": 22.712607096807304, "bge_top3": 0.6578030784924825, "bge_max": 0.6738914251327515, "title": "Lisinopril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Lisinopril: Pediatric drug information\")  Hypertension: Note: Compounded and commercially available oral solutions available in multiple concentrations; precautions sho…"}, {"doc_id": "obeticholic-acid-drug-information", "bm25_top3": 15.343220551800929, "bm25_max": 15.343220551800929, "bge_top3": null, "bge_max": null, "title": "Obeticholic acid: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic impairment prior to treatment initiation: Refer to adult dosing.  Hepatotoxicity during treatment:  Laboratory or clinical evidence of worsening liver function: Interrupt treatment and…"}, {"doc_id": "streptozocin-drug-information", "bm25_top3": 14.722247821613227, "bm25_max": 14.722247821613227, "bge_top3": null, "bge_max": null, "title": "Streptozocin: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in the manufacturer’s labeling; however, it is recommended to use clinical judgment weighing benefit vs risk of renal toxicity in patients with pre-existing renal i…"}, {"doc_id": "hydromorphone-drug-information", "bm25_top3": 14.601788723441564, "bm25_max": 14.601788723441564, "bge_top3": 0.6440669298171997, "bge_max": 0.6440669298171997, "title": "Hydromorphone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Injectable, oral (immediate release): Initiate with 25% to 50% of the usual starting dose depending on the degree of impairment. Use with caution and monitor closely for respiratory and CNS depr…"}, {"doc_id": "oxycodone-and-naloxone-drug-information", "bm25_top3": 14.531796352258596, "bm25_max": 14.531796352258596, "bge_top3": null, "bge_max": null, "title": "Oxycodone and naloxone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild or moderate impairment: Reduce dose to 33% to 50% of the usual starting dose; titrate cautiously; consider use of alternative treatments without naloxone in patients with severe renal impai…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": 14.443690948837176, "bm25_max": 14.443690948837176, "bge_top3": null, "bge_max": null, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Adult  VTE (prophylaxis): Oral: 160 mg as a single dose on day 1, followed by 80 mg once daily for 35 to 42 days  Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and…"}, {"doc_id": "apomorphine-drug-information", "bm25_top3": 13.84890491778469, "bm25_max": 13.84890491778469, "bge_top3": null, "bge_max": null, "title": "Apomorphine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild-to-moderate impairment: Initial test dose: 1 mg; Starting dose: 1 mg as needed  Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been stud…"}, {"doc_id": "oxymorphone-drug-information", "bm25_top3": 12.96922195605039, "bm25_max": 12.96922195605039, "bge_top3": null, "bge_max": null, "title": "Oxymorphone: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling.  CrCl <50 mL/minute: Use with caution; bioavailability increased.  Oral:  Extended release:  Opioid n…"}, {"doc_id": "salsalate-drug-information", "bm25_top3": 7.672100768149189, "bm25_max": 7.672100768149189, "bge_top3": null, "bge_max": null, "title": "Salsalate: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT.  • Hypertension: Use with caution; may cause new-onset hypertension or worsening of exis…"}, {"doc_id": "ketorolac-nasal-drug-information", "bm25_top3": 7.527947800641066, "bm25_max": 7.527947800641066, "bge_top3": null, "bge_max": null, "title": "Ketorolac (nasal): Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with hepatic impairment or a history of liver disease. Closely monitor patients with any abnormal LFT.  • Hypertension: Use with caution; may cause new-onset hypertensio…"}, {"doc_id": "piroxicam-drug-information", "bm25_top3": 7.527249691237284, "bm25_max": 7.527249691237284, "bge_top3": null, "bge_max": null, "title": "Piroxicam: Drug information", "rep_snippet": "• Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension. Monitor blood pressure closely with initiation and during piroxicam therapy.  • Renal impairment: NSAID use may co…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 6.887047936642549, "bm25_max": 6.887047936642549, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "• Renal impairment: Cumulative effects of hydrochlorothiazide may develop, including azotemia, in patients with impaired renal function. Avoid hydrochlorothiazide in severe renal disease (ineffective). Spironolactone may…"}, {"doc_id": "tiaprofenic-acid-united-states-not-available-drug-information", "bm25_top3": 6.49357466630808, "bm25_max": 6.49357466630808, "bge_top3": null, "bge_max": null, "title": "Tiaprofenic acid (United States: Not available): Drug information", "rep_snippet": "• Asthma: Do not administer to patients with asthma; severe bronchospasm may occur.  • Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal liver fu…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 4.703849364670123, "bm25_max": 6.300229055824033, "bge_top3": 0.6745490829149882, "bge_max": 0.7151833772659302, "title": "Spironolactone: Drug information", "rep_snippet": "• Renal impairment: Risk of hyperkalemia is increased with declining renal function and with the concurrent use of larger doses of ACE inhibitors (eg, ≥ lisinopril 10 mg daily in adults) (ACCF/AHA [Yancy 2013]). Use with…"}, {"doc_id": "captopril-drug-information", "bm25_top3": 5.485455283793925, "bm25_max": 5.485455283793925, "bge_top3": null, "bge_max": null, "title": "Captopril: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Captopril may be confused with calcitriol, Capitrol, carvedilol  International issues:  Acepril [Great Britain] may be confused with Accupril which is a brand nam…"}, {"doc_id": "quinapril-drug-information", "bm25_top3": 5.4834378136784, "bm25_max": 5.4834378136784, "bge_top3": null, "bge_max": null, "title": "Quinapril: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Accupril may be confused with Accolate, Accutane, AcipHex, Monopril  Quinapril may be confused with Quinagolide  International issues:  Accupril [U.S., Canada] ma…"}, {"doc_id": "celecoxib-drug-information", "bm25_top3": 5.325394153968258, "bm25_max": 5.325394153968258, "bge_top3": null, "bge_max": null, "title": "Celecoxib: Drug information", "rep_snippet": "• Renal impairment: NSAID use may compromise existing renal function. Dose-dependent decreases in prostaglandin synthesis may result from NSAID use, causing a reduction in renal blood flow which may cause renal decompens…"}, {"doc_id": "polyethylene-glycol-electrolyte-solution-drug-information", "bm25_top3": 5.042669900783675, "bm25_max": 5.042669900783675, "bge_top3": null, "bge_max": null, "title": "Polyethylene glycol electrolyte solution: Drug information", "rep_snippet": "Adverse Reactions  >10%:  Central nervous system: Sleep disorder (35%; evening prep vs oral sodium phosphate solution [90 mL]), rigors (34%; evening prep vs oral sodium phosphate solution [90 mL]), malaise (18% to 27%; M…"}, {"doc_id": "floctafenine-united-states-not-available-drug-information", "bm25_top3": 4.373373971324458, "bm25_max": 4.373373971324458, "bge_top3": null, "bge_max": null, "title": "Floctafenine (United States: Not available): Drug information", "rep_snippet": "• Renal impairment: Use with caution and monitor closely; consider initiating therapy at reduced dosage. Contraindicated in patients with deteriorating function or severe impairment (CrCl <30 mL/minute). NSAID use may co…"}, {"doc_id": "ibuprofen-pseudoephedrine-and-chlorpheniramine-drug-information", "bm25_top3": 4.270432108577097, "bm25_max": 4.270432108577097, "bge_top3": null, "bge_max": null, "title": "Ibuprofen, pseudoephedrine, and chlorpheniramine: Drug information", "rep_snippet": "• Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patient…"}, {"doc_id": "enalapril-drug-information", "bm25_top3": 4.223949090809484, "bm25_max": 4.223949090809484, "bge_top3": 0.6419035196304321, "bge_max": 0.6419035196304321, "title": "Enalapril: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Enalapril may be confused with Anafranil, Elavil, Eldepryl, ramipril  Administration issues:  Significant differences exist between oral and IV dosing. Use cautio…"}, {"doc_id": "baclofen-drug-information", "bm25_top3": 4.157927923235679, "bm25_max": 4.157927923235679, "bge_top3": null, "bge_max": null, "title": "Baclofen: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Baclofen may be confused with Bactroban  Lioresal may be confused with lisinopril, Lotensin  High alert medication:  The Institute for Safe Medication Practices (…"}, {"doc_id": "amlodipine-and-benazepril-drug-information", "bm25_top3": 4.060621313712769, "bm25_max": 4.060621313712769, "bge_top3": null, "bge_max": null, "title": "Amlodipine and benazepril: Drug information", "rep_snippet": "• Collagen vascular disease: Use benazepril with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.  • Hepatic impairment:…"}, {"doc_id": "fosinopril-drug-information", "bm25_top3": 3.83140985500512, "bm25_max": 3.83140985500512, "bge_top3": 0.6334631443023682, "bge_max": 0.6372162103652954, "title": "Fosinopril: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Fosinopril may be confused with FLUoxetine, Fosamax®, furosemide, lisinopril  Monopril may be confused with Accupril®, minoxidil, moexipril, Monoket®, Monurol®, r…"}, {"doc_id": "pegylated-liposomal-doxorubicin-drug-information", "bm25_top3": 3.7518112167614515, "bm25_max": 3.7518112167614515, "bge_top3": null, "bge_max": null, "title": "Pegylated liposomal doxorubicin: Drug information", "rep_snippet": "• Hepatic impairment: Pharmacokinetics in patients with hepatic impairment have not been adequately studied. Doxorubicin is predominantly eliminated hepatically; reduce doxorubicin liposomal dose in patients with serum b…"}, {"doc_id": "rasagiline-drug-information", "bm25_top3": 3.5027329024595577, "bm25_max": 3.5027329024595577, "bge_top3": null, "bge_max": null, "title": "Rasagiline: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • CNS effects: May cause new or worsening mental status and behavioral changes, which may be severe, including paranoid ideation, delusions, hallucinations, con…"}, {"doc_id": "nebivolol-and-valsartan-drug-information", "bm25_top3": 3.4374238371101313, "bm25_max": 3.4374238371101313, "bge_top3": null, "bge_max": null, "title": "Nebivolol and valsartan: Drug information", "rep_snippet": "• Psychiatric disease: Use beta blockers with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.  • Renal artery stenosis: Use valsartan with caution in patients with unste…"}, {"doc_id": "cladribine-drug-information", "bm25_top3": 3.2935872178078913, "bm25_max": 3.2935872178078913, "bge_top3": null, "bge_max": null, "title": "Cladribine: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with hepatic impairment.  • Renal impairment: Use with caution in patients with renal impairment.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": 3.26511085484157, "bm25_max": 3.26511085484157, "bge_top3": null, "bge_max": null, "title": "Atorvastatin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  AtorvaSTATin may be confused with atoMOXetine, lovastatin, nystatin, pitavastatin, pravastatin, rosuvastatin, simvastatin  Lipitor may be confused with labetalol,…"}, {"doc_id": "mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information", "bm25_top3": 3.178621777680398, "bm25_max": 3.178621777680398, "bge_top3": null, "bge_max": null, "title": "Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment as toxicity may be increased; may require dosage adjustment in severe impairment.  Concurrent drug therapy issues:  • Drug-drug interactions: Potenti…"}, {"doc_id": "sunitinib-drug-information", "bm25_top3": 3.0262127080735617, "bm25_max": 3.0262127080735617, "bge_top3": 0.6491862535476685, "bge_max": 0.6491862535476685, "title": "Sunitinib: Drug information", "rep_snippet": "• Renal insufficiency: An increased incidence of fatigue, thyroid dysfunction and treatment-induced hypertension was reported in patients with renal insufficiency (CrCl ≤60 mL/minute) who received sunitinib for the treat…"}, {"doc_id": "tolmetin-drug-information", "bm25_top3": 2.972986745033092, "bm25_max": 2.972986745033092, "bge_top3": null, "bge_max": null, "title": "Tolmetin: Drug information", "rep_snippet": "• Coronary artery bypass graft surgery: [US Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. Risk of MI and stroke may be increased…"}, {"doc_id": "ledipasvir-and-sofosbuvir-drug-information", "bm25_top3": 2.972539405796482, "bm25_max": 2.972539405796482, "bge_top3": null, "bge_max": null, "title": "Ledipasvir and sofosbuvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "hydrocodone-and-ibuprofen-drug-information", "bm25_top3": 2.9335762332280204, "bm25_max": 2.9335762332280204, "bge_top3": null, "bge_max": null, "title": "Hydrocodone and ibuprofen: Drug information", "rep_snippet": "• Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation (usually re…"}, {"doc_id": "tizanidine-drug-information", "bm25_top3": 2.8307865547007367, "bm25_max": 2.8307865547007367, "bge_top3": null, "bge_max": null, "title": "Tizanidine: Drug information", "rep_snippet": "Lisinopril: TiZANidine may enhance the hypotensive effect of Lisinopril. Risk C: Monitor therapy  Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Lormetazepam: May enhance t…"}, {"doc_id": "lamotrigine-drug-information", "bm25_top3": 2.786509156557054, "bm25_max": 2.786509156557054, "bge_top3": null, "bge_max": null, "title": "Lamotrigine: Drug information", "rep_snippet": "• Pediatric: Children are at increased risk for developing serious skin rashes during therapy; lower starting doses and slower dose escalations may decrease the risk of rash.  Dosage form specific issues:  • Polysorbate…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": 2.759986478958094, "bm25_max": 2.759986478958094, "bge_top3": null, "bge_max": null, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong…"}, {"doc_id": "etonogestrel-implant-drug-information", "bm25_top3": 2.7429149082144377, "bm25_max": 2.7429149082144377, "bge_top3": null, "bge_max": null, "title": "Etonogestrel implant: Drug information", "rep_snippet": "• Hyperlipidemia: Use caution in patients treated for hyperlipidemia; progestins may increase low-density lipoprotein (LDL) concentrations.  • Hypertension: According to the manufacturer, women with a history of hyperten…"}, {"doc_id": "oxycodone-and-ibuprofen-drug-information", "bm25_top3": 2.6432745181618493, "bm25_max": 2.6432745181618493, "bge_top3": null, "bge_max": null, "title": "Oxycodone and ibuprofen: Drug information", "rep_snippet": "• Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation (usually re…"}, {"doc_id": "lesinurad-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6651039123535156, "bge_max": 0.6651039123535156, "title": "Lesinurad: Drug information", "rep_snippet": "• Renal impairment: Evaluate renal function prior to treatment initiation and periodically, as clinically indicated, thereafter (more frequently in patients with estimated CrCl <60 mL/minute or with serum creatinine elev…"}, {"doc_id": "aldesleukin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6578405499458313, "bge_max": 0.6578405499458313, "title": "Aldesleukin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Renal impairment prior to treatment initiation:  Serum creatinine ≤1.5 mg/dL: There are no dosage adjustments provided in the manufacturer’s labeling.  Serum creatinine >1.5 mg/dL: Do n…"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6507626175880432, "bge_max": 0.6507626175880432, "title": "Hydrocodone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hysingla ER, Vantrela ER:  Mild impairment: No dosage adjustment necessary.  Moderate to severe impairment: Initial: Start with 50% of the initial dose; titrate carefully; monitor closely.  End-…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.648513913154602, "bge_max": 0.648513913154602, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment. Dosage adjustments may be necessary. Patients with mild to moderate renal impairment (eGFR ≥30 to 89 mL/minute/1.73 m2) may be at increased risk of…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6480940580368042, "bge_max": 0.6480940580368042, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Psoriasis (severe):  Abnormal renal function prior to treatment: Use is contraindicated.  Abnormal renal function during treatment:  Serum creatinine levels ≥25% above pretreatment levels: Take…"}, {"doc_id": "calcium-gluconate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6476494669914246, "bge_max": 0.6476494669914246, "title": "Calcium gluconate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Initiate with the lower limit of the dosage range (accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations)."}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6470937728881836, "bge_max": 0.6470937728881836, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "• Renal function deterioration: Perindopril may be associated with deterioration of renal function and/or increases in BUN and serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenos…"}, {"doc_id": "naloxegol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6469143033027649, "bge_max": 0.6469143033027649, "title": "Naloxegol: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥60 mL/minute: No dosage adjustment necessary.  CrCl <60 mL/minute and end-stage renal disease (ESRD): Initial dose 12.5 mg once daily; if well tolerated but opioid-induced constipation sym…"}, {"doc_id": "ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6465657949447632, "bge_max": 0.6465657949447632, "title": "Ticarcillin and clavulanate potassium (United States: Not available): Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.  • Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in t…"}, {"doc_id": "meropenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6446940898895264, "bge_max": 0.6446940898895264, "title": "Meropenem: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with creatinine clearance ≤50 mL/minute. Increased seizure risk and thrombocytopenia have been reported in pa…"}, {"doc_id": "levomilnacipran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6438791751861572, "bge_max": 0.6438791751861572, "title": "Levomilnacipran: Drug information", "rep_snippet": "• SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium <110 mmol/L). Age (the elderly), volume deplet…"}, {"doc_id": "lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6432639360427856, "bge_max": 0.6432639360427856, "title": "Lixisenatide: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with mild renal impairment (eGFR ≥60 to 89 mL/minute/1.73 m2) or moderate renal impairment (≥30 to <60 mL/minute/1.73 m2); may be at increased risk of adverse effects (eg,…"}, {"doc_id": "lesinurad-and-allopurinol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6421770453453064, "bge_max": 0.6421770453453064, "title": "Lesinurad and allopurinol: Drug information", "rep_snippet": "• Renal impairment: Evaluate renal function prior to treatment initiation and periodically thereafter. Evaluate more frequently in patients with estimated CrCl <60 mL/minute or with serum creatinine elevations 1.5 to 2 t…"}, {"doc_id": "lenvatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6413971185684204, "bge_max": 0.6413971185684204, "title": "Lenvatinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Preexisting renal impairment:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute:  Renal cell cancer, advanced: 10 mg once daily  Thyroid cancer, differentiated: 14 mg once…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6411333680152893, "bge_max": 0.6411333680152893, "title": "Eplerenone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hypertension:  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <50 mL/minute or serum creatinine >2 mg/dL (males) or >1.8 mg/dL (females): Use…"}, {"doc_id": "perindopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6408867835998535, "bge_max": 0.6408867835998535, "title": "Perindopril: Drug information", "rep_snippet": "Dosing: Adult  Heart failure (off-label use): Oral: Initial: 2 mg once daily with gradual dose titration to a target dose of 8 to 16 mg once daily (ACCF/AHA [Yancy 2013]).  Hypertension: Oral: Initial: 4 mg once daily; m…"}, {"doc_id": "cidofovir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6407705545425415, "bge_max": 0.6407705545425415, "title": "Cidofovir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Preexisting renal impairment: Serum creatinine >1.5 mg/dL, CrCl ≤55 mL/minute, or urine protein ≥100 mg/dL (≥2+ proteinuria): Use is contraindicated.  Changes in renal function during therapy:…"}, {"doc_id": "cisplatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6390101909637451, "bge_max": 0.6390101909637451, "title": "Cisplatin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The manufacturer(s) recommend that repeat courses of cisplatin should not be given until serum creatinine is <1.5 mg/dL and/or BUN is <25 mg/dL and use is contraindicated in preexisting re…"}, {"doc_id": "ramipril-and-hydrochlorothiazide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.638886034488678, "bge_max": 0.638886034488678, "title": "Ramipril and hydrochlorothiazide (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  CrCl >60 mL/minute/1.73 m2: No dosage adjustment necessary.  CrCl 30 to 60 mL/minute/1.73 m2: Initial dose: Ramipril 2.5 mg/hydrochlorothiazide 12.5 mg once daily; Maximum dose: Ramipril…"}, {"doc_id": "zoledronic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6374589800834656, "bge_max": 0.6374589800834656, "title": "Zoledronic acid: Drug information", "rep_snippet": "Oncology indications: Dosage adjustment required with renal impairment. Use is not recommended in patients with severe renal impairment (serum creatinine >3 mg/dL or CrCl <30 mL/minute) and bone metastases (limited data)…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2a-and-ribavirin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6363335847854614, "bge_max": 0.6363335847854614, "title": "Pegylated interferon (peginterferon) alfa-2a and ribavirin (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Peginterferon alfa-2a: SubQ:  CrCl >20 mL/minute: No dosage adjustment necessary. Monitor closely as dose reduction may be warranted with onset of adverse events.  End-stage renal diseas…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6347455978393555, "bge_max": 0.6347455978393555, "title": "Canagliflozin: Drug information", "rep_snippet": "• Renal impairment: Glycemic efficacy may be decreased in renal impairment. Assess renal function prior to initiation and periodically during treatment. Dosage adjustment recommended if eGFR <60 mL/minute/1.73m2; use is…"}, {"doc_id": "dalfampridine-fampridine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6341901421546936, "bge_max": 0.6341901421546936, "title": "Dalfampridine (fampridine): Drug information", "rep_snippet": "• Renal impairment: Use in renal impairment is associated with an increased risk of seizure and other adverse events, primarily neurologic effects, due to increased serum concentrations; elimination is predominately via…"}, {"doc_id": "maraviroc-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6340039372444153, "bge_max": 0.6340039372444153, "title": "Maraviroc: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥30 mL/minute: No dosage adjustment necessary  CrCl <30 mL/minute:  Concomitant potent CYP3A inhibitors (with or without a potent CYP3A inducer) or concomitant potent CYP3A inducer…"}, {"doc_id": "ramipril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6336650252342224, "bge_max": 0.6336650252342224, "title": "Ramipril: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl >40 mL/minute: No dosage adjustment necessary.  CrCl <40 mL/minute: Administer 25% of normal dose.  Heart failure post-MI: Initial: 1.25 mg once daily, may increase to 1.25 mg twice daily a…"}, {"doc_id": "ropinirole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6328361630439758, "bge_max": 0.6328361630439758, "title": "Ropinirole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Moderate renal impairment (CrCl 30 to 50 mL/minute): No dosage adjustment necessary.  Severe renal impairment (CrCl <30 mL/minute): There are no dosage adjustments provided in the manufacturer's…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6321505308151245, "bge_max": 0.6321505308151245, "title": "Erlotinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Renal impairment at treatment initiation: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied), although <9% of a single dose is excreted in the urine.…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6312886476516724, "bge_max": 0.6312886476516724, "title": "Amlodipine: Drug information", "rep_snippet": "Dosing: Geriatric  Dosing should start at the lower end of dosing range and titrated to response due to possible increased incidence of hepatic, renal, or cardiac impairment. Elderly patients also show decreased clearanc…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6312448382377625, "bge_max": 0.6312448382377625, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.  Concurrent drug therapy issues:  • Drug…"}, {"doc_id": "ramucirumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6308795809745789, "bge_max": 0.6308795809745789, "title": "Ramucirumab: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Infusion-related reaction:  Grade 1 or 2: Reduce infusion rate by 50%  Grade 3 or 4: Permanently discontinue  Hypertension:  Severe hypertension: Interrupt infusion until controlled with…"}, {"doc_id": "lomitapide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6307812929153442, "bge_max": 0.6307812929153442, "title": "Lomitapide: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to severe impairment (not receiving dialysis): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, it is possible that patients with ren…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6306719779968262, "bge_max": 0.6306719779968262, "title": "Mercaptopurine: Drug information", "rep_snippet": "Dosing: Geriatric  Due to renal decline with age, initiate treatment at the low end of recommended dose range."}, {"doc_id": "edetate-calcium-disodium-calcium-edta-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6304845213890076, "bge_max": 0.6304845213890076, "title": "Edetate calcium disodium (calcium EDTA): Drug information", "rep_snippet": "Dosing: Renal Impairment  Dose should be reduced with preexisting mild renal disease. Limiting the daily dose to 1 g in children and 2 g in adults may decrease risk of nephrotoxicity, although larger doses may be needed…"}, {"doc_id": "meropenem-and-vaborbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6304813027381897, "bge_max": 0.6304813027381897, "title": "Meropenem and vaborbactam: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with creatinine clearance <50 mL/minute. Increased seizure risk and thrombocytopenia have been reported in pa…"}, {"doc_id": "trifluridine-and-tipiracil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6304239630699158, "bge_max": 0.6304239630699158, "title": "Trifluridine and tipiracil: Drug information", "rep_snippet": "• Hepatic impairment: Patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST) were not included in studies; do not initiate in patients with baseline moderate or severe hepatic impairment. In a…"}, {"doc_id": "ezetimibe-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6298950910568237, "bge_max": 0.6298950910568237, "title": "Ezetimibe: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with severe renal impairment (CrCl ≤30 mL/minute/1.73 m2); systemic exposure is increased ~1.5-fold. If using concurrent simvastatin in patients with moderate to severe re…"}]}
{"qid": "Q14_abbr+brand", "query": "CAP outpatient adult — azithro standard ‘Z-Pak’ schedule specifics?", "base_qid": "Q14", "variant_type": "abbr+brand", "candidates": [{"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 21.03823344745506, "bm25_max": 29.165212864532375, "bge_top3": 0.5245866775512695, "bge_max": 0.5351369380950928, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Brand Names: US  Zithromax;  Zithromax Tri-Pak;  Zithromax Z-Pak;  Zmax"}, {"doc_id": "zinc-pyrithione-drug-information", "bm25_top3": 16.562745026235497, "bm25_max": 20.28628716719449, "bge_top3": null, "bge_max": null, "title": "Zinc pyrithione: Drug information", "rep_snippet": "Brand Names: International  Aeroseb (AR);  Dan Gard (AU, KR);  de-squaman (DE);  Desquaman (AE, CH, LU, QA);  Dos Ele (AR);  Fongitar (ZA);  Healing Shampoo (PL);  Min-Huil (AR);  Pirimed (MX);  Skaelud (DK);  Skin-Cap (…"}, {"doc_id": "lidocaine-and-prilocaine-drug-information", "bm25_top3": 14.953241332972883, "bm25_max": 19.05153037026298, "bge_top3": null, "bge_max": null, "title": "Lidocaine and prilocaine: Drug information", "rep_snippet": "Brand Names: US  AgonEaze;  Anodyne LPT;  DermacinRx Empricaine;  DermacinRx Prizopak;  Dolotranz;  EMLA [DSC];  Leva Set;  Lido BDK;  Lidopril;  Lidopril XR;  LiProZonePak;  Livixil Pak;  LP Lite Pak;  Medolor Pak;  Ora…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 17.77060398931347, "bm25_max": 17.77060398931347, "bge_top3": 0.5255208015441895, "bge_max": 0.5255208015441895, "title": "Doxycycline: Drug information", "rep_snippet": "Brand Names: US  Acticlate;  Adoxa Pak 1/100 [DSC];  Adoxa Pak 1/150 [DSC];  Adoxa Pak 2/100 [DSC];  Adoxa [DSC];  Alodox Convenience [DSC];  Avidoxy;  Doryx;  Doryx MPC;  Doxy 100;  Mondoxyne NL;  Monodox [DSC];  Morgid…"}, {"doc_id": "epinephrine-adrenaline-systemic-drug-information", "bm25_top3": 17.181265728273953, "bm25_max": 17.181265728273953, "bge_top3": null, "bge_max": null, "title": "Epinephrine (adrenaline) (systemic): Drug information", "rep_snippet": "Brand Names: US  Adrenaclick [DSC];  Adrenalin;  Adyphren;  Adyphren Amp;  Adyphren Amp II;  Adyphren II;  Auvi-Q;  Epinephrinesnap-v;  EpiPen 2-Pak;  EpiPen Jr 2-Pak;  EPIsnap;  EPY II [DSC];  EPY [DSC]"}, {"doc_id": "diclofenac-topical-drug-information", "bm25_top3": 17.115619659592717, "bm25_max": 17.115619659592717, "bge_top3": null, "bge_max": null, "title": "Diclofenac (topical): Drug information", "rep_snippet": "Brand Names: US  Diclo Gel;  Diclo Gel with Xrylix Sheets;  Diclozor;  DSG Pak [DSC];  DST Plus Pak;  EnovaRX-Diclofenac Sodium;  Flector;  Klofensaid II;  Lexixryl;  Pennsaid;  Rexaphenac;  Solaraze [DSC];  Voltaren;  V…"}, {"doc_id": "varenicline-drug-information", "bm25_top3": 15.529967515794205, "bm25_max": 16.566519369345958, "bge_top3": null, "bge_max": null, "title": "Varenicline: Drug information", "rep_snippet": "Brand Names: US  Chantix;  Chantix Continuing Month Pak;  Chantix Starting Month Pak"}, {"doc_id": "erythromycin-and-benzoyl-peroxide-drug-information", "bm25_top3": 16.45492030666395, "bm25_max": 16.45492030666395, "bge_top3": null, "bge_max": null, "title": "Erythromycin and benzoyl peroxide: Drug information", "rep_snippet": "Brand Names: US  Aktipak;  Benzamycin;  Benzamycin Pak [DSC]"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-drug-information", "bm25_top3": 15.68147523794103, "bm25_max": 15.68147523794103, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2b: Drug information", "rep_snippet": "Brand Names: US  Peg-Intron Redipen Pak 4 [DSC];  Peg-Intron Redipen [DSC];  PegIntron;  Sylatron"}, {"doc_id": "ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-drug-information", "bm25_top3": 14.576911806007445, "bm25_max": 14.818665972921703, "bge_top3": null, "bge_max": null, "title": "Ombitasvir, paritaprevir, ritonavir, plus dasabuvir: Drug information", "rep_snippet": "Brand Names: Canada  Holkira Pak"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 14.818665972921703, "bm25_max": 14.818665972921703, "bge_top3": null, "bge_max": null, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Brand Names: US  Omeclamox-Pak®"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 14.338216205432266, "bm25_max": 14.338216205432266, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Brand Names: International  Lanzopral Heli-Pak (PE);  PyloriPac (BR)"}, {"doc_id": "vilazodone-drug-information", "bm25_top3": 13.892480321720715, "bm25_max": 13.892480321720715, "bge_top3": null, "bge_max": null, "title": "Vilazodone: Drug information", "rep_snippet": "Brand Names: International  Viibryd (BB);  Viibryd Starter Pak (BB);  Vintix (AR);  Visdon (AR)"}, {"doc_id": "memantine-drug-information", "bm25_top3": 13.892480321720715, "bm25_max": 13.892480321720715, "bge_top3": null, "bge_max": null, "title": "Memantine: Drug information", "rep_snippet": "Brand Names: US  Namenda;  Namenda Titration Pak;  Namenda XR;  Namenda XR Titration Pack"}, {"doc_id": "barium-drug-information", "bm25_top3": 6.376609146375272, "bm25_max": 9.364689674815192, "bge_top3": null, "bge_max": null, "title": "Barium: Drug information", "rep_snippet": "Brand Names: US  Bar-Test [DSC];  E-Z-Cat Dry;  E-Z-Disk;  E-Z-Dose;  E-Z-HD;  E-Z-Paque;  E-Z-Paste;  Entero VU;  Liquid E-Z-Paque;  Liquid Polibar Plus;  Liquid Polibar [DSC];  Polibar ACB [DSC];  Readi-Cat 2;  Tagitol…"}, {"doc_id": "travoprost-drug-information", "bm25_top3": 5.602979232701825, "bm25_max": 6.95712644367744, "bge_top3": null, "bge_max": null, "title": "Travoprost: Drug information", "rep_snippet": "Brand Names: Canada  Apo-Travoprost Z;  IZBA;  Sandoz-Travoprost;  Teva-Travoprost Z Ophthalmic Solution;  Travatan Z"}, {"doc_id": "indinavir-drug-information", "bm25_top3": 6.3046095640220585, "bm25_max": 6.3046095640220585, "bge_top3": null, "bge_max": null, "title": "Indinavir: Drug information", "rep_snippet": "Dosing: Adult  HIV-1 infection, treatment: Oral:  Unboosted regimen: 800 mg every 8 hours  Ritonavir-boosted regimen (off-label dose): Indinavir 800 mg twice daily plus ritonavir 100 to 200 mg twice daily (HHS [adult] 20…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 6.18314465747336, "bm25_max": 6.18314465747336, "bge_top3": 0.5037532448768616, "bge_max": 0.5037532448768616, "title": "Telithromycin: Drug information", "rep_snippet": "Dosing: Adult  Note: Ketek has been discontinued in the United States for more than 1 year.  Community-acquired pneumonia (CAP): Oral: 800 mg once daily for 7-10 days"}, {"doc_id": "zinc-sulfate-drug-information", "bm25_top3": 5.55529372414418, "bm25_max": 5.55529372414418, "bge_top3": null, "bge_max": null, "title": "Zinc sulfate: Drug information", "rep_snippet": "Brand Names: International  Afazol Z (MX);  Ascazin (LK);  Avazinc (IL);  Dalidome (MX);  Daribur (MX);  Daryazinc (ID);  Exastrin (MX);  L-Zinc (ID);  Litezinc (KR);  Solvazinc (GB);  Solvezink (NO, SE);  Vytral (MX);…"}, {"doc_id": "codeine-and-chlorpheniramine-drug-information", "bm25_top3": 5.181546638377206, "bm25_max": 5.181546638377206, "bge_top3": null, "bge_max": null, "title": "Codeine and chlorpheniramine: Drug information", "rep_snippet": "Brand Names: US  Codar AR;  Lexuss 210 [DSC];  Tuzistra XR;  Z-Tuss AC [OTC]"}, {"doc_id": "dupilumab-drug-information", "bm25_top3": 4.843159610297359, "bm25_max": 4.843159610297359, "bge_top3": null, "bge_max": null, "title": "Dupilumab: Drug information", "rep_snippet": "Dosing: Adult  Atopic dermatitis: SubQ:  Initial: 600 mg (given as two 300 mg injections)  Maintenance: 300 mg once every other week  Missed doses: If a dose is missed, administer within 7 days from the missed dose and t…"}, {"doc_id": "phenylephrine-and-pramoxine-drug-information", "bm25_top3": 4.612943257801565, "bm25_max": 4.612943257801565, "bge_top3": null, "bge_max": null, "title": "Phenylephrine and pramoxine: Drug information", "rep_snippet": "Administration  Cleanse affected area by patting or blotting with cleansing wipe, and gently dry before applying cream. Apply externally or in the lower portion of the anal canal only. For application in the lower anal c…"}, {"doc_id": "travelers-diarrhea-cholera-vaccine-united-states-not-available-drug-information", "bm25_top3": 4.201619019157594, "bm25_max": 4.363489230715537, "bge_top3": null, "bge_max": null, "title": "Travelers’ diarrhea-cholera vaccine (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Cholera: Oral:  Primary immunization:  Children 2 to <6 years: 3 doses given at intervals of ≥1 week and completed at least 1 week prior to trip to endemic/epidemic areas; restart primary immunization…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": 3.99580391517404, "bm25_max": 3.99580391517404, "bge_top3": null, "bge_max": null, "title": "Ampicillin: Drug information", "rep_snippet": "Winpicillin (TW);  Z-Cil (ET);  Zampicillin (LK)"}, {"doc_id": "fulvestrant-drug-information", "bm25_top3": 3.964844433162142, "bm25_max": 3.964844433162142, "bge_top3": null, "bge_max": null, "title": "Fulvestrant: Drug information", "rep_snippet": "Administration  IM: For IM administration only. Administer 500 mg dose as two 5 mL IM injections (one in each buttocks [gluteal area]) slowly over 1 to 2 minutes per injection. If administering at the dorsogluteal site,…"}, {"doc_id": "hydroxyprogesterone-caproate-drug-information", "bm25_top3": 3.660922784947015, "bm25_max": 3.660922784947015, "bge_top3": null, "bge_max": null, "title": "Hydroxyprogesterone caproate: Drug information", "rep_snippet": "Dosing: Adult  Pregnancy indications: Preterm birth (Makena): Pregnant females ≥16 years of age: Note: Treatment may begin between 16 weeks 0 days and 20 weeks 6 days of gestation. Continue weekly administration until 37…"}, {"doc_id": "balanced-salt-solution-drug-information", "bm25_top3": 3.5868774983299936, "bm25_max": 3.5868774983299936, "bge_top3": null, "bge_max": null, "title": "Balanced salt solution: Drug information", "rep_snippet": "Dosing: Adult  Ocular irrigation: Ophthalmic: Based on standard for each surgical procedure"}, {"doc_id": "sodium-bicarbonate-drug-information", "bm25_top3": 3.29156563069799, "bm25_max": 3.29156563069799, "bge_top3": null, "bge_max": null, "title": "Sodium bicarbonate: Drug information", "rep_snippet": "Brand Names: International  Betsol \"Z\" (MX);  Natrium bicarbonicum (PL);  Sodibic (AU);  Solunate (PH)"}, {"doc_id": "sodium-thiosulfate-drug-information", "bm25_top3": 3.07347968348377, "bm25_max": 3.07347968348377, "bge_top3": null, "bge_max": null, "title": "Sodium thiosulfate: Drug information", "rep_snippet": "Brand Names: International  Krem Ochronny z Tiosiarczanem Sodu A (PL);  Soft Mate Consept 2 (PL)"}, {"doc_id": "triazolam-drug-information", "bm25_top3": 2.442791248015668, "bm25_max": 2.442791248015668, "bge_top3": null, "bge_max": null, "title": "Triazolam: Drug information", "rep_snippet": "Use: Off-Label  Oral sedation prior to outpatient dental procedures"}, {"doc_id": "gadoteridol-drug-information", "bm25_top3": 2.4240478926320304, "bm25_max": 2.4240478926320304, "bge_top3": null, "bge_max": null, "title": "Gadoteridol: Drug information", "rep_snippet": "Dosage Forms Considerations  ProHance prefilled syringe tip cap contains latex."}, {"doc_id": "interferon-beta-1b-drug-information", "bm25_top3": 2.3189723311994648, "bm25_max": 2.3189723311994648, "bge_top3": null, "bge_max": null, "title": "Interferon beta-1b: Drug information", "rep_snippet": "Dosage Forms Considerations  The Extavia diluent syringe cap may contain latex."}, {"doc_id": "zoledronic-acid-drug-information", "bm25_top3": 2.273396313407453, "bm25_max": 2.273396313407453, "bge_top3": null, "bge_max": null, "title": "Zoledronic acid: Drug information", "rep_snippet": "Brand Names: Canada  Aclasta;  Taro-Zoledronic Acid;  Taro-Zoledronic Acid Concentrate;  Zoledronic Acid Injection;  Zoledronic Acid for Injection;  Zoledronic Acid Z;  Zometa Concentrate"}, {"doc_id": "lisinopril-and-hydrochlorothiazide-drug-information", "bm25_top3": 2.273396313407453, "bm25_max": 2.273396313407453, "bge_top3": null, "bge_max": null, "title": "Lisinopril and hydrochlorothiazide: Drug information", "rep_snippet": "Brand Names: Canada  Apo-Lisinopril/Hctz;  Mylan-Lisinopril/Hctz;  Sandoz-Lisinopril/Hctz;  Teva-Lisinopril/Hctz (Type P);  Teva-Lisinopril/Hctz (Type Z);  Zestoretic"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 2.179472793002315, "bm25_max": 2.179472793002315, "bge_top3": null, "bge_max": null, "title": "Linezolid: Drug information", "rep_snippet": "Dosing: Obesity  According to one study, the use of the standard dose of 600 mg every 12 hours for patients who are ≤150 kg will provide AUC values similar to that seen in non-obese adult patients; patients >150 kg were…"}, {"doc_id": "sevoflurane-drug-information", "bm25_top3": 1.651738906457048, "bm25_max": 1.651738906457048, "bge_top3": null, "bge_max": null, "title": "Sevoflurane: Drug information", "rep_snippet": "Use  Anesthesia: Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery"}, {"doc_id": "cefuroxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5417875647544861, "bge_max": 0.5417875647544861, "title": "Cefuroxime: Drug information", "rep_snippet": "Note: Cefuroxime is considered an alternate therapy for CAP in adults caused by Streptococcus pneumoniae (with MICs <2 mcg/mL for penicillin); may also be used as outpatient empiric therapy in combination with a macrolid…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5280960996945699, "bge_max": 0.5395057201385498, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Salivary gland cancers, advanced (off-label use): IV: 50 mg/m2 on day 1 every 21 days (in combination with cisplatin and cyclophosphamide); continue until disease progression or unacceptable toxicity (Lictra 1996) or 50…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5189253091812134, "bge_max": 0.5295817852020264, "title": "Vancomycin: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (hospitalized patient): As a component of empiric therapy or pathogen-specific therapy for community-acquired methicillin-resistant S. aureus: 15 to 20 mg/kg/dose (usual maximum: 2 g/do…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5270361304283142, "bge_max": 0.5270723104476929, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Hospital-acquired or ventilator-associated pneumonia (HAP, VAP): IV: 4.5 g every 6 hours, in combination with other agent(s) when appropriate, for 7 days and individualized based on response to therapy (IDSA/ATS [Kalil 2…"}, {"doc_id": "cytarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5129843950271606, "bge_max": 0.5268553495407104, "title": "Cytarabine: Drug information", "rep_snippet": "Adults ≤70 years: 2000 mg/m2 over 3 hours every 12 hours day 2 (total of 2 doses/cycle) every 3 to 4 weeks for 6 to 10 cycles (in combination with dexamethasone and cisplatin) (Velasquez, 1988)  Adults >70 years: 1000 mg…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5268320441246033, "bge_max": 0.5268320441246033, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Bullous systemic lupus erythematosus (off-label use): Oral: 100 mg once daily with or without prednisone (Fabbri 2003).  Immune thrombocytopenia (ITP) (off-label use): Oral: 75 to 100 mg daily or 1 to 2 mg/kg/day; durati…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5259864330291748, "bge_max": 0.5259864330291748, "title": "Streptomycin: Drug information", "rep_snippet": "Mycobacterium avium complex (MAC) (off-label use): IM: Adjunct therapy (with macrolide, rifamycin, and ethambutol): 8 to 25 mg/kg 2 to 3 times weekly for first 2 to 3 months for severe disease (maximum single dose for ag…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5253573656082153, "bge_max": 0.5253573656082153, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Impetigo (off-label use): Oral: Immediate release: 875 mg every 12 hours for 7 days, depending on response (IDSA [Stevens 2014])  Febrile neutropenia, empiric therapy in low-risk cancer patients (off-label use): Oral: Im…"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5147165358066559, "bge_max": 0.5246872901916504, "title": "Hydrocodone: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Capsule ER 12 Hour Abuse-Deterrent, Oral, as bitartrate:…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5167180895805359, "bge_max": 0.5209821462631226, "title": "Prednisone: Drug information", "rep_snippet": "Autoimmune hepatitis (monotherapy or in combination with azathioprine) (off-label use): Infants, Children, and Adolescents: Oral: Initial: 1 to 2 mg/kg/day for 2 weeks (maximum: 60 mg/day), followed by a taper over 6 to…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5201491713523865, "bge_max": 0.5201491713523865, "title": "Clarithromycin: Drug information", "rep_snippet": "Presumed atypical (M. pneumoniae, C. pneumoniae, C. trachomatis) infection, mild-to-severe atypical infection or step-down therapy (alternative to azithromycin): 7.5 mg/kg/dose (maximum dose: 500 mg) every 12 hours (Brad…"}, {"doc_id": "canakinumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.519128680229187, "bge_max": 0.519128680229187, "title": "Canakinumab: Drug information", "rep_snippet": "Dosing: Adult  Cryopyrin-associated periodic syndromes (CAPS): SubQ: 150 mg (>40 kg) or 2 mg/kg (15 to 40 kg) every 8 weeks; in clinical trials, dosage adjustments up to 600 mg (>40 kg) or 8 mg/kg (≤40 kg) and/or increas…"}, {"doc_id": "paclitaxel-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5172096490859985, "bge_max": 0.5172096490859985, "title": "Paclitaxel (conventional): Drug information", "rep_snippet": "Intraperitoneal (off-label route): 60 mg/m2 on day 8 of a 21-day treatment cycle for 6 cycles, in combination with IV paclitaxel (135 mg/m2 over 24 hours on day 1) and intraperitoneal cisplatin (Armstrong, 2006). Note: A…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.514340877532959, "bge_max": 0.514340877532959, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Cystoisosporiasis (isosporiasis) (AIDS-associated) (off-label use): Adolescents: Refer to adult dosing.  Shigellosis: Infants ≥2 months of age, Children, and Adolescents: Note: Due to reported widespread resistance, empi…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5140537023544312, "bge_max": 0.5140537023544312, "title": "Amikacin: Drug information", "rep_snippet": "Intra-abdominal infection, complicated (off-label dose): Infants, Children and Adolescents: IV: 15 to 22.5 mg/kg/day divided every 8 to 24 hours (Solomkin 2010)  Mycobacterium, avium complex infection (MAC) (off-label us…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5131604075431824, "bge_max": 0.5131604075431824, "title": "Pantoprazole: Drug information", "rep_snippet": "Intermittent dosing: Loading dose of 80 mg followed by either 40 mg every 12 hours for 72 hours (Hung 2007; Yamada 2012) or 40 mg every 6 hours for 72 hours (Hsu, 2009). May also administer 40 mg every 12 hours for 72 ho…"}, {"doc_id": "alteplase-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.510430246591568, "bge_max": 0.5126432180404663, "title": "Alteplase: Drug information", "rep_snippet": "Acute peripheral arterial occlusion (off-label use): Intra-arterial:  Weight-based regimen: 0.001 to 0.02 mg/kg/hour (maximum dose: 2 mg/hour) (Semba 2000)  or  Fixed-dose regimen: 0.12 to 2 mg/hour (Semba 2000)  Note: T…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5117546916007996, "bge_max": 0.5117546916007996, "title": "Ceftazidime: Drug information", "rep_snippet": "Melioidosis (off-label use): IV: Note: Switching to meropenem therapy is indicated if patient condition worsens (eg, organ failure, new infection focus development, repeat blood cultures remained positive). Oral eradicat…"}, {"doc_id": "propafenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5105501413345337, "bge_max": 0.5105501413345337, "title": "Propafenone: Drug information", "rep_snippet": "Dosing: Adult  Note: Patients who exhibit significant widening of QRS complex or second- or third-degree AV block may need dose reduction.  Atrial fibrillation (to prevent recurrence): Oral:  Extended release capsule: In…"}, {"doc_id": "aspirin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5100387334823608, "bge_max": 0.5100387334823608, "title": "Aspirin: Drug information", "rep_snippet": "Ventricular assist device (VAD) placement (off-label use): Immediate release: Oral: 1 to 5 mg/kg/dose once daily initiated within 72 hours of VAD placement; should be used with heparin (initiated between 8 to 48 hours fo…"}, {"doc_id": "ifosfamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5080368518829346, "bge_max": 0.5080368518829346, "title": "Ifosfamide: Drug information", "rep_snippet": "Diffuse large B-cell lymphoma (RICE regimen): 5,000 mg/m2 (over 24 hours) beginning on day 4 every 2 weeks for 3 cycles (in combination with mesna, carboplatin, etoposide, and rituximab) (Kewalramani 2004)  Osteosarcoma…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5062988996505737, "bge_max": 0.5077303647994995, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Community-acquired (CAP): Oral, IV: 500 mg every 24 hours for 7 to 14 days or 750 mg every 24 hours for 5 days; Note: CAP guidelines recommend the 750 mg dose (IDSA/ATS [Mandell 2007])  Hospital-acquired or ventilator-…"}, {"doc_id": "valproate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5075099468231201, "bge_max": 0.5075099468231201, "title": "Valproate: Drug information", "rep_snippet": "Children and Adolescents 2 to 14 years: 9 hours (range: 3.5 to 20 hours) (Cloyd 1993)  Adults: 9 to 19 hours  Time to peak, serum:  Oral: Depakote tablet and sprinkle capsules: ~4 hours; Depakote ER: 4 to 17 hours; Stavz…"}, {"doc_id": "atovaquone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5073564052581787, "bge_max": 0.5073564052581787, "title": "Atovaquone: Drug information", "rep_snippet": "Dosing: Adult  Pneumocystis jirovecii pneumonia (PCP), prevention: Oral: 1,500 mg once daily with food  PCP, mild to moderate, treatment: Oral: 750 mg twice daily with food for 21 days  Babesiosis (off-label use): Oral:…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5071432590484619, "bge_max": 0.5071432590484619, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Osteomyelitis (diabetic foot) (Lipsky 2004): IV: 3 g every 6 hours  Pelvic inflammatory disease (alternative to preferred therapy): IV: 3 g every 6 hours with doxycycline oral or IV; transition from parenteral to oral th…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5050433278083801, "bge_max": 0.5050433278083801, "title": "Zidovudine: Drug information", "rep_snippet": "Oral (if IV not possible): Loading dose: 600 mg, then 400 mg every 3 hours (oral is not the preferred route of administration in the United States) (HHS [perinatal] 2017)  HIV-1 infection, treatment: Note: Use in combina…"}, {"doc_id": "carboplatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5042420029640198, "bge_max": 0.5042420029640198, "title": "Carboplatin: Drug information", "rep_snippet": "Dosing: Adult  Note: Doses for adults are commonly calculated by the target AUC using the Calvert formula, where Total dose (mg) = Target AUC x (GFR + 25). If estimating GFR instead of a measured GFR, the FDA recommends…"}, {"doc_id": "zileuton-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5041742324829102, "bge_max": 0.5041742324829102, "title": "Zileuton: Drug information", "rep_snippet": "Pricing: US  Tablet, 12-hour (Zileuton ER Oral)  600 mg (120): $3,862.15  Tablet, 12-hour (Zyflo CR Oral)  600 mg (120): $4,510.85  Tablets (Zyflo Oral)  600 mg (120): $4,510.85  Disclaimer: A representative AWP (Average…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.502820611000061, "bge_max": 0.502820611000061, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Moxifloxacin (systemic): Pediatric drug information\")  Community-acquired pneumonia (CAP) due to atypical pathogens (M. pneumoniae, Chlamydophila [also known as Chlamyd…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5019903779029846, "bge_max": 0.5019903779029846, "title": "Itraconazole: Drug information", "rep_snippet": "Adults: Oral: Single dose: 16 to 28 hours, Multiple doses: 42 to 49 hours; Cirrhosis (single dose): 37 hours (range: 20 to 54 hours)  Time to peak, plasma: Capsules/tablets: 2 to 5 hours; Oral solution: 2.5 hours  Excret…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5011568069458008, "bge_max": 0.5011568069458008, "title": "Procarbazine: Drug information", "rep_snippet": "PEP-C regimen: Oral: 50 mg daily at bedtime (length of induction cycle depends on phase of treatment and blood counts; frequency may vary based on tolerance in maintenance cycle; in combination with prednisone, etoposide…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.501100480556488, "bge_max": 0.501100480556488, "title": "Oxacillin: Drug information", "rep_snippet": "Catheter-related bloodstream infections: Infants and Children: IV: 150 to 200 mg/kg/day divided every 4 to 6 hours (Mermel 2009)  Community-acquired pneumonia (CAP), moderate to severe infection, S. aureus (methicillin-s…"}]}
{"qid": "Q14_noise", "query": "Community pneumonia (outpt) — confirm azithromycin dosing (day-by-day Z-Pak).", "base_qid": "Q14", "variant_type": "noise", "candidates": [{"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 31.443545078413628, "bm25_max": 36.83990822575346, "bge_top3": 0.6756104032198588, "bge_max": 0.6889513731002808, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "≥45.5 kg: Refer to adult dosing.  Chlamydia trachomatis  infection: Oral:  Cervicitis, urethritis (off-label): Children ≥45 kg: 1 g as a single dose (CDC [Workowski 2015])  Conjunctivitis (off-label use; alternative agen…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 28.653354534044237, "bm25_max": 28.653354534044237, "bge_top3": 0.6592801213264465, "bge_max": 0.6804368495941162, "title": "Doxycycline: Drug information", "rep_snippet": "Pneumonia, community-acquired (CAP): Children >7 years: Oral: Note: A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.  Presumed atypical, mild atypical (M. pneumoniae, C. pneumo…"}, {"doc_id": "gemifloxacin-united-states-not-available-drug-information", "bm25_top3": 14.317936374030548, "bm25_max": 25.160699849998974, "bge_top3": 0.6590582132339478, "bge_max": 0.6590582132339478, "title": "Gemifloxacin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Factive is no longer available in the United States.  Susceptible infections: Oral: 320 mg once daily  Acute exacerbations of chronic bronchitis: Oral: 320 mg once daily for 5 days  Community-acquire…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": 18.874488986802, "bm25_max": 22.586304609344275, "bge_top3": 0.6681470274925232, "bge_max": 0.6681470274925232, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Pneumonia, community-acquired; Group A Streptococcus, mild infection or step-down therapy (off-label use): Infants ≥3 months, Children, and Adolescents: Oral: 50 to 75 mg/kg/day in 3 to 4 divided doses (Bradley 2011); ma…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": 21.822578517865686, "bm25_max": 21.822578517865686, "bge_top3": null, "bge_max": null, "title": "Ampicillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ampicillin: Pediatric drug information\")  Usual dosage range: Infants, Children, and Adolescents:  Oral: 50 to 100 mg/kg/day divided every 6 hours (maximum: 2 to 4 g/da…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": 21.375600396155242, "bm25_max": 21.375600396155242, "bge_top3": null, "bge_max": null, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "Brand Names: US  Active Injection D;  Baycadron [DSC];  Decadron;  Dexamethasone Intensol;  DexPak 10 Day;  DexPak 13 Day;  DexPak 6 Day;  DoubleDex;  LoCort 11-Day;  LoCort 7-Day;  MAS Care-Pak;  ReadySharp Dexamethason…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": 21.03229001281956, "bm25_max": 21.03229001281956, "bge_top3": null, "bge_max": null, "title": "Cefazolin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefazolin: Pediatric drug information\")  Usual dosage range: IM, IV: Infants >1 month, Children, and Adolescents: 25 to 100 mg/kg/day divided every 6 to 8 hours; maximu…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 20.462795900429747, "bm25_max": 20.462795900429747, "bge_top3": 0.655057817697525, "bge_max": 0.6554224491119385, "title": "Vancomycin: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011): Infants >3 months, Children, and Adolescents: IV: Note: In children ≥5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out. Also c…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 20.018189359849607, "bm25_max": 20.018189359849607, "bge_top3": 0.6430553793907166, "bge_max": 0.6430553793907166, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Osteomyelitis due to MRSA (off-label use): IV, Oral: 10 to 13 mg/kg/dose every 6 to 8 hours for a minimum of 4 to 6 weeks (maximum: 40 mg/kg/day) (IDSA [Liu 2011])  Pharyngitis, group A streptococci (IDSA recommendations…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": 19.50546172152879, "bm25_max": 19.50546172152879, "bge_top3": null, "bge_max": null, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Adult  VTE (prophylaxis): Oral: 160 mg as a single dose on day 1, followed by 80 mg once daily for 35 to 42 days  Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 12.880942875736705, "bm25_max": 19.318855445104422, "bge_top3": 0.716617226600647, "bge_max": 0.716617226600647, "title": "Telithromycin: Drug information", "rep_snippet": "Dosing: Adult  Note: Ketek has been discontinued in the United States for more than 1 year.  Community-acquired pneumonia (CAP): Oral: 800 mg once daily for 7-10 days"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": 12.124869134448726, "bm25_max": 18.88364420642599, "bge_top3": 0.6559803485870361, "bge_max": 0.6559803485870361, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Adult  Pneumonia, community-acquired: IV: 600 mg every 12 hours for 5 to 7 days  Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": 18.453814643464288, "bm25_max": 18.453814643464288, "bge_top3": 0.6601366400718689, "bge_max": 0.6601366400718689, "title": "Ceftriaxone: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (IDSA/PIDS [Bradley 2011]) (off-label dose): Infants >3 months and Children: IV: 50 to 100 mg/kg/day once daily or divided every 12 hours (maximum: 2,000 mg daily). Note: May consider a…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": 18.377430697832153, "bm25_max": 18.377430697832153, "bge_top3": null, "bge_max": null, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Other susceptible organisms: Infants, Children, and Adolescents: 300,000 units/kg/day divided every 4 to 6 hours; maximum daily dose: 24 million units/day (Tunkel 2004)  Meningococcal disease: IV: Infants, Children, and…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": 17.91997754434865, "bm25_max": 17.91997754434865, "bge_top3": 0.6723313331604004, "bge_max": 0.6723313331604004, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Moxifloxacin (systemic): Pediatric drug information\")  Community-acquired pneumonia (CAP) due to atypical pathogens (M. pneumoniae, Chlamydophila [also known as Chlamyd…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 17.677832190600913, "bm25_max": 17.677832190600913, "bge_top3": 0.6502140462398529, "bge_max": 0.6597569584846497, "title": "Amoxicillin: Drug information", "rep_snippet": "Pneumonia, community-acquired (CAP) (Bradley [IDSA 2011]): Infants ≥3 months, Children, and Adolescents: Note: In pediatric patients 5 to 15 years of age, a macrolide antibiotic may be a more reasonable first choice as M…"}, {"doc_id": "enasidenib-drug-information", "bm25_top3": 17.61242008574706, "bm25_max": 17.61242008574706, "bge_top3": null, "bge_max": null, "title": "Enasidenib: Drug information", "rep_snippet": "Dosing: Adult  Note: Confirm IDH2 mutation status in the blood or bone marrow prior to treatment initiation.  Acute myeloid leukemia (relapsed/refractory): Oral: 100 mg once daily until disease progression or unacceptabl…"}, {"doc_id": "cefditoren-drug-information", "bm25_top3": 17.446628133673443, "bm25_max": 17.446628133673443, "bge_top3": 0.6600407958030701, "bge_max": 0.6600407958030701, "title": "Cefditoren: Drug information", "rep_snippet": "Dosing: Adult  Acute bacterial exacerbation of chronic bronchitis: Oral: 400 mg twice daily for 10 days  Community-acquired pneumonia: Oral: 400 mg twice daily for 14 days  Pharyngitis, tonsillitis, uncomplicated skin an…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": 16.31966397934368, "bm25_max": 17.344351044606086, "bge_top3": 0.6936741471290588, "bge_max": 0.6936741471290588, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Non–HIV-exposed/-positive patients: Bacillary angiomatosis [BA], peliosis hepatis [PH]: Infants, Children, and Adolescents: 40 mg/kg/day (ethylsuccinate) in 4 divided doses (maximum: 2 g daily) for 3 months (BA) or 4 mon…"}, {"doc_id": "trace-metals-drug-information", "bm25_top3": 17.297348079039374, "bm25_max": 17.297348079039374, "bge_top3": null, "bge_max": null, "title": "Trace metals: Drug information", "rep_snippet": "Dosing: Adult  Trace metal supplement for TPN: IV:  Manufacturer labeling:  Chromium: 10 to 15 mcg/day (20 mcg/day with intestinal fluid loss)  Copper: 500 to 1,500 mcg/day  Manganese: 150 to 800 mcg/day  Selenium: 20 to…"}, {"doc_id": "edaravone-drug-information", "bm25_top3": 17.10736781510375, "bm25_max": 17.10736781510375, "bge_top3": null, "bge_max": null, "title": "Edaravone: Drug information", "rep_snippet": "Dosing: Adult  Amyotrophic lateral sclerosis  (ALS): IV:  Initial cycle: 60 mg once daily for 14 days, followed by a 14-day drug-free period.  Subsequent cycles: 60 mg once daily for 10 days within a 14-day period, follo…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": 16.915553274881773, "bm25_max": 16.983464673411444, "bge_top3": 0.6462362408638, "bge_max": 0.6462362408638, "title": "Cefotaxime: Drug information", "rep_snippet": "Gonorrhea, disseminated infections (arthritis and arthritis-dermatitis syndrome) (alternative to preferred therapy) (off-label use): IV: 1 g every 8 hours in combination with azithromycin. Continue for 24 to 48 hours aft…"}, {"doc_id": "cephalexin-drug-information", "bm25_top3": 11.215745646770758, "bm25_max": 16.932197391057308, "bge_top3": null, "bge_max": null, "title": "Cephalexin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cephalexin: Pediatric drug information\")  Usual dosage range:  Children >1 year and Adolescents <15 years: Oral: 25 to 100 mg/kg/day in divided doses every 6 to 8 hours…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": 16.60750127269166, "bm25_max": 16.60750127269166, "bge_top3": null, "bge_max": null, "title": "Paroxetine: Drug information", "rep_snippet": "Dosing: Geriatric  Major depressive disorder (MDD), obsessive compulsive disorder (OCD), panic attack, social anxiety disorder:  Paxil, Pexeva: Oral: Initial: 10 mg/day; increase if needed by 10 mg/day increments at inte…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": 10.406232964050885, "bm25_max": 16.570320898394673, "bge_top3": null, "bge_max": null, "title": "Oxacillin: Drug information", "rep_snippet": "Catheter-related bloodstream infections: Infants and Children: IV: 150 to 200 mg/kg/day divided every 4 to 6 hours (Mermel 2009)  Community-acquired pneumonia (CAP), moderate to severe infection, S. aureus (methicillin-s…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": 11.447875613725056, "bm25_max": 16.513201861197135, "bge_top3": null, "bge_max": null, "title": "Oseltamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oseltamivir: Pediatric drug information\")  Community-acquired pneumonia (influenza suspected or confirmed) (off-label use) (IDSA [Bradley 2011]): Oral:  Prophylaxis:  I…"}, {"doc_id": "bacitracin-systemic-drug-information", "bm25_top3": 16.37895218152407, "bm25_max": 16.37895218152407, "bge_top3": null, "bge_max": null, "title": "Bacitracin (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Bacitracin (systemic): Pediatric drug information\")  Do not administer IV  Treatment of pneumonia and empyema: Infants: IM:  ≤2.5 kg: 900 units/kg/day in 2 to 3 divided…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-drug-information", "bm25_top3": 16.33710330638542, "bm25_max": 16.33710330638542, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2b and ribavirin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: Recommendations (per manufacturer labeling - also refer to dosing in renal and hepatic impairment):  Hemoglobin:  HCV genotype 1 (treatment-naive):  Hemoglobin <10 g/dL: Continue cu…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 15.443997555079356, "bm25_max": 15.443997555079356, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "Maintenance therapy for frequently relapsing SSNS: Taper previous dose down to lowest effective dose which maintains remission using an alternate day schedule; usual effective range: 0.1 to 0.5 mg/kg/day on alternating d…"}, {"doc_id": "tigecycline-drug-information", "bm25_top3": 10.018601755340637, "bm25_max": 10.018601755340637, "bge_top3": null, "bge_max": null, "title": "Tigecycline: Drug information", "rep_snippet": "Use  Pneumonia, community-acquired bacterial:  US labeling: Treatment of community-acquired bacterial pneumonia in patients 18 years and older caused by Streptococcus pneumoniae (penicillin-susceptible isolates), includi…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 6.356860179489434, "bm25_max": 6.356860179489434, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Use: Off-Label  Community-acquired pneumonia treatment in children 3 months to younger than 12 years caused by S. pneumoniae; Urinary tract infections in children (empiric)"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": 6.27956178610329, "bm25_max": 6.27956178610329, "bge_top3": 0.6467993259429932, "bge_max": 0.6508880853652954, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Use  Intra-abdominal infections: Treatment of appendicitis complicated by rupture or abscess and peritonitis caused by beta-lactamase-producing strains of Escherichia coli, Bacteroides fragilis, Bacteroides ovatus, Bacte…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 6.00691933701377, "bm25_max": 6.00691933701377, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Community-acquired pneumonia: Treatment of community-acquired pneumonia in adults and adolescents caused by H. influenzae (including beta-lactamase-producing strains), H. parainfluenzae (including beta-lactamase-producin…"}, {"doc_id": "ertapenem-drug-information", "bm25_top3": 4.93995596796206, "bm25_max": 4.93995596796206, "bge_top3": null, "bge_max": null, "title": "Ertapenem: Drug information", "rep_snippet": "Use  Moderate-to-severe infections:  Acute pelvic infections: For the treatment of acute pelvic infections, including postpartum endomyometritis, septic abortion, and postsurgical gynecologic infections caused by Strepto…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 4.174591100362676, "bm25_max": 4.174591100362676, "bge_top3": null, "bge_max": null, "title": "Linezolid: Drug information", "rep_snippet": "Use  Enterococcal infections (vancomycin-resistant): Treatment of vancomycin-resistant (VRE) Enterococcus faecium infections, including cases with concurrent bacteremia. Note: Not a preferred agent in resistant E. faecal…"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 3.742718955857221, "bm25_max": 3.742718955857221, "bge_top3": null, "bge_max": null, "title": "Cefpodoxime: Drug information", "rep_snippet": "Otitis media, acute: Treatment of acute otitis media caused by S. pneumoniae, (excluding penicillin-resistant strains), Streptococcus pyogenes, H. influenzae (including beta-lactamase-producing strains), or M. catarrhali…"}, {"doc_id": "azathioprine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6589286625385284, "bge_max": 0.6767134070396423, "title": "Azathioprine: Drug information", "rep_snippet": "Uveitis (off-label use): Oral: 2 to 3 mg/kg/day given either alone or in conjunction with corticosteroids and/or immunosuppressants (Pacheco 2008)  Dosage adjustment for concomitant use with allopurinol: Reduce azathiopr…"}, {"doc_id": "primaquine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6658799052238464, "bge_max": 0.6658799052238464, "title": "Primaquine: Drug information", "rep_snippet": "Pneumocystis pneumonia (PCP) treatment in HIV-infected patients (alternative to preferred therapy) (off-label use): Oral: 30 mg once daily for 21 days (in combination with clindamycin) (HHS [OI adult 2015])"}, {"doc_id": "pembrolizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6620388627052307, "bge_max": 0.6620388627052307, "title": "Pembrolizumab: Drug information", "rep_snippet": "Pneumonitis, severe (grade 3), life-threatening (grade 4), or moderate (grade 2) that recurs; also administer corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent] followed by a taper)."}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.648733655611674, "bge_max": 0.6596855521202087, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Impetigo (off-label use): Oral: Immediate release: 875 mg every 12 hours for 7 days, depending on response (IDSA [Stevens 2014])  Febrile neutropenia, empiric therapy in low-risk cancer patients (off-label use): Oral: Im…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6578749418258667, "bge_max": 0.6578749418258667, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Sequential regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, metronidazole 500 mg twice daily, and a standard…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6512055993080139, "bge_max": 0.6528421640396118, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (IDSA/PIDS 2011): Note: May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected; alternative to ceftriaxone or cefotaxime in patients…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6504537463188171, "bge_max": 0.6504537463188171, "title": "Tinidazole: Drug information", "rep_snippet": "Hybrid regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, tinidazole 500 mg twice dail…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6481130123138428, "bge_max": 0.6481130123138428, "title": "Trimethoprim: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Trimethoprim: Pediatric drug information\")  Otitis media, acute: Infants ≥6 months, Children, and Adolescents: Oral: 10 mg/kg/day in divided doses every 12 hours for 10…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.64597487449646, "bge_max": 0.6464195847511292, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Osteomyelitis (diabetic foot) (Lipsky 2004): IV: 3 g every 6 hours  Pelvic inflammatory disease (alternative to preferred therapy): IV: 3 g every 6 hours with doxycycline oral or IV; transition from parenteral to oral th…"}, {"doc_id": "terbutaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6464074850082397, "bge_max": 0.6464074850082397, "title": "Terbutaline: Drug information", "rep_snippet": "Administration  IV: Use infusion pump.  Oral: Administer around-the-clock to promote less variation in peak and trough serum levels"}, {"doc_id": "leucovorin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6461130976676941, "bge_max": 0.6461130976676941, "title": "Leucovorin: Drug information", "rep_snippet": "Chronic maintenance (secondary prophylaxis): 5 to 10 mg once daily (in combination with pyrimethamine)  Pneumocystis pneumonia (PCP): Prophylaxis (primary and secondary): 25 mg once weekly (in combination with pyrimetham…"}, {"doc_id": "gatifloxacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6457128524780273, "bge_max": 0.6457128524780273, "title": "Gatifloxacin: Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic:  Zymar [Canadian product]:  Days 1 and 2: Instill 1 drop into affected eye(s) every 2 hours while awake (maximum: 8 times/day).  Days 3 to 7: Instill 1 drop into affec…"}, {"doc_id": "acetic-acid-otic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6437664031982422, "bge_max": 0.6437664031982422, "title": "Acetic acid (otic): Drug information", "rep_snippet": "Dosing: Adult  Otitis externa: Otic: Insert saturated wick; keep moist 24 hours by adding 3 to 5 drops every 4 to 6 hours; remove wick after 24 hours and instill 5 drops 3 to 4 times/day"}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6433885097503662, "bge_max": 0.6433885097503662, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Pneumococcal pneumonia (uncomplicated, moderately severe): IM: 600,000 to 1,000,000 units daily.  Staphylococcal infections (moderately severe to severe): IM: 600,000 to 1,000,000 units daily  Streptococcal infections (G…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6430309414863586, "bge_max": 0.6430309414863586, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis: Oral: Rifampin 600 mg/isoniazid 300 mg once daily. Note: Concomitant antituberculosis medications should be administered according to current guideline recommendations (Nahid 2016)"}, {"doc_id": "aztreonam-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.642762303352356, "bge_max": 0.642762303352356, "title": "Aztreonam (systemic): Drug information", "rep_snippet": "Pneumonia, hospital-acquired or ventilator-associated (alternative therapy) (off-label dose): IV: 2 g every 8 hours for 7 days; may consider shorter or longer durations depending on rate of clinical improvement. When use…"}, {"doc_id": "aclidinium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6405525803565979, "bge_max": 0.6405525803565979, "title": "Aclidinium: Drug information", "rep_snippet": "Dosing: Adult  COPD, maintenance treatment: Inhalation, oral: 400 mcg (one inhalation) twice daily"}, {"doc_id": "glycerin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6403811573982239, "bge_max": 0.6403811573982239, "title": "Glycerin: Drug information", "rep_snippet": "Dosing: Adult  Constipation: Rectal: One adult suppository once daily as needed or as directed  Mouth/throat irritation: Oral: Apply a one-inch strip directly to tongue and oral cavity as needed"}, {"doc_id": "cefixime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6401471495628357, "bge_max": 0.6401471495628357, "title": "Cefixime: Drug information", "rep_snippet": "Gonococcal infection, expedited partner therapy (off-label use): Oral: 400 mg as a single dose in combination with oral azithromycin (CDC [Workowski 2015]). Note: To be used only for heterosexual partners with gonorrhea…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6398174166679382, "bge_max": 0.6398174166679382, "title": "Clarithromycin: Drug information", "rep_snippet": "Skin and skin structure infection, uncomplicated: Oral: 250 mg every 12 hours for 7 to 14 days  Dosage adjustment for concomitant therapy: Atazanavir: Decrease clarithromycin dose by 50%."}, {"doc_id": "aclidinium-and-formoterol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6394303441047668, "bge_max": 0.6394303441047668, "title": "Aclidinium and formoterol (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation, oral: Aclidinium 400 mcg/formoterol 12 mcg (one inhalation) twice daily (once in the morning and evening)."}]}
{"qid": "Q14_spelling", "query": "CAP OP — what’s the azithromycine regimen?", "base_qid": "Q14", "variant_type": "spelling", "candidates": [{"doc_id": "fidaxomicin-drug-information", "bm25_top3": 9.333853307237344, "bm25_max": 9.333853307237344, "bge_top3": null, "bge_max": null, "title": "Fidaxomicin: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Absorption: Oral: Minimal systemic absorption  Distribution: Largely confined to the gastrointestinal tract; in single- and multiple-dose studies, fecal concentrations of fidaxomicin and its ac…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": 4.759216263708132, "bm25_max": 6.2617143238422805, "bge_top3": 0.5153622428576151, "bge_max": 0.52022784948349, "title": "Ceftriaxone: Drug information", "rep_snippet": "Cervicitis, proctitis, urethritis (off-label  ), pharyngitis (off-label)  :  Dual-therapy regimen (preferred): IM: 250 mg in a single dose plus oral azithromycin (CDC [Workowski 2015])  Treatment  failure:  Note: Reinfec…"}, {"doc_id": "phenylephrine-and-pramoxine-drug-information", "bm25_top3": 5.780112736521115, "bm25_max": 5.780112736521115, "bge_top3": null, "bge_max": null, "title": "Phenylephrine and pramoxine: Drug information", "rep_snippet": "Administration  Cleanse affected area by patting or blotting with cleansing wipe, and gently dry before applying cream. Apply externally or in the lower portion of the anal canal only. For application in the lower anal c…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 5.062632539677043, "bm25_max": 5.062632539677043, "bge_top3": 0.5236721237500509, "bge_max": 0.5370835065841675, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to azithromycin, erythromycin, other macrolide (eg, azalide or ketolide) antibiotics, or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associate…"}, {"doc_id": "fulvestrant-drug-information", "bm25_top3": 4.95522296420665, "bm25_max": 4.95522296420665, "bge_top3": null, "bge_max": null, "title": "Fulvestrant: Drug information", "rep_snippet": "Administration  IM: For IM administration only. Administer 500 mg dose as two 5 mL IM injections (one in each buttocks [gluteal area]) slowly over 1 to 2 minutes per injection. If administering at the dorsogluteal site,…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 3.7894155742186966, "bm25_max": 4.178796848062076, "bge_top3": null, "bge_max": null, "title": "Linezolid: Drug information", "rep_snippet": "Use  Enterococcal infections (vancomycin-resistant): Treatment of vancomycin-resistant (VRE) Enterococcus faecium infections, including cases with concurrent bacteremia. Note: Not a preferred agent in resistant E. faecal…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 4.148443901263217, "bm25_max": 4.148443901263217, "bge_top3": 0.529655913511912, "bge_max": 0.5504521131515503, "title": "Vancomycin: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011): Infants >3 months, Children, and Adolescents: IV: Note: In children ≥5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out. Also c…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": 3.9921508063474143, "bm25_max": 3.9921508063474143, "bge_top3": 0.5473278760910034, "bge_max": 0.5473278760910034, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Moxifloxacin (systemic): Pediatric drug information\")  Community-acquired pneumonia (CAP) due to atypical pathogens (M. pneumoniae, Chlamydophila [also known as Chlamyd…"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": 3.811452924563488, "bm25_max": 3.811452924563488, "bge_top3": null, "bge_max": null, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. If CrCl <70 mL/minute, do not coadminister as part of a regimen that includes tenofovir disoproxil fumarate."}, {"doc_id": "perampanel-drug-information", "bm25_top3": 3.7954529373746855, "bm25_max": 3.7954529373746855, "bge_top3": null, "bge_max": null, "title": "Perampanel: Drug information", "rep_snippet": "Administration  Tablets: Administer at bedtime without regard to food.  Oral suspension: Shake well before every administration. Use a calibrated measuring device to measure dose (a household teaspoon or tablespoon is no…"}, {"doc_id": "granisetron-drug-information", "bm25_top3": 3.01038832063307, "bm25_max": 3.7904768896943057, "bge_top3": null, "bge_max": null, "title": "Granisetron: Drug information", "rep_snippet": "Transdermal patch: Prophylaxis of chemotherapy-related emesis: Apply 1 patch at least 24 hours prior to chemotherapy; may be applied up to 48 hours before chemotherapy. Remove patch a minimum of 24 hours after chemothera…"}, {"doc_id": "indinavir-drug-information", "bm25_top3": 3.6472975793529336, "bm25_max": 3.6472975793529336, "bge_top3": null, "bge_max": null, "title": "Indinavir: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Mild to moderate impairment due to cirrhosis (unboosted regimen): 600 mg every 8 hours  Severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": 3.459832718528231, "bm25_max": 3.459832718528231, "bge_top3": null, "bge_max": null, "title": "Cefazolin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefazolin: Pediatric drug information\")  Usual dosage range: IM, IV: Infants >1 month, Children, and Adolescents: 25 to 100 mg/kg/day divided every 6 to 8 hours; maximu…"}, {"doc_id": "asfotase-alfa-drug-information", "bm25_top3": 3.4371940515483796, "bm25_max": 3.4371940515483796, "bge_top3": null, "bge_max": null, "title": "Asfotase alfa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Asfotase alfa: Pediatric drug information\")  Hypophosphatasia (HPP): SubQ: Note: Round patient weight to the nearest kg when determining dose. Do not administer the 80…"}, {"doc_id": "gemifloxacin-united-states-not-available-drug-information", "bm25_top3": 3.397094632592502, "bm25_max": 3.397094632592502, "bge_top3": null, "bge_max": null, "title": "Gemifloxacin (United States: Not available): Drug information", "rep_snippet": "Use  Treatment of acute exacerbation of chronic bronchitis; treatment of community-acquired pneumonia (CAP), including pneumonia caused by multidrug-resistant strains of S. pneumoniae (MDRSP)  Limitations of use: Because…"}, {"doc_id": "beclomethasone-nasal-drug-information", "bm25_top3": 3.3916184134276897, "bm25_max": 3.3916184134276897, "bge_top3": null, "bge_max": null, "title": "Beclomethasone (nasal): Drug information", "rep_snippet": "Administration  Beconase AQ: Shake well prior to each use. Prior to initial use, prime pump 6 times (or until fine spray appears); repeat priming if product not used for ≥7 days. Spray in nostril(s); avoid spraying in ey…"}, {"doc_id": "interferon-beta-1b-drug-information", "bm25_top3": 3.3413367850354874, "bm25_max": 3.3413367850354874, "bge_top3": null, "bge_max": null, "title": "Interferon beta-1b: Drug information", "rep_snippet": "Dosage Forms Considerations  The Extavia diluent syringe cap may contain latex."}, {"doc_id": "typhoid-vaccine-drug-information", "bm25_top3": 3.0446389621633188, "bm25_max": 3.0446389621633188, "bge_top3": null, "bge_max": null, "title": "Typhoid vaccine: Drug information", "rep_snippet": "Use  Typhoid fever prevention: Active immunization against typhoid fever caused by Salmonella typhi:  Oral: Immunization of adults and children >6 years of age; complete the vaccine regimen at least 1 week before potenti…"}, {"doc_id": "chlorpromazine-drug-information", "bm25_top3": 2.9646339501524768, "bm25_max": 2.9646339501524768, "bge_top3": null, "bge_max": null, "title": "Chlorpromazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Chlorpromazine and its metabolites have been detected in breast milk; concentrations in the milk do not correlate with those in the mother and may be higher than what is in the maternal pla…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": 2.797350891237425, "bm25_max": 2.797350891237425, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "M. avium complex (nodular/bronchiectatic disease) (ATS/IDSA [Griffith 2007]): 600 mg 3 times weekly in combination with a 3-times-weekly regimen of a macrolide (azithromycin or clarithromycin) and ethambutol; continue tr…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": 2.617109661084738, "bm25_max": 2.617109661084738, "bge_top3": 0.5261165698369344, "bge_max": 0.5421361923217773, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Salivary gland cancers, advanced (off-label use): IV: 50 mg/m2 on day 1 every 21 days (in combination with cisplatin and cyclophosphamide); continue until disease progression or unacceptable toxicity (Lictra 1996) or 50…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": 2.5723276584900248, "bm25_max": 2.5723276584900248, "bge_top3": 0.5289527177810669, "bge_max": 0.5289527177810669, "title": "Cefotaxime: Drug information", "rep_snippet": "Gonorrhea, disseminated infections (arthritis and arthritis-dermatitis syndrome) (alternative to preferred therapy) (off-label use): IV: 1 g every 8 hours in combination with azithromycin. Continue for 24 to 48 hours aft…"}, {"doc_id": "raltitrexed-united-states-not-available-drug-information", "bm25_top3": 2.5699480725721706, "bm25_max": 2.5699480725721706, "bge_top3": null, "bge_max": null, "title": "Raltitrexed (United States: Not available): Drug information", "rep_snippet": "Dosing: Obesity  ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: Utilize patient’s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particula…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 2.5036648925658724, "bm25_max": 2.5036648925658724, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling.  CrCl <30 mL/minute: Use is not recommended per the manufacturer’s labeling although a decreased dose…"}, {"doc_id": "gadoteridol-drug-information", "bm25_top3": 2.4240478926320304, "bm25_max": 2.4240478926320304, "bge_top3": null, "bge_max": null, "title": "Gadoteridol: Drug information", "rep_snippet": "Dosage Forms Considerations  ProHance prefilled syringe tip cap contains latex."}, {"doc_id": "ethambutol-drug-information", "bm25_top3": 2.3722214351831887, "bm25_max": 2.3722214351831887, "bge_top3": null, "bge_max": null, "title": "Ethambutol: Drug information", "rep_snippet": "Nodular/bronchiectatic disease: 25 mg/kg 3 times weekly in combination with a 3-times-weekly regimen of a macrolide (azithromycin or clarithromycin) and rifampin; continue treatment until patient is culture negative on t…"}, {"doc_id": "clobetasol-drug-information", "bm25_top3": 2.357117258888545, "bm25_max": 2.357117258888545, "bge_top3": null, "bge_max": null, "title": "Clobetasol: Drug information", "rep_snippet": "Shampoo: Limit treatment to 4 consecutive weeks. Maximum dose: 50 g/week or 50 mL/week. Use on dry hair; do not wet hair prior to use. Do not use a shower cap or bathing cap while shampoo is on the scalp. Leave in place…"}, {"doc_id": "betaxolol-systemic-drug-information", "bm25_top3": 2.2390865436915313, "bm25_max": 2.2390865436915313, "bge_top3": null, "bge_max": null, "title": "Betaxolol (systemic): Drug information", "rep_snippet": "The maternal half-life and serum concentration of betaxolol immediately postpartum are not significantly different than what is observed in nonpregnant women (Boutroy 1990; Morselli 1990). Untreated chronic maternal hype…"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": 2.2345702488567856, "bm25_max": 2.2345702488567856, "bge_top3": null, "bge_max": null, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Administration  Immediate release: Administer twice daily without regard to meals.  Suspension: Prior to using for the first time, firmly insert the plastic adapter provided with the bottle. Cover adapter with child-resi…"}, {"doc_id": "adalimumab-including-biosimilars-of-adalimumab-drug-information", "bm25_top3": 2.2072971211334487, "bm25_max": 2.2072971211334487, "bge_top3": null, "bge_max": null, "title": "Adalimumab (including biosimilars of adalimumab): Drug information", "rep_snippet": "Administration  SubQ: For SubQ injection at separate sites in the thigh or lower abdomen (avoiding areas within 2 inches of navel); rotate injection sites. May leave at room temperature for ~15 to 30 minutes prior to use…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": 2.075744082661622, "bm25_max": 2.075744082661622, "bge_top3": 0.5209841132164001, "bge_max": 0.5209841132164001, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "(hospital-acquired infection, immunocompromised host, or coverage of P. aeruginosa) (off-label use): IV: 4.5 g every 6 hours (IDSA/ATS [Kalil 2016]). Note: Use in conjunction with surgical drainage. Additional agent for…"}, {"doc_id": "fluticasone-nasal-drug-information", "bm25_top3": 2.0609093595191794, "bm25_max": 2.0609093595191794, "bge_top3": null, "bge_max": null, "title": "Fluticasone (nasal): Drug information", "rep_snippet": "Administration  For intranasal use only; do not spray in eyes or mouth. Administer at regular intervals. Shake bottle gently before each use. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle up…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": 1.978186669649574, "bm25_max": 1.978186669649574, "bge_top3": null, "bge_max": null, "title": "Cefixime: Drug information", "rep_snippet": "Use  Treatment of uncomplicated urinary tract infections (due to Escherichia coli and Proteus mirabilis), otitis media (due to Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes), pharyngitis and t…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 1.9707569344378193, "bm25_max": 1.9707569344378193, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have…"}, {"doc_id": "tenofovir-alafenamide-and-emtricitabine-drug-information", "bm25_top3": 1.9375296072158434, "bm25_max": 1.9375296072158434, "bge_top3": null, "bge_max": null, "title": "Tenofovir alafenamide and emtricitabine: Drug information", "rep_snippet": "Pregnancy Implications  The Health and Human Services (HHS) Perinatal HIV Guidelines note there are insufficient data to recommend use of this combination product as an initial regimen in antiretroviral-naive pregnant fe…"}, {"doc_id": "rilpivirine-emtricitabine-and-tenofovir-alafenamide-drug-information", "bm25_top3": 1.9135003130697896, "bm25_max": 1.9135003130697896, "bge_top3": null, "bge_max": null, "title": "Rilpivirine, emtricitabine, and tenofovir alafenamide: Drug information", "rep_snippet": "Pregnancy Implications  The Health and Human Services (HHS) Perinatal HIV Guidelines note there are insufficient data to recommend use of this combination product as an initial regimen in antiretroviral-naive pregnant fe…"}, {"doc_id": "dolutegravir-and-rilpivirine-drug-information", "bm25_top3": 1.8803680809871004, "bm25_max": 1.8803680809871004, "bge_top3": null, "bge_max": null, "title": "Dolutegravir and rilpivirine: Drug information", "rep_snippet": "Pregnancy Implications  In general, females who become pregnant on a stable combination antiretroviral therapy regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieve…"}, {"doc_id": "dolutegravir-abacavir-and-lamivudine-drug-information", "bm25_top3": 1.8803680809871004, "bm25_max": 1.8803680809871004, "bge_top3": null, "bge_max": null, "title": "Dolutegravir, abacavir, and lamivudine: Drug information", "rep_snippet": "Pregnancy Implications  In general, females who become pregnant on a stable antiretroviral therapy (ART) regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, con…"}, {"doc_id": "bedaquiline-drug-information", "bm25_top3": 1.8756094184730188, "bm25_max": 1.8756094184730188, "bge_top3": null, "bge_max": null, "title": "Bedaquiline: Drug information", "rep_snippet": "• Appropriate use: Administer by directly observed therapy (DOT). Should not be used for latent, extrapulmonary (eg, CNS) or drug-sensitive tuberculosis, or nontuberculosis mycobacteria. May be used for 24 weeks in adult…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 0.7619433517340068, "bm25_max": 1.588336647896588, "bge_top3": 0.5132142305374146, "bge_max": 0.5132142305374146, "title": "Telithromycin: Drug information", "rep_snippet": "Dosing: Adult  Note: Ketek has been discontinued in the United States for more than 1 year.  Community-acquired pneumonia (CAP): Oral: 800 mg once daily for 7-10 days"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 1.4184099625539819, "bm25_max": 1.4184099625539819, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "danaparoid-united-states-not-available-drug-information", "bm25_top3": 0.7598529132797829, "bm25_max": 0.7598529132797829, "bge_top3": null, "bge_max": null, "title": "Danaparoid (United States: Not available): Drug information", "rep_snippet": ">90 kg: 750 units 1 to 4 hours preoperatively and at ≥6 hours postop, followed by 750 units every 8 hours or 1,250 units every 12 hours beginning day 1 post-op and continued for 7 to 10 days  Embolectomy:  55 to 90 kg: I…"}, {"doc_id": "rotavirus-vaccine-drug-information", "bm25_top3": 0.6967851869878405, "bm25_max": 0.6967851869878405, "bge_top3": null, "bge_max": null, "title": "Rotavirus vaccine: Drug information", "rep_snippet": "Administration  For oral administration only; do not give by injection. May be administered before or after food, milk, or breast milk. To avoid potential eye splashes caused by coughing, sneezing, and spitting, administ…"}, {"doc_id": "efinaconazole-drug-information", "bm25_top3": 0.5847515212376013, "bm25_max": 0.5847515212376013, "bge_top3": null, "bge_max": null, "title": "Efinaconazole: Drug information", "rep_snippet": "Administration  Topical: Affected toenail(s) should be clean and dry. Wait at least 10 minutes after showering, bathing, or washing the area prior to application. Remove bottle cap and hold the bottle directly over the a…"}, {"doc_id": "cefuroxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5770917534828186, "bge_max": 0.5770917534828186, "title": "Cefuroxime: Drug information", "rep_snippet": "Note: Cefuroxime is considered an alternate therapy for CAP in adults caused by Streptococcus pneumoniae (with MICs <2 mcg/mL for penicillin); may also be used as outpatient empiric therapy in combination with a macrolid…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5470716953277588, "bge_max": 0.5470716953277588, "title": "Amoxicillin: Drug information", "rep_snippet": "Concomitant regimen: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily; continue…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5385972857475281, "bge_max": 0.5451873540878296, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Clarithromycin triple regimen: 500 mg 3 times daily in combination with clarithromycin 500 mg twice daily and a standard-dose or double-dose proton pump inhibitor twice daily; continue regimen for 14 days. Note: Avoid us…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5424111485481262, "bge_max": 0.5424111485481262, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Osteomyelitis (diabetic foot) (Lipsky 2004): IV: 3 g every 6 hours  Pelvic inflammatory disease (alternative to preferred therapy): IV: 3 g every 6 hours with doxycycline oral or IV; transition from parenteral to oral th…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5350872278213501, "bge_max": 0.5350872278213501, "title": "Doxycycline: Drug information", "rep_snippet": "Pneumonia, community-acquired (CAP): Children >7 years: Oral: Note: A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.  Presumed atypical, mild atypical (M. pneumoniae, C. pneumo…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5320276618003845, "bge_max": 0.5320276618003845, "title": "Tinidazole: Drug information", "rep_snippet": "Hybrid regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, tinidazole 500 mg twice dail…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5228720903396606, "bge_max": 0.5274444818496704, "title": "Clarithromycin: Drug information", "rep_snippet": "Clarithromycin triple therapy: 500 mg twice daily, in combination with a standard-dose or double-dose proton pump inhibitor, and either amoxicillin 1 g twice daily or metronidazole 500 mg three times daily; continue regi…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5267030596733093, "bge_max": 0.5267030596733093, "title": "Rabeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times per day; continue regimen for 14 days. N…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5241579413414001, "bge_max": 0.5241579413414001, "title": "Omeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days. Not…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5241579413414001, "bge_max": 0.5241579413414001, "title": "Esomeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days. Not…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5163771112759908, "bge_max": 0.5211190581321716, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Community-acquired (CAP): Oral, IV: 500 mg every 24 hours for 7 to 14 days or 750 mg every 24 hours for 5 days; Note: CAP guidelines recommend the 750 mg dose (IDSA/ATS [Mandell 2007])  Hospital-acquired or ventilator-…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5174060463905334, "bge_max": 0.5174060463905334, "title": "Procarbazine: Drug information", "rep_snippet": "PEP-C regimen: Oral: 50 mg daily at bedtime (length of induction cycle depends on phase of treatment and blood counts; frequency may vary based on tolerance in maintenance cycle; in combination with prednisone, etoposide…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5159580111503601, "bge_max": 0.5159580111503601, "title": "Atorvastatin: Drug information", "rep_snippet": "Azithromycin (Systemic): May enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. Risk C: Monitor therapy  Bexarotene (Systemic): May decrease the serum concentration of AtorvaSTATin. Risk C: Monitor therapy  B…"}, {"doc_id": "mannitol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5135684609413147, "bge_max": 0.5135684609413147, "title": "Mannitol (systemic): Drug information", "rep_snippet": "Dosing: Adult  Intracranial pressure (ICP), cerebral edema, reduction (off-label dosing): IV: 0.25 to 1 g/kg/dose; may repeat every 6 to 8 hours as needed (BTF [Carney 2016]; Grape 2012). Some suggest maintaining serum o…"}, {"doc_id": "vincristine-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5121135711669922, "bge_max": 0.5121135711669922, "title": "Vincristine (conventional): Drug information", "rep_snippet": "VAD regimen: 0.4 mg/day continuous infusion for 4 days (over 96 hours) (total 1.6 mg/cycle) of a 28-day treatment cycle (Rifkin 2006)  Ovarian cancer (off-label use): IV: VAC regimen: 1.5 mg/m2/dose (maximum dose: 2 mg)…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5119103193283081, "bge_max": 0.5119103193283081, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Bullous systemic lupus erythematosus (off-label use): Oral: 100 mg once daily with or without prednisone (Fabbri 2003).  Immune thrombocytopenia (ITP) (off-label use): Oral: 75 to 100 mg daily or 1 to 2 mg/kg/day; durati…"}, {"doc_id": "paclitaxel-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5112716555595398, "bge_max": 0.5112716555595398, "title": "Paclitaxel (conventional): Drug information", "rep_snippet": "Cervical cancer, advanced (off-label use): IV: 135 or 175 mg/m2 every 3 weeks (in combination with bevacizumab and cisplatin) until disease progression or unacceptable toxicity (Tewari, 2014) or 175 mg/m2 every 3 weeks (…"}, {"doc_id": "ifosfamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5109664797782898, "bge_max": 0.5109664797782898, "title": "Ifosfamide: Drug information", "rep_snippet": "Diffuse large B-cell lymphoma (RICE regimen): 5,000 mg/m2 (over 24 hours) beginning on day 4 every 2 weeks for 3 cycles (in combination with mesna, carboplatin, etoposide, and rituximab) (Kewalramani 2004)  Osteosarcoma…"}, {"doc_id": "capsaicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5105937123298645, "bge_max": 0.5105937123298645, "title": "Capsaicin: Drug information", "rep_snippet": "Brand Names: International  Alacapsin (ES);  Antidol Forte (UY);  Axsain (GB, IE);  Capderm (TW);  Capsaicina (PY);  Capsain-P (IN);  Capser (TR);  Capsi (BD);  Capsicin (ES, VN);  Capsidol (ES, MX);  Capsika (TH);  Caps…"}, {"doc_id": "clopidogrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5105525255203247, "bge_max": 0.5105525255203247, "title": "Clopidogrel: Drug information", "rep_snippet": "Recent MI, recent stroke, or established peripheral arterial disease (PAD): Oral: 75 mg once daily.  Guideline recommendations regarding concomitant therapy and durations of therapy (off-label):  Minor ischemic stroke or…"}, {"doc_id": "acetazolamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5104019045829773, "bge_max": 0.5104019045829773, "title": "Acetazolamide: Drug information", "rep_snippet": "Prevention of cystine renal calculi (adjunctive therapy) (off-label use): Oral: 500 mg daily at bedtime in combination with potassium citrate and captopril (Sterrett 2008)  Respiratory stimulant in stable hypercapnic COP…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.510360598564148, "bge_max": 0.510360598564148, "title": "Simvastatin: Drug information", "rep_snippet": "Azithromycin (Systemic): May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Risk C: Monitor therapy  Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins)…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5097309350967407, "bge_max": 0.5097309350967407, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Presumed atypical (M. pneumoniae, Chlamydophila [also known as Chlamydia] pneumoniae, C. trachomatis) infection, mild atypical infection or step-down therapy (alternative to azithromycin): Oral: 10 mg/kg/dose every 6 hou…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5088674426078796, "bge_max": 0.5088674426078796, "title": "Amiodarone: Drug information", "rep_snippet": "Preoperative regimen: 150 mg loading dose, followed by 0.4 mg/kg/hour (~0.5 mg/minute for a 70 kg patient) for 3 days prior to surgery and for 5 days postoperative (Lee 2000).  Postoperative regimen: Starting at postop r…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5058057904243469, "bge_max": 0.5058057904243469, "title": "Streptomycin: Drug information", "rep_snippet": "Mycobacterium avium complex (MAC) (off-label use): IM: Adjunct therapy (with macrolide, rifamycin, and ethambutol): 8 to 25 mg/kg 2 to 3 times weekly for first 2 to 3 months for severe disease (maximum single dose for ag…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5054120421409607, "bge_max": 0.5054120421409607, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Azithromycin (Systemic): May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Risk C: Monitor therapy  Bezafibrate: May enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and c…"}, {"doc_id": "sodium-hypochlorite-solution-drug-information", "bm25_top3": 0.3358880327684357, "bm25_max": 0.3358880327684357, "bge_top3": null, "bge_max": null, "title": "Sodium hypochlorite solution: Drug information", "rep_snippet": "Administration  Topical: For external use only; do not ingest or use in eyes.  Gel: Varies with type of wound management needed. Refer to manufacturer’s product information for detailed administration directions.  Liquid…"}]}
{"qid": "Q15_abbr+allergy", "query": "Dental endocarditis ppx — amoxicillin adult dose; alternatives if PCN allergy?", "base_qid": "Q15", "variant_type": "abbr+allergy", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 29.534752972018236, "bm25_max": 29.85603671323523, "bge_top3": 0.5950974524021149, "bge_max": 0.5974133610725403, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Hemodialysis: Amoxicillin 8 to 20 mg/kg/dose every 24 hours; give after dialysis  Peritoneal dialysis: Amoxicillin 8 to 20 mg/kg/dose every 24 hours  Severe infection (high dose): Dosing based on amoxicillin 80 to 90 mg/…"}, {"doc_id": "mepivacaine-and-levonordefrin-drug-information", "bm25_top3": 21.820716602686936, "bm25_max": 29.289504054540377, "bge_top3": null, "bge_max": null, "title": "Mepivacaine and levonordefrin: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosage varies with the anesthetic procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. Always use the lowest effective do…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 21.71974168309889, "bm25_max": 28.799240219037873, "bge_top3": 0.6115998029708862, "bge_max": 0.6250406503677368, "title": "Amoxicillin: Drug information", "rep_snippet": "Ear, nose, throat, genitourinary tract, or skin/skin structure infections: Note: IDSA guidelines recommend amoxicillin-clavulanate as preferred first-line treatment of acute bacterial rhinosinusitis (ABRS) (IDSA [Chow 20…"}, {"doc_id": "triclosan-and-fluoride-dental-drug-information", "bm25_top3": 26.658891936940872, "bm25_max": 27.74873892543831, "bge_top3": null, "bge_max": null, "title": "Triclosan and fluoride (dental): Drug information", "rep_snippet": "Dosing: Adult  Prevention of dental caries and gingivitis: Oral: Brush teeth thoroughly after each meal or at least twice daily"}, {"doc_id": "lidocaine-and-epinephrine-drug-information", "bm25_top3": 17.87420547601809, "bm25_max": 22.72538707890088, "bge_top3": 0.5927243828773499, "bge_max": 0.5927243828773499, "title": "Lidocaine and epinephrine: Drug information", "rep_snippet": "Dosing: Adult  Anesthesia:  Dental: Oral infiltration/mandibular block: Initial: 1 to 5 mL (lidocaine 20 mg to 100 mg). Note: For most routine dental procedures, lidocaine 2% with epinephrine 1:100,000 is preferred. When…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": 11.848668767062161, "bm25_max": 18.8649975465265, "bge_top3": 0.6233549118041992, "bge_max": 0.6233549118041992, "title": "Cefazolin: Drug information", "rep_snippet": "Endocarditis, prophylaxis (off-label use): Dental and upper respiratory procedures: Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes before procedure; maximum dose: 1,000 mg (AHA [Wilson 2007]). Note…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 18.156761975030832, "bm25_max": 18.156761975030832, "bge_top3": 0.6023515462875366, "bge_max": 0.6023515462875366, "title": "Clarithromycin: Drug information", "rep_snippet": "Hybrid regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, a standard-dose PPI twice da…"}, {"doc_id": "tetracaine-and-oxymetazoline-drug-information", "bm25_top3": 17.5190371300816, "bm25_max": 17.5190371300816, "bge_top3": null, "bge_max": null, "title": "Tetracaine and oxymetazoline: Drug information", "rep_snippet": "Dosing: Adult  Anesthesia, dental: Intranasal: 2 sprays administered 4 to 5 minutes apart in the nostril ipsilateral (same side) to the maxillary tooth on which the dental procedure will be performed. Initiate the dental…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": 14.129677042446131, "bm25_max": 17.20774974975006, "bge_top3": 0.5996142228444418, "bge_max": 0.6053071022033691, "title": "Ampicillin: Drug information", "rep_snippet": "Genitourinary and gastrointestinal tract procedures: IM, IV: Note: Routine prophylaxis for GI/GU procedures is no longer recommended by the AHA. Consider only in patients with the highest risk of adverse outcome from end…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 16.891338837613446, "bm25_max": 16.891338837613446, "bge_top3": 0.594463586807251, "bge_max": 0.594463586807251, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Sequential regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, metronidazole 500 mg twice daily, and a standard…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 15.742144536539895, "bm25_max": 16.547174136349796, "bge_top3": 0.5992564558982849, "bge_max": 0.5992564558982849, "title": "Flucytosine: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage ranges: Oral: 50 to 150 mg/kg/day in divided doses every 6 hours  Candidiasis (off-label dose) (IDSA [Pappas 2016]): Oral:  Central nervous system (eg, meningitis): 25 mg/kg/dose 4 times daily…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": 16.488018113535105, "bm25_max": 16.488018113535105, "bge_top3": 0.6334331333637238, "bge_max": 0.6708564758300781, "title": "Ceftriaxone: Drug information", "rep_snippet": "Endocarditis, prophylaxis (off-label use): Dental and upper respiratory procedures (patients allergic to penicillins and/or unable to take oral): Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes prio…"}, {"doc_id": "dexchlorpheniramine-drug-information", "bm25_top3": 15.104910341196376, "bm25_max": 15.104910341196376, "bge_top3": null, "bge_max": null, "title": "Dexchlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  Allergy symptoms: Oral: 2 mg every 4 to 6 hours"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": 14.99955081265757, "bm25_max": 14.99955081265757, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Group A streptococci (GAS) chronic carrier, treatment (off-label use): Children and Adolescents: Refer to adult dosing.  Anaplasmosis, mild cases (patients with severe allergy to doxycycline) (off-label use): Children an…"}, {"doc_id": "fluorescein-drug-information", "bm25_top3": 14.52519663269917, "bm25_max": 14.52519663269917, "bge_top3": null, "bge_max": null, "title": "Fluorescein: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fluorescein: Pediatric drug information\")  Diagnostic staining: Children and Adolescents: Ophthalmic: Strips: Refer to adult dosing.  Ophthalmic angiography/angioscopy:…"}, {"doc_id": "carbamide-peroxide-drug-information", "bm25_top3": 14.427820671669322, "bm25_max": 14.427820671669322, "bge_top3": null, "bge_max": null, "title": "Carbamide peroxide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Carbamide peroxide: Pediatric drug information\")  Ear wax removal: Otic:  Children <12 years: Individualize the dose according to patient size; 3 drops (range: 1 to 5 d…"}, {"doc_id": "diphenhydramine-systemic-drug-information", "bm25_top3": 12.959021826959283, "bm25_max": 12.959021826959283, "bge_top3": null, "bge_max": null, "title": "Diphenhydramine (systemic): Drug information", "rep_snippet": "Brand Names: US  Aler-Dryl [OTC];  Allergy Relief Childrens [OTC];  Allergy Relief [OTC];  Altaryl [OTC] [DSC];  Anti-Hist Allergy [OTC];  Banophen [OTC];  Benadryl Allergy Childrens [OTC];  Benadryl Allergy [OTC];  Bena…"}, {"doc_id": "cetylpyridinium-and-benzocaine-united-states-not-available-drug-information", "bm25_top3": 12.249695666656553, "bm25_max": 12.249695666656553, "bge_top3": null, "bge_max": null, "title": "Cetylpyridinium and benzocaine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Antiseptic/anesthetic: Oral: Dissolve in mouth as needed for sore throat  Antiseptic/anesthetic (dental use): Oral: Dissolve in mouth as needed for pain"}, {"doc_id": "mepivacaine-drug-information", "bm25_top3": 11.776784189365717, "bm25_max": 11.776784189365717, "bge_top3": null, "bge_max": null, "title": "Mepivacaine: Drug information", "rep_snippet": "Use  Dental anesthesia: Production of local anesthesia for dental procedures by infiltration or nerve block in adult and pediatric patients.  Local or regional anesthesia (eg, epidural, caudal, or peripheral nerve blocks…"}, {"doc_id": "bupivacaine-drug-information", "bm25_top3": 4.937286766265839, "bm25_max": 4.937286766265839, "bge_top3": null, "bge_max": null, "title": "Bupivacaine: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: Anesthesia (route and dose dependent):  Epidural: Up to 17 minutes to spread to T6 dermatome (Scott 1980)  Infiltration: Fast (Barash 2009); Dental injection: 2 to 10 minutes…"}, {"doc_id": "diclofenac-systemic-drug-information", "bm25_top3": 4.889361534702722, "bm25_max": 4.889361534702722, "bge_top3": 0.591041088104248, "bge_max": 0.591041088104248, "title": "Diclofenac (systemic): Drug information", "rep_snippet": "• Bioequivalence: Different formulations of oral diclofenac are not bioequivalent, even if the milligram strength is the same; do not interchange products.  • Surgical/dental procedures: Withhold for at least 4 to 6 half…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": 4.746961862769247, "bm25_max": 4.746961862769247, "bge_top3": null, "bge_max": null, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Brucellosis; Endocarditis, treatment (viridans group streptococcus [VGS] and S. bovis [native or prosthetic valve]) (adults); Gonococcal infection, uncomplicated (patients with severe cephalosporin allerg…"}, {"doc_id": "liposomal-bupivacaine-drug-information", "bm25_top3": 2.636010273739643, "bm25_max": 2.636010273739643, "bge_top3": null, "bge_max": null, "title": "Liposomal bupivacaine: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Duration: Local: Systemic: 96 hours  Protein binding: 95%  Metabolism: Hepatic via conjugation; major metabolite pipecoloxylidine (PPX; inactive)  Half-life elimination: 24 to 34 hours  Time to…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 0.9040235082294359, "bm25_max": 0.9040235082294359, "bge_top3": 0.6117171049118042, "bge_max": 0.6117171049118042, "title": "Vancomycin: Drug information", "rep_snippet": "Use  Clostridium difficile infection (oral): Treatment of C. difficile infection (CDI)  Endocarditis (injection):  Corynebacteria (diphtheroids): Treatment of diphtheroid endocarditis in combination with either rifampin,…"}, {"doc_id": "cefadroxil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6130247116088867, "bge_max": 0.6130247116088867, "title": "Cefadroxil: Drug information", "rep_snippet": "Dosing: Adult  Cystitis, acute  uncomplicated (alternative agent): Oral: 500 mg twice daily for 5 to 7 days (Greenberg 1986; Hooton 2018)  Pharyngitis: Oral:  Manufacturer’s labeling: 1 g/day in a single or 2 divided dos…"}, {"doc_id": "fexofenadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6125336289405823, "bge_max": 0.6125336289405823, "title": "Fexofenadine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Suspension, Oral, as hydrochloride:  Allegra Allergy Chi…"}, {"doc_id": "daptomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6121009588241577, "bge_max": 0.6121009588241577, "title": "Daptomycin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Daptomycin: Pediatric drug information\")  Endocarditis, treatment (off-label use; AHA [Baltimore 2015]):  Due to Staphylococcus (MRSA or vancomycin resistant/intolerant…"}, {"doc_id": "budesonide-nasal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.60111004114151, "bge_max": 0.6109580993652344, "title": "Budesonide (nasal): Drug information", "rep_snippet": "Dosing: Adult  US labeling:  Rx: Allergic rhinitis: Intranasal: One spray (32 mcg) in each nostril once daily (total daily dose: 64 mcg/day). Some patients who do not achieve adequate control may benefit from increased d…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6091107130050659, "bge_max": 0.6091107130050659, "title": "Ceftazidime: Drug information", "rep_snippet": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day divided every 6 to 8 hours, maximum daily dose: 6 g/day; higher doses have been used: 200 to 400 mg/…"}, {"doc_id": "atovaquone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6086497902870178, "bge_max": 0.6086497902870178, "title": "Atovaquone: Drug information", "rep_snippet": "Dosing: Adult  Pneumocystis jirovecii pneumonia (PCP), prevention: Oral: 1,500 mg once daily with food  PCP, mild to moderate, treatment: Oral: 750 mg twice daily with food for 21 days  Babesiosis (off-label use): Oral:…"}, {"doc_id": "ketoprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6082922220230103, "bge_max": 0.6082922220230103, "title": "Ketoprofen: Drug information", "rep_snippet": "Dosing: Adult  Note: The enteric coated tablet and extended release formulations are not recommended for the treatment of acute pain. Lower doses should be considered in small or debilitated patients.  Oral:  Ankylosing…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6034486889839172, "bge_max": 0.6071702241897583, "title": "Paroxetine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral:  Paxil, Pexeva: Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/…"}, {"doc_id": "bismuth-subcitrate-metronidazole-and-tetracycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6060575842857361, "bge_max": 0.6060575842857361, "title": "Bismuth subcitrate, metronidazole, and tetracycline: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer associated with H. pylori infection: Oral: Three capsules (bismuth subcitrate 420 mg, metronidazole 375 mg, and tetracycline 375 mg) 4 times daily after meals and at bedtime (plus omeprazole…"}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6054048538208008, "bge_max": 0.6054048538208008, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Use  Anthrax, prophylaxis: To reduce the incidence of the disease following exposure to aerosolized Bacillus anthracis.  Anthrax, treatment: Treatment of anthrax, including post-exposure inhalational disease due to aeros…"}, {"doc_id": "articaine-and-epinephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6010275483131409, "bge_max": 0.6032893657684326, "title": "Articaine and epinephrine: Drug information", "rep_snippet": "Dosing: Adult  Dental anesthesia: Submucosal infiltration and/or nerve block: Articaine 4%/epinephrine: Note: These dosages are guides only; other dosages may be used; however, do not exceed maximum recommended dose. The…"}, {"doc_id": "prilocaine-with-epinephrine-dental-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6024183034896851, "bge_max": 0.6024183034896851, "title": "Prilocaine with epinephrine (dental): Drug information", "rep_snippet": "Dosing: Pediatric  Dental anesthesia:  Children <10 years: Doses >40 mg (1 mL) of prilocaine hydrochloride as a 4% solution with epinephrine 1:200,000 are rarely needed for procedures involving a single tooth, in a maxil…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6021411418914795, "bge_max": 0.6021411418914795, "title": "Doxycycline: Drug information", "rep_snippet": "Dosing: Adult  Note: Doxycycline is available as hyclate, monohydrate, and calcium salts. All doses are expressed as doxycycline base.  Usual dosage range:  Oral: Immediate-release and most extended-release formulations:…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5997560024261475, "bge_max": 0.5997560024261475, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Dosing: Adult  H. pylori eradication: Oral: Omeprazole 20 mg (one capsule), clarithromycin 500 mg (one tablet), and amoxicillin 1,000 mg (two capsules) administered together twice daily for 10 days.  Note: If patient has…"}, {"doc_id": "triprolidine-phenylephrine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5990794897079468, "bge_max": 0.5990794897079468, "title": "Triprolidine, phenylephrine, and codeine: Drug information", "rep_snippet": "Dosing: Adult  Common cold or upper respiratory allergies: Oral: Histex AC (codeine 10 mg, phenylephrine 10 mg, and triprolidine 2.5 mg per 5 mL): 5 mL every 4 hours (maximum: 20 mL per 24 hours)"}, {"doc_id": "procyclidine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5986826419830322, "bge_max": 0.5986826419830322, "title": "Procyclidine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Parkinson disease: Oral: Initial: 2.5 mg 3 times daily after meals; if tolerated, gradually increase to 5 mg 3 times daily after meals and 5 mg at bedtime as needed. Lower dosages may be effective in some…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5981178879737854, "bge_max": 0.5981178879737854, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Pharyngitis (including susceptible group A streptococci), tonsillitis (as an alternative agent in penicillin-allergic patients): Oral: 12 mg/kg (maximum: 500 mg) on day 1 followed by 6 mg/kg (maximum: 250 mg) once daily…"}, {"doc_id": "doxycycline-hyclate-periodontal-extended-release-liquid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5958191752433777, "bge_max": 0.5958191752433777, "title": "Doxycycline hyclate periodontal extended-release liquid: Drug information", "rep_snippet": "Dosing: Adult  Periodontitis: Subgingival application: Dose depends on size, shape and number of pockets treated. Contains 50 mg doxycycline hyclate per 500 mg of formulation in each final blended syringe product.  Atrid…"}, {"doc_id": "cephalexin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5954009294509888, "bge_max": 0.5954009294509888, "title": "Cephalexin: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: Oral: 250 to 1,000 mg every 6 hours or 500 mg every 12 hours (maximum: 4 g/day)  Indication-specific dosing:  Cellulitis (nonpurulent)/erysipelas, mild (alternative agent): Oral: 500 mg…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5944651961326599, "bge_max": 0.5949836373329163, "title": "Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Injection, suspension [preservative free]:  Kinrix: Diphtheria toxoid 25 Lf, tetanus…"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5942152738571167, "bge_max": 0.5942152738571167, "title": "Cefpodoxime: Drug information", "rep_snippet": "Children ≥12 years of age and Adolescents: Oral: Refer to adult dosing.  Pneumonia, community acquired: Children ≥12 years of age and Adolescents: Oral: Refer to adult dosing.  Rhinosinusitis, acute maxillary:  Infants ≥…"}, {"doc_id": "desloratadine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5933624505996704, "bge_max": 0.5933624505996704, "title": "Desloratadine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Clarinex-D 24 Hour has been discontinued in the US for more than 1 year.  Seasonal or allergic rhinitis: Oral: Adolescents ≥12 years: Refer to adult dosing."}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5930396318435669, "bge_max": 0.5930396318435669, "title": "Hydroxyzine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydroxyzine: Pediatric drug information\")  Antiemetic: IM: 1.1 mg/kg/dose  Anxiety: Oral:  Children <6 years: 50 mg/day in divided doses  Children ≥6 years and Adolesce…"}, {"doc_id": "tenoxicam-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.592684268951416, "bge_max": 0.592684268951416, "title": "Tenoxicam (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Ankylosing spondylitis, rheumatoid arthritis, osteoarthritis, and/or extra-articular inflammation: Oral: 10 to 20 mg once daily (higher doses associated with increased risk of adverse effects and usually d…"}, {"doc_id": "quinupristin-and-dalfopristin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5926210880279541, "bge_max": 0.5926210880279541, "title": "Quinupristin and dalfopristin: Drug information", "rep_snippet": "Dosing: Adult  Skin and skin structure infection, complicated: IV: 7.5 mg/kg every 12 hours for at least 7 days  Bacteremia (methicillin-resistant Staphylococcus aureus) (off-label use): IV: 7.5 mg/kg every 8 hours (Liu…"}, {"doc_id": "gemifloxacin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5917800068855286, "bge_max": 0.5917800068855286, "title": "Gemifloxacin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Factive is no longer available in the United States.  Susceptible infections: Oral: 320 mg once daily  Acute exacerbations of chronic bronchitis: Oral: 320 mg once daily for 5 days  Community-acquire…"}, {"doc_id": "liposomal-amphotericin-b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5916270017623901, "bge_max": 0.5916270017623901, "title": "Liposomal amphotericin B: Drug information", "rep_snippet": "Note: Premedication: For patients who experience nonanaphylactic immediate infusion-related reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal anti-inflammatory…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5909033417701721, "bge_max": 0.5909033417701721, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Adult  Upper respiratory allergies: Oral: One tablet (cetirizine 5 mg/pseudoephedrine 120 mg) twice daily (maximum: 2 tablets [cetirizine 10 mg/pseudoephedrine 240 mg] per day)"}, {"doc_id": "amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5908008217811584, "bge_max": 0.5908008217811584, "title": "Amphotericin B cholesteryl sulfate complex (United States: not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Amphotec has been discontinued in the US for more than 1 year.  Note: Lipid-based amphotericin formulations (Amphotec) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizo…"}]}
{"qid": "Q15_noise", "query": "Dental work IE prophylaxis — what’s the amox dose, and what if pen allergy?", "base_qid": "Q15", "variant_type": "noise", "candidates": [{"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 34.39690472973123, "bm25_max": 34.39690472973123, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Panzyga [Canadian product]: IV: 1,000 mg/kg/day for 2 consecutive days; may repeat treatment in patients who relapse  American College of Obstetricians and Gynecologists Guidelines: IV: Initial: 1,000 mg/kg as a one-time…"}, {"doc_id": "chlorhexidine-gluconate-oral-drug-information", "bm25_top3": 29.48947501009865, "bm25_max": 29.48947501009865, "bge_top3": 0.6020519733428955, "bge_max": 0.6020519733428955, "title": "Chlorhexidine gluconate (oral): Drug information", "rep_snippet": "Dosing: Adult  Gingivitis: Oral rinse: Swish for 30 seconds with 15 mL (one capful) of undiluted oral rinse after toothbrushing, then expectorate; repeat twice daily (morning and evening). Therapy should be initiated imm…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 21.362273360317896, "bm25_max": 28.56197408416349, "bge_top3": 0.5556383728981018, "bge_max": 0.5556383728981018, "title": "Amoxicillin: Drug information", "rep_snippet": "Peritonitis, prophylaxis (for patients receiving peritoneal dialysis who require dental procedures) (off-label use): Infants, Children, and Adolescents: Oral: 50 mg/kg administered 30 to 60 minutes before dental procedur…"}, {"doc_id": "colchicine-drug-information", "bm25_top3": 25.831937224603163, "bm25_max": 25.831937224603163, "bge_top3": null, "bge_max": null, "title": "Colchicine: Drug information", "rep_snippet": "Dosing: Adult  Familial Mediterranean fever (FMF): Oral: Tablet (eg, Colcrys): 1.2 to 2.4 mg daily in 1 to 2 divided doses. Titration: Increase or decrease dose in 0.3 mg daily increments based on efficacy or adverse eff…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 24.567531507620668, "bm25_max": 24.567531507620668, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-indacaterol-drug-information", "bm25_top3": 24.187780826653924, "bm25_max": 24.187780826653924, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and indacaterol: Drug information", "rep_snippet": "• Lactose: Some products may contain lactose; allergic reactions possible in patients with severe milk protein allergy. Use with caution in patients with severe hypersensitivity to milk proteins.  Other warnings:  • Appr…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 20.26543885747603, "bm25_max": 20.26543885747603, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "ceftazidime-and-avibactam-drug-information", "bm25_top3": 18.40668996555517, "bm25_max": 18.40668996555517, "bge_top3": null, "bge_max": null, "title": "Ceftazidime and avibactam: Drug information", "rep_snippet": "Disease-related concerns:  • Renal impairment: In a complicated intra-abdominal infection clinical trial, patients with a creatinine clearance (CrCl) of 30 to 50 mL/minute had lower clinical cure rates than those with Cr…"}, {"doc_id": "tranexamic-acid-drug-information", "bm25_top3": 17.39233605780382, "bm25_max": 17.754920319049734, "bge_top3": 0.5736735463142395, "bge_max": 0.5736735463142395, "title": "Tranexamic acid: Drug information", "rep_snippet": "Short-term prophylaxis (eg, for dental work): Oral: 75 mg/kg/day divided 2 to 3 times daily for 5 days before and 2 days after the event (Bowen 2004) or 1,000 mg 4 times daily for 48 hours before and after procedure (Gom…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": 17.046880047298355, "bm25_max": 17.046880047298355, "bge_top3": 0.6085824370384216, "bge_max": 0.6085824370384216, "title": "Ceftriaxone: Drug information", "rep_snippet": "Endocarditis, prophylaxis (off-label use): Dental and upper respiratory procedures (patients allergic to penicillins and/or unable to take oral): Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes prio…"}, {"doc_id": "rabies-immune-globulin-human-drug-information", "bm25_top3": 16.74036576264723, "bm25_max": 16.74036576264723, "bge_top3": null, "bge_max": null, "title": "Rabies immune globulin (human): Drug information", "rep_snippet": "Dosing: Adult  Postexposure prophylaxis: Local wound infiltration/IM: 20 units/kg in a single dose, RIG should always be administered as part of rabies vaccine regimen. If anatomically feasible, the full rabies immune gl…"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 16.68090731642484, "bm25_max": 16.68090731642484, "bge_top3": null, "bge_max": null, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Mechanism of Action  Combination of fluticasone (corticosteroid) and salmeterol (long-acting beta2-agonist) designed to improve pulmonary function and control over what is produced by either agent when used alone. Becaus…"}, {"doc_id": "recombinant-human-growth-hormone-somatropin-drug-information", "bm25_top3": 16.45622361304625, "bm25_max": 16.45622361304625, "bge_top3": null, "bge_max": null, "title": "Recombinant human growth hormone (somatropin): Drug information", "rep_snippet": "• Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "asfotase-alfa-drug-information", "bm25_top3": 16.381739809790126, "bm25_max": 16.381739809790126, "bge_top3": null, "bge_max": null, "title": "Asfotase alfa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Asfotase alfa: Pediatric drug information\")  Hypophosphatasia (HPP): SubQ: Note: Round patient weight to the nearest kg when determining dose. Do not administer the 80…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": 16.20188734699996, "bm25_max": 16.20188734699996, "bge_top3": null, "bge_max": null, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Acute bacterial rhinosinusitis: Oral, IV: 400 mg every 24 hours for 10 days (manufacturer’s labeling) or 5 to 7 days (Chow 2012). Note: Recommended in patients with beta-lactam allergy; may also be used if…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": 10.505647662479092, "bm25_max": 15.824822197782792, "bge_top3": 0.5715233981609344, "bge_max": 0.5848510265350342, "title": "Cefazolin: Drug information", "rep_snippet": "Endocarditis, prophylaxis (off-label use): Dental and upper respiratory procedures: Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes before procedure; maximum dose: 1,000 mg (AHA [Wilson 2007]). Note…"}, {"doc_id": "rho-d-immune-globulin-drug-information", "bm25_top3": 15.612919704242824, "bm25_max": 15.612919704242824, "bge_top3": null, "bge_max": null, "title": "Rho(D) immune globulin: Drug information", "rep_snippet": "Rho(D) suppression: Note: In general, a 300 mcg dose will suppress the immune response to a fetal-maternal hemorrhage with ≤15 mL of Rh-positive RBC. If exposure to >15 mL of Rh-positive RBC is suspected, an appropriate…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": 11.9178214930322, "bm25_max": 15.128237101647489, "bge_top3": 0.5973523259162903, "bge_max": 0.6211802959442139, "title": "Ampicillin: Drug information", "rep_snippet": "Endocarditis, prophylaxis (off-label use): Note: AHA guidelines (Baltimore 2015) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthet…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 14.99649451753181, "bm25_max": 14.99649451753181, "bge_top3": 0.5555383563041687, "bge_max": 0.5555383563041687, "title": "Vancomycin: Drug information", "rep_snippet": "S. pneumoniae, moderate to severe infection (MICs to penicillin ≥4.0 mcg/mL) (alternative to ceftriaxone in beta-lactam allergic patients): 40 to 60 mg/kg/day divided every 6 to 8 hours  Health care–associated pneumonia…"}, {"doc_id": "chlorpromazine-drug-information", "bm25_top3": 14.874327570931019, "bm25_max": 14.874327570931019, "bge_top3": null, "bge_max": null, "title": "Chlorpromazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Chlorpromazine and its metabolites have been detected in breast milk; concentrations in the milk do not correlate with those in the mother and may be higher than what is in the maternal pla…"}, {"doc_id": "exenatide-drug-information", "bm25_top3": 14.550838984310664, "bm25_max": 14.550838984310664, "bge_top3": null, "bge_max": null, "title": "Exenatide: Drug information", "rep_snippet": "Administration  SubQ: Administer via SubQ injection in the upper arm, thigh, or abdomen; rotate injection sites.  Immediate release: Use only if clear, colorless, and free of particulate matter. Administer within 60 minu…"}, {"doc_id": "zanamivir-drug-information", "bm25_top3": 14.386242074070974, "bm25_max": 14.386242074070974, "bge_top3": null, "bge_max": null, "title": "Zanamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Zanamivir: Pediatric drug information\")  Influenza: Oral inhalation:  Manufacturer's labeling:  Prophylaxis, household setting: Children ≥5 years (US labeling) or ≥7 ye…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": 13.490844176437133, "bm25_max": 13.740531637512554, "bge_top3": null, "bge_max": null, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Use  Fusospirochetosis (Vincent gingivitis and pharyngitis): Treatment of fusospirochetosis (Vincent gingivitis and pharyngitis), in conjunction with dental care for infections involving gum tissue.  Pneumococcal infecti…"}, {"doc_id": "betaxolol-systemic-drug-information", "bm25_top3": 9.692029678388632, "bm25_max": 9.692029678388632, "bge_top3": null, "bge_max": null, "title": "Betaxolol (systemic): Drug information", "rep_snippet": "The maternal half-life and serum concentration of betaxolol immediately postpartum are not significantly different than what is observed in nonpregnant women (Boutroy 1990; Morselli 1990). Untreated chronic maternal hype…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 8.595751310201695, "bm25_max": 9.188032438181335, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Bacterial infections (Mifeprex)  Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following mifepristone use…"}, {"doc_id": "levalbuterol-drug-information", "bm25_top3": 8.802256003620808, "bm25_max": 8.802256003620808, "bge_top3": null, "bge_max": null, "title": "Levalbuterol: Drug information", "rep_snippet": "Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 8.297973439755758, "bm25_max": 8.297973439755758, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have…"}, {"doc_id": "fingolimod-drug-information", "bm25_top3": 8.176151378957044, "bm25_max": 8.176151378957044, "bge_top3": null, "bge_max": null, "title": "Fingolimod: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": 8.076681109064097, "bm25_max": 8.076681109064097, "bge_top3": null, "bge_max": null, "title": "Paroxetine: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.  • Seizure disorder: Use with caution in patients with…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": 7.920196483876456, "bm25_max": 7.920196483876456, "bge_top3": null, "bge_max": null, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "Pregnancy Implications  Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthm…"}, {"doc_id": "modafinil-drug-information", "bm25_top3": 7.092488328096785, "bm25_max": 7.092488328096785, "bge_top3": null, "bge_max": null, "title": "Modafinil: Drug information", "rep_snippet": "Administration  For the treatment of narcolepsy and obstructive sleep apnea/hypopnea syndrome, administer dose in the morning. For the treatment of shift work sleep disorder, administer dose ~1 hour prior to start of wor…"}, {"doc_id": "etonogestrel-implant-drug-information", "bm25_top3": 6.8338862719642535, "bm25_max": 6.8338862719642535, "bge_top3": null, "bge_max": null, "title": "Etonogestrel implant: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Breast cancer: Breast cancer is a hormonal sensitive tumor and the prognosis for women with current or a recent history of breast cancer may be worse with pro…"}, {"doc_id": "bicalutamide-drug-information", "bm25_top3": 6.70230370701386, "bm25_max": 6.70230370701386, "bge_top3": null, "bge_max": null, "title": "Bicalutamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Gynecomastia: May cause gynecomastia or breast pain at higher (off-label) doses.  • Hematologic: Anemia may occur with testosterone suppression; monitor CBC p…"}, {"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 6.561608114740807, "bm25_max": 6.561608114740807, "bge_top3": null, "bge_max": null, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "Pregnancy Implications  Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy (Battista 2016). Uncontrolled asthma is associated with adverse events on pregnancy (increased…"}, {"doc_id": "olodaterol-drug-information", "bm25_top3": 6.548675868547635, "bm25_max": 6.548675868547635, "bge_top3": null, "bge_max": null, "title": "Olodaterol: Drug information", "rep_snippet": "• Bronchospasm: Rarely, paradoxical, life-threatening bronchospasm may occur with use of inhaled beta2-agonists; distinguish from inadequate response, discontinue medication immediately, institute alternative therapy.  •…"}, {"doc_id": "hydrocortisone-systemic-drug-information", "bm25_top3": 5.630775999556803, "bm25_max": 5.630775999556803, "bge_top3": null, "bge_max": null, "title": "Hydrocortisone (systemic): Drug information", "rep_snippet": "Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": 5.616046533484376, "bm25_max": 5.616046533484376, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": 5.310195121933019, "bm25_max": 5.310195121933019, "bge_top3": null, "bge_max": null, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported fo…"}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 5.232701117879955, "bm25_max": 5.232701117879955, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ i…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": 4.787442709614872, "bm25_max": 4.787442709614872, "bge_top3": null, "bge_max": null, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Brucellosis; Endocarditis, treatment (viridans group streptococcus [VGS] and S. bovis [native or prosthetic valve]) (adults); Gonococcal infection, uncomplicated (patients with severe cephalosporin allerg…"}, {"doc_id": "montelukast-drug-information", "bm25_top3": 2.8081766891386, "bm25_max": 2.8081766891386, "bge_top3": null, "bge_max": null, "title": "Montelukast: Drug information", "rep_snippet": "Use  Prophylaxis and chronic treatment of asthma; relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis; prevention of exercise-induced bronchoconstriction.  Note: American Academy of Otolaryng…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 2.800295434767161, "bm25_max": 2.800295434767161, "bge_top3": 0.575410783290863, "bge_max": 0.5767275094985962, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Acute bacterial rhinosinusitis; Acute otitis media (children); Anthrax; Babesiosis; Bacterial vaginosis; Bite wounds (animal); Community-acquired pneumonia (children); Diabetic foot infections; Group A st…"}, {"doc_id": "aminocaproic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5849406123161316, "bge_max": 0.5849406123161316, "title": "Aminocaproic acid: Drug information", "rep_snippet": "Intracranial hemorrhage associated with thrombolytics (plasminogen-activator) (eg, alteplase, reteplase, tenecteplase) (off-label use): IV: 4 to 5 g (as an alternative to cryoprecipitate); check fibrinogen levels after a…"}, {"doc_id": "conjugated-equine-estrogens-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5833398103713989, "bge_max": 0.5833398103713989, "title": "Conjugated equine estrogens (topical): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported and may develop at any time during therapy (reported to occur within minutes…"}, {"doc_id": "promethazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.576274037361145, "bge_max": 0.576274037361145, "title": "Promethazine: Drug information", "rep_snippet": "Dosing: Adult  Allergic conditions, treatment:  Oral, rectal: 25 mg at bedtime or 12.5 mg before meals and at bedtime (usual range: 6.25 to 12.5 mg 3 times daily)  IM, IV: 25 mg, may repeat in 2 hours when necessary; swi…"}, {"doc_id": "estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5720936059951782, "bge_max": 0.5720936059951782, "title": "Estradiol and norethindrone: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported and may develop at any time during therapy. Angioedema involving the face, f…"}, {"doc_id": "equine-conjugated-estrogens-and-medroxyprogesterone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5720936059951782, "bge_max": 0.5720936059951782, "title": "Equine conjugated estrogens and medroxyprogesterone acetate: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported and may develop at any time during therapy. Angioedema involving the face, f…"}, {"doc_id": "estradiol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5720936059951782, "bge_max": 0.5720936059951782, "title": "Estradiol (systemic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported and may develop at any time during therapy. Angioedema involving the face, f…"}, {"doc_id": "mepivacaine-and-levonordefrin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5689244866371155, "bge_max": 0.5689244866371155, "title": "Mepivacaine and levonordefrin: Drug information", "rep_snippet": "Other warnings/precautions:  • Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited…"}, {"doc_id": "prilocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5603726208209991, "bge_max": 0.568820059299469, "title": "Prilocaine: Drug information", "rep_snippet": "• Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absen…"}, {"doc_id": "articaine-and-epinephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5562048355738322, "bge_max": 0.5670117139816284, "title": "Articaine and epinephrine: Drug information", "rep_snippet": "Dosing: Adult  Dental anesthesia: Submucosal infiltration and/or nerve block: Articaine 4%/epinephrine: Note: These dosages are guides only; other dosages may be used; however, do not exceed maximum recommended dose. The…"}, {"doc_id": "carbamide-peroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5668054819107056, "bge_max": 0.5668054819107056, "title": "Carbamide peroxide: Drug information", "rep_snippet": "Dosing: Adult  Ear wax removal: Otic: Instill 5 to 10 drops twice daily up to 4 days.  Mouth, gum, or dental irritation: Oral: Use up to 4 times daily after meals and at bedtime. For direct application, place several dro…"}, {"doc_id": "dexpanthenol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5634276866912842, "bge_max": 0.5634276866912842, "title": "Dexpanthenol (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Dexpanthenol injection has been discontinued in the US for more than 1 year.  Minor dermatoses: Topical: Apply to affected area once or twice daily  Prevention of postoperative paralytic ileus: IM: 2…"}, {"doc_id": "fluoride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5632407069206238, "bge_max": 0.5632407069206238, "title": "Fluoride: Drug information", "rep_snippet": "Dosing: Adult  Cream or paste:  Clinpro 5000 paste, Control Rx 1.1%, Denta 5000 Plus: Once daily, in place of conventional toothpaste, brush teeth with a thin ribbon or pea-sized amount of paste for at least 2 minutes. B…"}, {"doc_id": "solifenacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5613951683044434, "bge_max": 0.5613951683044434, "title": "Solifenacin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema involving the face, lips, tongue, and/or larynx have been reported; some cases have occurred after the first dose. May be life-threaten…"}, {"doc_id": "prilocaine-with-epinephrine-dental-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.560594916343689, "bge_max": 0.560594916343689, "title": "Prilocaine with epinephrine (dental): Drug information", "rep_snippet": "Dosing: Pediatric  Dental anesthesia:  Children <10 years: Doses >40 mg (1 mL) of prilocaine hydrochloride as a 4% solution with epinephrine 1:200,000 are rarely needed for procedures involving a single tooth, in a maxil…"}, {"doc_id": "polysaccharide-iron-complex-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5602709650993347, "bge_max": 0.5602709650993347, "title": "Polysaccharide-iron complex: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Stool discoloration: Oral iron preparations commonly cause dark or black stools; patients should be informed of the effect.  Concurrent drug therapy issues:…"}, {"doc_id": "bupivacaine-and-epinephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5584858059883118, "bge_max": 0.5584858059883118, "title": "Bupivacaine and epinephrine: Drug information", "rep_snippet": "• Test dose: A test dose is recommended prior to epidural administration (prior to initial dose) and all reinforcing doses with continuous catheter technique.  • Trained personnel: Dental practitioners and/or clinicians…"}, {"doc_id": "house-dust-mite-sublingual-tablet-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5537292659282684, "bge_max": 0.5577030777931213, "title": "House dust mite sublingual tablet: Drug information", "rep_snippet": "• Experienced health care provider: Should be administered under the supervision of healthcare providers experienced in the diagnosis and treatment of allergic diseases.  • Monitoring: [US Boxed Warning]: Monitor all pat…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5574979782104492, "bge_max": 0.5574979782104492, "title": "Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "pramoxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5574297904968262, "bge_max": 0.5574297904968262, "title": "Pramoxine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Cream, External, as hydrochloride:  CeraVe Itch Relief: 1% (340 g) [contains cetyl al…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5563817024230957, "bge_max": 0.5563817024230957, "title": "Diazepam: Drug information", "rep_snippet": "Dosing: Adult  Note: Oral absorption is more reliable than IM  Acute ethanol withdrawal:  IV, IM: 10 mg initially; may administer 5 to 10 mg 3 to 4 hours later, if needed  Oral: 10 mg 3 to 4 times during first 24 hours,…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5520144701004028, "bge_max": 0.5520144701004028, "title": "Amoxapine: Drug information", "rep_snippet": "Ioflupane I 123: Amoxapine may diminish the diagnostic effect of Ioflupane I 123. Risk C: Monitor therapy  Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specif…"}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5518280267715454, "bge_max": 0.5518280267715454, "title": "Hydroxyzine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydroxyzine: Pediatric drug information\")  Antiemetic: IM: 1.1 mg/kg/dose  Anxiety: Oral:  Children <6 years: 50 mg/day in divided doses  Children ≥6 years and Adolesce…"}, {"doc_id": "equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5511221885681152, "bge_max": 0.5511221885681152, "title": "Equine serum heptavalent botulism antitoxin (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Delayed allergic reaction: Delayed allergic reaction or serum sickness (eg, arthralgia, fever, lymphadenopathy, myalgia, urticarial or maculopapular rash) may…"}, {"doc_id": "collagenase-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5509953498840332, "bge_max": 0.5509953498840332, "title": "Collagenase (systemic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Severe allergic reactions, including anaphylaxis, may occur in response to administration of foreign proteins (ie, collagenase). H…"}, {"doc_id": "benzocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5509588122367859, "bge_max": 0.5509588122367859, "title": "Benzocaine: Drug information", "rep_snippet": "Administration  Note: Avoid contact with eyes and other mucous membranes. Some spray products may contain flammable ingredients, do not use near fire, flame or heat. Some products may stain certain fabrics; avoid contact…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-recombinant-hepatitis-b-and-inactivated-poliovirus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5489897727966309, "bge_max": 0.5489897727966309, "title": "Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-and-haemophilus-influenzae-type-b-conjugate-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5489897727966309, "bge_max": 0.5489897727966309, "title": "Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b conjugate vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "telmisartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5485098958015442, "bge_max": 0.5485098958015442, "title": "Telmisartan: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially fo…"}, {"doc_id": "valsartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5485098958015442, "bge_max": 0.5485098958015442, "title": "Valsartan and hydrochlorothiazide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially fo…"}, {"doc_id": "olmesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5485098958015442, "bge_max": 0.5485098958015442, "title": "Olmesartan: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially fo…"}, {"doc_id": "amlodipine-olmesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5485098958015442, "bge_max": 0.5485098958015442, "title": "Amlodipine, olmesartan, and hydrochlorothiazide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially fo…"}, {"doc_id": "amlodipine-valsartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5485098958015442, "bge_max": 0.5485098958015442, "title": "Amlodipine, valsartan, and hydrochlorothiazide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially fo…"}, {"doc_id": "telmisartan-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5485098958015442, "bge_max": 0.5485098958015442, "title": "Telmisartan and amlodipine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially fo…"}, {"doc_id": "amlodipine-and-olmesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5485098958015442, "bge_max": 0.5485098958015442, "title": "Amlodipine and olmesartan: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially fo…"}]}
{"qid": "Q15_spelling", "query": "Dent proph for endocarditis — amox dose & pen-allergy options.", "base_qid": "Q15", "variant_type": "spelling", "candidates": [{"doc_id": "cefazolin-drug-information", "bm25_top3": 18.15320956359599, "bm25_max": 23.217298262892786, "bge_top3": 0.6198573708534241, "bge_max": 0.6198573708534241, "title": "Cefazolin: Drug information", "rep_snippet": "Endocarditis, prophylaxis (off-label use): Dental and upper respiratory procedures: Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes before procedure; maximum dose: 1,000 mg (AHA [Wilson 2007]). Note…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 20.354802941098498, "bm25_max": 20.354802941098498, "bge_top3": 0.5539417266845703, "bge_max": 0.5539417266845703, "title": "Amoxicillin: Drug information", "rep_snippet": "Brand Names: Canada  Novamoxin;  Pro-Amox-250;  Pro-Amox-500"}, {"doc_id": "recombinant-human-growth-hormone-somatropin-drug-information", "bm25_top3": 14.127426918797246, "bm25_max": 15.75703270802634, "bge_top3": null, "bge_max": null, "title": "Recombinant human growth hormone (somatropin): Drug information", "rep_snippet": "• Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "exenatide-drug-information", "bm25_top3": 13.597392616005664, "bm25_max": 15.751059982705735, "bge_top3": null, "bge_max": null, "title": "Exenatide: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Auto-injector, Subcutaneous:  Bydureon BCise: 2 mg/0.85 mL (0.85 mL)  Pen-injector, S…"}, {"doc_id": "insulin-nph-drug-information", "bm25_top3": 15.145616487411107, "bm25_max": 15.145616487411107, "bge_top3": null, "bge_max": null, "title": "Insulin NPH: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "adalimumab-including-biosimilars-of-adalimumab-drug-information", "bm25_top3": 14.079456230783524, "bm25_max": 14.921425921631398, "bge_top3": null, "bge_max": null, "title": "Adalimumab (including biosimilars of adalimumab): Drug information", "rep_snippet": "Brand Names: US  Humira;  Humira Pediatric Crohns Start;  Humira Pen;  Humira Pen-Crohns Starter;  Humira Pen-Psoriasis Starter"}, {"doc_id": "follitropin-beta-recombinant-human-follicle-stimulating-hormone-drug-information", "bm25_top3": 7.41787834151095, "bm25_max": 14.427105345815825, "bge_top3": null, "bge_max": null, "title": "Follitropin beta (recombinant human follicle stimulating hormone): Drug information", "rep_snippet": "Note: Dose adjustment for Follistim AQ Cartridge: When administered using the Follistim Pen, the Follistim AQ Cartridge delivers on average 18% more follitropin beta when compared to dissolved lyophilized follitropin bet…"}, {"doc_id": "secukinumab-drug-information", "bm25_top3": 13.544711090284304, "bm25_max": 13.544711090284304, "bge_top3": null, "bge_max": null, "title": "Secukinumab: Drug information", "rep_snippet": "Brand Names: US  Cosentyx;  Cosentyx 300 Dose;  Cosentyx Sensoready 300 Dose;  Cosentyx Sensoready Pen"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": 13.435405815382042, "bm25_max": 13.435405815382042, "bge_top3": 0.6031455000241598, "bge_max": 0.6144630908966064, "title": "Ampicillin: Drug information", "rep_snippet": "Use: Off-Label  Community-acquired pneumonia (children); Endocarditis, prophylaxis; Endocarditis, treatment (HACEK organisms) (adults); Osteomyelitis, native vertebral; Prophylaxis in patients with prosthetic joint impla…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": 13.24115671536171, "bm25_max": 13.24115671536171, "bge_top3": null, "bge_max": null, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Brand Names: Canada  Apo-Pen VK;  Novo-Pen-VK;  Nu-Pen-VK"}, {"doc_id": "loratadine-drug-information", "bm25_top3": 12.963747343668052, "bm25_max": 12.963747343668052, "bge_top3": null, "bge_max": null, "title": "Loratadine: Drug information", "rep_snippet": "Brand Names: US  Alavert [OTC];  Allergy Relief For Kids [OTC] [DSC];  Allergy Relief [OTC];  Allergy [OTC];  Childrens Loratadine [OTC];  Claritin Allergy Childrens [OTC];  Claritin Childrens [OTC];  Claritin Reditabs […"}, {"doc_id": "diphenhydramine-systemic-drug-information", "bm25_top3": 12.959021826959283, "bm25_max": 12.959021826959283, "bge_top3": null, "bge_max": null, "title": "Diphenhydramine (systemic): Drug information", "rep_snippet": "Brand Names: US  Aler-Dryl [OTC];  Allergy Relief Childrens [OTC];  Allergy Relief [OTC];  Altaryl [OTC] [DSC];  Anti-Hist Allergy [OTC];  Banophen [OTC];  Benadryl Allergy Childrens [OTC];  Benadryl Allergy [OTC];  Bena…"}, {"doc_id": "fexofenadine-drug-information", "bm25_top3": 12.864478788865696, "bm25_max": 12.864478788865696, "bge_top3": null, "bge_max": null, "title": "Fexofenadine: Drug information", "rep_snippet": "Brand Names: US  Allegra Allergy Childrens [OTC];  Allegra Allergy [OTC];  Allergy 24-HR [OTC];  Fexofenadine HCl Childrens [OTC];  Mucinex Allergy [OTC]"}, {"doc_id": "cetirizine-systemic-drug-information", "bm25_top3": 12.839854821701337, "bm25_max": 12.839854821701337, "bge_top3": null, "bge_max": null, "title": "Cetirizine (systemic): Drug information", "rep_snippet": "Brand Names: US  All Day Allergy Childrens [OTC];  All Day Allergy [OTC];  Cetirizine HCl Allergy Child [OTC];  Cetirizine HCl Childrens Alrgy [OTC];  Cetirizine HCl Childrens [OTC];  Cetirizine HCl Hives Relief [OTC];…"}, {"doc_id": "triamcinolone-nasal-drug-information", "bm25_top3": 12.830344492773026, "bm25_max": 12.830344492773026, "bge_top3": null, "bge_max": null, "title": "Triamcinolone (nasal): Drug information", "rep_snippet": "Brand Names: US  GoodSense Nasal Allergy Spray [OTC];  Nasacort Allergy 24HR Children [OTC];  Nasacort Allergy 24HR [OTC];  Nasal Allergy 24 Hour [OTC]"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 11.904023508229436, "bm25_max": 11.904023508229436, "bge_top3": 0.5753694375356039, "bge_max": 0.585716724395752, "title": "Vancomycin: Drug information", "rep_snippet": "Use  Clostridium difficile infection (oral): Treatment of C. difficile infection (CDI)  Endocarditis (injection):  Corynebacteria (diphtheroids): Treatment of diphtheroid endocarditis in combination with either rifampin,…"}, {"doc_id": "penicilloyl-polylysine-drug-information", "bm25_top3": 10.730603671007348, "bm25_max": 10.730603671007348, "bge_top3": null, "bge_max": null, "title": "Penicilloyl-polylysine: Drug information", "rep_snippet": "Brand Names: US  Pre-Pen"}, {"doc_id": "follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information", "bm25_top3": 10.411921257141763, "bm25_max": 10.411921257141763, "bge_top3": null, "bge_max": null, "title": "Follitropin alfa (recombinant human follicle stimulating hormone): Drug information", "rep_snippet": "Brand Names: Canada  Gonal-f;  Gonal-f Pen"}, {"doc_id": "insulin-detemir-drug-information", "bm25_top3": 3.934607242692625, "bm25_max": 3.934607242692625, "bge_top3": null, "bge_max": null, "title": "Insulin detemir: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "insulin-nph-and-insulin-regular-drug-information", "bm25_top3": 3.882978263640725, "bm25_max": 3.882978263640725, "bge_top3": null, "bge_max": null, "title": "Insulin NPH and insulin regular: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "semaglutide-drug-information", "bm25_top3": 3.328527181778698, "bm25_max": 3.7990669661792253, "bge_top3": null, "bge_max": null, "title": "Semaglutide: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution Pen-injector, Subcutaneous:  Ozempic: 1 mg per dose [2 mg/1.5 mL] (1.5 mL);…"}, {"doc_id": "insulin-lispro-protamine-and-insulin-lispro-drug-information", "bm25_top3": 3.7810273654808366, "bm25_max": 3.7810273654808366, "bge_top3": null, "bge_max": null, "title": "Insulin lispro protamine and insulin lispro: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "insulin-aspart-protamine-and-insulin-aspart-drug-information", "bm25_top3": 3.7810273654808366, "bm25_max": 3.7810273654808366, "bge_top3": null, "bge_max": null, "title": "Insulin aspart protamine and insulin aspart: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "insulin-glulisine-drug-information", "bm25_top3": 3.771298469007137, "bm25_max": 3.771298469007137, "bge_top3": null, "bge_max": null, "title": "Insulin glulisine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "lixisenatide-drug-information", "bm25_top3": 3.594541778360634, "bm25_max": 3.631284808219764, "bge_top3": null, "bge_max": null, "title": "Lixisenatide: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "insulin-degludec-drug-information", "bm25_top3": 2.4621957499298643, "bm25_max": 3.582197956220977, "bge_top3": null, "bge_max": null, "title": "Insulin degludec: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "insulin-glargine-drug-information", "bm25_top3": 1.2200624365353958, "bm25_max": 3.582197956220977, "bge_top3": null, "bge_max": null, "title": "Insulin glargine: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "insulin-lispro-drug-information", "bm25_top3": 3.092876868183863, "bm25_max": 3.092876868183863, "bge_top3": null, "bge_max": null, "title": "Insulin lispro: Drug information", "rep_snippet": "• Humalog KwikPen devices: Do not perform dose conversion when using KwikPen; the dose window shows the number of units to be delivered and no conversion is needed.  • Humalog U 200 (200 units/mL) KwikPen: Do not transfe…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": 2.891771181088794, "bm25_max": 2.891771181088794, "bge_top3": null, "bge_max": null, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": 2.746961862769247, "bm25_max": 2.746961862769247, "bge_top3": null, "bge_max": null, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Brucellosis; Endocarditis, treatment (viridans group streptococcus [VGS] and S. bovis [native or prosthetic valve]) (adults); Gonococcal infection, uncomplicated (patients with severe cephalosporin allerg…"}, {"doc_id": "insulin-degludec-and-insulin-aspart-drug-information", "bm25_top3": 2.7210461725369655, "bm25_max": 2.7210461725369655, "bge_top3": null, "bge_max": null, "title": "Insulin degludec and insulin aspart: Drug information", "rep_snippet": "• Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of t…"}, {"doc_id": "liraglutide-drug-information", "bm25_top3": 2.376980526464985, "bm25_max": 2.376980526464985, "bge_top3": null, "bge_max": null, "title": "Liraglutide: Drug information", "rep_snippet": "• Gastroparesis: Slows gastric emptying; has not been studied in patients with preexisting gastroparesis.  • Hepatic impairment: Use with caution in patients with hepatic impairment; limited experience.  • Renal impairme…"}, {"doc_id": "iodipamide-meglumine-drug-information", "bm25_top3": 2.190960335592573, "bm25_max": 2.190960335592573, "bge_top3": null, "bge_max": null, "title": "Iodipamide meglumine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Contrast media reactions: Adverse reactions (including delayed reactions) to iodine-containing contrast media have occurred, including serious and life-threat…"}, {"doc_id": "dyphylline-drug-information", "bm25_top3": 1.9342026762348539, "bm25_max": 1.9342026762348539, "bge_top3": null, "bge_max": null, "title": "Dyphylline: Drug information", "rep_snippet": "Brand Names: International  Diprophylline (RU);  Dydilene (KR);  Neophyllin-M (KR)"}, {"doc_id": "iohexol-drug-information", "bm25_top3": 1.8863942993092788, "bm25_max": 1.8863942993092788, "bge_top3": 0.5546181797981262, "bge_max": 0.5546181797981262, "title": "Iohexol: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Contrast media reactions: Adverse reactions (including delayed reactions) to iodine-containing contrast media have occurred. Most cases are minor; however, se…"}, {"doc_id": "recombinant-human-parathyroid-hormone-1-84-drug-information", "bm25_top3": 1.0221176284972096, "bm25_max": 1.0221176284972096, "bge_top3": null, "bge_max": null, "title": "Recombinant human parathyroid hormone (1-84): Drug information", "rep_snippet": "Administration  SubQ: Administer subcutaneously into the thigh (alternate thighs each day) using the provided Q-Cliq pen. Follow instructions provided with the medication cartridges and the Q-Cliq pen to prepare the inje…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.611611545085907, "bge_max": 0.6434990167617798, "title": "Ceftriaxone: Drug information", "rep_snippet": "Endocarditis, prophylaxis (off-label use): Dental and upper respiratory procedures (patients allergic to penicillins and/or unable to take oral): Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes prio…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5735796093940735, "bge_max": 0.5811018943786621, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Kit, Oral:  Entex PAC: Entex S liquid - Dextromethorphan…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5807064175605774, "bge_max": 0.5807064175605774, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Prophylaxis against infective endocarditis (off-label use):  Oral: 600 mg 30 to 60 minutes before procedure with no follow-up dose needed (Wilson 2007)  IM, IV: 600 mg 30 to 60 minutes before procedure. Intramuscular inj…"}, {"doc_id": "metoprolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5785989761352539, "bge_max": 0.5785989761352539, "title": "Metoprolol: Drug information", "rep_snippet": "Use  Angina (oral formulations): Long term treatment of angina pectoris.  Heart failure (extended-release oral formulation): Treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive…"}, {"doc_id": "fentanyl-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772511959075928, "bge_max": 0.5772511959075928, "title": "Fentanyl: Drug information", "rep_snippet": "Additional contraindications for transmucosal buccal tablets (Fentora), buccal films (Onsolis), lozenges (Actiq), sublingual tablets (Abstral), sublingual spray (Subsys), intranasal (Lazanda): Significant respiratory dep…"}, {"doc_id": "testosterone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5754836797714233, "bge_max": 0.5754836797714233, "title": "Testosterone: Drug information", "rep_snippet": "• Pulmonary oil microembolism: Testosterone undecanoate injection: [US Boxed Warning]: Serious pulmonary oil microembolism (POME) reactions and anaphylaxis have been reported with testosterone undecanoate injection. Reac…"}, {"doc_id": "daptomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5658294856548309, "bge_max": 0.5746310949325562, "title": "Daptomycin: Drug information", "rep_snippet": "Dosing: Adult  Diabetic foot infections without osteomyelitis (off-label use): IV: 4 mg/kg once daily (Lipsky 2005)  Endocarditis, treatment: IV:  S. aureus (right-sided, native valve): Note: Clinical trial demonstrating…"}, {"doc_id": "articaine-and-epinephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5660873651504517, "bge_max": 0.5730375647544861, "title": "Articaine and epinephrine: Drug information", "rep_snippet": "Dosing: Adult  Dental anesthesia: Submucosal infiltration and/or nerve block: Articaine 4%/epinephrine: Note: These dosages are guides only; other dosages may be used; however, do not exceed maximum recommended dose. The…"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5658652186393738, "bge_max": 0.5701066255569458, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Dietary Considerations  Advair Diskus powder for oral inhalation contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy."}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5699712038040161, "bge_max": 0.5699712038040161, "title": "Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "benzocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5687890648841858, "bge_max": 0.5687890648841858, "title": "Benzocaine: Drug information", "rep_snippet": "Administration  Note: Avoid contact with eyes and other mucous membranes. Some spray products may contain flammable ingredients, do not use near fire, flame or heat. Some products may stain certain fabrics; avoid contact…"}, {"doc_id": "hyaluronate-derivatives-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5660202503204346, "bge_max": 0.5660202503204346, "title": "Hyaluronate derivatives: Drug information", "rep_snippet": "Dosing: Adult  Surgical aid: Ophthalmic (Amvisc, Amvisc Plus, Provisc): Intraocular: Depends upon procedure (slowly introduce a sufficient quantity into eye)  Osteoarthritis of the knee: Intra-articular:  Durolane: Injec…"}, {"doc_id": "fibrin-sealant-kit-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5647364854812622, "bge_max": 0.5647364854812622, "title": "Fibrin sealant kit: Drug information", "rep_snippet": "Contraindications  Artiss: Hypersensitivity to aprotinin or any component of the formulation (including proteins such as fibrinogen, thrombin, and human albumin); injection directly into the circulatory system or into hi…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5646435022354126, "bge_max": 0.5646435022354126, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Endocarditis, bacterial, treatment: Children and Adolescents: IV: 200,000 to 300,000 units/kg/day in divided doses every 4 hours; maximum daily dose: 24 million units/day; treat for at least 4 weeks; longer durations may…"}, {"doc_id": "epinephrine-adrenaline-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5640904903411865, "bge_max": 0.5640904903411865, "title": "Epinephrine (adrenaline) (systemic): Drug information", "rep_snippet": "Endotracheal: 0.1 mg/kg (0.1 mL/kg of 1 mg/mL solution) (maximum single dose: 2.5 mg) every 3 to 5 minutes as needed until IV/Intraosseous access established. Note: Recent clinical studies suggest that lower epinephrine…"}, {"doc_id": "ketoprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5638759732246399, "bge_max": 0.5638759732246399, "title": "Ketoprofen: Drug information", "rep_snippet": "Dosing: Adult  Note: The enteric coated tablet and extended release formulations are not recommended for the treatment of acute pain. Lower doses should be considered in small or debilitated patients.  Oral:  Ankylosing…"}, {"doc_id": "nitroglycerin-glyceryl-trinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5612100958824158, "bge_max": 0.5612100958824158, "title": "Nitroglycerin (glyceryl trinitrate): Drug information", "rep_snippet": "Adverse Reactions  >10%: Central nervous system: Headache (patch, ointment: 50% to 64%; sublingual powder, lingual spray: >2%)  1% to 10%:  Cardiovascular: Hypotension (≤4%), syncope (≤4%), peripheral edema (lingual spra…"}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5612066984176636, "bge_max": 0.5612066984176636, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Use  Anthrax, prophylaxis: To reduce the incidence of the disease following exposure to aerosolized Bacillus anthracis.  Anthrax, treatment: Treatment of anthrax, including post-exposure inhalational disease due to aeros…"}, {"doc_id": "epoprostenol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5611264705657959, "bge_max": 0.5611264705657959, "title": "Epoprostenol: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Pulmonary edema: Some patients with PAH have developed pulmonary edema during dosing adjustment and acute vasodilator testing (an off-label use), which may be…"}, {"doc_id": "liposomal-amphotericin-b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5600818991661072, "bge_max": 0.5600818991661072, "title": "Liposomal amphotericin B: Drug information", "rep_snippet": "Note: Premedication: For patients who experience nonanaphylactic immediate infusion-related reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal anti-inflammatory…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.559747040271759, "bge_max": 0.559747040271759, "title": "Oxacillin: Drug information", "rep_snippet": "Dosing: Adult  Note: May contain a significant amount of sodium; consult product specific labeling for amount.  Catheter-related bloodstream infections (off-label use): IV: 2 g every 4 hours (Mermel 2009)  Endocarditis,…"}, {"doc_id": "chlorhexidine-gluconate-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5564793050289154, "bge_max": 0.5585734248161316, "title": "Chlorhexidine gluconate (oral): Drug information", "rep_snippet": "Dosing: Adult  Gingivitis: Oral rinse: Swish for 30 seconds with 15 mL (one capful) of undiluted oral rinse after toothbrushing, then expectorate; repeat twice daily (morning and evening). Therapy should be initiated imm…"}, {"doc_id": "brompheniramine-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5585120916366577, "bge_max": 0.5585120916366577, "title": "Brompheniramine, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Brand Names: US  Alahist DM [OTC] [DSC];  AP-Hist DM [OTC];  BPM-DM-Phen [OTC] [DSC];  BroveX PEB DM [OTC];  Cold/Cough Childrens [OTC];  Dimaphen DM Cold/Cough Child [OTC] [DSC];  Dimaphen DM Cold/Cough [OTC];  Dimetapp…"}, {"doc_id": "isosorbide-dinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5584238767623901, "bge_max": 0.5584238767623901, "title": "Isosorbide dinitrate: Drug information", "rep_snippet": "Use  Angina pectoris, prevention: Prevention of angina pectoris due to coronary artery disease.  Note: Due to slower onset of action, isosorbide dinitrate is not the drug of choice to abort an acute anginal episode."}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5581259727478027, "bge_max": 0.5581259727478027, "title": "Clarithromycin: Drug information", "rep_snippet": "Presumed atypical (M. pneumoniae, C. pneumoniae, C. trachomatis) infection, mild-to-severe atypical infection or step-down therapy (alternative to azithromycin): 7.5 mg/kg/dose (maximum dose: 500 mg) every 12 hours (Brad…"}, {"doc_id": "diclofenac-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5580569505691528, "bge_max": 0.5580569505691528, "title": "Diclofenac (systemic): Drug information", "rep_snippet": "Use  Ankylosing spondylitis (delayed-release tablets only): Acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis.  Dysmenorrhea (immediate-release tablets only): Treatment of primary dysme…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5580481290817261, "bge_max": 0.5580481290817261, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Sequential regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, metronidazole 500 mg twice daily, and a standard…"}, {"doc_id": "carbinoxamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.557054340839386, "bge_max": 0.557054340839386, "title": "Carbinoxamine: Drug information", "rep_snippet": "Use  Allergies: For the symptomatic treatment of seasonal and perennial allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis caused by inhalant allergens and foods; mild, uncomplicated allergic skin manifestati…"}, {"doc_id": "lidocaine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5547630786895752, "bge_max": 0.5547630786895752, "title": "Lidocaine (systemic): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type; Adam-Stokes syndrome; Wolff-Parkinson-White syndrome; severe degrees o…"}, {"doc_id": "tocilizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5543097257614136, "bge_max": 0.5543097257614136, "title": "Tocilizumab: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Hypersensitivity (anaphylaxis or other clinically significant hypersensitivity reaction): Stop immediately and discontinue permanently.  Infection (serious infection, opportunistic infect…"}, {"doc_id": "tacrolimus-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5542336702346802, "bge_max": 0.5542336702346802, "title": "Tacrolimus (systemic): Drug information", "rep_snippet": "Use  Organ rejection prophylaxis:  Astagraf XL: Prevention of organ rejection in kidney transplant recipients in combination with other immunosuppressants.  Envarsus XR: Prevention of organ rejection in kidney transplant…"}, {"doc_id": "apomorphine-drug-information", "bm25_top3": 0.5326959650591796, "bm25_max": 0.5326959650591796, "bge_top3": null, "bge_max": null, "title": "Apomorphine: Drug information", "rep_snippet": "Administration  SubQ: For subcutaneous administration only; do not administer IV (thrombus formation or pulmonary embolism may occur due to IV crystallization). Administer in abdomen, upper arm, or upper leg; change site…"}]}
{"qid": "Q16_abbr+CI-cue", "query": "Migraine acute — max daily dose & triptan contraindications (sumatriptan).", "base_qid": "Q16", "variant_type": "abbr+CI-cue", "candidates": [{"doc_id": "sumatriptan-and-naproxen-drug-information", "bm25_top3": 27.272137199666023, "bm25_max": 32.990417236816576, "bge_top3": 0.7068187197049459, "bge_max": 0.7283248901367188, "title": "Sumatriptan and naproxen: Drug information", "rep_snippet": "Dosing: Adult  Note: Use care when prescribing; there are 2 different Treximet tablet strengths available.  Migraine headache: Oral: Sumatriptan 85 mg/naproxen 500 mg. If a satisfactory response has not been obtained at…"}, {"doc_id": "sumatriptan-drug-information", "bm25_top3": 20.37374667767378, "bm25_max": 24.37814040035932, "bge_top3": 0.6815856496493021, "bge_max": 0.7014033794403076, "title": "Sumatriptan: Drug information", "rep_snippet": "Dosing: Adult  Migraine:  Oral: A single dose of 25 mg, 50 mg, or 100 mg (taken with fluids). If a satisfactory response has not been obtained at 2 hours, a second dose may be administered. Results from clinical trials s…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": 9.291498830218373, "bm25_max": 16.928038990797262, "bge_top3": null, "bge_max": null, "title": "Naproxen: Drug information", "rep_snippet": "Naproxen extended-release tablets: Initial: 1,000 to 1,500 mg once daily followed by 1,000 mg once daily until attack subsides  Pain (mild to moderate), dysmenorrhea, acute tendonitis, bursitis: Oral: Initial: 500 mg, fo…"}, {"doc_id": "zolmitriptan-drug-information", "bm25_top3": 8.865144064413041, "bm25_max": 16.765205593535846, "bge_top3": 0.6852839390436808, "bge_max": 0.6928055286407471, "title": "Zolmitriptan: Drug information", "rep_snippet": "Dosing: Adult  Migraine:  Initial dose: Note: Administer at the onset of migraine headache.  Nasal inhalation: 2.5 mg (maximum single dose: 5 mg)  Oral:  Tablet: 1.25 to 2.5 mg (maximum single dose: 5 mg)  Orally disinte…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": 15.898958094370341, "bm25_max": 15.898958094370341, "bge_top3": null, "bge_max": null, "title": "Amitriptyline: Drug information", "rep_snippet": "Irritable bowel syndrome (off-label use): Oral: Initial: 10 to 25 mg daily at bedtime; may increase dose based on response and tolerability up to 75 mg (Rajagopalan 1998; Vahedi 2008).  Migraine prophylaxis (off-label us…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": 8.899279371234522, "bm25_max": 15.024817822117354, "bge_top3": 0.6742639541625977, "bge_max": 0.6742639541625977, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Dosing: Adult  Migraine, cluster headache:  IM, SubQ: 1 mg at first sign of headache; repeat hourly to a maximum dose of 3 mg/day; maximum dose: 6 mg/week  IV: 1 mg at first sign of headache; repeat hourly up to a maximu…"}, {"doc_id": "asenapine-drug-information", "bm25_top3": 14.195344384941514, "bm25_max": 14.195344384941514, "bge_top3": null, "bge_max": null, "title": "Asenapine: Drug information", "rep_snippet": "Dosing: Adult  Schizophrenia: Sublingual: Initial: 5 mg twice daily; may increase to 10 mg twice daily after 1 week based on tolerability; maximum dose: 10 mg twice daily.  Bipolar disorder: Sublingual:  Acute manic or m…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 14.06475140337458, "bm25_max": 14.06475140337458, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Dosing: Adult  Bulimia nervosa (off-label use): Oral: Initial: 25 mg/day for 3 days, then increase in 25 to 50 mg increments every 3 to 5 days based on response and tolerability up to 300 mg/day. Average doses in clinica…"}, {"doc_id": "pizotifen-united-states-not-available-drug-information", "bm25_top3": 13.947422040933617, "bm25_max": 13.947422040933617, "bge_top3": 0.6782821416854858, "bge_max": 0.6835319995880127, "title": "Pizotifen (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Migraine prophylaxis: Oral: Initial: 0.5 mg at bedtime; may increase dose gradually to 1.5 mg daily administered as single dose at bedtime or in 3 divided doses; average maintenance dose: 1.5 mg daily; usu…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 8.18466677735489, "bm25_max": 13.5056694376027, "bge_top3": 0.6744371056556702, "bge_max": 0.6815876960754395, "title": "Naratriptan: Drug information", "rep_snippet": "Dosing: Adult  Note: If the first dose is ineffective, diagnosis needs to be re-evaluated. The safety of treating >4 migraines/month has not been established.  Acute migraine: Oral: Initial: 1 to 2.5 mg; if headache recu…"}, {"doc_id": "vitamin-b2-riboflavin-drug-information", "bm25_top3": 13.237662662657339, "bm25_max": 13.237662662657339, "bge_top3": null, "bge_max": null, "title": "Vitamin B2 (riboflavin): Drug information", "rep_snippet": "Dosing: Adult  Dietary supplement: Oral: 100 mg once or twice daily  Prevention of migraine headache (off-label use): Oral: 400 mg once daily (Rahimdel 2015; Schoenen 1998)"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 13.202117007033413, "bm25_max": 13.202117007033413, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Use: Off-Label  Pericarditis; Acute migraine headache; Ankylosing spondylitis; Cystic fibrosis; Gout; Juvenile idiopathic arthritis; Migraine prophylaxis"}, {"doc_id": "rucaparib-drug-information", "bm25_top3": 12.182678472200328, "bm25_max": 12.182678472200328, "bge_top3": null, "bge_max": null, "title": "Rucaparib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Consider therapy interruption or dose reduction if adverse events occur.  Recommended rucaparib dose reductions:  Starting dose: 600 mg twice daily  1st dose reduction: 500 mg twice daily…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 12.123691305829462, "bm25_max": 12.123691305829462, "bge_top3": null, "bge_max": null, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Brand Names: US  CCP Caffeine Free [OTC] [DSC];  GoodSense Cold & Head Congest [OTC];  GoodSense Pressure/Pain/Mucus [OTC];  GoodSense Sinus Relief Max St [OTC];  GoodSense Sinus Severe Daytime [OTC];  Mucinex Fast-Max C…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 11.150873052184043, "bm25_max": 11.150873052184043, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefdinir: Pediatric drug information\")  Infants ≥6 months and Children:  Acute bacterial otitis media, pharyngitis/tonsillitis: Oral: 7 mg/kg/dose twice daily for 5 to…"}, {"doc_id": "almotriptan-drug-information", "bm25_top3": 6.53497280036677, "bm25_max": 10.960605475514889, "bge_top3": 0.6991009910901388, "bge_max": 0.7101309299468994, "title": "Almotriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for treatment of acute migraine; it is not indicated for migraine prophylaxis, or for the treatment of cluster headaches, hemiplegic migraine, or basilar migraine. If a patient does not…"}, {"doc_id": "frovatriptan-drug-information", "bm25_top3": 4.762765534324274, "bm25_max": 8.671957525702553, "bge_top3": 0.672364334265391, "bge_max": 0.6782456636428833, "title": "Frovatriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for treatment of acute migraine; it is not indicated for migraine prophylaxis, or for the treatment of cluster headaches, hemiplegic or basilar migraine. If a patient does not respond to…"}, {"doc_id": "eletriptan-drug-information", "bm25_top3": 4.323955999127932, "bm25_max": 7.79433845530987, "bge_top3": 0.7018955945968628, "bge_max": 0.7280430793762207, "title": "Eletriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for treatment of acute migraine; not indicated for migraine prophylaxis, or for the treatment of cluster headache, hemiplegic or basilar migraine. If a patient does not respond to the fi…"}, {"doc_id": "rizatriptan-drug-information", "bm25_top3": 3.911081788828424, "bm25_max": 4.897255872958532, "bge_top3": 0.6897306442260742, "bge_max": 0.7016696929931641, "title": "Rizatriptan: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to rizatriptan or any component of the formulation; documented ischemic heart disease or other significant cardiovascular disease; coronary artery vasospasm (including Prinzmetal angin…"}, {"doc_id": "diclofenac-systemic-drug-information", "bm25_top3": 4.863619708923629, "bm25_max": 4.863619708923629, "bge_top3": 0.658720850944519, "bge_max": 0.658720850944519, "title": "Diclofenac (systemic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "fentanyl-drug-information", "bm25_top3": 4.677487932652209, "bm25_max": 4.677487932652209, "bge_top3": null, "bge_max": null, "title": "Fentanyl: Drug information", "rep_snippet": "Additional contraindications for transmucosal buccal tablets (Fentora), buccal films (Onsolis), lozenges (Actiq), sublingual tablets (Abstral), sublingual spray (Subsys), intranasal (Lazanda): Significant respiratory dep…"}, {"doc_id": "flunarizine-united-states-not-available-drug-information", "bm25_top3": -0.5794440119321855, "bm25_max": -0.5794440119321855, "bge_top3": 0.6730516850948334, "bge_max": 0.6798475980758667, "title": "Flunarizine (United States: Not available): Drug information", "rep_snippet": "Use  Note: Not approved in the US  Migraine: Prophylaxis of migraine (with and without aura) in patients with frequent and severe attacks, who have not responded satisfactorily to other treatments, and/or do not tolerate…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6674026250839233, "bge_max": 0.6674026250839233, "title": "Maprotiline: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to maprotiline or any component of the formulation; seizure disorder; use of MAO inhibitors (concurrently or within 14 days of discontinuing either maprotiline or the MAO inhibitor); u…"}, {"doc_id": "liposomal-morphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6586015820503235, "bge_max": 0.6586015820503235, "title": "Liposomal morphine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to morphine, morphine salts or any component of the formulation; respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected paralytic ileus;…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6578730344772339, "bge_max": 0.6578730344772339, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Rifampin (rifampicin): Pediatric drug information\")  Tuberculosis, active (drug-susceptible) (excludes meningitis): Oral, IV: Use as part of a multidrug regimen:  Manuf…"}, {"doc_id": "acetaminophen-paracetamol-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6570405960083008, "bge_max": 0.6570405960083008, "title": "Acetaminophen (paracetamol), aspirin, and caffeine: Drug information", "rep_snippet": "Dosing: Adult  Minor aches and pain: Oral:  Acetaminophen 194 mg/aspirin 227 mg/caffeine 33 mg: Two tablets every 6 hours as needed (maximum: 8 tablets per 24 hours)  Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: T…"}, {"doc_id": "altretamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6553499698638916, "bge_max": 0.6553499698638916, "title": "Altretamine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to altretamine or any component of the formulation; preexisting severe bone marrow suppression or severe neurologic toxicity"}, {"doc_id": "butalbital-acetaminophen-paracetamol-caffeine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6521148681640625, "bge_max": 0.6521148681640625, "title": "Butalbital, acetaminophen (paracetamol), caffeine, and codeine: Drug information", "rep_snippet": "Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen."}, {"doc_id": "pentazocine-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6521148681640625, "bge_max": 0.6521148681640625, "title": "Pentazocine and acetaminophen (paracetamol): Drug information", "rep_snippet": "Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen."}, {"doc_id": "methacholine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6518826484680176, "bge_max": 0.6518826484680176, "title": "Methacholine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to methacholine, other parasympathomimetic agents, or any component of the formulation; repeat administration (other than on the day of challenge with increasing doses); coadministrati…"}, {"doc_id": "morphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6518053412437439, "bge_max": 0.6518053412437439, "title": "Morphine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity (eg, anaphylaxis) to morphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of r…"}, {"doc_id": "anthralin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.651043176651001, "bge_max": 0.651043176651001, "title": "Anthralin: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to anthralin or any component of the formulation; acute psoriasis (acutely or actively inflamed psoriatic eruptions)"}, {"doc_id": "fenoterol-and-ipratropium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6501539945602417, "bge_max": 0.6501539945602417, "title": "Fenoterol and ipratropium (United States: Not available): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to ipratropium, fenoterol, sympathomimetic amines, atropine (and its derivatives), or any component of the formulation; tachyarrhythmias; hypertrophic obstructive cardiomyopathy"}, {"doc_id": "corticotropin-injection-gel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6501467823982239, "bge_max": 0.6501467823982239, "title": "Corticotropin injection gel: Drug information", "rep_snippet": "Dosing: Adult  Note: Sudden withdrawal may lead to adrenal insufficiency or recurrent symptoms; tapering the dose prior to discontinuation may be necessary following prolonged administration.  Acute exacerbation of multi…"}, {"doc_id": "reserpine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6497581005096436, "bge_max": 0.6497581005096436, "title": "Reserpine (United States: not available): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to reserpine or any component of the formulation; active peptic ulcer disease, ulcerative colitis; history of mental depression (especially with suicidal tendencies); patients receivin…"}, {"doc_id": "mirtazapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6495634913444519, "bge_max": 0.6495634913444519, "title": "Mirtazapine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to mirtazapine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either mirtazapine or…"}]}
{"qid": "Q16_noise", "query": "For a migraine attack, what’s sumatriptan max/day and key CIs?", "base_qid": "Q16", "variant_type": "noise", "candidates": [{"doc_id": "sumatriptan-and-naproxen-drug-information", "bm25_top3": 25.612791035068916, "bm25_max": 29.305583101599613, "bge_top3": 0.6349625587463379, "bge_max": 0.6587850451469421, "title": "Sumatriptan and naproxen: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Sumatriptan and naproxen: Pediatric drug information\")  Note: Use care when prescribing; there are 2 different Treximet tablet strengths available.  Migraine headache:…"}, {"doc_id": "sumatriptan-drug-information", "bm25_top3": 19.566074083409262, "bm25_max": 21.054410406407893, "bge_top3": 0.6382061441739401, "bge_max": 0.6710848808288574, "title": "Sumatriptan: Drug information", "rep_snippet": "An analysis of data collected between 1995 and 2008 using the Swedish Medical Birth Register reported pregnancy outcomes following 5-HT1B/1D agonist exposure. An increased risk of major congenital malformations was not o…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": 18.514657331325594, "bm25_max": 18.514657331325594, "bge_top3": null, "bge_max": null, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Brand Names: International  Ibalgin Grip (CZ);  Lemsip Max All Day Cold & Flu (GB);  Lemsip Max All Day Flu Relief (GB);  Lemsip Max All Night Cold & Flu (GB);  Lemsip Max All Night Flu Relief (GB);  Nurofen Sinus Pain R…"}, {"doc_id": "lidocaine-topical-drug-information", "bm25_top3": 17.803805075971102, "bm25_max": 17.803805075971102, "bge_top3": null, "bge_max": null, "title": "Lidocaine (topical): Drug information", "rep_snippet": "Dosage Forms Considerations  EnovaRX-Lidocaine, and Lidtopic Max creams are compounded from kits. Refer to manufacturer’s package insert for compounding instructions."}, {"doc_id": "naproxen-drug-information", "bm25_top3": 14.726186886364044, "bm25_max": 14.726186886364044, "bge_top3": 0.5808981657028198, "bge_max": 0.5808981657028198, "title": "Naproxen: Drug information", "rep_snippet": "Naproxen extended-release tablets: Initial: 1,000 to 1,500 mg once daily followed by 1,000 mg once daily until attack subsides  Pain (mild to moderate), dysmenorrhea, acute tendonitis, bursitis: Oral: Initial: 500 mg, fo…"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": 14.6311397647084, "bm25_max": 14.6311397647084, "bge_top3": 0.5881781578063965, "bge_max": 0.5881781578063965, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 14.623691305829462, "bm25_max": 14.623691305829462, "bge_top3": null, "bge_max": null, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Brand Names: US  CCP Caffeine Free [OTC] [DSC];  GoodSense Cold & Head Congest [OTC];  GoodSense Pressure/Pain/Mucus [OTC];  GoodSense Sinus Relief Max St [OTC];  GoodSense Sinus Severe Daytime [OTC];  Mucinex Fast-Max C…"}, {"doc_id": "glecaprevir-and-pibrentasvir-drug-information", "bm25_top3": 14.557631887326432, "bm25_max": 14.557631887326432, "bge_top3": null, "bge_max": null, "title": "Glecaprevir and pibrentasvir: Drug information", "rep_snippet": "HMG-CoA Reductase Inhibitors (Statins): Glecaprevir and Pibrentasvir may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with glecap…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 14.445524702397451, "bm25_max": 14.445524702397451, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Brand Names: US  Alka-Seltzer Plus Day Cold [OTC];  Comtrex Maximum Strength, Non-Drowsy Cold & Cough [OTC];  GoodSense Daytime Cold & Flu [OTC];  GoodSense Daytime Flu & Severe Cold [OTC];  GoodSense Daytime [OTC];  Goo…"}, {"doc_id": "eculizumab-drug-information", "bm25_top3": 8.92752464849385, "bm25_max": 8.92752464849385, "bge_top3": null, "bge_max": null, "title": "Eculizumab: Drug information", "rep_snippet": "Mechanism of Action  Eculizumab is a humanized monoclonal IgG antibody that binds to complement protein C5, preventing cleavage into C5a and C5b. Blocking the formation of C5b inhibits the subsequent formation of termina…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 6.479632662412903, "bm25_max": 8.182363282732911, "bge_top3": 0.5909133553504944, "bge_max": 0.5909133553504944, "title": "Naratriptan: Drug information", "rep_snippet": "Pregnancy Implications  Pregnancy outcome information for naratriptan is available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 57 infants/fetuses exposed to narat…"}, {"doc_id": "zolmitriptan-drug-information", "bm25_top3": 7.082402426947514, "bm25_max": 7.082402426947514, "bge_top3": 0.6015130281448364, "bge_max": 0.6214388608932495, "title": "Zolmitriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for acute treatment of migraine headache; not indicated for migraine prophylaxis (used off-label for menstrual migraine prophylaxis) or for the treatment of cluster headache. Acute migra…"}, {"doc_id": "zuclopenthixol-united-states-not-available-drug-information", "bm25_top3": 6.7915003348784335, "bm25_max": 6.7915003348784335, "bge_top3": 0.590108335018158, "bge_max": 0.590108335018158, "title": "Zuclopenthixol (United States: Not available): Drug information", "rep_snippet": "Mechanism of Action  Zuclopenthixol is a thioxanthene antipsychotic with a piperazine side chain; related to fluphenazine, the cis(z)-clopenthixol is the active isomer of this neuroleptic; blocks postsynaptic dopaminergi…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": 5.939661516722368, "bm25_max": 6.527911943170398, "bge_top3": 0.6511621475219727, "bge_max": 0.6511621475219727, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Administration  Intranasal: Prior to administration of nasal spray, the nasal spray applicator must be primed (pumped 4 times); in order to let the drug be absorbed through the skin in the nose, patients should not inhal…"}, {"doc_id": "vardenafil-drug-information", "bm25_top3": 6.05850191015473, "bm25_max": 6.05850191015473, "bge_top3": null, "bge_max": null, "title": "Vardenafil: Drug information", "rep_snippet": "Itraconazole: May increase the serum concentration of Vardenafil. Management: Limit vardenafil to a max of 5 mg/24 hours in patients receiving itraconazole 200 mg/day, and a max of 2.5 mg/24 hours in patients receiving i…"}, {"doc_id": "entacapone-drug-information", "bm25_top3": 5.879708405392771, "bm25_max": 5.879708405392771, "bge_top3": null, "bge_max": null, "title": "Entacapone: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: Rapid  Absorption: Rapid  Distribution: IV: Vdss: 20 L  Protein binding: 98%, primarily to albumin  Metabolism: Isomerization to the cis-isomer, followed by direct glucuronidat…"}, {"doc_id": "atovaquone-drug-information", "bm25_top3": 5.640844518316541, "bm25_max": 5.640844518316541, "bge_top3": null, "bge_max": null, "title": "Atovaquone: Drug information", "rep_snippet": "Mechanism of Action  Inhibits electron transport in mitochondria resulting in the inhibition of key metabolic enzymes responsible for the synthesis of nucleic acids and ATP"}, {"doc_id": "terbinafine-topical-drug-information", "bm25_top3": 5.602596563226921, "bm25_max": 5.602596563226921, "bge_top3": null, "bge_max": null, "title": "Terbinafine (topical): Drug information", "rep_snippet": "Mechanism of Action  Synthetic allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell membrane and results…"}, {"doc_id": "terbinafine-systemic-drug-information", "bm25_top3": 5.602596563226921, "bm25_max": 5.602596563226921, "bge_top3": null, "bge_max": null, "title": "Terbinafine (systemic): Drug information", "rep_snippet": "Mechanism of Action  Synthetic allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell membrane and results…"}, {"doc_id": "frovatriptan-drug-information", "bm25_top3": 5.1026332079937164, "bm25_max": 5.359500870907988, "bge_top3": 0.5902302265167236, "bge_max": 0.5902302265167236, "title": "Frovatriptan: Drug information", "rep_snippet": "• Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke (some fatal) have been reported with 5-HT1 agonist administration. Use is contraindicated in patients with a history of stroke or transient ischemic a…"}, {"doc_id": "almotriptan-drug-information", "bm25_top3": 5.134163206217717, "bm25_max": 5.333630366408816, "bge_top3": 0.6122822761535645, "bge_max": 0.6122822761535645, "title": "Almotriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for treatment of acute migraine; it is not indicated for migraine prophylaxis, or for the treatment of cluster headaches, hemiplegic migraine, or basilar migraine. If a patient does not…"}, {"doc_id": "cisplatin-drug-information", "bm25_top3": 5.290871275157626, "bm25_max": 5.290871275157626, "bge_top3": null, "bge_max": null, "title": "Cisplatin: Drug information", "rep_snippet": "Mechanism of Action  Inhibits DNA synthesis by the formation of DNA cross-links; denatures the double helix; covalently binds to DNA bases and disrupts DNA function; may also bind to proteins; the cis-isomer is 14 times…"}, {"doc_id": "eletriptan-drug-information", "bm25_top3": 4.890415900474723, "bm25_max": 4.890415900474723, "bge_top3": 0.5941795706748962, "bge_max": 0.5978645086288452, "title": "Eletriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for treatment of acute migraine; not indicated for migraine prophylaxis, or for the treatment of cluster headache, hemiplegic or basilar migraine. If a patient does not respond to the fi…"}, {"doc_id": "dinutuximab-drug-information", "bm25_top3": 4.812535881342912, "bm25_max": 4.812535881342912, "bge_top3": null, "bge_max": null, "title": "Dinutuximab: Drug information", "rep_snippet": "Use  Neuroblastoma: Treatment of high-risk neuroblastoma (in combination with granulocyte-macrophage colony-stimulating factor [GM-CSF; sargramostim], interleukin-2 [IL-2; aldesleukin] and 13-cis-retinoic acid [RA; isotr…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 4.629623793884406, "bm25_max": 4.629623793884406, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Dosing: Adult  Bulimia nervosa (off-label use): Oral: Initial: 25 mg/day for 3 days, then increase in 25 to 50 mg increments every 3 to 5 days based on response and tolerability up to 300 mg/day. Average doses in clinica…"}, {"doc_id": "rizatriptan-drug-information", "bm25_top3": 4.523992277640664, "bm25_max": 4.523992277640664, "bge_top3": 0.5896355708440145, "bge_max": 0.601893961429596, "title": "Rizatriptan: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to rizatriptan or any component of the formulation; documented ischemic heart disease or other significant cardiovascular disease; coronary artery vasospasm (including Prinzmetal angin…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 4.317584737638338, "bm25_max": 4.317584737638338, "bge_top3": null, "bge_max": null, "title": "Itraconazole: Drug information", "rep_snippet": "Ulipristal: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal. Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 4.1241307366775395, "bm25_max": 4.1241307366775395, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "• Patient education: [US Boxed Warning]: When used for the termination of pregnancy, patient must be instructed of the treatment procedure and expected effects. A signed agreement form must be kept in the patient's file.…"}, {"doc_id": "dasatinib-drug-information", "bm25_top3": 3.890215183277162, "bm25_max": 3.890215183277162, "bge_top3": null, "bge_max": null, "title": "Dasatinib: Drug information", "rep_snippet": "Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Manage…"}, {"doc_id": "isavuconazole-isavuconazonium-sulfate-drug-information", "bm25_top3": 3.717853630956734, "bm25_max": 3.717853630956734, "bge_top3": null, "bge_max": null, "title": "Isavuconazole (isavuconazonium sulfate): Drug information", "rep_snippet": "Mechanism of Action  Isavuconazonium sulfate is a prodrug that is rapidly hydrolyzed in the blood to active isavuconazole. Isavuconazole inhibits the synthesis of ergosterol, a key component of the fungal cell membrane,…"}, {"doc_id": "allopurinol-drug-information", "bm25_top3": 3.6946689773495525, "bm25_max": 3.6946689773495525, "bge_top3": null, "bge_max": null, "title": "Allopurinol: Drug information", "rep_snippet": "Dosing: Adult  Note: Oral doses >300 mg should be given in divided doses.  Gout: Oral:  Manufacturer’s labeling: Initial: 100 mg once daily; increase at weekly intervals in increments of 100 mg/day as needed to achieve d…"}, {"doc_id": "acitretin-drug-information", "bm25_top3": 3.527915520766097, "bm25_max": 3.527915520766097, "bge_top3": null, "bge_max": null, "title": "Acitretin: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Etretinate has been detected in serum for up to 3 years following therapy, possibly due to storage in adipose tissue.  Onset of action: May take 2 to 3 months for full effect; improvement may b…"}, {"doc_id": "onabotulinumtoxina-botox-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6173999309539795, "bge_max": 0.6173999309539795, "title": "OnabotulinumtoxinA (Botox): Drug information", "rep_snippet": "Chronic migraine: IM: Administer 5 units/0.1 mL per site. Recommended total dose is 155 units once every 12 weeks. Each 155 unit dose should be equally divided and administered bilaterally, into 31 total sites as describ…"}, {"doc_id": "penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5915806889533997, "bge_max": 0.5915806889533997, "title": "Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Drug information", "rep_snippet": "Dosing: Adult  Note: Bicillin C-R 900/300 is only indicated in pediatric patients.  Pneumococcal infections (except meningitis): IM: 1.2 million units on day 1; may be repeated every 2 or 3 days until afebrile for 48 hou…"}, {"doc_id": "acetaminophen-paracetamol-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5901087522506714, "bge_max": 0.5915060043334961, "title": "Acetaminophen (paracetamol), aspirin, and caffeine: Drug information", "rep_snippet": "Dosing: Adult  Minor aches and pain: Oral:  Acetaminophen 194 mg/aspirin 227 mg/caffeine 33 mg: Two tablets every 6 hours as needed (maximum: 8 tablets per 24 hours)  Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: T…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5906859040260315, "bge_max": 0.5906859040260315, "title": "Ibuprofen: Drug information", "rep_snippet": "Osteoarthritis: Oral: 400 to 800 mg 3 to 4 times daily (maximum: 3,200 mg/day)  Rheumatoid arthritis: Oral: 400 to 800 mg 3 to 4 times daily (maximum: 3,200 mg/day)  OTC labeling:  Analgesic, antipyretic: Oral: 200 mg ev…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5894078612327576, "bge_max": 0.5894078612327576, "title": "Ergotamine: Drug information", "rep_snippet": "Dosing: Adult  Vascular headache: Sublingual: 2 mg (1 tablet) under tongue at first sign of migraine, then 2 mg every 30 minutes if needed; maximum dose: 6 mg per 24 hours, 10 mg per week"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5873962044715881, "bge_max": 0.5873962044715881, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Dosing: Adult  Unasyn (ampicillin/sulbactam) is a combination product. Note: Dosage recommendations are expressed as grams of ampicillin/sulbactam combination.  Susceptible infections: IM, IV: 1.5 to 3 g every 6 hours (m…"}, {"doc_id": "propranolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5871090292930603, "bge_max": 0.5871090292930603, "title": "Propranolol: Drug information", "rep_snippet": "Dosing: Adult  Essential tremor: Oral: Immediate-release formulations: 40 mg twice daily initially; maintenance doses: Usually 120 to 320 mg/day  Hypertension: Oral:  Immediate-release formulations: 40 mg twice daily; in…"}, {"doc_id": "quetiapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.586516797542572, "bge_max": 0.586516797542572, "title": "Quetiapine: Drug information", "rep_snippet": "Clarithromycin: May enhance the QTc-prolonging effect of QUEtiapine. Clarithromycin may increase the serum concentration of QUEtiapine. Risk X: Avoid combination  CNS Depressants: May enhance the adverse/toxic effect of…"}, {"doc_id": "saquinavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5810351371765137, "bge_max": 0.5838057994842529, "title": "Saquinavir: Drug information", "rep_snippet": "Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan. Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CY…"}, {"doc_id": "penicillin-g-benzathine-long-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5835784077644348, "bge_max": 0.5835784077644348, "title": "Penicillin G benzathine (long-acting intramuscular): Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: IM: 1.2 to 2.4 million units as a single dose  Upper respiratory infection, group A streptococci: IM: 1.2 million units as a single dose  Secondary prevention of glomerulonephritis: 1.2…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5832564234733582, "bge_max": 0.5832564234733582, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "CYP3A4 Inhibitors (Strong): May increase the serum concentration of SAXagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhib…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5802417993545532, "bge_max": 0.5805050730705261, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan. Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CY…"}, {"doc_id": "isosorbide-dinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.580080509185791, "bge_max": 0.580080509185791, "title": "Isosorbide dinitrate: Drug information", "rep_snippet": "Dosing: Adult  Angina pectoris (prevention): Note: Due to slower onset of action, isosorbide dinitrate is not the drug of choice to abort an acute anginal episode. Tolerance to nitrate effects develops with chronic expos…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5799693465232849, "bge_max": 0.5799693465232849, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong…"}, {"doc_id": "suvorexant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5782542824745178, "bge_max": 0.5782542824745178, "title": "Suvorexant: Drug information", "rep_snippet": "Dosing: Adult  Insomnia: Oral: Note: Use the lowest effective dose for the patient. Usual dose: 10 mg once daily within 30 minutes of bedtime; may increase to a maximum of 20 mg once daily if the 10 mg dose is well toler…"}, {"doc_id": "acetaminophen-paracetamol-isometheptene-and-dichloralphenazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5781829953193665, "bge_max": 0.5781829953193665, "title": "Acetaminophen (paracetamol), isometheptene, and dichloralphenazone: Drug information", "rep_snippet": "Dosing: Adult  Migraine headache: Oral: Two capsules to start, followed by 1 capsule every hour until relief is obtained (maximum: 5 capsules/12 hours)  Tension headache: Oral: 1 to 2 capsules every 4 hours (maximum: 8 c…"}, {"doc_id": "pizotifen-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5781762003898621, "bge_max": 0.5781762003898621, "title": "Pizotifen (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Migraine prophylaxis: Oral: Initial: 0.5 mg at bedtime; may increase dose gradually to 1.5 mg daily administered as single dose at bedtime or in 3 divided doses; average maintenance dose: 1.5 mg daily; usu…"}, {"doc_id": "sildenafil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.577796995639801, "bge_max": 0.577796995639801, "title": "Sildenafil: Drug information", "rep_snippet": "Protease Inhibitors: May increase the serum concentration of Sildenafil. Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5776370167732239, "bge_max": 0.5776370167732239, "title": "Darunavir: Drug information", "rep_snippet": "Levomilnacipran: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran. Management: Do not exceed a maximum adult levomilnacipran dose of 80 mg/day in patients also receiving strong CYP3A4 in…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.577479898929596, "bge_max": 0.577479898929596, "title": "Ritonavir: Drug information", "rep_snippet": "Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib. Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors. Risk D: Consider…"}]}
{"qid": "Q16_spelling", "query": "Migrane tx — sumatriptan daily max + contrainidcations.", "base_qid": "Q16", "variant_type": "spelling", "candidates": [{"doc_id": "sumatriptan-and-naproxen-drug-information", "bm25_top3": 18.189150017032663, "bm25_max": 20.305584102618205, "bge_top3": 0.6753282944361368, "bge_max": 0.7082706093788147, "title": "Sumatriptan and naproxen: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Sumatriptan and naproxen: Pediatric drug information\")  Note: Use care when prescribing; there are 2 different Treximet tablet strengths available.  Migraine headache:…"}, {"doc_id": "sumatriptan-drug-information", "bm25_top3": 16.09532697008588, "bm25_max": 16.882977475606097, "bge_top3": 0.6400406956672668, "bge_max": 0.6746519804000854, "title": "Sumatriptan: Drug information", "rep_snippet": "An analysis of data collected between 1995 and 2008 using the Swedish Medical Birth Register reported pregnancy outcomes following 5-HT1B/1D agonist exposure. An increased risk of major congenital malformations was not o…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": 13.126046751658093, "bm25_max": 14.623691305829462, "bge_top3": null, "bge_max": null, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Brand Names: US  CCP Caffeine Free [OTC] [DSC];  GoodSense Cold & Head Congest [OTC];  GoodSense Pressure/Pain/Mucus [OTC];  GoodSense Sinus Relief Max St [OTC];  GoodSense Sinus Severe Daytime [OTC];  Mucinex Fast-Max C…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": 14.061956487994381, "bm25_max": 14.061956487994381, "bge_top3": null, "bge_max": null, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Brand Names: International  Ibalgin Grip (CZ);  Lemsip Max All Day Cold & Flu (GB);  Lemsip Max All Day Flu Relief (GB);  Lemsip Max All Night Cold & Flu (GB);  Lemsip Max All Night Flu Relief (GB);  Nurofen Sinus Pain R…"}, {"doc_id": "phenylephrine-and-pramoxine-drug-information", "bm25_top3": 12.709894708083159, "bm25_max": 12.709894708083159, "bge_top3": null, "bge_max": null, "title": "Phenylephrine and pramoxine: Drug information", "rep_snippet": "Brand Names: International  Preparation H Max (MX)"}, {"doc_id": "acetaminophen-paracetamol-and-phenylephrine-drug-information", "bm25_top3": 12.629665831859981, "bm25_max": 12.629665831859981, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol) and phenylephrine: Drug information", "rep_snippet": "Brand Names: International  Amcal Cold & Flu Relief Hot Drink (AU);  Amcal Sinus Pain Relief PE (AU);  Apracur Te Decongestivo (AR);  Beechams Cold & Flu Hot Lemon (MT);  Chemists' Own Sinus Pain Relief PE (AU);  Coldrex…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 11.92465815268298, "bm25_max": 11.97823733668013, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Pricing: US  Capsules (Mucinex Fast-Max Cold & Sinus Oral)  10-5-325 mg (16): $11.38  Capsules (Mucinex Fast-Max Cong Headache Oral)  10-5-325 mg (16): $12.41  Capsules (Robitussin Cold+Flu Daytime Oral)  10-5-325 mg (20…"}, {"doc_id": "famotidine-drug-information", "bm25_top3": 11.527206886993783, "bm25_max": 11.527206886993783, "bge_top3": null, "bge_max": null, "title": "Famotidine: Drug information", "rep_snippet": "Brand Names: US  Acid Reducer Maximum Strength [OTC];  Acid Reducer [OTC];  Heartburn Relief Max St [OTC];  Heartburn Relief [OTC];  Pepcid"}, {"doc_id": "pseudoephedrine-drug-information", "bm25_top3": 11.472951420986034, "bm25_max": 11.472951420986034, "bge_top3": null, "bge_max": null, "title": "Pseudoephedrine: Drug information", "rep_snippet": "Brand Names: US  Childrens Silfedrine [OTC];  Decongestant 12Hour Max St [OTC];  ElixSure Congestion [OTC] [DSC];  Genaphed [OTC];  Nasal Decongestant [OTC];  Nexafed [OTC];  Psudatabs [OTC] [DSC];  Shopko Nasal Deconges…"}, {"doc_id": "lidocaine-topical-drug-information", "bm25_top3": 11.368051682545039, "bm25_max": 11.368051682545039, "bge_top3": null, "bge_max": null, "title": "Lidocaine (topical): Drug information", "rep_snippet": "Dosage Forms Considerations  EnovaRX-Lidocaine, and Lidtopic Max creams are compounded from kits. Refer to manufacturer’s package insert for compounding instructions."}, {"doc_id": "oxymetazoline-nasal-drug-information", "bm25_top3": 11.023920627117674, "bm25_max": 11.023920627117674, "bge_top3": null, "bge_max": null, "title": "Oxymetazoline (nasal): Drug information", "rep_snippet": "Brand Names: US  12 Hour Nasal Relief Spray [OTC];  12 Hour Nasal Spray [OTC];  Afrin 12 Hour [OTC];  Afrin Extra Moisturizing [OTC] [DSC];  Afrin Menthol Spray [OTC];  Afrin Nasal Spray [OTC];  Afrin NoDrip Extra Moistu…"}, {"doc_id": "zolmitriptan-drug-information", "bm25_top3": 1.9092425210604909, "bm25_max": 3.219413760768836, "bge_top3": 0.6340766549110413, "bge_max": 0.6516335010528564, "title": "Zolmitriptan: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  ZOLMitriptan may be confused with SUMAtriptan"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 1.4292407300886039, "bm25_max": 2.958797658375815, "bge_top3": null, "bge_max": null, "title": "Naratriptan: Drug information", "rep_snippet": "Pregnancy Implications  Pregnancy outcome information for naratriptan is available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 57 infants/fetuses exposed to narat…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": 1.89670402686715, "bm25_max": 2.8375336728486573, "bge_top3": null, "bge_max": null, "title": "Amitriptyline: Drug information", "rep_snippet": "Irritable bowel syndrome (off-label use): Oral: Initial: 10 to 25 mg daily at bedtime; may increase dose based on response and tolerability up to 75 mg (Rajagopalan 1998; Vahedi 2008).  Migraine prophylaxis (off-label us…"}, {"doc_id": "lanreotide-drug-information", "bm25_top3": 2.3084403920160153, "bm25_max": 2.3084403920160153, "bge_top3": null, "bge_max": null, "title": "Lanreotide: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Lanreotide may be confused with octreotide, pasireotide  Somatuline may be confused with Soma, somatropin, SUMAtriptan"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 1.947599404959174, "bm25_max": 1.947599404959174, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Dosing: Adult  Bulimia nervosa (off-label use): Oral: Initial: 25 mg/day for 3 days, then increase in 25 to 50 mg increments every 3 to 5 days based on response and tolerability up to 300 mg/day. Average doses in clinica…"}, {"doc_id": "nadroparin-united-states-not-available-drug-information", "bm25_top3": 1.4148961365821737, "bm25_max": 1.4148961365821737, "bge_top3": null, "bge_max": null, "title": "Nadroparin (United States: Not available): Drug information", "rep_snippet": "Brand Names: International  Fraksyparyn (UA);  Fraxiparin (AT, DE, KW);  Fraxiparina (BR, ES, IT, PT, VE);  Fraxiparine (AE, AR, AU, BE, BG, BH, CH, CL, CN, CR, CU, CY, CZ, DO, EC, EE, EG, FI, FR, GR, GT, HK, HN, HR, HU,…"}, {"doc_id": "almotriptan-drug-information", "bm25_top3": 1.1202062021548667, "bm25_max": 1.1202062021548667, "bge_top3": 0.6211754381656647, "bge_max": 0.6230258345603943, "title": "Almotriptan: Drug information", "rep_snippet": "Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Risk C: Monitor therapy  Serotonin Modulators: May enhance the adverse/toxic effect of other Seroto…"}, {"doc_id": "vitamin-b2-riboflavin-drug-information", "bm25_top3": 1.0879478078905684, "bm25_max": 1.0879478078905684, "bge_top3": 0.626467764377594, "bge_max": 0.626467764377594, "title": "Vitamin B2 (riboflavin): Drug information", "rep_snippet": "Dosing: Adult  Dietary supplement: Oral: 100 mg once or twice daily  Prevention of migraine headache (off-label use): Oral: 400 mg once daily (Rahimdel 2015; Schoenen 1998)"}, {"doc_id": "rizatriptan-drug-information", "bm25_top3": 0.6892426598184862, "bm25_max": 0.6892426598184862, "bge_top3": 0.6152857542037964, "bge_max": 0.6152857542037964, "title": "Rizatriptan: Drug information", "rep_snippet": "Propranolol: May increase the serum concentration of Rizatriptan. Management: Rizatriptan adult dose should be reduced to 5 mg in patients who are also being treated with propranolol. Risk D: Consider therapy modificatio…"}, {"doc_id": "pizotifen-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6444817185401917, "bge_max": 0.6582313776016235, "title": "Pizotifen (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Migraine prophylaxis: Oral: Initial: 0.5 mg at bedtime; may increase dose gradually to 1.5 mg daily administered as single dose at bedtime or in 3 divided doses; average maintenance dose: 1.5 mg daily; usu…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.637891411781311, "bge_max": 0.637891411781311, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Dosing: Adult  Migraine, cluster headache:  IM, SubQ: 1 mg at first sign of headache; repeat hourly to a maximum dose of 3 mg/day; maximum dose: 6 mg/week  IV: 1 mg at first sign of headache; repeat hourly up to a maximu…"}, {"doc_id": "methenamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6378164291381836, "bge_max": 0.6378164291381836, "title": "Methenamine: Drug information", "rep_snippet": "Dosing: Adult  Urinary tract infection, prophylaxis/suppression: Oral:  Hippurate: 1,000 mg twice daily  Mandelate: 1,000 mg 4 times daily"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6318381428718567, "bge_max": 0.6364140510559082, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Tablet, variable release, oral:  Kombiglyze XR 2.5/1000: Saxagliptin 2.5 mg [immediat…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6257224977016449, "bge_max": 0.6357520222663879, "title": "Ergotamine: Drug information", "rep_snippet": "Brand Names: International  Antimigraine (TW);  Avamigran (PH);  Cafergot (MX, SE);  Cafeton (TW);  Caftar (MX);  Clavigrenin akut (DE);  Cornutamin (CZ);  Enxak (BR);  Ergam (HU);  ergo sanol (DE);  Ergo-Kranit (DE);  E…"}, {"doc_id": "protamine-sulfate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6313674449920654, "bge_max": 0.6313674449920654, "title": "Protamine sulfate: Drug information", "rep_snippet": "Dalteparin or tinzaparin (Fragmin prescribing information, 2010; Innohep prescribing information, 2010): 1 mg protamine for each 100 anti-Xa units of dalteparin or tinzaparin; if PTT prolonged 2 to 4 hours after first do…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6296393871307373, "bge_max": 0.6296393871307373, "title": "Naproxen: Drug information", "rep_snippet": "Naproxen extended-release tablets: Initial: 1,000 to 1,500 mg once daily followed by 1,000 mg once daily until attack subsides  Pain (mild to moderate), dysmenorrhea, acute tendonitis, bursitis: Oral: Initial: 500 mg, fo…"}, {"doc_id": "butalbital-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6295433044433594, "bge_max": 0.6295433044433594, "title": "Butalbital and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Adult  Tension or muscle contraction headache: Oral:  Butalbital 25 mg/acetaminophen 325 mg: 2 tablets every 4 hours as needed (maximum: 12 tablets [butalbital 300 mg/acetaminophen 3,900 mg] per 24 hours).  Butal…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6289626359939575, "bge_max": 0.6289626359939575, "title": "Pitavastatin: Drug information", "rep_snippet": "Erythromycin: Maximum pitavastatin dose: 1 mg/day  Rifampin: Maximum pitavastatin dose: 2 mg/day"}, {"doc_id": "topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6287429928779602, "bge_max": 0.6287429928779602, "title": "Topiramate: Drug information", "rep_snippet": "Immediate release: Initial: 25 mg (1 to 3 mg/kg/day) once daily (in evening) for 1 week; may increase every 1 to 2 weeks in increments of 1 to 3 mg/kg/day up to the recommended dose of 5 to 9 mg/kg/day in 2 divided doses…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6276859045028687, "bge_max": 0.6276859045028687, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis: Oral: Rifampin 600 mg/isoniazid 300 mg once daily. Note: Concomitant antituberculosis medications should be administered according to current guideline recommendations (Nahid 2016)"}, {"doc_id": "acetaminophen-caffeine-and-pyrilamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.625801682472229, "bge_max": 0.625801682472229, "title": "Acetaminophen, caffeine, and pyrilamine: Drug information", "rep_snippet": "Dosing: Adult  Menstrual period symptom relief: Oral: Two tablets (acetaminophen 1,000 mg/caffeine 120 mg/pyrilamine 30 mg) every 6 hours as needed; maximum: 6 tablets (acetaminophen 3,000 mg/caffeine 360 mg/pyrilamine 9…"}, {"doc_id": "flunarizine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6233895421028137, "bge_max": 0.6233895421028137, "title": "Flunarizine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Migraine prophylaxis: Adults <65 years: Oral: 10 mg once daily; incidence of adverse effects may be decreased by allowing 2 consecutive medication-free days each week. If no significant improvement is seen…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6202037930488586, "bge_max": 0.6202037930488586, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Olanzapine 5 mg + fluoxetine 20 mg = Symbyax® 6/25  Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax® 12/25  Olanzapine 5 mg + fluoxetine 50 mg = Symbyax® 6/50  Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax® 12/50"}, {"doc_id": "azilsartan-and-chlorthalidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6187108755111694, "bge_max": 0.6187108755111694, "title": "Azilsartan and chlorthalidone: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Dose is individualized.  Initial therapy: Azilsartan 40 mg/chlorthalidone 12.5 mg once daily; dose may be increased after 2 to 4 weeks of therapy to azilsartan 40 mg/chlorthalidon…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169391572475433, "bge_max": 0.6185839176177979, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Septrin (AE, AU, BF, BH, BJ, CI, CY, EG, ES, ET, GB, GH, GM, GN, ID, IE, IQ, IR, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, OM, PE, PH, QA, SA, SC, SD, SG, SL, SN, SY, TN, TZ, UG, VN, YE, ZM, ZW);  S…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6183432340621948, "bge_max": 0.6183432340621948, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Upper respiratory symptoms: Oral: 5 mL (promethazine 6.25 mg/phenylephrine 5 mg) every 4 to 6 hours; maximum: 30 mL (promethazine 37.5 mg/phenylephrine 30 mg)/24 hours"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6178250908851624, "bge_max": 0.6178250908851624, "title": "Rabeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times per day; continue regimen for 14 days. N…"}, {"doc_id": "acetaminophen-paracetamol-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6175939440727234, "bge_max": 0.6175939440727234, "title": "Acetaminophen (paracetamol), aspirin, and caffeine: Drug information", "rep_snippet": "Dosing: Adult  Minor aches and pain: Oral:  Acetaminophen 194 mg/aspirin 227 mg/caffeine 33 mg: Two tablets every 6 hours as needed (maximum: 8 tablets per 24 hours)  Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: T…"}, {"doc_id": "acetaminophen-paracetamol-isometheptene-and-dichloralphenazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6175686120986938, "bge_max": 0.6175686120986938, "title": "Acetaminophen (paracetamol), isometheptene, and dichloralphenazone: Drug information", "rep_snippet": "Dosing: Adult  Migraine headache: Oral: Two capsules to start, followed by 1 capsule every hour until relief is obtained (maximum: 5 capsules/12 hours)  Tension headache: Oral: 1 to 2 capsules every 4 hours (maximum: 8 c…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6175345778465271, "bge_max": 0.6175345778465271, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Augmentin XR: 1000: Amoxicillin 1000 mg and clavulanate acid 62.5 mg [contains potassium 12.6 mg (0.32 mEq) and sodium 29.3 mg (1.27 mEq) per tablet; packaged in either a 7-day or 10-day package]  Generic: 1000: Amoxicil…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6174852848052979, "bge_max": 0.6174852848052979, "title": "Amoxicillin: Drug information", "rep_snippet": "Concomitant regimen: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily; continue…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6174198389053345, "bge_max": 0.6174198389053345, "title": "Omeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days. Not…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6174198389053345, "bge_max": 0.6174198389053345, "title": "Esomeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days. Not…"}, {"doc_id": "meperidine-and-promethazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6157568097114563, "bge_max": 0.6157568097114563, "title": "Meperidine and promethazine: Drug information", "rep_snippet": "Dosing: Adult  Pain: Oral: One meperidine 50 mg/promethazine 25 mg capsule every 4 to 6 hours as needed."}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6153842210769653, "bge_max": 0.6153842210769653, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Patients switching from rosiglitazone or metformin alone or combination therapy: May titrate in increments of rosiglitazone 4 mg and/or metformin 500 mg per day; allow adequate time to assess therapeutic response prior t…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6153460741043091, "bge_max": 0.6153460741043091, "title": "Fenofibrate: Drug information", "rep_snippet": "Lipidil EZ [Canadian product]: 145 mg once daily; maximum dose: 145 mg/day  Lipidil Supra [Canadian product]: 160 mg once daily; maximum dose: 200 mg/day  Lipofen: 150 mg once daily  Lofibra (micronized): 200 mg once dai…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6150253415107727, "bge_max": 0.6150253415107727, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Tablet, oral:  Janumet 50/500: Sitagliptin 50 mg and metformin hydrochloride 500 mg…"}, {"doc_id": "telmisartan-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6146934032440186, "bge_max": 0.6146934032440186, "title": "Telmisartan and amlodipine: Drug information", "rep_snippet": "Dosing: Adult  Dose is individualized; combination product may be substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy…"}, {"doc_id": "butalbital-acetaminophen-paracetamol-caffeine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6141901612281799, "bge_max": 0.6141901612281799, "title": "Butalbital, acetaminophen (paracetamol), caffeine, and codeine: Drug information", "rep_snippet": "Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen."}, {"doc_id": "pentazocine-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6141901612281799, "bge_max": 0.6141901612281799, "title": "Pentazocine and acetaminophen (paracetamol): Drug information", "rep_snippet": "Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen."}, {"doc_id": "saxagliptin-drug-information", "bm25_top3": 0.36837238148563145, "bm25_max": 0.36837238148563145, "bge_top3": null, "bge_max": null, "title": "Saxagliptin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  SAXagliptin may be confused with SITagliptin, SUMAtriptan  High alert medication:  The Institute for Safe Medication Practices (ISMP) includes this medication amo…"}, {"doc_id": "calcium-carbonate-and-simethicone-drug-information", "bm25_top3": 0.200955579947518, "bm25_max": 0.200955579947518, "bge_top3": null, "bge_max": null, "title": "Calcium carbonate and simethicone: Drug information", "rep_snippet": "Pricing: US  Chewable (Alka-Seltzer Heartburn + Gas Oral)  750-80 mg (32): $4.62  Chewable (Gas-X with Maalox Ex St Oral)  500-125 mg (24): $5.70  Chewable (Maalox Advanced Max St Oral)  1000-60 mg (65): $4.07  Chewable…"}, {"doc_id": "eletriptan-drug-information", "bm25_top3": 0.13796746239336954, "bm25_max": 0.13796746239336954, "bge_top3": null, "bge_max": null, "title": "Eletriptan: Drug information", "rep_snippet": "Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be a…"}, {"doc_id": "timolol-systemic-drug-information", "bm25_top3": -0.0073130238557972405, "bm25_max": -0.0073130238557972405, "bge_top3": null, "bge_max": null, "title": "Timolol (systemic): Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: 10 mg twice daily, increase gradually every 7 days, usual dosage: 20 to 40 mg/day in 2 divided doses; maximum: 60 mg/day.  Migraine prophylaxis: Oral: Initial: 10 mg twice dail…"}, {"doc_id": "aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information", "bm25_top3": -0.02422445880636559, "bm25_max": -0.02422445880636559, "bge_top3": null, "bge_max": null, "title": "Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information", "rep_snippet": "Pricing: US  Chewable (Almacone Oral)  200-200-25 mg (100): $3.82  Chewable (Gelusil Oral)  200-200-25 mg (100): $6.67  Chewable (Mintox Plus Oral)  200-200-25 mg (100): $2.99  Suspension (Almacone Double Strength Oral)…"}, {"doc_id": "frovatriptan-drug-information", "bm25_top3": -0.10031619819860715, "bm25_max": -0.10031619819860715, "bge_top3": null, "bge_max": null, "title": "Frovatriptan: Drug information", "rep_snippet": "Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased. Risk C: Monitor therapy  Metoclopramide: Serotonin Modul…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": -0.11917574898715877, "bm25_max": -0.11917574898715877, "bge_top3": null, "bge_max": null, "title": "Sitagliptin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Januvia may be confused with Enjuvia, Janumet, Jantoven  SITagliptin may be confused with SAXagliptin, SUMAtriptan  High alert medication:  The Institute for Safe…"}]}
{"qid": "Q17_abbr+alcohol-cue", "query": "Bacterial vaginosis — std regimen; metronidazole alcohol warning (oral vs gel)?", "base_qid": "Q17", "variant_type": "abbr+alcohol-cue", "candidates": [{"doc_id": "metronidazole-topical-drug-information", "bm25_top3": 32.609330552759204, "bm25_max": 37.95647532926622, "bge_top3": 0.6510450839996338, "bge_max": 0.6585738062858582, "title": "Metronidazole (topical): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Metronidazole crosses the placenta and rapidly distributes into the fetal circulation following oral administration. The amoun…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 25.232079490517915, "bm25_max": 28.040801344879156, "bge_top3": 0.6009820699691772, "bge_max": 0.6093875169754028, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients (Amon 1981; Visser 1984; Wang 2011). Bacterial vaginosis has been associated with adverse pregnancy outcomes; metronidazole is recommen…"}, {"doc_id": "clindamycin-topical-drug-information", "bm25_top3": 17.08208998028551, "bm25_max": 24.501178715780593, "bge_top3": 0.5615654587745667, "bge_max": 0.5615654587745667, "title": "Clindamycin (topical): Drug information", "rep_snippet": "Use  Acne vulgaris: Treatment of acne vulgaris (topical gel, topical lotion, topical solution)  Bacterial vaginosis: Treatment of bacterial vaginosis (vaginal cream, vaginal suppository)"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": 14.98619471290527, "bm25_max": 21.42292791734386, "bge_top3": 0.583958625793457, "bge_max": 0.583958625793457, "title": "Tinidazole: Drug information", "rep_snippet": "Dosing: Adult  Amebiasis, intestinal: Oral: 2 g once daily for 3 days  Amebiasis, liver abscess: Oral: 2 g once daily for 3 to 5 days  Bacterial vaginosis: Oral: 2 g once daily for 2 days or 1 g once daily for 5 days  Ba…"}, {"doc_id": "bismuth-subcitrate-metronidazole-and-tetracycline-drug-information", "bm25_top3": 20.782887560795366, "bm25_max": 21.283535187650767, "bge_top3": null, "bge_max": null, "title": "Bismuth subcitrate, metronidazole, and tetracycline: Drug information", "rep_snippet": "Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum. Risk D: Consider therapy modification  Lithium: MetroNI…"}, {"doc_id": "metronidazole-and-nystatin-united-states-not-available-drug-information", "bm25_top3": 20.767043974740908, "bm25_max": 21.045757548426828, "bge_top3": 0.6326175729433695, "bge_max": 0.6628943681716919, "title": "Metronidazole and nystatin (United States: Not available): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alcohol (Ethyl): MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. M…"}, {"doc_id": "benzyl-alcohol-drug-information", "bm25_top3": 20.335678716307378, "bm25_max": 20.335678716307378, "bge_top3": null, "bge_max": null, "title": "Benzyl alcohol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Benzyl alcohol: Pediatric drug information\")  Oral pain: Topical: Gel: Children ≥2 years and Adolescents: Refer to adult dosing.  Head lice: Topical: Lotion: Infants ≥6…"}, {"doc_id": "secnidazole-drug-information", "bm25_top3": 19.380454102096564, "bm25_max": 20.06218027015836, "bge_top3": 0.58786940574646, "bge_max": 0.58786940574646, "title": "Secnidazole: Drug information", "rep_snippet": "Dosing: Adult  Bacterial vaginosis: Oral: 2 g single dose"}, {"doc_id": "disulfiram-drug-information", "bm25_top3": 18.814806063309184, "bm25_max": 18.814806063309184, "bge_top3": null, "bge_max": null, "title": "Disulfiram: Drug information", "rep_snippet": "Lopinavir: May enhance the adverse/toxic effect of Disulfiram. Specifically, the combination of lopinavir/ritonavir solution, which contains 42% alcohol, may result in a disulfiram-alcohol reaction if combined. Risk X: A…"}, {"doc_id": "cisplatin-drug-information", "bm25_top3": 16.829693947581596, "bm25_max": 16.829693947581596, "bge_top3": null, "bge_max": null, "title": "Cisplatin: Drug information", "rep_snippet": "Brand Names: Canada  Cisplatin Injection;  Cisplatin Injection BP;  Cisplatin Injection, Mylan STD"}, {"doc_id": "dronabinol-drug-information", "bm25_top3": 12.44692864049576, "bm25_max": 12.44692864049576, "bge_top3": null, "bge_max": null, "title": "Dronabinol: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to dronabinol, sesame oil (capsules), alcohol (oral solution) or any component of the formulation; receiving, or have recently received, disulfiram- or metronidazole-containing product…"}, {"doc_id": "polyethylene-glycol-electrolyte-solution-drug-information", "bm25_top3": 11.938632819737673, "bm25_max": 11.938632819737673, "bge_top3": null, "bge_max": null, "title": "Polyethylene glycol electrolyte solution: Drug information", "rep_snippet": "Adverse Reactions  >10%:  Central nervous system: Sleep disorder (35%; evening prep vs oral sodium phosphate solution [90 mL]), rigors (34%; evening prep vs oral sodium phosphate solution [90 mL]), malaise (18% to 27%; M…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 11.453566838675318, "bm25_max": 11.453566838675318, "bge_top3": null, "bge_max": null, "title": "Pantoprazole: Drug information", "rep_snippet": "Bismuth quadruple regimen: 40 mg twice daily in combination with tetracycline 500 mg 4 times per day, metronidazole 250 mg 4 times per day or 500 mg 3 or 4 times per day, and either bismuth subcitrate 120 to 300 mg 4 tim…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": 11.16181731637274, "bm25_max": 11.16181731637274, "bge_top3": null, "bge_max": null, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Methadone: May enhance the QTc-prolonging effect of Lopinavir. Lopinavir may decrease the serum concentration of Methadone. More specifically, the combination of Lopinavir and Ritonavir may decrease Methadone serum conce…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 11.158848087549629, "bm25_max": 11.158848087549629, "bge_top3": null, "bge_max": null, "title": "Amoxicillin: Drug information", "rep_snippet": "Concomitant regimen: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily; continue…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 10.32164523119769, "bm25_max": 10.886012256347882, "bge_top3": null, "bge_max": null, "title": "Omeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days. Not…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 10.64827694552592, "bm25_max": 10.886012256347882, "bge_top3": null, "bge_max": null, "title": "Esomeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days. Not…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 10.749069514476904, "bm25_max": 10.749069514476904, "bge_top3": null, "bge_max": null, "title": "Lansoprazole: Drug information", "rep_snippet": "Bismuth quadruple regimen: 30 mg twice daily in combination with tetracycline 500 mg 4 times daily, metronidazole 250 mg 4 times daily or 500 mg 3 or 4 times daily, and either bismuth subcitrate 120 to 300 mg 4 times dai…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 10.262234744822816, "bm25_max": 10.691513573908987, "bge_top3": null, "bge_max": null, "title": "Rabeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times per day; continue regimen for 14 days. N…"}, {"doc_id": "hyaluronate-derivatives-drug-information", "bm25_top3": 10.220269618881767, "bm25_max": 10.220269618881767, "bge_top3": null, "bge_max": null, "title": "Hyaluronate derivatives: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, topical [sodium hyaluronate]:  Bionect: 0.2% (25…"}, {"doc_id": "tetracycline-drug-information", "bm25_top3": 9.698369155097907, "bm25_max": 9.698369155097907, "bge_top3": null, "bge_max": null, "title": "Tetracycline: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: Oral: 250 to 500 mg every 6 to 12 hours  Acne: Oral: Initial dose: 1 g daily in divided doses; reduce gradually to 125 to 500 mg/day once improvement is noted (alternate day or intermit…"}, {"doc_id": "ethanol-topical-and-injection-drug-information", "bm25_top3": 9.683366469209677, "bm25_max": 9.683366469209677, "bge_top3": 0.598760187625885, "bge_max": 0.598760187625885, "title": "Ethanol (topical and injection): Drug information", "rep_snippet": "Methylphenidate: Alcohol (Ethyl) may enhance the adverse/toxic effect of Methylphenidate. Alcohol (Ethyl) may increase the serum concentration of Methylphenidate. Risk X: Avoid combination  MetroNIDAZOLE (Systemic): May…"}, {"doc_id": "levonorgestrel-intrauterine-device-drug-information", "bm25_top3": 9.541540395835261, "bm25_max": 9.541540395835261, "bge_top3": null, "bge_max": null, "title": "Levonorgestrel intrauterine device: Drug information", "rep_snippet": "Monitoring Parameters  Prior to insertion: Assessment of pregnancy status; bimanual examination and cervical inspection; weight (optional; BMI at baseline may be helpful to monitor changes during therapy); STD screen (un…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5777719020843506, "bge_max": 0.5777719020843506, "title": "Ceftriaxone: Drug information", "rep_snippet": "Prophylaxis against sexually transmitted diseases following sexual assault (off-label use): IM: 250 mg as a single dose in combination with azithromycin plus metronidazole (or tinidazole) (CDC [Workowski 2015])  Prosthet…"}, {"doc_id": "estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772584080696106, "bge_max": 0.5772584080696106, "title": "Estradiol and norethindrone: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "drospirenone-and-estradiol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772584080696106, "bge_max": 0.5772584080696106, "title": "Drospirenone and estradiol: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "estradiol-and-norgestimate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772584080696106, "bge_max": 0.5772584080696106, "title": "Estradiol and norgestimate: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "estradiol-and-levonorgestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772584080696106, "bge_max": 0.5772584080696106, "title": "Estradiol and levonorgestrel: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "esterified-estrogens-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5768013000488281, "bge_max": 0.5768013000488281, "title": "Esterified estrogens: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as a potentially inap…"}, {"doc_id": "equine-conjugated-estrogens-and-medroxyprogesterone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5768013000488281, "bge_max": 0.5768013000488281, "title": "Equine conjugated estrogens and medroxyprogesterone acetate: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as a potentially inap…"}, {"doc_id": "lidocaine-and-menthol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5767539739608765, "bge_max": 0.5767539739608765, "title": "Lidocaine and menthol: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, External:  AvaDERM: Lidocaine 4% and menthol 1% (…"}, {"doc_id": "bazedoxifene-and-conjugated-equine-estrogens-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.576350748538971, "bge_max": 0.576350748538971, "title": "Bazedoxifene and conjugated equine estrogens: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "estropipate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.576350748538971, "bge_max": 0.576350748538971, "title": "Estropipate: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "oxybutynin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5719790458679199, "bge_max": 0.5719790458679199, "title": "Oxybutynin: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Gel, Transdermal:  Gelnique: 3% (92 g [DSC]) [contains p…"}, {"doc_id": "testosterone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5713867545127869, "bge_max": 0.5713867545127869, "title": "Testosterone: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Secondary exposure (transdermal gel, transdermal solution):  Virilization has been reported in children who were secondarily exposed to topical testosterone gel and solution. Children should avoi…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5707966685295105, "bge_max": 0.5707966685295105, "title": "Cefotaxime: Drug information", "rep_snippet": "Complicated community-acquired intra-abdominal infection of mild-to-moderate severity, including hepatic abscess (in combination with metronidazole): IV: 1 to 2 g every 6 to 8 hours for 4 to 7 days (provided source contr…"}, {"doc_id": "estradiol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5664060115814209, "bge_max": 0.5664060115814209, "title": "Estradiol (systemic): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Alora may be confused with Aldara  Elestrin may be confused with alosetron  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical…"}, {"doc_id": "ethinyl-estradiol-and-ethynodiol-diacetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5654587745666504, "bge_max": 0.5654587745666504, "title": "Ethinyl estradiol and ethynodiol diacetate: Drug information", "rep_snippet": "• Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immo…"}, {"doc_id": "lidocaine-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5651968717575073, "bge_max": 0.5651968717575073, "title": "Lidocaine (topical): Drug information", "rep_snippet": "LidoRx: 3% (10 mL, 30 mL, 90 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]  Lidotrex: 2% (28.33 g) [contains trolamine (triethanolamine)]  Tranzarel: 4% (120 mL) [contains disodium edta, menthol, methylpa…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5649127960205078, "bge_max": 0.5649127960205078, "title": "Itraconazole: Drug information", "rep_snippet": "• Oral capsules/tablets: Absorption of itraconazole capsules is reduced when gastric acidity is reduced (eg, achlorhydria, acid suppressive therapy) administer capsules or tablets with an acidic beverage (eg, non-diet co…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5624905824661255, "bge_max": 0.5624905824661255, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Hematopoietic cell transplant (HCT) antibacterial prophylaxis (off-label use): Oral: 500 mg twice daily; begin at the time of stem cell infusion and continue until recovery of neutropenia or until initiation of empiric a…"}, {"doc_id": "synthetic-conjugated-estrogens-b-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.560847818851471, "bge_max": 0.560847818851471, "title": "Synthetic conjugated estrogens B (United States: Not available): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Enjuvia may be confused with Januvia  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without…"}]}
{"qid": "Q17_noise", "query": "BV therapy — dosing and is EtOH avoidance relevant for oral vs intravaginal metro?", "base_qid": "Q17", "variant_type": "noise", "candidates": [{"doc_id": "metronidazole-and-nystatin-united-states-not-available-drug-information", "bm25_top3": 29.84495568050156, "bm25_max": 29.84495568050156, "bge_top3": null, "bge_max": null, "title": "Metronidazole and nystatin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Vaginal infection, mixed: Females: Intravaginal:  Vaginal tablet (ovule): Insert 1 tablet daily at bedtime for 10 consecutive days. May repeat for an additional 10 days if cure is not achieved.  Vaginal cr…"}, {"doc_id": "hydrocodone-and-chlorpheniramine-drug-information", "bm25_top3": 26.690056634143886, "bm25_max": 26.690056634143886, "bge_top3": null, "bge_max": null, "title": "Hydrocodone and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydrocodone and chlorpheniramine: Pediatric drug information\")  Cough and upper respiratory tract symptoms: Oral: Note: Dosage units vary based on product formulation (…"}, {"doc_id": "prasterone-intravaginal-drug-information", "bm25_top3": 19.15544833712487, "bm25_max": 25.65129813554015, "bge_top3": null, "bge_max": null, "title": "Prasterone (intravaginal): Drug information", "rep_snippet": "Dosing: Adult  Dyspareunia: Females: Intravaginal: 6.5 mg once daily at bedtime"}, {"doc_id": "lumacaftor-and-ivacaftor-drug-information", "bm25_top3": 25.39022654551171, "bm25_max": 25.39022654551171, "bge_top3": null, "bge_max": null, "title": "Lumacaftor and ivacaftor: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Children ≥6 years, Adolescents, and Adults:  ALT or AST >5 times ULN without concomitant elevated bilirubin: Temporarily discontinue lumacaftor/ivacaftor; may resume if elevated transamin…"}, {"doc_id": "miconazole-topical-drug-information", "bm25_top3": 24.851392818786454, "bm25_max": 24.851392818786454, "bge_top3": null, "bge_max": null, "title": "Miconazole (topical): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Miconazole (topical): Pediatric drug information\")  Tinea corporis, tinea pedis, tinea cruris: Topical: Note: Not for OTC use in children <2 years: Refer to adult dosin…"}, {"doc_id": "clotrimazole-topical-drug-information", "bm25_top3": 24.386718098645133, "bm25_max": 24.386718098645133, "bge_top3": null, "bge_max": null, "title": "Clotrimazole (topical): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Clotrimazole (topical): Pediatric drug information\")  Cutaneous candidiasis:  Children and Adolescents: Topical: Cream, solution: Refer to adult dosing.  Children ≥2 ye…"}, {"doc_id": "progesterone-drug-information", "bm25_top3": 19.13651044198238, "bm25_max": 20.947039770538044, "bge_top3": 0.5885258316993713, "bge_max": 0.5885258316993713, "title": "Progesterone: Drug information", "rep_snippet": "Dosing: Adult  Females:  Amenorrhea: IM: 5 to 10 mg/day for 6 to 8 consecutive days.  Amenorrhea, secondary:  Intravaginal gel: 45 mg (4% gel) every other day for up to a total of 6 doses; if response is inadequate, may…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": 20.16810796474474, "bm25_max": 20.16810796474474, "bge_top3": null, "bge_max": null, "title": "Tinidazole: Drug information", "rep_snippet": "Dosing: Adult  Amebiasis, intestinal: Oral: 2 g once daily for 3 days  Amebiasis, liver abscess: Oral: 2 g once daily for 3 to 5 days  Bacterial vaginosis: Oral: 2 g once daily for 2 days or 1 g once daily for 5 days  Ba…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 17.805695122077317, "bm25_max": 18.38154898782364, "bge_top3": 0.577958345413208, "bge_max": 0.577958345413208, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Capsule, Oral:  Flagyl: 375 mg  Generic: 375 mg  Solutio…"}, {"doc_id": "estrone-united-states-not-available-drug-information", "bm25_top3": 18.291359104005483, "bm25_max": 18.291359104005483, "bge_top3": null, "bge_max": null, "title": "Estrone (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Vulvar and vaginal atrophy: Intravaginal: Insert 0.5 to 4 g daily; adjust to lowest effective dose which controls symptoms. Administration should be cyclic (3 weeks on, 1 week off). Intended for short term…"}, {"doc_id": "misoprostol-drug-information", "bm25_top3": 17.81997706652602, "bm25_max": 17.81997706652602, "bge_top3": 0.5849859714508057, "bge_max": 0.5849859714508057, "title": "Misoprostol: Drug information", "rep_snippet": "Dosing: Adult  NSAID-induced gastric ulcers, prevention: Oral: 200 mcg 4 times daily; if not tolerated, may decrease dose to 100 mcg 4 times daily  Termination of intrauterine pregnancy: Oral: Refer to Mifepristone monog…"}, {"doc_id": "sulfanilamide-drug-information", "bm25_top3": 17.601383613199896, "bm25_max": 17.601383613199896, "bge_top3": null, "bge_max": null, "title": "Sulfanilamide: Drug information", "rep_snippet": "Dosing: Adult  Vulvovaginitis: Intravaginal: Insert one applicatorful intravaginally once or twice daily for 30 days"}, {"doc_id": "butoconazole-drug-information", "bm25_top3": 16.774674113313186, "bm25_max": 16.774674113313186, "bge_top3": null, "bge_max": null, "title": "Butoconazole: Drug information", "rep_snippet": "Dosing: Adult  Vulvovaginal candidiasis: Intravaginal: Insert 1 applicatorful (∼5 g) intravaginally as a single dose"}, {"doc_id": "tioconazole-drug-information", "bm25_top3": 16.653548491683367, "bm25_max": 16.653548491683367, "bge_top3": null, "bge_max": null, "title": "Tioconazole: Drug information", "rep_snippet": "Dosing: Adult  Candidiasis, vulvovaginal: Intravaginal: Insert 1 applicatorful in vagina as a single dose at bedtime"}, {"doc_id": "tacrolimus-systemic-drug-information", "bm25_top3": 16.49413001630365, "bm25_max": 16.49413001630365, "bge_top3": null, "bge_max": null, "title": "Tacrolimus (systemic): Drug information", "rep_snippet": "Note: The initial postoperative dose of tacrolimus should begin no sooner than 6 hours after liver and heart transplant and within 24 hours of kidney transplant (but may be delayed until renal function has recovered). Ad…"}, {"doc_id": "betamethasone-and-clotrimazole-drug-information", "bm25_top3": 16.49106411913784, "bm25_max": 16.49106411913784, "bge_top3": null, "bge_max": null, "title": "Betamethasone and clotrimazole: Drug information", "rep_snippet": "Administration  For topical use only; not for oral, ophthalmic, or intravaginal use. Do not cover with occlusive dressings. Shake lotion well prior to use."}, {"doc_id": "nonoxynol-9-drug-information", "bm25_top3": 15.689055334862914, "bm25_max": 15.689055334862914, "bge_top3": null, "bge_max": null, "title": "Nonoxynol 9: Drug information", "rep_snippet": "Dosing: Pediatric  Contraception: Adolescents: Females: Intravaginal: Refer to adult dosing; not for use prior to menarche."}, {"doc_id": "terconazole-drug-information", "bm25_top3": 14.954218201049922, "bm25_max": 14.954218201049922, "bge_top3": null, "bge_max": null, "title": "Terconazole: Drug information", "rep_snippet": "Dosing: Adult  Vulvovaginal candidiasis: Intravaginal:  Vaginal cream 0.4%: Insert 1 applicatorful intravaginally at bedtime for 7 consecutive days.  Vaginal cream 0.8%: Insert 1 applicatorful intravaginally at bedtime f…"}, {"doc_id": "ivacaftor-drug-information", "bm25_top3": 14.836269331584479, "bm25_max": 14.836269331584479, "bge_top3": null, "bge_max": null, "title": "Ivacaftor: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  ALT or AST >5 times ULN: Hold ivacaftor; may resume if elevated transaminases resolved and after assessing benefits vs risks of continued treatment."}, {"doc_id": "hydroxyurea-hydroxycarbamide-drug-information", "bm25_top3": 14.65210934303855, "bm25_max": 14.65210934303855, "bge_top3": null, "bge_max": null, "title": "Hydroxyurea (hydroxycarbamide): Drug information", "rep_snippet": "Dosing: Renal Impairment  CML, head and neck cancer (manufacturer's labeling):  CrCl ≥60 mL/minute: No dosage adjustment (of initial dose) necessary.  CrCl <60 mL/minute: Reduce initial dose by 50%; titrate to response/a…"}, {"doc_id": "irbesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": 14.573299335075712, "bm25_max": 14.573299335075712, "bge_top3": null, "bge_max": null, "title": "Irbesartan and hydrochlorothiazide: Drug information", "rep_snippet": "• Surgical patients: In patients on chronic angiotensin receptor blocker (ARB) therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior…"}, {"doc_id": "eprosartan-and-hydrochlorothiazide-drug-information", "bm25_top3": 14.573299335075712, "bm25_max": 14.573299335075712, "bge_top3": null, "bge_max": null, "title": "Eprosartan and hydrochlorothiazide: Drug information", "rep_snippet": "• Surgical patients: In patients on chronic angiotensin receptor blocker (ARB) therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": 14.573299335075712, "bm25_max": 14.573299335075712, "bge_top3": null, "bge_max": null, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "• Surgical patients: In patients on chronic angiotensin receptor blocker (ARB) therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior…"}, {"doc_id": "olmesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": 14.573299335075712, "bm25_max": 14.573299335075712, "bge_top3": null, "bge_max": null, "title": "Olmesartan and hydrochlorothiazide: Drug information", "rep_snippet": "• Surgical patients: In patients on chronic angiotensin receptor blocker (ARB) therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior…"}, {"doc_id": "polyethylene-glycol-electrolyte-solution-drug-information", "bm25_top3": 6.243563508304806, "bm25_max": 8.438632819737673, "bge_top3": null, "bge_max": null, "title": "Polyethylene glycol electrolyte solution: Drug information", "rep_snippet": "Adverse Reactions  >10%:  Central nervous system: Sleep disorder (35%; evening prep vs oral sodium phosphate solution [90 mL]), rigors (34%; evening prep vs oral sodium phosphate solution [90 mL]), malaise (18% to 27%; M…"}, {"doc_id": "ketoconazole-topical-drug-information", "bm25_top3": 7.050689594085046, "bm25_max": 7.050689594085046, "bge_top3": null, "bge_max": null, "title": "Ketoconazole (topical): Drug information", "rep_snippet": "• Appropriate use: Avoid contact with the eyes and other mucous membranes. Not for ophthalmic, oral, or intravaginal use. If condition worsens or does not improve after the treatment period, discontinue use and contact h…"}, {"doc_id": "imiquimod-drug-information", "bm25_top3": 6.516661638389843, "bm25_max": 6.516661638389843, "bge_top3": null, "bge_max": null, "title": "Imiquimod: Drug information", "rep_snippet": "• Appropriate use: Not intended for oral, nasal, intravaginal, or ophthalmic use. Administration is not recommended until tissue is healed from any previous drug or surgical treatment. Treatment should not be prolonged b…"}, {"doc_id": "luliconazole-drug-information", "bm25_top3": 5.163332570049654, "bm25_max": 6.3390540459918725, "bge_top3": null, "bge_max": null, "title": "Luliconazole: Drug information", "rep_snippet": "Warnings/Precautions  Warnings/precautions:  • Appropriate use: For topical use only; not for oral, ophthalmic, or intravaginal use."}, {"doc_id": "trimethobenzamide-drug-information", "bm25_top3": 6.123163733270644, "bm25_max": 6.123163733270644, "bge_top3": null, "bge_max": null, "title": "Trimethobenzamide: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "ozenoxacin-drug-information", "bm25_top3": 5.051946847767702, "bm25_max": 5.959442864006721, "bge_top3": null, "bge_max": null, "title": "Ozenoxacin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Superinfection: Prolonged use may result in fungal or bacterial superinfection; discontinue use if superinfection occurs.  Other warnings/precautions:  • Appr…"}, {"doc_id": "sodium-polystyrene-sulfonate-drug-information", "bm25_top3": 5.953925363134644, "bm25_max": 5.953925363134644, "bge_top3": null, "bge_max": null, "title": "Sodium polystyrene sulfonate: Drug information", "rep_snippet": "• Appropriate use: Effective lowering of serum potassium from sodium polystyrene sulfonate may take hours to days after administration; consider alternative measures (eg, dialysis) or concomitant therapy (eg, IV sodium b…"}, {"doc_id": "sertaconazole-drug-information", "bm25_top3": 5.694967724430285, "bm25_max": 5.776081868689634, "bge_top3": null, "bge_max": null, "title": "Sertaconazole: Drug information", "rep_snippet": "Administration  For external use only. Not for oral, ophthalmic, or intravaginal use. Apply to affected area(s) as directed. Make sure skin is dry before applying; wash hands after application. Avoid use of occlusive dre…"}, {"doc_id": "nystatin-topical-drug-information", "bm25_top3": 4.821471972242634, "bm25_max": 5.691608586980452, "bge_top3": null, "bge_max": null, "title": "Nystatin (topical): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: May occur; immediately discontinue if signs of a hypersensitivity reaction occur.  • Irritation: Discontinue if irritation occurs.  Other wa…"}, {"doc_id": "halobetasol-drug-information", "bm25_top3": 5.66540916330041, "bm25_max": 5.66540916330041, "bge_top3": null, "bge_max": null, "title": "Halobetasol: Drug information", "rep_snippet": "Administration  Topical: For external use only; not for ophthalmic, oral, or intravaginal use; do not apply to the face, scalp, groin, or axillae. Use of occlusive dressings is not recommended unless directed by a health…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 5.360896067043885, "bm25_max": 5.360896067043885, "bge_top3": 0.5911402702331543, "bge_max": 0.5911402702331543, "title": "Dabigatran: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Dabigatran Ete…"}, {"doc_id": "crisaborole-drug-information", "bm25_top3": 5.00921057568296, "bm25_max": 5.00921057568296, "bge_top3": null, "bge_max": null, "title": "Crisaborole: Drug information", "rep_snippet": "Administration  For topical use only; not for ophthalmic, oral, or intravaginal use."}, {"doc_id": "selenium-sulfide-drug-information", "bm25_top3": 4.684307253023594, "bm25_max": 4.684307253023594, "bge_top3": null, "bge_max": null, "title": "Selenium sulfide: Drug information", "rep_snippet": "Administration  Shake well before using. For external use only; not for ophthalmic, oral, anal or intravaginal use. Do not use when acute inflammation or exudation is present or on damaged skin or mucous membranes. For c…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 4.645109122014773, "bm25_max": 4.645109122014773, "bge_top3": 0.5714327096939087, "bge_max": 0.5714327096939087, "title": "Amiodarone: Drug information", "rep_snippet": "CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk…"}, {"doc_id": "halcinonide-drug-information", "bm25_top3": 4.10926435545902, "bm25_max": 4.10926435545902, "bge_top3": null, "bge_max": null, "title": "Halcinonide: Drug information", "rep_snippet": "Administration  For external use only; not for oral, ophthalmic, or intravaginal use. Wash hands before and after use. Apply a thin film to clean, dry skin and rub in gently. Avoid use of topical preparations on weeping…"}, {"doc_id": "retapamulin-drug-information", "bm25_top3": 4.039484013590197, "bm25_max": 4.039484013590197, "bge_top3": null, "bge_max": null, "title": "Retapamulin: Drug information", "rep_snippet": "Administration  Topical: For external use only; not for intranasal, intravaginal, ophthalmic, oral, or mucosal application. May cover treatment area with sterile bandage or gauze dressing if needed. Wash hands after appl…"}, {"doc_id": "calcitriol-topical-drug-information", "bm25_top3": 3.5222644819042337, "bm25_max": 3.5222644819042337, "bge_top3": null, "bge_max": null, "title": "Calcitriol (topical): Drug information", "rep_snippet": "Administration  Topical: Apply externally; not for ophthalmic, oral, or intravaginal use. Do not apply to eyes, lips, or facial skins. Rub in gently so that no medication remains visible. Limit application to only the ar…"}, {"doc_id": "brentuximab-vedotin-drug-information", "bm25_top3": 3.389039903974256, "bm25_max": 3.389039903974256, "bge_top3": null, "bge_max": null, "title": "Brentuximab vedotin: Drug information", "rep_snippet": "• Renal impairment: Avoid use in patients with severe renal impairment (CrCl <30 mL/minute). The frequency of grade 3/4 toxicities (and deaths) was increased in patients with severe impairment (compared to patients with…"}, {"doc_id": "dimethyl-sulfoxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6108941435813904, "bge_max": 0.6108941435813904, "title": "Dimethyl sulfoxide: Drug information", "rep_snippet": "Administration  Intravesical: Instill directly into the bladder via catheter or syringe. To reduce bladder spasm, apply an analgesic lubricant (eg, lidocaine jelly) to urethra prior to catheter insertion; oral analgesics…"}, {"doc_id": "esmolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6015369296073914, "bge_max": 0.6015369296073914, "title": "Esmolol: Drug information", "rep_snippet": "Acute coronary syndromes (when relative contraindications to beta-blockade exist; off-label use): IV: 500 mcg/kg over 1 minute; follow with a 50 mcg/kg/minute infusion; if tolerated and response inadequate, may titrate u…"}, {"doc_id": "contraceptive-vaginal-ring-ethinyl-estradiol-and-etonogestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5982294082641602, "bge_max": 0.5982294082641602, "title": "Contraceptive vaginal ring (Ethinyl estradiol and etonogestrel): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "sotalol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5958435535430908, "bge_max": 0.5958435535430908, "title": "Sotalol: Drug information", "rep_snippet": "Administration  Oral: Administer without regard to meals.  IV:  Substitution for oral: Administer over 5 hours; may prolong duration of infusion if QT interval prolongs to ≥500 msec.  Hemodynamically stable monomorphic V…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.595207929611206, "bge_max": 0.595207929611206, "title": "Enoxaparin: Drug information", "rep_snippet": "Prevention of recurrent venous thromboembolism in pregnancy (off-label use): 40 mg once daily. Therapy should continue for 6 weeks postpartum in high-risk women (Bates 2012).  DVT treatment (acute) and pulmonary embolism…"}, {"doc_id": "conjugated-equine-estrogens-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5931499004364014, "bge_max": 0.5931499004364014, "title": "Conjugated equine estrogens (systemic): Drug information", "rep_snippet": "Administration  Injection: May be administered IV or IM; when administered IV, drug should be administered slowly to avoid the occurrence of a flushing reaction  Oral tablet: Administer at the same time each day. May be…"}, {"doc_id": "estradiol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5920670032501221, "bge_max": 0.5920670032501221, "title": "Estradiol (systemic): Drug information", "rep_snippet": "EstroGel: 1.25 g/day applied at the same time each day  Topical spray (Evamist): Initial: One spray (1.53 mg) per day. Adjust dose based on patient response. Dosing range: 1 to 3 sprays per day.  Transdermal (Alora, Clim…"}, {"doc_id": "indomethacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5897696018218994, "bge_max": 0.5897696018218994, "title": "Indomethacin: Drug information", "rep_snippet": "Administration  Oral: Administer with food, immediately after meals, or with milk or antacids to decrease GI adverse effects. Extended-release capsules must be swallowed whole; do not crush.  IV: Administer over 20 to 30…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5896663665771484, "bge_max": 0.5896663665771484, "title": "Rivaroxaban: Drug information", "rep_snippet": "Dosing: Adult  Note: Extremes of body weight (<50 kg or >120 kg) do not significantly influence rivaroxaban exposure (Kubitza 2007). However, The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline…"}, {"doc_id": "etoposide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5889894962310791, "bge_max": 0.5889894962310791, "title": "Etoposide: Drug information", "rep_snippet": "Administration  Oral etoposide is associated with a low (adults) or moderate (children) emetic potential; antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011; Roila 2016).  Oral: Doses ≤200 mg/day…"}, {"doc_id": "ethinyl-estradiol-and-norelgestromin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5880154967308044, "bge_max": 0.5880154967308044, "title": "Ethinyl estradiol and norelgestromin: Drug information", "rep_snippet": "• Thromboembolic disorders: [US Boxed Warning]: The pharmacokinetic profile of the patch is different from oral contraceptives; steady state concentrations of ethinyl estradiol are ~60% higher following use of the patch…"}, {"doc_id": "ethanol-topical-and-injection-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5842961072921753, "bge_max": 0.5842961072921753, "title": "Ethanol (topical and injection): Drug information", "rep_snippet": "Administration  Oral: Ethylene glycol or methanol poisoning: Dilute ethyl alcohol to ≤20% solution (to reduce the risk of gastritis) with water or juice and administer hourly by mouth or via nasogastric tube. Out-of-hosp…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5831028819084167, "bge_max": 0.5831028819084167, "title": "Furosemide: Drug information", "rep_snippet": "Administration  Parenteral: May administer IM or IV. In adults, undiluted direct IV injections may be administered at a rate of 20 to 40 mg per minute; maximum rate of administration for short-term intermittent infusion…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5828923583030701, "bge_max": 0.5828923583030701, "title": "Zidovudine: Drug information", "rep_snippet": "Dosing: Adult  Note: Patients should receive IV therapy only until oral therapy can be administered.  Prevention of perinatal HIV transmission: Zidovudine should be administered by continuous IV infusion near delivery re…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.581459105014801, "bge_max": 0.581459105014801, "title": "Edoxaban: Drug information", "rep_snippet": "Dosing: Obesity  The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of edoxaban (and other direct oral anticoagulants) in patients with a BMI >40 kg/m2 or weight >120…"}, {"doc_id": "abemaciclib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5813239812850952, "bge_max": 0.5813239812850952, "title": "Abemaciclib: Drug information", "rep_snippet": "Dosing: Adult  Breast cancer, HR-positive, HER2-negative (advanced or metastatic): Oral:  Initial endocrine-based therapy in postmenopausal females: 150 mg twice daily (in combination with an aromatase inhibitor); contin…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5812153816223145, "bge_max": 0.5812153816223145, "title": "Apixaban: Drug information", "rep_snippet": "Dosing: Adult  Deep venous thrombosis: Oral:  Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Note: LMWH is preferred over oral anticoagulation for treatment of patients with cancer.  Duration of th…"}, {"doc_id": "minocycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5809531807899475, "bge_max": 0.5809531807899475, "title": "Minocycline: Drug information", "rep_snippet": "Administration  IV: Infuse over 60 minutes; avoid rapid administration. The injectable route should be used only if the oral route is not feasible or adequate. Prolonged intravenous therapy may be associated with thrombo…"}, {"doc_id": "ergonovine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5806987285614014, "bge_max": 0.5806987285614014, "title": "Ergonovine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Treatment/prevention of postpartum or postabortion hemorrhage: IM, IV (IV should be reserved for emergency use only): 0.2 mg, may repeat dose every 2 to 4 hours if needed, up to maximum of 5 total doses  I…"}, {"doc_id": "hydromorphone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.580531120300293, "bge_max": 0.580531120300293, "title": "Hydromorphone: Drug information", "rep_snippet": "Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another."}, {"doc_id": "acebutolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5804591774940491, "bge_max": 0.5804591774940491, "title": "Acebutolol: Drug information", "rep_snippet": "Dosing: Adult  Ventricular arrhythmia (eg, ventricular premature beats): Oral: 400 mg daily in 2 divided doses; maintenance: 600 to 1,200 mg daily in divided doses; maximum: 1,200 mg daily  Hypertension: Oral: Initial: 4…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5800094604492188, "bge_max": 0.5800094604492188, "title": "Methotrexate: Drug information", "rep_snippet": "Administration  In children, doses ≥12 g/m2 are associated with a high emetic potential; doses ≥250 mg/m2 (IV) in adults and children are associated with moderate emetic potential (Dupuis 2011). Antiemetics may be recomm…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5799904465675354, "bge_max": 0.5799904465675354, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Obesity  The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of direct oral anticoagulants in patients with a BMI >40 kg/m2 or weight >120 kg due to the lack of…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5799717307090759, "bge_max": 0.5799717307090759, "title": "Diazepam: Drug information", "rep_snippet": "Administration  Oral: Administer with food or water. Dilute or mix oral concentrate with water, juice, soda, applesauce, or pudding before use; measure dose only with calibrated dropper provided.  IV: Administer undilute…"}, {"doc_id": "esterified-estrogens-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.579751193523407, "bge_max": 0.579751193523407, "title": "Esterified estrogens: Drug information", "rep_snippet": "Vasomotor symptoms associated with menopause: Oral: 1.25 mg/day administered cyclically (3 weeks on and 1 week off). If patient has not menstruated within the last 2 months or more, cyclic administration is started arbit…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5791835784912109, "bge_max": 0.5791835784912109, "title": "Posaconazole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Delayed-release tablets and oral suspension:  eGFR 20 to 80 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <20 mL/minute/1.73 m2: No dosage adjustment necessary; however, monitor for b…"}, {"doc_id": "rocuronium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5790925621986389, "bge_max": 0.5790925621986389, "title": "Rocuronium: Drug information", "rep_snippet": "Dosing: Adult  Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient.  Rapid sequence intubation: IV: 0.6 to 1.2 mg/kg  Obesity: In adult patien…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5788134336471558, "bge_max": 0.5788134336471558, "title": "Aprepitant: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing is for aprepitant (Emend Oral and Cinvanti IV); refer to the fosaprepitant monograph for Emend IV dosing.  Prevention of chemotherapy-induced nausea and vomiting:  Manufacturer's labeling:  Pr…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5774126052856445, "bge_max": 0.5774126052856445, "title": "Ondansetron: Drug information", "rep_snippet": "Guideline recommendations: Prevention of chemotherapy-induced nausea and vomiting:  Pediatric Oncology Group of Ontario (POGO)  (off-label dosing; Dupuis 2013; Patel 2017  ):  Highly emetogenic chemotherapy: Infants ≥1 m…"}, {"doc_id": "metoprolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772055387496948, "bge_max": 0.5772055387496948, "title": "Metoprolol: Drug information", "rep_snippet": "When switching between oral and intravenous dosage forms, in most cases, equivalent beta-blocking effect is achieved when doses in a 2.5:1 (Oral:IV) ratio is used. However, in one bioavailability study including healthy…"}, {"doc_id": "methylergonovine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5771166086196899, "bge_max": 0.5771166086196899, "title": "Methylergonovine: Drug information", "rep_snippet": "Dosing: Adult  Prevention of hemorrhage:  Oral: 0.2 mg 3 to 4 times daily in the puerperium for up to 7 days (maximum duration: 1 week)  IM, IV: 0.2 mg after delivery of anterior shoulder, after delivery of placenta, or…"}, {"doc_id": "metoclopramide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5768950581550598, "bge_max": 0.5768950581550598, "title": "Metoclopramide: Drug information", "rep_snippet": "IV: 1 to 2 mg/kg/dose before chemotherapy and repeat 2 hours after chemotherapy.  Oral: 0.5 mg/kg every 6 hours on days 2 to 4.  Prevention of postoperative nausea and vomiting:  IM, IV (off-label route): Usual dose: 10…"}, {"doc_id": "hyaluronidase-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5768031477928162, "bge_max": 0.5768031477928162, "title": "Hyaluronidase: Drug information", "rep_snippet": "Extravasation management (off-label use): Note: Administer as soon as extravasation is recognized. Do not use for extravasation of vasoconstrictors (eg, dopamine, norepinephrine [manage with phentolamine]). For extravasa…"}, {"doc_id": "levothyroxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5761553049087524, "bge_max": 0.5761553049087524, "title": "Levothyroxine: Drug information", "rep_snippet": "Administration  Oral: Administer consistently in the morning on an empty stomach, at least 30 to 60 minutes before food. Alternatively, may consistently administer at night 3 to 4 hours after the last meal (AACE/ATA [Gar…"}, {"doc_id": "cyproterone-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5760003328323364, "bge_max": 0.5760003328323364, "title": "Cyproterone (United States: Not available): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "octreotide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747413039207458, "bge_max": 0.5747413039207458, "title": "Octreotide: Drug information", "rep_snippet": "Diarrhea associated with acute graft-versus-host disease (GVHD) (off-label use): IV: 500 mcg every 8 hours; discontinue within 24 hours of diarrhea resolution to avoid ileus; Maximum duration of therapy if diarrhea is no…"}, {"doc_id": "vecuronium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5745492577552795, "bge_max": 0.5745492577552795, "title": "Vecuronium: Drug information", "rep_snippet": "Dosing: Adult  Dose to effect; doses will vary due to interpatient variability.  Surgical relaxation: IV (do not administer IM):  Tracheal intubation: IV: Initial: 0.08-0.1 mg/kg. Note: If intubation is performed using s…"}, {"doc_id": "doxazosin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5743715167045593, "bge_max": 0.5743715167045593, "title": "Doxazosin: Drug information", "rep_snippet": "Dosing: Adult  BPH: Oral:  Immediate release: Initial: 1 mg once daily; may titrate (by doubling the daily dose [eg, to 2 mg, then 4 mg, then 8 mg]) at 1- to 2-week intervals up to 8 mg once daily based on patient respon…"}, {"doc_id": "danazol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5737746357917786, "bge_max": 0.5737746357917786, "title": "Danazol: Drug information", "rep_snippet": "Dosing: Adult  Note: In females, begin treatment during menstruation:  Endometriosis (females): Oral:  Mild disease: Initial: 200 to 400 mg/day in 2 divided doses; gradually titrate dosage downward to maintain amenorrhea…"}, {"doc_id": "ethinyl-estradiol-and-ethynodiol-diacetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5736457109451294, "bge_max": 0.5736457109451294, "title": "Ethinyl estradiol and ethynodiol diacetate: Drug information", "rep_snippet": "• Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immo…"}, {"doc_id": "trospium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5728758573532104, "bge_max": 0.5728758573532104, "title": "Trospium: Drug information", "rep_snippet": "• Myasthenia gravis: Use with caution in patients with myasthenia gravis due to decreased GI motility.  • Renal impairment: Use immediate release formulation with caution in patients with renal impairment; dosage adjustm…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5726169943809509, "bge_max": 0.5726169943809509, "title": "Dalteparin: Drug information", "rep_snippet": "Mechanical heart valve (aortic or mitral position) to bridge anticoagulation (off-label use): SubQ: 100 units/kg/dose every 12 hours (ACCP [Douketis 2012]). Note: If used in pregnant patients, target anti-Xa level of 0.8…"}, {"doc_id": "propranolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5724548697471619, "bge_max": 0.5724548697471619, "title": "Propranolol: Drug information", "rep_snippet": "Administration  IV: IV dose is much smaller than oral dose. When administered acutely for cardiac treatment, monitor ECG and blood pressure. May administer by rapid infusion (IV push) at a rate of 1 mg/minute or by slow…"}, {"doc_id": "lamivudine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5716881155967712, "bge_max": 0.5716881155967712, "title": "Lamivudine: Drug information", "rep_snippet": "Dosing: Adult  Note: The formulation and dosage of Epivir HBV are not appropriate for patients infected with both HBV and HIV; tenofovir and lamivudine are a preferred nucleoside reverse transcriptase inhibitor (NRTI) ba…"}, {"doc_id": "liothyronine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5712642669677734, "bge_max": 0.5712642669677734, "title": "Liothyronine: Drug information", "rep_snippet": "Alternative recommendation (use in combination with levothyroxine) (off-label dose): Initial: 5 to 20 mcg loading dose; maintenance: 2.5 to 10 mcg every 8 hours; continue therapy as clinically indicated. Lower dosages sh…"}]}
{"qid": "Q17_spelling", "query": "Bact vaginosis — metro plan + alcohol issue?", "base_qid": "Q17", "variant_type": "spelling", "candidates": [{"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 13.489997054778701, "bm25_max": 17.729841256331, "bge_top3": 0.5120379229386648, "bge_max": 0.5396146774291992, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Brand Names: US  First-Metronidazole 100;  First-Metronidazole 50;  Flagyl;  Flagyl ER [DSC];  Metro;  MetroNIDAZOLE Benzo+SyrSpend"}, {"doc_id": "levonorgestrel-systemic-drug-information", "bm25_top3": 15.20457632070112, "bm25_max": 17.306850444400112, "bge_top3": null, "bge_max": null, "title": "Levonorgestrel (systemic): Drug information", "rep_snippet": "Brand Names: US  Aftera [OTC];  EContra EZ [OTC];  EContra One-Step [OTC];  Fallback Solo [OTC] [DSC];  My Choice [OTC];  My Way [OTC];  Next Choice One Dose [DSC];  Next Choice One Dose [OTC];  Opcicon One-Step [OTC];…"}, {"doc_id": "disulfiram-drug-information", "bm25_top3": 9.681961175095047, "bm25_max": 9.681961175095047, "bge_top3": null, "bge_max": null, "title": "Disulfiram: Drug information", "rep_snippet": "Food Interactions  Disulfiram inhibits the usual metabolism of alcohol. Patients can have a disulfiram reaction (headache, nausea, vomiting, chest, or abdominal pain) if they drink alcohol concurrently. Management: Avoid…"}, {"doc_id": "secnidazole-drug-information", "bm25_top3": 5.920866261110954, "bm25_max": 7.239023742113872, "bge_top3": 0.4943842887878418, "bge_max": 0.4943842887878418, "title": "Secnidazole: Drug information", "rep_snippet": "Use  Bacterial vaginosis: Treatment of bacterial vaginosis in adult women"}, {"doc_id": "clindamycin-topical-drug-information", "bm25_top3": 6.138319346270631, "bm25_max": 6.138319346270631, "bge_top3": 0.5014938116073608, "bge_max": 0.5014938116073608, "title": "Clindamycin (topical): Drug information", "rep_snippet": "Use  Acne vulgaris: Treatment of acne vulgaris (topical gel, topical lotion, topical solution)  Bacterial vaginosis: Treatment of bacterial vaginosis (vaginal cream, vaginal suppository)"}, {"doc_id": "metronidazole-topical-drug-information", "bm25_top3": 4.198117289286441, "bm25_max": 5.679102116965984, "bge_top3": 0.527759830156962, "bge_max": 0.5367521047592163, "title": "Metronidazole (topical): Drug information", "rep_snippet": "Use  Bacterial vaginosis: Vaginal gel: Treatment of bacterial vaginosis  Rosacea: Topical: Treatment of inflammatory lesions and erythema of rosacea  Trichomoniasis: Flagyl cream [Canadian product]: Treatment of trichomo…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": 1.0917456468891593, "bm25_max": 4.005693661756769, "bge_top3": 0.49806180596351624, "bge_max": 0.49806180596351624, "title": "Tinidazole: Drug information", "rep_snippet": "Use  Amebiasis: Treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in adults and pediatric patients older than 3 years.  Limitations of use: Not indicated for the treatment of asym…"}, {"doc_id": "buprenorphine-and-naloxone-drug-information", "bm25_top3": 3.021719528507651, "bm25_max": 3.021719528507651, "bge_top3": null, "bge_max": null, "title": "Buprenorphine and naloxone: Drug information", "rep_snippet": "Use  Opioid dependence: Treatment of opioid dependence.  General information: Buprenorphine/naloxone should be used as part of a complete treatment plan to include counseling and psychosocial support."}, {"doc_id": "gadoterate-meglumine-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadoterate meglumine: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "gadobenate-dimeglumine-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadobenate dimeglumine: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "gadofosveset-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadofosveset: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "gadobutrol-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadobutrol: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "gadopentetate-dimeglumine-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadopentetate dimeglumine: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "gadoteridol-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadoteridol: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "gadoversetamide-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadoversetamide: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "gadodiamide-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadodiamide: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "gadoxetate-drug-information", "bm25_top3": 2.044033825825066, "bm25_max": 2.044033825825066, "bge_top3": null, "bge_max": null, "title": "Gadoxetate: Drug information", "rep_snippet": "Further information can be found at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm.  Gadolinium-Based Contrast Agents for MRI Safety Review  May 2017  The FDA iden…"}, {"doc_id": "aztreonam-systemic-drug-information", "bm25_top3": 1.8997133293334887, "bm25_max": 1.8997133293334887, "bge_top3": null, "bge_max": null, "title": "Aztreonam (systemic): Drug information", "rep_snippet": "Pharmacologic Category  Antibiotic, Monobactam"}, {"doc_id": "aztreonam-oral-inhalation-drug-information", "bm25_top3": 1.8997133293334887, "bm25_max": 1.8997133293334887, "bge_top3": null, "bge_max": null, "title": "Aztreonam (oral inhalation): Drug information", "rep_snippet": "Pharmacologic Category  Antibiotic, Monobactam"}, {"doc_id": "metronidazole-and-nystatin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5233747959136963, "bge_max": 0.5536782741546631, "title": "Metronidazole and nystatin (United States: Not available): Drug information", "rep_snippet": "• Vaginal products: May limit the effectiveness of diaphragms and condoms; concurrent use with treatment is not recommended.  Other warnings/precautions:  • Alcohol consumption: Disulfiram-like reactions to ethanol have…"}, {"doc_id": "tapentadol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5206395387649536, "bge_max": 0.5206395387649536, "title": "Tapentadol: Drug information", "rep_snippet": "Food Interactions  Ethanol: Concomitant use with alcohol can increase the bioavailability of extended release tablets. Management: Avoid use of alcohol during therapy.  Food: When administered after a high fat/calorie me…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5183693766593933, "bge_max": 0.5183693766593933, "title": "Dalteparin: Drug information", "rep_snippet": "Multiple-dose vials contain benzyl alcohol (avoid in pregnant women due to association with gasping syndrome in premature infants); use of preservative-free formulation is recommended."}, {"doc_id": "hydrocodone-chlorpheniramine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5166710615158081, "bge_max": 0.5166710615158081, "title": "Hydrocodone, chlorpheniramine, and pseudoephedrine: Drug information", "rep_snippet": "Alcohol (Ethyl): May enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodone. Management: Patients using the Zohydro ER brand of extended-release hydrocodone…"}, {"doc_id": "ertapenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5131834745407104, "bge_max": 0.5131834745407104, "title": "Ertapenem: Drug information", "rep_snippet": "Use  Moderate-to-severe infections:  Acute pelvic infections: For the treatment of acute pelvic infections, including postpartum endomyometritis, septic abortion, and postsurgical gynecologic infections caused by Strepto…"}, {"doc_id": "ethanol-topical-and-injection-drug-information", "bm25_top3": -1.3855788827728341, "bm25_max": -1.3390568278848276, "bge_top3": 0.5036735832691193, "bge_max": 0.5107207298278809, "title": "Ethanol (topical and injection): Drug information", "rep_snippet": "Ezogabine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Ezogabine. Alcohol (Ethyl) may increase the serum concentration of Ezogabine. Risk C: Monitor therapy  Fesoterodine: Alcohol (Ethyl) may enhance the CNS…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5063964128494263, "bge_max": 0.5063964128494263, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Use  Intra-abdominal infections: Treatment of appendicitis complicated by rupture or abscess and peritonitis caused by beta-lactamase-producing strains of Escherichia coli, Bacteroides fragilis, Bacteroides ovatus, Bacte…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5021499395370483, "bge_max": 0.5021499395370483, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Use  Oral, IV:  Acute bacterial exacerbations of chronic obstructive pulmonary disease: Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) due to Haemophilus influenzae, Moraxella…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.500410258769989, "bge_max": 0.500410258769989, "title": "Enoxaparin: Drug information", "rep_snippet": "LMWH may also be used in women with mechanical heart valves (consult current guidelines for details) (Bates 2012; Nishimura 2014). Women who require long-term anticoagulation with warfarin and who are considering pregnan…"}, {"doc_id": "meropenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49890369176864624, "bge_max": 0.49890369176864624, "title": "Meropenem: Drug information", "rep_snippet": "Use: Off-Label  Bacterital meningitis; Catheter-related blood stream infections; Cystic fibrosis, pulmonary exacerbation; Febrile neutropenia; Gynecologic and pelvis infection; Melioidosis (Burkholderia pseudomallei); Pn…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4985545873641968, "bge_max": 0.4985545873641968, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Prevpac may be confused with Prevacid  Geriatric Patients: High-Risk Medication:  Beers Criteria: Proton pump inhibitors are identified in the Beers Criteria as p…"}, {"doc_id": "hydrocodone-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49719470739364624, "bge_max": 0.49719470739364624, "title": "Hydrocodone and pseudoephedrine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alcohol (Ethyl): May enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodon…"}, {"doc_id": "hydrocodone-pseudoephedrine-and-guaifenesin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49719470739364624, "bge_max": 0.49719470739364624, "title": "Hydrocodone, pseudoephedrine, and guaifenesin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alcohol (Ethyl): May enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodon…"}, {"doc_id": "metreleptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49689552187919617, "bge_max": 0.49689552187919617, "title": "Metreleptin: Drug information", "rep_snippet": "• Benzyl alcohol and derivatives: Injection contains benzyl alcohol when reconstituted with bacteriostatic water for injection (BWFI); large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potential…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49533262848854065, "bge_max": 0.49533262848854065, "title": "Everolimus: Drug information", "rep_snippet": "Genitourinary: Urinary tract infection (PNET: 16%; advanced HR + BC, RCC: 5% to 10%), irregular menses (TSC, PNET: 10% to 11%)  Hematologic & oncologic: Increase in fasting plasma glucose (PNET: 75%, grades 3/4: 17%; TSC…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4940229654312134, "bge_max": 0.4940229654312134, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dietary Considerations  Should be taken with meals. Avoid ethanol. Dietary modification based on ADA recommendations is a part of therapy."}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4934844970703125, "bge_max": 0.4934844970703125, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Use: Off-Label  Cytomegalovirus (CMV) esophagitis or colitis treatment in HIV-infected patients (adolescents and adults); CMV neurological disease in HIV-infected patients (adolescents and adults); CMV retinitis, seconda…"}, {"doc_id": "mitotane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49269935488700867, "bge_max": 0.49269935488700867, "title": "Mitotane: Drug information", "rep_snippet": "• Ovarian macrocysts: Ovarian macrocysts (often bilateral and multiple) have been reported in premenopausal females receiving mitotane. Complications due to the cysts have been reported (including adnexal torsion and hem…"}, {"doc_id": "morphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4924980700016022, "bge_max": 0.4924980700016022, "title": "Morphine: Drug information", "rep_snippet": "Food Interactions  Ethanol: Alcoholic beverages or ethanol-containing products may disrupt extended release formulation resulting in rapid release of entire morphine dose. Management: Avoid alcohol. Do not administer Avi…"}, {"doc_id": "esterified-estrogens-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4921149015426636, "bge_max": 0.4921149015426636, "title": "Esterified estrogens: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as a potentially inap…"}, {"doc_id": "equine-conjugated-estrogens-and-medroxyprogesterone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4921149015426636, "bge_max": 0.4921149015426636, "title": "Equine conjugated estrogens and medroxyprogesterone acetate: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as a potentially inap…"}, {"doc_id": "bazedoxifene-and-conjugated-equine-estrogens-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49167272448539734, "bge_max": 0.49167272448539734, "title": "Bazedoxifene and conjugated equine estrogens: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "estropipate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49167272448539734, "bge_max": 0.49167272448539734, "title": "Estropipate: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "ethinyl-estradiol-and-norelgestromin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4911504089832306, "bge_max": 0.4911504089832306, "title": "Ethinyl estradiol and norelgestromin: Drug information", "rep_snippet": "• Thromboembolic disorders: [US Boxed Warning]: The pharmacokinetic profile of the patch is different from oral contraceptives; steady state concentrations of ethinyl estradiol are ~60% higher following use of the patch…"}, {"doc_id": "estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49105480313301086, "bge_max": 0.49105480313301086, "title": "Estradiol and norethindrone: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "drospirenone-and-estradiol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49105480313301086, "bge_max": 0.49105480313301086, "title": "Drospirenone and estradiol: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "estradiol-and-norgestimate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49105480313301086, "bge_max": 0.49105480313301086, "title": "Estradiol and norgestimate: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "estradiol-and-levonorgestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.49105480313301086, "bge_max": 0.49105480313301086, "title": "Estradiol and levonorgestrel: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappr…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4910314083099365, "bge_max": 0.4910314083099365, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Brucellosis; Endocarditis, treatment (viridans group streptococcus [VGS] and S. bovis [native or prosthetic valve]) (adults); Gonococcal infection, uncomplicated (patients with severe cephalosporin allerg…"}, {"doc_id": "meloxicam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4909592866897583, "bge_max": 0.4909592866897583, "title": "Meloxicam: Drug information", "rep_snippet": "Medication Safety Issues  Geriatric Patients: High-Risk Medication:  Beers Criteria: Meloxicam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (u…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4907683730125427, "bge_max": 0.4907683730125427, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Use  Pneumonia, community-acquired: Extended-release tablets only: Treatment of patients with community-acquired pneumonia (CAP) caused by confirmed or suspected beta-lactamase-producing pathogens (ie, Haemophilus influe…"}, {"doc_id": "ethinyl-estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4906027317047119, "bge_max": 0.4906027317047119, "title": "Ethinyl estradiol and norethindrone: Drug information", "rep_snippet": "Food Interactions  Routine use of ethanol increases estrogen level and risk of breast cancer. Management: Avoid ethanol."}, {"doc_id": "synthetic-conjugated-estrogens-a-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4906027317047119, "bge_max": 0.4906027317047119, "title": "Synthetic conjugated estrogens A (United States: Not available): Drug information", "rep_snippet": "Food Interactions  Routine use of ethanol increases estrogen level and risk of breast cancer. Management: Avoid ethanol."}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 0.10268708984935415, "bm25_max": 0.10268708984935415, "bge_top3": null, "bge_max": null, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Clindamycin crosses the placenta and can be detected in the cord blood and fetal tissue (Philipson 1973; Weinstein 1976). Clindamycin injection contains benzyl alcohol which may also cross the pla…"}, {"doc_id": "quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-drug-information", "bm25_top3": -0.26950290638274943, "bm25_max": -0.26950290638274943, "bge_top3": null, "bge_max": null, "title": "Quadrivalent meningococcal polysaccharide vaccine (unconjugated/carrier-free) (United States: Not available): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  MPSV (meningococcal polysaccharide vaccine; MPSV4 is the correct abbreviation) may be confused with MCV4 (meningococcal ACWY conjugate vaccine)  MPSV (meningococc…"}, {"doc_id": "eszopiclone-drug-information", "bm25_top3": -0.7925446200316468, "bm25_max": -0.7925446200316468, "bge_top3": null, "bge_max": null, "title": "Eszopiclone: Drug information", "rep_snippet": "• Hypersensitivity reactions: Hypersensitivity reactions including anaphylaxis as well as angioedema have been reported, in some cases following initial dosing. Patients who develop severe reactions should not be rechall…"}, {"doc_id": "zolpidem-drug-information", "bm25_top3": -0.8855567083498492, "bm25_max": -0.8855567083498492, "bge_top3": null, "bge_max": null, "title": "Zolpidem: Drug information", "rep_snippet": "• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis as well as angioedema, have been reported after taking the first or subsequent doses. Do not rechallenge patient if such reactions occur.  •…"}, {"doc_id": "zaleplon-drug-information", "bm25_top3": -1.0653966212265296, "bm25_max": -1.0653966212265296, "bge_top3": null, "bge_max": null, "title": "Zaleplon: Drug information", "rep_snippet": "• Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving, cooking and eating food, having sex, and making phone calls while asleep have been noted; amnesia may also occur…"}, {"doc_id": "ciclopirox-drug-information", "bm25_top3": -1.087927484830308, "bm25_max": -1.087927484830308, "bge_top3": null, "bge_max": null, "title": "Ciclopirox: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, External, as olamine [strength expressed as base]…"}, {"doc_id": "suvorexant-drug-information", "bm25_top3": -1.1809257326699, "bm25_max": -1.1809257326699, "bge_top3": null, "bge_max": null, "title": "Suvorexant: Drug information", "rep_snippet": "• Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, making phone calls, or having sex while asleep have also been noted. Discontinue treatm…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": -1.3482275530180692, "bm25_max": -1.3482275530180692, "bge_top3": null, "bge_max": null, "title": "Telithromycin: Drug information", "rep_snippet": "Adverse Reactions  >10%: Gastrointestinal: Diarrhea (10% to 11%)  2% to 10%:  Central nervous system: Headache (2% to 6%), dizziness (3% to 4%)  Gastrointestinal: Nausea (7% to 8%), vomiting (2% to 3%), dysgeusia (2%), l…"}, {"doc_id": "clotrimazole-topical-drug-information", "bm25_top3": -1.3942133865665856, "bm25_max": -1.3942133865665856, "bge_top3": null, "bge_max": null, "title": "Clotrimazole (topical): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, External:  Clotrimazole GRx: 1% (14 g) [contains…"}, {"doc_id": "imiquimod-drug-information", "bm25_top3": -1.471504829468115, "bm25_max": -1.471504829468115, "bge_top3": null, "bge_max": null, "title": "Imiquimod: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Cream, External:  Aldara: 5% (12 ea) [contains benzyl alcohol, cetyl alcohol, methylp…"}, {"doc_id": "minoxidil-topical-drug-information", "bm25_top3": -1.541340339517129, "bm25_max": -1.541340339517129, "bge_top3": null, "bge_max": null, "title": "Minoxidil (topical): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Foam, External:  Rogaine Mens: 5% (60 g) [contains cetyl alcohol, sd alcohol 40b]  Ro…"}, {"doc_id": "acamprosate-drug-information", "bm25_top3": -1.628069638376945, "bm25_max": -1.628069638376945, "bge_top3": null, "bge_max": null, "title": "Acamprosate: Drug information", "rep_snippet": "Use  Alcohol abstinence: Maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation, as part of a comprehensive management program  Limitations of use: Efficacy h…"}, {"doc_id": "terbinafine-topical-drug-information", "bm25_top3": -1.6367888204945924, "bm25_max": -1.6367888204945924, "bge_top3": null, "bge_max": null, "title": "Terbinafine (topical): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, External, as hydrochloride:  LamISIL AT: 1% (12 g…"}, {"doc_id": "lidocaine-topical-drug-information", "bm25_top3": -1.680165320162188, "bm25_max": -1.680165320162188, "bge_top3": null, "bge_max": null, "title": "Lidocaine (topical): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, External:  AneCream: 4% (5 g, 15 g, 30 g) [contai…"}]}
{"qid": "Q18_abbr+DDI-cue", "query": "Acute gout — colchicine loading/maintenance & renal cautions; avoid with strong CYP3A4/P-gp inhibitors.", "base_qid": "Q18", "variant_type": "abbr+DDI-cue", "candidates": [{"doc_id": "colchicine-and-probenecid-drug-information", "bm25_top3": 49.94138063060885, "bm25_max": 49.94138063060885, "bge_top3": 0.7069463431835175, "bge_max": 0.7103772759437561, "title": "Colchicine and probenecid: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to colchicine, probenecid, or any component of the formulation; children <2 years of age; small- or large-dose aspirin therapy; blood dyscrasias; uric acid kidney stones; initiation du…"}, {"doc_id": "colchicine-drug-information", "bm25_top3": 40.02032231319327, "bm25_max": 43.09094767132224, "bge_top3": 0.7447129487991333, "bge_max": 0.7646728754043579, "title": "Colchicine: Drug information", "rep_snippet": "Contraindications  Concomitant use of a P-glycoprotein (P-gp) or strong CYP3A4 inhibitor in presence of renal or hepatic impairment  Mitigare: Patients with both renal and hepatic impairment.  Canadian labeling: Addition…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": 28.481065127270476, "bm25_max": 30.63554026126944, "bge_top3": null, "bge_max": null, "title": "Everolimus: Drug information", "rep_snippet": "Breast cancer, neuroendocrine tumors, RCC, renal angiomyolipoma:  CYP3A4/P-gp inducers: Strong inducers: Avoid coadministration with strong CYP3A4/P-gp inducers (eg, carbamazepine, phenobarbital, phenytoin, rifabutin, ri…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 28.061383592425244, "bm25_max": 28.061383592425244, "bge_top3": 0.6919232606887817, "bge_max": 0.6919232606887817, "title": "Itraconazole: Drug information", "rep_snippet": "Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. Risk X: Avoid combination  Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Managemen…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 27.530176823555998, "bm25_max": 27.530176823555998, "bge_top3": 0.6937510967254639, "bge_max": 0.6937510967254639, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 27.530176823555998, "bm25_max": 27.530176823555998, "bge_top3": 0.6937510967254639, "bge_max": 0.6937510967254639, "title": "Clarithromycin: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": 27.24957844129898, "bm25_max": 27.24957844129898, "bge_top3": 0.6947050094604492, "bge_max": 0.6947050094604492, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": 27.24957844129898, "bm25_max": 27.24957844129898, "bge_top3": 0.6947050094604492, "bge_max": 0.6947050094604492, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 25.23447483048868, "bm25_max": 25.23447483048868, "bge_top3": 0.6900039315223694, "bge_max": 0.6900039315223694, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": 22.48433475754743, "bm25_max": 25.101856178764955, "bge_top3": 0.6932457685470581, "bge_max": 0.6932457685470581, "title": "Ritonavir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "lumacaftor-and-ivacaftor-drug-information", "bm25_top3": 24.116935922201897, "bm25_max": 24.116935922201897, "bge_top3": null, "bge_max": null, "title": "Lumacaftor and ivacaftor: Drug information", "rep_snippet": "Clindamycin (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). Refer to the specific clindamycin (systemic) - rifampin drug interaction monograph for information concerni…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": 24.06849545757099, "bm25_max": 24.06849545757099, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "eliglustat-drug-information", "bm25_top3": 23.699987021113778, "bm25_max": 23.699987021113778, "bge_top3": 0.7096697092056274, "bge_max": 0.7096697092056274, "title": "Eliglustat: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": 23.149305855273326, "bm25_max": 23.149305855273326, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "daclatasvir-drug-information", "bm25_top3": 23.129462319984817, "bm25_max": 23.129462319984817, "bge_top3": null, "bge_max": null, "title": "Daclatasvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "ranolazine-drug-information", "bm25_top3": 22.604898094728483, "bm25_max": 22.604898094728483, "bge_top3": null, "bge_max": null, "title": "Ranolazine: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "neratinib-drug-information", "bm25_top3": 22.10781012843, "bm25_max": 22.10781012843, "bge_top3": 0.6868897676467896, "bge_max": 0.6868897676467896, "title": "Neratinib: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": 22.01672216874353, "bm25_max": 22.01672216874353, "bge_top3": 0.6859312057495117, "bge_max": 0.6859312057495117, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "atazanavir-drug-information", "bm25_top3": 22.01672216874353, "bm25_max": 22.01672216874353, "bge_top3": 0.6859312057495117, "bge_max": 0.6859312057495117, "title": "Atazanavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": 22.01672216874353, "bm25_max": 22.01672216874353, "bge_top3": 0.6859312057495117, "bge_max": 0.6859312057495117, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 22.01672216874353, "bm25_max": 22.01672216874353, "bge_top3": 0.6859312057495117, "bge_max": 0.6859312057495117, "title": "Telithromycin: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "rolapitant-drug-information", "bm25_top3": 21.999486677003087, "bm25_max": 21.999486677003087, "bge_top3": null, "bge_max": null, "title": "Rolapitant: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": 21.86510104037081, "bm25_max": 21.86510104037081, "bge_top3": null, "bge_max": null, "title": "Posaconazole: Drug information", "rep_snippet": "CloZAPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of CloZAPine. Risk C: Monitor therapy  Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. Risk X: Avoid…"}, {"doc_id": "ledipasvir-and-sofosbuvir-drug-information", "bm25_top3": 21.726751021462288, "bm25_max": 21.726751021462288, "bge_top3": null, "bge_max": null, "title": "Ledipasvir and sofosbuvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "ivacaftor-drug-information", "bm25_top3": 21.64281509520292, "bm25_max": 21.64281509520292, "bge_top3": null, "bge_max": null, "title": "Ivacaftor: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "tezacaftor-and-ivacaftor-drug-information", "bm25_top3": 21.64281509520292, "bm25_max": 21.64281509520292, "bge_top3": null, "bge_max": null, "title": "Tezacaftor and ivacaftor: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 21.604463847140316, "bm25_max": 21.604463847140316, "bge_top3": 0.6866528987884521, "bge_max": 0.6866528987884521, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib. Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or les…"}, {"doc_id": "dronedarone-drug-information", "bm25_top3": 21.550680599200103, "bm25_max": 21.550680599200103, "bge_top3": null, "bge_max": null, "title": "Dronedarone: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchic…"}, {"doc_id": "nefazodone-drug-information", "bm25_top3": 21.207171558188538, "bm25_max": 21.207171558188538, "bge_top3": null, "bge_max": null, "title": "Nefazodone: Drug information", "rep_snippet": "Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving strong inhibitors…"}, {"doc_id": "quinidine-drug-information", "bm25_top3": 21.162168966187128, "bm25_max": 21.162168966187128, "bge_top3": null, "bge_max": null, "title": "Quinidine: Drug information", "rep_snippet": "Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Risk D: Consider therapy modi…"}, {"doc_id": "mifepristone-and-misoprostol-united-states-not-available-drug-information", "bm25_top3": 20.76537108080741, "bm25_max": 20.76537108080741, "bge_top3": null, "bge_max": null, "title": "Mifepristone and misoprostol (United States: Not available): Drug information", "rep_snippet": "Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib. Management: If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest…"}, {"doc_id": "saquinavir-drug-information", "bm25_top3": 20.755517948284723, "bm25_max": 20.755517948284723, "bge_top3": null, "bge_max": null, "title": "Saquinavir: Drug information", "rep_snippet": "Cobicistat: May increase the serum concentration of Saquinavir. However, the magnitude of this change is unclear, and dosing recommendations for this combination are not available. Risk X: Avoid combination  Cobimetinib:…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information", "bm25_top3": 20.643011728166407, "bm25_max": 20.643011728166407, "bge_top3": 0.6975077390670776, "bge_max": 0.6975077390670776, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "indinavir-drug-information", "bm25_top3": 20.643011728166407, "bm25_max": 20.643011728166407, "bge_top3": 0.6975077390670776, "bge_max": 0.6975077390670776, "title": "Indinavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": 20.643011728166407, "bm25_max": 20.643011728166407, "bge_top3": 0.6975077390670776, "bge_max": 0.6975077390670776, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "nelfinavir-drug-information", "bm25_top3": 20.643011728166407, "bm25_max": 20.643011728166407, "bge_top3": 0.6975077390670776, "bge_max": 0.6975077390670776, "title": "Nelfinavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "cobicistat-drug-information", "bm25_top3": 20.643011728166407, "bm25_max": 20.643011728166407, "bge_top3": 0.6975077390670776, "bge_max": 0.6975077390670776, "title": "Cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": 20.452517161475214, "bm25_max": 20.452517161475214, "bge_top3": null, "bge_max": null, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 20.405030903120938, "bm25_max": 20.405030903120938, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Risk C: Monitor therapy  Co…"}, {"doc_id": "dextromethorphan-and-quinidine-drug-information", "bm25_top3": 20.34864426188592, "bm25_max": 20.34864426188592, "bge_top3": null, "bge_max": null, "title": "Dextromethorphan and quinidine: Drug information", "rep_snippet": "Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Risk D: Consider therapy modi…"}, {"doc_id": "lapatinib-drug-information", "bm25_top3": 20.33217473096383, "bm25_max": 20.33217473096383, "bge_top3": null, "bge_max": null, "title": "Lapatinib: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": 20.28186423287928, "bm25_max": 20.28186423287928, "bge_top3": null, "bge_max": null, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Clarithromycin: May increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Clarithromycin. Risk C: Monitor therapy  CloZAPine: CYP3A4 Inhibitors (Strong) may increase the serum…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": 20.172704812571656, "bm25_max": 20.172704812571656, "bge_top3": null, "bge_max": null, "title": "Verapamil: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchic…"}, {"doc_id": "glecaprevir-and-pibrentasvir-drug-information", "bm25_top3": 20.136112231304296, "bm25_max": 20.136112231304296, "bge_top3": null, "bge_max": null, "title": "Glecaprevir and pibrentasvir: Drug information", "rep_snippet": "Cobicistat: May increase the serum concentration of Glecaprevir and Pibrentasvir. Risk C: Monitor therapy  Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distri…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 20.11832659972771, "bm25_max": 20.11832659972771, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Cobicistat: Voriconazole may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Voriconazole. Management: Careful consideration of the risk/benefit ratio for voriconazole u…"}, {"doc_id": "allopurinol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7463406324386597, "bge_max": 0.7463406324386597, "title": "Allopurinol: Drug information", "rep_snippet": "• Acute gout attacks: Even when normal or subnormal serum uric acid levels have been attained, an increase in acute gout attacks has been reported during the early stages of allopurinol administration. When allopurinol i…"}, {"doc_id": "probenecid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7270350456237793, "bge_max": 0.7270350456237793, "title": "Probenecid: Drug information", "rep_snippet": "Use  Treatment of hyperuricemia associated with gout or gouty arthritis; prolongation and elevation of beta-lactam plasma levels  Guideline recommendations:  Gout: Uricosurics, such as probenecid, are recommended alone o…"}, {"doc_id": "pegloticase-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.710117777188619, "bge_max": 0.7268978357315063, "title": "Pegloticase: Drug information", "rep_snippet": "Dosing: Adult  Note: Discontinue use of oral antihyperuricemic agents prior to initiating pegloticase and do not initiate during the course of therapy. Premedicate with antihistamines and corticosteroids. Gout flare prop…"}, {"doc_id": "febuxostat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7136967778205872, "bge_max": 0.7257363200187683, "title": "Febuxostat: Drug information", "rep_snippet": "• Appropriate use: Administer concurrently with an NSAID or colchicine (up to 6 months) to prevent gout flare, which may occur upon initiation of therapy. Do not use to treat asymptomatic or secondary hyperuricemia."}, {"doc_id": "polyethylene-glycol-electrolyte-solution-and-sulfate-solution-kit-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7062811255455017, "bge_max": 0.7062811255455017, "title": "Polyethylene glycol electrolyte solution and sulfate solution kit (United States: Not available): Drug information", "rep_snippet": "• Renal impairment: Use caution in patients with renal impairment; adequate hydration is particularly important in these patients or in patients receiving concomitant medications that may affect renal function (eg, diure…"}, {"doc_id": "lesinurad-and-allopurinol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7012116312980652, "bge_max": 0.7012116312980652, "title": "Lesinurad and allopurinol: Drug information", "rep_snippet": "Use  Hyperuricemia associated with gout: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.  Limi…"}, {"doc_id": "alprazolam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6973198056221008, "bge_max": 0.6973198056221008, "title": "Alprazolam: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment or predisposition to urate nephropathy; has weak uricosuric properties.  • Respiratory disease: Use with caution in patients with respiratory disease…"}, {"doc_id": "tolterodine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6973087787628174, "bge_max": 0.6973087787628174, "title": "Tolterodine: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required.  Concurrent drug therapy issues:  • CYP3A4 inhibitors: Dosage adjustment is recommended in patients receiving CYP3A4…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6957388520240784, "bge_max": 0.6957388520240784, "title": "Ergotamine: Drug information", "rep_snippet": "• Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.  Concurrent drug therapy issues:  • CYP3A4 inhibitors: [US Boxed Warning]: Ergot alka…"}, {"doc_id": "methenamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6954074501991272, "bge_max": 0.6954074501991272, "title": "Methenamine: Drug information", "rep_snippet": "Warnings/Precautions  Disease-related concerns:  • Gout: Avoid use in patients with gout; may precipitate urate crystals in urine.  • Hepatic impairment: Use with caution in patients with hepatic impairment; reversible i…"}, {"doc_id": "inosine-pranobex-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6950575709342957, "bge_max": 0.6950575709342957, "title": "Inosine pranobex (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Uric acid: Inosine undergoes rapid metabolism to uric acid. Use with caution in patients with a history of gout, urolithiasis, nephrolithiasis, or renal impai…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6944530606269836, "bge_max": 0.6944530606269836, "title": "Ertugliflozin: Drug information", "rep_snippet": "• Renal effects: Acute kidney injury has been reported. Prior to initiation, consider risk factors for acute kidney injury (eg, hypovolemia, chronic renal insufficiency, heart failure, use of concomitant medications [eg,…"}, {"doc_id": "alosetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6922798156738281, "bge_max": 0.6922798156738281, "title": "Alosetron: Drug information", "rep_snippet": "• Hepatic impairment: Use caution in mild to moderate hepatic impairment (Child-Pugh class A or B) (extensively metabolized); contraindicated in severe impairment (Child-Pugh class C).  Special populations:  • Debilitate…"}, {"doc_id": "benazepril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6916817426681519, "bge_max": 0.6916817426681519, "title": "Benazepril and hydrochlorothiazide: Drug information", "rep_snippet": "• Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide. This risk may be increased with doses ≥25 mg (Gurwitz 1997…"}, {"doc_id": "quinapril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6916817426681519, "bge_max": 0.6916817426681519, "title": "Quinapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide. This risk may be increased with doses ≥25 mg (Gurwitz 1997…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6900972127914429, "bge_max": 0.6900972127914429, "title": "Canagliflozin: Drug information", "rep_snippet": "• Renal effects: Acute kidney injury has been reported. Prior to initiation, consider risk factors for acute kidney injury (eg, hypovolemia, chronic renal insufficiency, heart failure, use of concomitant medications [eg,…"}, {"doc_id": "metolazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.687475323677063, "bge_max": 0.687475323677063, "title": "Metolazone: Drug information", "rep_snippet": "Disease-related concerns:  • Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineraloc…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6858315467834473, "bge_max": 0.6858315467834473, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "• Alcoholism: Use with caution in patients with a history of alcoholism (even if ethanol consumption is discontinued during therapy).  • Diabetes: Use with caution in patients with diabetes mellitus; management of diabet…"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.685025155544281, "bge_max": 0.685025155544281, "title": "Vemurafenib: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "chlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6843326687812805, "bge_max": 0.6843326687812805, "title": "Chlorothiazide: Drug information", "rep_snippet": "Disease-related concerns:  • Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineraloc…"}]}
{"qid": "Q18_noise", "query": "Gout flare — how to dose colchicine (LD/MD), renal notes, and DDI red flags?", "base_qid": "Q18", "variant_type": "noise", "candidates": [{"doc_id": "colchicine-drug-information", "bm25_top3": 35.425642234169345, "bm25_max": 37.70439683421043, "bge_top3": 0.6546570261319479, "bge_max": 0.6659783124923706, "title": "Colchicine: Drug information", "rep_snippet": "Dosing: Adult  Familial Mediterranean fever (FMF): Oral: Tablet (eg, Colcrys): 1.2 to 2.4 mg daily in 1 to 2 divided doses. Titration: Increase or decrease dose in 0.3 mg daily increments based on efficacy or adverse eff…"}, {"doc_id": "colchicine-and-probenecid-drug-information", "bm25_top3": 26.710553833132078, "bm25_max": 34.78196977786196, "bge_top3": 0.6077059507369995, "bge_max": 0.6077059507369995, "title": "Colchicine and probenecid: Drug information", "rep_snippet": "Dosing: Adult  Gout: Oral: Colchicine 0.5 mg and probenecid 0.5 g: One tablet once daily for 1 week, then 1 tablet twice daily thereafter  Note: Current prescribing information states a maximum dose of 4 tablets per day;…"}, {"doc_id": "lesinurad-and-allopurinol-drug-information", "bm25_top3": 29.360643106229173, "bm25_max": 33.10350475230939, "bge_top3": 0.6029227375984192, "bge_max": 0.6029227375984192, "title": "Lesinurad and allopurinol: Drug information", "rep_snippet": "Dosing: Adult  Note: Use of this combination product is not recommended in patients taking allopurinol <300 mg/day (or <200 mg/day in patients with estimated CrCl <60 mL/min). Gout flare prophylaxis is recommended in pat…"}, {"doc_id": "pegloticase-drug-information", "bm25_top3": 19.574913866348076, "bm25_max": 26.086881011625426, "bge_top3": 0.6394115388393402, "bge_max": 0.6480526328086853, "title": "Pegloticase: Drug information", "rep_snippet": "Dosing: Adult  Note: Discontinue use of oral antihyperuricemic agents prior to initiating pegloticase and do not initiate during the course of therapy. Premedicate with antihistamines and corticosteroids. Gout flare prop…"}, {"doc_id": "febuxostat-drug-information", "bm25_top3": 19.815738287539727, "bm25_max": 24.232637834449687, "bge_top3": 0.6025920808315277, "bge_max": 0.6270409822463989, "title": "Febuxostat: Drug information", "rep_snippet": "Dosing: Adult  Note: It is recommended to take an NSAID or colchicine with initiation of therapy and may continue for up to 6 months to help prevent gout flares. If a gout flare occurs, febuxostat does not need to be dis…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": 19.95004264742108, "bm25_max": 19.95004264742108, "bge_top3": null, "bge_max": null, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 19.708865142501235, "bm25_max": 19.708865142501235, "bge_top3": null, "bge_max": null, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib. Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or les…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 19.381215604114388, "bm25_max": 19.381215604114388, "bge_top3": null, "bge_max": null, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "ledipasvir-and-sofosbuvir-drug-information", "bm25_top3": 18.920946642660777, "bm25_max": 18.920946642660777, "bge_top3": null, "bge_max": null, "title": "Ledipasvir and sofosbuvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information", "bm25_top3": 17.595323899968367, "bm25_max": 17.868903844041423, "bge_top3": null, "bge_max": null, "title": "Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Drug information", "rep_snippet": "Brand Names: International  Gastrografin (AU, CL, CY, EG, ES, FI, GR, KR, KW, MT, NO, NZ, QA, SA);  Gastrografine (FR);  MD 76 (AU);  MD Gastroview (AU, NZ, SG);  MD-76R (AR);  MD-Gastroview (LK);  Pielograf (CO)"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 17.233865335043127, "bm25_max": 17.28827386702301, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": 17.20197895247955, "bm25_max": 17.20197895247955, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "perindopril-and-indapamide-united-states-not-available-drug-information", "bm25_top3": 16.124842728570847, "bm25_max": 17.11048957195484, "bge_top3": null, "bge_max": null, "title": "Perindopril and indapamide (United States: Not available): Drug information", "rep_snippet": "Brand Names: Canada  Arcosyl Plus;  Arcosyl Plus LD;  Coversyl Plus;  Coversyl Plus HD;  Coversyl Plus LD"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": 17.081029505623448, "bm25_max": 17.081029505623448, "bge_top3": null, "bge_max": null, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": 17.081029505623448, "bm25_max": 17.081029505623448, "bge_top3": null, "bge_max": null, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "hydrochlorothiazide-and-triamterene-drug-information", "bm25_top3": 17.052787934838985, "bm25_max": 17.052787934838985, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and triamterene: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia may occur with hydrochlorothiazide.  • Gout: In certain patients with a histo…"}, {"doc_id": "glecaprevir-and-pibrentasvir-drug-information", "bm25_top3": 17.02001975803954, "bm25_max": 17.02001975803954, "bge_top3": null, "bge_max": null, "title": "Glecaprevir and pibrentasvir: Drug information", "rep_snippet": "Cobicistat: May increase the serum concentration of Glecaprevir and Pibrentasvir. Risk C: Monitor therapy  Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distri…"}, {"doc_id": "mifepristone-and-misoprostol-united-states-not-available-drug-information", "bm25_top3": 16.643894412827756, "bm25_max": 16.643894412827756, "bge_top3": null, "bge_max": null, "title": "Mifepristone and misoprostol (United States: Not available): Drug information", "rep_snippet": "Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib. Management: If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": 16.591495773628456, "bm25_max": 16.591495773628456, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "lesinurad-drug-information", "bm25_top3": 14.695649699756764, "bm25_max": 14.695649699756764, "bge_top3": 0.5644056499004364, "bge_max": 0.5729341506958008, "title": "Lesinurad: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Cardiovascular events: Major cardiac adverse events (cardiovascular deaths, non-fatal MI, or non-fatal strokes) were observed in clinical trials, although a c…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": 8.950042647421078, "bm25_max": 8.950042647421078, "bge_top3": null, "bge_max": null, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 8.381215604114388, "bm25_max": 8.381215604114388, "bge_top3": null, "bge_max": null, "title": "Clarithromycin: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 7.91067877214838, "bm25_max": 7.91067877214838, "bge_top3": null, "bge_max": null, "title": "Itraconazole: Drug information", "rep_snippet": "Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. Risk X: Avoid combination  Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Managemen…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": 7.703218754943016, "bm25_max": 7.703218754943016, "bge_top3": null, "bge_max": null, "title": "Verapamil: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchic…"}, {"doc_id": "dronedarone-drug-information", "bm25_top3": 7.610565709509498, "bm25_max": 7.610565709509498, "bge_top3": null, "bge_max": null, "title": "Dronedarone: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchic…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": 7.018956679410621, "bm25_max": 7.018956679410621, "bge_top3": null, "bge_max": null, "title": "Ritonavir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 6.355737420146358, "bm25_max": 6.355737420146358, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 6.339774585712629, "bm25_max": 6.339774585712629, "bge_top3": null, "bge_max": null, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Cisapride: Macrolide Antibiotics may enhance the QTc-prolonging effect of Cisapride. Macrolide Antibiotics may decrease the metabolism of Cisapride. Risk X: Avoid combination  Colchicine: P-glycoprotein/ABCB1 Inhibitors…"}, {"doc_id": "allopurinol-drug-information", "bm25_top3": 6.272009982110831, "bm25_max": 6.272009982110831, "bge_top3": 0.579778790473938, "bge_max": 0.6006796956062317, "title": "Allopurinol: Drug information", "rep_snippet": "• Acute gout attacks: Even when normal or subnormal serum uric acid levels have been attained, an increase in acute gout attacks has been reported during the early stages of allopurinol administration. When allopurinol i…"}, {"doc_id": "eliglustat-drug-information", "bm25_top3": 6.136673055290654, "bm25_max": 6.136673055290654, "bge_top3": null, "bge_max": null, "title": "Eliglustat: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 6.081029505623448, "bm25_max": 6.081029505623448, "bge_top3": null, "bge_max": null, "title": "Telithromycin: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "atazanavir-drug-information", "bm25_top3": 6.081029505623448, "bm25_max": 6.081029505623448, "bge_top3": null, "bge_max": null, "title": "Atazanavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "daclatasvir-drug-information", "bm25_top3": 5.778825688354793, "bm25_max": 5.778825688354793, "bge_top3": null, "bge_max": null, "title": "Daclatasvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "digoxin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.576491117477417, "bge_max": 0.576491117477417, "title": "Digoxin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Oral, IV:  Loading dose: There are no dosage adjustments provided in the manufacturer’s labeling, however, 50% to 70% of a digoxin dose is excreted unchanged in the urine. The following…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5665178000926971, "bge_max": 0.5758873224258423, "title": "Prednisone: Drug information", "rep_snippet": "Glucocorticoid remediable aldosteronism, treatment (off-label use): Oral: Initial: 2.5 to 5 mg once daily preferably at bedtime to suppress early morning ACTH surge (Funder 2016)  Gout, treatment of acute flare (off-labe…"}, {"doc_id": "glipizide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5746150016784668, "bge_max": 0.5746150016784668, "title": "Glipizide: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Immediate release: Glipizide is a preferred sulfonylurea (due to inactive metabolites) and no dosage adjustment is generally necessary in patients with chronic kidney disease (KDOQI 2012…"}, {"doc_id": "probenecid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5635527074337006, "bge_max": 0.5722880363464355, "title": "Probenecid: Drug information", "rep_snippet": "Dosing: Adult  Hyperuricemia with gout: Oral: 250 mg twice daily for 1 week; may increase to 500 mg twice daily; if needed, may increase to a maximum of 2 g/day (increase dosage in 500 mg increments every 4 weeks). If se…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5667913556098938, "bge_max": 0.5667913556098938, "title": "Ceftriaxone: Drug information", "rep_snippet": "Disseminated gonococcal infection (DGI) in infants including scalp abscess (off-label use): IM, IV:  Infants: 25 to 50 mg/kg/dose once daily for 7 days (10 to 14 days for meningitis) (CDC [Workowski 2015]); Note: Use con…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5665412545204163, "bge_max": 0.5665412545204163, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.56549072265625, "bge_max": 0.56549072265625, "title": "Sulfadiazine: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Oral: 2 to 4 g/day in 3 to 6 divided doses  Rheumatic fever prophylaxis (off-label dose) (Gerber [AHA 2009]): Oral:  ≤27 kg: 500 mg once daily  >27 kg: 1,000 mg once daily  Toxop…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5647565722465515, "bge_max": 0.5647565722465515, "title": "Doxycycline: Drug information", "rep_snippet": "Persistent localized infection (endocarditis, vascular infection): Oral: 100 mg every 12 hours in combination with hydroxychloroquine for ≥18 months depending on site of infection and serologic response (CDC [Anderson 20…"}, {"doc_id": "calcitriol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5646117925643921, "bge_max": 0.5646117925643921, "title": "Calcitriol (systemic): Drug information", "rep_snippet": "Note: KDIGO guidelines do not recommend routine vitamin D therapy (with vitamin D supplements or a vitamin D analog [eg, calcitriol]) for progressive or persistently elevated PTH concentrations in CKD patients (stages 3-…"}, {"doc_id": "anakinra-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5613094568252563, "bge_max": 0.5613094568252563, "title": "Anakinra: Drug information", "rep_snippet": "Dosing: Adult  Neonatal-onset multisystem inflammatory disease (NOMID): SubQ: Initial: 1 to 2 mg/kg daily in 1 to 2 divided doses; adjust dose in 0.5 to 1 mg/kg increments as needed; usual maintenance dose: 3 to 4 mg/kg…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5609347820281982, "bge_max": 0.5609347820281982, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Group A streptococci (GAS) chronic carrier, treatment (off-label use): Children and Adolescents: Refer to adult dosing.  Anaplasmosis, mild cases (patients with severe allergy to doxycycline) (off-label use): Children an…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5608552694320679, "bge_max": 0.5608552694320679, "title": "Methylprednisolone: Drug information", "rep_snippet": "Dermatomyositis/polymyositis (off-label dosing): IV (succinate): 1,000 mg daily for 3 to 5 days for severe muscle weakness, followed by conversion to oral prednisone (Drake 1996)  Gout, acute (off-label dosing): IV (succ…"}, {"doc_id": "potassium-citrate-and-citric-acid-powder-or-solution-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5580430626869202, "bge_max": 0.5580430626869202, "title": "Potassium citrate and citric acid (powder or solution): Drug information", "rep_snippet": "Dosing: Adult  Systemic alkalinizer, Acidosis, Gout (adjuvant): Oral:  Powder: One packet dissolved in water 4 times daily; adjust dose to urinary pH  Solution: 10 to 30 mL 4 times daily; adjust dose based on urinary pH"}, {"doc_id": "corticotropin-injection-gel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5577486753463745, "bge_max": 0.5577486753463745, "title": "Corticotropin injection gel: Drug information", "rep_snippet": "Dosing: Adult  Note: Sudden withdrawal may lead to adrenal insufficiency or recurrent symptoms; tapering the dose prior to discontinuation may be necessary following prolonged administration.  Acute exacerbation of multi…"}, {"doc_id": "durvalumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5566180944442749, "bge_max": 0.5566180944442749, "title": "Durvalumab: Drug information", "rep_snippet": "Colitis or diarrhea, grade 3 or 4: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) followed by a taper.  Infection: Grade 3 or 4: Withhold dose u…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5563933849334717, "bge_max": 0.5563933849334717, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Clostridium difficile-associated diarrhea (CDAD; off-label use): Infants, Children, and Adolescents: Oral: 30 mg/kg/day divided every 6 hours for ≥10 days (maximum: 2,000 mg/day) (Red Book [AAP 2015]; AAP [Schutze 2013])…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5558735132217407, "bge_max": 0.5558735132217407, "title": "Cefazolin: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: IM, IV: 1 to 1.5 g every 8 hours, depending on severity of infection; maximum: 12 g daily  Catheter-related bloodstream infections (off-label use): IV: 2 g every 8 hours (IDSA [Mermel 2…"}, {"doc_id": "gadopentetate-dimeglumine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5539121627807617, "bge_max": 0.5539121627807617, "title": "Gadopentetate dimeglumine: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  GFR >30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Risk for NSF development increases as renal function decreases.  GFR…"}, {"doc_id": "famotidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5523785352706909, "bge_max": 0.5523785352706909, "title": "Famotidine: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer:  IV: 20 mg every 12 hours  Oral: Acute therapy: 40 mg once daily at bedtime (or 20 mg twice daily) for 4 to 8 weeks; maintenance therapy: 20 mg once daily at bedtime  Gastric ulcer:  IV: 20…"}, {"doc_id": "dolutegravir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5521129965782166, "bge_max": 0.5521129965782166, "title": "Dolutegravir: Drug information", "rep_snippet": "Isoniazid: Dolutegravir may enhance the adverse/toxic effect of Isoniazid. Risk C: Monitor therapy  Magnesium Salts: May decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 ho…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5519734025001526, "bge_max": 0.5519734025001526, "title": "Fluconazole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Note: Renal function estimated using the Cockcroft-Gault formula  No adjustment for vaginal candidiasis single-dose therapy  For multiple dosing in adults, administer lo…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5514735579490662, "bge_max": 0.5514735579490662, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Dosing: Adult  Dermatitis herpetiformis: Oral: Start at 50 mg daily, increase to 300 mg daily, or higher to achieve full control, reduce to minimum maintenance dosage as soon as possible  Leprosy: Oral:  Tuberculoid (pau…"}, {"doc_id": "famotidine-calcium-carbonate-and-magnesium-hydroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5509957075119019, "bge_max": 0.5509957075119019, "title": "Famotidine, calcium carbonate, and magnesium hydroxide: Drug information", "rep_snippet": "DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. Risk C: Monitor therapy  Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir…"}, {"doc_id": "hemin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5505760908126831, "bge_max": 0.5505760908126831, "title": "Hemin: Drug information", "rep_snippet": "• Appropriate use: Although the manufacturer's labeling recommends initial therapy with glucose (ie, 400 g/day for 1 to 2 days), glucose may be appropriate for mild cases only and hemin should be initiated early for most…"}, {"doc_id": "gadoversetamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5504041314125061, "bge_max": 0.5504041314125061, "title": "Gadoversetamide: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  GFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution. Risk for NSF development increases as renal f…"}, {"doc_id": "gadodiamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5501184463500977, "bge_max": 0.5501184463500977, "title": "Gadodiamide: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  GFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution. Risk for NSF development increases as renal f…"}]}
{"qid": "Q18_spelling", "query": "Colchicin dosing for acute gout; watch CYP3A4/Pgp.", "base_qid": "Q18", "variant_type": "spelling", "candidates": [{"doc_id": "colchicine-drug-information", "bm25_top3": 23.24176667262841, "bm25_max": 24.534046177965763, "bge_top3": 0.7298347155253092, "bge_max": 0.7524842023849487, "title": "Colchicine: Drug information", "rep_snippet": "Patients <70 kg or unable to tolerate higher dosing regimen: 0.5 mg twice daily given on post-operative day 3, followed by 0.5 mg once daily for 1 month (Imazio 2010a).  Regimens without loading dose:  Patients ≥70 kg: 0…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": 23.911779903100328, "bm25_max": 23.911779903100328, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Dermatomyositis/polymyositis (off-label dosing): IV (succinate): 1,000 mg daily for 3 to 5 days for severe muscle weakness, followed by conversion to oral prednisone (Drake 1996)  Gout, acute (off-label dosing): IV (succ…"}, {"doc_id": "allopurinol-drug-information", "bm25_top3": 7.368009840489093, "bm25_max": 14.53560588016272, "bge_top3": 0.7018233239650726, "bge_max": 0.7183115482330322, "title": "Allopurinol: Drug information", "rep_snippet": "Dosing: Adult  Note: Oral doses >300 mg should be given in divided doses.  Gout: Oral:  Manufacturer’s labeling: Initial: 100 mg once daily; increase at weekly intervals in increments of 100 mg/day as needed to achieve d…"}, {"doc_id": "corticotropin-injection-gel-drug-information", "bm25_top3": 8.656136025645107, "bm25_max": 14.37818807073259, "bge_top3": 0.6675835847854614, "bge_max": 0.6675835847854614, "title": "Corticotropin injection gel: Drug information", "rep_snippet": "Dosing: Adult  Note: Sudden withdrawal may lead to adrenal insufficiency or recurrent symptoms; tapering the dose prior to discontinuation may be necessary following prolonged administration.  Acute exacerbation of multi…"}, {"doc_id": "colchicine-and-probenecid-drug-information", "bm25_top3": 5.694682668517169, "bm25_max": 14.16005847316112, "bge_top3": 0.719880223274231, "bge_max": 0.7614495158195496, "title": "Colchicine and probenecid: Drug information", "rep_snippet": "Dosing: Adult  Gout: Oral: Colchicine 0.5 mg and probenecid 0.5 g: One tablet once daily for 1 week, then 1 tablet twice daily thereafter  Note: Current prescribing information states a maximum dose of 4 tablets per day;…"}, {"doc_id": "pegloticase-drug-information", "bm25_top3": 6.259305981100505, "bm25_max": 13.052679325799037, "bge_top3": 0.70365771651268, "bge_max": 0.7430800199508667, "title": "Pegloticase: Drug information", "rep_snippet": "Dosing: Adult  Note: Discontinue use of oral antihyperuricemic agents prior to initiating pegloticase and do not initiate during the course of therapy. Premedicate with antihistamines and corticosteroids. Gout flare prop…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 12.267370990392568, "bm25_max": 12.267370990392568, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Use: Off-Label  Pericarditis; Acute migraine headache; Ankylosing spondylitis; Cystic fibrosis; Gout; Juvenile idiopathic arthritis; Migraine prophylaxis"}, {"doc_id": "febuxostat-drug-information", "bm25_top3": 11.820106422565729, "bm25_max": 11.820106422565729, "bge_top3": 0.6753854155540466, "bge_max": 0.6871535778045654, "title": "Febuxostat: Drug information", "rep_snippet": "Dosing: Adult  Note: It is recommended to take an NSAID or colchicine with initiation of therapy and may continue for up to 6 months to help prevent gout flares. If a gout flare occurs, febuxostat does not need to be dis…"}, {"doc_id": "potassium-citrate-and-citric-acid-powder-or-solution-drug-information", "bm25_top3": 4.578942822289641, "bm25_max": 11.656613585785198, "bge_top3": 0.6765402555465698, "bge_max": 0.6765402555465698, "title": "Potassium citrate and citric acid (powder or solution): Drug information", "rep_snippet": "Dosing: Adult  Systemic alkalinizer, Acidosis, Gout (adjuvant): Oral:  Powder: One packet dissolved in water 4 times daily; adjust dose to urinary pH  Solution: 10 to 30 mL 4 times daily; adjust dose based on urinary pH"}, {"doc_id": "celecoxib-drug-information", "bm25_top3": 7.195586433936592, "bm25_max": 11.45708888731556, "bge_top3": null, "bge_max": null, "title": "Celecoxib: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.  Acute pain or primary dysmenorrhea: Oral: Initial dose: 400 mg, followed by an ad…"}, {"doc_id": "probenecid-drug-information", "bm25_top3": 5.731866990459386, "bm25_max": 11.44264562501418, "bge_top3": 0.680813729763031, "bge_max": 0.6875488758087158, "title": "Probenecid: Drug information", "rep_snippet": "Dosing: Adult  Hyperuricemia with gout: Oral: 250 mg twice daily for 1 week; may increase to 500 mg twice daily; if needed, may increase to a maximum of 2 g/day (increase dosage in 500 mg increments every 4 weeks). If se…"}, {"doc_id": "pyrazinamide-drug-information", "bm25_top3": 2.468691895128649, "bm25_max": 3.4168706688960366, "bge_top3": null, "bge_max": null, "title": "Pyrazinamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hepatotoxicity: Dose-related hepatotoxicity ranging from transient ALT/AST elevations to jaundice, hepatitis and/or liver atrophy (rare) has occurred.  Diseas…"}, {"doc_id": "hydrochlorothiazide-drug-information", "bm25_top3": 3.053586107730613, "bm25_max": 3.053586107730613, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia may occur. Development of electrolyte disturbances can be min…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": 2.3890554251876424, "bm25_max": 2.3890554251876424, "bge_top3": null, "bge_max": null, "title": "Naproxen: Drug information", "rep_snippet": "Use  Acute gout, Ankylosing spondylitis, Bursitis, Polyarticular juvenile idiopathic arthritis, Osteoarthritis, Rheumatoid arthritis, Tendonitis (Rx products only): Relief of the signs and symptoms of acute gout, ankylos…"}, {"doc_id": "lesinurad-drug-information", "bm25_top3": -0.26993955084888466, "bm25_max": 1.9181035548401155, "bge_top3": 0.6990753412246704, "bge_max": 0.6990753412246704, "title": "Lesinurad: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Cardiovascular events: Major cardiac adverse events (cardiovascular deaths, non-fatal MI, or non-fatal strokes) were observed in clinical trials, although a c…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": 1.4609037619372192, "bm25_max": 1.4609037619372192, "bge_top3": null, "bge_max": null, "title": "Furosemide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Fluid/electrolyte loss: [US Boxed Warning]: If given in excessive amounts, furosemide, similar to other loop diuretics, can lead to profound diuresis, resulti…"}, {"doc_id": "canakinumab-drug-information", "bm25_top3": 1.2673709903925676, "bm25_max": 1.2673709903925676, "bge_top3": null, "bge_max": null, "title": "Canakinumab: Drug information", "rep_snippet": "Use: Off-Label  Gout, treatment of acute flares (when conventional therapy is ineffective, contraindicated, or not tolerated)"}, {"doc_id": "hydrochlorothiazide-and-triamterene-drug-information", "bm25_top3": 1.2608301403626694, "bm25_max": 1.2608301403626694, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and triamterene: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia may occur with hydrochlorothiazide.  • Gout: In certain patients with a histo…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": 0.28323727565132906, "bm25_max": 0.920060233356482, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "• Alcoholism: Use with caution in patients with a history of alcoholism (even if ethanol consumption is discontinued during therapy).  • Diabetes: Use with caution in patients with diabetes mellitus; management of diabet…"}, {"doc_id": "salmeterol-drug-information", "bm25_top3": 0.6858545088614392, "bm25_max": 0.6858545088614392, "bge_top3": null, "bge_max": null, "title": "Salmeterol: Drug information", "rep_snippet": "• Bronchospasm: Rarely, paradoxical bronchospasm, which may be life threatening, may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.  • Hypersensitivity reactions:…"}, {"doc_id": "lesinurad-and-allopurinol-drug-information", "bm25_top3": -1.2771182173634799, "bm25_max": -1.2771182173634799, "bge_top3": 0.663262814283371, "bge_max": 0.669001042842865, "title": "Lesinurad and allopurinol: Drug information", "rep_snippet": "Use  Hyperuricemia associated with gout: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.  Limi…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6628621220588684, "bge_max": 0.6628621220588684, "title": "Aprepitant: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchic…"}, {"doc_id": "eliglustat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6564007699489594, "bge_max": 0.6611312627792358, "title": "Eliglustat: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660342812538147, "bge_max": 0.660342812538147, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660342812538147, "bge_max": 0.660342812538147, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "nelfinavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660342812538147, "bge_max": 0.660342812538147, "title": "Nelfinavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "indinavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660342812538147, "bge_max": 0.660342812538147, "title": "Indinavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "cobicistat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660342812538147, "bge_max": 0.660342812538147, "title": "Cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "clofedanol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6596250534057617, "bge_max": 0.6596250534057617, "title": "Clofedanol (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Cough: Oral: 25 mg 3 to 4 times daily as needed"}, {"doc_id": "zinc-gluconate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6593804955482483, "bge_max": 0.6593804955482483, "title": "Zinc gluconate: Drug information", "rep_snippet": "Dosing: Adult  Common cold: Note: For best results, begin therapy 24 to 48 hours prior to symptom onset: Dissolve one 13.3 mg lozenge in mouth every 2 to 4 hours as needed. Maximum: 6 lozenges daily"}, {"doc_id": "aclidinium-and-formoterol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.658968448638916, "bge_max": 0.658968448638916, "title": "Aclidinium and formoterol (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation, oral: Aclidinium 400 mcg/formoterol 12 mcg (one inhalation) twice daily (once in the morning and evening)."}, {"doc_id": "mifepristone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6586388349533081, "bge_max": 0.6586388349533081, "title": "Mifepristone: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "hydrocodone-and-guaifenesin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6566824913024902, "bge_max": 0.6566824913024902, "title": "Hydrocodone and guaifenesin: Drug information", "rep_snippet": "Dosing: Adult  Cough: Oral: Hydrocodone 5 mg/guaifenesin 400 mg (10 mL) every 4 to 6 hours (maximum: hydrocodone 30 mg/guaifenesin 2,400 mg [60 mL] per 24 hours)"}, {"doc_id": "benzonatate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.654452383518219, "bge_max": 0.654452383518219, "title": "Benzonatate: Drug information", "rep_snippet": "Dosing: Adult  Cough: Oral: 100 to 200 mg 3 times/day as needed for cough (maximum single dose: 200 mg; maximum dose: 600 mg/day)"}, {"doc_id": "dextromethorphan-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6542390584945679, "bge_max": 0.6542390584945679, "title": "Dextromethorphan and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines; consult specific product labeling.  Cough, cold symptoms: Oral: Dextromethorphan 30 mg and chlorpheniramine 4 mg every 6 hours as needed (maximum: 120 mg dextromethorphan and 16…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6538146138191223, "bge_max": 0.6538146138191223, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib. Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or les…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6521391272544861, "bge_max": 0.6521391272544861, "title": "Ritonavir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "hydrocodone-and-homatropine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6506407260894775, "bge_max": 0.6506407260894775, "title": "Hydrocodone and homatropine: Drug information", "rep_snippet": "Dosing: Adult  Cough: Oral: Hydrocodone 5 mg/homatropine 1.5 mg (1 tablet or 5 mL every 4 to 6 hours as needed (maximum: hydrocodone 30 mg/homatropine 9 mg [6 tablets or 30 mL] per 24 hours)."}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6503438949584961, "bge_max": 0.6503438949584961, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6503438949584961, "bge_max": 0.6503438949584961, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "guaifenesin-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6501160860061646, "bge_max": 0.6501160860061646, "title": "Guaifenesin, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Also refer to specific product labeling.  Cough/decongestant: Oral:  Liquid (Robitussin Peak Cold Multi-Symptom Cold): Guaifenesin 200 mg, dextromethorphan 20 mg, and phenylephrine 10 mg (10 mL) every 4 ho…"}, {"doc_id": "guaifenesin-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6499311923980713, "bge_max": 0.6499311923980713, "title": "Guaifenesin and dextromethorphan: Drug information", "rep_snippet": "Dosing: Adult  Also refer to specific product labeling.  Cough (antitussive/expectorant): Oral:  General dosing guidelines: Guaifenesin 200 to 400 mg and dextromethorphan 10 to 20 mg every 4 hours (maximum dose: Guaifene…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6487611532211304, "bge_max": 0.6487611532211304, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6479997038841248, "bge_max": 0.6479997038841248, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6479997038841248, "bge_max": 0.6479997038841248, "title": "Clarithromycin: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "durvalumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6479649543762207, "bge_max": 0.6479649543762207, "title": "Durvalumab: Drug information", "rep_snippet": "Colitis or diarrhea, grade 3 or 4: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) followed by a taper.  Infection: Grade 3 or 4: Withhold dose u…"}, {"doc_id": "vitamin-b3-niacin-drug-information", "bm25_top3": 0.5061096728931602, "bm25_max": 0.5061096728931602, "bge_top3": null, "bge_max": null, "title": "Vitamin B3 (niacin): Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with unstable angina or in the acute phase of an MI. In patients with preexisting coronary artery disease, the incidence of atrial fibrillation was observed more fre…"}, {"doc_id": "mannitol-systemic-drug-information", "bm25_top3": 0.3675861323949725, "bm25_max": 0.3675861323949725, "bge_top3": null, "bge_max": null, "title": "Mannitol (systemic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Extravasation: Vesicant (at concentrations >5%); ensure proper catheter or needle position prior to and during IV infusion. Avoid extravasation of IV infusion…"}, {"doc_id": "anakinra-drug-information", "bm25_top3": 0.33731144951927305, "bm25_max": 0.33731144951927305, "bge_top3": null, "bge_max": null, "title": "Anakinra: Drug information", "rep_snippet": "Use: Off-Label  Familial Mediterranean fever; Gout, treatment of acute flares (when conventional therapy is ineffective, contraindicated, or not tolerated); Juvenile idiopathic arthritis; Pericarditis, recurrent"}, {"doc_id": "candesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": 0.2003168434492526, "bm25_max": 0.2003168434492526, "bge_top3": null, "bge_max": null, "title": "Candesartan and hydrochlorothiazide: Drug information", "rep_snippet": "• Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supple…"}, {"doc_id": "methyldopa-and-hydrochlorothiazide-drug-information", "bm25_top3": 0.04118177205750939, "bm25_max": 0.04118177205750939, "bge_top3": null, "bge_max": null, "title": "Methyldopa and hydrochlorothiazide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia can occur with hydrochlorothiazide.  • Gout: In certain patie…"}, {"doc_id": "benazepril-and-hydrochlorothiazide-drug-information", "bm25_top3": -0.03335654312642333, "bm25_max": -0.03335654312642333, "bge_top3": null, "bge_max": null, "title": "Benazepril and hydrochlorothiazide: Drug information", "rep_snippet": "• Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide. This risk may be increased with doses ≥25 mg (Gurwitz 1997…"}, {"doc_id": "quinapril-and-hydrochlorothiazide-drug-information", "bm25_top3": -0.03335654312642333, "bm25_max": -0.03335654312642333, "bge_top3": null, "bge_max": null, "title": "Quinapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide. This risk may be increased with doses ≥25 mg (Gurwitz 1997…"}, {"doc_id": "aliskiren-and-hydrochlorothiazide-drug-information", "bm25_top3": -0.058889031743634135, "bm25_max": -0.058889031743634135, "bge_top3": null, "bge_max": null, "title": "Aliskiren and hydrochlorothiazide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Electrolyte disturbances: Hyperkalemia may occur with renin inhibitors; risk increased in patients with renal impairment or diabetes, or concomitant use with…"}, {"doc_id": "chlorthalidone-drug-information", "bm25_top3": -0.10958211733697887, "bm25_max": -0.10958211733697887, "bge_top3": null, "bge_max": null, "title": "Chlorthalidone: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia may occur. Development of electrolyte disturbances can be min…"}, {"doc_id": "lovastatin-and-niacin-drug-information", "bm25_top3": -0.1973873146115963, "bm25_max": -0.1973873146115963, "bge_top3": null, "bge_max": null, "title": "Lovastatin and niacin: Drug information", "rep_snippet": "Disease-related concerns:  • Cardiovascular disease: Use niacin with caution in patients with unstable angina or MI. In patients with preexisting coronary artery disease, the incidence of atrial fibrillation was observed…"}, {"doc_id": "formoterol-drug-information", "bm25_top3": -0.46853468445047497, "bm25_max": -0.46853468445047497, "bge_top3": null, "bge_max": null, "title": "Formoterol: Drug information", "rep_snippet": "- Foradil Aerolizer: Do not use for acute bronchospasm. Short-acting beta2-agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do not initiate in patients with significant…"}]}
{"qid": "Q19_abbr+genotype-cue", "query": "Post-MI DAPT — clopidogrel maintenance & duration; CYP2C19 poor metabolizer issue.", "base_qid": "Q19", "variant_type": "abbr+genotype-cue", "candidates": [{"doc_id": "clopidogrel-drug-information", "bm25_top3": 34.5685801280731, "bm25_max": 36.58413994143311, "bge_top3": 0.7258708477020264, "bge_max": 0.7350013852119446, "title": "Clopidogrel: Drug information", "rep_snippet": "Duration of clopidogrel (in combination with aspirin) after stent placement for ACS: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to the ACC/AHA Durati…"}, {"doc_id": "prasugrel-drug-information", "bm25_top3": 15.275896240786588, "bm25_max": 23.43714238432388, "bge_top3": null, "bge_max": null, "title": "Prasugrel: Drug information", "rep_snippet": "Duration of prasugrel (in combination with aspirin) after stent placement: Premature interruption of therapy may result in stent thrombosis, MI, and death. According to the ACC/AHA Duration of Dual Antiplatelet Therapy (…"}, {"doc_id": "ticagrelor-drug-information", "bm25_top3": 15.138358909792196, "bm25_max": 16.43356277778283, "bge_top3": null, "bge_max": null, "title": "Ticagrelor: Drug information", "rep_snippet": "Duration of ticagrelor (in combination with aspirin) after stent placement: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to the ACC/AHA Duration of Dua…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 12.63819279222006, "bm25_max": 13.491170056650333, "bge_top3": 0.671139657497406, "bge_max": 0.671139657497406, "title": "Pantoprazole: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Note: Pediatric patients who have the poor metabolizer genotype of CYP2C19 (CYP2C19 *2/*2) exhibited greater than a 6-fold increase in AUC compared with pediatric extensive (CYP2C19 *1/*1) and…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 13.32795526737154, "bm25_max": 13.32795526737154, "bge_top3": 0.6770800352096558, "bge_max": 0.6770800352096558, "title": "Lansoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 13.247040548865954, "bm25_max": 13.247040548865954, "bge_top3": 0.6830450296401978, "bge_max": 0.6830450296401978, "title": "Dexlansoprazole: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 12.771338119030094, "bm25_max": 12.771338119030094, "bge_top3": 0.6702051162719727, "bge_max": 0.6702051162719727, "title": "Voriconazole: Drug information", "rep_snippet": "Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this com…"}, {"doc_id": "aspirin-drug-information", "bm25_top3": 12.70059571607251, "bm25_max": 12.70059571607251, "bge_top3": null, "bge_max": null, "title": "Aspirin: Drug information", "rep_snippet": "STEMI: Aspirin is recommended in combination with either clopidogrel, prasugrel, or ticagrelor given as early as possible or at time of PCI. In addition to dual antiplatelet therapy, parenteral anticoagulant therapy is i…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 11.888274594826374, "bm25_max": 11.888274594826374, "bge_top3": 0.668350100517273, "bge_max": 0.668350100517273, "title": "Rabeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 11.785215527789788, "bm25_max": 11.785215527789788, "bge_top3": 0.6696773171424866, "bge_max": 0.6696773171424866, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 11.48214346157922, "bm25_max": 11.48214346157922, "bge_top3": null, "bge_max": null, "title": "Fluconazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": 10.451106349821135, "bm25_max": 10.451106349821135, "bge_top3": 0.646934986114502, "bge_max": 0.6539391279220581, "title": "Fluvoxamine: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "brivaracetam-drug-information", "bm25_top3": 10.29693562864231, "bm25_max": 10.29693562864231, "bge_top3": 0.6650093793869019, "bge_max": 0.6650093793869019, "title": "Brivaracetam: Drug information", "rep_snippet": "• CYP2C19 poor metabolizers: Poor metabolizers of CYP2C19 may require dose reduction.  Other warnings/precautions:  • Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasi…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 9.885881139803345, "bm25_max": 9.885881139803345, "bge_top3": 0.646061509847641, "bge_max": 0.652475118637085, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination  Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. Risk C:…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 8.76077376562407, "bm25_max": 9.822945586912269, "bge_top3": 0.65172478556633, "bge_max": 0.6592167615890503, "title": "Esomeprazole: Drug information", "rep_snippet": "Clopidogrel: Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel prescribing information re…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 8.218905995338634, "bm25_max": 9.56516589766937, "bge_top3": 0.6945817470550537, "bge_max": 0.6945817470550537, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": 8.549687809320885, "bm25_max": 9.460462821074913, "bge_top3": 0.6713659167289734, "bge_max": 0.6713659167289734, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 8.153655187935135, "bm25_max": 9.371238416286285, "bge_top3": 0.6743682026863098, "bge_max": 0.6743682026863098, "title": "Fluoxetine: Drug information", "rep_snippet": "Clarithromycin: May enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine. Risk X: Avoid combination  Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease s…"}, {"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": 8.561162462342569, "bm25_max": 9.333032403120306, "bge_top3": 0.6660362482070923, "bge_max": 0.6660362482070923, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 8.366344111661729, "bm25_max": 9.034086278987584, "bge_top3": 0.6583590507507324, "bge_max": 0.6583590507507324, "title": "Omeprazole: Drug information", "rep_snippet": "Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. Risk C: Monitor therapy  Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. Risk X: Avoid combination  C…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 9.034086278987584, "bm25_max": 9.034086278987584, "bge_top3": 0.6664057672023773, "bge_max": 0.6864570379257202, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "clobazam-drug-information", "bm25_top3": 8.676199983480824, "bm25_max": 8.676199983480824, "bge_top3": 0.6368504762649536, "bge_max": 0.6368504762649536, "title": "Clobazam: Drug information", "rep_snippet": "• Benzodiazepines and opioids: [US Boxed Warning]: The concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these dru…"}, {"doc_id": "trandolapril-drug-information", "bm25_top3": 8.317878366552627, "bm25_max": 8.317878366552627, "bge_top3": null, "bge_max": null, "title": "Trandolapril: Drug information", "rep_snippet": "Use  Hypertension: Management of hypertension.  Post-myocardial infarction (MI) heart failure or left-ventricular dysfunction: Treatment of post-MI heart failure (HF) in patients who are symptomatic from HF within the fi…"}, {"doc_id": "vorapaxar-drug-information", "bm25_top3": 8.18848460415304, "bm25_max": 8.18848460415304, "bge_top3": null, "bge_max": null, "title": "Vorapaxar: Drug information", "rep_snippet": "Dosing: Adult  History of myocardial infarction (MI) or established peripheral arterial disease (PAD): Oral: 2.08 mg once daily in combination with aspirin and/or clopidogrel. Note: Vorapaxar 2.08 mg is equivalent to vor…"}, {"doc_id": "flibanserin-drug-information", "bm25_top3": 8.009101792557422, "bm25_max": 8.009101792557422, "bge_top3": null, "bge_max": null, "title": "Flibanserin: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Protein binding: ~98%, primarily to albumin  Metabolism: Primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C19 to inactive metabolites.  Bioavailability: Oral: 33%  Half-life elim…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 7.789292521564832, "bm25_max": 7.789292521564832, "bge_top3": 0.6660362482070923, "bge_max": 0.6660362482070923, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": 7.789292521564832, "bm25_max": 7.789292521564832, "bge_top3": 0.6660362482070923, "bge_max": 0.6660362482070923, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "ramipril-drug-information", "bm25_top3": 7.730550270918263, "bm25_max": 7.730550270918263, "bge_top3": null, "bge_max": null, "title": "Ramipril: Drug information", "rep_snippet": "Reduction in risk of MI, stroke, and death from cardiovascular causes: Oral: Initial: 2.5 mg once daily for 1 week, then 5 mg once daily for the next 3 weeks, then increase as tolerated to maintenance dose of 10 mg once…"}, {"doc_id": "carisoprodol-drug-information", "bm25_top3": 7.703951419206719, "bm25_max": 7.703951419206719, "bge_top3": 0.6534830331802368, "bge_max": 0.6534830331802368, "title": "Carisoprodol: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; carisoprodol undergoes renal excretion.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist,…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": 7.698601944335872, "bm25_max": 7.698601944335872, "bge_top3": 0.6593970060348511, "bge_max": 0.6593970060348511, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "atomoxetine-drug-information", "bm25_top3": 7.490148761709932, "bm25_max": 7.490148761709932, "bge_top3": 0.648693323135376, "bge_max": 0.648693323135376, "title": "Atomoxetine: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Note: The pharmacokinetics in pediatric patients ≥6 years of age have been shown to be similar to those of adult patients.  Duration of action: Up to 24 hours (Jain 2017)  Absorption: Rapid  Di…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": 7.148650674471169, "bm25_max": 7.148650674471169, "bge_top3": null, "bge_max": null, "title": "Eplerenone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hypertension:  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <50 mL/minute or serum creatinine >2 mg/dL (males) or >1.8 mg/dL (females): Use…"}, {"doc_id": "tofacitinib-drug-information", "bm25_top3": 6.752758948501345, "bm25_max": 6.752758948501345, "bge_top3": null, "bge_max": null, "title": "Tofacitinib: Drug information", "rep_snippet": "Concomitant moderate CYP3A4 inhibitors and potent CYP2C19 inhibitors (eg, fluconazole): Reduce dose to 5 mg (immediate release) once daily  Ulcerative colitis, moderate to severe (induction and maintenance) (off-label us…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 6.614751622899565, "bm25_max": 6.614751622899565, "bge_top3": null, "bge_max": null, "title": "Amiodarone: Drug information", "rep_snippet": "• CAST trial: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (>6 days but <2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may ha…"}, {"doc_id": "valbenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6628032922744751, "bge_max": 0.6628032922744751, "title": "Valbenazine: Drug information", "rep_snippet": "• Renal impairment: Use is not recommended in patients with severe renal impairment.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency…"}, {"doc_id": "dextromethorphan-and-quinidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6576284766197205, "bge_max": 0.6576284766197205, "title": "Dextromethorphan and quinidine: Drug information", "rep_snippet": "• Renal impairment: Safety and efficacy have not been established with severe renal impairment; increased serum concentrations may occur.  Special populations:  • CYP2D6 poor metabolizers: Dextromethorphan is metabolized…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6513029336929321, "bge_max": 0.6513029336929321, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "• CYP2D6 poor metabolizers: Dextromethorphan is metabolized by hepatic CYP2D6. Poor metabolizers of CYP2D6 may have exaggerated or prolonged effects of dextromethorphan. Increased risk may be seen with concomitant use of…"}, {"doc_id": "brompheniramine-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6510029435157776, "bge_max": 0.6510029435157776, "title": "Brompheniramine, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "piroxicam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6478928327560425, "bge_max": 0.6478928327560425, "title": "Piroxicam: Drug information", "rep_snippet": "• Poor CYP2C9 metabolizers: Use with caution; hepatic metabolism may be reduced resulting in elevated serum concentrations.  Other warnings/precautions:  • Surgical/dental procedures: Withhold for at least 4 to 6 half-li…"}, {"doc_id": "imipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6460577249526978, "bge_max": 0.6460577249526978, "title": "Imipramine: Drug information", "rep_snippet": "CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates (High…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6454257965087891, "bge_max": 0.6454257965087891, "title": "Acetaminophen (paracetamol), dextromethorphan, and doxylamine: Drug information", "rep_snippet": "• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjust…"}, {"doc_id": "deutetrabenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6441139578819275, "bge_max": 0.6441139578819275, "title": "Deutetrabenazine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "dexchlorpheniramine-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6428196430206299, "bge_max": 0.6428196430206299, "title": "Dexchlorpheniramine, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6424965262413025, "bge_max": 0.6424965262413025, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Clindamycin (Topical): Erythromycin (Systemic) may diminish the therapeutic effect of Clindamycin (Topical). Risk X: Avoid combination  Clopidogrel: Erythromycin (Systemic) may diminish the antiplatelet effect of Clopido…"}, {"doc_id": "selexipag-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6387315988540649, "bge_max": 0.6387315988540649, "title": "Selexipag: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors). Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including my…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6380259990692139, "bge_max": 0.6380259990692139, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (inclu…"}, {"doc_id": "metoclopramide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6373347043991089, "bge_max": 0.6373347043991089, "title": "Metoclopramide: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with moderate to severe renal impairment; risk of adverse reactions may be increased due to increased systemic exposure; dosage adjustment recommended.  • Surgical anastom…"}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6370066404342651, "bge_max": 0.6370066404342651, "title": "Fosphenytoin: Drug information", "rep_snippet": "CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contrain…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6370066404342651, "bge_max": 0.6370066404342651, "title": "Phenytoin: Drug information", "rep_snippet": "CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contrain…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6369967460632324, "bge_max": 0.6369967460632324, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Pioglitazone. Risk C: Monitor therapy  Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to c…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.636471152305603, "bge_max": 0.636471152305603, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "• CYP2D6 poor metabolizers: Dextromethorphan is metabolized by hepatic CYP2D6. Poor metabolizers of CYP2D6 may have exaggerated or prolonged effects of dextromethorphan. Increased risk may be seen with concomitant use of…"}, {"doc_id": "tetrabenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6361786723136902, "bge_max": 0.6361786723136902, "title": "Tetrabenazine: Drug information", "rep_snippet": "• QT prolongation: Has been shown to prolong the QT interval alone (minimal) and with other drugs with comparable effects on the QT interval (additive). Avoid use in patients with congenital QT prolongation, a history of…"}]}
{"qid": "Q19_noise", "query": "After MI on DAPT — what’s the standard clopidogrel dose/duration; any CYP2C19 concerns?", "base_qid": "Q19", "variant_type": "noise", "candidates": [{"doc_id": "clopidogrel-drug-information", "bm25_top3": 43.59529262705898, "bm25_max": 51.58898547631119, "bge_top3": 0.6790429751078287, "bge_max": 0.700218677520752, "title": "Clopidogrel: Drug information", "rep_snippet": "Duration of clopidogrel (in combination with aspirin) after stent placement for ACS: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to the ACC/AHA Durati…"}, {"doc_id": "prasugrel-drug-information", "bm25_top3": 23.8623617453111, "bm25_max": 37.81678418560621, "bge_top3": 0.6617492437362671, "bge_max": 0.6617492437362671, "title": "Prasugrel: Drug information", "rep_snippet": "Duration of prasugrel (in combination with aspirin) after stent placement: Premature interruption of therapy may result in stent thrombosis, MI, and death. According to the ACC/AHA Duration of Dual Antiplatelet Therapy (…"}, {"doc_id": "ticagrelor-drug-information", "bm25_top3": 17.812526370213213, "bm25_max": 31.417352126004186, "bge_top3": 0.6185944080352783, "bge_max": 0.6352806687355042, "title": "Ticagrelor: Drug information", "rep_snippet": "Duration of ticagrelor (in combination with aspirin) after stent placement: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to the ACC/AHA Duration of Dua…"}, {"doc_id": "cangrelor-drug-information", "bm25_top3": 20.856721963152975, "bm25_max": 20.856721963152975, "bge_top3": null, "bge_max": null, "title": "Cangrelor: Drug information", "rep_snippet": "Dosing: Adult  Percutaneous coronary intervention (PCI): IV: 30 mcg/kg bolus prior to PCI followed immediately by an infusion of 4 mcg/kg/minute continued for at least 2 hours or for the duration of the PCI, whichever is…"}, {"doc_id": "cilostazol-drug-information", "bm25_top3": 18.173216910712195, "bm25_max": 18.173216910712195, "bge_top3": 0.6259892582893372, "bge_max": 0.6259892582893372, "title": "Cilostazol: Drug information", "rep_snippet": "Dosing: Adult  Intermittent claudication: Oral: 100 mg twice daily. Note: The American College of Chest Physicians recommends use when refractory to exercise therapy and smoking cessation; use in combination with either…"}, {"doc_id": "vorapaxar-drug-information", "bm25_top3": 17.68848460415304, "bm25_max": 17.68848460415304, "bge_top3": null, "bge_max": null, "title": "Vorapaxar: Drug information", "rep_snippet": "Dosing: Adult  History of myocardial infarction (MI) or established peripheral arterial disease (PAD): Oral: 2.08 mg once daily in combination with aspirin and/or clopidogrel. Note: Vorapaxar 2.08 mg is equivalent to vor…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 15.851328836259412, "bm25_max": 15.851328836259412, "bge_top3": 0.6643379330635071, "bge_max": 0.6643379330635071, "title": "Voriconazole: Drug information", "rep_snippet": "Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this com…"}, {"doc_id": "caspofungin-drug-information", "bm25_top3": 15.814253554800532, "bm25_max": 15.814253554800532, "bge_top3": null, "bge_max": null, "title": "Caspofungin: Drug information", "rep_snippet": "Dosing: Adult  Note: Duration of caspofungin treatment should be determined by patient status and clinical response.  Aspergillosis, invasive (salvage therapy): IV: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 14.874613201088266, "bm25_max": 14.874613201088266, "bge_top3": 0.6142794489860535, "bge_max": 0.6142794489860535, "title": "Fluconazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": 14.177046506319712, "bm25_max": 14.177046506319712, "bge_top3": 0.6388543248176575, "bge_max": 0.6388543248176575, "title": "Fluvoxamine: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": 10.295974801049445, "bm25_max": 13.974936274071375, "bge_top3": 0.6184411644935608, "bge_max": 0.6184411644935608, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 13.543258642491523, "bm25_max": 13.543258642491523, "bge_top3": null, "bge_max": null, "title": "Omeprazole: Drug information", "rep_snippet": "Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. Risk C: Monitor therapy  Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. Risk X: Avoid combination  C…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": 12.632635714879125, "bm25_max": 12.632635714879125, "bge_top3": 0.6161441802978516, "bge_max": 0.6161441802978516, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 12.426944275494257, "bm25_max": 12.426944275494257, "bge_top3": null, "bge_max": null, "title": "Esomeprazole: Drug information", "rep_snippet": "Clopidogrel: Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel prescribing information re…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 11.201376651729156, "bm25_max": 11.201376651729156, "bge_top3": 0.6143479347229004, "bge_max": 0.6143479347229004, "title": "Dexlansoprazole: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 11.183211548022044, "bm25_max": 11.183211548022044, "bge_top3": null, "bge_max": null, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination  Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. Risk C:…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 10.817824514883327, "bm25_max": 10.817824514883327, "bge_top3": 0.6201919317245483, "bge_max": 0.6201919317245483, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 10.772892122661748, "bm25_max": 10.772892122661748, "bge_top3": 0.6067841053009033, "bge_max": 0.6067841053009033, "title": "Lansoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 10.607219846521446, "bm25_max": 10.607219846521446, "bge_top3": 0.6178003549575806, "bge_max": 0.6178003549575806, "title": "Fluoxetine: Drug information", "rep_snippet": "Clarithromycin: May enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine. Risk X: Avoid combination  Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease s…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 10.153386783688546, "bm25_max": 10.153386783688546, "bge_top3": 0.6296801567077637, "bge_max": 0.6296801567077637, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 8.361236021127386, "bm25_max": 9.99818886596092, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 9.99818886596092, "bm25_max": 9.99818886596092, "bge_top3": null, "bge_max": null, "title": "Pantoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 9.031642089848596, "bm25_max": 9.031642089848596, "bge_top3": null, "bge_max": null, "title": "Rabeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "formoterol-drug-information", "bm25_top3": 7.912002692906974, "bm25_max": 7.912002692906974, "bge_top3": null, "bge_max": null, "title": "Formoterol: Drug information", "rep_snippet": "Nebulization solution: Perforomist: Remove unit-dose vial from foil pouch immediately before use. Solution does not require dilution prior to administration; do not mix other medications with formoterol solution. Place c…"}, {"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": 7.210970562167636, "bm25_max": 7.779835378389748, "bge_top3": null, "bge_max": null, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "Chloroquine: Antacids may decrease the serum concentration of Chloroquine. Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chlo…"}, {"doc_id": "brivaracetam-drug-information", "bm25_top3": 7.3791601088479215, "bm25_max": 7.3791601088479215, "bge_top3": null, "bge_max": null, "title": "Brivaracetam: Drug information", "rep_snippet": "• CYP2C19 poor metabolizers: Poor metabolizers of CYP2C19 may require dose reduction.  Other warnings/precautions:  • Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasi…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 7.231462579558443, "bm25_max": 7.231462579558443, "bge_top3": null, "bge_max": null, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": 7.160450913003892, "bm25_max": 7.160450913003892, "bge_top3": null, "bge_max": null, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Cardiovascular events: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including fatal MI and stroke. Risk may be in…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 6.242542287466904, "bm25_max": 6.242542287466904, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "• Patient education: [US Boxed Warning]: When used for the termination of pregnancy, patient must be instructed of the treatment procedure and expected effects. A signed agreement form must be kept in the patient's file.…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": 6.237854289847142, "bm25_max": 6.237854289847142, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": 6.237854289847142, "bm25_max": 6.237854289847142, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": 6.237854289847142, "bm25_max": 6.237854289847142, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (…"}, {"doc_id": "clobazam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6421002149581909, "bge_max": 0.6421002149581909, "title": "Clobazam: Drug information", "rep_snippet": "CYP2C19 poor metabolizers: Initiate at lowest recommended doses; titrate slowly as tolerated to half of usual recommended maximum dose. If needed, dose may be further increased as tolerated to usual recommended maximum d…"}, {"doc_id": "aspirin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6176207661628723, "bge_max": 0.6326768398284912, "title": "Aspirin: Drug information", "rep_snippet": "Transcatheter aortic bioprosthetic valve: 50 to 100 mg once daily (in combination with clopidogrel) (ACCP [Guyatt 2012])  Stroke/TIA: Oral:  Acute ischemic stroke/TIA:  Immediate release (off-label dosing): Initial: 160…"}, {"doc_id": "eptifibatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6223056316375732, "bge_max": 0.6223056316375732, "title": "Eptifibatide: Drug information", "rep_snippet": "Primary percutaneous coronary intervention (PCI) during ST-elevation myocardial infarction with or without stenting or pretreatment with clopidogrel (off-label use): IV: Bolus of 180 mcg/kg (maximum: 22.6 mg) administere…"}, {"doc_id": "octreotide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6215386986732483, "bge_max": 0.6215386986732483, "title": "Octreotide: Drug information", "rep_snippet": "Dosing: Adult  Acromegaly:  SubQ, IV: Initial: 50 mcg 3 times/day; titrate to achieve growth hormone levels <5 ng/mL or IGF-I (somatomedin C) levels <1.9 units/mL in males and <2.2 units/mL in females. Usual effective do…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6132598519325256, "bge_max": 0.6132598519325256, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Pioglitazone. Risk C: Monitor therapy  Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to c…"}, {"doc_id": "treprostinil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6096672415733337, "bge_max": 0.6096672415733337, "title": "Treprostinil: Drug information", "rep_snippet": "Dosage adjustment for concurrent use in patients receiving strong CYP2C8 inhibitors (gemfibrozil): Initiate a starting dose of 0.125 mg every 12 hours; increase in increments of 0.125 mg every 12 hours every 3 to 4 days.…"}, {"doc_id": "acalabrutinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6072476506233215, "bge_max": 0.6072476506233215, "title": "Acalabrutinib: Drug information", "rep_snippet": "Dosing: Adult  Mantle cell lymphoma (previously treated): Oral: 100 mg approximately every 12 hours; continue until disease progression or unacceptable toxicity (Wang 2017).  Missed doses: If a dose is missed by more tha…"}, {"doc_id": "doxercalciferol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6071478724479675, "bge_max": 0.6071478724479675, "title": "Doxercalciferol: Drug information", "rep_snippet": "Dosing: Adult  Secondary hyperparathyroidism:  Oral:  Dialysis patients:  Initial dose: iPTH >400 pg/mL: 10 mcg 3 times/week at dialysis for 8 weeks  Dose titration:  iPTH level >300 pg/mL (dose should be titrated to low…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6052906513214111, "bge_max": 0.6052906513214111, "title": "Vortioxetine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder: Oral: Initial: 10 mg once daily; increase to 20 mg once daily as tolerated; consider 5 mg once daily for patients who do not tolerate higher doses. Maintenance: 5 to 20 mg once d…"}, {"doc_id": "bromocriptine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6052834987640381, "bge_max": 0.6052834987640381, "title": "Bromocriptine: Drug information", "rep_snippet": "Dosing: Adult  Acromegaly: Oral: Initial: 1.25 to 2.5 mg daily increasing by 1.25 to 2.5 mg daily as necessary every 3 to 7 days; usual dose: 20 to 30 mg daily (maximum: 100 mg/day)  Diabetes mellitus, type 2 (Cycloset o…"}, {"doc_id": "desmopressin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6051410436630249, "bge_max": 0.6051410436630249, "title": "Desmopressin: Drug information", "rep_snippet": "US labeling: Initial: 0.05 mg twice daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.1 to 1.2 mg divided 2 to 3 times daily). Fluid restriction should be observ…"}, {"doc_id": "eliglustat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6035475134849548, "bge_max": 0.6035475134849548, "title": "Eliglustat: Drug information", "rep_snippet": "Dosing: Adult  Gaucher disease: Oral: Note: Dosage is based on patient CYP2D6 metabolizer status (extensive metabolizers [EMs], intermediate metabolizers [IMs], or poor metabolizers [PMs]) determined by an FDA-cleared te…"}, {"doc_id": "cloxacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6030164957046509, "bge_max": 0.6030164957046509, "title": "Cloxacillin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Dose and duration of therapy can vary depending on infecting organism, severity of infection, and clinical response of patient. Treat severe staphylococcal infections for at least 14 days; endocardit…"}, {"doc_id": "celecoxib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6024485230445862, "bge_max": 0.6024485230445862, "title": "Celecoxib: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.  Acute pain or primary dysmenorrhea: Oral: Initial dose: 400 mg, followed by an ad…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6021631956100464, "bge_max": 0.6021631956100464, "title": "Citalopram: Drug information", "rep_snippet": "Dosing: Adult  Note: Doses >40 mg daily are not recommended due to the risk of QT prolongation.  Depression: Adults <60 years: Oral: Initial: 20 mg once daily; increase the dose by 20 mg at an interval of ≥1 week to a ma…"}, {"doc_id": "flupentixol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6016314029693604, "bge_max": 0.6016314029693604, "title": "Flupentixol (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Schizophrenia: Note: Initiate with oral therapy; upon stabilization, patients may then be transitioned to the depot injection.  IM (depot):  Initial:  Patients naive to treatment with long-acting depot ant…"}, {"doc_id": "metoclopramide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5995538234710693, "bge_max": 0.5995538234710693, "title": "Metoclopramide: Drug information", "rep_snippet": "Continuous dosing: 10 to 15 mg 4 times daily for 4 to 12 weeks (maximum: 60 mg/day). Note: 5 mg 4 times daily or 10 mg 3 times daily (maximum: 30 mg/day) is recommended for poor metabolizers of CYP2D6.  Intermittent dosi…"}, {"doc_id": "maraviroc-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5991210341453552, "bge_max": 0.5991210341453552, "title": "Maraviroc: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥30 mL/minute: No dosage adjustment necessary  CrCl <30 mL/minute:  Concomitant potent CYP3A inhibitors (with or without a potent CYP3A inducer) or concomitant potent CYP3A inducer…"}, {"doc_id": "valbenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5988186597824097, "bge_max": 0.5988186597824097, "title": "Valbenazine: Drug information", "rep_snippet": "Dosing: Adult  Tardive dyskinesia: Oral: Initial: 40 mg once daily; after 1 week, increase to 80 mg once daily. Continuation of 40 mg once daily may be considered for some patients based on response and tolerability.  Do…"}, {"doc_id": "fentanyl-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5988029837608337, "bge_max": 0.5988029837608337, "title": "Fentanyl: Drug information", "rep_snippet": "US labeling: A second dose may be given after 30 minutes; maximum of 2 doses/episode of breakthrough pain; separate treatment of subsequent episodes by ≥2 hours; limit treatment to ≤4 breakthrough episodes per day.  Cana…"}, {"doc_id": "liposomal-cytarabine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5985962748527527, "bge_max": 0.5985962748527527, "title": "Liposomal cytarabine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: DepoCyt is no longer available in the US.  Note: Initiate dexamethasone 4 mg twice daily (oral or IV) for 5 days, beginning on the day of cytarabine liposomal administration.  Lymphomatous meningitis…"}, {"doc_id": "brexpiprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5981443524360657, "bge_max": 0.5981443524360657, "title": "Brexpiprazole: Drug information", "rep_snippet": "Dosing: Adult  Major Depressive disorder (adjunct to antidepressants): Oral: Initial: 0.5 mg or 1 mg once daily; titrate at weekly intervals based on response and tolerability to 1 mg once daily (if initial dose is 0.5 m…"}, {"doc_id": "desirudin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5980463027954102, "bge_max": 0.5980463027954102, "title": "Desirudin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Moderate impairment (CrCl ≥31 to 60 mL/minute/1.73 m2): Initial dose: 5 mg every 12 hours. Interrupt therapy if aPTT exceeds 2 times control; resume at a reduced dose (based on the degree of aPT…"}, {"doc_id": "flibanserin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5980316996574402, "bge_max": 0.5980316996574402, "title": "Flibanserin: Drug information", "rep_snippet": "Dosing: Adult  Hypoactive sexual desire disorder: Females (premenopausal): Oral: 100 mg once daily at bedtime; assess treatment efficacy at 8 weeks and discontinue if symptoms have not improved.  Missed dose: If a dose i…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5975582599639893, "bge_max": 0.5975582599639893, "title": "Clozapine: Drug information", "rep_snippet": "Initiating clozapine with concomitant medication or adding a concomitant medication while taking clozapine: Concomitant use is not recommended. However, if the CYP3A4 inducer is necessary, monitor for decreased effective…"}]}
{"qid": "Q19_spelling", "query": "Post MI dual anti-platelet — clopidogrel maint + CYP2C19 note.", "base_qid": "Q19", "variant_type": "spelling", "candidates": [{"doc_id": "clopidogrel-drug-information", "bm25_top3": 25.764107496910544, "bm25_max": 27.766792118732884, "bge_top3": 0.6584911942481995, "bge_max": 0.6843715310096741, "title": "Clopidogrel: Drug information", "rep_snippet": "• CYP2C19 poor metabolizers: [US Boxed Warning]: Effectiveness of clopidogrel results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the CYP-450 system, principally CYP2C1…"}, {"doc_id": "undecylenic-acid-and-derivatives-drug-information", "bm25_top3": 17.416922303604654, "bm25_max": 18.65066043893096, "bge_top3": null, "bge_max": null, "title": "Undecylenic acid and derivatives: Drug information", "rep_snippet": "Brand Names: US  BioRx Sponix Anti-Fungal [OTC];  Elon Dual Defense Anti-Fungal [OTC];  Fungi-Nail Toe & Foot [OTC];  Fungi-Nail [OTC];  Gordochom [OTC];  Hongo Cura Anti-Fungal [OTC];  Myco Nail A [OTC]"}, {"doc_id": "aspirin-drug-information", "bm25_top3": 10.48616520013914, "bm25_max": 12.946448522284612, "bge_top3": 0.6219042539596558, "bge_max": 0.6219042539596558, "title": "Aspirin: Drug information", "rep_snippet": "STEMI: Aspirin is recommended in combination with either clopidogrel, prasugrel, or ticagrelor given as early as possible or at time of PCI. In addition to dual antiplatelet therapy, parenteral anticoagulant therapy is i…"}, {"doc_id": "ticagrelor-drug-information", "bm25_top3": 9.606267386522072, "bm25_max": 11.124361188337211, "bge_top3": 0.6021683812141418, "bge_max": 0.6021683812141418, "title": "Ticagrelor: Drug information", "rep_snippet": "• Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medi…"}, {"doc_id": "ticlopidine-united-states-not-available-drug-information", "bm25_top3": 10.897106438592218, "bm25_max": 10.897106438592218, "bge_top3": 0.6047387719154358, "bge_max": 0.6047387719154358, "title": "Ticlopidine (United States: Not available): Drug information", "rep_snippet": "• Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medi…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 7.847836111140802, "bm25_max": 10.771338119030094, "bge_top3": 0.6299337148666382, "bge_max": 0.6299337148666382, "title": "Voriconazole: Drug information", "rep_snippet": "Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this com…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": 7.7973072908022685, "bm25_max": 10.367911287439615, "bge_top3": 0.6289494037628174, "bge_max": 0.6289494037628174, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "prasugrel-drug-information", "bm25_top3": 7.77758972990373, "bm25_max": 9.969764796534307, "bge_top3": null, "bge_max": null, "title": "Prasugrel: Drug information", "rep_snippet": "• Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medi…"}, {"doc_id": "vorapaxar-drug-information", "bm25_top3": 9.61440721485939, "bm25_max": 9.61440721485939, "bge_top3": 0.6011448502540588, "bge_max": 0.6011448502540588, "title": "Vorapaxar: Drug information", "rep_snippet": "Dosing: Adult  History of myocardial infarction (MI) or established peripheral arterial disease (PAD): Oral: 2.08 mg once daily in combination with aspirin and/or clopidogrel. Note: Vorapaxar 2.08 mg is equivalent to vor…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 9.48214346157922, "bm25_max": 9.48214346157922, "bge_top3": 0.5966073274612427, "bge_max": 0.5966073274612427, "title": "Fluconazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "fondaparinux-drug-information", "bm25_top3": 9.050115725140849, "bm25_max": 9.050115725140849, "bge_top3": null, "bge_max": null, "title": "Fondaparinux: Drug information", "rep_snippet": "Reference Range  Note: Routine monitoring is not recommended; the following fondaparinux-specific anti-Xa concentrations have been reported (Garcia 2012):  Thromboprophylaxis dose: Anti-Xa activity at 3 hours post dose:…"}, {"doc_id": "cilostazol-drug-information", "bm25_top3": 8.948523428200978, "bm25_max": 8.948523428200978, "bge_top3": null, "bge_max": null, "title": "Cilostazol: Drug information", "rep_snippet": "Dosing: Adult  Intermittent claudication: Oral: 100 mg twice daily. Note: The American College of Chest Physicians recommends use when refractory to exercise therapy and smoking cessation; use in combination with either…"}, {"doc_id": "cangrelor-drug-information", "bm25_top3": 8.800053547034857, "bm25_max": 8.800053547034857, "bge_top3": 0.614366352558136, "bge_max": 0.614366352558136, "title": "Cangrelor: Drug information", "rep_snippet": "Clopidogrel: Cangrelor may diminish the antiplatelet effect of Clopidogrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Clopido…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": 8.451106349821135, "bm25_max": 8.451106349821135, "bge_top3": 0.5997876524925232, "bge_max": 0.5998494029045105, "title": "Fluvoxamine: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 8.119301944622944, "bm25_max": 8.119301944622944, "bge_top3": 0.606662392616272, "bge_max": 0.606662392616272, "title": "Lansoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 8.060926059701593, "bm25_max": 8.060926059701593, "bge_top3": 0.6049594879150391, "bge_max": 0.6049594879150391, "title": "Dexlansoprazole: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 6.48666367378423, "bm25_max": 7.885881139803345, "bge_top3": 0.6117470860481262, "bge_max": 0.6117470860481262, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination  Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. Risk C:…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 6.624471629275266, "bm25_max": 7.822945586912269, "bge_top3": 0.6246114373207092, "bge_max": 0.6246114373207092, "title": "Esomeprazole: Drug information", "rep_snippet": "Clopidogrel: Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel prescribing information re…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 7.56516589766937, "bm25_max": 7.56516589766937, "bge_top3": 0.6183890302975973, "bge_max": 0.6256017684936523, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 7.371238416286285, "bm25_max": 7.371238416286285, "bge_top3": 0.6121434569358826, "bge_max": 0.6121434569358826, "title": "Fluoxetine: Drug information", "rep_snippet": "Clarithromycin: May enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine. Risk X: Avoid combination  Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease s…"}, {"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": 7.333032403120306, "bm25_max": 7.333032403120306, "bge_top3": 0.6029171943664551, "bge_max": 0.6029171943664551, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 7.13060703965138, "bm25_max": 7.13060703965138, "bge_top3": null, "bge_max": null, "title": "Warfarin: Drug information", "rep_snippet": "Reference Range  INR = patient prothrombin time/mean normal prothrombin time  ISI = international sensitivity index  INR should be increased by 2 to 3.5 times depending upon indication. An INR >4 does not generally add a…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 7.0340862789875835, "bm25_max": 7.0340862789875835, "bge_top3": null, "bge_max": null, "title": "Omeprazole: Drug information", "rep_snippet": "Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. Risk C: Monitor therapy  Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. Risk X: Avoid combination  C…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 6.060766243376349, "bm25_max": 7.0340862789875835, "bge_top3": 0.6329154968261719, "bge_max": 0.6329154968261719, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "trandolapril-drug-information", "bm25_top3": 6.317878366552627, "bm25_max": 6.317878366552627, "bge_top3": null, "bge_max": null, "title": "Trandolapril: Drug information", "rep_snippet": "Use  Hypertension: Management of hypertension.  Post-myocardial infarction (MI) heart failure or left-ventricular dysfunction: Treatment of post-MI heart failure (HF) in patients who are symptomatic from HF within the fi…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 6.305812845176929, "bm25_max": 6.305812845176929, "bge_top3": 0.5963720083236694, "bge_max": 0.5963720083236694, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 6.305812845176929, "bm25_max": 6.305812845176929, "bge_top3": 0.597352921962738, "bge_max": 0.597352921962738, "title": "Pantoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 6.255607897050199, "bm25_max": 6.255607897050199, "bge_top3": 0.5988209247589111, "bge_max": 0.5988209247589111, "title": "Rabeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "abciximab-drug-information", "bm25_top3": 5.933419762373916, "bm25_max": 5.933419762373916, "bge_top3": null, "bge_max": null, "title": "Abciximab: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset: Rapid; platelet aggregation reduced to <20% of baseline at 10 minutes  Duration: Platelet function recovery: 24 to 48 hours (Tcheng 1994; Mascelli 1998); may be up to 72 hours for restor…"}, {"doc_id": "ibalizumab-uiyk-drug-information", "bm25_top3": 5.033111449332349, "bm25_max": 5.033111449332349, "bge_top3": null, "bge_max": null, "title": "Ibalizumab-uiyk: Drug information", "rep_snippet": "Pharmacologic Category  Anti-CD4 Monoclonal Antibody;  Antiretroviral, Monoclonal Antibody;  Antiretroviral, Post-Attachment Inhibitor;  Monoclonal Antibody"}, {"doc_id": "etravirine-drug-information", "bm25_top3": 4.8442507803280535, "bm25_max": 4.8442507803280535, "bge_top3": null, "bge_max": null, "title": "Etravirine: Drug information", "rep_snippet": "Metabolism/Transport Effects  Substrate of CYP2C19 (major), CYP2C9 (major), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2C19 (weak…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6131317019462585, "bge_max": 0.6131317019462585, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Pioglitazone. Risk C: Monitor therapy  Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to c…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.604541540145874, "bge_max": 0.6046258211135864, "title": "Paroxetine: Drug information", "rep_snippet": "Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration o…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6043484210968018, "bge_max": 0.6043484210968018, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "desvenlafaxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6032317876815796, "bge_max": 0.6032317876815796, "title": "Desvenlafaxine: Drug information", "rep_snippet": "ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6011489629745483, "bge_max": 0.6019077301025391, "title": "Dabigatran: Drug information", "rep_snippet": "Antiplatelet Agents (P2Y12 Inhibitors): May enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum con…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6002120971679688, "bge_max": 0.6002120971679688, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Clindamycin (Topical): Erythromycin (Systemic) may diminish the therapeutic effect of Clindamycin (Topical). Risk X: Avoid combination  Clopidogrel: Erythromycin (Systemic) may diminish the antiplatelet effect of Clopido…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.598651796579361, "bge_max": 0.5999696254730225, "title": "Duloxetine: Drug information", "rep_snippet": "Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effec…"}, {"doc_id": "paclitaxel-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5999058485031128, "bge_max": 0.5999058485031128, "title": "Paclitaxel (conventional): Drug information", "rep_snippet": "Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy  Clopidogrel: May increase the serum concentration of PACLitaxel (Conventional). Risk C: Monitor ther…"}, {"doc_id": "carisoprodol-and-aspirin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5988864898681641, "bge_max": 0.5988864898681641, "title": "Carisoprodol and aspirin: Drug information", "rep_snippet": "Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible. If concomitant therapy cannot be avoided, monitor cl…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5975114703178406, "bge_max": 0.5975114703178406, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (inclu…"}]}
{"qid": "Q20_abbr+trimester-cue", "query": "UTI in pregnancy — nitrofurantoin safety by trimester; preferred use?", "base_qid": "Q20", "variant_type": "abbr+trimester-cue", "candidates": [{"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 31.290776996208127, "bm25_max": 34.776686592708394, "bge_top3": 0.6627105275789896, "bge_max": 0.7140848636627197, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Pregnancy Implications  Adverse effects have not been observed in animal reproduction studies. Nitrofurantoin crosses the placenta (Perry 1967) and maternal serum concentrations may be lower in pregnancy (Philipson 1979)…"}, {"doc_id": "oxymetazoline-nasal-drug-information", "bm25_top3": 24.62595360590407, "bm25_max": 24.62595360590407, "bge_top3": 0.6061649322509766, "bge_max": 0.6061649322509766, "title": "Oxymetazoline (nasal): Drug information", "rep_snippet": "Pregnancy Implications  Adverse fetal/neonatal events have been noted in case reports following large doses or extended use of oxymetazoline nasal spray in the first trimester of pregnancy (Baxi 1985; Holm 1985; Menezes…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": 22.81368720561825, "bm25_max": 22.81368720561825, "bge_top3": 0.6069260239601135, "bge_max": 0.6069260239601135, "title": "Tinidazole: Drug information", "rep_snippet": "Pregnancy Implications  The manufacturer contraindicates use of tinidazole during the first trimester of pregnancy. Adverse events have been observed in some animal reproduction studies. Tinidazole crosses the human plac…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 21.140843742619325, "bm25_max": 21.140843742619325, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimeste…"}, {"doc_id": "triamcinolone-systemic-drug-information", "bm25_top3": 20.183141695879737, "bm25_max": 20.183141695879737, "bge_top3": null, "bge_max": null, "title": "Triamcinolone (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies.  Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts o…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": 20.183141695879737, "bm25_max": 20.183141695879737, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Methylprednisolone crosses the placenta (Anderson 1981). Some studies have shown an association between first…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 19.982950041193277, "bm25_max": 19.982950041193277, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Prednisolone may be used (alternative agent) to treat primary adrenal insufficiency (PAI) in pregnant women. Pregnant females with PAI should be monitored at least once each trimester (Bornstein 2016). Prednisolone may b…"}, {"doc_id": "hydrocortisone-systemic-drug-information", "bm25_top3": 18.213947781225514, "bm25_max": 19.88096861296258, "bge_top3": null, "bge_max": null, "title": "Hydrocortisone (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or…"}, {"doc_id": "pseudoephedrine-drug-information", "bm25_top3": 19.513967402924738, "bm25_max": 19.513967402924738, "bge_top3": null, "bge_max": null, "title": "Pseudoephedrine: Drug information", "rep_snippet": "Pregnancy Implications  Use of pseudoephedrine during the first trimester may be associated with a possible risk of gastroschisis, small intestinal atresia, and hemifacial microsomia due to pseudoephedrine's vasoconstric…"}, {"doc_id": "zopiclone-united-states-not-available-drug-information", "bm25_top3": 19.36676207171914, "bm25_max": 19.36676207171914, "bge_top3": null, "bge_max": null, "title": "Zopiclone (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  There is insufficient data on safety in pregnancy; however, benzodiazepines may cause congenital malformations during the 1st trimester and neonatal CNS depression during the last few weeks of pre…"}, {"doc_id": "phenylephrine-systemic-drug-information", "bm25_top3": 18.830365960662142, "bm25_max": 18.830365960662142, "bge_top3": 0.6230334043502808, "bge_max": 0.6230334043502808, "title": "Phenylephrine (systemic): Drug information", "rep_snippet": "Animal reproduction studies have not been conducted. Phenylephrine crosses the placenta at term. Maternal use of phenylephrine during the first trimester of pregnancy is not strongly associated with an increased risk of…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": 18.762766625552448, "bm25_max": 18.762766625552448, "bge_top3": null, "bge_max": null, "title": "Edoxaban: Drug information", "rep_snippet": "Pregnancy Implications  Ten pregnancies were reported in a study using edoxaban for the treatment of DVT or PE. Estimated exposure occurred during the first trimester with duration of exposure ~6 weeks; outcomes included…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 17.289241151047424, "bm25_max": 18.60096570822909, "bge_top3": null, "bge_max": null, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients (Amon 1981; Visser 1984; Wang 2011). Bacterial vaginosis has been associated with adverse pregnancy outcomes; metronidazole is recommen…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": 18.02711206250907, "bm25_max": 18.02711206250907, "bge_top3": null, "bge_max": null, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Pregnancy Implications  Penicillin crosses the placenta. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Due to pregnancy-induced physiologic changes, some pharmacoki…"}, {"doc_id": "dimenhydrinate-drug-information", "bm25_top3": 17.828108401603746, "bm25_max": 17.828108401603746, "bge_top3": null, "bge_max": null, "title": "Dimenhydrinate: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Dimenhydrinate crosses the placenta. The risk of fetal abnormalities was not increased following maternal use of dimenhydrinat…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": 17.33260183975367, "bm25_max": 17.33260183975367, "bge_top3": null, "bge_max": null, "title": "Ceftazidime: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Ceftazidime crosses the placenta and reaches the cord serum and amniotic fluid. An increase in most types of birth defects was…"}, {"doc_id": "hydrocortisone-topical-drug-information", "bm25_top3": 16.866959716395797, "bm25_max": 17.296393699318095, "bge_top3": null, "bge_max": null, "title": "Hydrocortisone (topical): Drug information", "rep_snippet": "The treatment of psoriasis in pregnancy is initiated with conservative treatment as in nonpregnant females. When a topical steroid is needed, low to moderate potency corticosteroids are preferred initially. High potency…"}, {"doc_id": "fluocinonide-drug-information", "bm25_top3": 17.241624816766596, "bm25_max": 17.241624816766596, "bge_top3": null, "bge_max": null, "title": "Fluocinonide: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic derm…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 17.086772814805233, "bm25_max": 17.086772814805233, "bge_top3": null, "bge_max": null, "title": "Naratriptan: Drug information", "rep_snippet": "Pregnancy Implications  Pregnancy outcome information for naratriptan is available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 57 infants/fetuses exposed to narat…"}, {"doc_id": "terconazole-drug-information", "bm25_top3": 16.801590439904057, "bm25_max": 16.801590439904057, "bge_top3": null, "bge_max": null, "title": "Terconazole: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Although the manufacturer recommends that use should be avoided during the first trimester of pregnancy (due to systemic abso…"}, {"doc_id": "phenylephrine-nasal-drug-information", "bm25_top3": 16.6852926550831, "bm25_max": 16.6852926550831, "bge_top3": null, "bge_max": null, "title": "Phenylephrine (nasal): Drug information", "rep_snippet": "Pregnancy Implications  When administered intravenously, phenylephrine crosses the placenta. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Short-term use (<3 days) of intranas…"}, {"doc_id": "thiothixene-drug-information", "bm25_top3": 16.615873130675162, "bm25_max": 16.615873130675162, "bge_top3": null, "bge_max": null, "title": "Thiothixene: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS])…"}, {"doc_id": "diflucortolone-united-states-not-available-drug-information", "bm25_top3": 16.510274619489433, "bm25_max": 16.510274619489433, "bge_top3": null, "bge_max": null, "title": "Diflucortolone (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids (including diflucortolone) in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such…"}, {"doc_id": "mometasone-topical-drug-information", "bm25_top3": 16.49265606351567, "bm25_max": 16.49265606351567, "bge_top3": null, "bge_max": null, "title": "Mometasone (topical): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies.  Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be further in…"}, {"doc_id": "triamcinolone-topical-drug-information", "bm25_top3": 16.4375257334735, "bm25_max": 16.4375257334735, "bge_top3": null, "bge_max": null, "title": "Triamcinolone (topical): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be furthe…"}, {"doc_id": "econazole-drug-information", "bm25_top3": 16.282417045320674, "bm25_max": 16.282417045320674, "bge_top3": null, "bge_max": null, "title": "Econazole: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. The manufacturer recommends avoiding use during pregnancy, especially during the first trimester."}, {"doc_id": "metaxalone-drug-information", "bm25_top3": 16.282417045320674, "bm25_max": 16.282417045320674, "bge_top3": null, "bge_max": null, "title": "Metaxalone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Use during pregnancy (especially first trimester) only if benefits outweigh risks."}, {"doc_id": "alclometasone-drug-information", "bm25_top3": 16.220975983699358, "bm25_max": 16.220975983699358, "bge_top3": null, "bge_max": null, "title": "Alclometasone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids following topical application in animal reproduction studies.  Systemic bioavailability of topical corticosteroids is variable (integrity of…"}, {"doc_id": "thyroid-extract-desiccated-thyroid-drug-information", "bm25_top3": 16.110970519813197, "bm25_max": 16.110970519813197, "bge_top3": null, "bge_max": null, "title": "Thyroid extract (desiccated thyroid): Drug information", "rep_snippet": "Pregnancy Implications  Endogenous thyroid hormones minimally cross the placenta. Desiccated thyroid has not been found to adversely affect the fetus following maternal use during pregnancy.  Uncontrolled maternal hypoth…"}, {"doc_id": "insulin-aspart-protamine-and-insulin-aspart-drug-information", "bm25_top3": 15.93554541689547, "bm25_max": 15.93554541689547, "bge_top3": null, "bge_max": null, "title": "Insulin aspart protamine and insulin aspart: Drug information", "rep_snippet": "Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018c). Insulin requirements tend to fall during the fir…"}, {"doc_id": "betamethasone-topical-drug-information", "bm25_top3": 15.87510453604042, "bm25_max": 15.87510453604042, "bge_top3": null, "bge_max": null, "title": "Betamethasone (topical): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic derm…"}, {"doc_id": "polyethylene-glycol-electrolyte-solution-drug-information", "bm25_top3": 15.819598262314546, "bm25_max": 15.819598262314546, "bge_top3": null, "bge_max": null, "title": "Polyethylene glycol electrolyte solution: Drug information", "rep_snippet": "Pregnancy Implications  Animal reproduction studies have not been conducted. Information related to the use of polyethylene glycol-electrolyte solution in pregnancy is limited (Neri, 2004). Colonoscopy in pregnant women…"}, {"doc_id": "sumatriptan-drug-information", "bm25_top3": 15.547304479293441, "bm25_max": 15.547304479293441, "bge_top3": null, "bge_max": null, "title": "Sumatriptan: Drug information", "rep_snippet": "An analysis of data collected between 1995 and 2008 using the Swedish Medical Birth Register reported pregnancy outcomes following 5-HT1B/1D agonist exposure. An increased risk of major congenital malformations was not o…"}, {"doc_id": "dicyclomine-dicycloverine-drug-information", "bm25_top3": 15.333734494299222, "bm25_max": 15.333734494299222, "bge_top3": null, "bge_max": null, "title": "Dicyclomine (dicycloverine): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. In epidemiologic studies, birth defects were not observed following maternal doses up to 40 mg daily throughout the first trim…"}, {"doc_id": "paromomycin-drug-information", "bm25_top3": 15.329455801539394, "bm25_max": 15.329455801539394, "bge_top3": null, "bge_max": null, "title": "Paromomycin: Drug information", "rep_snippet": "Pregnancy Implications  Paromomycin is poorly absorbed when given orally. Information related to the use of paromomycin in pregnancy is limited (Kreutner 1981). Use may be considered for the treatment of giardiasis throu…"}, {"doc_id": "cromolyn-sodium-cromoglicate-oral-inhalation-drug-information", "bm25_top3": 15.32139808025051, "bm25_max": 15.32139808025051, "bge_top3": null, "bge_max": null, "title": "Cromolyn (sodium cromoglicate) (oral inhalation): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were not observed in animal reproduction studies following SubQ administration. Limited data suggest little or no placental transfer (Brogden 1974). Uncontrolled asthma is associate…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 15.260347298577015, "bm25_max": 15.260347298577015, "bge_top3": 0.6193963885307312, "bge_max": 0.6193963885307312, "title": "Mercaptopurine: Drug information", "rep_snippet": "Pregnancy Implications  May cause fetal harm if administered during pregnancy. Case reports of fetal loss have been noted with mercaptopurine administration during the first trimester; adverse effects have also been note…"}, {"doc_id": "gabapentin-drug-information", "bm25_top3": 8.44325868390446, "bm25_max": 8.44325868390446, "bge_top3": null, "bge_max": null, "title": "Gabapentin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Neurontin may be confused with Motrin, Neoral, nitrofurantoin, Noroxin [DSC], Zarontin"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 6.471778420964995, "bm25_max": 6.471778420964995, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "Use  Candida/Cryptococcus infections: Adjunctive treatment of systemic fungal infections (eg, septicemia, endocarditis, UTI, meningitis, or pulmonary) caused by susceptible strains of Candida or Cryptococcus"}, {"doc_id": "fluocinolone-hydroquinone-and-tretinoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6331878900527954, "bge_max": 0.6331878900527954, "title": "Fluocinolone, hydroquinone, and tretinoin: Drug information", "rep_snippet": "Pregnancy Implications  There are no adequate and well-controlled studies in pregnant women. Tretinoin appears to have a low risk of teratogenicity when used topically since it is rapidly metabolized by the skin; however…"}, {"doc_id": "acitretin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.614651620388031, "bge_max": 0.6234579086303711, "title": "Acitretin: Drug information", "rep_snippet": "• Pregnancy: [US Boxed Warning]: Acitretin is a known teratogen and contraindicated in females who are or may become pregnant. Birth defects (including facial, ear, central nervous system, cardiovascular, limb, bone, and…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6217423677444458, "bge_max": 0.6217423677444458, "title": "Lithium: Drug information", "rep_snippet": "For planned pregnancies, use of lithium during the first trimester should be avoided if possible (Grandjean 2009). If lithium is needed during pregnancy, the minimum effective dose should be used, maternal serum concentr…"}, {"doc_id": "rilpivirine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6203141212463379, "bge_max": 0.6203141212463379, "title": "Rilpivirine: Drug information", "rep_snippet": "Pregnancy Implications  Rilpivirine has moderate to high placental transfer. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretrovir…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6183124780654907, "bge_max": 0.6183124780654907, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Tenofovir has a high level of transfer across the human placenta following maternal use of tenofovir disoproxil fumarate. No increased risk of overall birth defects has been observed following first trimester exposure ac…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6180324554443359, "bge_max": 0.6180324554443359, "title": "Ibuprofen: Drug information", "rep_snippet": "Pregnancy Implications  Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus…"}, {"doc_id": "nitroglycerin-glyceryl-trinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6178714632987976, "bge_max": 0.6178714632987976, "title": "Nitroglycerin (glyceryl trinitrate): Drug information", "rep_snippet": "Pregnancy Implications  Animal reproduction studies have not been conducted with all products; adverse events were not observed in animal reproduction studies conducted using the ointment. Nitroglycerin crosses the place…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6168432831764221, "bge_max": 0.6168432831764221, "title": "Fluoxetine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Fluoxetine and its metabolite cross the human placenta. Available studies evaluating teratogenic effects following maternal use of…"}, {"doc_id": "zidovudine-and-lamivudine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6166424751281738, "bge_max": 0.6166424751281738, "title": "Zidovudine and lamivudine: Drug information", "rep_snippet": "Pregnancy Implications  The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine in combination with zidovudine as an alternative NRTI backbone for initial therapy in antiretroviral-naive pregnant…"}, {"doc_id": "lamivudine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6164450645446777, "bge_max": 0.6164450645446777, "title": "Lamivudine: Drug information", "rep_snippet": "Lamivudine has a high level of transfer across the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnan…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6163368225097656, "bge_max": 0.6163368225097656, "title": "Nilotinib: Drug information", "rep_snippet": "Pregnancy Implications  Based on data from animal reproduction studies and the mechanism of action, nilotinib may cause fetal harm if administered during pregnancy. Verify pregnancy status in females of reproductive pote…"}, {"doc_id": "lurasidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6158647537231445, "bge_max": 0.6158647537231445, "title": "Lurasidone: Drug information", "rep_snippet": "Pregnancy Implications  Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Sympto…"}, {"doc_id": "gonadorelin-acetate-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6157240271568298, "bge_max": 0.6157240271568298, "title": "Gonadorelin acetate (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  The risk of fetal harm appears remote if gonadorelin is used during pregnancy. Clinical studies of pregnant women have not demonstrated an increased risk of fetal abnormalities during the first tr…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6149527430534363, "bge_max": 0.6149527430534363, "title": "Zidovudine: Drug information", "rep_snippet": "Zidovudine has a high level of transfer across the human placenta; the placenta also metabolizes zidovudine to the active metabolite. No increased risk of overall birth defects has been observed following first trimester…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.612860918045044, "bge_max": 0.612860918045044, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "The pharmacokinetics of sulfamethoxazole and trimethoprim are similar to nonpregnant values in early pregnancy (Ylikorkala 1973). Sulfamethoxazole and trimethoprim are recommended for the prophylaxis or treatment of Pneu…"}, {"doc_id": "uridine-triacetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.612296998500824, "bge_max": 0.612296998500824, "title": "Uridine triacetate: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were not observed in animal reproduction studies. Information related to the use of uridine triacetate for the treatment of hereditary orotic aciduria and fluoropyrimidine overdose/…"}, {"doc_id": "flurbiprofen-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.610346794128418, "bge_max": 0.610346794128418, "title": "Flurbiprofen (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6102988719940186, "bge_max": 0.6102988719940186, "title": "Ondansetron: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were not observed in animal reproduction studies. Ondansetron readily crosses the human placenta in the first trimester of pregnancy and can be detected in fetal tissue (Siu 2006).…"}, {"doc_id": "nivolumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6096354126930237, "bge_max": 0.6096354126930237, "title": "Nivolumab: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in animal reproduction studies. Nivolumab may be expected to cross the placenta; effects to the fetus may be greater in the second and third trimesters. Based on its m…"}, {"doc_id": "nitrous-oxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6093841195106506, "bge_max": 0.6093841195106506, "title": "Nitrous oxide: Drug information", "rep_snippet": "Pregnancy Implications  Nitrous oxide crosses the placenta in concentrations ~80% of those in the maternal plasma. The half-life in the neonate is ~3 minutes and it is quickly eliminated from neonatal lungs with the onse…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6080883145332336, "bge_max": 0.6080883145332336, "title": "Trimethoprim: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Trimethoprim crosses the placenta and can be detected in the fetal serum and amniotic fluid (Reid 1975). Adverse events may be ass…"}, {"doc_id": "isoflurane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6076553463935852, "bge_max": 0.6076553463935852, "title": "Isoflurane: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate (N…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6072883605957031, "bge_max": 0.6072883605957031, "title": "Warfarin: Drug information", "rep_snippet": "In pregnant women with high-risk mechanical heart valves, the benefits of warfarin therapy should be discussed with the risks of available treatments (ACCP [Bates 2012]; AHA/ACC [Nishimura 2014]); when possible avoid war…"}, {"doc_id": "propylthiouracil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6062349677085876, "bge_max": 0.6062349677085876, "title": "Propylthiouracil: Drug information", "rep_snippet": "[US Boxed Warning]: Because of the risk of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimeste…"}, {"doc_id": "etodolac-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6062237620353699, "bge_max": 0.6062237620353699, "title": "Etodolac: Drug information", "rep_snippet": "Pregnancy Implications  Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus…"}, {"doc_id": "lamivudine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6061778664588928, "bge_max": 0.6061778664588928, "title": "Lamivudine and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Pregnancy Implications  Lamivudine and tenofovir disoproxil fumarate have a high level of transfer across the human placenta.  The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine in combinati…"}, {"doc_id": "ketamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6057217717170715, "bge_max": 0.6057217717170715, "title": "Ketamine: Drug information", "rep_snippet": "Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity, may affect brain…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6056791543960571, "bge_max": 0.6056791543960571, "title": "Sulfadiazine: Drug information", "rep_snippet": "Sulfadiazine is recommended for use in pregnant women to prevent T. gondii infection of the fetus, for the maternal treatment of Toxoplasmic gondii encephalitis, and as an alternative agent for the secondary prevention o…"}, {"doc_id": "piroxicam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6051355600357056, "bge_max": 0.6051355600357056, "title": "Piroxicam: Drug information", "rep_snippet": "Pregnancy Implications  Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus…"}, {"doc_id": "all-trans-retinoic-acid-systemic-tretinoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6047678589820862, "bge_max": 0.6047678589820862, "title": "All-trans retinoic acid (systemic tretinoin): Drug information", "rep_snippet": "Adverse events were observed in animal reproduction studies. [US Boxed Warning]: High risk of teratogenicity; if treatment with tretinoin is required in women of childbearing potential, two reliable forms of contraceptio…"}, {"doc_id": "cyproheptadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6046674251556396, "bge_max": 0.6046674251556396, "title": "Cyproheptadine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Per the product labeling, an increased risk of congenital abnormalities was not observed following maternal use of cyproheptadine…"}, {"doc_id": "desflurane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6043756008148193, "bge_max": 0.6043756008148193, "title": "Desflurane: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate (N…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6042271852493286, "bge_max": 0.6042271852493286, "title": "Sertraline: Drug information", "rep_snippet": "Pregnancy Implications  Sertraline crosses the human placenta. Available studies evaluating teratogenic effects following maternal use of sertraline in the first trimester have not shown an overall increased risk of majo…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6035455465316772, "bge_max": 0.6035455465316772, "title": "Naproxen: Drug information", "rep_snippet": "Pregnancy Implications  Naproxen crosses the placenta (Brogden 1975). Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects,…"}, {"doc_id": "danaparoid-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6033506393432617, "bge_max": 0.6033506393432617, "title": "Danaparoid (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. The manufacturer labeling states that incidental observations in pregnant women during the last trimesters, gave no indication…"}, {"doc_id": "tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6030978560447693, "bge_max": 0.6030978560447693, "title": "Tenofovir disoproxil fumarate and emtricitabine: Drug information", "rep_snippet": "Pregnancy Implications  The Health and Human Services (HHS) Perinatal HIV Guidelines consider emtricitabine with tenofovir disoproxil fumarate to be a preferred NRTI backbone for initial therapy in antiretroviral-naive p…"}, {"doc_id": "nevirapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6030038595199585, "bge_max": 0.6030552387237549, "title": "Nevirapine: Drug information", "rep_snippet": "Pregnancy Implications  Nevirapine has a high level of transfer across the human placenta. No increased risk of overall birth defects following first trimester exposure according to data collected by the antiretroviral p…"}, {"doc_id": "indomethacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6028293371200562, "bge_max": 0.6028293371200562, "title": "Indomethacin: Drug information", "rep_snippet": "The clearance of indomethacin may be increased during pregnancy (Rytting 2014). NSAIDs have been used in the management of preterm labor. When choosing a specific agent, the benefits of the available tocolytic agents sho…"}, {"doc_id": "nelarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6027529239654541, "bge_max": 0.6027529239654541, "title": "Nelarabine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse effects were observed in animal reproduction studies and nelarabine may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to use effectiv…"}, {"doc_id": "neratinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6022793054580688, "bge_max": 0.6022793054580688, "title": "Neratinib: Drug information", "rep_snippet": "Pregnancy Implications  Based on the mechanism of action and data from animal reproduction studies, use of neratinib in pregnancy may cause fetal harm. Women of reproductive potential should have a pregnancy test prior t…"}]}
{"qid": "Q20_negation-trap", "query": "Pregnant UTI (no pyelo signs) — when is nitrofurantoin okay vs avoid (trimester-wise)?", "base_qid": "Q20", "variant_type": "negation-trap", "candidates": [{"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 32.0668385950213, "bm25_max": 37.76952569819315, "bge_top3": 0.6504347026348114, "bge_max": 0.6768137216567993, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Pregnancy Implications  Adverse effects have not been observed in animal reproduction studies. Nitrofurantoin crosses the placenta (Perry 1967) and maternal serum concentrations may be lower in pregnancy (Philipson 1979)…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 17.576313812304846, "bm25_max": 17.576313812304846, "bge_top3": null, "bge_max": null, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients (Amon 1981; Visser 1984; Wang 2011). Bacterial vaginosis has been associated with adverse pregnancy outcomes; metronidazole is recommen…"}, {"doc_id": "yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 13.954543225816005, "bm25_max": 16.876197794269665, "bge_top3": 0.5745031237602234, "bge_max": 0.5745031237602234, "title": "Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Avoid use in pregnant women unless travel to high-risk areas is unavoidable. Pregnant women may not produce an adequate immune response to the vaccine, particularly in the third trimester (CDC/ACIP [Staples 2015]). Adver…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 16.820920490855436, "bm25_max": 16.820920490855436, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Prednisolone may be used (alternative agent) to treat primary adrenal insufficiency (PAI) in pregnant women. Pregnant females with PAI should be monitored at least once each trimester (Bornstein 2016). Prednisolone may b…"}, {"doc_id": "liposomal-cytarabine-united-states-not-available-drug-information", "bm25_top3": 16.813360281670633, "bm25_max": 16.813360281670633, "bge_top3": null, "bge_max": null, "title": "Liposomal cytarabine (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  Adverse effects were observed in animal reproductive studies with conventional cytarabine. Conventional cytarabine has been associated with fetal malformations when given as a component of systemi…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 16.594178757307535, "bm25_max": 16.594178757307535, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimeste…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 16.409948019020813, "bm25_max": 16.409948019020813, "bge_top3": 0.5746111869812012, "bge_max": 0.5746111869812012, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Individually, erythromycin and sulfonamides may be used to treat infections in pregnant women when clinically appropriate for confirmed infections caused by susceptible organisms. Use of sulfonamides during the first tri…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 16.38416670451378, "bm25_max": 16.38416670451378, "bge_top3": 0.5871988534927368, "bge_max": 0.5871988534927368, "title": "Mercaptopurine: Drug information", "rep_snippet": "Pregnancy Implications  May cause fetal harm if administered during pregnancy. Case reports of fetal loss have been noted with mercaptopurine administration during the first trimester; adverse effects have also been note…"}, {"doc_id": "paromomycin-drug-information", "bm25_top3": 16.2024636853184, "bm25_max": 16.2024636853184, "bge_top3": null, "bge_max": null, "title": "Paromomycin: Drug information", "rep_snippet": "Pregnancy Implications  Paromomycin is poorly absorbed when given orally. Information related to the use of paromomycin in pregnancy is limited (Kreutner 1981). Use may be considered for the treatment of giardiasis throu…"}, {"doc_id": "dimercaprol-drug-information", "bm25_top3": 16.08827269305482, "bm25_max": 16.08827269305482, "bge_top3": null, "bge_max": null, "title": "Dimercaprol: Drug information", "rep_snippet": "Pregnancy Implications  Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.  Lead poisoning: Lead is known to cross the placenta in amounts related to…"}, {"doc_id": "edetate-calcium-disodium-calcium-edta-drug-information", "bm25_top3": 16.002103667509257, "bm25_max": 16.002103667509257, "bge_top3": null, "bge_max": null, "title": "Edetate calcium disodium (calcium EDTA): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies; there are no well controlled studies of edetate CALCIUM disodium in pregnant women. Lead is known to cross the placenta in amounts…"}, {"doc_id": "propafenone-drug-information", "bm25_top3": 15.960744820766092, "bm25_max": 15.960744820766092, "bge_top3": null, "bge_max": null, "title": "Propafenone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Propafenone and its metabolite cross the placenta and can be detected in the newborn (Libardoni 1991). Guidelines are available fo…"}, {"doc_id": "cortisone-acetate-drug-information", "bm25_top3": 15.561267617552087, "bm25_max": 15.561267617552087, "bge_top3": null, "bge_max": null, "title": "Cortisone acetate: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Cortisone crosses the placenta (Migeon 1957). Some studies have shown an association between first trimester…"}, {"doc_id": "pentamidine-oral-inhalation-drug-information", "bm25_top3": 15.070964355450684, "bm25_max": 15.070964355450684, "bge_top3": null, "bge_max": null, "title": "Pentamidine (oral inhalation): Drug information", "rep_snippet": "Pregnancy Implications  It is not known if clinically significant concentrations reach the fetus when administered via the aerosolized route. Information related to fetal outcomes following maternal use of pentamidine is…"}, {"doc_id": "methyltestosterone-drug-information", "bm25_top3": 15.05961517691848, "bm25_max": 15.05961517691848, "bge_top3": null, "bge_max": null, "title": "Methyltestosterone: Drug information", "rep_snippet": "Pregnancy Implications  Use is contraindicated in women who are or may become pregnant. May cause virilization of the external genitalis of the female fetus, including clitoromegaly, abnormal vaginal development, and fus…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 14.982082280499013, "bm25_max": 14.982082280499013, "bge_top3": 0.5808905363082886, "bge_max": 0.5808905363082886, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "The pharmacokinetics of sulfamethoxazole and trimethoprim are similar to nonpregnant values in early pregnancy (Ylikorkala 1973). Sulfamethoxazole and trimethoprim are recommended for the prophylaxis or treatment of Pneu…"}, {"doc_id": "hydrocortisone-systemic-drug-information", "bm25_top3": 14.972366425995759, "bm25_max": 14.972366425995759, "bge_top3": null, "bge_max": null, "title": "Hydrocortisone (systemic): Drug information", "rep_snippet": "For dermatologic disorders in pregnant women, systemic corticosteroids are generally not preferred for initial therapy; should be avoided during the first trimester; and used during the second or third trimester at the l…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": 14.965217282456628, "bm25_max": 14.965217282456628, "bge_top3": null, "bge_max": null, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi…"}, {"doc_id": "dimercaptosuccinic-acid-succimer-drug-information", "bm25_top3": 14.83253554610161, "bm25_max": 14.83253554610161, "bge_top3": null, "bge_max": null, "title": "Dimercaptosuccinic acid (succimer): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in animal reproduction studies.  Lead poisoning: Lead is known to cross the placenta in amounts related to maternal plasma levels. Prenatal lead exposure may be associ…"}, {"doc_id": "insulin-detemir-drug-information", "bm25_top3": 14.828787122857058, "bm25_max": 14.828787122857058, "bge_top3": null, "bge_max": null, "title": "Insulin detemir: Drug information", "rep_snippet": "Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018c). Insulin requirements tend to fall during the fir…"}, {"doc_id": "anthrax-vaccine-drug-information", "bm25_top3": 14.785850525767717, "bm25_max": 14.785850525767717, "bge_top3": null, "bge_max": null, "title": "Anthrax vaccine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were not observed in animal developmental toxicity studies. Data from the Department of Defense suggest the vaccine may be linked with a slightly increased number of atrial septal d…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": 14.711406100695623, "bm25_max": 14.711406100695623, "bge_top3": null, "bge_max": null, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "Albuterol may affect uterine contractility. Maternal pulmonary edema and other adverse events have been reported when albuterol was used for tocolysis. Albuterol is not approved for use as a tocolytic; use caution when n…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": 14.42534553020499, "bm25_max": 14.42534553020499, "bge_top3": 0.5833017826080322, "bge_max": 0.5833017826080322, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "Pregnancy Implications  Animal reproduction studies have not been conducted with this combination. Avoid use of ibuprofen/famotidine in pregnant women starting at 30 weeks of gestation (third trimester) due to the risk o…"}, {"doc_id": "sulfadiazine-drug-information", "bm25_top3": 14.160294911357708, "bm25_max": 14.160294911357708, "bge_top3": null, "bge_max": null, "title": "Sulfadiazine: Drug information", "rep_snippet": "Sulfadiazine is recommended for use in pregnant women to prevent T. gondii infection of the fetus, for the maternal treatment of Toxoplasmic gondii encephalitis, and as an alternative agent for the secondary prevention o…"}, {"doc_id": "triamcinolone-systemic-drug-information", "bm25_top3": 14.13405756269402, "bm25_max": 14.13405756269402, "bge_top3": null, "bge_max": null, "title": "Triamcinolone (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies.  Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts o…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": 14.13405756269402, "bm25_max": 14.13405756269402, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Methylprednisolone crosses the placenta (Anderson 1981). Some studies have shown an association between first…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": 14.126250088862859, "bm25_max": 14.126250088862859, "bge_top3": null, "bge_max": null, "title": "Theophylline: Drug information", "rep_snippet": "Pregnancy Implications  Adverse effects have been observed in animal reproduction studies. Theophylline crosses the placenta; adverse effects may be seen in the newborn. Use is generally safe when used at the recommended…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 14.095039641527077, "bm25_max": 14.095039641527077, "bge_top3": null, "bge_max": null, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "The Health and Human Services (HHS) Perinatal HIV Guidelines consider tenofovir disoproxil fumarate a component in preferred regimens for initial therapy in antiretroviral-naïve pregnant females. The guidelines also cons…"}, {"doc_id": "dicyclomine-dicycloverine-drug-information", "bm25_top3": 14.00839562584862, "bm25_max": 14.00839562584862, "bge_top3": null, "bge_max": null, "title": "Dicyclomine (dicycloverine): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. In epidemiologic studies, birth defects were not observed following maternal doses up to 40 mg daily throughout the first trim…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": 14.000322180043717, "bm25_max": 14.000322180043717, "bge_top3": null, "bge_max": null, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Safety data from an observational pregnancy study included 500 pregnant women exposed to artemether/lumefantrine and did not show…"}, {"doc_id": "ivabradine-drug-information", "bm25_top3": 13.92800963415544, "bm25_max": 13.92800963415544, "bge_top3": null, "bge_max": null, "title": "Ivabradine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies, and fetal harm may occur if ivabradine is administered to pregnant women. Effective contraception is recommended in women of repro…"}, {"doc_id": "influenza-virus-vaccine-inactivated-drug-information", "bm25_top3": 13.693299948131394, "bm25_max": 13.693299948131394, "bge_top3": null, "bge_max": null, "title": "Influenza virus vaccine (inactivated): Drug information", "rep_snippet": "Pregnancy Implications  Inactivated influenza vaccine has not been shown to cause fetal harm when given to pregnant women, although information related to use in the first trimester is limited. Maternal influenza infecti…"}, {"doc_id": "gonadorelin-acetate-united-states-not-available-drug-information", "bm25_top3": 13.69267562907897, "bm25_max": 13.69267562907897, "bge_top3": 0.5789589881896973, "bge_max": 0.5789589881896973, "title": "Gonadorelin acetate (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  The risk of fetal harm appears remote if gonadorelin is used during pregnancy. Clinical studies of pregnant women have not demonstrated an increased risk of fetal abnormalities during the first tr…"}, {"doc_id": "flecainide-drug-information", "bm25_top3": 13.608379853668707, "bm25_max": 13.608379853668707, "bge_top3": null, "bge_max": null, "title": "Flecainide: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Flecainide is recommended in the treatment of fetal tachycardia determined to be SVT. Flecainide may be also used for the ong…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 12.889158813173122, "bm25_max": 12.889158813173122, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "• Urinary tract infection: Serious urinary infections including urosepsis and pyelonephritis requiring hospitalization have been reported; treatment with SGLT2 inhibitors increase the risk for urinary tract infections (U…"}, {"doc_id": "citric-acid-bladder-mixture-drug-information", "bm25_top3": 11.278652847755737, "bm25_max": 11.278652847755737, "bge_top3": null, "bge_max": null, "title": "Citric acid bladder mixture: Drug information", "rep_snippet": "Administration  For local irrigation within the lower urinary tract. Discontinue irrigation immediately if fever, urinary tract infection (UTI), signs and symptoms of UTI, or persistent flank pain occurs. Maintain patenc…"}, {"doc_id": "levonorgestrel-intrauterine-device-drug-information", "bm25_top3": 8.442981939121132, "bm25_max": 8.442981939121132, "bge_top3": null, "bge_max": null, "title": "Levonorgestrel intrauterine device: Drug information", "rep_snippet": "Initiation of therapy: The device may be inserted at any time in the menstrual cycle once it is determined that the woman is not pregnant; immediately postpartum; or immediately after first or second trimester spontaneou…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 6.624422157455095, "bm25_max": 6.624422157455095, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Monitoring Parameters  HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (ADA 2018a); plas…"}, {"doc_id": "acitretin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5995192329088846, "bge_max": 0.6101441979408264, "title": "Acitretin: Drug information", "rep_snippet": "• Pregnancy: [US Boxed Warning]: Acitretin is a known teratogen and contraindicated in females who are or may become pregnant. Birth defects (including facial, ear, central nervous system, cardiovascular, limb, bone, and…"}, {"doc_id": "phenylephrine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6020216941833496, "bge_max": 0.6020216941833496, "title": "Phenylephrine (systemic): Drug information", "rep_snippet": "Animal reproduction studies have not been conducted. Phenylephrine crosses the placenta at term. Maternal use of phenylephrine during the first trimester of pregnancy is not strongly associated with an increased risk of…"}, {"doc_id": "triptorelin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5987846255302429, "bge_max": 0.5987846255302429, "title": "Triptorelin: Drug information", "rep_snippet": "Pregnancy Implications  Use is contraindicated in pregnant women. When used for ART, pregnancy must be ruled out prior to therapy and nonhormonal contraception should be used until menses occurs. Due to the short half-li…"}, {"doc_id": "lurasidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5965606570243835, "bge_max": 0.5965606570243835, "title": "Lurasidone: Drug information", "rep_snippet": "Pregnancy Implications  Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Sympto…"}, {"doc_id": "rilpivirine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5946773290634155, "bge_max": 0.5946773290634155, "title": "Rilpivirine: Drug information", "rep_snippet": "Pregnancy Implications  Rilpivirine has moderate to high placental transfer. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretrovir…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5928706526756287, "bge_max": 0.5928706526756287, "title": "Lithium: Drug information", "rep_snippet": "For planned pregnancies, use of lithium during the first trimester should be avoided if possible (Grandjean 2009). If lithium is needed during pregnancy, the minimum effective dose should be used, maternal serum concentr…"}, {"doc_id": "danaparoid-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5901937484741211, "bge_max": 0.5901937484741211, "title": "Danaparoid (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. The manufacturer labeling states that incidental observations in pregnant women during the last trimesters, gave no indication…"}, {"doc_id": "fluocinolone-hydroquinone-and-tretinoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.588743269443512, "bge_max": 0.588743269443512, "title": "Fluocinolone, hydroquinone, and tretinoin: Drug information", "rep_snippet": "Pregnancy Implications  There are no adequate and well-controlled studies in pregnant women. Tretinoin appears to have a low risk of teratogenicity when used topically since it is rapidly metabolized by the skin; however…"}, {"doc_id": "alitretinoin-systemic-united-states-not-available-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5855436623096466, "bge_max": 0.5865060091018677, "title": "Alitretinoin (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Pregnancy Implications  [Canadian Boxed Warning]: Alitretinoin is a known teratogen and is contraindicated in pregnancy. Females must avoid becoming pregnant while receiving alitretinoin and for at least 1 month after di…"}, {"doc_id": "econazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5860689878463745, "bge_max": 0.5860689878463745, "title": "Econazole: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. The manufacturer recommends avoiding use during pregnancy, especially during the first trimester."}, {"doc_id": "thiothixene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5856547951698303, "bge_max": 0.5856547951698303, "title": "Thiothixene: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS])…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5839022994041443, "bge_max": 0.5839022994041443, "title": "Spironolactone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. The antiandrogen effects of spironolactone have been shown to cause feminization of the male fetus in animal studies. Spirono…"}, {"doc_id": "propofol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5819010734558105, "bge_max": 0.5819010734558105, "title": "Propofol: Drug information", "rep_snippet": "Pregnancy Implications  Propofol crosses the placenta and may be associated with neonatal CNS and respiratory depression. Propofol is not recommended by the manufacturer for obstetrics, including cesarean section deliver…"}, {"doc_id": "tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5816993117332458, "bge_max": 0.5816993117332458, "title": "Tenofovir disoproxil fumarate and emtricitabine: Drug information", "rep_snippet": "Pregnancy Implications  The Health and Human Services (HHS) Perinatal HIV Guidelines consider emtricitabine with tenofovir disoproxil fumarate to be a preferred NRTI backbone for initial therapy in antiretroviral-naive p…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5803363919258118, "bge_max": 0.5803363919258118, "title": "Trimethoprim: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Trimethoprim crosses the placenta and can be detected in the fetal serum and amniotic fluid (Reid 1975). Adverse events may be ass…"}, {"doc_id": "lamivudine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5789251327514648, "bge_max": 0.5789251327514648, "title": "Lamivudine and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Pregnancy Implications  Lamivudine and tenofovir disoproxil fumarate have a high level of transfer across the human placenta.  The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine in combinati…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.578769326210022, "bge_max": 0.578769326210022, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Pregnancy Implications  According to the manufacturer, use is not recommended during the second and third trimesters. Refer to individual monographs."}, {"doc_id": "triamterene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5787043571472168, "bge_max": 0.5787043571472168, "title": "Triamterene: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Triamterene crosses the placenta and is found in cord blood. Use of triamterene to treat edema during normal pregnancies is no…"}, {"doc_id": "primidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5784920454025269, "bge_max": 0.5784920454025269, "title": "Primidone: Drug information", "rep_snippet": "Pregnancy Implications  Primidone and its metabolites (PEMA, phenobarbital, and p-hydroxyphenobarbital) cross the placenta; neonatal serum concentrations at birth are similar to those in the mother. Withdrawal symptoms m…"}, {"doc_id": "cariprazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5781746506690979, "bge_max": 0.5781746506690979, "title": "Cariprazine: Drug information", "rep_snippet": "Pregnancy Implications  Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Sympto…"}, {"doc_id": "efavirenz-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5778944492340088, "bge_max": 0.5778944492340088, "title": "Efavirenz: Drug information", "rep_snippet": "Efavirenz has a moderate level of transfer across the human placenta. Based on data from the Antiretroviral Pregnancy Registry, an increased risk of overall birth defects has not been observed following first trimester e…"}, {"doc_id": "nelfinavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5778821706771851, "bge_max": 0.5778821706771851, "title": "Nelfinavir: Drug information", "rep_snippet": "Pregnancy Implications  Nelfinavir has a minimal to low level of transfer across the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data colle…"}, {"doc_id": "metaxalone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5778787136077881, "bge_max": 0.5778787136077881, "title": "Metaxalone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Use during pregnancy (especially first trimester) only if benefits outweigh risks."}, {"doc_id": "dalteparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5771787166595459, "bge_max": 0.5771787166595459, "title": "Dalteparin: Drug information", "rep_snippet": "Pregnancy Implications  Low molecular weight heparin (LMWH) does not cross the placenta; increased risks of fetal bleeding or teratogenic effects have not been reported (Bates 2012).  LMWH is recommended over unfractiona…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5768636465072632, "bge_max": 0.5768636465072632, "title": "Zidovudine: Drug information", "rep_snippet": "Zidovudine has a high level of transfer across the human placenta; the placenta also metabolizes zidovudine to the active metabolite. No increased risk of overall birth defects has been observed following first trimester…"}, {"doc_id": "nitrous-oxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5762367248535156, "bge_max": 0.5762367248535156, "title": "Nitrous oxide: Drug information", "rep_snippet": "Pregnancy Implications  Nitrous oxide crosses the placenta in concentrations ~80% of those in the maternal plasma. The half-life in the neonate is ~3 minutes and it is quickly eliminated from neonatal lungs with the onse…"}, {"doc_id": "ethinyl-estradiol-drospirenone-and-levomefolate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5757947564125061, "bge_max": 0.5757947564125061, "title": "Ethinyl estradiol, drospirenone, and levomefolate: Drug information", "rep_snippet": "Use after childbirth (in women who are not breast-feeding) or after second trimester abortion: Therapy may be started ≥4 weeks postpartum. Pregnancy should be ruled out prior to treatment if menstrual periods have not re…"}, {"doc_id": "nevirapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.57578444480896, "bge_max": 0.57578444480896, "title": "Nevirapine: Drug information", "rep_snippet": "Pregnancy Implications  Nevirapine has a high level of transfer across the human placenta. No increased risk of overall birth defects following first trimester exposure according to data collected by the antiretroviral p…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.57540363073349, "bge_max": 0.57540363073349, "title": "Phenobarbital: Drug information", "rep_snippet": "Pregnancy Implications  Phenobarbital crosses the placenta (Harden 2009b). Barbiturates can be detected in the placenta, fetal liver, and fetal brain. Fetal and maternal blood concentrations may be similar following pare…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5753088593482971, "bge_max": 0.5753088593482971, "title": "Ibuprofen: Drug information", "rep_snippet": "Pregnancy Implications  Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus…"}, {"doc_id": "propylthiouracil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.575247049331665, "bge_max": 0.575247049331665, "title": "Propylthiouracil: Drug information", "rep_snippet": "[US Boxed Warning]: Because of the risk of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimeste…"}, {"doc_id": "timolol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.57524174451828, "bge_max": 0.57524174451828, "title": "Timolol (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were not observed in the initial animal reproduction studies. Timolol crosses the placenta (Schneider 1988) and decreased fetal heart rate has been observed following maternal use o…"}, {"doc_id": "bivalirudin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747509002685547, "bge_max": 0.5747509002685547, "title": "Bivalirudin: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Bivalirudin is used in conjunction with aspirin, which may lead to maternal or fetal adverse effects, especially during the th…"}, {"doc_id": "pyridostigmine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5744022130966187, "bge_max": 0.5744022130966187, "title": "Pyridostigmine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Pyridostigmine may cross the placenta (Buckley 1968). Use of pyridostigmine may be continued during pregnancy for the treatmen…"}, {"doc_id": "cyproheptadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5741641521453857, "bge_max": 0.5741641521453857, "title": "Cyproheptadine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Per the product labeling, an increased risk of congenital abnormalities was not observed following maternal use of cyproheptadine…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5734767317771912, "bge_max": 0.5734767317771912, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Pregnancy Implications  Use of this combination product is not recommended during the second or third trimesters of pregnancy. Refer to individual monographs."}, {"doc_id": "asunaprevir-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5732893347740173, "bge_max": 0.5732893347740173, "title": "Asunaprevir (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  According to the manufacturer, asunaprevir in combination with daclatasvir, peginterferon alfa, or ribavirin should not be administered during pregnancy, in women who are of childbearing potential…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5729187726974487, "bge_max": 0.5729187726974487, "title": "Sertraline: Drug information", "rep_snippet": "Pregnancy Implications  Sertraline crosses the human placenta. Available studies evaluating teratogenic effects following maternal use of sertraline in the first trimester have not shown an overall increased risk of majo…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5728330612182617, "bge_max": 0.5728330612182617, "title": "Ondansetron: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were not observed in animal reproduction studies. Ondansetron readily crosses the human placenta in the first trimester of pregnancy and can be detected in fetal tissue (Siu 2006).…"}]}
{"qid": "Q20_spelling", "query": "UTI pregnacy — nitrofurantoin status per trimester.", "base_qid": "Q20", "variant_type": "spelling", "candidates": [{"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 28.00938896641591, "bm25_max": 30.002809422560144, "bge_top3": 0.6329215367635092, "bge_max": 0.6715891361236572, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nitrofurantoin: Pediatric drug information\")  UTI, treatment:  Infants, Children, and Adolescents: Nitrofurantoin macrocrystals (Furadantin, Macrodantin): Oral: 5 to 7…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": 7.386377156037666, "bm25_max": 7.386377156037666, "bge_top3": null, "bge_max": null, "title": "Ceftazidime: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Ceftazidime crosses the placenta and reaches the cord serum and amniotic fluid. An increase in most types of birth defects was…"}, {"doc_id": "citric-acid-bladder-mixture-drug-information", "bm25_top3": 7.3388296143923455, "bm25_max": 7.3388296143923455, "bge_top3": null, "bge_max": null, "title": "Citric acid bladder mixture: Drug information", "rep_snippet": "Administration  For local irrigation within the lower urinary tract. Discontinue irrigation immediately if fever, urinary tract infection (UTI), signs and symptoms of UTI, or persistent flank pain occurs. Maintain patenc…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 7.303561172386615, "bm25_max": 7.303561172386615, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Pregnancy Implications  May cause fetal harm if administered during pregnancy. Case reports of fetal loss have been noted with mercaptopurine administration during the first trimester; adverse effects have also been note…"}, {"doc_id": "enalaprilat-intravenous-drug-information", "bm25_top3": 7.0451208043725835, "bm25_max": 7.0451208043725835, "bge_top3": null, "bge_max": null, "title": "Enalaprilat (intravenous): Drug information", "rep_snippet": "Pregnancy Risk Factor  C (1st trimester); D (2nd and 3rd trimesters) (show table)"}, {"doc_id": "amobarbital-drug-information", "bm25_top3": 6.867905745677016, "bm25_max": 6.867905745677016, "bge_top3": null, "bge_max": null, "title": "Amobarbital: Drug information", "rep_snippet": "Pregnancy Implications  Barbiturates cross the placenta and distribute in fetal tissue. Teratogenic effects have been reported with 1st trimester exposure. Exposure during the 3rd trimester may lead to symptoms of acute…"}, {"doc_id": "diclofenac-topical-drug-information", "bm25_top3": 6.831407461511626, "bm25_max": 6.831407461511626, "bge_top3": null, "bge_max": null, "title": "Diclofenac (topical): Drug information", "rep_snippet": "Voltaren Emulgel: Concomitant use with other diclofenac-containing products or oral NSAIDS; pregnancy (last trimester)"}, {"doc_id": "econazole-drug-information", "bm25_top3": 6.770353827408526, "bm25_max": 6.770353827408526, "bge_top3": null, "bge_max": null, "title": "Econazole: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. The manufacturer recommends avoiding use during pregnancy, especially during the first trimester."}, {"doc_id": "metaxalone-drug-information", "bm25_top3": 6.770353827408526, "bm25_max": 6.770353827408526, "bge_top3": null, "bge_max": null, "title": "Metaxalone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Use during pregnancy (especially first trimester) only if benefits outweigh risks."}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 6.769090478928211, "bm25_max": 6.769090478928211, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Prednisolone may be used (alternative agent) to treat primary adrenal insufficiency (PAI) in pregnant women. Pregnant females with PAI should be monitored at least once each trimester (Bornstein 2016). Prednisolone may b…"}, {"doc_id": "pseudoephedrine-drug-information", "bm25_top3": 6.737795280040627, "bm25_max": 6.737795280040627, "bge_top3": null, "bge_max": null, "title": "Pseudoephedrine: Drug information", "rep_snippet": "Pregnancy Implications  Use of pseudoephedrine during the first trimester may be associated with a possible risk of gastroschisis, small intestinal atresia, and hemifacial microsomia due to pseudoephedrine's vasoconstric…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": 6.625145625436428, "bm25_max": 6.625145625436428, "bge_top3": null, "bge_max": null, "title": "Tinidazole: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to tinidazole, nitroimidazole derivatives, or any component of the formulation; pregnancy (first trimester); breast-feeding"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": 6.343845513149784, "bm25_max": 6.343845513149784, "bge_top3": null, "bge_max": null, "title": "Edoxaban: Drug information", "rep_snippet": "Pregnancy Implications  Ten pregnancies were reported in a study using edoxaban for the treatment of DVT or PE. Estimated exposure occurred during the first trimester with duration of exposure ~6 weeks; outcomes included…"}, {"doc_id": "measles-mumps-and-rubella-vaccines-combined-drug-information", "bm25_top3": 6.269808900056114, "bm25_max": 6.269808900056114, "bge_top3": null, "bge_max": null, "title": "Measles, mumps, and rubella vaccines (combined): Drug information", "rep_snippet": "Adverse consequences of natural infection in unvaccinated pregnant women have been reported. Measles infection during pregnancy may increase the risk of premature labor, preterm delivery, spontaneous abortion and low bir…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 6.000737469812422, "bm25_max": 6.250945026398025, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Monitoring Parameters  Blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (A…"}, {"doc_id": "cosyntropin-tetracosactide-drug-information", "bm25_top3": 6.2283603363690965, "bm25_max": 6.2283603363690965, "bge_top3": null, "bge_max": null, "title": "Cosyntropin (tetracosactide): Drug information", "rep_snippet": "Pregnancy Implications  Animal reproduction studies have not been conducted with cosyntropin; adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association…"}, {"doc_id": "triamcinolone-systemic-drug-information", "bm25_top3": 6.191531555433443, "bm25_max": 6.191531555433443, "bge_top3": null, "bge_max": null, "title": "Triamcinolone (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies.  Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts o…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": 6.191531555433443, "bm25_max": 6.191531555433443, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Methylprednisolone crosses the placenta (Anderson 1981). Some studies have shown an association between first…"}, {"doc_id": "phenylephrine-systemic-drug-information", "bm25_top3": 5.9355712896825175, "bm25_max": 5.9355712896825175, "bge_top3": null, "bge_max": null, "title": "Phenylephrine (systemic): Drug information", "rep_snippet": "Animal reproduction studies have not been conducted. Phenylephrine crosses the placenta at term. Maternal use of phenylephrine during the first trimester of pregnancy is not strongly associated with an increased risk of…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 5.891625344443582, "bm25_max": 5.891625344443582, "bge_top3": null, "bge_max": null, "title": "Empagliflozin: Drug information", "rep_snippet": "Monitoring Parameters  Blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (A…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 5.889415093950561, "bm25_max": 5.889415093950561, "bge_top3": null, "bge_max": null, "title": "Canagliflozin: Drug information", "rep_snippet": "Monitoring Parameters  Blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (A…"}, {"doc_id": "oxymetazoline-nasal-drug-information", "bm25_top3": 5.877467189553428, "bm25_max": 5.877467189553428, "bge_top3": null, "bge_max": null, "title": "Oxymetazoline (nasal): Drug information", "rep_snippet": "Pregnancy Implications  Adverse fetal/neonatal events have been noted in case reports following large doses or extended use of oxymetazoline nasal spray in the first trimester of pregnancy (Baxi 1985; Holm 1985; Menezes…"}, {"doc_id": "cytarabine-drug-information", "bm25_top3": 5.807947614292495, "bm25_max": 5.807947614292495, "bge_top3": null, "bge_max": null, "title": "Cytarabine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse effects were demonstrated in animal reproduction studies. Limb and ear defects have been noted in case reports of cytarabine exposure during the first trimester of pregnancy. The following…"}, {"doc_id": "zopiclone-united-states-not-available-drug-information", "bm25_top3": 5.771067598590609, "bm25_max": 5.771067598590609, "bge_top3": null, "bge_max": null, "title": "Zopiclone (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  There is insufficient data on safety in pregnancy; however, benzodiazepines may cause congenital malformations during the 1st trimester and neonatal CNS depression during the last few weeks of pre…"}, {"doc_id": "abacavir-drug-information", "bm25_top3": 5.744694475242142, "bm25_max": 5.744694475242142, "bge_top3": null, "bge_max": null, "title": "Abacavir: Drug information", "rep_snippet": "Pregnancy Implications  Abacavir has a high level of transfer across the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the…"}, {"doc_id": "cortisone-acetate-drug-information", "bm25_top3": 5.673181332694082, "bm25_max": 5.673181332694082, "bge_top3": null, "bge_max": null, "title": "Cortisone acetate: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Cortisone crosses the placenta (Migeon 1957). Some studies have shown an association between first trimester…"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 5.608009546484375, "bm25_max": 5.608009546484375, "bge_top3": null, "bge_max": null, "title": "Cefpodoxime: Drug information", "rep_snippet": "Pregnancy Implications  Teratogenic events were not observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins."}, {"doc_id": "nitazoxanide-drug-information", "bm25_top3": 5.53364131516836, "bm25_max": 5.53364131516836, "bge_top3": null, "bge_max": null, "title": "Nitazoxanide: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Human data is not available; however, nitazoxanide may be used during pregnancy after the first trimester in women with severe…"}, {"doc_id": "aspirin-and-diphenhydramine-drug-information", "bm25_top3": 5.524298813857088, "bm25_max": 5.524298813857088, "bge_top3": null, "bge_max": null, "title": "Aspirin and diphenhydramine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to aspirin, other pain relievers or fever reducers; concurrent use of other products containing diphenhydramine (including topical); use in children <12 years of age; pregnancy (third…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 5.495501641834373, "bm25_max": 5.495501641834373, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin: Drug information", "rep_snippet": "Monitoring Parameters  Blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (A…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 4.840609587927837, "bm25_max": 4.840609587927837, "bge_top3": null, "bge_max": null, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Monitoring Parameters  Blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (A…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 4.440864080006477, "bm25_max": 4.440864080006477, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Monitoring Parameters  Blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (A…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 4.376849295877985, "bm25_max": 4.376849295877985, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Monitoring Parameters  HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (ADA 2018a); plas…"}, {"doc_id": "onabotulinumtoxina-botox-drug-information", "bm25_top3": 3.724311223160111, "bm25_max": 3.724311223160111, "bge_top3": null, "bge_max": null, "title": "OnabotulinumtoxinA (Botox): Drug information", "rep_snippet": "• Urinary retention: An increased incidence of urinary retention and need for catheterization has been observed in patients receiving therapy for bladder dysfunction (overactive bladder or detrusor overactivity associate…"}, {"doc_id": "gabapentin-drug-information", "bm25_top3": 3.1156585163560013, "bm25_max": 3.1156585163560013, "bge_top3": null, "bge_max": null, "title": "Gabapentin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Neurontin may be confused with Motrin, Neoral, nitrofurantoin, Noroxin [DSC], Zarontin"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 1.8984785750219668, "bm25_max": 1.8984785750219668, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "Use  Candida/Cryptococcus infections: Adjunctive treatment of systemic fungal infections (eg, septicemia, endocarditis, UTI, meningitis, or pulmonary) caused by susceptible strains of Candida or Cryptococcus"}, {"doc_id": "oxytocin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6035443147023519, "bge_max": 0.620704174041748, "title": "Oxytocin: Drug information", "rep_snippet": "Monitoring Parameters  Fluid intake and output during administration, uterine activity (tonus, amplitude, and frequency of contractions), maternal blood pressure; fetal heart rate in relation to uterine contractions."}, {"doc_id": "vismodegib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6131957769393921, "bge_max": 0.6131957769393921, "title": "Vismodegib: Drug information", "rep_snippet": "Monitoring Parameters  Pregnancy test within 1 week prior to treatment initiation."}, {"doc_id": "telavancin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6131791472434998, "bge_max": 0.6131791472434998, "title": "Telavancin: Drug information", "rep_snippet": "Monitoring Parameters  Renal function (prior to start, every 48 to 72 hours; more frequently if indicated, and following therapy), pregnancy test"}, {"doc_id": "palbociclib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6122617721557617, "bge_max": 0.6122617721557617, "title": "Palbociclib: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential (prior to treatment initiation, every 2 weeks for first 2 cycles, then prior to each cycle, and as clinically indicated; if neutropenia is limited to grades 1 or 2 in the firs…"}, {"doc_id": "letrozole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6121268272399902, "bge_max": 0.6121268272399902, "title": "Letrozole: Drug information", "rep_snippet": "Monitoring Parameters  Cholesterol, hepatic function tests; bone density; pregnancy test (prior to treatment in females of reproductive potential).  For infertility/ovarian stimulation (off-label use), a pregnancy test i…"}, {"doc_id": "nitroglycerin-glyceryl-trinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6060551404953003, "bge_max": 0.6060551404953003, "title": "Nitroglycerin (glyceryl trinitrate): Drug information", "rep_snippet": "Pregnancy Implications  Animal reproduction studies have not been conducted with all products; adverse events were not observed in animal reproduction studies conducted using the ointment. Nitroglycerin crosses the place…"}, {"doc_id": "cycloserine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6056180000305176, "bge_max": 0.6056180000305176, "title": "Cycloserine: Drug information", "rep_snippet": "Monitoring Parameters  Periodic renal, hepatic, hematological tests, and plasma cycloserine concentrations; assess neuropsychiatric status at monthly intervals and more frequently if symptoms occur (ATS 2003)."}, {"doc_id": "nusinersen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6045244932174683, "bge_max": 0.6045244932174683, "title": "Nusinersen: Drug information", "rep_snippet": "Monitoring Parameters  Platelet count, coagulation tests (prothrombin time; activated partial thromboplastin time), and quantitative spot urine protein testing at baseline, prior to each dose, and as clinically indicated…"}, {"doc_id": "ethinyl-estradiol-and-norelgestromin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6042848825454712, "bge_max": 0.6042848825454712, "title": "Ethinyl estradiol and norelgestromin: Drug information", "rep_snippet": "Monitoring Parameters  Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potentia…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6035627126693726, "bge_max": 0.6035627126693726, "title": "Trimethoprim: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Trimethoprim crosses the placenta and can be detected in the fetal serum and amniotic fluid (Reid 1975). Adverse events may be ass…"}, {"doc_id": "norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6022474765777588, "bge_max": 0.6022474765777588, "title": "Norethindrone: Drug information", "rep_snippet": "Monitoring Parameters  Norethindrone: Contraception: Assessment of pregnancy status (prior to therapy); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potential health status…"}, {"doc_id": "bethanechol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6022061705589294, "bge_max": 0.6022061705589294, "title": "Bethanechol: Drug information", "rep_snippet": "Use  Neurogenic bladder: Treatment of neurogenic atony of the urinary bladder with retention  Urinary retention: Treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention"}, {"doc_id": "carboprost-tromethamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6019992232322693, "bge_max": 0.6019992232322693, "title": "Carboprost tromethamine: Drug information", "rep_snippet": "Use  Termination of pregnancy: For aborting pregnancy between week 13 and 20 of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester a…"}, {"doc_id": "ibrutinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5986233353614807, "bge_max": 0.5986233353614807, "title": "Ibrutinib: Drug information", "rep_snippet": "Monitoring Parameters  Monitor blood counts monthly or as clinically necessary; renal and hepatic function; uric acid levels as clinically necessary; verify pregnancy status prior to treatment initiation (in women of rep…"}, {"doc_id": "lutetium-lu-177-dotatate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5971583127975464, "bge_max": 0.5971583127975464, "title": "Lutetium Lu-177 dotatate: Drug information", "rep_snippet": "Monitoring Parameters  Monitor blood cell counts; serum creatinine and creatinine clearance; transaminases, bilirubin, and albumin; verify pregnancy status in females of reproductive potential prior to initiating therapy…"}, {"doc_id": "multiple-vitamins-prenatal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5962086915969849, "bge_max": 0.5962086915969849, "title": "Multiple vitamins (prenatal): Drug information", "rep_snippet": "Use  Nutritional supplement for use prior to conception, during pregnancy, and postnatal (in lactating and nonlactating women)"}, {"doc_id": "nintedanib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5957833528518677, "bge_max": 0.5957833528518677, "title": "Nintedanib: Drug information", "rep_snippet": "Monitoring Parameters  Obtain liver function tests prior to initiation of treatment, at regular intervals during the first 3 months of treatment, and periodically thereafter or as clinically indicated; obtain pregnancy t…"}, {"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5957646369934082, "bge_max": 0.5957646369934082, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Monitoring Parameters  Magnesium levels (prior to initiation of therapy and periodically thereafter)."}, {"doc_id": "ethinyl-estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5954004526138306, "bge_max": 0.5954004526138306, "title": "Ethinyl estradiol and norethindrone: Drug information", "rep_snippet": "Monitoring Parameters  Hormonal contraceptives: Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during…"}, {"doc_id": "nilutamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5943925380706787, "bge_max": 0.5943925380706787, "title": "Nilutamide: Drug information", "rep_snippet": "Monitoring Parameters  CBC (periodic), liver function tests (transaminases; at baseline, regularly during the first 4 months of treatment, and then periodically thereafter; more frequently if clinically indicated), elect…"}, {"doc_id": "interferon-gamma-1b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5942403674125671, "bge_max": 0.5942403674125671, "title": "Interferon gamma-1b: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential, platelets, LFTs (monthly in children <1 year), electrolytes, BUN, creatinine, and urinalysis prior to therapy and at 3-month intervals"}, {"doc_id": "ethinyl-estradiol-and-levonorgestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.593242883682251, "bge_max": 0.593242883682251, "title": "Ethinyl estradiol and levonorgestrel: Drug information", "rep_snippet": "Monitoring Parameters  Contraception:  Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during therapy);…"}, {"doc_id": "nicardipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5930420756340027, "bge_max": 0.5930420756340027, "title": "Nicardipine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Nicardipine has been used for the treatment of severe hypertension in pregnancy and preterm labor. Nicardipine crosses the pl…"}, {"doc_id": "magnesium-sulfate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5905576944351196, "bge_max": 0.5905576944351196, "title": "Magnesium sulfate: Drug information", "rep_snippet": "Monitoring Parameters  IV: Rapid administration: ECG monitoring, vital signs, deep tendon reflexes; magnesium concentrations if frequent or prolonged dosing required particularly in patients with renal dysfunction, calci…"}, {"doc_id": "bortezomib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5899041295051575, "bge_max": 0.5899041295051575, "title": "Bortezomib: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelets (monitor frequently throughout therapy); liver function tests (in patients with existing hepatic impairment); verify pregnancy status in women of reproductive po…"}, {"doc_id": "ethinyl-estradiol-and-norgestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.58979731798172, "bge_max": 0.58979731798172, "title": "Ethinyl estradiol and norgestrel: Drug information", "rep_snippet": "Monitoring Parameters  Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potentia…"}, {"doc_id": "ethinyl-estradiol-and-norgestimate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.58979731798172, "bge_max": 0.58979731798172, "title": "Ethinyl estradiol and norgestimate: Drug information", "rep_snippet": "Monitoring Parameters  Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potentia…"}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5897462964057922, "bge_max": 0.5897462964057922, "title": "Fosphenytoin: Drug information", "rep_snippet": "Pregnancy Implications  Fosphenytoin is the prodrug of phenytoin. An increased risk of congenital malformations and adverse outcomes may occur following in utero phenytoin exposure. Reported malformations include orofaci…"}, {"doc_id": "dinoprostone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5895700454711914, "bge_max": 0.5895700454711914, "title": "Dinoprostone: Drug information", "rep_snippet": "Monitoring Parameters  Gel, insert: Fetal heart rate, uterine activity, progression of cervical dilation and effacement  Tablet: Uterine activity; excessive uterine activity is contractions > 5 per 10 minutes and/or the…"}, {"doc_id": "magnesium-carbonate-calcium-carbonate-and-folic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5895646810531616, "bge_max": 0.5895646810531616, "title": "Magnesium carbonate, calcium carbonate, and folic acid: Drug information", "rep_snippet": "Use  Prevention or treatment of nutritional deficiencies"}, {"doc_id": "nifedipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.58935546875, "bge_max": 0.58935546875, "title": "Nifedipine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in animal reproduction studies. Nifedipine crosses the placenta (Manninen 1991; Silberschmidt 2008). An increase in perinatal asphyxia, cesarean delivery, prematurity,…"}, {"doc_id": "abemaciclib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.588868260383606, "bge_max": 0.588868260383606, "title": "Abemaciclib: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelets (at baseline, every 2 weeks for the first 2 months, monthly for the next 2 months, then as clinically indicated); ALT, AST, and serum bilirubin (at baseline, eve…"}, {"doc_id": "mestranol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.588791012763977, "bge_max": 0.588791012763977, "title": "Mestranol and norethindrone: Drug information", "rep_snippet": "Monitoring Parameters  Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; body mass index at baseline may be helpful to monitor changes during therapy); ass…"}, {"doc_id": "ethinyl-estradiol-and-ethynodiol-diacetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.588710606098175, "bge_max": 0.588710606098175, "title": "Ethinyl estradiol and ethynodiol diacetate: Drug information", "rep_snippet": "Monitoring Parameters  Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potentia…"}, {"doc_id": "reteplase-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5878822803497314, "bge_max": 0.5878822803497314, "title": "Reteplase (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Monitor for signs of bleeding (hematuria, GI bleeding, gingival bleeding); CBC, PTT; ECG monitoring"}, {"doc_id": "deferiprone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5874545574188232, "bge_max": 0.5874545574188232, "title": "Deferiprone: Drug information", "rep_snippet": "Monitoring Parameters  Serum ferritin (every 2-3 months); ANC (at baseline and weekly during treatment); if ANC <1,500/mm3, monitor CBC, WBC (corrected for nucleated RBCs), ANC, and platelets daily until ANC recovery; AL…"}, {"doc_id": "estradiol-and-dienogest-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.587214469909668, "bge_max": 0.587214469909668, "title": "Estradiol and dienogest: Drug information", "rep_snippet": "Monitoring Parameters  Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potentia…"}, {"doc_id": "ethinyl-estradiol-and-desogestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.586309015750885, "bge_max": 0.586309015750885, "title": "Ethinyl estradiol and desogestrel: Drug information", "rep_snippet": "Monitoring Parameters  Assessment of pregnancy status (prior to therapy); blood pressure (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potentia…"}, {"doc_id": "sargramostim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5857804417610168, "bge_max": 0.5857804417610168, "title": "Sargramostim: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential (twice weekly during treatment), renal/liver function tests (at least every 2 weeks in patients displaying renal or hepatic dysfunction prior to treatment initiation); pulmona…"}, {"doc_id": "fulvestrant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5856922268867493, "bge_max": 0.5856922268867493, "title": "Fulvestrant: Drug information", "rep_snippet": "Monitoring Parameters  Liver function tests; pregnancy testing is recommended within 7 days prior to fulvestrant initiation (for females of reproductive potential); monitor for signs/symptoms of bleeding"}, {"doc_id": "total-parenteral-nutrition-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5853530168533325, "bge_max": 0.5853530168533325, "title": "Total parenteral nutrition: Drug information", "rep_snippet": "Pregnancy Implications  Severe malnutrition is associated with adverse pregnancy outcomes, including congenital malformations, intrauterine growth restriction, preterm delivery, perinatal mortality, and low birth weight…"}]}
{"qid": "Q21_abbr+QT-cue", "query": "CAP inpatient, severe PCN allergy — levofloxacin dosing/monitoring; QT cautions.", "base_qid": "Q21", "variant_type": "abbr+QT-cue", "candidates": [{"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": 15.182886554490524, "bm25_max": 22.430896323769772, "bge_top3": null, "bge_max": null, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Levofloxacin (systemic): Pediatric drug information\")  Acute bacterial rhinosinusitis (off-label use): Oral, IV: 10 to 20 mg/kg/day divided every 12 to 24 hours for 10…"}, {"doc_id": "loratadine-and-pseudoephedrine-drug-information", "bm25_top3": 22.34808586446652, "bm25_max": 22.34808586446652, "bge_top3": null, "bge_max": null, "title": "Loratadine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Loratadine and pseudoephedrine: Pediatric drug information\")  Cold, allergy symptoms: Children ≥12 years and Adolescents: Oral: Refer to adult dosing."}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 15.84009000042942, "bm25_max": 15.86117587103778, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Brand Names: US  Benadryl Allergy and Cold [OTC] [DSC];  Benadryl Allergy and Sinus Headache [OTC] [DSC];  Benadryl Maximum Strength Severe Allergy and Sinus Headache [OTC] [DSC];  Cold Control PE [OTC];  Delsym Children…"}, {"doc_id": "dexchlorpheniramine-drug-information", "bm25_top3": 14.330317828161697, "bm25_max": 14.330317828161697, "bge_top3": null, "bge_max": null, "title": "Dexchlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  Allergy symptoms: Oral: 2 mg every 4 to 6 hours"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 13.012465042516622, "bm25_max": 13.012465042516622, "bge_top3": null, "bge_max": null, "title": "Telithromycin: Drug information", "rep_snippet": "Dosing: Adult  Note: Ketek has been discontinued in the United States for more than 1 year.  Community-acquired pneumonia (CAP): Oral: 800 mg once daily for 7-10 days"}, {"doc_id": "levofloxacin-united-states-not-available-oral-inhalation-drug-information", "bm25_top3": 12.97479940161015, "bm25_max": 12.97479940161015, "bge_top3": 0.6739262640476227, "bge_max": 0.681128978729248, "title": "Levofloxacin (United States: Not available) (oral inhalation): Drug information", "rep_snippet": "Administration  Inhalation: Inhale over ~5 minutes using nebulizer handset recommended by manufacturer (see product labeling). Do not mix levofloxacin with other medications. In patients taking multiple inhaled therapies…"}, {"doc_id": "diphenhydramine-systemic-drug-information", "bm25_top3": 12.959021826959283, "bm25_max": 12.959021826959283, "bge_top3": null, "bge_max": null, "title": "Diphenhydramine (systemic): Drug information", "rep_snippet": "Brand Names: US  Aler-Dryl [OTC];  Allergy Relief Childrens [OTC];  Allergy Relief [OTC];  Altaryl [OTC] [DSC];  Anti-Hist Allergy [OTC];  Banophen [OTC];  Benadryl Allergy Childrens [OTC];  Benadryl Allergy [OTC];  Bena…"}, {"doc_id": "fexofenadine-drug-information", "bm25_top3": 12.864478788865696, "bm25_max": 12.864478788865696, "bge_top3": null, "bge_max": null, "title": "Fexofenadine: Drug information", "rep_snippet": "Brand Names: US  Allegra Allergy Childrens [OTC];  Allegra Allergy [OTC];  Allergy 24-HR [OTC];  Fexofenadine HCl Childrens [OTC];  Mucinex Allergy [OTC]"}, {"doc_id": "cetirizine-systemic-drug-information", "bm25_top3": 12.839854821701337, "bm25_max": 12.839854821701337, "bge_top3": null, "bge_max": null, "title": "Cetirizine (systemic): Drug information", "rep_snippet": "Brand Names: US  All Day Allergy Childrens [OTC];  All Day Allergy [OTC];  Cetirizine HCl Allergy Child [OTC];  Cetirizine HCl Childrens Alrgy [OTC];  Cetirizine HCl Childrens [OTC];  Cetirizine HCl Hives Relief [OTC];…"}, {"doc_id": "triamcinolone-nasal-drug-information", "bm25_top3": 12.830344492773026, "bm25_max": 12.830344492773026, "bge_top3": null, "bge_max": null, "title": "Triamcinolone (nasal): Drug information", "rep_snippet": "Brand Names: US  GoodSense Nasal Allergy Spray [OTC];  Nasacort Allergy 24HR Children [OTC];  Nasacort Allergy 24HR [OTC];  Nasal Allergy 24 Hour [OTC]"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": 12.48135132937984, "bm25_max": 12.48135132937984, "bge_top3": null, "bge_max": null, "title": "Cefazolin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefazolin: Pediatric drug information\")  Usual dosage range: IM, IV: Infants >1 month, Children, and Adolescents: 25 to 100 mg/kg/day divided every 6 to 8 hours; maximu…"}, {"doc_id": "influenza-virus-vaccine-live-attenuated-drug-information", "bm25_top3": 8.302114231634, "bm25_max": 8.302114231634, "bge_top3": 0.6734655499458313, "bge_max": 0.6734655499458313, "title": "Influenza virus vaccine (live attenuated): Drug information", "rep_snippet": "• Chicken egg protein: Manufactured with chicken egg protein. Allergy to eggs must be distinguished from allergy to the vaccine. Recommendations are available from the ACIP and NACI regarding influenza vaccination to per…"}, {"doc_id": "influenza-virus-vaccine-inactivated-drug-information", "bm25_top3": 6.09629325661542, "bm25_max": 6.09629325661542, "bge_top3": null, "bge_max": null, "title": "Influenza virus vaccine (inactivated): Drug information", "rep_snippet": "• Chicken egg protein: Most products are manufactured with chicken egg protein (expressed as ovalbumin content when content is disclosed on prescribing information). The ovalbumin content may vary from season to season a…"}, {"doc_id": "solifenacin-drug-information", "bm25_top3": 5.326258673732319, "bm25_max": 5.326258673732319, "bge_top3": null, "bge_max": null, "title": "Solifenacin: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with moderate hepatic impairment (Child-Pugh class B); dosage adjustment required; use is not recommended in patients with severe hepatic impairment (Child-Pugh class C)…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": 2.9104625221502904, "bm25_max": 4.467167080716752, "bge_top3": null, "bge_max": null, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": 4.318306215052324, "bm25_max": 4.318306215052324, "bge_top3": null, "bge_max": null, "title": "Furosemide: Drug information", "rep_snippet": "Monitoring Parameters  Monitor I & O (inpatient setting) and weight daily; blood pressure, orthostasis; serum electrolytes, renal function; monitor hearing with high doses or rapid IV administration"}, {"doc_id": "sotalol-drug-information", "bm25_top3": 4.283609119587798, "bm25_max": 4.283609119587798, "bge_top3": null, "bge_max": null, "title": "Sotalol: Drug information", "rep_snippet": "• Proarrhythmic effects: [US Boxed Warning]: Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation (ie, torsades de pointes). Do not initiate if baseline QTc interval is >450…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": 4.211654938888225, "bm25_max": 4.211654938888225, "bge_top3": null, "bge_max": null, "title": "Mirabegron: Drug information", "rep_snippet": "• QT prolongation: Use with caution in patients with a history of QT interval prolongation or those receiving medications known to prolong the QT interval. In one thorough QT study, supratherapeutic doses prolonged the Q…"}, {"doc_id": "alfuzosin-drug-information", "bm25_top3": 3.811989257573174, "bm25_max": 3.811989257573174, "bge_top3": null, "bge_max": null, "title": "Alfuzosin: Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with histories of tachyarrhythmia or with certain cardiovascular conditions, such as myocardial ischemia.  • Hepatic impairment: Use with caution in patients with mi…"}, {"doc_id": "gadoteridol-drug-information", "bm25_top3": 3.4240478926320304, "bm25_max": 3.4240478926320304, "bge_top3": null, "bge_max": null, "title": "Gadoteridol: Drug information", "rep_snippet": "Dosage Forms Considerations  ProHance prefilled syringe tip cap contains latex."}, {"doc_id": "interferon-beta-1b-drug-information", "bm25_top3": 3.3189723311994648, "bm25_max": 3.3189723311994648, "bge_top3": null, "bge_max": null, "title": "Interferon beta-1b: Drug information", "rep_snippet": "Dosage Forms Considerations  The Extavia diluent syringe cap may contain latex."}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 3.3081978510797736, "bm25_max": 3.3081978510797736, "bge_top3": null, "bge_max": null, "title": "Fluoxetine: Drug information", "rep_snippet": "• QT prolongation: QT prolongation and ventricular arrhythmia including torsade de pointes has occurred. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of pro…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 3.284524497850146, "bm25_max": 3.284524497850146, "bge_top3": null, "bge_max": null, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "• QT prolongation: Fluoxetine may cause QT prolongation and ventricular arrhythmia including torsade de pointes. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, histor…"}, {"doc_id": "granisetron-drug-information", "bm25_top3": 3.2296850716051484, "bm25_max": 3.2296850716051484, "bge_top3": null, "bge_max": null, "title": "Granisetron: Drug information", "rep_snippet": "• Long QT syndrome: Use with caution in patients with congenital long QT syndrome or other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomag…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": 2.931754121945211, "bm25_max": 2.931754121945211, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "If used in combination with amiodarone (or in patients who discontinued amiodarone just prior to initiating sofosbuvir/velpatasvir), inpatient cardiac monitoring for the first 48 hours of coadministration, then outpatien…"}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": 2.931754121945211, "bm25_max": 2.931754121945211, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "If used in combination with amiodarone (or in patients who discontinued amiodarone just prior to initiating sofosbuvir/velpatasvir), inpatient cardiac monitoring for the first 48 hours of coadministration, then outpatien…"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 2.9010883120622104, "bm25_max": 2.9010883120622104, "bge_top3": null, "bge_max": null, "title": "Cefpodoxime: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Beta-lactam allergy: Use with caution in patients with a history of beta-lactam allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urtic…"}, {"doc_id": "phenylephrine-and-pramoxine-drug-information", "bm25_top3": 2.6129432578015646, "bm25_max": 2.6129432578015646, "bge_top3": null, "bge_max": null, "title": "Phenylephrine and pramoxine: Drug information", "rep_snippet": "Administration  Cleanse affected area by patting or blotting with cleansing wipe, and gently dry before applying cream. Apply externally or in the lower portion of the anal canal only. For application in the lower anal c…"}, {"doc_id": "ranolazine-drug-information", "bm25_top3": 2.606741302459465, "bm25_max": 2.606741302459465, "bge_top3": null, "bge_max": null, "title": "Ranolazine: Drug information", "rep_snippet": "Monitoring Parameters  Baseline and follow up ECG to evaluate QT interval; monitor renal function periodically in patients with moderate to severe renal impairment, particularly for increases in serum creatinine accompan…"}, {"doc_id": "sulfanilamide-drug-information", "bm25_top3": 2.53438865760023, "bm25_max": 2.53438865760023, "bge_top3": null, "bge_max": null, "title": "Sulfanilamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Blood dyscrasias: Severe reactions (some fatal), including agranulocytosis, aplastic anemia, and other blood dyscrasias, have occurred with sulfonamides (rega…"}, {"doc_id": "degarelix-drug-information", "bm25_top3": 2.32227692524693, "bm25_max": 2.32227692524693, "bge_top3": null, "bge_max": null, "title": "Degarelix: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anemia: Testosterone suppression is associated with the development of anemia.  • Decreased bone mineral density: Androgen deprivation therapy is associated w…"}, {"doc_id": "sulfacetamide-ophthalmic-drug-information", "bm25_top3": 2.231540393432912, "bm25_max": 2.231540393432912, "bge_top3": null, "bge_max": null, "title": "Sulfacetamide (ophthalmic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Blood dyscrasias: Severe reactions (rare fatalities), including agranulocytosis, aplastic anemia, and other blood dyscrasias, have occurred with sulfonamides…"}, {"doc_id": "vernakalant-drug-information", "bm25_top3": 1.818467754473005, "bm25_max": 1.818467754473005, "bge_top3": null, "bge_max": null, "title": "Vernakalant: Drug information", "rep_snippet": "• Hypotension: Hypotension, some serious and/or severe, has been reported during and immediately following infusion. Observe patients carefully, assessing vital signs and continuous cardiac rhythm monitoring, during infu…"}, {"doc_id": "codeine-and-chlorpheniramine-drug-information", "bm25_top3": 1.7974734610205534, "bm25_max": 1.7974734610205534, "bge_top3": null, "bge_max": null, "title": "Codeine and chlorpheniramine: Drug information", "rep_snippet": "Monitoring Parameters  Relief of cough and allergy symptoms; signs/symptoms of addiction, abuse, or misuse."}, {"doc_id": "salmeterol-drug-information", "bm25_top3": 1.0103473140729164, "bm25_max": 1.0103473140729164, "bge_top3": null, "bge_max": null, "title": "Salmeterol: Drug information", "rep_snippet": "Dietary Considerations  Some products may contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy."}, {"doc_id": "perampanel-drug-information", "bm25_top3": 0.8086249708949484, "bm25_max": 0.8086249708949484, "bge_top3": null, "bge_max": null, "title": "Perampanel: Drug information", "rep_snippet": "Administration  Tablets: Administer at bedtime without regard to food.  Oral suspension: Shake well before every administration. Use a calibrated measuring device to measure dose (a household teaspoon or tablespoon is no…"}, {"doc_id": "chlorpheniramine-pseudoephedrine-and-codeine-drug-information", "bm25_top3": 0.7546733982488387, "bm25_max": 0.7546733982488387, "bge_top3": null, "bge_max": null, "title": "Chlorpheniramine, pseudoephedrine, and codeine: Drug information", "rep_snippet": "Monitoring Parameters  Relief of cough and allergy symptoms; respiratory and mental status, blood pressure, bowel function; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)."}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 0.7143369134354387, "bm25_max": 0.7143369134354387, "bge_top3": null, "bge_max": null, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Dietary Considerations  Advair Diskus powder for oral inhalation contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy."}, {"doc_id": "measles-mumps-rubella-and-varicella-virus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6893341541290283, "bge_max": 0.6893341541290283, "title": "Measles, mumps, rubella, and varicella virus vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "nafcillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.688897430896759, "bge_max": 0.688897430896759, "title": "Nafcillin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6879233121871948, "bge_max": 0.6879233121871948, "title": "Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.685539960861206, "bge_max": 0.685539960861206, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "filgrastim-including-biosimilars-of-filgrastim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6830524206161499, "bge_max": 0.6830524206161499, "title": "Filgrastim (including biosimilars of filgrastim): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse reactions:  • Allergic reactions: Serious allergic reactions (including anaphylaxis) have been reported, usually with the initial exposure; may be managed symptomatically…"}, {"doc_id": "levobunolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6797199249267578, "bge_max": 0.6797199249267578, "title": "Levobunolol: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse events:  • Anaphylactic reactions: Instill with caution in patients with history of severe anaphylaxis to a variety of allergens; patients taking beta-blockers may become…"}, {"doc_id": "atenolol-and-chlorthalidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6778015494346619, "bge_max": 0.6778015494346619, "title": "Atenolol and chlorthalidone: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse events:  • Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challe…"}, {"doc_id": "cloxacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750977635383606, "bge_max": 0.6750977635383606, "title": "Cloxacillin (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients o…"}, {"doc_id": "fluciclovine-f-18-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6740789413452148, "bge_max": 0.6740789413452148, "title": "Fluciclovine F-18: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Hypersensitivity reactions including anaphylaxis may occur in patients who receive fluciclovine F 18. Emergency resuscitation equipment and…"}, {"doc_id": "tetanus-immune-globulin-human-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6731395721435547, "bge_max": 0.6731395721435547, "title": "Tetanus immune globulin (human): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be a…"}, {"doc_id": "live-attenuated-cholera-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6727951169013977, "bge_max": 0.6727951169013977, "title": "Live attenuated cholera vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "vitamin-k-phytonadione-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6726988554000854, "bge_max": 0.6726988554000854, "title": "Vitamin K (phytonadione): Drug information", "rep_snippet": "Monitoring Parameters  PT, INR; monitor for hypersensitivity reactions if administering IV."}, {"doc_id": "laronidase-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.672002911567688, "bge_max": 0.672002911567688, "title": "Laronidase: Drug information", "rep_snippet": "• Hypersensitivity/anaphylactoid reactions: [US Boxed Warning]: Anaphylactic reactions have been observed during infusion, immediate treatment for hypersensitivity reactions should be available during administration. Add…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6716978549957275, "bge_max": 0.6716978549957275, "title": "Ceftriaxone: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Serious and sometimes fatal hypersensitivity has been reported. Use caution in patients with a history of any allergy (particularly drugs),…"}, {"doc_id": "penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6707561612129211, "bge_max": 0.6707561612129211, "title": "Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6701043248176575, "bge_max": 0.6701043248176575, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "cefaclor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6695214509963989, "bge_max": 0.6695214509963989, "title": "Cefaclor: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Anaphylactic reactions have occurred. If a serious hypersensitivity reaction occurs, discontinue and institute emergency supportive measures…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6690060496330261, "bge_max": 0.6690060496330261, "title": "Alirocumab: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity reactions, including some severe reactions requiring hospitalization (eg, hypersensitivity vasculitis), have been…"}, {"doc_id": "piperacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6689324378967285, "bge_max": 0.6689324378967285, "title": "Piperacillin (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients o…"}, {"doc_id": "gadodiamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6688106060028076, "bge_max": 0.6688106060028076, "title": "Gadodiamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medicat…"}, {"doc_id": "gadofosveset-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6688106060028076, "bge_max": 0.6688106060028076, "title": "Gadofosveset: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medicat…"}, {"doc_id": "gadoversetamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6688106060028076, "bge_max": 0.6688106060028076, "title": "Gadoversetamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medicat…"}, {"doc_id": "penicillin-g-benzathine-long-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6686503291130066, "bge_max": 0.6686503291130066, "title": "Penicillin G benzathine (long-acting intramuscular): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin th…"}, {"doc_id": "dicloxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6685409545898438, "bge_max": 0.6685409545898438, "title": "Dicloxacillin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have been reported in patients on pen…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6684520840644836, "bge_max": 0.6684520840644836, "title": "Aprepitant: Drug information", "rep_snippet": "Monitoring Parameters  In patients receiving concurrent warfarin, monitor INR/PT for 2 weeks (particularly at 7 to 10 days) following aprepitant administration; monitor for signs/symptoms of hypersensitivity reaction."}, {"doc_id": "yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6675752997398376, "bge_max": 0.6675752997398376, "title": "Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "besifloxacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6672016978263855, "bge_max": 0.6672016978263855, "title": "Besifloxacin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with systemic quinolone therapy. The spectrum of these rea…"}, {"doc_id": "lidocaine-and-prilocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6666358113288879, "bge_max": 0.6666358113288879, "title": "Lidocaine and prilocaine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Allergic and anaphylactic reactions may occur. Patients allergic to paraaminobenzoic acid derivatives (eg, procaine, tetracaine, benzocaine)…"}, {"doc_id": "combined-hepatitis-a-and-typhoid-vaccine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6663579940795898, "bge_max": 0.6663579940795898, "title": "Combined hepatitis A and typhoid vaccine (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "nebivolol-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6663395166397095, "bge_max": 0.6663395166397095, "title": "Nebivolol and valsartan: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic reactions: Use nebivolol with caution with history of severe anaphylaxis to a variety of allergens; patients taking beta-blockers may become more…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-recombinant-hepatitis-b-and-inactivated-poliovirus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6663317084312439, "bge_max": 0.6663317084312439, "title": "Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-and-haemophilus-influenzae-type-b-conjugate-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6663317084312439, "bge_max": 0.6663317084312439, "title": "Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b conjugate vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "galsulfase-recombinant-human-n-acetylgalactosamine-4-sulfatase-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6662375926971436, "bge_max": 0.6662375926971436, "title": "Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis, severe allergic reactions, shock, respiratory distress, dyspnea, bronchospasm, lar…"}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6655954122543335, "bge_max": 0.6655954122543335, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "insulin-regular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6651561260223389, "bge_max": 0.6651561260223389, "title": "Insulin regular: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Severe, life-threatening, generalized allergic reactions, including anaphylaxis, may occur. If hypersensitivity reactions occur, discontinue…"}, {"doc_id": "avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6651283502578735, "bge_max": 0.6651283502578735, "title": "Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "chlorhexidine-gluconate-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6649031043052673, "bge_max": 0.6649031043052673, "title": "Chlorhexidine gluconate (topical): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Serious allergic reactions, including anaphylaxis, have been reported.  Dosage form specific issues:"}, {"doc_id": "varicella-virus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6648763418197632, "bge_max": 0.6648763418197632, "title": "Varicella virus vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6648286581039429, "bge_max": 0.6648286581039429, "title": "Oxacillin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6646088361740112, "bge_max": 0.6646088361740112, "title": "Enoxaparin: Drug information", "rep_snippet": "Contraindications  Known hypersensitivity to enoxaparin (eg, pruritus, urticaria, anaphylactic/anaphylactoid reactions), heparin, pork products, or any component of the formulation (including benzyl alcohol in multiple-d…"}, {"doc_id": "antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6643241047859192, "bge_max": 0.6643241047859192, "title": "Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hematologic effects: Reversible leukopenia, neutropenia, thrombocytopenia, and lymphopenia may occur. Monitor blood counts. Leukopenia and/or thrombocytopenia…"}, {"doc_id": "telavancin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6637510657310486, "bge_max": 0.6637510657310486, "title": "Telavancin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported after first or subsequent doses; some ha…"}, {"doc_id": "hepatitis-b-immune-globulin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6637386083602905, "bge_max": 0.6637386083602905, "title": "Hepatitis B immune globulin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be a…"}, {"doc_id": "peramivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636971831321716, "bge_max": 0.6636971831321716, "title": "Peramivir: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Dermatologic reactions: Rare serious skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome) have been reported. If skin reactions are suspected or…"}, {"doc_id": "idelalisib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6632998585700989, "bge_max": 0.6632998585700989, "title": "Idelalisib: Drug information", "rep_snippet": "• Hypersensitivity reactions: Serious allergic/hypersensitivity reactions, including anaphylaxis, have been reported. Discontinue permanently for serious reactions and manage appropriately."}, {"doc_id": "cangrelor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6628915071487427, "bge_max": 0.6628915071487427, "title": "Cangrelor: Drug information", "rep_snippet": "Contraindications  Known hypersensitivity (eg, anaphylaxis) to cangrelor or any component of the formulation; significant active bleeding"}, {"doc_id": "anthrax-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6626507639884949, "bge_max": 0.6626507639884949, "title": "Anthrax vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "sevoflurane-drug-information", "bm25_top3": 0.5263888448459593, "bm25_max": 0.5263888448459593, "bge_top3": null, "bge_max": null, "title": "Sevoflurane: Drug information", "rep_snippet": "Use  Anesthesia: Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery"}, {"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 0.5249717810195573, "bm25_max": 0.5249717810195573, "bge_top3": null, "bge_max": null, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "Dietary Considerations  ArmonAir Respiclick, Arnuity Ellipta and Flovent Diskus may contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy."}, {"doc_id": "romidepsin-drug-information", "bm25_top3": 0.47666006438669584, "bm25_max": 0.47666006438669584, "bge_top3": null, "bge_max": null, "title": "Romidepsin: Drug information", "rep_snippet": "Monitoring Parameters  Serum electrolytes (baseline and periodic; especially potassium and magnesium); CBC with differential and platelets, ECG (baseline and periodic; in patients with significant cardiovascular disease,…"}, {"doc_id": "fulvestrant-drug-information", "bm25_top3": 0.46484443316214197, "bm25_max": 0.46484443316214197, "bge_top3": null, "bge_max": null, "title": "Fulvestrant: Drug information", "rep_snippet": "Administration  IM: For IM administration only. Administer 500 mg dose as two 5 mL IM injections (one in each buttocks [gluteal area]) slowly over 1 to 2 minutes per injection. If administering at the dorsogluteal site,…"}, {"doc_id": "fingolimod-drug-information", "bm25_top3": 0.3436085875714987, "bm25_max": 0.3436085875714987, "bge_top3": null, "bge_max": null, "title": "Fingolimod: Drug information", "rep_snippet": "ECG (baseline; repeat after initial dose observation period); heart rate, blood pressure, and signs and symptoms of bradycardia (hourly for 6 hours following first dose; continued observation (until resolved) required if…"}, {"doc_id": "valbenazine-drug-information", "bm25_top3": 0.20088871143272868, "bm25_max": 0.20088871143272868, "bge_top3": null, "bge_max": null, "title": "Valbenazine: Drug information", "rep_snippet": "Monitoring Parameters  Abnormal Involuntary Movement Scale (AIMS) or Dyskinesia Identification System Condensed User Scale (DISCUS); EKG (for patients at risk for QT prolongation)"}]}
{"qid": "Q21_noise", "query": "Hospital CAP with anaphylactic PCN history — how to dose levo and what to monitor (QT)?", "base_qid": "Q21", "variant_type": "noise", "candidates": [{"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": 21.86122687192455, "bm25_max": 27.769378310823665, "bge_top3": 0.5728655457496643, "bge_max": 0.5752254724502563, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "(hospital-acquired infection, immunocompromised host, or coverage of P. aeruginosa) (off-label use): IV: 4.5 g every 6 hours (IDSA/ATS [Kalil 2016]). Note: Use in conjunction with surgical drainage. Additional agent for…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": 27.505526245644173, "bm25_max": 27.505526245644173, "bge_top3": null, "bge_max": null, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Community-acquired (CAP): Oral, IV: 500 mg every 24 hours for 7 to 14 days or 750 mg every 24 hours for 5 days; Note: CAP guidelines recommend the 750 mg dose (IDSA/ATS [Mandell 2007])  Hospital-acquired or ventilator-…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 17.64160255689162, "bm25_max": 17.64160255689162, "bge_top3": null, "bge_max": null, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "• QT prolongation: Fluoxetine may cause QT prolongation and ventricular arrhythmia including torsade de pointes. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, histor…"}, {"doc_id": "imipenem-and-cilastatin-drug-information", "bm25_top3": 17.01507421304041, "bm25_max": 17.01507421304041, "bge_top3": null, "bge_max": null, "title": "Imipenem and cilastatin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": 16.199348126634547, "bm25_max": 16.199348126634547, "bge_top3": null, "bge_max": null, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • QT prolongation: Use associated with prolonging the QT interval; avoid use in patients at risk for QT prolongation, including patients with a history of long…"}, {"doc_id": "phenylephrine-and-pramoxine-drug-information", "bm25_top3": 15.053565837354824, "bm25_max": 15.053565837354824, "bge_top3": null, "bge_max": null, "title": "Phenylephrine and pramoxine: Drug information", "rep_snippet": "Administration  Cleanse affected area by patting or blotting with cleansing wipe, and gently dry before applying cream. Apply externally or in the lower portion of the anal canal only. For application in the lower anal c…"}, {"doc_id": "etelcalcetide-drug-information", "bm25_top3": 9.591697694289373, "bm25_max": 9.591697694289373, "bge_top3": null, "bge_max": null, "title": "Etelcalcetide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Adynamic bone disease: May develop if parathyroid hormone levels are chronically suppressed; reduce dose or discontinue etelcalcetide and/or vitamin D if para…"}, {"doc_id": "cinacalcet-drug-information", "bm25_top3": 9.512544933712725, "bm25_max": 9.512544933712725, "bge_top3": null, "bge_max": null, "title": "Cinacalcet: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Adynamic bone disease: May develop if intact parathyroid hormone (iPTH) levels are suppressed <100 pg/mL; reduce dose or discontinue use of cinacalcet and/or…"}, {"doc_id": "iron-dextran-drug-information", "bm25_top3": 7.496711692615422, "bm25_max": 8.23918121480364, "bge_top3": null, "bge_max": null, "title": "Iron dextran: Drug information", "rep_snippet": "• Hypersensitivity/anaphylactoid reactions: [U.S. Boxed Warning]: Deaths associated with parenteral administration following anaphylactic-type reactions have been reported (use only where resuscitation equipment and pers…"}, {"doc_id": "vandetanib-drug-information", "bm25_top3": 5.691674801095347, "bm25_max": 7.884847984437428, "bge_top3": 0.5788404941558838, "bge_max": 0.5788404941558838, "title": "Vandetanib: Drug information", "rep_snippet": "• QT prolongation/sudden death: [US Boxed Warning]: May prolong the QT interval; torsade de pointes and sudden death have been reported. Do not use in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT s…"}, {"doc_id": "primaquine-drug-information", "bm25_top3": 7.052683441632563, "bm25_max": 7.052683441632563, "bge_top3": null, "bge_max": null, "title": "Primaquine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Cardiovascular effects: May cause QT prolongation; monitor ECG in patients with cardiac disease, long QT syndrome, a history of ventricular arrhythmias, uncor…"}, {"doc_id": "methadone-drug-information", "bm25_top3": 6.82438897461801, "bm25_max": 6.82438897461801, "bge_top3": null, "bge_max": null, "title": "Methadone: Drug information", "rep_snippet": "• QT prolongation: [US Boxed Warning]: QT interval prolongation and serious arrhythmias (torsades de pointes) have occurred during treatment. Most cases involve patients being treated for pain with large, multiple daily…"}, {"doc_id": "quetiapine-drug-information", "bm25_top3": 6.821414251036867, "bm25_max": 6.821414251036867, "bge_top3": null, "bge_max": null, "title": "Quetiapine: Drug information", "rep_snippet": "• QT prolongation: Use has been associated with QT prolongation; postmarketing reports have occurred in patients with concomitant illness, quetiapine overdose, or who were receiving concomitant therapy known to increase…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": 6.785987063244285, "bm25_max": 6.785987063244285, "bge_top3": null, "bge_max": null, "title": "Clozapine: Drug information", "rep_snippet": "• QT prolongation: Clozapine is associated with QT prolongation and ventricular arrhythmias including torsade de pointes; cardiac arrest and sudden death may occur. Use caution in patients with conditions that may increa…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 6.680942897767409, "bm25_max": 6.680942897767409, "bge_top3": null, "bge_max": null, "title": "Fluoxetine: Drug information", "rep_snippet": "• QT prolongation: QT prolongation and ventricular arrhythmia including torsade de pointes has occurred. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of pro…"}, {"doc_id": "deutetrabenazine-drug-information", "bm25_top3": 6.656757043398986, "bm25_max": 6.656757043398986, "bge_top3": null, "bge_max": null, "title": "Deutetrabenazine: Drug information", "rep_snippet": "• Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity and/or autonomic instability. Discontinue with confirmed NMS; may recur with reintroductio…"}, {"doc_id": "pasireotide-drug-information", "bm25_top3": 6.601583336271535, "bm25_max": 6.601583336271535, "bge_top3": null, "bge_max": null, "title": "Pasireotide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Cardiac disorders: Bradycardia and QT prolongation have been observed with therapy. Use with caution in patients with preexisting cardiac disease, patients wi…"}, {"doc_id": "bilastine-united-states-not-available-drug-information", "bm25_top3": 5.110650812780683, "bm25_max": 6.2442723197668215, "bge_top3": null, "bge_max": null, "title": "Bilastine (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Disease-related concerns:  • QT interval prolongation: QTc interval prolongation has been reported with use; use is contraindicated in patients with a history of QT prolongation and/or Torsade de po…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": 5.610991035321037, "bm25_max": 6.092767062751392, "bge_top3": 0.5864759683609009, "bge_max": 0.5864759683609009, "title": "Nilotinib: Drug information", "rep_snippet": "ALERT: US Boxed Warning  QT Prolongation and Sudden Deaths:  Nilotinib prolongs the QT interval. Prior to nilotinib administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. Obt…"}, {"doc_id": "toremifene-drug-information", "bm25_top3": 6.0896546456844405, "bm25_max": 6.0896546456844405, "bge_top3": null, "bge_max": null, "title": "Toremifene: Drug information", "rep_snippet": "• QT prolongation: [US Boxed Warning]: May prolong the QT interval; QTc prolongation is dose-dependent and concentration-dependent. QT prolongation may lead to a form of ventricular tachycardia called torsades de pointes…"}, {"doc_id": "degarelix-drug-information", "bm25_top3": 5.970441343217807, "bm25_max": 5.970441343217807, "bge_top3": null, "bge_max": null, "title": "Degarelix: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anemia: Testosterone suppression is associated with the development of anemia.  • Decreased bone mineral density: Androgen deprivation therapy is associated w…"}, {"doc_id": "solifenacin-drug-information", "bm25_top3": 5.796506192049854, "bm25_max": 5.796506192049854, "bge_top3": null, "bge_max": null, "title": "Solifenacin: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with moderate hepatic impairment (Child-Pugh class B); dosage adjustment required; use is not recommended in patients with severe hepatic impairment (Child-Pugh class C)…"}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": 5.73703947499661, "bm25_max": 5.73703947499661, "bge_top3": null, "bge_max": null, "title": "Vemurafenib: Drug information", "rep_snippet": "• QT prolongation: QT prolongation (dose-dependent) has been observed; may lead to increased risk for ventricular arrhythmia, including torsade de pointes. Monitor electrolytes (calcium, magnesium and potassium) at basel…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": 5.660527607448557, "bm25_max": 5.660527607448557, "bge_top3": null, "bge_max": null, "title": "Mirabegron: Drug information", "rep_snippet": "• QT prolongation: Use with caution in patients with a history of QT interval prolongation or those receiving medications known to prolong the QT interval. In one thorough QT study, supratherapeutic doses prolonged the Q…"}, {"doc_id": "bedaquiline-drug-information", "bm25_top3": 5.655809371746614, "bm25_max": 5.655809371746614, "bge_top3": null, "bge_max": null, "title": "Bedaquiline: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Arrhythmias: [US Boxed Warning]: May prolong QTc interval. Use with drugs that prolong the QTc interval may cause additive prolongation. Monitor ECGs at basel…"}, {"doc_id": "tetrabenazine-drug-information", "bm25_top3": 5.638669202030897, "bm25_max": 5.638669202030897, "bge_top3": null, "bge_max": null, "title": "Tetrabenazine: Drug information", "rep_snippet": "• QT prolongation: Has been shown to prolong the QT interval alone (minimal) and with other drugs with comparable effects on the QT interval (additive). Avoid use in patients with congenital QT prolongation, a history of…"}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": 5.548593791204141, "bm25_max": 5.548593791204141, "bge_top3": null, "bge_max": null, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": 5.247353161234617, "bm25_max": 5.247353161234617, "bge_top3": null, "bge_max": null, "title": "Ondansetron: Drug information", "rep_snippet": "• QT prolongation: ECG changes, including dose-dependent QT interval prolongation, have been observed with ondansetron use. Cases of torsade de pointes have also been reported. Selective 5-HT3 antagonists, including onda…"}, {"doc_id": "ranolazine-drug-information", "bm25_top3": 5.182629872123844, "bm25_max": 5.182629872123844, "bge_top3": null, "bge_max": null, "title": "Ranolazine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Altered cardiac conduction: Has been shown to prolong QTc interval in a dose/plasma concentration-related manner. At Tmaxfollowing repeat dosing at 1000 mg tw…"}, {"doc_id": "tacrolimus-systemic-drug-information", "bm25_top3": 5.182274858153297, "bm25_max": 5.182274858153297, "bge_top3": null, "bge_max": null, "title": "Tacrolimus (systemic): Drug information", "rep_snippet": "• Cardiovascular: Myocardial hypertrophy has been reported; may be reversible with dose reduction or discontinuation. Prolongation of the QT/QTc and torsade de pointes may occur; avoid use in patients with congenital lon…"}, {"doc_id": "dofetilide-drug-information", "bm25_top3": 5.178227301917609, "bm25_max": 5.178227301917609, "bge_top3": null, "bge_max": null, "title": "Dofetilide: Drug information", "rep_snippet": "Monitoring Parameters  ECG monitoring with attention to QT (if heart rate <60 beats per minute) or QTc and occurrence of ventricular arrhythmias, baseline serum creatinine and changes in serum creatinine. Upon initiation…"}, {"doc_id": "nafcillin-drug-information", "bm25_top3": 5.168153796557524, "bm25_max": 5.168153796557524, "bge_top3": 0.5945462584495544, "bge_max": 0.5945462584495544, "title": "Nafcillin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "gemtuzumab-ozogamicin-drug-information", "bm25_top3": 5.1510819203336595, "bm25_max": 5.1510819203336595, "bge_top3": 0.5980991721153259, "bge_max": 0.5980991721153259, "title": "Gemtuzumab ozogamicin: Drug information", "rep_snippet": "• QT interval prolongation: Prolongation of the QT interval has been reported in patients treated with other calicheamicin-containing medications. Obtain ECGs and monitor electrolytes prior to therapy initiation and as c…"}, {"doc_id": "histrelin-drug-information", "bm25_top3": 5.1482059347137366, "bm25_max": 5.1482059347137366, "bge_top3": null, "bge_max": null, "title": "Histrelin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Cardiovascular effects: Androgen-deprivation therapy (ADT) may increase the risk for cardiovascular disease (Levine 2010). An increased risk of MI, sudden car…"}, {"doc_id": "rufinamide-drug-information", "bm25_top3": 5.079661624880295, "bm25_max": 5.079661624880295, "bge_top3": null, "bge_max": null, "title": "Rufinamide: Drug information", "rep_snippet": "Contraindications  Patients with familial short QT syndrome  Canadian labeling: Additional contraindications (not in US labeling): Family history of short QT syndrome; presence or history of short QT interval; hypersensi…"}, {"doc_id": "zoster-shingles-vaccine-live-attenuated-drug-information", "bm25_top3": 5.044158289721924, "bm25_max": 5.044158289721924, "bge_top3": 0.583008885383606, "bge_max": 0.583008885383606, "title": "Zoster (shingles) vaccine, live attenuated: Drug information", "rep_snippet": "• Varicella vaccine recipients: The ACIP does not recommend zoster vaccination in patients of any age who have received the varicella vaccine (CDC/ACIP [Harpaz 2008]).  Dosage form specific warnings:  • Gelatin: Contains…"}, {"doc_id": "dasatinib-drug-information", "bm25_top3": 5.031785790597915, "bm25_max": 5.031785790597915, "bge_top3": null, "bge_max": null, "title": "Dasatinib: Drug information", "rep_snippet": "• QT prolongation: Dasatinib may increase the risk for QT interval prolongation; there are reports of patients with QTcF >500 msec. Use caution in patients at risk for QT prolongation, including patients with long QT syn…"}, {"doc_id": "buprenorphine-drug-information", "bm25_top3": 4.979293125952076, "bm25_max": 4.979293125952076, "bge_top3": null, "bge_max": null, "title": "Buprenorphine: Drug information", "rep_snippet": "• QT prolongation: Buprenorphine has been observed to cause QTc prolongation. Do not exceed a dose of 900 mcg every 12 hours buccal film or one 20 mcg/hour transdermal patch. Avoid using in patients with a personal or fa…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 4.610529025005633, "bm25_max": 4.610529025005633, "bge_top3": null, "bge_max": null, "title": "Linezolid: Drug information", "rep_snippet": "Use  Enterococcal infections (vancomycin-resistant): Treatment of vancomycin-resistant (VRE) Enterococcus faecium infections, including cases with concurrent bacteremia. Note: Not a preferred agent in resistant E. faecal…"}, {"doc_id": "amphetamine-sulfate-drug-information", "bm25_top3": 4.434432560149439, "bm25_max": 4.434432560149439, "bge_top3": null, "bge_max": null, "title": "Amphetamine sulfate: Drug information", "rep_snippet": "Monitoring Parameters  Blood pressure, pulse; height and weight in children  When used for the treatment of ADHD, perform a targeted cardiac history (eg, patient history of previously detected cardiac disease, palpitatio…"}, {"doc_id": "fulvestrant-drug-information", "bm25_top3": 3.381141194351427, "bm25_max": 3.381141194351427, "bge_top3": null, "bge_max": null, "title": "Fulvestrant: Drug information", "rep_snippet": "Administration  IM: For IM administration only. Administer 500 mg dose as two 5 mL IM injections (one in each buttocks [gluteal area]) slowly over 1 to 2 minutes per injection. If administering at the dorsogluteal site,…"}, {"doc_id": "rho-d-immune-globulin-drug-information", "bm25_top3": 3.045576835191266, "bm25_max": 3.045576835191266, "bge_top3": null, "bge_max": null, "title": "Rho(D) immune globulin: Drug information", "rep_snippet": "Contraindications  HyperRHO S/D Full Dose, HyperRHO S/D Mini Dose: There are no contraindications listed in the manufacturer's labeling.  MICRhoGAM Ultra-Filtered Plus, RhoGAM Ultra-Filtered Plus: Use in Rh-positive indi…"}, {"doc_id": "bosutinib-drug-information", "bm25_top3": 2.8419666160146964, "bm25_max": 2.8419666160146964, "bge_top3": null, "bge_max": null, "title": "Bosutinib: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to bosutinib or any component of the formulation  Canadian labeling: Additional contraindications (not in the US labeling): History of long QT syndrome or with persistent QT interval >…"}, {"doc_id": "cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 2.62423481402071, "bm25_max": 2.62423481402071, "bge_top3": null, "bge_max": null, "title": "Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Drug information", "rep_snippet": "Cisapride is also contraindicated for patients with a prolonged electrocardiographic QT intervals (QTc >450 msec), a history of QTc prolongation, or known family history of congenital long QT syndrome; clinically signifi…"}, {"doc_id": "plerixafor-drug-information", "bm25_top3": 2.5577881872952073, "bm25_max": 2.5577881872952073, "bge_top3": null, "bge_max": null, "title": "Plerixafor: Drug information", "rep_snippet": "Contraindications  History of hypersensitivity to plerixafor or any component of the formulation (anaphylactic shock has occurred)."}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5976161956787109, "bge_max": 0.5976161956787109, "title": "Oxacillin: Drug information", "rep_snippet": "Monitoring Parameters  Observe for signs and symptoms of anaphylaxis during first dose; monitor periodic CBC, urinalysis, BUN, serum creatinine, AST and ALT"}, {"doc_id": "piperacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.59306800365448, "bge_max": 0.59306800365448, "title": "Piperacillin (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Observe for signs and symptoms of anaphylaxis during first dose; with extended therapy consider monitoring of electrolytes and cardiac status (patients with impaired cardiac function), serum creati…"}, {"doc_id": "hepatitis-a-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5921602845191956, "bge_max": 0.5921602845191956, "title": "Hepatitis A vaccine: Drug information", "rep_snippet": "Monitoring Parameters  Liver function tests; monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in…"}, {"doc_id": "bacillus-calmette-guerin-bcg-percutaneous-vaccine-us-product-consult-local-product-information-for-non-us-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.591463565826416, "bge_max": 0.591463565826416, "title": "Bacillus Calmette-Guerin (BCG) percutaneous vaccine (US product, consult local product information for non-US vaccine): Drug information", "rep_snippet": "Monitoring Parameters  PPD test prior to vaccination. Flu-like symptoms ≥72 hours, fever ≥103°F, acute local reactions lasting >2 to 3 days. Monitor for anaphylaxis and syncope for 15 minutes following administration (AC…"}, {"doc_id": "procainamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5891075134277344, "bge_max": 0.5891075134277344, "title": "Procainamide: Drug information", "rep_snippet": "Monitoring Parameters  ECG (with attention to the QRS duration and QT interval), blood pressure, renal function; with prolonged use monitor CBC with differential, platelet count; procainamide and NAPA blood concentration…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.587852418422699, "bge_max": 0.587852418422699, "title": "Acetylcysteine: Drug information", "rep_snippet": "Monitoring Parameters  Acetaminophen overdose: Monitor patient for the development of anaphylaxis or anaphylactoid reactions; monitor serum acetaminophen concentrations, AST, ALT, bilirubin, PT, INR, serum creatinine, BU…"}, {"doc_id": "human-papillomavirus-bivalent-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5877513885498047, "bge_max": 0.5877513885498047, "title": "Human papillomavirus bivalent vaccine: Drug information", "rep_snippet": "Monitoring Parameters  Gynecologic screening exam, papillomavirus test as per current guidelines; screening for HPV is not required prior to vaccination and screening for cervical cancer should continue as recommended fo…"}, {"doc_id": "polidocanol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.585908055305481, "bge_max": 0.585908055305481, "title": "Polidocanol: Drug information", "rep_snippet": "Monitoring Parameters  Monitor patient for anaphylactic or allergic reaction for at least 10 to 20 minutes after injection, and for signs/symptoms of DVT or PE."}, {"doc_id": "argatroban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5858293175697327, "bge_max": 0.5858293175697327, "title": "Argatroban: Drug information", "rep_snippet": "Monitoring Parameters  Monitor hemoglobin, hematocrit, signs and symptoms of bleeding.  HIT: Obtain baseline aPTT prior to start of therapy. Patient may not be at steady-state but check aPTT 2 hours after start of therap…"}, {"doc_id": "dicloxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5842170715332031, "bge_max": 0.5842170715332031, "title": "Dicloxacillin: Drug information", "rep_snippet": "Monitoring Parameters  Baseline and periodic CBC with differential; periodic BUN, serum creatinine, AST and ALT (especially with prolonged therapy); prothrombin time if patient concurrently on warfarin; signs of anaphyla…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5842070579528809, "bge_max": 0.5842070579528809, "title": "Ampicillin: Drug information", "rep_snippet": "Monitoring Parameters  With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; observe signs and symptoms of anaphylaxis during first dose"}, {"doc_id": "cephalexin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5833701491355896, "bge_max": 0.5833701491355896, "title": "Cephalexin: Drug information", "rep_snippet": "Monitoring Parameters  With prolonged therapy monitor renal, hepatic, and hematologic function periodically; monitor for signs of anaphylaxis during first dose"}, {"doc_id": "measles-mumps-rubella-and-varicella-virus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5819258689880371, "bge_max": 0.5819258689880371, "title": "Measles, mumps, rubella, and varicella virus vaccine: Drug information", "rep_snippet": "Monitoring Parameters  Rash, fever; monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or…"}, {"doc_id": "varicella-virus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5819258689880371, "bge_max": 0.5819258689880371, "title": "Varicella virus vaccine: Drug information", "rep_snippet": "Monitoring Parameters  Rash, fever; monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5819052457809448, "bge_max": 0.5819052457809448, "title": "Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "ceftibuten-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5815339088439941, "bge_max": 0.5815339088439941, "title": "Ceftibuten: Drug information", "rep_snippet": "Monitoring Parameters  Monitor renal, hepatic, and hematologic function periodically with prolonged therapy. Observe for signs and symptoms of anaphylaxis during first dose."}, {"doc_id": "vancomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5777300000190735, "bge_max": 0.58092200756073, "title": "Vancomycin: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (hospitalized patient): As a component of empiric therapy or pathogen-specific therapy for community-acquired methicillin-resistant S. aureus: 15 to 20 mg/kg/dose (usual maximum: 2 g/do…"}, {"doc_id": "liposomal-daunorubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5805104374885559, "bge_max": 0.5805104374885559, "title": "Liposomal daunorubicin: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelets (prior to each dose), liver function tests, renal function tests; evaluate cardiac function (baseline left ventricular ejection fraction [LVEF] prior to treatmen…"}, {"doc_id": "carmustine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5801531672477722, "bge_max": 0.5801531672477722, "title": "Carmustine: Drug information", "rep_snippet": "Monitoring Parameters  Injection: CBC with differential and platelet count (weekly for at least 6 weeks after a dose), pulmonary function tests (FVC, DLCO; at baseline and frequently during treatment), liver function (pe…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5796037316322327, "bge_max": 0.5796037316322327, "title": "Aminophylline: Drug information", "rep_snippet": "Monitoring Parameters  Heart rate; CNS effects (insomnia, irritability); respiratory rate (COPD patients often have resting controlled respiratory rates in low 20s); arterial or capillary blood gases (if applicable)  The…"}, {"doc_id": "yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.579014003276825, "bge_max": 0.579014003276825, "title": "Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Monitoring Parameters  Monitor for anaphylaxis and syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestab…"}, {"doc_id": "atovaquone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5788311958312988, "bge_max": 0.5788311958312988, "title": "Atovaquone: Drug information", "rep_snippet": "Dosing: Adult  Pneumocystis jirovecii pneumonia (PCP), prevention: Oral: 1,500 mg once daily with food  PCP, mild to moderate, treatment: Oral: 750 mg twice daily with food for 21 days  Babesiosis (off-label use): Oral:…"}, {"doc_id": "cloxacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5781551599502563, "bge_max": 0.5781551599502563, "title": "Cloxacillin (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Observe for signs and symptoms of anaphylaxis during first dose; CBC with differential (prior to initiating therapy and weekly thereafter), periodic urinalysis, BUN, creatinine, hepatic function"}, {"doc_id": "obinutuzumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5778952836990356, "bge_max": 0.5778952836990356, "title": "Obinutuzumab: Drug information", "rep_snippet": "Monitor for signs of active hepatitis B infection (during and for up to 12 months after therapy completion). Monitor for signs or symptoms of infusion reaction; signs of infection; fluid status; signs/symptoms of progres…"}, {"doc_id": "temozolomide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5777977108955383, "bge_max": 0.5777977108955383, "title": "Temozolomide: Drug information", "rep_snippet": "Concomitant phase: 75 mg/m2 once daily for 42 days with focal radiotherapy (60 Gy administered in 30 fractions). Note: PCP prophylaxis is required during concomitant phase and should continue in patients who develop lymp…"}, {"doc_id": "rabies-virus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5774557590484619, "bge_max": 0.5774557590484619, "title": "Rabies virus vaccine: Drug information", "rep_snippet": "Monitoring Parameters  Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenbur…"}, {"doc_id": "human-papillomavirus-quadrivalent-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5769369006156921, "bge_max": 0.5769369006156921, "title": "Human papillomavirus quadrivalent vaccine: Drug information", "rep_snippet": "Monitoring Parameters  Screening for HPV is not required prior to vaccination. Monitor for anaphylaxis and syncope for 15 minutes following administration (NACI 2017). If seizure-like activity associated with syncope occ…"}, {"doc_id": "iothalamate-meglumine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5768411159515381, "bge_max": 0.5768411159515381, "title": "Iothalamate meglumine: Drug information", "rep_snippet": "Monitoring Parameters  Renal function, blood pressure, hydration; monitor for extravasation during IV administration; monitor for hypersensitivity reactions for ≥30 to 60 minutes.  Direct cholangiography: Monitor patient…"}, {"doc_id": "meropenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5757616758346558, "bge_max": 0.5757616758346558, "title": "Meropenem: Drug information", "rep_snippet": "Monitoring Parameters  Perform culture and sensitivity testing prior to initiating therapy. Monitor for signs of anaphylaxis during first dose. During prolonged therapy, monitor renal function, liver function, CBC."}, {"doc_id": "ado-trastuzumab-emtansine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5757147669792175, "bge_max": 0.5757147669792175, "title": "Ado-trastuzumab emtansine: Drug information", "rep_snippet": "Monitoring Parameters  Platelet count (at baseline and prior to each dose), transaminases and bilirubin (at baseline and prior to each dose); verify pregnancy status prior to treatment initiation; HER2 expression status.…"}, {"doc_id": "aspirin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5751234889030457, "bge_max": 0.5751234889030457, "title": "Aspirin: Drug information", "rep_snippet": "Ventricular assist device (VAD) placement (off-label use): Immediate release: Oral: 1 to 5 mg/kg/dose once daily initiated within 72 hours of VAD placement; should be used with heparin (initiated between 8 to 48 hours fo…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747244358062744, "bge_max": 0.5747244358062744, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Monitoring Parameters  Periodic renal and hematologic function tests during prolonged therapy; monitor for signs of anaphylaxis during first dose"}, {"doc_id": "crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5744519829750061, "bge_max": 0.5744519829750061, "title": "Crotalinae (pit viper) equine immune F(ab')2 antivenom: Drug information", "rep_snippet": "Monitoring Parameters  Vital signs; CBC, platelet count, prothrombin time, aPTT, fibrinogen levels, fibrin split products, clot retraction, bleeding and coagulation times, BUN, electrolytes, bilirubin (prior to administr…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5727113485336304, "bge_max": 0.5727113485336304, "title": "Amoxicillin: Drug information", "rep_snippet": "Monitoring Parameters  With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; assess patient at beginning and throughout therapy for infection; monitor for signs of anaphylaxis during firs…"}, {"doc_id": "siltuximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.572658360004425, "bge_max": 0.572658360004425, "title": "Siltuximab: Drug information", "rep_snippet": "Monitoring Parameters  Monitor complete blood count with differential prior to each dose for the first 12 months and every 3 dosing cycles thereafter, or as clinically necessary; monitor for anaphylaxis and signs/symptom…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5725616216659546, "bge_max": 0.5725616216659546, "title": "Theophylline: Drug information", "rep_snippet": "Monitoring Parameters  Heart rate, CNS effects (insomnia, irritability); respiratory rate (COPD patients often have resting controlled respiratory rates in low 20s); arterial or capillary blood gases (if applicable); flu…"}, {"doc_id": "propofol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5717456936836243, "bge_max": 0.5717456936836243, "title": "Propofol: Drug information", "rep_snippet": "Monitoring Parameters  Cardiac monitor, blood pressure, oxygen saturation (during monitored anesthesia care sedation), arterial blood gas (with prolonged infusions). With prolonged infusions (eg, ICU sedation), monitor f…"}, {"doc_id": "sotalol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5716621279716492, "bge_max": 0.5716621279716492, "title": "Sotalol: Drug information", "rep_snippet": "Monitoring Parameters  Serum creatinine (creatinine clearance), magnesium, potassium; heart rate, blood pressure; ECG (eg, QTc interval, PR interval). If baseline QTc >450 msec (or JT interval >330 msec if QRS over 100 m…"}, {"doc_id": "aztreonam-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5709296464920044, "bge_max": 0.5709296464920044, "title": "Aztreonam (systemic): Drug information", "rep_snippet": "Monitoring Parameters  Injection: Periodic liver function test; monitor for signs of anaphylaxis during first dose"}, {"doc_id": "dextromethorphan-and-quinidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5708290338516235, "bge_max": 0.5708290338516235, "title": "Dextromethorphan and quinidine: Drug information", "rep_snippet": "Monitoring Parameters  QT interval at baseline and 3 to 4 hours after the first dose in patients at risk for QTc prolongation; potassium and magnesium prior to and during therapy; CBC, liver and renal function tests; per…"}, {"doc_id": "infliximab-including-biosimilars-of-infliximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5703203082084656, "bge_max": 0.5703203082084656, "title": "Infliximab (including biosimilars of infliximab): Drug information", "rep_snippet": "Monitoring Parameters  Monitor improvement of symptoms and physical function assessments. During infusion, if reaction is noted, monitor vital signs every 2 to 10 minutes, depending on reaction severity, until normal. If…"}, {"doc_id": "smallpox-vaccine-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5702933669090271, "bge_max": 0.5702933669090271, "title": "Smallpox vaccine (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information", "rep_snippet": "Monitoring Parameters  Observe for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenbur…"}]}
{"qid": "Q21_spelling", "query": "Inpt CAP, PCN-allergic — levoflox regimen; QT watchouts.", "base_qid": "Q21", "variant_type": "spelling", "candidates": [{"doc_id": "zinc-pyrithione-drug-information", "bm25_top3": 14.683351062244153, "bm25_max": 14.683351062244153, "bge_top3": null, "bge_max": null, "title": "Zinc pyrithione: Drug information", "rep_snippet": "Brand Names: International  Aeroseb (AR);  Dan Gard (AU, KR);  de-squaman (DE);  Desquaman (AE, CH, LU, QA);  Dos Ele (AR);  Fongitar (ZA);  Healing Shampoo (PL);  Min-Huil (AR);  Pirimed (MX);  Skaelud (DK);  Skin-Cap (…"}, {"doc_id": "bedaquiline-drug-information", "bm25_top3": 5.966008484715272, "bm25_max": 7.930029306531498, "bge_top3": null, "bge_max": null, "title": "Bedaquiline: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Increased mortality:  An increased risk of death was seen in the bedaquiline treatment group (9/79, 11.4%) compared with the placebo treatment group (2/81, 2.5%) in 1 placebo-controlled trial. On…"}, {"doc_id": "phenylephrine-and-pramoxine-drug-information", "bm25_top3": 6.612943257801565, "bm25_max": 6.612943257801565, "bge_top3": null, "bge_max": null, "title": "Phenylephrine and pramoxine: Drug information", "rep_snippet": "Administration  Cleanse affected area by patting or blotting with cleansing wipe, and gently dry before applying cream. Apply externally or in the lower portion of the anal canal only. For application in the lower anal c…"}, {"doc_id": "fulvestrant-drug-information", "bm25_top3": 5.964844433162142, "bm25_max": 5.964844433162142, "bge_top3": null, "bge_max": null, "title": "Fulvestrant: Drug information", "rep_snippet": "Administration  IM: For IM administration only. Administer 500 mg dose as two 5 mL IM injections (one in each buttocks [gluteal area]) slowly over 1 to 2 minutes per injection. If administering at the dorsogluteal site,…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 5.316832818596605, "bm25_max": 5.316832818596605, "bge_top3": 0.6226935982704163, "bge_max": 0.6226935982704163, "title": "Vancomycin: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011): Infants >3 months, Children, and Adolescents: IV: Note: In children ≥5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out. Also c…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 5.135477565840878, "bm25_max": 5.135477565840878, "bge_top3": null, "bge_max": null, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Allergic reactions (eg, angioedema, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis and drug reaction with eosin…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": 4.617109661084738, "bm25_max": 4.617109661084738, "bge_top3": null, "bge_max": null, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Salivary gland cancers, advanced (off-label use): IV: 50 mg/m2 on day 1 every 21 days (in combination with cisplatin and cyclophosphamide); continue until disease progression or unacceptable toxicity (Lictra 1996) or 50…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 4.524504717916473, "bm25_max": 4.524504717916473, "bge_top3": null, "bge_max": null, "title": "Fluoxetine: Drug information", "rep_snippet": "• QT prolongation: QT prolongation and ventricular arrhythmia including torsade de pointes has occurred. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of pro…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 4.511224911475697, "bm25_max": 4.511224911475697, "bge_top3": null, "bge_max": null, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "• QT prolongation: Fluoxetine may cause QT prolongation and ventricular arrhythmia including torsade de pointes. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, histor…"}, {"doc_id": "perampanel-drug-information", "bm25_top3": 4.437554989932286, "bm25_max": 4.437554989932286, "bge_top3": null, "bge_max": null, "title": "Perampanel: Drug information", "rep_snippet": "Administration  Tablets: Administer at bedtime without regard to food.  Oral suspension: Shake well before every administration. Use a calibrated measuring device to measure dose (a household teaspoon or tablespoon is no…"}, {"doc_id": "toremifene-drug-information", "bm25_top3": 2.7210163585298477, "bm25_max": 4.432317282256474, "bge_top3": null, "bge_max": null, "title": "Toremifene: Drug information", "rep_snippet": "• QT prolongation: [US Boxed Warning]: May prolong the QT interval; QTc prolongation is dose-dependent and concentration-dependent. QT prolongation may lead to a form of ventricular tachycardia called torsades de pointes…"}, {"doc_id": "gadoteridol-drug-information", "bm25_top3": 4.42404789263203, "bm25_max": 4.42404789263203, "bge_top3": null, "bge_max": null, "title": "Gadoteridol: Drug information", "rep_snippet": "Dosage Forms Considerations  ProHance prefilled syringe tip cap contains latex."}, {"doc_id": "interferon-beta-1b-drug-information", "bm25_top3": 4.318972331199465, "bm25_max": 4.318972331199465, "bge_top3": null, "bge_max": null, "title": "Interferon beta-1b: Drug information", "rep_snippet": "Dosage Forms Considerations  The Extavia diluent syringe cap may contain latex."}, {"doc_id": "saquinavir-drug-information", "bm25_top3": 3.9122621108976627, "bm25_max": 4.224592148212672, "bge_top3": null, "bge_max": null, "title": "Saquinavir: Drug information", "rep_snippet": "Dosing: Adult  Note: ECG should be done prior to starting therapy; do not initiate therapy if pretreatment QT interval ≥450 msec. Saquinavir should always be used with concomitant ritonavir.  HIV-1 infection, treatment:…"}, {"doc_id": "total-parenteral-nutrition-drug-information", "bm25_top3": 4.087717340575111, "bm25_max": 4.087717340575111, "bge_top3": null, "bge_max": null, "title": "Total parenteral nutrition: Drug information", "rep_snippet": "• Hypersensitivity: Allergic or hypersensitivity reactions (eg, altered mentation, bronchospasm, cyanosis, flushing, dyspnea, headache, hypotension, hypoxia, rash, sweating, tachycardia, tachypnea, vomiting) may occur; d…"}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": 3.9201877310488307, "bm25_max": 3.9201877310488307, "bge_top3": null, "bge_max": null, "title": "Hydroxyzine: Drug information", "rep_snippet": "• QT prolongation/torsades de pointes: Has been reported, with the majority occurring in patients with other risk factors for QT prolongation/torsades de pointes (eg, preexisting cardiac disease, electrolyte imbalances,…"}, {"doc_id": "vandetanib-drug-information", "bm25_top3": 2.7467850704456254, "bm25_max": 3.8789930973528044, "bge_top3": null, "bge_max": null, "title": "Vandetanib: Drug information", "rep_snippet": "• QT prolongation/sudden death: [US Boxed Warning]: May prolong the QT interval; torsade de pointes and sudden death have been reported. Do not use in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT s…"}, {"doc_id": "cinacalcet-drug-information", "bm25_top3": 3.8351313117091905, "bm25_max": 3.8351313117091905, "bge_top3": null, "bge_max": null, "title": "Cinacalcet: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Adynamic bone disease: May develop if intact parathyroid hormone (iPTH) levels are suppressed <100 pg/mL; reduce dose or discontinue use of cinacalcet and/or…"}, {"doc_id": "mirtazapine-drug-information", "bm25_top3": 3.7594978717886764, "bm25_max": 3.7594978717886764, "bge_top3": null, "bge_max": null, "title": "Mirtazapine: Drug information", "rep_snippet": "• Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": 3.7450566784958195, "bm25_max": 3.7450566784958195, "bge_top3": null, "bge_max": null, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Anthrax; Bacterial meningitis; Bite wounds (animal/human); Diabetic foot infections; Mycoplasma genitalium; Nocardiosis; Pelvic inflammatory disease; Surgical prophylaxis; Tuberculosis (second-line therap…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": 3.7445263092411736, "bm25_max": 3.7445263092411736, "bge_top3": null, "bge_max": null, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • QT prolongation: Use associated with prolonging the QT interval; avoid use in patients at risk for QT prolongation, including patients with a history of long…"}, {"doc_id": "degarelix-drug-information", "bm25_top3": 3.6851483659397424, "bm25_max": 3.6851483659397424, "bge_top3": 0.6216279864311218, "bge_max": 0.6216279864311218, "title": "Degarelix: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anemia: Testosterone suppression is associated with the development of anemia.  • Decreased bone mineral density: Androgen deprivation therapy is associated w…"}, {"doc_id": "quetiapine-drug-information", "bm25_top3": 3.6851483659397424, "bm25_max": 3.6851483659397424, "bge_top3": null, "bge_max": null, "title": "Quetiapine: Drug information", "rep_snippet": "• QT prolongation: Use has been associated with QT prolongation; postmarketing reports have occurred in patients with concomitant illness, quetiapine overdose, or who were receiving concomitant therapy known to increase…"}, {"doc_id": "fluticasone-nasal-drug-information", "bm25_top3": 3.669139794959854, "bm25_max": 3.669139794959854, "bge_top3": null, "bge_max": null, "title": "Fluticasone (nasal): Drug information", "rep_snippet": "Administration  For intranasal use only; do not spray in eyes or mouth. Administer at regular intervals. Shake bottle gently before each use. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle up…"}, {"doc_id": "clobetasol-drug-information", "bm25_top3": 3.5819675127554564, "bm25_max": 3.5819675127554564, "bge_top3": null, "bge_max": null, "title": "Clobetasol: Drug information", "rep_snippet": "Shampoo: Limit treatment to 4 consecutive weeks. Maximum dose: 50 g/week or 50 mL/week. Use on dry hair; do not wet hair prior to use. Do not use a shower cap or bathing cap while shampoo is on the scalp. Leave in place…"}, {"doc_id": "atomoxetine-drug-information", "bm25_top3": 3.2028420258009884, "bm25_max": 3.2028420258009884, "bge_top3": null, "bge_max": null, "title": "Atomoxetine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Aggressive behavior: New or worsening symptoms of hostility or aggressive behaviors have been associated with atomoxetine, particularly with the initiation of…"}, {"doc_id": "evolocumab-drug-information", "bm25_top3": 3.1886747958568673, "bm25_max": 3.1886747958568673, "bge_top3": null, "bge_max": null, "title": "Evolocumab: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity reactions (eg, rash, urticaria) have been reported, some requiring discontinuation. Discontinue treatment and ini…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": 2.4722615095711227, "bm25_max": 2.4722615095711227, "bge_top3": null, "bge_max": null, "title": "Clozapine: Drug information", "rep_snippet": "• QT prolongation: Clozapine is associated with QT prolongation and ventricular arrhythmias including torsade de pointes; cardiac arrest and sudden death may occur. Use caution in patients with conditions that may increa…"}, {"doc_id": "chlorpheniramine-drug-information", "bm25_top3": 2.256705947271252, "bm25_max": 2.256705947271252, "bge_top3": null, "bge_max": null, "title": "Chlorpheniramine: Drug information", "rep_snippet": "Use  Allergic symptoms, allergic rhinitis, urticaria, pruritus: Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria, pruritus"}, {"doc_id": "rufinamide-drug-information", "bm25_top3": 2.1733193495676577, "bm25_max": 2.1733193495676577, "bge_top3": null, "bge_max": null, "title": "Rufinamide: Drug information", "rep_snippet": "Contraindications  Patients with familial short QT syndrome  Canadian labeling: Additional contraindications (not in US labeling): Family history of short QT syndrome; presence or history of short QT interval; hypersensi…"}, {"doc_id": "desflurane-drug-information", "bm25_top3": 2.1687362045257252, "bm25_max": 2.1687362045257252, "bge_top3": null, "bge_max": null, "title": "Desflurane: Drug information", "rep_snippet": "• Malignant hyperthermia: May trigger malignant hyperthermia (MH); some reported cases have been fatal. Use is contraindicated in patients susceptible to MH.  • QT prolongation: Cases of QT prolongation in association wi…"}, {"doc_id": "cyproheptadine-drug-information", "bm25_top3": 2.0250257882689997, "bm25_max": 2.0250257882689997, "bge_top3": null, "bge_max": null, "title": "Cyproheptadine: Drug information", "rep_snippet": "Use  Allergic conditions: Perennial and seasonal allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis caused by inhalant allergens and foods; mild, uncomplicated allergic skin manifestations of urticaria and an…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": 1.9721218326279821, "bm25_max": 1.9721218326279821, "bge_top3": null, "bge_max": null, "title": "Ondansetron: Drug information", "rep_snippet": "• QT prolongation: ECG changes, including dose-dependent QT interval prolongation, have been observed with ondansetron use. Cases of torsade de pointes have also been reported. Selective 5-HT3 antagonists, including onda…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 1.3233709668046538, "bm25_max": 1.9355500555714258, "bge_top3": null, "bge_max": null, "title": "Telithromycin: Drug information", "rep_snippet": "Use  Community-acquired pneumonia: Treatment of mild to moderate community-acquired pneumonia (CAP) due to Streptococcus pneumoniae (including multidrug-resistant isolates), Haemophilus influenzae, Moraxella catarrhalis,…"}, {"doc_id": "bilastine-united-states-not-available-drug-information", "bm25_top3": 1.845778052152994, "bm25_max": 1.845778052152994, "bge_top3": null, "bge_max": null, "title": "Bilastine (United States: Not available): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to bilastine or any component of the formulation; history of QT prolongation and/or torsades de pointes, including congenital long QT syndromes."}, {"doc_id": "granisetron-drug-information", "bm25_top3": 1.837790593402385, "bm25_max": 1.837790593402385, "bge_top3": null, "bge_max": null, "title": "Granisetron: Drug information", "rep_snippet": "• Long QT syndrome: Use with caution in patients with congenital long QT syndrome or other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomag…"}, {"doc_id": "mometasone-nasal-drug-information", "bm25_top3": 1.7081712266588784, "bm25_max": 1.7081712266588784, "bge_top3": null, "bge_max": null, "title": "Mometasone (nasal): Drug information", "rep_snippet": "Use  Allergic rhinitis (seasonal and perennial): Treatment of nasal symptoms of seasonal allergic and perennial allergic rhinitis in adults and pediatric patients ≥2 years.  Nasal congestion associated with seasonal rhin…"}, {"doc_id": "etelcalcetide-drug-information", "bm25_top3": 1.6557607665517722, "bm25_max": 1.6557607665517722, "bge_top3": null, "bge_max": null, "title": "Etelcalcetide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Adynamic bone disease: May develop if parathyroid hormone levels are chronically suppressed; reduce dose or discontinue etelcalcetide and/or vitamin D if para…"}, {"doc_id": "dexchlorpheniramine-drug-information", "bm25_top3": 1.65346556396236, "bm25_max": 1.65346556396236, "bge_top3": null, "bge_max": null, "title": "Dexchlorpheniramine: Drug information", "rep_snippet": "Use  Hypersensitivity reactions: For the treatment of perennial and seasonal allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; a…"}, {"doc_id": "fingolimod-drug-information", "bm25_top3": 1.641141419156579, "bm25_max": 1.641141419156579, "bge_top3": null, "bge_max": null, "title": "Fingolimod: Drug information", "rep_snippet": "• Respiratory effects: Reductions of forced expiratory volume in the first second of expiration (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) are dose dependent and may occur within the first month of the…"}, {"doc_id": "bepotastine-ophthalmic-drug-information", "bm25_top3": 1.5409003909573915, "bm25_max": 1.5409003909573915, "bge_top3": null, "bge_max": null, "title": "Bepotastine (ophthalmic): Drug information", "rep_snippet": "Use  Allergic conjunctivitis: Treatment of itching associated with allergic conjunctivitis"}, {"doc_id": "nedocromil-drug-information", "bm25_top3": 1.5409003909573915, "bm25_max": 1.5409003909573915, "bge_top3": null, "bge_max": null, "title": "Nedocromil: Drug information", "rep_snippet": "Use  Allergic conjunctivitis: Treatment of itching associated with allergic conjunctivitis"}, {"doc_id": "alcaftadine-drug-information", "bm25_top3": 1.5409003909573915, "bm25_max": 1.5409003909573915, "bge_top3": null, "bge_max": null, "title": "Alcaftadine: Drug information", "rep_snippet": "Use  Allergic conjunctivitis: Prevention of itching associated with allergic conjunctivitis"}, {"doc_id": "cetirizine-ophthalmic-drug-information", "bm25_top3": 1.4933962931587565, "bm25_max": 1.4933962931587565, "bge_top3": null, "bge_max": null, "title": "Cetirizine (ophthalmic): Drug information", "rep_snippet": "Use  Allergic conjunctivitis: Treatment of ocular itching associated with allergic conjunctivitis."}, {"doc_id": "vitamin-k-phytonadione-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.663294792175293, "bge_max": 0.663294792175293, "title": "Vitamin K (phytonadione): Drug information", "rep_snippet": "Monitoring Parameters  PT, INR; monitor for hypersensitivity reactions if administering IV."}, {"doc_id": "tropicamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6432944536209106, "bge_max": 0.6432944536209106, "title": "Tropicamide: Drug information", "rep_snippet": "Monitoring Parameters  Ophthalmic exam, intraocular pressure, CNS reactions (especially in pediatric patients)."}, {"doc_id": "hydroxyamphetamine-and-tropicamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6432944536209106, "bge_max": 0.6432944536209106, "title": "Hydroxyamphetamine and tropicamide: Drug information", "rep_snippet": "Monitoring Parameters  Ophthalmic exam, intraocular pressure, CNS reactions (especially in pediatric patients)."}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6377208828926086, "bge_max": 0.6377208828926086, "title": "Vemurafenib: Drug information", "rep_snippet": "Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Warfarin: Vemurafenib may increase the serum concentration of Warfarin. Risk C: Monitor therapy  Xipam…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6362680196762085, "bge_max": 0.6362680196762085, "title": "Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "dextromethorphan-and-quinidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6357945203781128, "bge_max": 0.6357945203781128, "title": "Dextromethorphan and quinidine: Drug information", "rep_snippet": "Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax. Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations. Risk D: Consider therapy mo…"}, {"doc_id": "cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6357000470161438, "bge_max": 0.6357000470161438, "title": "Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Drug information", "rep_snippet": "Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk C: Monit…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6351737976074219, "bge_max": 0.6351737976074219, "title": "Aprepitant: Drug information", "rep_snippet": "Monitoring Parameters  In patients receiving concurrent warfarin, monitor INR/PT for 2 weeks (particularly at 7 to 10 days) following aprepitant administration; monitor for signs/symptoms of hypersensitivity reaction."}, {"doc_id": "dolasetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6344727873802185, "bge_max": 0.6344727873802185, "title": "Dolasetron: Drug information", "rep_snippet": "Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Risk X: Avoid combination  Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Risk C: Mon…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6318902969360352, "bge_max": 0.6318902969360352, "title": "Citalopram: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to citalopram or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either citalopram or t…"}, {"doc_id": "measles-mumps-rubella-and-varicella-virus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6309198141098022, "bge_max": 0.6309198141098022, "title": "Measles, mumps, rubella, and varicella virus vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6307020783424377, "bge_max": 0.6307020783424377, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax. Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations. Risk D: Consider therapy mo…"}, {"doc_id": "olopatadine-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6300675868988037, "bge_max": 0.6300675868988037, "title": "Olopatadine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic:  Pataday, Pazeo: Instill 1 drop into each affected eye once daily  Patanol: Instill 1 drop into each affected eye twice daily (allowing 6 to 8 hours between doses)"}, {"doc_id": "equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.630016565322876, "bge_max": 0.630016565322876, "title": "Equine serum heptavalent botulism antitoxin (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information", "rep_snippet": "Monitoring Parameters  Monitor vital signs and for the presence of infusion-related reactions and acute hypersensitivity reactions during and immediately following infusion; monitor for delayed allergic reactions for 10…"}, {"doc_id": "procarbazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6296890377998352, "bge_max": 0.6296890377998352, "title": "Procarbazine: Drug information", "rep_snippet": "PEP-C regimen: Oral: 50 mg daily at bedtime (length of induction cycle depends on phase of treatment and blood counts; frequency may vary based on tolerance in maintenance cycle; in combination with prednisone, etoposide…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6291811466217041, "bge_max": 0.6291811466217041, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Monitoring Parameters  Creatinine, BUN, CBC with differential, PT, PTT, serum electrolytes, LFTs, urinalysis; signs of bleeding; monitor for signs of anaphylaxis during first dose"}, {"doc_id": "sebelipase-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6287573575973511, "bge_max": 0.6287573575973511, "title": "Sebelipase alfa: Drug information", "rep_snippet": "Monitoring Parameters  Signs and symptoms of hypersensitivity reaction (during infusion and for at least 4 hours after completion of infusion); lipid panel; anti-drug antibody assessment; hepatic function (ALT)."}, {"doc_id": "reslizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6281309127807617, "bge_max": 0.6281309127807617, "title": "Reslizumab: Drug information", "rep_snippet": "Monitoring Parameters  Anaphylaxis/hypersensitivity reactions (during and after infusion); peak flow, and/or other pulmonary function tests; monitor for signs of infection"}, {"doc_id": "benralizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6281309127807617, "bge_max": 0.6281309127807617, "title": "Benralizumab: Drug information", "rep_snippet": "Monitoring Parameters  Anaphylaxis/hypersensitivity reactions (during and after infusion); peak flow, and/or other pulmonary function tests; monitor for signs of infection"}, {"doc_id": "dinutuximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6276401877403259, "bge_max": 0.6276401877403259, "title": "Dinutuximab: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential, serum electrolytes, renal function, blood pressure; monitor for signs/symptoms of infusion reactions (during and for at least 4 hours after infusion), pain, peripheral neurop…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6270608305931091, "bge_max": 0.6270608305931091, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax. Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations. Risk D: Consider therapy mo…"}, {"doc_id": "infliximab-including-biosimilars-of-infliximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6261200904846191, "bge_max": 0.6261200904846191, "title": "Infliximab (including biosimilars of infliximab): Drug information", "rep_snippet": "• Hypersensitivity or infusion reactions: Acute infusion reactions may occur. Hypersensitivity reactions, including anaphylaxis, may occur within 2 hours of infusion. Medication and equipment for management of hypersensi…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6259738802909851, "bge_max": 0.6259738802909851, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "Use  Note: Treatment guidelines recommend the use of high dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011], NICE 2014).  Oral, IV or IM injection:  Allergic states: Contr…"}, {"doc_id": "teniposide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6258970499038696, "bge_max": 0.6258970499038696, "title": "Teniposide: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelet count, renal and hepatic function tests; blood pressure; monitor for hypersensitivity reaction (observe continuously for first 60 minutes of infusion, frequently…"}, {"doc_id": "escitalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6255861520767212, "bge_max": 0.6255861520767212, "title": "Escitalopram: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to escitalopram, citalopram, or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either…"}, {"doc_id": "trihexyphenidyl-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6244155764579773, "bge_max": 0.6244155764579773, "title": "Trihexyphenidyl: Drug information", "rep_snippet": "Monitoring Parameters  Gonioscopic evaluations (prior to therapy initiation); IOP (periodically); anticholinergic adverse reactions (patients on long-term therapy)"}, {"doc_id": "lapatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6242126822471619, "bge_max": 0.6242126822471619, "title": "Lapatinib: Drug information", "rep_snippet": "Monitoring Parameters  LVEF (baseline and periodic), CBC with differential, liver function tests, including transaminases, bilirubin, and alkaline phosphatase (baseline and every 4-6 weeks during treatment); electrolytes…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6240239143371582, "bge_max": 0.6240239143371582, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential, BUN, creatinine, liver function test periodically with prolonged use; hypersensitivity reactions"}, {"doc_id": "hepatitis-b-immune-globulin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6236202716827393, "bge_max": 0.6236202716827393, "title": "Hepatitis B immune globulin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be a…"}, {"doc_id": "ziprasidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6222626566886902, "bge_max": 0.6222626566886902, "title": "Ziprasidone: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to ziprasidone or any component of the formulation; history of (or current) prolonged QT; congenital long QT syndrome; recent myocardial infarction; uncompensated heart failure; concur…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.621878981590271, "bge_max": 0.621878981590271, "title": "Lansoprazole: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Carcinoma: No reports of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia has occurred.  • Clostridium difficile-associated diarrhea (CDAD…"}, {"doc_id": "ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6214513182640076, "bge_max": 0.6214513182640076, "title": "Ovine polyvalent crotalidae North and South American snake antivenom: Drug information", "rep_snippet": "Monitoring Parameters  Vital signs; CBC, platelet count, prothrombin time, aPTT, fibrinogen levels, fibrin split products, clot retraction, bleeding and coagulation times, BUN, electrolytes, bilirubin; size of bite area…"}, {"doc_id": "centruroides-antivenom-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6210622787475586, "bge_max": 0.6210622787475586, "title": "Centruroides antivenom: Drug information", "rep_snippet": "Administration  IV: Administer over 10 minutes; monitor for return of symptoms of envenomation and repeat as needed. Medications (eg, epinephrine, corticosteroids, diphenhydramine) and equipment for resuscitation should…"}, {"doc_id": "antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6206038594245911, "bge_max": 0.6206038594245911, "title": "Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hematologic effects: Reversible leukopenia, neutropenia, thrombocytopenia, and lymphopenia may occur. Monitor blood counts. Leukopenia and/or thrombocytopenia…"}, {"doc_id": "eliglustat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6203972697257996, "bge_max": 0.6203972697257996, "title": "Eliglustat: Drug information", "rep_snippet": "Monitoring Parameters  Adverse reactions (especially in PMs); CBC, platelets, prothrombin, electrolytes, chitotriosidase, angiotensin-converting enzyme (ACE), tartrate-resistant acid phosphatase (TRAP); MRI or CT scan (l…"}, {"doc_id": "belimumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6198590993881226, "bge_max": 0.6198590993881226, "title": "Belimumab: Drug information", "rep_snippet": "Monitoring Parameters  Monitor during and for an appropriate time after administration for hypersensitivity and/or infusion reactions; infections; worsening of depression, mood changes, or suicidal thoughts"}, {"doc_id": "penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6197314858436584, "bge_max": 0.6197314858436584, "title": "Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Drug information", "rep_snippet": "Monitoring Parameters  Hypersensitivity reactions with first dose, injection-site reactions, periodic renal and hematologic function tests with prolonged therapy"}, {"doc_id": "levofloxacin-united-states-not-available-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6196240186691284, "bge_max": 0.6196240186691284, "title": "Levofloxacin (United States: Not available) (oral inhalation): Drug information", "rep_snippet": "Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Risk C: Monitor therapy  Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Risk X: Av…"}, {"doc_id": "cosyntropin-tetracosactide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6193610429763794, "bge_max": 0.6193610429763794, "title": "Cosyntropin (tetracosactide): Drug information", "rep_snippet": "Monitoring Parameters  Synacthen Depot [Canadian product]: Observe patient for ~1 hour after administration for signs/symptoms of hypersensitivity; for diagnosis of adrenocortical Insufficiency measure plasma cortisol pr…"}, {"doc_id": "brentuximab-vedotin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6183032989501953, "bge_max": 0.6183032989501953, "title": "Brentuximab vedotin: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential prior to each dose (more frequently if clinically indicated); liver and renal function tests. Pregnancy test (in women of reproductive potential) prior to treatment initiation…"}, {"doc_id": "oxybutynin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6171512603759766, "bge_max": 0.6171512603759766, "title": "Oxybutynin: Drug information", "rep_snippet": "Monitoring Parameters  Incontinence episodes, postvoid residual (PVR), anticholinergic reactions."}, {"doc_id": "prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169046759605408, "bge_max": 0.6169046759605408, "title": "Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Drug information", "rep_snippet": "Contraindications  Kcentra, Beriplex P/N [Canadian product]: Hypersensitivity (ie, anaphylaxis or severe systemic reaction) to prothrombin complex concentrate (PCC) or any component of the formulation including factors I…"}, {"doc_id": "nafcillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6163872480392456, "bge_max": 0.6163872480392456, "title": "Nafcillin: Drug information", "rep_snippet": "Monitoring Parameters  Baseline and periodic CBC with differential, urinalysis, BUN, serum creatinine; baseline and periodic serum bilirubin, AST, ALT, alkaline phosphatase and gamma glutamyl transferase (especially when…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6162565350532532, "bge_max": 0.6162565350532532, "title": "Acetylcysteine: Drug information", "rep_snippet": "Monitoring Parameters  Acetaminophen overdose: Monitor patient for the development of anaphylaxis or anaphylactoid reactions; monitor serum acetaminophen concentrations, AST, ALT, bilirubin, PT, INR, serum creatinine, BU…"}, {"doc_id": "propafenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6161736845970154, "bge_max": 0.6161736845970154, "title": "Propafenone: Drug information", "rep_snippet": "Venlafaxine: Propafenone may increase the serum concentration of Venlafaxine. Management: Monitor for increased venlafaxine levels/adverse effects (e.g., hallucinations, agitation, confusion) with propafenone initiation/…"}, {"doc_id": "paliperidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6158778071403503, "bge_max": 0.6158778071403503, "title": "Paliperidone: Drug information", "rep_snippet": "HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be…"}, {"doc_id": "alemtuzumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6156139969825745, "bge_max": 0.6156139969825745, "title": "Alemtuzumab: Drug information", "rep_snippet": "Monitoring Parameters  Campath: CBC with differential and platelets (weekly, more frequent if worsening); signs and symptoms of infection; CD4+ lymphocyte counts (after treatment until recovery); CMV antigen (routinely d…"}, {"doc_id": "zoster-shingles-vaccine-live-attenuated-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6155079007148743, "bge_max": 0.6155079007148743, "title": "Zoster (shingles) vaccine, live attenuated: Drug information", "rep_snippet": "Monitoring Parameters  Fever, rash; monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or…"}]}
{"qid": "Q22_abbr+route-cue", "query": "Oral candidiasis — nystatin suspension dosing + swish-and-swallow instructions.", "base_qid": "Q22", "variant_type": "abbr+route-cue", "candidates": [{"doc_id": "nystatin-oral-drug-information", "bm25_top3": 39.321044720684164, "bm25_max": 51.73453448957069, "bge_top3": 0.7648030519485474, "bge_max": 0.7803654670715332, "title": "Nystatin (oral): Drug information", "rep_snippet": "Dosing: Adult  Oral candidiasis: Suspension (swish and swallow): 400,000-600,000 units 4 times/day; swish in the mouth and retain for as long as possible (several minutes) before swallowing  Intestinal infections: Oral t…"}, {"doc_id": "cetylpyridinium-drug-information", "bm25_top3": 19.271906551224074, "bm25_max": 27.847874978017096, "bge_top3": 0.6855708360671997, "bge_max": 0.6855708360671997, "title": "Cetylpyridinium: Drug information", "rep_snippet": "Dosing: Adult  Antiseptic (OTC labeling): Oral: Swish 20 mL thoroughly between teeth for 30 seconds then spit; use twice daily; may be used before or after brushing; do not swallow."}, {"doc_id": "artificial-saliva-drug-information", "bm25_top3": 16.092293024129553, "bm25_max": 27.541747664003175, "bge_top3": 0.6644498109817505, "bge_max": 0.6644498109817505, "title": "Artificial saliva: Drug information", "rep_snippet": "Dosing: Adult  Mucositis (due to high-dose chemotherapy or radiation therapy): Oral:  Caphosol, NeutraSal: Swish and spit 4 to 10 doses daily (use for the duration of chemo- or radiation therapy).  SalivaMax, SalivateRx:…"}, {"doc_id": "clotrimazole-oral-drug-information", "bm25_top3": 26.908372953462813, "bm25_max": 26.908372953462813, "bge_top3": 0.6568242907524109, "bge_max": 0.6568242907524109, "title": "Clotrimazole (oral): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Clotrimazole (oral): Pediatric drug information \")  Oropharyngeal candidiasis (treatment): Children ≥3 years and Adolescents: Refer to adult dosing."}, {"doc_id": "nystatin-topical-drug-information", "bm25_top3": 20.46494877255064, "bm25_max": 24.97255290789007, "bge_top3": 0.6624867916107178, "bge_max": 0.6624867916107178, "title": "Nystatin (topical): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nystatin (topical): Pediatric drug information\")  Fungal infections (cutaneous and mucocutaneous): Infants, Children, and Adolescents: Topical: Refer to adult dosing."}, {"doc_id": "anidulafungin-drug-information", "bm25_top3": 17.935427454255642, "bm25_max": 17.935427454255642, "bge_top3": null, "bge_max": null, "title": "Anidulafungin: Drug information", "rep_snippet": "Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients in units with a high incidence of invasive candidiasis) (alternative therapy; off-label use): IV: Initial dose: 200 mg on day 1; subsequent do…"}, {"doc_id": "glycopyrrolate-glycopyrronium-oral-inhalation-drug-information", "bm25_top3": 17.803117185510967, "bm25_max": 17.803117185510967, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) (oral inhalation): Drug information", "rep_snippet": "Administration  Inhalation: For oral inhalation only.  Dry powder inhaler (capsule): Do not swallow capsules. Administer at the same time each day; use only with the Neohaler device. Do not remove capsules from blister u…"}, {"doc_id": "carbamide-peroxide-drug-information", "bm25_top3": 17.206724911847694, "bm25_max": 17.206724911847694, "bge_top3": 0.6476219892501831, "bge_max": 0.6476219892501831, "title": "Carbamide peroxide: Drug information", "rep_snippet": "Dosing: Adult  Ear wax removal: Otic: Instill 5 to 10 drops twice daily up to 4 days.  Mouth, gum, or dental irritation: Oral: Use up to 4 times daily after meals and at bedtime. For direct application, place several dro…"}, {"doc_id": "colesevelam-drug-information", "bm25_top3": 16.95478543679652, "bm25_max": 16.95478543679652, "bge_top3": 0.6559286713600159, "bge_max": 0.6559286713600159, "title": "Colesevelam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Colesevelam: Pediatric drug information\")  Heterozygous familial hypercholesterolemia: Children 10 to 17 years (males and postmenarchal females): Oral: 3.75 g once dail…"}, {"doc_id": "ciclopirox-drug-information", "bm25_top3": 16.909540885087786, "bm25_max": 16.909540885087786, "bge_top3": null, "bge_max": null, "title": "Ciclopirox: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciclopirox: Pediatric drug information\")  Tinea pedis, tinea corporis: Topical:  Cream and suspension: Children >10 years and Adolescents: Refer to adult dosing.  Gel:…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 14.720887048648116, "bm25_max": 14.720887048648116, "bge_top3": null, "bge_max": null, "title": "Vancomycin: Drug information", "rep_snippet": "Dosage Forms Considerations  First-Vancomycin oral solution and Vancomycin+SyrSpend SF oral suspension are compounding kits. Refer to manufacturer’s labeling for compounding instructions."}, {"doc_id": "triamcinolone-neomycin-gramicidin-and-nystatin-topical-united-states-not-available-drug-information", "bm25_top3": 13.678985206102215, "bm25_max": 13.678985206102215, "bge_top3": null, "bge_max": null, "title": "Triamcinolone, neomycin, gramicidin, and nystatin (topical) (United States: Not available): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to triamcinolone, neomycin, gramicidin, nystatin, or any component of the formulation; tuberculosis and most viral skin lesions (including herpes simplex, vaccinia, varicella), fungal…"}, {"doc_id": "ursodeoxycholic-acid-ursodiol-drug-information", "bm25_top3": 13.579242370107274, "bm25_max": 13.579242370107274, "bge_top3": null, "bge_max": null, "title": "Ursodeoxycholic acid (ursodiol): Drug information", "rep_snippet": "Dosage Forms Considerations  Ursodiol+SyrSpend SF PH4 oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "midazolam-drug-information", "bm25_top3": 13.579242370107274, "bm25_max": 13.579242370107274, "bge_top3": null, "bge_max": null, "title": "Midazolam: Drug information", "rep_snippet": "Dosage Forms Considerations  Midazolam+SyrSpend SF PH4 oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "cyclobenzaprine-drug-information", "bm25_top3": 13.504007225307785, "bm25_max": 13.504007225307785, "bge_top3": null, "bge_max": null, "title": "Cyclobenzaprine: Drug information", "rep_snippet": "Dosage Forms Considerations  EnovaRX-Cyclobenzaprine and Active-Cyclobenzaprine creams are compounded from kits. Refer to manufacturer’s labeling for compounding instructions.  Tabradol FusePaq is a compounding kit for t…"}, {"doc_id": "atenolol-drug-information", "bm25_top3": 13.252164522493821, "bm25_max": 13.252164522493821, "bge_top3": null, "bge_max": null, "title": "Atenolol: Drug information", "rep_snippet": "Dosage Forms Considerations  Atenolol+SyrSpend SF PH4 oral suspension is available as a compounding kit. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "amlodipine-drug-information", "bm25_top3": 13.252164522493821, "bm25_max": 13.252164522493821, "bge_top3": null, "bge_max": null, "title": "Amlodipine: Drug information", "rep_snippet": "Dosage Forms Considerations  AmLODIPine Bes+SyrSpend SF oral suspension is available as a compounding kit. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "diphenhydramine-systemic-drug-information", "bm25_top3": 13.0926896126477, "bm25_max": 13.0926896126477, "bge_top3": null, "bge_max": null, "title": "Diphenhydramine (systemic): Drug information", "rep_snippet": "Dosage Forms Considerations  Dicopanol FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 13.0926896126477, "bm25_max": 13.0926896126477, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "Dosage Forms Considerations  Deprizine FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "gabapentin-drug-information", "bm25_top3": 13.005352575843531, "bm25_max": 13.005352575843531, "bge_top3": null, "bge_max": null, "title": "Gabapentin: Drug information", "rep_snippet": "Dosage Forms Considerations  Gralise is the extended release formulation.  Fanatrex FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions.…"}, {"doc_id": "tramadol-drug-information", "bm25_top3": 10.228201057882096, "bm25_max": 10.228201057882096, "bge_top3": null, "bge_max": null, "title": "Tramadol: Drug information", "rep_snippet": "Dosage Forms Considerations  ConZip extended release capsules are formulated as a biphasic product, providing immediate and extended release components:  100 mg: 25 mg (immediate release) and 75 mg (extended release)  20…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": 10.185001800915266, "bm25_max": 10.185001800915266, "bge_top3": null, "bge_max": null, "title": "Oseltamivir: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Tamiflu may be confused with Tambocor, Thera-Flu  Other safety concerns:  Oseltamivir (Tamiflu) oral suspension is available in a 6 mg/mL concentration. Instructi…"}, {"doc_id": "baclofen-drug-information", "bm25_top3": 9.869360960508558, "bm25_max": 9.869360960508558, "bge_top3": null, "bge_max": null, "title": "Baclofen: Drug information", "rep_snippet": "Dosage Forms Considerations  EnovaRX-Baclofen and Equipto-Baclofen creams are compounded from kits. Refer to manufacturer’s labeling for compounding instructions.  First-Baclofen suspension is a compounding kit. Refer to…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 9.233439838539425, "bm25_max": 9.233439838539425, "bge_top3": null, "bge_max": null, "title": "Omeprazole: Drug information", "rep_snippet": "Administration  Administer 30 to 60 minutes before meals; may take with antacids. If administering twice daily, first dose should be administered before breakfast and the second dose before dinner (ACG [Katz 2013]; Hersc…"}, {"doc_id": "candesartan-drug-information", "bm25_top3": 8.956476415371426, "bm25_max": 8.956476415371426, "bge_top3": null, "bge_max": null, "title": "Candesartan: Drug information", "rep_snippet": "Administration  Administer without regard to meals. An oral suspension may be prepared for children unable to swallow tablets (refer to Extemporaneously Prepared information)."}, {"doc_id": "axitinib-drug-information", "bm25_top3": 8.811905053956004, "bm25_max": 8.811905053956004, "bge_top3": null, "bge_max": null, "title": "Axitinib: Drug information", "rep_snippet": "Administration  Oral: Swallow tablet whole with a glass of water. May be taken with or without food. If a dose is missed or vomited, do not make up; resume dosing with the next scheduled dose. A suspension may be prepare…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 8.657092604469348, "bm25_max": 8.657092604469348, "bge_top3": null, "bge_max": null, "title": "Lansoprazole: Drug information", "rep_snippet": "Dosage Forms Considerations  First-Lansoprazole suspension is a compounding kit. Refer to manufacturer’s labeling for compounding instructions."}, {"doc_id": "naproxen-drug-information", "bm25_top3": 8.495106451739737, "bm25_max": 8.495106451739737, "bge_top3": null, "bge_max": null, "title": "Naproxen: Drug information", "rep_snippet": "Administration  Oral: Administer with food, milk, or antacids to decrease GI adverse effects.  Suspension: Shake suspension well before administration.  Tablet, delayed or extended release: Swallow tablet whole; do not b…"}, {"doc_id": "simethicone-drug-information", "bm25_top3": 8.308812347286612, "bm25_max": 8.308812347286612, "bge_top3": 0.669575572013855, "bge_max": 0.669575572013855, "title": "Simethicone: Drug information", "rep_snippet": "Administration  Oral: Chewable tablet: Chew thoroughly and swallow  Oral suspension (drops): Shake well before using; may mix with 30 mL water, infant formula, or other liquids. Fill enclosed dropper to recommended dosag…"}, {"doc_id": "sevelamer-drug-information", "bm25_top3": 7.434291877268521, "bm25_max": 7.434291877268521, "bge_top3": 0.6588980555534363, "bge_max": 0.6588980555534363, "title": "Sevelamer: Drug information", "rep_snippet": "Administration  Administer with meals.  Powder for oral suspension: May prepare an oral suspension in water using the directed amount of water appropriate for the packet size or may premix the entire content of the packe…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 7.311345299559571, "bm25_max": 7.311345299559571, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Suspension: Shake well for at least 30 seconds to ensure suspension is mixed thoroughly (suspension is viscous). Measure dose with an oral dosing syringe (a 1 mL and a 5 mL oral dosing syringe are supplied by the manufac…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": 7.0765154948260545, "bm25_max": 7.0765154948260545, "bge_top3": null, "bge_max": null, "title": "Aprepitant: Drug information", "rep_snippet": "Administration  IV: Infuse over 30 minutes approximately one-half hour (30 minutes) prior to chemotherapy. Use only non-DEHP tubing for administration. Administration information is for aprepitant IV (Cinvanti); refer to…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": 6.6824169092275145, "bm25_max": 6.6824169092275145, "bge_top3": null, "bge_max": null, "title": "Clozapine: Drug information", "rep_snippet": "Administration  Administer without regard to food. Total daily dose may be divided into uneven doses with larger dose administered at bedtime.  Orally disintegrating tablet: Remove from foil blister by peeling apart (do…"}, {"doc_id": "deferasirox-drug-information", "bm25_top3": 6.453312084856677, "bm25_max": 6.453312084856677, "bge_top3": null, "bge_max": null, "title": "Deferasirox: Drug information", "rep_snippet": "Tablets for suspension (Exjade): Administer tablets by making an oral suspension; do not chew or swallow tablets whole. Completely disperse tablets in water, orange juice, or apple juice (use 105 mL for total doses <1 g;…"}, {"doc_id": "cefuroxime-drug-information", "bm25_top3": 6.281420119462588, "bm25_max": 6.281420119462588, "bge_top3": null, "bge_max": null, "title": "Cefuroxime: Drug information", "rep_snippet": "Administration  Oral suspension: Administer with food. Shake well before use.  Oral tablet: May administer with or without food. Swallow tablet whole (crushed tablet has strong, persistent, bitter taste).  IM: Inject dee…"}, {"doc_id": "nitisinone-drug-information", "bm25_top3": 5.744451021124188, "bm25_max": 5.744451021124188, "bge_top3": null, "bge_max": null, "title": "Nitisinone: Drug information", "rep_snippet": "Administration  Capsules: Administer at least 1 hour prior to, or 2 hours after a meal. Capsules may be opened and contents suspended in a small quantity of water, formula, or apple sauce; administer immediately.  Suspen…"}, {"doc_id": "hydrogen-peroxide-drug-information", "bm25_top3": 4.682168700746601, "bm25_max": 4.682168700746601, "bge_top3": null, "bge_max": null, "title": "Hydrogen peroxide: Drug information", "rep_snippet": "Removal of oral secretions: Solution (3%): Mix with equal amounts of water; swish around mouth over affected area for at least 1 minute, then spit out.  Mouth, gum, or dental irritation:  Oral rinse (1.4%): Swish around…"}, {"doc_id": "amphotericin-b-deoxycholate-conventional-drug-information", "bm25_top3": 4.450135569997165, "bm25_max": 4.450135569997165, "bge_top3": null, "bge_max": null, "title": "Amphotericin B deoxycholate (conventional): Drug information", "rep_snippet": "Use: Off-Label  Candidiasis, endophthalmitis (intravitreal); Candidiasis, esophageal (non-HIV-infected patients); Candidiasis, esophageal, in HIV-infected patients (adolescents and adults); Candidiasis, esophageal, in HI…"}, {"doc_id": "ketoconazole-topical-drug-information", "bm25_top3": 4.447942029595277, "bm25_max": 4.447942029595277, "bge_top3": null, "bge_max": null, "title": "Ketoconazole (topical): Drug information", "rep_snippet": "Use: Off-Label  Cream: Susceptible fungal infections in the oral cavity including candidiasis, oral thrush, and chronic mucocutaneous candidiasis"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": 4.206412455430556, "bm25_max": 4.206412455430556, "bge_top3": null, "bge_max": null, "title": "Posaconazole: Drug information", "rep_snippet": "Use  Prophylaxis of invasive Aspergillus and Candida infections: Suspension and delayed-release tablets (13 years and older) and injection (18 years and older): Prophylaxis of invasive Aspergillus and Candida infections…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 3.813301692582044, "bm25_max": 3.813301692582044, "bge_top3": null, "bge_max": null, "title": "Itraconazole: Drug information", "rep_snippet": "Oropharyngeal/Esophageal candidiasis (oral solution): Treatment of oropharyngeal and esophageal candidiasis  Canadian labeling: Oral capsules: Additional indications (not in US labeling):  Candidiasis, oral and/or esopha…"}, {"doc_id": "rufinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6817774176597595, "bge_max": 0.6817774176597595, "title": "Rufinamide: Drug information", "rep_snippet": "Administration  Oral: Administer with food. Tablets may be swallowed whole, split in half, or crushed. Oral suspension should be administered using the provided adapter and calibrated oral syringe; shake well before each…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6654699444770813, "bge_max": 0.6654699444770813, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Administration  Administer prepared suspension orally. Not to be taken in dry form. Suspension should not be sipped or held in mouth for prolonged periods (may cause tooth discoloration or enamel decay). Administration a…"}, {"doc_id": "miconazole-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6645995378494263, "bge_max": 0.6645995378494263, "title": "Miconazole (oral): Drug information", "rep_snippet": "Dosing: Adult  Oropharyngeal candidiasis: Buccal tablet: 50 mg (1 tablet) applied to the upper gum region once daily for 14 days"}, {"doc_id": "antiseptic-mouthwash-dental-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6640010476112366, "bge_max": 0.6640010476112366, "title": "Antiseptic mouthwash (dental): Drug information", "rep_snippet": "Dosing: Adult  Plaque/gingivitis prevention: Oral: Rinse full strength for 30 seconds with 20 mL morning and night"}, {"doc_id": "buspirone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6626160144805908, "bge_max": 0.6626160144805908, "title": "Buspirone: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food, but must be consistent."}, {"doc_id": "amiloride-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6617281436920166, "bge_max": 0.6617281436920166, "title": "Amiloride and hydrochlorothiazide: Drug information", "rep_snippet": "Administration  Oral: Administer with food."}, {"doc_id": "tenofovir-alafenamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6617281436920166, "bge_max": 0.6617281436920166, "title": "Tenofovir alafenamide: Drug information", "rep_snippet": "Administration  Oral: Administer with food."}, {"doc_id": "tiagabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6617281436920166, "bge_max": 0.6617281436920166, "title": "Tiagabine: Drug information", "rep_snippet": "Administration  Oral: Administer with food."}, {"doc_id": "glycerin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6583038568496704, "bge_max": 0.6583038568496704, "title": "Glycerin: Drug information", "rep_snippet": "Dosing: Adult  Constipation: Rectal: One adult suppository once daily as needed or as directed  Mouth/throat irritation: Oral: Apply a one-inch strip directly to tongue and oral cavity as needed"}, {"doc_id": "nitrofurantoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6569933891296387, "bge_max": 0.6569933891296387, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Dosing: Adult  Cystitis, acute uncomplicated, treatment:  Nitrofurantoin monohydrate/macrocrystals (Macrobid): Oral: 100 mg twice daily for 5 days (Gupta 2011; Gupta 2007).  Nitrofurantoin macrocrystals (Furadantin, Macr…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Eplerenone: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "rifaximin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Rifaximin: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "daclatasvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Daclatasvir: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "dofetilide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Dofetilide: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "cariprazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Cariprazine: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "bictegravir-emtricitabine-and-tenofovir-alafenamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Bictegravir, emtricitabine, and tenofovir alafenamide: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "ledipasvir-and-sofosbuvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Ledipasvir and sofosbuvir: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "olmesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Olmesartan and hydrochlorothiazide: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "brexpiprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656596839427948, "bge_max": 0.656596839427948, "title": "Brexpiprazole: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "flavocoxid-united-states-note-fda-has-issued-a-warning-against-use-of-this-product-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6559287905693054, "bge_max": 0.6559287905693054, "title": "Flavocoxid (United States – Note: FDA has issued a warning against use of this product): Drug information", "rep_snippet": "Administration  Oral: Administer with or without meals."}, {"doc_id": "vigabatrin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.654829740524292, "bge_max": 0.654829740524292, "title": "Vigabatrin: Drug information", "rep_snippet": "Administration  Administer without regard to meals.  Oral solution: Mix with water immediately prior to administration. Administer using an oral syringe (provided)."}, {"doc_id": "raltegravir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6540778875350952, "bge_max": 0.6540778875350952, "title": "Raltegravir: Drug information", "rep_snippet": "Administration  May be administered without regard to meals.  Chewable tablets: May be chewed or swallowed whole; the 100 mg chewable tablet may be divided into equal halves.  Film-coated tablets: Must be swallowed whole…"}, {"doc_id": "nevirapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6512824892997742, "bge_max": 0.6512824892997742, "title": "Nevirapine: Drug information", "rep_snippet": "Administration  Oral: May be administered with or without food; may be administered with an antacid or didanosine. Shake suspension gently prior to administration; the use of an oral dosing syringe is recommended, especi…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6505694389343262, "bge_max": 0.6505694389343262, "title": "Phenytoin: Drug information", "rep_snippet": "Medication Guide and/or Vaccine Information Statement (VIS)  An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:  Dilantin che…"}, {"doc_id": "chlorzoxazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6502110362052917, "bge_max": 0.6502110362052917, "title": "Chlorzoxazone: Drug information", "rep_snippet": "Administration  Administer orally."}, {"doc_id": "magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6502110362052917, "bge_max": 0.6502110362052917, "title": "Magnesium carbonate: Drug information", "rep_snippet": "Administration  Administer orally."}, {"doc_id": "methyltestosterone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6502110362052917, "bge_max": 0.6502110362052917, "title": "Methyltestosterone: Drug information", "rep_snippet": "Administration  Administer orally."}, {"doc_id": "clidinium-and-chlordiazepoxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6501110196113586, "bge_max": 0.6501110196113586, "title": "Clidinium and chlordiazepoxide: Drug information", "rep_snippet": "Administration  Oral: Administer before meals and at bedtime."}, {"doc_id": "pirfenidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6500189304351807, "bge_max": 0.6500189304351807, "title": "Pirfenidone: Drug information", "rep_snippet": "Administration  Oral: Administer with food at the same time each day."}, {"doc_id": "cabergoline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6481369733810425, "bge_max": 0.6481369733810425, "title": "Cabergoline: Drug information", "rep_snippet": "Administration  Oral: Administer with meals (may increase tolerability)."}, {"doc_id": "osimertinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6477474570274353, "bge_max": 0.6477474570274353, "title": "Osimertinib: Drug information", "rep_snippet": "Administration  Oral: May be administered with or without food.  For patients who have difficulty swallowing tablets, disperse tablet in 60 mL of noncarbonated water (only), stir until tablet is dispersed into small piec…"}, {"doc_id": "megestrol-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6476010084152222, "bge_max": 0.6476010084152222, "title": "Megestrol acetate: Drug information", "rep_snippet": "Administration  Oral: Shake suspension well before use.  The 625 mg/5 mL suspension may be administered without regard to meals."}, {"doc_id": "trimebutine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6469796299934387, "bge_max": 0.6469796299934387, "title": "Trimebutine (United States: Not available): Drug information", "rep_snippet": "Administration  Oral: Administer before meals."}, {"doc_id": "pyrimethamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6465879678726196, "bge_max": 0.6465879678726196, "title": "Pyrimethamine: Drug information", "rep_snippet": "Administration  Oral: Administer with meals to minimize GI distress."}, {"doc_id": "iodoquinol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6462521553039551, "bge_max": 0.6462521553039551, "title": "Iodoquinol: Drug information", "rep_snippet": "Administration  Oral: Administer after meals. Complete full course of therapy."}, {"doc_id": "rilpivirine-emtricitabine-and-tenofovir-alafenamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6459852457046509, "bge_max": 0.6459852457046509, "title": "Rilpivirine, emtricitabine, and tenofovir alafenamide: Drug information", "rep_snippet": "Administration  Oral: Administer with a meal."}, {"doc_id": "acetaminophen-paracetamol-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6447296142578125, "bge_max": 0.6447296142578125, "title": "Acetaminophen (paracetamol) and codeine: Drug information", "rep_snippet": "Administration  Oral solution or suspension: Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon or tablespoon to measure dose (overdosage may occur).…"}, {"doc_id": "potassium-citrate-and-citric-acid-powder-or-solution-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6439257264137268, "bge_max": 0.6439257264137268, "title": "Potassium citrate and citric acid (powder or solution): Drug information", "rep_snippet": "Administration  Oral: Administer after meals (to avoid laxative effect) and at bedtime. Administer additional water after the dose, if needed."}]}
{"qid": "Q22_noise", "query": "Thrush — how to dose nystatin oral susp and exactly how to use it?", "base_qid": "Q22", "variant_type": "noise", "candidates": [{"doc_id": "nystatin-topical-drug-information", "bm25_top3": 23.50881028300243, "bm25_max": 27.04277991697601, "bge_top3": 0.6009742021560669, "bge_max": 0.6009742021560669, "title": "Nystatin (topical): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if nystatin is excreted in breast milk; however, absorption following oral use is poor and nystatin is not absorbed following application to mucous membranes or intact skin.…"}, {"doc_id": "nystatin-oral-drug-information", "bm25_top3": 20.09772989394239, "bm25_max": 24.29551043082333, "bge_top3": 0.640070637067159, "bge_max": 0.6603145599365234, "title": "Nystatin (oral): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nystatin (oral): Pediatric drug information\")  Oral candidiasis:  Suspension:  Premature infants: 100,000 units 4 times/day; paint suspension into recesses of the mouth…"}, {"doc_id": "five-grass-pollen-sublingual-tablet-drug-information", "bm25_top3": 19.399588040273496, "bm25_max": 19.399588040273496, "bge_top3": null, "bge_max": null, "title": "Five-grass pollen sublingual tablet: Drug information", "rep_snippet": "• Appropriate use: [US Boxed Warning]: Use may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators due to concomitant drug therapy. The effect of epinephrine may be potentiated…"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 19.294069725435055, "bm25_max": 19.294069725435055, "bge_top3": null, "bge_max": null, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Administration  Following administration, rinse mouth with water after use (do not swallow) to reduce risk of oral candidiasis.  Advair Diskus: Dry powder inhaler: After removing from box and foil pouch, write the “Pouch…"}, {"doc_id": "mifepristone-and-misoprostol-united-states-not-available-drug-information", "bm25_top3": 17.572217030717322, "bm25_max": 17.572217030717322, "bge_top3": null, "bge_max": null, "title": "Mifepristone and misoprostol (United States: Not available): Drug information", "rep_snippet": "Prescribing and Access Restrictions  Prior to initiating therapy, patients are required to sign a consent form and both the patient and physician must sign a patient information card. Physicians are also required to comp…"}, {"doc_id": "ammonium-lactate-topical-drug-information", "bm25_top3": 17.399779614618446, "bm25_max": 17.399779614618446, "bge_top3": null, "bge_max": null, "title": "Ammonium lactate (topical): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known how this medication affects normal levels of lactic acid in human milk. Because studies have not been done in nursing women, use with caution when needed."}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 17.279961442081902, "bm25_max": 17.279961442081902, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Mercaptopurine is the active metabolite of azathioprine. Following administration of azathioprine, mercaptopurine can be detected in breast milk (Gardiner 2006). It is not known if/how much…"}, {"doc_id": "ketoconazole-topical-drug-information", "bm25_top3": 12.823434791784548, "bm25_max": 16.835710334069816, "bge_top3": null, "bge_max": null, "title": "Ketoconazole (topical): Drug information", "rep_snippet": "US labeling: Tinea corporis, cruris: 2 weeks; tinea pedis: 6 weeks.  Canadian labeling: Tinea corporis: 3 to 4 weeks; tinea cruris: 2 to 4 weeks; tinea pedis: 4 to 6 weeks.  Tinea versicolor: Topical:  Cream: Apply once…"}, {"doc_id": "fluticasone-and-vilanterol-drug-information", "bm25_top3": 15.335676692859206, "bm25_max": 15.335676692859206, "bge_top3": null, "bge_max": null, "title": "Fluticasone and vilanterol: Drug information", "rep_snippet": "• Lower respiratory infections: An increase in the incidence of pneumonia and other lower respiratory tract infections (some fatal) have been reported in patients with COPD following use; monitor COPD patients closely si…"}, {"doc_id": "metronidazole-and-nystatin-united-states-not-available-drug-information", "bm25_top3": 13.251003191681006, "bm25_max": 14.708430092652891, "bge_top3": null, "bge_max": null, "title": "Metronidazole and nystatin (United States: Not available): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to metronidazole, nystatin, imidazoles, or any component of the formulation. Combined treatment with oral metronidazole should be avoided in active neurological disorders or in patient…"}, {"doc_id": "nystatin-and-triamcinolone-drug-information", "bm25_top3": 13.649248593490913, "bm25_max": 14.582622572562936, "bge_top3": null, "bge_max": null, "title": "Nystatin and triamcinolone: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Cream, External: Nystatin 100,000 units and triamcinolone acetonide 0.1% (15 g, 30 g,…"}, {"doc_id": "activated-charcoal-drug-information", "bm25_top3": 14.32908591074791, "bm25_max": 14.32908591074791, "bge_top3": null, "bge_max": null, "title": "Activated charcoal: Drug information", "rep_snippet": "Brand Names: Canada  Charac-25 [OTC];  Charac-50 [OTC];  Charactol-25 [OTC];  Charactol-50 [OTC];  Charcodote Susp [OTC];  Charcodote TFS [OTC];  Charcodote-Aqueous Sus;  Premium Activated Charcoal [OTC]"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 13.99603719803462, "bm25_max": 13.99603719803462, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 13.99603719803462, "bm25_max": 13.99603719803462, "bge_top3": null, "bge_max": null, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 13.80510151626719, "bm25_max": 13.80510151626719, "bge_top3": null, "bge_max": null, "title": "Clofazimine (United States: Available via National Hansen’s Disease Program and FDA investigational drug [IND] protocol only): Drug information", "rep_snippet": "International: No longer available commercially. In nations where a national leprosy elimination program exists, the Ministries of Health make an official request to the World Health Organization (WHO) for clofazimine. I…"}, {"doc_id": "triamcinolone-neomycin-gramicidin-and-nystatin-topical-united-states-not-available-drug-information", "bm25_top3": 13.604390713289463, "bm25_max": 13.604390713289463, "bge_top3": null, "bge_max": null, "title": "Triamcinolone, neomycin, gramicidin, and nystatin (topical) (United States: Not available): Drug information", "rep_snippet": "Breast-Feeding Considerations  See individual monographs for triamcinolone, neomycin, and nystatin."}, {"doc_id": "sacrosidase-drug-information", "bm25_top3": 12.46787141356468, "bm25_max": 12.46787141356468, "bge_top3": null, "bge_max": null, "title": "Sacrosidase: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Sucraid® is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to http://www.sucraid.net/how-to-order-sucraid or call 1-866-740-2743."}, {"doc_id": "amphotericin-b-deoxycholate-conventional-drug-information", "bm25_top3": 11.659941363944128, "bm25_max": 11.659941363944128, "bge_top3": null, "bge_max": null, "title": "Amphotericin B deoxycholate (conventional): Drug information", "rep_snippet": "ALERT: US Boxed Warning  Appropriate use:  This drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; it should not be used to treat noninvasive form…"}, {"doc_id": "uridine-triacetate-drug-information", "bm25_top3": 11.615194756722435, "bm25_max": 11.615194756722435, "bge_top3": 0.5928694605827332, "bge_max": 0.5928694605827332, "title": "Uridine triacetate: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Fluorouracil accidental overdose/overexposure: Uridine triacetate (formerly called vistonuridine) is available through select specialty pharmacies. Procurement information is availabl…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 11.60248179779672, "bm25_max": 11.60248179779672, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Korlym is only available through a restricted access program. For prescriber registration and patient enrollment forms, please refer to http://www.korlym.com/hcp/how-to-prescribe-korl…"}, {"doc_id": "lutropin-alfa-united-states-not-available-drug-information", "bm25_top3": 10.741165720897225, "bm25_max": 10.741165720897225, "bge_top3": null, "bge_max": null, "title": "Lutropin alfa (United States: Not available): Drug information", "rep_snippet": "Administration  SubQ: Administer in the stomach or thigh; rotate injection sites. Do not shake solution; allow any bubbles to settle prior to administration. Contents of lutropin alfa vial may be mixed in the same syring…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 9.481422739492434, "bm25_max": 9.481422739492434, "bge_top3": null, "bge_max": null, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "The highest average milk concentration occurred 2 to 4 hours after a single oral maternal dose; the half-life in breast milk was ~9 to 10 hours (Erickson 1982). Metronidazole and its active metabolite can be detected in…"}, {"doc_id": "house-dust-mite-sublingual-tablet-drug-information", "bm25_top3": 8.906864273247827, "bm25_max": 8.906864273247827, "bge_top3": null, "bge_max": null, "title": "House dust mite sublingual tablet: Drug information", "rep_snippet": "• Experienced health care provider: Should be administered under the supervision of healthcare providers experienced in the diagnosis and treatment of allergic diseases.  • Monitoring: [US Boxed Warning]: Monitor all pat…"}, {"doc_id": "felbamate-drug-information", "bm25_top3": 8.17008568291019, "bm25_max": 8.17008568291019, "bge_top3": null, "bge_max": null, "title": "Felbamate: Drug information", "rep_snippet": "Treatment with felbamate should be initiated only in individuals without active liver disease and with normal baseline serum transaminases. It has not been proved that periodic serum transaminase testing will prevent ser…"}, {"doc_id": "timothy-grass-pollen-sublingual-tablet-drug-information", "bm25_top3": 7.81042202422973, "bm25_max": 7.81042202422973, "bge_top3": null, "bge_max": null, "title": "Timothy grass pollen sublingual tablet: Drug information", "rep_snippet": "• Appropriate use: [US Boxed Warning]: Use may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators due to concomitant drug therapy. The effect of epinephrine may be potentiated…"}, {"doc_id": "ragweed-pollen-sublingual-tablet-drug-information", "bm25_top3": 7.714996902653013, "bm25_max": 7.714996902653013, "bge_top3": null, "bge_max": null, "title": "Ragweed pollen sublingual tablet: Drug information", "rep_snippet": "• Appropriate use: [US Boxed Warning}: Use may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators due to concomitant drug therapy. The effect of epinephrine may be potentiated…"}, {"doc_id": "lindane-drug-information", "bm25_top3": 7.322667707374887, "bm25_max": 7.579350402081353, "bge_top3": null, "bge_max": null, "title": "Lindane: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Appropriate use:  Only use lindane in patients who cannot tolerate or have failed first-line treatment with safer medications for the treatment of scabies. Instruct patients on the proper use of…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": 5.475767229765534, "bm25_max": 5.475767229765534, "bge_top3": null, "bge_max": null, "title": "Nilotinib: Drug information", "rep_snippet": "Special Alerts  Nilotinib Treatment Discontinuation  December 2017  The FDA has updated the product label for Novartis' Tasigna (nilotinib) oral capsules to include information on how to discontinue the drug in certain p…"}, {"doc_id": "glucagon-drug-information", "bm25_top3": 5.431539783590338, "bm25_max": 5.431539783590338, "bge_top3": null, "bge_max": null, "title": "Glucagon: Drug information", "rep_snippet": "Use  Diagnostic aid: As a diagnostic aid during radiologic examinations to temporarily inhibit movement of the GI tract in adults.  Hypoglycemia: Treatment of severe hypoglycemia in pediatric and adult patients. Note: Th…"}, {"doc_id": "esmolol-drug-information", "bm25_top3": 5.2826984413240865, "bm25_max": 5.2826984413240865, "bge_top3": null, "bge_max": null, "title": "Esmolol: Drug information", "rep_snippet": "Administration  IV: Loading doses may be administered over 30 seconds to 1 minute depending on how urgent the need for effect. Infusion into small veins or through a butterfly catheter should be avoided (can cause thromb…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": 3.4331164565982917, "bm25_max": 3.4331164565982917, "bge_top3": null, "bge_max": null, "title": "Phenytoin: Drug information", "rep_snippet": "Vitamin B: Phenytoin use has been associated with low serum concentrations of vitamin B2 (riboflavin), B6 (pyridoxine) and B12 (cyanocobalamin), which may contribute to hyperhomocysteinemia. Hyperhomocysteinemia may cont…"}, {"doc_id": "fibrin-sealant-kit-drug-information", "bm25_top3": 3.2240505718128993, "bm25_max": 3.2240505718128993, "bge_top3": null, "bge_max": null, "title": "Fibrin sealant kit: Drug information", "rep_snippet": "Evarrest: For topical use only; apply to surface of bleeding site only. Prior to applying, remove excess blood or fluid from the site of application to improve visibility. The anatomic location and surface area of the bl…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 3.007968256590848, "bm25_max": 3.007968256590848, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Breast-Feeding Considerations  Cefdinir was not detectable in breast milk following a single cefdinir 600 mg dose. In general, if antibiotics are present in breast milk, nondose-related modification of bowel flora may oc…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 2.996037198034619, "bm25_max": 2.996037198034619, "bge_top3": null, "bge_max": null, "title": "Clarithromycin: Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "cetylpyridinium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6324962377548218, "bge_max": 0.6324962377548218, "title": "Cetylpyridinium: Drug information", "rep_snippet": "Dosing: Adult  Antiseptic (OTC labeling): Oral: Swish 20 mL thoroughly between teeth for 30 seconds then spit; use twice daily; may be used before or after brushing; do not swallow."}, {"doc_id": "artificial-saliva-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6239016056060791, "bge_max": 0.6239016056060791, "title": "Artificial saliva: Drug information", "rep_snippet": "Dosing: Adult  Mucositis (due to high-dose chemotherapy or radiation therapy): Oral:  Caphosol, NeutraSal: Swish and spit 4 to 10 doses daily (use for the duration of chemo- or radiation therapy).  SalivaMax, SalivateRx:…"}, {"doc_id": "methocarbamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6231918334960938, "bge_max": 0.6231918334960938, "title": "Methocarbamol: Drug information", "rep_snippet": "Dosing: Adult  Muscle spasm:  Oral: 1.5 g 4 times/day for 2-3 days (up to 8 g/day may be given in severe conditions), then decrease to 4-4.5 g/day in 3-6 divided doses  IM, IV: Initial: 1 g; may repeat every 8 hours if o…"}, {"doc_id": "tizanidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6215073466300964, "bge_max": 0.6215073466300964, "title": "Tizanidine: Drug information", "rep_snippet": "Dosing: Adult  Spasticity: Oral: Initial: 2 mg up to 3 times daily (at 6- to 8-hour intervals) as needed; may titrate to optimal effect in 2-4 mg increments per dose (with a minimum of 1-4 days between dose increases); m…"}, {"doc_id": "nitrofurantoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6051547527313232, "bge_max": 0.6191039085388184, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Dosing: Adult  Cystitis, acute uncomplicated, treatment:  Nitrofurantoin monohydrate/macrocrystals (Macrobid): Oral: 100 mg twice daily for 5 days (Gupta 2011; Gupta 2007).  Nitrofurantoin macrocrystals (Furadantin, Macr…"}, {"doc_id": "tiopronin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6088130176067352, "bge_max": 0.6186343431472778, "title": "Tiopronin: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosage should be adjusted to reduce urinary cystine level to below the solubility limit (generally <250 mg/L).  Prevention of nephrolithiasis (cystine): Oral: Initial: 800 mg/day in 3 divided doses;…"}, {"doc_id": "nabiximols-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6035328209400177, "bge_max": 0.6165769100189209, "title": "Nabiximols (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Spasticity or neuropathic pain associated with multiple sclerosis (MS), cancer pain: Buccal spray:  Initial: One spray in the morning and one spray in the afternoon or evening (maximum initial dose: 2 spra…"}, {"doc_id": "tetracaine-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.609817624092102, "bge_max": 0.609817624092102, "title": "Tetracaine (topical): Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines:  Topical anesthetic: Apply thin layer to affected area 3 to 4 times daily  Product-specific dosing:  Numfast Tetracaine Green: Apply 1 to 2 g to affected area; wait 12 to 60 minu…"}, {"doc_id": "nitroglycerin-glyceryl-trinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6003550887107849, "bge_max": 0.6071144938468933, "title": "Nitroglycerin (glyceryl trinitrate): Drug information", "rep_snippet": "Manufacturer's labeling: 1 to 2 sprays onto or under tongue approximately every 5 minutes for maximum of 3 sprays in 15 minutes, may also be used prophylactically 5 to 10 minutes prior to activities which may provoke an…"}, {"doc_id": "glycerin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6070913076400757, "bge_max": 0.6070913076400757, "title": "Glycerin: Drug information", "rep_snippet": "Dosing: Adult  Constipation: Rectal: One adult suppository once daily as needed or as directed  Mouth/throat irritation: Oral: Apply a one-inch strip directly to tongue and oral cavity as needed"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6062940955162048, "bge_max": 0.6062940955162048, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Nephropathic cystinosis: Oral: Note: Begin therapy as soon as the diagnosis of nephropathic cystinosis has been confirmed.  Immediate release (Cystagon):  Initial: Initiate therapy with 1/6 to 1/4 of maint…"}, {"doc_id": "dicloxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6048245429992676, "bge_max": 0.6048245429992676, "title": "Dicloxacillin: Drug information", "rep_snippet": "Administration  Oral: Administer 1 hour before or 2 hours after meals with at least 120 mL of water. Administer around-the-clock to promote less variation in peak and trough serum levels. Should not be administered in th…"}, {"doc_id": "glycerol-phenylbutyrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6043840050697327, "bge_max": 0.6043840050697327, "title": "Glycerol phenylbutyrate: Drug information", "rep_snippet": "Administration  Administer with food. Administer directly into mouth using oral syringe or dosing cup. May be administered via nasogastric or gastronomy tube; use an oral syringe to withdraw the prescribed dosage from bo…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6034756898880005, "bge_max": 0.6034756898880005, "title": "Omeprazole: Drug information", "rep_snippet": "Administration  Administer 30 to 60 minutes before meals; may take with antacids. If administering twice daily, first dose should be administered before breakfast and the second dose before dinner (ACG [Katz 2013]; Hersc…"}, {"doc_id": "nimodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6029496192932129, "bge_max": 0.6029496192932129, "title": "Nimodipine: Drug information", "rep_snippet": "Administration  For enteral administration ONLY. Life-threatening adverse events have occurred when administered parenterally. Administer on an empty stomach at least 1 hour before or 2 hours after meals.  Oral:  US labe…"}, {"doc_id": "miglustat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6028072834014893, "bge_max": 0.6028072834014893, "title": "Miglustat: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Miglustat: Pediatric drug information\")  Niemann-Pick Type C disease (off-label use; Patterson 2012): Oral:  Children <12 years: Limited data available. Note: Therapy i…"}, {"doc_id": "talc-sterile-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.600986659526825, "bge_max": 0.600986659526825, "title": "Talc (sterile): Drug information", "rep_snippet": "Slurry for tube thoracostomy: Shake syringe well prior to administration to redisperse talc and avoid settling. Immediately prior to administration, vent the 10 mL air headspace from each syringe and administer talc susp…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5995790064334869, "bge_max": 0.6002293229103088, "title": "Hyoscyamine: Drug information", "rep_snippet": "Administration  Oral:  Elixir (Hyosyne): Administration prior to meals (~30 to 60 minutes) is recommended (but not required) when used to treat gastrointestinal disorders.  Drops (Hyosyne): Administration prior to meals…"}, {"doc_id": "ruxolitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.599535346031189, "bge_max": 0.599535346031189, "title": "Ruxolitinib: Drug information", "rep_snippet": "Administration  Oral: May be administered orally with or without food. If a dose is missed, return to the usual dosing schedule and do not administer an additional dose.  If unable to ingest tablets, may administer throu…"}, {"doc_id": "naloxegol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5988113880157471, "bge_max": 0.5988113880157471, "title": "Naloxegol: Drug information", "rep_snippet": "Administration  Avoid consumption of grapefruit or grapefruit juice during treatment.  Oral: Administer on an empty stomach at least 1 hour prior to or 2 hours after the first meal of the day. Swallow tablets whole, do n…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5983919501304626, "bge_max": 0.5983919501304626, "title": "Amoxicillin: Drug information", "rep_snippet": "Administration  Oral: Administer around-the-clock to promote less variation in peak and trough serum levels.  Extended release: Administer within 1 hour of finishing a meal; do not chew or crush tablet.  Suspension: Shak…"}, {"doc_id": "glycopyrrolate-glycopyrronium-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5976024270057678, "bge_max": 0.5976024270057678, "title": "Glycopyrrolate (glycopyrronium) (systemic): Drug information", "rep_snippet": "Administration  IM: May administer undiluted.  IV: May be administered IV without dilution or may dilute in a compatible solution. In perioperative setting, usually administered over 1 to 2 minutes (eg, in adults: 0.2 mg…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5946183800697327, "bge_max": 0.5946183800697327, "title": "Ritonavir: Drug information", "rep_snippet": "Infants >1 month and Children: Oral: Initiate dose at 250 mg/m2/dose twice daily; titrate dose upward every 2 to 3 days by 50 mg/m2 twice daily to recommended dosage of 350 to 400 mg/m2/dose twice daily (maximum dose: 60…"}, {"doc_id": "pilocarpine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5945789217948914, "bge_max": 0.5945789217948914, "title": "Pilocarpine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Xerostomia: Oral:  Associated with head and neck cancer: Initial: 5 mg 3 times daily; may titrate dose based on response and tolerability; usual dosage range: 15 to 30 mg/day; maximum: 10 mg/dose  Sjögren…"}, {"doc_id": "perampanel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5939778089523315, "bge_max": 0.5939778089523315, "title": "Perampanel: Drug information", "rep_snippet": "Administration  Tablets: Administer at bedtime without regard to food.  Oral suspension: Shake well before every administration. Use a calibrated measuring device to measure dose (a household teaspoon or tablespoon is no…"}, {"doc_id": "cefaclor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5928557515144348, "bge_max": 0.5928557515144348, "title": "Cefaclor: Drug information", "rep_snippet": "Administration  Oral: Administer around-the-clock to promote less variation in peak and trough serum levels.  Capsules and oral suspension: Administer without regard to meals; shake oral suspension well before using  Ext…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5926283597946167, "bge_max": 0.5926283597946167, "title": "Acetylcysteine: Drug information", "rep_snippet": "Inhalation, nebulization (face mask, mouth piece, tracheostomy): Acetylcysteine 10% and 20% solution (dilute 20% solution with sodium chloride or sterile water for inhalation); 10% solution may be used undiluted: 3 to 5…"}, {"doc_id": "fosfomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5924333333969116, "bge_max": 0.5924333333969116, "title": "Fosfomycin: Drug information", "rep_snippet": "Dosing: Adult  Urinary tract infections, uncomplicated: Oral: Females: Single dose of 3 g in 3 to 4 oz (90 to 120 mL) of water  Complicated UTI (off-label): Males: Oral: 3 g every 2 to 3 days for 3 doses (Neuner 2012; Pu…"}, {"doc_id": "nicotine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5919840931892395, "bge_max": 0.5919840931892395, "title": "Nicotine: Drug information", "rep_snippet": "Administration  Gum: Chew slowly until it tingles, then place gum between cheek and gum until tingle is gone; repeat process until most of tingle is gone (~30 minutes). Do not eat or drink 15 minutes before using or whil…"}, {"doc_id": "penicillamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5919770002365112, "bge_max": 0.5919770002365112, "title": "Penicillamine: Drug information", "rep_snippet": "Administration  Oral: Doses ≤500 mg may be administered as a single dose; doses >500 mg should be administered in divided doses. For patients who have difficulty swallowing, the contents of the capsules may be administer…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5918055176734924, "bge_max": 0.5918055176734924, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "Administration  Oral: Administer with meals to help prevent GI upset. May administer antacids between meals to help prevent peptic ulcers.  Oral concentrate: Use only the calibrated dropper provided. Draw dose into dropp…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5912821292877197, "bge_max": 0.5912821292877197, "title": "Rosuvastatin: Drug information", "rep_snippet": "Alternate recommendations: Limited data available: Children and Adolescents (≥8 years and ≥32 kg): Oral: Initial dose: 20 mg once daily; titrate at 6-week intervals to 40 mg once daily. Although higher doses have been us…"}, {"doc_id": "levocetirizine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5911135673522949, "bge_max": 0.5911135673522949, "title": "Levocetirizine: Drug information", "rep_snippet": "Administration  Administer in the evening with or without food. Use an accurate measuring device for the oral solution; a household teaspoon is not an accurate measuring device."}, {"doc_id": "sumatriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5905715227127075, "bge_max": 0.5905715227127075, "title": "Sumatriptan: Drug information", "rep_snippet": "Administration  Administer as soon as symptoms appear.  Intranasal:  Powder: For intranasal administration with the Xsail device only. Remove the clear device cap from the reusable delivery device; remove one 11 mg dispo…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5905675292015076, "bge_max": 0.5905675292015076, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Note: Sequential therapy (IV to oral) may be instituted based on prescriber's discretion.  Acute bacterial rhinosinusitis: Oral, IV:  Manufacturer's labeling: 750 mg every 24 hours for 5 days or 500 mg eve…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.590225100517273, "bge_max": 0.590225100517273, "title": "Diazepam: Drug information", "rep_snippet": "Administration  Oral: Administer with food or water. Dilute or mix oral concentrate with water, juice, soda, applesauce, or pudding before use; measure dose only with calibrated dropper provided.  IV: Administer undilute…"}, {"doc_id": "midazolam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5901458859443665, "bge_max": 0.5901458859443665, "title": "Midazolam: Drug information", "rep_snippet": "Administration  Intranasal (off-label route): Note: Due to the low pH of the solution, burning upon administration is likely to occur. Use of an atomizer, such as the MAD 300 Mucosal Atomizer which attaches to a tubercul…"}, {"doc_id": "trimeprazine-alimemazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5895863175392151, "bge_max": 0.5895863175392151, "title": "Trimeprazine (alimemazine): Drug information", "rep_snippet": "Dosing: Adult  Cough, pruritus: Note: Initiate at low dosage and titrate as needed.  Oral: 2.5 mg to 5 mg twice daily after meals and 5 mg at bedtime or 5 mg to 10 mg once daily at bedtime; for severe pruritus, up to 80…"}, {"doc_id": "vitamin-b3-niacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5895808935165405, "bge_max": 0.5895808935165405, "title": "Vitamin B3 (niacin): Drug information", "rep_snippet": "Administration  Administer with food. To attenuate flushing symptoms, may premedicate with aspirin 30 minutes before dose; avoid ingestion of alcohol, hot or spicy foods/liquids concurrently with niacin. May also use oth…"}, {"doc_id": "phenazopyridine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5895399451255798, "bge_max": 0.5895399451255798, "title": "Phenazopyridine: Drug information", "rep_snippet": "Dosing: Adult  Dysuria, symptomatic relief: Oral:  OTC labeling: Two tablets (190 mg) 3 times daily administered with or after meals for up to 2 days.  Rx labeling: 200 mg 3 times daily after meals for 2 days when used c…"}]}
{"qid": "Q22_spelling", "query": "Oral candiasis — nystatin dose & admin steps.", "base_qid": "Q22", "variant_type": "spelling", "candidates": [{"doc_id": "nystatin-oral-drug-information", "bm25_top3": 17.97645700792904, "bm25_max": 21.066986314077766, "bge_top3": 0.6816399892171224, "bge_max": 0.7306684255599976, "title": "Nystatin (oral): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nystatin (oral): Pediatric drug information\")  Oral candidiasis:  Suspension:  Premature infants: 100,000 units 4 times/day; paint suspension into recesses of the mouth…"}, {"doc_id": "nystatin-topical-drug-information", "bm25_top3": 18.251934631981317, "bm25_max": 20.089674137009453, "bge_top3": 0.620075136423111, "bge_max": 0.6327149868011475, "title": "Nystatin (topical): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nystatin (topical): Pediatric drug information\")  Fungal infections (cutaneous and mucocutaneous): Infants, Children, and Adolescents: Topical: Refer to adult dosing."}, {"doc_id": "nystatin-and-triamcinolone-drug-information", "bm25_top3": 11.127626770112755, "bm25_max": 13.497645873139275, "bge_top3": null, "bge_max": null, "title": "Nystatin and triamcinolone: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Cream, External: Nystatin 100,000 units and triamcinolone acetonide 0.1% (15 g, 30 g,…"}, {"doc_id": "triamcinolone-neomycin-gramicidin-and-nystatin-topical-united-states-not-available-drug-information", "bm25_top3": 10.939328994175423, "bm25_max": 12.517675179899689, "bge_top3": null, "bge_max": null, "title": "Triamcinolone, neomycin, gramicidin, and nystatin (topical) (United States: Not available): Drug information", "rep_snippet": "Breast-Feeding Considerations  See individual monographs for triamcinolone, neomycin, and nystatin."}, {"doc_id": "metronidazole-and-nystatin-united-states-not-available-drug-information", "bm25_top3": 10.582008787174724, "bm25_max": 12.440867070192239, "bge_top3": null, "bge_max": null, "title": "Metronidazole and nystatin (United States: Not available): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to metronidazole, nystatin, imidazoles, or any component of the formulation. Combined treatment with oral metronidazole should be avoided in active neurological disorders or in patient…"}, {"doc_id": "filgrastim-including-biosimilars-of-filgrastim-drug-information", "bm25_top3": 11.051842398832271, "bm25_max": 11.051842398832271, "bge_top3": null, "bge_max": null, "title": "Filgrastim (including biosimilars of filgrastim): Drug information", "rep_snippet": "Acute myeloid leukemia (AML) following induction or consolidation chemotherapy (Neupogen, Zarxio, Grastofil [Canadian product]): SubQ, IV: 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) ac…"}, {"doc_id": "fentanyl-drug-information", "bm25_top3": 10.600164157977193, "bm25_max": 10.600164157977193, "bge_top3": null, "bge_max": null, "title": "Fentanyl: Drug information", "rep_snippet": "Dose titration: If titration required, titrate to a dose that provides adequate analgesia (with tolerable side effects) using the following titration steps: If no relief with 100 mcg dose, increase to 200 mcg dose (using…"}, {"doc_id": "daratumumab-drug-information", "bm25_top3": 8.512966429904248, "bm25_max": 8.512966429904248, "bge_top3": null, "bge_max": null, "title": "Daratumumab: Drug information", "rep_snippet": "Grade 3 (severe) infusion reaction: Once symptoms resolve, consider resuming the infusion at no more than 50% of the rate at which the reaction occurred. If no further reactions are observed, may escalate the infusion ra…"}, {"doc_id": "nitrofurantoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6524772644042969, "bge_max": 0.6524772644042969, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Dosing: Adult  Cystitis, acute uncomplicated, treatment:  Nitrofurantoin monohydrate/macrocrystals (Macrobid): Oral: 100 mg twice daily for 5 days (Gupta 2011; Gupta 2007).  Nitrofurantoin macrocrystals (Furadantin, Macr…"}, {"doc_id": "miconazole-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.644338846206665, "bge_max": 0.644338846206665, "title": "Miconazole (oral): Drug information", "rep_snippet": "Dosing: Adult  Oropharyngeal candidiasis: Buccal tablet: 50 mg (1 tablet) applied to the upper gum region once daily for 14 days"}, {"doc_id": "anidulafungin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.63096022605896, "bge_max": 0.6400126218795776, "title": "Anidulafungin: Drug information", "rep_snippet": "Dosing: Adult  Candidemia, intra-abdominal or peritoneal candidiasis: IV: Initial dose: 200 mg on day 1; subsequent dosing: 100 mg daily; treatment should continue until 14 days after last positive culture. Note: IDSA Ca…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6387761235237122, "bge_max": 0.6387761235237122, "title": "Flucytosine: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage ranges: Oral: 50 to 150 mg/kg/day in divided doses every 6 hours  Candidiasis (off-label dose) (IDSA [Pappas 2016]): Oral:  Central nervous system (eg, meningitis): 25 mg/kg/dose 4 times daily…"}, {"doc_id": "clotrimazole-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6355345845222473, "bge_max": 0.6355345845222473, "title": "Clotrimazole (oral): Drug information", "rep_snippet": "Dosing: Adult  Oropharyngeal candidiasis (prophylaxis): Oral: 10 mg dissolved slowly 3 times daily for the duration of chemotherapy or until steroids are reduced to maintenance levels.  Oropharyngeal candidiasis (treatme…"}, {"doc_id": "artificial-saliva-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6346961259841919, "bge_max": 0.6346961259841919, "title": "Artificial saliva: Drug information", "rep_snippet": "Dosing: Adult  Mucositis (due to high-dose chemotherapy or radiation therapy): Oral:  Caphosol, NeutraSal: Swish and spit 4 to 10 doses daily (use for the duration of chemo- or radiation therapy).  SalivaMax, SalivateRx:…"}, {"doc_id": "albendazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.633292555809021, "bge_max": 0.633292555809021, "title": "Albendazole: Drug information", "rep_snippet": "Dosing: Adult  Neurocysticercosis: Oral:  <60 kg: 15 mg/kg/day in 2 divided doses (maximum: 800 mg/day) for 8 to 30 days  ≥60 kg: 800 mg/day in 2 divided doses for 8 to 30 days  Note: Give concurrent anticonvulsant and c…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6213758885860443, "bge_max": 0.6291666030883789, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Nephropathic cystinosis: Oral: Note: Begin therapy as soon as the diagnosis of nephropathic cystinosis has been confirmed.  Immediate release (Cystagon):  Initial: Initiate therapy with 1/6 to 1/4 of maint…"}, {"doc_id": "caspofungin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6278243660926819, "bge_max": 0.6278243660926819, "title": "Caspofungin: Drug information", "rep_snippet": "Candidiasis, osteoarticular infections (osteomyelitis or septic arthritis) (alternative therapy) (off-label use): IV: 50 to 70 mg daily for at least 14 days, followed by fluconazole (IDSA [Pappas 2016])  Candidiasis, pro…"}, {"doc_id": "tiopronin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6158658266067505, "bge_max": 0.6249240040779114, "title": "Tiopronin: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosage should be adjusted to reduce urinary cystine level to below the solubility limit (generally <250 mg/L).  Prevention of nephrolithiasis (cystine): Oral: Initial: 800 mg/day in 3 divided doses;…"}, {"doc_id": "pentosan-polysulfate-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6244041919708252, "bge_max": 0.6244041919708252, "title": "Pentosan polysulfate sodium: Drug information", "rep_snippet": "Dosing: Adult  Interstitial cystitis: Oral: 100 mg 3 times daily  Note: Patients should be re-evaluated after 3 months; therapy may continue for an additional 3 months if there has been no improvement and if there are no…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6176151931285858, "bge_max": 0.6239976286888123, "title": "Itraconazole: Drug information", "rep_snippet": "Blastomycosis: Manufacturer labeling: Oral capsule: Initial: 200 mg once daily; if no clinical improvement or evidence of progressive infection, may increase dose in increments of 100 mg up to maximum of 400 mg daily. Do…"}, {"doc_id": "oral-mucosal-barrier-gel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6227585077285767, "bge_max": 0.6227585077285767, "title": "Oral mucosal barrier gel: Drug information", "rep_snippet": "Dosing: Adult  Mucosal protection: Oral:  Episil: Apply 1 to 3 pumps to the oral cavity 2 to 3 times daily, or as needed; maximum duration for continuous use: 30 days  Gelclair: Rinse, gargle, and spit 15 mL (1 single-us…"}, {"doc_id": "cefadroxil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.622055172920227, "bge_max": 0.622055172920227, "title": "Cefadroxil: Drug information", "rep_snippet": "Dosing: Adult  Cystitis, acute  uncomplicated (alternative agent): Oral: 500 mg twice daily for 5 to 7 days (Greenberg 1986; Hooton 2018)  Pharyngitis: Oral:  Manufacturer’s labeling: 1 g/day in a single or 2 divided dos…"}, {"doc_id": "tizanidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6192583441734314, "bge_max": 0.6192583441734314, "title": "Tizanidine: Drug information", "rep_snippet": "Dosing: Adult  Spasticity: Oral: Initial: 2 mg up to 3 times daily (at 6- to 8-hour intervals) as needed; may titrate to optimal effect in 2-4 mg increments per dose (with a minimum of 1-4 days between dose increases); m…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6187978982925415, "bge_max": 0.6187978982925415, "title": "Voriconazole: Drug information", "rep_snippet": "Manufacturer's labeling: Maintenance dose: Note: If patient has inadequate clinical response, titrate in 50 mg/dose increments for weight <40 kg and 100 mg/dose increments for weight ≥40 kg  Weight <40 kg: 100 mg every 1…"}, {"doc_id": "desloratadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.617484986782074, "bge_max": 0.617484986782074, "title": "Desloratadine: Drug information", "rep_snippet": "Dosing: Adult  Chronic idiopathic urticaria: Oral: 5 mg once daily. In one clinical trial, the titrated use of higher doses (up to 10 mg twice daily) in adults demonstrated clinical improvement (Staevska 2010).  Seasonal…"}, {"doc_id": "miglustat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6159451007843018, "bge_max": 0.6159451007843018, "title": "Miglustat: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Miglustat: Pediatric drug information\")  Niemann-Pick Type C disease (off-label use; Patterson 2012): Oral:  Children <12 years: Limited data available. Note: Therapy i…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6156222820281982, "bge_max": 0.6156222820281982, "title": "Fluconazole: Drug information", "rep_snippet": "Candiduria (asymptomatic), patients undergoing a urologic procedure: Oral: 400 mg once daily (6 mg/kg/day) several days before and after the procedure.  Cystitis (symptomatic): Oral: 200 mg once daily (3 mg/kg/day) for 2…"}, {"doc_id": "antiseptic-mouthwash-dental-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6134927868843079, "bge_max": 0.6134927868843079, "title": "Antiseptic mouthwash (dental): Drug information", "rep_snippet": "Dosing: Adult  Plaque/gingivitis prevention: Oral: Rinse full strength for 30 seconds with 20 mL morning and night"}, {"doc_id": "cromolyn-sodium-cromoglicate-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6126536726951599, "bge_max": 0.6126536726951599, "title": "Cromolyn (sodium cromoglicate) (systemic): Drug information", "rep_snippet": "Dosing: Adult  Systemic mastocytosis: Oral: 200 mg 4 times/day. If control of symptoms is not seen within 2 to 3 weeks, dose may be increased to a maximum 40 mg/kg/day"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6124444007873535, "bge_max": 0.6124444007873535, "title": "Trimethoprim: Drug information", "rep_snippet": "Dosing: Adult  Cystitis (acute uncomplicated), treatment: Oral: 100 mg every 12 hours for 3 days (Gupta 2011)  According to the manufacturer, 200 mg once daily for 10 days may also be used.  Acne vulgaris (alternative th…"}, {"doc_id": "nimodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6096932291984558, "bge_max": 0.6096932291984558, "title": "Nimodipine: Drug information", "rep_snippet": "Administration  For enteral administration ONLY. Life-threatening adverse events have occurred when administered parenterally. Administer on an empty stomach at least 1 hour before or 2 hours after meals.  Oral:  US labe…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6084485054016113, "bge_max": 0.6084485054016113, "title": "Posaconazole: Drug information", "rep_snippet": "Prophylaxis (disseminated candidiasis, immunocompromised host):  Oral:  Suspension: 200 mg 3 times daily; duration of therapy is based on recovery from neutropenia or immunosuppression  Tablets (delayed release): Oral: I…"}, {"doc_id": "tetracaine-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6081027984619141, "bge_max": 0.6081027984619141, "title": "Tetracaine (topical): Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines:  Topical anesthetic: Apply thin layer to affected area 3 to 4 times daily  Product-specific dosing:  Numfast Tetracaine Green: Apply 1 to 2 g to affected area; wait 12 to 60 minu…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6078207492828369, "bge_max": 0.6078207492828369, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Dosing: Adult  Fungal infections (systemic): Oral: 200 mg once daily; may increase to 400 mg once daily if response is insufficient. Continue until active fungal infection is resolved; some infections may require a treat…"}, {"doc_id": "uridine-triacetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.607805073261261, "bge_max": 0.607805073261261, "title": "Uridine triacetate: Drug information", "rep_snippet": "Administration with food: May be mixed in food (ie, 3 to 4 ounces of applesauce, pudding, or yogurt) and administered immediately, followed by drinking at least 120 mL water. Do not chew the granules. Do not save for lat…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6072229743003845, "bge_max": 0.6072229743003845, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Acute otitis media (off-label use): Oral: 30 to 40 mg/kg/day in 3 divided doses for 5 to 10 days. Use with or without concomitant third-generation cephalosporin for failure of initial antibiotic therapy; use with a third…"}, {"doc_id": "nitroglycerin-glyceryl-trinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.606866717338562, "bge_max": 0.606866717338562, "title": "Nitroglycerin (glyceryl trinitrate): Drug information", "rep_snippet": "Administration  IV: Prepare in glass bottles, EXCEL or PAB containers. Adsorption occurs to soft plastic (eg, PVC); use administration sets intended for nitroglycerin. Avoid in-line IV filters that adsorb nitroglycerin.…"}, {"doc_id": "chloral-hydrate-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6067203879356384, "bge_max": 0.6067203879356384, "title": "Chloral hydrate (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Procedural sedation: Oral: 500 to 1,000 mg 30 minutes prior to procedure"}, {"doc_id": "neomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6058238744735718, "bge_max": 0.6058238744735718, "title": "Neomycin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Neomycin: Pediatric drug information\")  Surgical (perioperative) prophylaxis: Children and Adolescents: Oral: 15 mg/kg/dose for 3 doses administered over 10 hours (eg,…"}, {"doc_id": "fidaxomicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6048098206520081, "bge_max": 0.6048098206520081, "title": "Fidaxomicin: Drug information", "rep_snippet": "Dosing: Adult  Treatment of diarrhea due to Clostridium difficile (CDAD): Oral: 200 mg twice daily for 10 days"}, {"doc_id": "micafungin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6045393943786621, "bge_max": 0.6045393943786621, "title": "Micafungin: Drug information", "rep_snippet": "Candidiasis, osteoarticular infections (osteomyelitis or septic arthritis) (alternative therapy) (off-label use): IV: 100 mg daily for at least 14 days, followed by fluconazole therapy (IDSA [Pappas 2016])  Candidiasis,…"}, {"doc_id": "isosorbide-mononitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6044632196426392, "bge_max": 0.6044632196426392, "title": "Isosorbide mononitrate: Drug information", "rep_snippet": "Dosing: Adult  Angina pectoris: Oral: Note: Tolerance to nitrate effects develops with chronic exposure. Dose escalation does not overcome this effect. Tolerance can only be overcome by short periods of nitrate absence f…"}, {"doc_id": "cephalexin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6042701601982117, "bge_max": 0.6042701601982117, "title": "Cephalexin: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: Oral: 250 to 1,000 mg every 6 hours or 500 mg every 12 hours (maximum: 4 g/day)  Indication-specific dosing:  Cellulitis (nonpurulent)/erysipelas, mild (alternative agent): Oral: 500 mg…"}, {"doc_id": "hyoscyamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6038187146186829, "bge_max": 0.6038187146186829, "title": "Hyoscyamine: Drug information", "rep_snippet": "Dosing: Adult  Gastrointestinal disorders:  Oral:  Tablet, dispersible:  Anaspaz, ED-SPAZ, NuLev, Symax FasTab: 0.125 to 0.25 mg every 4 hours or as needed; maximum: 1.5 mg/day  Oscimin: 0.125 to 0.25 mg 3 to 4 times dai…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6028985977172852, "bge_max": 0.6028985977172852, "title": "Aluminum hydroxide and magnesium carbonate: Drug information", "rep_snippet": "Dosing: Adult  Antacid: Oral:  Chewable tablet: Acid Gone Extra Strength, Gaviscon Extra Strength (aluminum hydroxide 160 mg/magnesium carbonate 105 mg): Chew 2 to 4 tablets 4 times daily (maximum: 16 tablets per 24 hour…"}, {"doc_id": "cetylpyridinium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6025919914245605, "bge_max": 0.6025919914245605, "title": "Cetylpyridinium: Drug information", "rep_snippet": "Dosing: Adult  Antiseptic (OTC labeling): Oral: Swish 20 mL thoroughly between teeth for 30 seconds then spit; use twice daily; may be used before or after brushing; do not swallow."}, {"doc_id": "doxycycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6025913953781128, "bge_max": 0.6025913953781128, "title": "Doxycycline: Drug information", "rep_snippet": "Severe malaria, treatment (alternative agent) (off-label use): IV, Oral: 100 mg every 12 hours for 7 days in combination with quinidine gluconate. Note: IV therapy should be administered for at least 24 hours or until or…"}, {"doc_id": "calcium-carbonate-and-magnesium-hydroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.602575957775116, "bge_max": 0.602575957775116, "title": "Calcium carbonate and magnesium hydroxide: Drug information", "rep_snippet": "Dosing: Adult  Antacid: Oral:  Chewable tablet: Calcium carbonate 700 mg/magnesium hydroxide 300 mg: Chew 2 to 4 tablets 4 times daily (maximum: 8 tablets per 24 hours)  Liquid: Calcium carbonate 400 mg/magnesium hydroxi…"}, {"doc_id": "efinaconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6024366021156311, "bge_max": 0.6024366021156311, "title": "Efinaconazole: Drug information", "rep_snippet": "Dosing: Adult  Onychomycosis: Topical: Apply to affected toenail(s) once daily for 48 weeks."}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": -1.0326867288659471, "bm25_max": -1.0326867288659471, "bge_top3": null, "bge_max": null, "title": "Rosuvastatin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Rosuvastatin may be confused with atorvaSTATin, nystatin, pitavastatin"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": -1.0326867288659471, "bm25_max": -1.0326867288659471, "bge_top3": null, "bge_max": null, "title": "Fluvastatin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Fluvastatin may be confused with fluoxetine, nystatin, pitavastatin"}, {"doc_id": "rotavirus-vaccine-drug-information", "bm25_top3": -1.204002092389043, "bm25_max": -1.204002092389043, "bge_top3": null, "bge_max": null, "title": "Rotavirus vaccine: Drug information", "rep_snippet": "Medication Safety Issues  Administration issues:  Rotavirus vaccines (Rotarix and RotaTeq) are only available for ORAL administration. The live oral rotavirus vaccines have been inadvertently administered as an injection…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": -1.4393156107109029, "bm25_max": -1.4393156107109029, "bge_top3": null, "bge_max": null, "title": "Pitavastatin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Pitavastatin may be confused with atorvaSTATin, fluvastatin, lovastatin, nystatin, pravastatin, rosuvastatin, simvastatin"}, {"doc_id": "inhaled-insulin-drug-information", "bm25_top3": -1.5114689397554795, "bm25_max": -1.5114689397554795, "bge_top3": null, "bge_max": null, "title": "Inhaled insulin: Drug information", "rep_snippet": "For oral inhalation only. Administer at the beginning of the meal. Remove the amount/strength of cartridges needed for a single dose from packaging; multiple cartridges may be needed to achieve the correct dose. Allow ca…"}, {"doc_id": "aspirin-citric-acid-and-sodium-bicarbonate-drug-information", "bm25_top3": -1.6217008595000273, "bm25_max": -1.6217008595000273, "bge_top3": null, "bge_max": null, "title": "Aspirin, citric acid, and sodium Bicarbonate: Drug information", "rep_snippet": "Administration  Oral: Prior to administration, fully dissolve each dose (2 tablets) in 120 mL of water"}, {"doc_id": "chlorambucil-drug-information", "bm25_top3": -1.7158585344158954, "bm25_max": -1.7158585344158954, "bge_top3": null, "bge_max": null, "title": "Chlorambucil: Drug information", "rep_snippet": "Administration  Oral: May be administered as a single daily dose."}, {"doc_id": "methenamine-and-sodium-acid-phosphate-drug-information", "bm25_top3": -1.7966528907486126, "bm25_max": -1.7966528907486126, "bge_top3": null, "bge_max": null, "title": "Methenamine and sodium acid phosphate: Drug information", "rep_snippet": "Administration  Oral: Administer each dose with a full glass of water."}, {"doc_id": "pravastatin-drug-information", "bm25_top3": -1.9103258629905469, "bm25_max": -1.9103258629905469, "bge_top3": null, "bge_max": null, "title": "Pravastatin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Pravachol may be confused with atorvaSTATin, Prevacid, Prinivil, propranolol  Pravastatin may be confused with nystatin, pitavastatin, prasugrel"}, {"doc_id": "liraglutide-drug-information", "bm25_top3": -2.2476416195010103, "bm25_max": -2.2476416195010103, "bge_top3": null, "bge_max": null, "title": "Liraglutide: Drug information", "rep_snippet": "Medication Safety Issues  Other safety concerns:  Cross-contamination may occur if pens are shared among multiple patients. Steps should be taken to prohibit sharing of pens."}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": -2.5889969853939174, "bm25_max": -2.5889969853939174, "bge_top3": null, "bge_max": null, "title": "Atorvastatin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  AtorvaSTATin may be confused with atoMOXetine, lovastatin, nystatin, pitavastatin, pravastatin, rosuvastatin, simvastatin  Lipitor may be confused with labetalol,…"}, {"doc_id": "glutamine-supplements-drug-information", "bm25_top3": -2.595480170001867, "bm25_max": -2.595480170001867, "bge_top3": null, "bge_max": null, "title": "Glutamine supplements: Drug information", "rep_snippet": "Brand Names: International  Adamin-G (CZ);  An Kai Shu (CN);  Convales (IN);  Diamin (BR);  Glutamin (AR);  Glutapak-10 (MX);  Glutapure (EC);  Glutaven (IT);  Glutrop (ID);  Pure Warrior Powered By Swisse (AU);  Shi Lin…"}, {"doc_id": "semaglutide-drug-information", "bm25_top3": -3.546584299534924, "bm25_max": -3.546584299534924, "bge_top3": null, "bge_max": null, "title": "Semaglutide: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Ozempic may be confused with Ozerlik, international brand name for gatifloxacin [UA].  Other safety concerns:  Cross-contamination may occur if pens are shared am…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": -3.660659559859953, "bm25_max": -3.660659559859953, "bge_top3": null, "bge_max": null, "title": "Simvastatin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Simvastatin may be confused with atorvaSTATin, nystatin, pitavastatin  Zocor may be confused with Cozaar, Lipitor, Zoloft, ZyrTEC  International issues:  Cardin […"}, {"doc_id": "nitric-oxide-drug-information", "bm25_top3": -4.014268222650088, "bm25_max": -4.014268222650088, "bge_top3": null, "bge_max": null, "title": "Nitric oxide: Drug information", "rep_snippet": "Administration  Inhalation: Administration of nitric oxide should be done by a health care professional who has completed a comprehensive training program. INOmax may only be administered using a calibrated INOmax DSIR n…"}, {"doc_id": "insulin-degludec-and-insulin-aspart-drug-information", "bm25_top3": -4.227571681057363, "bm25_max": -4.227571681057363, "bge_top3": null, "bge_max": null, "title": "Insulin degludec and insulin aspart: Drug information", "rep_snippet": "Medication Safety Issues  High-alert medication:  The Institute for Safe Medication Practices (ISMP) includes insulins among its classes of drugs that have a heightened risk of causing significant patient harm when used…"}]}
{"qid": "Q23_abbr+labs", "query": "Seizure maintenance — valproic acid therapeutic trough range, toxicity signs, and monitoring labs.", "base_qid": "Q23", "variant_type": "abbr+labs", "candidates": [{"doc_id": "valproate-drug-information", "bm25_top3": 29.553621792995752, "bm25_max": 32.197314186544304, "bge_top3": 0.7050611674785614, "bge_max": 0.729385256767273, "title": "Valproate: Drug information", "rep_snippet": "Epilepsy: Although seizure control may improve at levels >100 mcg/mL (SI: 700 micromole/L), toxicity may occur at levels of 100 to 150 mcg/mL (SI: 700 to 1,050 micromole/L)  Mania: Clinical response seen with trough leve…"}, {"doc_id": "imipenem-and-cilastatin-drug-information", "bm25_top3": 21.9195033383485, "bm25_max": 21.9195033383485, "bge_top3": null, "bge_max": null, "title": "Imipenem and cilastatin: Drug information", "rep_snippet": "• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": 20.71937454984715, "bm25_max": 20.71937454984715, "bge_top3": null, "bge_max": null, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, sign…"}, {"doc_id": "carnitine-supplements-levocarnitine-drug-information", "bm25_top3": 14.434351016382518, "bm25_max": 17.97519622169051, "bge_top3": 0.6750606894493103, "bge_max": 0.6750606894493103, "title": "Carnitine supplements (Levocarnitine): Drug information", "rep_snippet": "Monitoring Parameters  Carnitine concentrations (initially, weekly, and monthly for IV therapy)  Metabolic disorders: Monitor blood chemistry, vital signs, and plasma carnitine levels (maintain between 35 to 60 μmol/L).…"}, {"doc_id": "ethosuximide-drug-information", "bm25_top3": 16.637286560563965, "bm25_max": 16.637286560563965, "bge_top3": 0.6804717183113098, "bge_max": 0.6804717183113098, "title": "Ethosuximide: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency; trough serum concentrations, CBC, platelets, liver enzymes (periodic), urinalysis (periodic); signs of rash; suicidality (eg, suicidal thoughts, depression, behavioral changes)"}, {"doc_id": "lamotrigine-drug-information", "bm25_top3": 15.31277717807098, "bm25_max": 15.472215698176974, "bge_top3": null, "bge_max": null, "title": "Lamotrigine: Drug information", "rep_snippet": "Regimens containing carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir, and without valproic acid: Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg once daily; Week 5: 200 mg…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 14.021369722800298, "bm25_max": 14.021369722800298, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Valproic Acid and Derivatives: Cholestyramine Resin may decrease the serum concentration of Valproic Acid and Derivatives. Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whene…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 12.359471537055233, "bm25_max": 13.503663373008646, "bge_top3": null, "bge_max": null, "title": "Itraconazole: Drug information", "rep_snippet": "Reference Range  Invasive aspergillosis:  Timing of concentrations: Obtain trough after steady state has been reached (4 to 7 days after therapy initiation); the need for continued or repeat monitoring is a patient speci…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": 13.200224088150776, "bm25_max": 13.200224088150776, "bge_top3": null, "bge_max": null, "title": "Apalutamide: Drug information", "rep_snippet": "Monitoring Parameters  Monitor thyroid function (eg, TSH) as clinically necessary. Monitor for signs/symptoms of seizure and dermatologic toxicity. Assess for fall and fracture risk. Monitor adherence."}, {"doc_id": "melphalan-drug-information", "bm25_top3": 12.894635338180528, "bm25_max": 12.894635338180528, "bge_top3": null, "bge_max": null, "title": "Melphalan: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelet count, serum electrolytes, renal/liver function tests, serum uric acid; signs/symptoms of hypersensitivity reaction, pulmonary toxicity, and gastrointestinal toxi…"}, {"doc_id": "kanamycin-united-states-not-available-drug-information", "bm25_top3": 12.558753205644773, "bm25_max": 12.558753205644773, "bge_top3": null, "bge_max": null, "title": "Kanamycin (United States: Not available): Drug information", "rep_snippet": "Reference Range  Therapeutic: Peak: 15-30 mcg/mL; Trough: 5-10 mcg/mL; Toxic: Peak: >35 mcg/mL; Trough: >10 mcg/mL"}, {"doc_id": "factor-xiii-a-subunit-recombinant-human-drug-information", "bm25_top3": 12.317593899077838, "bm25_max": 12.317593899077838, "bge_top3": null, "bge_max": null, "title": "Factor XIII A-subunit, recombinant human: Drug information", "rep_snippet": "Monitoring Parameters  Factor XIII trough levels in conjunction with clinical response to assess efficacy; factor XIII inhibitory antibodies if inadequate clinical response and/or factor XIII trough levels are suboptimal…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 12.304772529290549, "bm25_max": 12.304772529290549, "bge_top3": null, "bge_max": null, "title": "Streptomycin: Drug information", "rep_snippet": "Reference Range  Therapeutic: Peak: 20 to 30 mcg/mL; Trough: <5 mcg/mL (Edson 1991); Toxic: Peak: >50 mcg/mL; Trough: >10 mcg/mL"}, {"doc_id": "bupropion-drug-information", "bm25_top3": 12.060006601621822, "bm25_max": 12.060006601621822, "bge_top3": null, "bge_max": null, "title": "Bupropion: Drug information", "rep_snippet": "Reference Range  Therapeutic levels have not been well established and are not routinely recommended. Studies have suggested optimal antidepressant response may occur at trough bupropion plasma concentrations <100 µg/L (…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 12.04061405777172, "bm25_max": 12.04061405777172, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Monitoring Parameters  IV: Serum calcium, sodium and phosphorus levels; renal function; after IV phosphate repletion, repeat serum phosphorus level should be checked 2-4 hours later  Oral: Bowel cleansing: Baseline and p…"}, {"doc_id": "nelarabine-drug-information", "bm25_top3": 11.868863391563249, "bm25_max": 11.868863391563249, "bge_top3": null, "bge_max": null, "title": "Nelarabine: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential, liver and kidney function; monitor closely for neurologic toxicity (severe somnolence, seizure, peripheral neuropathy, confusion, ataxia, paresthesia, hypoesthesia, coma, or…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": 11.01232556503688, "bm25_max": 11.649453369889084, "bge_top3": null, "bge_max": null, "title": "Everolimus: Drug information", "rep_snippet": "Initial: 4.5 mg/m2 once daily; round to nearest tablet (tablet or tablet for oral suspension) size; continue until disease progression or unacceptable toxicity.  If trough <5 ng/mL: Increase dose by 2.5 mg daily (tablets…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 11.233798613867412, "bm25_max": 11.549559313201193, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Monitoring of serum trough concentrations is recommended in the following infections: invasive aspergillosis treatment (and prolonged prophylaxis); endophthalmitis; meningitis or osteoarticular infections due to Exserohi…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 11.537740148076129, "bm25_max": 11.537740148076129, "bge_top3": null, "bge_max": null, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Use  Note: Not approved in the US  Dravet syndrome: Adjunctive treatment of refractory generalized tonic-clonic seizures in conjunction with clobazam and valproic acid in patients with severe myoclonic epilepsy in infanc…"}, {"doc_id": "omacetaxine-drug-information", "bm25_top3": 10.815254355570893, "bm25_max": 10.815254355570893, "bge_top3": null, "bge_max": null, "title": "Omacetaxine: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelets (weekly during induction and initial maintenance cycles, then every 2 weeks or as clinically indicated after initial maintenance cycles); blood glucose (frequent…"}, {"doc_id": "ertapenem-drug-information", "bm25_top3": 10.690578665957947, "bm25_max": 10.690578665957947, "bge_top3": null, "bge_max": null, "title": "Ertapenem: Drug information", "rep_snippet": "• Valproic acid and derivatives: Carbapenems, including ertapenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibi…"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": 10.37000634174884, "bm25_max": 10.638840799999258, "bge_top3": 0.6637141108512878, "bge_max": 0.6637141108512878, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency; serum sodium as deemed necessary (particularly during first 3 months of therapy); symptoms of CNS depression (dizziness, headache, somnolence); hypersensitivity reactions. Additi…"}, {"doc_id": "factor-xiii-concentrate-from-human-plasma-drug-information", "bm25_top3": 10.62474413407896, "bm25_max": 10.62474413407896, "bge_top3": null, "bge_max": null, "title": "Factor XIII, concentrate from human plasma: Drug information", "rep_snippet": "Monitoring Parameters  Factor XIII trough levels in conjunction with clinical response to assess efficacy (ie, approximately every 28 days for prophylaxis, during and after surgery for perioperative management of surgica…"}, {"doc_id": "pegademase-bovine-drug-information", "bm25_top3": 10.416257200152256, "bm25_max": 10.416257200152256, "bge_top3": null, "bge_max": null, "title": "Pegademase bovine: Drug information", "rep_snippet": "Reference Range  Plasma ADA activity: Recommended maintenance trough level: 15-35 micromole/hour/mL  Red cell dATP: After 2 months of maintenance therapy, levels should decrease to ≤0.005-0.015 micromole/mL (normal dATP…"}, {"doc_id": "daptomycin-drug-information", "bm25_top3": 10.356267281145044, "bm25_max": 10.356267281145044, "bge_top3": null, "bge_max": null, "title": "Daptomycin: Drug information", "rep_snippet": "Reference Range  Trough concentrations at steady-state:  4 mg/kg once daily: 5.9 ± 1.6 mcg/mL  6 mg/kg once daily: 6.7 ± 1.6 mcg/mL  Note: Routine trough monitoring is not recommended. Trough concentrations are not predi…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": 10.217912395600937, "bm25_max": 10.217912395600937, "bge_top3": null, "bge_max": null, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Reference Range  Reference ranges are method dependent and specimen dependent; use the same analytical method consistently  Method-dependent and specimen-dependent: Trough levels should be obtained:  Oral: 12 hours after…"}, {"doc_id": "flecainide-drug-information", "bm25_top3": 10.1756312418688, "bm25_max": 10.1756312418688, "bge_top3": null, "bge_max": null, "title": "Flecainide: Drug information", "rep_snippet": "Reference Range  Therapeutic: Trough concentration: 0.2 to 1 mcg/mL. Note: Pediatric patients may respond at the lower end of the recommended therapeutic range (0.2 to 0.5 mcg/mL) but up to 0.8 mcg/mL may be required."}, {"doc_id": "factor-x-concentrate-from-human-plasma-drug-information", "bm25_top3": 9.76821980024538, "bm25_max": 9.76821980024538, "bge_top3": null, "bge_max": null, "title": "Factor X, concentrate from human plasma: Drug information", "rep_snippet": "Monitoring Parameters  Factor X levels in conjunction with clinical response to assess efficacy. Factor X inhibitory antibodies if inadequate clinical response and/or factor X trough levels are suboptimal. Signs/symptoms…"}, {"doc_id": "chloroprocaine-drug-information", "bm25_top3": 9.760022981073732, "bm25_max": 9.760022981073732, "bge_top3": null, "bge_max": null, "title": "Chloroprocaine: Drug information", "rep_snippet": "Monitoring Parameters  Cardiovascular and respiratory status; mental status; vital signs; signs of CNS toxicity"}, {"doc_id": "enzalutamide-drug-information", "bm25_top3": 9.65959089810329, "bm25_max": 9.65959089810329, "bge_top3": null, "bge_max": null, "title": "Enzalutamide: Drug information", "rep_snippet": "Monitoring Parameters  Monitor for signs/symptoms of seizure, loss of consciousness, dizziness, and hallucinations; CBC with differential and liver function tests (baseline and periodic); additional INR monitoring (if on…"}, {"doc_id": "haloperidol-drug-information", "bm25_top3": 9.631295429609501, "bm25_max": 9.631295429609501, "bge_top3": null, "bge_max": null, "title": "Haloperidol: Drug information", "rep_snippet": "Reference Range  Schizophrenia: Therapeutic drug monitoring is not routinely warranted; a clear correlation between plasma concentrations and therapeutic response has not been demonstrated. Clinical studies suggest a the…"}, {"doc_id": "perampanel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6839921474456787, "bge_max": 0.6839921474456787, "title": "Perampanel: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency/duration; suicidality (eg, suicidal thoughts, depression, behavioral changes) during therapy and for at least 1 month after discontinuation; weight"}, {"doc_id": "tiagabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6800979375839233, "bge_max": 0.6800979375839233, "title": "Tiagabine: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency, liver function tests (periodically), suicidality (eg, suicidal thoughts, depression, behavioral changes)"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6791428327560425, "bge_max": 0.6791428327560425, "title": "Trimipramine: Drug information", "rep_snippet": "• Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure thre…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6788212656974792, "bge_max": 0.6788212656974792, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency; liver enzymes (baseline); serum sodium and chloride as deemed necessary during maintenance treatment, particularly in patients receiving other medications known to decrease sodiu…"}, {"doc_id": "varenicline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6745588183403015, "bge_max": 0.6745588183403015, "title": "Varenicline: Drug information", "rep_snippet": "• Seizures: Seizures have been reported in patients with or without a history of seizures. Seizures generally occurred within the first month of therapy. Consider the risks against the benefits before initiating in patie…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6670838594436646, "bge_max": 0.6741428375244141, "title": "Desipramine: Drug information", "rep_snippet": "• Seizure disorder: Use with extreme caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seiz…"}, {"doc_id": "rufinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6724640130996704, "bge_max": 0.6724640130996704, "title": "Rufinamide: Drug information", "rep_snippet": "Monitoring Parameters  Seizure (frequency and duration); serum levels of concurrent anticonvulsants; suicidality (eg, suicidal thoughts, depression, behavioral changes); rash (may indicate multi-organ hypersensitivity re…"}, {"doc_id": "risperidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6688190698623657, "bge_max": 0.6688190698623657, "title": "Risperidone: Drug information", "rep_snippet": "• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.…"}, {"doc_id": "etelcalcetide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6670314073562622, "bge_max": 0.6670314073562622, "title": "Etelcalcetide: Drug information", "rep_snippet": "• Seizure disorder: Use with caution in patients with a history of seizure disorder; seizure threshold is lowered by significant decreases in serum calcium. Monitor corrected serum calcium levels closely.  Concurrent dru…"}, {"doc_id": "molindone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6630517244338989, "bge_max": 0.6660785675048828, "title": "Molindone: Drug information", "rep_snippet": "• Seizure disorder: Use with caution in patients at risk of seizures.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, ad…"}, {"doc_id": "bupropion-and-naltrexone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6642122268676758, "bge_max": 0.6642122268676758, "title": "Bupropion and naltrexone: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "acetaminophen-paracetamol-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6607073545455933, "bge_max": 0.6607073545455933, "title": "Acetaminophen (paracetamol), aspirin, and caffeine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "cariprazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6582061350345612, "bge_max": 0.6605451703071594, "title": "Cariprazine: Drug information", "rep_snippet": "• Seizures: Use with caution in patients at risk of seizures or with conditions that potentially lower the seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predis…"}, {"doc_id": "quetiapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Quetiapine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "amitriptyline-and-perphenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Amitriptyline and perphenazine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "flupentixol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Flupentixol (United States: Not available): Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "clomipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Clomipramine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Clozapine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "orphenadrine-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Orphenadrine, aspirin, and caffeine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "amitriptyline-and-chlordiazepoxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Amitriptyline and chlordiazepoxide: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "prochlorperazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Prochlorperazine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "loxapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660024881362915, "bge_max": 0.660024881362915, "title": "Loxapine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "lurasidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6592646241188049, "bge_max": 0.6592646241188049, "title": "Lurasidone: Drug information", "rep_snippet": "• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures or conditions that lower the seizure threshold such as Alzheimer disease. Elderly patients may be at increased risk…"}, {"doc_id": "butalbital-acetaminophen-paracetamol-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6585301756858826, "bge_max": 0.6585301756858826, "title": "Butalbital, acetaminophen (paracetamol), and caffeine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "acetaminophen-paracetamol-caffeine-and-codeine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6585301756858826, "bge_max": 0.6585301756858826, "title": "Acetaminophen (paracetamol), caffeine, and codeine (United States: Not available): Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "acetaminophen-paracetamol-caffeine-and-dihydrocodeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6585301756858826, "bge_max": 0.6585301756858826, "title": "Acetaminophen (paracetamol), caffeine, and dihydrocodeine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "butalbital-acetaminophen-paracetamol-caffeine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6585301756858826, "bge_max": 0.6585301756858826, "title": "Butalbital, acetaminophen (paracetamol), caffeine, and codeine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "benzhydrocodone-and-acetaminophen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6579220294952393, "bge_max": 0.6579220294952393, "title": "Benzhydrocodone and acetaminophen: Drug information", "rep_snippet": "Monitoring Parameters  Pain relief, respiratory and mental status, blood pressure; signs of misuse, abuse, and addiction."}, {"doc_id": "methamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.657673180103302, "bge_max": 0.657673180103302, "title": "Methamphetamine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "lisdexamfetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.657673180103302, "bge_max": 0.657673180103302, "title": "Lisdexamfetamine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "amphetamine-sulfate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.657673180103302, "bge_max": 0.657673180103302, "title": "Amphetamine sulfate: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "dextroamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.657673180103302, "bge_max": 0.657673180103302, "title": "Dextroamphetamine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "dextroamphetamine-and-amphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.657673180103302, "bge_max": 0.657673180103302, "title": "Dextroamphetamine and amphetamine: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "iloperidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6558670997619629, "bge_max": 0.6558670997619629, "title": "Iloperidone: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "tramadol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6558670997619629, "bge_max": 0.6558670997619629, "title": "Tramadol: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "phentermine-and-topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6558670997619629, "bge_max": 0.6558670997619629, "title": "Phentermine and topiramate: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "brexpiprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6558670997619629, "bge_max": 0.6558670997619629, "title": "Brexpiprazole: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "protriptyline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6552300453186035, "bge_max": 0.6552300453186035, "title": "Protriptyline: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6552300453186035, "bge_max": 0.6552300453186035, "title": "Amitriptyline: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "doxepin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6552300453186035, "bge_max": 0.6552300453186035, "title": "Doxepin (systemic): Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "nortriptyline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6552300453186035, "bge_max": 0.6552300453186035, "title": "Nortriptyline: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6552300453186035, "bge_max": 0.6552300453186035, "title": "Amoxapine: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}]}
{"qid": "Q23_noise", "query": "Chronic seizures — what VPA level to aim for; what toxicity looks like; what labs track?", "base_qid": "Q23", "variant_type": "noise", "candidates": [{"doc_id": "methylprednisolone-drug-information", "bm25_top3": 24.957779870860364, "bm25_max": 24.957779870860364, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased…"}, {"doc_id": "chlorpromazine-drug-information", "bm25_top3": 23.26753184600406, "bm25_max": 23.26753184600406, "bge_top3": 0.5847477912902832, "bge_max": 0.5847477912902832, "title": "Chlorpromazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Chlorpromazine and its metabolites have been detected in breast milk; concentrations in the milk do not correlate with those in the mother and may be higher than what is in the maternal pla…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 21.82210700255453, "bm25_max": 21.82210700255453, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "betaxolol-systemic-drug-information", "bm25_top3": 21.630284421568025, "bm25_max": 21.630284421568025, "bge_top3": null, "bge_max": null, "title": "Betaxolol (systemic): Drug information", "rep_snippet": "The maternal half-life and serum concentration of betaxolol immediately postpartum are not significantly different than what is observed in nonpregnant women (Boutroy 1990; Morselli 1990). Untreated chronic maternal hype…"}, {"doc_id": "nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information", "bm25_top3": 20.542447007386354, "bm25_max": 20.542447007386354, "bge_top3": null, "bge_max": null, "title": "Nanoparticle albumin bound paclitaxel (nabpaclitaxel): Drug information", "rep_snippet": "Neutropenic fever: Withhold therapy for grade 3 or 4 fever. Resume therapy at next lower dose level when fever resolves and ANC is ≥1500 cells/mm3.  Peripheral neuropathy: Withhold therapy for grade 3 or 4 peripheral neu…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 19.539330965180174, "bm25_max": 19.539330965180174, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": 17.584566754731465, "bm25_max": 17.584566754731465, "bge_top3": null, "bge_max": null, "title": "Paroxetine: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.  • Seizure disorder: Use with caution in patients with…"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 16.586564380530344, "bm25_max": 16.586564380530344, "bge_top3": null, "bge_max": null, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Mechanism of Action  Combination of fluticasone (corticosteroid) and salmeterol (long-acting beta2-agonist) designed to improve pulmonary function and control over what is produced by either agent when used alone. Becaus…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": 16.284495714334888, "bm25_max": 16.284495714334888, "bge_top3": null, "bge_max": null, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "Pregnancy Implications  Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthm…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-indacaterol-drug-information", "bm25_top3": 16.250047429146562, "bm25_max": 16.250047429146562, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and indacaterol: Drug information", "rep_snippet": "• Lactose: Some products may contain lactose; allergic reactions possible in patients with severe milk protein allergy. Use with caution in patients with severe hypersensitivity to milk proteins.  Other warnings:  • Appr…"}, {"doc_id": "triprolidine-pseudoephedrine-and-codeine-drug-information", "bm25_top3": 15.882621679181089, "bm25_max": 15.882621679181089, "bge_top3": null, "bge_max": null, "title": "Triprolidine, pseudoephedrine, and codeine: Drug information", "rep_snippet": "Hypersensitivity to triprolidine or other antihistamines of similar chemical structure, pseudoephedrine or other sympathomimetic amines, codeine or other opioids, or any component of the formulation (some formulations co…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 15.844921129450256, "bm25_max": 15.844921129450256, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "fingolimod-drug-information", "bm25_top3": 14.548910790585559, "bm25_max": 14.548910790585559, "bge_top3": 0.5849389433860779, "bge_max": 0.5849389433860779, "title": "Fingolimod: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "levalbuterol-drug-information", "bm25_top3": 14.548910790585559, "bm25_max": 14.548910790585559, "bge_top3": null, "bge_max": null, "title": "Levalbuterol: Drug information", "rep_snippet": "Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased…"}, {"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 14.437600888767768, "bm25_max": 14.437600888767768, "bge_top3": null, "bge_max": null, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "Pregnancy Implications  Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy (Battista 2016). Uncontrolled asthma is associated with adverse events on pregnancy (increased…"}, {"doc_id": "etonogestrel-implant-drug-information", "bm25_top3": 14.298565332742033, "bm25_max": 14.298565332742033, "bge_top3": null, "bge_max": null, "title": "Etonogestrel implant: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Breast cancer: Breast cancer is a hormonal sensitive tumor and the prognosis for women with current or a recent history of breast cancer may be worse with pro…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 12.921909334020889, "bm25_max": 13.908711300254065, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Bacterial infections (Mifeprex)  Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following mifepristone use…"}, {"doc_id": "montelukast-drug-information", "bm25_top3": 13.476653795242825, "bm25_max": 13.476653795242825, "bge_top3": null, "bge_max": null, "title": "Montelukast: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Birth defects have been reported (rarely) following maternal use; however, a causal relationship with montelukast has not been…"}, {"doc_id": "asfotase-alfa-drug-information", "bm25_top3": 13.228610550952908, "bm25_max": 13.228610550952908, "bge_top3": null, "bge_max": null, "title": "Asfotase alfa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Asfotase alfa: Pediatric drug information\")  Hypophosphatasia (HPP): SubQ: Note: Round patient weight to the nearest kg when determining dose. Do not administer the 80…"}, {"doc_id": "ceftazidime-and-avibactam-drug-information", "bm25_top3": 13.227035124941505, "bm25_max": 13.227035124941505, "bge_top3": null, "bge_max": null, "title": "Ceftazidime and avibactam: Drug information", "rep_snippet": "Disease-related concerns:  • Renal impairment: In a complicated intra-abdominal infection clinical trial, patients with a creatinine clearance (CrCl) of 30 to 50 mL/minute had lower clinical cure rates than those with Cr…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 12.661699700472667, "bm25_max": 12.661699700472667, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased…"}, {"doc_id": "hydrocortisone-systemic-drug-information", "bm25_top3": 12.593839530698283, "bm25_max": 12.593839530698283, "bge_top3": null, "bge_max": null, "title": "Hydrocortisone (systemic): Drug information", "rep_snippet": "Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have…"}, {"doc_id": "bicalutamide-drug-information", "bm25_top3": 11.614034376493152, "bm25_max": 11.614034376493152, "bge_top3": null, "bge_max": null, "title": "Bicalutamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Gynecomastia: May cause gynecomastia or breast pain at higher (off-label) doses.  • Hematologic: Anemia may occur with testosterone suppression; monitor CBC p…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": 11.103408281826422, "bm25_max": 11.103408281826422, "bge_top3": null, "bge_max": null, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported fo…"}, {"doc_id": "olodaterol-drug-information", "bm25_top3": 10.806302011351104, "bm25_max": 10.806302011351104, "bge_top3": null, "bge_max": null, "title": "Olodaterol: Drug information", "rep_snippet": "• Bronchospasm: Rarely, paradoxical, life-threatening bronchospasm may occur with use of inhaled beta2-agonists; distinguish from inadequate response, discontinue medication immediately, institute alternative therapy.  •…"}, {"doc_id": "colchicine-drug-information", "bm25_top3": 10.027801441161763, "bm25_max": 10.027801441161763, "bge_top3": null, "bge_max": null, "title": "Colchicine: Drug information", "rep_snippet": "Dosing: Adult  Familial Mediterranean fever (FMF): Oral: Tablet (eg, Colcrys): 1.2 to 2.4 mg daily in 1 to 2 divided doses. Titration: Increase or decrease dose in 0.3 mg daily increments based on efficacy or adverse eff…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 10.019271186503563, "bm25_max": 10.019271186503563, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Panzyga [Canadian product]: IV: 1,000 mg/kg/day for 2 consecutive days; may repeat treatment in patients who relapse  American College of Obstetricians and Gynecologists Guidelines: IV: Initial: 1,000 mg/kg as a one-time…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 7.985379930348348, "bm25_max": 7.985379930348348, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Monitoring Parameters  IV: Serum calcium, sodium and phosphorus levels; renal function; after IV phosphate repletion, repeat serum phosphorus level should be checked 2-4 hours later  Oral: Bowel cleansing: Baseline and p…"}, {"doc_id": "carfilzomib-drug-information", "bm25_top3": 6.91132333524338, "bm25_max": 7.8730112582108, "bge_top3": 0.5989928245544434, "bge_max": 0.5989928245544434, "title": "Carfilzomib: Drug information", "rep_snippet": "Renal toxicity during treatment: Serum creatinine ≥2 times baseline, CrCl <15 mL/minute or CrCl decreases to ≤50% of baseline, or patient requires dialysis: Withhold dose and monitor renal function. If renal toxicity is…"}, {"doc_id": "butorphanol-drug-information", "bm25_top3": 7.180090123498838, "bm25_max": 7.180090123498838, "bge_top3": null, "bge_max": null, "title": "Butorphanol: Drug information", "rep_snippet": "Administration  Intranasal: Fully prime pump prior to initial use; if not used for ≥48 hours, re-prime with one or two strokes. Aim spray away from self and others when priming.  Parenteral: Administer IV or IM."}, {"doc_id": "irinotecan-conventional-drug-information", "bm25_top3": 5.668193160693154, "bm25_max": 6.795220492687346, "bge_top3": null, "bge_max": null, "title": "Irinotecan (conventional): Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  It is recommended that new courses begin only after the granulocyte count recovers to ≥1,500/mm3, the platelet counts recover to ≥100,000/mm3, and treatment-related diarrhea has fully res…"}, {"doc_id": "vitamin-d3-cholecalciferol-drug-information", "bm25_top3": 6.470888482669075, "bm25_max": 6.470888482669075, "bge_top3": null, "bge_max": null, "title": "Vitamin D3 (cholecalciferol): Drug information", "rep_snippet": "Infants: 2,000 units daily or 50,000 units once weekly for 6 weeks to achieve a serum 25(OH)D level >20 ng/mL; followed by a maintenance dose of 400 to 1,000 units daily. Note: For patients at high risk of fractures a se…"}, {"doc_id": "enzalutamide-drug-information", "bm25_top3": 6.014705783081208, "bm25_max": 6.014705783081208, "bge_top3": 0.5914096832275391, "bge_max": 0.592577338218689, "title": "Enzalutamide: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  If ≥ grade 3 toxicity or intolerable side effects occur, withhold treatment for 1 week or until symptom(s) improve to ≤ grade 2, then resume at same dose, or reduce dose to 120 mg or 80 m…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 5.7355215174821055, "bm25_max": 5.7355215174821055, "bge_top3": null, "bge_max": null, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "In breastfeeding women with hepatitis B infection (not coinfected with HIV), the AASLD chronic hepatitis B treatment guidelines do not consider antiviral therapy a contraindication to breastfeeding; antivirals are minima…"}, {"doc_id": "cabazitaxel-drug-information", "bm25_top3": 5.70798253569899, "bm25_max": 5.70798253569899, "bge_top3": null, "bge_max": null, "title": "Cabazitaxel: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: If receiving cabazitaxel 20 mg/m2 and a dose reduction is required, decrease the dose to 15 mg/m2. If receiving cabazitaxel 25 mg/m2, the dose should decrease to 20 mg/m2; one addit…"}, {"doc_id": "ferric-gluconate-drug-information", "bm25_top3": 5.655581230758594, "bm25_max": 5.655581230758594, "bge_top3": null, "bge_max": null, "title": "Ferric gluconate: Drug information", "rep_snippet": "Reference Range  CKD patients should have sufficient iron to achieve and maintain hemoglobin of 11-12 g/dL. To achieve and maintain this target hemoglobin, sufficient iron should be administered to maintain a TSAT of 20%…"}, {"doc_id": "trabectedin-drug-information", "bm25_top3": 5.492153487181723, "bm25_max": 5.492153487181723, "bge_top3": null, "bge_max": null, "title": "Trabectedin: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Soft tissue sarcoma:  Recommended dose reduction levels (once a dose is reduced it should not be increased in subsequent cycles):  First dose reduction: 1.2 mg/m2 once every 3 weeks  Seco…"}, {"doc_id": "capecitabine-drug-information", "bm25_top3": 5.379196881518919, "bm25_max": 5.379196881518919, "bge_top3": null, "bge_max": null, "title": "Capecitabine: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  See table (Note: Capecitabine dosing recommendations apply to both monotherapy and when used in combination therapy with docetaxel).  Monitor carefully for toxicity and adjust dose as nec…"}, {"doc_id": "trametinib-drug-information", "bm25_top3": 5.344905245064968, "bm25_max": 5.344905245064968, "bge_top3": null, "bge_max": null, "title": "Trametinib: Drug information", "rep_snippet": "Intolerable Grade 2 adverse reaction or any Grade 3 adverse reaction: Interrupt therapy. If toxicity improves to ≤ grade 1 following therapy interruption, resume at a lower dose level. If toxicity does not improve follow…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": 5.327455506674577, "bm25_max": 5.327455506674577, "bge_top3": null, "bge_max": null, "title": "Methotrexate: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Methotrexate toxicities:  Nonhematologic toxicity: Diarrhea, stomatitis, or vomiting which may lead to dehydration: Discontinue until recovery  Hematologic toxicity:  Psoriasis, rheumatoi…"}, {"doc_id": "ribociclib-drug-information", "bm25_top3": 3.51115542251416, "bm25_max": 3.7463977625307354, "bge_top3": null, "bge_max": null, "title": "Ribociclib: Drug information", "rep_snippet": "Grade 3: Interrupt treatment until recovery to grade 1 or lower and then resume ribociclib at the same dose level. If grade 3 toxicity recurs, interrupt treatment until recovery to grade 1 or lower and then resume riboci…"}, {"doc_id": "erwinia-asparaginase-drug-information", "bm25_top3": 3.7059642905219032, "bm25_max": 3.7059642905219032, "bge_top3": null, "bge_max": null, "title": "Erwinia asparaginase: Drug information", "rep_snippet": "Hyperglycemia: Continue therapy for uncomplicated hyperglycemia. If hyperglycemia requires insulin therapy, hold asparaginase (and any concomitant corticosteroids) until blood glucose controlled; resume dosing at prior d…"}, {"doc_id": "e-coli-asparaginase-united-states-not-available-drug-information", "bm25_top3": 3.674769574877848, "bm25_max": 3.674769574877848, "bge_top3": null, "bge_max": null, "title": "E. coli asparaginase (United States: Not available): Drug information", "rep_snippet": "Hyperglycemia: Continue therapy for uncomplicated hyperglycemia. If hyperglycemia requires insulin therapy, hold asparaginase (and any concomitant corticosteroids) until blood glucose controlled; resume dosing at prior d…"}, {"doc_id": "vitamin-b6-pyridoxine-drug-information", "bm25_top3": 3.189318399826991, "bm25_max": 3.189318399826991, "bge_top3": null, "bge_max": null, "title": "Vitamin B6 (pyridoxine): Drug information", "rep_snippet": "Use: Off-Label  Gyromitrin-containing mushroom (false morel) overdose/toxicity (treatment/prophylaxis); Nausea and vomiting of pregnancy; Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose (p…"}, {"doc_id": "valproate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6165189146995544, "bge_max": 0.6251440644264221, "title": "Valproate: Drug information", "rep_snippet": "Reference Range  Note: In general, trough concentrations should be used to assess adequacy of therapy; peak concentrations may also be drawn if clinically necessary (eg, concentration-related toxicity). Within 2 to 4 day…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6243889331817627, "bge_max": 0.6243889331817627, "title": "Lithium: Drug information", "rep_snippet": "Reference Range  Obtain levels twice weekly until both patient's clinical status and levels are stable then levels may be obtained no less than every 6 months (APA 2002).  Timing of serum samples: Draw trough just before…"}, {"doc_id": "blinatumomab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6164786219596863, "bge_max": 0.6164786219596863, "title": "Blinatumomab: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  If the interruption after an adverse event is no longer than 7 days, continue the same cycle to a total of 28 days of infusion inclusive of days before and after the interruption in that…"}, {"doc_id": "axicabtagene-ciloleucel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6022889614105225, "bge_max": 0.6131303906440735, "title": "Axicabtagene ciloleucel: Drug information", "rep_snippet": "Neurologic toxicity: Note: Patients with ≥ grade 2 neurologic toxicity should be monitored with continuous cardiac telemetry and pulse oximetry. Severe or life-threatening neurologic toxicity may require intensive care s…"}, {"doc_id": "lorazepam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.611891508102417, "bge_max": 0.611891508102417, "title": "Lorazepam: Drug information", "rep_snippet": "Monitoring Parameters  Respiratory and cardiovascular status, blood pressure, heart rate, symptoms of anxiety  Long-term therapy: CBC, liver function tests, LDH  High-dose or continuous IV use or IV use in patients with…"}, {"doc_id": "ethosuximide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6035874485969543, "bge_max": 0.6035874485969543, "title": "Ethosuximide: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency; trough serum concentrations, CBC, platelets, liver enzymes (periodic), urinalysis (periodic); signs of rash; suicidality (eg, suicidal thoughts, depression, behavioral changes)"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.602718710899353, "bge_max": 0.602718710899353, "title": "Theophylline: Drug information", "rep_snippet": "Monitoring Parameters  Heart rate, CNS effects (insomnia, irritability); respiratory rate (COPD patients often have resting controlled respiratory rates in low 20s); arterial or capillary blood gases (if applicable); flu…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6017147302627563, "bge_max": 0.6017147302627563, "title": "Vancomycin: Drug information", "rep_snippet": "Monitoring Parameters  Intravenous: Periodic renal function tests, CBC; serum trough vancomycin concentrations in select patients (eg, aggressive dosing, life-threatening infection, seriously ill, unstable renal function…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5987235903739929, "bge_max": 0.5987235903739929, "title": "Diazepam: Drug information", "rep_snippet": "Monitoring Parameters  Heart rate, respiratory rate, blood pressure, and mental status; liver enzymes and CBC with long-term therapy; clinical signs of propylene glycol toxicity (for continuous high-dose and/or long dura…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5917535622914633, "bge_max": 0.5969984531402588, "title": "Clozapine: Drug information", "rep_snippet": "BEN severe neutropenia (<500/mm3): Interrupt therapy, recommend hematology consultation, and begin daily ANC monitoring until ANC ≥500/mm3. Follow with 3 times weekly monitoring until ANC greater than or equal to patient…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5966209769248962, "bge_max": 0.5966209769248962, "title": "Apalutamide: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Grade 3 or higher toxicity (or intolerable adverse reaction): Withhold dosing until symptoms improve to baseline or to grade 1 or lower, then resume either at the same dose or (if warrant…"}, {"doc_id": "carnitine-supplements-levocarnitine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5941392183303833, "bge_max": 0.5941392183303833, "title": "Carnitine supplements (Levocarnitine): Drug information", "rep_snippet": "Monitoring Parameters  Carnitine concentrations (initially, weekly, and monthly for IV therapy)  Metabolic disorders: Monitor blood chemistry, vital signs, and plasma carnitine levels (maintain between 35 to 60 μmol/L).…"}, {"doc_id": "methoxy-polyethylene-glycol-epoetin-beta-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5909473299980164, "bge_max": 0.5909473299980164, "title": "Methoxy polyethylene glycol-epoetin beta: Drug information", "rep_snippet": "• Chronic kidney disease: [US Boxed Warning]: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5886185169219971, "bge_max": 0.5886185169219971, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency; liver enzymes (baseline); serum sodium and chloride as deemed necessary during maintenance treatment, particularly in patients receiving other medications known to decrease sodiu…"}, {"doc_id": "interferon-alfa-2b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5878102779388428, "bge_max": 0.5878102779388428, "title": "Interferon alfa-2b: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Hematologic toxicity (also refer to indication specified adjustments below): ANC <500/mm3 or platelets <25,000/mm3: Discontinue treatment.  Hypersensitivity reaction (acute, serious), oph…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5869241952896118, "bge_max": 0.5869241952896118, "title": "Aminophylline: Drug information", "rep_snippet": "Monitoring Parameters  Heart rate; CNS effects (insomnia, irritability); respiratory rate (COPD patients often have resting controlled respiratory rates in low 20s); arterial or capillary blood gases (if applicable)  The…"}, {"doc_id": "darbepoetin-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5869118571281433, "bge_max": 0.5869118571281433, "title": "Darbepoetin alfa: Drug information", "rep_snippet": "• Chronic kidney disease patients: [US Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke was reported in chronic kidney disease patients administered ESAs to target hemoglobin levels >…"}, {"doc_id": "trifluoperazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5866115093231201, "bge_max": 0.5866115093231201, "title": "Trifluoperazine: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "pericyazine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5866115093231201, "bge_max": 0.5866115093231201, "title": "Pericyazine (United States: Not available): Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "perphenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5866115093231201, "bge_max": 0.5866115093231201, "title": "Perphenazine: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "levomepromazine-methotrimeprazine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5866115093231201, "bge_max": 0.5866115093231201, "title": "Levomepromazine (methotrimeprazine) (United States: Not available): Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "thiothixene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5866115093231201, "bge_max": 0.5866115093231201, "title": "Thiothixene: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "fluphenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5866115093231201, "bge_max": 0.5866115093231201, "title": "Fluphenazine: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5852230787277222, "bge_max": 0.5852230787277222, "title": "Everolimus: Drug information", "rep_snippet": "Grade 2: If toxicity is tolerable, no dosage adjustment is necessary; initiate appropriate medical intervention and monitor. If toxicity becomes intolerable, temporarily interrupt treatment until improvement to ≤grade 1…"}, {"doc_id": "haloperidol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5847477912902832, "bge_max": 0.5847477912902832, "title": "Haloperidol: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "droperidol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5847477912902832, "bge_max": 0.5847477912902832, "title": "Droperidol: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "risperidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5847477912902832, "bge_max": 0.5847477912902832, "title": "Risperidone: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "olanzapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5842902064323425, "bge_max": 0.5842902064323425, "title": "Olanzapine: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "pentobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5840358734130859, "bge_max": 0.5840358734130859, "title": "Pentobarbital: Drug information", "rep_snippet": "Monitoring Parameters  Respiratory status (for conscious sedation, includes pulse oximetry), cardiovascular status, CNS status; cardiac monitor and blood pressure monitor required; clinical signs of propylene glycol toxi…"}, {"doc_id": "lurasidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5823865532875061, "bge_max": 0.5823865532875061, "title": "Lurasidone: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "lenvatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5823627710342407, "bge_max": 0.5823627710342407, "title": "Lenvatinib: Drug information", "rep_snippet": "• Renal toxicity: Proteinuria (including grade 3 toxicity) was commonly observed. Monitor for proteinuria at baseline and periodically throughout therapy. If urine dipstick for proteinuria is 2+, obtain a 24-hour urine p…"}, {"doc_id": "imipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5820801258087158, "bge_max": 0.5820801258087158, "title": "Imipramine: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "meperidine-and-promethazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5795069336891174, "bge_max": 0.5795069336891174, "title": "Meperidine and promethazine: Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "ezogabine-retigabine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5793930292129517, "bge_max": 0.5793930292129517, "title": "Ezogabine (retigabine) (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Seizures; electrolytes, bilirubin, QT interval (in patients with risk factors for QT prolongation), renal and hepatic function; urologic symptoms; observe patient for excessive sedation, confusion,…"}, {"doc_id": "aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5791680812835693, "bge_max": 0.5791680812835693, "title": "Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "aripiprazole-lauroxil-long-acting-injectable-aristada-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5791680812835693, "bge_max": 0.5791680812835693, "title": "Aripiprazole lauroxil (long-acting injectable [Aristada]): Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "pipotiazine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5791680812835693, "bge_max": 0.5791680812835693, "title": "Pipotiazine (United States: Not available): Drug information", "rep_snippet": "Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizu…"}, {"doc_id": "osimertinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5791655778884888, "bge_max": 0.5791655778884888, "title": "Osimertinib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Cardiotoxicity:  QTc interval >500 msec on at least 2 separate ECGs: Withhold treatment until QTc interval is <481 msec or recovers to baseline (if baseline QTc ≥481 msec) and then resume…"}, {"doc_id": "ponatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5790693759918213, "bge_max": 0.5790693759918213, "title": "Ponatinib: Drug information", "rep_snippet": "Asymptomatic grade 3 or 4 serum lipase elevation (>2 times ULN) or asymptomatic radiologic pancreatitis (grade 2): If toxicity occurs at a dose of 45 mg daily, interrupt therapy; upon recovery to ≤grade 1 (<1.5 times ULN…"}, {"doc_id": "atropine-and-pralidoxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5785870552062988, "bge_max": 0.5785870552062988, "title": "Atropine and pralidoxime: Drug information", "rep_snippet": "Reference Range  Direct measurement of RBC acetylcholinesterase activity provides a measure of degree of toxicity, although symptoms may not correlate with the degree of inactivation unless activity is reduced to <50%. S…"}]}
{"qid": "Q23_spelling", "query": "Valproate maint — target trough & tox sxs; which labs?", "base_qid": "Q23", "variant_type": "spelling", "candidates": [{"doc_id": "valproate-drug-information", "bm25_top3": 15.353250722745601, "bm25_max": 17.784241196083972, "bge_top3": 0.4949326813220978, "bge_max": 0.5081790685653687, "title": "Valproate: Drug information", "rep_snippet": "Salicylates: May increase the serum concentration of Valproate Products. Risk C: Monitor therapy  Sodium Oxybate: Valproate Products may increase the serum concentration of Sodium Oxybate. Management: Consider a sodium o…"}, {"doc_id": "sirolimus-drug-information", "bm25_top3": 7.034396084739534, "bm25_max": 8.252530859212662, "bge_top3": 0.48740777373313904, "bge_max": 0.4954935610294342, "title": "Sirolimus: Drug information", "rep_snippet": "Conversion from a calcineurin inhibitor (CNI) (ie, cyclosporine, tacrolimus): Reduce cyclosporine by 25 mg twice daily or tacrolimus by 1 mg twice daily followed by initiation of sirolimus 1 mg once daily; adjust sirolim…"}, {"doc_id": "sodium-phenylbutyrate-drug-information", "bm25_top3": 7.997341883272508, "bm25_max": 7.997341883272508, "bge_top3": null, "bge_max": null, "title": "Sodium phenylbutyrate: Drug information", "rep_snippet": "Valproate Products: May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Valproate Products may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorde…"}, {"doc_id": "human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information", "bm25_top3": 6.721792117806874, "bm25_max": 7.005736617757062, "bge_top3": null, "bge_max": null, "title": "Human-plasma derived von Willebrand factor (contains factor VIII): Drug information", "rep_snippet": "Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 50 to 60 units/dL and target peak plasma FVIII:C concentration of 40 to 50 units/dL; administer 1 to 2 hours prior to surg…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": 5.018287406449029, "bm25_max": 6.478488118169924, "bge_top3": null, "bge_max": null, "title": "Everolimus: Drug information", "rep_snippet": "SEGA: Adjustment to initial dose may not be necessary; subsequent dosing is based on therapeutic drug monitoring (monitor ~2 weeks after initiation, dosage modifications, or after any change in hepatic status; target tro…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 5.150090698143968, "bm25_max": 6.2654530313421635, "bge_top3": 0.4848553389310837, "bge_max": 0.4906182587146759, "title": "Vancomycin: Drug information", "rep_snippet": "Monitoring Parameters  Intravenous: Periodic renal function tests, CBC; serum trough vancomycin concentrations in select patients (eg, aggressive dosing, life-threatening infection, seriously ill, unstable renal function…"}, {"doc_id": "glycerol-phenylbutyrate-drug-information", "bm25_top3": 5.698527357160888, "bm25_max": 5.698527357160888, "bge_top3": null, "bge_max": null, "title": "Glycerol phenylbutyrate: Drug information", "rep_snippet": "Probenecid: May increase serum concentrations of the active metabolite(s) of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased. Risk C: Monitor therapy…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": 5.444866463108401, "bm25_max": 5.444866463108401, "bge_top3": 0.5018690228462219, "bge_max": 0.5018690228462219, "title": "Posaconazole: Drug information", "rep_snippet": "Reference Range  Timing of concentrations: Obtain trough after steady state has been reached (>7 days after therapy initiation [steady state usually occurs between 7 and 10 days for the oral suspension and at 6 days for…"}, {"doc_id": "factor-xiii-concentrate-from-human-plasma-drug-information", "bm25_top3": 4.183288835860907, "bm25_max": 4.183288835860907, "bge_top3": null, "bge_max": null, "title": "Factor XIII, concentrate from human plasma: Drug information", "rep_snippet": "Dosing: Adult  Congenital factor XIII deficiency: IV:  Prophylaxis:  Initial: 40 units/kg  Maintenance: Dose adjustment should be based on factor XIII activity trough levels (target level of 5% to 20% using Berichrom act…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": 2.651894909608428, "bm25_max": 3.7737997114367126, "bge_top3": 0.48844873905181885, "bge_max": 0.5032230615615845, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Alternative monitoring (renal transplant): Two-hour post cyclosporine dose level (obtaining a level 2 hours after administration correlates well with drug exposure throughout the 12-hour dosing interval [Schiff 2007])  I…"}, {"doc_id": "tacrolimus-systemic-drug-information", "bm25_top3": 3.4316281701861846, "bm25_max": 3.63811454310763, "bge_top3": null, "bge_max": null, "title": "Tacrolimus (systemic): Drug information", "rep_snippet": "IV: Initial: 0.01 mg/kg/day as a continuous infusion  Conversion from oral to continuous IV infusion: According to the ISHLT guidelines for the care of heart transplant recipients, convert from oral to IV by administerin…"}, {"doc_id": "protein-c-concentrate-from-human-plasma-drug-information", "bm25_top3": 3.4263080892865894, "bm25_max": 3.4263080892865894, "bge_top3": null, "bge_max": null, "title": "Protein C, concentrate from human plasma: Drug information", "rep_snippet": "Reference Range  Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. After resolution of the acute episode or for long-term prophylaxis, maintain trough levels of protein C a…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 2.6789597951487822, "bm25_max": 3.348018430801492, "bge_top3": null, "bge_max": null, "title": "Streptomycin: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT): Administer 7.5 mg/kg/dose every 24 hours; monitor levels. Note: Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate…"}, {"doc_id": "methylfolate-drug-information", "bm25_top3": 3.2284442111629765, "bm25_max": 3.2284442111629765, "bge_top3": null, "bge_max": null, "title": "Methylfolate: Drug information", "rep_snippet": "Valproate Products: Methylfolate may decrease the serum concentration of Valproate Products. Risk C: Monitor therapy"}, {"doc_id": "factor-xiii-a-subunit-recombinant-human-drug-information", "bm25_top3": 2.8264460606574726, "bm25_max": 2.8264460606574726, "bge_top3": null, "bge_max": null, "title": "Factor XIII A-subunit, recombinant human: Drug information", "rep_snippet": "Dosing: Adult  Factor XIII A-subunit deficiency: IV: 35 units/kg once monthly to achieve a target trough level of factor XIII activity ≥10% using a validated assay; consider dose adjustment if adequate coverage is not ac…"}, {"doc_id": "tiagabine-drug-information", "bm25_top3": 2.7555110266818836, "bm25_max": 2.7555110266818836, "bge_top3": null, "bge_max": null, "title": "Tiagabine: Drug information", "rep_snippet": "Reference Range  A therapeutic range for tiagabine plasma concentrations has not been established. Because of the potential for pharmacokinetic interactions between tiagabine and drugs that induce or inhibit hepatic meta…"}, {"doc_id": "methylfolate-methylcobalamin-and-acetylcysteine-drug-information", "bm25_top3": 2.4789721079468503, "bm25_max": 2.4789721079468503, "bge_top3": null, "bge_max": null, "title": "Methylfolate, methylcobalamin, and acetylcysteine: Drug information", "rep_snippet": "SulfaSALAzine: May decrease the serum concentration of Methylfolate. Risk C: Monitor therapy  Valproate Products: Methylfolate may decrease the serum concentration of Valproate Products. Risk C: Monitor therapy"}, {"doc_id": "ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-drug-information", "bm25_top3": 2.313975053681954, "bm25_max": 2.313975053681954, "bge_top3": null, "bge_max": null, "title": "Ovine polyvalent crotalidae North and South American snake antivenom: Drug information", "rep_snippet": "Mechanism of Action  A venom-specific fragment of IgG, which binds and neutralizes venom toxin, helping to remove the toxin from the target tissue and eliminate it from the body."}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": 2.2705276283234603, "bm25_max": 2.2705276283234603, "bge_top3": null, "bge_max": null, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Synergy dosing (off-label dose): Children and Adolescents: IV: 3 to 6 mg/kg/day divided every 8 hours in combination with other antibiotics; adjust dose to achieve a target peak concentration of 3 to 4 mcg/mL and trough…"}, {"doc_id": "kanamycin-united-states-not-available-drug-information", "bm25_top3": 2.125313211866919, "bm25_max": 2.125313211866919, "bge_top3": null, "bge_max": null, "title": "Kanamycin (United States: Not available): Drug information", "rep_snippet": "Reference Range  Therapeutic: Peak: 15-30 mcg/mL; Trough: 5-10 mcg/mL; Toxic: Peak: >35 mcg/mL; Trough: >10 mcg/mL"}, {"doc_id": "centruroides-antivenom-drug-information", "bm25_top3": 1.9704043063273353, "bm25_max": 1.9704043063273353, "bge_top3": null, "bge_max": null, "title": "Centruroides antivenom: Drug information", "rep_snippet": "Mechanism of Action  Contains venom-specific F(ab’)2 fragments of IgG which bind and neutralize venom toxins; thereby helping to remove the toxin from the target tissue and eliminate it from the body."}, {"doc_id": "meropenem-drug-information", "bm25_top3": 1.955526211556716, "bm25_max": 1.955526211556716, "bge_top3": 0.46708717942237854, "bge_max": 0.46708717942237854, "title": "Meropenem: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Kuti 2005; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close mon…"}, {"doc_id": "radium-223-drug-information", "bm25_top3": 1.9516571101277371, "bm25_max": 1.9516571101277371, "bge_top3": null, "bge_max": null, "title": "Radium-223: Drug information", "rep_snippet": "Mechanism of Action  Alpha particle-emitting isotope; emits high energy, short-range alpha particles which target bone metastases; mimics calcium to form complexes with bone mineral in areas with increased bone turnover.…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 1.7597706582867527, "bm25_max": 1.7597706582867527, "bge_top3": 0.47261476516723633, "bge_max": 0.4768355190753937, "title": "Voriconazole: Drug information", "rep_snippet": "Infants and Children <2 years (off-label): IV, Oral (oral suspension): Initial: 9 mg/kg/dose every 12 hours followed by monitoring of serum trough concentrations typically initiated after 3 to 5 days; adjust dose to achi…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 1.695463166234486, "bm25_max": 1.695463166234486, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Monitoring Parameters  IV: Serum calcium, sodium and phosphorus levels; renal function; after IV phosphate repletion, repeat serum phosphorus level should be checked 2-4 hours later  Oral: Bowel cleansing: Baseline and p…"}, {"doc_id": "daptomycin-drug-information", "bm25_top3": 1.5826901064376333, "bm25_max": 1.5826901064376333, "bge_top3": 0.4798511266708374, "bge_max": 0.4798511266708374, "title": "Daptomycin: Drug information", "rep_snippet": "Reference Range  Trough concentrations at steady-state:  4 mg/kg once daily: 5.9 ± 1.6 mcg/mL  6 mg/kg once daily: 6.7 ± 1.6 mcg/mL  Note: Routine trough monitoring is not recommended. Trough concentrations are not predi…"}, {"doc_id": "carbamazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5018506646156311, "bge_max": 0.5018506646156311, "title": "Carbamazepine: Drug information", "rep_snippet": "Valproate Products: May increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased, decreased, or unchanged. CarBAMazepine may decrease the serum conc…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4919808506965637, "bge_max": 0.4919808506965637, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "Tenofovir Disoproxil Fumarate: Velpatasvir may increase the serum concentration of Tenofovir Disoproxil Fumarate. Risk C: Monitor therapy  Tipranavir: May decrease the serum concentration of Sofosbuvir. Risk X: Avoid com…"}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4919808506965637, "bge_max": 0.4919808506965637, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "Tenofovir Disoproxil Fumarate: Velpatasvir may increase the serum concentration of Tenofovir Disoproxil Fumarate. Risk C: Monitor therapy  Tipranavir: May decrease the serum concentration of Sofosbuvir. Risk X: Avoid com…"}, {"doc_id": "tipranavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4817473888397217, "bge_max": 0.4817473888397217, "title": "Tipranavir: Drug information", "rep_snippet": "St John's Wort: May decrease the serum concentration of Tipranavir. Risk X: Avoid combination  Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic). Risk D: Consider therapy mod…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.47760602831840515, "bge_max": 0.47760602831840515, "title": "Phenobarbital: Drug information", "rep_snippet": "Valbenazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. Risk X: Avoid combination  Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease th…"}, {"doc_id": "hyoscyamine-atropine-scopolamine-and-phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.47760602831840515, "bge_max": 0.47760602831840515, "title": "Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information", "rep_snippet": "Valbenazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. Risk X: Avoid combination  Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease th…"}, {"doc_id": "bexarotene-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4775770306587219, "bge_max": 0.4775770306587219, "title": "Bexarotene (systemic): Drug information", "rep_snippet": "Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. Risk X: Avoid combination  Tamoxifen: Bexarotene (Systemic) may decrease the serum concentration of Tamoxifen. Risk C: Monitor ther…"}, {"doc_id": "etravirine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4766293466091156, "bge_max": 0.4766293466091156, "title": "Etravirine: Drug information", "rep_snippet": "Telaprevir: Etravirine may decrease the serum concentration of Telaprevir. Risk C: Monitor therapy  Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. Risk C:…"}, {"doc_id": "rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.47661134600639343, "bge_max": 0.47661134600639343, "title": "Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy  Simeprevir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Simeprevir. Sime…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.47062626481056213, "bge_max": 0.4745742678642273, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Absorption: Oral: Rapid; almost completely (90% to 100%)  Distribution: Both SMX and TMP distribute to middle ear fluid, sputum, vaginal fluid; TMP also distributes into bronchial secretions  V…"}, {"doc_id": "modafinil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.47454699873924255, "bge_max": 0.47454699873924255, "title": "Modafinil: Drug information", "rep_snippet": "Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy  Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. Risk…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.47240665555000305, "bge_max": 0.47240665555000305, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Valbenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine. Risk C: Monitor therapy  Valproate Products: May decrease the serum concentration of OLANZapine. Risk…"}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.47170522809028625, "bge_max": 0.47170522809028625, "title": "Fosphenytoin: Drug information", "rep_snippet": "Valproate Products: May decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentration…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.47170522809028625, "bge_max": 0.47170522809028625, "title": "Phenytoin: Drug information", "rep_snippet": "Valproate Products: May decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentration…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.46632957458496094, "bge_max": 0.47100359201431274, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Suspension, Oral:  Entre-Cough Tannate: Guaifenesin 175 mg, pseudoephedrine hydrochloride 30 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (473 mL [DSC]) [contains aspartame, fd&c red #40, methylparaben, sodium be…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4687842130661011, "bge_max": 0.4687842130661011, "title": "Topiramate: Drug information", "rep_snippet": "Children 4 to 17 years: Mean range: 1 to 2.8 hours (Rosenfeld 1999)  Adults: 2 hours; range: 1.4 to 4.3 hours  Extended release: Qudexy XR: ~20 hours; Trokendi XR: ~24 hours  Excretion: Urine (~70% as unchanged drug); ma…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4684624969959259, "bge_max": 0.4684624969959259, "title": "Apalutamide: Drug information", "rep_snippet": "Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan. Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) m…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4677228629589081, "bge_max": 0.4677228629589081, "title": "Fluconazole: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4675123393535614, "bge_max": 0.4675123393535614, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Rosuvastatin: Eslicarbazepine may decrease the serum concentration of Rosuvastatin. Risk C: Monitor therapy  Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. Risk X: Avoid combin…"}, {"doc_id": "ethosuximide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4672253131866455, "bge_max": 0.4672253131866455, "title": "Ethosuximide: Drug information", "rep_snippet": "Valproate Products: Ethosuximide may decrease the serum concentration of Valproate Products. Valproate Products may increase the serum concentration of Ethosuximide. Risk C: Monitor therapy  Zolpidem: CNS Depressants may…"}, {"doc_id": "chlorpromazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4669555723667145, "bge_max": 0.4669555723667145, "title": "Chlorpromazine: Drug information", "rep_snippet": "Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination  Valproate Products: ChlorproMAZINE may increase the serum concentration of Valproate Products. Risk C: Monitor th…"}, {"doc_id": "protamine-sulfate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4658316373825073, "bge_max": 0.4658316373825073, "title": "Protamine sulfate: Drug information", "rep_snippet": "Dalteparin, nadroparin, and tinzaparin: 1 mg protamine for every 100 anti-Xa units of LMWH administered in the past 3 to 5 half-lives; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If life…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4657256007194519, "bge_max": 0.4657256007194519, "title": "Theophylline: Drug information", "rep_snippet": "Quibron TSR (LK);  Respicur retard (AT);  Retafyllin (EE, HU);  Slo-Phyllin (AE, BH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);  Slo-Theo (HK);  Solosin (DE);  Somofillina (IT);  Teoclear (KR);  Teoclear LA…"}, {"doc_id": "rolapitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.46425795555114746, "bge_max": 0.46425795555114746, "title": "Rolapitant: Drug information", "rep_snippet": "St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindic…"}, {"doc_id": "efavirenz-lamivudine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.46391645073890686, "bge_max": 0.46391645073890686, "title": "Efavirenz, lamivudine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Trimethoprim: May increase the serum concentration of LamiVUDine. Risk C: Monitor therapy  Ulipristal: Efavirenz may decrea…"}, {"doc_id": "pralatrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4638727605342865, "bge_max": 0.4638727605342865, "title": "Pralatrexate: Drug information", "rep_snippet": "Sulfamethoxazole: May increase the serum concentration of PRALAtrexate. More specifically, sulfamethoxazole may decrease excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum level and/o…"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4637352228164673, "bge_max": 0.4637352228164673, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Reference Range  The metabolite of oxcarbazepine, 10-monohydroxy metabolite (MHD), is considered the active entity primarily responsible for the therapeutic effects. A number of studies have suggested optimal MHD concent…"}, {"doc_id": "temsirolimus-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.46207475662231445, "bge_max": 0.46207475662231445, "title": "Temsirolimus: Drug information", "rep_snippet": "Mechanism of Action  Temsirolimus and its active metabolite, sirolimus, are targeted inhibitors of mTOR (mechanistic target of rapamycin) kinase activity. Temsirolimus (and sirolimus) bind to FKBP-12, an intracellular pr…"}, {"doc_id": "salsalate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.46127837896347046, "bge_max": 0.46127837896347046, "title": "Salsalate: Drug information", "rep_snippet": "Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. Risk C: Monitor therapy  Valproate Products: Salicylates may increase the serum conce…"}, {"doc_id": "haloperidol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.4610098600387573, "bge_max": 0.4610098600387573, "title": "Haloperidol: Drug information", "rep_snippet": "Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Risk X: Avoid combination  Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C…"}, {"doc_id": "efavirenz-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.46055716276168823, "bge_max": 0.46055716276168823, "title": "Efavirenz, emtricitabine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy  Ulipristal: Efavirenz may decrease the serum concentration of Ulipristal. Risk X: Avoid combination  Velpatasvir: CYP2B6 In…"}]}
{"qid": "Q24_abbr+timing-cue", "query": "Hypothyroidism — levothyroxine dose conversion & admin timing; interactions (food/iron/Ca).", "base_qid": "Q24", "variant_type": "abbr+timing-cue", "candidates": [{"doc_id": "levothyroxine-drug-information", "bm25_top3": 33.334616065728696, "bm25_max": 34.623972130789376, "bge_top3": 0.7309927145640055, "bge_max": 0.7444260716438293, "title": "Levothyroxine: Drug information", "rep_snippet": "Food Interactions  Taking levothyroxine with enteral nutrition may cause reduced bioavailability and may lower serum thyroxine levels leading to signs or symptoms of hypothyroidism. Soybean flour (infant formula), soy, g…"}, {"doc_id": "ferrous-sulfate-drug-information", "bm25_top3": 32.098216723668926, "bm25_max": 32.098216723668926, "bge_top3": null, "bge_max": null, "title": "Ferrous sulfate: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "polysaccharide-iron-complex-drug-information", "bm25_top3": 32.098216723668926, "bm25_max": 32.098216723668926, "bge_top3": null, "bge_max": null, "title": "Polysaccharide-iron complex: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information", "bm25_top3": 31.24812969889871, "bm25_max": 31.24812969889871, "bge_top3": 0.678009033203125, "bge_max": 0.678009033203125, "title": "Polysaccharide-iron complex, vitamin B12, and folic acid: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "polysaccharide-iron-complex-and-folic-acid-drug-information", "bm25_top3": 31.24812969889871, "bm25_max": 31.24812969889871, "bge_top3": 0.678009033203125, "bge_max": 0.678009033203125, "title": "Polysaccharide-iron complex and folic acid: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "multiple-vitamins-drug-information", "bm25_top3": 27.019750559485985, "bm25_max": 27.019750559485985, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins: Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "multiple-vitamins-pediatric-drug-information", "bm25_top3": 27.019750559485985, "bm25_max": 27.019750559485985, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins (pediatric): Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "iron-dextran-drug-information", "bm25_top3": 25.614303909441176, "bm25_max": 25.614303909441176, "bge_top3": null, "bge_max": null, "title": "Iron dextran: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving…"}, {"doc_id": "liotrix-drug-information", "bm25_top3": 21.23879646032951, "bm25_max": 25.001651557719587, "bge_top3": 0.7424508333206177, "bge_max": 0.7477983832359314, "title": "Liotrix: Drug information", "rep_snippet": "Dosing: Adult  Hypothyroidism: Oral:  Initial: Levothyroxine 25 mcg/liothyronine 6.25 mcg once daily; a lower initial dose (levothyroxine 12.5 mcg/liothyronine 3.1 mcg) is recommended in patients with long-standing myxed…"}, {"doc_id": "ferric-citrate-drug-information", "bm25_top3": 15.163722318603071, "bm25_max": 21.441953766724247, "bge_top3": 0.6837021112442017, "bge_max": 0.6837021112442017, "title": "Ferric citrate: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "ferrous-fumarate-drug-information", "bm25_top3": 21.098216723668926, "bm25_max": 21.098216723668926, "bge_top3": null, "bge_max": null, "title": "Ferrous fumarate: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "ferrous-gluconate-drug-information", "bm25_top3": 21.098216723668926, "bm25_max": 21.098216723668926, "bge_top3": null, "bge_max": null, "title": "Ferrous gluconate: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "orlistat-drug-information", "bm25_top3": 17.38170083899989, "bm25_max": 17.38170083899989, "bge_top3": null, "bge_max": null, "title": "Orlistat: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amiodarone: Orlistat may decrease the serum concentration of Amiodarone. Risk C: Monitor therapy  Anticonvulsants: Orlistat may decrease…"}, {"doc_id": "sucroferric-oxyhydroxide-drug-information", "bm25_top3": 16.92559429911721, "bm25_max": 16.92559429911721, "bge_top3": 0.6741589903831482, "bge_max": 0.6741589903831482, "title": "Sucroferric oxyhydroxide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Levothyroxine: Sucroferric Oxyhydroxide may decrease the serum concentration of Levothyroxine. Management: Avoid the use of oral/enteral…"}, {"doc_id": "multiple-vitamins-prenatal-drug-information", "bm25_top3": 16.019750559485985, "bm25_max": 16.019750559485985, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins (prenatal): Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "vitamin-b-complex-drug-information", "bm25_top3": 16.019750559485985, "bm25_max": 16.019750559485985, "bge_top3": null, "bge_max": null, "title": "Vitamin B complex: Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "famciclovir-drug-information", "bm25_top3": 15.539098321995425, "bm25_max": 15.539098321995425, "bge_top3": null, "bge_max": null, "title": "Famciclovir: Drug information", "rep_snippet": "Food Interactions  Rate of absorption and/or conversion to penciclovir and peak concentration are reduced with food, but bioavailability is not affected. Management: Administer without regard to meals."}, {"doc_id": "calcium-carbonate-drug-information", "bm25_top3": 15.416074079124265, "bm25_max": 15.416074079124265, "bge_top3": null, "bge_max": null, "title": "Calcium carbonate: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer with food."}, {"doc_id": "calcium-glubionate-drug-information", "bm25_top3": 15.300691837495997, "bm25_max": 15.300691837495997, "bge_top3": null, "bge_max": null, "title": "Calcium glubionate: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer preferably with…"}, {"doc_id": "calcium-and-vitamin-d-drug-information", "bm25_top3": 15.300691837495997, "bm25_max": 15.300691837495997, "bge_top3": null, "bge_max": null, "title": "Calcium and vitamin D: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer preferably with…"}, {"doc_id": "entacapone-drug-information", "bm25_top3": 15.21460493369785, "bm25_max": 15.21460493369785, "bge_top3": null, "bge_max": null, "title": "Entacapone: Drug information", "rep_snippet": "Food Interactions  Entacapone has been reported to chelate iron and decreasing serum iron levels were noted in clinical trials; however, clinically significant anemia has not been observed."}, {"doc_id": "etidronate-and-calcium-united-states-not-available-drug-information", "bm25_top3": 14.85436487713449, "bm25_max": 14.85436487713449, "bge_top3": null, "bge_max": null, "title": "Etidronate and calcium (United States: Not available): Drug information", "rep_snippet": "Food Interactions  Food decreases the absorption and bioavailability of etidronate. Management: Administer on an empty stomach with a full glass of water 2 hours before or after food/supplements with calcium, iron, or ma…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 13.783557501266532, "bm25_max": 13.783557501266532, "bge_top3": null, "bge_max": null, "title": "Doxycycline: Drug information", "rep_snippet": "Food Interactions  Ethanol: Chronic ethanol ingestion may reduce the serum concentration of doxycycline.  Food: Doxycycline serum levels may be slightly decreased if taken with high-fat meal or milk. Administration with…"}, {"doc_id": "carvedilol-drug-information", "bm25_top3": 13.781961162384228, "bm25_max": 13.781961162384228, "bge_top3": null, "bge_max": null, "title": "Carvedilol: Drug information", "rep_snippet": "Food Interactions  Food decreases rate but not extent of absorption. Management: Administration with food minimizes risks of orthostatic hypotension."}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 13.330577104727777, "bm25_max": 13.330577104727777, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Food Interactions  Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron. Management: Supplementation of…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 13.053248890954976, "bm25_max": 13.053248890954976, "bge_top3": 0.6818920969963074, "bge_max": 0.6818920969963074, "title": "Amiodarone: Drug information", "rep_snippet": "Food Interactions  Food increases the rate and extent of absorption of amiodarone. Grapefruit juice increases bioavailability of oral amiodarone by 50% and decreases the conversion of amiodarone to N-DEA (active metaboli…"}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 12.691317248081155, "bm25_max": 12.691317248081155, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "Food Interactions  All food and beverages may interfere with absorption. Coadministration with dairy products may decrease absorption. Beverages (especially orange juice and coffee), food, and medications (eg, antacids,…"}, {"doc_id": "penicillamine-drug-information", "bm25_top3": 12.420655153375266, "bm25_max": 12.420655153375266, "bge_top3": null, "bge_max": null, "title": "Penicillamine: Drug information", "rep_snippet": "Food Interactions  Penicillamine serum levels may be decreased if taken with food. Management: Administer on an empty stomach 1 hour before or 2 hours after meals and at least 1 hour apart from other drugs, milk, antacid…"}, {"doc_id": "etidronate-drug-information", "bm25_top3": 12.35815578829839, "bm25_max": 12.35815578829839, "bge_top3": null, "bge_max": null, "title": "Etidronate: Drug information", "rep_snippet": "Food Interactions  Food and/or supplements decrease the absorption and bioavailability of the drug. Management: Administer tablet on an empty stomach with a full glass of plain water or fruit juice (6-8 oz) 2 hours befor…"}, {"doc_id": "telotristat-ethyl-drug-information", "bm25_top3": 11.63644650780163, "bm25_max": 11.63644650780163, "bge_top3": null, "bge_max": null, "title": "Telotristat ethyl: Drug information", "rep_snippet": "Food Interactions  Administration with food results in higher exposure to telotristat ethyl and telotristat."}, {"doc_id": "patiromer-drug-information", "bm25_top3": 11.534698898125548, "bm25_max": 11.534698898125548, "bge_top3": null, "bge_max": null, "title": "Patiromer: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Ciprofloxacin (Systemic): Patiromer may decrease the serum concentration of Ciprofloxacin (Systemic). Management: Administer oral ciprofl…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": 11.116353095217491, "bm25_max": 11.116353095217491, "bge_top3": null, "bge_max": null, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Dietary Considerations  Take with food. The type or timing of a meal is not important as long as dose is taken with food."}, {"doc_id": "imatinib-drug-information", "bm25_top3": 10.277135079659871, "bm25_max": 10.277135079659871, "bge_top3": 0.6722055673599243, "bge_max": 0.6722055673599243, "title": "Imatinib: Drug information", "rep_snippet": "• Gastric surgery: Imatinib exposure may be reduced in patients who have had gastric surgery (eg, bypass, major gastrectomy, or resection); monitor imatinib trough concentrations (Liu 2011; Pavlovsky 2009; Yoo 2010).  •…"}, {"doc_id": "ferumoxytol-drug-information", "bm25_top3": 10.252131158382312, "bm25_max": 10.252131158382312, "bge_top3": 0.6894335746765137, "bge_max": 0.6894335746765137, "title": "Ferumoxytol: Drug information", "rep_snippet": "Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult d…"}, {"doc_id": "sunitinib-drug-information", "bm25_top3": 9.654375379725288, "bm25_max": 9.654375379725288, "bge_top3": null, "bge_max": null, "title": "Sunitinib: Drug information", "rep_snippet": "• Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported rarely (some fatal). Symptoms of RPLS include confusion, headache, hypertension, lethargy, s…"}, {"doc_id": "methimazole-drug-information", "bm25_top3": 7.681980964000974, "bm25_max": 7.681980964000974, "bge_top3": 0.6871272027492523, "bge_max": 0.7022558450698853, "title": "Methimazole: Drug information", "rep_snippet": "• Hypothyroidism: May cause hypothyroidism; routinely monitor TSH and free T4 levels, adjust dose to maintain euthyroid state.  • Lupus-like syndrome: A lupus-like syndrome may occur.  • Vasculitis: ANCA-positive vasculi…"}, {"doc_id": "tacrolimus-systemic-drug-information", "bm25_top3": 6.000828345177437, "bm25_max": 6.000828345177437, "bge_top3": null, "bge_max": null, "title": "Tacrolimus (systemic): Drug information", "rep_snippet": "Dietary Considerations  Capsule: Administer immediate release with or without food; be consistent with timing and composition of meals, food decreases bioavailability. Administer extended release on an empty stomach 1 ho…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": 4.037154460023855, "bm25_max": 4.037154460023855, "bge_top3": null, "bge_max": null, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "Administration  Administer with or without food. Do not take within 2 hours of sucralfate, didanosine, iron, zinc, or antacids containing magnesium, calcium, or aluminum."}, {"doc_id": "liothyronine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7065413395563761, "bge_max": 0.730583906173706, "title": "Liothyronine: Drug information", "rep_snippet": "Dosing: Adult  Hypothyroidism: Oral: Initial: 25 mcg once daily; may increase by up to 25 mcg/day every 1 to 2 weeks; usual maintenance dose: 25 to 75 mcg once daily  Patients with cardiovascular disease: Initial: 5 mcg…"}, {"doc_id": "thyroid-extract-desiccated-thyroid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7001389265060425, "bge_max": 0.7055222988128662, "title": "Thyroid extract (desiccated thyroid): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "digoxin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6968683004379272, "bge_max": 0.6968683004379272, "title": "Digoxin: Drug information", "rep_snippet": "• Thyroid disease: Use with caution in patients with hypothyroidism, higher digoxin concentrations may result due to significant reduction in digoxin clearance (Burk 2010). In patients with hyperthyroidism, lower digoxin…"}, {"doc_id": "propranolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6893028020858765, "bge_max": 0.6893028020858765, "title": "Propranolol: Drug information", "rep_snippet": "• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid st…"}, {"doc_id": "carbidopa-levodopa-and-entacapone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6869683861732483, "bge_max": 0.6869683861732483, "title": "Carbidopa, levodopa, and entacapone: Drug information", "rep_snippet": "Dietary Considerations  Distribute protein intake throughout the day to avoid fluctuations in levodopa absorption. Separate dosing of iron supplements and multivitamins with minerals."}, {"doc_id": "fludrocortisone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6865531802177429, "bge_max": 0.6865531802177429, "title": "Fludrocortisone: Drug information", "rep_snippet": "• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.  Concurrent drug therapy issue…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6864275932312012, "bge_max": 0.6864275932312012, "title": "Apalutamide: Drug information", "rep_snippet": "• Thyroid dysfunction: Hypothyroidism and elevated thyroid stimulating hormone (TSH) have been reported with apalutamide; the median onset was ~4 months (there were no grade 3 or 4 hypothyroid events). Thyroid replacemen…"}, {"doc_id": "cortisone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6864221096038818, "bge_max": 0.6864221096038818, "title": "Cortisone acetate: Drug information", "rep_snippet": "• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.  Concurrent drug therapy issue…"}, {"doc_id": "propylthiouracil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6820251941680908, "bge_max": 0.6822733879089355, "title": "Propylthiouracil: Drug information", "rep_snippet": "Dosing: Adult  Hyperthyroidism: Oral: Initial: 300 mg daily in 3 equally divided doses (~8-hour intervals); 400 mg daily in patients with severe hyperthyroidism and/or very large goiters; an occasional patient will requi…"}, {"doc_id": "sotalol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6809053421020508, "bge_max": 0.6809053421020508, "title": "Sotalol: Drug information", "rep_snippet": "• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid st…"}, {"doc_id": "buprenorphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6777807474136353, "bge_max": 0.6777807474136353, "title": "Buprenorphine: Drug information", "rep_snippet": "• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.  Concurrent drug therapy issues:"}, {"doc_id": "pasireotide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6743645668029785, "bge_max": 0.6743645668029785, "title": "Pasireotide: Drug information", "rep_snippet": "• Hypocortisolism: Suppression of the adrenocorticotropic hormone (ACTH) from therapy may lead to hypocortisolism in Cushing disease. Monitor all patients for signs or symptoms of hypocortisolism (eg, anorexia, fatigue,…"}, {"doc_id": "recombinant-human-parathyroid-hormone-1-84-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6728638410568237, "bge_max": 0.6728638410568237, "title": "Recombinant human parathyroid hormone (1-84): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "latanoprost-and-timolol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6725612282752991, "bge_max": 0.6725612282752991, "title": "Latanoprost and timolol (United States: Not available): Drug information", "rep_snippet": "• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid st…"}, {"doc_id": "darbepoetin-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6717047691345215, "bge_max": 0.6717047691345215, "title": "Darbepoetin alfa: Drug information", "rep_snippet": "Dosing: Adult  Note: Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is <100 ng/mL or serum transferrin saturation (TSAT)…"}]}
{"qid": "Q24_noise", "query": "Primary hypoT — how to convert to levo, when to take it, and what to separate it from?", "base_qid": "Q24", "variant_type": "noise", "candidates": [{"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 27.793386027898137, "bm25_max": 27.793386027898137, "bge_top3": 0.5500843524932861, "bge_max": 0.5500843524932861, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if immune globulin from these preparations is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy sho…"}, {"doc_id": "daclizumab-withdrawn-from-market-drug-information", "bm25_top3": 23.596026801080832, "bm25_max": 23.596026801080832, "bge_top3": null, "bge_max": null, "title": "Daclizumab (Withdrawn from market): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if daclizumab is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the ris…"}, {"doc_id": "betamethasone-and-gentamicin-united-states-not-available-drug-information", "bm25_top3": 23.482669939423996, "bm25_max": 23.482669939423996, "bge_top3": null, "bge_max": null, "title": "Betamethasone and gentamicin (United States: Not available): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if betamethasone/gentamicin is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": 23.260229270141657, "bm25_max": 23.260229270141657, "bge_top3": null, "bge_max": null, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if artemether or lumefantrine are excreted into breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 18.662042682473995, "bm25_max": 18.662042682473995, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Mercaptopurine is the active metabolite of azathioprine. Following administration of azathioprine, mercaptopurine can be detected in breast milk (Gardiner 2006). It is not known if/how much…"}, {"doc_id": "hydromorphone-drug-information", "bm25_top3": 18.50398477623105, "bm25_max": 18.50398477623105, "bge_top3": null, "bge_max": null, "title": "Hydromorphone: Drug information", "rep_snippet": "Conversion from other opioids to hydromorphone ER: Discontinue all other around-the-clock opioids when therapy is initiated. Substantial interpatient variability exists in relative potency. Therefore, it is safer to unde…"}, {"doc_id": "brodalumab-drug-information", "bm25_top3": 16.793386027898137, "bm25_max": 16.793386027898137, "bge_top3": null, "bge_max": null, "title": "Brodalumab: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if immune globulin from this preparation is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy shou…"}, {"doc_id": "felbamate-drug-information", "bm25_top3": 16.645045940072524, "bm25_max": 16.645045940072524, "bge_top3": null, "bge_max": null, "title": "Felbamate: Drug information", "rep_snippet": "Treatment with felbamate should be initiated only in individuals without active liver disease and with normal baseline serum transaminases. It has not been proved that periodic serum transaminase testing will prevent ser…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 16.258443948302734, "bm25_max": 16.258443948302734, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Mechanism of Action  Reacts with cystine within the lysosome to convert it to cysteine and to a cysteine-cysteamine mixed disulfide, both of which can then exit the lysosome in patients with cystinosis, an inherited defe…"}, {"doc_id": "cysteamine-ophthalmic-drug-information", "bm25_top3": 15.726312636970754, "bm25_max": 15.726312636970754, "bge_top3": null, "bge_max": null, "title": "Cysteamine (ophthalmic): Drug information", "rep_snippet": "Mechanism of Action  Reacts with cystine within the lysosome to convert it to cysteine and to a cysteine-cysteamine mixed disulfide, both of which can then exit the lysosome to reduce corneal cystine crystal accumulation…"}, {"doc_id": "recombinant-human-parathyroid-hormone-1-84-drug-information", "bm25_top3": 15.631983821279885, "bm25_max": 15.631983821279885, "bge_top3": null, "bge_max": null, "title": "Recombinant human parathyroid hormone (1-84): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if parathyroid hormone from this preparation is excreted into breast milk. According to the manufacturer, the decision breast-feed should take into account the risk of expos…"}, {"doc_id": "carvedilol-drug-information", "bm25_top3": 15.390993300770255, "bm25_max": 15.390993300770255, "bge_top3": null, "bge_max": null, "title": "Carvedilol: Drug information", "rep_snippet": "Conversion from immediate release to extended release (Coreg CR):  Current dose immediate-release tablets 3.125 mg twice daily: Convert to extended-release capsules 10 mg once daily  Current dose immediate-release tablet…"}, {"doc_id": "ammonium-lactate-topical-drug-information", "bm25_top3": 15.138109114783262, "bm25_max": 15.138109114783262, "bge_top3": null, "bge_max": null, "title": "Ammonium lactate (topical): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known how this medication affects normal levels of lactic acid in human milk. Because studies have not been done in nursing women, use with caution when needed."}, {"doc_id": "tacrolimus-systemic-drug-information", "bm25_top3": 15.100992975484754, "bm25_max": 15.100992975484754, "bge_top3": 0.5697810649871826, "bge_max": 0.5801345109939575, "title": "Tacrolimus (systemic): Drug information", "rep_snippet": "Note: May convert from twice-daily dosing to once-daily dosing (on a mg per mg basis) using the extended-release formulation (Astagraf XL [US] or Advagraf [Canada]) in stable lung transplant recipients (Mendez 2014). May…"}, {"doc_id": "pimavanserin-drug-information", "bm25_top3": 14.944995061130381, "bm25_max": 14.944995061130381, "bge_top3": null, "bge_max": null, "title": "Pimavanserin: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if pimavanserin is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infa…"}, {"doc_id": "fentanyl-drug-information", "bm25_top3": 14.689460847522405, "bm25_max": 14.689460847522405, "bge_top3": null, "bge_max": null, "title": "Fentanyl: Drug information", "rep_snippet": "Initial: To convert patients from oral or parenteral opioids to fentanyl transdermal patch, a 24-hour analgesic requirement should be calculated (based on prior opioid use). Using the tables below, the appropriate initia…"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": 14.679809584341466, "bm25_max": 14.679809584341466, "bge_top3": 0.5522236227989197, "bge_max": 0.5522236227989197, "title": "Hydrocodone: Drug information", "rep_snippet": "Conversion from other oral opioids (see tables): Discontinue all other around-the-clock opioids when hydrocodone ER is initiated. Substantial interpatient variability exists in relative potency and formulations. Therefor…"}, {"doc_id": "methadone-drug-information", "bm25_top3": 14.671990589973142, "bm25_max": 14.671990589973142, "bge_top3": null, "bge_max": null, "title": "Methadone: Drug information", "rep_snippet": "Manufacturer's labeling: Discontinue all other around-the-clock opioids when methadone therapy is initiated; fatalities have occurred in opioid-tolerant patients during conversion to methadone. Substantial interpatient v…"}, {"doc_id": "hepatitis-a-vaccine-drug-information", "bm25_top3": 14.607517346489395, "bm25_max": 14.607517346489395, "bge_top3": null, "bge_max": null, "title": "Hepatitis A vaccine: Drug information", "rep_snippet": "Dosing: Adult  Immunization: Note: Although it is preferred to use the vaccines according to their approved labeling, Havrix and VAQTA are considered to be interchangeable for booster doses (CDC/ACIP [Fiore 2006]).  Prim…"}, {"doc_id": "gallium-citrate-ga-67-drug-information", "bm25_top3": 14.357274459814256, "bm25_max": 14.357274459814256, "bge_top3": null, "bge_max": null, "title": "Gallium citrate Ga-67: Drug information", "rep_snippet": "Mechanism of Action  Gallium citrate Ga-67 is a radioactive diagnostic agent which accumulates in lysosomes and is bound to a soluble intracellular protein. It has been found to concentrate in certain viable primary and…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": 14.282525734294659, "bm25_max": 14.282525734294659, "bge_top3": null, "bge_max": null, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi…"}, {"doc_id": "crisaborole-drug-information", "bm25_top3": 13.782216488893624, "bm25_max": 13.782216488893624, "bge_top3": null, "bge_max": null, "title": "Crisaborole: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if crisaborole is excreted in breast milk; however, it is absorbed systemically following topical application. According to the manufacturer, the decision to continue or dis…"}, {"doc_id": "bromfenac-drug-information", "bm25_top3": 13.657671131076846, "bm25_max": 13.657671131076846, "bge_top3": null, "bge_max": null, "title": "Bromfenac: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if bromfenac is excreted in breast milk. The manufacturer recommends that caution be exercised when administering bromfenac to nursing women. According to one manufacturer,…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 13.622853707847831, "bm25_max": 13.622853707847831, "bge_top3": null, "bge_max": null, "title": "Iodixanol: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if iodixanol is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of infant exposure, the be…"}, {"doc_id": "ranolazine-drug-information", "bm25_top3": 12.944995061130381, "bm25_max": 12.944995061130381, "bge_top3": null, "bge_max": null, "title": "Ranolazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if ranolazine is excreted into breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the inf…"}, {"doc_id": "lesinurad-drug-information", "bm25_top3": 12.944995061130381, "bm25_max": 12.944995061130381, "bge_top3": null, "bge_max": null, "title": "Lesinurad: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if lesinurad is excreted in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant…"}, {"doc_id": "ixekizumab-drug-information", "bm25_top3": 12.944995061130381, "bm25_max": 12.944995061130381, "bge_top3": null, "bge_max": null, "title": "Ixekizumab: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if ixekizumab is excreted in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infan…"}, {"doc_id": "eluxadoline-drug-information", "bm25_top3": 12.944995061130381, "bm25_max": 12.944995061130381, "bge_top3": null, "bge_max": null, "title": "Eluxadoline: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if eluxadoline is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infan…"}, {"doc_id": "asenapine-drug-information", "bm25_top3": 12.944995061130381, "bm25_max": 12.944995061130381, "bge_top3": null, "bge_max": null, "title": "Asenapine: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if asenapine is excreted into breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infa…"}, {"doc_id": "fosaprepitant-drug-information", "bm25_top3": 12.944995061130381, "bm25_max": 12.944995061130381, "bge_top3": null, "bge_max": null, "title": "Fosaprepitant: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if fosaprepitant is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the inf…"}, {"doc_id": "rolapitant-drug-information", "bm25_top3": 12.944995061130381, "bm25_max": 12.944995061130381, "bge_top3": null, "bge_max": null, "title": "Rolapitant: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if rolapitant is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant…"}, {"doc_id": "plecanatide-drug-information", "bm25_top3": 12.93909243817447, "bm25_max": 12.93909243817447, "bge_top3": null, "bge_max": null, "title": "Plecanatide: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if plecanatide is present in breast milk; plecanatide and its metabolite are not measurable in plasma when used at recommended doses. According to the manufacturer, the deci…"}, {"doc_id": "ibrutinib-drug-information", "bm25_top3": 12.827159046005065, "bm25_max": 12.827159046005065, "bge_top3": null, "bge_max": null, "title": "Ibrutinib: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if ibrutinib is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the breastf…"}, {"doc_id": "mipomersen-drug-information", "bm25_top3": 12.827159046005065, "bm25_max": 12.827159046005065, "bge_top3": null, "bge_max": null, "title": "Mipomersen: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if mipomersen is excreted in breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infa…"}, {"doc_id": "obeticholic-acid-drug-information", "bm25_top3": 12.827159046005065, "bm25_max": 12.827159046005065, "bge_top3": null, "bge_max": null, "title": "Obeticholic acid: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if obeticholic acid is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the…"}, {"doc_id": "teriparatide-recombinant-human-parathyroid-hormone-1-34-drug-information", "bm25_top3": 12.827159046005065, "bm25_max": 12.827159046005065, "bge_top3": null, "bge_max": null, "title": "Teriparatide (recombinant human parathyroid hormone [1-34]): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if teriparatide is excreted in breast milk. According to the manufacturer, the decision to discontinue teriparatide or discontinue breast-feeding should take into account th…"}, {"doc_id": "nitazoxanide-drug-information", "bm25_top3": 12.827159046005065, "bm25_max": 12.827159046005065, "bge_top3": null, "bge_max": null, "title": "Nitazoxanide: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if nitazoxanide is excreted in breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the in…"}, {"doc_id": "linaclotide-drug-information", "bm25_top3": 12.734509762303123, "bm25_max": 12.734509762303123, "bge_top3": null, "bge_max": null, "title": "Linaclotide: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if linaclotide is excreted in breast milk; linaclotide and its metabolite are not measurable in plasma when used at recommended doses. According to the manufacturer, the dec…"}, {"doc_id": "edrophonium-drug-information", "bm25_top3": 12.710846537572984, "bm25_max": 12.710846537572984, "bge_top3": null, "bge_max": null, "title": "Edrophonium: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if edrophonium is excreted in breast milk. According to the Canadian manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure t…"}, {"doc_id": "sebelipase-alfa-drug-information", "bm25_top3": 12.710846537572984, "bm25_max": 12.710846537572984, "bge_top3": null, "bge_max": null, "title": "Sebelipase alfa: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if sebelipase alfa is excreted in breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the…"}, {"doc_id": "riboflavin-5-phosphate-ophthalmic-drug-information", "bm25_top3": 12.710846537572984, "bm25_max": 12.710846537572984, "bge_top3": null, "bge_max": null, "title": "Riboflavin 5'-phosphate (ophthalmic): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if riboflavin 5'-phosphate is excreted in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure…"}, {"doc_id": "uridine-triacetate-drug-information", "bm25_top3": 12.710846537572984, "bm25_max": 12.710846537572984, "bge_top3": null, "bge_max": null, "title": "Uridine triacetate: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if uridine triacetate is excreted into breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure t…"}, {"doc_id": "factor-ix-recombinant-human-with-albumin-fusion-drug-information", "bm25_top3": 12.596026801080832, "bm25_max": 12.596026801080832, "bge_top3": null, "bge_max": null, "title": "Factor IX, recombinant human with albumin fusion: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if factor IX (recombinant) is excreted in breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposur…"}, {"doc_id": "lacosamide-drug-information", "bm25_top3": 12.596026801080832, "bm25_max": 12.596026801080832, "bge_top3": null, "bge_max": null, "title": "Lacosamide: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if lacosamide is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the ris…"}, {"doc_id": "brexpiprazole-drug-information", "bm25_top3": 12.596026801080832, "bm25_max": 12.596026801080832, "bge_top3": null, "bge_max": null, "title": "Brexpiprazole: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if brexpiprazole is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the…"}, {"doc_id": "physostigmine-drug-information", "bm25_top3": 12.482669939423996, "bm25_max": 12.482669939423996, "bge_top3": null, "bge_max": null, "title": "Physostigmine: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if physostigmine is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account th…"}, {"doc_id": "protriptyline-drug-information", "bm25_top3": 12.482669939423996, "bm25_max": 12.482669939423996, "bge_top3": null, "bge_max": null, "title": "Protriptyline: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if protriptyline is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account th…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": 12.482669939423996, "bm25_max": 12.482669939423996, "bge_top3": null, "bge_max": null, "title": "Phenelzine: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if phenelzine is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the r…"}, {"doc_id": "trospium-drug-information", "bm25_top3": 12.482669939423996, "bm25_max": 12.482669939423996, "bge_top3": null, "bge_max": null, "title": "Trospium: Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if trospium is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the ris…"}, {"doc_id": "cetirizine-ophthalmic-drug-information", "bm25_top3": 12.33274065700843, "bm25_max": 12.33274065700843, "bge_top3": null, "bge_max": null, "title": "Cetirizine (ophthalmic): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known if cetirizine is present in breast milk following ophthalmic administration. When administered orally, cetirizine enters breast milk. The amount of cetirizine absorbed syste…"}, {"doc_id": "desmopressin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5737131834030151, "bge_max": 0.5737131834030151, "title": "Desmopressin: Drug information", "rep_snippet": "• Primary nocturnal enuresis: When using desmopressin for primary nocturnal enuresis, treatment should be interrupted if the patient experiences an acute illness (eg, fever, recurrent vomiting or diarrhea), vigorous exer…"}, {"doc_id": "captopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5709397196769714, "bge_max": 0.5709397196769714, "title": "Captopril: Drug information", "rep_snippet": "LV dysfunction following MI: Oral: Initial: 6.25 mg; if tolerated, follow with 12.5 mg 3 times daily; then increase to 25 mg 3 times daily during next several days and then gradually increase over next several weeks to t…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5690711140632629, "bge_max": 0.5690711140632629, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Prophylaxis (primary or secondary; alternative to preferred therapy): 100 mg daily once daily or in 2 divided doses as monotherapy or 50 mg daily in combination with weekly pyrimethamine and leucovorin or 200 mg weekly i…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5649893879890442, "bge_max": 0.5649893879890442, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Acute graft versus host disease (aGVHD), prevention (off-label use): Infants, Children, and Adolescents: IV followed by oral: Initial: 3 to 5 mg/kg/day in 2 divided doses (every 12 hours) administered over 2 hours or as…"}, {"doc_id": "nesiritide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5602990388870239, "bge_max": 0.5602990388870239, "title": "Nesiritide: Drug information", "rep_snippet": "Administration  IV: Do not administer through a heparin-coated catheter (concurrent administration of heparin via a separate catheter is acceptable, per manufacturer).  Prime IV tubing with 5 mL of infusion prior to conn…"}, {"doc_id": "vasopressin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5600917339324951, "bge_max": 0.5600917339324951, "title": "Vasopressin: Drug information", "rep_snippet": "Discontinuation (off-label): If vasopressin is used concurrently with other catecholamines (eg, norepinephrine), patients may experience hypotension if vasopressin is discontinued first (Bauer 2010). To prevent subsequen…"}, {"doc_id": "metoprolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5543883840243021, "bge_max": 0.5594149827957153, "title": "Metoprolol: Drug information", "rep_snippet": "Secondary prevention (off-label use): Oral: Immediate release (metoprolol tartrate): 25 to 100 mg twice daily; optimize dose based on heart rate and blood pressure; continue indefinitely (Olsson 1992).  Supraventricular…"}, {"doc_id": "sotalol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5581497550010681, "bge_max": 0.5581497550010681, "title": "Sotalol: Drug information", "rep_snippet": "Administration  Oral: Administer without regard to meals.  IV:  Substitution for oral: Administer over 5 hours; may prolong duration of infusion if QT interval prolongs to ≥500 msec.  Hemodynamically stable monomorphic V…"}, {"doc_id": "enalapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5565009117126465, "bge_max": 0.5565009117126465, "title": "Enalapril: Drug information", "rep_snippet": "Dosing: Adult  Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe HF, decreased renal function, or in those receiving diuretics.  Asymptomatic left ventricular dysfunction: Oral: Initial: 2.…"}, {"doc_id": "basiliximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5560866594314575, "bge_max": 0.5560866594314575, "title": "Basiliximab: Drug information", "rep_snippet": "Heart transplant (prophylaxis of acute rejection) (off-label use): IV: 20 mg on the day of transplant, followed by a second 20 mg dose on day 4 post-transplantation (in combination with other immunosuppressants) (Mehra 2…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5555457472801208, "bge_max": 0.5555457472801208, "title": "Everolimus: Drug information", "rep_snippet": "Liver transplantation, rejection prophylaxis (begin at least 30 days posttransplant): Oral: Initial: 1 mg twice daily (in combination with tacrolimus [reduced dose required] and a corticosteroid; adjust maintenance dose…"}, {"doc_id": "levothyroxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5482698082923889, "bge_max": 0.5540876388549805, "title": "Levothyroxine: Drug information", "rep_snippet": "Administration  Oral: Administer consistently in the morning on an empty stomach, at least 30 to 60 minutes before food. Alternatively, may consistently administer at night 3 to 4 hours after the last meal (AACE/ATA [Gar…"}, {"doc_id": "valproate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5536803603172302, "bge_max": 0.5536803603172302, "title": "Valproate: Drug information", "rep_snippet": "Conversion to Depakote ER from a stable dose of Depakote: May require an increase in the total daily dose between 8% and 20% to maintain similar serum concentrations.  Conversion to monotherapy from adjunctive therapy: T…"}, {"doc_id": "entacapone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5529099106788635, "bge_max": 0.5529099106788635, "title": "Entacapone: Drug information", "rep_snippet": "Administration  Always administer in association with levodopa/carbidopa; can be combined with both the immediate and sustained release formulations of levodopa/carbidopa. May be administered without regard to meals. Sho…"}, {"doc_id": "leucovorin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5524790287017822, "bge_max": 0.5524790287017822, "title": "Leucovorin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Leucovorin: Pediatric drug information\")  Note: Because oral absorption is saturable at doses >25 mg, administering single oral doses >25 mg is not recommended (convert…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.549777626991272, "bge_max": 0.5499171018600464, "title": "Phenytoin: Drug information", "rep_snippet": "Free phenytoin: 1 to 2.5 mg/L (SI: 4 to 10 micromole/L)  Total phenytoin:  Toxic: >30 mg/L (SI: >119 micromole/L)  Lethal: >100 mg/L (SI: >396 micromole/L)  When to draw levels (Winter 2010):  Key points: Time of samplin…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5466681122779846, "bge_max": 0.5498822331428528, "title": "Warfarin: Drug information", "rep_snippet": "Oral: Initial dosing must be individualized. Consider the patient (hepatic function, cardiac function, age, nutritional status, concurrent therapy, risk of bleeding) in addition to prior dose response (if available) and…"}, {"doc_id": "all-trans-retinoic-acid-systemic-tretinoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5498207211494446, "bge_max": 0.5498207211494446, "title": "All-trans retinoic acid (systemic tretinoin): Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  APL differentiation syndrome: Initiate dexamethasone 10 mg IV every 12 hours for 3 to 5 days; consider interrupting tretinoin until resolution of hypoxia  Liver function tests >5 times th…"}, {"doc_id": "letermovir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.54939204454422, "bge_max": 0.54939204454422, "title": "Letermovir: Drug information", "rep_snippet": "Dosing: Adult  Cytomegalovirus (CMV) prophylaxis, hematopoietic stem cell transplant (HSCT) patients: IV, Oral: 480 mg once daily beginning between day 0 and day 28 postallogeneic HSCT for CMV-seropositive recipients; co…"}, {"doc_id": "liothyronine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5490176677703857, "bge_max": 0.5490176677703857, "title": "Liothyronine: Drug information", "rep_snippet": "Alternative recommendation (use in combination with levothyroxine) (off-label dose): Initial: 5 to 20 mcg loading dose; maintenance: 2.5 to 10 mcg every 8 hours; continue therapy as clinically indicated. Lower dosages sh…"}, {"doc_id": "oxymorphone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5452853739261627, "bge_max": 0.5484009385108948, "title": "Oxymorphone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Mild impairment: Use with caution.  Oral:  Extended release:  Opioid naive: Initial: 5 mg/dose; titrate slowly with careful monitoring.  Prior opioid therapy: Initiate oxymorphone ER at 50% lo…"}, {"doc_id": "sirolimus-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5479565858840942, "bge_max": 0.5479565858840942, "title": "Sirolimus: Drug information", "rep_snippet": "GVHD (prevention): 12 mg loading dose on day -3, followed by 4 mg daily (target trough level: 3 to 12 ng/mL); taper off after 6 to 9 months (Armand 2008; Cutler 2007). Additional trials may be necessary to further define…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5469076633453369, "bge_max": 0.5469076633453369, "title": "Rivaroxaban: Drug information", "rep_snippet": "Postoperative DVT thromboprophylaxis: Oral: Note: Initiate therapy after hemostasis has been established, 6 to 10 hours postoperatively.  Knee replacement: 10 mg once daily; recommended total duration of therapy: 12 days…"}, {"doc_id": "nadroparin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.546258270740509, "bge_max": 0.546258270740509, "title": "Nadroparin (United States: Not available): Drug information", "rep_snippet": "LMWH is recommended over unfractionated heparin for the treatment of acute venous thromboembolism (VTE) in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with c…"}, {"doc_id": "morphine-sulfate-and-naltrexone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5444307923316956, "bge_max": 0.5457706451416016, "title": "Morphine sulfate and naltrexone: Drug information", "rep_snippet": "Conversion from other (non-morphine) oral/parenteral opioids to oral morphine: Specific recommendations are not available; refer to published relative potency data realizing that such ratios are only approximations. It i…"}, {"doc_id": "poractant-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5455523133277893, "bge_max": 0.5455523133277893, "title": "Poractant alfa: Drug information", "rep_snippet": "Insert the first aliquot (1.25 mL/kg birth weight) and position the infant so that either the right or left side is dependent for the aliquot. Remove the catheter and manually ventilate the infant with 100% oxygen at a r…"}, {"doc_id": "ado-trastuzumab-emtansine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5452941656112671, "bge_max": 0.5452941656112671, "title": "Ado-trastuzumab emtansine: Drug information", "rep_snippet": "LVEF 40% to ≤45% and decrease is ≥10% points from baseline: Withhold treatment and repeat LVEF assessment within 3 weeks; if repeat LVEF has not recovered to within 10% points from baseline, discontinue treatment.  LVEF…"}, {"doc_id": "alemtuzumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5450623631477356, "bge_max": 0.5450623631477356, "title": "Alemtuzumab: Drug information", "rep_snippet": "Graft versus host disease (GVHD), acute, steroid refractory, treatment (off-label use): Campath: IV: 10 mg daily for 5 consecutive days, then 10 mg weekly on days 8, 15, and 22 if CR not achieved (Martinez 2009) or 10 mg…"}, {"doc_id": "hemin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5441656112670898, "bge_max": 0.5441656112670898, "title": "Hemin: Drug information", "rep_snippet": "• Appropriate use: Although the manufacturer's labeling recommends initial therapy with glucose (ie, 400 g/day for 1 to 2 days), glucose may be appropriate for mild cases only and hemin should be initiated early for most…"}, {"doc_id": "tapentadol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5433506965637207, "bge_max": 0.5441436767578125, "title": "Tapentadol: Drug information", "rep_snippet": "Conversion from tapentadol immediate release to ER: Convert using same total daily dose but divide into 2 equal doses and administer every 12 hours.  Conversion from methadone to extended release tapentadol: Close monito…"}, {"doc_id": "vinorelbine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5434478521347046, "bge_max": 0.5434478521347046, "title": "Vinorelbine: Drug information", "rep_snippet": "Administration  For IV use only; FATAL IF GIVEN INTRATHECALLY. Administer as a direct intravenous push or rapid bolus, over 6 to 10 minutes (up to 30 minutes). Longer infusions may increase the risk of pain and phlebitis…"}, {"doc_id": "fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5431292653083801, "bge_max": 0.5431292653083801, "title": "Fresh frozen plasma (FFP), solvent/detergent treated: Drug information", "rep_snippet": "Dosing: Adult  Note: Administer based on ABO-blood compatibility.  Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or when undergoing cardiac surgery or liver trans…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5430827736854553, "bge_max": 0.5430827736854553, "title": "Ondansetron: Drug information", "rep_snippet": "American Society of Clinical Oncology Antiemetic Guideline recommendations (ASCO [Hesketh 2017]): Give before each fraction throughout radiation therapy for high emetic risk (with dexamethasone; continue for at least 24…"}, {"doc_id": "fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5429373383522034, "bge_max": 0.5429373383522034, "title": "Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Drug information", "rep_snippet": "Serious hemodynamic or other instability secondary to highly lipid soluble substances (off-label use): Administer initial bolus over 1 to 3 minutes followed by a continuous infusion. Chest compressions should continue du…"}, {"doc_id": "propranolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5421223640441895, "bge_max": 0.5421223640441895, "title": "Propranolol: Drug information", "rep_snippet": "Performance anxiety (off-label use): Oral: Immediate-release formulations: 40 mg 60 to 90 minutes prior to anxiety-provoking event (Hartley 1983). Additional data may be necessary to further define the role of propranolo…"}]}
{"qid": "Q24_spelling", "query": "Levothyroxin — dosing conversion + timing; iron/calcium food issues.", "base_qid": "Q24", "variant_type": "spelling", "candidates": [{"doc_id": "calcium-carbonate-drug-information", "bm25_top3": 24.306072310236807, "bm25_max": 24.306072310236807, "bge_top3": null, "bge_max": null, "title": "Calcium carbonate: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer with food."}, {"doc_id": "calcium-and-vitamin-d-drug-information", "bm25_top3": 21.029008248752632, "bm25_max": 24.19593236931095, "bge_top3": null, "bge_max": null, "title": "Calcium and vitamin D: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer preferably with…"}, {"doc_id": "calcium-glubionate-drug-information", "bm25_top3": 18.336922595187538, "bm25_max": 24.19593236931095, "bge_top3": null, "bge_max": null, "title": "Calcium glubionate: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer preferably with…"}, {"doc_id": "ferrous-sulfate-drug-information", "bm25_top3": 22.561558877194997, "bm25_max": 23.995164423144715, "bge_top3": 0.6796426177024841, "bge_max": 0.6796426177024841, "title": "Ferrous sulfate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ferrous sulfate: Pediatric drug information\")  Note: Multiple concentrations of ferrous sulfate oral liquid exist; close attention must be paid to the concentration whe…"}, {"doc_id": "etidronate-and-calcium-united-states-not-available-drug-information", "bm25_top3": 18.888143927745453, "bm25_max": 21.444837261093724, "bge_top3": 0.6791219115257263, "bge_max": 0.6791219115257263, "title": "Etidronate and calcium (United States: Not available): Drug information", "rep_snippet": "Food Interactions  Food decreases the absorption and bioavailability of etidronate. Management: Administer on an empty stomach with a full glass of water 2 hours before or after food/supplements with calcium, iron, or ma…"}, {"doc_id": "polysaccharide-iron-complex-drug-information", "bm25_top3": 21.12795333124528, "bm25_max": 21.12795333124528, "bge_top3": 0.6796426177024841, "bge_max": 0.6796426177024841, "title": "Polysaccharide-iron complex: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information", "bm25_top3": 20.593739198155056, "bm25_max": 20.593739198155056, "bge_top3": 0.6824638843536377, "bge_max": 0.7106499671936035, "title": "Polysaccharide-iron complex, vitamin B12, and folic acid: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "polysaccharide-iron-complex-and-folic-acid-drug-information", "bm25_top3": 20.593739198155056, "bm25_max": 20.593739198155056, "bge_top3": 0.6902868151664734, "bge_max": 0.7106499671936035, "title": "Polysaccharide-iron complex and folic acid: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "calcium-lactate-drug-information", "bm25_top3": 18.661054499081207, "bm25_max": 18.661054499081207, "bge_top3": null, "bge_max": null, "title": "Calcium lactate: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Gastrointestinal effects: Constipation, bloating, and gas are common with calcium supplements (especially carbonate salt).  Disease-related concerns:  • Achlo…"}, {"doc_id": "deferasirox-drug-information", "bm25_top3": 18.19878413220653, "bm25_max": 18.19878413220653, "bge_top3": 0.6773505210876465, "bge_max": 0.6773505210876465, "title": "Deferasirox: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Deferasirox: Pediatric drug information\")  Note: Calculate dose to the nearest whole tablet size or nearest whole granules packet. When calculating dose, consider chang…"}, {"doc_id": "calcium-polystyrene-sulfonate-united-states-not-available-drug-information", "bm25_top3": 17.584663318217242, "bm25_max": 17.584663318217242, "bge_top3": null, "bge_max": null, "title": "Calcium polystyrene sulfonate (United States: Not available): Drug information", "rep_snippet": "Sorbitol: May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis. Risk X: Avoid combination  Thyroid Produc…"}, {"doc_id": "darbepoetin-alfa-drug-information", "bm25_top3": 16.222793472505654, "bm25_max": 17.240747321864777, "bge_top3": 0.6908742785453796, "bge_max": 0.6908742785453796, "title": "Darbepoetin alfa: Drug information", "rep_snippet": "Dosing: Adult  Note: Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is <100 ng/mL or serum transferrin saturation (TSAT)…"}, {"doc_id": "multiple-vitamins-drug-information", "bm25_top3": 16.4409635296756, "bm25_max": 16.4409635296756, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins: Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "multiple-vitamins-pediatric-drug-information", "bm25_top3": 16.4409635296756, "bm25_max": 16.4409635296756, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins (pediatric): Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "iron-sucrose-drug-information", "bm25_top3": 13.650890726515634, "bm25_max": 13.650890726515634, "bge_top3": null, "bge_max": null, "title": "Iron sucrose: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Iron sucrose may be confused with ferumoxytol"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 10.444842289781246, "bm25_max": 10.444842289781246, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Food Interactions  Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron. Management: Supplementation of…"}, {"doc_id": "ferric-citrate-drug-information", "bm25_top3": 10.400962388387764, "bm25_max": 10.400962388387764, "bge_top3": 0.6948844194412231, "bge_max": 0.7167190909385681, "title": "Ferric citrate: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "ferrous-gluconate-drug-information", "bm25_top3": 10.12795333124528, "bm25_max": 10.12795333124528, "bge_top3": 0.6796426177024841, "bge_max": 0.6796426177024841, "title": "Ferrous gluconate: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "ferrous-fumarate-drug-information", "bm25_top3": 10.12795333124528, "bm25_max": 10.12795333124528, "bge_top3": 0.6796426177024841, "bge_max": 0.6796426177024841, "title": "Ferrous fumarate: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "dolutegravir-and-rilpivirine-drug-information", "bm25_top3": 9.331731042880792, "bm25_max": 9.4687255160256, "bge_top3": 0.6707947254180908, "bge_max": 0.6774376630783081, "title": "Dolutegravir and rilpivirine: Drug information", "rep_snippet": "Dietary Considerations  Take with a meal (not a protein supplement drink alone). Take 4 hours before or 6 hours after cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or b…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 9.204332915764084, "bm25_max": 9.204332915764084, "bge_top3": null, "bge_max": null, "title": "Doxycycline: Drug information", "rep_snippet": "Food Interactions  Ethanol: Chronic ethanol ingestion may reduce the serum concentration of doxycycline.  Food: Doxycycline serum levels may be slightly decreased if taken with high-fat meal or milk. Administration with…"}, {"doc_id": "dolutegravir-abacavir-and-lamivudine-drug-information", "bm25_top3": 9.204332915764084, "bm25_max": 9.204332915764084, "bge_top3": null, "bge_max": null, "title": "Dolutegravir, abacavir, and lamivudine: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food. If patient is on concomitant therapy with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampin an additional daily single-component d…"}, {"doc_id": "levothyroxine-drug-information", "bm25_top3": 9.007697267946867, "bm25_max": 9.007697267946867, "bge_top3": 0.7099445859591166, "bge_max": 0.7371517419815063, "title": "Levothyroxine: Drug information", "rep_snippet": "Iron Salts: May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with parenterally admin…"}, {"doc_id": "dolutegravir-drug-information", "bm25_top3": 8.764342662074588, "bm25_max": 8.977801519768434, "bge_top3": 0.6754661798477173, "bge_max": 0.6754661798477173, "title": "Dolutegravir: Drug information", "rep_snippet": "Dietary Considerations  Take 2 hours before or 6 hours after cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, dolutegravir and supp…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": 8.679453802564325, "bm25_max": 8.679453802564325, "bge_top3": null, "bge_max": null, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Dietary Considerations  Take with food. The type or timing of a meal is not important as long as dose is taken with food."}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 8.079503438368857, "bm25_max": 8.079503438368857, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "Food Interactions  All food and beverages may interfere with absorption. Coadministration with dairy products may decrease absorption. Beverages (especially orange juice and coffee), food, and medications (eg, antacids,…"}, {"doc_id": "etidronate-drug-information", "bm25_top3": 7.763129537612272, "bm25_max": 7.763129537612272, "bge_top3": 0.6713155508041382, "bge_max": 0.6713155508041382, "title": "Etidronate: Drug information", "rep_snippet": "Food Interactions  Food and/or supplements decrease the absorption and bioavailability of the drug. Management: Administer tablet on an empty stomach with a full glass of plain water or fruit juice (6-8 oz) 2 hours befor…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": 7.454726662756261, "bm25_max": 7.454726662756261, "bge_top3": null, "bge_max": null, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "Administration  Administer with or without food. Do not take within 2 hours of sucralfate, didanosine, iron, zinc, or antacids containing magnesium, calcium, or aluminum."}, {"doc_id": "tacrolimus-systemic-drug-information", "bm25_top3": 6.000828345177437, "bm25_max": 6.000828345177437, "bge_top3": null, "bge_max": null, "title": "Tacrolimus (systemic): Drug information", "rep_snippet": "Dietary Considerations  Capsule: Administer immediate release with or without food; be consistent with timing and composition of meals, food decreases bioavailability. Administer extended release on an empty stomach 1 ho…"}, {"doc_id": "famciclovir-drug-information", "bm25_top3": 5.68745538335671, "bm25_max": 5.68745538335671, "bge_top3": null, "bge_max": null, "title": "Famciclovir: Drug information", "rep_snippet": "Food Interactions  Rate of absorption and/or conversion to penciclovir and peak concentration are reduced with food, but bioavailability is not affected. Management: Administer without regard to meals."}, {"doc_id": "multiple-vitamins-prenatal-drug-information", "bm25_top3": 5.440963529675598, "bm25_max": 5.440963529675598, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins (prenatal): Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "vitamin-b-complex-drug-information", "bm25_top3": 5.440963529675598, "bm25_max": 5.440963529675598, "bge_top3": null, "bge_max": null, "title": "Vitamin B complex: Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "entacapone-drug-information", "bm25_top3": 5.328071314985216, "bm25_max": 5.328071314985216, "bge_top3": null, "bge_max": null, "title": "Entacapone: Drug information", "rep_snippet": "Food Interactions  Entacapone has been reported to chelate iron and decreasing serum iron levels were noted in clinical trials; however, clinically significant anemia has not been observed."}, {"doc_id": "zinc-sulfate-drug-information", "bm25_top3": 4.135338850173156, "bm25_max": 4.135338850173156, "bge_top3": null, "bge_max": null, "title": "Zinc sulfate: Drug information", "rep_snippet": "Food Interactions  Avoid foods high in calcium or phosphorus."}, {"doc_id": "demeclocycline-drug-information", "bm25_top3": 3.930702112348108, "bm25_max": 3.930702112348108, "bge_top3": null, "bge_max": null, "title": "Demeclocycline: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: SIADH: 2 to 5 days (Sherlock 2010)  Absorption: 66% (Agwuh 2006); extent of absorption is reduced by food and by certain antacids and dairy products containing aluminum, calciu…"}, {"doc_id": "gemifloxacin-united-states-not-available-drug-information", "bm25_top3": 3.805677668731507, "bm25_max": 3.805677668731507, "bge_top3": null, "bge_max": null, "title": "Gemifloxacin (United States: Not available): Drug information", "rep_snippet": "Administration  Oral: May be administered with or without food. Do not administer with dairy products (eg, milk, yogurt) or calcium-fortified juices alone; however, may be administered with a meal that contains these pro…"}, {"doc_id": "ferumoxytol-drug-information", "bm25_top3": 3.7856182710023365, "bm25_max": 3.7856182710023365, "bge_top3": 0.6935290098190308, "bge_max": 0.6935290098190308, "title": "Ferumoxytol: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Ferumoxytol may be confused with ferric carboxymaltose, ferric gluconate, iron dextran complex, iron sucrose"}, {"doc_id": "alfacalcidol-united-states-not-available-drug-information", "bm25_top3": 2.846371883240229, "bm25_max": 2.846371883240229, "bge_top3": null, "bge_max": null, "title": "Alfacalcidol (United States: Not available): Drug information", "rep_snippet": "Mechanism of Action  Alfacalcidol is rapidly converted to the active metabolite of vitamin D (1,25-dihydroxyvitamin D3) in the liver, effectively bypassing renal metabolic conversion; promotes intestinal absorption of ca…"}, {"doc_id": "sucroferric-oxyhydroxide-drug-information", "bm25_top3": 2.3577514744528614, "bm25_max": 2.3577514744528614, "bge_top3": 0.6669158935546875, "bge_max": 0.6669158935546875, "title": "Sucroferric oxyhydroxide: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Sucroferric oxyhydroxide may be confused with iron sucrose (Venofer). sucrose"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": 2.179478423899763, "bm25_max": 2.179478423899763, "bge_top3": null, "bge_max": null, "title": "Betrixaban: Drug information", "rep_snippet": "Mechanism of Action  Inhibits fibrin clot formation via direct and selective inhibition of factor Xa (FXa). FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, and phospholipid, catalyz…"}, {"doc_id": "equine-conjugated-estrogens-and-medroxyprogesterone-acetate-drug-information", "bm25_top3": 2.0514781205507546, "bm25_max": 2.0514781205507546, "bge_top3": null, "bge_max": null, "title": "Equine conjugated estrogens and medroxyprogesterone acetate: Drug information", "rep_snippet": "Dietary Considerations  Administration with food decreases nausea, administer with food. Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis."}, {"doc_id": "rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 1.8937076670302524, "bm25_max": 1.8937076670302524, "bge_top3": null, "bge_max": null, "title": "Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Dietary Considerations  Take with food. Consider calcium and vitamin D supplementation."}, {"doc_id": "carbidopa-levodopa-and-entacapone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7307199239730835, "bge_max": 0.7307199239730835, "title": "Carbidopa, levodopa, and entacapone: Drug information", "rep_snippet": "Dietary Considerations  Distribute protein intake throughout the day to avoid fluctuations in levodopa absorption. Separate dosing of iron supplements and multivitamins with minerals."}, {"doc_id": "liotrix-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6923358142375946, "bge_max": 0.6944668292999268, "title": "Liotrix: Drug information", "rep_snippet": "Dosing: Geriatric  Hypothyroidism: Oral: Initial: Levothyroxine 12.5 to 25 mcg/liothyronine 3.1 to 6.25 mcg once daily; may increase by levothyroxine 12.5 mcg/liothyronine 3.1 mcg every 2 to 3 weeks"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6829348802566528, "bge_max": 0.6829348802566528, "title": "Methotrexate: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Methotrexate toxicities:  Nonhematologic toxicity: Diarrhea, stomatitis, or vomiting which may lead to dehydration: Discontinue until recovery  Hematologic toxicity:  Psoriasis, rheumatoi…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-trisilicate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6825816035270691, "bge_max": 0.6825816035270691, "title": "Aluminum hydroxide and magnesium trisilicate: Drug information", "rep_snippet": "Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir. Management: Separate the administration of ledipasvir and antacids by 4 hours. Risk D: Consider therapy modification  Levothyroxine: Aluminum Hydro…"}, {"doc_id": "aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6825816035270691, "bge_max": 0.6825816035270691, "title": "Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information", "rep_snippet": "Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir. Management: Separate the administration of ledipasvir and antacids by 4 hours. Risk D: Consider therapy modification  Levothyroxine: Aluminum Hydro…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6825816035270691, "bge_max": 0.6825816035270691, "title": "Aluminum hydroxide and magnesium carbonate: Drug information", "rep_snippet": "Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir. Management: Separate the administration of ledipasvir and antacids by 4 hours. Risk D: Consider therapy modification  Levothyroxine: Aluminum Hydro…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-hydroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6825816035270691, "bge_max": 0.6825816035270691, "title": "Aluminum hydroxide and magnesium hydroxide: Drug information", "rep_snippet": "Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir. Management: Separate the administration of ledipasvir and antacids by 4 hours. Risk D: Consider therapy modification  Levothyroxine: Aluminum Hydro…"}, {"doc_id": "liothyronine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6791533529758453, "bge_max": 0.6798713207244873, "title": "Liothyronine: Drug information", "rep_snippet": "Dosing: Adult  Hypothyroidism: Oral: Initial: 25 mcg once daily; may increase by up to 25 mcg/day every 1 to 2 weeks; usual maintenance dose: 25 to 75 mcg once daily  Patients with cardiovascular disease: Initial: 5 mcg…"}, {"doc_id": "penicillamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6776201128959656, "bge_max": 0.6776201128959656, "title": "Penicillamine: Drug information", "rep_snippet": "Should be taken at least 1 hour before or 2 hours after meals on an empty stomach (Note: Canadian labeling recommends administration at least 2 hours before meals in patients with lead poisoning). Pyridoxine supplementat…"}, {"doc_id": "deferiprone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.676062285900116, "bge_max": 0.676062285900116, "title": "Deferiprone: Drug information", "rep_snippet": "Dosing: Adult  Note: Round dose to the nearest 250 mg (or 1/2 tablet) or 2.5 mL (oral solution). If serum ferritin falls consistently below 500 mcg/L, consider temporary treatment interruption.  Transfusional iron overlo…"}, {"doc_id": "fludrocortisone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.675626277923584, "bge_max": 0.675626277923584, "title": "Fludrocortisone: Drug information", "rep_snippet": "• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.  Concurrent drug therapy issue…"}, {"doc_id": "levoleucovorin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6736235618591309, "bge_max": 0.6743098497390747, "title": "LEVOleucovorin: Drug information", "rep_snippet": "Dosing: Adult  Note: Levoleucovorin, when substituted in place of leucovorin calcium (the racemic form), is dosed at one-half the usual dose of leucovorin calcium:  Colorectal cancer, metastatic: IV: The following regime…"}, {"doc_id": "quinidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6728232502937317, "bge_max": 0.6728232502937317, "title": "Quinidine: Drug information", "rep_snippet": "• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.  • G6PD deficiency: Hemolysis may occur in patients with G6PD (glucose-6-phosphate…"}, {"doc_id": "magnesium-salicylate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6711338758468628, "bge_max": 0.6711338758468628, "title": "Magnesium salicylate: Drug information", "rep_snippet": "Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours. Risk D: Consider therapy modif…"}, {"doc_id": "calcium-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6697466969490051, "bge_max": 0.6697466969490051, "title": "Calcium acetate: Drug information", "rep_snippet": "• Minerals/other oral drugs: Calcium administration interferes with absorption of some minerals and drugs; use with caution.  Dosage form specific issues:  • Maltitol: Oral solution may contain maltitol (a sugar substitu…"}, {"doc_id": "chloramphenicol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6682997941970825, "bge_max": 0.6682997941970825, "title": "Chloramphenicol: Drug information", "rep_snippet": "Dietary Considerations  May have increased dietary need for riboflavin, pyridoxine, and vitamin B12. Some products may contain sodium."}, {"doc_id": "cortisone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6680339574813843, "bge_max": 0.6680339574813843, "title": "Cortisone acetate: Drug information", "rep_snippet": "• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.  Concurrent drug therapy issue…"}, {"doc_id": "sodium-picosulfate-magnesium-oxide-and-citric-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6673809289932251, "bge_max": 0.6673809289932251, "title": "Sodium picosulfate, magnesium oxide, and citric acid: Drug information", "rep_snippet": "Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours. Risk D: Consider therapy modif…"}, {"doc_id": "hydrocortisone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6665624976158142, "bge_max": 0.6665624976158142, "title": "Hydrocortisone (systemic): Drug information", "rep_snippet": "• Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.  • Thyroid disease: Changes in thyroid status may necessitate dosage…"}]}
{"qid": "Q25_abbr+CYP2C19-cue", "query": "GERD — standard omeprazole dose; interaction relevance with clopidogrel (CYP2C19).", "base_qid": "Q25", "variant_type": "abbr+CYP2C19-cue", "candidates": [{"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": 29.906951423355032, "bm25_max": 38.9606183101401, "bge_top3": 0.6856084863344828, "bge_max": 0.7034267783164978, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 32.53277091689424, "bm25_max": 37.744840414905056, "bge_top3": 0.669564684232076, "bge_max": 0.6792139410972595, "title": "Omeprazole: Drug information", "rep_snippet": "Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. Risk C: Monitor therapy  Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. Risk X: Avoid combination  C…"}, {"doc_id": "clopidogrel-drug-information", "bm25_top3": 30.859924201763096, "bm25_max": 32.411293960868264, "bge_top3": 0.6528799335161845, "bge_max": 0.6617398858070374, "title": "Clopidogrel: Drug information", "rep_snippet": "Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Omeprazole: May diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum con…"}, {"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": 28.81546198951882, "bm25_max": 31.421820600561382, "bge_top3": 0.6718436082204183, "bge_max": 0.6893232464790344, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 27.089382336524537, "bm25_max": 31.33725164542788, "bge_top3": 0.6615472237269083, "bge_max": 0.6773974895477295, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "cilostazol-drug-information", "bm25_top3": 21.54485413320281, "bm25_max": 21.54485413320281, "bge_top3": 0.637982189655304, "bge_max": 0.637982189655304, "title": "Cilostazol: Drug information", "rep_snippet": "Dosing: Adult  Intermittent claudication: Oral: 100 mg twice daily. Note: The American College of Chest Physicians recommends use when refractory to exercise therapy and smoking cessation; use in combination with either…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 11.591295211786935, "bm25_max": 19.078324033881124, "bge_top3": 0.6681307554244995, "bge_max": 0.6681307554244995, "title": "Voriconazole: Drug information", "rep_snippet": "Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this com…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 18.39792416189262, "bm25_max": 18.39792416189262, "bge_top3": 0.647728830575943, "bge_max": 0.6507899761199951, "title": "Dexlansoprazole: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 17.846669178991892, "bm25_max": 17.846669178991892, "bge_top3": 0.6535934209823608, "bge_max": 0.6535934209823608, "title": "Fluconazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 17.660668528701635, "bm25_max": 17.660668528701635, "bge_top3": null, "bge_max": null, "title": "Lansoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": 16.989238607210225, "bm25_max": 16.989238607210225, "bge_top3": 0.6426568627357483, "bge_max": 0.6426568627357483, "title": "Fluvoxamine: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 14.197228244941204, "bm25_max": 16.523725130450504, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 16.523725130450504, "bm25_max": 16.523725130450504, "bge_top3": 0.6656401753425598, "bge_max": 0.6656401753425598, "title": "Pantoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": 13.068638445872459, "bm25_max": 15.722157714417481, "bge_top3": 0.6703033447265625, "bge_max": 0.6703033447265625, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 11.036405308100337, "bm25_max": 14.577424298464319, "bge_top3": 0.6402852733929952, "bge_max": 0.6433194875717163, "title": "Rabeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 10.584247218869288, "bm25_max": 14.325161218941332, "bge_top3": 0.6493117809295654, "bge_max": 0.6593030691146851, "title": "Esomeprazole: Drug information", "rep_snippet": "Clopidogrel: Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel prescribing information re…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 9.144710481506657, "bm25_max": 14.003565929284772, "bge_top3": null, "bge_max": null, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination  Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. Risk C:…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 13.99121397258007, "bm25_max": 13.99121397258007, "bge_top3": null, "bge_max": null, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 9.083167519552244, "bm25_max": 13.880480005375947, "bge_top3": 0.6365912556648254, "bge_max": 0.6365912556648254, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 13.782852754959702, "bm25_max": 13.782852754959702, "bge_top3": null, "bge_max": null, "title": "Fluoxetine: Drug information", "rep_snippet": "Clarithromycin: May enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine. Risk X: Avoid combination  Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease s…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": 11.688450721601441, "bm25_max": 11.688450721601441, "bge_top3": 0.6500412225723267, "bge_max": 0.6500412225723267, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "etravirine-drug-information", "bm25_top3": 4.015156810008886, "bm25_max": 4.015156810008886, "bge_top3": null, "bge_max": null, "title": "Etravirine: Drug information", "rep_snippet": "Metabolism/Transport Effects  Substrate of CYP2C19 (major), CYP2C9 (major), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2C19 (weak…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6629081964492798, "bge_max": 0.6629081964492798, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Tablet, extended release, Oral:  ZyrTEC-D Allergy & Congestion: Cetirizine hydrochlor…"}, {"doc_id": "repaglinide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6616256237030029, "bge_max": 0.6616256237030029, "title": "Repaglinide: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Repaglinide. Management: Avoid use of clopidogrel and repaglinide if possible; if the combination must be used, limit total repaglinide daily dose to no more than 4 mg…"}, {"doc_id": "luliconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6578019857406616, "bge_max": 0.6578019857406616, "title": "Luliconazole: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 5…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656046450138092, "bge_max": 0.656046450138092, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Pioglitazone. Risk C: Monitor therapy  Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to c…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6531202793121338, "bge_max": 0.6531202793121338, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Concomitant use with clopidogrel: Initial dose: Repaglinide 0.5 mg before each meal (maximum dose: 4 mg/day). Note: Combination repaglinide/metformin dosage forms will not accommodate the reduced initial repaglinide dose…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6448115110397339, "bge_max": 0.6448115110397339, "title": "Mirabegron: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. Risk C: Monitor therapy  Anticholinergic…"}, {"doc_id": "fesoterodine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6437296271324158, "bge_max": 0.6437296271324158, "title": "Fesoterodine: Drug information", "rep_snippet": "Dosing: Adult  Overactive bladder: Oral: 4 mg once daily; may be increased to 8 mg once daily based on individual response and tolerability  Dosing adjustment for concomitant strong CYP3A4 inhibitors (eg, ketoconazole, i…"}, {"doc_id": "ciprofloxacin-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6381014585494995, "bge_max": 0.6381014585494995, "title": "Ciprofloxacin and dexamethasone: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Suspension, otic:  Ciprodex: Ciprofloxacin 0.3% and dexamethasone 0.1% (7.5 mL) [cont…"}, {"doc_id": "maraviroc-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6376577019691467, "bge_max": 0.6376577019691467, "title": "Maraviroc: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥30 mL/minute: No dosage adjustment necessary  CrCl <30 mL/minute:  Concomitant potent CYP3A inhibitors (with or without a potent CYP3A inducer) or concomitant potent CYP3A inducer…"}]}
{"qid": "Q25_noise", "query": "Reflux — typical omeprazole regimen and does it matter for patients on clopidogrel?", "base_qid": "Q25", "variant_type": "noise", "candidates": [{"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": 26.110099589481102, "bm25_max": 30.264474169783952, "bge_top3": 0.6098009049892426, "bge_max": 0.6102054715156555, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "clopidogrel-drug-information", "bm25_top3": 27.214930396653497, "bm25_max": 29.55164093974879, "bge_top3": 0.6195433139801025, "bge_max": 0.6317340731620789, "title": "Clopidogrel: Drug information", "rep_snippet": "Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Omeprazole: May diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum con…"}, {"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": 26.073466660155162, "bm25_max": 29.459010838817136, "bge_top3": 0.6129806935787201, "bge_max": 0.6165650486946106, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 25.891896761659915, "bm25_max": 29.188827307445383, "bge_top3": 0.610224187374115, "bge_max": 0.6110520362854004, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 29.02898340332996, "bm25_max": 29.02898340332996, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 25.447352473257332, "bm25_max": 28.422211141262007, "bge_top3": 0.6089936296145121, "bge_max": 0.6144546270370483, "title": "Omeprazole: Drug information", "rep_snippet": "Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. Risk C: Monitor therapy  Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. Risk X: Avoid combination  C…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": 26.00016140630442, "bm25_max": 26.00016140630442, "bge_top3": 0.5925562977790833, "bge_max": 0.594397246837616, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; avoid use in severe hepatic impairment.  • Renal impairment: Avoid use in patients with advanced renal disease.  Concurrent dru…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": 25.74816652956264, "bm25_max": 25.74816652956264, "bge_top3": 0.5939107537269592, "bge_max": 0.5939107537269592, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": 20.49898823119881, "bm25_max": 20.49898823119881, "bge_top3": null, "bge_max": null, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Intensification: High-risk patients: 30 mg/m2 on day 1 of every 3-week cycle (with dexrazoxane; cumulative doxorubicin dose: 300 mg/m2) (Vrooman 2013)  Ewing sarcoma: Children and Adolescents: IV:  VAC/IE regimen: 75 mg/…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 20.244868479149588, "bm25_max": 20.244868479149588, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this com…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 14.751685531934234, "bm25_max": 18.02898340332996, "bge_top3": 0.5933293104171753, "bge_max": 0.5933293104171753, "title": "Pantoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 13.984389829774118, "bm25_max": 16.49439199900973, "bge_top3": 0.5854730606079102, "bge_max": 0.5854730606079102, "title": "Lansoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 13.54036037555287, "bm25_max": 16.407477185663126, "bge_top3": 0.5972064137458801, "bge_max": 0.5972064137458801, "title": "Dexlansoprazole: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 13.142138834832775, "bm25_max": 14.809890009127042, "bge_top3": 0.6059909264246622, "bge_max": 0.6356959342956543, "title": "Rabeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 14.748166529562639, "bm25_max": 14.748166529562639, "bge_top3": 0.5880906581878662, "bge_max": 0.5911243557929993, "title": "Esomeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "pyrazinamide-drug-information", "bm25_top3": 11.800790125331018, "bm25_max": 11.942409298465122, "bge_top3": null, "bge_max": null, "title": "Pyrazinamide: Drug information", "rep_snippet": "Regimens: Treatment regimens for pulmonary tuberculosis consist of an initial 2-month phase of a 4-drug regimen that includes pyrazinamide, followed by a continuation phase of a 2-drug regimen (does not include pyrazinam…"}, {"doc_id": "hyaluronate-derivatives-drug-information", "bm25_top3": 10.862961941625102, "bm25_max": 10.862961941625102, "bge_top3": null, "bge_max": null, "title": "Hyaluronate derivatives: Drug information", "rep_snippet": "Note: Formulations differ in terms of recommended injection depth: Juvederm (all formulations except Voluma XC), Restylane, Restylane Defyne, Restylane-L, and Restylane Refyne are intended for mid to deep intradermal inj…"}, {"doc_id": "ethambutol-drug-information", "bm25_top3": 10.740666502611582, "bm25_max": 10.740666502611582, "bge_top3": null, "bge_max": null, "title": "Ethambutol: Drug information", "rep_snippet": "Regimens: Treatment regimens for pulmonary tuberculosis consist of an initial 2-month phase of a 4-drug regimen that includes ethambutol, followed by a continuation phase consisting of a 2-drug regimen (does not include…"}, {"doc_id": "flutemetamol-f-18-drug-information", "bm25_top3": 10.421758532731474, "bm25_max": 10.421758532731474, "bge_top3": null, "bge_max": null, "title": "Flutemetamol F-18: Drug information", "rep_snippet": "• Risk for misinterpretation and other errors: Errors in estimating brain neuritic plaque density may occur when using flutemetamol F 18 PET images. In addition, the use of clinical information in the interpretation of i…"}, {"doc_id": "cilostazol-drug-information", "bm25_top3": 10.35886215761137, "bm25_max": 10.35886215761137, "bge_top3": null, "bge_max": null, "title": "Cilostazol: Drug information", "rep_snippet": "Dosing: Adult  Intermittent claudication: Oral: 100 mg twice daily. Note: The American College of Chest Physicians recommends use when refractory to exercise therapy and smoking cessation; use in combination with either…"}, {"doc_id": "ticagrelor-drug-information", "bm25_top3": 9.824107949053293, "bm25_max": 9.824107949053293, "bge_top3": 0.6040514707565308, "bge_max": 0.6040514707565308, "title": "Ticagrelor: Drug information", "rep_snippet": "• Respiratory: Dyspnea (often mild to moderate and transient) was observed more frequently in patients receiving ticagrelor compared to clopidogrel or aspirin alone during clinical trials (14% to 19% vs 6% to 8%) (Bonaca…"}, {"doc_id": "methadone-drug-information", "bm25_top3": 9.477440035293728, "bm25_max": 9.477440035293728, "bge_top3": null, "bge_max": null, "title": "Methadone: Drug information", "rep_snippet": "Manufacturer's labeling: Discontinue all other around-the-clock opioids when methadone therapy is initiated; fatalities have occurred in opioid-tolerant patients during conversion to methadone. Substantial interpatient v…"}, {"doc_id": "bedaquiline-drug-information", "bm25_top3": 9.45446409609094, "bm25_max": 9.45446409609094, "bge_top3": null, "bge_max": null, "title": "Bedaquiline: Drug information", "rep_snippet": "• Appropriate use: Administer by directly observed therapy (DOT). Should not be used for latent, extrapulmonary (eg, CNS) or drug-sensitive tuberculosis, or nontuberculosis mycobacteria. May be used for 24 weeks in adult…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 9.252995900615609, "bm25_max": 9.252995900615609, "bge_top3": null, "bge_max": null, "title": "Warfarin: Drug information", "rep_snippet": "Reference Range  INR = patient prothrombin time/mean normal prothrombin time  ISI = international sensitivity index  INR should be increased by 2 to 3.5 times depending upon indication. An INR >4 does not generally add a…"}, {"doc_id": "fexofenadine-drug-information", "bm25_top3": 7.925034393580811, "bm25_max": 7.925034393580811, "bge_top3": null, "bge_max": null, "title": "Fexofenadine: Drug information", "rep_snippet": "Mechanism of Action  Fexofenadine is an active metabolite of terfenadine and like terfenadine it competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels and respirator…"}, {"doc_id": "erwinia-asparaginase-drug-information", "bm25_top3": 7.385648689866876, "bm25_max": 7.385648689866876, "bge_top3": null, "bge_max": null, "title": "Erwinia asparaginase: Drug information", "rep_snippet": "Special Alerts  Erwinaze/Erwinase Safety Alert  July 2017  Particulate matter has been observed bound to the stopper and/or present on the lyophilized cake in some vials of Erwinaze [US product] and Erwinase [Canadian pr…"}, {"doc_id": "amlodipine-and-benazepril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6005159020423889, "bge_max": 0.6005159020423889, "title": "Amlodipine and benazepril: Drug information", "rep_snippet": "• Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk…"}, {"doc_id": "lamotrigine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5984302759170532, "bge_max": 0.5984302759170532, "title": "Lamotrigine: Drug information", "rep_snippet": "Regimens containing carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir, and without valproic acid: Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg daily in 2 divided doses;…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5976291298866272, "bge_max": 0.5976291298866272, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Impetigo (off-label use): Oral: Immediate release: 875 mg every 12 hours for 7 days, depending on response (IDSA [Stevens 2014])  Febrile neutropenia, empiric therapy in low-risk cancer patients (off-label use): Oral: Im…"}, {"doc_id": "oxaliplatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5959312915802002, "bge_max": 0.5959312915802002, "title": "Oxaliplatin: Drug information", "rep_snippet": "Biliary adenocarcinoma, advanced (off-label use): IV:  GEMOX regimen: 100 mg/m2 on day 2 every 2 weeks (in combination with gemcitabine) until disease progression or unacceptable toxicity (Andre 2004) or  CAPOX regimen:…"}, {"doc_id": "bismuth-subcitrate-metronidazole-and-tetracycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5953356027603149, "bge_max": 0.5953356027603149, "title": "Bismuth subcitrate, metronidazole, and tetracycline: Drug information", "rep_snippet": "Adverse Reactions  Also see individual agents. Adverse reactions are associated with concomitant administration of omeprazole.  >10%: Gastrointestinal: Abnormal stools (16%)  1% to 10%:  Central nervous system: Headache…"}, {"doc_id": "alprazolam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5929675698280334, "bge_max": 0.5929675698280334, "title": "Alprazolam: Drug information", "rep_snippet": "Ophthalmic: Blurred vision (extended-release: ≥1%)  Respiratory: Dyspnea (extended-release: 2%), hyperventilation (extended-release: ≥1%), nasal congestion (extended-release: ≥1%), allergic rhinitis (extended-release: 1%…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5910166501998901, "bge_max": 0.5910166501998901, "title": "Amoxapine: Drug information", "rep_snippet": "Ioflupane I 123: Amoxapine may diminish the diagnostic effect of Ioflupane I 123. Risk C: Monitor therapy  Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specif…"}, {"doc_id": "rituximab-intravenous-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5899535417556763, "bge_max": 0.5899535417556763, "title": "Rituximab (intravenous): Drug information", "rep_snippet": "Pemphigus vulgaris, refractory (off-label use): IV: 375 mg/m2 once weekly for 4 doses (some patients also continued immunosuppressant therapy); may repeat a second time (based on response) if needed (Cholera 2016; El Tal…"}, {"doc_id": "ruxolitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5896124243736267, "bge_max": 0.5896124243736267, "title": "Ruxolitinib: Drug information", "rep_snippet": "• Withdrawal syndrome: Acute relapse of myelofibrosis symptoms (eg, fever, respiratory distress, hypotension, DIC, multiorgan failure), splenomegaly, worsening cytopenias, hemodynamic compensation, and septic shock-like…"}, {"doc_id": "dihydrocodeine-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5894182920455933, "bge_max": 0.5894182920455933, "title": "Dihydrocodeine, aspirin, and caffeine: Drug information", "rep_snippet": "- Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; patients s…"}, {"doc_id": "repaglinide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.588776707649231, "bge_max": 0.588776707649231, "title": "Repaglinide: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Repaglinide. Management: Avoid use of clopidogrel and repaglinide if possible; if the combination must be used, limit total repaglinide daily dose to no more than 4 mg…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5880300402641296, "bge_max": 0.5880300402641296, "title": "Tinidazole: Drug information", "rep_snippet": "Hybrid regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, tinidazole 500 mg twice dail…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5874217748641968, "bge_max": 0.5874217748641968, "title": "Amoxicillin: Drug information", "rep_snippet": "Concomitant regimen: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily; continue…"}, {"doc_id": "ropinirole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5873993635177612, "bge_max": 0.5873993635177612, "title": "Ropinirole: Drug information", "rep_snippet": "Extended-release tablet: Initial: 2 mg once daily for 1 to 2 weeks, followed by increases of 2 mg/day at weekly or longer intervals based on therapeutic response and tolerability; there was no additional benefit shown fo…"}, {"doc_id": "aspirin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5871691107749939, "bge_max": 0.5871691107749939, "title": "Aspirin: Drug information", "rep_snippet": "Cryptogenic with patent foramen ovale (PFO) or atrial septal aneurysm (off-label use): Immediate release: 50 to 100 mg once daily (ACCP [Guyatt 2012])  Intracranial atherosclerosis (50% to 99% stenosis of a major intracr…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.585688591003418, "bge_max": 0.585688591003418, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Group A streptococci (GAS) chronic carrier, treatment (off-label use): Children and Adolescents: Refer to adult dosing.  Anaplasmosis, mild cases (patients with severe allergy to doxycycline) (off-label use): Children an…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5852749943733215, "bge_max": 0.5852749943733215, "title": "Methylprednisolone: Drug information", "rep_snippet": "COPD exacerbation (off-label use): Note: Dose, frequency, and duration of therapy not established. GOLD guidelines recommend the use of oral prednisone; however, methylprednisolone may be used as an alternative (GOLD [De…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5847930908203125, "bge_max": 0.5847930908203125, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Concomitant use with clopidogrel: Initial dose: Repaglinide 0.5 mg before each meal (maximum dose: 4 mg/day). Note: Combination repaglinide/metformin dosage forms will not accommodate the reduced initial repaglinide dose…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5841970443725586, "bge_max": 0.5841970443725586, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary ed…"}]}
{"qid": "Q25_spelling", "query": "GORD/GERD — omep dose + clopidogrrel interaction?", "base_qid": "Q25", "variant_type": "spelling", "candidates": [{"doc_id": "omeprazole-drug-information", "bm25_top3": 17.47123167652649, "bm25_max": 22.10333524369039, "bge_top3": 0.5705373684565226, "bge_max": 0.596025824546814, "title": "Omeprazole: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer: Oral: 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks. Up to 40 mg once daily has been used in patients with ulcers refractive to other therapies (eg, H2 antag…"}, {"doc_id": "famotidine-drug-information", "bm25_top3": 8.322790877458955, "bm25_max": 14.386724088815658, "bge_top3": null, "bge_max": null, "title": "Famotidine: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer:  IV: 20 mg every 12 hours  Oral: Acute therapy: 40 mg once daily at bedtime (or 20 mg twice daily) for 4 to 8 weeks; maintenance therapy: 20 mg once daily at bedtime  Gastric ulcer:  IV: 20…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 7.009455345207201, "bm25_max": 13.826637993772392, "bge_top3": 0.5538204908370972, "bge_max": 0.5538204908370972, "title": "Lansoprazole: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Lansoprazole: Pediatric drug information\")  GERD, erosive esophagitis: Children 1 to 11 years: Oral:  ≤30 kg: 15 mg once daily for up to 12 weeks  >30 kg: 30 mg once da…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 9.132289840014957, "bm25_max": 13.064310429800262, "bge_top3": 0.5555483400821686, "bge_max": 0.5601163506507874, "title": "Rabeprazole: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer: Tablets: Oral: 20 mg once daily for ≤4 weeks; additional therapy to achieve healing may be required for some patients.  Gastric ulcers: Canadian labeling: Tablets: Oral: 20 mg once daily up…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 6.709942474799272, "bm25_max": 12.73866262488154, "bge_top3": 0.5543479025363922, "bge_max": 0.5587999224662781, "title": "Pantoprazole: Drug information", "rep_snippet": "Dosing: Adult  Erosive esophagitis associated with GERD:  Oral:  Treatment: 40 mg once daily for up to 8 weeks; an additional 8 weeks may be used in patients who have not healed after an 8-week course. Lower doses (20 mg…"}, {"doc_id": "cisapride-united-states-available-via-limited-access-fda-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 6.280481358844406, "bm25_max": 12.168149871634258, "bge_top3": null, "bge_max": null, "title": "Cisapride (United States: Available via limited access/FDA investigational drug [IND] protocol only): Drug information", "rep_snippet": "Dosing: Adult  GERD or gastrointestinal dysmotility: Oral: Initial: 5-10 mg 4 times/day at least 15 minutes before meals and at bedtime; in some patients the dosage will need to be increased to 20 mg to obtain a satisfac…"}, {"doc_id": "clopidogrel-drug-information", "bm25_top3": 8.573566245724313, "bm25_max": 11.721976822737817, "bge_top3": 0.577543298403422, "bge_max": 0.5906961560249329, "title": "Clopidogrel: Drug information", "rep_snippet": "Percutaneous coronary intervention (PCI) for acute coronary syndrome (eg, NSTE-ACS or STEMI) (off-label use): 600 mg (loading dose) given as early as possible before or at the time of PCI, followed by 75 mg once daily (i…"}, {"doc_id": "ticagrelor-drug-information", "bm25_top3": 9.597386240166902, "bm25_max": 9.597386240166902, "bge_top3": null, "bge_max": null, "title": "Ticagrelor: Drug information", "rep_snippet": "Conversion from clopidogrel to ticagrelor: May initiate ticagrelor 90 mg twice daily beginning 24 hours after last clopidogrel dose (loading or maintenance). Patients who are in the acute phase of an acute coronary syndr…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 9.298524266368405, "bm25_max": 9.298524266368405, "bge_top3": null, "bge_max": null, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Concomitant use with clopidogrel: Initial dose: Repaglinide 0.5 mg before each meal (maximum dose: 4 mg/day). Note: Combination repaglinide/metformin dosage forms will not accommodate the reduced initial repaglinide dose…"}, {"doc_id": "nizatidine-drug-information", "bm25_top3": 8.74218848456374, "bm25_max": 8.74218848456374, "bge_top3": null, "bge_max": null, "title": "Nizatidine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nizatidine: Pediatric drug information\")  GERD: Oral:  Children ≥12 years and Adolescents: (oral solution only): 150 mg twice daily for up to 8 weeks (maximum: 300 mg/d…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 4.91606718867352, "bm25_max": 8.480375086165102, "bge_top3": 0.5604749321937561, "bge_max": 0.5604749321937561, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving strong inhibitors…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 4.273545847829443, "bm25_max": 5.679011293668658, "bge_top3": 0.5712154507637024, "bge_max": 0.6131967306137085, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": 4.266610879166318, "bm25_max": 5.66514135634241, "bge_top3": 0.5760148962338766, "bge_max": 0.6131967306137085, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 2.4133580620869686, "bm25_max": 5.594868122514917, "bge_top3": 0.5656982660293579, "bge_max": 0.5656982660293579, "title": "Dexlansoprazole: Drug information", "rep_snippet": "Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren. Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 5.555850995562809, "bm25_max": 5.555850995562809, "bge_top3": null, "bge_max": null, "title": "Fluconazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 5.515045941388342, "bm25_max": 5.515045941388342, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this com…"}, {"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": 2.868080401990227, "bm25_max": 2.868080401990227, "bge_top3": 0.5964966416358948, "bge_max": 0.6131967306137085, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": 2.7902959329474974, "bm25_max": 2.7902959329474974, "bge_top3": 0.5993146896362305, "bge_max": 0.5993146896362305, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 0.1200989805320436, "bm25_max": 2.7902959329474974, "bge_top3": 0.5955100655555725, "bge_max": 0.5955100655555725, "title": "Esomeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": 1.1064729458784495, "bm25_max": 1.1064729458784495, "bge_top3": 0.5659273266792297, "bge_max": 0.5659273266792297, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; avoid use in severe hepatic impairment.  • Renal impairment: Avoid use in patients with advanced renal disease.  Concurrent dru…"}, {"doc_id": "olaparib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.577417254447937, "bge_max": 0.577417254447937, "title": "Olaparib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  Bitter…"}, {"doc_id": "oxytocin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5747162699699402, "bge_max": 0.5747162699699402, "title": "Oxytocin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Carboprost Tromethamine: May enhance the adverse/toxic effect of Oxytocic Agents. Specifically, oxytocic effects may be enhanced. Risk X:…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5613252520561218, "bge_max": 0.5613252520561218, "title": "Methylprednisolone: Drug information", "rep_snippet": "COPD exacerbation (off-label use): Note: Dose, frequency, and duration of therapy not established. GOLD guidelines recommend the use of oral prednisone; however, methylprednisolone may be used as an alternative (GOLD [De…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5612987279891968, "bge_max": 0.5612987279891968, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination  Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. Risk C:…"}, {"doc_id": "osimertinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5577386617660522, "bge_max": 0.5577386617660522, "title": "Osimertinib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "thiotepa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5556233525276184, "bge_max": 0.5556233525276184, "title": "Thiotepa: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "telotristat-ethyl-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5551084876060486, "bge_max": 0.5551084876060486, "title": "Telotristat ethyl: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. Risk C: Monitor therapy  NiMODipine: CYP3A4 Inducers…"}, {"doc_id": "oxaliplatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5543016791343689, "bge_max": 0.5543016791343689, "title": "Oxaliplatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5531718730926514, "bge_max": 0.5531718730926514, "title": "Mirabegron: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. Risk C: Monitor therapy  Anticholinergic…"}, {"doc_id": "vindesine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5528547763824463, "bge_max": 0.5528547763824463, "title": "Vindesine (United States: Not available): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "mitoxantrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5526807308197021, "bge_max": 0.5526807308197021, "title": "Mitoxantrone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "clomiphene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5500594973564148, "bge_max": 0.5500594973564148, "title": "Clomiphene: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance advers…"}, {"doc_id": "vinorelbine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5497822761535645, "bge_max": 0.5497822761535645, "title": "Vinorelbine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  BCG (Intraves…"}, {"doc_id": "edetate-calcium-disodium-calcium-edta-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5487935543060303, "bge_max": 0.5487935543060303, "title": "Edetate calcium disodium (calcium EDTA): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  Chloram…"}, {"doc_id": "carfilzomib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5482407808303833, "bge_max": 0.5482407808303833, "title": "Carfilzomib: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  Chloram…"}, {"doc_id": "lomitapide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5480716228485107, "bge_max": 0.5480716228485107, "title": "Lomitapide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alcohol (Ethyl): May enhance the hepatotoxic effect of Lomitapide. Management: Advise patients to limit alcohol consumption to 1 drink pe…"}, {"doc_id": "gemcitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.547976016998291, "bge_max": 0.547976016998291, "title": "Gemcitabine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "romidepsin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5479537844657898, "bge_max": 0.5479537844657898, "title": "Romidepsin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.547747015953064, "bge_max": 0.547747015953064, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Pioglitazone. Risk C: Monitor therapy  Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to c…"}, {"doc_id": "eribulin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5476670265197754, "bge_max": 0.5476670265197754, "title": "Eribulin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  Chloram…"}, {"doc_id": "decitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5476670265197754, "bge_max": 0.5476670265197754, "title": "Decitabine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  Chloram…"}, {"doc_id": "topotecan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.547539472579956, "bge_max": 0.547539472579956, "title": "Topotecan: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination  BCG (Intrave…"}, {"doc_id": "leuprolide-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.547452449798584, "bge_max": 0.547452449798584, "title": "Leuprolide and norethindrone: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Allergic reactions: Anaphylactoid reactions and asthma exacerbations have been reported with therapy in patients with histories of asthma, sinusitis, or envir…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": -0.38730998487786117, "bm25_max": -0.38730998487786117, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "Pregnancy Implications  Ranitidine crosses the placenta (Armentano 1989). Histamine H2 antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD) as well as gastric and duodenal ulcers du…"}, {"doc_id": "cimetidine-drug-information", "bm25_top3": -0.4965233884212097, "bm25_max": -0.4965233884212097, "bge_top3": null, "bge_max": null, "title": "Cimetidine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Cimetidine crosses the placenta (Howe 1981). Histamine H2 antagonists have been evaluated for the treatment of gastroesophagea…"}]}
{"qid": "Q26_abbr+BBW-cue", "query": "Depression — sertraline time to effect, BBW, dose range; tapering guidance.", "base_qid": "Q26", "variant_type": "abbr+BBW-cue", "candidates": [{"doc_id": "sertraline-drug-information", "bm25_top3": 25.38342680750404, "bm25_max": 31.629552716802145, "bge_top3": 0.6790637175242106, "bge_max": 0.6890188455581665, "title": "Sertraline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "tranylcypromine-drug-information", "bm25_top3": 19.382173873788425, "bm25_max": 19.382173873788425, "bge_top3": 0.6911160945892334, "bge_max": 0.6911160945892334, "title": "Tranylcypromine: Drug information", "rep_snippet": "Dosing: Adult  Major depression: Oral: Initial: 10 mg/day; if symptoms do not improve after 2 weeks, increase dose by 10 mg/day increments at 1- to 3-week intervals; usual dosage range 30 to 60 mg/day in divided doses (A…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": 12.685543115213274, "bm25_max": 18.95301689245273, "bge_top3": 0.6570838987827301, "bge_max": 0.6682039499282837, "title": "Amitriptyline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "selegiline-drug-information", "bm25_top3": 18.47138434282299, "bm25_max": 18.47138434282299, "bge_top3": 0.6604709923267365, "bge_max": 0.662895917892456, "title": "Selegiline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant or antiparkinsonian therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptom…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 18.47107929526396, "bm25_max": 18.47107929526396, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Recurrent pericarditis: 600 mg every 8 hours (range: 1,200 to 2,400 mg) for weeks to months until complete symptom resolution followed by a gradual tapering of the dose by 200 to 400 mg every 1 to 2 weeks (ESC [Adler 201…"}, {"doc_id": "onabotulinumtoxina-botox-drug-information", "bm25_top3": 18.316962994729145, "bm25_max": 18.316962994729145, "bge_top3": null, "bge_max": null, "title": "OnabotulinumtoxinA (Botox): Drug information", "rep_snippet": "Dose may be increased up to twice the previous dose if the response from the initial dose lasted ≤2 months; maximum dose per site: 5 units. Tolerance may occur if treatments are given more often than every 3 months, but…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 17.85810784267984, "bm25_max": 17.85810784267984, "bge_top3": 0.6480413675308228, "bge_max": 0.6480413675308228, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant and antipsychotic therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms.…"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": 11.923519174070377, "bm25_max": 17.63642832139847, "bge_top3": 0.7008453607559204, "bge_max": 0.7008453607559204, "title": "Trimipramine: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral: Initial: 25 to 50 mg daily at bedtime or in divided doses; initial doses of 100 mg daily may be considered in hospitalized patients. Gradually increase dose based on response and tolerabi…"}, {"doc_id": "amitriptyline-and-chlordiazepoxide-drug-information", "bm25_top3": 11.858108295878315, "bm25_max": 17.505606565014347, "bge_top3": 0.6718053817749023, "bge_max": 0.6718053817749023, "title": "Amitriptyline and chlordiazepoxide: Drug information", "rep_snippet": "Dosing: Adult  Depression and anxiety: Oral: Amitriptyline 12.5 mg/chlordiazepoxide 5 mg or amitriptyline 25 mg/chlordiazepoxide 10 mg tablets:  Initial: 3 or 4 tablets daily in one or more divided doses; titrate to resp…"}, {"doc_id": "mirtazapine-drug-information", "bm25_top3": 17.492294524998012, "bm25_max": 17.492294524998012, "bge_top3": 0.6931797862052917, "bge_max": 0.6931797862052917, "title": "Mirtazapine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: Initial: 15 mg nightly, may titrate dose up no more frequently than every 1 to 2 weeks to a maximum of 45 mg/day; dosage range: 15 to 45 mg daily  Discontinuation of…"}, {"doc_id": "protriptyline-drug-information", "bm25_top3": 12.026467843424241, "bm25_max": 17.409069118311923, "bge_top3": 0.6967309713363647, "bge_max": 0.6967309713363647, "title": "Protriptyline: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral: Initial: 10 to 20 mg daily divided in 3 to 4 doses; gradually increase based on response and tolerability to a usual dose of 20 to 60 mg/day in 3 to 4 divided doses; maximum 60 mg/day (AP…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": 17.117868374251845, "bm25_max": 17.117868374251845, "bge_top3": null, "bge_max": null, "title": "Theophylline: Drug information", "rep_snippet": "Patients who have not received theophylline in the previous 24 hours: 4.6 mg/kg/dose IV (preferred route) or 5 mg/kg orally (immediate release only [oral solution]). Note: Loading dose intended to achieve a serum level o…"}, {"doc_id": "levomilnacipran-drug-information", "bm25_top3": 17.113917342424024, "bm25_max": 17.113917342424024, "bge_top3": 0.7019262909889221, "bge_max": 0.7019262909889221, "title": "Levomilnacipran: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral: Initial: 20 mg once daily for 2 days; increase to 40 mg once daily; may then be increased in increments of 40 mg at intervals of 2 or more days; Maintenance: 40-120 mg once daily; Maximum…"}, {"doc_id": "tetrabenazine-drug-information", "bm25_top3": 16.423535848787743, "bm25_max": 16.423535848787743, "bge_top3": null, "bge_max": null, "title": "Tetrabenazine: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  For toxicity/adverse reaction, including akathisia, restlessness, parkinsonism, insomnia, depression, suicidality, anxiety, sedation (intolerable): Suspend upward dosage titration and red…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 14.300260122722007, "bm25_max": 14.300260122722007, "bge_top3": null, "bge_max": null, "title": "Warfarin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Warfarin: Pediatric drug information\")  Note: Coumadin injection has been discontinued in the US for more than 1 year.  Note: Labeling identifies genetic factors which…"}, {"doc_id": "flunisolide-oral-inhalation-drug-information", "bm25_top3": 9.176173074263264, "bm25_max": 9.176173074263264, "bge_top3": null, "bge_max": null, "title": "Flunisolide (oral inhalation): Drug information", "rep_snippet": "• Pediatric: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize th…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": 9.003724402468531, "bm25_max": 9.003724402468531, "bge_top3": null, "bge_max": null, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "• Pediatric: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimiz…"}, {"doc_id": "ciclesonide-oral-inhalation-drug-information", "bm25_top3": 7.235087686065967, "bm25_max": 7.235087686065967, "bge_top3": null, "bge_max": null, "title": "Ciclesonide (oral inhalation): Drug information", "rep_snippet": "• Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawin…"}, {"doc_id": "disulfiram-drug-information", "bm25_top3": 6.839364842321444, "bm25_max": 6.839364842321444, "bge_top3": null, "bge_max": null, "title": "Disulfiram: Drug information", "rep_snippet": "Phenytoin: Disulfiram may increase the serum concentration of Phenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible. Phenytoin dose adjustment will likely be necessary when starting and/o…"}, {"doc_id": "nortriptyline-drug-information", "bm25_top3": 6.643866568536559, "bm25_max": 6.643866568536559, "bge_top3": 0.6612764894962311, "bge_max": 0.6710609197616577, "title": "Nortriptyline: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "clomipramine-drug-information", "bm25_top3": 6.643866568536559, "bm25_max": 6.643866568536559, "bge_top3": 0.6606272459030151, "bge_max": 0.6606272459030151, "title": "Clomipramine: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": 6.643866568536559, "bm25_max": 6.643866568536559, "bge_top3": 0.6554558575153351, "bge_max": 0.6581907272338867, "title": "Amoxapine: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "amitriptyline-and-perphenazine-drug-information", "bm25_top3": 6.611624368482545, "bm25_max": 6.611624368482545, "bge_top3": 0.6686444282531738, "bge_max": 0.6686444282531738, "title": "Amitriptyline and perphenazine: Drug information", "rep_snippet": "Serotonin Reuptake Inhibitor/Antagonists: Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Serotonin Reuptake Inhibitor/Antagonists. Specifically, this may be manifest as symptoms consistent…"}, {"doc_id": "doxepin-systemic-drug-information", "bm25_top3": 6.418069337973817, "bm25_max": 6.418069337973817, "bge_top3": 0.6667778491973877, "bge_max": 0.6667778491973877, "title": "Doxepin (systemic): Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "imipramine-drug-information", "bm25_top3": 6.418069337973817, "bm25_max": 6.418069337973817, "bge_top3": 0.6586392223834991, "bge_max": 0.6682308316230774, "title": "Imipramine: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 6.418069337973817, "bm25_max": 6.418069337973817, "bge_top3": 0.6728623509407043, "bge_max": 0.6728623509407043, "title": "Desipramine: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "cobimetinib-drug-information", "bm25_top3": 6.007390691562746, "bm25_max": 6.007390691562746, "bge_top3": null, "bge_max": null, "title": "Cobimetinib: Drug information", "rep_snippet": "• Dermatologic toxicity: Severe rash and other skin reactions (including grades 3 and 4 toxicity) may occur; some events required hospitalization. The median time to onset of grade 3 and 4 rash events was 11 days (range:…"}, {"doc_id": "mometasone-nasal-drug-information", "bm25_top3": 5.935564666917601, "bm25_max": 5.935564666917601, "bge_top3": null, "bge_max": null, "title": "Mometasone (nasal): Drug information", "rep_snippet": "• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users or in p…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 5.891778543234082, "bm25_max": 5.891778543234082, "bge_top3": null, "bge_max": null, "title": "Amiodarone: Drug information", "rep_snippet": "IV single dose: Mean range: 9 to 36 days  N-desethylamiodarone (active metabolite):  Single dose: 36 days (range: 14 to 75 days)  Oral chronic therapy: 61 days  IV single dose: Mean range: 9 to 30 days  Time to peak, ser…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 5.6992802614050575, "bm25_max": 5.6992802614050575, "bge_top3": null, "bge_max": null, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy  SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. Risk…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": 5.593701421014519, "bm25_max": 5.593701421014519, "bge_top3": null, "bge_max": null, "title": "Phenobarbital: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor…"}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": 5.112732931144832, "bm25_max": 5.112732931144832, "bge_top3": null, "bge_max": null, "title": "Fosphenytoin: Drug information", "rep_snippet": "Rufinamide: Fosphenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Fosphenytoin. Risk C: Monitor therapy  Ruxolitinib: CYP3A4 Inducers (Strong) may decrease th…"}, {"doc_id": "ticagrelor-drug-information", "bm25_top3": 4.8492870503668755, "bm25_max": 4.8492870503668755, "bge_top3": null, "bge_max": null, "title": "Ticagrelor: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of inhibition of platelet aggregation (IPA): 180 mg loading dose: ~41% within 30 minutes (similar to clopidogrel 600 mg at 8 hours)  Peak effect: Time to maximal IPA: 180 mg loading dose:…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 4.229656819881507, "bm25_max": 4.229656819881507, "bge_top3": null, "bge_max": null, "title": "Dabigatran: Drug information", "rep_snippet": "Reference Range  Routine coagulation testing is not required or necessary for DOACs. There are currently no FDA-approved assays or calibration reagents available.  In clinical situations when assessment of the anticoagul…"}, {"doc_id": "baclofen-drug-information", "bm25_top3": 3.312030436093636, "bm25_max": 3.312030436093636, "bge_top3": null, "bge_max": null, "title": "Baclofen: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: Intrathecal bolus: 30 minutes to 1 hour; Continuous infusion: 6 to 8 hours after infusion initiation  Peak effect: Intrathecal bolus: 4 hours (effects may last 4 to 8 hours); C…"}, {"doc_id": "human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information", "bm25_top3": 2.9545932474244623, "bm25_max": 2.9545932474244623, "bge_top3": null, "bge_max": null, "title": "Human-plasma derived von Willebrand factor (contains factor VIII): Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset: Shortening of bleeding time: Immediate  Maximum effect: 1 to 2 hours  Duration: von Willebrand disease: Shortening of bleeding time: <6 hours postinfusion; presence of VWF multimers dete…"}, {"doc_id": "atropine-ophthalmic-drug-information", "bm25_top3": 0.7975386316347439, "bm25_max": 0.7975386316347439, "bge_top3": null, "bge_max": null, "title": "Atropine (ophthalmic): Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Onset of action: Ophthalmic solution: Within minutes; maximum effect: within hours  Duration: Multiple days  Absorption: Well absorbed from all dosage forms  Metabolism: Hepatic via enzymatic h…"}, {"doc_id": "isocarboxazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6798109710216522, "bge_max": 0.6923771500587463, "title": "Isocarboxazid: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral: Initial: 10 mg 2 times/day; may increase by 10 mg/day every 2 to 4 days to 40 mg/day by the end of the first week (divided into 2 to 4 doses). After first week, may increase by up to 20 m…"}, {"doc_id": "methylphenidate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6842010021209717, "bge_max": 0.6842010021209717, "title": "Methylphenidate: Drug information", "rep_snippet": "Extended and sustained release tablets (Metadate ER, Ritalin-SR): May be given in place of immediate release products (duration of action ~8 hours), once the immediate release formulation daily dose is titrated and the t…"}, {"doc_id": "desvenlafaxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6832125186920166, "bge_max": 0.6832125186920166, "title": "Desvenlafaxine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: 50 mg once daily; doses up to 400 mg once daily have been studied and have shown to be effective; however, the manufacturer states there is no additional benefit at d…"}, {"doc_id": "escitalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6723690032958984, "bge_max": 0.6723690032958984, "title": "Escitalopram: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.67094886302948, "bge_max": 0.67094886302948, "title": "Maprotiline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6601818799972534, "bge_max": 0.6672447919845581, "title": "Phenelzine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.666793942451477, "bge_max": 0.666793942451477, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.665479302406311, "bge_max": 0.665479302406311, "title": "Citalopram: Drug information", "rep_snippet": "Premature Ejaculation (off-label use): Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability up to 40 mg/day (Althof 2014; Safarinejad 2006). Additional data may be necessary to further de…"}, {"doc_id": "nefazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6559753020604452, "bge_max": 0.6646032333374023, "title": "Nefazodone: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral: Initial: 100 mg twice daily; alternatively depression treatment guidelines suggest starting doses of 50 to 100 mg daily (APA, 2010; Bauer 2013). Based on response and tolerability, gradua…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6644845604896545, "bge_max": 0.6644845604896545, "title": "Duloxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "trazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6542759239673615, "bge_max": 0.6623448729515076, "title": "Trazodone: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6616497039794922, "bge_max": 0.6616497039794922, "title": "Paroxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6585675477981567, "bge_max": 0.6585675477981567, "title": "Vortioxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6576409339904785, "bge_max": 0.6576409339904785, "title": "Fluvoxamine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6568850874900818, "bge_max": 0.6568850874900818, "title": "Fluoxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "milnacipran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.655270516872406, "bge_max": 0.655270516872406, "title": "Milnacipran: Drug information", "rep_snippet": "Dosing: Adult  Fibromyalgia: Oral: 50 mg twice daily.  Titration schedule: 12.5 mg once on day 1, then 12.5 mg twice daily on days 2-3, 25 mg twice daily on days 4-7, then 50 mg twice daily thereafter. Dose may be increa…"}, {"doc_id": "venlafaxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6507604718208313, "bge_max": 0.6507604718208313, "title": "Venlafaxine: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral:  Immediate-release tablets: Initial: 37.5 to 75 mg/day, administered in 2 or 3 divided doses; may increase in ≤75 mg/day increments at intervals of ≥4 days as tolerated; usual dosage: 75…"}, {"doc_id": "vilazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6495226621627808, "bge_max": 0.6495226621627808, "title": "Vilazodone: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: Initial: 10 mg once daily for 7 days, then increase to 20 mg once daily; may increase up to 40 mg once daily after a minimum of 7 days based on response and tolerabil…"}, {"doc_id": "quetiapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6481313705444336, "bge_max": 0.6481313705444336, "title": "Quetiapine: Drug information", "rep_snippet": "Dosing: Geriatric  Bipolar disorder or schizophrenia: Oral: Immediate release and extended release: Initial: 50 mg daily; may increase in increments of 50 mg daily to an effective dose, based on individual clinical respo…"}, {"doc_id": "liothyronine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6453313231468201, "bge_max": 0.6453313231468201, "title": "Liothyronine: Drug information", "rep_snippet": "Suppression test (T3): Oral: 75 to 100 mcg once daily for 7 days. Radioactive iodide uptake is determined before and after administration.  Antidepressant augmentation (off-label use): Oral: Initial: 25 mcg/day; may be i…"}]}
{"qid": "Q26_noise", "query": "MDD — what to tell pt about when Zoloft starts working, black-box, dosing window, and taper?", "base_qid": "Q26", "variant_type": "noise", "candidates": [{"doc_id": "ethinyl-estradiol-and-norelgestromin-drug-information", "bm25_top3": 28.207862750536137, "bm25_max": 28.207862750536137, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and norelgestromin: Drug information", "rep_snippet": "Dosing: Adult  Females: Contraception: Topical:  Apply one patch each week for 3 weeks (21 total days); followed by one week that is patch-free. Each patch should be applied on the same day each week (“patch change day”)…"}, {"doc_id": "ethinyl-estradiol-and-drospirenone-drug-information", "bm25_top3": 27.41931608611148, "bm25_max": 27.41931608611148, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and drospirenone: Drug information", "rep_snippet": "Dosing: Adult  Acne (Gianvi, Loryna, Nikki, Vestura, Yaz): Females: Oral: Refer to dosing for contraception.  PMDD (Gianvi, Yaz): Females: Oral: Refer to dosing for contraception.  Contraception: Female: Oral: One tablet…"}, {"doc_id": "ethinyl-estradiol-and-levonorgestrel-drug-information", "bm25_top3": 27.08042373515123, "bm25_max": 27.08042373515123, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and levonorgestrel: Drug information", "rep_snippet": "Dosing: Adult  Females:  Contraception: Oral: One tablet once daily. General dosing guidelines; refer to prescribing information for product specific information:  Schedule 1 (Sunday starter): Dose begins on first Sunday…"}, {"doc_id": "aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information", "bm25_top3": 25.941575190375442, "bm25_max": 25.941575190375442, "bge_top3": null, "bge_max": null, "title": "Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing.  Psychosis/agitation associated with dementia (off-label use):  IM, immediate release: Initial: 2.5 to 10 mg once; a repeat dose of 2.5 to 5 mg may be given at ≥2-hour intervals…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": 17.370899674986973, "bm25_max": 21.120732148006798, "bge_top3": 0.5246372024218241, "bge_max": 0.5259596705436707, "title": "Sertraline: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Concentrate, Oral:  Zoloft: 20 mg/mL (60 mL) [contains alcohol, usp, menthol]  Generi…"}, {"doc_id": "vilazodone-drug-information", "bm25_top3": 21.06602090284708, "bm25_max": 21.06602090284708, "bge_top3": 0.5369511842727661, "bge_max": 0.5369511842727661, "title": "Vilazodone: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: Initial: 10 mg once daily for 7 days, then increase to 20 mg once daily; may increase up to 40 mg once daily after a minimum of 7 days based on response and tolerabil…"}, {"doc_id": "desvenlafaxine-drug-information", "bm25_top3": 17.925737439885452, "bm25_max": 17.925737439885452, "bge_top3": 0.5531021952629089, "bge_max": 0.5531021952629089, "title": "Desvenlafaxine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: 50 mg once daily; doses up to 400 mg once daily have been studied and have shown to be effective; however, the manufacturer states there is no additional benefit at d…"}, {"doc_id": "clonidine-and-chlorthalidone-drug-information", "bm25_top3": 17.770258110576545, "bm25_max": 17.770258110576545, "bge_top3": null, "bge_max": null, "title": "Clonidine and chlorthalidone: Drug information", "rep_snippet": "• Discontinuation of therapy: Gradual withdrawal of clonidine is needed (taper gradually over 2-4 days to avoid rebound hypertension) if drug needs to be stopped. Patients should be instructed about abrupt discontinuatio…"}, {"doc_id": "mirtazapine-drug-information", "bm25_top3": 17.01180807252995, "bm25_max": 17.01180807252995, "bge_top3": 0.5556633472442627, "bge_max": 0.5556633472442627, "title": "Mirtazapine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: Initial: 15 mg nightly, may titrate dose up no more frequently than every 1 to 2 weeks to a maximum of 45 mg/day; dosage range: 15 to 45 mg daily  Discontinuation of…"}, {"doc_id": "quinapril-and-hydrochlorothiazide-drug-information", "bm25_top3": 16.378194049378035, "bm25_max": 16.378194049378035, "bge_top3": null, "bge_max": null, "title": "Quinapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Black patients: Effectiveness of ACE inhibitors is less in black patients than in non-black patients. In addition, ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.  • Pregn…"}, {"doc_id": "iloperidone-drug-information", "bm25_top3": 16.242282133798106, "bm25_max": 16.242282133798106, "bge_top3": null, "bge_max": null, "title": "Iloperidone: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: One-third to one-half the usual dose to treat psychosis in younger adults or the smallest available…"}, {"doc_id": "cariprazine-drug-information", "bm25_top3": 16.242282133798106, "bm25_max": 16.242282133798106, "bge_top3": null, "bge_max": null, "title": "Cariprazine: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: One-third to one-half the usual dose to treat psychosis in younger adults or the smallest available…"}, {"doc_id": "lurasidone-drug-information", "bm25_top3": 16.242282133798106, "bm25_max": 16.242282133798106, "bge_top3": null, "bge_max": null, "title": "Lurasidone: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: One-third to one-half the usual dose to treat psychosis in younger adults or the smallest available…"}, {"doc_id": "asenapine-drug-information", "bm25_top3": 11.228756435365314, "bm25_max": 16.242282133798106, "bge_top3": null, "bge_max": null, "title": "Asenapine: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing.  Psychosis/agitation associated with dementia (off-label use): Sublingual: Initial: One-third to one-half the usual dose to treat psychosis in younger adults or the smallest avai…"}, {"doc_id": "brexpiprazole-drug-information", "bm25_top3": 16.242282133798106, "bm25_max": 16.242282133798106, "bge_top3": null, "bge_max": null, "title": "Brexpiprazole: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: One-third to one-half the usual dose to treat psychosis in younger adults or the smallest available…"}, {"doc_id": "thalidomide-drug-information", "bm25_top3": 16.236920752454193, "bm25_max": 16.236920752454193, "bge_top3": null, "bge_max": null, "title": "Thalidomide: Drug information", "rep_snippet": "Dosing: Adult  Erythema nodosum leprosum, acute cutaneous: Oral: Initial: 100 to 300 mg once daily at bedtime, continue until signs/symptoms subside (usually ~2 weeks), then taper off in 50 mg decrements every 2 to 4 wee…"}, {"doc_id": "loxapine-drug-information", "bm25_top3": 16.173229790187975, "bm25_max": 16.173229790187975, "bge_top3": null, "bge_max": null, "title": "Loxapine: Drug information", "rep_snippet": "Dosing: Geriatric  Reduced dosing may be indicated due to risks of adverse events associated with high-dose therapy. Refer to adult dosing.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: On…"}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": 16.128051277213146, "bm25_max": 16.128051277213146, "bge_top3": null, "bge_max": null, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "molindone-drug-information", "bm25_top3": 16.075870533063693, "bm25_max": 16.075870533063693, "bge_top3": null, "bge_max": null, "title": "Molindone: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. Use lower initial doses.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: One-third to one-half the usual dose to treat psychosis in younger adults o…"}, {"doc_id": "aclidinium-and-formoterol-united-states-not-available-drug-information", "bm25_top3": 15.764691313273351, "bm25_max": 15.764691313273351, "bge_top3": null, "bge_max": null, "title": "Aclidinium and formoterol (United States: Not available): Drug information", "rep_snippet": "Inhalation: Administer via oral inhalation. Prior to first use, remove from sealed pouch immediately before use. Prior to each use, remove protective cap from the inhaler and prepare inhaler by pressing and releasing the…"}, {"doc_id": "paliperidone-drug-information", "bm25_top3": 15.74594102495572, "bm25_max": 15.74594102495572, "bge_top3": 0.5445200204849243, "bge_max": 0.5445200204849243, "title": "Paliperidone: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing; use with caution. Additional monitoring of renal function and orthostatic blood pressure may be warranted.  Psychosis/agitation associated with dementia (off-label use): Oral: In…"}, {"doc_id": "trifluoperazine-drug-information", "bm25_top3": 15.669437873602863, "bm25_max": 15.669437873602863, "bge_top3": null, "bge_max": null, "title": "Trifluoperazine: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. Dose selection should start at the low end of the dosage range and titration must be gradual.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: One-th…"}, {"doc_id": "trandolapril-and-verapamil-drug-information", "bm25_top3": 15.497111779181449, "bm25_max": 15.497111779181449, "bge_top3": null, "bge_max": null, "title": "Trandolapril and verapamil: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "enalapril-and-hydrochlorothiazide-drug-information", "bm25_top3": 15.494278981299841, "bm25_max": 15.494278981299841, "bge_top3": null, "bge_max": null, "title": "Enalapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Black patients: ACE inhibitors effectiveness is less in black patients than in non-blacks. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.  • Pregnancy: [US Boxed Warn…"}, {"doc_id": "perphenazine-drug-information", "bm25_top3": 15.422452366056033, "bm25_max": 15.422452366056033, "bge_top3": null, "bge_max": null, "title": "Perphenazine: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing; initiate dosing at the lower end of the dosing range.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: 0.05 mg/kg/day for 3 days, then 0.1 mg/kg/day…"}, {"doc_id": "fluphenazine-drug-information", "bm25_top3": 14.9498815782109, "bm25_max": 14.9498815782109, "bge_top3": null, "bge_max": null, "title": "Fluphenazine: Drug information", "rep_snippet": "Dosing: Geriatric  Psychosis: Oral: Initial: 1 to 2.5 mg daily; titrated gradually based on patient response.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: One-third to one-half the usual…"}, {"doc_id": "gabapentin-enacarbil-drug-information", "bm25_top3": 14.942846456900519, "bm25_max": 14.942846456900519, "bge_top3": null, "bge_max": null, "title": "Gabapentin enacarbil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.  PHN:  CrCl 30-59 mL/minute: Initial: 300 mg every morning for 3 days, then in…"}, {"doc_id": "trazodone-drug-information", "bm25_top3": 14.930403534990624, "bm25_max": 14.930403534990624, "bge_top3": 0.536173403263092, "bge_max": 0.536173403263092, "title": "Trazodone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Trazodone: Pediatric drug information\")  Insomnia (off-label use): Oral: Immediate-release:  Children 18 months to <3 years (Pranzatelli 2005)  : Initial: 25 mg at bedt…"}, {"doc_id": "thiothixene-drug-information", "bm25_top3": 14.713788581484, "bm25_max": 14.713788581484, "bge_top3": null, "bge_max": null, "title": "Thiothixene: Drug information", "rep_snippet": "Dosing: Geriatric  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: 1 mg 2 to 3 times daily; may increase total daily dose by 2 mg every 2 days; total daily doses as high as 18 mg have been st…"}, {"doc_id": "niraparib-drug-information", "bm25_top3": 14.6731299748741, "bm25_max": 14.6731299748741, "bge_top3": null, "bge_max": null, "title": "Niraparib: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Hepatic function estimated using the National Cancer Institute Organ Dysfunction Working Group Criteria.  Mild impairment: No dosage adjustment necessary.  Moderate to severe impairment: There…"}, {"doc_id": "ziprasidone-drug-information", "bm25_top3": 14.098120202919018, "bm25_max": 14.098120202919018, "bge_top3": null, "bge_max": null, "title": "Ziprasidone: Drug information", "rep_snippet": "Dosing: Geriatric  No dosage adjustment is recommended; consider initiating at a low end of the dosage range, with slower titration.  Psychosis/agitation associated with dementia (off-label use): Oral: Initial: 20 to 40…"}, {"doc_id": "salmeterol-drug-information", "bm25_top3": 13.046167193151433, "bm25_max": 13.046167193151433, "bge_top3": null, "bge_max": null, "title": "Salmeterol: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Salmeterol may be confused with Salbutamol, SOLU-Medrol  Serevent may be confused with Atrovent, Combivent, sertraline, Sinemet, Spiriva, Zoloft"}, {"doc_id": "quinapril-drug-information", "bm25_top3": 5.22422236715707, "bm25_max": 5.22422236715707, "bge_top3": null, "bge_max": null, "title": "Quinapril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "enalapril-drug-information", "bm25_top3": 4.904535503234705, "bm25_max": 4.904535503234705, "bge_top3": null, "bge_max": null, "title": "Enalapril: Drug information", "rep_snippet": "Special populations:  • Black patients: ACE inhibitors effectiveness is less in black patients than in non-blacks. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.  • Pre…"}, {"doc_id": "moexipril-drug-information", "bm25_top3": 4.904535503234705, "bm25_max": 4.904535503234705, "bge_top3": null, "bge_max": null, "title": "Moexipril: Drug information", "rep_snippet": "Special populations:  • Black patients: ACE inhibitors effectiveness is less in black patients than in non-blacks. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.  • Pre…"}, {"doc_id": "captopril-drug-information", "bm25_top3": 4.904535503234705, "bm25_max": 4.904535503234705, "bge_top3": null, "bge_max": null, "title": "Captopril: Drug information", "rep_snippet": "Special populations:  • Black patients: ACE inhibitors effectiveness is less in black patients than in non-blacks. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.  • Pre…"}, {"doc_id": "aclidinium-drug-information", "bm25_top3": 4.736311282809675, "bm25_max": 4.736311282809675, "bge_top3": null, "bge_max": null, "title": "Aclidinium: Drug information", "rep_snippet": "Administer via oral inhalation. Remove inhaler from sealed pouch immediately prior to first use. Prior to each use, remove protective cap from the inhaler and prepare inhaler by pressing and releasing the green button (w…"}, {"doc_id": "benazepril-drug-information", "bm25_top3": 4.567533431159662, "bm25_max": 4.567533431159662, "bge_top3": null, "bge_max": null, "title": "Benazepril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "trandolapril-drug-information", "bm25_top3": 4.567533431159662, "bm25_max": 4.567533431159662, "bge_top3": null, "bge_max": null, "title": "Trandolapril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "perindopril-drug-information", "bm25_top3": 4.532221708841684, "bm25_max": 4.532221708841684, "bge_top3": null, "bge_max": null, "title": "Perindopril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "ramipril-drug-information", "bm25_top3": 4.532221708841684, "bm25_max": 4.532221708841684, "bge_top3": null, "bge_max": null, "title": "Ramipril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "budesonide-nasal-drug-information", "bm25_top3": 3.0235510536299, "bm25_max": 3.0235510536299, "bge_top3": null, "bge_max": null, "title": "Budesonide (nasal): Drug information", "rep_snippet": "Administration  Inhalation:  Powder for nasal inhalation: Rhinocort Turbuhaler [Canadian product]: To prepare inhaler prior to use, load dose by holding inhaler in upright position and turn grey grip as far as it will go…"}, {"doc_id": "idelalisib-drug-information", "bm25_top3": 2.9721974905337056, "bm25_max": 2.9721974905337056, "bge_top3": null, "bge_max": null, "title": "Idelalisib: Drug information", "rep_snippet": "Special Alerts  Idelalisib Safety Alert  December 2017  After reviewing the potential risk of progressive multifocal leukoencephalopathy (PML) with the use of idelalisib (Zydelig), Health Canada has determined that a pos…"}, {"doc_id": "alteplase-drug-information", "bm25_top3": 2.787614668096447, "bm25_max": 2.787614668096447, "bge_top3": null, "bge_max": null, "title": "Alteplase: Drug information", "rep_snippet": "Note: The AHA/ASA 2016 scientific statement has provided updated evidence on certain patients presenting in the 3 to 4.5 hour after initial symptoms window excluded in the aforementioned earlier guidelines, including: pa…"}, {"doc_id": "anthrax-vaccine-drug-information", "bm25_top3": 2.7128433801720817, "bm25_max": 2.7128433801720817, "bge_top3": null, "bge_max": null, "title": "Anthrax vaccine: Drug information", "rep_snippet": "• Persons working in postal facilities"}, {"doc_id": "droxidopa-drug-information", "bm25_top3": 2.488725800388437, "bm25_max": 2.488725800388437, "bge_top3": null, "bge_max": null, "title": "Droxidopa: Drug information", "rep_snippet": "Use  Neurogenic orthostatic hypotension: Treatment of orthostatic dizziness, light-headedness, or the “feeling that you are about to black out” in adults with symptomatic neurogenic orthostatic hypotension (NOH) caused b…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5623859167098999, "bge_max": 0.5623859167098999, "title": "Lansoprazole: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication, patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools. Prior to use, patients should c…"}, {"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5532416105270386, "bge_max": 0.5532416105270386, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication (OTC), patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools. Prior to use, patients sh…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5394786596298218, "bge_max": 0.5394786596298218, "title": "Alirocumab: Drug information", "rep_snippet": "Monitoring Parameters  LDL-C within 4 to 8 weeks of initiation or dose titration. For patients receiving 300 mg every 4 weeks, measure LDL-C just prior to the next scheduled dose (LDL-C varies considerably between doses…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5360023975372314, "bge_max": 0.5360023975372314, "title": "Amitriptyline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5343291163444519, "bge_max": 0.5343291163444519, "title": "Duloxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "acetaminophen-caffeine-and-pyrilamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5340480804443359, "bge_max": 0.5340480804443359, "title": "Acetaminophen, caffeine, and pyrilamine: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication, notify health care provider prior to use if you have glaucoma, liver disease, difficultly in urination due to enlargement of the prostate gland, emphysema, or c…"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5331052541732788, "bge_max": 0.5331052541732788, "title": "Hydrocodone: Drug information", "rep_snippet": "Zohydro ER: For patients on long term opioid therapy, gradually titrate the dose downward every 2 to 4 days to prevent signs and symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous…"}, {"doc_id": "inotuzumab-ozogamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5328589081764221, "bge_max": 0.5328589081764221, "title": "Inotuzumab ozogamicin: Drug information", "rep_snippet": "Monitoring Parameters  Complete blood counts (prior to each dose), liver function tests including ALT, AST, total bilirubin, and alkaline phosphatase (prior to and following each dose); for patients who proceed to HSCT,…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5326026678085327, "bge_max": 0.5326026678085327, "title": "Ranitidine: Drug information", "rep_snippet": "• OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: Frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexpl…"}, {"doc_id": "docusate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.531875729560852, "bge_max": 0.531875729560852, "title": "Docusate: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication (OTC), patients should be instructed to contact healthcare provider prior to use if nausea, stomach pain, or vomiting are present, or if a sudden change in bowel…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5266658365726471, "bge_max": 0.5318484306335449, "title": "Citalopram: Drug information", "rep_snippet": "Premature Ejaculation (off-label use): Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability up to 40 mg/day (Althof 2014; Safarinejad 2006). Additional data may be necessary to further de…"}, {"doc_id": "gemtuzumab-ozogamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5307332277297974, "bge_max": 0.5307332277297974, "title": "Gemtuzumab ozogamicin: Drug information", "rep_snippet": "Monitoring Parameters  Monitor liver function tests (ALT, AST, total bilirubin, and alkaline phosphatase) prior to each dose, and more frequently if clinically indicated, particularly if veno-occlusive disease (VOD) is s…"}, {"doc_id": "famotidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5306978821754456, "bge_max": 0.5306978821754456, "title": "Famotidine: Drug information", "rep_snippet": "• OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: Frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexpl…"}, {"doc_id": "methadone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5300846099853516, "bge_max": 0.5300846099853516, "title": "Methadone: Drug information", "rep_snippet": "Respiratory depression, including fatal cases, has been reported during initiation and conversion of patients to methadone, and even when the drug has been used as recommended and not misused or abused. Proper dosing and…"}, {"doc_id": "triprolidine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5286217927932739, "bge_max": 0.5286217927932739, "title": "Triprolidine and pseudoephedrine: Drug information", "rep_snippet": "Other warnings/precautions:  • Self-medication (OTC use): When used for self medication (OTC), do not exceed recommended doses; discontinue use and contact health care provider if symptoms do not improve within 7 days or…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5269429981708527, "bge_max": 0.5281609892845154, "title": "Maprotiline: Drug information", "rep_snippet": "Warnings/Precautions  Major psychiatric warnings:  • Suicidal thinking/behavior: [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.527694582939148, "bge_max": 0.527694582939148, "title": "Guaifenesin, pseudoephedrine, and codeine: Drug information", "rep_snippet": "• Self-medication (OTC use): Prior to self-medication (OTC), notify health care provider if you have heart disease, hypertension, thyroid disease, diabetes, trouble urinating due to enlargement of the prostate gland, cou…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5274443030357361, "bge_max": 0.5274443030357361, "title": "Vortioxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "atropine-and-pralidoxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.527112603187561, "bge_max": 0.527112603187561, "title": "Atropine and pralidoxime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atropine and pralidoxime: Pediatric drug information\")  Note: If exposure is suspected, antidotal therapy should be given immediately as soon as symptoms appear (critic…"}, {"doc_id": "guaifenesin-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.527084231376648, "bge_max": 0.527084231376648, "title": "Guaifenesin and pseudoephedrine: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. Discontinue and contact hea…"}, {"doc_id": "tranylcypromine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5268628001213074, "bge_max": 0.5268628001213074, "title": "Tranylcypromine: Drug information", "rep_snippet": "Dosing: Adult  Major depression: Oral: Initial: 10 mg/day; if symptoms do not improve after 2 weeks, increase dose by 10 mg/day increments at 1- to 3-week intervals; usual dosage range 30 to 60 mg/day in divided doses (A…"}, {"doc_id": "naproxen-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5260251760482788, "bge_max": 0.5260251760482788, "title": "Naproxen and pseudoephedrine: Drug information", "rep_snippet": "• Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had recurring heartburn, stomach pain or upset, ulcers, bleeding problems, asthma, high blood pressure, hear…"}, {"doc_id": "nortriptyline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5259113311767578, "bge_max": 0.5259113311767578, "title": "Nortriptyline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5255788564682007, "bge_max": 0.5255788564682007, "title": "Esomeprazole: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication (OTC), notify health care provider before use if any of the following are present: heartburn for >3 months; frequent wheezing, particularly with heartburn; unexp…"}, {"doc_id": "ibuprofen-phenylephrine-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5249794721603394, "bge_max": 0.5249794721603394, "title": "Ibuprofen, phenylephrine, and chlorpheniramine: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication (OTC), contact a health care provider before use if you have a breathing problem such as emphysema or chronic bronchitis or have a history or stomach problems su…"}, {"doc_id": "methylcellulose-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5249229669570923, "bge_max": 0.5249229669570923, "title": "Methylcellulose: Drug information", "rep_snippet": "Warnings/Precautions  Other warnings/precautions:  • Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have abdominal pain, nausea, vomiting, or a sudden change in b…"}, {"doc_id": "escitalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5248024463653564, "bge_max": 0.5248024463653564, "title": "Escitalopram: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "chlophedianol-and-dexbrompheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5242242813110352, "bge_max": 0.5242242813110352, "title": "Chlophedianol and dexbrompheniramine: Drug information", "rep_snippet": "• Self-medication (OTC use): Discontinue use and notify health care provider if cough or symptoms do not improve within 7 days, recur, are accompanied by fever, rash, or persistent headache, or new symptoms occur."}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5239101052284241, "bge_max": 0.5239101052284241, "title": "Paroxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5231932103633881, "bge_max": 0.5239033102989197, "title": "Fluoxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "dextromethorphan-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5236040353775024, "bge_max": 0.5236040353775024, "title": "Dextromethorphan and chlorpheniramine: Drug information", "rep_snippet": "• Self-medication (OTC use): Patients with glaucoma or prostatic hyperplasia should consult healthcare provider prior to use. Patients with chronic cough (associated with COPD or smoking) and/or productive cough (eg, cop…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5229909420013428, "bge_max": 0.5229909420013428, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "doxepin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5226559638977051, "bge_max": 0.5226559638977051, "title": "Doxepin (systemic): Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5219609141349792, "bge_max": 0.5219609141349792, "title": "Amoxapine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5218707919120789, "bge_max": 0.5218707919120789, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "• Self-medication (OTC use): When used for self-medication (OTC), discontinue use and notify health care provider if pain or nasal congestion does not improve or gets worse within 7 days; fever gets worse or lasts >3 day…"}, {"doc_id": "isocarboxazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5216215252876282, "bge_max": 0.5216215252876282, "title": "Isocarboxazid: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5216215252876282, "bge_max": 0.5216215252876282, "title": "Phenelzine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "amitriptyline-and-perphenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5214537978172302, "bge_max": 0.5214537978172302, "title": "Amitriptyline and perphenazine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}]}
{"qid": "Q26_spelling", "query": "Sertralin — onset, BB warning, dosing, and how to wean.", "base_qid": "Q26", "variant_type": "spelling", "candidates": [{"doc_id": "milrinone-drug-information", "bm25_top3": 16.884022715958018, "bm25_max": 16.884022715958018, "bge_top3": null, "bge_max": null, "title": "Milrinone: Drug information", "rep_snippet": "Postoperative inotropic support in heart transplant recipients (off-label use): IV: 0.375 to 0.75 mcg/kg/minute; use the lowest effective dose and wean as tolerated over the first 3 to 5 days (ISHLT [Costanzo 2010])."}, {"doc_id": "nitric-oxide-drug-information", "bm25_top3": 6.816858111540987, "bm25_max": 14.830737848465043, "bge_top3": null, "bge_max": null, "title": "Nitric oxide: Drug information", "rep_snippet": "Hypoxic respiratory failure associated with pulmonary hypertension: Neonates (>34 weeks gestational age): Inhalation: 20 parts per million (ppm); maintain treatment up to 14 days or until resolution of oxygen desaturatio…"}, {"doc_id": "colistin-colistimethate-drug-information", "bm25_top3": 13.89490959829005, "bm25_max": 13.89490959829005, "bge_top3": null, "bge_max": null, "title": "Colistin (colistimethate): Drug information", "rep_snippet": "Nebulization (via ventilator circuit): 150 mg CBA every 8 hours delivered over 60 minutes for 14 days or until successful wean from mechanical ventilation (treatment duration range: 7 to 19 days) (Lu 2012). May consider…"}, {"doc_id": "epinephrine-adrenaline-systemic-drug-information", "bm25_top3": 12.559027418209169, "bm25_max": 12.559027418209169, "bge_top3": null, "bge_max": null, "title": "Epinephrine (adrenaline) (systemic): Drug information", "rep_snippet": "Twinject [Canadian product]: IM, SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5 to 15 minutes using the same device after partial disassembly  Hypotension/shock:  Manufacturer's labeling: Septi…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": 4.854689163996284, "bm25_max": 11.991995994792825, "bge_top3": 0.588611880938212, "bge_max": 0.6073126792907715, "title": "Sertraline: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing sertraline and initiation of an MAO inhibitor intended to treat psychiatric disorders."}, {"doc_id": "alglucosidase-alfa-drug-information", "bm25_top3": 11.878278142220807, "bm25_max": 11.883729338559805, "bge_top3": null, "bge_max": null, "title": "Alglucosidase alfa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Alglucosidase alfa: Pediatric drug information\")  Pompe disease: IV:  Infantile-onset (Lumizyme, Myozyme): Infants ≥1 month, Children, and Adolescents: 20 mg/kg every 2…"}, {"doc_id": "zinc-gluconate-drug-information", "bm25_top3": 10.53218739208242, "bm25_max": 11.637077931858821, "bge_top3": null, "bge_max": null, "title": "Zinc gluconate: Drug information", "rep_snippet": "Dosing: Adult  Common cold: Note: For best results, begin therapy 24 to 48 hours prior to symptom onset: Dissolve one 13.3 mg lozenge in mouth every 2 to 4 hours as needed. Maximum: 6 lozenges daily"}, {"doc_id": "pamabrom-drug-information", "bm25_top3": 11.631754625440053, "bm25_max": 11.631754625440053, "bge_top3": null, "bge_max": null, "title": "Pamabrom: Drug information", "rep_snippet": "Dosing: Adult  Premenstrual or menstrual symptoms: Oral: 50 mg after breakfast, may repeat in 6 hours as needed (maximum: 200 mg/24 hours); should be taken 5-6 days prior to onset of menstrual period and continued until…"}, {"doc_id": "epoprostenol-drug-information", "bm25_top3": 11.120076003716711, "bm25_max": 11.120076003716711, "bge_top3": null, "bge_max": null, "title": "Epoprostenol: Drug information", "rep_snippet": "Nebulization via ventilator circuit: Using a 20,000 ng/mL concentration, prime nebulizer chamber with 15 mL; administer remainder at a constant rate of 8 mL/hour; delivers ~38 ng/kg/minute (based on a 70 kg patient); set…"}, {"doc_id": "cisatracurium-drug-information", "bm25_top3": 10.88057269862604, "bm25_max": 10.88057269862604, "bge_top3": null, "bge_max": null, "title": "Cisatracurium: Drug information", "rep_snippet": "Dosing: Renal Impairment  Because slower times to onset of complete neuromuscular block were observed in renal dysfunction patients, extending the interval between the administration of cisatracurium and intubation attem…"}, {"doc_id": "levothyroxine-drug-information", "bm25_top3": 10.788785753188883, "bm25_max": 10.788785753188883, "bge_top3": null, "bge_max": null, "title": "Levothyroxine: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Cardiac symptoms (onset or worsening): Manufacturer labeling recommends reducing dosage or withholding therapy for 7 days and then resuming therapy at reduced dosage. Specific dosing reco…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 10.60840098036885, "bm25_max": 10.60840098036885, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 10.60840098036885, "bm25_max": 10.60840098036885, "bge_top3": null, "bge_max": null, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "mifepristone-and-misoprostol-united-states-not-available-drug-information", "bm25_top3": 10.439984614369866, "bm25_max": 10.439984614369866, "bge_top3": null, "bge_max": null, "title": "Mifepristone and misoprostol (United States: Not available): Drug information", "rep_snippet": "Prescribing and Access Restrictions  Prior to initiating therapy, patients are required to sign a consent form and both the patient and physician must sign a patient information card. Physicians are also required to comp…"}, {"doc_id": "brivaracetam-drug-information", "bm25_top3": 10.280874593224953, "bm25_max": 10.280874593224953, "bge_top3": 0.5753500759601593, "bge_max": 0.583175539970398, "title": "Brivaracetam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Brivaracetam: Pediatric drug information\")  Partial onset seizures (monotherapy or adjunctive therapy): Adolescents ≥16 years: Oral, IV: Refer to adult dosing."}, {"doc_id": "peramivir-drug-information", "bm25_top3": 9.799261248530664, "bm25_max": 9.799261248530664, "bge_top3": null, "bge_max": null, "title": "Peramivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Peramivir: Pediatric drug information\")  Influenza: IV: Note: Administer within 2 days of onset of symptoms of influenza.  Children: 2 to 12 years: 12 mg/kg as a single…"}, {"doc_id": "triptorelin-drug-information", "bm25_top3": 9.34342379506215, "bm25_max": 9.34342379506215, "bge_top3": null, "bge_max": null, "title": "Triptorelin: Drug information", "rep_snippet": "Dosing: Pediatric  Central precocious puberty: Triptodur: Children ≥2 years and Adolescents: IM: 22.5 mg once every 24 weeks; discontinue therapy at appropriate age of onset of puberty."}, {"doc_id": "insulin-aspart-protamine-and-insulin-aspart-drug-information", "bm25_top3": 9.157134464451804, "bm25_max": 9.157134464451804, "bge_top3": null, "bge_max": null, "title": "Insulin aspart protamine and insulin aspart: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Note: Onset and duration of hypoglycemic effects depend upon the route of administration (adsorption and onset of action are more rapid after deeper IM injections than after SubQ), site of inje…"}, {"doc_id": "perampanel-drug-information", "bm25_top3": 6.9434772284362225, "bm25_max": 6.9434772284362225, "bge_top3": null, "bge_max": null, "title": "Perampanel: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Perampanel: Pediatric drug information\")  Note: Reduce the dosage in patients who experience serious psychiatric or behavioral reactions; discontinue immediately if sym…"}, {"doc_id": "lindane-drug-information", "bm25_top3": 1.9413212383383804, "bm25_max": 2.4382097445515747, "bge_top3": null, "bge_max": null, "title": "Lindane: Drug information", "rep_snippet": "• Appropriate use: [US Boxed Warning]: Not a drug of first choice; use only in patients who have failed or cannot tolerate first-line agents. Instruct patients on proper use, including the amount to apply, how long to le…"}, {"doc_id": "irinotecan-conventional-drug-information", "bm25_top3": 2.341575937869756, "bm25_max": 2.341575937869756, "bge_top3": null, "bge_max": null, "title": "Irinotecan (conventional): Drug information", "rep_snippet": "• Diarrhea: [US Boxed Warning]: Severe diarrhea may be dose-limiting and potentially fatal; early-onset and late-onset diarrhea may occur. Early diarrhea occurs during or within 24 hours of receiving irinotecan and is ch…"}, {"doc_id": "ammonium-lactate-topical-drug-information", "bm25_top3": 2.3372268198668493, "bm25_max": 2.3372268198668493, "bge_top3": null, "bge_max": null, "title": "Ammonium lactate (topical): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known how this medication affects normal levels of lactic acid in human milk. Because studies have not been done in nursing women, use with caution when needed."}, {"doc_id": "brentuximab-vedotin-drug-information", "bm25_top3": 2.1764520706423625, "bm25_max": 2.1764520706423625, "bge_top3": null, "bge_max": null, "title": "Brentuximab vedotin: Drug information", "rep_snippet": "• Progressive multifocal leukoencephalopathy: [US Boxed Warning]: Cases of progressive multifocal leukoencephalopathy (PML) and death due to JC virus infection have been reported. Immunosuppression due to prior chemother…"}, {"doc_id": "sacrosidase-drug-information", "bm25_top3": 2.1724310213346634, "bm25_max": 2.1724310213346634, "bge_top3": null, "bge_max": null, "title": "Sacrosidase: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Sucraid® is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to http://www.sucraid.net/how-to-order-sucraid or call 1-866-740-2743."}, {"doc_id": "propofol-drug-information", "bm25_top3": 2.0012295834487404, "bm25_max": 2.0012295834487404, "bge_top3": null, "bge_max": null, "title": "Propofol: Drug information", "rep_snippet": "• Abrupt discontinuation: Avoid abrupt discontinuation prior to weaning or daily wake up assessments. Abrupt discontinuation can result in rapid awakening, anxiety, agitation, and resistance to mechanical ventilation; we…"}, {"doc_id": "uridine-triacetate-drug-information", "bm25_top3": 1.9865409591316094, "bm25_max": 1.9865409591316094, "bge_top3": null, "bge_max": null, "title": "Uridine triacetate: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Fluorouracil accidental overdose/overexposure: Uridine triacetate (formerly called vistonuridine) is available through select specialty pharmacies. Procurement information is availabl…"}, {"doc_id": "obinutuzumab-drug-information", "bm25_top3": 1.8821649310603714, "bm25_max": 1.8821649310603714, "bge_top3": null, "bge_max": null, "title": "Obinutuzumab: Drug information", "rep_snippet": "• Progressive multifocal leukoencephalopathy: [US Boxed Warning]: Progressive multifocal leukoencephalopathy (PML) resulting in death may occur with treatment. PML is due to JC virus infection. Consider PML in any patien…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 1.8617441727942623, "bm25_max": 1.8617441727942623, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Korlym is only available through a restricted access program. For prescriber registration and patient enrollment forms, please refer to http://www.korlym.com/hcp/how-to-prescribe-korl…"}, {"doc_id": "dacarbazine-drug-information", "bm25_top3": 1.6281710173032895, "bm25_max": 1.6281710173032895, "bge_top3": null, "bge_max": null, "title": "Dacarbazine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis: May occur following dacarbazine administration.  • Bone marrow suppression: [US Boxed Warning]: Bone marrow suppression is the most common toxici…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 1.2836158191434013, "bm25_max": 1.2836158191434013, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Mercaptopurine is the active metabolite of azathioprine. Following administration of azathioprine, mercaptopurine can be detected in breast milk (Gardiner 2006). It is not known if/how much…"}, {"doc_id": "omalizumab-drug-information", "bm25_top3": 1.0077727859647858, "bm25_max": 1.0077727859647858, "bge_top3": null, "bge_max": null, "title": "Omalizumab: Drug information", "rep_snippet": "• Hypersensitivity/anaphylactoid reactions: [US Boxed Warning]: Anaphylaxis, including delayed-onset anaphylaxis, has been reported following administration; anaphylaxis may present as bronchospasm, hypotension, syncope,…"}, {"doc_id": "ponatinib-drug-information", "bm25_top3": 0.6050281828850359, "bm25_max": 0.6050281828850359, "bge_top3": null, "bge_max": null, "title": "Ponatinib: Drug information", "rep_snippet": "• Hepatotoxicity: [US Boxed Warning]: Liver failure and death resulting from ponatinib-induced hepatotoxicity were observed; monitor liver function prior to and at least monthly (or as clinically indicated) during treatm…"}, {"doc_id": "bexarotene-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5969180762767792, "bge_max": 0.6047523021697998, "title": "Bexarotene (systemic): Drug information", "rep_snippet": "[U.S. Boxed Warning]: Bexarotene is a retinoid, a drug class associated with birth defects in humans; do not administer during pregnancy. Bexarotene caused birth defects when administered orally to pregnant rats. It must…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5835867921511332, "bge_max": 0.5881268382072449, "title": "Verapamil: Drug information", "rep_snippet": "Dosing: Geriatric  Hypertension: Oral: Note: When switching from immediate-release to extended-release formulations, the total daily dose remains the same unless formulation strength does not allow for equal conversion.…"}, {"doc_id": "bosentan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5763388474782308, "bge_max": 0.5846644639968872, "title": "Bosentan: Drug information", "rep_snippet": "Estrogen Derivatives (Contraceptive): Bosentan may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of chi…"}, {"doc_id": "drospirenone-and-estradiol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5830765962600708, "bge_max": 0.5830765962600708, "title": "Drospirenone and estradiol: Drug information", "rep_snippet": "Bexarotene (Systemic): May decrease the serum concentration of Progestins (Contraceptive). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at lea…"}, {"doc_id": "cyproterone-and-ethinyl-estradiol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5737121999263763, "bge_max": 0.5825849771499634, "title": "Cyproterone and ethinyl estradiol (United States: Not available): Drug information", "rep_snippet": "Bexarotene (Systemic): May decrease the serum concentration of Estrogen Derivatives (Contraceptive). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (includ…"}, {"doc_id": "irbesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5819580554962158, "bge_max": 0.5819580554962158, "title": "Irbesartan: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Fetal toxicity:  When pregnancy is detected, discontinue irbesartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing…"}, {"doc_id": "cisplatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5790943503379822, "bge_max": 0.5790943503379822, "title": "Cisplatin: Drug information", "rep_snippet": "Dosing: Adult  VERIFY ANY CISPLATIN DOSE EXCEEDING 100 mg/m2 PER COURSE. Pretreatment hydration with 1 to 2 L of IV fluid is recommended. Cisplatin is associated with a high emetic potential; antiemetics are recommended…"}, {"doc_id": "acitretin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5779319405555725, "bge_max": 0.5779319405555725, "title": "Acitretin: Drug information", "rep_snippet": "• Pregnancy: [US Boxed Warning]: Acitretin is a known teratogen and contraindicated in females who are or may become pregnant. Birth defects (including facial, ear, central nervous system, cardiovascular, limb, bone, and…"}, {"doc_id": "ethinyl-estradiol-drospirenone-and-levomefolate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.577083945274353, "bge_max": 0.5771403908729553, "title": "Ethinyl estradiol, drospirenone, and levomefolate: Drug information", "rep_snippet": "Boceprevir: May increase the serum concentration of Drospirenone. Risk X: Avoid combination  Bosentan: May decrease the serum concentration of Estrogen Derivatives (Contraceptive). Management: Use an alternative (i.e., n…"}, {"doc_id": "ethinyl-estradiol-and-drospirenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.577083945274353, "bge_max": 0.5771403908729553, "title": "Ethinyl estradiol and drospirenone: Drug information", "rep_snippet": "Boceprevir: May increase the serum concentration of Drospirenone. Risk X: Avoid combination  Bosentan: May decrease the serum concentration of Estrogen Derivatives (Contraceptive). Management: Use an alternative (i.e., n…"}, {"doc_id": "benazepril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5771366357803345, "bge_max": 0.5771366357803345, "title": "Benazepril: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Fetal toxicity:  When pregnancy is detected, discontinue benazepril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to a developing fetus."}, {"doc_id": "meningococcal-group-b-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5723892450332642, "bge_max": 0.5769205689430237, "title": "Meningococcal group B vaccine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Meningococcal group B vaccine: Pediatric drug information\")  Meningococcal group B disease prevention:  US labeling (Bexsero): Children ≥10 years and Adolescents: IM: 0…"}, {"doc_id": "rimabotulinumtoxinb-myobloc-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5769078135490417, "bge_max": 0.5769078135490417, "title": "RimabotulinumtoxinB (Myobloc): Drug information", "rep_snippet": "Dosing: Adult  Cervical dystonia: IM: Initial: 2,500 to 5,000 units divided among the affected muscles in patients previously treated with botulinum toxin; initial dose in previously untreated patients should be lower. S…"}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.576524555683136, "bge_max": 0.576524555683136, "title": "Fosphenytoin: Drug information", "rep_snippet": "Erlotinib: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Erlotinib. Management: Avoid use of erlotinib with phenytoin when possible. If req…"}, {"doc_id": "bacitracin-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5763545036315918, "bge_max": 0.5763545036315918, "title": "Bacitracin (topical): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Bacitracin (topical): Pediatric drug information\")  Prevention of infection: Children and Adolescents: Topical: Refer to adult dosing."}, {"doc_id": "sulfacetamide-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5763120651245117, "bge_max": 0.5763120651245117, "title": "Sulfacetamide (topical): Drug information", "rep_snippet": "SEB-Prev: Wash affected areas twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5744839310646057, "bge_max": 0.5744839310646057, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Monitoring Parameters  Creatinine, BUN, CBC with differential, PT, PTT, serum electrolytes, LFTs, urinalysis; signs of bleeding; monitor for signs of anaphylaxis during first dose"}, {"doc_id": "incobotulinumtoxina-xeomin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5743716955184937, "bge_max": 0.5743716955184937, "title": "IncobotulinumtoxinA (Xeomin): Drug information", "rep_snippet": "Dosing: Adult  Blepharospasm: IM:  US labeling: Initial: Total dose should be the same as previously administered onabotulinumtoxinA dose. If prior onabotulinumtoxinA dose is not known: 1.25 to 2.5 units/injection site (…"}, {"doc_id": "losartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5729845762252808, "bge_max": 0.5729845762252808, "title": "Losartan: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Fetal toxicity:  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue losartan as soon as possible."}, {"doc_id": "belatacept-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5728740096092224, "bge_max": 0.5728740096092224, "title": "Belatacept: Drug information", "rep_snippet": "Monitoring Parameters  Monitor for new-onset or worsening neurological, cognitive, or behavioral signs/symptoms; signs/symptoms of infection or malignancy; gastrointestinal side effects (eg, nausea, vomiting, diarrhea);…"}, {"doc_id": "eprosartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5727906227111816, "bge_max": 0.5727906227111816, "title": "Eprosartan: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Fetal toxicity:  When pregnancy is detected, discontinue eprosartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5693761110305786, "bge_max": 0.5693761110305786, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Bosentan: Ritonavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg daily or every other day in adult patients who have been on ritonavir for at least 10 days. Temporarily stop bosentan…"}, {"doc_id": "dicloxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5693609714508057, "bge_max": 0.5693609714508057, "title": "Dicloxacillin: Drug information", "rep_snippet": "Monitoring Parameters  Baseline and periodic CBC with differential; periodic BUN, serum creatinine, AST and ALT (especially with prolonged therapy); prothrombin time if patient concurrently on warfarin; signs of anaphyla…"}, {"doc_id": "bovine-lipid-extract-surfactant-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5689170360565186, "bge_max": 0.5689170360565186, "title": "Bovine lipid extract surfactant (United States: Not available): Drug information", "rep_snippet": "• Appropriate use: For intratracheal administration only. Correct any acidosis, hypoglycemia, hypothermia, or hypotension prior to administration.  • Monitoring: [Canadian Boxed Warning]: BLES rapidly affects oxygenation…"}, {"doc_id": "sonidegib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5688595771789551, "bge_max": 0.5688595771789551, "title": "Sonidegib: Drug information", "rep_snippet": "Dosing: Adult  Note: Verify pregnancy status of females of reproductive potential prior to therapy initiation. Measure serum creatine kinase (CK) levels and renal function tests in all patients prior to starting treatmen…"}, {"doc_id": "black-widow-spider-latrodectus-mactans-antivenom-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5683014392852783, "bge_max": 0.5683014392852783, "title": "Black widow spider (Latrodectus mactans) antivenom: Drug information", "rep_snippet": "Envenomation due to Latrodectus mactans (black widow spider); envenomation due to other Latrodectus spp (off-label use) (Clark 2001; Isbister 2003): If a positive reaction to a skin or conjunctival test occurs and antive…"}, {"doc_id": "gabapentin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5675751566886902, "bge_max": 0.5675751566886902, "title": "Gabapentin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Gabapentin: Pediatric drug information\")  Seizures, partial onset: Immediate release:  Children 3 to 4 years: Oral: Initial: 10 to 15 mg/kg/day in 3 divided doses; titr…"}, {"doc_id": "aztreonam-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5666248798370361, "bge_max": 0.5666248798370361, "title": "Aztreonam (oral inhalation): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Aztreonam (oral inhalation): Pediatric drug information\")  Cystic fibrosis: Note: Pretreatment with a bronchodilator is recommended.  US labeling: Children ≥7 years and…"}, {"doc_id": "vigabatrin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5665547847747803, "bge_max": 0.5665547847747803, "title": "Vigabatrin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Vigabatrin: Pediatric drug information\")  Infantile spasms: Infants and Children 1 month to 2 years: Oral: Powder for suspension only: Initial dosing: 50 mg/kg/day divi…"}, {"doc_id": "enalapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5662447214126587, "bge_max": 0.5662447214126587, "title": "Enalapril: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Fetal toxicity:  When pregnancy is detected, discontinue enalapril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus."}, {"doc_id": "buserelin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5647083520889282, "bge_max": 0.5647083520889282, "title": "Buserelin (United States: Not available): Drug information", "rep_snippet": "• Disease flare: [Canadian Boxed Warning]: A transient (usual duration <10 days) exacerbation of the signs and symptoms of the disease process may be observed with the initiation of therapy. Prostate cancer patients may…"}, {"doc_id": "ethinyl-estradiol-and-norgestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5643943548202515, "bge_max": 0.5643943548202515, "title": "Ethinyl estradiol and norgestrel: Drug information", "rep_snippet": "Barbiturates: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended. Risk D: Consider therapy modi…"}, {"doc_id": "ethinyl-estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5643943548202515, "bge_max": 0.5643943548202515, "title": "Ethinyl estradiol and norethindrone: Drug information", "rep_snippet": "Barbiturates: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended. Risk D: Consider therapy modi…"}, {"doc_id": "ethinyl-estradiol-and-desogestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5643943548202515, "bge_max": 0.5643943548202515, "title": "Ethinyl estradiol and desogestrel: Drug information", "rep_snippet": "Barbiturates: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended. Risk D: Consider therapy modi…"}, {"doc_id": "rituximab-intravenous-drug-information", "bm25_top3": 0.43915698313795914, "bm25_max": 0.43915698313795914, "bge_top3": null, "bge_max": null, "title": "Rituximab (intravenous): Drug information", "rep_snippet": "• Mucocutaneous reactions: [US Boxed Warning]: Severe and sometimes fatal mucocutaneous reactions (lichenoid dermatitis, paraneoplastic pemphigus, Stevens-Johnson syndrome, toxic epidermal necrolysis and vesiculobullous…"}, {"doc_id": "lutropin-alfa-united-states-not-available-drug-information", "bm25_top3": 0.2155184948614206, "bm25_max": 0.2155184948614206, "bge_top3": null, "bge_max": null, "title": "Lutropin alfa (United States: Not available): Drug information", "rep_snippet": "Administration  SubQ: Administer in the stomach or thigh; rotate injection sites. Do not shake solution; allow any bubbles to settle prior to administration. Contents of lutropin alfa vial may be mixed in the same syring…"}, {"doc_id": "aldesleukin-drug-information", "bm25_top3": 0.20683702786264568, "bm25_max": 0.20683702786264568, "bge_top3": null, "bge_max": null, "title": "Aldesleukin: Drug information", "rep_snippet": "• Infections: [US Boxed Warning]: Impaired neutrophil function is associated with treatment; patients are at risk for disseminated infection (including sepsis and bacterial endocarditis), and central line-related gram-po…"}, {"doc_id": "pazopanib-drug-information", "bm25_top3": 0.20217688225343977, "bm25_max": 0.20217688225343977, "bge_top3": null, "bge_max": null, "title": "Pazopanib: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Hepatotoxicity:  Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended."}, {"doc_id": "vilazodone-drug-information", "bm25_top3": -0.37982939912625646, "bm25_max": -0.37982939912625646, "bge_top3": null, "bge_max": null, "title": "Vilazodone: Drug information", "rep_snippet": "Brand Names: International  Viibryd (BB);  Viibryd Starter Pak (BB);  Vintix (AR);  Visdon (AR)"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": -0.3915990196311494, "bm25_max": -0.3915990196311494, "bge_top3": null, "bge_max": null, "title": "Clarithromycin: Drug information", "rep_snippet": "Special Alerts  Clarithromycin Safety Alert  February 2018  The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death…"}, {"doc_id": "esmolol-drug-information", "bm25_top3": -1.1771198193711712, "bm25_max": -1.1771198193711712, "bge_top3": null, "bge_max": null, "title": "Esmolol: Drug information", "rep_snippet": "Administration  IV: Loading doses may be administered over 30 seconds to 1 minute depending on how urgent the need for effect. Infusion into small veins or through a butterfly catheter should be avoided (can cause thromb…"}, {"doc_id": "asfotase-alfa-drug-information", "bm25_top3": -1.243699453659577, "bm25_max": -1.243699453659577, "bge_top3": null, "bge_max": null, "title": "Asfotase alfa: Drug information", "rep_snippet": "Local: Erythema at injection site (juvenile-onset HPP: 75%; perinatal/infantile-onset HPP: 23% to 44%), atrophy at injection site (juvenile-onset HPP: 40%; perinatal/infantile-onset HPP: 6% to 15%), skin discoloration at…"}, {"doc_id": "insulin-nph-drug-information", "bm25_top3": -1.332946049772545, "bm25_max": -1.332946049772545, "bge_top3": null, "bge_max": null, "title": "Insulin NPH: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Note: Onset and duration of hypoglycemic effects depend upon the route of administration (adsorption and onset of action are more rapid after deeper IM injections than after SubQ), site of inje…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": -1.7200799385544414, "bm25_max": -1.7200799385544414, "bge_top3": null, "bge_max": null, "title": "Nilotinib: Drug information", "rep_snippet": "Special Alerts  Nilotinib Treatment Discontinuation  December 2017  The FDA has updated the product label for Novartis' Tasigna (nilotinib) oral capsules to include information on how to discontinue the drug in certain p…"}]}
{"qid": "Q27_abbr+device-cue", "query": "Asthma rescue — albuterol HFA dosing, spacer/technique notes, and max puffs/day.", "base_qid": "Q27", "variant_type": "abbr+device-cue", "candidates": [{"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 35.71630486024915, "bm25_max": 38.19718833466653, "bge_top3": 0.6970982551574707, "bge_max": 0.7162238359451294, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "US labeling: Note: Dosing based on previous asthma therapy and asthma severity. May increase dose after 2 weeks of therapy in patients who are not adequately controlled.  Metered dose inhaler: Initial (patients with no p…"}, {"doc_id": "ipratropium-and-albuterol-drug-information", "bm25_top3": 26.691344110077083, "bm25_max": 34.695567839647964, "bge_top3": 0.6972438097000122, "bge_max": 0.6972438097000122, "title": "Ipratropium and albuterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Oral inhalation:  Metered dose inhaler (MDI): One inhalation 4 times daily (maximum: 6 inhalations/day)  Nebulization solution: Initial: 1 vial (3 mL) (ipratropium bromide 0.5 mg/albuterol 2.5 mg) ev…"}, {"doc_id": "oxycodone-and-naloxone-drug-information", "bm25_top3": 32.7989333284837, "bm25_max": 32.7989333284837, "bge_top3": null, "bge_max": null, "title": "Oxycodone and naloxone: Drug information", "rep_snippet": "Currently on other oral opioids: Discontinue all other around-the-clock opioids. Initiate oxycodone/naloxone at the lowest available strength; adequate rescue medication should be provided. Maximum single dose: Oxycodone…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": 29.426133535707965, "bm25_max": 30.14645475400385, "bge_top3": 0.7041983902454376, "bge_max": 0.7100165486335754, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Asthma: Inhalation (doses should be titrated to the lowest effective dose once asthma is controlled):  US labeling: Metered-dose inhaler:  QVAR/QVAR RediHaler: Note: Dosing based on previous asthma therapy…"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 29.781113119407237, "bm25_max": 29.781113119407237, "bge_top3": 0.6873881220817566, "bge_max": 0.6883952617645264, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fluticasone and salmeterol: Pediatric drug information\")  Asthma: Inhalation: Note: The recommended starting dose is based upon asthma severity; may increase dose after…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 27.474148930332234, "bm25_max": 28.903573620525563, "bge_top3": 0.6993509531021118, "bge_max": 0.7091456651687622, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Adult  Dose depends upon condition being treated and response of patient. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dos…"}, {"doc_id": "ciclesonide-oral-inhalation-drug-information", "bm25_top3": 21.348849642252894, "bm25_max": 22.352556618515674, "bge_top3": 0.7204374670982361, "bge_max": 0.7204374670982361, "title": "Ciclesonide (oral inhalation): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciclesonide (oral inhalation): Pediatric drug information \")  Asthma: Inhalation: Note: Titrate to the lowest effective dose once asthma stability is achieved:  US labe…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": 21.860858935694896, "bm25_max": 22.138876943318003, "bge_top3": 0.6776862343152364, "bge_max": 0.6902763843536377, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "Pricing: US  Aerosol powder (ProAir RespiClick Inhalation)  108 (90 Base) mcg/ACT (1): $67.44  Aerosol solution (ProAir HFA Inhalation)  108 (90 Base) mcg/ACT (8.5 g): $71.48  Aerosol solution (Proventil HFA Inhalation)…"}, {"doc_id": "formoterol-and-mometasone-drug-information", "bm25_top3": 19.881477244657134, "bm25_max": 19.881477244657134, "bge_top3": 0.6958670914173126, "bge_max": 0.7119153141975403, "title": "Formoterol and mometasone: Drug information", "rep_snippet": "• Appropriate use: Do not use for acute bronchospasm. Short-acting beta-2 agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do not initiate in patients with significantl…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": 18.177424905195025, "bm25_max": 18.815249654276922, "bge_top3": null, "bge_max": null, "title": "Methotrexate: Drug information", "rep_snippet": "Adults >65 years: IV: 100 mg/m2 over 1 hour (on day 10) followed by 900 mg/m2 over 23 hours (with leucovorin rescue)  Hyper-CVAD alternating with high-dose methotrexate/cytarabine regimen: IV: 1,000 mg/m2 over 24 hours o…"}, {"doc_id": "metoclopramide-drug-information", "bm25_top3": 18.414048679316373, "bm25_max": 18.414048679316373, "bge_top3": null, "bge_max": null, "title": "Metoclopramide: Drug information", "rep_snippet": "IV: 10 to 20 mg as a single dose (AHS [Orr 2016]; EFNS [Evers 2009]).  Prevention of radiation therapy-induced nausea and vomiting (minimal emetic risk) (off-label use): Oral: 20 mg as rescue therapy; if rescue therapy i…"}, {"doc_id": "levalbuterol-drug-information", "bm25_top3": 18.093134439739803, "bm25_max": 18.093134439739803, "bge_top3": 0.6876347064971924, "bge_max": 0.6966452598571777, "title": "Levalbuterol: Drug information", "rep_snippet": "• Asthma: Optimize anti-inflammatory treatment before initiating maintenance treatment with levalbuterol. Do not use as a component of long-term therapy without an anti-inflammatory agent. Only the mildest form of asthma…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": 18.014657331325594, "bm25_max": 18.014657331325594, "bge_top3": null, "bge_max": null, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Brand Names: International  Ibalgin Grip (CZ);  Lemsip Max All Day Cold & Flu (GB);  Lemsip Max All Day Flu Relief (GB);  Lemsip Max All Night Cold & Flu (GB);  Lemsip Max All Night Flu Relief (GB);  Nurofen Sinus Pain R…"}, {"doc_id": "formoterol-drug-information", "bm25_top3": 11.290162513508719, "bm25_max": 16.7677405499537, "bge_top3": 0.6673243045806885, "bge_max": 0.6673243045806885, "title": "Formoterol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Formoterol: Pediatric drug information\")  Note: Foradil Aerolizer is no longer available in the US.  Asthma: Inhalation: Note: For asthma control, long-acting beta2-ago…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 16.205327778412265, "bm25_max": 16.205327778412265, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Dosing: Adult  Bulimia nervosa (off-label use): Oral: Initial: 25 mg/day for 3 days, then increase in 25 to 50 mg increments every 3 to 5 days based on response and tolerability up to 300 mg/day. Average doses in clinica…"}, {"doc_id": "cromolyn-sodium-cromoglicate-oral-inhalation-drug-information", "bm25_top3": 16.018069365208206, "bm25_max": 16.018069365208206, "bge_top3": 0.7171187400817871, "bge_max": 0.7171187400817871, "title": "Cromolyn (sodium cromoglicate) (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Asthma: Nebulization solution: Initial: 20 mg 4 times/day; usual dose: 20 mg 3 to 4 times/day  Note: For chronic control of asthma, taper frequency to the lowest effective dose (ie, 4 times/day to 3 times/…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": 15.368024583525578, "bm25_max": 15.368024583525578, "bge_top3": null, "bge_max": null, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Preoperative: 75 mg/m2 administered as a continuous infusion over 24 hours on day 3 of weeks 1 and 7 (in combination with methotrexate, cisplatin, and ifosfamide) (Bacci 2003)  Postoperative: 90 mg/m2 administered as a c…"}, {"doc_id": "ipratropium-oral-inhalation-drug-information", "bm25_top3": 12.256328347591705, "bm25_max": 12.256328347591705, "bge_top3": 0.6796829700469971, "bge_max": 0.6796829700469971, "title": "Ipratropium (oral inhalation): Drug information", "rep_snippet": "Brand Names: US  Atrovent HFA"}, {"doc_id": "benralizumab-drug-information", "bm25_top3": 6.885131283214166, "bm25_max": 6.885131283214166, "bge_top3": null, "bge_max": null, "title": "Benralizumab: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) may occur, typically within hours of administration. Delayed hyper…"}, {"doc_id": "reslizumab-drug-information", "bm25_top3": 6.55583136782573, "bm25_max": 6.55583136782573, "bge_top3": 0.6993524432182312, "bge_max": 0.6993524432182312, "title": "Reslizumab: Drug information", "rep_snippet": "• Asthma: Not indicated for the treatment of acute asthma symptoms (eg, acute bronchospasm) or acute exacerbations, including status asthmaticus. Appropriate rescue medication should be available. Patients who experience…"}, {"doc_id": "montelukast-drug-information", "bm25_top3": 5.948821342012433, "bm25_max": 5.948821342012433, "bge_top3": null, "bge_max": null, "title": "Montelukast: Drug information", "rep_snippet": "• Neuropsychiatric events: Postmarketing reports of behavioral changes (eg, abnormal dreams, agitation, aggression, anxiety, attention deficit, depression, disorientation, hallucinations, hostility, insomnia, irritabilit…"}, {"doc_id": "vardenafil-drug-information", "bm25_top3": 5.4874613162906325, "bm25_max": 5.4874613162906325, "bge_top3": null, "bge_max": null, "title": "Vardenafil: Drug information", "rep_snippet": "Itraconazole: May increase the serum concentration of Vardenafil. Management: Limit vardenafil to a max of 5 mg/24 hours in patients receiving itraconazole 200 mg/day, and a max of 2.5 mg/24 hours in patients receiving i…"}, {"doc_id": "iron-dextran-drug-information", "bm25_top3": 4.274253915469179, "bm25_max": 4.274253915469179, "bge_top3": null, "bge_max": null, "title": "Iron dextran: Drug information", "rep_snippet": "Administration  Note: A test dose should be given on the first day of therapy; patient should be observed for 1 hour for hypersensitivity reaction, then the remainder of the day’s dose (dose minus test dose) should be gi…"}, {"doc_id": "flunisolide-oral-inhalation-drug-information", "bm25_top3": 2.852729687305402, "bm25_max": 2.852729687305402, "bge_top3": null, "bge_max": null, "title": "Flunisolide (oral inhalation): Drug information", "rep_snippet": "Administration  Metered-dose inhaler: Shake well before using. Prime inhaler prior to first use and when the inhaler has not been used for >2 weeks by releasing 2 test sprays away from the face. Rinse mouth with water (w…"}, {"doc_id": "zileuton-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7345626354217529, "bge_max": 0.7345626354217529, "title": "Zileuton: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Oral:  Immediate release: 600 mg 4 times daily  Extended release: 1,200 mg twice daily"}, {"doc_id": "fluticasone-and-vilanterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7337420582771301, "bge_max": 0.7337420582771301, "title": "Fluticasone and vilanterol: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Inhalation: Note: Recommended starting dose is determined according to asthma severity. For patients not adequately controlled on the lower combination dose, consider the higher dose combination. R…"}, {"doc_id": "tiotropium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6897075474262238, "bge_max": 0.7087639570236206, "title": "Tiotropium: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Inhalation: Spiriva Respimat (1.25 mcg/actuation): Metered-dose inhaler: Two inhalations (2.5 mcg) once daily (maximum: 2 inhalations per 24 hours). Note: Maximum benefits may take up to 4 to 8 wee…"}, {"doc_id": "ephedrine-and-guaifenesin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6946876645088196, "bge_max": 0.6946876645088196, "title": "Ephedrine and guaifenesin: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Oral: Ephedrine 12.5 to 25 mg/guaifenesin 200 to 400 mg every 4 hours as needed. Maximum: Ephedrine 150 mg/guaifenesin 2400 mg per 24 hours."}, {"doc_id": "terbutaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6939536333084106, "bge_max": 0.6939536333084106, "title": "Terbutaline: Drug information", "rep_snippet": "Dosing: Adult  Asthma/bronchospasm:  Oral: 5 mg 3 times daily (approximately every 6 hours); reduce dose to 2.5 mg 3 times daily if side effects occur; maximum: 15 mg/24 hours  SubQ:  Manufacturer's labeling: 0.25 mg/dos…"}, {"doc_id": "salmeterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6867328882217407, "bge_max": 0.6867328882217407, "title": "Salmeterol: Drug information", "rep_snippet": "Dosing: Adult  Note: Do not use for the relief of acute bronchospasm.  Asthma/Bronchospasm (maintenance and prevention): Inhalation: One inhalation twice daily (~12 hours apart); maximum: 1 inhalation twice daily. Note:…"}, {"doc_id": "budesonide-and-formoterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6856126189231873, "bge_max": 0.6856126189231873, "title": "Budesonide and formoterol: Drug information", "rep_snippet": "Dosing: Adult  Note: If asthma or COPD symptoms occur in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.  Asthma: Inhalation:  Starting dose is based on asthma sever…"}, {"doc_id": "dyphylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6847821474075317, "bge_max": 0.6847821474075317, "title": "Dyphylline: Drug information", "rep_snippet": "Dosing: Adult  Bronchoconstriction (asthma, COPD): Oral: Up to 15 mg/kg 4 times daily, individualize dosage"}, {"doc_id": "zafirlukast-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6834985017776489, "bge_max": 0.6834985017776489, "title": "Zafirlukast: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Oral: 20 mg twice daily  Chronic urticaria (off-label use): Oral: 20 mg twice daily (Bagenstose, 2004)"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6807569861412048, "bge_max": 0.6807569861412048, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "Dosing: Adult  COPD (maintenance): Oral inhalation: Two inhalations (glycopyrrolate 9 mcg/formoterol 4.8 mcg per inhalation) twice daily; (maximum: 2 inhalations twice daily)."}, {"doc_id": "olodaterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6738713383674622, "bge_max": 0.6738713383674622, "title": "Olodaterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation: Two inhalations once daily (maximum: 2 inhalations per day.)"}, {"doc_id": "fenoterol-and-ipratropium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6713801622390747, "bge_max": 0.6713801622390747, "title": "Fenoterol and ipratropium (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Initiate therapy under medical supervision (eg, hospital setting). May consider home administration in exceptional cases (eg, severe symptoms or experienced patients requiring higher doses) when rapi…"}, {"doc_id": "metaproterenol-orciprenaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6711655855178833, "bge_max": 0.6711655855178833, "title": "Metaproterenol (orciprenaline): Drug information", "rep_snippet": "Dosing: Adult  Asthma/Bronchospasm: Oral: 20 mg 3 or 4 times daily Note: Oral bronchodilators are not recommended for routine use in the management of acute asthma or long-term daily maintenance treatment due to a slower…"}, {"doc_id": "ketotifen-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6697746515274048, "bge_max": 0.6697746515274048, "title": "Ketotifen (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  Atopic asthma (prophylactic treatment): Oral:  Infants and Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg/dose twice daily (maxim…"}, {"doc_id": "arformoterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.669109582901001, "bge_max": 0.669109582901001, "title": "Arformoterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Nebulization: 15 mcg twice daily; maximum: 30 mcg daily"}, {"doc_id": "iloprost-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6684779524803162, "bge_max": 0.6684779524803162, "title": "Iloprost: Drug information", "rep_snippet": "Dosing: Adult  Pulmonary arterial hypertension (PAH): Inhalation: Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose. Administer 6-9 times daily (dosing at intervals ≥2 hours while awake according to individual…"}, {"doc_id": "flunisolide-nasal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6679998636245728, "bge_max": 0.6679998636245728, "title": "Flunisolide (nasal): Drug information", "rep_snippet": "Dosing: Adult  Rhinitis (seasonal/perennial): Intranasal: Two sprays (50 mcg) in each nostril twice daily (total daily dose: 200 mcg/day); may increase to 2 sprays in each nostril 3 times daily (total daily dose: 300 mcg…"}, {"doc_id": "codeine-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6675221920013428, "bge_max": 0.6675221920013428, "title": "Codeine and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  Cough and upper respiratory symptoms: Oral: 10 mL every 12 hours; maximum dose: 20 mL per 24 hours"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6669491529464722, "bge_max": 0.6669491529464722, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Oral inhalation: Two inhalations once daily (maximum: 2 inhalations per day)"}, {"doc_id": "triamcinolone-nasal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6666625738143921, "bge_max": 0.6666625738143921, "title": "Triamcinolone (nasal): Drug information", "rep_snippet": "Dosing: Adult  Allergic rhinitis/upper respiratory symptoms: Intranasal: Two sprays (110 mcg) in each nostril once daily; once symptoms controlled reduce to 1 spray (55 mcg) in each nostril once daily (maximum: 2 sprays…"}, {"doc_id": "fluticasone-umeclidinium-and-vilanterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6662348508834839, "bge_max": 0.6662348508834839, "title": "Fluticasone, umeclidinium, and vilanterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation: Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily (maximum dose: 1 inhalation/day)"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.66436767578125, "bge_max": 0.66436767578125, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Upper respiratory symptoms: Oral: 5 mL (promethazine 6.25 mg/phenylephrine 5 mg) every 4 to 6 hours; maximum: 30 mL (promethazine 37.5 mg/phenylephrine 30 mg)/24 hours"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.664252519607544, "bge_max": 0.664252519607544, "title": "Methylprednisolone: Drug information", "rep_snippet": "Status asthmaticus (previous NAEPP guidelines; still used by some clinicians): Children: IV: Loading dose: 2 mg/kg/dose, then 0.5 to 1 mg/kg/dose every 6 hours; Note: See NAEPP 2007 guidelines for asthma exacerbations (e…"}]}
{"qid": "Q27_noise", "query": "Acute wheeze plan — how to use albuterol inhaler, any spacer tips, daily puff limit?", "base_qid": "Q27", "variant_type": "noise", "candidates": [{"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": 28.87560486801303, "bm25_max": 29.400902936446883, "bge_top3": 0.6103520393371582, "bge_max": 0.6156882047653198, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "Administration  IV: Infusion solution [Canadian product]: Do not inject undiluted. Reduce concentration by at least 50% before infusing. Administer as a continuous infusion via infusion pump.  Inhalation:  Metered-dose i…"}, {"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 24.60307386085267, "bm25_max": 29.063005776760917, "bge_top3": 0.6067609588305155, "bge_max": 0.6236497759819031, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "Administration  Inhalation, oral:  Dry powder inhaler:  ArmonAir Respiclick: Administer the dose at approximately the same time every day. Does not require priming and do not use with a spacer or volume holding chamber.…"}, {"doc_id": "flunisolide-oral-inhalation-drug-information", "bm25_top3": 24.754121630460062, "bm25_max": 24.754121630460062, "bge_top3": 0.5759873986244202, "bge_max": 0.5759873986244202, "title": "Flunisolide (oral inhalation): Drug information", "rep_snippet": "Administration  Metered-dose inhaler: Shake well before using. Prime inhaler prior to first use and when the inhaler has not been used for >2 weeks by releasing 2 test sprays away from the face. Rinse mouth with water (w…"}, {"doc_id": "ipratropium-and-albuterol-drug-information", "bm25_top3": 21.876002846227607, "bm25_max": 23.365061355558993, "bge_top3": 0.6113996505737305, "bge_max": 0.6113996505737305, "title": "Ipratropium and albuterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Oral inhalation:  Metered dose inhaler (MDI): One inhalation 4 times daily (maximum: 6 inhalations/day)  Nebulization solution: Initial: 1 vial (3 mL) (ipratropium bromide 0.5 mg/albuterol 2.5 mg) ev…"}, {"doc_id": "budesonide-and-formoterol-drug-information", "bm25_top3": 21.150110884701995, "bm25_max": 21.756078117974475, "bge_top3": 0.588552325963974, "bge_max": 0.5972967147827148, "title": "Budesonide and formoterol: Drug information", "rep_snippet": "Reliever therapy: Symbicort 100 Turbuhaler or Symbicort 200 Turbuhaler: 1 additional inhalation as needed, may repeat if no relief for up to 6 inhalations total (maximum: 8 inhalations/day)  COPD: Inhalation:  Budesonide…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": 12.51139119700777, "bm25_max": 19.34329045239787, "bge_top3": 0.5830984711647034, "bge_max": 0.5903071165084839, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "Administration  Metered-dose inhaler: Canister does not need shaken prior to use. Prime canister by spraying twice into the air prior to initial use or if not in use for >10 days; the RediHaler does not require priming b…"}, {"doc_id": "levonorgestrel-systemic-drug-information", "bm25_top3": 19.306850444400112, "bm25_max": 19.306850444400112, "bge_top3": null, "bge_max": null, "title": "Levonorgestrel (systemic): Drug information", "rep_snippet": "Brand Names: US  Aftera [OTC];  EContra EZ [OTC];  EContra One-Step [OTC];  Fallback Solo [OTC] [DSC];  My Choice [OTC];  My Way [OTC];  Next Choice One Dose [DSC];  Next Choice One Dose [OTC];  Opcicon One-Step [OTC];…"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 13.241098874335217, "bm25_max": 19.274791113958038, "bge_top3": 0.584425171216329, "bge_max": 0.5953986048698425, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "AirDuo RespiClick: Dry powder inhaler: Inhaler does not require priming and do not use with a spacer or volume holding chamber. Do not wash or place any part of inhaler in water; if mouthpiece needs cleaning, gently wipe…"}, {"doc_id": "formoterol-drug-information", "bm25_top3": 14.653562602664852, "bm25_max": 18.607472869695236, "bge_top3": 0.5891504287719727, "bge_max": 0.601551353931427, "title": "Formoterol: Drug information", "rep_snippet": "Administration  Dry powder inhaler:  Foradil Aerolizer: Remove capsule from foil blister immediately before use. Place capsule in the capsule-chamber in the base of the Aerolizer Inhaler. Capsules must not be swallowed w…"}, {"doc_id": "fluticasone-umeclidinium-and-vilanterol-drug-information", "bm25_top3": 18.2461996958138, "bm25_max": 18.2461996958138, "bge_top3": 0.5805673599243164, "bge_max": 0.5805673599243164, "title": "Fluticasone, umeclidinium, and vilanterol: Drug information", "rep_snippet": "• Transfer to oral inhaler: When transferring to oral inhaler, previously suppressed allergic conditions (arthritis, rhinitis, conjunctivitis, eczema, eosinophilic conditions) may be unmasked.  • Patient information: Pat…"}, {"doc_id": "formoterol-and-mometasone-drug-information", "bm25_top3": 13.493602604738747, "bm25_max": 17.486218038281656, "bge_top3": 0.5912902355194092, "bge_max": 0.5912902355194092, "title": "Formoterol and mometasone: Drug information", "rep_snippet": "Administration  Metered-dose inhaler: Prior to first use, inhaler must be primed by releasing 4 test sprays into the air; shake well before each spray. Inhaler must be reprimed if not used for >5 days. Shake well before…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-indacaterol-drug-information", "bm25_top3": 15.104470366191762, "bm25_max": 15.104470366191762, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and indacaterol: Drug information", "rep_snippet": "• Lactose: Some products may contain lactose; allergic reactions possible in patients with severe milk protein allergy. Use with caution in patients with severe hypersensitivity to milk proteins.  Other warnings:  • Appr…"}, {"doc_id": "levalbuterol-drug-information", "bm25_top3": 12.298720336607415, "bm25_max": 14.521655478171667, "bge_top3": 0.5899586081504822, "bge_max": 0.6041102409362793, "title": "Levalbuterol: Drug information", "rep_snippet": "Administration  Inhalation: For oral inhalation only.  Metered-dose inhaler: Shake well before use, avoid spraying in the eyes. Prime with 4 test sprays prior to first use or if inhaler has not been used for more than 3…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 14.449736243642644, "bm25_max": 14.449736243642644, "bge_top3": 0.5783517956733704, "bge_max": 0.5783517956733704, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "umeclidinium-drug-information", "bm25_top3": 11.12426392684213, "bm25_max": 11.12426392684213, "bge_top3": null, "bge_max": null, "title": "Umeclidinium: Drug information", "rep_snippet": "Administration  Inhalation: Administer via oral inhalation once daily at the same time each day; do not use more than 1 inhalation every 24 hours. Do not shake inhaler. Remove from sealed pouch immediately prior to first…"}, {"doc_id": "tiotropium-drug-information", "bm25_top3": 10.46724248803073, "bm25_max": 11.031609613278132, "bge_top3": 0.5973483324050903, "bge_max": 0.5973483324050903, "title": "Tiotropium: Drug information", "rep_snippet": "Spiriva Respimat: Metered dose inhaler: Prior to first use, insert cartridge into the inhaler and prime the unit by actuating the inhaler toward the ground until an aerosol cloud is visible; repeat three more times and t…"}, {"doc_id": "fluticasone-and-vilanterol-drug-information", "bm25_top3": 9.052061000590802, "bm25_max": 10.71900284373001, "bge_top3": 0.6075922250747681, "bge_max": 0.6075922250747681, "title": "Fluticasone and vilanterol: Drug information", "rep_snippet": "• Patient information: Patients must be instructed to use short-acting beta-2 agonist (eg, albuterol) for acute COPD symptoms and to seek medical attention in cases where acute symptoms are not relieved or a previous lev…"}, {"doc_id": "inhaled-insulin-drug-information", "bm25_top3": 10.478385082415858, "bm25_max": 10.478385082415858, "bge_top3": null, "bge_max": null, "title": "Inhaled insulin: Drug information", "rep_snippet": "For oral inhalation only. Administer at the beginning of the meal. Remove the amount/strength of cartridges needed for a single dose from packaging; multiple cartridges may be needed to achieve the correct dose. Allow ca…"}, {"doc_id": "indacaterol-drug-information", "bm25_top3": 10.2760664036626, "bm25_max": 10.2760664036626, "bge_top3": 0.5920171141624451, "bge_max": 0.5920171141624451, "title": "Indacaterol: Drug information", "rep_snippet": "Administration  Inhalation: Dry powder inhaler: Administer via oral inhalation at the same time each day using Neohaler inhaler (US labeling) or Onbrez Breezhaler (Canadian labeling) only. Do not swallow capsules. Use th…"}, {"doc_id": "ciclesonide-oral-inhalation-drug-information", "bm25_top3": 9.782165848773683, "bm25_max": 9.856007040421996, "bge_top3": null, "bge_max": null, "title": "Ciclesonide (oral inhalation): Drug information", "rep_snippet": "Administration  Metered dose inhaler: Prime the inhaler by actuating 3 times before the first use or when the inhaler has not been used for more than 10 consecutive days; no need to shake inhaler before use.  Remove mout…"}, {"doc_id": "aclidinium-drug-information", "bm25_top3": 9.582721074359107, "bm25_max": 9.582721074359107, "bge_top3": null, "bge_max": null, "title": "Aclidinium: Drug information", "rep_snippet": "Administer via oral inhalation. Remove inhaler from sealed pouch immediately prior to first use. Prior to each use, remove protective cap from the inhaler and prepare inhaler by pressing and releasing the green button (w…"}, {"doc_id": "aclidinium-and-formoterol-united-states-not-available-drug-information", "bm25_top3": 9.319713826478253, "bm25_max": 9.319713826478253, "bge_top3": null, "bge_max": null, "title": "Aclidinium and formoterol (United States: Not available): Drug information", "rep_snippet": "Inhalation: Administer via oral inhalation. Prior to first use, remove from sealed pouch immediately before use. Prior to each use, remove protective cap from the inhaler and prepare inhaler by pressing and releasing the…"}, {"doc_id": "lutropin-alfa-united-states-not-available-drug-information", "bm25_top3": 8.37672113784442, "bm25_max": 8.37672113784442, "bge_top3": null, "bge_max": null, "title": "Lutropin alfa (United States: Not available): Drug information", "rep_snippet": "Administration  SubQ: Administer in the stomach or thigh; rotate injection sites. Do not shake solution; allow any bubbles to settle prior to administration. Contents of lutropin alfa vial may be mixed in the same syring…"}, {"doc_id": "buprenorphine-and-naloxone-drug-information", "bm25_top3": 7.552559212553298, "bm25_max": 7.552559212553298, "bge_top3": null, "bge_max": null, "title": "Buprenorphine and naloxone: Drug information", "rep_snippet": "Use  Opioid dependence: Treatment of opioid dependence.  General information: Buprenorphine/naloxone should be used as part of a complete treatment plan to include counseling and psychosocial support."}, {"doc_id": "methacholine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5996018052101135, "bge_max": 0.5996018052101135, "title": "Methacholine: Drug information", "rep_snippet": "Dosing: Adult  Note: For inhalation only mixed in solution; do not inhale powder.  Bronchial airway hyperreactivity (diagnosis): Inhalation: Before inhalation challenge, perform baseline pulmonary function tests; the pat…"}, {"doc_id": "umeclidinium-and-vilanterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5955531597137451, "bge_max": 0.5955531597137451, "title": "Umeclidinium and vilanterol: Drug information", "rep_snippet": "Dosing: Adult  Chronic obstructive pulmonary disease (COPD): Dry powder inhaler: Umeclidinium 62.5 mcg/vilanterol 25 mcg: One inhalation once daily; maximum dose: 1 inhalation/day"}, {"doc_id": "camphor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5943024158477783, "bge_max": 0.5943024158477783, "title": "Camphor: Drug information", "rep_snippet": "Dosing: Adult  Cough: Inhalation: Inhale via vaporizer up to 3 times per day.  Pain: Topical cream: Apply to affected area up to 4 times per day for 2 weeks. For maximum benefit, use daily for at least 2 weeks and contin…"}, {"doc_id": "ipratropium-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5929485559463501, "bge_max": 0.5929485559463501, "title": "Ipratropium (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation:  Metered-dose inhaler (MDI): 2 inhalations (34 mcg) 4 times daily; maximum dose: 12 inhalations (204 mcg)/day  Nebulization solution: 0.5 mg (500 mcg, one unit-dose vial) every 6 to 8 hou…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5917612910270691, "bge_max": 0.5917612910270691, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Adult  Dose depends upon condition being treated and response of patient. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dos…"}, {"doc_id": "glycopyrrolate-glycopyrronium-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5860714316368103, "bge_max": 0.5860714316368103, "title": "Glycopyrrolate (glycopyrronium) (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Chronic obstructive pulmonary disease (COPD): Inhalation:  Dry powder inhaler (capsule): One capsule (15.6 mcg) inhaled twice daily (maximum: 15.6 mcg twice daily)  Seebri Breezhaler [Canadian product]: On…"}, {"doc_id": "dornase-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5837613344192505, "bge_max": 0.5837613344192505, "title": "Dornase alfa: Drug information", "rep_snippet": "Dosing: Adult  Cystic fibrosis: Inhalation: 2.5 mg daily through selected jet nebulizers in conjunction with a Pulmo-Aide, Pari-Proneb, Mobilaire, or Porta-Neb compressor system or eRapid Nebulizer System  Patients unabl…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5831688642501831, "bge_max": 0.5831688642501831, "title": "Methylprednisolone: Drug information", "rep_snippet": "Asthma, long-term (maintenance) (NAEPP 2007): Oral: 7.5 to 60 mg once daily in the morning or every other day as needed for asthma control  Multiple sclerosis, acute exacerbation:  Note: Treatment guidelines recommend hi…"}, {"doc_id": "isosorbide-dinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.582750141620636, "bge_max": 0.582750141620636, "title": "Isosorbide dinitrate: Drug information", "rep_snippet": "Dosing: Adult  Angina pectoris (prevention): Note: Due to slower onset of action, isosorbide dinitrate is not the drug of choice to abort an acute anginal episode. Tolerance to nitrate effects develops with chronic expos…"}, {"doc_id": "salmeterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5826632976531982, "bge_max": 0.5826632976531982, "title": "Salmeterol: Drug information", "rep_snippet": "Dosing: Adult  Note: Do not use for the relief of acute bronchospasm.  Asthma/Bronchospasm (maintenance and prevention): Inhalation: One inhalation twice daily (~12 hours apart); maximum: 1 inhalation twice daily. Note:…"}, {"doc_id": "terbutaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5821214318275452, "bge_max": 0.5821214318275452, "title": "Terbutaline: Drug information", "rep_snippet": "Dosing: Adult  Asthma/bronchospasm:  Oral: 5 mg 3 times daily (approximately every 6 hours); reduce dose to 2.5 mg 3 times daily if side effects occur; maximum: 15 mg/24 hours  SubQ:  Manufacturer's labeling: 0.25 mg/dos…"}, {"doc_id": "mannitol-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5809065103530884, "bge_max": 0.5809065103530884, "title": "Mannitol (oral inhalation): Drug information", "rep_snippet": "Administration  Inhalation: Administer using supplied single patient use inhaler; do not puncture capsule more than once; do not swallow capsules. A nose clip may be used if preferred. The patient should exhale completel…"}, {"doc_id": "corticotropin-injection-gel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5797736048698425, "bge_max": 0.5797736048698425, "title": "Corticotropin injection gel: Drug information", "rep_snippet": "Dosing: Adult  Note: Sudden withdrawal may lead to adrenal insufficiency or recurrent symptoms; tapering the dose prior to discontinuation may be necessary following prolonged administration.  Acute exacerbation of multi…"}, {"doc_id": "alteplase-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.576034426689148, "bge_max": 0.576034426689148, "title": "Alteplase: Drug information", "rep_snippet": "High-dose regimen: Load with 10 mg, followed by 90 mg over 90 to 180 minutes (without heparin during infusion)  Low-dose regimen (preferred for very small adults): Load with 20 mg, followed by 10 mg/hour for 3 hours (wit…"}, {"doc_id": "valproate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5754802227020264, "bge_max": 0.5754802227020264, "title": "Valproate: Drug information", "rep_snippet": "Administration  Oral: Oral valproate products may cause GI upset; taking with food or slowly increasing the dose may decrease GI upset should it occur.  Depakote ER: Swallow whole; do not crush or chew.  Depakote Sprinkl…"}, {"doc_id": "ketamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5752130746841431, "bge_max": 0.5752130746841431, "title": "Ketamine: Drug information", "rep_snippet": "Analgesia (subanesthetic dosing) (off-label use):  Acute pain: Intranasal (off-label route): 0.5 to 1 mg/kg; may repeat in 10 to 15 minutes with 0.25 to 0.5 mg/kg if necessary (Andolfatto 2013; Corrigan 2015; Yeaman 2014…"}, {"doc_id": "cromolyn-sodium-cromoglicate-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.575039803981781, "bge_max": 0.575039803981781, "title": "Cromolyn (sodium cromoglicate) (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Asthma: Nebulization solution: Initial: 20 mg 4 times/day; usual dose: 20 mg 3 to 4 times/day  Note: For chronic control of asthma, taper frequency to the lowest effective dose (ie, 4 times/day to 3 times/…"}, {"doc_id": "gabapentin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5734526515007019, "bge_max": 0.5734526515007019, "title": "Gabapentin: Drug information", "rep_snippet": "Cough, chronic (refractory) (off-label use): Oral: Immediate release: 300 mg once daily on day 1, followed by dosage escalation in increments of 300 mg/day until cough symptoms cease, side effects are intolerable, or a m…"}]}
{"qid": "Q27_spelling", "query": "Albeterol MDI — dosing + technique; maximum per day?", "base_qid": "Q27", "variant_type": "spelling", "candidates": [{"doc_id": "acetaminophen-and-pseudoephedrine-drug-information", "bm25_top3": 32.91144663687491, "bm25_max": 32.91144663687491, "bge_top3": null, "bge_max": null, "title": "Acetaminophen and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Adult  Sinus congestion/headache: Oral: 2 tablets every 4 to 6 hours as needed (maximum: 8 tablets [acetaminophen 2,600 mg/pseudoephedrine 240 mg] per day)."}, {"doc_id": "guaifenesin-and-dextromethorphan-drug-information", "bm25_top3": 29.85555531607455, "bm25_max": 29.85555531607455, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Guaifenesin and dextromethorphan: Pediatric drug information\")  Also refer to specific product labeling.  Cough (antitussive/expectorant): Oral:  Children <4 years: Not…"}, {"doc_id": "ipratropium-and-albuterol-drug-information", "bm25_top3": 24.90907948141021, "bm25_max": 28.265261731606792, "bge_top3": null, "bge_max": null, "title": "Ipratropium and albuterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Oral inhalation:  Metered dose inhaler (MDI): One inhalation 4 times daily (maximum: 6 inhalations/day)  Nebulization solution: Initial: 1 vial (3 mL) (ipratropium bromide 0.5 mg/albuterol 2.5 mg) ev…"}, {"doc_id": "ciclesonide-nasal-drug-information", "bm25_top3": 24.89558597817874, "bm25_max": 24.89558597817874, "bge_top3": null, "bge_max": null, "title": "Ciclesonide (nasal): Drug information", "rep_snippet": "Dosing: Adult  Perennial allergic rhinitis, seasonal allergic rhinitis:  Omnaris: Two sprays (50 mcg/spray) per nostril once daily; maximum: 200 mcg/day  Zetonna: One spray (37 mcg/spray) per nostril once daily; maximum:…"}, {"doc_id": "loratadine-and-pseudoephedrine-drug-information", "bm25_top3": 24.68488552857915, "bm25_max": 24.68488552857915, "bge_top3": null, "bge_max": null, "title": "Loratadine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Adult  Cold, allergy symptoms: Oral:  Loratadine 5 mg/pseudoephedrine 120 mg per tablet: One tablet every 12 hours (maximum: 2 tablets/day)  Loratadine 10 mg/pseudoephedrine 240 mg per tablet: One tablet daily (m…"}, {"doc_id": "ciclesonide-oral-inhalation-drug-information", "bm25_top3": 20.68107409771661, "bm25_max": 24.35199312022867, "bge_top3": null, "bge_max": null, "title": "Ciclesonide (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Asthma: Inhalation: Note: Titrate to the lowest effective dose once asthma stability is achieved:  US labeling (metered dose inhaler [MDI]):  Prior therapy with bronchodilators alone: Initial: 80 mcg twice…"}, {"doc_id": "ipratropium-oral-inhalation-drug-information", "bm25_top3": 24.200319748657837, "bm25_max": 24.200319748657837, "bge_top3": null, "bge_max": null, "title": "Ipratropium (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation:  Metered-dose inhaler (MDI): 2 inhalations (34 mcg) 4 times daily; maximum dose: 12 inhalations (204 mcg)/day  Nebulization solution: 0.5 mg (500 mcg, one unit-dose vial) every 6 to 8 hou…"}, {"doc_id": "olodaterol-drug-information", "bm25_top3": 24.11299445258627, "bm25_max": 24.11299445258627, "bge_top3": null, "bge_max": null, "title": "Olodaterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation: Two inhalations once daily (maximum: 2 inhalations per day.)"}, {"doc_id": "hydrocodone-and-phenyltoloxamine-united-states-not-available-drug-information", "bm25_top3": 23.9894484069512, "bm25_max": 23.9894484069512, "bge_top3": null, "bge_max": null, "title": "Hydrocodone and phenyltoloxamine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Cough: Oral:  Suspension (hydrocodone 5 mg and phenyltoloxamine 10 mg per 5 mL): 5 mL every 8 to 12 hours; maximum: 10 mL (hydrocodone 10 mg/phenyltoloxamine 20 mg) per day  Tablet (hydrocodone 5 mg and ph…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 23.937443025624223, "bm25_max": 23.937443025624223, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Oral inhalation: Two inhalations once daily (maximum: 2 inhalations per day)"}, {"doc_id": "colchicine-and-probenecid-drug-information", "bm25_top3": 23.471779088449136, "bm25_max": 23.471779088449136, "bge_top3": null, "bge_max": null, "title": "Colchicine and probenecid: Drug information", "rep_snippet": "Dosing: Adult  Gout: Oral: Colchicine 0.5 mg and probenecid 0.5 g: One tablet once daily for 1 week, then 1 tablet twice daily thereafter  Note: Current prescribing information states a maximum dose of 4 tablets per day;…"}, {"doc_id": "hydrocodone-and-chlorpheniramine-drug-information", "bm25_top3": 21.183602568549023, "bm25_max": 23.320765026475335, "bge_top3": null, "bge_max": null, "title": "Hydrocodone and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  Cough and upper respiratory tract symptoms: Oral: Note: Dosage units vary based on product formulation (extended release vs. immediate release); use caution when verifying dose with product formulation.  E…"}, {"doc_id": "fluticasone-nasal-drug-information", "bm25_top3": 21.388504901051256, "bm25_max": 22.643225357910694, "bge_top3": null, "bge_max": null, "title": "Fluticasone (nasal): Drug information", "rep_snippet": "Dosing: Adult  Allergic rhinitis (fluticasone furoate): Intranasal:  Veramyst (Rx): Initial: Two sprays (27.5 mcg/spray) per nostril once daily (110 mcg/day); once symptoms are controlled, may reduce dosage to 1 spray pe…"}, {"doc_id": "butalbital-compound-drug-information", "bm25_top3": 22.638606858676994, "bm25_max": 22.638606858676994, "bge_top3": null, "bge_max": null, "title": "Butalbital compound: Drug information", "rep_snippet": "Dosing: Adult  Tension or muscle contraction headache: Oral: 1 to 2 capsules every 4 hours as needed; maximum: 6 capsules per day."}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": 21.073557312554286, "bm25_max": 22.52806408637983, "bge_top3": null, "bge_max": null, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: Perindopril 3.5 mg/amlodipine 2.5 mg once daily; adjust dose to response in 7- to 14-day intervals; maximum dose: perindopril 14 mg/amlodipine 10 mg per day"}, {"doc_id": "camphor-drug-information", "bm25_top3": 22.485794811685814, "bm25_max": 22.485794811685814, "bge_top3": null, "bge_max": null, "title": "Camphor: Drug information", "rep_snippet": "Dosing: Adult  Cough: Inhalation: Inhale via vaporizer up to 3 times per day.  Pain: Topical cream: Apply to affected area up to 4 times per day for 2 weeks. For maximum benefit, use daily for at least 2 weeks and contin…"}, {"doc_id": "poly-l-lactic-acid-drug-information", "bm25_top3": 22.23253940421258, "bm25_max": 22.23253940421258, "bge_top3": null, "bge_max": null, "title": "Poly-L-lactic acid: Drug information", "rep_snippet": "Dosing: Adult  Facial fat loss (lipoatrophy) (Sculptra): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized.…"}, {"doc_id": "mitotane-drug-information", "bm25_top3": 22.136043928234663, "bm25_max": 22.136043928234663, "bge_top3": null, "bge_max": null, "title": "Mitotane: Drug information", "rep_snippet": "Dosing: Adult  Note: Mitotane is associated with a moderate emetic potential; antiemetics may be needed to prevent nausea and vomiting.  Adrenocortical carcinoma: Oral: Initial: 2 to 6 g per day in 3 to 4 divided doses,…"}, {"doc_id": "ezogabine-retigabine-united-states-not-available-drug-information", "bm25_top3": 21.342746621159822, "bm25_max": 22.103257537567643, "bge_top3": null, "bge_max": null, "title": "Ezogabine (retigabine) (United States: Not available): Drug information", "rep_snippet": "Dosing: Hepatic Impairment (Adult)  Mild impairment (Child-Pugh 5 to 6): No dosage adjustment necessary.  Moderate impairment (Child-Pugh 7 to 9): Initial: 50 mg 3 times daily; may increase at weekly intervals in increme…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": 21.911446636874917, "bm25_max": 21.911446636874917, "bge_top3": null, "bge_max": null, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Adult  Upper respiratory allergies: Oral: One tablet (cetirizine 5 mg/pseudoephedrine 120 mg) twice daily (maximum: 2 tablets [cetirizine 10 mg/pseudoephedrine 240 mg] per day)"}, {"doc_id": "ferric-carboxymaltose-drug-information", "bm25_top3": 21.629201912157278, "bm25_max": 21.629201912157278, "bge_top3": null, "bge_max": null, "title": "Ferric carboxymaltose: Drug information", "rep_snippet": "Dosing: Adult  Note: Dose expressed as elemental iron  Iron-deficiency anemia: IV:  <50 kg: 15 mg/kg elemental iron on day 1; repeat dose after at least 7 days (maximum: 1,500 mg elemental iron per course). May repeat co…"}, {"doc_id": "enalapril-and-hydrochlorothiazide-drug-information", "bm25_top3": 21.486165161173197, "bm25_max": 21.486165161173197, "bge_top3": null, "bge_max": null, "title": "Enalapril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: Enalapril 10 mg/hydrochlorothiazide 25 mg once daily; may increase dose based on patient response after 2 to 3 weeks (maximum: enalapril 20 mg/hydrochlorothiazide 50 mg per day…"}, {"doc_id": "aliskiren-and-amlodipine-drug-information", "bm25_top3": 21.241880981922726, "bm25_max": 21.241880981922726, "bge_top3": 0.6388562321662903, "bge_max": 0.6388562321662903, "title": "Aliskiren and amlodipine: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Dosage must be individualized. Prior to initiation, correct hypovolemia and/or closely monitor volume status in patients on concurrent diuretics during treatment initiation.  Init…"}, {"doc_id": "aliskiren-amlodipine-and-hydrochlorothiazide-drug-information", "bm25_top3": 21.125475900859144, "bm25_max": 21.125475900859144, "bge_top3": 0.6238836646080017, "bge_max": 0.6238836646080017, "title": "Aliskiren, amlodipine, and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Not for initial therapy. Dose is individualized. Prior to initiation, correct hypovolemia and/or closely monitor volume status during treatment initiation.  Add-on/switch therapy:…"}, {"doc_id": "acetaminophen-paracetamol-and-tramadol-drug-information", "bm25_top3": 21.02144301390934, "bm25_max": 21.02144301390934, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol) and tramadol: Drug information", "rep_snippet": "Dosing: Adult  Pain management: Oral: Acetaminophen 325 mg/tramadol 37.5 mg: Two tablets every 4 to 6 hours as needed for pain relief (maximum: 8 tablets/day [acetaminophen 2,600 mg/tramadol 300 mg per day]); do not exce…"}, {"doc_id": "amlodipine-and-olmesartan-drug-information", "bm25_top3": 21.000285527319875, "bm25_max": 21.000285527319875, "bge_top3": 0.6229684948921204, "bge_max": 0.6229684948921204, "title": "Amlodipine and olmesartan: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Dosage is individualized. Initial: Amlodipine 5 mg/olmesartan 20 mg once daily; dose may be increased after 1 to 2 weeks of therapy. Maximum dose: Amlodipine 10 mg/olmesartan 40 m…"}, {"doc_id": "olmesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": 19.540790790331865, "bm25_max": 20.866051235709016, "bge_top3": null, "bge_max": null, "title": "Olmesartan and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral:  Replacement therapy: Combination product may be substituted for individual titrated agents.  Initiation of combination therapy when monotherapy has failed to achieve desired effects:…"}, {"doc_id": "deferoxamine-drug-information", "bm25_top3": 20.862299989350745, "bm25_max": 20.862299989350745, "bge_top3": null, "bge_max": null, "title": "Deferoxamine: Drug information", "rep_snippet": "Dosing: Adult  Acute iron toxicity: Note: The IV route is preferred and is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or gastrointestinal blee…"}, {"doc_id": "guaifenesin-and-codeine-drug-information", "bm25_top3": 20.73881441985448, "bm25_max": 20.73881441985448, "bge_top3": null, "bge_max": null, "title": "Guaifenesin and codeine: Drug information", "rep_snippet": "Dosing: Adult  Dosing may vary by product. Consult specific product labeling.  Cough: Oral:  Guaifenesin 100 mg/codeine 6.33 mg per 5 mL: 15 mL every 4 to 6 hours (maximum: 90 mL per 24 hours)  Guaifenesin 100 to 200 mg/…"}, {"doc_id": "aliskiren-and-hydrochlorothiazide-drug-information", "bm25_top3": 20.69168208991063, "bm25_max": 20.69168208991063, "bge_top3": null, "bge_max": null, "title": "Aliskiren and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosage must be individualized. Prior to initiation, correct hypovolemia and/or closely monitor volume status during treatment initiation. Not recommended for use as initial therapy in patients with i…"}, {"doc_id": "diclofenac-topical-drug-information", "bm25_top3": 20.625833279580178, "bm25_max": 20.625833279580178, "bge_top3": null, "bge_max": null, "title": "Diclofenac (topical): Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.  Actinic keratosis (AK): Topical: Apply 3% gel to lesion area twice daily for 60 t…"}, {"doc_id": "trimethoprim-and-polymyxin-b-drug-information", "bm25_top3": 20.542225643113056, "bm25_max": 20.542225643113056, "bge_top3": null, "bge_max": null, "title": "Trimethoprim and polymyxin B: Drug information", "rep_snippet": "Dosing: Adult  Conjunctivitis, blepharoconjunctivitis: Ophthalmic: Instill 1 drop in affected eye(s) every 3 hours (maximum: 6 doses per day) for 7-10 days; has also been used 4 times daily for 5-7 days (Williams, 2013;…"}, {"doc_id": "paraldehyde-united-states-not-available-drug-information", "bm25_top3": 20.528049911991733, "bm25_max": 20.528049911991733, "bge_top3": null, "bge_max": null, "title": "Paraldehyde (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Canadian labeling: Second- or third-line therapy: Note: Do not administer >5 mL per injection site.  Alcohol withdrawal: IM: 5 mL every 4-6 hours for 24 hours (maximum: 30 mL on day 1), followed by every 6…"}, {"doc_id": "atenolol-and-chlorthalidone-drug-information", "bm25_top3": 20.40215577503412, "bm25_max": 20.40215577503412, "bge_top3": null, "bge_max": null, "title": "Atenolol and chlorthalidone: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl >35 mL/minute per 1.73 m2: No dosage adjustment necessary.  CrCl 15 to 35 mL/minute per 1.73 m2: Maximum dose: Atenolol 50 mg/chlorthalidone 25 mg once daily  CrCl <15 mL/minute/1.73 m2: Ma…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 20.397045431387305, "bm25_max": 20.397045431387305, "bge_top3": null, "bge_max": null, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: Oral: Initial doses should be based on the current dose of sitagliptin and metformin; titrate gradually per glycemic response. Total daily dose should be administered in 2 equall…"}, {"doc_id": "acetaminophen-caffeine-and-pyrilamine-drug-information", "bm25_top3": 20.38325783431956, "bm25_max": 20.38325783431956, "bge_top3": null, "bge_max": null, "title": "Acetaminophen, caffeine, and pyrilamine: Drug information", "rep_snippet": "Dosing: Adult  Menstrual period symptom relief: Oral: Two tablets (acetaminophen 1,000 mg/caffeine 120 mg/pyrilamine 30 mg) every 6 hours as needed; maximum: 6 tablets (acetaminophen 3,000 mg/caffeine 360 mg/pyrilamine 9…"}, {"doc_id": "propranolol-and-hydrochlorothiazide-drug-information", "bm25_top3": 20.322891990630502, "bm25_max": 20.322891990630502, "bge_top3": null, "bge_max": null, "title": "Propranolol and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: Propranolol 40 mg/hydrochlorothiazide 25 mg twice daily; may titrate gradually based on blood pressure response (maximum: propranolol 160 mg/hydrochlorothiazide 50 mg per day).…"}, {"doc_id": "doxylamine-and-pyridoxine-drug-information", "bm25_top3": 20.18033618394002, "bm25_max": 20.18033618394002, "bge_top3": null, "bge_max": null, "title": "Doxylamine and pyridoxine: Drug information", "rep_snippet": "Dosing: Adult  Nausea and vomiting associated with pregnancy: Oral: Note: Tablets should be taken as scheduled and not on an as needed basis.  Doxylamine 10 mg/pyridoxine 10 mg (Diclegis): Initial: Two tablets at bedtime…"}, {"doc_id": "atropine-ophthalmic-drug-information", "bm25_top3": 19.951213788402857, "bm25_max": 19.951213788402857, "bge_top3": null, "bge_max": null, "title": "Atropine (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atropine (ophthalmic): Pediatric drug information\")  Amblyopia, healthy eye penalization: Ophthalmic: Solution:  Infants ≥3 months and Children <3 years: Instill 1 drop…"}, {"doc_id": "isoniazid-drug-information", "bm25_top3": 19.01008761856939, "bm25_max": 19.01008761856939, "bge_top3": null, "bge_max": null, "title": "Isoniazid: Drug information", "rep_snippet": "Note: Once weekly regimen of isoniazid and rifapentine may also be considered in children ≥2 or <12 years if completion of 9 month regimen (preferred) is unlikely and the hazard of tuberculosis is great (CDC 2013). Refer…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 18.350708446336647, "bm25_max": 18.350708446336647, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "acebutolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6516972780227661, "bge_max": 0.6516972780227661, "title": "Acebutolol: Drug information", "rep_snippet": "Dosing: Adult  Ventricular arrhythmia (eg, ventricular premature beats): Oral: 400 mg daily in 2 divided doses; maintenance: 600 to 1,200 mg daily in divided doses; maximum: 1,200 mg daily  Hypertension: Oral: Initial: 4…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6512628793716431, "bge_max": 0.6512628793716431, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Metronidazole (systemic): Pediatric drug information\")  Note: Some clinicians recommend using adjusted body weight in obese children. Dosing weight = IBW + 0.45 (TBW-IB…"}, {"doc_id": "cytarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6396494805812836, "bge_max": 0.6471011638641357, "title": "Cytarabine: Drug information", "rep_snippet": "Dosing: Adult  Note: Doses >1000 mg/m2 are associated with a moderate emetic potential in adults (Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.  Acute myeloid leukemia (AML) remis…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.646125316619873, "bge_max": 0.646125316619873, "title": "Oxacillin: Drug information", "rep_snippet": "Necrotizing infection due to MSSA (off-label use): IV: 200 mg/kg/day in divided doses every 6 hours; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6429446339607239, "bge_max": 0.6429446339607239, "title": "Streptomycin: Drug information", "rep_snippet": "Manufacturer’s labeling: IM:  Daily therapy: 15 mg/kg/day (maximum: 1 g)  Directly observed therapy (DOT), twice weekly: 25 to 30 mg/kg (maximum: 1.5 g)  Directly observed therapy (DOT), 3 times weekly: 25 to 30 mg/kg (m…"}, {"doc_id": "azacitidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.641867995262146, "bge_max": 0.641867995262146, "title": "Azacitidine: Drug information", "rep_snippet": "Dosing: Adult  Note: Azacitidine is associated with a moderate emetic potential (Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.  Myelodysplastic syndromes (MDS): IV, SubQ: Initial…"}, {"doc_id": "quetiapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6338323056697845, "bge_max": 0.640730619430542, "title": "Quetiapine: Drug information", "rep_snippet": "Dosing: Adult  Bipolar disorder: Oral:  Depressive episodes: Note: In clinical trials, doses up to 600 mg/day were not associated with any further benefit compared to 300 mg/day.  Immediate release: Initial: 50 mg once d…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6377176642417908, "bge_max": 0.6377176642417908, "title": "Fenofibrate: Drug information", "rep_snippet": "Dosing: Adult  Note: At least 2 to 3 months of therapy is required to determine efficacy.  Hypertriglyceridemia: Oral: Initial:  Antara (micronized): 30 to 90 mg once daily; maximum dose: 90 mg/day  Fenofibrate (microniz…"}, {"doc_id": "dextroamphetamine-and-amphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6360135674476624, "bge_max": 0.637542724609375, "title": "Dextroamphetamine and amphetamine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Immediate release and Adderall XR extended release: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; the potential exists for elimination of amphetamine…"}, {"doc_id": "pregabalin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6374996900558472, "bge_max": 0.6374996900558472, "title": "Pregabalin: Drug information", "rep_snippet": "Dosing: Adult  Note: When discontinuing, taper off gradually over at least 1 week.  Fibromyalgia: Immediate release: Oral: Initial: 150 mg daily in divided doses (75 mg twice daily); may be increased to 300 mg daily (150…"}, {"doc_id": "allopurinol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6359094381332397, "bge_max": 0.6359094381332397, "title": "Allopurinol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Allopurinol: Pediatric drug information\")  Cancer therapy-induced hyperuricemia:  Oral: Note: Oral doses >300 mg should be given in divided doses. Adjust dose as necess…"}, {"doc_id": "amlodipine-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6339616179466248, "bge_max": 0.6339616179466248, "title": "Amlodipine and valsartan: Drug information", "rep_snippet": "Dosing: Adult  Note: Dose must be individualized.  Hypertension: Oral:  Initial therapy: Amlodipine 5 mg/valsartan 160 mg once daily; dose may be titrated after 1 to 2 weeks. Maximum dose: amlodipine 10 mg/valsartan 320…"}, {"doc_id": "glipizide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.633449137210846, "bge_max": 0.633449137210846, "title": "Glipizide: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: Oral:  Immediate release: Initial: Manufacturer recommends 5 mg once daily, alternatively 2.5 mg once daily has been recommended (Rendel 2004); titrate in 2.5 to 5 mg increments…"}, {"doc_id": "tramadol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6327909231185913, "bge_max": 0.6327909231185913, "title": "Tramadol: Drug information", "rep_snippet": "Dosing: Adult  Pain management: Oral: Note: Doses should be titrated to appropriate analgesic effect; use the lowest effective dose for the shortest period of time:  Immediate release: 50 to 100 mg every 4 to 6 hours (ma…"}, {"doc_id": "altretamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6326159834861755, "bge_max": 0.6326159834861755, "title": "Altretamine: Drug information", "rep_snippet": "Dosing: Adult  Note: Altretamine is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016)  Ovarian cancer (persistent or recurrent): Oral: 260 mg/m…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6319636702537537, "bge_max": 0.6319636702537537, "title": "Clozapine: Drug information", "rep_snippet": "Dosing: Adult  Note: Prior to initiating treatment, obtain a baseline CBC, including the ANC; the ANC must be ≥1,500/mm3 for the general population and ≥1,000/mm3 for patients with documented Benign Ethnic Neutropenia (B…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6317837238311768, "bge_max": 0.6317837238311768, "title": "Ibuprofen: Drug information", "rep_snippet": "Dosing: Adult  Analgesia (mild to moderate pain):  Oral:  Manufacturer’s labeling: 400 mg every 4 to 6 hours as needed; maximum: 3,200 mg/day  American Pain Society (off-label): 200 to 400 mg every 4 to 6 hours; maximum:…"}, {"doc_id": "aldesleukin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6308141946792603, "bge_max": 0.6308141946792603, "title": "Aldesleukin: Drug information", "rep_snippet": "Dosing: Adult  Consider premedication with an antipyretic to reduce fever, an H2 antagonist for prophylaxis of gastrointestinal irritation/bleeding, antiemetics, and antidiarrheals; continue for 12 hours after the last a…"}, {"doc_id": "thioguanine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6306542158126831, "bge_max": 0.6306542158126831, "title": "Thioguanine: Drug information", "rep_snippet": "Dosing: Adult  Acute myeloid leukemia (AML): Oral: 2 mg/kg once daily for 4 weeks; if no clinical improvement after 4 weeks and ANC and platelet counts are not depressed, may increase dose to 3 mg/kg once daily with care…"}, {"doc_id": "lisdexamfetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.629947304725647, "bge_max": 0.629947304725647, "title": "Lisdexamfetamine: Drug information", "rep_snippet": "Dosing: Adult  Note: Prior to treatment, assess for presence of cardiac disease and assess for risk of abuse.  Attention-deficit/hyperactivity disorder (ADHD): Oral: Initial: 30 mg once daily in the morning; may increase…"}, {"doc_id": "ruxolitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.62956303358078, "bge_max": 0.62956303358078, "title": "Ruxolitinib: Drug information", "rep_snippet": "Dosing: Adult  Note: Consider gradually tapering off (by 5 mg twice daily each week) if discontinuing for reasons other than thrombocytopenia.  Myelofibrosis: Oral: Initial dose (based on platelet count, titrate dose the…"}, {"doc_id": "decitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6292316317558289, "bge_max": 0.6292316317558289, "title": "Decitabine: Drug information", "rep_snippet": "Dosing: Adult  Myelodysplastic syndromes (MDS): IV:  15 mg/m2 over 3 hours every 8 hours (45 mg/m2/day) for 3 days (135 mg/m2/cycle) every 6 weeks; treatment is recommended for at least 4 cycles and may continue until th…"}, {"doc_id": "amphotericin-b-lipid-complex-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6292170882225037, "bge_max": 0.6292170882225037, "title": "Amphotericin B lipid complex: Drug information", "rep_snippet": "Dosing: Adult  Note: Lipid-based amphotericin formulations (Abelcet) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6288506388664246, "bge_max": 0.6288506388664246, "title": "Duloxetine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder: Oral: Initial: 40 to 60 mg daily; dose may be divided (ie, 20 or 30 mg twice daily) or given as a single daily dose of 60 mg. For some patients it may be desirable to start at 30…"}, {"doc_id": "atenolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6264523267745972, "bge_max": 0.628747284412384, "title": "Atenolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atenolol: Pediatric drug information\")  Hypertension: Oral: Children and Adolescents: Initial: 0.5 to 1 mg/kg/dose either once daily or divided in doses twice daily; ti…"}, {"doc_id": "repaglinide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6276920437812805, "bge_max": 0.6276920437812805, "title": "Repaglinide: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: Oral:  Patients whose HbA1c is <8%: Initial: 0.5 mg before each meal (2, 3, or 4 times/day depending on number of meals); may double the dose with each meal at intervals of ≥1 we…"}, {"doc_id": "idarubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6272588968276978, "bge_max": 0.6272588968276978, "title": "Idarubicin: Drug information", "rep_snippet": "Dosing: Adult  Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).  Acute myeloid leukemia (AML): IV:  Manufacturer labeling:…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6272124648094177, "bge_max": 0.6272124648094177, "title": "Amlodipine: Drug information", "rep_snippet": "Dosing: Geriatric  Dosing should start at the lower end of dosing range and titrated to response due to possible increased incidence of hepatic, renal, or cardiac impairment. Elderly patients also show decreased clearanc…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6271079778671265, "bge_max": 0.6271079778671265, "title": "Sertraline: Drug information", "rep_snippet": "Premenstrual dysphoric disorder (PMDD): Oral: 50 mg daily either daily throughout menstrual cycle or limited to the luteal phase of menstrual cycle. Patients not responding to 50 mg daily may benefit from dose increases…"}, {"doc_id": "liposomal-amphotericin-b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6268859505653381, "bge_max": 0.6268859505653381, "title": "Liposomal amphotericin B: Drug information", "rep_snippet": "Dosing: Adult  Note: Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin…"}, {"doc_id": "amphotericin-b-deoxycholate-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6266425848007202, "bge_max": 0.6266425848007202, "title": "Amphotericin B deoxycholate (conventional): Drug information", "rep_snippet": "Initial: 0.25 to 0.5 mg/kg/dose once daily; gradually increase daily, usually in 0.25 mg/kg increments until the desired daily dose is reached (maximum daily dose: 1.5 mg/kg/day); in critically ill patients, more rapid d…"}, {"doc_id": "cilazapril-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6263599395751953, "bge_max": 0.6263599395751953, "title": "Cilazapril (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Heart failure: Oral: Initial: 0.5 mg once daily; per response and tolerability, increase to 1 mg once daily within 5 days; may further titrate as necessary to usual maintenance dose of 2.5 mg once daily (m…"}, {"doc_id": "memantine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6258670687675476, "bge_max": 0.6258670687675476, "title": "Memantine: Drug information", "rep_snippet": "Dosing: Adult  Alzheimer disease, moderate to severe: Oral:  Immediate release: Initial: 5 mg daily; increase dose by 5 mg daily (if previous dose well tolerated) to a target dose of 20 mg daily; wait ≥1 week between dos…"}, {"doc_id": "valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6251053810119629, "bge_max": 0.6251053810119629, "title": "Valsartan: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Initial: 80 mg or 160 mg once daily (in patients who are not volume depleted); dose may be increased to achieve desired effect; usual dosage range (ASH/ISH [Weber 2014]): 80 to 320 mg once da…"}, {"doc_id": "vilazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.625052273273468, "bge_max": 0.625052273273468, "title": "Vilazodone: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: Initial: 10 mg once daily for 7 days, then increase to 20 mg once daily; may increase up to 40 mg once daily after a minimum of 7 days based on response and tolerabil…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6246820688247681, "bge_max": 0.6246820688247681, "title": "Rosuvastatin: Drug information", "rep_snippet": "Dosing: Adult  Note: Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more.  Hy…"}, {"doc_id": "diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6243518590927124, "bge_max": 0.6243518590927124, "title": "Diphenhydramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Note: Aldex has been discontinued in the US for more than 1 year.  Allergic symptoms, nasal congestion: Oral:  Aldex CT: 1 to 2 tablets every 6 hours (maximum: 4 doses/24 hours)  OTC labeling: Note: Refer…"}, {"doc_id": "methylphenidate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6240057945251465, "bge_max": 0.6240057945251465, "title": "Methylphenidate: Drug information", "rep_snippet": "- Patients taking methylphenidate SR 20 mg daily: 18 mg once every morning  - Patients taking methylphenidate SR 40 mg daily: 36 mg once every morning  - Patients taking methylphenidate SR 60 mg daily: 54 mg once every m…"}, {"doc_id": "melphalan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6240023970603943, "bge_max": 0.6240023970603943, "title": "Melphalan: Drug information", "rep_snippet": "140 mg/m2 2 days prior to transplantation (combined with busulfan) (Fermand 2005) or  140 mg/m2 2 days prior to transplantation (combined with total body irradiation [TBI]) (Moreau 2002) or  140 mg/m2 5 days prior to tra…"}, {"doc_id": "aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6235626339912415, "bge_max": 0.6235626339912415, "title": "Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information", "rep_snippet": "Monotherapy: Initial: 15 mg once daily. May increase to 30 mg once daily if clinically indicated (maximum 30 mg/day); safety of doses >30 mg/day has not been evaluated  Adjunct to lithium or valproic acid: Initial: 10 to…"}, {"doc_id": "metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6234188079833984, "bge_max": 0.6234188079833984, "title": "Metformin: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: Oral: Note: Clinically significant responses may not be seen at doses <1,500 mg/day; however, a lower recommended starting dose and gradual increased dosage is recommended to min…"}, {"doc_id": "mitoxantrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6230283975601196, "bge_max": 0.6230283975601196, "title": "Mitoxantrone: Drug information", "rep_snippet": "Dosing: Adult  Details concerning dosing in combination regimens should also be consulted.  US labeling:  Acute nonlymphocytic leukemias (ANLL): IV:  Acute myeloid leukemia (AML) induction: 12 mg/m2 once daily for 3 days…"}]}
{"qid": "Q28_abbr+contact-lens-cue", "query": "Bacterial conjunctivitis — ofloxacin ophthalmic dosing; contact lens precautions.", "base_qid": "Q28", "variant_type": "abbr+contact-lens-cue", "candidates": [{"doc_id": "ofloxacin-ophthalmic-drug-information", "bm25_top3": 32.01388477569656, "bm25_max": 47.29042572982151, "bge_top3": 0.7381639877955118, "bge_max": 0.7701306939125061, "title": "Ofloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ofloxacin (ophthalmic): Pediatric drug information\")  Bacterial conjunctivitis: Ophthalmic: Children ≥1 year and Adolescents: Refer to adult dosing.  Corneal ulcer: Oph…"}, {"doc_id": "moxifloxacin-ophthalmic-drug-information", "bm25_top3": 37.00373468054599, "bm25_max": 37.00373468054599, "bge_top3": 0.7401609718799591, "bge_max": 0.7406681180000305, "title": "Moxifloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Moxifloxacin (ophthalmic): Pediatric drug information\")  Bacterial conjunctivitis: Ophthalmic:  Children ≥4 months and Adolescents (Moxeza): Refer to adult dosing.  Neo…"}, {"doc_id": "ciprofloxacin-ophthalmic-drug-information", "bm25_top3": 31.94153261251813, "bm25_max": 36.24296390039645, "bge_top3": 0.7239350279172262, "bge_max": 0.7383990287780762, "title": "Ciprofloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin (ophthalmic): Pediatric drug information\")  Bacterial conjunctivitis: Ophthalmic:  Solution: Children ≥1 year and Adolescents: Refer to adult dosing.  Oin…"}, {"doc_id": "bepotastine-ophthalmic-drug-information", "bm25_top3": 32.60762774742653, "bm25_max": 33.627696344160924, "bge_top3": 0.7276906967163086, "bge_max": 0.7435091733932495, "title": "Bepotastine (ophthalmic): Drug information", "rep_snippet": "Warnings/Precautions  Special populations:  • Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 10 minutes before reinserting.…"}, {"doc_id": "azelastine-ophthalmic-drug-information", "bm25_top3": 26.38512979462623, "bm25_max": 31.42716588465927, "bge_top3": 0.7438650131225586, "bge_max": 0.7438650131225586, "title": "Azelastine (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Azelastine (ophthalmic): Pediatric drug information\")  Allergic conjunctivitis: Children ≥3 years and Adolescents: Ophthalmic: Refer to adult dosing."}, {"doc_id": "ketotifen-ophthalmic-drug-information", "bm25_top3": 27.589562967860786, "bm25_max": 31.42716588465927, "bge_top3": 0.7215611934661865, "bge_max": 0.7215611934661865, "title": "Ketotifen (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ketotifen (ophthalmic): Pediatric drug information\")  Allergic conjunctivitis: Children ≥3 years and Adolescents: Ophthalmic: Refer to adult dosing."}, {"doc_id": "betaxolol-ophthalmic-drug-information", "bm25_top3": 31.33462506837191, "bm25_max": 31.33462506837191, "bge_top3": 0.7247236967086792, "bge_max": 0.7247236967086792, "title": "Betaxolol (ophthalmic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "fusidic-acid-united-states-not-available-ophthalmic-drug-information", "bm25_top3": 31.282145616200424, "bm25_max": 31.282145616200424, "bge_top3": 0.725503146648407, "bge_max": 0.735772967338562, "title": "Fusidic acid (United States: Not available) (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  Ophthalmic infections/conjunctivitis: Children ≥2 years and Adolescents: Refer to adult dosing."}, {"doc_id": "cetirizine-ophthalmic-drug-information", "bm25_top3": 30.802895882063037, "bm25_max": 31.282145616200424, "bge_top3": 0.7200594246387482, "bge_max": 0.7394120097160339, "title": "Cetirizine (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  Allergic conjunctivitis: Ophthalmic: Children ≥2 years and Adolescents: Refer to adult dosing."}, {"doc_id": "cromolyn-sodium-cromoglicate-ophthalmic-drug-information", "bm25_top3": 28.871096991911724, "bm25_max": 31.073353284033615, "bge_top3": 0.7227258086204529, "bge_max": 0.7227258086204529, "title": "Cromolyn (sodium cromoglicate) (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cromolyn (sodium cromoglicate) (ophthalmic): Pediatric drug information\")  Conjunctivitis and keratitis: Ophthalmic: Children ≥4 years and Adolescents: Refer to adult d…"}, {"doc_id": "travoprost-drug-information", "bm25_top3": 29.12449173490961, "bm25_max": 29.12449173490961, "bge_top3": 0.7025538682937622, "bge_max": 0.7025538682937622, "title": "Travoprost: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.  • Ocular effects: May permanently change…"}, {"doc_id": "epinastine-drug-information", "bm25_top3": 28.729932332471144, "bm25_max": 28.729932332471144, "bge_top3": 0.7368206977844238, "bge_max": 0.7385638952255249, "title": "Epinastine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.  Special populations:  • Contact lens wea…"}, {"doc_id": "netarsudil-drug-information", "bm25_top3": 28.60591526036103, "bm25_max": 28.60591526036103, "bge_top3": 0.7331225275993347, "bge_max": 0.7331225275993347, "title": "Netarsudil: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.  Special populations:  • Contact lens wea…"}, {"doc_id": "olopatadine-ophthalmic-drug-information", "bm25_top3": 28.072400541962153, "bm25_max": 28.072400541962153, "bge_top3": null, "bge_max": null, "title": "Olopatadine (ophthalmic): Drug information", "rep_snippet": "Warnings/Precautions  Other warnings/precautions:  • Contact lens: Not for use to treat contact lens-related irritation. Solution contains benzalkonium chloride; remove lens prior to administration and wait at least 10 m…"}, {"doc_id": "besifloxacin-drug-information", "bm25_top3": 22.189782691160044, "bm25_max": 27.770287805357984, "bge_top3": 0.7807169556617737, "bge_max": 0.8023749589920044, "title": "Besifloxacin: Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic: Instill 1 drop into affected eye(s) 3 times daily (4 to 12 hours apart) for 7 days"}, {"doc_id": "gatifloxacin-drug-information", "bm25_top3": 21.542839096024984, "bm25_max": 26.220736505834626, "bge_top3": 0.7534679472446442, "bge_max": 0.7567099928855896, "title": "Gatifloxacin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Gatifloxacin: Pediatric drug information\")  Bacterial conjunctivitis: Children ≥1 year and Adolescents: Ophthalmic: Refer to adult dosing."}, {"doc_id": "cysteamine-ophthalmic-drug-information", "bm25_top3": 26.182911138915628, "bm25_max": 26.182911138915628, "bge_top3": null, "bge_max": null, "title": "Cysteamine (ophthalmic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Intracranial hypertension/papilledema: Intracranial hypertension (pseudotumor cerebri) and/or papilledema have been reported with oral cysteamine treatment; m…"}, {"doc_id": "carteolol-ophthalmic-drug-information", "bm25_top3": 25.3599052458139, "bm25_max": 25.3599052458139, "bge_top3": null, "bge_max": null, "title": "Carteolol (ophthalmic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "emedastine-drug-information", "bm25_top3": 21.109019276083195, "bm25_max": 21.109019276083195, "bge_top3": 0.7508867383003235, "bge_max": 0.7508867383003235, "title": "Emedastine: Drug information", "rep_snippet": "Warnings/Precautions  Special populations:  • Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove contact lenses prior to use and wait ≥10 minutes before reinserting.…"}, {"doc_id": "alcaftadine-drug-information", "bm25_top3": 20.935367174340534, "bm25_max": 20.935367174340534, "bge_top3": 0.7383869886398315, "bge_max": 0.7383869886398315, "title": "Alcaftadine: Drug information", "rep_snippet": "Warnings/Precautions  Special populations:  • Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lenses prior to administration and wait 10 minutes before reinsertin…"}, {"doc_id": "natamycin-drug-information", "bm25_top3": 17.87808467313605, "bm25_max": 17.87808467313605, "bge_top3": 0.7036710977554321, "bge_max": 0.7036710977554321, "title": "Natamycin: Drug information", "rep_snippet": "Warnings/Precautions  Disease-related concerns:  • Epithelial ulceration: Suspension may adhere to epithelial ulcers; retention of the suspension in the fornices occurs regularly.  Special populations:  • Contact lens we…"}, {"doc_id": "nedocromil-drug-information", "bm25_top3": 16.57025685230706, "bm25_max": 17.71745772646041, "bge_top3": 0.7297646999359131, "bge_max": 0.7304407358169556, "title": "Nedocromil: Drug information", "rep_snippet": "Warnings/Precautions  Dosage form specific issues:  • Ophthalmic solution: Contains benzalkonium chloride, which may be absorbed by contact lenses; users of contact lenses should not wear them during periods of symptomat…"}, {"doc_id": "framycetin-united-states-not-available-drug-information", "bm25_top3": 17.367299075712758, "bm25_max": 17.367299075712758, "bge_top3": 0.6989889144897461, "bge_max": 0.6989889144897461, "title": "Framycetin (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Superinfection: Prolonged use may result in fungal or bacterial superinfection.  Special populations:  • Contact lens wearers: Formulation contains benzalkoni…"}, {"doc_id": "brinzolamide-and-timolol-united-states-not-available-drug-information", "bm25_top3": 16.924671374267945, "bm25_max": 16.924671374267945, "bge_top3": null, "bge_max": null, "title": "Brinzolamide and timolol (United States: Not available): Drug information", "rep_snippet": "• Contact lens wearers: Formulation contains benzalkonium chloride which may be absorbed by soft contact lenses and discolor lenses; remove lens prior to administration and wait 15 minutes before reinserting.  Other warn…"}, {"doc_id": "lifitegrast-drug-information", "bm25_top3": 16.57980272817327, "bm25_max": 16.57980272817327, "bge_top3": null, "bge_max": null, "title": "Lifitegrast: Drug information", "rep_snippet": "Warnings/Precautions  Special Populations:  • Contact lens wearers: Remove contact lens prior to administration and wait 15 minutes before reinserting."}, {"doc_id": "loteprednol-drug-information", "bm25_top3": 15.98410717536062, "bm25_max": 15.98410717536062, "bge_top3": null, "bge_max": null, "title": "Loteprednol: Drug information", "rep_snippet": "• Herpes simplex: Corticosteroids should not be used to treat ocular herpes simplex; may exacerbate the severity of the infection. Use extreme caution in patients with history of herpes simplex.  Special populations:  •…"}, {"doc_id": "dorzolamide-and-timolol-drug-information", "bm25_top3": 12.022225382064272, "bm25_max": 15.222006491133332, "bge_top3": null, "bge_max": null, "title": "Dorzolamide and timolol: Drug information", "rep_snippet": "• Contact lens wearers: Some products may contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.  Other warnings/precaution…"}, {"doc_id": "tobramycin-and-dexamethasone-drug-information", "bm25_top3": 15.07097669487003, "bm25_max": 15.07097669487003, "bge_top3": 0.7071472704410553, "bge_max": 0.7086640000343323, "title": "Tobramycin and dexamethasone: Drug information", "rep_snippet": "• Ocular herpes simplex: Use with extreme caution in patients with a history of ocular herpes simplex; use of corticosteroids may prolong the course and exacerbate severity of infection.  Special populations:  • Contact…"}, {"doc_id": "metipranolol-drug-information", "bm25_top3": 13.087234454686804, "bm25_max": 13.087234454686804, "bge_top3": null, "bge_max": null, "title": "Metipranolol: Drug information", "rep_snippet": "• Peripheral vascular disease (PVD): Use with caution in patients with PVD (including Raynaud's).  • Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS de…"}, {"doc_id": "latanoprost-and-timolol-united-states-not-available-drug-information", "bm25_top3": 12.669363612699811, "bm25_max": 12.669363612699811, "bge_top3": null, "bge_max": null, "title": "Latanoprost and timolol (United States: Not available): Drug information", "rep_snippet": "• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid st…"}, {"doc_id": "dorzolamide-drug-information", "bm25_top3": 12.51204297205124, "bm25_max": 12.51204297205124, "bge_top3": null, "bge_max": null, "title": "Dorzolamide: Drug information", "rep_snippet": "Administration  Ophthalmic: If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. Remove contact lens prior to administration and wait 15 minutes before reinserting. Avoid…"}, {"doc_id": "lodoxamide-tromethamine-drug-information", "bm25_top3": 12.405876543040783, "bm25_max": 12.405876543040783, "bge_top3": null, "bge_max": null, "title": "Lodoxamide tromethamine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Irritation: May cause discomfort or transient burning or stinging upon instillation.  • Ocular effects: May cause temporary blurred vision or other visual dis…"}, {"doc_id": "brimonidine-and-timolol-drug-information", "bm25_top3": 12.242576679448177, "bm25_max": 12.242576679448177, "bge_top3": null, "bge_max": null, "title": "Brimonidine and timolol: Drug information", "rep_snippet": "• Contact lens wearers: Product contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.  • Pediatric: Safety and efficacy h…"}, {"doc_id": "homatropine-drug-information", "bm25_top3": 11.795064916063339, "bm25_max": 11.795064916063339, "bge_top3": null, "bge_max": null, "title": "Homatropine: Drug information", "rep_snippet": "• Contact lens wearers: Some strengths may contain benzalkonium chloride which may be adsorbed by contact lenses (Chapman 1990); remove contacts prior to administration and wait 15 minutes before reinserting.  Other warn…"}, {"doc_id": "artificial-tears-drug-information", "bm25_top3": 10.852101065998934, "bm25_max": 10.852101065998934, "bge_top3": null, "bge_max": null, "title": "Artificial tears: Drug information", "rep_snippet": "Warnings/Precautions  Special populations:  • Contact lens wearers: Ophthalmic solutions may contain benzalkonium chloride which may be absorbed by contact lenses. Remove contact lenses before using.  Dosage form specifi…"}, {"doc_id": "malathion-drug-information", "bm25_top3": 10.250703520749845, "bm25_max": 10.250703520749845, "bge_top3": null, "bge_max": null, "title": "Malathion: Drug information", "rep_snippet": "Adverse Reactions  Frequency not defined.  Dermatologic: Skin irritation (including scalp irritation), stinging of the skin  Ophthalmic: Conjunctivitis (following contact with eyes)  Miscellaneous: Burn (chemical; includ…"}, {"doc_id": "levobunolol-drug-information", "bm25_top3": 10.123435690936475, "bm25_max": 10.123435690936475, "bge_top3": null, "bge_max": null, "title": "Levobunolol: Drug information", "rep_snippet": "Administration  For topical ophthalmic use only. Wash hands before and after use. Some solutions contain benzalkonium chloride; remove contact lens prior to administration. Wait 15 minutes before reinserting. Do not touc…"}, {"doc_id": "trimethoprim-and-polymyxin-b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7369179129600525, "bge_max": 0.7369179129600525, "title": "Trimethoprim and polymyxin B: Drug information", "rep_snippet": "Dosing: Adult  Conjunctivitis, blepharoconjunctivitis: Ophthalmic: Instill 1 drop in affected eye(s) every 3 hours (maximum: 6 doses per day) for 7-10 days; has also been used 4 times daily for 5-7 days (Williams, 2013;…"}, {"doc_id": "sulfacetamide-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.73093581199646, "bge_max": 0.73093581199646, "title": "Sulfacetamide (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Conjunctivitis, other superficial ocular infections: Note: Taper dose by increasing dosage time interval as condition responds; usual duration of treatment: 7 to 10 days:  Ophthalmic solution: Instill 1 to…"}, {"doc_id": "neomycin-polymyxin-b-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7104500532150269, "bge_max": 0.7214248776435852, "title": "Neomycin, polymyxin B, and dexamethasone: Drug information", "rep_snippet": "Dosing: Adult  Inflammatory ocular conditions: Ophthalmic:  Suspension: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 to 6 times daily. In severe disease, drops may be used hourly; frequency sho…"}, {"doc_id": "tetrahydrozoline-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.721386194229126, "bge_max": 0.721386194229126, "title": "Tetrahydrozoline (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular decongestant: Ophthalmic: Instill 1 to 2 drops in the affected eye(s) up to 4 times daily"}, {"doc_id": "bacitracin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7150229513645172, "bge_max": 0.7183066606521606, "title": "Bacitracin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ophthalmic infection: Ophthalmic: Apply 1 to 3 times daily"}, {"doc_id": "prednisolone-and-gentamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7173876762390137, "bge_max": 0.7173876762390137, "title": "Prednisolone and gentamicin: Drug information", "rep_snippet": "Dosing: Adult  Inflammatory conditions and superficial ocular infections: Ophthalmic:  Ointment: Apply 1/2 inch ribbon into the conjunctival sac of the affected eye(s) 1 to 3 times per day  Suspension: Instill 1 drop int…"}, {"doc_id": "tobramycin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7118734121322632, "bge_max": 0.7118734121322632, "title": "Tobramycin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular infections: Ophthalmic:  Ointment: Apply half-inch ribbon into affected eye(s) 2 or 3 times daily for mild to moderate infections; for severe infections, apply every 3 to 4 hours until improvement (…"}, {"doc_id": "lincomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7044451236724854, "bge_max": 0.7044451236724854, "title": "Lincomycin: Drug information", "rep_snippet": "Dosing: Adult  Bacterial infection (serious): Note: Administration frequency may be increased if needed due to severity of infection  IM: 600 mg every 12 to 24 hours  IV: 600 mg to 1 g every 8 to 12 hours (maximum dose:…"}, {"doc_id": "bacitracin-and-polymyxin-b-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7007468938827515, "bge_max": 0.7007468938827515, "title": "Bacitracin and polymyxin B (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Bacitracin and polymyxin B (ophthalmic): Pediatric drug information\")  Conjunctivitis: Infants, Children, and Adolescents: Ophthalmic: Apply to affected eye(s) 4 times…"}, {"doc_id": "fluorometholone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7006348371505737, "bge_max": 0.7006348371505737, "title": "Fluorometholone: Drug information", "rep_snippet": "Dosing: Adult  Ocular inflammation: Ophthalmic:  Ointment: Apply small amount (~1/2 inch ribbon) to conjunctival sac 1 to 3 times daily; may increase application to every 4 hours during the initial 24 to 48 hours  Suspen…"}, {"doc_id": "bacitracin-neomycin-and-polymyxin-b-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7000536918640137, "bge_max": 0.7000536918640137, "title": "Bacitracin, neomycin, and polymyxin B (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Bacitracin, neomycin, and polymyxin B (ophthalmic): Pediatric drug information\")  Conjunctivitis (off-label): Limited data available: Children and Adolescents: Ophthalm…"}, {"doc_id": "povidone-iodine-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6988885998725891, "bge_max": 0.6988885998725891, "title": "Povidone iodine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Antiseptic: Ophthalmic solution:  Eyelids: Apply to area with a sterile cotton-tipped applicator; repeat once  Periocular region: Apply in a circular expanding pattern until the entire field is covered; re…"}, {"doc_id": "rimexolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.69869464635849, "bge_max": 0.69869464635849, "title": "Rimexolone: Drug information", "rep_snippet": "• Contact lens wearers: Some preparations contain benzalkonium chloride which may be adsorbed by contact lenses.  Other warnings/precautions:  • Appropriate use: Patients should be re-evaluated if symptoms fail to improv…"}, {"doc_id": "erythromycin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6986488103866577, "bge_max": 0.6986488103866577, "title": "Erythromycin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular infections, superficial: Ophthalmic: Instill ~1 cm ribbon into affected eye(s) up to 6 times daily, depending on the severity of the infection"}]}
{"qid": "Q28_noise", "query": "Pink eye (bacterial) — how to use ofloxacin drops and what if pt wears contacts?", "base_qid": "Q28", "variant_type": "noise", "candidates": [{"doc_id": "naphazoline-and-antazoline-ophthalmic-united-states-not-available-drug-information", "bm25_top3": 25.967125131712553, "bm25_max": 31.420424907683028, "bge_top3": 0.5910229086875916, "bge_max": 0.5910229086875916, "title": "Naphazoline and antazoline (ophthalmic) (United States: Not available): Drug information", "rep_snippet": "Administration  Ophthalmic: Wash hands before use. Do not touch tip of container to eye. Remove contact lenses prior to administration. After instilling drops, wait before inserting contact lenses. Do not insert contacts…"}, {"doc_id": "ofloxacin-ophthalmic-drug-information", "bm25_top3": 24.28906100560471, "bm25_max": 27.108239928877445, "bge_top3": 0.5942293405532837, "bge_max": 0.5942293405532837, "title": "Ofloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic: Instill 1 to 2 drops in affected eye(s) every 2 to 4 hours for the first 2 days, then instill 1 to 2 drops 4 times daily for an additional 5 days.  Corneal ulcer: Opht…"}, {"doc_id": "tetrahydrozoline-ophthalmic-drug-information", "bm25_top3": 23.311706270639558, "bm25_max": 24.684422441327726, "bge_top3": 0.6003879904747009, "bge_max": 0.6152878403663635, "title": "Tetrahydrozoline (ophthalmic): Drug information", "rep_snippet": "• Self-medication (OTC use): For ophthalmic use only. When used for self-medication, discontinue and contact a health care provider if eye pain, vision changes, continued redness, or eye irritation occurs or if condition…"}, {"doc_id": "framycetin-gramicidin-and-dexamethasone-united-states-not-available-drug-information", "bm25_top3": 22.707005074817282, "bm25_max": 24.46186033668252, "bge_top3": 0.602034330368042, "bge_max": 0.6050612926483154, "title": "Framycetin, gramicidin, and dexamethasone (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Ophthalmic infections/inflammation: Ophthalmic:  Drops: Acute conditions: 1 or 2 drops in affected eye(s) every 1 to 2 hours usually for 2 or 3 days, then follow with 1 or 2 drops 3 to 4 times daily.  Oint…"}, {"doc_id": "azelastine-ophthalmic-drug-information", "bm25_top3": 24.43090014507255, "bm25_max": 24.43090014507255, "bge_top3": 0.6046107411384583, "bge_max": 0.6046107411384583, "title": "Azelastine (ophthalmic): Drug information", "rep_snippet": "Administration  For topical ophthalmic use only. Wash hands prior to use. Do not touch tip of container to any surface, the eyelids, or surrounding areas. After instilling drops, wait at least 10 minutes before inserting…"}, {"doc_id": "neomycin-polymyxin-b-and-dexamethasone-drug-information", "bm25_top3": 22.69161185273295, "bm25_max": 22.69161185273295, "bge_top3": 0.6156362096468607, "bge_max": 0.6227543354034424, "title": "Neomycin, polymyxin B, and dexamethasone: Drug information", "rep_snippet": "Dosing: Adult  Inflammatory ocular conditions: Ophthalmic:  Suspension: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 to 6 times daily. In severe disease, drops may be used hourly; frequency sho…"}, {"doc_id": "naphazoline-and-pheniramine-drug-information", "bm25_top3": 20.70179904564396, "bm25_max": 22.619440765536368, "bge_top3": 0.5874088406562805, "bge_max": 0.5909994840621948, "title": "Naphazoline and pheniramine: Drug information", "rep_snippet": "• Appropriate use: For ophthalmic use only. Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis; avoid contamination.  • Self-medication (OTC use): When used for self-medicatio…"}, {"doc_id": "naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-drug-information", "bm25_top3": 22.501288896395195, "bm25_max": 22.501288896395195, "bge_top3": null, "bge_max": null, "title": "Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Drug information", "rep_snippet": "Dosing: Adult  Decrease in eye redness (vasoconstrictor): Ophthalmic:  Rx: 0.1% solution: 1 to 2 drops into conjunctival sac every 3 to 4 hours as needed  OTC: 0.012% or 0.03% solution: 1 to 2 drops into affected eye(s)…"}, {"doc_id": "ketotifen-ophthalmic-drug-information", "bm25_top3": 22.43313945821237, "bm25_max": 22.43313945821237, "bge_top3": 0.599750816822052, "bge_max": 0.5999240279197693, "title": "Ketotifen (ophthalmic): Drug information", "rep_snippet": "Administration  Ophthalmic: For use in eyes only. Wash hands before use. Do not let tip of applicator touch eye; do not contaminate tip of applicator. Remove soft contact lenses prior to administration. Wait 10 minutes b…"}, {"doc_id": "neomycin-polymyxin-b-and-gramicidin-drug-information", "bm25_top3": 21.649424373869387, "bm25_max": 21.649424373869387, "bge_top3": null, "bge_max": null, "title": "Neomycin, polymyxin B, and gramicidin: Drug information", "rep_snippet": "Dosing: Adult  Superficial ocular infections: Ophthalmic: Instill 1-2 drops into affected eye(s) every 4 hours or 2 drops per hour for severe infections for 7 to 10 days"}, {"doc_id": "latanoprost-drug-information", "bm25_top3": 21.36811918671551, "bm25_max": 21.36811918671551, "bge_top3": 0.5886957049369812, "bge_max": 0.5886957049369812, "title": "Latanoprost: Drug information", "rep_snippet": "Administration  Ophthalmic: May be used with other eye drops to lower IOP. If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. Remove contact lenses prior to administrat…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": 20.875338287435476, "bm25_max": 20.875338287435476, "bge_top3": null, "bge_max": null, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "Mechanism of Action  Ofloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA re…"}, {"doc_id": "neomycin-polymyxin-b-and-hydrocortisone-ophthalmic-drug-information", "bm25_top3": 20.795594776195543, "bm25_max": 20.795594776195543, "bge_top3": null, "bge_max": null, "title": "Neomycin, polymyxin B, and hydrocortisone (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular inflammatory conditions: Ophthalmic: Instill 1 to 2 drops into affected eye(s) every 3 to 4 hours, or more frequently as required for severe infections Reevaluate patient if improvement not observed…"}, {"doc_id": "framycetin-united-states-not-available-drug-information", "bm25_top3": 20.263223125471463, "bm25_max": 20.756350936415952, "bge_top3": null, "bge_max": null, "title": "Framycetin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Ophthalmic infections/conditions: Ophthalmic: Instill 1 to 2 drops in affected eye(s) 3 to 4 times daily; to obtain rapid relief in acute conditions, instill 1 to 2 drops every 1 to 2 hours (generally for…"}, {"doc_id": "loteprednol-drug-information", "bm25_top3": 15.481587529468634, "bm25_max": 20.597674404821845, "bge_top3": 0.5945264399051666, "bge_max": 0.604850172996521, "title": "Loteprednol: Drug information", "rep_snippet": "Administration  For topical ophthalmic use only; to avoid contamination, do not touch dropper or tube tip to eyelids or other surfaces. Remove contacts prior to administration; when used for the treatment of seasonal all…"}, {"doc_id": "olopatadine-ophthalmic-drug-information", "bm25_top3": 20.03952538152337, "bm25_max": 20.03952538152337, "bge_top3": 0.6067672371864319, "bge_max": 0.6067672371864319, "title": "Olopatadine (ophthalmic): Drug information", "rep_snippet": "Administration  For topical ophthalmic use only. Wash hands prior to use. Do not touch tip of container to eye. After instilling drops, wait at least 5 to 10 minutes before inserting contact lenses. Do not insert contact…"}, {"doc_id": "artificial-tears-drug-information", "bm25_top3": 19.107847895162532, "bm25_max": 19.107847895162532, "bge_top3": null, "bge_max": null, "title": "Artificial tears: Drug information", "rep_snippet": "Dosing: Adult  Ocular dryness/irritation: Ophthalmic: 1-2 drops into eye(s) as needed to relieve symptoms"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 15.078940720563718, "bm25_max": 15.078940720563718, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Bacterial infections (Mifeprex)  Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following mifepristone use…"}, {"doc_id": "ciprofloxacin-ophthalmic-drug-information", "bm25_top3": 14.701556845841537, "bm25_max": 14.701556845841537, "bge_top3": 0.6174818277359009, "bge_max": 0.6174818277359009, "title": "Ciprofloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic:  Solution: Instill 1 to 2 drops into the conjunctival sac every 2 hours while awake for 2 days and 1 to 2 drops every 4 hours while awake for the next 5 days  Ointment…"}, {"doc_id": "nepafenac-drug-information", "bm25_top3": 13.881976505836665, "bm25_max": 13.881976505836665, "bge_top3": 0.6026700735092163, "bge_max": 0.6026700735092163, "title": "Nepafenac: Drug information", "rep_snippet": "Administration  Ophthalmic: For topical ophthalmic use only; shake well prior to use. Remove contact lenses prior to using solutions containing benzalkonium chloride. To avoid contamination, do not touch tip of container…"}, {"doc_id": "cetirizine-ophthalmic-drug-information", "bm25_top3": 12.900174496950306, "bm25_max": 12.900174496950306, "bge_top3": 0.59601891040802, "bge_max": 0.59601891040802, "title": "Cetirizine (ophthalmic): Drug information", "rep_snippet": "Administration  For topical ophthalmic use only. Wash hands before use. Do not touch dropper tip to eyelids, surrounding areas, or any surface. Remove contact lenses prior to administration. After instilling drops, wait…"}, {"doc_id": "ketorolac-ophthalmic-drug-information", "bm25_top3": 12.787650452965895, "bm25_max": 12.787650452965895, "bge_top3": 0.590883195400238, "bge_max": 0.590883195400238, "title": "Ketorolac (ophthalmic): Drug information", "rep_snippet": "Administration  For topical ophthalmic use only. Remove contact lenses prior to administration and wait 10 minutes before reinserting. May be used with other eye drops. If using more than 1 ophthalmic product, wait at le…"}, {"doc_id": "bromfenac-drug-information", "bm25_top3": 12.739958973145477, "bm25_max": 12.739958973145477, "bge_top3": 0.5923635363578796, "bge_max": 0.5923635363578796, "title": "Bromfenac: Drug information", "rep_snippet": "Administration  For topical ophthalmic use only; wash hands prior to use. Remove contact lenses prior to administration and wait 10 minutes before reinserting. May be used with other eye drops. If using more than 1 ophth…"}, {"doc_id": "homatropine-drug-information", "bm25_top3": 12.698397610633311, "bm25_max": 12.698397610633311, "bge_top3": null, "bge_max": null, "title": "Homatropine: Drug information", "rep_snippet": "Dosing: Adult  Note: Patients with heavily pigmented irides may require increased dose.  Refraction: Ophthalmic: 2% or 5% solution: 1 to 2 drops into the affected eye(s); may repeat in 5 to 10 minutes if necessary  Uveit…"}, {"doc_id": "bimatoprost-drug-information", "bm25_top3": 12.518919397038623, "bm25_max": 12.518919397038623, "bge_top3": null, "bge_max": null, "title": "Bimatoprost: Drug information", "rep_snippet": "Administration  Latisse: Remove make-up and contact lenses prior to application; ensure face is clean. Apply with the sterile applicator provided only; do not use other brushes or applicators. Use a tissue or cloth to bl…"}, {"doc_id": "tropicamide-drug-information", "bm25_top3": 11.747826903397119, "bm25_max": 11.747826903397119, "bge_top3": 0.586799681186676, "bge_max": 0.586799681186676, "title": "Tropicamide: Drug information", "rep_snippet": "Dosing: Adult  Note: Individuals with heavily pigmented eyes may require higher strength or additional doses:  Cycloplegia: Ophthalmic: Instill 1 to 2 drops (1%) in the eye(s); repeat in 5 minutes. If the patient is not…"}, {"doc_id": "alcaftadine-drug-information", "bm25_top3": 11.70111437126856, "bm25_max": 11.70111437126856, "bge_top3": null, "bge_max": null, "title": "Alcaftadine: Drug information", "rep_snippet": "Administration  For topical ophthalmic use only. Contact lenses should be removed prior to application, and may be reinserted 10 minutes after administration. Separate administration of other ophthalmic agents by 5 minut…"}, {"doc_id": "latanoprostene-bunod-drug-information", "bm25_top3": 10.827393306673468, "bm25_max": 10.827393306673468, "bge_top3": null, "bge_max": null, "title": "Latanoprostene bunod: Drug information", "rep_snippet": "Administration  To avoid contamination, do not allow tip of dropper to contact the eye, fingers, or other surfaces. May be used with other eye drops to lower IOP. If more than one topical ophthalmic drug is being used, a…"}, {"doc_id": "phenylephrine-ophthalmic-drug-information", "bm25_top3": 10.632108439948649, "bm25_max": 10.632108439948649, "bge_top3": 0.5927711725234985, "bge_max": 0.5927711725234985, "title": "Phenylephrine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Mydriasis: Ophthalmic: 2.5% or 10% solution: Instill 1 drop every 3 to 5 minutes as needed (maximum dose: 3 drops per eye). If necessary, dose may be repeated."}, {"doc_id": "proparacaine-drug-information", "bm25_top3": 10.204258093530445, "bm25_max": 10.204258093530445, "bge_top3": 0.5924352407455444, "bge_max": 0.5924352407455444, "title": "Proparacaine: Drug information", "rep_snippet": "Dosing: Adult  Anesthesia, ocular:  Short corneal and conjunctival procedures: Ophthalmic: Instill 1 drop in eye(s) every 5 to 10 minutes for 5 to 7 doses  Tonometry, gonioscopy, suture removal: Ophthalmic: Instill 1 to…"}, {"doc_id": "epinastine-drug-information", "bm25_top3": 10.076363480188956, "bm25_max": 10.076363480188956, "bge_top3": null, "bge_max": null, "title": "Epinastine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.  Special populations:  • Contact lens wea…"}, {"doc_id": "trifluridine-drug-information", "bm25_top3": 9.952092415185337, "bm25_max": 9.952092415185337, "bge_top3": null, "bge_max": null, "title": "Trifluridine: Drug information", "rep_snippet": "Dosing: Adult  Herpes keratoconjunctivitis, keratitis: Ophthalmic: Instill 1 drop into affected eye(s) every 2 hours while awake, to a maximum of 9 drops/day, until re-epithelialization of corneal ulcer occurs; then use…"}, {"doc_id": "apraclonidine-drug-information", "bm25_top3": 9.837166468664222, "bm25_max": 9.837166468664222, "bge_top3": null, "bge_max": null, "title": "Apraclonidine: Drug information", "rep_snippet": "Dosing: Adult  Intraocular pressure reduction: Ophthalmic:  0.5%: Instill 1 to 2 drops in the affected eye(s) 3 times daily.  1%: Instill 1 drop in operative eye 1 hour prior to anterior segment laser surgery, second dro…"}, {"doc_id": "difluprednate-drug-information", "bm25_top3": 9.817713085978209, "bm25_max": 9.817713085978209, "bge_top3": null, "bge_max": null, "title": "Difluprednate: Drug information", "rep_snippet": "Administration  Ophthalmic: Wash hands prior to use and avoid touching tip of dropper. Remove contact lenses prior to use. Do not reinsert contact lenses within 10 minutes of difluprednate eye drops. The use of the same…"}, {"doc_id": "nedocromil-drug-information", "bm25_top3": 9.78415732575155, "bm25_max": 9.78415732575155, "bge_top3": null, "bge_max": null, "title": "Nedocromil: Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic: 1 to 2 drops in each eye twice daily throughout the period of exposure to allergen"}, {"doc_id": "lodoxamide-tromethamine-drug-information", "bm25_top3": 9.647882772089304, "bm25_max": 9.647882772089304, "bge_top3": null, "bge_max": null, "title": "Lodoxamide tromethamine: Drug information", "rep_snippet": "Dosing: Adult  Ocular disorders: Ophthalmic: Instill 1 to 2 drops in each affected eye 4 times daily for up to 3 months"}, {"doc_id": "riboflavin-5-phosphate-ophthalmic-drug-information", "bm25_top3": 9.549978289256323, "bm25_max": 9.549978289256323, "bge_top3": null, "bge_max": null, "title": "Riboflavin 5'-phosphate (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Corneal ectasia following refractive surgery; Keratoconus, progressive: Ophthalmic: Instill 1 drop every 2 minutes for 30 minutes following debridement of the epithelium to a diameter of ~9 mm. After 30 mi…"}, {"doc_id": "betaxolol-ophthalmic-drug-information", "bm25_top3": 8.196179999641362, "bm25_max": 8.196179999641362, "bge_top3": null, "bge_max": null, "title": "Betaxolol (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic:  Solution: Instill 1 to 2 drops into affected eye(s) twice daily.  Suspension (Betoptic S): Instill 1 drop into affected eye(s) twice daily."}, {"doc_id": "betamethasone-and-gentamicin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6142608225345612, "bge_max": 0.6289411187171936, "title": "Betamethasone and gentamicin (United States: Not available): Drug information", "rep_snippet": "Administration  For topical use only. The same bottle should not be used to treat ocular and otic infections, nor should it be used by more than one person.  Ophthalmic use: Contact lenses should not be worn during thera…"}, {"doc_id": "tobramycin-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6110544800758362, "bge_max": 0.6227742433547974, "title": "Tobramycin and dexamethasone: Drug information", "rep_snippet": "Administration  Contact lenses should not be worn during therapy. For topical ophthalmic use only; to avoid contamination, do not touch container tip to eyelids or other surfaces when placing drops or ointment in eyes.…"}, {"doc_id": "tobramycin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6058341860771179, "bge_max": 0.613828718662262, "title": "Tobramycin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular infections: Ophthalmic:  Ointment: Apply half-inch ribbon into affected eye(s) 2 or 3 times daily for mild to moderate infections; for severe infections, apply every 3 to 4 hours until improvement (…"}, {"doc_id": "prednisolone-and-gentamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6034122109413147, "bge_max": 0.6129262447357178, "title": "Prednisolone and gentamicin: Drug information", "rep_snippet": "Administration  Ophthalmic: Note: Contact lenses should not be worn during therapy. Do not touch the bottle or tube tip to eyelid(s) or any other surface.  Ointment: Apply into pocket between eyeball and lower lid; patie…"}, {"doc_id": "besifloxacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.611141562461853, "bge_max": 0.611141562461853, "title": "Besifloxacin: Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic: Instill 1 drop into affected eye(s) 3 times daily (4 to 12 hours apart) for 7 days"}, {"doc_id": "neomycin-polymyxin-b-and-hydrocortisone-otic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5931298136711121, "bge_max": 0.5984634160995483, "title": "Neomycin, polymyxin B, and hydrocortisone (otic): Drug information", "rep_snippet": "• Appropriate use: For otic use only; do not use in the eyes. If infection is not improved after 1 week, preform cultures and susceptibility tests. Avoid contaminating the bottle tip with material from the ear, fingers,…"}, {"doc_id": "neomycin-colistin-hydrocortisone-and-thonzonium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5984634160995483, "bge_max": 0.5984634160995483, "title": "Neomycin, colistin, hydrocortisone, and thonzonium: Drug information", "rep_snippet": "• Appropriate use: For otic use only; do not use in the eyes. If infection is not improved after 1 week, preform cultures and susceptibility tests. Avoid contaminating the bottle tip with material from the ear, fingers,…"}, {"doc_id": "moxifloxacin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5961614847183228, "bge_max": 0.5961614847183228, "title": "Moxifloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic:  Moxeza: Instill 1 drop into affected eye(s) 2 times daily for 7 days  Vigamox: Instill 1 drop into affected eye(s) 3 times daily for 7 days  Surgical prophylaxis (off…"}, {"doc_id": "sulfacetamide-and-prednisolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5951069593429565, "bge_max": 0.5951069593429565, "title": "Sulfacetamide and prednisolone: Drug information", "rep_snippet": "Administration  For topical ophthalmic use only; to avoid contamination, do not touch container tip to eyelids or other surfaces when placing drops or ointment in eyes. Do not apply with silver preparations. Discontinue…"}, {"doc_id": "cysteamine-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5926041603088379, "bge_max": 0.5926041603088379, "title": "Cysteamine (ophthalmic): Drug information", "rep_snippet": "Administration  For topical ophthalmic use only; to avoid contamination, do not touch dropper eyelids or other surfaces when placing drops in eyes. Contact lenses should be removed prior to administration and may be rein…"}, {"doc_id": "emedastine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5913859605789185, "bge_max": 0.5913859605789185, "title": "Emedastine: Drug information", "rep_snippet": "Administration  Ophthalmic: For topical ophthalmic use only, not for injection. Wash hands before use. To avoid contamination, do not touch dropper tip to eyelids or other surfaces when placing drops in eyes. Remove cont…"}, {"doc_id": "loteprednol-and-tobramycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.586814284324646, "bge_max": 0.5907837748527527, "title": "Loteprednol and tobramycin: Drug information", "rep_snippet": "Administration  Contact lenses should not be worn during therapy. Shake well before using; tilt head back, instill suspension in conjunctival sac and close eye(s). Do not touch dropper to eye. Apply light finger pressure…"}, {"doc_id": "travoprost-and-timolol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5907283425331116, "bge_max": 0.5907283425331116, "title": "Travoprost and timolol (United States: Not available): Drug information", "rep_snippet": "Administration  Ophthalmic: Wash hands prior to and following use. Remove contact lenses prior to administration; wait 15 minutes before reinserting. Tilt head back, pull down lower eyelid and instill drop into pocket be…"}, {"doc_id": "carteolol-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.587045431137085, "bge_max": 0.587045431137085, "title": "Carteolol (ophthalmic): Drug information", "rep_snippet": "Administration  For topical ophthalmic use only. Wash hands before use. To avoid contamination, do not touch dropper tip to eyelids or other surfaces when placing drops in eyes. Remove contact lenses prior to administrat…"}, {"doc_id": "gatifloxacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5863990783691406, "bge_max": 0.5863990783691406, "title": "Gatifloxacin: Drug information", "rep_snippet": "Bacterial keratitis (off-label use): Ophthalmic: Instill 1 drop into affected eye(s) every 1 hour around the clock until healing begins (usually 48 to 72 hours); dosing frequency is then gradually reduced until the ulcer…"}, {"doc_id": "flurandrenolide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5843039751052856, "bge_max": 0.5843039751052856, "title": "Flurandrenolide: Drug information", "rep_snippet": "• Appropriate use: Avoid contact with eyes; generally not for routine use on the face, underarms, or groin area (including diaper area). Avoid use with occlusive dressing (including tight-fitting diapers or plastic pants…"}, {"doc_id": "fusidic-acid-united-states-not-available-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5823352336883545, "bge_max": 0.5823352336883545, "title": "Fusidic acid (United States: Not available) (ophthalmic): Drug information", "rep_snippet": "Administration  Ophthalmic: For ophthalmic use only. Tilt head back, pull down lower eyelid and instill drop into eye. Wash hands before and after instillation; avoid touching tip of applicator to eye or other surfaces.…"}]}
{"qid": "Q28_spelling", "query": "Conjuctivitis — oflox eye drop regimen; lens advice.", "base_qid": "Q28", "variant_type": "spelling", "candidates": [{"doc_id": "azelastine-ophthalmic-drug-information", "bm25_top3": 27.65503120045794, "bm25_max": 27.65503120045794, "bge_top3": 0.7031702995300293, "bge_max": 0.7031702995300293, "title": "Azelastine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic: Instill 1 drop into affected eye(s) twice daily."}, {"doc_id": "ketotifen-ophthalmic-drug-information", "bm25_top3": 24.855005450903477, "bm25_max": 24.855005450903477, "bge_top3": 0.6775626540184021, "bge_max": 0.6775626540184021, "title": "Ketotifen (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: OTC labeling: Ophthalmic: Instill 1 drop into the affected eye(s) twice daily every 8 to 12 hours (maximum: do not exceed 2 applications/day)"}, {"doc_id": "pilocarpine-ophthalmic-drug-information", "bm25_top3": 21.147039641052334, "bm25_max": 21.97885274988214, "bge_top3": null, "bge_max": null, "title": "Pilocarpine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill one drop into the affected eye(s) up to 4 times daily; initiate pilocarpine-naive patients on the 1% concentration. Note: Strength of solution and frequen…"}, {"doc_id": "olopatadine-ophthalmic-drug-information", "bm25_top3": 17.73675191393717, "bm25_max": 17.73675191393717, "bge_top3": 0.6423353552818298, "bge_max": 0.6423353552818298, "title": "Olopatadine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic:  Pataday, Pazeo: Instill 1 drop into each affected eye once daily  Patanol: Instill 1 drop into each affected eye twice daily (allowing 6 to 8 hours between doses)"}, {"doc_id": "gatifloxacin-drug-information", "bm25_top3": 15.419368564665618, "bm25_max": 17.002497351205992, "bge_top3": 0.6578453183174133, "bge_max": 0.6578453183174133, "title": "Gatifloxacin: Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic:  Zymar [Canadian product]:  Days 1 and 2: Instill 1 drop into affected eye(s) every 2 hours while awake (maximum: 8 times/day).  Days 3 to 7: Instill 1 drop into affec…"}, {"doc_id": "alcaftadine-drug-information", "bm25_top3": 12.863840756361753, "bm25_max": 16.868674243763465, "bge_top3": 0.6986207962036133, "bge_max": 0.6986207962036133, "title": "Alcaftadine: Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic: Instill 1 drop into each eye once daily."}, {"doc_id": "bepotastine-ophthalmic-drug-information", "bm25_top3": 12.212553309294702, "bm25_max": 16.445178768280797, "bge_top3": 0.7001631855964661, "bge_max": 0.7001631855964661, "title": "Bepotastine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic: Instill 1 drop into the affected eye(s) twice daily"}, {"doc_id": "emedastine-drug-information", "bm25_top3": 16.239016950645812, "bm25_max": 16.239016950645812, "bge_top3": 0.7033154368400574, "bge_max": 0.7033154368400574, "title": "Emedastine: Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic: Instill 1 drop in affected eye up to 4 times daily"}, {"doc_id": "cetirizine-ophthalmic-drug-information", "bm25_top3": 16.036449237530704, "bm25_max": 16.036449237530704, "bge_top3": 0.6913120746612549, "bge_max": 0.6913120746612549, "title": "Cetirizine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic: Instill 1 drop in affected eye(s) twice daily (~8 hours apart)."}, {"doc_id": "besifloxacin-drug-information", "bm25_top3": 14.891517509660517, "bm25_max": 14.891517509660517, "bge_top3": 0.6915340423583984, "bge_max": 0.6915340423583984, "title": "Besifloxacin: Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic: Instill 1 drop into affected eye(s) 3 times daily (4 to 12 hours apart) for 7 days"}, {"doc_id": "epinastine-drug-information", "bm25_top3": 14.711669342100201, "bm25_max": 14.711669342100201, "bge_top3": 0.7003714442253113, "bge_max": 0.7003714442253113, "title": "Epinastine: Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic: Instill 1 drop into each eye twice daily. Continue throughout period of exposure, even in the absence of symptoms."}, {"doc_id": "ketorolac-ophthalmic-drug-information", "bm25_top3": 14.567683203713955, "bm25_max": 14.567683203713955, "bge_top3": null, "bge_max": null, "title": "Ketorolac (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Postoperative ocular inflammation following cataract extraction (0.5% solution): Ophthalmic: Instill 1 drop into affected eye(s) 4 times daily beginning 24 hours after surgery; continue for 2 weeks  Postop…"}, {"doc_id": "trimethoprim-and-polymyxin-b-drug-information", "bm25_top3": 13.825998986520126, "bm25_max": 13.825998986520126, "bge_top3": 0.6877517700195312, "bge_max": 0.6877517700195312, "title": "Trimethoprim and polymyxin B: Drug information", "rep_snippet": "Dosing: Adult  Conjunctivitis, blepharoconjunctivitis: Ophthalmic: Instill 1 drop in affected eye(s) every 3 hours (maximum: 6 doses per day) for 7-10 days; has also been used 4 times daily for 5-7 days (Williams, 2013;…"}, {"doc_id": "fusidic-acid-united-states-not-available-ophthalmic-drug-information", "bm25_top3": 10.373821166066731, "bm25_max": 13.530974276031799, "bge_top3": 0.6945010423660278, "bge_max": 0.6945010423660278, "title": "Fusidic acid (United States: Not available) (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ophthalmic infections/conjunctivitis: Ophthalmic: Instill 1 drop into the conjunctival sac of each eye every 12 hours for 7 days; reassess if infection has not resolved after 7 days"}, {"doc_id": "netarsudil-drug-information", "bm25_top3": 13.417148774548277, "bm25_max": 13.417148774548277, "bge_top3": null, "bge_max": null, "title": "Netarsudil: Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop into affected eye(s) once daily in the evening (maximum: 1 drop into affected eye(s) once daily)."}, {"doc_id": "brimonidine-ophthalmic-drug-information", "bm25_top3": 13.063665489789447, "bm25_max": 13.063665489789447, "bge_top3": null, "bge_max": null, "title": "Brimonidine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure:  US labeling: Ophthalmic: Instill 1 drop in affected eye(s) 3 times/day (approximately every 8 hours)  Canadian labeling: Ophthalmic:  Solution 0.15%: Instill 1 drop in affec…"}, {"doc_id": "apraclonidine-drug-information", "bm25_top3": 12.581354250910614, "bm25_max": 12.581354250910614, "bge_top3": null, "bge_max": null, "title": "Apraclonidine: Drug information", "rep_snippet": "Dosing: Adult  Intraocular pressure reduction: Ophthalmic:  0.5%: Instill 1 to 2 drops in the affected eye(s) 3 times daily.  1%: Instill 1 drop in operative eye 1 hour prior to anterior segment laser surgery, second dro…"}, {"doc_id": "moxifloxacin-ophthalmic-drug-information", "bm25_top3": 11.654839282125831, "bm25_max": 11.654839282125831, "bge_top3": 0.6570570468902588, "bge_max": 0.6570570468902588, "title": "Moxifloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic:  Moxeza: Instill 1 drop into affected eye(s) 2 times daily for 7 days  Vigamox: Instill 1 drop into affected eye(s) 3 times daily for 7 days  Surgical prophylaxis (off…"}, {"doc_id": "bromfenac-drug-information", "bm25_top3": 11.091073417596363, "bm25_max": 11.091073417596363, "bge_top3": null, "bge_max": null, "title": "Bromfenac: Drug information", "rep_snippet": "Dosing: Adult  Postoperative ocular inflammation/pain:  Ophthalmic (0.07%): Instill 1 drop into affected eye(s) once daily beginning 1 day prior to cataract surgery and continue on the day of surgery and for 14 days post…"}, {"doc_id": "atropine-ophthalmic-drug-information", "bm25_top3": 11.002170006423029, "bm25_max": 11.002170006423029, "bge_top3": 0.6772481203079224, "bge_max": 0.6772481203079224, "title": "Atropine (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atropine (ophthalmic): Pediatric drug information\")  Amblyopia, healthy eye penalization: Ophthalmic: Solution:  Infants ≥3 months and Children <3 years: Instill 1 drop…"}, {"doc_id": "brinzolamide-drug-information", "bm25_top3": 10.575867264811048, "bm25_max": 10.575867264811048, "bge_top3": null, "bge_max": null, "title": "Brinzolamide: Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop in affected eye(s) 3 times daily"}, {"doc_id": "dorzolamide-and-timolol-drug-information", "bm25_top3": 9.618931184579314, "bm25_max": 10.50607315853033, "bge_top3": null, "bge_max": null, "title": "Dorzolamide and timolol: Drug information", "rep_snippet": "Adverse Reactions  Frequency not always defined. Percentages as reported with combination product. Also see individual agents.  >5%:  Gastrointestinal: Dysgeusia (≤30%)  Ophthalmic: Burning sensation of eyes (≤30%), stin…"}, {"doc_id": "brinzolamide-and-brimonidine-drug-information", "bm25_top3": 10.422663570979736, "bm25_max": 10.422663570979736, "bge_top3": 0.6489925384521484, "bge_max": 0.6489925384521484, "title": "Brinzolamide and brimonidine: Drug information", "rep_snippet": "Dosing: Adult  Reduction of intraocular pressure: Ophthalmic: Instill 1 drop in affected eye(s) 3 times daily"}, {"doc_id": "dorzolamide-drug-information", "bm25_top3": 10.422663570979736, "bm25_max": 10.422663570979736, "bge_top3": null, "bge_max": null, "title": "Dorzolamide: Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop in the affected eye(s) 3 times daily"}, {"doc_id": "lifitegrast-drug-information", "bm25_top3": 10.380372356649964, "bm25_max": 10.380372356649964, "bge_top3": null, "bge_max": null, "title": "Lifitegrast: Drug information", "rep_snippet": "Dosing: Adult  Dry eye disease: Ophthalmic: Instill 1 drop into each eye every 12 hours."}, {"doc_id": "nepafenac-drug-information", "bm25_top3": 10.230309083860082, "bm25_max": 10.230309083860082, "bge_top3": null, "bge_max": null, "title": "Nepafenac: Drug information", "rep_snippet": "Dosing: Adult  Ocular pain and inflammation associated with cataract surgery: Ophthalmic:  0.1% suspension: Instill 1 drop into affected eye(s) 3 times daily, beginning 1 day prior to surgery, the day of surgery, and thr…"}, {"doc_id": "levobunolol-drug-information", "bm25_top3": 10.148503360806917, "bm25_max": 10.148503360806917, "bge_top3": null, "bge_max": null, "title": "Levobunolol: Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 to 2 drops into affected eye(s) once daily; may increase to 1 drop twice daily in patients with severe or uncontrolled glaucoma. Doses >1 drop twice dai…"}, {"doc_id": "difluprednate-drug-information", "bm25_top3": 9.601539494951108, "bm25_max": 9.601539494951108, "bge_top3": 0.6501380205154419, "bge_max": 0.6501380205154419, "title": "Difluprednate: Drug information", "rep_snippet": "Dosing: Adult  Endogenous anterior uveitis: Ophthalmic: Instill 1 drop into conjunctival sac of the affected eye(s) 4 times daily for 14 days, then taper as clinically indicated  Inflammation/pain associated with ocular…"}, {"doc_id": "loteprednol-drug-information", "bm25_top3": 9.496407399595043, "bm25_max": 9.496407399595043, "bge_top3": 0.6584571599960327, "bge_max": 0.6584571599960327, "title": "Loteprednol: Drug information", "rep_snippet": "Dosing: Adult  Seasonal allergic conjunctivitis: Ophthalmic: 0.2% suspension: Instill 1 drop into affected eye(s) 4 times daily.  Steroid-responsive inflammatory conditions: Ophthalmic: 0.5% suspension: Instill 1 to 2 dr…"}, {"doc_id": "proparacaine-drug-information", "bm25_top3": 9.119981967690386, "bm25_max": 9.119981967690386, "bge_top3": null, "bge_max": null, "title": "Proparacaine: Drug information", "rep_snippet": "Dosing: Adult  Anesthesia, ocular:  Short corneal and conjunctival procedures: Ophthalmic: Instill 1 drop in eye(s) every 5 to 10 minutes for 5 to 7 doses  Tonometry, gonioscopy, suture removal: Ophthalmic: Instill 1 to…"}, {"doc_id": "proparacaine-and-fluorescein-drug-information", "bm25_top3": 8.836981582815408, "bm25_max": 8.836981582815408, "bge_top3": null, "bge_max": null, "title": "Proparacaine and fluorescein: Drug information", "rep_snippet": "Dosing: Adult  Short corneal and conjunctival surgical procedures requiring deep ophthalmic anesthesia: Ophthalmic: Instill 1 drop in each eye every 5-10 minutes for 5-7 doses  Tonometry, gonioscopy, foreign body or sutu…"}, {"doc_id": "cysteamine-ophthalmic-drug-information", "bm25_top3": 8.731789210628296, "bm25_max": 8.731789210628296, "bge_top3": null, "bge_max": null, "title": "Cysteamine (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular cystinosis: Ophthalmic: Instill 1 drop in each eye every hour while awake"}, {"doc_id": "latanoprost-and-timolol-united-states-not-available-drug-information", "bm25_top3": 8.731789210628296, "bm25_max": 8.731789210628296, "bge_top3": null, "bge_max": null, "title": "Latanoprost and timolol (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop into affected eye(s) once daily"}, {"doc_id": "brimonidine-and-timolol-drug-information", "bm25_top3": 8.731789210628296, "bm25_max": 8.731789210628296, "bge_top3": null, "bge_max": null, "title": "Brimonidine and timolol: Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop into affected eye(s) twice daily"}, {"doc_id": "carteolol-ophthalmic-drug-information", "bm25_top3": 8.731789210628296, "bm25_max": 8.731789210628296, "bge_top3": null, "bge_max": null, "title": "Carteolol (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop in affected eye(s) twice daily"}, {"doc_id": "metipranolol-drug-information", "bm25_top3": 8.575867264811048, "bm25_max": 8.575867264811048, "bge_top3": null, "bge_max": null, "title": "Metipranolol: Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop in the affected eye(s) twice daily"}, {"doc_id": "brinzolamide-and-timolol-united-states-not-available-drug-information", "bm25_top3": 8.575867264811048, "bm25_max": 8.575867264811048, "bge_top3": null, "bge_max": null, "title": "Brinzolamide and timolol (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Elevation of intraocular pressure: Ophthalmic: Instill 1 drop in affected eye(s) twice daily."}, {"doc_id": "betaxolol-ophthalmic-drug-information", "bm25_top3": 7.75234941228627, "bm25_max": 8.47895266906631, "bge_top3": null, "bge_max": null, "title": "Betaxolol (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic:  Solution: Instill 1 to 2 drops into affected eye(s) twice daily.  Suspension (Betoptic S): Instill 1 drop into affected eye(s) twice daily."}, {"doc_id": "cyclopentolate-and-phenylephrine-drug-information", "bm25_top3": 8.422663570979736, "bm25_max": 8.422663570979736, "bge_top3": null, "bge_max": null, "title": "Cyclopentolate and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Diagnostic aid (mydriasis): Ophthalmic: Instill 1 drop into the eye every 5 to 10 minutes."}, {"doc_id": "unoprostone-drug-information", "bm25_top3": 8.272107660764192, "bm25_max": 8.272107660764192, "bge_top3": 0.654112696647644, "bge_max": 0.654112696647644, "title": "Unoprostone: Drug information", "rep_snippet": "Dosing: Adult  Open-angle glaucoma or ocular hypertension: Ophthalmic: Instill 1 drop into affected eye(s) twice daily"}, {"doc_id": "travoprost-and-timolol-united-states-not-available-drug-information", "bm25_top3": 7.978669289674542, "bm25_max": 7.978669289674542, "bge_top3": null, "bge_max": null, "title": "Travoprost and timolol (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop into affected eye(s) once daily in the morning or evening"}, {"doc_id": "travoprost-drug-information", "bm25_top3": 6.772818978980265, "bm25_max": 6.772818978980265, "bge_top3": 0.6417851448059082, "bge_max": 0.6417851448059082, "title": "Travoprost: Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop into affected eye(s) once daily in the evening; do not exceed once-daily dosing (may decrease IOP-lowering effect)."}, {"doc_id": "neomycin-polymyxin-b-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6723017394542694, "bge_max": 0.6980140805244446, "title": "Neomycin, polymyxin B, and dexamethasone: Drug information", "rep_snippet": "Dosing: Adult  Inflammatory ocular conditions: Ophthalmic:  Suspension: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 to 6 times daily. In severe disease, drops may be used hourly; frequency sho…"}, {"doc_id": "nedocromil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6963351964950562, "bge_max": 0.6963351964950562, "title": "Nedocromil: Drug information", "rep_snippet": "Dosing: Adult  Allergic conjunctivitis: Ophthalmic: 1 to 2 drops in each eye twice daily throughout the period of exposure to allergen"}, {"doc_id": "cromolyn-sodium-cromoglicate-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6962409615516663, "bge_max": 0.6962409615516663, "title": "Cromolyn (sodium cromoglicate) (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Conjunctivitis and keratitis: Ophthalmic: Instill 1 to 2 drops in each eye 4 to 6 times daily. Symptomatic response is often evident within a few days; continue therapy as long as required."}, {"doc_id": "sulfacetamide-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6872670650482178, "bge_max": 0.6872670650482178, "title": "Sulfacetamide (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Conjunctivitis, other superficial ocular infections: Note: Taper dose by increasing dosage time interval as condition responds; usual duration of treatment: 7 to 10 days:  Ophthalmic solution: Instill 1 to…"}, {"doc_id": "naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6858600378036499, "bge_max": 0.6858600378036499, "title": "Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Drug information", "rep_snippet": "Dosing: Adult  Decrease in eye redness (vasoconstrictor): Ophthalmic:  Rx: 0.1% solution: 1 to 2 drops into conjunctival sac every 3 to 4 hours as needed  OTC: 0.012% or 0.03% solution: 1 to 2 drops into affected eye(s)…"}, {"doc_id": "prednisolone-and-gentamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6855390071868896, "bge_max": 0.6855390071868896, "title": "Prednisolone and gentamicin: Drug information", "rep_snippet": "Dosing: Adult  Inflammatory conditions and superficial ocular infections: Ophthalmic:  Ointment: Apply 1/2 inch ribbon into the conjunctival sac of the affected eye(s) 1 to 3 times per day  Suspension: Instill 1 drop int…"}, {"doc_id": "ciprofloxacin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.684200644493103, "bge_max": 0.684200644493103, "title": "Ciprofloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic:  Solution: Instill 1 to 2 drops into the conjunctival sac every 2 hours while awake for 2 days and 1 to 2 drops every 4 hours while awake for the next 5 days  Ointment…"}, {"doc_id": "tetrahydrozoline-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6822781562805176, "bge_max": 0.6822781562805176, "title": "Tetrahydrozoline (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular decongestant: Ophthalmic: Instill 1 to 2 drops in the affected eye(s) up to 4 times daily"}, {"doc_id": "rimexolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6789261102676392, "bge_max": 0.6789261102676392, "title": "Rimexolone: Drug information", "rep_snippet": "Dosing: Adult  Note: Vexol has been discontinued in the United States for more than 1 year.  Anterior uveitis: Ophthalmic: Instill 1 to 2 drops in conjunctival sac of affected eye every hour during waking hours for the f…"}, {"doc_id": "tobramycin-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6618798971176147, "bge_max": 0.6764003038406372, "title": "Tobramycin and dexamethasone: Drug information", "rep_snippet": "Dosing: Adult  Ocular inflammatory conditions: Ophthalmic:  Ointment: Apply ~1/2-inch ribbon in the conjunctival sac of the affected eye(s) up to 3 to 4 times daily  Suspension:  TobraDex: Instill 1 to 2 drops into the c…"}, {"doc_id": "ofloxacin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.672531008720398, "bge_max": 0.672531008720398, "title": "Ofloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic: Instill 1 to 2 drops in affected eye(s) every 2 to 4 hours for the first 2 days, then instill 1 to 2 drops 4 times daily for an additional 5 days.  Corneal ulcer: Opht…"}, {"doc_id": "hydroxyamphetamine-and-tropicamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6698252558708191, "bge_max": 0.6698252558708191, "title": "Hydroxyamphetamine and tropicamide: Drug information", "rep_snippet": "Dosing: Adult  Mydriasis: Ophthalmic: Instill 1 to 2 drops into conjunctival sac(s)"}, {"doc_id": "fluorometholone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6691964268684387, "bge_max": 0.6691964268684387, "title": "Fluorometholone: Drug information", "rep_snippet": "Dosing: Adult  Ocular inflammation: Ophthalmic:  Ointment: Apply small amount (~1/2 inch ribbon) to conjunctival sac 1 to 3 times daily; may increase application to every 4 hours during the initial 24 to 48 hours  Suspen…"}, {"doc_id": "cyclopentolate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6640872955322266, "bge_max": 0.6640872955322266, "title": "Cyclopentolate: Drug information", "rep_snippet": "Dosing: Adult  Mydriasis, cycloplegia: Ophthalmic: Instill 1 or 2 drops of 0.5%, 1%, or 2% solution; may repeat in 5 to 10 minutes; heavily pigmented irides may require use of higher strengths.  Anterior uveitis (off-lab…"}, {"doc_id": "sulfacetamide-and-prednisolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.653496116399765, "bge_max": 0.6639600396156311, "title": "Sulfacetamide and prednisolone: Drug information", "rep_snippet": "Dosing: Adult  Inflammatory ocular conditions: Ophthalmic:  Ointment: Apply ~1/2 inch ribbon to lower conjunctival sac 3 to 4 times daily and 1 to 2 times at night  Solution: Instill 2 drops every 4 hours  Suspension: In…"}, {"doc_id": "hydroxypropyl-methylcellulose-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6573867797851562, "bge_max": 0.6573867797851562, "title": "Hydroxypropyl methylcellulose: Drug information", "rep_snippet": "Dosing: Adult  Dry eyes: Ophthalmic: Instill 1-2 drops in affected eye(s) as needed"}, {"doc_id": "tobramycin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6565622687339783, "bge_max": 0.6565622687339783, "title": "Tobramycin (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular infections: Ophthalmic:  Ointment: Apply half-inch ribbon into affected eye(s) 2 or 3 times daily for mild to moderate infections; for severe infections, apply every 3 to 4 hours until improvement (…"}, {"doc_id": "phenylephrine-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6526746153831482, "bge_max": 0.6526746153831482, "title": "Phenylephrine (ophthalmic): Drug information", "rep_snippet": "Administration  Ophthalmic: Wash hands before and after application. For topical ophthalmic use only; to avoid contamination, do not touch dropper tip to eyelids or other surfaces when placing drops in eyes. Solution sho…"}, {"doc_id": "carboxymethylcellulose-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6522723436355591, "bge_max": 0.6522723436355591, "title": "Carboxymethylcellulose: Drug information", "rep_snippet": "Dosing: Adult  Dry eyes: Ophthalmic: Instill 1-2 drops into eye(s) 3-4 times/day"}, {"doc_id": "trifluridine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6517602801322937, "bge_max": 0.6517602801322937, "title": "Trifluridine: Drug information", "rep_snippet": "Dosing: Adult  Herpes keratoconjunctivitis, keratitis: Ophthalmic: Instill 1 drop into affected eye(s) every 2 hours while awake, to a maximum of 9 drops/day, until re-epithelialization of corneal ulcer occurs; then use…"}, {"doc_id": "naphazoline-and-pheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.651688814163208, "bge_max": 0.651688814163208, "title": "Naphazoline and pheniramine: Drug information", "rep_snippet": "Dosing: Adult  Ocular itching/redness: Ophthalmic: Instill 1 to 2 drops into the affected eye(s) up to 4 times daily"}, {"doc_id": "lodoxamide-tromethamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6514558792114258, "bge_max": 0.6514558792114258, "title": "Lodoxamide tromethamine: Drug information", "rep_snippet": "Dosing: Adult  Ocular disorders: Ophthalmic: Instill 1 to 2 drops in each affected eye 4 times daily for up to 3 months"}, {"doc_id": "natamycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6511732339859009, "bge_max": 0.6511732339859009, "title": "Natamycin: Drug information", "rep_snippet": "Dosing: Adult  Fungal keratitis: Ophthalmic: Instill 1 drop in conjunctival sac every 1 to 2 hours, after 3 to 4 days reduce to one drop 6 to 8 times daily; usual course of therapy is 2 to 3 weeks or until resolution of…"}, {"doc_id": "artificial-tears-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6492006182670593, "bge_max": 0.6492006182670593, "title": "Artificial tears: Drug information", "rep_snippet": "Dosing: Adult  Ocular dryness/irritation: Ophthalmic: 1-2 drops into eye(s) as needed to relieve symptoms"}, {"doc_id": "latanoprost-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6458063125610352, "bge_max": 0.6458063125610352, "title": "Latanoprost: Drug information", "rep_snippet": "Administration  Ophthalmic: May be used with other eye drops to lower IOP. If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. Remove contact lenses prior to administrat…"}, {"doc_id": "neomycin-polymyxin-b-and-hydrocortisone-otic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6426295638084412, "bge_max": 0.6426295638084412, "title": "Neomycin, polymyxin B, and hydrocortisone (otic): Drug information", "rep_snippet": "Dosing: Adult  Note: Duration of use should be limited to 10 days unless otherwise directed by the health care provider.  Otic infections: Otic: Instill 4 drops 3 to 4 times daily; otic suspension is the preferred otic p…"}, {"doc_id": "latanoprostene-bunod-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6416028141975403, "bge_max": 0.6416028141975403, "title": "Latanoprostene bunod: Drug information", "rep_snippet": "Dosing: Adult  Elevated intraocular pressure: Ophthalmic: Instill 1 drop into affected eye(s) once daily in the evening; do not exceed the once daily dosage (may decrease the IOP-lowering effect)"}, {"doc_id": "framycetin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6408579349517822, "bge_max": 0.6408579349517822, "title": "Framycetin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Ophthalmic infections/conditions: Ophthalmic: Instill 1 to 2 drops in affected eye(s) 3 to 4 times daily; to obtain rapid relief in acute conditions, instill 1 to 2 drops every 1 to 2 hours (generally for…"}]}
{"qid": "Q29_abbr+monitor-cue", "query": "CKD stage 3 — spironolactone start dose and K+ monitoring frequency; hyperK risk.", "base_qid": "Q29", "variant_type": "abbr+monitor-cue", "candidates": [{"doc_id": "paricalcitol-drug-information", "bm25_top3": 20.54950390316809, "bm25_max": 23.698966444393633, "bge_top3": 0.6492336392402649, "bge_max": 0.6492336392402649, "title": "Paricalcitol: Drug information", "rep_snippet": "Dosing: Adult  Note: In stage 3 to 5 CKD maintain Ca x P <55 mg2/dL2, reduce or interrupt dosing if recommended calcium phosphorus product (Ca x P) is exceeded or hypercalcemia is observed (K/DOQI Clinical Practice Guide…"}, {"doc_id": "etelcalcetide-drug-information", "bm25_top3": 21.438475168161524, "bm25_max": 21.438475168161524, "bge_top3": null, "bge_max": null, "title": "Etelcalcetide: Drug information", "rep_snippet": "Reference Range  Target goals of PTH, calcium, and phosphorus in adult CKD patients on hemodialysis (ie, CKD stage 5), per clinical practice guidelines:  Corrected serum calcium: CKD stage 5: 8.4 to 9.5 mg/dL (2.1 to 2.3…"}, {"doc_id": "lanthanum-carbonate-drug-information", "bm25_top3": 19.72584514735759, "bm25_max": 21.17602342048997, "bge_top3": 0.6487374305725098, "bge_max": 0.6487374305725098, "title": "Lanthanum carbonate: Drug information", "rep_snippet": "Reference Range  Corrected total serum calcium (K/DOQI 2003): CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stage 5 and 5D (KDIGO 2009)  Phosphorus (K/DOQI 200…"}, {"doc_id": "doxercalciferol-drug-information", "bm25_top3": 18.445037453434196, "bm25_max": 19.686297818034742, "bge_top3": null, "bge_max": null, "title": "Doxercalciferol: Drug information", "rep_snippet": "iPTH level >70 pg/mL with stage 3 disease or >110 pg/mL with stage 4 disease (dose should be titrated to lower iPTH to 35 to 70 pg/mL with stage 3 disease or to 70 to 110 pg/mL with stage 4 disease): Increase dose by 0.5…"}, {"doc_id": "alfacalcidol-united-states-not-available-drug-information", "bm25_top3": 19.088443604399075, "bm25_max": 19.35718958390354, "bge_top3": 0.6585269570350647, "bge_max": 0.6585269570350647, "title": "Alfacalcidol (United States: Not available): Drug information", "rep_snippet": "Reference Range  Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for a…"}, {"doc_id": "sevelamer-drug-information", "bm25_top3": 16.10957496938087, "bm25_max": 19.19160673935668, "bge_top3": 0.6541111469268799, "bge_max": 0.6541111469268799, "title": "Sevelamer: Drug information", "rep_snippet": "Monitoring Parameters  Serum chemistries, including bicarbonate and chloride  Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progress…"}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": 19.113532992169873, "bm25_max": 19.113532992169873, "bge_top3": null, "bge_max": null, "title": "Hydrocodone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hysingla ER, Vantrela ER:  Mild impairment: No dosage adjustment necessary.  Moderate to severe impairment: Initial: Start with 50% of the initial dose; titrate carefully; monitor closely.  End-…"}, {"doc_id": "calcifediol-drug-information", "bm25_top3": 14.263350894313078, "bm25_max": 18.67911160838335, "bge_top3": null, "bge_max": null, "title": "Calcifediol: Drug information", "rep_snippet": "Reference Range  Corrected total serum calcium (K/DOQI 2003): CKD stages 3 and 4: 8.4 to 10.2 mg/dL (2.1 to 2.6 mmol/L); CKD stage 5: 8.4 to 9.5 mg/dL (2.1 to 2.37 mmol/L); KDIGO guidelines recommend maintaining normal r…"}, {"doc_id": "deferoxamine-drug-information", "bm25_top3": 17.44918477139639, "bm25_max": 18.634848924274213, "bge_top3": null, "bge_max": null, "title": "Deferoxamine: Drug information", "rep_snippet": "Diagnosis of aluminum-induced toxicity with CKD (off-label use) (K/DOQI guidelines 2003): IV: Test dose: 5 mg/kg during the last hour of dialysis if baseline serum aluminum concentrations are 60 to 200 mcg/L, or clinical…"}, {"doc_id": "cinacalcet-drug-information", "bm25_top3": 18.491941248811, "bm25_max": 18.491941248811, "bge_top3": null, "bge_max": null, "title": "Cinacalcet: Drug information", "rep_snippet": "Reference Range  CKD K/DOQI guidelines definition of stages; chronic disease is kidney damage or GFR <60 mL/minute/1.73 m2 for ≥3 months:  Stage 2: GFR 60 to 89 mL/minute/1.73 m2 (kidney damage with mild decrease GFR)  S…"}, {"doc_id": "calcium-acetate-drug-information", "bm25_top3": 14.592177028793456, "bm25_max": 17.19010204576435, "bge_top3": null, "bge_max": null, "title": "Calcium acetate: Drug information", "rep_snippet": "Reference Range  Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for a…"}, {"doc_id": "e-coli-asparaginase-united-states-not-available-drug-information", "bm25_top3": 16.27094978539389, "bm25_max": 16.27094978539389, "bge_top3": null, "bge_max": null, "title": "E. coli asparaginase (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Note: Dose, frequency, number of doses, and start date may vary by protocol and treatment phase.  Acute lymphoblastic leukemia (ALL): Children and Adolescents: Refer to adult dosing.  CCG 1922 protocol…"}, {"doc_id": "insulin-degludec-drug-information", "bm25_top3": 16.175351209065337, "bm25_max": 16.175351209065337, "bge_top3": null, "bge_max": null, "title": "Insulin degludec: Drug information", "rep_snippet": "Dosage adjustment: Individualize and titrate dose every 3 to 4 days based on patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal.  Missed dose: Decision to administer or withhold dose u…"}, {"doc_id": "calcitriol-systemic-drug-information", "bm25_top3": 10.680971775633703, "bm25_max": 14.584203400462592, "bge_top3": 0.6696297526359558, "bge_max": 0.6696297526359558, "title": "Calcitriol (systemic): Drug information", "rep_snippet": "CKD stage 3: Serum calcium and phosphorus, every 6 to 12 months; PTH: monitor based on baseline level and CKD progression  CKD stage 4: Serum calcium and phosphorus every 3 to 6 months; PTH every 6 to 12 months  CKD stag…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 9.554786713140228, "bm25_max": 9.554786713140228, "bge_top3": 0.6529757380485535, "bge_max": 0.6569608449935913, "title": "Warfarin: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy  Simeprevir: May enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy  SORA…"}, {"doc_id": "pravastatin-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Pravastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Simvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Fluvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Alirocumab: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Atorvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Rosuvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "evolocumab-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Evolocumab: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "lovastatin-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Lovastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Pitavastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "ezetimibe-drug-information", "bm25_top3": 8.398548669502652, "bm25_max": 8.398548669502652, "bge_top3": null, "bge_max": null, "title": "Ezetimibe: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "colestipol-drug-information", "bm25_top3": 8.357382898765216, "bm25_max": 8.357382898765216, "bge_top3": null, "bge_max": null, "title": "Colestipol: Drug information", "rep_snippet": "Reference Range  Lipid treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 8.357382898765216, "bm25_max": 8.357382898765216, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Reference Range  Lipid treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <…"}, {"doc_id": "colesevelam-drug-information", "bm25_top3": 7.44208361783609, "bm25_max": 7.44208361783609, "bge_top3": null, "bge_max": null, "title": "Colesevelam: Drug information", "rep_snippet": "Moderate (≤2 risk factors; 10-year risk <10%) or high risk (diabetes; CKD stage 3 to 4; ≥2 risk factors and 10-year risk 10% to 20%):  Non-HDL-C: <130 mg/dL  LDL-C: <100 mg/dL  Apo B: <90 mg/dL  Very high risk (ACS; caro…"}, {"doc_id": "capecitabine-drug-information", "bm25_top3": 7.0762704283841344, "bm25_max": 7.0762704283841344, "bge_top3": null, "bge_max": null, "title": "Capecitabine: Drug information", "rep_snippet": "Adverse Reactions  Frequency listed derived from monotherapy trials. Incidence reported for all indications and usage, unless otherwise noted. Frequency not always defined.  >10%:  Cardiovascular: Edema (≤15%)  Central n…"}, {"doc_id": "flutamide-drug-information", "bm25_top3": 5.93781023551939, "bm25_max": 5.93781023551939, "bge_top3": null, "bge_max": null, "title": "Flutamide: Drug information", "rep_snippet": "Use  Prostate cancer: Management of locally confined Stage B2 to C and Stage D2 metastatic prostate cancer (in combination with a luteinizing hormone-releasing hormone [LHRH] agonist). For Stage B2 to C prostate cancer,…"}, {"doc_id": "darbepoetin-alfa-drug-information", "bm25_top3": 5.69425893824992, "bm25_max": 5.69425893824992, "bge_top3": null, "bge_max": null, "title": "Darbepoetin alfa: Drug information", "rep_snippet": "Monitoring Parameters  Hemoglobin (at least once per week until maintenance dose established and after dosage changes; monitor less frequently once hemoglobin is stabilized); CKD patients should be also be monitored at l…"}, {"doc_id": "vitamin-d3-cholecalciferol-drug-information", "bm25_top3": 4.792199262619693, "bm25_max": 4.792199262619693, "bge_top3": 0.6534487009048462, "bge_max": 0.6534487009048462, "title": "Vitamin D3 (cholecalciferol): Drug information", "rep_snippet": "Vitamin D deficiency/insufficiency in patients with CKD stages 3 to 4: Measure serum 25(OH)D levels after 3 months of treatment in children or after 6 months in adults. Measure corrected total calcium and phosphorous aft…"}, {"doc_id": "vitamin-d2-ergocalciferol-drug-information", "bm25_top3": 4.569214440317534, "bm25_max": 4.569214440317534, "bge_top3": 0.6402722597122192, "bge_max": 0.6402722597122192, "title": "Vitamin D2 (ergocalciferol): Drug information", "rep_snippet": "Vitamin D deficiency/insufficiency in patients with CKD stages 3 to 4: Measure serum 25(OH)D levels after 3 months of treatment in children or after 6 months in adults. Measure corrected total calcium and phosphorous aft…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6625674962997437, "bge_max": 0.6625674962997437, "title": "Fluconazole: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Fluconazole may increase the serum concentration of Vitamin K Antagonists. Risk D: Consider therapy modification  Voriconazole: Fluconazole may increase the serum concentration of Vo…"}, {"doc_id": "sonidegib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6603000164031982, "bge_max": 0.6603000164031982, "title": "Sonidegib: Drug information", "rep_snippet": "Monitoring Parameters  Serum creatine kinase (CK) and serum creatinine (baseline, periodically during treatment, and at least weekly with musculoskeletal toxicity and CK elevations >2.5 times ULN until resolution), liver…"}, {"doc_id": "dronedarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6570665240287781, "bge_max": 0.6570665240287781, "title": "Dronedarone: Drug information", "rep_snippet": "Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. Risk C: Monitor therapy  Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid…"}, {"doc_id": "acenocoumarol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6507838765780131, "bge_max": 0.6544848680496216, "title": "Acenocoumarol (United States: Not available): Drug information", "rep_snippet": "Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Penicillins: May enhance the anticoagulant effect of Vitamin K Antagonists. Exception…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6484832167625427, "bge_max": 0.6484832167625427, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Lansoprazole may increase the serum concentration of Vitamin K Antagonists. Risk C: Monitor therapy  Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vor…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6477267742156982, "bge_max": 0.6477267742156982, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "Mitotane: Spironolactone may diminish the therapeutic effect of Mitotane. Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeut…"}, {"doc_id": "methadone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6467623710632324, "bge_max": 0.6467623710632324, "title": "Methadone: Drug information", "rep_snippet": "Monitoring Parameters  Pain relief, respiratory and mental status, blood pressure; signs of misuse, abuse, and addiction; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013). Also evaluate constipation, na…"}, {"doc_id": "nicardipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6466292142868042, "bge_max": 0.6466292142868042, "title": "Nicardipine: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6420227289199829, "bge_max": 0.6465388536453247, "title": "Citalopram: Drug information", "rep_snippet": "Monitoring Parameters  ECG (patients at increased risk for QT-prolonging effects due to certain conditions); electrolytes (potassium and magnesium concentrations [prior to initiation and periodically during therapy in pa…"}, {"doc_id": "amlodipine-olmesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6463989615440369, "bge_max": 0.6463989615440369, "title": "Amlodipine, olmesartan, and hydrochlorothiazide: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6458784341812134, "bge_max": 0.6458784341812134, "title": "Clarithromycin: Drug information", "rep_snippet": "Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Risk C: Monitor therapy  Zidovudine: Clarithromycin may enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decr…"}, {"doc_id": "iron-sucrose-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.645715594291687, "bge_max": 0.645715594291687, "title": "Iron sucrose: Drug information", "rep_snippet": "Monitoring Parameters  CKD patients: Hematocrit, hemoglobin, serum ferritin, serum iron, transferrin, percent transferrin saturation (TSAT), TIBC (takes ~4 weeks of treatment to see increased serum iron and ferritin, and…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6442739367485046, "bge_max": 0.6442739367485046, "title": "Fluoxetine: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy  Vortioxetine: CYP2D6 Inhibitors (Strong) may increase…"}, {"doc_id": "hydrocodone-chlorpheniramine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6437695622444153, "bge_max": 0.6437695622444153, "title": "Hydrocodone, chlorpheniramine, and pseudoephedrine: Drug information", "rep_snippet": "Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.643222451210022, "bge_max": 0.643222451210022, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Omeprazole may increase the serum concentration of Vitamin K Antagonists. Risk C: Monitor therapy  Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorap…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6430913805961609, "bge_max": 0.6430913805961609, "title": "Sertraline: Drug information", "rep_snippet": "Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Risk X: Avoid combination  Urokinase: Agents with Antiplatelet Properties may enhance the ant…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6423821449279785, "bge_max": 0.6423821449279785, "title": "Amiodarone: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Amiodarone may enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists. Management: Monitor patients extra…"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6412164568901062, "bge_max": 0.6412164568901062, "title": "Trimipramine: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}, {"doc_id": "amitriptyline-and-chlordiazepoxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6412164568901062, "bge_max": 0.6412164568901062, "title": "Amitriptyline and chlordiazepoxide: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}, {"doc_id": "pseudoephedrine-and-ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6406115293502808, "bge_max": 0.6406115293502808, "title": "Pseudoephedrine and ibuprofen: Drug information", "rep_snippet": "Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart…"}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6406115293502808, "bge_max": 0.6406115293502808, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart…"}, {"doc_id": "hydrocodone-and-homatropine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6404055953025818, "bge_max": 0.6404055953025818, "title": "Hydrocodone and homatropine: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}, {"doc_id": "hydrocodone-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6404055953025818, "bge_max": 0.6404055953025818, "title": "Hydrocodone and chlorpheniramine: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}, {"doc_id": "epoetin-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6402857899665833, "bge_max": 0.6402857899665833, "title": "Epoetin alfa: Drug information", "rep_snippet": "Dosing: Adult  Note: Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is <100 ng/mL or serum transferrin saturation (TSAT)…"}, {"doc_id": "venlafaxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6401927471160889, "bge_max": 0.6401927471160889, "title": "Venlafaxine: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}, {"doc_id": "mitotane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6401650905609131, "bge_max": 0.6401650905609131, "title": "Mitotane: Drug information", "rep_snippet": "Spironolactone: May diminish the therapeutic effect of Mitotane. Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failur…"}, {"doc_id": "dolasetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6397382616996765, "bge_max": 0.6397382616996765, "title": "Dolasetron: Drug information", "rep_snippet": "QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  QTc-Prolonging Agents (Indeterminate R…"}, {"doc_id": "clomipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6396933197975159, "bge_max": 0.6396933197975159, "title": "Clomipramine: Drug information", "rep_snippet": "Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased. Risk C: Monitor therapy  Metoclopramide: May enhance the…"}, {"doc_id": "escitalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6391098499298096, "bge_max": 0.6391098499298096, "title": "Escitalopram: Drug information", "rep_snippet": "Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. Risk X: Avoid combination  Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Ris…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6389864683151245, "bge_max": 0.6389864683151245, "title": "Voriconazole: Drug information", "rep_snippet": "Vinflunine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. Risk X: Avoid combination  Vitamin K Antagonists (eg, warfarin): Voriconazole may increase the serum concentration of Vitamin K A…"}, {"doc_id": "orphenadrine-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6387794613838196, "bge_max": 0.6387794613838196, "title": "Orphenadrine, aspirin, and caffeine: Drug information", "rep_snippet": "Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart…"}, {"doc_id": "dihydrocodeine-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6387794613838196, "bge_max": 0.6387794613838196, "title": "Dihydrocodeine, aspirin, and caffeine: Drug information", "rep_snippet": "Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart…"}, {"doc_id": "telmisartan-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6380545496940613, "bge_max": 0.6380545496940613, "title": "Telmisartan and amlodipine: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6380545496940613, "bge_max": 0.6380545496940613, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks…"}]}
{"qid": "Q29_noise", "query": "Stage 3 CKD — initiating spironolactone: what dose and how often to check potassium?", "base_qid": "Q29", "variant_type": "noise", "candidates": [{"doc_id": "paricalcitol-drug-information", "bm25_top3": 17.408231603133675, "bm25_max": 19.656217314559388, "bge_top3": 0.6667947371800741, "bge_max": 0.6878343820571899, "title": "Paricalcitol: Drug information", "rep_snippet": "Dosing: Adult  Note: In stage 3 to 5 CKD maintain Ca x P <55 mg2/dL2, reduce or interrupt dosing if recommended calcium phosphorus product (Ca x P) is exceeded or hypercalcemia is observed (K/DOQI Clinical Practice Guide…"}, {"doc_id": "epoetin-alfa-drug-information", "bm25_top3": 19.579744588236185, "bm25_max": 19.579744588236185, "bge_top3": 0.6230668425559998, "bge_max": 0.6230668425559998, "title": "Epoetin alfa: Drug information", "rep_snippet": "Dosing: Adult  Note: Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is <100 ng/mL or serum transferrin saturation (TSAT)…"}, {"doc_id": "doxercalciferol-drug-information", "bm25_top3": 14.435055044388244, "bm25_max": 18.916406447192173, "bge_top3": 0.6557666261990865, "bge_max": 0.6938184499740601, "title": "Doxercalciferol: Drug information", "rep_snippet": "iPTH level >70 pg/mL with stage 3 disease or >110 pg/mL with stage 4 disease (dose should be titrated to lower iPTH to 35 to 70 pg/mL with stage 3 disease or to 70 to 110 pg/mL with stage 4 disease): Increase dose by 0.5…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 18.15293617942418, "bm25_max": 18.15293617942418, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • CNS effects: Somnolence and dizziness have been reported with use; advise patients to use caution when driving or operating machinery until response to initia…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": 17.715356878297747, "bm25_max": 17.715356878297747, "bge_top3": null, "bge_max": null, "title": "Furosemide: Drug information", "rep_snippet": "Ascites, due to cirrhosis (off-label dose): Oral: Initial: 40 mg once daily; titrate every 3 to 5 days as clinically indicated (usual maximum: 160 mg once daily); a furosemide to spironolactone dosing ratio of 40 mg (fur…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 16.02821714042475, "bm25_max": 16.02821714042475, "bge_top3": 0.6432763338088989, "bge_max": 0.6588153839111328, "title": "Spironolactone: Drug information", "rep_snippet": "Cholestyramine Resin: May enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination. Risk C: Monitor therapy  Cipr…"}, {"doc_id": "cinacalcet-drug-information", "bm25_top3": 14.325520510596562, "bm25_max": 14.325520510596562, "bge_top3": 0.6353479623794556, "bge_max": 0.6423025727272034, "title": "Cinacalcet: Drug information", "rep_snippet": "Reference Range  CKD K/DOQI guidelines definition of stages; chronic disease is kidney damage or GFR <60 mL/minute/1.73 m2 for ≥3 months:  Stage 2: GFR 60 to 89 mL/minute/1.73 m2 (kidney damage with mild decrease GFR)  S…"}, {"doc_id": "calcitriol-systemic-drug-information", "bm25_top3": 12.462376268946466, "bm25_max": 13.880247370527734, "bge_top3": 0.6684304475784302, "bge_max": 0.7045450210571289, "title": "Calcitriol (systemic): Drug information", "rep_snippet": "CKD stage 3: Serum calcium and phosphorus, every 6 to 12 months; PTH: monitor based on baseline level and CKD progression  CKD stage 4: Serum calcium and phosphorus every 3 to 6 months; PTH every 6 to 12 months  CKD stag…"}, {"doc_id": "alfacalcidol-united-states-not-available-drug-information", "bm25_top3": 12.109124087671026, "bm25_max": 12.590979050954932, "bge_top3": 0.6637854178746542, "bge_max": 0.6957050561904907, "title": "Alfacalcidol (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral a…"}, {"doc_id": "calcifediol-drug-information", "bm25_top3": 11.571912519167638, "bm25_max": 12.518881005188465, "bge_top3": 0.6662773489952087, "bge_max": 0.6662773489952087, "title": "Calcifediol: Drug information", "rep_snippet": "Reference Range  Corrected total serum calcium (K/DOQI 2003): CKD stages 3 and 4: 8.4 to 10.2 mg/dL (2.1 to 2.6 mmol/L); CKD stage 5: 8.4 to 9.5 mg/dL (2.1 to 2.37 mmol/L); KDIGO guidelines recommend maintaining normal r…"}, {"doc_id": "etelcalcetide-drug-information", "bm25_top3": 7.7329703560446, "bm25_max": 11.907592848836124, "bge_top3": 0.6406516432762146, "bge_max": 0.6433348059654236, "title": "Etelcalcetide: Drug information", "rep_snippet": "Reference Range  Target goals of PTH, calcium, and phosphorus in adult CKD patients on hemodialysis (ie, CKD stage 5), per clinical practice guidelines:  Corrected serum calcium: CKD stage 5: 8.4 to 9.5 mg/dL (2.1 to 2.3…"}, {"doc_id": "sevelamer-drug-information", "bm25_top3": 10.357158741635397, "bm25_max": 11.715454098450895, "bge_top3": 0.6703859567642212, "bge_max": 0.6858616471290588, "title": "Sevelamer: Drug information", "rep_snippet": "Monitoring Parameters  Serum chemistries, including bicarbonate and chloride  Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progress…"}, {"doc_id": "lanthanum-carbonate-drug-information", "bm25_top3": 10.10026507340925, "bm25_max": 11.557842342991822, "bge_top3": 0.6592932939529419, "bge_max": 0.6592932939529419, "title": "Lanthanum carbonate: Drug information", "rep_snippet": "Reference Range  Corrected total serum calcium (K/DOQI 2003): CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stage 5 and 5D (KDIGO 2009)  Phosphorus (K/DOQI 200…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": 10.209103009589324, "bm25_max": 10.209103009589324, "bge_top3": 0.6390256285667419, "bge_max": 0.6607086658477783, "title": "Eplerenone: Drug information", "rep_snippet": "Monitoring Parameters  Blood pressure; serum potassium (prior to therapy, within the first week, 1 month after start of treatment or dose adjustment, then periodically as clinically indicated); additionally, check serum…"}, {"doc_id": "calcium-acetate-drug-information", "bm25_top3": 9.695160483712128, "bm25_max": 9.994252011822564, "bge_top3": 0.635442703962326, "bge_max": 0.6549180746078491, "title": "Calcium acetate: Drug information", "rep_snippet": "Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for…"}, {"doc_id": "pravastatin-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Pravastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Simvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Fluvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Alirocumab: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Atorvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Rosuvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "evolocumab-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Evolocumab: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "lovastatin-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Lovastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Pitavastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "ezetimibe-drug-information", "bm25_top3": 4.947770207762609, "bm25_max": 4.947770207762609, "bge_top3": null, "bge_max": null, "title": "Ezetimibe: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "colestipol-drug-information", "bm25_top3": 4.906982112612759, "bm25_max": 4.906982112612759, "bge_top3": null, "bge_max": null, "title": "Colestipol: Drug information", "rep_snippet": "Reference Range  Lipid treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 4.906982112612759, "bm25_max": 4.906982112612759, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Reference Range  Lipid treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <…"}, {"doc_id": "colesevelam-drug-information", "bm25_top3": 4.054491931603476, "bm25_max": 4.054491931603476, "bge_top3": null, "bge_max": null, "title": "Colesevelam: Drug information", "rep_snippet": "Moderate (≤2 risk factors; 10-year risk <10%) or high risk (diabetes; CKD stage 3 to 4; ≥2 risk factors and 10-year risk 10% to 20%):  Non-HDL-C: <130 mg/dL  LDL-C: <100 mg/dL  Apo B: <90 mg/dL  Very high risk (ACS; caro…"}, {"doc_id": "saquinavir-drug-information", "bm25_top3": 4.045986875109815, "bm25_max": 4.045986875109815, "bge_top3": null, "bge_max": null, "title": "Saquinavir: Drug information", "rep_snippet": "Monitoring Parameters  Monitor ECG [prior to therapy and after 3 to 4 days of therapy (patients already receiving saquinavir/ritonavir and initiating concomitant QT prolonging therapy) or after ~10 days of therapy (patie…"}, {"doc_id": "flutamide-drug-information", "bm25_top3": 4.013954019084881, "bm25_max": 4.013954019084881, "bge_top3": null, "bge_max": null, "title": "Flutamide: Drug information", "rep_snippet": "Use  Prostate cancer: Management of locally confined Stage B2 to C and Stage D2 metastatic prostate cancer (in combination with a luteinizing hormone-releasing hormone [LHRH] agonist). For Stage B2 to C prostate cancer,…"}, {"doc_id": "tromethamine-tham-united-states-not-available-drug-information", "bm25_top3": 3.6445520818679853, "bm25_max": 3.6445520818679853, "bge_top3": null, "bge_max": null, "title": "Tromethamine (THAM) (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Serum electrolytes (especially potassium, blood glucose); renal function, arterial blood gases, ECG monitoring, fluid status, ventilation rate  Check infusion site frequently during administration."}, {"doc_id": "goserelin-drug-information", "bm25_top3": 3.3225597131265374, "bm25_max": 3.3225597131265374, "bge_top3": null, "bge_max": null, "title": "Goserelin: Drug information", "rep_snippet": "Use  Breast cancer, advanced (3.6 mg only): Palliative treatment of advanced breast cancer in pre- and perimenopausal women (estrogen and progesterone receptor values may help to predict if goserelin is likely to be bene…"}, {"doc_id": "primaquine-drug-information", "bm25_top3": 2.9787880934418567, "bm25_max": 2.9787880934418567, "bge_top3": null, "bge_max": null, "title": "Primaquine: Drug information", "rep_snippet": "Monitoring Parameters  Periodic CBC (in G6PD normal patients), visual color check of urine, glucose, electrolytes; if hemolysis suspected, monitor CBC, haptoglobin, peripheral smear, urinalysis dipstick for occult blood,…"}, {"doc_id": "capecitabine-drug-information", "bm25_top3": 2.9682782492155884, "bm25_max": 2.9682782492155884, "bge_top3": null, "bge_max": null, "title": "Capecitabine: Drug information", "rep_snippet": "Adverse Reactions  Frequency listed derived from monotherapy trials. Incidence reported for all indications and usage, unless otherwise noted. Frequency not always defined.  >10%:  Cardiovascular: Edema (≤15%)  Central n…"}, {"doc_id": "vitamin-d3-cholecalciferol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6562058329582214, "bge_max": 0.6562058329582214, "title": "Vitamin D3 (cholecalciferol): Drug information", "rep_snippet": "Vitamin D deficiency/insufficiency in patients with CKD stages 3 to 4: Measure serum 25(OH)D levels after 3 months of treatment in children or after 6 months in adults. Measure corrected total calcium and phosphorous aft…"}, {"doc_id": "vitamin-d2-ergocalciferol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6429922580718994, "bge_max": 0.6429922580718994, "title": "Vitamin D2 (ergocalciferol): Drug information", "rep_snippet": "Vitamin D deficiency/insufficiency in patients with CKD stages 3 to 4: Measure serum 25(OH)D levels after 3 months of treatment in children or after 6 months in adults. Measure corrected total calcium and phosphorous aft…"}, {"doc_id": "potassium-phosphate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6332884430885315, "bge_max": 0.6332884430885315, "title": "Potassium phosphate: Drug information", "rep_snippet": "Monitoring Parameters  IV: Serum potassium, calcium, phosphorus, magnesium (to facilitate potassium repletion); cardiac monitor (if intermittent infusion or potassium infusion rates >0.5 mEq/kg/hour in children or >10 mE…"}, {"doc_id": "potassium-chloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6313852667808533, "bge_max": 0.6313852667808533, "title": "Potassium chloride: Drug information", "rep_snippet": "Monitoring Parameters  Electrolytes (including serum potassium, calcium, chloride, magnesium, phosphate, sodium), acid/base balance; renal function; cardiac monitor (if intermittent infusion or potassium infusion rates 0…"}, {"doc_id": "ropinirole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6294926404953003, "bge_max": 0.6294926404953003, "title": "Ropinirole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Moderate renal impairment (CrCl 30 to 50 mL/minute): No dosage adjustment necessary.  Severe renal impairment (CrCl <30 mL/minute): There are no dosage adjustments provided in the manufacturer's…"}, {"doc_id": "calcium-polystyrene-sulfonate-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6262894868850708, "bge_max": 0.6262894868850708, "title": "Calcium polystyrene sulfonate (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Hyperkalemia: Initiate treatment if potassium level >6 mmol/L (6 mEq/L); discontinue when potassium ≤5 mmol/L (5 mEq/L).  Oral: Usual dose: 15 g 3 to 4 times daily; dose should be based on clinical present…"}, {"doc_id": "baclofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6246055364608765, "bge_max": 0.6246055364608765, "title": "Baclofen: Drug information", "rep_snippet": "Dosing: Adult  Spasticity:  Oral: Initial: 5 mg 3 times daily; may increase by 5 mg per dose every 3 days (ie, 5 mg 3 times daily for 3 days, then 10 mg 3 times daily for 3 days, etc.) until optimal response is reached.…"}, {"doc_id": "total-parenteral-nutrition-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6243637204170227, "bge_max": 0.6243637204170227, "title": "Total parenteral nutrition: Drug information", "rep_snippet": "At baseline and 1 to 2 times per week in stable patients/daily in critically-ill patients: Electrolytes (sodium, potassium, chloride, carbon dioxide, magnesium, calcium, phosphorus) (upon initiation, 3 times daily); BUN,…"}, {"doc_id": "vandetanib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6205106973648071, "bge_max": 0.6205106973648071, "title": "Vandetanib: Drug information", "rep_snippet": "Dosing: Adult  Note: Do not initiate treatment unless QTcF <450 msec. Avoid concomitant use of QT-prolonging agents and strong CYP3A4 inducers. To reduce the risk of QT prolongation, maintain serum calcium and magnesium…"}, {"doc_id": "darbepoetin-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6204862594604492, "bge_max": 0.6204862594604492, "title": "Darbepoetin alfa: Drug information", "rep_snippet": "Dosing: Adult  Note: Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is <100 ng/mL or serum transferrin saturation (TSAT)…"}, {"doc_id": "zoledronic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6199826598167419, "bge_max": 0.6199826598167419, "title": "Zoledronic acid: Drug information", "rep_snippet": "Paget disease: Alkaline phosphatase at 6 to 12 weeks for initial response to treatment (when bone turnover will have shown a substantial decline) and potentially at 6 months (maximal suppression of high bone turnover); f…"}, {"doc_id": "potassium-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6196848750114441, "bge_max": 0.6196848750114441, "title": "Potassium acetate: Drug information", "rep_snippet": "Monitoring Parameters  Electrolytes (including serum potassium, bicarbonate, and magnesium), acid/base status; cardiac monitor (if intermittent infusion or potassium infusion rates 0.5 mEq/kg/hour in children or >10 mEq/…"}, {"doc_id": "ferric-citrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6188479065895081, "bge_max": 0.6188479065895081, "title": "Ferric citrate: Drug information", "rep_snippet": "Dosing: Adult  Note: Each tablet contains 210 mg of ferric iron equivalent to 1 g ferric citrate.  Hyperphosphatemia: Oral:  Initial: Two tablets (420 mg ferric iron) 3 times daily  Maintenance: Increase or decrease dose…"}, {"doc_id": "potassium-citrate-tablet-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6171842813491821, "bge_max": 0.6171842813491821, "title": "Potassium citrate (tablet): Drug information", "rep_snippet": "Monitoring Parameters  Serum electrolytes (potassium, chloride, sodium), bicarbonate, serum creatinine, and CBC every 4 months (more frequently with cardiac/renal disease or acidosis); urinary citrate and/or urinary pH a…"}, {"doc_id": "sodium-bicarbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.617132306098938, "bge_max": 0.617132306098938, "title": "Sodium bicarbonate: Drug information", "rep_snippet": "Initial: 15.4 to 23.1 mEq/day in divided doses (eg, 650 mg tablet 2 to 3 times daily); titrate to normal serum bicarbonate concentrations (eg, 23 to 29 mEq/L) or up to 5850 mg/day; baking soda may be used as an alternati…"}]}
{"qid": "Q29_spelling", "query": "Spironolacton in CKD3 — start dose + K monitoring.", "base_qid": "Q29", "variant_type": "spelling", "candidates": [{"doc_id": "vitamin-k-phytonadione-drug-information", "bm25_top3": 23.798411708663984, "bm25_max": 23.798411708663984, "bge_top3": null, "bge_max": null, "title": "Vitamin K (phytonadione): Drug information", "rep_snippet": "If INR >10 (no evidence of bleeding): The 2012 ACCP guidelines recommend administration of oral vitamin K (dose not specified) in this setting (Guyatt 2012). Previously, the 2008 ACCP guidelines recommended to hold warfa…"}, {"doc_id": "liposomal-daunorubicin-and-cytarabine-drug-information", "bm25_top3": 12.037203774950303, "bm25_max": 12.037203774950303, "bge_top3": null, "bge_max": null, "title": "Liposomal daunorubicin and cytarabine: Drug information", "rep_snippet": "Consolidation: Daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 (liposomal) on days 1 and 3; administer the first consolidation cycle 5 to 8 weeks after the start of the last induction; administer the second consolidation c…"}, {"doc_id": "ethinyl-estradiol-and-drospirenone-drug-information", "bm25_top3": 11.95785350040062, "bm25_max": 11.95785350040062, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and drospirenone: Drug information", "rep_snippet": "Dosing: Adult  Acne (Gianvi, Loryna, Nikki, Vestura, Yaz): Females: Oral: Refer to dosing for contraception.  PMDD (Gianvi, Yaz): Females: Oral: Refer to dosing for contraception.  Contraception: Female: Oral: One tablet…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": 11.658833798094479, "bm25_max": 11.658833798094479, "bge_top3": null, "bge_max": null, "title": "Enoxaparin: Drug information", "rep_snippet": "Note: The following recommendations are based on use of therapeutic doses of enoxaparin (eg, 1 mg/kg every 12 hours). If converting from a prophylactic enoxaparin dose (eg, 30 mg twice daily) to a therapeutic IV UFH dose…"}, {"doc_id": "isavuconazole-isavuconazonium-sulfate-drug-information", "bm25_top3": 11.332236589646154, "bm25_max": 11.51444467530256, "bge_top3": null, "bge_max": null, "title": "Isavuconazole (isavuconazonium sulfate): Drug information", "rep_snippet": "Oral: Initial: 372 mg (isavuconazole 200 mg) every 8 hours for 6 doses; Maintenance: 372 mg (isavuconazole 200 mg) once daily. Start maintenance dose 12 to 24 hours after the last loading dose."}, {"doc_id": "hydrocodone-drug-information", "bm25_top3": 11.14421463573705, "bm25_max": 11.484238146643257, "bge_top3": null, "bge_max": null, "title": "Hydrocodone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hysingla ER, Vantrela ER:  Mild impairment: No dosage adjustment necessary.  Moderate to severe impairment: Initial: Start with 50% of the initial dose; titrate carefully; monitor closely.  End-…"}, {"doc_id": "ethinyl-estradiol-and-norgestimate-drug-information", "bm25_top3": 11.392507988576087, "bm25_max": 11.392507988576087, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol and norgestimate: Drug information", "rep_snippet": "Dosing: Adult  Females:  Acne (Ortho Tri-Cyclen, Tri-Estaryllla, TriNessa, Tri-Previfem, Tri-Sprintec): Oral: Refer to dosing for contraception  Contraception: Oral: 1 tablet once daily  Schedule 1 (Sunday starter): Dose…"}, {"doc_id": "ethinyl-estradiol-drospirenone-and-levomefolate-drug-information", "bm25_top3": 11.279531535832675, "bm25_max": 11.279531535832675, "bge_top3": null, "bge_max": null, "title": "Ethinyl estradiol, drospirenone, and levomefolate: Drug information", "rep_snippet": "If ≥2 consecutive doses are missed (≥48 hours since dose should have been taken): Take the most recently missed dose as soon as possible, discard any other missed doses. Continue remaining doses at the usual time (even i…"}, {"doc_id": "dextroamphetamine-drug-information", "bm25_top3": 10.628265676597769, "bm25_max": 10.628265676597769, "bge_top3": null, "bge_max": null, "title": "Dextroamphetamine: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing; start at lowest dose. Use with caution."}, {"doc_id": "trifluridine-and-tipiracil-drug-information", "bm25_top3": 9.692461687010198, "bm25_max": 9.692461687010198, "bge_top3": null, "bge_max": null, "title": "Trifluridine and tipiracil: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  A maximum of 3 dose reductions are allowed (to a minimum dose of 20 mg/m2). Do not re-escalate dose after it has been reduced.  Hematologic toxicity:  ANC <500/mm3 (uncomplicated or resul…"}, {"doc_id": "valganciclovir-drug-information", "bm25_top3": 8.11700385858495, "bm25_max": 8.11700385858495, "bge_top3": null, "bge_max": null, "title": "Valganciclovir: Drug information", "rep_snippet": "Note: Calculated using modified Schwartz formula where k is as follows:  Infants with low birth weight for gestational age: k = 0.33  Infants with birth weight appropriate for gestational age: k = 0.45  Children 1 to <2…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 1.17103945693537, "bm25_max": 2.4311527208367263, "bge_top3": 0.6077559590339661, "bge_max": 0.6150947213172913, "title": "Warfarin: Drug information", "rep_snippet": "Selective Serotonin Reuptake Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy  Simeprevir: May enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy  SORA…"}, {"doc_id": "acenocoumarol-united-states-not-available-drug-information", "bm25_top3": 0.7607569925331923, "bm25_max": 0.8480870735888644, "bge_top3": 0.6062807242075602, "bge_max": 0.6087779998779297, "title": "Acenocoumarol (United States: Not available): Drug information", "rep_snippet": "Amiodarone: May enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists. Management: Monitor patients extra closely for evidence of increased an…"}, {"doc_id": "mitotane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6296201944351196, "bge_max": 0.6296201944351196, "title": "Mitotane: Drug information", "rep_snippet": "Spironolactone: May diminish the therapeutic effect of Mitotane. Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failur…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6220967769622803, "bge_max": 0.6220967769622803, "title": "Fluconazole: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Fluconazole may increase the serum concentration of Vitamin K Antagonists. Risk D: Consider therapy modification  Voriconazole: Fluconazole may increase the serum concentration of Vo…"}, {"doc_id": "dronedarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6088932156562805, "bge_max": 0.6217795014381409, "title": "Dronedarone: Drug information", "rep_snippet": "Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. Risk C: Monitor therapy  Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6193844676017761, "bge_max": 0.6193844676017761, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Lansoprazole may increase the serum concentration of Vitamin K Antagonists. Risk C: Monitor therapy  Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vor…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6082781950632731, "bge_max": 0.6152834892272949, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "Mitotane: Spironolactone may diminish the therapeutic effect of Mitotane. Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeut…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.607331782579422, "bge_max": 0.6137872934341431, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used o…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6122794151306152, "bge_max": 0.6122794151306152, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Omeprazole may increase the serum concentration of Vitamin K Antagonists. Risk C: Monitor therapy  Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorap…"}, {"doc_id": "sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.612109363079071, "bge_max": 0.612109363079071, "title": "Sodium stibogluconate (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Monitoring Parameters  Baseline and weekly EKG, serum creatinine, liver function tests, serum amylase, and CBC; patients requiring >20 days of treatment should begin twice-weekly EKG monitoring during week 3 of therapy;…"}, {"doc_id": "antithymocyte-globulin-equine-atgam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6103238463401794, "bge_max": 0.6103238463401794, "title": "Antithymocyte globulin (equine, Atgam): Drug information", "rep_snippet": "Monitoring Parameters  Complete blood count with differential and platelet count, monitor vital signs during administration; monitor for infusion reactions; monitor for signs/symptoms of infection.  Solid organ transplan…"}, {"doc_id": "bosentan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.607379138469696, "bge_max": 0.607379138469696, "title": "Bosentan: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Bosentan may increase the metabolism of Vitamin K Antagonists. Risk C: Monitor therapy  Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. Risk C:…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 0.6067142394520104, "bm25_max": 0.6067142394520104, "bge_top3": 0.6073781847953796, "bge_max": 0.6073781847953796, "title": "Amiodarone: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): Amiodarone may enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists. Management: Monitor patients extra…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6072949171066284, "bge_max": 0.6072949171066284, "title": "Clarithromycin: Drug information", "rep_snippet": "Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). Risk C: Monitor therapy  Zidovudine: Clarithromycin may enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decr…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6032897531986237, "bge_max": 0.607192873954773, "title": "Spironolactone: Drug information", "rep_snippet": "Neuromuscular-Blocking Agents (Nondepolarizing): Spironolactone may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy  Nicergoline: May enhance the hypo…"}, {"doc_id": "cosyntropin-tetracosactide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6063991189002991, "bge_max": 0.6063991189002991, "title": "Cosyntropin (tetracosactide): Drug information", "rep_snippet": "Monitoring Parameters  Synacthen Depot [Canadian product]: Observe patient for ~1 hour after administration for signs/symptoms of hypersensitivity; for diagnosis of adrenocortical Insufficiency measure plasma cortisol pr…"}, {"doc_id": "calcitriol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6059907078742981, "bge_max": 0.6059907078742981, "title": "Calcitriol (systemic): Drug information", "rep_snippet": "CKD stage 3: Serum calcium and phosphorus, every 6 to 12 months; PTH: monitor based on baseline level and CKD progression  CKD stage 4: Serum calcium and phosphorus every 3 to 6 months; PTH every 6 to 12 months  CKD stag…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 0.37967219118326234, "bm25_max": 0.37967219118326234, "bge_top3": 0.6040711402893066, "bge_max": 0.6040711402893066, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to concomitant therapy with these agents. If concomitant the…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6040157079696655, "bge_max": 0.6040157079696655, "title": "Posaconazole: Drug information", "rep_snippet": "VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal). Risk X: Avoid combination  Vinflunine: CYP3A4 Inhibitors (Strong) may increase the serum concentration…"}, {"doc_id": "phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6039870977401733, "bge_max": 0.6039870977401733, "title": "Phenobarbital: Drug information", "rep_snippet": "Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone. Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients rece…"}, {"doc_id": "hyoscyamine-atropine-scopolamine-and-phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6039870977401733, "bge_max": 0.6039870977401733, "title": "Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information", "rep_snippet": "Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone. Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients rece…"}, {"doc_id": "diclofenac-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6033674478530884, "bge_max": 0.6033674478530884, "title": "Diclofenac (topical): Drug information", "rep_snippet": "Monitoring Parameters  CBC, liver enzymes (periodically during chronic therapy starting 4 to 8 weeks after initiation), BUN/serum creatinine; potassium; monitor urine output; occult blood loss; blood pressure (baseline a…"}, {"doc_id": "epoetin-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6026163697242737, "bge_max": 0.6026163697242737, "title": "Epoetin alfa: Drug information", "rep_snippet": "Dosing: Adult  Note: Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is <100 ng/mL or serum transferrin saturation (TSAT)…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6020146012306213, "bge_max": 0.6020146012306213, "title": "Clozapine: Drug information", "rep_snippet": "Initiating clozapine with concomitant medication or adding a concomitant medication while taking clozapine: Concomitant use is not recommended. However, if the CYP3A4 inducer is necessary, monitor for decreased effective…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.601814329624176, "bge_max": 0.601814329624176, "title": "Voriconazole: Drug information", "rep_snippet": "Vinflunine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. Risk X: Avoid combination  Vitamin K Antagonists (eg, warfarin): Voriconazole may increase the serum concentration of Vitamin K A…"}, {"doc_id": "inotuzumab-ozogamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6016172170639038, "bge_max": 0.6016172170639038, "title": "Inotuzumab ozogamicin: Drug information", "rep_snippet": "Monitoring Parameters  Complete blood counts (prior to each dose), liver function tests including ALT, AST, total bilirubin, and alkaline phosphatase (prior to and following each dose); for patients who proceed to HSCT,…"}, {"doc_id": "foscarnet-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.601300835609436, "bge_max": 0.601300835609436, "title": "Foscarnet: Drug information", "rep_snippet": "Monitoring Parameters  24-hour creatinine clearance, ECG, and electrolytes at baseline and periodically thereafter (when clinically appropriate). During induction therapy: Obtain complete blood counts, and electrolytes (…"}, {"doc_id": "brigatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5999109745025635, "bge_max": 0.5999109745025635, "title": "Brigatinib: Drug information", "rep_snippet": "Monitoring Parameters  ALK positivity; monitor creatine phosphokinase (CPK) and amylase/lipase levels periodically throughout therapy; fasting serum glucose at baseline and periodically thereafter; monitor heart rate and…"}, {"doc_id": "ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Ombitasvir, paritaprevir, ritonavir, plus dasabuvir: Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya): Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Itraconazole: Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "indinavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Indinavir: Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "atazanavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Atazanavir: Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "nefazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5977315306663513, "bge_max": 0.5977315306663513, "title": "Nefazodone: Drug information", "rep_snippet": "Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Moni…"}, {"doc_id": "gliclazide-united-states-not-available-drug-information", "bm25_top3": -0.06420652989919873, "bm25_max": -0.06420652989919873, "bge_top3": null, "bge_max": null, "title": "Gliclazide (United States: Not available): Drug information", "rep_snippet": "Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia. Risk D: Consider therapy mo…"}, {"doc_id": "prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information", "bm25_top3": -0.2624263890146139, "bm25_max": -0.2624263890146139, "bge_top3": null, "bge_max": null, "title": "Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Drug information", "rep_snippet": "• Coagulation factor deficiency: Hepatic synthesis of the prothrombin complex (Factors II, VII, IX and X) coagulation factors is vitamin K dependent. Severe hepatic dysfunction, inadequate absorption of vitamin K (eg, pa…"}, {"doc_id": "argatroban-drug-information", "bm25_top3": -0.28840080854621064, "bm25_max": -0.28840080854621064, "bge_top3": null, "bge_max": null, "title": "Argatroban: Drug information", "rep_snippet": "Monitoring Parameters  Monitor hemoglobin, hematocrit, signs and symptoms of bleeding.  HIT: Obtain baseline aPTT prior to start of therapy. Patient may not be at steady-state but check aPTT 2 hours after start of therap…"}, {"doc_id": "butalbital-compound-and-codeine-drug-information", "bm25_top3": -0.33071489963044165, "bm25_max": -0.33071489963044165, "bge_top3": null, "bge_max": null, "title": "Butalbital compound and codeine: Drug information", "rep_snippet": "Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin…"}, {"doc_id": "dolutegravir-drug-information", "bm25_top3": -0.4067173244518223, "bm25_max": -0.4067173244518223, "bge_top3": null, "bge_max": null, "title": "Dolutegravir: Drug information", "rep_snippet": "• Renal impairment: Use with caution in integrase strand transfer inhibitor (INSTI)-experienced patients with severe renal impairment; decreases in dolutegravir concentrations were observed and may result in loss of ther…"}, {"doc_id": "telavancin-drug-information", "bm25_top3": -0.4259937680414758, "bm25_max": -0.4259937680414758, "bge_top3": null, "bge_max": null, "title": "Telavancin: Drug information", "rep_snippet": "Monitoring Parameters  Renal function (prior to start, every 48 to 72 hours; more frequently if indicated, and following therapy), pregnancy test"}, {"doc_id": "potassium-chloride-drug-information", "bm25_top3": -0.7784858177390053, "bm25_max": -0.6486457611029444, "bge_top3": null, "bge_max": null, "title": "Potassium chloride: Drug information", "rep_snippet": "Brand Names: International  Addi-K (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM);  Alkay ER (LK);  Apo-K (HK, JO, MY, SG);  Beacon K (MY);  Budaxiu (CN);  Chloropota…"}, {"doc_id": "testosterone-drug-information", "bm25_top3": -0.7392813806007705, "bm25_max": -0.7392813806007705, "bge_top3": null, "bge_max": null, "title": "Testosterone: Drug information", "rep_snippet": "Hypogonadal men with osteoporosis or low trauma fracture: Monitor after 1 to 2 years of therapy (Endocrine Society [Bhasin 2010]).  PSA: In men >40 years of age with baseline PSA >0.6 ng/mL, PSA and prostate exam at 3 to…"}, {"doc_id": "albendazole-drug-information", "bm25_top3": -0.8503657963517419, "bm25_max": -0.8503657963517419, "bge_top3": null, "bge_max": null, "title": "Albendazole: Drug information", "rep_snippet": "Monitoring Parameters  LFTs and CBC with differential at start of each 28-day cycle and every 2 weeks during therapy (more frequent monitoring for patients with liver disease); ophthalmic exam for retinal lesions (patien…"}, {"doc_id": "potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information", "bm25_top3": -0.8757295207460167, "bm25_max": -0.8757295207460167, "bge_top3": null, "bge_max": null, "title": "Potassium bicarbonate and potassium citrate (effervescent): Drug information", "rep_snippet": "Brand Names: US  Effer-K;  K-Effervescent;  K-Prime;  K-Vescent;  Klor-Con/EF"}, {"doc_id": "rubidium-rb-82-drug-information", "bm25_top3": -1.0151880888052975, "bm25_max": -1.0151880888052975, "bge_top3": null, "bge_max": null, "title": "Rubidium rb-82: Drug information", "rep_snippet": "Stress imaging: Begin study 10 minutes after completion of rest dose infusion; administer pharmacologic stress agent; after 3 minutes infuse single dose of rubidium-82 chloride; start imaging 60 to 90 seconds after compl…"}, {"doc_id": "modafinil-drug-information", "bm25_top3": -1.1585416637946242, "bm25_max": -1.1585416637946242, "bge_top3": null, "bge_max": null, "title": "Modafinil: Drug information", "rep_snippet": "Administration  For the treatment of narcolepsy and obstructive sleep apnea/hypopnea syndrome, administer dose in the morning. For the treatment of shift work sleep disorder, administer dose ~1 hour prior to start of wor…"}, {"doc_id": "potassium-citrate-tablet-drug-information", "bm25_top3": -1.2200612159774114, "bm25_max": -1.2200612159774114, "bge_top3": null, "bge_max": null, "title": "Potassium citrate (tablet): Drug information", "rep_snippet": "Brand Names: US  Urocit-K 10;  Urocit-K 15;  Urocit-K 5"}, {"doc_id": "apixaban-drug-information", "bm25_top3": -1.2486810407972548, "bm25_max": -1.2486810407972548, "bge_top3": null, "bge_max": null, "title": "Apixaban: Drug information", "rep_snippet": "Monitoring Parameters  Renal function and CBC prior to initiation, when clinically indicated, and at least annually in all patients (AHA/ACC/HRS [January 2014]; AHA [Raval 2017]), hepatic function; signs of bleeding. Rou…"}, {"doc_id": "vitamin-b6-pyridoxine-drug-information", "bm25_top3": -1.2541155643630866, "bm25_max": -1.2541155643630866, "bge_top3": null, "bge_max": null, "title": "Vitamin B6 (pyridoxine): Drug information", "rep_snippet": "Brand Names: US  Neuro-K-250 T.D. [OTC];  Neuro-K-250 Vitamin B6 [OTC];  Neuro-K-50 [OTC];  Neuro-K-500 [OTC];  Pyri 500 [OTC]"}, {"doc_id": "primidone-drug-information", "bm25_top3": -1.5802587379296966, "bm25_max": -1.5802587379296966, "bge_top3": null, "bge_max": null, "title": "Primidone: Drug information", "rep_snippet": "Monitoring Parameters  Serum primidone and phenobarbital concentration, neurological status. Monitor CBC and comprehensive metabolic panel at 6-month intervals to compare with baseline obtained at start of therapy. Monit…"}, {"doc_id": "recombinant-human-cerliponase-alfa-drug-information", "bm25_top3": -2.466620505164137, "bm25_max": -2.466620505164137, "bge_top3": null, "bge_max": null, "title": "Recombinant human cerliponase alfa: Drug information", "rep_snippet": "Monitoring Parameters  Vital signs (blood pressure, heart rate) prior to start of infusion, periodically during infusion and post-infusion; skin integrity (prior to infusion); routine CSF samples (to detect subclinical d…"}]}
{"qid": "Q30_abbr+admin-cue", "query": "Osteoporosis — alendronate weekly dose & admin (upright 30 min, empty stomach, water only).", "base_qid": "Q30", "variant_type": "abbr+admin-cue", "candidates": [{"doc_id": "alendronate-and-cholecalciferol-drug-information", "bm25_top3": 30.7975067496303, "bm25_max": 35.03645634998573, "bge_top3": 0.7534576058387756, "bge_max": 0.8112666606903076, "title": "Alendronate and cholecalciferol: Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis: Males or postmenopausal females: Oral: One tablet (alendronate 70 mg/cholecalciferol 2,800 units or alendronate 70 mg/cholecalciferol 5,600 units) once weekly. Note: The optimal duration of o…"}, {"doc_id": "fexofenadine-drug-information", "bm25_top3": 26.377842238880504, "bm25_max": 26.377842238880504, "bge_top3": null, "bge_max": null, "title": "Fexofenadine: Drug information", "rep_snippet": "Administration  Orally disintegrating tablet: Administer on an empty stomach. Remove tablet from individual blister and place immediately on tongue; tablet will disintegrate with or without water (do not administer with…"}, {"doc_id": "alendronate-drug-information", "bm25_top3": 24.12233859810329, "bm25_max": 24.12233859810329, "bge_top3": 0.7184337973594666, "bge_max": 0.7364466786384583, "title": "Alendronate: Drug information", "rep_snippet": "Food Interactions  All food and beverages interfere with absorption. Coadministration with dairy products may decrease alendronate absorption. Beverages (especially orange juice, coffee, and mineral water) and food may r…"}, {"doc_id": "tegaserod-united-states-available-via-fda-emergency-access-protocol-only-drug-information", "bm25_top3": 23.31599883918694, "bm25_max": 23.31599883918694, "bge_top3": null, "bge_max": null, "title": "Tegaserod (United States: Available via FDA emergency access protocol only): Drug information", "rep_snippet": "Dietary Considerations  Take on an empty stomach, 30 minutes before meals."}, {"doc_id": "etidronate-drug-information", "bm25_top3": 22.351532969293146, "bm25_max": 22.351532969293146, "bge_top3": null, "bge_max": null, "title": "Etidronate: Drug information", "rep_snippet": "Administration  Administer tablet on an empty stomach with a full glass of plain water (6 to 8 oz) 2 hours before food. Patients should be instructed to stay upright (not to lie down) after taking the medication. If gast…"}, {"doc_id": "carbinoxamine-drug-information", "bm25_top3": 19.869260798529638, "bm25_max": 19.869260798529638, "bge_top3": null, "bge_max": null, "title": "Carbinoxamine: Drug information", "rep_snippet": "Administration  Administer orally on an empty stomach with water. Shake suspension well before administering dose."}, {"doc_id": "risedronate-drug-information", "bm25_top3": 19.249000077917795, "bm25_max": 19.249000077917795, "bge_top3": 0.7169799407323202, "bge_max": 0.7368903160095215, "title": "Risedronate: Drug information", "rep_snippet": "Administration  Oral: Note: Avoid administration of oral calcium supplements, antacids, magnesium supplements/laxatives, and iron preparations within 30 minutes of risedronate administration.  Immediate release tablet: R…"}, {"doc_id": "trospium-drug-information", "bm25_top3": 18.930147967710578, "bm25_max": 18.930147967710578, "bge_top3": 0.6976644396781921, "bge_max": 0.6976644396781921, "title": "Trospium: Drug information", "rep_snippet": "Administration  Immediate release: Administer with water on an empty stomach at least 1 hour prior to meals.  Extended release: Administer in the morning with water on an empty stomach at least 1 hour before a meal."}, {"doc_id": "l-lysine-drug-information", "bm25_top3": 18.597397888589445, "bm25_max": 18.597397888589445, "bge_top3": null, "bge_max": null, "title": "L-Lysine: Drug information", "rep_snippet": "Administration  Administer with water on an empty stomach."}, {"doc_id": "methylnaltrexone-drug-information", "bm25_top3": 18.325090554983827, "bm25_max": 18.325090554983827, "bge_top3": null, "bge_max": null, "title": "Methylnaltrexone: Drug information", "rep_snippet": "Administration  SubQ: Administer by subcutaneous injection into the upper arm, abdomen, or thigh. Rotate injection sites with each dose.  Tablet: Oral: Administer with water on an empty stomach at least 30 minutes before…"}, {"doc_id": "ferrous-fumarate-drug-information", "bm25_top3": 17.518404082173006, "bm25_max": 17.518404082173006, "bge_top3": null, "bge_max": null, "title": "Ferrous fumarate: Drug information", "rep_snippet": "Administration  Should be administered with water or juice on an empty stomach."}, {"doc_id": "ferrous-sulfate-drug-information", "bm25_top3": 15.808114170665043, "bm25_max": 15.808114170665043, "bge_top3": null, "bge_max": null, "title": "Ferrous sulfate: Drug information", "rep_snippet": "Administration  Oral: Do not chew or crush extended-release preparations; administer with water or juice on an empty stomach."}, {"doc_id": "sucralfate-drug-information", "bm25_top3": 14.399722199550126, "bm25_max": 15.745690158202681, "bge_top3": 0.7052861452102661, "bge_max": 0.7052861452102661, "title": "Sucralfate: Drug information", "rep_snippet": "Dietary Considerations  Take with water on an empty stomach."}, {"doc_id": "doxylamine-and-pyridoxine-drug-information", "bm25_top3": 15.5803906782943, "bm25_max": 15.5803906782943, "bge_top3": null, "bge_max": null, "title": "Doxylamine and pyridoxine: Drug information", "rep_snippet": "Administration  Administer on an empty stomach with a glass of water. Swallow tablets whole, do not chew crush or split."}, {"doc_id": "fexofenadine-and-pseudoephedrine-drug-information", "bm25_top3": 14.101244787785602, "bm25_max": 15.51441555077783, "bge_top3": null, "bge_max": null, "title": "Fexofenadine and pseudoephedrine: Drug information", "rep_snippet": "Dietary Considerations  Doses should be administered on an empty stomach with water."}, {"doc_id": "didanosine-drug-information", "bm25_top3": 12.58854005253152, "bm25_max": 14.271458611143672, "bge_top3": null, "bge_max": null, "title": "Didanosine: Drug information", "rep_snippet": "Administration  Oral: Pediatric powder for oral solution: Administer on an empty stomach at least 30 minutes before or 2 hours after eating. Shake well prior to use.  Oral: Videx EC: Administer on an empty stomach at lea…"}, {"doc_id": "zinc-acetate-drug-information", "bm25_top3": 13.06091232326387, "bm25_max": 13.933363972330028, "bge_top3": null, "bge_max": null, "title": "Zinc acetate: Drug information", "rep_snippet": "Food Interactions  Food and beverages other than water may interfere with zinc absorption. Management: Administer on empty stomach at least 1 hour before or 2 to 3 hours after meals and at least 1 hour separated from bev…"}, {"doc_id": "cloxacillin-united-states-not-available-drug-information", "bm25_top3": 13.703698782821288, "bm25_max": 13.703698782821288, "bge_top3": null, "bge_max": null, "title": "Cloxacillin (United States: Not available): Drug information", "rep_snippet": "Food Interactions  Food decreases cloxacillin absorption; serum levels are reduced by ~50%. Management: Administer with water on an empty stomach 1 hour before or 2 hours after meals."}, {"doc_id": "thyroid-extract-desiccated-thyroid-drug-information", "bm25_top3": 13.279782480526933, "bm25_max": 13.279782480526933, "bge_top3": null, "bge_max": null, "title": "Thyroid extract (desiccated thyroid): Drug information", "rep_snippet": "Administration  Oral: Administer on an empty stomach (eg, 30 to 60 minutes prior to breakfast) to increase absorption."}, {"doc_id": "eltrombopag-drug-information", "bm25_top3": 13.143202068514157, "bm25_max": 13.143202068514157, "bge_top3": null, "bge_max": null, "title": "Eltrombopag: Drug information", "rep_snippet": "Administration  Administer on an empty stomach, 1 hour before or 2 hours after a meal. Swallow tablets whole; do not crush and mix with food or liquids. Prepare the suspension with cool or cold water only (do not use hot…"}, {"doc_id": "ivermectin-systemic-drug-information", "bm25_top3": 12.937036784562398, "bm25_max": 12.937036784562398, "bge_top3": null, "bge_max": null, "title": "Ivermectin (systemic): Drug information", "rep_snippet": "Administration  Oral: Administer on an empty stomach with water.  Pediculosis pubis and scabies treatment: To increase bioavailability in the epidermis, ivermectin is recommended to be taken with food (CDC [Workowski 201…"}, {"doc_id": "dicloxacillin-drug-information", "bm25_top3": 12.835303973307497, "bm25_max": 12.835303973307497, "bge_top3": null, "bge_max": null, "title": "Dicloxacillin: Drug information", "rep_snippet": "Food Interactions  Food decreases drug absorption rate and serum concentration. Management: Administer around-the-clock on an empty stomach with a large glass of water 1 hour before or 2 hours after meals."}, {"doc_id": "loperamide-and-simethicone-drug-information", "bm25_top3": 12.755313173309368, "bm25_max": 12.755313173309368, "bge_top3": null, "bge_max": null, "title": "Loperamide and simethicone: Drug information", "rep_snippet": "Administration  Administer with plenty of clear fluids to prevent dehydration. Administer non-chewable tablets with a full glass of water and on an empty stomach (1 hour before or 2 hours after a meal)."}, {"doc_id": "nimodipine-drug-information", "bm25_top3": 12.692579423280144, "bm25_max": 12.692579423280144, "bge_top3": null, "bge_max": null, "title": "Nimodipine: Drug information", "rep_snippet": "Administration  For enteral administration ONLY. Life-threatening adverse events have occurred when administered parenterally. Administer on an empty stomach at least 1 hour before or 2 hours after meals.  Oral:  US labe…"}, {"doc_id": "abiraterone-drug-information", "bm25_top3": 12.6738357886498, "bm25_max": 12.6738357886498, "bge_top3": null, "bge_max": null, "title": "Abiraterone: Drug information", "rep_snippet": "Administration  Oral: Administer abiraterone orally on an empty stomach, at least 1 hour before and 2 hours after food. No food should be consumed for at least 2 hours before or for at least 1 hour after the abiraterone…"}, {"doc_id": "etidronate-and-calcium-united-states-not-available-drug-information", "bm25_top3": 12.362366821620387, "bm25_max": 12.66953615807833, "bge_top3": 0.7030872404575348, "bge_max": 0.7142040133476257, "title": "Etidronate and calcium (United States: Not available): Drug information", "rep_snippet": "Food Interactions  Food decreases the absorption and bioavailability of etidronate. Management: Administer on an empty stomach with a full glass of water 2 hours before or after food/supplements with calcium, iron, or ma…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": 12.515181033420255, "bm25_max": 12.515181033420255, "bge_top3": null, "bge_max": null, "title": "Nilotinib: Drug information", "rep_snippet": "Administration  Oral: Administer twice daily with doses ~12 hours apart. Administer on an empty stomach, at least 1 hour before or 2 hours after food. Capsules should be swallowed whole with water. If unable to swallow w…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": 11.725482100072092, "bm25_max": 11.725482100072092, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Food Interactions  Food decreases the extent of absorption; rifampin concentrations may be decreased if taken with food. Management: Administer on an empty stomach with a glass of water (ie, 1 hour prior to, or 2 hours a…"}, {"doc_id": "norfloxacin-united-states-not-available-drug-information", "bm25_top3": 10.646238820773425, "bm25_max": 11.725482100072092, "bge_top3": null, "bge_max": null, "title": "Norfloxacin (United States: not available): Drug information", "rep_snippet": "Food Interactions  Norfloxacin average peak serum concentrations may be decreased if taken with food or dairy products. Management: Administer on an empty stomach with water at least 1 hour before or 2 hours after meals,…"}, {"doc_id": "ferrous-gluconate-drug-information", "bm25_top3": 11.722779974556637, "bm25_max": 11.722779974556637, "bge_top3": null, "bge_max": null, "title": "Ferrous gluconate: Drug information", "rep_snippet": "Administration  Oral: Should be administered with water or juice on an empty stomach (Liu 2012). Administration of iron preparations to premature infants with vitamin E deficiency may cause increased red cell hemolysis a…"}, {"doc_id": "liotrix-drug-information", "bm25_top3": 11.488619830708096, "bm25_max": 11.488619830708096, "bge_top3": null, "bge_max": null, "title": "Liotrix: Drug information", "rep_snippet": "Dietary Considerations  Take once a day on an empty stomach 30-60 minutes before meals."}, {"doc_id": "entecavir-drug-information", "bm25_top3": 11.395167945540365, "bm25_max": 11.395167945540365, "bge_top3": null, "bge_max": null, "title": "Entecavir: Drug information", "rep_snippet": "Administration  Administer on an empty stomach (2 hours before or after a meal). Do not dilute or mix oral solution with water or other beverages; use calibrated oral dosing syringe. Oral solution and tablet are bioequiv…"}, {"doc_id": "magaldrate-and-simethicone-drug-information", "bm25_top3": 11.312314127522392, "bm25_max": 11.312314127522392, "bge_top3": null, "bge_max": null, "title": "Magaldrate and simethicone: Drug information", "rep_snippet": "Administration  Administer on empty stomach."}, {"doc_id": "estramustine-drug-information", "bm25_top3": 10.771877585578551, "bm25_max": 10.771877585578551, "bge_top3": null, "bge_max": null, "title": "Estramustine: Drug information", "rep_snippet": "Administration  Estramustine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.  Administer on an empty stomach, at least 1 hour before or 2 hours after eating. Ad…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 10.726105667268865, "bm25_max": 10.726105667268865, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Dietary Considerations  Bowel cleansing: Should be taken on an empty stomach with clear liquids; a clear liquid diet should be used for 12 hours prior to and during tablet administration. Clear liquids may include water,…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 10.68064863535384, "bm25_max": 10.68064863535384, "bge_top3": null, "bge_max": null, "title": "Doxycycline: Drug information", "rep_snippet": "Administration  Oral administration is preferable unless patient has significant nausea and vomiting; IV and oral routes are bioequivalent.  Oral: In general, administer with meals to decrease GI upset; however, some man…"}, {"doc_id": "naloxegol-drug-information", "bm25_top3": 10.596053993176255, "bm25_max": 10.596053993176255, "bge_top3": null, "bge_max": null, "title": "Naloxegol: Drug information", "rep_snippet": "Administration  Avoid consumption of grapefruit or grapefruit juice during treatment.  Oral: Administer on an empty stomach at least 1 hour prior to or 2 hours after the first meal of the day. Swallow tablets whole, do n…"}, {"doc_id": "albendazole-drug-information", "bm25_top3": 10.553062817342397, "bm25_max": 10.553062817342397, "bge_top3": null, "bge_max": null, "title": "Albendazole: Drug information", "rep_snippet": "Administration  Administer with a high-fat meal if treating a systemic infection (to increase absorption). Administration on an empty stomach may be appropriate for treating an intraluminal infection with no systemic inv…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": 10.533463676522018, "bm25_max": 10.533463676522018, "bge_top3": null, "bge_max": null, "title": "Ampicillin: Drug information", "rep_snippet": "Dietary Considerations  Take on an empty stomach 30 minutes before or 2 hours after meals. Some products may contain sodium."}, {"doc_id": "linaclotide-drug-information", "bm25_top3": 10.493746960424758, "bm25_max": 10.493746960424758, "bge_top3": null, "bge_max": null, "title": "Linaclotide: Drug information", "rep_snippet": "Dietary Considerations  Administer at least 30 minutes before the first meal of the day on an empty stomach. Loose stools and greater stool frequency may occur after administration with a high-fat breakfast."}, {"doc_id": "deferasirox-drug-information", "bm25_top3": 9.916256426613472, "bm25_max": 9.916256426613472, "bge_top3": null, "bge_max": null, "title": "Deferasirox: Drug information", "rep_snippet": "Dietary Considerations  Tablets for oral suspension: Bioavailability increased variably when taken with food; take on empty stomach 30 minutes before a meal.  Granules and Tablets: Bioavailability decreased slightly (not…"}, {"doc_id": "moexipril-and-hydrochlorothiazide-drug-information", "bm25_top3": 9.700184968867816, "bm25_max": 9.700184968867816, "bge_top3": null, "bge_max": null, "title": "Moexipril and hydrochlorothiazide: Drug information", "rep_snippet": "Administration  Oral: Administer on an empty stomach 1 hour prior to a meal."}, {"doc_id": "equine-conjugated-estrogens-and-medroxyprogesterone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7464275360107422, "bge_max": 0.7464275360107422, "title": "Equine conjugated estrogens and medroxyprogesterone acetate: Drug information", "rep_snippet": "Dietary Considerations  Administration with food decreases nausea, administer with food. Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis."}, {"doc_id": "ibandronate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7186720768610636, "bge_max": 0.740638017654419, "title": "Ibandronate: Drug information", "rep_snippet": "Administration  Oral: Administer 60 minutes before the first food or drink of the day (other than water) and prior to taking any oral medications or supplements (eg, calcium, antacids, vitamins). Ibandronate should be ta…"}, {"doc_id": "abaloparatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7248159646987915, "bge_max": 0.7248159646987915, "title": "Abaloparatide: Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis: SubQ: 80 mcg once daily"}, {"doc_id": "teriparatide-recombinant-human-parathyroid-hormone-1-34-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7222699522972107, "bge_max": 0.7222699522972107, "title": "Teriparatide (recombinant human parathyroid hormone [1-34]): Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis (men, postmenopausal women, glucocorticoid induced): SubQ: 20 mcg once daily; Note: Initial administration should occur under circumstances in which the patient may sit or lie down, in the eve…"}, {"doc_id": "raloxifene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.706949253877004, "bge_max": 0.72194904088974, "title": "Raloxifene: Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis: Females: Oral: 60 mg once daily  Risk reduction for invasive breast cancer: Females (postmenopausal): Oral: 60 mg once daily.  Duration of therapy for breast cancer risk reduction: 5 years; m…"}, {"doc_id": "flavocoxid-united-states-note-fda-has-issued-a-warning-against-use-of-this-product-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7178555130958557, "bge_max": 0.7178555130958557, "title": "Flavocoxid (United States – Note: FDA has issued a warning against use of this product): Drug information", "rep_snippet": "Dosing: Adult  Osteoarthritis: Oral: 250 to 500 mg (with or without zinc) every 12 hours"}, {"doc_id": "bazedoxifene-and-conjugated-equine-estrogens-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7170039415359497, "bge_max": 0.7170039415359497, "title": "Bazedoxifene and conjugated equine estrogens: Drug information", "rep_snippet": "Dosing: Adult  Menopause (moderate-to-severe vasomotor symptoms), prevention of postmenopausal osteoporosis: Females: Oral: One tablet daily"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7151563167572021, "bge_max": 0.7151563167572021, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Dosing: Adult  Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis: Oral: One tablet (naproxen 375 mg/esomeprazole 20 mg or naproxen 500 mg/esomeprazole 20 mg) twice daily  Note: If a total daily dose of esomepr…"}, {"doc_id": "estradiol-and-levonorgestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7116783857345581, "bge_max": 0.7116783857345581, "title": "Estradiol and levonorgestrel: Drug information", "rep_snippet": "Dosing: Adult  Note: Patients should be treated with the lowest effective dose and for the shortest duration, consistent with treatment goals.  Treatment of moderate to severe vasomotor symptoms associated with menopause…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7076846361160278, "bge_max": 0.7076846361160278, "title": "Omeprazole: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer: Oral: 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks. Up to 40 mg once daily has been used in patients with ulcers refractive to other therapies (eg, H2 antag…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7060776352882385, "bge_max": 0.7060776352882385, "title": "Dexlansoprazole: Drug information", "rep_snippet": "Dosing: Adult  Note: Doses >30 mg do not provide additional benefit during maintenance phase.  Erosive esophagitis: Oral:  Healing: 60 mg once daily for up to 8 weeks  Maintenance: 30 mg once daily  Gastroesophageal refl…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7057257294654846, "bge_max": 0.7057257294654846, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "Dosing: Adult  Osteoarthritis, rheumatoid arthritis: Oral: One tablet (ibuprofen 800 mg/famotidine 26.6 mg) 3 times daily."}, {"doc_id": "tolmetin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7057003378868103, "bge_max": 0.7057003378868103, "title": "Tolmetin: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest possible duration.  Osteoarthritis/RA: Oral: Initial: 400 mg 3 times daily; adjust dose according to patient response after 1 to 2 weeks; Maintenance: 6…"}, {"doc_id": "ethinyl-estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7003989815711975, "bge_max": 0.7003989815711975, "title": "Ethinyl estradiol and norethindrone: Drug information", "rep_snippet": "Postmenopausal indications: General dosing guidelines: When treating postmenopausal women, use estrogens for the shortest duration possible at the lowest effective dose consistent with treatment goals. Reevaluate patient…"}, {"doc_id": "hydrocodone-and-ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6980173587799072, "bge_max": 0.6980173587799072, "title": "Hydrocodone and ibuprofen: Drug information", "rep_snippet": "Dosing: Adult  Pain management: Oral: One tablet (hydrocodone 2.5 mg to 10 mg/ibuprofen 200 mg) every 4 to 6 hours as needed; (maximum: 5 tablets [hydrocodone 12.5 to 50 mg/ibuprofen 1,000 mg] per 24 hours). Note: Short-…"}, {"doc_id": "norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.697873592376709, "bge_max": 0.697873592376709, "title": "Norethindrone: Drug information", "rep_snippet": "Endometriosis: Females: Oral: Norethindrone acetate: 5 mg/day for 14 days; increase at increments of 2.5 mg/day every 2 weeks to reach 15 mg/day; continue for 6 to 9 months or until breakthrough bleeding demands temporar…"}, {"doc_id": "nizatidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6965842843055725, "bge_max": 0.6965842843055725, "title": "Nizatidine: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer: Oral:  Treatment: 300 mg once daily at bedtime or 150 mg twice daily for up to 8 weeks  Maintenance of healing: 150 mg once daily at bedtime  Gastric ulcer, benign: Oral: 150 mg twice daily…"}, {"doc_id": "methenamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6964593529701233, "bge_max": 0.6964593529701233, "title": "Methenamine: Drug information", "rep_snippet": "Administration  Restrict alkalinizing foods and medications to maintain urine pH ≤5.5.  Hippurate: Administer twice daily (morning and night).  Mandelate: Administer 4 times daily (after each meal and at bedtime)."}, {"doc_id": "vitamin-d2-ergocalciferol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6958297491073608, "bge_max": 0.6958297491073608, "title": "Vitamin D2 (ergocalciferol): Drug information", "rep_snippet": "Dosing: Adult  Note: 1 mcg = 40 units  Osteoporosis prevention (off-label use): Adults ≥50 years: 800 to 1000 units/day (NOF guidelines, 2014)  Vitamin D deficiency treatment (off-label dose): (Holick, 2011): Oral: 6000…"}, {"doc_id": "difenoxin-and-atropine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6953810453414917, "bge_max": 0.6953810453414917, "title": "Difenoxin and atropine: Drug information", "rep_snippet": "Dosing: Adult  Diarrhea: Oral: Initial: 2 tablets, then 1 tablet after each loose stool or 1 tablet every 3 to 4 hours as needed, up to 8 tablets in a 24-hour period; if no improvement after 48 hours, continued administr…"}, {"doc_id": "conjugated-equine-estrogens-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6917757987976074, "bge_max": 0.6917757987976074, "title": "Conjugated equine estrogens (systemic): Drug information", "rep_snippet": "Hypoestrogenism (female) due to hypogonadism: Oral: 0.3 or 0.625 mg/day given cyclically*; dose may be titrated in 6- to 12-month intervals; progestin treatment should be added to maintain bone mineral density once skele…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6917727589607239, "bge_max": 0.6917727589607239, "title": "Mirabegron: Drug information", "rep_snippet": "Dosing: Adult  Overactive bladder (OAB): Oral: Initial: 25 mg once daily; efficacy is observed within 8 weeks for 25 mg dose. May increase to 50 mg once daily based on individual patient efficacy and tolerability."}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6911685466766357, "bge_max": 0.6911685466766357, "title": "Esomeprazole: Drug information", "rep_snippet": "Dosing: Adult  Note: All dosing is expressed in terms of esomeprazole base, regardless of the salt associated with the dosing information. Esomeprazole strontium 24.65 mg is equivalent to 20 mg of esomeprazole base; esom…"}, {"doc_id": "glycerin-and-lidocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6909034252166748, "bge_max": 0.6909034252166748, "title": "Glycerin and lidocaine: Drug information", "rep_snippet": "Dosing: Adult  Anorectal disorders: Topical: Apply to the affected area ≤6 times daily (morning, evening, and after each bowel movement)."}, {"doc_id": "estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6900888681411743, "bge_max": 0.6900888681411743, "title": "Estradiol and norethindrone: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Females: These combination products are indicated for women with a uterus. When treating postmenopausal women, use for the shortest duration possible at the lowest effective dose…"}, {"doc_id": "dimethyl-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6900444030761719, "bge_max": 0.6900444030761719, "title": "Dimethyl fumarate: Drug information", "rep_snippet": "Dosing: Adult  Multiple sclerosis (relapsing): Oral: Initial: 120 mg twice daily; after 7 days, increase to the maintenance dose: 240 mg twice daily"}, {"doc_id": "estradiol-and-norgestimate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6894387006759644, "bge_max": 0.6894387006759644, "title": "Estradiol and norgestimate: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: For use in women with a uterus. When treating postmenopausal women, use estrogens for the shortest duration possible at the lowest effective dose consistent with treatment goals.…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6883991360664368, "bge_max": 0.6883991360664368, "title": "Lansoprazole: Drug information", "rep_snippet": "Dosing: Adult  Symptomatic GERD: Oral: Short-term treatment: 15 mg once daily for up to 8 weeks  Erosive esophagitis: Oral: Short-term treatment: 30 mg once daily for up to 8 weeks; continued treatment for an additional…"}, {"doc_id": "orlistat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.687766432762146, "bge_max": 0.687766432762146, "title": "Orlistat: Drug information", "rep_snippet": "Dosing: Adult  Obesity management: Oral:  Xenical: 120 mg 3 times daily with each main meal containing fat (during or up to 1 hour after the meal); omit dose if meal is occasionally missed or contains no fat.  Alli: OTC…"}, {"doc_id": "denosumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6872832179069519, "bge_max": 0.6872832179069519, "title": "Denosumab: Drug information", "rep_snippet": "Treatment of osteoporosis in men or in postmenopausal women: SubQ: 60 mg as a single dose, once every 6 months  Bone destruction caused by rheumatoid arthritis (off-label use): SubQ: 60 mg or 180 mg as a single one time…"}, {"doc_id": "gemcitabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6866635084152222, "bge_max": 0.6866635084152222, "title": "Gemcitabine: Drug information", "rep_snippet": "Osteosarcoma, refractory: 675 mg/m2 over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Navid 2008) or 1,000 mg/m2 weekly for 7 weeks followed by 1 week rest; then weekly for 3 weeks…"}]}
{"qid": "Q30_noise", "query": "For weekly alendronate, what dose and exactly how to take it (position, timing, fluids)?", "base_qid": "Q30", "variant_type": "noise", "candidates": [{"doc_id": "alendronate-and-cholecalciferol-drug-information", "bm25_top3": 21.19822398854222, "bm25_max": 32.98503366063501, "bge_top3": 0.6633524298667908, "bge_max": 0.6953301429748535, "title": "Alendronate and cholecalciferol: Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis: Males or postmenopausal females: Oral: One tablet (alendronate 70 mg/cholecalciferol 2,800 units or alendronate 70 mg/cholecalciferol 5,600 units) once weekly. Note: The optimal duration of o…"}, {"doc_id": "insulin-lispro-protamine-and-insulin-lispro-drug-information", "bm25_top3": 30.663675530864772, "bm25_max": 30.663675530864772, "bge_top3": null, "bge_max": null, "title": "Insulin lispro protamine and insulin lispro: Drug information", "rep_snippet": "Initial: Insulin lispro protamine and insulin lispro premix dose is obtained by dividing the current total daily basal insulin dose into 2 doses administered either as two-thirds of the dose before the morning meal and o…"}, {"doc_id": "alendronate-drug-information", "bm25_top3": 20.13309495910108, "bm25_max": 29.931974052931643, "bge_top3": 0.6790412664413452, "bge_max": 0.6790412664413452, "title": "Alendronate: Drug information", "rep_snippet": "Prevention (off-label use): 5 mg once daily; a dose of 10 mg once daily should be used in postmenopausal females who are not receiving estrogen (Saag 1998). Note: Use is not recommended in women who are pregnant or who p…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 27.384962618575834, "bm25_max": 28.595442930813682, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Note: Provided the total weekly dose is maintained, any dosing interval from daily up to biweekly (every 2 weeks) may be used. For patients switching to Hizentra from a different SubQ formulation, the previous weekly Sub…"}, {"doc_id": "insulin-nph-and-insulin-regular-drug-information", "bm25_top3": 27.789605535298108, "bm25_max": 27.789605535298108, "bge_top3": null, "bge_max": null, "title": "Insulin NPH and insulin regular: Drug information", "rep_snippet": "To reach self-monitoring glucose target: Adjust dose by 10% to 15% or 1 to 2 units; may adjust at weekly or twice weekly intervals (ADA 2017f)  For hypoglycemia: If no clear reason for hypoglycemia, decrease dose by 2 to…"}, {"doc_id": "asfotase-alfa-drug-information", "bm25_top3": 19.077051419212015, "bm25_max": 19.077051419212015, "bge_top3": null, "bge_max": null, "title": "Asfotase alfa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Asfotase alfa: Pediatric drug information\")  Hypophosphatasia (HPP): SubQ: Note: Round patient weight to the nearest kg when determining dose. Do not administer the 80…"}, {"doc_id": "ivacaftor-drug-information", "bm25_top3": 18.895401166704424, "bm25_max": 18.895401166704424, "bge_top3": null, "bge_max": null, "title": "Ivacaftor: Drug information", "rep_snippet": "Dosing: Adult  Cystic fibrosis: Oral: Tablet: 150 mg every 12 hours  Dosage adjustment for ivacaftor with concomitant medications:  CYP3A strong inhibitors (eg, ketoconazole, itraconazole, posaconazole, voriconazole, cla…"}, {"doc_id": "epoetin-alfa-drug-information", "bm25_top3": 18.506220647218203, "bm25_max": 18.506220647218203, "bge_top3": null, "bge_max": null, "title": "Epoetin alfa: Drug information", "rep_snippet": "600 units/kg once weekly for 4 doses, given 21-, 14-, and 7 days before surgery, and on the day of surgery  RBC transfusion refusal (substitute) (off-label use): Note: Concomitantly administer iron (with or without vitam…"}, {"doc_id": "interferon-beta-1a-drug-information", "bm25_top3": 18.12940457712204, "bm25_max": 18.360463039948126, "bge_top3": null, "bge_max": null, "title": "Interferon beta-1a: Drug information", "rep_snippet": "Initial: 4.4 mcg (20% of target dose) 3 times weekly for 2 weeks  Titration: 11 mcg (50% of target dose) 3 times weekly for 2 weeks  Target dose: 22 mcg 3 times weekly  Single demyelinating event (Canadian labeling [Rebi…"}, {"doc_id": "insulin-degludec-drug-information", "bm25_top3": 18.158918645794987, "bm25_max": 18.158918645794987, "bge_top3": null, "bge_max": null, "title": "Insulin degludec: Drug information", "rep_snippet": "Initial: 10 units or 0.1 to 0.2 units/kg once daily, usually in combination with metformin +/- other noninsulin agent (ADA 2017f). Alternatively, if HbA1c >8% prior to initiation of basal insulin, 0.2 to 0.3 units/kg onc…"}, {"doc_id": "selexipag-drug-information", "bm25_top3": 17.335271476536875, "bm25_max": 17.335271476536875, "bge_top3": null, "bge_max": null, "title": "Selexipag: Drug information", "rep_snippet": "Dosing: Adult  Pulmonary arterial hypertension: Oral: Initial: 200 mcg twice daily; increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose (maximum dose: 1,600 mcg twice daily). If a…"}, {"doc_id": "crizotinib-drug-information", "bm25_top3": 17.17790733393792, "bm25_max": 17.17790733393792, "bge_top3": null, "bge_max": null, "title": "Crizotinib: Drug information", "rep_snippet": "Dosing: Adult  Note: Crizotinib is associated with a moderate emetic potential (Hesketh 2017); antiemetics may be needed to prevent nausea and vomiting.  Non-small cell lung cancer (NSCLC), metastatic (ALK- or ROS1-posit…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": 16.678159339486754, "bm25_max": 16.678159339486754, "bge_top3": null, "bge_max": null, "title": "Methotrexate: Drug information", "rep_snippet": "Nonleukemic meningeal cancer (off-label uses): Intrathecal: 12 mg/dose twice weekly for 4 weeks, then weekly for 4 doses, then monthly for 4 doses (Glantz 1998) or 10 mg twice weekly for 4 weeks, then weekly for 1 month,…"}, {"doc_id": "insulin-detemir-drug-information", "bm25_top3": 16.529862790641893, "bm25_max": 16.529862790641893, "bge_top3": null, "bge_max": null, "title": "Insulin detemir: Drug information", "rep_snippet": "Conversion from insulin glargine or NPH insulin: Initial: May be substituted on an equivalent unit-per-unit basis; in one Type 2 diabetes clinical trial, higher doses of insulin detemir were required than insulin NPH.  A…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 16.441607737966677, "bm25_max": 16.441607737966677, "bge_top3": null, "bge_max": null, "title": "Dexlansoprazole: Drug information", "rep_snippet": "Dosing: Adult  Note: Doses >30 mg do not provide additional benefit during maintenance phase.  Erosive esophagitis: Oral:  Healing: 60 mg once daily for up to 8 weeks  Maintenance: 30 mg once daily  Gastroesophageal refl…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-drug-information", "bm25_top3": 14.780736180033212, "bm25_max": 16.422296362511673, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2b: Drug information", "rep_snippet": "Treatment duration: 48 weeks for genotype 1, 24 weeks for genotypes 2 and 3, or 48 weeks for patients who previously failed therapy (regardless of genotype)  Monotherapy: Note: Monotherapy is not recommended in HCV treat…"}, {"doc_id": "recombinant-hemagglutinin-influenza-vaccine-drug-information", "bm25_top3": 16.413513011624076, "bm25_max": 16.413513011624076, "bge_top3": null, "bge_max": null, "title": "Recombinant hemagglutinin influenza vaccine: Drug information", "rep_snippet": "Dosing: Adult  It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available (and, if possible, by the e…"}, {"doc_id": "telaprevir-united-states-not-available-drug-information", "bm25_top3": 16.318249052689545, "bm25_max": 16.318249052689545, "bge_top3": null, "bge_max": null, "title": "Telaprevir (United States: Not available): Drug information", "rep_snippet": "HCV-RNA detectable (level >1000 units/mL) at week 4 or week 12: Discontinue telaprevir, peginterferon alfa, and ribavirin at week 12  HCV-RNA detectable (level greater than ~10-15 units/mL) at week 24: Discontinue pegint…"}, {"doc_id": "risedronate-drug-information", "bm25_top3": 16.22047438936122, "bm25_max": 16.22047438936122, "bge_top3": 0.6173281669616699, "bge_max": 0.6173281669616699, "title": "Risedronate: Drug information", "rep_snippet": "Once-weekly: If a once-weekly dose is missed, it should be given the next morning after remembered; may then return to the original once-weekly schedule (original scheduled day of the week), however, do not give 2 doses…"}, {"doc_id": "sodium-picosulfate-magnesium-oxide-and-citric-acid-drug-information", "bm25_top3": 15.67943460340172, "bm25_max": 15.67943460340172, "bge_top3": null, "bge_max": null, "title": "Sodium picosulfate, magnesium oxide, and citric acid: Drug information", "rep_snippet": "Administration  Oral:  Clenpiq: Ready to drink oral solution; dilution is not required. Consume only clear liquids on the day prior to the colonoscopy and up until 2 hours before the time of the procedure; stop consumpti…"}, {"doc_id": "ixazomib-drug-information", "bm25_top3": 14.920986114582025, "bm25_max": 14.920986114582025, "bge_top3": null, "bge_max": null, "title": "Ixazomib: Drug information", "rep_snippet": "Dosing: Renal Impairment  The International Myeloma Working Group (IMWG) recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Dis…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": 14.531266089505074, "bm25_max": 14.531266089505074, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Three-times-weekly directly observed therapy (DOT): Note: Although suggested dosing based on experience with twice-weekly regimen; experts suggest three-times-weekly regimens are more effective than twice-weekly DOT regi…"}, {"doc_id": "etanercept-including-biosimilars-of-etanercept-drug-information", "bm25_top3": 14.458476424149673, "bm25_max": 14.458476424149673, "bge_top3": null, "bge_max": null, "title": "Etanercept (including biosimilars of etanercept): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Etanercept (including biosimilars of etanercept): Pediatric drug information\")  Note: Erelzi is approved as biosimilar to Enbrel.  Juvenile idiopathic arthritis: Childr…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 13.958173339437085, "bm25_max": 13.958173339437085, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2a-drug-information", "bm25_top3": 13.26934350788304, "bm25_max": 13.26934350788304, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2a: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Dosage modifications for adverse reactions and/or toxicity:  Children  ≥3 years and Adolescents: HBV:  Based on hematologic parameters:  ANC 750 to 999/mm3: No dosage adjustment necessary…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": 8.52531157148836, "bm25_max": 8.52531157148836, "bge_top3": null, "bge_max": null, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Dietary Considerations  Take with food. The type or timing of a meal is not important as long as dose is taken with food."}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 7.740382116259731, "bm25_max": 7.740382116259731, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Mercaptopurine is the active metabolite of azathioprine. Following administration of azathioprine, mercaptopurine can be detected in breast milk (Gardiner 2006). It is not known if/how much…"}, {"doc_id": "iohexol-drug-information", "bm25_top3": 5.168635687979055, "bm25_max": 5.168635687979055, "bge_top3": null, "bge_max": null, "title": "Iohexol: Drug information", "rep_snippet": "Discontinue neuroleptic medications (including phenothiazines) at least 48 hours prior to procedure. May maintain a normal diet up to 2 hours before the procedure. Ensure hydration fluids up to the procedure (hydrate wel…"}, {"doc_id": "ammonium-lactate-topical-drug-information", "bm25_top3": 4.562001604084896, "bm25_max": 4.562001604084896, "bge_top3": null, "bge_max": null, "title": "Ammonium lactate (topical): Drug information", "rep_snippet": "Breast-Feeding Considerations  It is not known how this medication affects normal levels of lactic acid in human milk. Because studies have not been done in nursing women, use with caution when needed."}, {"doc_id": "formoterol-drug-information", "bm25_top3": 4.3254003669052175, "bm25_max": 4.3254003669052175, "bge_top3": null, "bge_max": null, "title": "Formoterol: Drug information", "rep_snippet": "Oxeze Turbuhaler [Canadian product]: Hold inhaler upright. Turn colored grip as far as it will go in one direction and then turn back to original position; a clicking sound should be heard which means the inhaler is read…"}, {"doc_id": "probenecid-drug-information", "bm25_top3": 4.22567327130831, "bm25_max": 4.22567327130831, "bge_top3": null, "bge_max": null, "title": "Probenecid: Drug information", "rep_snippet": "Dietary Considerations  Drug may cause GI upset; take with food if GI upset. Drink plenty of fluids."}, {"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 2.435533940355599, "bm25_max": 3.255603842034766, "bge_top3": null, "bge_max": null, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "Arnuity Ellipta: Administer the dose at the same time every day. Do not shake inhaler. When ready to use, open and prepare mouthpiece of the inhaler and slide the cover down to activate the first dose. Exhale fully (not…"}, {"doc_id": "intravesical-bacillus-calmette-guerin-drug-information", "bm25_top3": 3.1615438404809098, "bm25_max": 3.1615438404809098, "bge_top3": null, "bge_max": null, "title": "Intravesical Bacillus Calmette-Guerin: Drug information", "rep_snippet": "Administration  For intravesicular (bladder instillation) administration only; do not administer IV, SubQ, IM, or intradermally.  Intravesicular: Patients should not drink fluids for 4 hours prior to instillation. Empty…"}, {"doc_id": "tetracycline-drug-information", "bm25_top3": 3.0220183732005683, "bm25_max": 3.0220183732005683, "bge_top3": null, "bge_max": null, "title": "Tetracycline: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics  Absorption: Oral: 77% to 88% (Agwuh 2006); IM: Poor, with less than 60% of dose absorbed  Distribution: Widely distributed to most body fluids and tissues including ascitic, synovial and pleura…"}, {"doc_id": "terbutaline-drug-information", "bm25_top3": 2.9349462188802136, "bm25_max": 2.9349462188802136, "bge_top3": null, "bge_max": null, "title": "Terbutaline: Drug information", "rep_snippet": "Inhalation: Bricanyl Turbuhaler [Canadian product]: After removing lid, patient should hold inhaler upright and turn blue grip as far as it will go in one direction then turn it back to original position. Clicking sound…"}, {"doc_id": "polycarbophil-drug-information", "bm25_top3": 2.558541154878313, "bm25_max": 2.558541154878313, "bge_top3": null, "bge_max": null, "title": "Polycarbophil: Drug information", "rep_snippet": "Administration  Patient should drink adequate fluids (8 oz of water or other fluids) with each dose."}, {"doc_id": "budesonide-nasal-drug-information", "bm25_top3": 2.188026279179926, "bm25_max": 2.188026279179926, "bge_top3": null, "bge_max": null, "title": "Budesonide (nasal): Drug information", "rep_snippet": "Administration  Inhalation:  Powder for nasal inhalation: Rhinocort Turbuhaler [Canadian product]: To prepare inhaler prior to use, load dose by holding inhaler in upright position and turn grey grip as far as it will go…"}, {"doc_id": "mefloquine-drug-information", "bm25_top3": 1.2593873637819488, "bm25_max": 1.2593873637819488, "bge_top3": null, "bge_max": null, "title": "Mefloquine: Drug information", "rep_snippet": "Administration  Administer with food and with at least 240 mL of water. When used for malaria prophylaxis, dose should be taken once weekly on the same day each week. If vomiting occurs within 30 minutes after the dose,…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": 0.9320795790885992, "bm25_max": 0.9320795790885992, "bge_top3": null, "bge_max": null, "title": "Mifepristone: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Korlym is only available through a restricted access program. For prescriber registration and patient enrollment forms, please refer to http://www.korlym.com/hcp/how-to-prescribe-korl…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6325207750002543, "bge_max": 0.6463878154754639, "title": "Amiodarone: Drug information", "rep_snippet": "Administration  Oral: Administer consistently with regard to meals. Take in divided doses with meals if GI upset occurs or if taking large daily dose. If GI intolerance occurs with single-dose therapy, use twice daily do…"}, {"doc_id": "norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6432122588157654, "bge_max": 0.6432122588157654, "title": "Norethindrone: Drug information", "rep_snippet": "Dosing: Adult  Abnormal uterine bleeding and amenorrhea: Females: Oral: Norethindrone acetate: 2.5 to 10 mg/day for 5 to 10 days. Secretory transformation of the endometrium will occur when adequately primed with endogen…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6267945766448975, "bge_max": 0.6346958875656128, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Dosing: Adult  Amebiasis (acute dysentery): Oral: Immediate-release tablets and capsules: 750 mg every 8 hours for 5 to 10 days  Amebic liver abscess: Oral:  Immediate-release tablets: 500 to 750 mg every 8 hours for 5 t…"}, {"doc_id": "laronidase-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6338651776313782, "bge_max": 0.6338651776313782, "title": "Laronidase: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Laronidase: Pediatric drug information\")  Note: Premedicate with antipyretic and/or antihistamines 1 hour prior to start of infusion.  MPS I (Hurler syndrome, Hurler-Sc…"}, {"doc_id": "vardenafil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6336514949798584, "bge_max": 0.6336514949798584, "title": "Vardenafil: Drug information", "rep_snippet": "Dosing: Adult  Note: Oral disintegrating tablets should not be used interchangeably with film-coated tablets; patients requiring a dose other than 10 mg should use the film-coated tablets.  Erectile dysfunction: Oral:  F…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6294949650764465, "bge_max": 0.6327856779098511, "title": "Spironolactone: Drug information", "rep_snippet": "Dosing: Adult  Note: Suspension is NOT therapeutically equivalent to tablets. In patients requiring >100 mg/dose, use tablets (>100 mg/dose of suspension may result in spironolactone concentration higher than expected).…"}, {"doc_id": "thioguanine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6316413879394531, "bge_max": 0.6316413879394531, "title": "Thioguanine: Drug information", "rep_snippet": "Dosing: Adult  Acute myeloid leukemia (AML): Oral: 2 mg/kg once daily for 4 weeks; if no clinical improvement after 4 weeks and ANC and platelet counts are not depressed, may increase dose to 3 mg/kg once daily with care…"}, {"doc_id": "melphalan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6309778094291687, "bge_max": 0.6309778094291687, "title": "Melphalan: Drug information", "rep_snippet": "4 mg/m2/day for 7 days every 4 weeks (in combination with prednisone or with prednisone and thalidomide) (Palumbo 2006; Palumbo 2008) or  6 mg/m2/day for 7 days every 4 weeks (in combination with prednisone) (Palumbo 200…"}, {"doc_id": "ibandronate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6296088695526123, "bge_max": 0.6296088695526123, "title": "Ibandronate: Drug information", "rep_snippet": "Administration  Oral: Administer 60 minutes before the first food or drink of the day (other than water) and prior to taking any oral medications or supplements (eg, calcium, antacids, vitamins). Ibandronate should be ta…"}, {"doc_id": "mefenamic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.628278374671936, "bge_max": 0.628278374671936, "title": "Mefenamic acid: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest possible duration.  Pain, mild to moderate: Oral: Initial: 500 mg, then 250 mg every 6 hours as needed; usually not to exceed 1 week.  Primary dysmenorr…"}, {"doc_id": "nifedipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6275194883346558, "bge_max": 0.6275194883346558, "title": "Nifedipine: Drug information", "rep_snippet": "Dosing: Adult  Dosage adjustments should occur at 7- to 14-day intervals to allow for adequate assessment of new dose; however, if clinically indicated, titration may be done more rapidly with appropriate monitoring; whe…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6214995980262756, "bge_max": 0.6273142695426941, "title": "Amlodipine: Drug information", "rep_snippet": "Dosing: Geriatric  Dosing should start at the lower end of dosing range and titrated to response due to possible increased incidence of hepatic, renal, or cardiac impairment. Elderly patients also show decreased clearanc…"}, {"doc_id": "clonidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6214585602283478, "bge_max": 0.6264381408691406, "title": "Clonidine: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing is expressed as the salt (clonidine hydrochloride) unless otherwise noted. Formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to…"}, {"doc_id": "human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6262616515159607, "bge_max": 0.6262616515159607, "title": "Human-plasma derived von Willebrand factor (contains factor VIII): Drug information", "rep_snippet": "Initial: 80 to 100 units/dL  Initial: 1 to 7 days  Maintenance: 50 units/dL  Maintenance: 8 to 14 days  Gastrointestinal  Initial: 80 to 100 units/dL  Initial: 7 to 14 days  Maintenance: 50 units/dL  Maintenance: Not spe…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6258841753005981, "bge_max": 0.6258841753005981, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Dosing: Adult  Note: Dose is based on the amoxicillin component. Dose and frequency are product specific; not all products are interchangeable. Using a product with the incorrect amoxicillin:clavulanate ratio could resul…"}, {"doc_id": "baclofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6235514879226685, "bge_max": 0.6235514879226685, "title": "Baclofen: Drug information", "rep_snippet": "Note: Dosage adjustments may be required often during the first few months of therapy to adjust for life style changes due to alleviation of spasticity. Maintain lowest dose that produces adequate response. Most patients…"}, {"doc_id": "isosorbide-dinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6231289505958557, "bge_max": 0.6231289505958557, "title": "Isosorbide dinitrate: Drug information", "rep_snippet": "Dosing: Adult  Angina pectoris (prevention): Note: Due to slower onset of action, isosorbide dinitrate is not the drug of choice to abort an acute anginal episode. Tolerance to nitrate effects develops with chronic expos…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6230891942977905, "bge_max": 0.6230891942977905, "title": "Rabeprazole: Drug information", "rep_snippet": "Sequential regimen: 20 mg twice daily plus amoxicillin 1 g twice daily for 5 to 7 days; then continue rabeprazole along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily fo…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6225987672805786, "bge_max": 0.6225987672805786, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Note: Sequential therapy (IV to oral) may be instituted based on prescriber's discretion.  Acute bacterial rhinosinusitis: Oral, IV:  Manufacturer's labeling: 750 mg every 24 hours for 5 days or 500 mg eve…"}, {"doc_id": "nimodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.62181556224823, "bge_max": 0.62181556224823, "title": "Nimodipine: Drug information", "rep_snippet": "Dosing: Adult  Note: For oral administration ONLY.  Subarachnoid hemorrhage: Oral: 60 mg every 4 hours for 21 consecutive days. Note: Start therapy within 96 hours of the onset of subarachnoid hemorrhage."}, {"doc_id": "oxybutynin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6201797127723694, "bge_max": 0.6201797127723694, "title": "Oxybutynin: Drug information", "rep_snippet": "Dosing: Adult  Overactive bladder:  Oral:  Immediate release: 5 mg 2 to 3 times daily; maximum: 5 mg 4 times daily  Extended release: Initial: 5 to 10 mg once daily, adjust dose in 5 mg increments at weekly intervals; ma…"}, {"doc_id": "sildenafil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6201416254043579, "bge_max": 0.6201416254043579, "title": "Sildenafil: Drug information", "rep_snippet": "Dosing: Adult  Erectile dysfunction (Viagra): Oral: Usual dose: 50 mg once daily 1 hour (range: 30 minutes to 4 hours) before sexual activity as needed; dosing range: 25 to 100 mg once daily; maximum dose: 100 mg once da…"}, {"doc_id": "hydrocortisone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6197731494903564, "bge_max": 0.6197731494903564, "title": "Hydrocortisone (systemic): Drug information", "rep_snippet": "Acute adrenal insufficiency (adrenal crisis) (off-label dose): 100 mg IV bolus, immediately followed by 200 mg over 24 hours as a continuous IV infusion or in divided doses (IM or IV) every 6 hours, then 100 mg over 24 h…"}, {"doc_id": "lidocaine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6195797920227051, "bge_max": 0.6195797920227051, "title": "Lidocaine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Antiarrhythmic (ACLS 2010; ACLS 2015):  VF or pulseless VT (after defibrillation attempts, CPR, and vasopressor administration), alternative to amiodarone: IV, intraosseous (IO): Initial: 1 to 1.5 mg/kg. I…"}, {"doc_id": "meropenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6191356182098389, "bge_max": 0.6191356182098389, "title": "Meropenem: Drug information", "rep_snippet": "Manufacturer’s labeling: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied)  Alternate recommendations (off-label dosing; Aronoff 2007):  GFR 30 to 50 mL/minute: Administer 20…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6190995573997498, "bge_max": 0.6190995573997498, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "Dosing: Adult  Adrenal crisis (shock due to adrenal insufficiency and unresponsive to conventional therapy) (off-label dose): IV: 4 to 10 mg as a single dose, which may be repeated if necessary. Note: Hydrocortisone is t…"}, {"doc_id": "sodium-phenylacetate-and-sodium-benzoate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6184788346290588, "bge_max": 0.6184788346290588, "title": "Sodium phenylacetate and sodium benzoate: Drug information", "rep_snippet": "Dosing: Adult  Note: Administer as a loading dose over 90 to 120 minutes, followed by an equivalent maintenance infusion given over 24 hours. Initiate therapy as soon as the diagnosis of hyperammonemia is made; hyperammo…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6173705458641052, "bge_max": 0.6173705458641052, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Note: Extended-release tablets and immediate-release formulations are not interchangeable. Unless otherwise specified, oral dosing reflects the use of immediate-release formulations.  Anthrax:  Note: Consu…"}, {"doc_id": "arginine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6170148253440857, "bge_max": 0.6170148253440857, "title": "Arginine: Drug information", "rep_snippet": "Unconfirmed/pending diagnosis: IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (NORD 2012); if ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 mg/kg/day  BSA-dir…"}, {"doc_id": "sodium-bicarbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169935464859009, "bge_max": 0.6169935464859009, "title": "Sodium bicarbonate: Drug information", "rep_snippet": "Administer 1/2 dose initially, then remaining 1/2 dose over the next 24 hours; monitor pH, serum HCO3-, and clinical status. Note: These equations provide an estimated replacement dose. The underlying cause and degree of…"}, {"doc_id": "promethazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169764995574951, "bge_max": 0.6169764995574951, "title": "Promethazine: Drug information", "rep_snippet": "Dosing: Adult  Allergic conditions, treatment:  Oral, rectal: 25 mg at bedtime or 12.5 mg before meals and at bedtime (usual range: 6.25 to 12.5 mg 3 times daily)  IM, IV: 25 mg, may repeat in 2 hours when necessary; swi…"}, {"doc_id": "mitoxantrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6168949604034424, "bge_max": 0.6168949604034424, "title": "Mitoxantrone: Drug information", "rep_snippet": "Dosing: Adult  Details concerning dosing in combination regimens should also be consulted.  US labeling:  Acute nonlymphocytic leukemias (ANLL): IV:  Acute myeloid leukemia (AML) induction: 12 mg/m2 once daily for 3 days…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6168639063835144, "bge_max": 0.6168639063835144, "title": "Fluvastatin: Drug information", "rep_snippet": "Dosing: Adult  Heterozygous familial and nonfamilial hypercholesterolemia: Oral:  Immediate release: 40 mg once daily in the evening or 40 mg twice daily  Extended release: 80 mg once daily (anytime)  Mixed dyslipidemia:…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6164590120315552, "bge_max": 0.6164590120315552, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Acute bacterial rhinosinusitis: Oral, IV: 400 mg every 24 hours for 10 days (manufacturer’s labeling) or 5 to 7 days (Chow 2012). Note: Recommended in patients with beta-lactam allergy; may also be used if…"}, {"doc_id": "carvedilol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6158995628356934, "bge_max": 0.6158995628356934, "title": "Carvedilol: Drug information", "rep_snippet": "Extended release: Initial: 10 mg once daily for 2 weeks; if the dose is tolerated, increase dose to 20 mg, 40 mg, and 80 mg over successive intervals of at least 2 weeks. Maintain on lower dose if higher dose is not tole…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6156923770904541, "bge_max": 0.6156923770904541, "title": "Pantoprazole: Drug information", "rep_snippet": "Dosing: Adult  Erosive esophagitis associated with GERD:  Oral:  Treatment: 40 mg once daily for up to 8 weeks; an additional 8 weeks may be used in patients who have not healed after an 8-week course. Lower doses (20 mg…"}, {"doc_id": "lamotrigine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6145604848861694, "bge_max": 0.6145604848861694, "title": "Lamotrigine: Drug information", "rep_snippet": "Dosing: Adult  Note: Drugs that induce lamotrigine glucuronidation include carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir, and atazanavir/ritonavir. Valproic acid inhibits lamotrigine g…"}, {"doc_id": "minocycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6145281195640564, "bge_max": 0.6145281195640564, "title": "Minocycline: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range:  IV: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours (maximum: 400 mg daily)  Oral: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours; more frequent dosing i…"}, {"doc_id": "dantrolene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.614128828048706, "bge_max": 0.614128828048706, "title": "Dantrolene: Drug information", "rep_snippet": "Dosing: Adult  Chronic spasticity: Oral:  Note: Dose should be titrated and individualized for maximum effect; use the lowest dose compatible with optimal response. Some patients may not respond until a higher daily dosa…"}, {"doc_id": "mineral-oil-drug-information", "bm25_top3": 0.5277026113586274, "bm25_max": 0.5277026113586274, "bge_top3": null, "bge_max": null, "title": "Mineral oil: Drug information", "rep_snippet": "Administration  Oral: Mineral oil may be more palatable if refrigerated (NASGHAN, 2006). Due to risk of aspiration, do not administer to patient in supine position.  Plain (nonemulsified): Administer on an empty stomach.…"}]}
{"qid": "Q30_spelling", "query": "Alendronat weekly — dosing + admin rules.", "base_qid": "Q30", "variant_type": "spelling", "candidates": [{"doc_id": "alendronate-and-cholecalciferol-drug-information", "bm25_top3": 24.583383186216494, "bm25_max": 24.583383186216494, "bge_top3": 0.6142290035883585, "bge_max": 0.619655191898346, "title": "Alendronate and cholecalciferol: Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis: Males or postmenopausal females: Oral: One tablet (alendronate 70 mg/cholecalciferol 2,800 units or alendronate 70 mg/cholecalciferol 5,600 units) once weekly. Note: The optimal duration of o…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 12.043852609056518, "bm25_max": 14.67948483480004, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Note: Provided the total weekly dose is maintained, any dosing interval from daily up to biweekly (every 2 weeks) may be used. For patients switching to Hizentra from a different SubQ formulation, the previous weekly Sub…"}, {"doc_id": "c1-esterase-inhibitor-recombinant-human-drug-information", "bm25_top3": 13.761944352613444, "bm25_max": 13.761944352613444, "bge_top3": null, "bge_max": null, "title": "C1 esterase inhibitor, recombinant human: Drug information", "rep_snippet": "Dosing: Adult  Hereditary angioedema (treatment): IV:  Weight <84 kg: 50 units/kg (maximum dose: 4,200 units) as a single dose  Weight ≥84 kg: 4,200 units as a single dose  Note: If attack symptoms persist, one additiona…"}, {"doc_id": "pyrazinamide-drug-information", "bm25_top3": 12.229171285983572, "bm25_max": 13.616296272802987, "bge_top3": null, "bge_max": null, "title": "Pyrazinamide: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis, treatment (drug-susceptible): Oral: Note: Always administer in combination with other antitubercular drugs (Nahid 2016).  ATS/CDC/IDSA drug-sensitive tuberculosis guideline recommendations (N…"}, {"doc_id": "dulaglutide-drug-information", "bm25_top3": 13.514911977019086, "bm25_max": 13.514911977019086, "bge_top3": null, "bge_max": null, "title": "Dulaglutide: Drug information", "rep_snippet": "Dosing: Adult  Type 2 diabetes mellitus: SubQ: Initial: 0.75 mg once weekly; may increase to 1.5 mg once weekly if inadequate glycemic response; maximum: 1.5 mg/week  Missed doses: If a dose is missed, administer as soon…"}, {"doc_id": "isoniazid-drug-information", "bm25_top3": 11.92596971839291, "bm25_max": 13.271553250526273, "bge_top3": null, "bge_max": null, "title": "Isoniazid: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis, active (drug susceptible): Oral, IM: Note: Always administer in combination with other antitubercular drugs. Concomitant pyridoxine is also recommended in any patient at risk for neuropathy (…"}, {"doc_id": "etanercept-including-biosimilars-of-etanercept-drug-information", "bm25_top3": 11.693337301805808, "bm25_max": 12.982473151482486, "bge_top3": null, "bge_max": null, "title": "Etanercept (including biosimilars of etanercept): Drug information", "rep_snippet": "Dosing: Adult  Note: Erelzi is approved as biosimilar to Enbrel.  Ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis: SubQ: Note: May continue methotrexate, glucocorticoids, salicylates, NSAIDs, or analges…"}, {"doc_id": "albiglutide-drug-information", "bm25_top3": 12.822946263402134, "bm25_max": 12.822946263402134, "bge_top3": null, "bge_max": null, "title": "Albiglutide: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: SubQ: 30 mg once weekly; may increase to 50 mg once weekly if inadequate glycemic response. Titration to 50 mg once weekly occurred at week 12 in a monotherapy trial and after a…"}, {"doc_id": "interferon-beta-1a-drug-information", "bm25_top3": 12.323547724662516, "bm25_max": 12.79666070596966, "bge_top3": 0.6065967679023743, "bge_max": 0.6065967679023743, "title": "Interferon beta-1a: Drug information", "rep_snippet": "Dosing: Adult  Multiple sclerosis (MS): Note: Analgesics and/or antipyretics may help decrease flu-like symptoms on treatment days:  IM (Avonex):  US labeling: 30 mcg once weekly; to decrease flu-like symptoms, may initi…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": 10.07502501616229, "bm25_max": 12.111268722378409, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Dosing: Adult  Meningococcal prophylaxis: Oral, IV: 600 mg twice daily for 2 days  Tuberculosis, active (drug-susceptible): Oral, IV: Note: Always administer in combination with other antitubercular drugs (Nahid 2016).…"}, {"doc_id": "emicizumab-kxwh-drug-information", "bm25_top3": 11.968780868642094, "bm25_max": 11.968780868642094, "bge_top3": null, "bge_max": null, "title": "Emicizumab-kxwh: Drug information", "rep_snippet": "Dosing: Adult  Hemophilia A, prophylaxis: SubQ: Initial: 3 mg/kg once weekly for 4 weeks, then 1.5 mg/kg once weekly thereafter"}, {"doc_id": "mipomersen-drug-information", "bm25_top3": 11.641551243227735, "bm25_max": 11.641551243227735, "bge_top3": null, "bge_max": null, "title": "Mipomersen: Drug information", "rep_snippet": "Dosing: Adult  Homozygous familial hypercholesterolemia (HoFH): SubQ: 200 mg once weekly. Note: Maximal LDL-C reduction seen after ~6 months.  Missed dose: If dose is missed, administer at least 3 days before the next we…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2a-drug-information", "bm25_top3": 10.214752499984499, "bm25_max": 11.42075564963961, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2a: Drug information", "rep_snippet": "Dosing: Adult  Chronic hepatitis C (monoinfection or coinfection with HIV): SubQ: 180 mcg once weekly, duration of therapy varies with HCV genotype and concurrent HCV antivirals. Note: Use of peginterferon is not recomme…"}, {"doc_id": "eteplirsen-drug-information", "bm25_top3": 11.28726713708392, "bm25_max": 11.28726713708392, "bge_top3": null, "bge_max": null, "title": "Eteplirsen: Drug information", "rep_snippet": "Dosing: Adult  Duchenne muscular dystrophy: IV: 30 mg/kg once weekly"}, {"doc_id": "interferon-alfa-2b-drug-information", "bm25_top3": 11.146911793003127, "bm25_max": 11.146911793003127, "bge_top3": null, "bge_max": null, "title": "Interferon alfa-2b: Drug information", "rep_snippet": "Dosing: Adult  Consider premedication with acetaminophen prior to administration to reduce the incidence of some adverse reactions. Not all dosage forms and strengths are appropriate for all indications; refer to product…"}, {"doc_id": "interferon-gamma-1b-drug-information", "bm25_top3": 9.860846051121266, "bm25_max": 11.119511805701197, "bge_top3": null, "bge_max": null, "title": "Interferon gamma-1b: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing expressed in mcg; 50 mcg is equivalent to 1 million units (50 mcg/m2 is equivalent to 1 million units/m2).  Chronic granulomatous disease: SubQ: 50 mcg/m2 (1 million units/m2) 3 times weekly;…"}, {"doc_id": "idursulfase-drug-information", "bm25_top3": 11.092414332994473, "bm25_max": 11.092414332994473, "bge_top3": null, "bge_max": null, "title": "Idursulfase: Drug information", "rep_snippet": "Dosing: Adult  Mucopolysaccharidosis II (Hunter syndrome): IV: 0.5 mg/kg once weekly"}, {"doc_id": "alpha-1-proteinase-inhibitor-drug-information", "bm25_top3": 11.087589937772425, "bm25_max": 11.087589937772425, "bge_top3": null, "bge_max": null, "title": "Alpha-1 proteinase inhibitor: Drug information", "rep_snippet": "Dosing: Adult  Note: The vial strength (mg) of some products (ie, Prolastin-C, Zemaira) varies by manufacturer lot; consult individual vial labels for exact amount prior to preparation for administration.  Alpha1-antitry…"}, {"doc_id": "asfotase-alfa-drug-information", "bm25_top3": 11.085002681417603, "bm25_max": 11.085002681417603, "bge_top3": null, "bge_max": null, "title": "Asfotase alfa: Drug information", "rep_snippet": "Dosing: Adult  Hypophosphatasia (HPP): SubQ: Note: Round patient weight to the nearest kg when determining dose. Injection-site reactions may limit the tolerability of the 6 times per week regimen:  Juvenile-onset HPP: 2…"}, {"doc_id": "semaglutide-drug-information", "bm25_top3": 11.00979093850812, "bm25_max": 11.00979093850812, "bge_top3": null, "bge_max": null, "title": "Semaglutide: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: SubQ: Initial: 0.25 mg once weekly for 4 weeks then increase to 0.5 mg once weekly for at least 4 weeks; if further glycemic control is necessary increase to a maximum of 1 mg on…"}, {"doc_id": "calcitriol-topical-drug-information", "bm25_top3": 10.99760405526632, "bm25_max": 10.99760405526632, "bge_top3": null, "bge_max": null, "title": "Calcitriol (topical): Drug information", "rep_snippet": "Dosing: Adult  Psoriasis: Topical: Apply twice daily to affected areas (maximum: 200 g weekly)"}, {"doc_id": "alendronate-drug-information", "bm25_top3": 10.838060794773698, "bm25_max": 10.838060794773698, "bge_top3": 0.6475145220756531, "bge_max": 0.6475145220756531, "title": "Alendronate: Drug information", "rep_snippet": "Brand Names: International  Adronat (AU, IT, PT);  Albinax (VN);  Aldren 70 (PH, TH);  Aldron (HR);  Aldrox (CL);  Alenato (AR);  Alend (KR);  Alendomax (JO);  Alendovenir (IL);  Alendra (PH);  Alendrate (NZ);  Alendrex…"}, {"doc_id": "rilonacept-drug-information", "bm25_top3": 10.828731440421244, "bm25_max": 10.828731440421244, "bge_top3": null, "bge_max": null, "title": "Rilonacept: Drug information", "rep_snippet": "Dosing: Adult  Cryopyrin-associated periodic syndromes: SubQ:  Initial: 320 mg given as 2 separate injections (160 mg [2 mL] per injection) on the same day at 2 different sites  Maintenance: 160 mg once weekly. Note: Beg…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 10.822867403342176, "bm25_max": 10.822867403342176, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis, pulmonary: IM, IV:  Manufacturer's labeling: 1 g once daily (maximum: 20 mg/kg/dose) for 60 to 120 days, followed by 1 g 2 to 3 times weekly  Alternate dosing: 15 mg/kg once daily (maximum: 1…"}, {"doc_id": "rituximab-intravenous-drug-information", "bm25_top3": 10.787356607573031, "bm25_max": 10.787356607573031, "bge_top3": null, "bge_max": null, "title": "Rituximab (intravenous): Drug information", "rep_snippet": "Graft-versus-host disease (GVHD), chronic, refractory (off-label use): IV: 375 mg/m2 once weekly for 4 doses; a second course of 4 weekly doses may be administered 8 weeks after initial therapy for lack of or incomplete…"}, {"doc_id": "bedaquiline-drug-information", "bm25_top3": 10.768057007647087, "bm25_max": 10.768057007647087, "bge_top3": null, "bge_max": null, "title": "Bedaquiline: Drug information", "rep_snippet": "Dosing: Adult  Note: Use with ≥3 drugs also active against the patient's M. tuberculosis isolate.  Tuberculosis (multidrug-resistant), pulmonary: Oral: Directly observed therapy (DOT):  Weeks 1 to 2: 400 mg once daily. N…"}, {"doc_id": "belimumab-drug-information", "bm25_top3": 10.717408301384278, "bm25_max": 10.717408301384278, "bge_top3": null, "bge_max": null, "title": "Belimumab: Drug information", "rep_snippet": "Dosing: Adult  Systemic lupus erythematosus (SLE):  IV: Initial: 10 mg/kg every 2 weeks for 3 doses; Maintenance: 10 mg/kg every 4 weeks  SubQ: 200 mg once weekly  Switching from IV therapy: Administer the first SubQ dos…"}, {"doc_id": "heparin-unfractionated-drug-information", "bm25_top3": 10.370122523804682, "bm25_max": 10.370122523804682, "bge_top3": null, "bge_max": null, "title": "Heparin (unfractionated): Drug information", "rep_snippet": "Once-weekly dosing regimen: Instill the combination of 20,000 units of heparin, lidocaine 4% (5 mL), and sodium bicarbonate 7% (25 mL) into an empty bladder via catheter once weekly for 12 weeks and allow to dwell for 30…"}, {"doc_id": "mefloquine-drug-information", "bm25_top3": 9.763418687495015, "bm25_max": 9.763418687495015, "bge_top3": null, "bge_max": null, "title": "Mefloquine: Drug information", "rep_snippet": "30 to 45 kg: 3/4 of 250 mg tablet (187.5 mg) once weekly  >45 kg: One tablet (250 mg) once weekly  Off-label dosing (CDC 2014):  ≤9 kg: 5 mg/kg/dose once weekly  >9 to 19 kg: 1/4 of 250 mg tablet (62.5 mg) once weekly  >…"}, {"doc_id": "irinotecan-conventional-drug-information", "bm25_top3": 9.630822350686532, "bm25_max": 9.630822350686532, "bge_top3": 0.615580141544342, "bge_max": 0.615580141544342, "title": "Irinotecan (conventional): Drug information", "rep_snippet": "Dosing: Geriatric  Weekly dosing schedule: No dosing adjustment is recommended  Every 3-week dosing colorectal cancer schedule: Recommended initial dose is 300 mg/m2/dose for patients ≥70 years"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-drug-information", "bm25_top3": 9.498965967124686, "bm25_max": 9.498965967124686, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2b: Drug information", "rep_snippet": "105 to 125 kg: 108 mcg once weekly; may further reduce to 64 mcg once weekly if needed  >125 kg: 135 mcg once weekly; may further reduce to 72 mcg once weekly if needed  Peginterferon alfa-2b monotherapy: Reduce to avera…"}, {"doc_id": "ethambutol-drug-information", "bm25_top3": 8.585815273667972, "bm25_max": 8.585815273667972, "bge_top3": null, "bge_max": null, "title": "Ethambutol: Drug information", "rep_snippet": "Three-times-weekly DOT: Note: Although suggested dosing based on experience with twice-weekly regimen; experts suggest three-times-weekly regimens are more effective than twice-weekly DOT regimens; consult guidelines for…"}, {"doc_id": "sebelipase-alfa-drug-information", "bm25_top3": 8.388417806818339, "bm25_max": 8.388417806818339, "bge_top3": 0.611953616142273, "bge_max": 0.611953616142273, "title": "Sebelipase alfa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Sebelipase alfa: Pediatric drug information\")  Rapidly progressive lysosomal acid lipase (LAL) deficiency presenting within the first 6 months of life: Infants: IV: Ini…"}, {"doc_id": "human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information", "bm25_top3": 8.303000118665308, "bm25_max": 8.303000118665308, "bge_top3": 0.6219631433486938, "bge_max": 0.6219631433486938, "title": "Human-plasma derived von Willebrand factor (contains factor VIII): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Human-plasma derived von Willebrand factor (contains factor VIII): Pediatric drug information\")  Hemophilia A (Factor VIII deficiency):  Product-specific dosing:  Alpha…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 8.2494033425941, "bm25_max": 8.2494033425941, "bge_top3": null, "bge_max": null, "title": "Fluoxetine: Drug information", "rep_snippet": "Note: Weekly formulation results in greater fluctuations between peak and trough concentrations of fluoxetine and norfluoxetine compared to once-daily dosing (24% daily/164% weekly; 17% daily/43% weekly, respectively). T…"}, {"doc_id": "factor-viii-recombinant-human-drug-information", "bm25_top3": 6.529100502309703, "bm25_max": 6.529100502309703, "bge_top3": null, "bge_max": null, "title": "Factor VIII, recombinant human: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Factor VIII, recombinant human: Pediatric drug information\")  Hemophilia A: Children and Adolescents: IV: Individualize dosage based on coagulation studies performed pr…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": 0.9178191516423055, "bm25_max": 0.9178191516423055, "bge_top3": 0.6105207800865173, "bge_max": 0.6105207800865173, "title": "Methotrexate: Drug information", "rep_snippet": "• Administration schedules: Errors have occurred (some resulting in death) when methotrexate was administered as a “daily” dose instead of a “weekly” dose intended for some indications. The ISMP Targeted Medication Safet…"}, {"doc_id": "clobazam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6243363320827484, "bge_max": 0.627993643283844, "title": "Clobazam: Drug information", "rep_snippet": "Dosing: Geriatric  US labeling:  Lennox-Gastaut (adjunctive): Oral:  ≤30 kg: Initial: 5 mg once daily for ≥1 week, then increase to 5 mg twice daily; after ≥1 week may increase to 10 mg twice daily based on patient toler…"}, {"doc_id": "lamotrigine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6196727355321249, "bge_max": 0.6252580285072327, "title": "Lamotrigine: Drug information", "rep_snippet": "Regimens not containing carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir, or valproic acid: Initial: Weeks 1 and 2: 0.3 mg/kg/day in 1 to 2 divided doses; Weeks 3 and 4: 0.6 mg/kg/day in…"}, {"doc_id": "lanreotide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6225454211235046, "bge_max": 0.6225454211235046, "title": "Lanreotide: Drug information", "rep_snippet": "Dosing: Adult  Acromegaly: SubQ: Initial dose: 90 mg once every 4 weeks for 3 months; after initial 3 months, continue monitoring and adjust dose as necessary based on clinical response of patient, growth hormone (GH) le…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6198688745498657, "bge_max": 0.6198688745498657, "title": "Acetylcysteine: Drug information", "rep_snippet": "Dosing: Adult"}, {"doc_id": "antithymocyte-globulin-equine-atgam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6198688745498657, "bge_max": 0.6198688745498657, "title": "Antithymocyte globulin (equine, Atgam): Drug information", "rep_snippet": "Dosing: Adult"}, {"doc_id": "oxybutynin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6191624402999878, "bge_max": 0.6191624402999878, "title": "Oxybutynin: Drug information", "rep_snippet": "Dosing: Adult  Overactive bladder:  Oral:  Immediate release: 5 mg 2 to 3 times daily; maximum: 5 mg 4 times daily  Extended release: Initial: 5 to 10 mg once daily, adjust dose in 5 mg increments at weekly intervals; ma…"}, {"doc_id": "thioguanine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6188512444496155, "bge_max": 0.6188512444496155, "title": "Thioguanine: Drug information", "rep_snippet": "Dosing: Adult  Acute myeloid leukemia (AML): Oral: 2 mg/kg once daily for 4 weeks; if no clinical improvement after 4 weeks and ANC and platelet counts are not depressed, may increase dose to 3 mg/kg once daily with care…"}, {"doc_id": "glycerin-and-lidocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6163254976272583, "bge_max": 0.6163254976272583, "title": "Glycerin and lidocaine: Drug information", "rep_snippet": "Dosing: Adult  Anorectal disorders: Topical: Apply to the affected area ≤6 times daily (morning, evening, and after each bowel movement)."}, {"doc_id": "perampanel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6156423687934875, "bge_max": 0.6156423687934875, "title": "Perampanel: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. Increase dose no more frequently than every 2 weeks."}, {"doc_id": "propiverine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.614857017993927, "bge_max": 0.614857017993927, "title": "Propiverine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Overactive bladder: Oral: Modified release: Initial: 30 mg once daily; may increase to a maximum of 45 mg once daily."}, {"doc_id": "synthetic-conjugated-estrogens-a-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6144145727157593, "bge_max": 0.6144145727157593, "title": "Synthetic conjugated estrogens A (United States: Not available): Drug information", "rep_snippet": "Administration  Administer at the same time each day."}, {"doc_id": "acenocoumarol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6144145727157593, "bge_max": 0.6144145727157593, "title": "Acenocoumarol (United States: Not available): Drug information", "rep_snippet": "Administration  Administer at the same time each day."}, {"doc_id": "equine-conjugated-estrogens-and-medroxyprogesterone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6144145727157593, "bge_max": 0.6144145727157593, "title": "Equine conjugated estrogens and medroxyprogesterone acetate: Drug information", "rep_snippet": "Administration  Administer at the same time each day."}, {"doc_id": "terazosin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6144145727157593, "bge_max": 0.6144145727157593, "title": "Terazosin: Drug information", "rep_snippet": "Administration  Administer at the same time each day."}, {"doc_id": "lorcaserin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6140949726104736, "bge_max": 0.6140949726104736, "title": "Lorcaserin: Drug information", "rep_snippet": "Dosing: Adult  Weight management: Oral: Note: Evaluate response by week 12; if patient has not lost ≥5% of baseline body weight, discontinue therapy  Extended release: 20 mg once daily (maximum: 20 mg/day).  Immediate re…"}, {"doc_id": "bromocriptine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6134570240974426, "bge_max": 0.6134570240974426, "title": "Bromocriptine: Drug information", "rep_snippet": "Dosing: Adult  Acromegaly: Oral: Initial: 1.25 to 2.5 mg daily increasing by 1.25 to 2.5 mg daily as necessary every 3 to 7 days; usual dose: 20 to 30 mg daily (maximum: 100 mg/day)  Diabetes mellitus, type 2 (Cycloset o…"}, {"doc_id": "potassium-citrate-and-citric-acid-powder-or-solution-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6129083633422852, "bge_max": 0.6129083633422852, "title": "Potassium citrate and citric acid (powder or solution): Drug information", "rep_snippet": "Dosing: Adult  Systemic alkalinizer, Acidosis, Gout (adjuvant): Oral:  Powder: One packet dissolved in water 4 times daily; adjust dose to urinary pH  Solution: 10 to 30 mL 4 times daily; adjust dose based on urinary pH"}, {"doc_id": "arsenic-trioxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6120542287826538, "bge_max": 0.6120542287826538, "title": "Arsenic trioxide: Drug information", "rep_snippet": "Dosing: Adult  Note: Arsenic trioxide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.  Acute promyelocytic leukemia (APL), newly diagnosed, low-risk: IV: Note:…"}, {"doc_id": "diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6113946437835693, "bge_max": 0.6113946437835693, "title": "Diphenhydramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Note: Aldex has been discontinued in the US for more than 1 year.  Allergic symptoms, nasal congestion: Oral:  Aldex CT: 1 to 2 tablets every 6 hours (maximum: 4 doses/24 hours)  OTC labeling: Note: Refer…"}, {"doc_id": "trospium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6103538870811462, "bge_max": 0.6103538870811462, "title": "Trospium: Drug information", "rep_snippet": "Dosing: Adult  Overactive bladder: Oral:  Immediate release: 20 mg twice daily  Extended release: 60 mg once daily in the morning"}, {"doc_id": "sarilumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6093106269836426, "bge_max": 0.6093106269836426, "title": "Sarilumab: Drug information", "rep_snippet": "Dosing: Adult  Note: Do not initiate if ANC is <2,000/mm3, platelets are <150,000/mm3 or if ALT or AST are >1.5 times ULN.  Rheumatoid arthritis: SubQ: 200 mg once every 2 weeks. Note: May use as monotherapy or in combin…"}, {"doc_id": "reserpine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6092769503593445, "bge_max": 0.6092769503593445, "title": "Reserpine (United States: not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Reserpine tablets are no longer available in the US.  Hypertension:  Manufacturer's labeling: Initial: 0.5 mg/day for 1-2 weeks; maintenance: 0.1-0.25 mg/day  Note: Clinically, the need for a “loadin…"}, {"doc_id": "cyproheptadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.609153151512146, "bge_max": 0.609153151512146, "title": "Cyproheptadine: Drug information", "rep_snippet": "Dosing: Adult  Allergic conditions: Oral: Initial: 4 mg 3 times daily; maintenance: 4 to 20 mg daily in divided doses; maximum: 0.5 mg/kg/day; some patients may require up to 32 mg/day for adequate control of symptoms  D…"}, {"doc_id": "isosorbide-dinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6091514825820923, "bge_max": 0.6091514825820923, "title": "Isosorbide dinitrate: Drug information", "rep_snippet": "Dosing: Adult  Angina pectoris (prevention): Note: Due to slower onset of action, isosorbide dinitrate is not the drug of choice to abort an acute anginal episode. Tolerance to nitrate effects develops with chronic expos…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6087807416915894, "bge_max": 0.6087807416915894, "title": "Topiramate: Drug information", "rep_snippet": "Extended release: Initial: 25 mg once daily; increase based on response and tolerability in weekly increments of 25 mg to the recommended dose of 100 mg once daily. Increased intervals between dose adjustments may be con…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6087794303894043, "bge_max": 0.6087794303894043, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Note: Extended-release tablets and immediate-release formulations are not interchangeable. Unless otherwise specified, oral dosing reflects the use of immediate-release formulations.  Anthrax:  Note: Consu…"}, {"doc_id": "urea-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6086668968200684, "bge_max": 0.6086668968200684, "title": "Urea (topical): Drug information", "rep_snippet": "Dosing: Adult  Hyperkeratotic conditions: Topical: Apply 1-3 times daily."}, {"doc_id": "secukinumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6084019541740417, "bge_max": 0.6084019541740417, "title": "Secukinumab: Drug information", "rep_snippet": "Dosing: Adult  Ankylosing spondylitis: SubQ:  With a loading dose: 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks  Without a loading dose: 150 mg every 4 weeks  Plaque psoriasis: SubQ: 300 mg once wee…"}, {"doc_id": "edaravone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.60741126537323, "bge_max": 0.60741126537323, "title": "Edaravone: Drug information", "rep_snippet": "Dosing: Adult  Amyotrophic lateral sclerosis  (ALS): IV:  Initial cycle: 60 mg once daily for 14 days, followed by a 14-day drug-free period.  Subsequent cycles: 60 mg once daily for 10 days within a 14-day period, follo…"}, {"doc_id": "mepolizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6073382496833801, "bge_max": 0.6073382496833801, "title": "Mepolizumab: Drug information", "rep_snippet": "Dosing: Adult  Asthma: SubQ: 100 mg once every 4 weeks  Eosinophilic granulomatosis with polyangiitis (treatment): SubQ: 300 mg once every 4 weeks  Eosinophilic granulomatosis with polyangiitis (relapsing or refractory)…"}, {"doc_id": "cyclophosphamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6069765686988831, "bge_max": 0.6069765686988831, "title": "Cyclophosphamide: Drug information", "rep_snippet": "Dosing: Adult  Cyclophosphamide is associated with a moderate to high emetic potential (depending on dose, regimen, or administration route); antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017; Roil…"}, {"doc_id": "nelarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6067882180213928, "bge_max": 0.6067882180213928, "title": "Nelarabine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution, Intravenous:  Arranon: 5 mg/mL (50 mL)"}, {"doc_id": "drospirenone-and-estradiol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6066117286682129, "bge_max": 0.6066117286682129, "title": "Drospirenone and estradiol: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Tablet:  Angeliq®: Drospirenone 0.25 mg and estradiol 0.5 mg; drospirenone 0.5 mg and…"}, {"doc_id": "rufinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.60658860206604, "bge_max": 0.60658860206604, "title": "Rufinamide: Drug information", "rep_snippet": "Dosing: Adult  Lennox-Gastaut syndrome (adjunctive): Oral: 400 to 800 mg daily in 2 equally divided doses; increase dose by 400 to 800 mg daily every other day to a maximum dose of 3,200 mg daily in 2 equally divided dos…"}, {"doc_id": "zuclopenthixol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6062235832214355, "bge_max": 0.6062235832214355, "title": "Zuclopenthixol (United States: Not available): Drug information", "rep_snippet": "150 mg of acetate injection every 2 to 3 days = 300 mg of decanoate injection every 2 weeks"}, {"doc_id": "minocycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6059330701828003, "bge_max": 0.6059330701828003, "title": "Minocycline: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range:  IV: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours (maximum: 400 mg daily)  Oral: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours; more frequent dosing i…"}, {"doc_id": "olanzapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6057422161102295, "bge_max": 0.6057422161102295, "title": "Olanzapine: Drug information", "rep_snippet": "Dosing: Adult  Schizophrenia:  Oral: Initial: 5 to 10 mg once daily (increase to 10 mg once daily within 5 to 7 days); thereafter, adjust by 5 mg daily at 1-week intervals, up to a recommended maximum of 20 mg/day. Maint…"}, {"doc_id": "ipratropium-and-albuterol-drug-information", "bm25_top3": -1.3503698599857987, "bm25_max": -1.3503698599857987, "bge_top3": null, "bge_max": null, "title": "Ipratropium and albuterol: Drug information", "rep_snippet": "Brand Names: Canada  Apo-Salvent-Ipravent Sterules;  Combivent Respimat;  Combivent UDV;  ratio-Ipra Sal UDV;  Teva-Combo Sterinebs"}]}
